Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Clinical Packet
November 4, 2020

Table of Contents

Pharmacy and Therapeutics (P&T) Committee
Helpful Hints/Reference Document
P&T Charge

As defined by §22-6-122

The Medicaid Pharmacy and Therapeutics (P&T) Committee shall review and recommend classes of drugs to the Medicaid Commissioner for inclusion in the Medicaid Preferred Drug Plan. Class means a therapeutic group of pharmaceutical agents approved by the FDA as defined by the American Hospital Formulary Service.

The P&T Committee shall develop its preferred drug list recommendations by considering the clinical efficacy, safety and cost effectiveness of a product. Within each covered class, the Committee shall review and recommend drugs to the Medicaid Commissioner for inclusion on a preferred drug list. Medicaid should strive to insure any restriction on pharmaceutical use does not increase overall health care costs to Medicaid.

The recommendations of the P&T Committee regarding any limitations to be imposed on any drug or its use for a specific indication shall be based on sound clinical evidence found in labeling, drug compendia and peer reviewed clinical literature pertaining to use of the drug. Recommendations shall be based upon use in the general population. Medicaid shall make provisions in the prior approval criteria for approval of non-preferred drugs that address needs of sub-populations among Medicaid beneficiaries. The clinical basis for recommendations regarding the PDL shall be made available through a written report that is publicly available. If the recommendation of the P&T Committee is contrary to prevailing clinical evidence found in labeling, drug compendia and/or peer-reviewed literature, such recommendation shall be justified in writing.

Preferred Drug List/Program Definitions

Preferred Drug: Listed on the Agency's Preferred Drug Lists and will not require a prior authorization (PA).

Preferred with Clinical Criteria: Listed on the Agency's Preferred Drug Lists but will require a prior authorization. Clinical criteria must be met in order to be approved.

Non Preferred Drug: Covered by the Agency, if it is determined and supported by medical records to be medically necessary, but will require a PA.

Non Covered Drug: In accordance with Medicaid Drug Amendments contained in the Omnibus Budget Reconciliation Act of 1990 (OBRA 90 federal legislation), the Agency has the option to not cover (or pay for) some drugs. Alabama Medicaid does not cover/pay for the following:

- Drugs used for anorexia, weight loss or weight gain, with the exception of those specified by the Alabama Medicaid Agency
- Drugs used to promote fertility with the exception of those specified by the Alabama Medicaid Agency
- Drugs used for cosmetic purposes or hair growth
- Over-the-counter/non prescription drugs, with the exception of those specified by the Alabama Medicaid Agency
- Covered outpatient drugs when the manufacturer requires as a condition of sale that associated test and/or monitoring services be purchased exclusively from the manufacturer or designee
- DESI (Drug Efficacy Study Implementation [less than effective drugs identified by the FDA]) and IRS (Identical, Related and Similar [drugs removed from the market]) drugs which may be restricted in accordance with Section 1927(d) (2) of the Social Security Act
- Agents when used for the symptomatic relief of cough and colds except for those specified by the Alabama Medicaid Agency
- Prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations and others as specified by the Alabama Medicaid Agency
- Agents when used for the treatment of sexual or erectile dysfunction, unless authorized for pulmonary hypertension.

(From Alabama Medicaid Agency Administrative Code, Chapter 16 and Alabama Medicaid Agency Provider Billing Manual, Chapter 27.)

Prior Authorization (PA): Process that allows drugs that require approval prior to payment to be reimbursed for an individual patient. Drugs may require PA if they are preferred with clinical criteria, are non-preferred status, or if they required PA prior to the PDL.

Medicaid may require prior authorization for generic drugs only in instances when the cost of the generic product is significantly greater than the net cost of the brand product in the same AHFS therapeutic class or when there is a clinical concern regarding safety, overuse or abuse of the product.

Although a product may require PA, the product is considered a covered product and Medicaid will pay for the product only once the PA has been approved.

Override: Process where drugs require approval prior to payment to be reimbursed for an individual patient if the claim falls outside a predetermined limit or criteria. Overrides differ from PA in that drugs or drug classes that require an override will automatically allow payment of the drug unless something on the claim hits a predetermined limit or criteria. The different types of overrides include:

Accumulation Edit
Brand Limit Switchover
Dispense As Written Override
Early Refill
Ingredient Duplication
Maintenance Supply Opt Out
Maximum Unit/Max Cost Limitations
Short Acting Opioid Naïve Override
Therapeutic Duplication

Electronic PA (EPA): The EPA system checks patient-specific claims history to determine if pharmacy and medical PA requirements are met at the Point-of-Sale claim submission for a non-preferred drug. If it is determined that all criteria are met and the request is approved, the claim will pay and no manual PA request will be required. Electronic PA results in a reduction in workload for providers because the claim is electronically approved within a matter of seconds with no manual PA required.

Prior Authorization Criteria Definitions

Appropriate Diagnosis: Diagnosis(es) that justifies the need for the drug requested. Diagnosis(es) **or** ICD-10 code(s) may be used. Use of ICD-10 codes provides specificity and legibility and will usually expedite review.

Prior Treatment Trials: Prior authorization requires that two (2) prescribed generic, OTC or brand name drugs have been utilized unsuccessfully relative to efficacy and/or safety within six (6) months prior to requesting the PA. The PA request must indicate that two (2) generic, OTC or other brand drugs have been utilized for a period of at least thirty (30) days each (14 days for Triptans, 3 days for EENT Vasoconstrictor Agents), **unless** there is an adverse/allergic response or contraindication. If the prescribing practitioner feels there is a medical reason for which the patient should not be on a generic, OTC or brand drug or drug trial, medical justification may be submitted in lieu of previous drug therapy. One prior therapy is acceptable in those instances when a class has only one preferred agent, either generic, OTC, or brand.

Stable Therapy: Allows for approval of a PA for patients who have been determined to be stable on a medication (same drug, same strength) for a specified timeframe and who continue to require therapy. Medications paid for through insurance, private pay or Medicaid are also counted toward the requirement. Providers will be required to document this information on the PA request form and note the program or method through which the medication was dispensed.

Medical Justification: An explanation of the reason the drug is required and any additional information necessary. Medical justification is documentation to support the physician's choice of the requested course of treatment. Documentation from the patient record (history and physical, tests, past or current medication/treatments, patient's response to treatment, etc) illustrates and supports the physician's request for the drug specified. For example, if a recommended therapy trial is contraindicated by the patient's condition or a history of allergy to a first-line drug, and the physician wants to order a non-preferred drug, documentation from the patient record would support that decision. In addition, medical justification may include peer reviewed literature to support the use of a non-preferred medication.

External Criteria

Alzheimer's Agents

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least one other prescribed and preferred Alzheimer's agent in this class, either generic, OTC or brand, within the past 6 months, or have a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Stable therapy for this class is defined as a 90-day or greater timeframe. Approval may be given for those who have documented stable therapy on the requested medication for 90 consecutive days or greater.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Alzheimer's agents are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Antidepressants

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred antidepressant agents in this class, either generic, OTC or brand within the past 6 months, or have a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Approval may be given to those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Antidepressants are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Cerebral Stimulants/Agents Used for ADHD

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

- For agents with an FDA-approved indication of Idiopathic hypersomnia in children 18 and under, narcolepsy, or obstructive sleep apnea, the patient must have an appropriate diagnosis supported by documentation in the patient record of appropriate diagnostic testing.

Prior Therapy

- If the request is for a *short- or intermediate-acting* cerebral stimulant/agent used to treat ADHD, the patient must also have failed 30-day treatment trials with at least two prescribed and preferred short- or intermediate-acting cerebral stimulants/agents used for ADHD, either generic, OTC or brand, within the past 6 months.

- If the request is for a *long-acting* cerebral stimulant/agent used for ADHD, the patient must also have failed 30-day treatment trials with at least two prescribed and preferred long-acting cerebral stimulants/agents used for ADHD, either generic, OTC or brand within the past 6 months.

- If the request is for Strattera®, the patient must also have failed 30-day treatment trials with at least two prescribed and preferred cerebral stimulants (short-, intermediate- or long-acting), either generic, OTC or brand within the past 6 months. If prior usage requirements have not been met, approval may be given if there is a history of substance abuse or concern regarding substance abuse in the patient's household.

- If the request is for Kapvay®, the patient must also have failed a 30-day treatment trial with immediate-release clonidine within the past 6 months. If prior usage requirements have not been met, approval may be given if there is a history of substance abuse or concern regarding substance abuse in the patient's household.

- In lieu of prior usage requirements, approval may be given if there is a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Approval may be given to those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Cerebral Stimulant/Agent Used for ADHD agents are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Anxiolytics/Sedatives/Hypnotics

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred agents in this class, either generic, OTC or brand within the past 6 months, or have a documented allergy or contraindication to all preferred agents in this class.

- If the request is for Onfi® for a diagnosis of Lennox-Gastaut syndrome, the patient must also be ≥2 years of age, have a diagnosis by a pediatric neurologist and have failed 30-day treatment trials of valproic acid, lamotrigine, and topiramate within the past 6 months, or have a documented allergy or contraindication to all of those agents.

- If the request is for Onfi® for a diagnosis of intractable seizures, the patients must also have a diagnosis by a neurologist (diagnosis by a pediatric neurologist is required for patients <18 years of age) and have failed 30-day treatment trials with a minimum of four anti-convulsant medications within the past 6 months, or have a documented allergy or contraindication to other anti-convulsant medications.

Stable Therapy

- Approval may be given for children age 18 years and under who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 3 months for initial request and up to 6 months for renewal requests.

Electronic Prior Authorization (PA)

- Anxiolytic, sedative and hypnotic agents are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Genitourinary Smooth Muscle Relaxants

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred agents in this class, either generic, OTC or brand, within the past 6 months or have a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Approval may be given for children age 18 years and under who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Genitourinary smooth muscle relaxants are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

AGENDA

ALABAMA MEDICAID AGENCY
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

November 4, 2020
9:00 a.m. – 12:00 noon

---

1. Opening remarks……..……..……....…...Chair
2. Approval August 5, 2020 P&T Committee Meeting minutes……....…….....…...Chair
3. Pharmacy program update……....…..Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers' representatives (prior to each class review)
5. Pharmacotherapy class re-reviews…….…..……..…..UMass Clinical Pharmacy Services
   - **Alzheimer's Agents**
     - **Parasympathomimetic (Cholinergic) Agents** – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, Razadyne®, and Razadyne ER® only)
     - **Central Nervous System Agents, Miscellaneous** – AHFS Class 289200 (current brands to be included: Namenda®, Namenda XR®, and Namzaric® only)
   - **Antidepressants** – AHFS 281604
   - **Cerebral Stimulants/Agents Used for ADHD**
     - **Central Alpha-Agonists** – AHFS 240816
     - **Amphetamine Derivatives** – AHFS 282004 (current brands to be included: Adderall®, Adderall XR®, Adzenys ER®, Adzenys XR-ODT®, Desoxyn®, Dexedrine®, Dyanavel XR®, Evekeo®, Mydayis ER®, ProCentra®, Vyvanse® and Zenzedi® only)
     - **Respiratory and CNS Stimulants** – AHFS 282032 (current brands to be included: Adhansia XR®, Aptensio XR®, Cotempla XR-ODT®, Concerta®, Daytrana®, Focalin®, Focalin XR®, Jornay PM®, Methylin®, Quillichew ER®, Quillivant XR®, Relexxii ER®, Ritalin®, and Ritalin LA® only)
     - **Central Nervous System Agents, Miscellaneous** – AHFS 289200 (current brands to be included: Intuniv® and Strattera® only)
   - **Wakefulness Promoting Agents** – AHFS 282080 (current brands to be included: Nuvigil®, Provigil®, Sunosi®, Wakix®, and Xyrem® only)
   - **Anxiolytics, Sedatives, and Hypnotics** – **Barbiturates** – AHFS 282404
   - **Anxiolytics, Sedatives, and Hypnotics** – **Benzodiazepines** – AHFS 282408
   - **Anxiolytics, Sedatives, and Hypnotics** – **Miscellaneous** – AHFS 282492
   - **Genitourinary Smooth Muscle Relaxants: Antimuscarinics** – AHFS 861204
   - **Genitourinary Smooth Muscle Relaxants: Beta-3 Adrenergic Agonists** – AHFS 861208
   - **Disease-Modifying Antirheumatic Agents** – AHFS 923600
6. New drug review…….……..…..……..…..UMass Clinical Pharmacy Services
   - Vumerity® (diroximel fumarate) – AHFS 922000
7. Results of voting announced…….....……...……...……...…Chair
8. New Business……...……..Chair
   - Election of new Chair and Vice-Chair
9. Next meeting dates
   - February 3, 2021
   - May 5, 2021
   - August 4, 2021
   - November 3, 2021
10. Adjourn

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Alzheimer's Agents
Parasympathomimetic (Cholinergic) Agents, AHFS Class 120400
Central Nervous System Agents, Miscellaneous, AHFS Class 289200
November 4, 2020

I. Overview

Alzheimer's disease is a progressive neurodegenerative disorder in older adults that affects cognition, behavior, and activities of daily living.[1,2] It is the most common form of dementia and the average life expectancy from the onset of symptoms to death is approximately 10 years.[1-3] Diagnostic features include memory impairment and one or more of the following: aphasia, apraxia, agnosia, and/or disturbance in executive functioning.[1]

The pathophysiologic mechanisms are not entirely understood; however, the disease is characterized by the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques in various regions of the brain. Inflammation and free radical processes lead to neuron dysfunction and death. It is thought that memory loss is partially the result of a deficiency of cholinergic neurotransmission.[2-3] Glutamate, an excitatory neurotransmitter, may also play a role in the pathophysiology of Alzheimer's disease. Glutamate activates N-methyl-D-aspartate (NMDA) receptors and is involved in learning and memory. However, excessive amounts of glutamate in the brain may lead to excitotoxicity and cell death.[3]

There are five agents approved for the treatment of Alzheimer's disease, including cholinesterase inhibitors (donepezil, galantamine, and rivastigmine), an NMDA receptor antagonist (memantine), and a combination product (memantine-donepezil).[4-11] Although none of the agents delay the progression of neurodegeneration, they do delay the progression of symptoms. The cholinesterase inhibitors enhance cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Memantine blocks NMDA receptors and inhibits their overstimulation by glutamate. The combination product containing memantine and donepezil (Namzaric®) was launched in May 2015 with the indication for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily.[11]

The Alzheimer's agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All products with the exception of memantine-donepezil are available in a generic formulation. This class was last reviewed in August 2018.

Table 1. Alzheimer's Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Parasympathomimetic (Cholinergic Agents)			
Donepezil	orally disintegrating tablet, tablet	Aricept®*	donepezil, Aricept®*
Galantamine	extended-release capsule, solution, tablet	Razadyne®*, Razadyne ER®*	galantamine
Rivastigmine	capsule, transdermal patch	Exelon®*	rivastigmine
Central Nervous System Agents, Miscellaneous			
Memantine	extended-release capsule, solution, tablet	Namenda®*, Namenda XR®*	memantine
Combination Products			
Memantine and donepezil	extended-release capsule	Namzaric®	none

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the Alzheimer's agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Alzheimer's Agents

Clinical Guideline	Recommendation(s)
European Federation of Neurological Societies: **Guidelines for the Diagnosis and Management of Alzheimer's Disease (2010)**[12]	• Patients and caregivers should be provided with education and support. • There is insufficient evidence to support the use of any drugs purely for the primary prevention of dementia. Cholinesterase inhibitors, vitamin E, gingko and estrogens should not be used as treatments for those with mild cognitive impairment. • In patients with Alzheimer's disease, treatment with cholinesterase inhibitors (donepezil, galantamine, or rivastigmine) should be considered at the time of diagnosis, taking into account expected therapeutic benefits and potential safety issues. Benefits on cognitive and non-cognitive symptoms have been demonstrated in those with mild, moderate and severe disease. Realistic expectations for treatment effects and potential side effects should be discussed with the patient and caregivers. • In patients with moderate to severe Alzheimer's disease, treatment with memantine should be considered taking into account expected therapeutic benefits and potential safety issues. Benefits on cognitive and noncognitive symptoms are apparent, some non-cognitive symptoms (agitation, delusions) may respond better than others. Realistic expectations for treatment effects and potential side effects should be discussed with the patient and caregivers. • Regular patient follow-up should be an integral part of management. • Aspirin should not be used as a treatment for Alzheimer's disease, though it can be used in those with Alzheimer's disease who also have other indications for its use (e.g. to prevent cardiovascular events). • Vitamin E should not be used as a treatment for Alzheimer's disease. • Currently, there is insufficient evidence to support the use of other agents including, anti-inflammatory drugs, nootropics (including piracetam, nicergoline), selegiline, oestrogens, pentoxyphylins, or statins in the treatment or prevention of Alzheimer's disease. • Cognitive stimulation or rehabilitation may be considered in patients with mild to moderate Alzheimer's disease. • Management of behavioral and psychological symptoms of dementia should begin with a careful search for triggers and causative factors (i.e. physical illness). Where possible, initial treatment should be non-pharmacological. • Antipsychotics should only be used for moderate or severe behavioral and psychological symptoms of dementia causing significant distress which have either not responded to other treatments (like non-pharmacological measures or cholinesterase inhibitors) or when other treatments are not appropriate. Low dose of atypical agents should be used only after assessment of risk benefit and full discussion with patient (when capacity allows) and caregiver. • Atypical agents have fewer side effects and do not confer a greater risk of stroke or mortality than conventional drugs. • Selective serotonin reuptake inhibitors rather than tricyclic antidepressants should be used to treat depression in Alzheimer's disease.
National Institute for Health and Care Excellence: **Dementia: assessment, management and support for people living with dementia**	Pharmacological management of Alzheimer's disease • The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended as options for managing mild to moderate Alzheimer's disease. • Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: ○ moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or

Clinical Guideline	Recommendation(s)
and their carers (2018)[13]	○ severe Alzheimer's disease. • For people with an established diagnosis of Alzheimer's disease who are already taking an AChE inhibitor: ○ consider memantine in addition to an AChE inhibitor if they have moderate disease ○ offer memantine in addition to an AChE inhibitor if they have severe disease. • Treatment should be under the following conditions: ○ For people who are not taking an AChE inhibitor or memantine, prescribers should only start treatment with these on the advice of a clinician who has the necessary knowledge and skills. This could include: ▪ secondary care medical specialists such as psychiatrists, geriatricians and neurologists ▪ other healthcare professionals (such as general practitioners (GPs), nurse consultants and advanced nurse practitioners), if they have specialist expertise in diagnosing and treating Alzheimer's disease. ○ Once a decision has been made to start an AChE inhibitor or memantine, the first prescription may be made in primary care. ○ For people with an established diagnosis of Alzheimer's disease who are already taking an AChE inhibitor, primary care prescribers may start treatment with memantine without taking advice from a specialist clinician. ○ Do not stop AChE inhibitors in people with Alzheimer's disease because of disease severity alone. • If prescribing an AChE inhibitor (donepezil, galantamine or rivastigmine), treatment should normally be started with the drug with the lowest acquisition cost (taking into account required daily dose and the price per dose once shared care has started). However, an alternative AChE inhibitor could be prescribed if it is considered appropriate when taking into account adverse event profile, expectations about adherence, medical comorbidity, possibility of drug interactions and dosing profiles. • When using assessment scales to determine the severity of Alzheimer's disease, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the results and make any adjustments they consider appropriate. Healthcare professionals should also be mindful of the need to secure equality of access to treatment for patients from different ethnic groups, in particular those from different cultural backgrounds. • When assessing the severity of Alzheimer's disease and the need for treatment, healthcare professionals should not rely solely on cognition scores in circumstances in which it would be inappropriate to do so. These include: ○ if the cognition score is not, or is not by itself, a clinically appropriate tool for assessing the severity of that patient's dementia because of the patient's learning difficulties or other disabilities (for example, sensory impairments), linguistic or other communication difficulties or level of education or ○ if it is not possible to apply the tool in a language in which the patient is sufficiently fluent for it to be appropriate for assessing the severity of dementia or ○ if there are other similar reasons why using a cognition score, or the score alone, would be inappropriate for assessing the severity of dementia. ○ In such cases healthcare professionals should determine the need for initiation or continuation of treatment by using another appropriate method of assessment. • Do not offer the following specifically to slow the progress of Alzheimer's disease, except as part of a randomized controlled trial:

Clinical Guideline	Recommendation(s)
	○ diabetes medicines ○ hypertension medicines ○ statins ○ non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin. Pharmacological management of non-Alzheimer's dementia • Offer donepezil or rivastigmine to people with mild to moderate dementia with Lewy bodies. • Only consider galantamine for people with mild to moderate dementia with Lewy bodies if donepezil and rivastigmine are not tolerated. • Consider donepezil or rivastigmine for people with severe dementia with Lewy bodies. • Consider memantine for people with dementia with Lewy bodies if AChE inhibitors are not tolerated or are contraindicated. • Only consider AChE inhibitors or memantine for people with vascular dementia if they have suspected comorbid Alzheimer's disease, Parkinson's disease dementia or dementia with Lewy bodies. • Do not offer AChE inhibitors or memantine to people with frontotemporal dementia. • Do not offer AChE inhibitors or memantine to people with cognitive impairment caused by multiple sclerosis.
American Academy of Neurology: **Practice Guideline Update Summary: Mild Cognitive Impairment (2018)**[14]	Pharmacologic treatments for patients diagnosed with mild cognitive impairment (MCI) • Donepezil use over three years is possibly ineffective for reducing the chances of a progression to possible or probably Alzheimer dementia. In patients with MCI, it is unknown whether donepezil slows progression on various cognitive scales. • Galantamine use over 24 months is probably ineffective for reducing progression to dementia. • Rivastigmine use up to 48 months is possibly ineffective for reducing the rate of progression to possible or probable Alzheimer dementia. Recommendations for management of MCI • For patients diagnosed with MCI, clinicians should wean patients from medications that can contribute to cognitive impairment (where feasible and medically appropriate) and treat modifiable risk factors that may be contributing. • There are no FDA-approved medications for the treatment of MCI. Moreover, there are no high-quality, long-term studies identifying pharmacologic or dietary agents that either improve cognition or delay progression in patients with MCI. For patients diagnosed with MCI, clinicians should counsel the patients and families that there are no pharmacologic or dietary agents currently shown to have symptomatic cognitive benefit in MCI and that no medications are FDA-approved for this purpose. • Studies of cholinesterase inhibitors showed no benefit on cognitive outcomes or reduction in progression from MCI to dementia, although some studies could not exclude an important effect. In addition to lacking efficacy, side effects of cholinesterase inhibitors are common, including gastrointestinal symptoms and cardiac concerns. For patients diagnosed with MCI, clinicians may choose not to offer cholinesterase inhibitors. If clinicians choose to offer cholinesterase inhibitors, they must first discuss with patients the fact that this is an off-label prescription not currently backed by empirical evidence. • For patients diagnosed with MCI who are interested in pharmacologic treatment, clinicians may inform these patients of centers or organizations that can connect patients to clinical trials. • For patients diagnosed with MCI, clinicians should recommend regular exercise (twice per week) as part of an overall approach to management.

Clinical Guideline	Recommendation(s)
	• In patients with MCI, cognitive interventions may be beneficial in improving measures of cognitive function.
American College of Physicians/American Academy of Family Physicians: **Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline (2008)**[15]	• The decision to initiate therapy should be based on evaluation of benefits and risks associated with an individual patient. All of the drugs have known adverse events, and the decision to manage patients with dementia should balance harms against modest or even no benefit. • Although the evidence shows statistically significant benefits of treatment with some cholinesterase inhibitors and memantine for all kinds of dementia, these benefits, on average, are not clinically significant for cognition and are modest for global assessments. Currently, there is no way to predict which patients might have a clinically important response. The evidence does not support prescribing these medications for every patient with dementia. • Evidence is insufficient to determine the optimal duration of therapy. No evidence demonstrates when it is appropriate to stop the treatment if the patient becomes unresponsive or shows decline in various domains of dementia. If slowing decline is no longer a goal, treatment with memantine or a cholinesterase inhibitor is no longer appropriate. • The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. Because few trials compare one drug with another, evidence about effectiveness is insufficient to support the choice of specific drugs for the treatment of dementia. Assessment of the effectiveness of combination therapy is lacking. • Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile and ease of use.
The Movement Disorder Society: **Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease (2019)**[16]	Treatment of dementia in Parkinson's disease • Rivastigmine is efficacious for the treatment of dementia in Parkinson's disease. • There is insufficient evidence for donepezil and galantamine for the treatment of dementia in Parkinson's disease. • Safety conclusions are that the acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine have an acceptable risk without specialized monitoring. • The practice implications are that rivastigmine is clinically useful for the treatment of dementia in Parkinson's disease, while the practice implications for donepezil and galantamine are that they are both possibly useful for the treatment of dementia in Parkinson's disease. • The practice implications for memantine are that it is investigational for the treatment of dementia in Parkinson's disease. Treatment of non-dementia cognitive impairment in Parkinson's disease • There is "insufficient evidence" to conclude on the efficacy of rivastigmine or rasagiline for the treatment of cognitive impairment in Parkinson's disease; practice implications are investigational.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the Alzheimer's agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Single Entity Alzheimer's Agents[4]

Indication	Parasympathomimetic (Cholinergic Agents)			Central Nervous System Agents, Miscellaneous
	Donepezil	Galantamine	Rivastigmine	Memantine
Mild-to-moderate dementia of the Alzheimer's type		✔	✔ †	
Mild, moderate, and severe dementia of the Alzheimer's type	✔		✔ ‡	
Moderate-to-severe dementia of the Alzheimer's type				✔
Mild-to-moderate dementia associated with Parkinson's disease			✔	

†Capsule and solution.
‡Transdermal patch.

Table 4. FDA-Approved Indications for the Combination Product Alzheimer's Agents[4]

Indication	Memantine and Donepezil
Moderate-to-severe dementia of the Alzheimer's type	✔ *

*In patients stabilized on 10 mg of donepezil hydrochloride once daily.

IV. Pharmacokinetics

The pharmacokinetic parameters of the Alzheimer's agents are listed in Table 5. Pharmacokinetic properties of the combination products are in line with the properties of their individual components listed below.

Table 5. Pharmacokinetic Parameters of the Alzheimer's Agents[5]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Parasympathomimetic (Cholinergic Agents)					
Donepezil	100	96	Liver (% not reported)	Renal (57) Feces (9 to 15)	70*
Galantamine	Tablet: 90 to 100 Solution: 83 to 90	18	Liver (75)	Renal (95) Feces (5)	7
Rivastigmine	Oral: 36 to 72	40	Liver, extensive Brain, extensive	Renal (>90)	Oral: 1.4 to 1.7 Transdermal: 3.0
Central Nervous System Agents, Miscellaneous					
Memantine	Well absorbed	45	Liver, partial	Renal (48)	60 to 80

* Half-life of 104 hours in subjects over 55 years of age.

V. Drug Interactions

Major drug interactions with the Alzheimer's agents are listed in Table 6.

Table 6. Major Drug Interactions with the Alzheimer's Agents[5]

Generic Name(s)	Interaction	Mechanism
Parasympathomimetic (Cholinergic Agents)		
Donepezil	Azole antifungals	Concomitant use of donepezil, a CYP3A4 substrate that is associated with prolongation of the QT interval, is contraindicated with certain drugs that prolong QT interval and strongly inhibit CYP3A4.

Generic Name(s)	Interaction	Mechanism
Donepezil	Anticholinergic agents	Concomitant use of a cholinesterase inhibitor, such as donepezil, and an anticholinergic agent may result in interference with the efficacy of both agents
Donepezil	QT interval prolonging agents	Concurrent use of donepezil and QT interval prolonging agents may result in increased risk of QT-interval prolongation and torsade de pointes.
Donepezil	CYP3A4 inhibitors and inducers	Concurrent use of donepezil and CYP3A4 inhibitors/inducers may results in increased/decreased donepezil exposure.
Donepezil	Select CYP2D6 inhibitors (clobazam, terbinafine, cinacalcet, peginterferon alfa-2b)	Concurrent use of donepezil and selected CYP2D6 inhibitors may result in increased donepezil exposure.
Donepezil	Seizure threshold lowering agents	Concurrent use of donepezil and seizure threshold lowering agents may result in reduced seizure threshold.
Galantamine	QT interval prolonging agents	Concurrent use of galantamine and QT interval prolonging agents may result in increased risk of QT-interval prolongation and torsade de pointes.
Rivastigmine	Metoclopramide	The concomitant use of metoclopramide and rivastigmine is contraindicated due to potential additive effects of extrapyramidal reactions.
Rivastigmine	Beta blockers	Concomitant use of rivastigmine and beta-blockers, especially cardioselective agents, is not recommended due to additive bradycardic effects resulting in syncope.
Central Nervous System Agents, Miscellaneous		
Memantine	Dextromethorphan, Amantadine, Ketamine	Concurrent use of memantine and selected N-methyl-D-aspartate antagonists may result in increased adverse events of N-methyl-D-aspartate antagonists.
Memantine	Carbonic anhydrase inhibitors	Concurrent use of memantine and carbonic anhydrase inhibitors may result in reduced clearance of memantine due to urinary alkalinization.

VI. Adverse Drug Events

The most common adverse drug events reported with the Alzheimer's agents are listed in Table 7. Adverse drug reactions associated with the combination products are in line with the individual components listed below.[4]

Table 7. Adverse Drug Events (%) Reported with the Single Entity Alzheimer's Agents[4,6-11]

Adverse Events	Parasympathomimetic (Cholinergic Agents)			Central Nervous System Agents, Miscellaneous
	Donepezil	Galantamine	Rivastigmine	Memantine
Cardiovascular				
Angina pectoris	-	-	≥1	-
Atrial fibrillation	≥1	-	≥1	-
Bradycardia	≥1	2	≥1	-
Chest pain	1 to 2	≥1	-	-
Heart failure	-	-	≥1	≥1
Hemorrhage	2	-	-	-
Hypertension	1 to 3	-	3	4
Hypotension	≥1	-	≥1	-
Myocardial infarction	-	-	≥1	-
Palpitation	-	-	≥1	-
Peripheral edema	≥1	-	-	≥2
Postural hypotension	-	-	≥1	-

Adverse Events	Parasympathomimetic (Cholinergic Agents)			Central Nervous System Agents, Miscellaneous
	Donepezil	Galantamine	Rivastigmine	Memantine
Syncope	2	2	3	≥1
Vasodilation	≥1	-	-	-
Central Nervous System				
Abnormal crying	≥1	-	-	-
Abnormal dreams	3	-	-	-
Aggression	≥1	-	3	≥1
Agitation	-	-	≥1	≥2
Anxiety	-	-	4 to 5; 3*	≥2
Aphasia	≥1	-	-	-
Bradykinesia	-	-	≥1	-
Cerebrovascular accident	-	-	-	≥1
Confusion	2	-	1 to 8	6
Convulsion	≥1	-	≥1	-
Delusions	≥1	-	-	-
Depression	2 to 3	7	1 to 6; 4*	≥2
Dizziness	2 to 8	9	6 to 21; 2 to 7*	7
Dyskinesia	-	-	≥1	-
Emotional lability	2	-	-	-
Fatigue	5	5	4 to 9; 2*	2
Gait abnormality	-	-	≥1	≥2
Hallucination	3	-	4	3
Headache	3 to 10	8	4 to 17; 3 to 4*	6
Hostility	3	-	-	-
Hypokinesia	-	-	-	≥1
Insomnia	2 to 14	5	3 to 9; 1 to 4*	≥2
Irritability	≥1	-	-	-
Malaise	-	≥1	5	-
Nervousness	1 to 3	-	-	-
Paranoid reaction	-	-	≥1	-
Paresthesia	≥1	-	≥1	-
Parkinson's disease worsening	-	-	3	-
Parkinsonism	-	-	2	-
Personality disorder	2	-	-	-
Restlessness	≥1	-	≥1	-
Somnolence	2	4	4 to 5	3
Transient ischemic attack	-	-	≥1	≥1
Tremor	≥1	3	4 to 10; ≥1*	-
Vertigo	≥1	-	≥1; 0 to 2*	≥1
Wandering	≥1	-	-	-
Dermatological				
Diaphoresis	≥1	-	4	-
Eczema	3	-	-	-
Pruritus	≥1	-	≥1*	-
Rash	≥1	-	≥1	≥1
Skin ulcer	≥1	-	-	-
Urticaria	≥1	-	-	-
Gastrointestinal				
Abdominal pain	≥1	5	4 to 13; 2 to 4*	-
Anorexia	4 to 8	7 to 9	6 to 17; 3 to	≥2

Adverse Events	Parasympathomimetic (Cholinergic Agents)			Central Nervous System Agents, Miscellaneous
	Donepezil	Galantamine	Rivastigmine	Memantine
			9*	
Bloating	≥1	-	-	-
Constipation	≥1	-	5; ≥1*	5
Diarrhea	5 to 15	6 to 12	7 to 19; 6 to 10*	≥2
Dyspepsia	≥1	5	1 to 9	-
Epigastric pain	≥1	-	-	-
Eructation	-	-	2	-
Fecal incontinence	≥1	-	≥1	-
Flatulence	-	≥1	4	-
Gastritis	-	-	≥1; ≥1*	-
Gastrointestinal bleeding	≥1	-	-	-
Nausea	3 to 19	13 to 24	29 to 47; 7 to 21*	≥2
Toothache	≥1	-	-	-
Vomiting	3 to 9	6 to 13	17 to 31; 6 to 19*	3
Weight decrease	1 to 3	5 to 7	3; 3 to 8*	≥1
Genitourinary				
Cystitis	≥1	-	-	-
Frequent urination	2	-	-	≥1
Glycosuria	≥1	-	-	-
Hematuria	≥1	3	≥1	-
Libido increased	≥1	-	-	-
Urinary incontinence	2	≥1	≥1*	≥2
Urinary tract infection	≥1	8	7; 2*	≥2
Laboratory Test Abnormalities				
Alkaline phosphatase increased	≥1	-	-	≥1
Creatinine increased	3	-	-	-
Hyperlipemia	2	-	-	-
Hypokalemia	-	-	≥1	-
Lactate dehydrogenase increased	≥1	-	-	-
Musculoskeletal				
Arthralgia	-	-	-	≥2
Arthritis	1 to 2	-	≥1	-
Asthenia	≥1	≥1	2 to 6; 2 to 3*	-
Ataxia	≥1	-	≥1	≥1
Back pain	3	-	≥1	3
Bone fracture	≥1	-	-	-
Leg cramps	-	-	≥1	-
Muscle cramps	3 to 8	-	-	-
Myalgia	-	-	≥1	-
Rigors	-	-	≥1	-
Respiratory				
Bronchitis	≥1	-	-	≥2
Cough increased	≥1	-	-	4
Dyspnea	≥1	-	≥1	2
Pharyngitis	≥1	-	-	-
Pneumonia	≥1	-	≥1*	≥1
Respiratory tract infection	-	-	-	≥2
Rhinitis	-	4	4	-
Sore Throat	≥1	-	-	-

Adverse Events	Parasympathomimetic (Cholinergic Agents)			Central Nervous System Agents, Miscellaneous
	Donepezil	Galantamine	Rivastigmine	Memantine
Special Senses				
Blurred vision	≥1	-	-	-
Cataract	≥1	-	≥1	≥1
Conjunctivitis	-	-	-	≥1
Eye irritation	≥1	-	-	-
Tinnitus	-	-	≥1	-
Other				
Accident	7 to 13	-	-	-
Accidental trauma	-	-	1 to 10	-
Allergy	-	-	≥1	-
Anemia	-	3	≥1; ≥1*	≥1
Dehydration	1 to 2	-	1 to 2; ≥1*	-
Ecchymosis	4 to 5	-	-	-
Edema	≥1	-	≥1	-
Epistaxis	-	-	≥1	-
Fall	-	-	≥1*	≥2
Fever	2	≥1	≥1	-
Flu syndrome	≥1	-	3	≥2
Hot flashes	≥1	-	≥1	-
Infection	1 to 11	-	-	-
Inflicted injury	-	-	-	≥2
Influenza	≥1	-	-	-
Pain	3 to 9	-	-	3

✔ Percent not specified.
- Event not reported or incidence <1%.
*Transdermal patch.

VII. Dosing and Administration

The usual dosing regimens for the Alzheimer's agents are listed in Table 8.

Table 8. Usual Dosing Regimens for the Alzheimer's Agents[4,6-11]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Parasympathomimetic (Cholinergic Agents)			
Donepezil	Dementia of the Alzheimer's type (mild to moderate): Tablet and orally disintegrating tablet: initial, 5 mg daily; may increase to 10 mg daily after four to six weeks; maintenance, 5 to 10 mg daily Dementia of the Alzheimer's type (moderate to severe): Tablet: initial, 5 mg daily; may increase to 10 mg daily after four to six weeks; may increase to 23 mg daily after three months on 10 mg daily dose Orally disintegrating tablet: initial, 5 mg daily; may increase to 10 mg daily after four to six weeks	Safety and efficacy not established in the pediatric population.	Orally disintegrating tablet: 5 mg 10 mg Tablet: 5 mg 10 mg 23 mg
Galantamine	Mild-to-moderate dementia of the	Safety and efficacy	Extended release

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Alzheimer's type: Extended-release capsule: initial, 8 mg daily; maintenance, 16 to 24 mg daily Tablet and oral solution: initial, 4 mg twice a day with the morning and evening meals; maintenance: 8 to 12 mg twice a daily	not established in the pediatric population.	capsule: 8 mg 16 mg 24 mg Solution: 4 mg/mL Tablet: 4 mg 8 mg 12 mg
Rivastigmine	Mild-to-moderate dementia of the Alzheimer's type: Capsule: initial, 1.5 mg twice daily with the morning and evening meals; maintenance, 3 to 6 mg twice daily Transdermal patch: initial, 4.6 mg/24 hours; maintenance, 9.5 or 13.3 mg/24 hours Severe dementia of the Alzheimer's type: Transdermal patch: initial, 4.6 mg/24 hours; maintenance, 13.3 mg/24 hours Mild-to-moderate dementia associated with Parkinson's disease: Capsule: initial, 1.5 mg twice daily with the morning and evening meals; maintenance, 3 to 6 mg twice daily Transdermal patch: initial, 4.6 mg/24 hours; maintenance, 9.5 or 13.3 mg/24 hours	Safety and efficacy not established in the pediatric population.	Capsule: 1.5 mg 3 mg 4.5 mg 6 mg Transdermal patch: 4.6 mg/24 hours 9.5 mg/24 hours 13.3 mg/24 hours
Central Nervous System Agents, Miscellaneous			
Memantine	Moderate-to-severe dementia of the Alzheimer's type: Solution and tablet: initial, 5 mg once daily, increase dose by 5 mg at weekly intervals (twice daily dosing); maintenance, 10 mg twice daily Extended release capsule: initial, 7 mg once daily; maintenance, 28 mg once daily	Safety and efficacy not established in the pediatric population.	Extended release capsule: 7 mg 14 mg 21 mg 28 mg Extended release capsule dose pack: 7 mg (7 count)-14 mg (7 count)-21 mg (7 count)-28 mg (7 count) Solution: 10 mg/5 mL Tablet: 5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
			10 mg Tablet dose pack: 5 mg (28 count)-10 mg (21 count)
Combination products			
Memantine and donepezil	Moderate-to-severe dementia of the Alzheimer's type: Extended release capsule: patients stabilized on memantine hydrochloride (10 mg twice daily or 28 mg extended-release once daily) and donepezil hydrochloride 10 mg can be switched to 28 mg-10 mg combination capsule, taken once a day in the evening	Safety and efficacy not established in the pediatric population.	Extended release capsule: 7-10 mg 14-10 mg 21-10 mg 28-10 mg Extended release capsule dose pack: 7-10 mg (7 count)-14-10 mg (7 count)-21-10 mg (7 count)-28-10 mg (7 count)

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the Alzheimer's agents are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Alzheimer's Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Alzheimer's Disease				
Geldmacher et al.[17] (2003) Donepezil 5 mg/day	OS Patients with Alzheimer's disease	N=1,115 Variable duration	Primary: Time to nursing home placement Secondary: Not reported	Primary: Use of donepezil of 5 mg/day or more was associated with significant delays in nursing home placement. A cumulative dose-response relationship was observed between longer-term sustained donepezil use and delay of nursing home placement. When donepezil was taken at effective doses for at least nine to 12 months, conservative estimates of the time gained before nursing home placement were 21.4 months for first-dementia-related nursing home placement and 17.5 months for permanent nursing home placement. Secondary: Not reported
Burns et al.[18] (2007) Donepezil 5 to 10 mg/day	MC, OL Patients ≥50 years of age with mild-to-moderate Alzheimer's disease	N=579 132 weeks	Primary: ADAS-cog, CDR-SB, IDDD, QoLS, and adverse events Secondary: Not reported	Primary: Mean changes in ADAS-cog scores of all patients were improved by approximately two points after six weeks (cumulative week 36) and one point after 12 weeks (cumulative week 42), with improvement compared to the start of OL treatment. At week 24 (cumulative week 54), mean ADAS-cog scores still showed improvement (approximately 0.5 points) compared to those scores reported at the start of OL treatment. From 24 weeks, ADAS-cog scores declined over the remainder of the study. At the end of 132 weeks of OL treatment (162 weeks total follow-up), the change from DB baseline was 15.6 points for all patients. No difference was seen between patients who had previously received placebo in the DB phase vs those receiving donepezil for the entire treatment period. CDR-SB scores improved slightly over the first 12 weeks (up to cumulative week 42) of OL treatment and then slowly declined for the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				remainder of the study period (up to cumulative week 162). Mean IDDD total scores were maintained over the first 24 weeks of OL treatment to within approximately 1 point relative to those at the beginning of this study period. Mean IDDD scores were 138.1 at week 0, 136.9 at week 12, 138.9 at week 24 and 170.8 at week 132 (162 weeks of total follow-up). At the start of the OL extension, QoLS scores were improved compared to baseline, with a mean change of 3.03. The scores remained above the baseline level at weeks six and 12 of OL treatment. At the end of 132 weeks of OL treatment, the decline from the baseline for the DB study was -46.2. Overall, 85% of patients experienced at least one treatment-emergent adverse event. The most common adverse events included diarrhea (12%), nausea (11%), infection (11%) and accidental injury (10%). Nonfatal all-causality and treatment-related serious adverse events were reported for 25 and 7% of patients, respectively. Seventeen patients died during the study or within four weeks after discontinuation of donepezil. The most common causes of death were pneumonia (seven patients) and cerebrovascular accident (two patients). Fifteen deaths were considered unrelated to donepezil. Two deaths, one due to a cerebral hemorrhage diagnosed on day five of treatment and another due to a suspected myocardial infarction on day 55, were considered by the investigators to be possibly related to donepezil. Secondary: Not reported
Hashimoto et al.[19] (2009) Donepezil 5 mg/day	OS, PRO Patients with Alzheimer's disease	N=416 12 weeks	Primary: MMSE Secondary: Not reported	Primary: There were significant changes in mean scores on the MMSE (0.9; P<0.01) from baseline to week 12. There was a significant decrease in the personal strain score at week 12 (P=0.002). There was no significant improvement was in role strain.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant decrease in the time spent supervising Alzheimer's disease patients. Secondary: Not reported
Homma et al.[20] (2009) Donepezil 10 mg/day	OL Japanese patients ≥50 years of age with severe Alzheimer's disease (modified Hachinski Ischemic Score ≤6, FAST ≥6, MMSE score of 1 to 12	N=189 52 weeks	Primary: SIB, and BEHAVE-AD Secondary: Not reported	Primary: The mean change in SIB scores during the OL study showed improvement until week 24, followed by a decline by week 36. For those patients receiving 52 weeks of treatment, the mean change in SIB from baseline (enrollment in OL study) was –6.1. The mean change in SIB declined more rapidly after 24 weeks. For the BEHAVE-AD, little change was observed during the OL study. The change from baseline to week 24 and week 52 was 0.7 and 0.5, respectively. The level of behavioral symptoms in the study population was low. Overall, 177 patients (93.7%) experienced at least one adverse event. Severe adverse events were reported by 15 patients (7.9%) and serious adverse events were reported by 33 patients (17.5%). The most common adverse events were nasopharyngitis, diarrhea, nausea and vomiting. Secondary: Not reported
Courtney et al.[21] (2004) Donepezil 5 to 10 mg/day vs placebo	DB, RCT Patients with Alzheimer's disease	N=565 156 weeks	Primary: MMSE, BADLS, time to entering institution Secondary: Not reported	Primary: Cognition averaged 0.8 MMSE points better (95% CI, 0.5 to 1.2; P<0.0001) and functionality 1.0 BADLS points better (95% CI, 0.5 to 1.6; P<0.0001) with donepezil over the first two years. No significant benefits were seen with donepezil compared to placebo in institutionalization (42 vs 44% at three years; P=0.4) or progression of disability (58 vs 59% at three years; P=0.4). The RR of entering institutional care in the donepezil group compared to placebo was 0.97 (95% CI, 0.72 to 1.30; P=0.8); the RR of progression of disability or entering institutional care was 0.96 (95% CI, 0.74 to 1.24; P=0.7).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Similarly, no significant differences were seen between donepezil and placebo in behavioral and psychological symptoms, caregiver psychopathology, adverse events or deaths, or between 5 and 10 mg donepezil. Secondary: Not reported
Sabbagh et al.[22] (2013) Donepezil 23 or 10 mg/day	Post hoc of a 24-week, DB, RCT Patients with moderate to severe Alzheimer's disease (baseline MMSE 0 to 20)	N= Duration not specified	Primary: Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics Secondary: Not reported	Primary: Donepezil 23 mg/day provided statistically significant incremental cognitive benefits over donepezil 10 mg/day irrespective of baseline functional severity, measured by scores on the ADCS-ADL -severe version (P<0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/day over 10 mg/day were seen in both subgroups when based on MMSE scores of 0 to 9 vs 10 to 20 (P<0.02 and P<0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0 to 16 vs 17 to 20 (P<0.0001 and P>0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/day over 10 mg/day were also observed regardless of age, gender, weight, or pre-study donepezil 10mg/day treatment duration (P<0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. Secondary: Not reported
Tariot et al.[23] (2012) Donepezil 23 mg/day	OL Patients with Alzheimer's disease	N=915 12 months	Primary: Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events;	Primary: In total, 674 patients (74.7%) reported at least one adverse event; in 320 of these patients (47.5%) at least one adverse event was considered to be possibly or probably study drug related. The majority of patients reporting adverse events (81.9%) had adverse events of mild or moderate severity. There were 268 patients (29.7%) who discontinued early, of which 123 (13.6%) were due to adverse events.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			changes in weight, electrocardiogram, vital signs, and laboratory parameters; and discontinuation due to adverse events all at months three, six, nine, and 12 Secondary: Not reported	Patients who had increased donepezil dose from 10 mg/day to 23 mg/day had slightly higher rates of adverse events than patients who were already receiving 23 mg (78.0 and 16.9 vs 72.8 and 14.0%, respectively). The incidence of new adverse events declined rapidly after the first two weeks and remained low throughout the duration of the study. Secondary: Not reported
Winblad et al.[24] (2006) RCT Donepezil 10 mg/day vs placebo OL Donepezil 5 mg daily for 28 days, then 10 mg/day per clinician's judgment	DB, OL, PC Patients 40 to 90 years of age with a probable or possible diagnosis of Alzheimer's disease	N=286 52-week RCT with a 2-year OL extension phase	Primary: GBS Secondary: MMSE, GDS, PDS, NPI	Primary: The GBS total scores indicate that both the continuous-treatment group and delayed-start groups had declined, with the difference between the two groups favoring the continuous-donepezil group, over the three-year period (P=0.056). Secondary: The MMSE declined significantly less in the continuous-treatment group than in the delayed-start group over the course of the study (P=0.004, P=0.057, respectively). GDS declined significantly less over the three-year study period in patients in the continuous-treatment group than in those in the delayed-start group (P=0.0231). There was a trend favoring continuous-donepezil treatment over delayed-start treatment on the PDS, although it was not statistically significant (P=0.091). NPI results showed no significant treatment differences between the groups.
Rogers et al.[25] (1998)	DB, MC, PC, RCT Patients with mild-	N=473 24 weeks	Primary: ADAS-Cog, CIBIC	Primary: Out of 473 patients, 80% of placebo patients, 85% of 5 mg patients and 68% of 10 mg patients completed the study. Those that discontinued due

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Donepezil 5 mg/day vs donepezil 10 mg/day vs placebo	to-moderate Alzheimer's disease		Secondary: Not reported	to adverse effects were 7, 6, and 16% in the placebo, 5 and 10 mg groups, respectively. Primary outcome measure was mean change in scores from baseline to endpoint in the ADAS-Cog. Both donepezil doses were statistically better than placebo (P<0.0001). Global functioning as measured by the CIBIC plus were statistically better for both donepezil groups compared to placebo at endpoint (P<0.005). Donepezil 5 and 10 mg treatment showed no statistical difference in improvements. Secondary: Not reported
Winblad et al.[26] (2006) Donepezil 10 mg/day vs placebo	DB, PC, PG Patients ≥50 years of age with severe Alzheimer's disease (MMSE score of 1 to 10 and a FAST rating of stage 5 to 7c)	N=248 6 months	Primary: SIB Secondary: MMSE, NPI, and CGI-I	Primary: At six months, patients assigned donepezil had significantly better mean change from baseline scores than those taking placebo for SIB (P<0.05). Secondary: CGI-I scores and the mean change from screening scores on the MMSE at six- month follow-up favored donepezil treatment over placebo (all P<0.05). There was no significant difference between treatment groups on the NPI for the modified intention-to-treat population (P=0.43).
Black et al.[27] (2007) Donepezil 10 mg/day vs placebo	DB, MC, PC, RCT Patients ≥50 years of age with severe Alzheimer's disease (MMSE score of 1 to 12, modified Hachinski Ischemic score ≤6, and FAST score ≥6)	N=343 24 weeks	Primary: SIB and CIBIC-Plus Secondary: ADCS-ADL-sev, NPI, MMSE, CBQ, RUSP	Primary: Donepezil was more efficacious when compared to placebo on SIB score change from baseline to endpoint, as well as on CIBIC-Plus score (P<0.05 for all results). Secondary: On the ADCS-ADL-sev, both the donepezil group and the placebo group declined from baseline, and the treatment difference was NS (P=0.3574). On the NPI, donepezil was not significantly different from placebo (P=0.4612).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The donepezil group showed significant improvement from screening to endpoint on the MMSE compared to placebo (P=0.0267). The CBQ stress measure showed no significant change from baseline for either group. The RUSP scores also had low average responses with little movement from baseline and no significant differences.
Homma et al.[28] (2008) Donepezil 5 to 10 mg/day vs placebo	DB, MC, PC, RCT Japanese patients ≥50 years of age with severe Alzheimer's disease (modified Hachinski Ischemic Score ≤6, FAST ≥6, MMSE score of 1 to 12 and diagnosis confirmed by neuroimaging)	N=302 24 weeks	Primary: SIB and CIBIC-Plus Secondary: ADCS-ADL-sev and BEHAVE-AD	Primary: Donepezil 5 and 10 mg/day were more effective than placebo on the SIB. At week 24, patients in the donepezil 5 mg/day group had a significant change from baseline of 2.5 points and those in the donepezil 10 mg/day group had a significant change from baseline of 4.7 points. Patients in the placebo group showed significant worsening (–4.2 points) during the course of the study (P<0.001 vs placebo). For the CIBIC-Plus, the analysis was performed on the seven categories of change as well as the three collapsed categories of improved, no change and worsened. In the seven-category analysis, the distribution of CIBIC-Plus scores in the donepezil 10 mg/day group was better than placebo (P=0.003); however, there was no difference with 5 mg/day (P=0.151). In the collapsed-category analysis, the distribution of CIBIC-Plus scores in the donepezil 10 mg/day group was better than placebo (P=0.001); however, there was no difference with 5 mg/day (P=0.129). Secondary: For the ADCS-ADL-sev, there was no significant differences between donepezil and placebo (placebo group, –1.1 points; donepezil 5 mg/day group, –0.1 points; donepezil 10 mg/day group, –0.3 points). For the BEHAVE-AD, there was no significant differences between donepezil and placebo (placebo group, –0.5; donepezil 5 mg/day group, –0.5; donepezil 10 mg/ day group, –0.1). Treatment-emergent adverse events were reported by 73.3% of placebo patients, 78.2% of donepezil 5 mg/day patients and 83.3% of donepezil 10

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mg/day patients. There was no significant difference in adverse events between the donepezil groups and the placebo group. The most common adverse events reported are consistent with the known cholinergic side effects of donepezil. Serious adverse events were reported by 15 placebo patients (14.3%), 12 donepezil 5 mg/day patients (11.9%) and 10 donepezil 10 mg/day patients (10.4%). Five patients died during the treatment period. The causes of death were acute pneumonia (placebo group), acute myocardial infarction (donepezil 5 mg/day group), suspected stomach cancer (donepezil 5 mg/day group; the patient died 80 days after discontinuation), vomit-induced tracheal occlusion (donepezil 10 mg/day group; the patient died seven days after completion) and arrhythmia (donepezil 10 mg/day group).
Birks et al.[29] (2006) Donepezil 5 to 10 mg/day vs placebo	MA Patients with Alzheimer's disease	N=5,796 (24 trials) 12 to 60 weeks	Primary: ADAS-Cog, MMSE, CIBIC-Plus, ADL, withdrawals and adverse events Secondary: Not reported	Primary: A significant difference was seen on the ADAS-Cog scale for patients treated with donepezil 5 mg at 24 weeks (WMD, -2.02 points; 95% CI, -2.77 to -1.26; P<0.00001) and 10 mg at 24 weeks (WMD,–2.81 points; 95% CI, –3.55 to –2.06; P<0.00001). A significant difference was seen on the MMSE for patients treated with donepezil 10 mg/day as compared to placebo at 52 weeks (WMD, 1.84 points; 95% CI, 0.53 to 3.15; P=0.006). Global Clinical State, CIBIC-Plus scores showed significant benefit in patients treated with donepezil 5 and 10 mg/day (OR, 2.38; 95% CI, 1.78 to 3.19; P<0.00001 and OR, 1.82; 95% CI, 1.42 to 2.35; P<0.00001). Improvements were seen in ADL scores for patients in the donepezil group over those in the placebo group (P<0.01 for all scales used). Significantly more patients treated with donepezil 10 mg/day withdrew from treatment (24 vs 20%; P=0.003); however, there was no difference in withdrawal rates between the 5 mg/day and placebo group (P=0.56). Adverse events that occurred significantly more frequently in both the 5 and 10 mg/day treatment groups as compared to placebo are: anorexia, diarrhea, and muscle cramps.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Wallin et al.[30] (2007) Donepezil 5 to 10 mg/day vs historical data	MC, PRO Patients ≥40 years of age with probable Alzheimer's disease	N=435 3 years	Primary: MMSE, ADAS-Cog, CIBIC, IADL Secondary: Not reported	Primary: For the MMSE, patients had a mean score of 22.0 at baseline and 19.1 at 36 months. After 36 months of donepezil treatment, the mean decline was 3.8 points (95% CI, 3.0 to 4.7). For ADAS-Cog, patients had a mean score of 20.7 at baseline and 26.1 at 36 months. After 36 months, the mean increase was 8.2 points (95% CI, 6.4 to 10.0). A modeling equation predicts an increase in ADAS-Cog to be 4 to 9 points in 12 months without treatment. Scores for the treatment group were significantly better than predicted scores for non-treatment (95% CI, 14.5 to 16.6). For CIBIC, at two months, 34% of patients were considered improved, 59% unchanged and 7% were worse. At six months, 28% of patients were considered improved, 46% unchanged and 26% were worse. At 12 months, 20% of patients were considered improved, 29% unchanged and 51% were worse. At 36 months, 30% of patients were considered improved or unchanged. The IADL change from baseline at six months was 1.01, at 12 months 2.19, and at 36 months 6.18. Secondary: Not reported
Farlow et al.[31] (2010) Donepezil 10 mg/day vs donepezil 23 mg/day	DB, MC, RCT Patients 45 to 90 years of age with moderate-to-severe Alzheimer's disease who took donepezil 10 mg/day ≥12 weeks	N=1,467 24 weeks	Primary: Efficacy as measured by SIB-cognition and CIBIC-global function rating; tolerability Secondary: Not reported	Primary: After 24 weeks, the change in SIB-cognition score was significantly greater with donepezil 23 mg/day compared to donepezil 10 mg/day (2.6 vs 0.4, respectively; P<0.001). There was no significant different in CIBIC score with donepezil 23 mg/day compared to donepezil 10 mg/day (4.23 vs 4.29, respectively). In a post-hoc analysis, the least square mean changes in SIB score and CIBIC treatment effect at end point were greater with donepezil 23 mg/day compared to donepezil 10 mg/day in patients with more advanced

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Alzheimer's disease compared to less impaired patients (SIB, 1.6 vs -1.5, respectively; P<0.001; CIBIC, 4.31 vs 4.42; P=0.028). Treatment emergent adverse events were reported in 73.7% of patients who received donepezil 23 mg/day and in 63.7% of patients who received donepezil 10 mg/day. Adverse events were reported as follows with donepezil 23 mg/day: mild (30.8%), moderate (34.5%), and severe (8.4%). The most common treatment emergent adverse events were nausea (6.1%), vomiting (5%) and diarrhea (3.2%). Severe treatment emergent adverse events that were reported included nausea (0.9%), dizziness (0.7%) and vomiting (0.6%). Adverse events were reported as follows with donepezil 10 mg/day: mild (31.2%), moderate (25.3%), and severe (7.2%). The most common treatment emergent adverse events were nausea (1.9%), vomiting (0.8%) and diarrhea (1.5%). Severe treatment emergent adverse events that were reported included nausea (0.2%) and dizziness (0.2%). Secondary: Not reported
Ferris et al.[32] (2011) Donepezil 10 mg/day vs donepezil 23 mg/day	DB, MC, RCT (post-hoc analysis) Patients 45 to 90 years of age with moderate-to-severe Alzheimer's disease who took donepezil 10 mg/day ≥12 weeks	N=1,467 24 weeks	Primary: SIB-Language scale and 21-item SIB-derived language scale Secondary: Correlation of SIB-Language scale and SIB-derived language scale with ADCS-ADL-sev, CIBIC-plus/CIBIC-plus, and MMSE	Primary: At week 24, there was an improvement in language noted with donepezil 23 mg/day compared to a decline in language function with donepezil 10 mg/day (SIB-Language scale treatment difference, 0.8; P=0.0013, SIB-derived language scale treatment difference, 0.8; P=0.0009). Secondary: At week 24, SIB-Language scale and SIB-derived language scale scores were moderately correlated with scores on the ADCS-ADL-sev and CIBIC-plus. Results were similar in both moderate (MMSE, 17 to 20) and severe (MMSE, 0 to 16) Alzheimer's disease patients.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Farlow et al.[33] (2011) Donepezil 10 mg/day vs donepezil 23 mg/day	DB, MC, RCT (post-hoc analysis) Patients 45 to 90 years of age with moderate-to-severe Alzheimer's disease who took donepezil 10 mg/day ≥12 weeks	N=1,434 24 weeks	Primary: Safety and tolerability Secondary: Not reported	Primary: Of the 963 patients receiving donepezil 23 mg/day and 471 patients receiving donepezil 10 mg/day, a total of 71.1 and 84.7% completed the study, respectively. The most common adverse events causing early discontinuation were higher in the donepezil 23 mg/day group compared to the donepezil 10 mg/day group (18.6 vs 7.9%, respectively). Adverse events that contributed the most to the discontinuations were vomiting (2.9 vs 0.4%, respectively), nausea (1.9 vs 0.4%, respectively), diarrhea (1.7 vs 0.4%, respectively), and dizziness (1.1 and 0%, respectively). The most common adverse events with donepezil 23 mg/day compared to donepezil 10 mg/day were nausea (11.8 vs 3.4%, respectively), vomiting (9.2 vs 2.5%, respectively) and diarrhea (8.3 vs 5.3%, respectively). Serious adverse events occurred in 8.3% of patients receiving donepezil 23 mg/day and in 9.6% of patients receiving donepezil 10 mg/day. These included urinary tract infection (0.6 vs 0.4%, respectively), fall (0.6 vs 0.4%, respectively), pneumonia (0.3 vs 0.6%, respectively), syncope (0.2 vs 1.1%, respectively), aggression (0.2 vs 0.8%, respectively), and confusional state (0.1 vs 0.6%, respectively). Secondary: Not reported
Doody et al.[34] (2012) Donepezil 23 mg/day vs donepezil 10 mg/day Patients were	DB, MC Patients with moderate-to-severe Alzheimer's disease	N=not specified 24 weeks	Primary: Efficacy and safety Secondary: Not reported	Primary: At week 24, donepezil 23 mg/day provided significant cognitive benefits over 10 mg/day (P<0.01) on the SIB, with or without concomitant memantine. The higher dose showed no benefit on the global function, MMSE or ADL measures in either memantine subgroup. Rates of treatment-emergent adverse events were higher for donepezil 23 mg/day with memantine (80.7%) than 23 mg/day without memantine (69.7%) or 10 mg/day with/without memantine (66.7/62.0%); across all treatment groups, most events were mild/moderate in severity. Individual

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
allowed to also take memantine.				rates of serious adverse events were low (<1.0%), regardless of concomitant memantine use. Secondary: Not reported
Raskind et al.[35] (2004) Galantamine 24 mg/day	OL Patients with mild-to-moderate Alzheimer's disease	N=194 36 months	Primary: ADAS-Cog, adverse events Secondary: Not reported	Primary: Patients treated continuously with galantamine for 36 months increased a mean of 10.2±0.9 points on the ADAS-Cog. This was a substantially smaller cognitive decline (approximately 50%) than that predicted for the placebo group. Patients discontinuing galantamine therapy before 36 months had declined at a similar rate before discontinuation as those completing 36 months of treatment. Almost 80% of patients who received galantamine for 36 months seemed to demonstrate cognitive benefits compared to those predicted for untreated patients. Secondary: Not reported
Rockwood et al.[36] (2008) Galantamine 24 mg/day	MC, OL Patients with Alzheimer's disease who had received galantamine treatment for up to 36 months	N=240 Up to 48 months	Primary: ADAS-Cog, DAD, adverse events Secondary: Not reported	Primary: Mean ADAS-Cog worsened from 22.6±8.6 at baseline to 31.3±13.1 at 48 months. DAD worsened from 73.4±18.1 at baseline to 36.1±29.0 at 48 months. Fifty one patients withdrew from the study. Secondary: Not reported
Wallin et al.[37] (2011) Galantamine 24 mg/day	MC, OL, PRO Patients with Alzheimer's disease and no previous cholinesterase	N=280 36 months	Primary: MMSE, ADAS-cog, IADL, CIBIC Secondary: Subgroup analysis	Primary: From baseline to 36 months, MMSE decreased from 23.3 to 21.74. The MMSE score was significantly better at two months (P<0.001) and at six months (P=0.006) compared to baseline, and was stable at 12 months (P=0.616) compared to baseline. The total mean decline in MMSE score from baseline after three years of treatment was 2.6

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	inhibitor therapy		by K-means cluster analysis	From baseline to 36 months, ADAS-cog increased from 16.85 to 19.39. The total change in ADAS-cog score after three years of treatment was 5.6 points above baseline values. The ADAS-cog scores at six months were not different from baseline (P=0.248), but deteriorated after that. Mean IADL scores demonstrated deteriorated at all time points compared to baseline (12.76 to 17.13). According to CIBIC scores at two months, 93% of patients remaining in the study were "improved or unchanged", at months six, 12, 24, and 36; 81, 69, 50, and 41% of the patients were "improved or unchanged", respectively. Secondary: Cluster analysis identified two response clusters. Cluster 1 included patients with low ability in ADAS-cog and IADL scores at baseline. These patients were older and less educated, but responded better at six months compared to cluster two patients. Cluster 2 patients included better ADAS-cog and IADL scores at baseline. Cluster 2 patients had a higher frequency of the APOE ε4 allele.
Brodaty et al.[38] (2006) Galantamine 2 to 50 mg/day	OL, OS, PRO Patients diagnosed with mild-to-moderately severe dementia	N=345 ITT N= 229 PP 6 month follow-up	Primary: MMSE, ADAS-Cog, CIBIC-Plus, IADL Secondary: Not reported	Primary: For the MMSE 65% of PP patients had an increased score at the three-month assessment as compared to baseline with an overall 92% response rate. 70% of PP patients had an increased score at the six-month assessment as compared to baseline with an overall 91% response rate. 44% of ITT patients had an increased score at the six-month assessment as compared to baseline (P values were not reported). For ADAS-Cog at 6 months, 86% of the PP patients and 33% of the ITT patients had a decrease in ADAS-Cog score. P value was not reported. For CIBIC-Plus at three months, 91% of PP patients were considered responders by their physicians; 28% were unchanged, 38% were minimally improved, 22% were much improved, 4% were very much

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				improved (P values not reported). For CIBIC-Plus at six months, 86% of PP patients were considered responders by their physicians; 20% were unchanged, 26% were minimally improved, 32% were much improved, 7% were very much improved. In the ITT patients, 54 % were classified as responders at six months (P values not reported). Most PP patients had no change in IADL scores at three and six months (P value not reported). Most PP patients had no change in behavior scores at three and six months (P value not reported). Secondary: Not reported
Richarz et al.[39] (2014) Galantamine 8 to 24 mg/day	OL, PRO Patients ≥45 years of age with mild to moderate Alzheimer's disease	N=75 (36 months) N=159 (24 months) N=269 (6 months) Up to 36 months	Primary: ADAS-cog/11 Secondary: Bayer-ADL, NPI, CGI-C, adverse events	Primary: Mean ADAS-cog score improved significantly during the first six months, with improvement maintained until month 12. During follow-up, mean ADAS-cog score returned to baseline levels between months 18 and 24; after 36 months, it had deteriorated (increased) by 2.87 ± 11.07 points. Secondary: Mean NPI score improved significantly in the first 12 months and worsened thereafter. In the 36-month sample, patient self-rated Bayer ADL scores remained stable until 24 months of treatment; then, a significant deterioration had occurred; a significant deterioration from baseline in caregivers' Bayer ADL scores occurred after month 12. After six months of treatment, 84% of the patients who completed the six-month observation period were considered to be improved or unchanged compared with baseline on the CGI-C. In the 36-month sample, the corresponding value was 54%. In the 36-month sample, 54 patients (72%) reported at least one treatment-emergent adverse event throughout the treatment period, with most events occurring during the first two years of treatment.
Cummings et al.[40] (2004)	DB, PC, RCT Patients with mild-	N=978 21 weeks	Primary: NPI, caregiver distress related to	Primary: NPI scores worsened with placebo, whereas patients treated with 16 or 24 mg/day of galantamine had no change in NPI scores.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Galantamine 8 to 24 mg/day vs placebo	moderate Alzheimer's disease		patients' behavior Secondary: Not reported	Behavioral improvement in patients symptomatic at baseline ranged from 29 to 48%. Changes were evident in patients receiving 16 and 24 mg/day of galantamine. High-dose galantamine was associated with a significant reduction in caregiver distress. Secondary: Not reported
Scarpini et al.[41] (2011) <u>Phase 1</u> Galantamine 8 to 16 mg/day <u>Phase 2</u> Galantamine 16 mg/day vs placebo	<u>Phase 1</u> MC, OL <u>Phase 2</u> DB, MC, RCT Mild to moderate Alzheimer's disease in patients ≥50 years of age (MMSE, 11 to 24)	N=393 36 months	Primary: ADAS-cog/11 deterioration ≥4 points Secondary: CIBIC-plus, adverse events	<u>Phase1</u> Primary: Cognitive functions improved significantly on the ADAS-cog/11 scale with galantamine treatment at month seven relative to baseline (from 24.1 to 22.9, difference, -1.2; 95% CI, -2.3 to -0.1; P<0.01). Scores were similar to baseline values at the end of the OL phase at month 12 (mean score at baseline, 24.1; mean score at month 12, 24.7; 95% CI, -0.5 to 1.7, P=0.16). Secondary: CIBIC-plus score improved in 34.3%, was unchanged in 30.9%, and worsened in 34.9% of patients when compared to baseline. A total of 50.4% of patients reported adverse events, of which the most common was gastrointestinal disorders (21.3%), nervous system disorders (9.8%), and psychiatric disorders (19.7%). Serious adverse events were reported in 12.2%. <u>Phase 2</u> Primary: Patients receiving placebo were more likely to discontinue therapy prematurely compared to galantamine for any reason (HR, 1.76; 95% CI, 1.10 to 2.81; P=0.02) or lack of efficacy (HR, 1.80; 95% CI, 1.02 to 3.18; P=0.04). No significant difference was observed by ADAS-cog >4 between the groups (HR, 1.66; 95% CI, 0.78 to 3.54; P=0.19). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no significant differences between the treatment groups concerning mean values of the CIBIC-plus scale. A total of 34.1% of patients receiving galantamine and 27% of patients receiving placebo experienced adverse events. The most common adverse events were nervous system disorders (6.6%) and psychiatric disorders (5.3%). Serious adverse events were reported in 14.5% of galantamine-treated patients compared to 6.3% of patients in the placebo group.
Kavanagh et al.[42] (2011) Galantamine 16 to 24 mg/day vs placebo	OL, RCT Patients with mild-to-moderate Alzheimer's disease	N=3,523 (5 trials) 5 to 6 months	Primary: Changes from baseline in ADAS-Cog 11 at trial endpoint (two to five months after reaching maintenance doses) Secondary: Not reported	Primary: The proportion of patients who met criteria for "improved", "stable", or "non-rapid decline" at trial endpoint were 45.8, 59.5, and 87.6%, respectively with galantamine compared to 27.2, 37.1, and 67.7%, respectively with placebo. Changes in ADAS-Cog 11 scores with galantamine were -4.9, -4.7, and -2.9 points, respectively, for "improved", "stable" and "non-rapid decline" compared to -3.6, -3.4, and -1.2, respectively with placebo. Patients receiving galantamine who were reported to be "improved" or "stable" experienced improvement in ADAS-Cog 11 scores until 18 months after starting treatment, and attenuated deterioration thereafter. For galantamine-treated patients exhibiting "non-rapid decline", mean ADAS-Cog 11 score returned to baseline after approximately 12 months. Secondary: Not reported
Burns et al.[43] (2009) Galantamine 24 mg/day vs placebo	DB, MC, PC, RCT Patients 40 to 95 years of age with severe dementia of the Alzheimer type or probable Alzheimer's disease (MMSE, 5 to 12 points)	N=407 6 months	Primary: SIB, MDS-ADL, and adverse events Secondary: Not reported	Primary: In the completer analysis, the mean total SIB score of the galantamine group increased to 69.1 points at week 26. The mean SIB score in the placebo group decreased to 66.9. The between group least squares mean difference was 4.36 (95% CI, 1.3 to 7.5; P=0.006). In the completer analysis, the mean total MDS-ADL self-performance score worsened in both groups: scores at week 26 were 13.0 points in the galantamine group and 13.6 points in the placebo group. The between-group least squares mean difference was –0.41 points (95% CI, –1.3 to 0.5; P=0.383).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				In the LOCF analysis, the mean SIB score in the galantamine group increased to 69.3 points. In the placebo group, the mean SIB score decreased by 3.2 points. The between-group least squares mean difference was 5.02 points (95% CI, 2.17 to 7.86; P=0.0006). In the LOCF analysis, the mean total seven-item MDS-ADL self-performance score in the galantamine group worsened at endpoint to 13.1 points and to 14.0 points in the placebo group. Changes from baseline in the seven-item MDS-ADL self-performance score were 1.3 points and 1.7 points, respectively. The between-group least squares mean difference was –0.50 (95% CI, –1.39 to 0.39; P=0.394). Significant between-group differences were seen in the galantamine group for memory (P=0.006), praxis (P=0.010), and visuospatial ability (P=0.002). There were no significant differences in language (P=0.064) or attention (P=0.075). Scores for all eleven-item MDS-ADL self-performance subscales worsened in both treatment arms. The deterioration in the subscale score for locomotion on unit was significantly less in the galantamine group (P=0.021). During the study, 88% of patients who received galantamine and 89% who received placebo had at least one adverse event. The most common adverse events in both treatment groups were urinary tract infections, vomiting, diarrhea, nausea, and falls. Secondary: Not reported
Raskind et al.[44] (2004) Galantamine 24 mg/day vs	DB, PC, RCT Patients with mild-moderate Alzheimer's disease	N=194 36 months	Primary: ADAS-Cog, adverse events Secondary: Not reported	Primary: Patients treated continuously with galantamine for 36 months increased a mean of 10.2±0.9 points on the ADAS-Cog. This was a substantially smaller cognitive decline (approximately 50%) than that predicted for the placebo group. Patients discontinuing galantamine therapy before 36 months had declined

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				at a similar rate before discontinuation as those completing 36 months of treatment. Almost 80% of patients who received galantamine for 36 months seemed to demonstrate cognitive benefits compared to those predicted for untreated patients. Secondary: Not reported
Wilcock et al.[45] (2000) Galantamine 24 mg/day vs galantamine 32 mg/day vs placebo	DB Patients with mild-moderate Alzheimer's disease	N=653 6 months	Primary: ADAS-Cog, adverse events Secondary: Not reported	Primary: Both doses of galantamine were statistically better than placebo in the mean change in ADAS-Cog from baseline to endpoint (P<0.0001). Patients taking galantamine 24 mg had a -0.5 point mean change on the ADAS-Cog scale, while the 32 mg group had a -0.8 change. This compares to a +2.4 change for the placebo group. Statistical comparisons between the 24 mg group and the 32 mg group were not conducted. Discontinuations due to adverse events were 9, 14 and 22% in the placebo, 24 and 32 mg dose groups, respectively. Secondary: Not reported
Dunbar et al.[46] (2006) Galantamine IR 8 to 16 or 24 mg/day vs galantamine ER 8 to 16 or 24 mg/day vs	Post hoc analysis, DB, MC, PC, RCT Patients with mild-to-moderate probable Alzheimer's disease	N=965 7 months	Primary: Nausea and vomiting Secondary: Not reported	Primary: Nausea reports were as follows: 16.9% of the galantamine ER group, 13.8% of galantamine IR group and 5.0% of placebo group. Vomiting reports were as follows: 6.6% of the galantamine ER groups, 8.6% of the galantamine IR group and 2.2% of the placebo group. During dose titration, the area under the curve of daily percentage of patients reporting nausea or vomiting was significantly higher in the galantamine IR group compared to placebo (320.9 vs 102.9; P=0.01) but for galantamine ER vs placebo and galantamine ER vs galantamine IR no significant differences were seen ([173.5 vs 102.9; P=NS], [320.9 vs 173.5; P=NS]).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				The mean daily nausea rate and the mean daily vomiting rate for galantamine ER and galantamine IR were not significantly different but when both were compared to placebo, significance was seen (P<0.05). The galantamine IR had a greater mean percentage of days with nausea compared to galantamine ER (38 vs 18.4%; P=0.014) while there was no significance for both galantamine groups compared to placebo. Secondary: Not reported
Brodaty et al.[47] (2005) Galantamine IR 8 to 16 or 24 mg/day vs galantamine ER 8 to 16 or 24 mg/day vs placebo	AC, DB, MC, PC, PG, RCT Patients with mild-to-moderate probable Alzheimer's disease	N=971 6 months	Primary: ADAS-cog/11, CIBIC-Plus Secondary: ADCS-ADL, NPI, ADAS-cog/13, nonmemory ADAS-cog/ memory, ADAS-Cog	Primary: Compared to placebo, galantamine was significantly more effective with improvement from baseline in ADAS-cog/11 scores (mean change, 1.3 and -1.4, respectively; P<0.001; 95% CI, –3.74 to –1.68; LOCF mean change, 1.2 and -1.3, respectively; P<0.001; 95% CI, –3.34 to –1.49). Galantamine also showed similar results when compared to placebo (OC mean change, –1.8 and 1.3, respectively; P<0.001; 95% CI, –4.17 to –2.08; LOCF mean change, –1.6 and 1.2, respectively; P<0.01; 95% CI, –3.70 to –1.86). Secondary: ADCS-ADL scores were significantly improved in the galantamine group vs placebo (P=0.003; 95% CI, 0.85 to 4.03; LOCF; P<0.001; 95% CI, 1.09 to 3.91). In galantamine groups vs placebo, NPI scores were not statistically significant but instead numerically significant (P=0.451; 95% CI, –2.77 to 1.23; LOCF; P=0.941; 95% CI, –1.85 to 1.82), (OC; P<0.205; 95% CI, –3.31 to 0.71; LOCF; P<0.102; 95% CI, –3.42 to 0.23). Statistical significance was found in cognition improvement from baseline for both galantamine groups compared to placebo based on ADAS-cog/13, non-memory ADAS-Cog, and memory ADAS-Cog scores.
Loy et al.[48] (2006)	MA (10 trials) Patients diagnosed	N=6,805 12 weeks-2	Primary: CIBIC-plus, ADAS-Cog,	Primary: Statistically significant difference was seen on the global rating scales for patients treated with galantamine, at all durations and all doses but 8

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Galantamine 8 to 36 mg/day vs placebo	with mild cognitive impairment or Alzheimer's disease	years	ADCS-ADL, DAD, NPI Secondary: Not reported	mg/day (P values varied). Statistically significant difference was seen on the ADAS-Cog scale for patients treated with galantamine at all doses, with greater effect at six months than three months (P values varied). When reported, ADCS-ADL, DAD, and NPI scores for patients treated with galantamine were significantly improved over those in the placebo group (P values not reported). Secondary: Not reported
Herrmann et al.[49] (2011) Memantine 20 mg/day	OL Patients with moderate-to-severe Alzheimer's disease	N=31 3 months	Primary NPI-NH change in agitation and aggression subscale, CGI-C scale, caregiver impact, and effect on nursing burden measured by M-NCAS Secondary: Caregiver distress subscale of the NPI-NH, changes in psychotropic medications	Primary: There was a significant decrease in the NPI-NH agitation/aggression subscale score with memantine (P=0.014). According to the CGI-C scores, 48% of patients were improved (much improved or minimally improved). A total of 52% of patients did not benefit from treatment (no change, minimally worse or much worse). There was a significant decrease in the M-NCAS total score (P=0.005), as well as decreases on the attitude (P=0.009) and strain (P=0.013) subscales with memantine therapy. Secondary: The NPI-NH subscale score decreased significantly with memantine therapy (P=0.009). Psychotropic medications were available in 28 patients, with 64.3% receiving at least one dose during the study. Lorazepam was the most commonly used psychotropic (P=0.046). Overall, seven patients decreased psychotropic medication use during the study, while three increased usage; Most remained the same for psychotropic usage.
Bakchine et al.[50] (2007) Memantine 20	DB, PC Patients with mild-to-moderate	N=470 24 weeks	Primary: ADAS-COG and CIBIC-plus	Primary: Patients in the memantine group showed a statistically significant improvement relative to placebo in ADAS-COG and CIBIC-plus at weeks 12 and 18. There was no significant difference between the groups at week

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs placebo	Alzheimer's disease		Secondary: Not reported	24. Secondary: Not reported
Reisberg et al.[51] (2003) Memantine 20 mg/day vs placebo	DB, PG Patients with moderate-to-severe Alzheimer's disease	N=252 28 weeks	Primary: CIBIC-Plus and ADCS-ADL Secondary: SIB	Primary: A significantly greater effect was observed in the memantine group compared to the placebo group on the ADCS-ADL (P=0.03). There was a significant difference in favor of memantine at week 28 on the CIBIC-Plus using the observed-cases analysis (mean score, 4.7 placebo vs 4.4, memantine; P=0.03), and a numerical difference at study endpoint in favor of memantine using the last-observed-carried-forward analysis (mean score, 4.8 placebo vs 4.5 memantine; P=0.06). Secondary: Memantine patients showed significantly less cognitive decline on the SIB total score compared to placebo-treated patients over the 28-week study period (P=0.002).
Winblad et al.[52] (1999) Memantine 10 mg/day vs placebo	DB, PC Patients in Latvia with severe dementia, either Alzheimer's disease or vascular dementia	N=166 12 weeks	Primary: CGI-C and BGP Secondary: Safety	Primary: Significantly greater improvement was observed in the memantine group compared to the placebo group on the BGP and the CGI-C (P<0.016 and P<0.001, respectively). Separate analyses of the Alzheimer's disease population alone also yielded statistically significant results in favor of patients receiving memantine, by either the last-observed-carried-forward analysis or the observed-cases analysis on both outcome measures. At study endpoint, memantine patients showed significantly greater functional improvement compared to patients who received placebo, at study endpoint (P=0.012). Secondary: No significant differences in safety were found between the groups.
Winblad et al.[53] (2007)	MA	N=1,826 in subgroup with	Primary: CIBIC-Plus, SIB,	Primary: There was a statistically significant advantage for the memantine group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Memantine 20 mg/day vs placebo	Four studies: memantine as monotherapy, 2 studies of memantine vs placebo in patients already taking an acetylcholinesterase inhibitor; patients diagnosed with moderate-to-severe Alzheimer's disease	moderate-to-severe Alzheimer's disease 24 to 28 weeks	ADAS-Cog, ADCS-ADL, NPI Secondary: Not reported	over the placebo group in all 4 efficacy domains: CIBIC-Plus or global status (P<0.001), SIB or ADAS-Cog status (P<0.001), ADCS-ADL (P<0.001) and NPI (P=0.03). Secondary: Not reported
Wilkinson et al.[54] (2007) Memantine 20 mg/day vs placebo	MA Patients diagnosed with moderate-to-severe Alzheimer's disease	N=1,826 24 to 28 weeks	Primary: ADAS-Cog, SIB, CIBIC-Pus, ADCS-ADL Secondary: Not reported	Primary: Significantly more patients in the placebo group (21%) had marked clinical worsening, as demonstrated by deteriorating scores, than in the memantine group (11%; P<0.001). Significantly more patients in the placebo group (28%) compared to the memantine group (18%) had documentation of worsening in any outcome measure (P<0.001). Secondary: Not reported
McShane et al.[55] (2006) Memantine 10 to 30 mg/day vs placebo	MA (12 trials) Patients diagnosed with mild-to-moderate, moderate-to-severe and mild-to-moderate vascular dementia	N=3,731 (15 trials) Variable duration	Primary: CIBIC-Plus, SIB, ADAS-Cog, ADCS-ADL, NPI Secondary: Not reported	Primary: Significant improvement at six months was seen for patients with mild-to-moderate dementia treated with memantine on the ADAS-Cog scale (P=0.03); however, there was no significant difference seen for behavior and ADL scales. Significant improvement at six months was seen for patients with moderate-to-severe dementia treated with memantine for the following scales: CIBIC-Plus (P<0.00001), SIB (P<0.00001), ADCS-ADL (P=0.003) and NPI (P=0.004). Patients with vascular dementia treated with memantine had significant improvement in cognition scores and behavior scores but no significant change in global rating scales (ADAS-Cog; P=0.0002, NPI; P=0.03).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Grossberg et al.[56] (2013) Memantine extended-release 28 mg once daily vs placebo	DB, MC, RCT Outpatients with Alzheimer's disease (MMSE scores of three to 14) who were receiving stable, ongoing cholinesterase inhibitor treatment	N=677 24 weeks	Primary: Baseline-to-endpoint score change on the SIB and the endpoint score on the CIBIC-Plus Secondary: Baseline-to-endpoint score change on the ADCS-ADL19; additional parameters included the baseline-to-endpoint score changes on the NPI and verbal fluency test	Primary: At 24 weeks memantine-treated patients significantly outperformed placebo-treated patients on the SIB (2.6; 95% CI, 1.0 to 4.2; P=0.001) and CIBIC-Plus (P=0.008). Secondary: At 24 weeks memantine-treated patients significantly outperformed placebo-treated patients on the NPI (P=0.005), and verbal fluency test (P=0.004); the effect did not achieve significance on ADCS-ADL19 (P=0.177). Adverse events with a frequency of >5.0 % that were more prevalent in the memantine group were headache (5.6 vs 5.1 %) and diarrhea (5.0 vs 3.9 %).
Grossberg et al.[57] (2018) Memantine extended-release 28 mg once daily vs placebo	Post-hoc analysis of DB, RCT Outpatients with Alzheimer's disease (MMSE scores of three to 14) who were receiving stable, ongoing cholinesterase inhibitor (ChEI) treatment	N=677 24 weeks	Primary: Comparing patients receiving memantine ER/ cholinesterase inhibitor (ChEI) to placebo/ChEI for time to onset of response and if the response was maintained (achieving improvement at	Primary: Greater percentages of memantine ER/ChEI patients achieved an early response that was maintained on SIB, NPI, and CIBIC-Plus (P<0.05) versus placebo/ChEI. Greater percentages of memantine ER/ChEI-treated patients achieved and maintained a clinically notable response on ADL/NPI, SIB/ADL/NPI, and SIB/ADL/CIBIC-Plus, compared with placebo/ChEI (P<0.05). Memantine ER results in early, maintained improvement in patients with moderate to severe Alzheimer's disease concurrently taking ChEIs, compared with cholinesterase treatment alone. Secondary: When comparing memantine ER/ChEI-treated versus placebo/ChEI-treated responders for all possible combinations of two, three, or four

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			weeks eight, 12, or 18 and maintaining through endpoint/week 24) Secondary: Comparing percentages of patients for all possible combinations of two to four assessments with either no decline or clinically notable response	efficacy measures, a greater proportion of memantine ER/ChEI patients showed no decline and clinically notable response versus ChEI alone. The difference between treatments for patients who showed no decline did not reach statistical significance; the combination of efficacy outcomes with the greatest difference was SIB/CIBIC-Plus (P=0.0541).
Hager et al.[58] (2016) Galantamine vs placebo Memantine was taken at baseline and throughout the study by 24.5% of galantamine-treated patients and 24.0% of placebo-treated patients	Post-hoc analysis of DB, PC, PRO, RCT Patients with mild-to-moderate Alzheimer's disease or mixed dementia stratified by the presence or absence of concomitant memantine	N=2,045 2 years	Primary: Mortality and efficacy parameters including MMSE scores, DAD scores, and nursing home placement Secondary: Not reported	Primary: In memantine users, mortality rates were not reduced by galantamine (HR, 1.25; 95% CI, 0.63 to 2.46) as they were in nonusers (HR, 0.33; 95% CI, 0.18 to 0.61). Mortality rates in the galantamine-treated groups, compared with placebo, were lower in patient groups with ≥ median age and higher MMSE score (18 to 26). In memantine users, galantamine did not reduce MMSE decline at any time point. In contrast, in memantine nonusers the galantamine group showed reduced decline in MMSE scores as compared with the placebo group at all time points, with a numerical increase in the effect size over time (P>0.05 for all comparisons). Examination of DAD scores at month 24 demonstrated a benefit in galantamine-treated memantine nonusers, with attenuation of this benefit in the memantine user group across the range of baseline MMSE scores. In memantine users, the risk of new nursing home admission during year one was higher in the galantamine group than in the placebo group (3.70; 95% CI, 1.04 to 13.23; P=0.03). In memantine nonusers, the risk of nursing home placement tended to be lower in galantamine-treated

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				patients than in placebo-treated patients in year two (RR, 0.19; 95% CI, 0.02 to 1.57; P=0.08). The cumulative numerical percentages of nursing home placements were 5.0% and 18.8% in memantine users on placebo and galantamine, respectively, and 5.0% and 1.8% in memantine nonusers on placebo and galantamine. Overall, the beneficial effects of galantamine at two years post treatment were not observed in patients who had been placed on background memantine. Secondary: Not reported
Burns et al.[59] (2004) Rivastigmine	RETRO Patients with moderately severe Alzheimer's disease/dementia	N=2,126 3 trials, each 6 months	Primary: Effectiveness Secondary: Not reported	Primary: Mean ADAS-Cog score declined by 6.3 points in the placebo group and increased by 0.2 points in the rivastigmine group (P<0.001). Clinical benefits were also observed with the MMSE, the six-item PDS, and items of the BEHAV-AD assessed efficacy. Rivastigmine showed the same pattern of adverse events as in other studies, but the RR of dropping out due to adverse events was lower than in subjects with milder Alzheimer's disease. Secondary: Not reported
Dantoine et al.[60] (2006) Rivastigmine 3 to 12 mg/day Addition of memantine 5 to 20 mg/day was allowed for non-responders of rivastigmine at the	MC, OL Patients at least 50 years of age with probable Alzheimer's disease according to criteria of DSM-IV, baseline scores of <18 for MMSE or scores of >4 on GDS, previously	N=202 16 weeks of rivastigmine monotherapy (Phase 1) Additional 12 weeks of rivastigmine and memantine	Primary: MMSE Secondary: MMSE, Mini-Zarit inventory, NPI, Ten-point Clock-drawing Test, D-KEFS verbal fluency test, CGI-C	Primary: Based on MMSE scores, 46.3% of patients improved or stabilized on rivastigmine monotherapy at the end of Phase 1. For those patients previously on donepezil or galantamine, responder rates were also similar (46.6 and 46.4%). At the end of Phase 2 with combination therapy of rivastigmine and memantine, according to MMSE scores, 77.9% of patients improved or stabilized. Patients switching to combination therapy from galantamine responded

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
end of week 16.	treated for at least 6 months prior with donepezil 5 to 10 mg/day or galantamine 16 to 24 mg/day and considered not stabilized, current stabilized medications allowed	combination therapy for non-responders of rivastigmine monotherapy (Phase 2) Total 28 weeks		more significantly than those who switched from donepezil (84.2 vs 72.3%; P=0.047). Secondary: According to CGI-C data, no change or improvement was seen in 76.5% of patients who completed the study at the end of Phase 1. For the 82.6% who worsened from baseline at the end of Phase 1, 81.4% improved or had no change at the end of Phase 2 with the addition of memantine on the CGI-C. At the end of Phase 1, MMSE and NPI showed significant improvements (P<0.001 and P<0.05, respectively) while there was no change from baseline for Ten-point Clock-drawing Test and D-KEFS verbal fluency test scores and the Mini-Zarit interview. At the end of Phase 2, D-KEFS verbal fluency test, Mini-Zarit, and especially MMSE scores showed significant improvement (P<0.05, P<0.001 and P<0.001, respectively).
Olin et al.[61] (2010) Rivastigmine 6 to 12 mg/day and memantine 20 mg/day	MC, OL, PRO Patients ≥50 years of age with moderate-to-severe Alzheimer's disease (MMSE ≥10 to ≤20)	N=116 26 weeks	Primary: Safety and tolerability Secondary: ADCS-CGIC, ADCS-ADL measured	Primary: Nausea and vomiting occurred in 26.7 and 10.3% of patients, respectively. Most cases were mild with few severe cases reported (2.6 and 2.6%, respectively). At least one treatment-emergent adverse event was experienced by 81.9% of patients. The most common adverse events were nausea (26.7%), dizziness (11.2%), vomiting (10.3%), and diarrhea (10.3%). No patients exhibited clinically significant ECG abnormalities. Secondary: At week 26, 59% of patients experienced no decline in MMSE total score from baseline. The mean change from baseline in MMSE total score was 0.7. At week 26, there was no change in global ADCS-CGIC scores.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Patient and caregiver assessed mental/cognitive state, behavior and functioning severity scores were maintained to a similar extent throughout the study. The mean overall rating on the ADCS-CGIC was 4.0. At week 26, 64.5% of patients were considered unchanged or improved. The mean ADAS-ADL scores significantly declined by -2.9. At week 26, cognition, behavior and global functioning were unchanged or improved in 63.2, 71.1 and 77.6% of patients respectively.
Gauthier et al.[62] (2010) Rivastigmine 3 to 12 mg/day	MC, OL, OS, PRO Patients with mild-moderate Alzheimer's disease	N=3,800 12 months	Primary: Physician-assessed abbreviated CGI-C, MMSE, psychotropic medication use Secondary: Not reported	Primary: At six months, the proportion of patients who were reported as being improved vs no change vs deteriorating were 46.4 vs 44.9 vs 8.8% for attention; 42.8 vs 50.0 vs 7.2% for apathy; 41.1 vs 49.5 vs 9.4% for anxiety; 33.8 vs 68.4 vs 7.7% for agitation; 35.1 vs 54.8 vs 10.1% for irritability; and 30.8 vs 63.8 vs 5.4% for sleep disturbance. At 12 months, the proportion of patients who were reported as being improved vs no change vs deteriorating were 47.9 vs 41.0 vs 11.1 for attention; 44.1 vs 46.7 vs 9.2% for apathy; 41.8 vs 47.3 vs 10.9% for anxiety; 33.5 vs 57.6 vs 8.9% for agitation; 33.8 vs 56.4 vs 9.8% for irritability; and 29.7 vs 64.7 vs 5.6% for sleep disturbance. Overall, CGI-C at six and 12 months demonstrated a larger percentage of patients with improvement vs deterioration. At six months, 54% of patients overall demonstrated no change. At 12 months, 52% of patients overall demonstrated no change. MMSE scores were 20.8 at baseline, 21.5 after three months, 21.3 after six months, and 21.3 after 12 months. At baseline, 61.3% of patients were not taking a psychotropic medication. At six months, the proportion of patients not taking any psychotropic medications increased to 70.8%; at 12 months, it was 84.7%.
Birks et al.[63] (2000)	MA (8 trials)	N=3,660	Primary: ADAS-Cog, ADL,	Primary: Statistically significant differences were seen in patients treated with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rivastigmine 6 to 12 mg/day vs placebo	Patients diagnosed with Alzheimer's disease	12 to 52 weeks	adverse events Secondary: Not reported	rivastigmine at doses of 6 to 12 mg/day as compared to placebo for the following outcomes: ADAS-Cog (WMD, -2.09; 95% CI, –2.65 to –1.54) and ADL (WMD, -2.15; 95% CI, –3.16 to –1.13). At 26 weeks, 55% of patient had severe dementia in the rivastigmine group as compared to 59% in the placebo group (OR, 0.78; 95% CI, 0.64 to 0.94). Adverse events (nausea, vomiting, diarrhea, anorexia, headache, syncope, abdominal pain and dizziness) were reported significantly more frequently in the rivastigmine group than with placebo. Secondary: Not reported
Birks et al.[64] (2009) Rivastigmine vs placebo	MA Patients diagnosed with probable Alzheimer's disease	N=4,775 (9 trials) Variable duration	Primary: Cognitive function, global impression, activities of daily living, behavioral disturbance, withdrawal rates, and incidence of adverse effects Secondary: Not reported	Primary: <u>Cognitive function</u> The meta-analysis, using WMD, demonstrated benefit on cognitive function as measured by ADAS-Cog test scores for rivastigmine compared to placebo as follows: rivastigmine 1 to 4 mg/day at 18 weeks (WMD, -1.07; 95% CI, -1.66 to -0.48; P=0.0004) and 26 weeks (WMD, -0.84; 95% CI, -1.48 to -0.19; P=0.01); rivastigmine 6 to 12 mg/day at 12 weeks (WMD, -1.49; 95% CI, -1.96 to -1.01; P<0.00001), 18 weeks (WMD, -1.79; 95% CI, -2.30 to -1.29; P<0.00001) and 26 weeks (WMD, -1.99; 95% CI, -2.49 to -1.50; P<0.00001). An additional analysis of ADAS-Cog dichotomized into those showing less than four points improvement and those showing four or more points improvement at 26 weeks shows benefit for cognitive function for the 6 to 12 mg daily of rivastigmine compared to placebo (83% did not show four points improvement compared to 89%; OR, 0.6; 95% CI, 0.4 to 0.8). There was no difference for the 1 to 4 mg/day dose compared to placebo (88% did not show four points improvement compared to 90%; OR, 0.84; 95% CI, 0.60 to 1.19). MMSE shows similar results in favor of rivastigmine at 26 weeks compared to placebo as follows: rivastigmine 1 to 4 mg/day at 26 weeks (WMD, 0.43; 95% CI, 0.08 to 0.78; P=0.02) and rivastigmine 6 to 12

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mg/day at 26 weeks (WMD, 0.82; 95% CI, 0.56 to 1.08; P<0.00001). One study used the SIB, which shows benefit associated with higher dose rivastigmine compared to placebo at 26 weeks (WMD, 4.53; 95% CI, 0.47 to 8.59; P=0.03). <u>Global assessment</u> Using the CIBIC-Plus scale or the ADCS-CGIC scale, there were benefits associated with rivastigmine compared to placebo as follows: rivastigmine 6 to 12 mg/day at 12 weeks (OR, 0.74; 95% CI, 0.60 to 0.92; P=0.008), 18 weeks (OR, 0.79; 95% CI, 0.64 to 0.98; P=0.03) and at 26 weeks (OR, 0.66; 95% CI, 0.55 to 0.79; P<0.00001); rivastigmine 1 to 4 mg/day at 26 weeks (OR, 0.71; 95% CI, 0.55 to 0.93; P=0.01). Using GDS, there were benefits associated with rivastigmine 6 to 12 mg/day compared to placebo (55% showed the worse condition compared to 59%; OR, 0.78; 95% CI, 0.64 to 0.94; P=0.01) but not with 1 to 4 mg daily rivastigmine compared to placebo. <u>ADL</u> The PDS showed an improvement associated with rivastigmine compared to placebo as follows: rivastigmine 6 to 12 mg/day at 12 weeks (WMD, 1.08; 95% CI, 0.19 to 1.98; P=0.02), 18 weeks (WMD, 1.90; 95% CI, 0.93 to 2.88; P=0.0001), and 26 weeks (WMD, 2.15; 95% CI, 1.13 to 3.16; P<0.0001). One study assessing ADL using the ADCS-ADL scale and showed benefit for rivastigmine 6 to 12 mg/day at 24 weeks (WMD, 1.80; 95% CI, 0.20 to 3.40; P=0.03). <u>Behavioral disturbance</u> There was no difference between rivastigmine and placebo in behavioral disturbance found in two studies using the neuropsychiatric instrument (NPI-10, and NPI-12). <u>Withdrawals before the end of treatment</u> There were no significant differences in withdrawal rates with rivastigmine 1 to 4 mg/day and placebo at 12, 18 and 26 weeks.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were significant differences in withdrawal rates for the higher dose group in favor of placebo as follows: rivastigmine 6 to 12 mg/day at 12 weeks (OR, 2.60; 95% CI, 1.19 to 5.68; P=0.02), 18 weeks (OR, 4.02; 95% CI, 1.31 to 12.32; P=0.01), and 26 weeks (OR, 2.19; 95% CI, 1.83 to 2.63; P<0.00001). Adverse events There were no significant differences in the numbers of patients with at least one adverse event between the lower dose rivastigmine (1 to 4 mg/day) and placebo groups. There were significant differences between the higher dose rivastigmine (6 to 12 mg/day) and placebo groups in favor of placebo by the end of the titration period (OR, 2.96; 95% CI, 2.39 to 3.68; P<0.00001) and by 26 weeks (OR, 2.49; 95% CI, 2.05 to 3.02; P<0.00001). There were no significant differences in the numbers of patients with at least one severe adverse event between the lower dose rivastigmine (1 to 4 mg/day) and placebo groups. There were significant differences between the higher dose rivastigmine (6 to 12 mg daily) and placebo groups in favor of the placebo group for the titration period (OR, 1.88; 95% CI, 1.39 to 2.55; P<0.0001). There were significant differences, in favor of placebo, for the rivastigmine 6 to 12 mg/day group by the end of the titration period, and by 26 weeks for the number of patients suffering nausea, vomiting, diarrhea, anorexia, headache, syncope, abdominal pain and dizziness. There were significant differences in favor of placebo, for the rivastigmine 1 to 4 mg/day group by the end of the titration period and by 26 weeks for the number of patients suffering nausea, vomiting, diarrhea, and anorexia. Secondary: Not reported
Rosler et al.[65] (1999) Rivastigmine 1 to 4 mg/day	DB, MC, PC, RCT Patients 50 to 85 years of age and not able to bear	N=725 Dose titration over the first 12 weeks with	Primary: Improvements in cognitive function and overall clinical status measured by	Primary: Significant improvement in cognitive function assessed by the ADAS-Cog was observed with the higher dose group by ≥4 points compared to placebo (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs rivastigmine 6 to 12 mg/day vs placebo	children, all patients met criteria for Alzheimer's type dementia as described in the DSM-IV and criteria for probable Alzheimer's disease	a subsequent assessment period of 14 weeks, total of 26 weeks	the ADAS-Cog, CIBIC, PDS, MMSE and GDS Secondary: Safety and tolerability	At week 26, significantly more patients in both rivastigmine groups had improved in global function as assessed by the CIBIC compared to those in the placebo group (P<0.05). Mean scores on the PDS improved from baseline in the higher dose group but fell in the placebo group (P<0.05). At week 26, mean scores in the MMSE and the GDS significantly improved in patients receiving rivastigmine 6 to 12 mg/day (P<0.05). Secondary: Discontinuation rates for any reason were significantly higher in the higher dose group than in the lower dose or placebo group (33% vs 14%). Adverse events related to treatment including nausea, vomiting, diarrhea, abdominal pain and anorexia, were generally mild and occurred most frequently during the dose escalation phase (23% in higher dose group, 7% in lower dose group and 7% in placebo group).
Articus et al.[66] (2011) Rivastigmine patch 9.5 mg/24 hours	MC, OL Patients with Alzheimer's disease	N=208 24 weeks	Primary: Proportion of patients treated with rivastigmine for ≥8 weeks at week 24 Secondary: Tolerability, week 24 MMSE, ADCS-CGIC, ADCS-ADL, ADCPQ, Zarit Burden Interview Score	Primary: In the ITT population, 80.8% of patients (95% CI, 75.0 to 86.5) were treated for at least eight weeks with rivastigmine. A total of 74.2% of patients (95% CI, 67.8 to 80.5) were treated for at least eight weeks and completed the study. A total of 74.2% of patients treated rivastigmine patch were able to reach and maintain the maximum dose for at least eight weeks. The most common adverse events being nausea (10.1%), erythema (8.7%), pruritus (8.2%), and vomiting (7.2%). Secondary: The most common adverse events were nausea (10.1%), erythema (8.7%), pruritus (8.2%), vomiting (7.2%), diarrhea (4.3%) and agitation (4.3%). At week 24, improvements were seen on: MMSE (1.3), and ADCS-ADL (1.3). At week 24, improvements in ADCS-CGIC were demonstrated in 34.6%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				of patients as assessed by patients, and in 29.7% of patients as assessed by the caregiver. ADCPQ scores improved 18.5 points, and Zarit Burden Interview Score improved slightly at each visit until week 24 (-0.4).
Grossberg et al.[67] (2009) Rivastigmine patch 9.5 mg/24 hours to 17.4 mg/24 hours	OL Patients 50 to 85 years of age with Alzheimer's disease (MMSE scores 10 to 20)	N=870 28 weeks (weeks 25 to 52 of open-label extension)	Primary: Safety and tolerability Secondary: ADAS-cog	Primary: During the first four weeks of the open-label extension, patients formerly randomized to rivastigmine treatment (capsule or patch) reported fewer adverse events than those formerly randomized to placebo (≤15.2 vs 28.2%). This prior exposure effect was noted for nausea (≤2.5 vs 8.5%) and vomiting (≤1.9 vs 6.0%). A total of 57.6% of patients reported adverse events during the OL extension (weeks 25 to 52), with nausea and vomiting being reported most frequently (15.7 and 14.3%, respectively). During the OL extension, over 90% of all patients experienced ''no, slight, or mild'' skin irritation as their most severe application-site reaction. The symptoms that were most commonly reported as moderate or severe were erythema and pruritus (7.7 and 5.6%, respectively). Serious adverse events occurred in 1.0% of patients during the first four weeks of the OL extension phase (weeks 25 to 28) and 9.4% of patients during the full open-label extension phase (weeks 25 to 52). The most common serious adverse events were gastrointestinal disorders (2.0%), infections and infestations (2.0%), cardiac disorders (1.7%), and nervous system disorders (1.5%). Eight deaths occurred during the OL extension phase and a further two occurred during the 30-day follow-up period. The causes of death were most commonly cardiac disorders (n=5) and nervous system disorders (n=3). None were considered treatment related. Secondary: Patients previously randomized to placebo who were switched to the 9.5 mg/24 hour rivastigmine patch during the OL extension experienced a 1.3-point increase in their ADAS-cog scores during weeks 24 to 40. There

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				was no overall change in ADAS-cog score at week 40 compared to baseline (95% CI, -1.4 to 0.6). The increase in ADAS-cog score was not sustained beyond week 40. Patients receiving rivastigmine treatment for the entire study (weeks 0 to 52) showed a deterioration of 0.3 points (95% CI, -0.4 to 0.9) on the ADAS-cog at week 52. Those receiving placebo for weeks 0 to 24, followed by the patch, showed a deterioration of 0.9 points [95% CI, -0.4 to 2.1).
Gauthier et al.[68] (2013) Rivastigmine transdermal patch 4.6 mg/24 hours or 9.5 mg/24 hours, once daily	OS Patients with Alzheimer's disease with MMSE score of 10 to 26 and GDS score of 4 to 6	N=1,204 18 months	Primary: Change in MMSE from baseline to 18 months Secondary: Change in MMSE at six and 12 months and change in GDS, assessment of patient ability, overall patient assessment rating, caregiver-reported compliance and treatment satisfaction at six, 12, and 18 months	Primary: Over 18 months of treatment there were no clinically significant changes in MMSE. Secondary: Over 18 months of treatment there were no clinically significant changes in GDS. The majority of patients showed improvement or no change in GDS, assessment of patient ability and overall patient assessment rating over 18 months. The proportion with reported improvement in GDS, assessment of patient ability and overall patient assessment rating was higher than the proportion that deteriorated. Compliance improved from baseline to 18 months and for 88.2% of patient's caregivers preferred the transdermal patch to oral medications.
Sadowsky et al.[69] (2010) US13 and US18 Rivastigmine capsules 3 to 12 mg/day US38	US13 and US18 PRO, MC, OL US38 RCT, MC, OL Patients ≥49 years of age with a diagnosis of	N=592 25 to 26 weeks	Primary: Safety and tolerability	Primary: In US13 and US18, 67.7% of patients completed the studies and 32.3% of patients withdrew due to adverse events (59.8%), unsatisfactory treatment effect (15.9%), withdrawal of consent (15%), and loss to follow-up (6.5%). The remaining 2.7% of patients discontinued due to protocol deviation, administrative problem, or death. In US13 and US18, the most frequently reported adverse events (AEs) were nausea (32.9%), vomiting (24.1%), dizziness (11.8%), weight loss

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rivastigmine patch 4.6 mg/24 hours for 5 weeks, then rivastigmine patch 9.5 mg/24 hours for 20 weeks	dementia of the Alzheimer type (MMSE ≥8 to ≤26 or MMSE ≥10 to ≤24) who showed a poor response to donepezil			(9.1%) agitation (7.9%), fall (7.9%) and confused state (7.9%). Serious AE's were reported in 6% of patients and included pneumonia (1.8%), syncope (1.2%), dehydration (1.2%) and vomiting (1.2%). In US38, 67.4% of patients completed the study. The primary reasons for not completing the study were adverse events (44.7%), withdrawal of consent (29.4%), unsatisfactory treatment effect (10.6%), protocol deviation (7.1%), and loss to follow-up (3.5%). The remaining 4.7% of patients discontinued due to administrative problems, abnormal test procedure, or death. In US38, 70.5% of patients reported at least 1 AE. More patients in the immediate-switch group (73.3%) experienced at least one AE during the study than in the delayed-switch group (67.7%). The most common adverse events were application site reaction (15.3%), and agitation (6.9%). The most common serious AEs reported were syncope (1.1%), dehydration (0.8%) and pneumonia (0.4%). Discontinuation due to AE (14.6%) was the most common reason for patients not completing the extension phase in both immediate- and delayed-switch groups; the differences between the groups were NS. Discontinuations occurred for the following reasons: application site reaction (4.2%), disease progression (2.3%), and agitation (1.5%). Discontinuation due to gastrointestinal AEs was lower for the rivastigmine patch compared to the capsules.
Cummings et al.[70] (2012) 10 cm^2 rivastigmine patch (9.5 mg/24 hours) vs 15 cm^2 rivastigmine patch (13.3 mg/24 hours)	DB, PG. RCT Patients 50 to 85 years of age with MMSE scores of 10 to 24 diagnosed with Alzheimer's disease, all patients were required to be living with someone or to be in daily contact with a	N=567 48 weeks	Primary: ADCS-IADL scale and ADAS-cog Secondary: Time to functional decline on the ADCS-IADL, change in the Trail Making Test parts A and B, and	Primary: The 13.3 mg/24 hours patch was statistically superior to the 9.5 mg/24 hours patch on the ADCS-IADL scale from week 16 (P=0.025) onwards including week 48 (P = 0.002), and ADAS-cog at week 24 (P= 0.027), but not at week 48 (P = 0.227). Secondary: Functional decline on the ADCS-IADL tended to occur later in the 13.3 mg/24 h patch group than in the 9.5 mg/24 hours patch group, but the observed difference did not reach significance. Proportion of patients with functional decline was 77.0% in the 13.3

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	caregiver		change in the NPI-10, and the NPI-caregiver distress scale.	mg/24 hours patch group compared to 81.2% with the 9.5 mg/24 hours patch Group. The difference was not statistically significant. Patients in the 13.3 mg/24 hours patch group had smaller increases in time to complete the Trail Making Test parts A at weeks 24 and 48 compared to those in the 9.5 mg/24 hours patch group, but the observed difference did not reach significance. Differences were not significantly different in changes in the change in the 10-item (NPI-10), and the NPI-caregiver distress scale. The most frequently reported adverse events by primary system organ class were gastrointestinal disorders (29.3 vs. 19.1%, 13.3 and 9.5 mg/24 hours patch, respectively), psychiatric disorders (25.4 vs. 21.6%, respectively) and nervous system disorders (21.4 vs. 18.4%, respectively). Skin and subcutaneous tissue disorders were less frequently observed with the 13.3 mg/24 hours than the 9.5 mg/24 hours patch (2.1 vs 6%).
Cummings et al.[71] (2010) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine patch 17.4 mg/24 hours vs placebo	DB, PC, PRO, RCT Patients 50 to 85 years of age with mild-to-moderate Alzheimer's disease	N=1,195 24 to 52 weeks	Primary: Tolerability at 24 weeks Secondary: Patients skin condition at the application site at 28 weeks	Primary: No serious skin reactions were reported in either the 24 or 28 week phases of the study. During the 24 week period, 574 patients wearing an active patch and 579 patients wearing a placebo patch underwent at least one assessment of application-site skin condition. Of patients on the 9.5 mg/24 hour patch, erythema and pruritus were the most commonly reported reactions (moderate in 7.6% of patients and severe in 6.7% of patients). A total of 89.6% of patients in the patch group had "no, slight, or mild" signs and symptoms for their most severe application site reaction. Secondary: A total of 870 patients entered the 28 week phase of the study and received rivastigmine 9.5 mg/24 hours patch. Overall, the skin tolerability profile was similar to the DB phase. A total of 91.5% of patients experienced "no, slight, or mild" symptoms as their most severe application site reaction, with erythema and pruritus being the most common finding. A total of 3.7% of patients discontinued treatment

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				due to skin reactions during the open-label extension, and there was no increase in the severity of skin reaction noted.
Molinuevo et al.[72] (2012) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine 3 to 12 mg/day	MC, OS, PRO Patients with mild-to-moderate Alzheimer's disease	N=649 6 months	Primary: Adherence rates Secondary: Strategies followed by a physician to improve adherence and reasons for nonadherence reported by patients	Primary: At baseline, 0.6% of patients were taking ≥80% of their medication as prescribed. At three and six months, 77 and 88.1%, respectively, were noted to be taking more than 80% of their medication as prescribed (P<0.0001 vs baseline). The proportion of adherent patients at three months was 73.6% and at six months was 85.9% (P<0.0001). Secondary: Modification of Alzheimer's disease treatment was the only intervention that substantially improved adherence at three months (P<0.0001). At the six month visit, psychoeducation was the only effective strategy that reached statistical significance (P<0.0001). The most common reasons for nonadherence include forgetfulness (56.4%), avoidance of adverse events (30.7%), and refusal of treatment (25.3%).
Boada et al.[73] (2013) Rivastigmine transdermal patch vs rivastigmine capsules	OL Patients treated with rivastigmine	N=1,078 Duration not specified	Primary: Patient satisfaction (Treatment Satisfaction with Medicines and the Morisky-Green questionnaires) Secondary: Not reported	Primary: Satisfaction reported was greater with transdermal than oral rivastigmine: mean+standard deviation of the total Treatment Satisfaction with Medicines score, 72.5+14.1 vs 65.2+12.5; P<0.001. The proportion of adherent patients was greater with transdermal than with oral rivastigmine (65.0 vs 41.4%; P<0.001). Satisfaction, in turn, was significantly greater in adherent cases than in nonadherent cases. Secondary: Not reported
Blesa González et al.[74] (2011) Rivastigmine 6 to 12 mg/day (RO)	MC, OL, RCT Patients ≥60 years of age with mild-to-moderate Alzheimer's disease	N=142 3 months	Primary: Gastrointestinal adverse events Secondary: Overall tolerance,	Primary: Gastrointestinal adverse events were reported in <5% of patients receiving patches (4.7% in RPT and 4.3% in RP) vs 6.1% in RO patients. No statistical significance was reached (P=0.8667). Gastrointestinal adverse events were noted in 11 cases, two in RPT patients, six in RP patients, and three in the RO patients (P=0.3067).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs rivastigmine patch titrated to 9.5 mg/24 hours (RPT) vs rivastigmine patch 9.5 mg/24 hours (RP)	who were previously treated with oral rivastigmine		local tolerance for those patients on patches, satisfaction level, and cognitive state by MMSE	Secondary: Overall tolerability did not reveal any significant differences among the groups (P=0.8239). Local tolerability revealed skin or subcutaneous tissue adverse events reported in 11.6% of patients in the RPT group vs 17% of patients in the RP group (P=0.4055). All skin adverse events were reported as slight or moderate intensity. RP was defined by 72% of patients as very easy to use, while RO was considered very easy to use by 30% of patients (P=0.0005). In RP patients, 67% considered it very easy to follow compared to 19% of RO patients (<0.0001). A total of 72% of RP patients confirmed the treatment never interfered with their daily lives vs 40% of the RO group (P=0.0085). Overall satisfaction comparisons revealed that in RP patients, 60% were very satisfied vs 14% in RO patients (P<0.0001). MMSE did not demonstrate significant differences among treatment groups when compared at one and three month visits.
Winblad et al.[75] (2007) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine patch 17.4 mg/24 hours vs rivastigmine 12 mg/day vs	DD, PC, RCT Patients 50 to 85 years of age with MMSE scores of 10 to 20 diagnosed with Alzheimer's disease, all patients were required to be living with someone or to be in daily contact with a caregiver	N=1,195 Dose titration in 4-week intervals over 16 weeks and maintained at their highest well-tolerated dose for a further 8 weeks, total of 24 weeks	Primary: ADAS-Cog subscale (assess orientation, memory, language, visuospatial and praxis function), ADCS-CGIC (assess single global rating) Secondary: ADCS-ADL, MMSE, NPI, Ten Point Clock-drawing Test, and Trail-making Test	Primary: Patients in all rivastigmine groups (patch and capsule) showed significant improvements compared to placebo at week 24 with respect to ADAS-Cog and the ADCS-CGIC (all P<0.05 vs placebo). Secondary: All rivastigmine groups (patch and capsule) showed statistically significant benefits over placebo on the ADCS-ADL, MMSE and Trail-making Test part A (all P<0.05 vs placebo). Statistically significant treatment effects were not attained on the NPI or Ten Point Clock-drawing Test (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo			part A	
Winblad, Kawata et al.[76] (2007) 10 cm^2 rivastigmine patch (9.5 mg/24 hours) vs 20 cm^2 rivastigmine patch (17.4 mg/24 hours) vs rivastigmine 6 mg capsules twice daily vs placebo	DB, DD, PC ACs included different size rivastigmine patches and rivastigmine capsules	N=1,059 24 week	Primary: ADCPQ Secondary: Not reported	Primary: At 8 weeks, general preference was seen for the patch: 68% of caregivers preferred the patch over capsule form (P<0.0001). 70% of caregivers preferred the patch due to ease of schedule (P<0.0001). 55% of caregivers preferred the patch due to ease of use (P=0.0008). At 24 weeks, general preference was seen for the patch: 72% of caregivers preferred the patch over capsule form (P<0.0001). 74% of caregivers preferred the patch due to ease of schedule (P<0.0001). 64% of caregivers preferred the patch due to ease of use (P<0.0001). Caregivers preferred the patch over capsule dosage form, regardless of size of patch (P<0.0001). At 8 weeks, caregivers indicated greater satisfaction overall (P<0.0001), greater satisfaction with administration (P<0.0001), less interference with daily life with the patch than the capsule (P<0.01). Secondary: Not reported
Winblad et al.[77] (2007) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine patch 17.4 mg/24 hours vs	DB, DD, MC, PG Women or men 50 to 85 years of age with a diagnosis of dementia of the Alzheimer's type according to the DSM-IV, and probable Alzheimer's disease	N=1,195 24 weeks	Primary: ADAS-Cog, ADCS-CGIC Secondary: ADCS-ADL scale; NPI for behavior and psychiatric symptoms; MMSE for cognition; Ten Point Clock-drawing Test for	Primary: Patients receiving rivastigmine patches or capsules showed significant benefits compared to placebo at week 24 on the ADAS-Cog subscale (P<0.05 vs placebo for all rivastigmine groups). Treatment differences on the ADCS-CGIC were statistically significant for the 10 cm^2 patch and capsule group (all P<0.05 vs placebo). The 20 cm^2 patch did not achieve statistical significance compared to placebo in the analysis (P=0.054). Secondary: Rivastigmine patches and capsule provided statistically significant benefits

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
rivastigmine 12 mg/day vs placebo			assessment of visuospatial and executive functions; Trail Making Test Part A for assessment of attention, visual tracking and motor processing speed	over placebo on the ADCS-ADL, MMSE and Trail-making Test A (all P<0.05 vs placebo). Changes from baseline on the NPI, NPI-distress subscale, and Ten-point Clock-drawing Test in the rivastigmine groups were not significantly different from those in the placebo groups (all P>0.05).
Blesa et al.[78] (2007) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine patch 17.4 mg/24 hours vs rivastigmine 12 mg/day vs placebo	DB, DD, PC ACs included different size rivastigmine patches and rivastigmine capsules, caregiver preference based on data generated during the IDEAL trial (Winblad et al)	N=1,059 24 week	Primary: ADCPQ Secondary: Not reported	Primary: At 8 weeks, general preference was seen for the patch: 68% of caregivers preferred the patch over capsule form (P<0.0001). 70% of caregivers preferred the patch due to ease of schedule (P<0.0001). 55% of caregivers preferred the patch due to ease of use (P=0.0008). At 24 weeks, general preference was seen for the patch: 72% of caregivers preferred the patch over capsule form (P<0.0001). 74% of caregivers preferred the patch due to ease of schedule (P<0.0001). 64% of caregivers preferred the patch due to ease of use (P<0.0001). Caregivers preferred the patch over capsule dosage form, regardless of size of patch (P<0.0001). At eight weeks, caregivers indicated greater satisfaction overall (P<0.0001), greater satisfaction with administration (P<0.0001), less interference with daily life with the patch than the capsule (P<0.01). Secondary: Not reported
Farlow et al.[79] (2011) Rivastigmine patch 9.5 mg/24 hours vs rivastigmine patch	RETRO Patients with mild-to-severe Alzheimer's disease	N=1,050 24 weeks	Primary: ADAS-cog, ADCS-CGIC, and ADCS-ADL Secondary: Not reported	Primary: In patients with moderate disease, there was a significant improvement on ADAS-cog scores with the rivastigmine 17.4 mg/24 hour patch (P=0.0009) and rivastigmine capsule (P=0.0128). For patients with moderately severe disease, there was a significant improvement in ADAS-cog scores with the rivastigmine 17.4 mg/24 hour patch (P=0.006), rivastigmine 9.5 mg/24 hour patch (P=0.0163), and rivastigmine capsule (P=0.0071) compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
17.4 mg/24 hours vs rivastigmine 12 mg/day vs placebo				For patients with severe disease, there was a significant improvement on ADCS-CGIC scores with the rivastigmine 9.5 mg/24 hour patch (P=0.037) and rivastigmine capsule (P=0.0073) compared to placebo. For patients with moderately severe disease, there was a significant improvement on ADCS-CGIC scores with the rivastigmine 17.4 mg/24 hour patch (P=0.043) and rivastigmine 9.5 mg/24 hour patch (P=0.0116) compared to placebo. Significant improvement on ADCS-CGIC scores were seen with the rivastigmine 17.4 mg/24 hour patch in patients with moderate disease (P=0.03) and mild to moderate disease (P=0.0455) compared to placebo. For patients with moderately severe disease, there was a significant improvement on ADCS-ADL scores with the rivastigmine 17.4 mg/24 hour patch (P=0.0211) compared to placebo. For patients with moderate disease, there was a significant improvement on ADCS-ADL scores with the rivastigmine 17.4 mg/24 hour patch (P=0.0194) and rivastigmine capsule (P=0.0077) compared to placebo. There was no significant difference in ADCS-ADL scores among the treatment groups in patients with severe AD.
Choi et al.[80] (2011) Rivastigmine patch 4.6 mg/24 hours for 4 weeks, then rivastigmine patch 9.5 mg/24 hours for 4 weeks, then rivastigmine patch 9.5 mg/24 hours and memantine 5 mg/day titrated to	MC, OL, RCT Patients with mild-to-moderate Alzheimer's disease	N=172 24 weeks	Primary: Tolerability Secondary: Efficacy as measured by CMAI-K, ADAS-cog, K-MMSE, FAB, CGA-NPI, ADCS-ADL and CDR-SB scores	Primary: The incidence of adverse events (53.4 vs 50.6%) and discontinuation due to adverse events (6.8 vs 4.8%) was not different between patients with and without memantine, respectively. The most common adverse events were skin irritation in both treatment groups (42 vs 34.9%; P=0.71), but discontinuation was rare (4.5 vs 2.4%; P=0.74). Secondary: CMAI-K scores favored rivastigmine monotherapy vs combination therapy at the end of treatment (P=0.01). Changes in other efficacy measures (ADAS-cog, K-MMSE, FAB, CGA-NPI, ADCS-ADL and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
20 mg/day vs rivastigmine patch 9.5 mg/24 hours				CDR-SB) were not significantly different.
Farlow et al.[81] (2010) Rivastigmine patch 9.5 mg/24 hours and memantine vs rivastigmine patch 9.5 mg/24 hours	OL, RCT Patients ≥50 years of age with mild-to-moderate Alzheimer's disease who had been receiving donepezil for at least 6 months and at a stable dose of 5-10 mg/day for a minimum of 3 months	N=261 25 weeks	Primary: Safety and tolerability of rivastigmine transdermal patch, with or without concomitant memantine Secondary: Changes in cognition, global functioning and activities of daily living measured by MMSE and ADCS-ADL using the CGIC	Primary: The incidences of adverse events (73.3 vs 67.5%) and serious adverse events (10.4 vs 7.1%) were both slightly higher in patients receiving concomitant memantine, but the differences were NS (95% CIs, -5.2 to 16.9 and -3.6 to 10.1 for adverse events and serious adverse events, respectively). The most frequent adverse events in the combination therapy group and the rivastigmine monotherapy group were application site reactions (17.5 vs 13.5%, respectively) and agitation (5.9 vs 7.9%, respectively). Secondary: Concomitant memantine was associated with no significant changes in efficacy, as assessed by CGIC and MMSE scores. Global functioning remained unchanged or improved (CGIC rating ≤4) in 57.7 and 67.2% of patients with memantine and patients without memantine, respectively (P=0.604). ADCS-ADL scores deteriorated from baseline in both groups, with significant worsening in patients receiving memantine compared to those not receiving memantine (mean change from baseline rivastigmine and memantine vs rivastigmine monotherapy: -5.3 vs -2.0; P=0.043).
Harry et al.[82] (2005) Donepezil with doses ranging from 5 to 10 mg/day or	MA Patients with mild-to-moderate Alzheimer's disease, and without diagnosis of any other psychiatric or neurological	N=3,353 3 donepezil studies 5 galantamine studies	Primary: ADAS-Cog or MMSE Secondary: Not reported	Primary: The majority of patients showed no difference compared to placebo. There was no significant difference in efficacy between the groups. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
galantamine with doses ranging from 8 to 36 mg/day vs placebo	disorder	Duration varied		
Wilcock et al.[83] (2003) Donepezil 10 mg/day vs galantamine 24 mg/day	MC, PG, RCT Patients with Alzheimer's disease	N=182 52 weeks	Primary: BrADL Secondary: MMSE, ADAS-Cog, NPI	Primary: BrADL total score showed no significant difference between treatment groups in mean change from baseline to week 52. Secondary: Galantamine patients' scores on the MMSE at week 52 did not differ significantly from baseline, whereas donepezil patients' scores deteriorated significantly from baseline (P<0.0005).The between group difference in MMSE change did not reach statistical significance. In the ADAS-Cog analysis, between group differences for the total population were NS, whereas galantamine treated patients with MMSE scores of 12 to 18 demonstrated an increase (worsening) in the ADAS-Cog score of 1.61+/-0.80 vs baseline, compared to an increase of 4.08+/-0.84 for patients treated with donepezil. More caregivers of patients receiving galantamine reported reductions in burden compared to donepezil. Changes from baseline in NPI were similar for both treatments.
Jones et al.[84] (2004) Donepezil 10 mg/day vs galantamine 12 mg twice daily	OL, RCT Patients with Alzheimer's disease	N=120 12 weeks	Primary: Ease of use and tolerability, ADAS-Cog, effects on cognition and activities of daily living Secondary:	Primary: Physicians and caregivers reported statistically significant greater satisfaction/ ease of use with donepezil compared to galantamine at weeks four and 12. Significantly greater improvements in cognition were observed for donepezil vs galantamine on the ADAS-Cog at week 12 and at endpoint. Activities of daily living improved significantly in the donepezil group compared to the galantamine group at weeks four and 12 (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Not reported	Forty-six percent of galantamine patients reported gastrointestinal adverse events vs 25% of donepezil patients. Secondary: Not reported
Modrego et al.[85] (2010) Donepezil 10 mg/day vs memantine 20 mg/day	PG, RCT, SB Patients with mild-to-moderate Alzheimer's disease	N=63 6 months	Primary: ADAS-cog, NPI, DAD, changes in N-acetylaspartate metabolite levels Secondary: Not reported	Primary: There were no significant differences in the clinical scales with donepezil and memantine (donepezil: ADAS-cog, -0.12; P=NS, NPI, -0.04; P=NS, DAD, 6.67; P=0.014) (memantine: ADAS-cog, -1.37; P=NS, NPI, 1.25; P=NS, DAD, 4.46; P=NS). More patients worsened than improved on either drug. Daily living activities decreased by 4.4% in the memantine group and 6.6% in the donepezil group (P=0.6). At baseline, N-acetylaspartate/Cr ratio in the PCG correlated significantly with the ADAS-cog (P=0.02) and MEC (P=0.02). The N-acetylaspartate/Cr ratio correlated with the baseline ADAS-cog (P=0.02) in the left temporal lobe. At week 24, the PCG was the only area where the correlation was significant. The patients who improved in the ADAS-cog showed increases in the N-acetylaspartate/Cr ratios (P=0.004). None of the baseline metabolite levels predicted response to treatment in any of the examined areas. Secondary: Not reported
Wilkinson et al.[86] (2002) Donepezil 10 mg/day vs	OL, RCT Patients with mild-to-moderate Alzheimer's disease	N=111 12 weeks	Primary: ADAS-Cog, tolerability Secondary: Not reported	Primary: More patients taking donepezil completed the study (89.3%) compared to the rivastigmine group (69.1%; P=0.009). 10.7% of the donepezil group and 21.8% of the rivastigmine group discontinued treatment due to adverse events. 87.5% of the donepezil patients and 47.3% of the rivastigmine patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
rivastigmine 6 mg twice daily				remained on the maximum approved dose of each drug at the last study visit. Both groups showed comparable improvements in ADAS-Cog administered at weeks four and 12. Secondary: Not reported
Van Puyvelde et al.[87] (2011) Galantamine vs donepezil or rivastigmine (safety control group)	MC, OS, PRO Patients with mild-to-moderate Alzheimer's disease	N=128 6 months	Primary: Safety, patients and caregiver satisfaction, global impression as reported by the physician Secondary; Not reported	Primary: Adverse events were similar among both treatment groups (galantamine, 34%; SCG, 34.4%). The incidence of serious (12 events) and severe (15 events) adverse events with galantamine was similar to the SCG group (serious: galantamine 9.3% vs safety control group 9.7%); severe: galantamine 11.3% vs safety control group 12.9%. A total of 84.5% of patients treated with galantamine continued their treatment after six months. Patients receiving galantamine reported their condition as improved (49%), unchanged (47%) and worsened (4%). Caregivers rated global evaluation as better (37%), unchanged (41%) and worse (22%) with galantamine. Physicians rated global clinical impression of change as better (46%), unchanged (34%) and worse (20%) with galantamine. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). Secondary: Not reported
Tariot et al.[88] (2004) Memantine 20 mg/day	DB, MC, PC, RCT Patients with moderate-to-severe Alzheimer's disease	N=404 24 weeks	Primary: SIB, ADCS-ADL, CIBIC-Plus, BGP Secondary:	Primary: A significantly greater therapeutic effect was observed in the memantine group than in the placebo group on the ADCS-ADL, SIB and CIBIC-Plus. Patients receiving memantine in combination with donepezil demonstrated

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs donepezil	who received stable doses of donepezil		Not reported	significantly less decline in ADCS-ADL scores compared to patients receiving donepezil-placebo over the 24-week study period (P=0.02). Patients receiving memantine showed significantly less cognitive decline in SIB scores compared to patients receiving placebo. Therapy with memantine-donepezil resulted in sustained cognitive performance above baseline compared to the progressive decline seen with the donepezil-placebo treatment. The change in total mean scores favored memantine vs placebo for the CIBIC-Plus (possible score range was 1-7), 4.41 vs 4.66, respectively (P=0.03). Treatment discontinuations due to adverse events for memantine vs placebo were 7.4% of the patients compared to 12.4%. Secondary: Not reported
Bullock et al.[89] (2005) Rivastigmine 3 to 12 mg/day vs donepezil 5 to 10 mg/day	DB, MC, RCT Patients 50 to 85 years of age with moderate to moderately-severe Alzheimer's disease (MMSE score 10-20)	N=994 24 months	Primary: SIB Secondary: GDS, ADCS-ADL, MMSE, NPI	Primary: Donepezil-treated patients declined 9.91 points from baseline on the SIB as compared to rivastigmine-treated patients, who declined by 9.30 points (P=NS). Secondary: Rivastigmine was more effective than donepezil on the ADCS–ADL, on which there was a between-treatment difference of 2.1 points after two years (P=0.007), and greater efficacy on the GDS (P=0.049). There were no significant differences in MMSE and NPI between the treatment groups. More patients receiving rivastigmine reported 'any adverse event' compared to those receiving donepezil during the titration phase (82.0 and 64.7%, respectively). Adverse events were higher with rivastigmine during the titration phase and included nausea (32.9 vs 15.2%) and vomiting (27.9 vs 5.8%). In the maintenance phase, adverse event rates in the two groups were similar (78.7% for the rivastigmine group and 76.9% for the donepezil group). Premature discontinuations due to adverse events were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				higher in the rivastigmine group during the titration phase (14.1 vs 7.0% for donepezil) but similar in the maintenance phase (17.9 vs 14.1% for donepezil).
Mossello et al.[90] (2004) Donepezil 5 to 10 mg/day vs galantamine 16 to 24 mg/day vs rivastigmine 6 to 12 mg/day	OL, OS Patients with mild-to-moderate Alzheimer's disease	N=407 9 months	Primary: MMSE, ADL and IADL Secondary: Not reported	Primary: There were no differences amongst the three groups in regard to any of the outcome measures (galantamine was not included in the MMSE comparison due to the small number of treated patients). Discontinuation due to adverse effects was lower in those patients on donepezil (3%) vs rivastigmine (17%; P=0.01) and vs galantamine (21%; P=0.01). Secondary: Not reported
Aguglia et al.[91] (2004) Donepezil vs galantamine vs rivastigmine	OL Patients with Alzheimer's disease	N=242 6 months	Primary: MMSE, ADAS-Cog, ADL and IADL Secondary: Not reported	Primary: There were no statistical differences on changes in the MMSE, ADAS-Cog, ADL or IADL measures amongst the three groups. There were no differences on changes in the IADL measure among the three groups. In the ADL measure, donepezil and galantamine patients showed a decrease while there was no change for rivastigmine patients. Rivastigmine showed a small numerical advantage (but not statistically) compared to donepezil and galantamine on the ADAS-Cog. Secondary: Not reported
Lopez-Pousa et al.[92] (2005)	OL, PRO Patients with mild-to-moderate	N=147 6 months	Primary: MMSE Secondary:	Primary: All three treatment groups had better MMSE scores compared to control (donepezil; P<0.001, galantamine; P<0.01, and rivastigmine; P<0.03).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Donepezil vs galantamine vs rivastigmine vs historical controls	Alzheimer's disease		Not reported	There were no statistical differences between the groups on measures of cognitive decline (via MMSE). Secondary: Not reported
Rodda et al.[93] (2009) Donepezil 5 to 10 mg/day vs galantamine 8 to 24 mg/day vs rivastigmine 9 to 17.4 mg/day	RETRO Patients with Alzheimer's disease being treated with donepezil, rivastigmine or galantamine monotherapy	N=6,110 12 to 170 weeks	Primary: NPI Secondary: Not reported	Primary: Three of the 14 studies reviewed reported statistically significant improvement in overall NPI score or in the agitation/aggression item of the NPI only. One study demonstrated a significant difference in NPI score between groups randomized to either continuation or discontinuation of donepezil (placebo following an initial OL treatment phase. Of these four positive studies, two specified a minimum level of behavioral disturbance at baseline and used behavioral scores as a primary outcome. Secondary: Not reported
Howard et al.[94] (2012) Donepezil 10 mg/day vs memantine 20	DB, MC, RCT Community-based patients with moderate-to-severe Alzheimer's disease who were taking donepezil 10 mg/day for ≥3	N=295 52 weeks	Primary: Standardized Mini-Mental State Examination and BADLS scores Secondary: NPI, caregiver health status	Primary: Mean donepezil vs placebo Standardized Mini-Mental State Examination scores were higher with donepezil (better cognitive function) by an average of 1.9 points (95% CI, 1.3 to 2.5; P<0.001) and BADLS scores were lower (less functional impairment) by 3.0 points (95% CI, 1.3 to 2.5; P<0.001). Both outcomes demonstrated significant heterogeneity in treatment efficacy over tome (P=0.002 and P=0.004, respectively), with less benefit apparent at the six week assessment than at later time points. From six weeks onward, differences were roughly parallel.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs donepezil 10 mg/day and memantine 20 mg/day vs placebo	months		assessed by General Health Questionnaire 12	Mean donepezil+memantine vs placebo+memantine Standardized Mini-Mental State Examination scores were higher with donepezil by an average of 1.2 points (95% CI, 0.6 to 1.8; P<0.001) and BADLS scores were lower by 1.8 points (95% CI, 0.3 to 2.8; P<0.001). Both outcomes were smaller than the minimum clinically important difference. Interactions of memantine therapy with visit were NS. Both donepezil and memantine demonstrated benefits on both Standardized Mini-Mental State Examination and BADLS larger in the absence of other agents alone, though statistically insignificant (P=0.14 and P=0.09, respectively). No significant benefits were seen adding memantine to donepezil on Standardized Mini-Mental State Examination scores (0.8 points higher with memantine and placebo; 95% CI, -0.1 to 1.6; P=0.07) or BADLS scores (0.5 points lower with memantine than placebo; 95% CI, 2.2 to 1.2; P=0.57). Secondary: NPI scores were lower for patients on memantine compared to placebo, indicating fewer behavioral and psychological symptoms by 4.0 points (99% CI, 0.6 to 7.4; P=0.002). No observable NPI differences noted with continuation, as compared to discontinuation of donepezil therapy (2.3 points lower with continuation; 95% CI, -1.1 to 5.7; P=0.08). Donepezil+memantine vs donepezil demonstrated a lower NPI score by 5.1 points (99% CI, 0.3 to 9.8; P=0.006). Continuation of donepezil and donepezil+memantine compared to the placebo and memantine + placebo demonstrated larger average decreases (indicating fewer psychological symptoms) across trial visits in General Health Questionnaire 12 scores for caregiver health status. There was a 0.5 point larger decrease with continuation vs discontinuation of donepezil (99% CI, -0.01 to 1.0; P=0.01) and 0.5 point larger decrease with memantine vs placebo (95% CI, -0.1 to 0.9; P=0.03), though significance was not reached to allow for multiple secondary outcomes.
Porsteinsson et	PC, R	N=433	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
al.[95] (2008) Memantine 20 mg/day plus cholinesterase inhibitor vs cholinesterase inhibitor plus placebo	Patients with probable Alzheimer's disease, MMSE scores between 10 to 22, concurrently taking a cholinesterase inhibitor	24 weeks	ADAS-cog, CIBIC-Plus Secondary: ADCS-ADL, NPI, MMSE	No significant difference in ADAS-cog and CIBIC-Plus was found between memantine and placebo. Secondary: No significant difference in ADCS-ADL, NPI or MMSE was found between memantine and placebo.
Cumming et al.[96] (2006) Memantine 20 mg/day plus donepezil vs donepezil	DB, PC, PG, PRO Patients with moderate-to-severe Alzheimer's disease who received stable doses of donepezil	N=404 24 weeks	Primary: NPI Secondary: Not reported	Primary: NPI scores significantly favored the memantine group at 12 weeks and at 24 weeks. At week 12, NPI scores increased (worsening behavior) 1.7 points in the placebo group and decreased 2.5 points in the memantine group (P<0.001). At week 24, NPI scores increased 3.7 points (worsening behavior) in the placebo groups and the memantine group returned to baseline (P=0.002). Fewer patients developed delusions in the memantine treatment group than the placebo group (P=0.011). Secondary: Not reported
Maidment et al.[97] Memantine 20 mg daily vs placebo or	MA Patients with probable Alzheimer's disease	N=1,750 Duration varied	Primary: NPI Secondary: Not reported	Primary: Compared to the placebo group patients receiving memantine improved by 1.99 on the NPI scale (95% CI, -0.08 to -3.91; P=0.041). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
memantine 20 mg daily in combination with a cholinesterase inhibitor (doses varied) vs placebo in combination with a cholinesterase inhibitor (doses varied)				
Wilkinson et al.[98] (2009) Cholinesterase inhibitors (donepezil 5 or 10 mg/day) vs placebo	MA Patients with mild-to-moderate Alzheimer's disease	N=906 (3 trials) 24 weeks	Primary: MMSE Secondary: Not reported	Primary: A significantly greater percentage of placebo patients than donepezil-treated patients met the specified criteria for all three definitions of clinical worsening. The OR for clinical worsening were significantly reduced for donepezil-treated patients compared to placebo patients (P<0.0001 for all definitions). Among patients meeting criteria for clinical worsening, mean declines in MMSE scores were greater for placebo than donepezil-treated patients. This outcome was also apparent when milder (MMSE, 18 to 26) and more moderate (MMSE, 10 to 17) subgroups were analyzed separately. Secondary: Not reported
Feldman et al.[99] (2009) Cholinesterase inhibitors	OS, PRO Alzheimer's disease patients with and without cerebrovascular disease	N=548 7 years	Primary: Time to nursing home placement Secondary: Identify factors noted to reduce risk of NHP,	Primary: The overall median time to permanent institutional admission was 42.4 months (95% CI, 38.0 to 48.0 months). Secondary: Factors noted to reduce the risk of being admitted to a nursing home included higher baseline DAD and MMSE scores, Alzheimer's disease diagnosis, living with caregiver, country, and treatment duration (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			including measurement of DAD and MMSE	Each year of treatment demonstrated a reduced risk of nursing home admission (galantamine, -31%, other cholinesterase inhibitors, -29%).
Trinh et al.[100] (2003) Cholinesterase inhibitors vs placebo	MA Trials included outpatients with mild or moderate Alzheimer's disease who were treated for at least one month with a cholinesterase inhibitor	29 trials Duration varied	Primary: NPI, ADAS-noncog, ADL and IADL Secondary: Not reported	Primary: Cholinesterase inhibitors improved the NPI statistically better than placebo (95% CI, 0.87 to 2.57). Cholinesterase inhibitors improved the ADAS-noncog measure numerically but not statistically compared to placebo (95% CI, 0.0 to 0.05). Cholinesterase inhibitors improved ADL numerically but not significantly better than placebo (95% CI, 0.0 to 0.19). Cholinesterase inhibitors improved IADL statistically compared to placebo (95% CI, 0.01 to 0.17). Secondary: Not reported
Lanctot et al.[101] (2003) Cholinesterase inhibitors vs placebo	MA Adult patients diagnosed with Alzheimer's disease	N=7,954 16 trials that varied in duration	Primary: Global responders, using CGI-C, CIBIC, adverse, events, dropouts Secondary: Not reported	Primary: For cholinesterase inhibitors the pooled mean proportion of global responders was in excess by 9% when compared to the placebo treatment (9%; 95% CI, 6 to 12). In the cholinesterase inhibitor treatment groups the rates of adverse events, dropout for any reason and dropout because of adverse events were higher compared to the placebo treatment groups (8%; 95% CI, 5 to 11; 8%; 95% CI, 5 to 11; and 7%; 95% CI, 3 to 10). The number needed to treat for one additional patient to benefit was 7 (95% CI, 6 to 9) for stabilization or better, 12 (95% CI, 9 to 16) for minimal improvement or better and 42 (95% CI, 26 to 114) for marked improvement. The number needed to treat for one additional patient to experience an adverse event was 12 (95% CI, 10 to 18).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Birks et al.[102] (2006) Cholinesterase inhibitors vs placebo	MA Patients diagnosed with mild, moderate or severe dementia due to Alzheimer's disease	N=7,298 Minimum 6 months	Primary: CIBIC-Plus, GBS, GDS, ADAS-Cog, MMSE, SIB, NPI, ADL scored by PDS and DAD Secondary: Withdrawals prior to six months, adverse events	*Cholinesterase inhibitor vs placebo (12 trials)* Primary: Significant benefit was seen in CIBIC-Plus for patients treated with a cholinesterase inhibitor over placebo; more patients were scored as "showed improvement" than "showed decline/no change" (OR, 1.56; 95% CI, 1.32 to 1.85; P<0.00001): eight studies. No significant difference was seen in GBS between the cholinesterase inhibitor and placebo groups at one year (P value not reported): one trial. Significant improvement in ADAS-Cog was found for patients treated with donepezil, galantamine, or rivastigmine over placebo (WMD, –2.66; 95% CI, –3.02 to –2.31; P<0.00001): 10 studies. Significant benefit was seen in MMSE for patients treated with a cholinesterase inhibitor over placebo (WMD, 1.37; 95% CI, 1.13 to 1.61; P<0.00001): nine studies. Significant benefit was seen in ADL-PDS and DAD for patients treated with a cholinesterase inhibitor over placebo (WMD, 2.40; 95% CI, 1.55 to 3.37; P<0.00001 for PDS; and WMD, 4.39; 95% CI, 1.96 to 6.81; P=0.0004 for DAD). Significant benefit was seen in NPI for patients treated with a cholinesterase inhibitor over placebo (WMD, –2.44; 95% CI, –4.12 to –0.76; P=0.004). Secondary: Significantly more patients treated with a cholinesterase inhibitor (29%) withdrew prior to six months than those in the placebo groups (18%; P<0.00001). Adverse events that occurred significantly more frequently in the cholinesterase inhibitor group than the placebo group, from pooled data from at least 6 trials included: abdominal pain, anorexia, dizziness,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				diarrhea, headache (P<0.0001), insomnia (P=0.007), nausea, vomiting (P<0.00001 unless noted). *Donepezil vs rivastigmine (one trial)* Primary: There was no statistically significant difference between the treatment groups for cognitive function, ADL scales, behavior disturbances and global assessment (P values not reported). Secondary: Significantly fewer patients in the donepezil group withdrew from treatment after 2 years than in the rivastigmine group (OR, 0.64; 95% CI, 0.50 to 0.83; P=0.0006). Adverse events that occurred significantly more frequently at 12-16 weeks of treatment in the rivastigmine group than in the donepezil group included: nausea (P<0.00001), vomiting (P<0.00001), falls (P=0.01), hypertension (P=0.01), anorexia (P=0.0005) and weight loss (P=0.001), and after 16 weeks to 2 years of treatment: nausea (P=0.0002), vomiting (P<0.00001) and anorexia (P=0.02). No significant difference between treatment groups for serious adverse events was noted (P value not reported).
Hansen et al.[103] (2008) Cholinesterase inhibitors	MA Patients with Alzheimer's disease	26 trials Variable duration	Primary: Cognition (ADAS-cog), function, behavior (NPI), global assessment of change (CIBIC+ and CGI-C) Secondary: Not reported	Primary: <u>Cognition (14 studies)</u> The pooled WMD in change between active treatment and placebo was -2.67 (95% CI -3.28 to -2.06) for donepezil, -2.76 (95% CI -3.17 to -2.34) for galantamine, and -3.01 (95% CI -3.80 to -2.21) for rivastigmine. <u>Function (14 studies)</u> The pooled standardized mean difference between active treatment and placebo was 0.31 (95% CI, 0.21 to 0.40) for donepezil, 0.27 (95% CI, 0.18 to 0.36) for galantamine, and 0.26 (95% CI, 0.11 to 0.40) for rivastigmine. <u>Behavior (seven studies)</u> The pooled WMD in NPI score between active treatment and placebo was -4.3 (95% CI, -5.95 to -2.65) for donepezil and -1.44 (95% CI, -2.39 to -

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				0.48) for galantamine. Global assessment of change (nine studies) The pooled RR of responding for active treatment compared to placebo was 1.88 (95% CI, 1.50 to 2.34) for donepezil, 1.15 (95% CI, 0.96 to 1.39) for galantamine, and 1.64 (95% CI, 1.29 to 2.09) for rivastigmine. Secondary: Not reported
Kim et al.[104] (2011) Cholinesterase inhibitors	MA Cognitively impaired older adults	54 trials Variable duration	Primary: Falls, syncope, fracture and accidental injury reported Secondary: Not reported	Primary: Cholinesterase inhibitors usage was associated with the greatest risk of syncope compared to placebo (OR, 1.53; 95% CI, 1.02 to 2.30), but not with any other events: falls (OR, 0.88; 95% CI, 0.74 to 1.04); fracture (OR, 1.39; 95% CI, 0.75 to 2.56); accidental injury (OR, 1.13; 95% CI, 0.87 to 1.45). Memantine was associated with fewer fractures (OR, 0.21; 95% CI, 0.05 to 0.85), but not with other events: falls (OR, 0.92; 95% CI, 0.72 to 1.18), syncope (OR, 1.04; 95% CI, 0.35 to 3.04); accidental injury (OR, 0.80; 95% CI, 0.56 to 1.12). There were no differential effects noted according to type and severity of cognitive impairment, residential status, or length of follow-up.
Parkinson's Disease				
Emre et al.[105] (2004) Rivastigmine 3 to 12 mg/day; average dose 8.6 mg/day vs placebo	DB, MC, PC, RCT Patients at least 50 years of age with mild-to-moderate dementia developed 2 years after the diagnosis of Parkinson's disease	N=541 Dose titration over the first 16 weeks with a subsequent assessment period of 8 weeks Total of 24 weeks	Primary: ADAS-Cog, ADCS-CGIC Secondary: ADCS-ADL, NPI-10, MMSE, CDR power of attention tests, D-KEFS verbal fluency test, Ten Point Clock-drawing Test	Primary: Patients who were receiving rivastigmine had significant improvement of 2.1 points in the 70-point ADAS-Cog scores vs worsening of 0.7 point in the placebo group from baseline (P<0.001). 19.8% of patients in the rivastigmine group and 14.5% in the placebo group clinically improved in the ADCS-CGIC scores. 13% of patients in the rivastigmine group and 23.1% in the placebo group clinically worsened in the ADCS-CGIC scores (P=0.007). Secondary: All secondary outcomes were significantly better in the rivastigmine group compared to placebo, as reflected by the changes in the ADCS-ADL score

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P=0.02), NPI-10 (P=0.02), MMSE (P=0.03), CDR power of attention tests (P=0.009), D-KEFS verbal fluency test (P<0.001), and the Ten Point Clock-drawing Test (P=0.02).
Wesnes et al.[106] (2005) Rivastigmine 3 to 12 mg/day, average dose 8.6 mg/day vs placebo	DB, MC, PC, RCT Patients at least 50 years old with Parkinson's disease	N=487 24 weeks	Primary: Power of attention, continuity of attention, cognitive reaction time, reaction time variability Secondary: Not reported	Primary: At week 16, there was no statistical significance from baseline scores between rivastigmine and placebo for power of attention (P=0.11) but there was a significance at week 24 (P<0.01). By week 16, there was a significant improvement with continuity of attention (P=0.001) compared to placebo and this parameter continued to improve at week 24 (P=0.0001). Cognitive reaction time showed significant improvement by the end of week 24 (P<0.001) vs week 16 (P=0.064) but declined with placebo. Reaction time variability continued to show improvement over placebo from week 16 (P<0.05) to week 24 (P<0.001). Secondary: Not reported
Schmitt et al.[107] (2010) Rivastigmine 3 to 12 mg/day vs placebo	DB, MC, PC, RCT Patients with Parkinson's disease dementia	N=541 24 weeks	Primary: Executive function as assessed by D-KEFS measures Secondary: Not reported	Primary: Rivastigmine was associated with significantly more correct responses, fewer set loss errors, and more total responses made (within time available), compared to placebo (all P<0.05). There was no significant difference in total repetition errors (P=0.57). Rivastigmine was associated with a significantly higher Card Sorting recognition description score than placebo (P=0.03). Word reading errors, word comprehension, and sort recognition errors were NS. There were significantly more correct substitutions on the Symbol Digit Modalities Test compared to placebo (P=0.02). Rivastigmine was associated with significantly fewer self-corrected errors on the Color-Word Interference inhibition/switching subtest compared to placebo (P=0.049). Treatment differences in numbers of correct responses were near statistical significance (P=0.050). Other treatment differences in this battery of executive function tests were not statistically significant.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Olin et al.[108] (2010) Rivastigmine 3 to 12 mg/day vs placebo	DB, MC, PC, RCT Patients ≥50 years of age with Parkinson's disease dementia	N=541 24 weeks	Primary: Tolerability and efficacy as measured by ADCS-ADL Secondary: Not reported	Primary: A total of 75.8% of patients completed the study (rivastigmine, 72.7% vs placebo, 82.1%). The primary reasons for discontinuation were adverse events (17.1% for rivastigmine vs 7.8% for placebo) and withdrawal of consent (5.8% rivastigmine vs 1.1% placebo). At 24 weeks, rivastigmine was associated with significantly less deterioration compared to placebo based on ADCS-ADL total scores (-1.1 vs -3.6, respectively; P=0.023). Similar improvements were seen with rivastigmine compared to placebo on the basic ADCS-ADL subscale (-0.5 vs -1.7, respectively; P=0.025), and on high level function ADLs (0.1 vs -1.0; P=0.017). No other measures were significantly different among the treatment groups. Secondary: Not reported
Maidment et al.[109] (2006) Rivastigmine 3 to 12 mg/day vs placebo	MA Patients diagnosed with mild-to-moderately severe dementia, which developed at least 2 years after Parkinson's disease was diagnosed	N=541 (1 study) 24 weeks	Primary: ADAS-Cog, ADCS-CGIC Secondary: MMSE, ADCS-ADL, NPI, CDR, D-KEFS, Ten Point Clock-drawing Test, UPDRS, adverse events	Primary: Significant improvement in ADAS-Cog was found for patients treated with rivastigmine over placebo (WMD, –2.80; 95% CI, –4.26 to –1.34; P=0.0002). Results in ADCS-CGIC significantly favored patients treated with rivastigmine over placebo (WMD, –0.50; 95% CI, –0.77 to –0.23; P=0.0004). 19.8% of rivastigmine patients experienced "clinically meaningful (moderate or marked) improvement" compared to 14.5% of the placebo group; 13.0% of rivastigmine patients experienced "clinically meaningful worsening" compared to 23.1% in the placebo group (P values not reported). Secondary: Results for MMSE significantly favored patients treated with rivastigmine over placebo (WMD, 1.00; 95% CI, 0.33 to 1.67; P=0.003). Results for ADCS-ADL significantly favored patients treated with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				rivastigmine over placebo (WMD, 2.50; 95% CI, 0.43 to 4.57; P=0.02). Results for NPI significantly favored patients treated with rivastigmine over placebo (WMD, –2.00; 95% CI, –3.91 to –0.09; P=0.04). For CDR no statistically significant difference was found (P=0.25). For D-KEFS, results significantly favored patients treated with rivastigmine over placebo (WMD, 2.80; 95% CI, 1.47 to 4.13; P<0.0001). Full UPDRS was not reported. No statistically significant difference was found for motor score, including tremor (P=0.83 and P=0.84). Significantly more patients in the rivastigmine group than the placebo group experienced one or more adverse events (P=0.0006). Adverse events included: nausea, vomiting, tremor, and dizziness. Significantly more patients treated with rivastigmine withdrew from treatment for any reason than those treated with placebo (P=0.02).
Emre et al.[110] (2014) Rivastigmine capsules 6 mg twice daily vs rivastigmine patch 9.5 mg/24 hours	OL, PRO, RCT Patients 50 to 85 years of age with mild-to-moderately severe Parkinson disease dementia, which developed at least one year after Parkinson's disease was diagnosed	N=583 76 weeks	Primary: Incidence of predefined adverse events due to worsening Parkinson's disease motor symptoms (tremor, rigidity, bradykinesia, and falls) and discontinuation rate due to predefined potential adverse effects with capsules	Primary: The incidence of adverse effects due to worsening motor symptoms in the capsule groups was 36.1% (95% CI, 30.6 to 41.8), with tremor the most commonly reported (24.5%; 95% CI, 19.7 to 29.8). Overall, 4.4% (95% CI, 2.4 to 7.4) of capsule-treated patients discontinued due to worsening motor symptoms. Secondary: The incidence of adverse effects due to worsening motor symptoms in the patch group (31.9%; 95% CI, 26.6 to 37.7) was similar to capsules. Fewer patients experienced tremor with patch (9.7%; 95% CI, 6.6 to 13.7) compared to capsules. The incidences of bradykinesia, rigidity, and fall were similar between groups. The incidence of discontinuation due to worsening of motor symptoms was 2.4% (95% CI, 1.0 to 4.9) with patch. Efficacy: Improvements on Mattis Dementia Rating Scale and NPI-10 from baseline were observed in both groups at weeks 24 and 52. Deterioration in ADCS-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Secondary: Same as primary but with patch Efficacy: Mattis Dementia Rating Scale, ADCS-ADL, NPI-10	ADL score from baseline was observed in both groups at all time points. The size of initial improvement on the Mattis Dementia Rating Scale and NPI-10 gradually declined in both groups; decline was greater in the patch group. In the overall population, there was a statistically significant difference in favor of capsules compared with patch at weeks 24 to 76 for MDRS; weeks 52 and 76 for ADCS-ADL; and weeks 24 and 76 for NPI-10.

Study abbreviations: AC=active control, CI=confidence interval, DB=double blind, DD=double dummy, ER=extended release, HR=hazard ratio, IR=immediate release, ITT=intent to treat, LOCF=last observation carried forward, MA=meta-analysis, MC=multicenter, NS=not significant, OL=open label, OR=odds ratio, OS=observational study, PC=placebo controlled, PG=parallel group, PP=per protocol, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, RR=relative risk, SB=Single-blind, WMD=weighted mean difference
Efficacy Measures Key: ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive subscale, ADAS-cog/10=10-item cognitive subscale of the Alzheimer's Disease Assessment Scale, ADAS-cog/11=11-item cognitive subscale of the Alzheimer's Disease Assessment Scale, ADAS-cog/13=13-item cognitive subscale of the Alzheimer's Disease Assessment Scale, ADAS-cog/memory=Alzheimer's Disease Assessment Scale-Cognitive/Memory, ADAS-noncog=Alzheimer Disease Assessment Scale-Noncognitive, ADCPQ=Alzheimer's Disease Caregiver Preference Questionnaire, ADCS-ADL=Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, ADCS-ADL-sev=Alzheimer Disease Cooperative Study-Activities of Daily Living-severe version, ADCS-CGIC=Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change, ADL=Activity of Daily Living, BADLS=Bristol Activities of Daily Living Scale, BEHAV-AD=Behavioral Pathology in Alzheimer's Disease Rating Scale, BGP=Behavioral Rating Scale for Geriatric Patients, BrADL=Bristol Activities of Daily Living Scale, CBQ=Caregiver Burden Questionnaire, CDR=Cognitive Drug Research, CDR-SB=Clinical Dementia Rating Scale-Sum of Boxes, CGA-NPI=Caregiver-Administered Neuropsychiatric Inventory, CGI-C=Clinical Global Impression of Change, CGI-I=Clinical Global Impression of Improvement scale, CIBIC=Clinician Interview-Based Impression of Change Scale, CIBIC-Plus=Clinician's Interview-Based Impression of Change Plus Caregiver Input, CMAI-K=Cohen Mansfield Agitation Inventory-Korean type, DAD=Disability Assessment, D-KEFS=Delis-Kaplan Executive Function System, ECG=electrocardiogram, FAB=Frontal Assessment Battery, FAST=Functional Assessment Staging, GBS=Gottfried-Bråne-Steen scale, GDS=Global Deterioration Scale, IADL=Instrumental Activity of Daily Living, IDDD=Interview for Deterioration in Daily Functioning Activities in Dementia, K-MMSE=Korean Mini-Mental Status Exam, MDS-ADL=Minimum Data Set-Activities of Daily Living, MMSE=Mini-Mental Status Exam, M-NCAS=Modified Nursing Care Assessment Scale, NPI=Neuropsychiatric Inventory, NPI-10=10-item Neuropsychiatric Inventory, QOL=quality of life, QoLS=Quality of Life Scale, PDS=Progressive Deterioration Scale, RUSP=Resource Utilization for Severe Alzheimer Disease Patients, SIB=Severe Impairment Battery, UPDRS=Unified Parkinson's Disease Rating Scale

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
The cholinesterase inhibitors exhibit similar pharmacologic properties, and evidence from comparative studies support a switch strategy when patients are intolerant to one drug or when a therapeutic dose cannot be reached.[111] Gauthier et al. reported that when switched from donepezil to rivastigmine, approximately 50% of those who had adverse events or a lack of efficacy with donepezil tolerated or responded well to rivastigmine.[112] Wilkinson et al. found no difference in tolerability when patients were switched from donepezil to galantamine using either a four-day washout period or a seven-day washout period.[113] Sadowsky et al. evaluated immediate switch (no washout) or delayed switch (seven-day washout) from oral donepezil to transdermal rivastigmine following a four-week treatment period with donepezil.[114] The authors found that the rates of discontinuation due to any reason or adverse events were similar between the treatment groups. They concluded that both switch strategies were safe and well tolerated. Sakka et al. evaluated patients with moderate-to-severe Alzheimer's disease who were switched to donepezil after experiencing a treatment failure or intolerance with memantine.[115] The authors concluded that donepezil was effective and well tolerated in patients who discontinued memantine monotherapy, including those patients with previous exposure to cholinesterase inhibitors. A post-hoc analysis of five-month trial data with galantamine demonstrated that patients had similar efficacy outcomes, whether or not they had received prior anticholinesterase therapy, suggesting that a previous failure did not predict response to galantamine.[116]

Impact on Physician Visits
Fillenbaum et al. evaluated the frequency of outpatient visits for patients with Alzheimer's disease.[117] Outpatient visit ranged from 81 to 95% and was not related to the stage of dementia or institutional status. Leibson et al. demonstrated that the onset of Alzheimer's disease is not associated with greater use of acute care services, nor is the high use of nursing home care offset by fewer emergency room or hospital encounters.[118] Clark et al. evaluated a telephone intervention program where healthcare professionals work with patients and caregivers to determine resources within the family of an Alzheimer's patient.[119] Alzheimer's patients in the program felt less embarrassed and isolated because of their memory problems and reported less problems coping with their disease. Intervention patients with more severe impairment had fewer physician visits, were less likely to have an emergency room visit or hospital admission, and had decreased depression and strain. Wimo et al. demonstrated that the use of memantine in patients with moderate-to-severe Alzheimer's disease was associated with less total caregiver time compared to placebo.[120] There were also fewer patients institutionalized at week 28 in the memantine group compared to placebo.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx

Relative Cost Index Scale	
$$$$$	Over $200 per Rx

Rx=prescription

Table 10. Relative Cost of the Alzheimer's Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Parasympathomimetic (Cholinergic Agents)				
Donepezil	orally disintegrating tablet, tablet	Aricept®*	$$$$$	$
Galantamine	extended-release capsule, solution, tablet	Razadyne®*, Razadyne ER®*	$$$$ - $$$$$	$$$
Rivastigmine	capsule, solution, transdermal patch	Exelon®*	$$$$$	$$$
Central Nervous System Agents, Miscellaneous				
Memantine	extended-release capsule, solution, tablet	Namenda®*, Namenda XR®*	$$$$$	$$$
Combination Products				
Memantine and donepezil	extended-release capsule	Namzaric®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The cholinesterase inhibitors are approved for the treatment of mild-to-moderate Alzheimer's disease. Donepezil is also approved for the treatment of severe disease. The N-Methyl-D-aspartate (NMDA) receptor antagonist, memantine, has only been approved for the treatment of moderate-to-severe Alzheimer's disease. Although these agents provide symptomatic benefit, they have not been shown to delay the progression of neurodegeneration. All products with the exception of memantine-donepezil are available in a generic formulation.

There are several guidelines which discuss the role of these agents in the management of Alzheimer's disease.[12-16] The primary goal of treatment is to delay the progression of symptoms and preserve functional ability. The use of a cholinesterase inhibitor may lead to modest improvements in some patients; therefore, it is appropriate to offer a trial of one of these agents for patients with mild-to-moderate disease.[15] In patients with Alzheimer's disease, treatment with cholinesterase inhibitors (donepezil, galantamine, or rivastigmine) should be considered at the time of diagnosis, taking into account expected therapeutic benefits and potential safety issues. In patients with moderate to severe Alzheimer's disease, treatment with memantine should be considered taking into account expected therapeutic benefits and potential safety issues.[12-13] Guidelines do not give preference to one agent over another. Clinicians should base the treatment decision on tolerability, adverse events, and ease of use.[15]

Numerous clinical trials have evaluated the efficacy and safety of the cholinesterase inhibitors and memantine. Several outcomes have been assessed (using more than 40 different instruments), including cognition, global function, behavior, and quality of life. There is consistent evidence from well-designed studies that donepezil, galantamine, rivastigmine, and memantine positively affect cognition and global function, although the improvements are modest. The findings are less consistent for other outcomes, including behavior and quality of life. In most cases, the duration of these clinical trials was less than one year. Thus, there is insufficient evidence to determine the optimal duration of therapy.[15] There are relatively few studies that directly compare the efficacy and safety of the Alzheimer's agents. Most of the trials have compared active treatment to placebo or no treatment. The studies also differ with regards to design, patient population, and treatment duration, which make it difficult to compare the results.[17-110]

There is insufficient evidence to support that one brand Alzheimer's agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand Alzheimer's agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand Alzheimer's agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
2. Wolk DA, Dickerson BC. Clinical manifestations and diagnosis of Alzheimer disease. In: UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun]. Available from: http://www.utdol.com/utd/index.do.
3. Press D, Alexander M. Treatment of dementia. In: UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun]. Available from: http://www.utdol.com/utd/index.do.
4. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jun]. Available from: http://online.factsandcomparisons.com.
5. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jun]. Available from: http://www.thomsonhc.com/.
6. Aricept® [package insert]. Woodcliff Lake, NJ: Eisai, Inc.; December 2018.
7. Razadyne® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2020.
8. Exelon® Patch [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.
9. Namenda® [package insert]. Madison, NJ: Allergan USA, Inc.; November 2018.
10. Namenda XR® [package insert]. Madison, NJ: Allergan USA, Inc.; November 2019.
11. Namzaric® [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; July 2016.
12. Hort J, O'Brien JT, Gainotti G, et al. EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236–48.
13. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. National Institute for Health and Care Excellence (NICE); June 2018. Available at: https://www.nice.org.uk/guidance/ng97. Accessed June 2019.
14. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-135. doi:10.1212/WNL.0000000000004826.
15. Qaseem A, Snow V, Cross J, et al. American College of Physicians/American Academy of Family Physicians Panel on Dementia. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370-8.
16. Seppi K, Chaudhuri KR, Coelho M, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2018 Dec. Available at https://www.movementdisorders.org/MDS/Resources/Publications-Reviews/EBM-Reviews.htm.
17. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003 Jul;51(7):937-44.
18. Burns A, Gauthier S, Perdomo C, et al. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:806-12.
19. Hashimoto M, Yatabe Y, Kaneda K, et al. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease. Psychogeriatrics. 2009;9:196-203.
20. Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27:232-9.
21. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105-15.
22. Sabbagh M. Cummings J. Christensen D. Doody R. Farlow M. Liu L. Mackell J. Fain R. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics. 2013;13:56.
23. Tariot P. Salloway S. Yardley J. Mackell J. Moline M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes. 2012;5:283.
24. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21(5-6):353-63.

25. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136-45.
26. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL Jansson-Blixt C, et al; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006 Apr 1;367(9516):1057-65.
27. Black SE, Doody R, Li H, McRae T, Jambor KM, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459-69.
28. Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25:399-407.
29. Birks J, Harvey RD. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. doi: 10.1002/14651858.CD001190.pub2.
30. Wallin A et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dementia and Geriatric Cognitive Disorders. 2007;23:150-60.
31. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) vs standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32:1234-51.
32. Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther. 2011;3:22.
33. Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol. 2011;11:57.
34. Doody RS. Geldmacher DS. Farlow MR. Sun Y. Moline M. Mackell J. Efficacy and safety of donepezil 23 mg vs donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia & Geriatric Cognitive Disorders. 2012;3(2-3):164-73.
35. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004 Feb;61(2):252-6.
36. Rockwood K, Dai D, Mitnitski A, et al. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry. 2008;23:207-14.
37. Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat. 2011;7:565-76.
38. Brodaty H et al. A Naturalistic Study of Galantamine for Alzheimer's disease. CNS Drugs. 2006;20(11):935-46.
39. Richarz U, Gaudig M, Rettig K, Schauble B. Galantamine treatment in outpatients with mild Alzheimer's disease. Acta Neurol Scand. 2014 Jun;129(6):382-92.
40. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004 Mar;161(3):532-8.
41. Scarpini E, Bruno G, Zappalà G, et al. Cessation vs continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011;26:211-20.
42. Kavanagh S, Howe I, Brashear HR, et al. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. Curr Alzheimer Res. 2011;8:175-86.
43. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8:39-47.
44. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004 Feb;61(2):252-6.
45. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000 Dec 9;321(7274):1445-9.
46. Dunbar F, Zhu Y, Brashear H. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther. 2006 Mar;28(3):365-72.

47. Brodaty H, Corey-Bloom J, Potocnik F, Truyen L, Gold M, et al. Galantamine prolonged-release formulation in the treatment of mild-to-moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2005;20:120-32.
48. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006, Issue 1.Art.No.:CD001747. DOI: 10.1002/14651858.CD001747.pub3.
49. Herrmann N, Cappell J, Eryavec GM, Lanctôt KL. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs. 2011;25:425-33.
50. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11:471-9.
51. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.
52. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135-46.
53. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-7.
54. Wilkinson D and Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate-to-severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2007;24:138-45.
55. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2.Art.No.:CD003154. DOI: 10.1002/14651858.CD003154.pub5.
56. Grossberg GT. Manes F. Allegri RF. Gutierrez-Robledo LM. Gloger S. Xie L. Jia XD. Pejovic V. Miller ML. Perhach JL. Graham SM. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013 Jun;27(6):469-78.
57. Grossberg GT, Alva G, Hendrix S, Ellison N, Kane MC, Edwards J. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors. Alzheimer Dis Assoc Disord. 2018;32(3):173-178. doi:10.1097/WAD.0000000000000261.
58. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimers Res Ther. 2016 Nov 15;8(1):47.
59. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry. 2004 Mar;19(3):243-9
60. Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice. 2006;60(1):110-8.
61. Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry. 2010;25:419-26.
62. Gauthier S, Juby A, Dalziel W, Réhel B, Schecter R; EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Curr Med Res Opin. 2010;26:1149-60.
63. Birks J, Grimely EJ, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000, Issue 4. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.
64. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009; (2); Cochrane AN: CD001191.
65. Rosler M, Anand R, Cicin-Sain A, Gauthier S, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999;318:633-40.
66. Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract. 2011;65:790-6.
67. Grossberg G, Sadowsky C, Fröstl H, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord. 2009;23:158-64.
68. Gauthier S. Robillard A. Cohen S. Black S. Sampalis J. Colizza D. de Takacsy F. Schecter R. EMBRACE investigators. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study. Current Medical Research & Opinion. 2013 Aug;29(8):989-1000.

69. Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared to rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract. 2010;64:188-93.
70. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33(5):341-53.
71. Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig. 2010;30:41-9.
72. Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother. 2012;12:31-7.
73. Boada M. Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dementia & Geriatric Cognitive Disorders. 2013;35(1-2):23-33.
74. Blesa González R, Boada Rovira M, Martínez Parra C, et al. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurologia. 2011;26:262-71.
75. Winblad B, Grossberg G, Frolich L, Farlow M, et al. IDEAL: a 6 month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(Suppl1):S14-S22.
76. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007 May;22(5):485-91.
77. Winblad B, Cummings J, Andreasen N, Grossberg G, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch vs capsule. International Journal of Geriatric Psychiatry. 2007;22:456-67.
78. Blesa R, et al. Caregiver preference for rivastigmine patches vs capsules for the treatment of Alzheimer disease. Neurology. 2007;69(Suppl 1):S23-S28.
79. Farlow MR, Grossberg GT, Meng X, et al. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43.
80. Choi SH, Park KW, Na DL, et al.; Expect Study Group. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin. 2011;27:1375-83.
81. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin. 2010;26:263-9.
82. Harry RD, Zakzanis KK. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Hum Psychopharmacol. 2005 Apr;20(3):183-7.
83. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P; GAL-GBR-2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20(10):777-89.
84. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild-to-moderate Alzheimer's disease. Int J Geriatr Psychiatry. 2004 Jan;19(1):58-67.
85. Modrego PJ, Fayed N, Errea JM, et al. Memantine vs donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol. 2010;17:405-12.
86. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild-to-moderate Alzheimer's disease. Int J Clin Pract. 2002;56(6):441-6.
87. Van Puyvelde K, Mets T; RODOS Study Group. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population. Geriatr Gerontol Int. 2011;11:256-61.
88. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate-to-severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24.
89. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21:1317-1327.
90. Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Arch Gerontol Geriatr Suppl. 2004;(9):297-307.

91. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin. 2004 Nov;20(11):1747-52.
92. Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernandez-Ferrandiz M, Morante-Munoz V, Isern-Vila A, Gelada-Batlle E, Majo-Llopart J. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord. 2005;19(4):189-95.
93. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813-24.
94. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366:893-903.
95. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83-9.
96. Cumming JL, Schneider E, Tariot P, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63.
97. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42:32-8.
98. Wilkinson D, Schindler R, Schwam E, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dement Geriatr Cogn Disord. 2009;28:244-51.
99. Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009;24:479-88.
100. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003 Jan 8;289(2):210-6.
101. Lanctôt K, Herrmann N, Yau K, Khan L, Liu B et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003 Sept 16;(6) 2003;169.
102. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006, Issue1.Art.No.:CD005593.DOI: 10.1002/14651858.CD005593.
103. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211-25.
104. Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011 Jun;59(6):1019-31.
105. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. NEJM. 2004;351(24):2509-18.
106. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654-6.
107. Schmitt FA, Farlow MR, Meng X, et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010;16:330-6.
108. Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord. 2010;29(6):510-5.
109. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev. 2006, Issue 1.Art. No.: CD004747. DOI: 10.1002/14651858.CD004747.pub2.
110. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014 Jan-Feb;37(1):9-16.
111. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003 Sep;2(9):539-47.
112. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19(8):707-14.
113. Wilkinson DG, Howe I. Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Int J Geriatr Psychiatry. 2005 May;20(5):489-91.
114. Sadowsky CH, Dengiz A, Olin JT, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2009;24:267-75.
115. Sakka P, Tsolaki M, Hort J, et al. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. Curr Med Res Opin. 2007;23:3153-65.

116. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl. 2002 Jun;(127):64-72.
117. Fillenbaum G, Heyman A, Peterson BL, Pieper CF, Weiman AL. Use and cost of outpatient visits of AD patients: CERAD XXII. Neurology. 2001 Jun 26;56(12):1706-11.
118. Leibson C, Owens T, O'Brien P, Waring S, Tangalos E, Hanson V, Plevak M, Kokmen E. Use of physician and acute care services by persons with and without Alzheimer's disease: a population-based comparison. J Am Geriatr Soc. 1999 Jul;47(7):864-9.
119. Clark PA, Bass DM, Looman WJ, McCarthy CA, Eckert S. Outcomes for patients with dementia from the Cleveland Alzheimer's Managed Care Demonstration. Aging Ment Health. 2004 Jan;8(1):40-51.
120. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilization and cost analysis of memantine in patients with moderate-to-severe Alzheimer's disease. Pharmacoeconomics. 2003;21(5):327-40.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Antidepressants
AHFS Class 281604
November 4, 2020

I. Overview

The antidepressants are approved to treat a variety of mental disorders, including anxiety disorders, depressive disorders, eating disorders (bulimia nervosa), and premenstrual dysphoric disorder.[1-32] Anxiety disorders include agoraphobia, anxiety disorder due to another medical condition, generalized anxiety disorder, other specified anxiety disorder, panic disorder, selective mutism, separation anxiety disorder, social anxiety disorder or social phobia, specific phobia, substance/medication induced anxiety disorder, and unspecified anxiety disorder.[33] Some of the antidepressants are also approved to treat nonpsychiatric conditions, such as chronic musculoskeletal pain, diabetic peripheral neuropathy, fibromyalgia, insomnia, moderate to severe vasomotor symptoms associated with menopause, nocturnal enuresis, and tobacco abuse.[1-32]

The antidepressants are categorized into six different American Hospital Formulary Service (AHFS) subclasses, including monoamine oxidase inhibitors (MAOIs), selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs), selective serotonin-reuptake inhibitors (SSRIs), serotonin modulators, tricyclic antidepressants (TCAs), and miscellaneous agents. The agents which make up these subclasses differ with respect to their Food and drug Administration (FDA)-approved indications, mechanism of action, pharmacokinetics, adverse events, and drug interactions.

Monoamine oxidase is an enzyme that is distributed in various tissues throughout the body. This enzyme is responsible for the catabolism of monoamines ingested in food, as well as for the inactivation of neurotransmitters (e.g., serotonin, norepinephrine, and dopamine).[1,2] MAOIs increase the concentration of these neurotransmitters, which leads to their antidepressant activity. There are two types of monoamine oxidase, including MAO-A and MAO-B. The MAOIs differ with regards to selectivity for MAO receptor type and reversibility.[3-5,32] The SNRIs are potent inhibitors of neuronal norepinephrine and serotonin reuptake.[1,2,32] The SSRIs inhibit the neuronal uptake of serotonin and have minimal effects on norepinephrine or dopamine neuronal uptake.[1,2,32] The clinical efficacy of the SNRIs and SSRIs is thought to be related to the potentiation of neurotransmitter activity in the central nervous system. The exact mechanism of action of the serotonin modulators is unknown. Nefazodone inhibits neuronal uptake of serotonin and norepinephrine, and is a direct antagonist of serotonin ($5\text{-}HT_2$) receptors. Nefazodone and trazodone also block $alpha_1$-adrenergic receptors, which may be associated with postural hypotension.[1,2,32] Trazodone is thought to selectively inhibit serotonin uptake at the presynaptic neuronal membrane.[1,2] Vilazodone is a SSRI and partial serotonin $5\text{-}HT_{1A}$ receptor agonist.[19] Vortioxetine exhibits various serotonergic activities including the inhibition of the reuptake of serotonin, antagonistic effects at the $5\text{-}HT_3$, $5\text{-}HT_7$, and $5\text{-}HT_{1D}$ receptors, inhibition of the serotonin transporter, agonistic effects at $5\text{-}HT_{1A}$ receptors, and partial agonistic effects at $5\text{-}HT_{1B}$ receptors.[20] The TCAs interact with a wide variety of central nervous system receptor types, and as a result, cause many undesirable side effects. Clinically, they inhibit the reuptake of norepinephrine (secondary amines) and serotonin (tertiary amines) at the presynaptic neuron.[1,2,24-29,32] The miscellaneous antidepressants include brexanolone, bupropion, esketamine and mirtazapine. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine; it does not inhibit monoamine oxidase or the reuptake of serotonin.[25-28,32] Mirtazapine is a tetracyclic compound, but is unrelated to the TCAs. It acts as an antagonist at central $alpha_2$-adrenergic receptors, which is thought to result in an increase in central noradrenergic and serotonergic activity.[29,32] Mirtazapine is also a potent antagonist of histamine receptors and is a moderate peripheral $alpha_1$-adrenergic receptor antagonist, which results in sedation and orthostatic hypotension.[29] Brexanolone is a neuroactive steroid gamma-aminobutyric acid-A receptor positive modulator that is chemically identical to endogenous allopregnanolone, which is a potent neuroactive steroid that rises with progesterone levels during pregnancy. Brexanolone is indicated for the treatment of postpartum depression in adults and is administered intravenously.[30] Esketamine nasal spray is indicated in conjunction with an oral antidepressant for the treatment of adults with treatment-resistant depression or depressive symptoms with major depressive disorder with acute suicidal ideation or behavior. Esketamine is the S-enantiomer of racemic ketamine, and a non-selective, noncompetitive antagonist of the N-methyl-D-aspartate receptor. The precise mechanism of action of esketamine in major depressive disorder is unknown.[31]

The antidepressants that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. The majority of the products are available in a generic formulation, and there is at least one generic product available in each antidepressant subclass. This class was last reviewed in August 2018.

Table 1. Antidepressants Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Monoamine Oxidase Inhibitors			
Isocarboxazid	tablet	Marplan®	none
Phenelzine	tablet	Nardil®*	phenelzine
Selegiline	transdermal patch	Emsam®	none
Tranylcypromine	tablet	N/A	tranylcypromine
Selective Serotonin- and Norepinephrine-reuptake Inhibitors			
Desvenlafaxine	extended-release tablet	Pristiq®*	desvenlafaxine
Duloxetine	delayed-release capsule	Cymbalta®*, Drizalma Sprinkle®	duloxetine
Levomilnacipran	extended-release capsule	Fetzima®	none
Venlafaxine	extended-release capsule, extended-release tablet, tablet	Effexor XR®*	venlafaxine
Selective Serotonin-reuptake Inhibitors			
Citalopram	solution, tablet	Celexa®*	citalopram
Escitalopram	solution, tablet	Lexapro®*	escitalopram
Fluoxetine	capsule, delayed-release capsule, solution, tablet	Prozac®*, Sarafem®*	fluoxetine
Fluvoxamine	extended-release capsule, tablet	N/A	fluvoxamine
Paroxetine	capsule, extended-release tablet, suspension, tablet	Brisdelle®*, Paxil®*, Paxil CR®*, Pexeva®	paroxetine
Sertraline	oral concentrate, tablet	Zoloft®*	sertraline
Serotonin Modulators			
Nefazodone	tablet	N/A	nefazodone
Trazodone	tablet	N/A	trazodone
Vilazodone	tablet	Viibryd®	none
Vortioxetine	tablet	Trintellix®	none
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Single Entity Agents			
Amitriptyline	tablet	N/A	amitriptyline
Amoxapine	tablet	N/A	amoxapine
Clomipramine	capsule	Anafranil®*	clomipramine
Desipramine	tablet	Norpramin®*	desipramine
Doxepin	capsule, oral concentrate, tablet	Silenor®*	doxepin
Imipramine	capsule, tablet	Tofranil®*	imipramine
Maprotiline	tablet	N/A	maprotiline
Nortriptyline	capsule, solution	Pamelor®*	nortriptyline
Protriptyline	tablet	N/A	protriptyline
Trimipramine	capsule	N/A	trimipramine
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Combination Products			
Amitriptyline and chlordiazepoxide	tablet	N/A	amitriptyline and chlordiazepoxide
Antidepressants, Miscellaneous			
Brexanolone	injection	Zulresso®	none
Bupropion	extended-release tablet, sustained-release tablet, tablet	Aplenzin®, Forfivo XL®*, Wellbutrin SR®*, Wellbutrin XL®*	bupropion

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Esketamine	nasal spray	Spravato®	none
Mirtazapine	orally disintegrating tablet, tablet	Remeron®*	mirtazapine

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.
N/A=Not available.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the antidepressants are summarized in Table 2.

Table 2. Treatment Guidelines Using the Antidepressants

Clinical Guideline	Recommendation(s)
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition (2010)**[34]	Acute phase • Pharmacotherapy: o An antidepressant medication is recommended as an initial treatment choice for patients with mild to moderate major depressive disorder (MDD) and should be provided for those with severe MDD. o Due to the fact that the effectiveness of antidepressant medications is generally comparable between classes and within classes of medications, the initial selection of an antidepressant medication will largely be based on the anticipated side effects; the safety or tolerability of these side effects; pharmacological properties of the medication and additional factors such as medication response in prior episodes, cost and patient preference. o For the majority of patients, a selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), bupropion or mirtazapine is optimal. o In general, the use of nonselective monoamine oxidase inhibitors (MAOIs) should be restricted to patients who do not respond to other treatments. o During the acute phase of treatment, patients should be carefully and systematically monitored on a regular basis to assess their response to pharmacotherapy. o If side effects do occur, an initial strategy is to lower the dose of the antidepressants or to change to an antidepressant that is not associated with those side effects. • Assessing the adequacy of treatment response: o It is important to establish that treatment has been administered for a sufficient duration and at a sufficient frequency or, in the case of medication, dose. o Generally, four to eight weeks of treatment are needed before concluding that a patient is partially responsive or unresponsive to a specific intervention. • Strategies to address non-response: o For individuals who have not responded fully to treatment, the acute phase of treatment should not be concluded prematurely, as an incomplete response to treatment is often associated with poor functional outcomes. o If at least a moderate improvement in symptoms is not observed within four to eight weeks of treatment initiation, the diagnosis should be reappraised, side effects assessed, complicating co-occurring conditions and psychosocial factors reviewed and the treatment plan adjusted. o It is important to assess the quality of the therapeutic alliance and

Clinical Guideline	Recommendation(s)
	treatment adherence. ○ If medications are prescribed, the psychiatrist should determine whether pharmacokinetic or pharmacodynamic factors suggest a need to adjust medication dose. ○ After an additional four to eight weeks of treatment, if the patient continues to show minimal or no improvement in symptoms, the psychiatrist should conduct another thorough review of possible contributory factors and make additional changes in the treatment plan. ○ There are a number of strategies available when a change in treatment seems necessary. ▪ For patients treated with an antidepressant, optimizing the medication dose is a reasonable first step if the side effect burden is tolerable and the upper limit of a medication dose has not been reached. ▪ In patients who have shown minimal improvement or experienced significant medication side effects, other options include augmenting the antidepressant with a depression-focused psychotherapy or with other agents or with changing to another non-MAOI antidepressant. ▪ Patients may be changed to an antidepressant from the same pharmacological class or to one from a different class. ▪ Patients who have not responded to an SSRI, may respond to SNRI. ▪ Augmentation of antidepressant medications can utilize another non-MAOI antidepressant, generally from a different pharmacological class, or a non-antidepressant medication, such as lithium, thyroid hormone or a second generation antipsychotic. <u>Continuation phase</u> • During the continuation phase of treatment, the patient should be carefully monitored for signs of possible relapse. • Systematic assessment of symptoms, side effects, adherence and functional status is essential and may be facilitated through the use of clinician- and/or patient-administered rating scales. • To reduce the risk of relapse, patients who have been treated successfully with antidepressant medications in the acute phase should continue treatment with these agents for four to nine months. • In general, the dose used in the acute phase should be used in the continuation phase. • To prevent a relapse of depression in the continuation phase, depression-focused psychotherapy is recommended, with the best evidence available for cognitive behavioral therapy (CBT). <u>Maintenance phase</u> • In order to reduce the risk of a recurrent depressive episode, patients who have had three or more prior MDD episodes or who have chronic MDD should proceed to the maintenance phase of treatment after completing the continuation phase. • Maintenance therapy should also be considered for patients with additional risk factors for recurrence. • Additional considerations that may play a role in the decision to use maintenance therapy include patient preference, the type of treatment received, the presence of side effects during continuation therapy, the probability of recurrence, the frequency and severity of prior depressive episodes, the persistence of depressive symptoms after recovery and the presence of co-

Clinical Guideline	Recommendation(s)

	occurring disorders. Such factors also contribute to decisions about the duration of the maintenance phase.
	• For many patients, some form of maintenance treatment will be required indefinitely.
	• An antidepressant medication that produced symptom remission during the acute phase and maintained remission during the continuation phase should be continued at a full therapeutic dose.
	• For patients whose depressive episodes have not previously responded to acute or continuation treatment with medications or a depression-focused psychotherapy but who have shown a response to electroconvulsive therapy (ECT), maintenance ECT may be considered.
	• Due to the risk of recurrence, patients should be monitored systematically and at regular intervals during the maintenance phase.
	
	<u>Discontinuation of treatment</u>
	• When pharmacotherapy is being discontinued, it is best to taper the medication over the course of at least several weeks.
	• To minimize the likelihood of discontinuation symptoms, patients should be advised not to stop medications abruptly and to take medications with them when they travel or are away from home.
	• A slow taper or temporary change to a longer half-life antidepressant may reduce the risk of discontinuation syndrome when discontinuing antidepressants or reducing antidepressant doses.
	• Before the discontinuation of active treatment, patients should be informed of the potential for a depressive relapse and a plan should be established for seeking treatment in the event of recurrent symptoms.
	• After discontinuation of medications, patients should continue to be monitored over the next several months and should receive another course of adequate acute phase treatment if symptoms recur.
	
	<u>Pharmacologic Treatment for Postpartum Depression (PPD)</u>
	• Antidepressants are most commonly prescribed for PPD according to the same principles for other types of MDD, despite a limited number of controlled studies.
	  ○ SSRIs have shown variable efficacy results in two placebo-controlled trials.
	  ▪ Fluoxetine demonstrated higher efficacy than placebo and paroxetine demonstrated comparable efficacy to placebo on the primary outcome of improvement in depressive symptoms.
	  ○ There was no difference in response and remission rates in a randomized controlled trial of sertraline versus nortriptyline.
	  ○ Open studies of other antidepressants in postpartum women suggest efficacy.
	  ○ Paroxetine alone and paroxetine plus CBT both produced a significant change from baseline in one study, although there was no placebo-only group for comparison.
	• Antidepressant medications are considered compatible with breastfeeding, but long-term data is lacking.
	  ○ Most studies show low levels of exposure via breast milk with the exception of fluoxetine (which appears to have a dose-related risk for detectable level in infant serum).

National Institute for Health and Clinical Excellence:	<u>Persistent subthreshold depressive symptoms or mild to moderate depression</u> • Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression.

Clinical Guideline	Recommendation(s)
Depression in Adults: recognition and management (2009)[35] **Last updated: April 2016**	• Consider antidepressants for the following people: o A past history of moderate or severe depression. o Initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least two years). o Subthreshold depressive symptoms or mild depression that persist(s) after other interventions. <u>Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions, and moderate and severe depression</u> • For patients with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: o An antidepressant (normally an SSRI) or a high intensity psychosocial intervention. • For people with moderate or severe depression, provide a combination of an antidepressant medication and a high intensity psychological intervention. • The choice of intervention should be influenced by the duration of the episodes of depression and the trajectory of symptoms, previous course of depression and response to treatment, likelihood of adherence to treatment and any potential adverse effects and the patient's treatment preference and priorities. <u>Antidepressant drugs</u> • Choice of antidepressant: o Discuss the choice of antidepressant with the patient, including any anticipated adverse events and potential drug interactions, and their perception of the efficacy and tolerability of any antidepressant they have previously taken. o When an antidepressant is used, it should normally be an SSRI in a generic form. The SSRIs are equally effective as other antidepressants and have a favorable risk-benefit ratio. Fluoxetine, fluvoxamine and paroxetine are associated with a higher propensity for drug interactions than other SSRIs, and paroxetine is associated with a higher incidence of discontinuation symptoms than other SSRIs. o Take into account toxicity in overdose when choosing an antidepressant for people at significant risk for suicide. Be aware that compared to other equally effective antidepressants routinely used in primary care, venlafaxine is associated with a greater risk of death from overdose, and tri-cyclic antidepressants (TCAs), except lofepramine, are associated with the greatest risk in overdose. o When prescribing drugs other than SSRIs, take the following into account: the increased likelihood of the person stopping treatment because of side effects with duloxetine, venlafaxine and TCAs, the specific cautions, contraindications and monitoring requirements for some drugs, that non-reversible MAOIs should normally be prescribed only by specialists. • Starting and initial phase of treatment: o When prescribing antidepressants, explore any concerns the patient has. Explain the gradual development of the full antidepressant effect, the importance of taking the medication as prescribed, the need to continue treatment after remission, potential side effects, the potential for interactions with other medications, the risk and nature of discontinuation symptoms with all antidepressants and how these symptoms can be minimized and the fact that addiction does not occur with antidepressants. o If side effects develop early in antidepressant treatment, provide

Clinical Guideline	Recommendation(s)
	appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the patient, stop the antidepressant, change to a different antidepressant if the person prefers or consider short term concomitant treatment with a benzodiazepine if anxiety, agitation and/or insomnia are problematic (this should usually be for no longer than two weeks in order to prevent the development of dependence). ○ Patients who start on low dose TCAs and who have clear clinical response can be maintained on that dose with careful monitoring. ○ If the patient's depression shows no improvement after two to four weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. ○ If response is absent or minimal after three to four weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support and consider increasing the dose in line with the summary of product characteristics if there are no significant side effects or switching to another antidepressant. • If the patient's depression shows some improvement by four weeks, continue treatment for another two to four weeks. Consider switching to another antidepressant if response is still not adequate, there are side effects, or the person prefers to change treatment.
National Institute for Health and Care Excellence: **Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance (2014)**[36] Last Updated February 2020	Interventions for Depression • Consider facilitated self-help for pregnant or postnatal women with persistent subthreshold depressive symptoms, or mild to moderate depression. • Consider a TCA, SSRI, or SNRI for women with a history of severe depression who initially presented with mild depression in pregnancy or the postnatal period. • For women with moderate or severe depression in pregnancy or the postanal period consider: ○ A high-intensity psychological intervention (i.e., CBT) ○ TCA, SSRI or SNRI if the patient has expressed a preference for medication, declines psychological interventions, or has symptoms which have not responses to psychological interventions, or ○ A high-intensity psychological intervention in combination with medication following no response, or limited response, to a high-intensity psychological intervention or medication alone • Consider gradually stopping the medication and facilitating therapy in women using a TCA, SSRI, or SNRI for mild/moderate depression who become pregnant. • In pregnant women taking a TCA, SSRI, or SNRI for severe depression, evaluate any previous response to treatment, stage of pregnancy, risk of relapse, risk associated with the patient's preferred therapies, and consider: ○ Continuing the current medication ○ Changing medications if there is an effective drug with a lower risk of adverse effects ○ Combining the medication with a psychological intervention (e.g., CBT); or ○ Switching to a high-intensity psychological intervention.
National Institute for Clinical Excellence: **Generalized Anxiety Disorder and Panic Disorder in Adults: management (2011)**[37]	Stepped care for people with generalized anxiety disorder (GAD) • If a person with GAD chooses drug treatment, offer a SSRI, specifically sertraline. • If sertraline is ineffective, offer an alternative SSRI or a SNRI, taking into account the following factors: ○ Tendency to produce a withdrawal syndrome (especially with paroxetine and venlafaxine).

Clinical Guideline	Recommendation(s)
Last updated July 2019	○ The side-effect profile and the potential for drug interactions. ○ The risk of suicide and likelihood of toxicity in overdose (especially with venlafaxine). ○ The person's prior experience of treatment with individual drugs (particularly adherence, effectiveness, side effects, experience of withdrawal syndrome and the person's preference). • If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin. • Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises. • Do not offer an antipsychotic for the treatment of GAD in primary care. <u>Panic disorder general considerations</u> • Benzodiazepines are associated with a less effective outcome in the long term and should not be prescribed for panic disorder. • Sedating antihistamines or antipsychotics should not be prescribed for panic disorder. • Interventions with evidence for the longest duration of effect are listed in descending order, where preference of the patient should be taken into account: ○ Psychological therapy (i.e., cognitive behavioral therapy, structured problem solving, psychoeducation). ○ Pharmacological therapy (antidepressant therapy). ○ Self-help interventions (i.e., bibliotherapy, support groups, exercise, cognitive behavioral therapy via a computer interface). • Antidepressants should be the only pharmacologic intervention used in the longer term. • The classes of antidepressants that have an evidence base for effectiveness are the SSRIs, SNRIs and TCAs. • Unless otherwise indicated, an SSRI (e.g., paroxetine, fluvoxamine, citalopram) licensed for panic disorder should be offered. If an SSRI is not suitable or there is no improvement after a 12-week course and if further medication is appropriate, imipramine or clomipramine may be considered. • If the patient is showing improvement, the medication should be continued for at least six months after optimal dose is reached, after which the dose may be tapered slowly over an extended period of time to minimize the risk of discontinuation/withdrawal symptoms.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Panic Disorder, Second Edition (2009)[38]**	• SSRIs, SNRIs, TCAs, and benzodiazepines have demonstrated efficacy in numerous controlled trials and are recommended for treatment of panic disorder. • Because SSRIs, SNRIs, TCAs, and benzodiazepines appear roughly comparable in their efficacy for panic disorder, selecting a medication involves considerations of side effects, pharmacological properties, potential drug interactions, prior treatment history, and comorbid medical and psychiatric conditions. • The relatively favorable safety and side effect profile of SSRIs and SNRIs makes them the best initial choice for many patients with panic disorder. • There is no evidence of differential efficacy between the SSRIs, although differences in the side-effect profile (e.g., potential for weight gain, discontinuation-related symptoms), half-life, propensity for drug interactions, and availability of generic formulations may be clinically relevant. They are safer than TCAs and monoamine oxidase inhibitors. They are rarely lethal in overdose and have few serious effects on cardiovascular function. • Venlafaxine extended release has been shown to be effective for panic disorder. It is generally well tolerated and has a side effect profile similar to the SSRIs. No systematic data are currently available supporting the use of duloxetine, in panic disorder, although its mechanism of action suggests it might be an

Clinical Guideline	Recommendation(s)
	effective agent. • Although TCAs are effective, the side effects and greater toxicity in overdose limit their acceptability to patients and clinical utility. Given the equivalency of TCAs in treating depression, there is little reason to expect other TCAs to work less well for panic disorder. TCAs that are more noradrenergic (e.g., desipramine, maprotiline) may be less effective than agents that are more serotonergic. • SSRIs, SNRIs, and TCAs are all preferable to benzodiazepines as monotherapies for patients with comorbid depression or substance use disorders. Benzodiazepines may be especially useful adjunctively with antidepressants to treat residual anxiety symptoms. • Benzodiazepines may be preferred for patients with very distressing or impairing symptoms in whom rapid symptom control is critical. The benefit of more rapid response to benzodiazepines must be balanced against the possibilities of troublesome side effects and physiological dependence that may lead to difficulty discontinuing the medication. • MAOIs appear effective for panic disorder but, because of their safety profile, they are generally reserved for patients who have failed to respond to several first-line treatments. • Neither trazodone nor nefazodone can be recommended as a first-line treatment for panic disorder. There is minimal support for the use of trazodone in panic disorder and it appears less effective than imipramine and alprazolam. There are a few small, uncontrolled studies showing benefits of nefazodone in some patients with panic disorder; however, its use has been limited by concerns about liver toxicity. • Bupropion was effective in one small trial and ineffective in another. It cannot be recommended as a first line treatment for panic disorder. • Other medications with less empirical data may be considered as monotherapies or adjunctive treatments for panic disorder when patients have failed to respond to several standard treatments or based on other individual circumstances.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder (2012)[39]**	• The psychiatric assessment of children and adolescents should routinely screen for the presence of obsessions and/or compulsions or repetitive behaviors. • If screening suggests obsessive-compulsive symptoms, clinicians should fully evaluate the child using the DSM-IV-TR criteria and scalar assessment. • A complete psychiatric evaluation should be performed, including information from all available sources and compromising standard elements of history and a mental state examination, with attention to the presence of commonly occurring comorbid psychiatric disorders. • It is possible that three out of four children with obsessive-compulsive disorder (OCD) meet criteria for at least one comorbid diagnosis, and these children have lower response rates to CBT than children without comorbid diagnoses. • Identification of MDD and bipolar disorder is very important before initiating treatment with a SSRI. • Comorbid eating disorders are infrequent in younger children; however, comorbid eating disorders become more prevalent in adolescents. • A full medical, developmental, family and school history should be included with the psychiatric history and examination. • CBT is the first-line treatment for mild to moderate OCD in children, whenever possible. • For moderate to severe OCD, medication is indicated in addition to CBT. • Serotonin reuptake inhibitors (SRIs) are the first-line medications recommended for OCD in children, including clomipramine (a TCA) and certain SSRIs (fluoxetine, fluvoxamine, paroxetine and sertraline). • There is no SRI that is proven to be more efficacious over another. • The modality of assigned treatment should be guided by empirical evidence on

Clinical Guideline	Recommendation(s)
	the moderators and predictors of treatment response. • Multimodal treatment with CBT and medication is recommended if CBT fails to achieve a clinical response after several months or in more severe cases. • Medication augmentation strategies are reserved for treatment-resistant cases in which impairments are deemed moderate in at least one important domain of function despite adequate monotherapy. • Adding clomipramine to an SSRI is a useful medication augmentation strategy. • Augmenting with an atypical neuroleptic is also a strategy employed by experts (e.g. haloperidol and risperidone combined) based on studies in adults with OCD; however, controlled data for the use of atypical antipsychotics in children with OCD does not exist. • A minimum of two adequate SSRI trials or an SSRI and clomipramine trial is recommended before atypical augmentation. • Empirically validated medication and psychosocial treatments for comorbid disorders should be considered.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder (2007; 2013 update)[40]**	<u>General considerations</u> • OCD is a chronic illness which typically waxes and wanes. • Patients who have symptoms interfering with daily functioning should be treated. • Clinical remission and recovery may not always occur and will not occur rapidly. • Goals of treatment include improving symptoms, patient functioning, and quality of life. <u>Initial treatment options</u> • The choice of treatment depends on the patient's ability to comply with therapy, whether psychotherapy, pharmacotherapy, or both. • First-line treatments include cognitive-behavioral therapy, SRIs, or a combination of the two. The choice depends on past treatment history, comorbid psychiatric conditions, severity of symptoms, and functional limitations. • Cognitive-behavioral therapy or SRI therapy may be used alone or in combination, and combination therapy may be considered in patients who do not respond fully to monotherapy, those with severe symptoms, those with comorbid psychiatric illnesses for which an SRI is indicated, or in patients who wish to limit SRI exposure. • All SRIs appear to be equally effective, though patients may respond to agents differently. • Prescribers should consider the safety, side effects, FDA warnings, drug interactions, past response to treatment, and comorbid medical conditions when choosing a medication for treatment. • Most patients do not experience a significant improvement until four to six weeks after treatment initiation, and some may ultimately respond after as many as 10 to 12 weeks. • Patients not responding after 10 to 12 weeks may respond to a higher dose of the same medication. <u>Changing treatments and pursuing sequential treatment trials</u> • Augmentation strategies may be preferred to switching strategies in patients who have a partial response to the initial treatment. • Augmentation of SRIs with trials of different antipsychotic medications or with cognitive-behavioral therapy or augmentation of cognitive-behavioral therapy with an SRI. • Patients who do not respond to their first SRI may have their medication switched to a different SRI. A switch to venlafaxine is less likely to produce an

Clinical Guideline	Recommendation(s)
	adequate response. • For patients who have not benefitted from their first SSRI trial, a switch to mirtazapine can be considered. • After first- and second-line treatments and well-supported augmentation strategies have been exhausted, less well-supported treatment strategies may be considered. These include augmenting SRIs with clomipramine, buspirone, pindolol, riluzole, or once- weekly oral morphine sulfate. • Evidence for beneficial effects of benzodiazepines as monotherapy for OCD is limited to case reports with clonazepam and alprazolam. Modest doses of benzodiazepines may relieve anxiety and distress in OCD without directly diminishing the frequency or duration of obsessions or compulsions. Given their limited evidence for efficacy, benzodiazepines cannot be recommended as monotherapy for OCD, except in those rare individuals who are unable or unwilling to take standard anti-OCD medications.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents With Posttraumatic Stress Disorder (2010)**[41]	• The psychiatric evaluation of children and adolescents should routinely include questions about traumatic experiences and posttraumatic stress disorder (PTSD) symptoms. • If the evaluation indicates symptoms of PTSD, the clinician should formally determine if PTSD is present, the severity of PTSD symptoms and the degree of functional impairment. Caregivers should be included in the formal evaluation. • A differential diagnosis should be conducted in order to rule out diagnoses with symptoms that can mimic PTSD symptoms. • The treatment plan should be comprehensive in approach and should consider the severity of symptoms and impairment, as well as comorbid psychiatric conditions. • Trauma-focused psychotherapies should be considered first-line in children and adolescents with PTSD, including psychoanalytic, attachment and cognitive behavioral treatment models. • SSRIs can be considered for treatment of children and adolescents with PTSD. • The effect of SSRIs in children with PTSD may be more consistent with a placebo effect. • Other medications such as clonidine and propranolol may be useful in decreasing symptoms of hyperarousal, and anticonvulsants may beneficial in treating PTSD symptoms other than avoidance. • Benzodiazepines have not been found to be beneficial in treating PTSD symptoms. • School-based accommodations are recommended for children with PTSD, especially in children with school-based trauma, such as bullying. • The use of restrictive, "rebirthing," binding or other coercive therapies are not recommended. • Screening for PTSD in the school or community should be conducted after traumatic events that affect significant numbers of children.
American Psychiatric Association: **Guideline Watch: Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder (2009)**[42]	• Meta-analyses and several randomized controlled trials published since 2004 (2004 Guideline summarized below) support the greater efficacy of SSRIs and SNRIs over placebo for non-combat-related PTSD. • The evidence base for pharmacological intervention in combat-related PTSD has not been significantly augmented by recent studies. Studies suggest that SSRIs may not be recommended with the previous level of confidence for the treatment of PTSD in this particular population. Further research is needed to answer why these populations have been shown to have differential responses to SSRI treatment. • As described in the 2004 guideline, no significant differences among antidepressants, including the SSRIs, were found in the few head-to-head studies then available. Since that time, studies have been published comparing nefazodone and sertraline, venlafaxine and sertraline, the SNRI reboxetine and

Clinical Guideline	Recommendation(s)
	fluvoxamine, and fluoxetine, moclobemide, and tianeptine. These studies have generally demonstrated the greater efficacy of antidepressants to placebo but have done little to clarify the relative utility of these different antidepressants. • There is a relatively robust evidence basis for pharmacological treatment with antidepressant medications (particularly SSRIs and SNRIs for noncombat PTSD) as compared to other classes of medications. • Comparison of other treatments with the SSRIs and SNRIs is complicated by methodological differences in the available studies. SSRIs and SNRIs have mostly been studied in rigorous trials compared to placebo; other agents have been studied against "treatment as usual" or as augmentation agents in patients with refractory illness.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder (2004)[43]**	• Goals of treatment for patients with PTSD and acute stress disorder (ASD) include lessening the severity of symptoms and preventing trauma-related comorbid conditions. • Clinical trial data and randomized studies are limited and difficult to perform. • Treatment includes pharmacotherapy, psychotherapy and supportive measures. • SSRIs are first-line therapy for PTSD and ASD and if found effective, treatment should be continued in order to continue to see benefit. • Second-line treatment agents include TCAs (specifically amitriptyline and imipramine, but not desipramine) and MAOIs. • Benzodiazepines should not be used as monotherapy, but may be effective as sedatives and anxiolytics. • Atypical antipsychotics may be necessary for patients experiencing psychotic symptoms. • Anticonvulsants (divalproex, carbamazepine, topiramate and lamotrigine) have produced mixed results for treating PTSD and ASD but may prove to be beneficial. • Limited data exists for the use of adrenergic inhibitors and their use is not part of the guideline at this time. • An adequate trial of therapy requires a minimum of three months of treatment. If treatment is effective, it should be continued for up to 12 months or longer.
American Academy of Family Physicians: **Premenstrual Syndrome and Premenstrual Dysphoric Disorder (2016)[44]**	• SSRIs are first-line treatment for severe symptoms of PMS and PMDD. Sertraline, paroxetine, fluoxetine, citalopram, and escitalopram can be used to treat the psychiatric symptoms of PMS and PMDD and have been shown to relieve some of the physical symptoms. • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) such as venlafaxine have been used off-label to treat PMDD in women with predominantly psychological symptoms. The effect is achieved over a relatively short period, three to four weeks, and sustained throughout subsequent menstrual cycles. • Studies have suggested that oral contraceptives provide benefit when treating physical and psychiatric symptoms of PMS or PMDD. Oral contraceptives with and without drospirenone seem to be effective at relieving abdominal bloating, mastalgia, headache, weight gain, and swelling of extremities. Trials that extend beyond three months are needed for further analysis. • Calcium supplementation has been evaluated as treatment for PMS. Women with PMS and mood instability have been noted to have associated cyclic changes in their calcium levels; the exact mechanism of action is unknown. • Although gonadotropin-releasing hormone agonists have been used since the 1980s and are effective, they are not practical for long-term use because of the increased cardiovascular and osteoporosis risks associated with extended use. Long-term users often need hormone add-back therapy to counteract many of their hypoestrogenic effects, which may cause a return of PMS symptoms.
American Psychiatric Association: **Practice Guideline for**	• Patients with eating disorders should be treated with nutritional rehabilitation. • Psychosocial therapy should be used in the treatment of anorexia. • SSRIs may be considered in the treatment of anorexia.

Clinical Guideline	Recommendation(s)
the Treatment of Patients with Eating Disorders (2006)[45] **Reaffirmed August 2012**	• Bupropion, TCAs, and MAOIs should be avoided in patients with eating disorders. • Atypical antipsychotics may be used in patients with severe symptoms. • SSRIs may be considered in patients with bulimia.
American College of Physicians: **Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain (2017)[46]**	• Given that most patients with acute or subacute low back pain improve over time regardless of treatment, select nonpharmacologic treatment with superficial heat, massage, acupuncture, or spinal manipulation. If pharmacologic treatment is desired, select nonsteroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxants. • For patients with chronic low back pain, initially select nonpharmacologic treatment with exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor control exercise, progressive relaxation, electromyography biofeedback, low-level laser therapy, operant therapy, cognitive behavioral therapy, or spinal manipulation. Nonpharmacologic interventions are considered as first-line options in patients with chronic low back pain because fewer harms are associated with these types of therapies than with pharmacologic options. • Pharmacologic therapy should be considered for patients with chronic low back pain who do not improve with nonpharmacologic interventions. In patients with chronic low back pain who have had an inadequate response to nonpharmacologic therapy, consider pharmacologic treatment with NSAIDs as first-line therapy, or tramadol or duloxetine as second-line therapy. Only consider opioids as an option in patients who have failed the aforementioned treatments and only if the potential benefits outweigh the risks for individual patients and after a discussion of known risks and realistic benefits with patients.
American College of Rheumatology/Arthritis Foundation: **Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019)[47]**	Pharmacological Management • Topical NSAIDs are strongly recommended for patients with knee osteoarthritis and conditionally recommended for patients with hand osteoarthritis. • Topical capsaicin is conditionally recommended for patients with knee osteoarthritis and conditionally recommended against in patients with hand osteoarthritis. • Oral NSAIDs are strongly recommended for patients with knee, hip, and/or hand osteoarthritis. • Intraarticular glucocorticoid injections are strongly recommended for patients with knee and/or hip osteoarthritis and conditionally recommended for patients with hand osteoarthritis. • Ultrasound guidance for intraarticular glucocorticoid injection is strongly recommended for injection into hip joints. • Intraarticular glucocorticoid injections versus other injections are conditionally recommended for patients with knee, hip, and/or hand osteoarthritis. • Acetaminophen is conditionally recommended for patients with knee, hip, and/or hand osteoarthritis. • Duloxetine is conditionally recommended for patients with knee, hip, and/or hand osteoarthritis. • Tramadol is conditionally recommended for patients with knee, hip, and/or osteoarthritis. • Non-tramadol opioids are conditionally recommended against in patients with knee, hand, and/or hip osteoarthritis with the recognition that they may be used under certain circum-stances, particularly when alternatives have been exhausted. • Colchicine is conditionally recommended against in patients with knee, hip,

Clinical Guideline	Recommendation(s)
	and/or hand osteoarthritis. • Fish oil is conditionally recommended against in patients with knee, hip, and/or hand osteoarthritis. • Vitamin D is conditionally recommended against in patients with knee, hip, and/or hand osteoarthritis. • Bisphosphonates are strongly recommended against in patients with knee, hip, and/or hand osteoarthritis. • Glucosamine is strongly recommended against in patients with knee, hip, and/or hand osteoarthritis. • Chondroitin sulfate is strongly recommended against in patients with knee and/or hip osteoarthritis as are combination products that include glucosamine and chondroitin sulfate, but is conditionally recommended for patients with hand osteoarthritis. • Hydroxychloroquine is strongly recommended against in patients with knee, hip, and/or hand osteoarthritis • Methotrexate is strongly recommended against in patients with knee, hip, and/or hand osteoarthritis. • Intraarticular hyaluronic acid injections are conditionally recommended against in patients with knee and/or first carpometacarpal joint osteoarthritis and strongly recommended against in patients with hip osteoarthritis. • Intraarticular botulinum toxin injections are conditionally recommended against in patients with knee and/or hip osteoarthritis. • Prolotherapy is conditionally recommended against in patients with knee and/or hip osteoarthritis. • Platelet-rich plasma treatment is strongly recommended against in patients with knee and/or hip osteoarthritis. • Stem cell injections are strongly recommended against in patients with knee and/or hip osteoarthritis • Tumor necrosis factor inhibitors and interleukin-1 receptor antagonists are strongly recommended against in patients with knee, hip, and/or hand osteoarthritis.

American Academy of Orthopedic Surgeons: **Clinical Practice Guideline on Osteoarthritis of the Knee (2013)**[48]	• Conservative treatments
	  ○ It is recommended that patients with symptomatic osteoarthritis of the knee participate in self-management programs, strengthening, low-impact aerobic exercises, and neuromuscular education; and engage in physical activity consistent with national guidelines.
	  ○ Weight loss for patients with symptomatic osteoarthritis of the knee and a body mass index ≥25 is recommended.
	  ○ The guideline cannot recommend acupuncture in patients with symptomatic osteoarthritis of the knee.
	  ○ No recommendation can be made concerning the use of physical agents (including electrotherapeutic modalities) in patients with symptomatic osteoarthritis of the knee.
	  ○ No recommendation can be made concerning manual therapy in patients with symptomatic osteoarthritis of the knee.
	  ○ The guideline cannot suggest a valgus directing force brace (medial compartment unloader) for patients with symptomatic osteoarthritis of the knee.
	  ○ No recommendation can be made concerning a lateral wedge insole be used for patients with symptomatic medial compartment osteoarthritis of the knee.
	  ○ The guideline cannot recommend using glucosamine and chondroitin for patients with symptomatic osteoarthritis of the knee.
	• Pharmacologic treatments
	  ○ NSAIDs; oral or topical or tramadol for patients with symptomatic

Clinical Guideline	Recommendation(s)
	osteoarthritis of the knee are recommended. o No recommendation can be made concerning the use of acetaminophen, opioids, or pain patches for patients with symptomatic osteoarthritis of the knee. • Procedural treatments o No recommendation can be made concerning the use of intraarticular corticosteroids for patients with symptomatic osteoarthritis of the knee. o The guideline cannot recommend using hyaluronic acid for patients with symptomatic osteoarthritis of the knee. o No recommendation can be made concerning growth factor injections and/or platelet rich plasma for patients with symptomatic osteoarthritis of the knee. o The guideline cannot suggest that the practitioner use needle lavage for patients with symptomatic osteoarthritis of the knee. • Surgical treatments o The guideline cannot recommend performing arthroscopy with lavage and/or debridement in patients with a primary diagnosis of symptomatic osteoarthritis of the knee. o No recommendation can be made concerning arthroscopic partial meniscectomy in patients with osteoarthritis of the knee with a torn meniscus. o The practitioner might perform a valgus producing proximal tibial osteotomy in patients with symptomatic medial compartment osteoarthritis of the knee. • In the absence of reliable evidence, it is the opinion of the work group not to use the free-floating (un-fixed) interpositional device in patients with symptomatic medial compartment osteoarthritis of the knee.
European League Against Rheumatism: **Evidence-based Recommendations for the Management of Fibromyalgia (2016)[49]**	• Optimal management requires prompt diagnosis. Full understanding of fibromyalgia requires comprehensive assessment of pain, function and psychosocial context. It should be recognized as a complex and heterogeneous condition where there is abnormal pain processing and other secondary features. In general, the management of fibromyalgia should take the form of a graduated approach. • Management of fibromyalgia should aim at improving health-related quality of life balancing benefit and risk of treatment that often requires a multidisciplinary approach with a combination of non-pharmacological and pharmacological treatment modalities tailored according to pain intensity, function, associated features (such as depression), fatigue, sleep disturbance, and patient preferences and comorbidities; by shared decision-making with the patient. Initial management should focus on non-pharmacological therapies. • Non-pharmacological management o Aerobic and strengthening exercise (only recommendation designated as 'strong for'; all others are 'weak for') o Cognitive behavioral therapies o Multicomponent therapies o Defined physical therapies: acupuncture or hydrotherapy o Meditative movement therapies (qigong, yoga, tai chi) and mindfulness-based stress reduction • Pharmacological management o Amitriptyline (low dose) o Duloxetine or milnacipran o Tramadol o Pregabalin o Cyclobenzaprine • Several pharmacological therapies including NSAIDs, MAOIs and SSRIs were

Clinical Guideline	Recommendation(s)
	not recommended because of lack of efficacy, and a 'strong against' evaluation was specifically given to growth hormone, sodium oxybate, strong opioids and corticosteroids based on lack of efficacy and high risk of side effects.
American Academy of Neurology/American Association of Neuromuscular and Electrodiagnostic Medicine/American Academy of Physical Medicine and Rehabilitation: **Treatment of Painful Diabetic Neuropathy (2011)**[50]	<u>Anticonvulsants</u> • If clinically appropriate, pregabalin should be offered for treatment. • Gabapentin and sodium valproate should be considered for treatment. • There is insufficient evidence to support or refute the use of topiramate for treatment. • Oxcarbazepine, lamotrigine, and lacosamide should probably not be considered for treatment. <u>Antidepressants</u> • Amitriptyline, venlafaxine, and duloxetine should be considered for the treatment of painful diabetic neuropathy. Data are insufficient to recommend one of these agents over another. • Venlafaxine may be added to gabapentin for a better response. • There is insufficient evidence to support or refute the use of desipramine, imipramine, fluoxetine, or the combination of nortriptyline and fluphenazine in the treatment of painful diabetic neuropathy. <u>Opioids</u> • Dextromethorphan, morphine sulfate, tramadol, and oxycodone should be considered for treatment. Data are insufficient to recommend one agent over the other. <u>Other pharmacologic options</u> • Capsaicin and isosorbide dinitrate spray should be considered for treatment. • Clonidine, pentoxifylline, and mexiletine should probably not be considered for treatment. • Lidocaine patch may be considered for treatment. • There is insufficient evidence to support or refute the usefulness of vitamins and α-lipoic acid for treatment. <u>Nonpharmacologic options</u> • Percutaneous electrical nerve stimulation should be considered for treatment. • Electromagnetic field treatment, low-intensity laser treatment, and Reiki therapy should probably not be considered for treatment. • Evidence is insufficient to support or refute the use of amitriptyline plus electrotherapy for treatment.
European Federation of Neurological Societies: **Guidelines on the Pharmacological Treatment of Neuropathic Pain (2010)**[51]	<u>Painful polyneuropathy</u> • Diabetic and non-diabetic painful polyneuropathy are similar in symptomatology and with respect to treatment response, with the exception of human immunodeficiency virus (HIV)-induced neuropathy. • Recommended first-line treatments include tricyclic antidepressants (TCA), gabapentin, pregabalin, and SNRIs (duloxetine, venlafaxine). • Tramadol is recommended second line, except for patients with exacerbations of pain or those with predominant coexisting non-neuropathic pain. • Strong opioids are recommended third-line treatments due to concerns regarding long-term safety, including addiction potential and misuse. • In HIV-associated polyneuropathy, only lamotrigine (in patients receiving antiretroviral treatment), smoking cannabis, and capsaicin patches were found moderately useful. <u>Post herpetic neuropathy</u>

Clinical Guideline	Recommendation(s)
	• Recommended first-line treatments include a TCA, gabapentin, or pregabalin. • Topical lidocaine with its excellent tolerability may be considered first-line in the elderly, especially if there are concerns of adverse events of oral medications. • Strong opioids and capsaicin cream are recommended as second-line therapies.
American Association of Clinical Endocrinologists/ College Of Endocrinology: **Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan (2015)**[52]	Diabetic neuropathy • Diabetic painful neuropathy is diagnosed clinically and must be differentiated from other neurologic conditions. • Interventions that reduce oxidative stress, improve glycemic control, and/or improve dyslipidemia and hypertension might have a beneficial effect on diabetic neuropathy. • Exercise and balance training may also be beneficial. • Tricyclic antidepressants, anticonvulsants, and serotonin and norepinephrine reuptake inhibitors are useful treatments. • Large-fiber neuropathies are managed with strength, gait, and balance training; pain management; orthotics to treat and prevent foot deformities; tendon lengthening for pes equinus from Achilles tendon shortening; and/or surgical reconstruction and full contact casting as needed. • Small-fiber neuropathies are managed with foot protection (e.g., padded socks), supportive shoes with orthotics if necessary, regular foot and shoe inspection, prevention of heat injury, and use of emollient creams; however, for pain management, the medications mentioned above must be used.
American Diabetes Association: **Diabetic Neuropathy: A Position Statement (2017)**[53]	General recommendations • Optimize glucose control as early as possible to prevent or delay the development of distal symmetric polyneuropathy and cardiovascular autonomic neuropathy in people with type 1 diabetes. • Optimize glucose control to prevent or slow the progression of distal symmetric polyneuropathy in people with type 2 diabetes. • Consider a multifactorial approach targeting glycemia among other risk factors to prevent cardiovascular autonomic neuropathy in people with type 2 diabetes. Pain management • Consider either pregabalin or duloxetine as the initial approach in the symptomatic treatment for neuropathic pain in diabetes. • Gabapentin may also be used as an effective initial approach, taking into account patients' socioeconomic status, comorbidities, and potential drug interactions. • Although not approved by the U.S. Food and Drug Administration, tricyclic antidepressants are also effective for neuropathic pain in diabetes but should be used with caution given the higher risk of serious side effects. • Given the high risks of addiction and other complications, the use of opioids, including tapentadol or tramadol, is not recommended as first- or second-line agents for treating the pain associated with distal symmetric polyneuropathy.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the antidepressants are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Antidepressants[1-32]

Generic Name(s)	Depression /Major Depressive Disorder	Generalized Anxiety Disorder	Mixed Anxiety/ Depressive Disorder	Obsessive-Compulsive Disorder	Panic Disorder	Postpartum Depression	Posttraumatic Stress Disorder	Premenstrual Dysphoric Disorder	Seasonal Affective Disorder	Social Anxiety Disorder	Other
Monoamine Oxidase Inhibitors											
Isocarboxazid	✔										
Phenelzine	✔										
Selegiline	✔										
Tranylcypromine	✔										
Selective Serotonin- and Norepinephrine-reuptake Inhibitors											
Desvenlafaxine	✔										
Duloxetine	✔	✔									Chronic musculoskeletal pain; fibromyalgia*; neuropathic pain associated with diabetic peripheral neuropathy
Levomilnacipran	✔										
Venlafaxine	✔	✔‡			✔‡					✔‡	
Selective Serotonin-reuptake Inhibitors											
Citalopram	✔										
Escitalopram	✔	✔									
Fluoxetine	✔			✔	✔			✔†			Bulimia nervosa
Fluvoxamine				✔							
Paroxetine	✔	✔§		✔§	✔		✔§	✔‡		✔	Moderate to severe vasomotor symptoms associated with menopause‖
Sertraline	✔			✔	✔		✔	✔		✔	
Serotonin Modulators											
Nefazodone	✔										
Trazodone	✔										
Vilazodone	✔										
Vortioxetine	✔										
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Single Entity Agents											
Amitriptyline	✔										
Amoxapine	✔										
Clomipramine				✔							
Desipramine	✔										
Doxepin	✔		✔								Insomnia¶
Imipramine	✔										Pediatric nocturnal enuresis
Maprotiline	✔		✔								

Generic Name(s)	Depression /Major Depressive Disorder	Generalized Anxiety Disorder	Mixed Anxiety/ Depressive Disorder	Obsessive-Compulsive Disorder	Panic Disorder	Postpartum Depression	Posttraumatic Stress Disorder	Premenstrual Dysphoric Disorder	Seasonal Affective Disorder	Social Anxiety Disorder	Other
Nortriptyline	✔										
Protriptyline	✔										
Trimipramine	✔										
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Combination Products											
Amitriptyline and chlordiazepoxide			✔								
Antidepressants, Miscellaneous											
Brexanolone						✔					
Bupropion	✔								✔ ‡		Smoking cessation‡
Esketamine	✔ #										
Mirtazapine	✔										

*Excluding Irenka® formulation.
‡Extended-release formulation only.
†Sarafem® formulation only; Sarafem® is not approved for other indications.
§Immediate-release formulation only.
‖Brisdelle® formulation only.
¶ Silenor® formulation only.
# Treatment-resistant depression or depressive symptoms with major depressive disorder with acute suicidal ideation or behavior

IV. Pharmacokinetics

The pharmacokinetic parameters of the antidepressants are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Antidepressants[1-32]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Monoamine Oxidase Inhibitors					
Isocarboxazid	Not reported	Not reported	Liver	Renal	Not reported
Phenelzine	Not reported	Not reported	Liver	Renal (79)	11.6
Selegiline	25 to 30	90	Liver	Renal (10) Feces (2)	18 to 25
Tranylcypromine	Not reported	Not reported	Not reported	Renal	1.5 to 3.5
Selective Serotonin- and Norepinephrine-reuptake Inhibitors					
Desvenlafaxine	80	30	Liver	Renal (45)	10 to 11
Duloxetine	30 to 80	>90	Liver	Renal (70) Feces (20)	8 to 17
Levomilnacipran	92	22	Liver	Renal (85)	12
Venlafaxine	12.6 to 45.0	27 to 30	Liver	Renal (87) Feces (2)	5
Selective Serotonin-reuptake Inhibitors					
Citalopram	80	80	Liver	Renal (20) Feces	24 to 48
Escitalopram	80	56	Liver	Renal (8)	22 to 32
Fluoxetine	100	95	Liver	Renal (60) Feces (12)	96 to 144
Fluvoxamine	53	80	Liver	Renal (94)	15 to 16
Paroxetine	Completely absorbed	93 to 95	Liver	Renal (64 to 67) Feces (36 to 37)	15 to 22
Sertraline	Not reported	99	Liver	Renal (40 to 45) Feces (40 to 45)	24
Serotonin Modulators					
Nefazodone	20	>99	Liver	Renal (55) Feces (20 to 30)	1.9 to 5.3
Trazodone	65	89 to 95	Liver	Renal (70 to 75) Feces (21)	7 to 8
Vilazodone	72	96 to 99	Liver	Renal (1) Feces (2)	25
Vortioxetine	75	98	Liver	Renal (59) Feces (26)	66
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Single Entity Agents					
Amitriptyline	100	90 to 95	Liver	Renal (18)	9 to 25
Amoxapine	18 to 54	90	Liver	Renal (69) Feces (18)	8
Clomipramine	20 to 78	97	Liver	Renal (51 to 60) Feces (24 to 32)	19 to 37
Desipramine	Not reported	Not reported	Liver	Renal (70)	14.3 to 24.7
Doxepin	Not reported	79 to 84	Liver	Bile	16.8
Imipramine	94 to 96	89	Liver	Renal	6 to 18
Maprotiline	100	88	Liver	Renal (70) Feces (30)	27 to 53
Nortriptyline	60	86 to 95	Liver	Renal (2) Bile	15 to 39
Protriptyline	Not reported	Not reported	Liver	Renal (50)	54 to 198

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Trimipramine	Not reported	95	Liver	Renal	23
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Combination Products					
Amitriptyline and chlordiazepoxide	100	90 to 98	Liver	Renal (18)	9.0 to 27.0; 6.6 to 48.0
Antidepressants, Miscellaneous					
Brexanolone	<5	>99	Liver	Renal (42) Feces (47)	9
Bupropion	Not reported	84	Liver	Renal (87)	14 to 21
Esketamine	48	43 to 45	Liver	Renal (≥78) Feces (≤2)	7 to 12
Mirtazapine	50	85	Liver	Renal (75) Feces (15)	20 to 40

V. Drug Interactions

Major drug interactions with the antidepressants are listed in Table 5.

Table 5. Major Drug Interactions with the Antidepressants[2]

Generic Name(s)	Interaction	Mechanism
MAOIs		
MAOIs	Central nervous system depressants (e.g., alcohol, barbiturates, narcotics)	Severe hypertension may occur. Concurrent use is contraindicated.
MAOIs	Central nervous system stimulants (e.g., amphetamines, cocaine, methylphenidate, dexmethylphenidate)	Hypertensive crisis may occur. Coadministration is contraindicated.
MAOIs	MAOIs	Do not administer MAOIs with other MAOIs because hypertensive crisis and convulsive seizures, coma, or circulatory collapse may occur.
MAOIs	Methylphenidates	Pharmacological effects of methylphenidates may be increased by MAOIs. Headache, gastrointestinal symptoms and hypertension may occur. Concomitant use of methylphenidates and MAOIs is contraindicated.
MAOIs	Norepinephrine reuptake inhibitors (including tapentadol)	Coadministration may increase risk of toxic effects. Serious and sometimes fatal reactions have occurred. Use of norepinephrine reuptake inhibitors within 14 days of MAOIs is contraindicated.
MAOIs	SNRIs and SSRIs	A serotonin syndrome may occur. Concomitant use is contraindicated. At least 14 days should elapse between discontinuation of a MAOI and the start of an SSRI or vice versa. Allow at least five weeks between discontinuation of fluoxetine and initiation of a MAOI and at least 14 days between discontinuation of a MAOI and initiation of fluoxetine.
MAOIs	Sympathomimetics	The MAOIs' potentiation of indirect- or mixed-acting sympathomimetic substances, including anorexiants, may result in severe headache, hypertension, high fever, and hyperpyrexia,

Generic Name(s)	Interaction	Mechanism
		possibly resulting in hypertensive crisis; avoid coadministration.
MAOIs	TCAs	Do not administer MAOIs with or immediately following TCAs. There have been reports of serious, sometimes fata, reactions. These reactions include hyperthermia, rigidity, myoclonus, autonomic instability with possible vital sign fluctuations, and mental status changes that can include extreme agitation and confusion progressing to delirium and coma.
MAOIs	Triptans	Prolonged vasospastic reaction is a possibility when triptans and MAOIs are coadministered. The potential for development of serotonin syndrome also exists. Coadministration is not recommended.
MAOIs	Apraclonidine	Coadministration of MAOIs and apraclonidine is contraindicated. MAOIs and apraclonidine should not be administered within 14 days of discontinuation of either agent.
MAOIs	Atomoxetine	Toxic effects may be increased with concurrent administration of atomoxetine and MAOIs. Serious and sometimes fatal reactions have occurred. Use of atomoxetine within 14 days of MAOIs is contraindicated.
MAOIs	Bupropion	Coadministration is contraindicated. Risk of acute bupropion toxicity may be increased. Allow at least 14 days to elapse between discontinuing an MAOI and starting bupropion.
MAOIs	Buspirone	The risk of hypertension induced by MAOIs may be increased by co-administration of buspirone. It should be noted for selegiline that only higher dosages participate in this interaction. Allow at least 10 days between discontinuation of isocarboxazid and institution of buspirone.
MAOIs	Cyclobenzaprine	Because cyclobenzaprine is structurally related to the TCAs, use with caution with MAOIs. It should be noted for selegiline that only higher doses participate in this interaction.
MAOIs	Dextromethorphan	Hyperpyrexia, abnormal muscle movement, psychosis, bizarre behavior, hypotension, coma, and death have been associated with this combination.
MAOIs	Levodopa	Hypertensive reactions occur if levodopa is given to patients receiving MAOIs.
MAOIs	Linezolid	Adverse effects may be increased with concurrent administration of linezolid and MAOIs.
MAOIs	Meperidine	Coadministration of these agents may result in agitation, seizures, diaphoresis, and fever with the potential to progress to coma, apnea, and death. Reactions may be delayed and occur several weeks following withdrawal of MAOIs. Avoid this combination. Administer other narcotic analgesics with caution.
MAOIs	Nefazodone	The combination of MAOIs and nefazodone is contraindicated. The combination may be useful for treating depression; however, unexpected

Generic Name(s)	Interaction	Mechanism
		toxicity may occur.
MAOIs	Tetrabenazine	The combination of MAOIs and tetrabenazine may produce severe unexpected toxicity. Coadministration is contraindicated.
MAOIs	Tramadol	Coadministration may enhance seizure risk, and/or cause a severe reaction potentially involving the respiratory, cardiac, and central nervous system. Avoid coadministration.
MAOIs	Trazodone	The potential for the development of serotonin syndrome exists with concurrent use of MAOIs and trazodone.
MAOIs	Vilazodone	Do not administer MAOIs and vilazodone within 14 days of one another. Serotonin syndrome may result from concurrent administration.
MAOIs	Vortioxetine	Coadministration of MAOI used to treat psychiatric disorders and vortioxetine is contraindicated in the official package labeling of vortioxetine. In addition, the initiation of vortioxetine in patients receiving linezolid is contraindicated. Serotonin syndrome (unexpected irritability, increased muscle tone, altered consciousness and myoclonus) may result from concurrent administration.
MAOIs (selegiline)	Methadone	A severe reaction potentially involving the respiratory, cardiac and central nervous systems may occur shortly after administering methadone to patients receiving selegiline. At least 14 days should elapse between discontinuation of selegiline and administration of methadone.
MAOIs	Insulins	The hypoglycemic effect of insulin may be increased by MAOIs.
MAOIs	Meglitinides	The hypoglycemic effects of meglitinides may be increased by MAOIs.
MAOIs	Sulfonylureas	MAOIs enhance the hypoglycemic action of sulfonylureas.
MAOIs	Carbamazepine	While the manufacturer's data states that carbamazepine is contraindicated with MAOIs, other conflicting data suggest safe coadministration. It should be noted that only higher doses of selegiline (e.g. antidepressant doses) participate in this interaction.
MAOIs	Ginseng	Use of MAOIs with ginseng may produce unexpected toxic effects.
MAOIs	Tryptophan	Coadministration may result in hyperreflexia, confusion, disorientation, shivering, myoclonic jerks, agitation, amnesia, delirium, hypomanic signs, ataxia, ocular oscillations, Babinski signs.
MAOIs (isocarboxazid, phenelzine, tranylcypromine)	COMT inhibitors	The combination of these MAOIs with COMT inhibitors may result in inhibition of the majority of pathways responsible for normal catecholamine metabolism. Excessive sympathetic stimulation may result. Coadministration of COMT inhibitors and non-selective MAOIs is not recommended.
MAOIs	Narcotic analgesics	A severe reaction potentially involving the

Generic Name(s)	Interaction	Mechanism
(isocarboxazid, phenelzine, tranylcypromine)		respiratory, cardiac and central nervous systems may occur shortly after administering narcotic analgesics to patients receiving these MAOIs. At least 14 days should elapse after discontinuation of an MAOI before initiation of treatment with a narcotic analgesic.
SNRIs		
SNRIs	MAOIs	Coadministration of SNRIs and MAOIs is contraindicated. Serious, sometimes fatal, reactions may occur, including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. It is recommended that SNRIs not be used within at least 14 days of discontinuing treatment with an MAOI.
SNRIs	Linezolid	Serotonin syndrome may occur, possibly due to excessive accumulation of serotonin. Initiation of an SNRI is contraindicated in patients receiving linezolid.
SNRIs	Methylene blue	Coadministration of methylene blue and desvenlafaxine may increase the risk of central nervous system toxicity, including serotonin syndrome.
SNRIs	Tramadol	Increased risk of seizures is a possibility when tramadol and SNRIs are coadministered. Serotonin syndrome is also a risk with this combination. Concomitant use is not recommended.
SNRIs (duloxetine)	Phenothiazines (thioridazine)	Plasma concentrations and pharmacologic effects of thioridazine may be increased by duloxetine. The possibility of serious ventricular dysrhythmias should be considered. Do not coadminister.
SNRIs (duloxetine)	Tamoxifen	Pharmacologic effects of Tamoxifen may be decreased by Duloxetine. Coadministration of Duloxetine with Tamoxifen may increase the risk of breast cancer recurrence.
SNRIs	Anticoagulants	The risk of bleeding with Anticoagulants may be potentiated with concomitant use of these SNRIs and patients are at an increased risk of bleeding. The mechanism of this interaction is unknown.
SNRIs	SSRIs	The development of serotonin syndrome is possible when the combination of SNRIs and serotonin reuptake blockers are coadministered. In addition, plasma concentrations of SNRIs may be increased by serotonin reuptake blockers.
SNRIs	Iobenguane	SNRIs may reduce uptake and diagnostic efficacy of Iobenguane. False-negative Iobenguane imaging tests may result.
SNRIs	L-Tryptophan	Coadministration may lead to the development of serotonin syndrome.
SNRIs (desvenlafaxine, venlafaxine)	NSAIDs	The toxic effects may be increased with concurrent administration of NSAIDs and desvenlafaxine/venlafaxine. The risk of upper

Generic Name(s)	Interaction	Mechanism
		gastrointestinal bleeding may be increased. Patients taking concurrent SNRIs and NSAIDs should be educated about the signs and symptoms of gastrointestinal bleeding.
SNRIs (desvenlafaxine, venlafaxine)	Salicylates	The risk of upper gastrointestinal bleeding may be increased with concurrent administration of salicylates and desvenlafaxine or venlafaxine. The mechanism is unknown. Prolonged use of desvenlafaxine or venlafaxine may lead to depletion of serotonin, which is thought to play an important role in hemostasis.
SNRIs (desvenlafaxine, venlafaxine)	Cyproheptadine	Decreased pharmacologic effects of venlafaxine may result. Since cyproheptadine is a serotonin antagonist, the interaction may occur at the receptor level.
SNRIs (desvenlafaxine, venlafaxine)	Lithium	Coadministration of lithium and desvenlafaxine or venlafaxine may cause central nervous system toxicity, including serotonin syndrome. Serum lithium concentrations may be increased due to increased serotonergic neurotransmission.
SNRIs (desvenlafaxine, venlafaxine)	St. John's wort	Unexpected toxicity may occur when St. John's wort and desvenlafaxine/ venlafaxine are coadministered; the mechanism is unknown.
SNRIs (desvenlafaxine, venlafaxine)	Trazodone	Unexpected toxic effects may occur when trazodone is combined with desvenlafaxine or venlafaxine. The mechanism is unknown.
SNRIs (duloxetine)	TCAs	Plasma concentrations of TCAs may be increased by duloxetine. Inhibition of cytochrome CYP2D6 isoenzymes by duloxetine may decrease the metabolic elimination of TCAs.
SNRIs (duloxetine)	Ciprofloxacin	Plasma concentrations and pharmacologic effects of duloxetine may be increased when coadministered with ciprofloxacin. Inhibition of CYP1A2 by ciprofloxacin may decrease the metabolic elimination of duloxetine.
SNRIs (duloxetine)	Flecainide	Plasma concentrations of flecainide may be increased by duloxetine. Clinical outcome is unknown.
SNRIs (duloxetine)	Propafenone	Plasma concentrations of propafenone may be increased by duloxetine due to inhibition of CYP2D6 isoenzymes.
SNRIs (levomilnacipran)	Alcoholic beverages	Consumption of alcohol may interfere with the delayed release mechanism of levomilnacipran.
SNRIs (venlafaxine)	Bupropion	Unexpected adverse effects, including serotonin syndrome, may occur when Venlafaxine and Bupropion are coadministered. The mechanism of this interaction is unknown.
SNRIs (venlafaxine)	Terbinafine	Plasma concentrations and pharmacologic effects of venlafaxine may be increased when coadministered with terbinafine. The potential for adverse effects due to venlafaxine may be increased. Inhibition of CYP2D6-mediated metabolism of venlafaxine by terbinafine is suspected.
SSRIs		

Generic Name(s)	Interaction	Mechanism
SSRIs	Linezolid	Serotonin syndrome may occur as a result of excessive accumulation of serotonin. The coadministration of linezolid and SSRIs should be handled with caution.
SSRIs	Tramadol	Increased risk of seizures is possible when tramadol and SSRIs are coadministered. Serotonin syndrome is also a potential risk when tramadol and SSRIs are coadministered.
SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)	Clozapine	These SSRIs may increase plasma concentrations and pharmacologic effects of clozapine. Severe toxicity may occur. Inhibition of cytochrome P450 1A2 isoenzymes by these SSRIs may decrease the metabolic elimination of clozapine.
SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline)	Pimozide	Plasma concentrations of pimozide may be increased by SSRIs. The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased. The mechanism is unknown.
SSRIs (fluoxetine, fluvoxamine paroxetine)	Phenothiazines (chlorpromazine, thioridazine)	Pharmacologic effects and plasma concentrations of phenothiazines may be increased by SSRIs. Neurologic toxicity, including extrapyramidal effects, and cardiac toxicity, including the potential for torsade de pointes, may occur.
SSRIs (fluoxetine, paroxetine sertraline)	Tamoxifen	Pharmacologic effects of tamoxifen may be decreased by certain SSRIs. Coadministration may increase the risk of breast cancer recurrence.
SSRIs (citalopram, escitalopram)	Cimetidine	Pharmacologic effects and plasma concentrations of citalopram may be increased by cimetidine. Cimetidine may inhibit the metabolic and/or renal elimination of citalopram.
SSRIs (citalopram, fluoxetine)	Nilotinib	Additive QT prolongation may occur during coadministration of vandetanib and certain SSRIs. The black box warning contained in the official package labeling for vandetanib states that the use of vandetanib with medications that prolong the QT interval should be avoided.
SSRIs (citalopram, fluoxetine)	Vandetanib	Additive QT prolongation may occur during coadministration of vandetanib and certain SSRIs. The black box warning contained in the official package labeling for vandetanib states that the use of vandetanib with medications that prolong the QT interval should be avoided.
SSRIs (fluvoxamine)	Ramelteon	Plasma concentrations of ramelteon may be increased by coadministration of fluvoxamine. Coadministration of fluvoxamine and ramelteon is contraindicated.
SSRIs (fluvoxamine)	Tizanidine	Tizanidine plasma concentrations and pharmacologic effects may be increased by fluvoxamine. Adverse effects associated with tizanidine, including significant hypotension, may be expected. Concomitant use is contraindicated.
SSRIs	Anticoagulants	The risk of bleeding with anticoagulants may be potentiated with concomitant use of SSRIs and patients are at an increased risk of bleeding.
SSRIs	NSAIDs	Toxic effects may be increased with concurrent

Generic Name(s)	Interaction	Mechanism
		administration of NSAIDs and SSRIs. The risk of upper gastrointestinal bleeding may be increased. Patients taking both SSRIs and NSAIDs should be educated about the signs and symptoms of gastrointestinal bleeding.
SSRIs	Salicylates	Toxic effects may be increased with concurrent administration of salicylates and SSRIs. The risk of upper gastrointestinal bleeding may be increased. Patients taking both salicylates and NSAIDs should be educated about the signs and symptoms of gastrointestinal bleeding.
SSRIs	SNRIs	Serotonin syndrome has been reported during coadministration of SSRIs and SNRIs. If coadministration is necessary, the patient should be closely monitored, especially when starting treatment of increasing doses. Plasma concentrations of duloxetine may be increased by CYP2D6 inhibitors, such as fluoxetine and paroxetine.
SSRIs	Cyproheptadine	Decreased pharmacologic effects of SSRIs may result. Since cyproheptadine is a serotonin antagonist, the interaction may occur at the receptor level.
SSRIs	L-tryptophan	Coadministration may lead to the development of serotonin syndrome.
SSRIs	St. John’s wort	Unexpected toxicity may occur when St. John's wort and SSRIs are coadministered.
SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, sertraline)	Beta-blockers	Coadministration of SSRIs and beta-blockers may increase risk of bradycardia and hypotension.
SSRIs (fluoxetine, sertraline)	Bupropion	Unexpected adverse effects, including serotonin syndrome, may occur when these SSRIs and bupropion are coadministered. The mechanism of this interaction is unknown.
SSRIs (fluoxetine, sertraline)	Carbamazepine	Plasma concentrations and pharmacologic effects of carbamazepine may be increased by these SSRIs. Toxicity may occur. Toxic serotonin syndrome may also occur.
SSRIs (fluoxetine, paroxetine)	Iloperidone	Plasma concentrations and pharmacologic effects of iloperidone may be increased by these SSRIs. A modification of the iloperidone dose is recommended.
SSRIs (fluoxetine, paroxetine)	Risperidone	These SSRIs may increase plasma concentrations and pharmacologic effects of risperidone. Additionally, concomitant use has resulted in reported cases of serotonin syndrome. Worsening of obsessive-compulsive disorder has also been reported with combined use.
SSRIs (fluoxetine, paroxetine)	Tetrabenazine	Plasma concentrations and pharmacologic effects of tetrabenazine may be increased by these SSRIs. Dosage adjustment is recommended.
SSRIs (fluoxetine)	HIV protease inhibitors	HIV protease inhibitors may increase plasma concentrations of fluoxetine resulting in possible fluoxetine toxicity. Similarly, fluoxetine may

Generic Name(s)	Interaction	Mechanism
		increase plasma concentrations of HIV protease inhibitors.
SSRIs (fluoxetine)	Hydantoins	Serum hydantoin concentrations may be elevated. Close monitoring of hydantoin levels and observing patients for toxicity or loss of therapeutic activity if fluoxetine is started or stopped is advised. Fosphenytoin may enhance QTc-prolonging effect of fluoxetine.
SSRIs (fluvoxamine)	Theophyllines	Pharmacological effects of the theophyllines may be increased by fluvoxamine. Elevated theophylline concentrations and toxicity including nausea, vomiting, cardiovascular instability and seizures may occur.
SSRIs (paroxetine)	Abiraterone	Plasma concentrations and pharmacologic effects of paroxetine may be increased by abiraterone, due to the inhibition of CYP2D6 by abiraterone.
Serotonin Modulators		
Serotonin modulators	MAOIs	Coadministration of the Serotonin Modulators and MAOIs is contraindicated due to increased risk for serotonin syndrome.
Serotonin modulators	Linezolid	Coadministration of the Serotonin Modulators and linezolid is contraindicated due to risk of serotonin syndrome.
Serotonin modulators (vilazodone, vortioxetine)	Methylene blue	Coadministration of certain Serotonin Modulators may increase the risk of central nervous system toxicity, including serotonin syndrome. Initiation of certain Serotonin Modulators in patients receiving methylene blue is contraindicated.
Nefazodone	Statins	The risk of rhabdomyolysis and myositis may be increased with certain statins. Coadministration of nefazodone with lovastatin or simvastatin is contraindicated.
Nefazodone	Tyrosine kinase receptor inhibitors	Plasma concentrations and pharmacologic effects of tyrosine kinase receptor inhibitors may be increased by nefazodone due to the inhibition of CYP3A4 by nefazodone.
Nefazodone	Vasopressin receptor agonists	Plasma concentrations and pharmacologic effects of vasopressin receptor antagonists may be increased by nefazodone. Coadministration of nefazodone and conivaptan or tolvaptan is contraindicated.
Nefazodone	Colchicine	Plasma concentrations of colchicine may be increased by nefazodone and life-threatening and fatal colchicine toxicity may occur. Dosage adjustment of colchicine is required for coadministration of these agents. Coadministration is contraindicated in patients with renal or hepatic impairment.
Nefazodone	Docetaxel	Plasma concentrations and pharmacologic effects of docetaxel may be increased by nefazodone. Use of nefazodone with docetaxel may increase the risk and/or severity of docetaxel-related toxicity. Coadministration should be avoided.
Nefazodone	Dronedarone	Plasma concentrations and pharmacologic effects of dronedarone may be increased by nefazodone. Coadministration is contraindicated.

Generic Name(s)	Interaction	Mechanism
Nefazodone	Lurasidone	Plasma concentrations and pharmacologic effects of lurasidone may be increased by nefazodone. Coadministration is contraindicated.
Nefazodone	Pimozide	Pharmacologic effects of pimozide may be increased by nefazodone. Elevated plasma concentrations and cardiovascular toxicity may occur. Coadministration is contraindicated.
Nefazodone	Ranolazine	Plasma concentrations and pharmacologic effects of ranolazine may be increased when coadministered with nefazodone. Coadministration is contraindicated.
Nefazodone	Ticagrelor	Plasma concentrations and pharmacologic effects of ticagrelor may be increased by nefazodone. Coadministration of nefazodone and ticagrelor should be avoided according to official package labeling.
Nefazodone	Toremifene	Plasma concentrations and pharmacologic effects of toremifene may be increased by nefazodone. Toxicity, including QT prolongation may occur. Coadministration of nefazodone and toremifene should be avoided according to a black box warning in official package labeling.
Trazodone	Sodium oxybate	Concurrent use of sodium oxybate and trazodone may result in an increase in sleep duration and central nervous system depression. Coadministration is contraindicated.
Vilazodone	Tramadol	Increased risk of seizures is listed in the manufacturer's package labeling as a possibility when tramadol and vilazodone are coadministered. Serotonin syndrome is also a potential risk with this combination.
Serotonin modulators (nefazodone, vilazodone, vortioxetine)	Triptans	Coadministration of certain serotonin modulators and Triptans may cause central nervous system toxicity, and rarely, serotonin syndrome.
Serotonin modulators (nefazodone, vilazodone)	Narcotic analgesics	Plasma concentrations and pharmacologic effects of some narcotic analgesics may be increased by certain serotonin modulators. Toxic effects of vilazodone may be increased by fentanyl, resulting in the development of serotonin syndrome.
Serotonin modulators (trazodone, vilazodone)	HIV protease inhibitors	HIV protease inhibitors may increase the plasma concentration of trazodone and vilazodone.
Nefazodone	Benzodiazepines	Nefazodone may increase the pharmacologic effects of certain benzodiazepines. Impaired psychomotor performance and increased sedation may result from elevated benzodiazepine plasma concentrations.
Nefazodone	MTOR inhibitors	Pharmacologic effects of MTOR inhibitors may be increased by nefazodone. Official package labeling for MTOR inhibitors states that coadministration with strong CYP3A4 inhibitors, such as nefazodone, should be avoided.
Nefazodone	Muscarinic receptor antagonists	Plasma concentrations and pharmacologic effects of muscarinic receptor antagonists may be

Generic Name(s)	Interaction	Mechanism
		increased by nefazodone. Official package labeling recommends a reduced maximum dose of muscarinic receptor antagonists in patients receiving strong CYP3A4 inhibitors, such as nefazodone.
Nefazodone	Brentuximab	Plasma concentrations and pharmacologic effects of brentuximab may be increased by nefazodone. The inhibition of CYP3A4 by nefazodone may increase the plasma concentrations of monomethyl auristatin E, the microtubule disrupting agent in brentuximab.
Nefazodone	Budesonide	Plasma concentrations and pharmacologic effects of oral or inhaled budesonide may be increased by nefazodone. Corticosteroid toxicity and/or adrenal suppression may occur.
Nefazodone	Buspirone	Plasma concentrations and pharmacologic effects of buspirone may be increased by nefazodone. The risk of buspirone-induced adverse reactions may be increased. Inhibition of CYP3A4 isoenzymes by nefazodone may decrease the metabolic elimination of buspirone.
Nefazodone	Cabazitaxel	Plasma concentrations and pharmacologic effects cabazitaxel may be increased by nefazodone due to the inhibition of CYP3A4 by nefazodone.
Nefazodone	Cilostazol	Plasma concentration and pharmacologic effects of cilostazol may be increased by nefazodone due to the inhibition of CYP3A4 by nefazodone.
Nefazodone	Cyclosporine	Cyclosporine concentration and pharmacologic effects may be increased by nefazodone. Cyclosporine toxicity may occur.
Nefazodone	Eszopiclone	Plasma concentrations and the pharmacologic effects of eszopiclone may be increased by nefazodone.
Nefazodone	Iloperidone	Plasma concentrations and pharmacologic effects of iloperidone may be increased by nefazodone. A modification of the iloperidone dose is recommended.
Nefazodone	Ivacaftor	Plasma concentrations and pharmacologic effects of ivacaftor may be increased by nefazodone. A reduction in the ivacaftor dose is recommended in patients receiving both medications according to the official package labeling.
Nefazodone	Ixabepilone	The pharmacologic effects of epothilones may be increased by nefazodone. Strong CYP3A4 inhibitors, such as nefazodone, should be avoided in patients receiving ixabepilone.
Nefazodone	Maraviroc	The pharmacologic effects of maraviroc may be increased by nefazodone. A dosage adjustment is recommended for maraviroc during concomitant therapy with strong CYP3A4 inhibitors, such as nefazodone. Coadministration is contraindicated in patients with severe renal impairment.
Nefazodone	Mifepristone	Plasma concentrations and pharmacologic effects of mifepristone may be increased by nefazodone.
Nefazodone	Ruxolitinib	Plasma concentrations and pharmacologic effects of ruxolitinib may be increased by nefazodone. A

Generic Name(s)	Interaction	Mechanism
		dose reduction of ruxolitinib or avoidance of ruxolitinib is recommended in patients receiving nefazodone.
Nefazodone	Saxagliptin	Plasma concentrations and pharmacologic effects of saxagliptin may be increased by nefazodone.
Trazodone	SSRIs	Unexpected toxic effects may occur when trazodone and certain SSRIs are coadministered. The mechanism of this interaction is unknown.
Trazodone	Delavirdine	Plasma concentrations of trazodone may be increased when coadministered with delavirdine. Inhibition of CYP3A4 isoenzymes by delavirdine may decrease the metabolic elimination of trazodone.
Vilazodone	Cyproheptadine	Pharmacologic effects of may be decreased or reversed by cyproheptadine. Symptoms of depression may recur, because cyproheptadine may directly antagonize the serotonin receptor activity of vilazodone.
Vilazodone	Lithium	Coadministration of lithium and vilazodone may cause central nervous system toxicity, including serotonin syndrome. Serum lithium concentrations may be increased lithium and vilazodone may increase serotonergic neurotransmission.
Vilazodone	L-tryptophan	Both agents acutely increase central nervous system serotonin activity. Coadministration of these two agents could result in serotonin syndrome.
Vilazodone	NSAIDs	Toxic effects may be increased with concurrent administration of NSAIDs and vilazodone. The risk of upper gastrointestinal bleeding may be increased. The mechanism of this interaction is unknown.
Vilazodone	Salicylates	The risk of upper gastrointestinal bleeding may be increased with concurrent administration of salicylates and vilazodone. The mechanism of this interaction is unknown.
Vilazodone	SNRIs	The potential exists for the occurrence of additive serotonergic activity. Inhibition of cytochrome P450 2D6 isoenzymes by vilazodone may decrease the metabolic elimination of SNRIs. The development of serotonin syndrome is possible when the combination of SNRIs and vilazodone are coadministered. In addition, plasma concentrations of SNRIs may be increased by vilazodone.
Vilazodone	Strong CYP3A4 inhibitors	Strong CYP3A4 inhibitors may decrease the metabolic elimination of vilazodone, increasing the plasma concentrations and pharmacological effects of vilazodone.
Vilazodone	St. John’s wort	Unexpected toxicity may occur when St. John's wort and vilazodone are coadministered. The mechanism of this is unknown.
Vortioxetine	CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine)	Pharmacologic effects of vortioxetine may be increased by CYP2D6 inhibitors.

Generic Name(s)	Interaction	Mechanism
Tricyclics and Other Norepinephrine-reuptake Inhibitors		
TCAs	MAOIs	Although the combination of MAOIs and TCAs may be useful for treating depression, severe, sometimes lethal, toxicity may occur. Mechanism of this interaction is unknown.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Mibefradil	Pharmacologic and toxic effects of certain TCAs may be enhanced by mibefradil due to its effect on oxidative metabolism of coadministered agents. Substantial dosage adjustment of TCA may be necessary during concurrent administration with mibefradil.
TCAs (amitriptyline, desipramine, imipramine, maprotiline)	Droperidol	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when droperidol and certain TCAs are coadministered.
TCAs (doxepin, maprotiline, nortriptyline)	Arsenic	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when these TCAs and Arsenic are coadministered.
TCAs (amitriptyline, desipramine, imipramine)	Pimozide	Certain TCAs and pimozide may cause additive adverse effects when coadministered. Cardiovascular toxicity may occur due to additive QT-interval prolongation.
TCAs (doxepin, maprotiline, nortriptyline)	Toremifene	Prolongation of the QT interval with possible development of cardiac arrhythmias, including torsades de pointes, should be considered when toremifene is coadministered with these TCAs.
TCAs (doxepin, maprotiline, nortriptyline)	Vandetanib	Additive QT prolongation may occur during coadministration of vandetanib and these TCAs.
TCAs (amitriptyline-chlordiazepoxide)	Azole antifungals	Inhibition of cytochrome P450 3A4 isoenzymes by azole antifungals may decrease the metabolic elimination of chlordiazepoxide and amitriptyline, increasing the pharmacological effects and duration of action of chlordiazepoxide and amitriptyline.
TCAs (amitriptyline-chlordiazepoxide)	Clozapine	Delirium, sedation, sialorrhea, and ataxia may occur when amitriptyline-chlordiazepoxide and clozapine are coadministered. Severe orthostatic hypotension and respiratory depression may occur when clozapine combined with amitriptyline-chlordiazepoxide. The mechanism of this interaction is unknown. Clozapine and amitriptyline- chlordiazepoxide should not be started simultaneously.
TCAs (amitriptyline-chlordiazepoxide)	Sodium oxybate	Concurrent use of sodium oxybate and amitriptyline-chlordiazepoxide may result in an additive increase in sleep duration and central nervous system depression.
TCAs (clomipramine)	Methylene blue	Coadministration of clomipramine and methylene blue may increase the risk of central nervous system toxicity, including serotonin syndrome.

Generic Name(s)	Interaction	Mechanism
TCAs (maprotiline)	Class III antiarrhythmics	Additive QT prolongation may occur when class III antiarrhythmics and maprotiline are coadministered. Use of class III antiarrhythmics and maprotiline is not recommended.
TCAs (maprotiline)	Quinolones	The risk of life-threatening cardiac arrhythmias may be increased. The exact mechanism is unknown. Levofloxacin should be avoided, while gatifloxacin and moxifloxacin should be used with caution.
TCAs (maprotiline)	Furazolidone	Concomitant administration of maprotiline and furazolidone may enhance the sympathomimetic effects of maprotiline. The mechanism is unknown.
TCAs (maprotiline)	Halofantrine	Prolonged QT interval and cardiac arrhythmias are a potential when halofantrine and maprotiline are used concomitantly.
TCAs (maprotiline)	Nilotinib	Additive QT prolongation may occur during coadministration of nilotinib and maprotiline.
TCAs (nortriptyline)	Quinidine	Pharmacologic effects of nortriptyline may be increased by quinidine. Elevated plasma concentrations with toxicity characterized by QT prolongation including torsades de pointes may occur. Mechanism: Inhibition of CYP2D6 isoenzymes by quinidine may decrease the metabolic elimination of nortriptyline which may increase the risk for concentration-dependent prolongation of the QT interval.
TCAs	Tramadol	Increased risk of seizures may occur when tramadol and TCAs are coadministered.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Cimetidine	Therapeutic efficacy and frequency of side effects of TCAs may be altered by concurrent therapy with cimetidine.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Clonidine	The antihypertensive effects of clonidine may be decreased by TCAs. TCAs may worsen rebound reactions from abrupt clonidine withdrawal.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline,	Fluconazole	Fluconazole may increase plasma concentrations and toxic effects of these TCAs.

Generic Name(s)	Interaction	Mechanism
trimipramine)		
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Fluoxetine	The pharmacologic and toxic effects of TCAs may be increased by fluoxetine, despite reports of increased clinical efficacy.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Fluvoxamine	The pharmacologic and toxic effects of TCAs may be increased by fluvoxamine. Toxicity may result.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Guanfacine	The antihypertensive effect of guanfacine may be decreased by TCAs.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Iobenguane	TCAs may reduce uptake and diagnostic efficacy of iobenguane. False-negative iobenguane imaging tests may result.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Paroxetine	The pharmacologic/toxic effects and plasma concentrations of TCAs may be increased by paroxetine.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)	Rasagiline	The combination of rasagiline and these TCAs may precipitate symptoms of serotonin syndrome.
TCAs (amitriptyline,	Sertraline	The pharmacologic and toxic effects of TCAs may be increased by sertraline.

Generic Name(s)	Interaction	Mechanism
amoxapine, clomipramine, desipramine, doxepin, imipramine, protriptyline, trimipramine)		
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline)	Phenothiazines	Plasma concentrations of phenothiazines and TCAs may be increased when coadministered. Risk of toxicity associated with TCAs and/or risk for potential additive QT prolongation is possible with some when some TCAs are coadministered with phenothiazines.
TCAs (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline)	Carbamazepine	Serum carbamazepine levels may be elevated, increasing pharmacologic and toxic effects, while TCA levels may be decreased. Carbamazepine may alter the parent drug-hydroxylated metabolite ratio, resulting in increased risk of toxicity or loss of efficacy of TCAs.
TCAs (amoxapine, clomipramine, desipramine, maprotiline, nortriptyline)	Abiraterone	Plasma concentrations and pharmacologic effects of these TCAs may be increased by abiraterone. Coadministration of these TCAs and abiraterone should be avoided.
TCAs (amitriptyline, desipramine, doxepin, imipramine, nortriptyline)	Duloxetine	Plasma concentrations of these TCAs may be increased by duloxetine. Serotonin syndrome is also a risk with this combination.
TCAs (amitriptyline, clomipramine, desipramine, imipramine, nortriptyline)	Terbinafine	The pharmacologic and toxic effects of TCAs may be increased by terbinafine. Toxic signs may occur.
TCAs (amitriptyline, clomipramine, nortriptyline)	Valproic acid and derivatives	Plasma concentrations and toxic effects of these TCAs may be increased by valproic acid and its derivatives.
TCAs (amitriptyline-chlordiazepoxide)	Hydantoins	Pharmacologic effects of hydantoins may be increased by amitriptyline-chlordiazepoxide. Elevated hydantoin plasma concentrations and toxicity may occur. Serum concentrations and pharmacologic effects of amitriptyline-chlordiazepoxide may be decreased by hydantoins.
TCAs (amitriptyline-chlordiazepoxide)	Rifamycins	Pharmacologic effects of chlordiazepoxide-amitriptyline may be decreased by rifamycins.
TCAs (amitriptyline-chlordiazepoxide)	Disulfiram	Pharmacologic and toxic effects of amitriptyline-chlordiazepoxide may be increased by disulfiram. Disulfiram may inhibit hepatic metabolism of amitriptyline- chlordiazepoxide.
TCAs	Nefazodone	Nefazodone may increase the pharmacologic

Generic Name(s)	Interaction	Mechanism
(amitriptyline-chlordiazepoxide)		effects of amitriptyline-chlordiazepoxide. Impaired psychomotor performance and increased sedation may result from elevated amitriptyline-chlordiazepoxide plasma concentrations.
Antidepressants, Miscellaneous		
Brexanolone, esketamine	CNS depressants	Concomitant use of brexanolone or esketamine with CNS depressants (e.g., opioids, benzodiazepines, alcohol) may increase the likelihood or severity of adverse reactions related to sedation.
Bupropion	MAOIs	The use of bupropion with MAOIs is contraindicated due to the potential for hypertensive crisis. Only very high doses of selegiline participate in this interaction.
Bupropion	Linezolid	Manufacturer's literature states that the use of bupropion with linezolid is contraindicated due to risk for hypertensive crisis.
Bupropion	Methylene blue	Coadministration of bupropion and methylene blue may increase the risk of hypertensive reactions. The official package labeling of bupropion contraindicates the initiation of bupropion in patients receiving methylene blue.
Bupropion	Pimozide	Plasma concentrations of pimozide may be increased by bupropion. Coadministration of pimozide with bupropion is contraindicated.
Bupropion	Tamoxifen	Pharmacologic effects of tamoxifen may be decreased by bupropion. Coadministration of bupropion with tamoxifen may increase the risk of breast cancer recurrence.
Esketamine	MAOIs	Concomitant use with MAOIs may increase blood pressure. Closely monitor blood pressure with concomitant use of esketamine with MAOIs.
Esketamine	Psychostimulants	Concomitant use with psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) may increase blood pressure. Closely monitor blood pressure with concomitant use of esketamine with psychostimulants.
Mirtazapine	MAOIs	Concomitant administration of mirtazapine and MAOIs may enhance the sympathomimetic effects of mirtazapine. Concomitant use of mirtazapine and MAOIs is contraindicated. Only higher doses of selegiline participate in this interaction.
Mirtazapine	Furazolidone	Concomitant administration of mirtazapine and furazolidone may enhance the sympathomimetic effects of mirtazapine. The mechanism is unknown.
Mirtazapine	Linezolid	Coadministration of mirtazapine and linezolid may increase the risk of central nervous system toxicity, including serotonin syndrome. Coadministration of mirtazapine and linezolid is contraindicated. The initiation of mirtazapine is contraindicated in patients receiving linezolid according to the package labeling of mirtazapine.
Mirtazapine	Methylene blue	Coadministration of mirtazapine and methylene

Generic Name(s)	Interaction	Mechanism
		blue may increase the risk of central nervous system toxicity, including serotonin syndrome. The official package labeling of mirtazapine contraindicates the initiation of mirtazapine in patients receiving methylene blue.
Mirtazapine	Perampanel	The central nervous system effects of mirtazapine may be enhanced by perampanel. In addition, increased levels of confusion, depression, anger and aggression may occur.
Bupropion	Lopinavir/ritonavir	Plasma concentrations and pharmacologic effects of bupropion may be decreased by lopinavir/ritonavir.
Bupropion	Rifamycins	Bupropion plasma concentrations may be reduced secondary to increased metabolism of bupropion. In patients receiving bupropion, close monitoring of clinical efficacy is advised when rifamycins is coadministered.
Bupropion	Ritonavir	Plasma concentrations and pharmacologic effects of bupropion may be decreased by ritonavir.
Bupropion	Tiagabine	The potential exists for seizures to occur in patients receiving tiagabine who are also receiving drugs such as bupropion that are known to lower the seizure threshold.
Mirtazapine	Hydantoins	Mirtazapine plasma concentrations may be reduced by hydantoins.

CNS=central nervous system, COMT=catechol-O-methyltransferase, HIV=human immunodeficiency virus, MAOI=monoamine oxidase inhibitors, MTOR=mammalian target of rapamycin, NSAIDS=nonsteroidal anti-inflammatory drugs, SNRI=serotonin–norepinephrine reuptake inhibitors, SSRI=selective serotonin re-uptake inhibitors, TCA=tricyclic antidepressants

VI. Adverse Drug Events

The most common adverse drug events reported with the antidepressants are listed in Tables 6a to 6f. The boxed warnings for the antidepressants are listed in Tables 7 to 12.

Table 6a. Adverse Drug Events (%) Reported with the Monoamine Oxidase Inhibitors[1-32]

Adverse Events	Isocarboxazid	Phenelzine	Selegiline	Tranylcypromine
Cardiovascular				
Arrhythmia	-	-	<1	-
Atrial fibrillation	-	-	<1	-
Bradycardia	-	-	<1	-
Cardiovascular depression	-	✔	-	-
Chest pain	-	-	≥1	-
Hypertension	-	-	≥1	-
Hypotension	-	-	3 to 10	-
Myocardial infarct	-	-	<1	-
Orthostatic hypotension	4	✔	-	✔
Palpitation	2	-	<1	✔
Peripheral edema	-	-	≥1	-
Peripheral vascular disorder	-	-	<1	-
Postural hypotension	-	✔	-	-
Syncope	2	-	<1	-
Tachycardia	-	✔	<1	✔
Vasodilation	-	-	<1	-

Adverse Events	Isocarboxazid	Phenelzine	Selegiline	Tranylcypromine
Central Nervous System				
Abnormal thinking	-	-	>1	-
Agitation	-	-	>1	✔
Akathisia	✔	-	-	-
Akinesia	-	-	-	✔
Amnesia	-	-	>1	-
Anxiety	2	✔	-	✔
Ataxia	✔	✔	<1	✔
Behavior changes	-	-	>1	-
Bradykinesia	-	-	>1	-
Coma	✔	✔	-	-
Confusion	-	-	<1	✔
Convulsions	-	✔	-	-
Delirium	-	✔	-	-
Delusions	-	-	<1	-
Depersonalization	-	-	<1	-
Depression	-	-	<1	-
Disorientation	-	-	-	✔
Dizziness	15 to 29	✔	-	✔
Drowsiness	4	✔	-	✔
Emotional lability	-	-	<1	-
Euphoria	✔	✔	<1	-
Fatigue	-	✔	-	✔
Forgetfulness	2	-	-	-
Hallucinations	<1	-	-	-
Headache	6 to 15	✔	18	✔
Hostility	-	-	<1	-
Hyperactivity	2	-	-	-
Hyperesthesia	-	-	<1	-
Hyperkinesias	-	-	<1	-
Hyperreflexia	-	✔	-	✔
Hypersomnia	-	✔	-	-
Insomnia	4 to 6	✔	12	✔
Jitteriness	-	✔	-	-
Lethargy	2	-	-	-
Loss of balance	-	-	<1	-
Manic symptoms	-	✔	<1	✔
Migraine	-	-	<1	-
Neuritis	✔	-	-	-
Neurosis	-	-	<1	-
Numbness	-	-	-	✔
Palilalia	-	✔	-	-
Paranoid reaction	-	-	<1	-
Parasomnia	-	-	>1	-
Paresthesia	2	✔	>1	✔
Restlessness	-	-	-	✔
Schizophrenia precipitation	-	✔	-	-
Sedation	2	-	-	-
Seizure	-	✔	-	-
Sleep disturbance	2 to 5	✔	-	✔
Tremor	4	✔	<1	✔
Twitching	-	✔	<1	✔
Vertigo	-	-	<1	-
Weakness	-	✔	-	✔

Adverse Events	Isocarboxazid	Phenelzine	Selegiline	Tranylcypromine
Dermatological				
Acne	-	-	≥1	-
Alopecia	-	-	<1	✔
Application site reaction	-	-	24	-
Bruising	-	-	≥1	-
Cystic acne flare-up	-	-	-	✔
Maculopapular rash	-	-	<1	-
Photosensitivity	✔	-	<1	-
Pruritus	-	✔	≥1	✔
Rash	-	✔	4	✔
Scleroderma	-	-	-	✔
Skin benign neoplasm	-	-	<1	-
Skin hypertrophy	-	-	<1	-
Urticaria	-	-	<1	✔
Vesiculobullous rash	-	-	<1	-
Gastrointestinal				
Abdominal pain	-	-	-	✔
Anorexia	-	-	≥1	✔
Appetite increased	-	-	<1	-
Black tongue	✔	-	-	-
Colitis	-	-	<1	-
Constipation	4 to 7	✔	>11	✔
Dental caries	-	-	<1	-
Diarrhea	2	-	9	✔
Dyspepsia	-	-	4	-
Eructation	-	-	<1	-
Flatulence	≥1	-	≥1	-
Gastritis	<1	-	<1	-
Gastroenteritis	≥1	-	≥1	-
Gastrointestinal disturbances	-	✔	-	-
Melena	<1	-	<1	-
Nausea	4 to 6	✔	-	✔
Rectal hemorrhage	<1	-	<1	-
Salivation increased	-	-	<1	-
Taste perversion	-	-	≥1	-
Tongue edema	-	-	<1	-
Vomiting	≥1	✔	≥1	-
Weight gain	-	✔	-	-
Weight loss	-	-	5	-
Xerostomia	6 to 9	✔	8	✔
Genitourinary				
Anorgasmia	-	✔	-	-
Cystitis	-	-	<1	-
Dysmenorrhea	-	-	≤1	-
Dysuria	✔	-	<1	-
Ejaculation disturbances	-	✔	-	✔
Hematuria	-	-	<1	-
Impotence	2	✔	-	✔
Incontinence	✔	-	-	-
Kidney calculus	-	-	<1	-
Libido increased	-	-	<1	-
Menorrhagia	-	-	<1	-
Pelvic pain	-	-	<1	-
Polyuria	-	-	<1	-

Adverse Events	Isocarboxazid	Phenelzine	Selegiline	Tranylcypromine
Prostatic hyperplasia	-	-	<1	-
Sexual disturbances	✔	✔	≤1	-
Urinary frequency	2	-	<1	✔
Urinary hesitancy	1	-	-	-
Urinary retention	✔	✔	<1	✔
Urinary tract infection	-	-	≥1	-
Urinary urgency	-	-	<1	-
Urination impaired	-	-	<1	-
Vaginal hemorrhage	-	-	<1	-
Vaginal moniliasis	-	-	<1	-
Hematologic				
Agranulocytosis	-	-	-	✔
Anemia	-	-	<1	✔
Hematologic changes	✔	-	-	-
Leukocytosis	-	-	<1	-
Leukopenia	-	✔	<1	✔
Thrombocytopenia	-	-	-	✔
Hepatic				
Hepatitis	-	✔ -	-	✔
Jaundice	-	✔	-	-
Liver function tests abnormal	-	-	<1	-
Hepatocellular damage	-	✔	-	-
Transaminases increased	-	✔	-	-
Laboratory Test Abnormalities				
Alkaline phosphatase increased	-	-	<1	-
Hypercholesterolemia	-	-	<1	-
Hyperglycemia	-	-	<1	-
Hypernatremia	-	✔	-	-
Hypoglycemic reaction	-	-	<1	-
Hyponatremia	-	-	<1	✔
Lactate dehydrogenase increased	-	-	<1	-
Musculoskeletal				
Generalized spasm	-	-	<1	-
Heavy feeling	2	✔	-	-
Hypertonia	-	-	<1	-
Myalgia	-	-	≥1	-
Myasthenia	-	-	<1	-
Myoclonic jerks/movements	2	✔	<1	✔
Neck pain	-	-	≥1	-
Tenosynovitis	-	-	<1	-
Respiratory				
Asthma	-	-	<1	-
Bronchitis	-	-	≥1	-
Cough	-	-	≥1	-
Dyspnea	-	-	<1	-
Laryngismus	-	-	<1	-
Pharyngitis	-	-	3	-
Pneumonia	-	-	<1	-
Respiratory depression	-	✔	-	-
Sinusitis	-	-	3	-
Special Senses				
Blurred vision	✔	✔	-	✔
Glaucoma	-	✔	-	✔

Adverse Events	Isocarboxazid	Phenelzine	Selegiline	Tranylcypromine
Nystagmus	-	✔	-	-
Tinnitus	-	-	<1	✔
Visual field defect	-	-	<1	-
Toxic amblyopia	✔	-	-	-
Other				
Bacterial infection	-	-	<1	-
Bilirubinemia	-	-	<1	-
Breast Pain	-	-	<1	-
Chills	2	-	<1	✔
Circumoral paresthesia	-	-	<1	-
Dehydration	-	-	<1	-
Diaphoresis	2	✔	≥1	✔
Edema	-	✔	<1	✔
Edema of the glottis	-	✔	-	-
Epistaxis	-	-	<1	-
Facial edema	-	-	<1	-
Fever	-	✔	<1	-
Fungal infection	-	-	<1	-
Glossitis	-	-	<1	-
Heat stroke	-	-	<1	-
Hernia	-	-	<1	-
Hypermetabolic syndrome	-	✔	-	✔
Impaired water secretion	✔	-	-	✔
Lupus-like syndrome	-	✔	-	-
Lymphadenopathy	-	-	<1	-
Moniliasis	-	-	<1	-
Neoplasia	-	-	<1	-
Osteoporosis	-	-	<1	-
Otitis external	-	-	<1	-
Parasitic infection	-	-	<1	-
Periodontal abscess	-	-	<1	-
Syndrome of inappropriate antidiuretic hormone secretion	✔	✔	-	✔
Suicide attempt	-	-	<1	-
Sweating	2	✔	>1	-
Toxic delirium	-	✔	-	-
Viral infection	-	-	<1	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 6b. Adverse Drug Events (%) Reported with the Selective Serotonin- and Norepinephrine-reuptake Inhibitors[1-32]

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Cardiovascular				
Aneurysm	-	-	-	<1
Angina pectoris	-	-	<2	<1
Arrhythmia	-	-	-	<1
Atrial fibrillation	-	<1	-	-
Atrioventricular block	-	-	-	<1
Bigeminy	-	-	-	<1
Blood pressure increase	1 to 2	-	3	-
Bradycardia	-	-	-	<1
Bundle branch block	-	<1	-	<1

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Cardiovascular disorder	-	-	-	<1
Cerebral ischemia	-	-	-	<1
Chest pain	-	-	<2	2
Congestive heart failure	-	<1	-	<1
Coronary artery disease	-	-	-	<1
Edema	-	-	-	✔
Electrocardiogram abnormalities	-	-	-	<1
Extrasystoles	-	-	<2	<1
Heart arrest	-	-	-	<1
Heart rate increase	-	-	6	-
Hemorrhage	-	-	-	<1
Hypertension, dose related and dose independent	<1	-	3	3 to 13
Hypertensive crisis	-	<1	-	-
Hypotension	-	-	3	<1
Myocardial infarct	<2	<1	-	<1
Myocardial ischemia	<1	-	-	-
Orthostatic hypotension	<2	<1	10 to 12	-
Palpitation	≤3	1 to 2	5	3
Peripheral edema	-	<1	-	-
Postural hypotension	-	-	-	1
Syncope	<2	<1	<2	<1
Tachycardia	<1	<1	6	2
Vasodilation	-	-	-	3 to 4
Central Nervous System				
Abnormal dreams	2 to 3	2 to 3	-	3 to 7
Abnormal thinking	-	-	-	2
Agitation	-	5 to 6	<2	2 to 4
Aggression	-	<1	<2	-
Amnesia	-	-	-	✔
Anger	-	-	<2	-
Anxiety	3 to 5	3	-	5 to 6
Ataxia	-	<1	-	<1
Blurred vision	-	4	-	4 to 6
Bradykinesia	-	-	-	<1
Chills	-	-	-	3
Concentration decreased	≤1	-	-	-
Confusion	-	-	-	2
Deafness	-	-	-	<1
Delusions	-	-	-	<1
Dementia	-	-	-	<1
Depersonalization	<2	-	-	1
Depression	-	-	-	1 to 3
Diplopia	-	<1	-	-
Disorientation	-	<1	-	-
Dizziness	10 to 13	6 to 17	-	11 to 20
Dystonia	-	-	-	<1
Extrapyramidal symptoms	<2	-	<2	-
Fatigue	7	2 to 15	-	-
Fever	-	1 to 3	-	✔
Guillain-Barre syndrome	-	-	-	<1
Hostility	-	-	-	<1
Hypoesthesia	-	1	-	-

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Headache	-	13	-	25 to 38
Hypoesthesia	-	1	-	✔
Hypomania	<2	-	-	-
Insomnia	9 to 12	8 to 6	-	15 to 23
Irritability	2	1	-	-
Lethargy	-	1	-	-
Loss of consciousness	-	-	-	<1
Mania	-	<1	-	-
Migraine	-	-	<2	✔
Mood swings	-	<1	-	-
Nervousness	-	1	-	6 to 21
Neuropathy	-	-	-	<1
Neutropenia	-	-	-	<1
Nightmares	-	1	-	-
Panic attack	-	-	<2	-
Paresthesia	≤2	1	<2	2 to 3
Parkinsonism	<1	-	-	-
Photopsia	-	<1	-	-
Photosensitivity	-	<1	-	-
Restlessness	-	1	-	-
Seizure	-	<1	-	<1
Sleep disorder	-	1	-	-
Somnolence	≤9	13 to 20	-	12 to 23
Tension	-	-	<2	-
Trismus	-	-	-	✔
Vertigo	-	1	-	✔
Yawning	-	1	<2	3 to 5
Dermatological				
Acne	-	<1	-	-
Alopecia	-	<1	-	-
Bruising	-	-	-	✔
Ecchymosis	-	<1	-	-
Eczema	-	<1	-	-
Erythema	-	<1	-	-
Erythema multiforme	-	-	-	<1
Exfoliative dermatitis	-	-	-	<1
Dry skin	-	-	<2	-
Hyperhidrosis	10 to 21	6 to 8	9	-
Maculopapular rash	-	-	-	<1
Miliaria	-	-	-	<1
Pruritus	-	3	<2	1
Rash	1	4	2	3
Skin atrophy	-	-	-	<1
Stevens-Johnson syndrome	-	<1	-	<1
Toxic epidermal necrolysis	-	-	-	<1
Urticaria	-	<1	<2	-
Endocrine and Metabolic				
Bilirubin increased	-	<1	-	<1
Blood urea nitrogen increased	-	-	-	<1
Cholesterol increased	3 to 4	<1	-	-
Creatinine increased	-	-	-	<1
Diabetes mellitus	-	-	-	<1
Dyslipidemia	-	<1	-	-

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Electrolyte abnormalities	-	-	-	<1
Hepatic steatosis	-	<1	-	-
Hepatitis	-	<1	-	<1
Hot flushes	-	2	<2	-
Hypercalcinuria	-	-	-	<1
Hyperchlorhydria	-	-	-	<1
Hypercholesterolemia	-	<1	-	<15
Hyperglycemia	-	-	-	<1
Hyperkalemia	-	-	-	<1
Hyperlipidemia	-	<1	-	<1
Hyperphosphatemia	-	-	-	<1
Hyperthyroidism	-	-	-	<1
Hypertriglyceridemia	-	<1	-	-
Hyperuricemia	-	-	-	<1
Hypocholesterolemia	-	-	-	<1
Hypoglycemia	-	1	-	<1
Hypokalemia	-	-	-	<1
Hyponatremia	-	<1	-	<1
Hypophosphatemia	-	-	-	<1
Hypothyroidism	-	-	-	<1
Increased blood cholesterol	-	-	<2	-
Increased liver function tests	-	-	<2	-
Jaundice	-	<1	-	<1
Kidney function abnormal	-	-	-	<1
Low-density lipoprotein increased	≤1	-	-	-
Liver enzymes increased	≤2	-1	-	<1
Syndrome of inappropriate antidiuretic hormone secretion	-	<1	-	<1
Transaminase elevation	-	1	-	-
Triglycerides increased	-	-	-	✔
Weight gain	-	<1	-	✔
Weight loss	≤2	1 to 2	-	1 to 4
Gastrointestinal				
Abdominal pain	-	<1	<2	6
Abnormal taste	-	-	-	2
Anorexia	5 to 8	3 to 5	-	8 to 20
Aphthous stomatitis	-	<1	-	-
Appetite decreased	-	3 to 11	3	-
Appetite increased	-	-	-	✔
Bloody stools	-	<1	-	-
Cholelithiasis	-	-	-	<1
Colitis	-	<1	-	-
Constipation	9 to 11	5 to 15	9	8 to 15
Diarrhea	9 to 11	7 to 13	-	6 to 8
Diverticulitis	-	<1	-	-
Dyspepsia	-	4 to 5	-	7
Dysphagia	-	<1	-	-
Eructation	-	<1	-	-
Esophageal stenosis	-	<1	-	-
Flatulence	-	-	<2	3 to 4
Gastric emptying impaired	-	<1	-	-
Gastric irritation	-	<1	-	-

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Gastric ulcer	-	<1	-	<1
Gastritis	-	1	-	-
Hematemesis	-	-	-	<1
Intestinal obstruction	-	-	-	<1
Irritable bowel syndrome	-	<1	-	-
Loose stools	-	2 to 3	-	-
Melena	-	<1	-	-
Nausea	22 to 26	14 to 30	17	21 to 58
Vomiting	≤4	1 to 6	5	3 to 6
Xerostomia	11 to 17	5 to 18	-	12 to 22
Genitourinary				
Crystalluria	-	-	-	<1
Dysuria	-	1	-	-
Ejaculation abnormality	≤1	1 to 4	5	2 to 19
Erectile dysfunction	3 to 6	1 to 5	6	-
Hematuria	-	-	<2	-
Impotence	-	-	-	4 to 10
Libido decreased	4 to 5	2 to 4	-	3 to 9
Menstrual abnormalities	-	-	-	<1
Micturition urgency	-	<1	-	-
Nocturia	-	<1	-	-
Pollakiuria	-	1 to 5	<2	-
Prostatic disorder	-	-	-	✔
Proteinuria	6 to 8	-	<2	-
Pyelonephritis	-	-	-	<1
Pyuria	-	-	-	<1
Testicular pain	-	-	4	-
Urinary frequency	-	-	-	3
Urinary hesitation	-	-	4	-
Urinary retention	-	<1	-	1
Urinary symptoms	≤1	1	-	-
Urination impaired	-	-	-	2
Hematologic				
Agranulocytosis	-	-	-	<1
Anemia	-	<1	-	-
Aplastic anemia	-	-	-	<1
Bleeding time increased	-	-	-	<1
Eosinophilia	-	-	-	<1
Hypoproteinemia	-	-	-	<1
Leukocytosis	-	-	-	<1
Leukoderma	-	-	-	<1
Leukopenia	-	<1	-	<1
Lymphadenopathy	-	<1	-	<1
Lymphocytosis	-	-	-	<1
Pancytopenia	-	-	-	<1
Thrombocytopenia	-	<1	-	<1
Thrombophlebitis	-	-	-	<1
Musculoskeletal				
Arthralgia	-	-	-	✔
Dysarthria	-	<1	-	-
Extrapyramidal symptoms	-	-	<2	<1
Hypertonia	-	-	-	3
Malaise	-	<1	-	-
Muscle cramp	-	4 to 5	-	-

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Muscle pain	-	1 to 5	-	-
Muscle tightness	-	1	-	1 to 2
Muscle twitching	-	4	-	<1
Myalgia	-	1 to 3	-	-
Myasthenia	-	-	-	<1
Myopathy	-	-	-	<1
Neck pain/rigidity	-	-	-	✔
Neuroleptic malignant-like syndrome	-	-	-	<1
Osteoporosis	-	-	-	<1
Rhabdomyolysis	-	-	-	<1
Rheumatoid arthritis	-	-	-	<1
Rigors	-	1	-	-
Tendon rupture	-	-	-	<1
Tremor	≤3	3 to 4	-	4 to 10
Weakness	≤2	2 to 8	-	8 to 19
Respiratory				
Asthma	-	-	-	<1
Atelectasis	-	-	-	<1
Cough	-	3 to 6	-	✔
Dyspnea	-	-	-	✔
Epistaxis	<2	-	-	-
Nasopharyngitis	-	7 to 9	-	-
Pharyngitis	-	-	-	7
Pharyngolaryngeal pain	-	1 to 6	-	-
Pleurisy	-	-	-	<1
Pneumonia	-	-	-	<1
Sinusitis	-	-	-	2
Upper respiratory infection	-	7	-	-
Other				
Anaphylactic reaction	-	<1	-	<1
Angioneurotic edema	-	<1	-	-
Arteritis	-	-	-	<1
Bacteremia	-	-	-	<1
Basophilia	-	-	-	<1
Blurred/abnormal vision	-	1 to 3	<2	4 to 6
Bruxism	-	<1	<2	-
Cataract	-	-	-	<1
Catatonia	-	-	-	<1
Cellulites	-	-	-	<1
Conjunctival hemorrhage	-	-	<2	-
Cyanosis	-	-	-	<1
Deep vein thrombosis	-	-	-	<1
Dehydration	-	<1	-	<1
Diaphoresis increased	10 to 14	6	-	10 to 14
Embolus	-	-	-	<1
Facial edema	-	<1	-	-
Facial paralysis	-	-	-	<1
Fasciitis	-	-	-	<1
Flu-like syndrome	-	<1	-	6
Gingivitis	-	<1	-	-
Glaucoma	-	<1	-	<1
Homicidal ideation	-	-	-	<1
Hot flushes	-	2 to 3	<2	-

Adverse Events	Desvenlafaxine	Duloxetine	Levomilnacipran	Venlafaxine
Hyperacusis	-	-	-	<1
Hypersensitivity reaction	<2	-	-	-
Infection	-	-	-	6
Keratoconjunctivitis sicca	-	<1	-	-
Larynx edema	-	-	-	<1
Macular degeneration	-	<1	-	-
Maculopathy	-	<1	-	-
Moniliasis	-	-	-	<1
Multiple myeloma	-	-	-	<1
Mydriasis	2	-	-	2
Nephropathy	-	<1	-	-
Night sweats	-	1	-	-
Oropharyngeal edema	-	<1	-	-
Phlebitis	-	<1	-	-
Retinal detachment	-	<1	-	-
Serotonin syndrome	-	-	-	<1
Stomatitis	-	<1	-	-
Suicidal ideation/attempt	-	<1	-	<1 to 2
Thirst	-	<1	<2	-
Tinnitus	2	-	-	2
Trauma	-	-	-	2
Trismus	-	-	-	✔
Visual disturbance	-	<1	-	-
Withdrawal syndrome	-	<1	-	<1

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 6c. Adverse Drug Events (%) Reported with the Selective Serotonin-reuptake Inhibitors[1-32]

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Cardiovascular						
Angina	-	-	<1	<1	<1	-
Arrhythmia	-	-	<1	-	-	-
Atrial arrhythmia	-	-	-	-	<1	<1
Atrial fibrillation	-	<1	<1	-	-	-
Atrioventricular block	-	-	-	<1	-	<1
Bradycardia	1 to 10	<1	-	<1	<1	<1
Cardiomyopathy	-	-	-	<1	-	-
Cerebrovascular accident	-	<1	<1	<1	<1	-
Chest pain	<1	<1	>1	3	3	>1
Chest tightness	-	<1	-	-	<1	-
Congestive heart failure	-	-	<1	<1	<1	-
Coronary artery disease	-	-	-	<1	-	-
Electrocardiogram abnormal	-	<1	-	<1	-	-
Edema	<1	<1	<1	≤1	-	<1
Hemorrhage	-	-	✔	<1	-	-
Hypertension	<1	<1	>1	1 to 2	≥1	<1
Myocardial infarct	-	-	<1	<1	<1	-
Orthostatic hypotension	-	<1	-	≤1	<1	-
Palpitation	-	<1	>1	3	2 to 3	>1
Pericarditis	-	-	-	<1	-	-
Peripheral edema	-	-	<1	-	-	<1
Postural hypotension	1 to 10	-	<1	-	<1	<1
Pulmonary hypertension	-	-	<1	-	-	<1
QT_c prolongation	<1	<1	<1	-	-	<1
Supraventricular extrasystoles	-	-	-	<1	-	-
Syncope	-	<1	<1	≤1	<1	<1
Tachycardia	1 to 10	<1	<1	≤1	≥1	-
Vasculitis	-	<1	<1	<1	<1	<1
Vasodilation	-	-	1 to 5	2	2 to 4	-
Ventricular arrhythmia	<1	<1	-	-	<1	-
Ventricular tachycardia	<1	<1	<1	<1	<1	<1
Central Nervous System						
Abnormal dreams	-	3	1 to 5	3	3 to 4	<1
Abnormal gait	-	<1	<1	-	-	<1
Abnormal thinking	-	-	2	3	<1	-

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Aggression	-	<1	-	-	-	<1
Agitation	3 to 10	<1	>1	2 to 3	3 to 5	5
Akathisia	-	<1	<1	-	-	-
Akinesia	-	-	-	<1	<1	-
Amnesia	>1	<1	>1	✔	2	<1
Anxiety	4	<1	6 to 15	5 to 8	5	4
Apathy	>1	<1	<1	1 to 3	-	<1
Aphasia	-	-	-	-	<1	-
Asthenia	-	-	-	14	-	>1
Ataxia	-	-	<1	<1	<1	<1
Auditory hallucination	-	<1	-	-	-	-
Blindness	-	-	-	-	-	<1
Blurred vision	-	1 to 10	-	-	-	-
Chills	-	-	>1	2	<1	-
Central nervous system stimulation	-	-	<1	2	-	-
Concentration impaired	✔	1 to 10	-	-	3 to 4	<1
Confusion	>1	<1	>1	<1	1	<1
Deafness	-	-	-	-	<1	-
Delirium	<1	<1	-	-	<1	-
Depersonalization	-	<1	<1	-	≤3	-
Depression	>1	<1	>1	2	-	<1
Dizziness	-	5	9	11 to 15	6 to 14	12
Dyskinesias	<1	<1	<1	<1	<1	-
Dystonia	-	-	-	<1	<1	<1
Emotional lability	-	<1	>1	-	>1	<1
Euphoria	-	-	<1	-	<1	<1
Excitability	-	<1	-	-	-	-
Extrapyramidal symptoms	-	-	<1	<1	<1	<1
Fatigue	5	5 to 8	-	-	-	12
Fever	2	<1	2	-	-	-
Guillain-Barre syndrome	-	-	-	-	<1	-
Hallucinations	-	<1	<1	<1	<1	<1
Headache	-	24	21	22 to 35	17 to 18	25
Hiccup	-	-	<1	-	-	-
Hyperkinesia	-	-	<1	✔	-	<1
Hyperreflexia	-	<1	-	-	-	-
Hypertonia	-	-	<1	2	<1	>1

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Hypoesthesia	-	<1	-	-	-	1 to 10
Hypokinesia	-	-	-	✔	-	<1
Hypomania	-	-	-	<1	-	-
Insomnia	>10	9 to 12	10 to 33	21 to 35	11 to 24	21
Irritability	-	<1	-	-	-	-
Lethargy	-	3	-	-	-	-
Lightheadedness	-	<1	-	-	-	-
Malaise	-	<1	<1	✔	-	1 to 10
Mania	-	-	-	✔	-	-
Meningitis	-	-	-	-	<1	-
Migraine	>1	<1	<1	-	<1	<1
Nervousness	-	-	8 to 14	10 to 12	4 to 9	5
Neuralgia	-	-	<1	<1	-	-
Neuropathy	-	-	<1	<1	<1	-
Neurosis	-	-	<1	2	<1	-
Nystagmus	-	<1	-	-	-	<1
Optic neuritis	-	-	<1	-	-	<1
Panic reaction	-	<1	-	-	-	-
Paralysis	-	-	-	<1	<1	-
Paresthesia	>1	2	-	3	4	2
Parkinsonism	-	<1	-	-	-	-
Psychiatric disturbances	-	<1	-	✔	-	<1
Seizure	-	✔	-	<1	<1	-
Somnolence	>10	6 to 13	5 to 17	22 to 27	15 to 24	13
Tardive dyskinesia	-	<1	-	<1	-	-
Tetany	-	-	-	-	<1	-
Tremors	8	-	9	4	-	8
Vertigo	-	<1	<1	-	>1	<1
Yawning	<10	2	<11	2 to 5	2 to 4	>1
Dermatological						
Acne	-	-	<1	2	<1	<1
Alopecia	-	-	<1	<1	<1	<1
Angioedema	-	-	-	<1	<1	<1
Bruising	-	-	<1	4	<1	-
Bullous eruption	-	-	-	<1	-	-
Cellulitis	-	-	-	-	<1	-
Ecchymosis	-	-	<1	2	<1	<1

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Eczema	-	-	<1	<1	<1	<1
Epidermal necrolysis	<1	<1	<1	-	<1	-
Erythema multiforme	<1	<1	<1	-	<1	-
Erythema nodosum	>1	-	<1	-	-	-
Exfoliative dermatitis	>1	-	<1	-	<1	-
Photosensitivity	<1	-	<1	<1	<1	<1
Pruritus	✔	-	4	-	>1	<1
Rash	✔	<1	2 to 6	-	2 to 3	>10
Stevens-Johnson syndrome	-	-	<1	<1	-	<1
Urticaria	<1	-	-	<1	<1	<1
Endocrine and Metabolic						
Albuminuria	-	-	<1	-	-	-
Alkaline phosphatase increased	-	-	-	-	<1	-
Bilirubin increased	-	<1	-	-	<1	<1
Blood urea nitrogen increased	-	-	-	-	<1	-
Cholecystitis	-	-	-	<1	-	-
Cholelithiasis	-	-	<1	<1	<1	-
Cholestatic jaundice	-	-	<1	-	-	-
Diabetes mellitus	-	<1	-	-	<1	-
Galactorrhea	-	-	-	-	-	<1
Goiter	-	-	-	<1	<1	-
Gynecomastia	-	<1	<1	-	5	<1
Hepatic failure	-	-	<1	-	-	<1
Hepatic necrosis	<1	<1	<1	-	<1	-
Hepatitis	-	<1	-	<1	<1	<1
Hepatomegaly	-	-	-	-	-	<1
Hot flashes	-	<1	-	-	-	-
Hypercholesterolemia	-	<1	<1	<1	<1	-
Hyperglycemia	-	<1	-	<1	<1	<1
Hyperprolactinemia	-	-	<1	-	-	<1
Hyperthyroidism	-	-	-	-	<1	-
Hypoglycemia	-	<1	-	<1	<1	<1
Hypokalemia	-	<1	<1	<1	-	-
Hyponatremia	<1	-	<1	<1	-	-
Hypothyroidism	-	-	<1	<1	<1	<1
Jaundice	-	-	<1	<1	<1	<1
Syndrome of inappropriate antidiuretic hormone	<1	<1	-	-	-	<1

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Transaminase elevation	-	-	-	-	<1	<1
Weight gain	>1	<1	>1	<1	>1	>1
Weight loss	>1	<1	2	1 to 2	<1	-
Gastrointestinal						
Abdominal cramps	-	1 to 10	-	-	-	-
Abdominal pain	3	2	-	5	4	<1
Abnormal taste	✔	<1	✔	2 to 3	2	-
Anorexia	4	-	4 to 17	6 to 14	5 to 9	6
Aphthous stomatitis	-	-	<1	-	<1	<1
Appetite decreased	-	3	-	4	5 to 9	-
Appetite increased	>1	1 to 10	✔	-	2 to 4	>1
Carbohydrate craving	-	<1	-	-	-	-
Cholelithiasis	-	-	<1	-	-	-
Colitis	-	-	<1	<1	<1	-
Constipation	-	3 to 5	5	4 to 10	5 to 16	6
Diarrhea	8	8	8 to 18	11 to 18	9 to 12	20
Dyspepsia	5	-	6 to 10	8 to 10	2 to 5	8
Dysphagia	-	<1	<1	2	<1	<1
Esophagitis	-	-	<1	-	-	<1
Flatulence	>1	2	3	4	4	1 to 10
Gastritis	-	-	<1	-	<1	-
Gastroenteritis	-	<1	<1	-	<1	<1
Gastrointestinal bleeding	-	-	-	<1	-	-
Gastrointestinal ulcer	-	-	<1	-	<1	-
Gingivitis	-	-	-	2	<1	-
Glossitis	-	-	<1	-	<1	-
Heartburn	-	<1	-	-	-	-
Hematemesis	-	-	-	<1	<1	-
Indigestion	-	3	-	10	-	-
Intestinal obstruction	-	-	-	<1	<1	-
Melena	-	-	<1	-	-	-
Nausea	>10	15	12 to 29	34 to 40	19 to 26	25
Pancreatitis	<1	<1	<1	<1	<1	<1
Vomiting	4	1 to 10	3	4 to 6	2 to 3	4
Xerostomia	>10	6 to 9	4 to 12	10 to 14	9 to 18	>10
Genitourinary						
Acute renal failure	<1	<1	<1	<1	<1	<1

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Anorgasmia	-	2 to 6	2	2 to 5	2 to 9	-
Anuria	-	-	-	<1	-	-
Ejaculation disorder	6	9 to 14	<7	7 to 11	13 to 28	7 to 19
Hematuria	-	-	<1	<1	<1	<1
Impotence	3	2 to 3	<7	2	2 to 9	>1
Libido decreased	1 to 4	3 to 7	1 to 11	2 to 10	3 to 15	6
Menstrual cramps	-	1 to 10	-	-	-	-
Menstrual disorder	3	<1	<1 to 2	3	5	<1
Micturition disorders	✔	-	-	-	-	<1
Priapism	<1	<1	<1	-	-	<1
Sexual dysfunction	✔	-	-	2 to 4	-	>1
Urinary frequency	-	<1	✔	2 to 3	2 to 3	<1
Urinary incontinence	<1	-	<1	<1	<1	<1
Urinary retention	<1	-	<1	1	<1	<1
Urinary tract infection	-	<1	-	2	2	-
Hematologic						
Agranulocytosis	-	-	-	<1	-	<1
Anemia	-	<1	<1	<1	<1	-
Aplastic anemia	-	<1	<1	-	-	<1
Blood dyscrasias	-	-	-	-	<1	-
Hemolytic anemia	<1	<1	<1	-	-	-
Increased bleeding	-	-	-	-	<1	<1
Ketosis	-	-	-	-	<1	-
Leukocytosis	<1	-	-	<1	<1	-
Leukopenia	-	-	-	<1	<1	<1
Liver enzymes increased	<1	-	<1	1 to 2	<1	-
Lymphadenopathy	-	-	-	<1	<1	-
Pancytopenia	-	-	<1	-	<1	-
Platelet count abnormalities	-	-	-	-	<1	-
Porphyria	-	-	-	<1	-	-
Prothrombin decreased	-	<1	-	-	-	-
Purpura	<1	<1	<1	<1	-	>2
Thrombosis	-	<1	-	-	<1	-
Thrombocytopenia	-	<1	<1	<1	<1	<1
Thrombocytopenic purpura	-	-	<1	-	-	-
Musculoskeletal						
Arthralgia	2	<1	-	-	>1	<1

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Arthritis	-	-	<1	-	<1	-
Back pain	-	-	-	-	3	>1
Bursitis	-	-	<1	-	-	-
Choreoathetosis	-	<1	-	-	-	-
Limb pain	-	1 to 10	-	-	-	-
Muscle contractions	-	<1	-	2	-	-
Muscle cramp	-	<1	<1	-	-	<1
Myalgia	2	<1	-	5 to 8	2 to 4	>1
Myoclonus	<1	-	-	-	2 to 3	-
Neck/shoulder pain	-	1 to 10	-	-	<1	-
Neuroleptic malignant syndrome	<1	<1	<1	<1	<1	<1
Osteoporosis	-	-	-	-	<1	-
Rhabdomyolysis	<1	<1	-	-	-	-
Rigors	<1	-	-	-	-	-
Tics	-	<1	-	-	-	-
Tremor	8	1 to 10	3 to 13	5 to 8	4 to 11	-
Weakness	-	<1	7 to 21	14 to 26	12 to 22	<1
Respiratory						
Asthma	-	-	<1	<1	<1	-
Bronchitis	-	<1	-	2	<1	<1
Cough	>1	1 to 10	-	✔	-	<1
Dyspnea	-	-	<1	2	<1	<1
Eosinophilic pneumonia	-	-	<1	-	-	-
Epistaxis	-	-	≥2	2	<1	<1
Hemoptysis	-	-	-	<1	<1	<1
Hyperventilation	-	-	<1	-	<1	<1
Laryngeal edema	-	-	<1	-	-	-
Laryngitis	-	-	-	3	-	<1
Laryngospasm	-	-	<1	-	-	-
Nasal congestion	-	1 to 10	-	-	-	-
Pharyngitis	-	-	3 to 11	6	4	-
Pulmonary embolism	-	<1	<1	<1	<1	-
Pulmonary fibrosis	-	-	<1	-	<1	-
Pulmonary hypertension	-	-	<1	-	<1	-
Respiratory infection	5	-	-	9	7	<1
Rhinitis	5	5	-	-	3	>1
Sinus headache	-	<1	-	-	-	-

Adverse Events	Citalopram	Escitalopram	Fluoxetine	Fluvoxamine	Paroxetine	Sertraline
Sinusitis	3	3	1 to 6	✔	4	<1
Other						
Allergic reaction	-	<1	-	<1	>1	<1
Allergy	-	<1	<1	-	<1	-
Amblyopia	-	-	-	2 to 3	-	-
Anaphylaxis	<1	<1	<1	<1	<1	<1
Angioedema	<1	<1	-	-	-	-
Blindness	-	-	-	-	-	<1
Blurred/abnormal vision	-	<1	✔	<1	2 to 4	3
Cataract	-	-	<1	-	<1	<1
Dehydration	-	-	<1	-	<1	-
Diaphoresis	>10	4 to 5	2 to 8	6 to 7	5 to 14	4 to 6
Ear ache	-	<1	✔	-	-	-
Flu-like syndrome	-	5	3 to 10	3	-	-
Gout	-	-	<1	-	-	-
Gum hyperplasia	-	-	-	-	-	<1
Infection	-	-	-	-	5 to 6	-
Lupus-like syndrome	-	-	<1	-	-	<1
Oculogyric crisis	-	-	-	-	-	<1
Pain	-	-	<1	10	-	1 to 10
Retinal detachment	-	-	-	<1	-	-
Sepsis	-	-	-	-	<1	-
Serotonin syndrome	<1	<1	<1	<1	<1	<1
Serum sickness	-	-	-	-	-	<1
Spontaneous abortion	-	<1	-	-	-	-
Suicidal tendency	✔	<1	-	<1	<1	<1
Thirst	<1	<1	≥2	-	-	-
Tinnitus	-	<1	>1	-	>1	>1
Tooth disorder	-	2	-	2 to 3	-	-
Vasculitis	-	-	<1	-	-	-
Visual difficulty	-	<1	2	-	2 to 4	<1
Withdrawal syndrome	<1	<1	-	-	-	<1

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 6d. Adverse Drug Events (%) Reported with the Serotonin Modulators[1-32]

Adverse Events	Nefazodone	Trazodone	Vilazodone	Vortioxetine
Cardiovascular				
Atrioventricular block	<1	-	-	-
Bradycardia	1 to 10	<1	-	-
Edema	-	1 to 10	-	-
Hypertension	-	1 to 10	-	-
Hypotension	1 to 10	1 to 10	-	-
Palpitation	-	-	1 to 2	-
Peripheral edema	1 to 10	-	-	-
Postural hypotension	1 to 10	-	-	-
Syncope	-	1 to 10	-	-
Tachycardia	-	<1	-	-
Vasodilation	1 to 10	-	-	-
Ventricular extrasystoles	-	-	<1	-
Central Nervous System				
Abnormal dreams	1 to 10	-	3	<1 to 3
Agitation	>10	<1	-	-
Anxiety	-	<1	-	-
Ataxia	1 to 10	-	-	-
Chills	1 to 10	-	-	-
Concentration decreased	1 to 10	1 to 10	-	-
Confusion	1 to 10	1 to 10	-	-
Dizziness	>10	>10	6 to 8	6 to 9
Drowsiness	>10	>10	4 to 5	-
Fatigue	-	1 to 10	4	-
Fever	1 to 10	-	-	-
Hallucinations	<1	-	✔	-
Headache	>10	>10	15	-
Incoordination	1 to 10	1 to 10	-	-
Insomnia	>10	-	6 to 7	-
Lightheadedness	1 to 10	-	-	-
Mania	-	-	<1	-
Memory impairment	1 to 10	-	-	-
Panic attacks	-	-	<1	-
Paresthesia	1 to 10	-	3	-
Psychomotor retardation	1 to 10	-	-	-
Restlessness	-	-	3	-
Sedation	-	>10	>1	-
Seizure	<1	<1	-	-
Speech impairment	-	<1	-	-
Dermatological				
Alopecia	-	<1	-	-
Hyperhidrosis	-	-	≤1	-
Photosensitivity	<1	-	-	-
Pruritus	1 to 10	-	-	1 to 3
Rash	1 to 10	<1	✔	-
Stevens-Johnson syndrome	<1	-	-	-
Endocrine and Metabolic				
Galactorrhea	<1	-	-	-
Gynecomastia	<1	-	-	-
Hepatic failure	<1	-	-	-
Hepatic necrosis	<1	-	-	-
Hepatitis	<1	-	-	-
Hyponatremia	<1	-	✔	-

Adverse Events	Nefazodone	Trazodone	Vilazodone	Vortioxetine
Liver function tests abnormal	<1	-	-	-
Prolactin increased	<1	-	-	-
Weight gain	-	1 to 10	-	-
Weight loss	-	1 to 10	-	-
Gastrointestinal				
Abnormal taste	1 to 10	-	-	-
Appetite decreased	-	-	1 to 10	-
Appetite increased	1 to 10	-	2	-
Constipation	>10	1 to 10	-	3 to 6
Diarrhea	1 to 10	1 to 10	26 to 29	7 to 10
Dry mouth	-	-	-	6 to 8
Dyspepsia	1 to 10	-	3	-
Flatulence	-	-	3	1 to 3
Gastroenteritis	1 to 10	-	2	-
Nausea	>10	>10	22 to 24	21 to 32
Vomiting	1 to 10	>10	4 to 5	3 to 6
Xerostomia	>10	>10	7 to 8	7 to 8
Genitourinary				
Ejaculation delayed	-	-	1 to 2	-
Erectile dysfunction	-	-	2	-
Impotence	1 to 10	-	-	-
Libido decreased	1 to 10	-	3 to 5	-
Orgasm abnormal	-	-	2 to 4	-
Priapism	<1	<1	-	-
Sexual dysfunction	-	-	<2	≥10
Urinary frequency	1 to 10	-	-	-
Urinary retention	1 to 10	<1	-	-
Hematologic				
Hematocrit decreased	1 to 10	-	-	-
Leukopenia	<1	-	-	-
Thrombocytopenia	<1	-	-	-
Musculoskeletal				
Arthralgia	1 to 10	-	2	-
Extrapyramidal symptoms	-	<1	-	-
Hypertonia	1 to 10	-	-	-
Jittery	-	-	2	-
Myalgia	-	1 to 10	-	-
Neck rigidity	1 to 10	-	-	-
Rhabdomyolysis	<1	-	-	-
Tremor	1 to 10	1 to 10	2	-
Weakness	>10	-	-	-
Respiratory				
Bronchitis	1 to 10	-	-	-
Cough	1 to 10	-	-	-
Dyspnea	1 to 10	-	-	-
Nasal congestion	-	1 to 10	-	-
Pharyngitis	1 to 10	-	-	-
Other				
Abnormal feeling	-	-	<1	-
Abnormal taste	-	-	<1	-
Allergic reaction	<1	<1	-	-
Angioedema	<1	-	-	-
Blurred/abnormal vision	7 to 9	>10	≤1	-
Breast pain	1 to 10	-	-	-

Adverse Events	Nefazodone	Trazodone	Vilazodone	Vortioxetine
Cataracts	-	-	<1	-
Eye pain	1 to 10	-	-	-
Flu syndrome	1 to 10	-	-	-
Infection	1 to 10	-	-	-
Night sweats	-	-	≤1	-
Serotonin syndrome	<1	-	-	-
Thirst	1 to 10	-	-	-
Tinnitus	1 to 10	-	-	-
Visual field defect	1 to 10	-	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 6e. Adverse Drug Events (%) Reported with the Tricyclics and Other Norepinephrine-reuptake Inhibitors[1-32]

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Cardiovascular											
Aneurysm	-	-	<1	-	-	-	-	-	-	-	-
Arrhythmia	✔	✔	<1	✔	-	✔	✔	✔	✔	✔	✔
Atrial flutter	-	-	<1	-	-	-	-	-	-	-	-
Atrioventricular conduction changes	✔	-	-	-	-	-	-	-	-	-	✔
Bradycardia	-	-	<1	-	-	-	-	-	-	-	-
Bundle branch block	-	-	<1	-	-	-	-	-	-	-	-
Cardiac arrest	-	-	<1	-	-	-	-	-	-	-	-
Cardiomyopathy	✔	-	-	-	-	-	-	-	-	-	✔
Cerebral hemorrhage	-	-	<1	-	-	-	-	-	-	-	-
Chest pain	-	-	4	-	-	-	-	-	-	-	-
Chills	-	-	2	-	-	-	-	-	-	-	-
Congestive heart failure	-	-	-	-	-	✔	-	-	-	-	-
Cyanosis	-	-	<1	-	-	-	-	-	-	-	-
Electrocardiogram changes	✔	1 to 7	<1	-	-	✔	-	-	-	-	✔
Edema	✔	1 to 7	3	✔	✔	-	-	✔	-	-	-
Encephalopathy	-	-	<1	-	-	-	-	-	-	-	-
Extrasystole	-	-	<1	-	-	-	-	-	-	-	-
Heart block	✔	✔	<1	-	-	✔	✔	✔	✔	✔	✔
Hypertension	✔	<1	-	✔	✔	✔	✔	✔	✔	✔	✔
Hypotension	✔	<1	1 to 10	✔	✔	-	✔	✔	✔	✔	✔
Myocardial infarction	✔	✔	<1	✔	-	✔	-	✔	✔	✔	✔
Myocardial ischemia	-	-	<1	-	-	-	-	-	-	-	-
Orthostatic hypotension	✔	-	20	-	-	✔	-	✔	-	-	✔
Palpitations	✔	1 to 7	4	✔	-	✔	-	✔	✔	✔	✔
Peripheral ischemia	-	-	<1	-	-	-	-	-	-	-	-
Stroke	✔	✔	-	✔	-	✔	-	✔	✔	✔	✔
Syncope	✔	<1	>1	-	-	-	✔	✔	-	-	✔
Tachycardia	✔	<1	4	✔	✔	✔	-	✔	✔	✔	✔
Vasospasm	-	-	<1	-	-	-	-	-	-	-	-
Central Nervous System											
Abnormal dreaming	-	-	3	-	-	-	-	-	-	-	-
Aggressiveness	-	-	2	-	-	-	-	-	-	-	-
Agitation	-	-	3	✔	-	✔	1 to 10	✔	✔	✔	-
Akathisia	-	-	-	-	-	-	<1	-	-	-	1 to 10
Anxiety	✔	1 to 7	9	✔	-	✔	1 to 10	✔	✔	✔	✔
Aphasia	-	-	<1	-	-	-	-	-	-	-	-
Apraxia	-	-	<1	-	-	-	-	-	-	-	-
Ataxia	✔	1 to 7	<1	✔	✔	-	<1	✔	✔	-	>10
Catalepsy	-	-	<1	-	-	-	-	-	-	-	-
Confusion	-	1 to 7	3	-	✔	-	-	✔	✔	-	1 to 10
Cognitive function (impaired)	✔	-	-	-	-	-	-	-	-	-	✔
Coma	✔	-	<1	-	-	-	-	-	-	-	✔

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Confusion	✔	>1	3	✔	✔	✔	✔	✔	-	✔	✔
Coordination impairment	✔	<1	5	✔	-	✔	-	✔	✔	✔	✔
Deafness	-	-	<1	-	-	-	-	-	-	-	-
Delirium	-	-	<1	✔	-	-	-	✔	✔	✔	-
Delusions	✔	✔	<1	-	-	✔	✔	✔	✔	✔	✔
Depersonalization	-	-	2	-	-	-	-	-	-	-	-
Depression	-	-	5	-	<1	-	-	✔	-	-	-
Disinhibition	-	-	-	-	-	-	-	-	-	-	1 to 10
Disorientation	✔	<1	-	✔	✔	✔	✔	✔	-	✔	✔
Dizziness	✔	1 to 7	54	✔	>1	✔	-	✔	✔	✔	✔
Drowsiness	✔	14	46 to 54	✔	✔	✔	16	✔	✔	✔	✔
Dysarthria	✔	-	-	-	-	-	✔	-	-	-	>10
Dyskinesia	-	-	<1	-	-	-	-	-	-	-	-
Dysphagia	-	-	-	-	-	-	<1	-	-	-	-
Dysphonia	-	-	<1	-	-	-	-	-	-	-	-
Dystonia	-	-	<1	-	-	-	-	-	-	-	-
Emotional lability	-	-	2	-	-	-	-	-	-	-	-
Euphoria	✔	-	-	-	-	-	-	-	-	-	✔
Excitement	✔	1 to 7	-	-	-	-	-	-	-	-	✔
Extrapyramidal symptoms	✔	<1	<1	✔	✔	✔	✔	✔	✔	✔	✔
Fatigue	✔	1 to 7	35 to 39	✔	<1	✔	4	✔	✔	✔	✔
Fever	✔	<1	4	✔	-	-	-	✔	-	-	✔
Flushing	-	-	8	✔	<1	-	-	✔	-	✔	-
Hallucinations	✔	-	<1	✔	✔	✔	✔	✔	✔	✔	✔
Hangover effect	-	-	-	-	-	-	-	-	✔	-	-
Headache	✔	1 to 7	52	✔	✔	✔	4	✔	-	✔	✔
Hemiparesis	-	-	<1	-	-	-	-	-	-	-	-
Hostility	-	-	<1	-	-	-	-	-	-	-	-
Hyperesthesia	-	-	<1	-	-	-	-	-	-	-	-
Hyperkinesia	-	-	<1	-	-	-	-	-	-	-	-
Hyperreflexia	-	-	<1	-	-	-	-	-	-	-	-
Hypertonia	-	-	4	-	-	-	-	-	-	-	-
Hypoesthesia	-	-	<1	-	-	-	-	-	-	-	-
Hypokinesia	-	-	<1	-	-	-	-	-	-	-	-
Hypomania	-	-	-	✔	-	-	-	✔	✔	-	-
Ideation	-	-	<1	-	-	-	-	-	-	-	-
Insomnia	✔	1 to 7	25	✔	-	✔	2	✔	✔	✔	✔
Irritability	-	-	2	-	-	-	-	-	-	-	-
Malaise	✔	-	>1	-	-	-	-	✔	-	✔	✔
Mania	-	-	<1	-	-	-	✔	-	-	-	-
Memory impairment	-	-	9	-	-	-	✔	-	-	-	-
Migraine	-	-	3	-	-	-	-	-	-	-	-
Nervousness	-	1 to 7	18	✔	-	-	6	-	-	✔	-
Neuralgia	-	-	<1	-	-	-	-	-	-	-	-

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Neuropathy	-	-	<1	-	-	-	-	-	-	-	-
Nightmares	✔	1 to 7	-	-	-	✔	✔	✔	✔	✔	✔
Oculogyric crisis	-	-	<1	-	-	-	-	-	-	-	-
Oculomotor nerve paralysis	-	-	<1	-	-	-	-	-	-	-	-
Panic	-	-	1	-	-	-	-	✔	✔	-	-
Paranoia	-	-	<1	-	-	-	-	-	-	-	-
Paresis	-	-	9	-	-	-	-	-	-	-	-
Paresthesia	-	-	2	-	-	-	-	-	-	-	-
Parkinsonian syndrome	-	-	-	✔	-	-	-	-	-	-	-
Psychosis exacerbation	-	-	<1	✔	-	✔	-	✔	✔	✔	-
Psychosomatic disorder	-	-	3	-	-	-	-	-	-	-	-
Restlessness	✔	1 to 7	-	✔	-	✔	-	✔	✔	✔	✔
Sedation	✔	-	-	-	-	-	-	-	-	-	✔
Sensory disturbance	-	-	<1	-	-	-	-	-	-	-	-
Seizure	✔	<1	<1	✔	✔	✔	<1	✔	✔	✔	✔
Somnolence	✔	-	-	-	-	-	-	-	-	-	✔
Sleep Disorder	-	-	4	-	-	-	-	-	-	-	-
Speech disorder	-	-	3	-	-	-	-	-	-	-	-
Stupor	-	-	<1	-	-	-	-	-	-	-	-
Syncope	-	<1	-	-	-	-	<1	-	-	-	-
Twitching	-	-	7	-	-	-	-	-	-	-	-
Yawning	-	-	3	-	-	-	-	-	-	-	-
Dermatological											
Acne	-	-	2	-	-	-	-	-	-	-	-
Alopecia	✔	-	<1	✔	✔	<1	-	✔	✔	✔	✔
Cellulitis	-	-	<1	-	-	-	-	-	-	-	-
Cheilitis	-	-	<1	-	-	-	-	-	-	-	-
Dermatitis	-	-	2	-	-	-	-	-	-	-	-
Dry skin	-	-	2	-	-	-	-	-	-	-	-
Petechiae	-	-	-	✔	-	<1	-	✔	✔	✔	-
Photosensitivity	✔	<1	<1	✔	✔	<1	<1	✔	✔	✔	✔
Pruritus	-	<1	6	✔	✔	<1	-	✔	✔	✔	✔
Rash	✔	1 to 7	8	✔	✔	<1	<1	✔	✔	✔	✔
Skin discoloration	-	-	<1	-	-	-	-	-	-	-	-
Skin ulceration	-	-	<1	-	-	-	-	-	-	-	-
Urticaria	✔	<1	1	✔	-	<1	-	✔	✔	✔	✔
Endocrine and Metabolic											
Breast enlargement	✔	-	2	✔	✔	✔	-	✔	✔	✔	✔
Breast pain	-	-	1	-	-	-	-	-	-	-	-
Diabetes mellitus	-	-	<1	-	-	-	-	-	-	-	-
Galactorrhea	✔	<1	<1	✔	✔	✔	-	✔	✔	✔	✔
Goiter	-	-	<1	-	-	-	-	-	-	-	-
Glycosuria	-	-	<1	-	-	-	-	-	-	-	-
Gynecomastia	✔	-	<1	-	-	✔	-	✔	✔	-	✔

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Hyperglycemia	✔	-	<1	✔	✔	✔	-	✔	-	✔	✔
Hypoglycemia	✔	-	-	✔	✔	✔	-	-	-	✔	✔
Lactation	-	-	4	-	-	-	-	-	-	-	-
Prolactin levels increased	-	1 to 7	-	-	-	-	-	-	-	-	-
Syndrome of inappropriate antidiuretic hormone secretion	✔	<1	<1	✔	✔	✔	-	✔	✔	✔	✔
Thirst	-	-	2	-	-	-	-	-	-	-	-
Gastrointestinal											
Abdominal pain/cramps	-	<1	11	✔	<1	✔	-	✔	-	✔	-
Anorexia	✔	-	12	✔	✔	✔	-	✔	✔	✔	✔
Appetite decreased	-	-	11	-	<1	-	-	✔	-	-	✔
Appetite increased	-	1 to 7	11	-	<1	-	-	✔	✔	✔	✔
Black tongue	✔	✔	-	✔	-	✔	-	✔	-	✔	✔
Blood in stool	-	-	<1	-	-	-	-	-	-	-	-
Chronic enteritis	-	-	<1	-	-	-	-	-	-	-	-
Constipation	✔	12	47	✔	<1	✔	6	✔	✔	✔	✔
Diarrhea	✔	<1	13	✔	✔	✔	-	✔	✔	✔	✔
Dysphagia	-	-	2	-	-	-	-	-	-	-	-
Dyspepsia	-	-	22	✔	<1	-	-	✔	-	-	-
Eructation	-	-	>1	-	-	-	-	-	-	-	-
Esophageal sphincter tone decrease	-	-	-	✔	✔	-	-	-	✔	✔	-
Esophagitis	-	-	1	-	-	-	-	-	-	-	-
Flatulence	-	<1	6	-	-	-	-	-	-	-	-
Gastric/peptic ulcer	-	-	<1	-	-	-	-	-	-	-	-
Indigestion	-	-	-	-	✔	-	-	-	✔	✔	-
Intestinal obstruction	-	-	<1	-	-	-	-	-	-	-	-
Irritable bowel syndrome	-	-	<1	-	-	-	-	-	-	-	-
Nausea	✔	1 to 7	33	✔	✔	✔	2	✔	✔	✔	✔
Paralytic ileus	✔	✔	<1	✔	-	✔	-	-	-	✔	✔
Reflux	-	-	<1	-	<1	-	-	✔	-	-	-
Salivation decreased	-	-	-	-	-	-	✔	-	-	-	✔
Salivation increased	-	-	<1	-	-	-	-	-	-	-	✔
Stomatitis	✔	✔	>1	✔	✔	✔	-	-	-	✔	✔
Taste changes	✔	<1	8	✔	✔	✔	-	✔	✔	✔	✔
Tongue ulceration	-	-	<1	-	-	-	-	-	-	-	-
Vomiting	✔	<1	7	✔	<1	✔	<1	✔	✔	✔	✔
Weight gain	✔	<1	18	✔	✔	✔	-	✔	✔	✔	✔
Weight loss	✔	<1	>1	✔	-	✔	-	✔	✔	✔	✔
Xerostomia	✔	14	84	✔	✔	✔	22	✔	✔	✔	✔
Genitourinary											
Albuminuria	-	-	<1	-	-	-	-	-	-	-	-
Cervical dysplasia	-	-	<1	-	-	-	-	-	-	-	-
Cystitis	-	-	2	-	-	-	-	-	-	-	-
Dysmenorrhea	-	-	12	-	-	-	-	-	-	-	-

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Dysuria	-	-	2	-	-	-	-	-	-	-	-
Ejaculation failure	-	-	42	-	-	-	-	-	-	-	-
Epididymitis	-	-	<1	-	-	-	-	-	-	-	-
Hematuria	-	-	<1	-	-	-	-	-	-	-	-
Impotence	✔	<1	20	✔	-	✔	<1	✔	✔	✔	✔
Incontinence	-	-	<1	-	-	-	-	-	-	-	✔
Leucorrhea	-	-	2	-	-	-	-	-	-	-	-
Menstrual Disorder	-	-	4	-	-	-	-	-	-	-	-
Micturition disorder/difficulty	-	-	4 to 14	-	-	-	<1	✔	✔	-	>10
Micturition frequency	-	-	5	-	-	-	-	-	-	-	-
Polyuria	-	-	-	✔	-	-	-	-	-	-	-
Pyelonephritis	-	-	<1	-	-	-	-	-	-	-	-
Renal calculus	-	-	<1	-	-	-	-	-	-	-	-
Renal cyst	-	-	<1	-	-	-	-	-	-	-	-
Sexual dysfunction	-	-	-	✔	-	-	-	✔	-	✔	✔
Testicular edema	✔	<1	-	✔	✔	✔	-	✔	✔	✔	-
Urinary retention	✔	<1	2	✔	✔	✔	<1	✔	✔	✔	✔
Urinary tract infection	-	-	6	-	-	-	-	<1	-	-	-
Vaginal hemorrhage	-	-	<1	-	-	-	-	-	-	-	-
Vaginitis	-	-	2	-	-	-	-	-	-	-	-
Hematologic											
Agranulocytosis	✔	<1	-	✔	✔	<1	-	✔	✔	✔	✔
Aphasia	-	-	<1	-	-	-	-	-	-	-	-
Aphasia	-	-	<1	-	-	-	-	<1	-	-	-
Bone marrow depression	✔	-	<1	-	✔	-	-	✔	-	✔	✔
Eosinophilia	✔	-	-	✔	✔	<1	-	✔	✔	✔	✔
Hemoptysis	-	-	<1	-	-	-	-	-	-	-	-
Leukemoid reaction	-	-	<1	-	-	-	-	-	-	-	-
Leukopenia	✔	<1	-	-	✔	-	-	-	✔	-	✔
Lymphadenopathy	-	-	<1	-	-	-	-	-	-	-	-
Lymphoma-like disorder	-	-	<1	-	-	-	-	-	-	-	-
Purpura	✔	-	3	✔	✔	<1	-	✔	✔	✔	✔
Thrombocytopenia	-	-	-	✔	✔	<1	-	✔	✔	✔	-
Thrombophlebitis	-	-	<1	-	-	-	-	-	-	-	-
Hepatic											
Cholestatic jaundice	✔	-	-	✔	-	<1	-	✔	✔	✔	✔
Hepatitis	✔	<1	<1	✔	-	-	-	-	-	-	✔
Liver enzymes increased	✔	<1	-	✔	-	<1	-	✔	✔	✔	✔
Neuromuscular and skeletal											
Arthralgia	-	-	3	-	-	-	-	<1	-	-	-
Back pain	-	-	6	-	-	-	-	<1	-	-	-
Choreoathetosis	-	-	<1	-	-	-	-	-	-	-	-
Myalgia	-	-	13	-	-	-	-	<1	-	-	-
Myoclonus	-	-	13	-	-	-	-	-	-	-	-

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Myositis	-	-	<1	-	-	-	-	-	-	-	-
Neuroleptic malignant syndrome	✔	<1	-	-	-	-	-	-	-	-	✔
Numbness	✔	<1	-	✔	✔	✔	✔	✔	✔	✔	✔
Paresthesia	✔	<1	1 to 10	✔	✔	✔	-	✔	-	✔	✔
Peripheral neuropathy	✔	-	-	✔	-	✔	-	✔	-	✔	✔
Tardive dyskinesia	✔	<1	-	-	✔	-	-	-	-	-	✔
Tingling	✔	<1	-	✔	-	✔	✔	✔	✔	✔	✔
Torticollis	-	-	<1	-	-	-	-	-	-	-	-
Tremor	✔	1 to 7	54	✔	✔	✔	3	✔	✔	✔	✔
Weakness	✔	1 to 7	1	✔	✔	✔	1 to 10	-	✔	✔	✔
Ocular											
Abnormal Vision	-	-	18	-	-	-	-	-	-	-	-
Accommodation disturbances	✔	<1	<1	✔	-	✔	<1	✔	-	✔	✔
Anisocoria	-	-	>1	-	-	-	-	-	-	-	-
Blepharitis	-	-	<1	-	-	-	-	-	-	-	-
Blepharospasm	-	-	>1	-	-	-	-	-	-	-	-
Blurred vision	✔	7	1 to 10	✔	<1	✔	4	✔	✔	✔	✔
Conjunctival hemorrhage	-	-	<1	-	-	-	-	-	-	-	-
Conjunctivitis	-	-	1	-	-	-	-	-	-	-	-
Exophthalmos	-	-	<1	-	-	-	-	-	-	-	-
Eye pain	-	-	1 to 10	-	-	-	-	✔	✔	✔	-
Glaucoma,	-	-	<1	-	-	-	-	-	-	-	-
Intraocular pressure increased	✔	<1	-	✔	-	-	-	-	✔	✔	✔
Keratitis	-	-	<1	-	-	-	-	-	-	-	-
Lacrimation abnormal	-	-	3	-	-	-	-	-	-	-	-
Mydriasis	✔	<1	2	✔	-	✔	-	✔	-	✔	✔
Ocular Allergy	-	-	>1	-	-	-	-	-	-	-	-
Scleritis	-	-	<1	-	-	-	-	-	-	-	-
Strabismus	-	-	<1	-	-	-	-	-	-	-	-
Otic											
Hyperacusis	-	-	<1	-	-	-	-	-	-	-	-
Tinnitus	✔	<1	6	✔	✔	✔	<1	✔	✔	✔	1 to 10
Respiratory											
Bronchitis	-	-	<1	-	-	-	-	-	-	-	-
Bronchospasm	-	-	2	-	-	-	-	-	-	-	-
Cough	-	-	6	-	-	-	-	✔	-	-	-
Dyspnea	-	-	>1	-	-	-	-	-	-	-	-
Hypo/hyperventilation	-	-	<1	-	-	-	-	-	-	-	-
Epistaxis	-	-	2	-	-	-	-	-	-	-	-
Laryngitis	-	-	>1	-	-	-	-	-	-	-	-
Nasal congestion	-	<1	-	-	-	-	-	✔	-	-	✔
Pharyngitis	-	-	14	-	-	-	-	-	-	-	-
Pneumonia	-	-	<1	-	-	-	-	-	-	-	-
Rhinitis	-	-	12	-	-	-	-	-	-	-	-

Adverse Events	Single Entity Agents										Combination Products
	Amitriptyline	Amoxapine	Clomipramine	Desipramine	Doxepin	Imipramine	Maprotiline	Nortriptyline	Protriptyline	Trimipramine	Amitriptyline-Chlordiazepoxide
Sinusitis	-	-	6	-	-	-	-	✔	-	-	-
Other											
Allergic reactions	-	<1	3	✔	✔	-	-	✔	✔	✔	-
Dehydration	-	-	<1	-	-	-	-	-	-	-	-
Diaphoresis	✔	1 to 7	29	✔	✔	✔	-	✔	✔	-	✔
Diplopia	✔	-	<1	-	-	-	-	✔	-	-	✔
Endometrial hyperplasia	-	-	<1	-	-	-	-	-	-	-	-
Endometriosis	-	-	<1	-	-	-	-	-	-	-	-
Halitosis	-	-	>1	-	-	-	-	-	-	-	-
Ovarian cyst	-	-	<1	-	-	-	-	-	-	-	-
Pain	-	-	3	-	-	-	-	-	-	-	-
Parosmia	-	-	<1	-	-	-	-	-	-	-	-
Polyarteritis nodosa	-	-	<1	-	-	-	-	-	-	-	-
Serotonin syndrome	✔	-	-	-	-	-	-	-	-	-	✔
Suicide ideation/attempt	✔	-	<1	-	-	-	-	-	-	-	✔
Tooth caries	-	-	<1	-	-	-	-	-	-	-	-
Tooth disorder	-	-	5	-	-	-	-	-	-	-	-
Uterine hemorrhage	-	-	<1	-	-	-	-	-	-	-	-
Uterine inflammation	-	-	<1	-	-	-	-	-	-	-	-
Visual field defect	-	-	<1	-	-	-	-	-	-	-	-
Withdrawal reactions	✔	-	<1	-	-	-	-	-	-	-	✔

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 6f. Adverse Drug Events (%) Reported with the Antidepressants, Miscellaneous[1-32]

Adverse Events	Brexanolone	Bupropion	Esketamine	Mirtazapine
Cardiovascular				
Arrhythmias	-	5	-	-
Atrioventricular block	-	✔	-	-
Chest pain	-	3 to 4	-	-
Electrocardiogram abnormality	-	✔	-	-
Extrasystoles	-	✔	-	-
Hypertension	-	2 to 4	10	2
Hypotension	-	3	-	-
Myocardial infarct	-	✔	-	<1
Orthostatic hypotension	-	-	-	<1
Palpitation	-	2 to 6	-	-
Peripheral edema	-	<1	-	2
Postural hypotension	-	✔	-	-
Stroke	-	✔	-	-
Syncope	-	✔	-	<1
Tachycardia	3	≤11	2	-
Vasodilation	-	✔	-	2
Central Nervous System				
Abnormal dreams	-	3	-	4
Abnormal thinking	-	-	-	3
Aggression	-	✔	-	-
Agitation	-	2 to 32	-	>
Akathisia	-	2	-	-
Akinesia	-	✔	-	-
Amnesia	-	✔	-	>1
Anxiety	-	5 to 7	13	>1
Aphasia	-	✔	-	-
Ataxia	-	✔	-	<1
Blurred vision	-	2 to 3	-	-
Central nervous system stimulation	-	1 to 2	-	-
Chills	-	<1	-	<1
Coma	-	✔	-	-
Confusion	-	8	-	2
Delirium	-	✔	-	<1
Delusions	-	✔	-	<1
Depersonalization	-	✔	-	<1
Depression	-	✔	-	-
Derealization	-	✔	-	-
Diplopia	-	✔	-	<1
Dissociation	-	-	41	-
Dizziness	12 to 13	6 to 22	29	7
Drowsiness	-	-	-	54
Dysarthria	-	-	4	-
Dysgeusia	-	-	19	-
Dyskinesia	-	✔	-	-
Dysphoria	-	✔	-	-
Dystonia	-	✔	-	<1
Emotional lability	-	✔	-	<1
Euphoria	-	✔	4	-
Fever	-	1 to 2	-	<1
Hallucinations	-	✔	-	<1
Headache	-	25 to 34	20	-
Hostility	-	6	-	<1

Adverse Events	Brexanolone	Bupropion	Esketamine	Mirtazapine
Hyperkinesia	-	✔	-	<1
Hypertonia	-	✔	-	-
Hypoesthesia	-	✔	18	-
Hypokinesia	-	✔	-	<1
Hypomania	-	✔	-	-
Incoordination	-	✔	-	-
Insomnia	-	11 to 20	8	-
Irritability	-	2 to 3	-	-
Lethargy	-	-	11	-
Loss of consciousness	3 to 5	-	-	-
Malaise	-	✔	-	✔
Manic reaction	-	✔	-	<1
Memory decreased	-	<3	-	-
Mental impairment	-	-	3	-
Migraine	-	1 to 4	-	<1
Nervousness	-	3 to 5	-	-
Neuropathy	-	✔	-	-
Pain	-	2 to 3	-	-
Paranoia	-	✔	-	<1
Paresthesia	-	1 to 2	-	<1
Restlessness	-	✔	-	-
Seizure	-	✔	-	-
Sensory disturbance	-	4	-	-
Sleep disturbance	-	4	-	-
Somnolence	13 to 21	2 to 3	23	54
Vertigo	-	✔	23	-
Dermatological				
Maculopapular rash	-	✔	-	-
Photosensitivity	-	<1	-	<1
Pruritus	-	2 to 4	-	>1
Rash	-	1 to 5	-	>1
Urticaria	-	1 to 2	-	<1
Endocrine and Metabolic				
Appetite increased	-	4	-	17
Glycosuria	-	✔	-	-
Gynecomastia	-	✔	-	-
Hepatic damage	-	✔	-	-
Hepatitis	-	✔	-	-
Hypercholesterolemia	-	-	-	✔
Hyperglycemia	-	✔	-	-
Hypertriglyceridemia	-	-	-	✔
Hypoglycemia	-	✔	-	-
Hot flashes	-	1 to 3	-	-
Jaundice	-	<1	-	-
Liver function abnormal	-	<1	-	<1
Syndrome of inappropriate antidiuretic hormone	-	✔	-	-
Weight gain	-	-	-	12
Weight loss	-	14 to 23	-	<1
Gastrointestinal				
Abdominal pain	-	2 to 9	-	>1
Abnormal taste	-	2 to 4	-	-
Anorexia	-	3 to 5	-	>1
Colitis	-	✔	-	<1

Adverse Events	Brexanolone	Bupropion	Esketamine	Mirtazapine
Constipation	-	8 to 26	3	13
Diarrhea	2 to 3	5 to 7	7	-
Dry mouth	3 to 11	-	5	-
Dysphagia	-	<2	-	-
Dyspepsia	2	3	-	-
Flatulence	-	6	-	-
Gastric reflux	-	<1	-	-
Gastrointestinal hemorrhage	-	✔	-	-
Intestinal perforation	-	✔	-	-
Nausea	-	1 to 18	28	<1
Oropharyngeal pain	2 to 3	-	-	-
Pancreatitis	-	✔	-	-
Stomach ulcer	-	✔	-	<1
Vomiting	-	2 to 4	9	>1
Xerostomia	-	10 to 28	-	25
Genitourinary				
Cystitis	-	✔	-	-
Dyspareunia	-	✔	-	-
Ejaculation abnormality	-	✔	-	-
Impotence	-	<1	-	<1
Libido decreased	-	3	-	-
Libido increased	-	✔	-	-
Menopause	-	✔	-	-
Menstrual complaints	-	2 to 5	-	<1
Painful erection	-	✔	-	-
Pollakiuria	-	-	3	-
Prostate disorder	-	✔	-	-
Salpingitis	-	✔	-	-
Urinary frequency	-	2 to 5	-	2
Urinary incontinence	-	✔	-	<1
Urinary retention	-	✔	-	<1
Urinary tract infection	-	<1	-	>1
Urinary urgency	-	<2	-	-
Vaginal hemorrhage	-	<2	-	-
Vaginitis	-	✔	-	>1
Hematologic				
Agranulocytosis	-	-	-	<1
Anemia	-	✔	-	-
Leukocytosis	-	✔	-	-
Leukopenia	-	✔	-	-
Neutropenia	-	-	-	<1
Pancytopenia	-	✔	-	-
Thrombocytopenia	-	✔	-	-
Musculoskeletal				
Arthralgia	-	1 to 4	-	2
Arthritis	-	2	-	-
Back pain	-	-	-	2
Dysarthria	-	✔	-	-
Extrapyramidal syndrome	-	✔	-	-
Musculoskeletal chest pain	-	✔	-	-
Myalgia	-	2 to 6	-	2
Neck pain	-	✔	-	<1
Rhabdomyolysis	-	✔	-	-
Rigidity	-	✔	-	-

Adverse Events	Brexanolone	Bupropion	Esketamine	Mirtazapine
Tardive dyskinesia	-	✔	-	-
Tremor	-	3 to 21	3	2
Twitching	-	1 to 2	-	<1
Weakness	-	2 to 4	-	8
Respiratory				
Bronchospasm	-	✔	-	-
Cough	-	1 to 4	-	-
Dyspnea	-	-	-	1
Nasal discomfort	-	-	7	-
Oropharyngeal pain	-	-	3	-
Pharyngitis	-	3 to 13	-	-
Pneumonia	-	✔	-	-
Pulmonary embolism	-	✔	-	-
Sinusitis	-	1 to 5	-	-
Throat irritation	-	-	7	-
Upper respiratory infection	-	9	-	-
Other				
Accommodation abnormality	-	<1	-	<1
Allergic reaction	-	✔	-	-
Amblyopia	-	2	-	-
Angioedema	-	✔	-	-
Auditory disturbance	-	5	-	-
Bruxism	-	✔	-	-
Deafness	-	✔	-	<1
Dehydration	-	-	-	<1
Diaphoresis	-	5 to 22	-	-
Dry eye	-	✔	-	-
Ecchymosis	-	✔	-	-
Edema	-	-	-	1
Esophagitis	-	✔	-	-
Facial edema	-	✔	-	-
Feeling abnormal	-	-	3	-
Feeling drunk	-	-	5	-
Flu-like syndrome	-	-	-	1
Flushing	2 to 5	-	-	-
Gingivitis	-	✔	-	-
Glossitis	-	✔	-	-
Gum hemorrhage	-	✔	-	-
Hirsutism	-	✔	-	-
Hyperhidrosis	-	-	4	-
Hypersensitivity reactions	-	✔	-	-
Infection	-	8 to 9	-	-
Intraocular pressure increased	-	✔	-	-
Leg cramps	-	<1	-	-
Lymphadenopathy	-	✔	-	<1
Mouth ulcers	-	✔	-	-
Mydriasis	-	✔	-	-
Phlebitis	-	✔	-	-
Salivation increased	-	<1	-	<1
Sciatica	-	✔	-	-
Stomatitis	-	✔	-	-
Suicidal ideation	-	✔	-	-
Thirst	-	<1	-	>1
Tinnitus	-	3 to 6	-	-

Adverse Events	Brexanolone	Bupropion	Esketamine	Mirtazapine
Tongue edema	-	✔	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 7. Boxed Warning for the Antidepressants[1]

WARNING
Suicidality and antidepressant drugs: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Anyone considering the use of antidepressants in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults older than 24 years of age; there was a reduction in risk with antidepressants compared to placebo in adults 65 years of age and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Monitor patients of all ages who are started on antidepressant therapy appropriately and observe them closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Amitriptyline, amoxapine, bupropion, citalopram, desipramine, desvenlafaxine, doxepin, esketamine, fluvoxamine (extended-release capsules), isocarboxazid, levomilnacipran, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone and vortioxetine are not approved for use in pediatric patients. Clomipramine, fluvoxamine, and sertraline are not approved for use in pediatric patients, except for patients with obsessive compulsive disorder. Escitalopram is not approved for use in children younger than 12 years of age. Fluoxetine (except Sarafem®) is approved for use in children with major depressive disorder (aged eight years and older) and obsessive-compulsive disorder (aged seven years and older). Imipramine is not approved for use in pediatric patients, except for patients with nocturnal enuresis. Selegiline is not approved for use in pediatric patients. Furthermore, selegiline at any dose should not be used in children younger than 12 years of age, even when administered with dietary modifications.

Table 8. Boxed Warning for Bupropion[1]

WARNING
Use in Smoking Cessation Treatment: Forfivo XL®, Wellbutrin®, Wellbutrin SR®, and Wellbutrin XL® are not approved for smoking cessation treatment, but bupropion under the name Zyban® is approved for this use. Although Zyban® is not indicated for treatment of depression, it contains the same active ingredient as the antidepressant medications Wellbutrin®, Wellbutrin SR®, and Wellbutrin XL®. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

Table 9. Boxed Warning for Nefazodone[1]

WARNING
Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone. The reported rate in the United States is approximately one case of liver failure resulting in death or transplant per 250,000 to 300,000 patient-years of nefazodone treatment. The total patient-years is a summation of each patient's duration of exposure expressed in years. For example, one patient-year is equal to two patients each treated for six months, three patients each treated for four months, etc. Ordinarily, treatment with nefazodone should not be initiated in individuals with active liver disease or with elevated baseline serum transaminases. There is no evidence that preexisting liver disease increases the likelihood of developing liver failure; however, baseline abnormalities can complicate patient monitoring. Advise patients to be alert for signs and symptoms of liver

WARNING
dysfunction (e.g., jaundice, anorexia, gastrointestinal complaints, malaise) and to report them to their health care provider immediately if they occur. Discontinue nefazodone if clinical signs or symptoms suggest liver failure. If nefazodone-treated patients develop evidence of hepatocellular injury such as increased serum aspartate aminotransferase or serum alanine aminotransferase levels greater than or equal to three times the upper limit of normal, withdraw the drug. These patients should be presumed to be at increased risk for liver injury if nefazodone is reintroduced. Accordingly, do not consider such patients for retreatment.

Table 10. Boxed Warning for Tranylcypromine[1]

WARNING
Hypertensive crisis with significant tyramine use: Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine or after tranylcypromine discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals between administration of tranylcypromine and interacting drugs. Instruct patients to avoid ingestion of foods and beverages with high tyramine content.

Table 11. Boxed Warning for Brexanolone[1]

WARNING
Excessive sedation and sudden loss of consciousness: Patients are at risk of excessive sedation or sudden loss of consciousness during administration of brexanolone. Because of the risk of serious harm, patients must be monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. Patients must be accompanied during interactions with their child(ren). Because of these risks, brexanolone is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ZULRESSO REMS.

Table 12. Boxed Warning for Esketamine[1]

WARNING
Sedation, dissociation, abuse and misuse: Patients are at risk for sedation and dissociation after administration of esketamine. Patients are at risk for dissociative or perceptual changes after administration of esketamine. Because of the risks of sedation and dissociation, patients must be monitored for at least two hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Esketamine has the potential to be abused and misused. Consider the risks and benefits of prescribing esketamine prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse. Because of the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse and misuse, esketamine is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS.

VII. Dosing and Administration

The usual dosing regimens for the antidepressants are listed in Table 13.

Table 13. Usual Dosing Regimens for the Antidepressants[1-32]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Monoamine Oxidase Inhibitors			
Isocarboxazid	Depression: Tablet: 10 mg twice per day; maximum, 60 mg/day; reduce dose to 10 to 20 mg/day when condition improves	Safety and efficacy in children have not been established.	Tablet: 10 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Phenelzine	Depression: Tablet: 15 mg three times per day; may increase to 60 to 90 mg/day during the early phase of treatment, then reduce dose for maintenance therapy slowly after maximum benefit is obtained	Safety and efficacy in children have not been established.	Tablet: 15 mg
Selegiline	Depression: Transdermal patch: initial, 6 mg/24 hours once daily; may titrate based on clinical response in increments of 3 mg/day every two weeks up to a maximum of 12 mg/24 hours	Safety and efficacy in children have not been established.	Transdermal patch: 6 mg/24 hours 9 mg/24 hours 12 mg/24 hours
Tranylcypromine	Depression: Tablet: 10 mg twice daily; increase by 10 mg increments at one- to three-week intervals; maximum, 60 mg/day; usual effective dose, 30 mg/day	Safety and efficacy in children have not been established.	Tablet: 10 mg
Selective Serotonin- and Norepinephrine-reuptake Inhibitors			
Desvenlafaxine	Major depressive disorder: Extended-release tablet: 50 mg once-daily	Safety and efficacy in children have not been established.	Extended-release tablet: 25 mg 50 mg 100 mg
Duloxetine	Chronic musculoskeletal pain: Delayed-release capsule: initial, 30 mg/day; maintenance, 60 mg once-daily; maximum, 60 mg/day Fibromyalgia: Delayed-release capsule: initial, 30 mg/day; maintenance, 60 mg once daily; maximum, 60 mg/day Neuropathic pain associated with diabetic peripheral neuropathy: Delayed-release capsule: 60 mg once-daily Generalized anxiety disorder: Delayed-release capsule: initial, 60 mg/day; maintenance, 60 mg once-daily; maximum, 120 mg/day Major depressive disorder: Delayed-release capsule: initial, 40 to 60 mg/day; maintenance (acute treatment), 40 (20 mg twice-daily) to 60 mg/day (once-daily or 30 mg twice-daily); maintenance, 60 mg/day; maximum, 120 mg/day	Generalized anxiety disorder in patients 7 to 17 years of age: Delayed-release capsule: initial, 30 mg/day; maintenance, 30 to 60 mg once daily; maximum, 120 mg/day Fibromyalgia in patients 13 to 17 years of age: Delayed-release capsule: initial, 30 mg/day; maintenance, 60 mg once daily; maximum, 60 mg/day	Delayed-release capsule: 20 mg 30 mg 40 mg 60 mg
Levomilnacipran	Major depressive disorder: Extended-release capsule: initial, 20 mg once daily for two days, then increase to 40 mg once daily; maintenance, 40 to 120 mg once daily; maximum, 120 mg once daily	Safety and efficacy in children have not been established.	Extended-release capsules: 20 mg 40 mg 80 mg 120 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
			Extended-release capsule dose pack: 20 mg (2 capsules), 40 mg (26 tablets)
Venlafaxine	Generalized anxiety disorder: Extended-release capsule: initial, 75 mg once-daily; maximum, 225 mg/day Major depressive disorder: Extended-release capsule: initial, 75 mg once-daily; maximum, 225 mg/day Extended-release tablet: initial, 75 mg/day; maintenance, 75 to 225 mg/day; maximum, 225 mg/day Tablet: initial, 37.5 to 75 mg/day administered in two or three divided doses; maintenance, 75 to 225 mg/day; maximum, 375 mg/day Treatment of panic disorder, with or without agoraphobia: Extended-release capsule: initial, 37.5 mg once-daily for one week; maintenance, 75 to 225 mg/day; maximum, 225 mg/day Treatment of social anxiety disorder: Extended-release capsule, extended-release tablet: 75 mg once-daily	Safety and efficacy in children have not been established.	Extended-release capsule: 37.5 mg 75 mg 150 mg Extended-release tablet: 37.5 mg 75 mg 150 mg 225 mg Tablet: 25 mg 37.5 mg 50 mg 75 mg 100 mg
Selective Serotonin-reuptake Inhibitors			
Citalopram	Depression: Solution, tablet: initial, 20 mg/day; increase dose in 20 mg increments at intervals of no less than one week; maximum dose, 40 mg/day	Safety and efficacy in children have not been established.	Solution: 10 mg/5 mL Tablet: 10 mg 20 mg 40 mg
Escitalopram	Depression: Solution, tablet: initial, 10 mg/day; dose may be increased to 20 mg/day after at least one week Generalized anxiety disorder: Solution, tablet: Initial, 10 mg/day; dose may be increased to 20 mg/day after at least one week	Depression ≥12 years of age: Solution, tablet: initial, 10 mg/day; dose may be increased to 20 mg/day after at least three weeks	Solution: 5 mg/5 mL Tablet: 5 mg 10 mg 20 mg
Fluoxetine	Bulimia nervosa: Immediate release capsule and tablet, solution: 20 mg once daily; usual dose: 60 mg/day; maximum, 60 mg/day; doses >20 mg may be given once daily or divided twice daily	Depression eight to 18 years of age: Immediate release capsule and tablet, solution: 10 to 20 mg/day; lower-	Delayed release capsule: 90 mg Immediate release capsule: 10 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Depression: Immediate release capsule and tablet, solution: 20 mg once daily; usual dose, 20 to 40 mg/day; maximum, 80 mg/day; doses >20 mg may be given once daily or divided twice daily Delayed release capsule: patients maintained on fluoxetine immediate release 20 mg/day may be changed to fluoxetine delayed release capsule 90 mg/week, starting dose seven days after the last 20 mg/day dose Obsessive-compulsive disorder: Immediate release capsule and tablet, solution: 20 mg once daily; usual dose: 40 to 80 mg/day; maximum, 80 mg/day; doses >20 mg may be given once daily or divided twice daily Delayed release capsule: patients maintained on fluoxetine immediate release 20 mg/day may be changed to fluoxetine delayed release capsule 90 mg/week, starting dose seven days after the last 20 mg/day dose Panic disorder: Immediate release capsule and tablet, solution: initial, 10 mg/day; after one1 week, increase to 20 mg/day; may increase after several weeks; doses >60 mg/day have not been evaluated Delayed release capsule: patients maintained on fluoxetine immediate release 20 mg/day may be changed to fluoxetine delayed release capsule 90 mg/week, starting dose seven days after the last 20 mg/day dose Premenstrual dysphoric disorder: Immediate release tablet (Sarafem®): 20 mg/day continuously or 20 mg/day starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle)	weight children may be started on 10 mg/day; may increase to 20 mg/day after one week if needed Obsessive-compulsive disorder seven to 18 years of age: Immediate release capsule and tablet, solution: 10 mg/day; in adolescents and higher-weight children, dose may be increased to 20 mg/day after two weeks; range, 10 to 60 mg/day	20 mg 40 mg Immediate release tablet: 10 mg 20 mg 60 mg Solution: 20 mg/5 mL
Fluvoxamine	Obsessive-compulsive disorder: Immediate release tablet: initial, 50 mg at bedtime; adjust dose in 50 mg increments every four to seven days; usual dose, 100 to 300 mg/day; divide total daily dose into two doses;	Obsessive-compulsive disorder eight to 17 years of age: Immediate release tablet: initial, 25	Extended release capsule: 100 mg 150 mg Immediate release tablet: 25 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	administer larger portion at bedtime; when total daily dose exceeds 100 mg, the dose should be given in two divided doses Extended release capsule: initial, 100 mg at bedtime; may be increased in 50 mg increments at intervals of at least one week; usual dose range, 100 to 300 mg/day	mg at bedtime; adjust in 25 mg increments at four- to seven-day intervals; range, 50 to 200 mg/day	50 mg 100 mg
Paroxetine	Depression: Immediate release tablet, suspension: initial, 20 mg once daily; increase by 10 mg/day increments at intervals of at least one week; maximum dose, 50 mg/day Extended release tablet: initial, 25 mg once daily; increase if needed by 12.5 mg/day increments at intervals of at least one week; maximum dose, 62.5 mg/day Generalized anxiety disorder: Immediate release tablet, suspension: initial, 20 mg once daily; increase if needed by 10 mg/day increments at intervals of at least one week; doses of 20 to 50 mg/day were used in clinical trials; however, no greater benefit was seen with doses >20 mg Obsessive-compulsive disorder: Immediate release tablet, suspension: initial, 20 mg once daily; increase if needed by 10 mg/day increments at intervals of at least one week; recommended dose, 40 mg/day; range, 20 to 60 mg/day Moderate to severe vasomotor symptoms associated with menopause: Immediate release capsule: 7.5 mg once daily at bedtime Panic disorder: Immediate release tablet, suspension: initial, 10 mg once daily; increase if needed by 10 mg/day increments at intervals of at least one week; recommended dose, 40 mg/day; range, 10 to 60 mg/day Extended release tablet: initial, 12.5 mg once daily in the morning; increase if needed by 12.5 mg/day increments at intervals of at least one week; maximum	Safety and efficacy in children have not been established.	Extended release tablet: 12.5 mg 25 mg 37.5 mg Immediate release capsule: 7.5 mg Suspension: 10 mg/5 mL Immediate release tablet: 10 mg 20 mg 30 mg 40 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	dose, 75 mg/day Premenstrual dysphoric disorder: Extended release tablet: initial, 12.5 mg once daily in the morning; dose may be increased to 25 mg/day; dosing changes should occur at intervals of at least one week; may be given daily throughout the menstrual cycle or limited to the luteal phase Posttraumatic stress disorder: Immediate release tablet, suspension: initial, 20 mg once daily; increase if needed by 10 mg/day increments at intervals of at least one week; range, 20 to 50 mg; limited data suggest doses of 40 mg/day were not more efficacious than 20 mg/day Social anxiety disorder: Immediate release tablet, suspension: initial, 20 mg once daily, preferably in the morning; recommended dose, 20 mg/day; range, 20 to 60 mg/day; doses >20 mg/day may not have additional benefit Extended release tablet: initial, 12.5 mg once daily; increase if needed by 12.5 mg/day increments at intervals of at least one week; maximum dose, 37.5 mg/day		
Sertraline	Depression: Oral concentrate, tablet: initial, 50 mg/day; may increase daily dose, at intervals of not less than one week; maximum, 200 mg/day; if somnolence is noted, give at bedtime Obsessive-compulsive disorder: Oral concentrate, tablet: initial, 50 mg/day; may increase daily dose, at intervals of not less than one week; maximum, 200 mg/day; if somnolence is noted, give at bedtime Panic disorder: Oral concentrate, tablet: initial, 25 mg once daily; increased after one week to 50 mg once daily Posttraumatic stress disorder: Oral concentrate, tablet: initial, 25 mg once daily; increased after one week to 50 mg once daily	Obsessive-compulsive disorder six to 12 years of age: Oral concentrate, tablet: initial, 25 mg once daily Obsessive-compulsive disorder 13 to 17 years of age: Oral concentrate, tablet: initial, 50 mg once daily May increase daily dose, at intervals of not less than one week; maximum, 200 mg/day; if somnolence is	Oral concentrate: 20 mg/mL Tablet: 25 mg 50 mg 100 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Premenstrual dysphoric disorder: Oral concentrate, tablet: 50 mg daily throughout menstrual cycle or limited to the luteal phase of menstrual cycle; patients not responding to 50 mg/day may benefit from dose increases (50 mg increments per menstrual cycle) up to 150 mg/day when dosing throughout menstrual cycle or up to 100 mg/day when dosing during luteal phase only Social anxiety disorder: Oral concentrate, tablet: initial, 25 mg once daily; increased after one week to 50 mg once daily; range, 50 to 200 mg/day	noted, give at bedtime	
Serotonin Modulators			
Nefazodone	Depression: Tablet: 200 mg/day divided in two doses initially, with a range of 300 to 600 mg/day in two divided doses thereafter	Safety and efficacy in children have not been established.	Tablet: 50 mg 100 mg 150 mg 200 mg 250 mg
Trazodone	Major depressive disorder: Tablet: initial, 150 mg/day in three divided doses; maintenance, dose may be increased by 50 mg/day every three to seven days; maximum, 400 (outpatients) and 600 (inpatients) mg/day	Safety and efficacy in children have not been established.	Immediate release tablet: 50 mg 100 mg 150 mg 300 mg
Vilazodone	Major depressive disorder: Tablet: Initial, 10 mg once daily for seven days, then increase to 20 mg once daily for seven days, then may increase to 40 mg daily	Safety and efficacy in children have not been established.	Tablet: 10 mg 20 mg 40 mg Tablet dose pack: 10 mg (7 tablets), 20 mg (23 tablets)
Vortioxetine	Major depressive disorder: Tablet: initial, 10 mg once daily; maintenance, increase to 20 mg once daily, as tolerated; maximum, 20 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg 20 mg
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Single Entity Agents			
Amitriptyline	Depression: Tablet: 25 to 50 mg/day as a single dose at bedtime or in divided doses; dose may be gradually increased up to 300 mg/day	Depression >12 years of age: Tablet: 10 mg three times per day and 20 mg at bedtime	Tablet: 10 mg 25 mg 50 mg 75 mg 100 mg 150 mg
Amoxapine	Depression: Tablet: initial, 25 mg two to three times/day; if tolerated, dosage may be increased to 100 mg two to three	Safety and efficacy in children have not been established.	Tablet: 25 mg 50 mg 100 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	times/day; may be given in a single bedtime dose when dosage <300 mg/day; maximum daily dose, 600 mg (inpatients) and 400 mg (outpatients)		150 mg
Clomipramine	Obsessive-compulsive disorder: Capsule: initial, 25 mg/day and gradually increase, as tolerated, to 100 mg/day the first two weeks; maximum, 250 mg/day	Obsessive-compulsive disorder >10 years of age: Capsule: initial, 25 mg/day and gradually increase, as tolerated; maximum, 3 mg/kg/day or 200 mg/day, whichever is smaller	Capsule: 25 mg 50 mg 75 mg
Desipramine	Depression: Tablet: initial, 25 to 50 mg/day; increase gradually to 100 to 200 mg/day in divided or single dose; maximum, 300 mg/day	Depression >12 years of age: Tablet: initial, 25 to 50 mg/day; gradually increase to 100 mg/day in single or divided doses; maximum, 150 mg/day	Tablet: 10 mg 25 mg 50 mg 75 mg 100 mg 150 mg
Doxepin	Anxiety: Capsule, oral concentrate: initial, 25 to 75 mg/day at bedtime or in two to three divided doses; may gradually increase up to 300 mg/day; single dose should not exceed 150 mg; select patients may respond to 25 to 50 mg/day Depression: Capsule, oral concentrate: initial, 25 to 75 mg/day at bedtime or in two to three divided doses; may gradually increase up to 300 mg/day; single dose should not exceed 150 mg; select patients may respond to 25 to 50 mg/day Insomnia: Tablet: 3 to 6 mg once daily at bedtime; maximum, 6 mg/day	Safety and efficacy in children have not been established.	Capsule: 10 mg 25 mg 50 mg 75 mg 100 mg 150 mg Oral concentrate: 10 mg/mL Tablet: 3 mg 6 mg
Imipramine	Depression: Capsule: initial, 75 mg/day; dosage may be increased to 150 to 200 mg/day; doses >75 mg/day may be administered once daily; in some patients, it may be necessary to employ a divided-dose schedule Tablet: initial, 25 mg three to four times/day; increase dose gradually, total	Depression (adolescents): Tablet: initial, 30 to 40 mg/day; increase gradually; maximum, 100 mg/day in single or divided doses Pediatric nocturnal	Capsule: 75 mg 100 mg 125 mg 150 mg Tablet: 10 mg 25 mg 50 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	dose may be given at bedtime; maximum, 300 mg/day	enuresis >6 years of age: Tablet: initial, 25 mg one hour before bedtime; if inadequate response after one week of therapy, increase by 25 mg/day; dose should not exceed 2.5 mg/kg/day or 50 mg at bedtime (if 6 to 12 years of age) or 75 mg at bedtime (if ≥12 years of age)	
Maprotiline	Depression (mild to moderate): Tablet: initial, 25 to 75 mg/day for two weeks; increase by 25 mg as tolerated up to 150 mg/day; given in divided doses or in a single daily dose Depression (severe): Tablet: initial, 100 to 150 mg/day for 2 weeks; increase by 25 mg as tolerated up to 225 mg/day; given in divided doses or in a single daily dose	Safety and efficacy in children have not been established.	Tablet: 25 mg 50 mg 75 mg
Nortriptyline	Depression: Capsule, solution: 25 mg three to four times daily, up to 150 mg/day	Safety and efficacy in children have not been established.	Capsule: 10 mg 25 mg 50 mg 75 mg Solution: 10 mg/5 mL
Protriptyline	Depression: Tablet: 15 to 60 mg/day in three to four divided doses	Depression (adolescents): Tablet: 15 to 20 mg/day in three divided doses	Tablet: 5 mg 10 mg
Trimipramine	Depression: Capsule: 50 to 150 mg/day as a single bedtime dose; maximum, 200 mg/day for outpatients and 300 mg/day for inpatients	Depression (adolescents): Capsule: initial, 50 mg/day, with gradual increments up to 100 mg/day	Capsule: 25 mg 50 mg 100 mg
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Combination Products			
Amitriptyline and chlordiazepoxide	Mixed anxiety/depressive disorder: Tablet: initial, three to four tablets in divided doses; may be increased to six tablets per day as required; some patients respond to smaller doses and can be maintained on two tablets	Safety and efficacy in children have not been established.	Tablet: 12.5-5 mg 25-10 mg

<table>
<tr><th>Generic Name(s)</th><th>Usual Adult Dose</th><th>Usual Pediatric Dose</th><th>Availability</th></tr>
<tr><td colspan="4">Antidepressants, Miscellaneous</td></tr>
<tr><td>Brexanolone</td><td><u>Postpartum depression:</u>
Intravenous infusion:

<table><tr><th>Time Interval</th><th>Dose</th></tr><tr><td>0 to 4 hours</td><td>30 µg/kg/hour</td></tr><tr><td>4 to 24 hours</td><td>60 µg/kg/hour</td></tr><tr><td>24 to 52 hours</td><td>90 µg/kg/hour*</td></tr><tr><td>52 to 56 hours</td><td>60 µg/kg/hour</td></tr><tr><td>56 to 60 hours</td><td>30 µg/kg/hour</td></tr></table>*A reduction in dosage to 60 µg/kg/hour may be considered during the 24 to 52-hour time period for patients who do not tolerate 90 µg/kg/hour.</td><td>Safety and efficacy in children have not been established.</td><td>Injection:
100 mg/20 mL single-dose vial</td></tr>
<tr><td>Bupropion</td><td><u>Depression:</u>
Extended release tablet: initial, 150 mg/day in the morning; may increase as early as day four of dosing to 300 mg/day; maximum dose: 450 mg/day

Extended release tablet: initial, 174 mg/day in the morning; may increase as early as day four to 348 mg/day; maximum dose: 522 mg/day

Immediate release tablet: initial, 100 mg twice daily; maximum, 450 mg/day

Sustained release tablet: initial, 150 mg/day; may increase to 150 mg twice daily by day four if tolerated; target dose, 150 mg twice daily; maximum dose, 400 mg/day

<u>Seasonal affective disorder:</u>
Sustained release tablet: initial, 150 mg/day in the morning; if tolerated, may increase after one week to 300 mg/day

<u>Smoking cessation:</u>
Immediate release tablet: initial, 150 mg once daily for three days; increase to 150 mg twice daily; treatment should continue for seven to twelve weeks</td><td>Safety and efficacy in children have not been established.</td><td>Extended release tablet:
150 mg (Wellbutrin XL®)
174 mg (Aplenzin®)
300 mg (Wellbutrin XL®)
348 mg (Aplenzin®)
450 mg (Forfivo®)
522 mg (Aplenzin®)

Immediate release tablet:
75 mg
100 mg

Sustained release tablet (Wellbutrin SR®):
100 mg
150 mg
200 mg</td></tr>
<tr><td>Esketamine</td><td>Depressive symptoms with major depressive disorder with acute suicidal ideation or behavior (in conjunction with an oral antidepressant):
Nasal spray: Weeks one to four;
84 mg twice per week; may reduce to 56 mg twice per week based on tolerability.
Evaluate the need for continued treatment beyond four weeks; treatment beyond 4 weeks with an oral antidepressant has not been evaluated.</td><td>Safety and efficacy in children have not been established.</td><td>Nasal spray:
28 mg
56 mg kit (28 mg x 2)
84 mg kit (28 mg x 3)</td></tr>
</table>

<table>
<tr><th>Generic Name(s)</th><th>Usual Adult Dose</th><th>Usual Pediatric Dose</th><th>Availability</th></tr>
<tr><td></td><td>Treatment-resistant depression (in conjunction with an oral antidepressant):
Nasal spray:

<table><tr><td colspan="3">Induction Phase</td></tr><tr><td>Weeks one to four</td><td>Administer twice per week</td><td>First dose: 56 mg

Subsequent doses: 56 mg or 84 mg</td></tr><tr><td colspan="3">Maintenance Phase</td></tr><tr><td>Weeks five to eight</td><td>Administer once per week</td><td>56 mg or 84 mg</td></tr><tr><td>Weeks nine and after</td><td>Administer every two weeks or once per week*</td><td>56 mg or 84 mg</td></tr></table>*Dosing frequency should be individualized to the least frequent dosing to maintain remission/response.</td><td></td><td></td></tr>
<tr><td>Mirtazapine</td><td>Depression:
Orally disintegrating tablet, tablet: initial, 15 mg at bedtime; titrate up to 15 to 45 mg/day with dose increases made no more frequently than every one to two weeks</td><td>Safety and efficacy in children have not been established.</td><td>Orally disintegrating tablet:
15 mg
30 mg
45 mg

Tablet:
7.5 mg
15 mg
30 mg
45 mg</td></tr>
</table>

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the antidepressants are summarized in Table 14.

Table 14. Comparative Clinical Trials with the Antidepressants

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td colspan="5">Depression</td></tr>
<tr>
<td>Meltzer-Brody et al[54] (2018) HUMMINGBIRD study (202B)

Brexanolone 60 µg/kg/hour infusion

vs

brexanolone 90 µg/kg/hour infusion

vs

placebo</td>
<td>DB, MC, PC, RCT

Patients aged 18 to 45 years old that are ≤6 months postpartum with moderate PPD defined as a HAM-D score ≥26 (study 1) or 20 to 25 (study 2) with onset of an MDE no earlier than the third trimester or within four weeks postpartum</td>
<td>N=138

30 days</td>
<td>Primary:
Change from baseline in mean Hamilton Depression Rating Scale (HAM-D) total score at the end of the 60-hour infusion

Secondary:
Change from baseline in HAM-D total score at all time points throughout the study period, proportion of achieving HAM-D response, proportion of patients achieving HAM-D remission, response in Clinical Global Impression-Improvement (CGI-I), change from baseline in Montgomery-Asberg Depression</td>
<td>Primary:
At the end of the 60-hour infusion, the LS mean reduction in HAM-D total score was 19.5 points in the brexanolone 60 µg/kg/hour group (BRX60) and 17.7 points in the brexanolone 90 µg/kg/hour group (BRX90) compared to 14.0 points in the placebo group, with a mean difference compared to placebo of -5.5 for the BRX60 group (95% CI, -8.8 to -2.2; P=0.0013) and -3.7 for the BRX90 group (95% CI, -6.9 to -0.5; P=0.0252) respectively.

Secondary:
The change from baseline in HAM-D total scores at all time points throughout the study period are outlined below.

LS mean change in HAM-D scores from baseline
<table>
<tr><th rowspan="2">Time from infusion initiation</th><th colspan="3">LS mean change from baseline (SE)</th></tr>
<tr><th>BRX60</th><th>BRX90</th><th>Placebo</th></tr>
<tr><td>2 hours</td><td>-5.0 (0.7)</td><td>-4.9 (0.7)</td><td>-5.0 (0.7)</td></tr>
<tr><td>4 hours</td><td>-9.0 (0.9)</td><td>-7.2 (0.9)</td><td>-6.9 (0.8)</td></tr>
<tr><td>8 hours</td><td>-10.2 (1.0)</td><td>-8.5 (1.0)</td><td>-8.1 (0.9)</td></tr>
<tr><td>12 hours</td><td>-11.0 (1.1)</td><td>-9.1 (1.0)</td><td>-9.8 (1.0)</td></tr>
<tr><td>24 hours</td><td>-15.0 (1.2)</td><td>-13.0 (1.2)</td><td>-10.7 (1.1)</td></tr>
<tr><td>36 hours</td><td>-17.7 (1.2)</td><td>-13.9 (1.2)</td><td>-12.6 (1.1)</td></tr>
<tr><td>48 hours</td><td>-18.0 (1.3)</td><td>-16.9 (1.2)</td><td>-13.6 (1.2)</td></tr>
<tr><td>72 hours</td><td>-19.7 (1.3)</td><td>-17.2 (1.2)</td><td>-14.7 (1.2)</td></tr>
<tr><td>7 days</td><td>-17.4 (1.4)</td><td>-14.9 (1.3)</td><td>-13.3 (1.3)</td></tr>
<tr><td>30 days</td><td>-19.5 (1.4)</td><td>-17.6 (1.4)</td><td>-13.8 (1.3)</td></tr>
</table>
The percentage of patients achieving HAM-D response defined as a ≥50% reduction from baseline in HAM-D total score was 86.5% for BRX60, 74.4% for BRX90, and 55.8% for placebo at hour 60 (P=0.0052 and</td>
</tr>
</table>

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td></td><td></td><td></td><td>Rating Scale (MADRS) total score</td><td>P=0.0493, respectively) and 82.9% for BRX60, 69.4% for BRX90, and 50.0% for placebo at day 30 (P=0.0052 for BRX60).

The percentage of patients achieving HAM-D remission (defined as a total score ≤7) for BRX60, BRX90, and placebo was 51.4%, 30.8%, and 16.3%, respectively at hour 60 (P=0.0013 for BRX60) and 48.6%, 38.9% and 31.0%, respectively at day 30 (P values not reported).

The LS mean difference in CGI-I score as compared to placebo was -0.83 for BRX60 and -0.67 for BRX90 at hour 60 (P=0.0003 and P=0.0029, respectively) and -0.80 for BRX60 and -0.53 for BRX90 at day 30 (P=0.0019 and P=0.0341, respectively).

The proportion of patients who achieved a CGI-I response at 60 hours after the infusion was 83.8% (31/37) in the BRX60 group and 82.1% (32/39) in the BRX90 group compared to 55.8% (24/43) in the placebo group (OR, 4.0; 95% CI, 1.3 to 11.7; P=0.0131 and OR, 4.0; 95% CI, 1.4 to 11.6; P=0.0095, respectively).

The change from baseline in MADRS total score was -6.9 for BRX60 and -4.2 for BRX90 at hour 60 versus placebo (P=0.0054 and P=NS, respectively).</td></tr>
<tr><td>Meltzer-Brody et al[54] (2018) HUMMINGBIRD study (202C)

Brexanolone 90 µg/kg/hour infusion

vs

placebo</td><td>DB, MC, PC, RCT

Patients aged 18 to 45 years old that are ≤6 months postpartum with moderate PPD defined as a HAM-D score between 20 and 25 with onset of an MDE during the third trimester or within four weeks postpartum</td><td>N=108

30 days</td><td>Primary:
Change from baseline in mean HAM-D total score at the end of the 60-hour infusion

Secondary:
Change from baseline in HAM-D total score at all time points throughout the study period, proportion of</td><td>Primary:
At the end of the 60-hour infusion, the LS mean reduction in HAM-D total score was 14.6 points in the brexanolone 90 µg/kg/hour group (BRX90) compared to 12.1 points in the placebo group (P=0.0160).

Secondary:
The change from baseline in HAM-D total scores at all time points throughout the study period are outlined below.

LS mean change in HAM-D scores from baseline
<table>
<tr><th rowspan="2">Time from infusion initiation</th><th colspan="2">LS mean change from baseline (SE)</th></tr>
<tr><th>BRX90</th><th>Placebo</th></tr>
<tr><td>2 hours</td><td>-4.6 (0.6)</td><td>-4.0 (0.6)</td></tr>
<tr><td>4 hours</td><td>-7.3 (0.7)</td><td>-6.6 (0.7)</td></tr>
<tr><td>8 hours</td><td>-8.4 (0.7)</td><td>-7.4 (0.7)</td></tr>
</table></td></tr>
</table>

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td></td><td></td><td></td><td>patients achieving HAM-D response, proportion of patients achieving HAM-D remission, response in CGI-I, change from baseline in MADRS total score</td><td>
<table>
<tr><td>12 hours</td><td>-9.1 (0.8)</td><td>-8.0 (0.8)</td></tr>
<tr><td>24 hours</td><td>-11.4 (0.8)</td><td>-9.8 (0.8)</td></tr>
<tr><td>36 hours</td><td>-12.3 (0.8)</td><td>-10.5 (0.8)</td></tr>
<tr><td>48 hours</td><td>-13.0 (0.9)</td><td>-10.6 (0.9)</td></tr>
<tr><td>72 hours</td><td>-15.3 (0.8)</td><td>-11.8 (0.8)</td></tr>
<tr><td>7 days</td><td>-14.0 (1.1)</td><td>-10.7 (1.0)</td></tr>
<tr><td>30 days</td><td>-14.7 (1.0)</td><td>-15.2 (0.9)</td></tr>
</table>

The percentage of patients achieving HAM-D response defined as a ≥50% reduction from baseline in HAM-D total score was 67.3% for BRX90 and 49.1% for placebo at hour 48 (P=0.0146) and 66.0% for BRX90 and 50.9% for placebo at day 7 (P=0.0482).

The percentage of patients achieving HAM-D remission (defined as a total score ≤7) for BRX90 and placebo was 42.9% vs 24.5% at hour 48 (P=0.0158) and 56.0% vs 32.1% at day seven (P=0.0046).

The proportion of patients who achieved a CGI-I response at 60 hours after the infusion was 79.6% (39/49) in the BRX90 group compared to 55.8% (29/52) in the placebo group (OR, 5.0; 95% CI, 2.0 to 12.5; P=0.005). The LS mean difference in CGI-I score for BRX90 as compared to placebo was -0.51 at hour 24 (P=0.0047) and -0.53 at day seven (P=0.0266).

The change from baseline in MADRS total score was -4.9 at hour 60 versus placebo (P=0.0.0033).</td></tr>
<tr><td>Koshino et al.[55] (2013)

Bupropion SR 150 mg daily

vs

bupropion SR 150 mg BID</td><td>DB, MC, PC, RCT

Patients 18 to 64 years of age with MDD in Japan or South Korea</td><td>N=569

8 weeks</td><td>Primary:
Mean change from baseline in MADRS total score at week eight

Secondary:
Comparison of change from baseline for each group in MADRS</td><td>Primary:
The mean change from baseline in MADRS total scores was decreased for bupropion SR 150 mg daily, bupropion 150 mg BID and placebo; however no significant difference from placebo (-14.4; P=0.853, -12.9; P value not reported, -13.9; P value not reported, respectively).

Secondary:
Both MADRS and IDS-SR total scores consistently decreased (weeks one, two, four, six and eight) throughout the study for all groups, including placebo; however, neither bupropion treatment group significantly differed from placebo in either MADRS or IDS-SR in total scores. When MADRS</td></tr>
</table>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			total scores and IDS-SR total scores at weeks one, two, four, six and eight; MADRS total scores stratified by location at week eight for each group	results were stratified by location (Japan or South Korea), no significant differences were observed in change from baseline in MADRS total score at week eight.
Clayton et al.[56] (2006) Bupropion ER 300 to 450 mg daily vs escitalopram 10 to 20 mg daily vs placebo	DB, PC, RCT Adult outpatients with moderate-to-severe MDD with normal sexual function	N=830 8 weeks	Primary: Orgasm dysfunction at eight weeks and incidence of worsened sexual functioning; CSFQ, HAM-D_{17} Secondary: Not reported	Primary: The incidence of worsened sexual functioning at the end of the treatment period was statically significantly lower with bupropion ER than with escitalopram (P<0.05), not statistically different between bupropion ER and placebo (P>0.067), and statistically significantly higher with escitalopram than with placebo (P<0.001). The percentages of patient with orgasm dysfunction at week eight were 15% with bupropion ER, 30% with escitalopram, and 15% with placebo. The mean change in CSFQ sores for all domains at week eight was statistically significantly worse for escitalopram compared to bupropion ER (P<0.05). Bupropion did not statistically differ from escitalopram with respect to mean change in HAM-D_{17} total score, response or remission rates. Secondary: Not reported
Hewett et al.[57] (2009) Bupropion ER 150 mg/day for 4 weeks, then 300 mg/day	DB, MC, PC, RCT Patients 18 to 64 years of age with MDD	N=576 8 weeks	Primary: Mean change from baseline at week eight in the MADRS total score (LOCF) Secondary:	Primary: The mean changes from baseline at week eight (LOCF) in MADRS total score were greater for patients receiving bupropion ER and venlafaxine ER compared to patients receiving placebo: -16.0 for bupropion ER (P=0.006 vs placebo), -17.1 for venlafaxine ER (P<0.001 vs placebo) and -13.5 for placebo. There was no significant difference between the bupropion ER group and the venlafaxine ER group (95% CI, -0.7 to 2.9).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs venlafaxine ER 75 mg/day for 4 weeks, then 150 mg/day vs placebo			MADRS total score (observed cases), MADRS subscore, percentage of MADRS responders and remitters at week eight; CGI-I score at week eight; CGI-S score and HAMA total score at weeks one, two, four, six and eight	Secondary: The mean changes from baseline to week eight (observed cases) in MADRS total scores were significantly greater for bupropion ER and venlafaxine ER patients compared to the placebo group: -18.2 for bupropion ER (P=0.003), -18.5 for venlafaxine ER (P<0.001) and -15.8 for placebo. Significant improvements from baseline in MADRS sadness and concentration difficulties scores were observed for bupropion ER (-2.2; P<0.001 and -1.8; P=0.004, respectively) and venlafaxine ER (-2.3; P<0.001 and -1.9; P<0.001, respectively) compared to placebo at week eight (-1.7 and -1.4, respectively). Significant improvements in MADRS lassitude score were found for venlafaxine ER compared to placebo (-1.8 vs -1.5; P=0.009), but not for bupropion ER (-1.7 vs -1.5; P=0.140). A larger proportion of patients in the bupropion ER and venlafaxine ER groups were classified as MADRS responders (≥50% reduction in MADRS total score) and remitters (MADRS total score ≤11) at week eight compared to the placebo group. Response rates were 57% for bupropion ER (P=0.033), 65% for venlafaxine ER (P<0.001), and 46% for placebo. Remission rates were 47% for bupropion ER (P=0.004), 51% for venlafaxine ER (P<0.001), and 32% for placebo. CGI-I response rates for both active treatment groups were significantly better than placebo with 68% of bupropion ER patients (P<0.001) and 65% of venlafaxine ER patients (P=0.009) rated ‘much improved’ or ‘very much improved’ at week eight compared to 53% of placebo patients. Significantly greater mean decreases from baseline in SDS total scores were observed for bupropion ER (-8.4; P=0.003) and venlafaxine ER (-9.0; P<0.001) compared to placebo (-6.2). The mean change from baseline in patient satisfaction with study medication was significantly greater for bupropion ER (4.9; P=0.005) and venlafaxine ER (5.2; P<0.001) than placebo (4.4).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Weihs et al.[58] (2000) Bupropion SR 100 to 300 mg/day vs paroxetine 10 to 40 mg/day	DB, MC, RCT Patients ≥60 years of age with MDD	N=100 6 weeks	Primary: HAM-D, HAMA, CGI-I, CGI-S scores Secondary: Adverse effects	Primary: Measurements of efficacy were similar between the treatment groups, with both showing improved scores on all depression rating scales. Secondary: Somnolence and diarrhea were more common in paroxetine-treated patients (P<0.05). Headache, insomnia, dry mouth, agitation, dizziness, and nausea occurred in >10% of patients in both groups.
Kavoussi et al.[59] (1997) Bupropion SR 100 to 300 mg/day vs sertraline 50 to 200 mg/day	DB, PG, RCT Outpatients with moderate-to-severe MDD	N=248 16 weeks	Primary: HAM-D, HAMA, CGI-I, CGI-S Secondary: Adverse effects	Primary: Mean HAM-D, HAMA, CGI-I, and CGI-S scores improved over the course of treatment in both the bupropion SR group and the sertraline group; no between-group differences were observed on any of the scales. Secondary: Orgasm dysfunction was significantly (P<0.001) more common in sertraline-treated patients compared to bupropion SR-treated patients. Adverse events (nausea, diarrhea, somnolence, and sweating) were experienced more frequently (P<0.05) in sertraline-treated patients. No differences were noted between the treatments for vital signs and weight.
Rocca et al.[60] (2005) Citalopram 20 mg/day vs sertraline 50 mg/day	DB, RCT Patients >65 years of age with minor depressive disorder or subsyndromal depressive symptomatology	N=138 8 weeks	Primary: Change in depressive symptoms and remission rates (HAM-D) Secondary; Not reported	Primary: Both treatments induced notable improvement of depressive symptoms. No statistically significant differences were found between the two treatments in decreases from baseline HAM-D scores. At the end of the trial, the mean total HAM-D score had fallen 55.0% in the citalopram group and 52.7% in the sertraline group. No significant differences in remission rates were observed between the two agents. For one month, three month, and end follow-up periods, P=0.3466, 0.7570, and 0.2537, respectively. Secondary; Not reported
Clayton et al.[61]	DB	N=422	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2013) Desvenlafaxine 50 mg/day vs placebo	Adult outpatients with MDD	12 weeks	Mean change from baseline Arizona Sexual Experiences Scale scores Secondary: Not reported	Among women (desvenlafaxine, n=184; placebo, n=92), baseline scores were 20.0 (5.2) and 20.5 (5.3) for desvenlafaxine and placebo, respectively; mean changes at week 12 were -1.93 (0.37) and -1.03 (0.54), respectively (mean difference: 0.90 [-0.38 to 2.18]; P=0.169). Among men (desvenlafaxine, n=97; placebo, n=49), baseline scores were 16.4 (4.9) and 15.9 (4.8) for desvenlafaxine and placebo, respectively; mean changes at week 12 were -1.13 (0.47) and -1.06 (0.70), respectively (mean difference: 0.07 [-1.59 to 1.74]; P=0.932). Significantly greater orgasmic dysfunction at week 12 was observed in the subgroup of men without baseline sexual dysfunction treated with desvenlafaxine relative to placebo. Conversely, women without baseline sexual dysfunction experienced poorer overall sexual functioning and orgasm satisfaction at week 12 with placebo relative to desvenlafaxine treatment. Subgroup analyses of treatment responders and nonresponders found no difference in the proportion of men or women that developed or had resolution of sexual dysfunction in the desvenlafaxine and placebo groups.
Rosenthal et al.[62] (2013) Desvenlafaxine 50 mg/day vs placebo	DB, MC, PC, RCT Adult outpatients age >18 years of age with MDD (DSM-IV criteria) and a HDRS17 total score >20 at screening and baseline	N=874 11 months	Primary: Time to relapse (HDRS17 total score >16, discontinuation for unsatisfactory response, hospitalization for depression, suicide attempt, or suicide) Secondary: Safety and tolerability	Primary: Time to relapse was significantly shorter for placebo vs desvenlafaxine (P<0.001). At the end of the six-month DB treatment, the estimated probability of relapse was 30.2% for placebo vs 14.3% for desvenlafaxine 50 mg/day. Secondary: Safety and tolerability results were generally consistent with those in short-term studies of desvenlafaxine 50 mg/day.
Dunlop et al.[63] (2011)	DB, PC, RCT Gainfully employed	N=427 12 weeks	Primary: HAM-D-17 total score	Primary: Desvenlafaxine demonstrated superiority over placebo beginning at week two, which continued through week 12. Adjusted mean endpoint scores

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Desvenlafaxine 50 mg/day vs placebo	(≥20 hours/week) outpatients with MDD		Secondary: SDS, safety	with desvenlafaxine and placebo were 9.33 and 11.45, respectively. Mean change scores were -12.61±0.45 and -10.50±0.60 with desvenlafaxine and placebo, respectively. The adjusted mean difference in change from baseline between desvenlafaxine and placebo at week 12 was 2.12 (95% CI, 0.78 to 3.46; P=0.002). Secondary: The adjusted mean difference in change from baseline score on the SDS between the desvenlafaxine and placebo at week 12 was 1.33 (95% CI, -0.09 to 2.76), which narrowly missed significance (P=0.067). There were six serious adverse events (no deaths) that occurred in four and two desvenlafaxine- and placebo-treated patients. None of these events were considered non-treatment related. No new safety concerns about desvenlafaxine were identified from safety analyses.
Kornstein et al.[64] (2010) Desvenlafaxine 100 or 200 mg/day vs placebo	DB, MC, PC, RCT Perimenopausal and post-menopausal women 40 to 70 years of age with MDD, single or recurrent episode	N=387 8 weeks	Primary: HAM-D-17 total score Secondary: CGI-I, CGI-S, MADRS, HAMA, QIDS-SR, MRS, EQ-5D, VAS-PI, safety	Primary: Baseline reductions in HAM-D-17 total scores were significantly greater with desvenlafaxine (adjusted mean change, -12.64) compared to placebo (-8.33; P<0.01). Significant differences between treatments were observed at week one (P=0.044) and were sustained though week eight (week two; P=0.013, weeks three to eight; P<0.001). Both perimenopausal (adjusted mean change, -10.96; P=0.003) and postmenopausal (-11.09; P<0.001) subgroups achieved significant reductions in HAM-D-17 total scores with desvenlafaxine compared to placebo. The treatment effect (adjusted mean difference from placebo) in these two populations were -4.07 (95% CI, -6.77 to -1.37) and -2.37 (95% CI, -5.07 to -1.47). HAM-D-17 based response (58.6%) and remission (38.2%) rates were significantly higher with desvenlafaxine compared to placebo (31.6 and 22.4%; P<0.001 and P=0.008, respectively). Secondary: Desvenlafaxine achieved significant improvement compared to placebo on all secondary outcomes. Desvenlafaxine-treated patients had significantly lower CGI-I scores at week eight compared to placebo-treated patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(2.00 vs 2.82; P<0.001); a significantly higher percentage of patients receiving desvenlafaxine had scored 1 (very much improved) or 2 (much improved) compared to patients receiving placebo (67.7 vs 41.2%; P<0.001). In total, 7.4 and 3.2% of desvenlafaxine- and placebo-treated patients discontinued study medication due to an adverse event. The event cited most commonly by patients discontinuing due to an adverse event was hypertension (five vs zero patients). Treatment-emergent adverse events were reported by 85.2 and 75.2% of desvenlafaxine- and placebo-treated patients. Most events were mild or moderate in severity. The most common treatment-emergent adverse events were dry mouth (24 vs 10%), somnolence (15 vs 7%), constipation (14 vs 6%), hypertension (7 vs 2%), sweating (7 vs 2%), dyspepsia (6 vs 2%), and anorexia (6 vs <1%). Serious adverse events were reported by three patients receiving desvenlafaxine (chest pain and hypertension, medication error and psychotic depression, and infection) and two patients receiving placebo (cerebrovascular disorder and skin carcinoma). No deaths were reported during the study or within 30 days after its conclusion.
Rickels et al.[65] (2010) Desvenlafaxine 200 to 400 mg/day vs placebo After 12 weeks of OL treatment with desvenlafaxine, patients with HAM-D-17 total score ≤11 were randomized to	DB, PC, RCT Patients 18 to 75 years of age with MDD, single or recurrent episode, without psychotic features	N=374 (DB phase) N=575 (OL phase) 12 weeks of OL treatment, followed by a 6-month, DB phase	Primary: Time until relapse (HAMD-D-17 total score ≥16 at any visit, CGI-I score ≥6 at any visit, or discontinuation due to unsatisfactory response) Secondary: HAM-D-17 total score, CGI-I, CGI-S, HAM-D-6, Covi Anxiety score, safety	Primary: Patients receiving desvenlafaxine experienced significantly longer times to relapse of MDD compared to patients receiving placebo during DB treatment (P<0.0001). The proportions of patients relapsing were 42 and 24% of patients receiving placebo and desvenlafaxine, respectively (P<0.001). Secondary: A significant difference in HAM-D-17 total scores in favor of desvenlafaxine was observed from DB week three onward (P<0.001). At the final evaluation, adjusted mean changes were 0.85 and 5.03 for desvenlafaxine and placebo, respectively. Desvenlafaxine was also associated with significant differences compared to placebo on CGI-I, CGI-S, HAM-D-6, and Covi Anxiety scores. The most common primary reason cited for discontinuation of treatment

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
continue desvenlafaxine or be switched to placebo.				during the OL phase was adverse events (19%), which consisted of nausea, dizziness, and insomnia. A total of 101 (55%) and 58 (31%) patients receiving placebo and desvenlafaxine discontinued treatment during the DB phase. The most frequent adverse event reported as the reason for discontinuation during the DB phase was depression (14 patients receiving placebo vs seven patients receiving desvenlafaxine). During the OL phase the most commonly reported adverse events with desvenlafaxine were nausea (42%), dry mouth (32%), headache (26%), dizziness (23%), hyperhidrosis (21%), insomnia (20%), constipation (15%), decreased appetite (12%), fatigue (12%), somnolence (11%), diarrhea (10%), tremor (10%), vomiting (8%), sedation (5%), and blurred vision (5%). During the DB phase, treatment-emergent adverse events were reported by 73 and 82% of patients receiving desvenlafaxine and placebo, respectively. The most commonly reported events with desvenlafaxine were headache (24%), dizziness (15%), nausea (14%), fatigue (13%), hyperhidrosis (13%), diarrhea (9%), abnormal dreams (9%), depression (8%), insomnia (8%), influenza (7%), irritability (7%) , back pain (6%), upper respiratory tract infection (6%), abdominal pain (5%), anxiety (5%), muscle spasms (5%), nasopharyngitis (5%), tremor (5%), delayed ejaculation (5% in men), erectile dysfunction (5% in men), vomiting (4%), vertigo (3%), myalgia (2%), paresthesia (2%), and altered mood (1%).
Clayton et al.[66] (abstract) (2009) Desvenlafaxine 50 to 400 mg/day vs placebo	DB, PC, RCTs (integrated analysis of short-term 9 trials) Adult outpatients with MDD	N=2,950 8 weeks	Primary: Treatment-emergent adverse events, laboratory values, vital signs, discontinuation symptoms Secondary: Not reported	Primary: The most common treatment-emergent adverse event was transient nausea that was generally mild to moderate. The most common sexual dysfunction associated with desvenlafaxine treatment was erectile dysfunction in men (7 vs 1%) and anorgasmia in women (1 vs 0%). One patient receiving desvenlafaxine died of a completed suicide; there were four suicide attempts (three vs one patient[s]) and eight cases of suicidal ideation (five vs three patients) during the on-therapy period. Desvenlafaxine was associated with small but significant mean changes in laboratory assessments, particularly lipid and liver enzyme elevations, and ECGs; few cases of these changes were clinically relevant. Small but significant changes in mean blood pressure occurred with all

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				desvenlafaxine doses; clinically meaningful changes were observed in 1 and 2% of placebo- and desvenlafaxine-treated patients. In the overall population, adverse events resulted in discontinuations in 3 and 12% of placebo- and desvenlafaxine-treated patients; in the subset of fixed-dose trials, the rates were 4 and 4 to 18% with placebo and desvenlafaxine. Secondary: Not reported
Feiger et al.[67] (2009) Desvenlafaxine 200 to 400 mg/day vs placebo	DB, MC, PC, PG, RCT Outpatients ≥18 years of age with MDD	N=235 8 weeks (plus a 2-week tapering phase)	Primary: HAM-D-17 Secondary: CGI-I, CGI-S, MADRS, HAM-D-6, safety	Primary: No significant difference was observed in the adjusted mean change from baseline in the HAM-D-17 total score between desvenlafaxine and placebo at the final evaluation (difference in adjusted means, 1.6; 95% CI, -0.2 to 3.4). No significant differences were observed between desvenlafaxine and placebo groups for HAM-D-17 clinical response rates at the final evaluation; the logistic regression analysis demonstrated adjusted ORs of 1.456 (95% CI, 0.85 to 2.50; P=0.175) for HAM-D-17 response. No significant difference in HAM-D-17 remission rates was observed between desvenlafaxine and placebo groups at final evaluation; the logistic regression analysis showed an adjusted OR of 1.158 (95% CI, 0.60 to 2.22; P=0.66). Secondary: At final evaluation, significant differences between desvenlafaxine and placebo were observed for the CGI-I (difference in adjusted means: 0.3; 95% CI, 0.0 to 0.6), CGI-S (0.3; 95% CI, 0.0 to 0.6), MADRS (2.9; 95% CI, 0.3 to 5.4), and HAM-D-6 (1.5; 95% CI, 0.5 to 2.6). A significant difference was observed between desvenlafaxine and placebo groups for MADRS clinical response rates; the logistic regression analysis demonstrated an adjusted OR of 1.754 (95% CI, 1.03 to 3.00; P=0.04). Treatment-emergent adverse events were reported by 112 patients (96%)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and 101 patients (86%) receiving desvenlafaxine and placebo. Treatment-emergent adverse events reported by ≥5% of patients receiving desvenlafaxine and at a frequency at least twice that of the placebo group included nausea, dry mouth, hyperhidrosis, insomnia, somnolence, decreased appetite, tremor, blurred vision, yawning, sedation, vomiting, mydriasis, middle insomnia, initial insomnia, erectile dysfunction, constipation, feeling jittery, and dyspepsia. Nausea, the most frequently reported adverse event in patients receiving desvenlafaxine (36%), was mild to moderate in the majority of cases (88%). Treatment-emergent adverse events resulted in reduction in dose of study medication for six (5%) and two (2%) patients receiving desvenlafaxine and placebo. Taper/post-study-emergent adverse events were consistent with what has been seen in pervious trials of desvenlafaxine and with the SNRIs. Significantly more patients receiving desvenlafaxine (12%) discontinued the study because of treatment-emergent adverse events compared to patients receiving placebo (3%; P=0.008). No deaths or serious adverse events occurred during the study.
Thase et al.[68] (2009) Desvenlafaxine 50 to 400 mg/day vs placebo	MA (9 trials) Outpatients ≥18 years of age with MDD	N=3,023 8 weeks	Primary: HAM-D-17 total score Secondary: MADRS, HAM-D-6, CGI-I, CGI-S, remission and response rates, safety	Primary: Significantly greater improvement with desvenlafaxine vs placebo on HAM-D-17 total scores was observed for the full data set (difference in adjusted means, -1.9; P<0.001). Significance was observed in all fixed-dose (P<0.001 for all) and flexible-dose trials (P=0.24). Secondary: For the overall desvenlafaxine group significant improvement from baseline was observed on all secondary outcome measures at the final evaluation. Overall, desvenlafaxine had a significantly greater change from baseline compared to placebo on the CGI-I, CGI-S, and MADRS total scores from week two onward and in the core symptoms of depression (HAM-D-6 total score) from week one onward. Overall rates of HAM-D-17 response (53 vs 41%) and remission (32 vs 23%) were significantly greater with desvenlafaxine vs placebo (P<0.001 for all). Discontinuation rates due to adverse events increased with desvenlafaxine dose (4 to 18 vs 3%). The most common treatment-emergent adverse

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				events in the overall data set were nausea, dry mouth, hyperhidrosis, dizziness, and constipation.
Clayton et al.[69] (2015) Desvenlafaxine 50 and 100 mg/day vs placebo	DB, PC, RCT Outpatients ≥18 years of age with MDD, depressive symptoms for ≥30 days before screening and baseline HAM-D-17 total score ≥20; HAM-D-17 item 1 (depressed mood) score ≥2; and CGI-S ≥4	N=909 8 weeks	Primary: HDRS-17 total score Secondary: CGI-I, CGI-S, ASEX	Primary: A statistically significantly greater change from baseline in HDRS-17 total score was observed for both desvenlafaxine groups compared with placebo after adjusting for multiplicity (desvenlafaxine 50 mg, P=0.006; desvenlafaxine 100 mg, P<0.001). Secondary: Statistically significant improvement from baseline in CGI-S scores was observed at week eight for both desvenlafaxine dose groups compared with placebo. The adjusted mean difference versus placebo was 0.20 (95% CI, 0.05 to 0.34; P=0.009) for the desvenlafaxine 50-mg group and 0.28 (95% CI, 0.13 to 0.43; P<0.001) for the desvenlafaxine 100-mg group. Pairwise comparisons of CGI-I scores for each desvenlafaxine group versus placebo were statistically significant (desvenlafaxine 50 mg, P=0.029; desvenlafaxine 100 mg, P<0.001, without adjustment for multiplicity). At week eight (LOCF), ASEX total and individual item scores were comparable for both 50 and 100 mg doses of desvenlafaxine and placebo, with widely overlapping confidence intervals.
Boyer et al.[70] (2008) Desvenlafaxine 50 and 100 mg/day vs placebo	DB, MC, PC, PG, RCT Outpatients ≥18 years of age with MDD, depressive symptoms for ≥30 days before screening and baseline HAM-D-17 total score ≥20; HAM-D-17 item 1 (depressed mood) score ≥2; and CGI-S ≥4	N=438 8 weeks (plus a 1-week taper phase)	Primary: HAM-D-17 total score Secondary: CGI-I, MADRS, CGI-S, VAS-PI, Covi Anxiety Scale total scores, remission rates, responder rates, safety	Primary: In a LOCF analysis, adjusted mean baseline changes in HAM-D-17 total scores were significantly greater with desvenlafaxine 50 (-13.2; P=0.002) and 100 mg/day (-13.7; P<0.001) compared to placebo (-10.7). Secondary: Significant differences on CGI-I scores were observed with desvenlafaxine 50 (P=0.002) and 100 mg/day (P<0.001) compared to placebo. For MADRS total score, the between-group difference vs placebo in adjusted mean was 3.1 (95% CI, 1.0 to 5.2) with desvenlafaxine 50 mg/day and 4.2 (95% CI, 2.1 to 6.3) with desvenlafaxine 100 mg/day. Adjusted mean changes from baseline were significantly greater with desvenlafaxine compared to placebo starting at week four (P=0.036 and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				P=0.004, respectively), and were sustained until the final evaluation (P=0.004 and P<0.001, respectively). For CGI-S score at final evaluation, adjusted mean changes from baseline were significantly greater than placebo for desvenlafaxine 50 (P=0.003) and 100 mg/day (P<0.001). Significant separation from placebo was observed beginning at week six and four for desvenlafaxine 50 (P=0.002) and 100 mg/day (P=0.027), and both groups remained significantly different through the final evaluation. Results of the VAS-PI are not reported because of the heterogeneity of the format of the translated scale; it was impossible to properly analyze the corresponding data. For Covi Anxiety Scale total score at final evaluation, adjusted mean changes from baseline were significantly greater than placebo for desvenlafaxine 50 (P=0.001) and 100 mg/day (P=0.004). The adjusted OR for response relative to placebo was 1.943 (95% CI, 1.24 to 3.05) and 1.798 (95% CI, 1.14 to 2.83) with desvenlafaxine 50 and 100 mg/day (P=0.004 and P=0.011). For remission rates, the adjusted OR for remission relative to placebo was 1.488 (95% CI, 0.93 to 2.38) and 2.117 (95% CI, 1.32 to 3.39) with desvenlafaxine 50 and 100 mg/day (P=0.099 and P=0.002). Responder rates were significantly higher with desvenlafaxine 50 (65%) and 100 mg/day (63%) compared to placebo (50%; P=0.005 and P=0.018, respectively; NNT, 6.5 and 7.4). Significantly more patients receiving desvenlafaxine 100 mg/day achieved remission compared to patients receiving placebo (45 vs 29%, respectively; P=0.003; NNT, 6.1). Most of the treatment-emergent adverse events were mild or moderate in severity. The most common treatment-emergent adverse events were nausea, dizziness, insomnia, constipation, fatigue, anxiety, and decreased appetite.
Liebowitz et al.[71] (abstract) (2008)	DB, MC, PC, PG, RCT	N=447 8 weeks	Primary: Change from baseline to final	Primary: There was a significant decrease in the HAM-D-17 score from baseline in the desvenlafaxine 50 mg group (-11.5; P=0.018) but not for the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Desvenlafaxine 50 or 100 mg/day vs placebo	Patients 18 to 75 years of age with a primary diagnosis of MDD, depressive symptoms ≥30 days prior to screening, HAM-D-17 total score ≥20, and CGI-S score ≥4	(plus a 1-week taper)	on-therapy evaluation on HAM-D-17score Secondary: Change from baseline in CGI-I, CGI-S, MADRS, VAS-PI, HAM-D-17 rate of response (percentage of patients with a HAM-D-17 score decrease of ≥50%), HAM-D-17 rate of remission (percentage of patients with a HAM-D-17score decrease to ≤7%), SDS, WHO-5, safety	desvenlafaxine 100 mg group (-11; P=0.065) compared to the placebo group (-9.53). Secondary: The decrease from baseline in the CGI-I score was not considered significant for the desvenlafaxine 50 mg group (P=0.085) and the 100 mg group (P=0.076) compared to the placebo group. The decrease from baseline in CGI-S scores were not significantly different than the desvenlafaxine 50 mg (P=0.074) and 100 mg groups (P=0.208) compared to the placebo group. There was a significant decrease from baseline in MADRS scores in the desvenlafaxine 50 mg group (P=0.022) but not the 100 mg group (P=0.095). VAS-PI overall pain score showed significant improvement compared to baseline in the 100 mg group (P=0.041) but not for the 50 mg group (P=0.223). There was no significant difference between the desvenlafaxine 50 and 100 mg groups compared to the placebo group in terms of HAM-D-17 rates of response (P=0.133, P=0.246, respectively) and remission (P=0.075, P=0.194, respectively). The desvenlafaxine 50 mg group showed significant improvements from baseline in SDS score (-8.96; P=0.012) and WHO-5 score (6.68; P=0.020) compared to the placebo group. There were no significant differences from baseline in the 100 mg group compared to the placebo group in SDS or WHO-5 score. The most common adverse events seen (incidence ≥10% and at twice the rate in the placebo group) with desvenlafaxine treatment included: dry mouth, constipation, insomnia, decreased appetite, hyperhidrosis and dizziness (P values not reported).
Liebowitz et al.[72] (2007)	DB, MC, PC, PG, RCT	N=247 8 weeks	Primary: Change from baseline to final	Primary: There was no significant difference in the reduction of HAM-D-17 score from baseline between the desvenlafaxine and placebo group (14.1 vs 15.1

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Desvenlafaxine 100 mg/day for days 1 to 14, increasing to 200 mg/day vs placebo	Patients 18 to 75 years of age with a primary diagnosis of MDD, depressive symptoms ≥30 days prior to screening, HAM-D-17 total score ≥20, a HAM-D item 1 (depressed mood) score ≥2 and CGI-S score ≥4		on-therapy evaluation on HAM-D-17 score Secondary: Change from baseline in CGI-I, MADRS, CGI-S, VAS-PI, vital signs, safety	respectively; P=0.277). Secondary: There was no significant difference between CGI-I scores between the desvenlafaxine and the placebo group compared to baseline (2.5 vs 2.7 respectively; P value not reported). The CGI-S showed no difference from baseline between the desvenlafaxine and placebo groups (3.1 vs 3.3 respectively; P value not reported). Improvement was demonstrated at final evaluation between desvenlafaxine and placebo on the MADRS scale (16.8 vs 19.5 respectively; P=0.047), the VAS-PI overall pain scale (15.6 vs 11.6 respectively; P=0.008), the VAS-PI back pain scale (13.1 vs 20.5 respectively; P=0.006) and the VAS-PI arm, leg or joint pain scale (13.3 vs 21.6 respectively; P<0.001). There was a significant increase from baseline in supine SBP (3.76 vs -1.59; P<0.001, respectively) and supine DBP (1.85 vs -0.91; P=0.003 respectively) in the desvenlafaxine group compared to the placebo group. There was a significant decrease in body weight seen in the desvenlafaxine group compared to the placebo group (-0.74 vs 0.36 kg; P<0.001). There was an increase in heart rate from baseline observed in the desvenlafaxine group (4.27 beats per minute; P<0.01) and a decrease from baseline in the placebo group (-2.27 beats per minute; P<0.01). A decrease in the QT interval was observed in the desvenlafaxine group from baseline (-4.27 ms; P value not significant) and an increase in QT interval from baseline was observed in the placebo group (4.90; P<0.05). The difference in these values was considered to be statistically significant (P=0.01). Anorexia (P<0.001), constipation (P<0.05), dry mouth (P<0.01), nausea (P<0.001), tremor (P<0.01) and yawning (P<0.01) were seen more commonly in the desvenlafaxine group compared to the placebo group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Demartinis et al.[73] (2007) Desvenlafaxine 100, 200, or 400 mg/day vs placebo	DB, MC, PC, PG, RCT Patients 18 to 75 years of age with a primary diagnosis of MDD, depressive symptoms ≥30 days prior to screening, HAM-D-17 total score ≥20, a Ham-D item 1 (depressed mood) score ≥2 and CGI-S score ≥4	N=461 8 weeks (plus a 2-week taper)	Primary: Change from baseline to final on-therapy evaluation on HAM-D-17 score Secondary: Change from baseline in CGI-I, CGI-S, MADRS, VAS-PI, HAM-D-17 rate of response (percentage of patients with a HAM-D-17 score decrease ≥50%), HAM-D-17 rate of remission (percentage of patients with a HAM-D-17 score decrease to ≤7%), SDS, WHO-5, vital signs, safety	Primary: Decrease in HAM-D-17 score from baseline was significantly greater at final on-therapy evaluation in the 100 mg (-10.60; P=0.0038) and 400 mg (-10.75; P=0.0023) groups compared to the placebo group (-7.65). However, the decrease in HAM-D-17 score from baseline in the 200 mg group was not significant (-9.63; P=0.0764) compared to the placebo group. Secondary: There were significant decreases in CGI-I score from baseline for the 100 mg (2.3; P=0.008), 200 mg (2.5; P=0.0462) and 400 mg (2.4; P=0.0129) groups compared to the placebo treated group (2.8). There were significant decreases in CGI-S scores from baseline in the 100 mg (-1.5; 95% CI, 0.2 to 0.8; P=0.002) and 400 mg (-1.5; 95% CI, 0.2 to 0.9; P<0.001) groups compared to the placebo group (-1.0). The CGI-S score difference observed in the 200 mg group was not significant (-1.13; 95% CI, 0.0 to 0.6; P=0.056). The decrease from baseline in MADRS score was significant for the 100 mg group (-13.6; 95% CI, 1.3 to 6.4; P=0.004), the 200 mg group (-13.5; 95% CI, 1.3 to 6.2; P=0.005), and the 400 mg group (-15.2; 95% CI, 3.1 to 8.3; P<0.001) compared to the placebo group (-9.9). Patients in the desvenlafaxine 100 mg group showed a significant improvement from baseline in overall pain score compared to the placebo group on the VAS-PI scale (-13.9 vs 5.9; P=0.002, respectively). There was no significant difference in either the 200 mg (-5.4; P=0.357) or the 400 mg (-10.1; P=0.069) groups. There was a significantly higher OR for response to the 100 mg group (2.15; 95% CI, 1.25 to 3.73; P=0.006) and 400 mg group (1.91; 95% CI, 1.11 to 3.32; P=0.020). The OR for response to the 200 mg group was not significant (1.60; 95% CI, 0.93 to 2.76; P=0.089) compared to the placebo group. There was a significantly higher OR for remission in the 400 mg group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				compared to the placebo group (2.20; 95% CI, 1.17 to 4.14; P=0.014). The OR of the 100 mg group (1.86; 95% CI, 0.99 to 3.52; P=0.053) and 200 mg group (1.73; 95% CI, 0.92 to 3.26; P=0.088) were not significant compared to the placebo group. There was a statistically significant increase in supine pulse rate in the desvenlafaxine 400 mg group compared to baseline (4.19; P<0.001). The increase was considered statistically significant when compared to the placebo group (0.15; P<0.05). The change in supine pulse rate from baseline in the desvenlafaxine 100 mg (-0.03) and 200 mg (1.06) groups were not considered significant compared to the placebo group (P value not significant). The mean increase in supine SBP was considered significant in all groups compared to baseline compared to the placebo group (P<0.05). The increase in DBP was considered significant in all treatment groups compared to baseline (P<0.001 for the 200 and 400 mg groups and P<0.01 for 100 mg group). There was a significant increase in DBP from baseline in both the desvenlafaxine 200 and 400 mg groups compared to the placebo group (P<0.05). The increase in DBP from baseline in the 100 mg group was not considered significant compared to the placebo group (P value not significant). There was a significant decrease in body weight in all desvenlafaxine treatment groups compared to baseline (P<0.001) and to the placebo group (P<0.05). Adverse events that occurred at twice the rate of placebo in at least 5% of desvenlafaxine-treated subjects included: nausea, somnolence, insomnia, dry mouth, sweating, dizziness, nervousness, anorexia, constipation, abnormal ejaculation/orgasm, asthenia and tremor (P values not reported).
Septein-Velez et al.[74] (2007) Desvenlafaxine 200 or 400 mg/day vs	DB, MC, PC, PG, RCT Outpatients 18 to 75 years of age with a primary diagnosis of MDD, depressive symptoms ≥30 days	N=369 8 weeks (plus a 2-week taper)	Primary: Change from baseline to final on-therapy evaluation on HAM-D-17 score Secondary:	Primary: The decrease from baseline in HAM-D-17 score was significantly greater in the 200 mg group (-12.6; P=0.002) and the 400 mg group (-12.1; P=0.008) compared to the placebo group (-9.3). Secondary: A lower CGI-I score was observed in the 200 mg group (P=0.004) and the 400 mg group (P=0.028) compared to the placebo group. There was a

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	prior to screening, HAM-D-17 total score ≥20, and CGI-S score ≥4		Change from baseline in CGI-I, CGI-S, MADRS, VAS-PI, HAM-D-17 rate of response (percentage of patients with a HAM-D-17 score decrease ≥50%), HAM-D-17 rate of remission (percentage of patients with a HAM-D-17 score decrease to ≤7%), SDS, WHO-5	significant difference in change in MADRS score from baseline favoring desvenlafaxine in the 200 mg (P=0.001) and 400 mg (P=0.005) groups compared to the placebo group. There was a significant difference in change in CGI-S score from baseline favoring patients treated with desvenlafaxine compared to patient treated with placebo (P=0.001 and P=0.013 for the desvenlafaxine 200 and 400 mg groups, respectively). There was a greater response on the HAM-D-17 rate of response assessment for the 200 mg (60%; P<0.001) and 400 mg (56%; P=0.005) groups compared to the placebo group (38%). A greater degree of remission was observed for the 200 mg group (37%; P=0.017) compared to the placebo group (23%). The degree of remission was not significant for the 400 mg group (P value not reported). The change in VAS-PI overall pain score from baseline favored the desvenlafaxine 200 mg group (P=0.002) compared to the placebo group. The difference between the 400 mg group and the placebo group was not considered significant (P=0.053). There was a significant improvement from baseline in SDS total score for the desvenlafaxine 200 mg (P=0.004) and 400 mg (P=0.004) groups compared to the placebo group. There was a significant improvement from baseline in WHO-5 score for the desvenlafaxine 200 mg (P=0.001) and 400 mg (P=0.005) groups compared to the placebo group.
Tourian et al.[75] (2013) Desvenlafaxine 25 mg/day from days 1 to 14, with subsequent upward titration, to a maximum of 100 mg/day, determined by	MC, OL Japanese patients with MDD who had completed an 8-week, DB, PC study in which patients received 25 or 50 mg/day desvenlafaxine or placebo	N=304 10 weeks	Primary: Safety, HAM-D17 Secondary: Not reported	Primary: Treatment-emergent adverse events were reported by 240 patients (78.9%) during the on-therapy period; the most common adverse events were nasopharyngitis (37.2%), somnolence (11.5%), headache (10.5%), and nausea (10.2%). For the ITT-LOCF population, the mean change from baseline in the HAM-D17 total score was -4.76 (95% CI, -5.47 to -4.05). Continued numerical improvements in the HAM-D17 total scores and other depression outcome measures were observed irrespective of treatment in the previous study.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
clinical response				Secondary: Not reported
Soares et al.[76] (2011) Desvenlafaxine 100 to 200 mg/day	MC, OL Post-menopausal women 40 to 70 years of age with MDD who did not achieve clinical response to acute, DB treatment with desvenlafaxine or escitalopram	N=123 6 months	Primary: HAM-D-17 total score Secondary: CGI-I, HAMA, QIDS-SR, VAS-PI, MADRS, CSFQ, EQ-5D, health state today, MRS, SDS, treatment response (HAM-D-17 and MADRS based), safety	Primary: At final evaluation, mean reductions from acute-phase baseline HAM-D-17 total scores were -11.33 and -11.41 with desvenlafaxine/desvenlafaxine and escitalopram/desvenlafaxine. Mean reductions from week eight of acute phase at the final evaluation of the OL extension phase were -6.13 and -6.59, respectively. Consistent improvements in mean HAM-D-17 total scores were observed among patients in both treatment groups from baselines of both the DB acute phase and the OL extension phase. Secondary: Improvements were demonstrated for additional efficacy and health outcome measures for patients in both groups during the OL extension phase. Throughout the course of the overall study, desvenlafaxine/ desvenlafaxine patients achieved mean improvements from baseline in CSFQ total scores after the acute phase and OL extension phase of 1.58±6.84 and 1.84±4.01, respectively; escitalopram/desvenlafaxine patients experienced improvements of 0.71±6.08 and 2.60±6.28 from respective baselines. HAM-D-17 response or remission rates after six months were achieved in 56 to 58 and 41 to 48% of desvenlafaxine/desvenlafaxine and escitalopram/desvenlafaxine patients. MADRS response rates were 72 and 64%, respectively. The median time to remission was 68 (95% CI, 41 to 84) and 70 days (95% CI, 44 to 125) with desvenlafaxine/desvenlafaxine and escitalopram/ desvenlafaxine patients. Treatment-emergent adverse events were reported by 91% of patients, the most common being headache (17%), insomnia (17%), nausea (16%), dizziness (15%), infection (15%), abnormal dreams (12%), dry mouth (11%), pain (11%), and sweating (10%).
Ferguson et al.[77] (2010) Desvenlafaxine	MC, OL Outpatients ≥65 years of age with	N=52 (safety analysis)	Primary: Safety Secondary:	Primary: The most frequently reported adverse events were mild or moderate nausea (40%), dizziness (25%), and headache (21%). Primary and secondary adverse events led to discontinuation of treatment for 18 (35%)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
100 or 200 mg/day	MDD	≤6 months	HAM-D-17 total scores	patients. The most common event cited as reasons for discontinuation were hypertension (10%) and nausea (10%). Two patients experienced three serious adverse events. Secondary: After three months of treatment, mean total HAM-D-17 score decreased 9.20 points (LOCF) from a baseline score of 21.68±3.20. This improvement was maintained for the duration of the trial; the mean change from baseline at final evaluation at month six was -9.28 points, resulting in a mean HAM-D-17 total score of 12.40±7.19. These improvements were maintained without dose escalation. HAM-D-17 based response rates were 42% (LOCF) at month three. The clinical responses were maintained by 65% of patients at month six. HAM-D-17 based remission rates were 28% at month two, which were maintained by 30% of patients at month six.
Soares et al.[78] (2010) Desvenlafaxine 100 to 200 mg/day vs escitalopram 10 to 20 mg/day	AC, DB, MC, RCT Postmenopausal women 40 to 70 years of age with MDD	N=607 Acute phase: 8 weeks Continuation phase: 6 months	Primary: HAM-D_{17} total score, response and remission rates, anxiety scores, QOL, menopause-related symptoms, safety and tolerability Secondary: Not reported	Primary: <u>Acute phase</u> There was no significant difference in HAM-D_{17} total score with desvenlafaxine and escitalopram (-13.63 vs -14.30, respectively; P=0.243). There were no significant differences in secondary efficacy and health outcomes data related to depression between treatment groups. On assessments of menopause-related symptoms, there were no significant between-group differences, and improvements from baseline were comparable for both groups. Significantly higher rates were found for escitalopram compared to desvenlafaxine for HAM-D_{17} remission (48 vs 38%, respectively; P<0.01) and response (73 vs 64%, respectively; P<0.05). No significant differences between the escitalopram and desvenlafaxine groups were observed in rates of response on the MADRS (70 and 67%, respectively) and CGI-I (75 and 70%, respectively). <u>Continuation phase</u>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The proportion of women who maintained or improved their HAM-D_{17} response to treatment was similar between the treatment groups (desvenlafaxine, 82%; escitalopram, 80%; P=0.702). There were no significant differences between treatment groups in the proportion of women who achieved HAM-D_{17} remission during the continuation phase or at endpoint (desvenlafaxine, 68%; escitalopram, 61%; P=0.234). There were no significant differences between the desvenlafaxine and escitalopram groups in rates of response on the MADRS (92 and 88%, respectively) and CGI-I (90 and 86%, respectively). No significant differences between groups were found at endpoint in the analyses of secondary efficacy data or core health outcome measures, including assessments of menopause-related symptoms. In both phases, desvenlafaxine and escitalopram were generally safe and well tolerated. Secondary: Not reported
Acharya et al.[79] (2006) Duloxetine 40 to 120 mg daily vs placebo	MA (12 trials) Patients taking duloxetine for MDD	N=2,996 Duration varied	Primary: Incidence of suicide-related events with duloxetine (MHID, MHRD, HAM-D Item-3) Secondary: Not reported	Primary: There were no significant differences in the incidence of suicide-related events with duloxetine vs placebo. The MHID for suicide-related behaviors was -0.03% (95% CI, -0.48 to 0.42) and MHRD -0.002 (95% CI, -0.02 to 0.02). Changes in HAM-D Item-3 suicidality scores showed a greater improvement with duloxetine (P<0.001) and less worsening of suicidal ideation with duloxetine (P<0.001). Secondary: Not reported
Gaynor et al.[80] (2011)	DB, MC, PC, RCT	N=528	Primary: Mean change in	Primary: Treatment with duloxetine resulted in a significantly greater improvement

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Duloxetine 60 mg QD vs placebo	Patients ≥18 years of age with a current episode of MDD and at least moderate pain	8 weeks	MADRS total score and BPI average pain rating Secondary: Remission, PGI-I, SDS global functional impairment score, safety	in MADRS total score compared to treatment with placebo (-16.77 vs -12.73, respectively; 57.9 vs 44.3% improvement from baseline, respectively; P<0.001). Duloxetine was more effective than placebo beginning at week two and at all remaining visits (P≤0.001). There was a significantly greater reduction in average pain rating from baseline to week eight with duloxetine compared to placebo (-1.93 vs -1.31, respectively; 35.1 vs 22.9% reduction in pain, respectively; P≤0.001). Patients also had a greater improvement in their average pain rating at weeks one, two, four, and eight with duloxetine compared to placebo (all P≤0.005). Secondary: A significantly greater proportion of patients receiving duloxetine met the criteria for remission than patients receiving placebo (P≤0.01). Overall scores for 'worst pain' and 'least pain' in the last 24 hours and for 'pain right now' were also reduced with duloxetine vs placebo (all P≤0.001). The least squares mean PGI-I score demonstrated significantly greater improvements with duloxetine compared to placebo (P≤0.021). Scores of 1 ('very much better') or 2 ('much better') were reported by a significantly greater percentage of patients in the duloxetine group (50.8%) compared to the placebo group (35.2%; P≤0.001). Patients receiving duloxetine demonstrated significantly greater improvements in the SDS global functional impairment score compared to patients receiving placebo (48.2 vs 37.7%, respectively; P=0.019). Improvements in the individual items addressing social life/leisure activities and family life/home responsibilities were greater with duloxetine compared to placebo (P≤0.05). The improvement in the item addressing school/work life was not significantly different between duloxetine and placebo (P=0.112). Treatment emergent adverse events with duloxetine were nausea, somnolence, constipation, decreased appetite, and hyperhidrosis. Rates of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				discontinuation due to adverse events were greater for duloxetine than placebo (8.0 vs 3.4%, respectively; P=0.024).
Gaynor et al.[81] (2011) Duloxetine 60 mg QD vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with a current episode of MDD and at least moderate pain	N=527 8 weeks	Primary: Mean change in MADRS total score and BPI average pain rating Secondary: Remission, PGI-I, SDS global functional impairment score	Primary: Treatment with duloxetine resulted in a significantly greater improvement in MADRS total score compared to treatment with placebo (-14.96 vs -10.77, respectively; 48.3 vs 34.8% improvement from baseline, respectively; P<0.001). There was a significantly greater reduction in average pain rating from baseline to week eight with duloxetine compared to placebo (-1.66 vs -1.17, respectively; 27.7 vs 18.9% reduction in pain, respectively; P<0.001). Patients also had greater improvement in their average pain rating at weeks two, four, and eight with duloxetine compared to placebo (all P<0.01). Secondary: A significantly higher percentage of patients receiving duloxetine (37.3%) met the criteria for remission compared to patients receiving placebo (23.0%; P<0.001). Greater improvements were observed for the other pain severity ratings (worst pain; P<0.001, least pain; P=0.003, pain right now; P<0.001), as well as ratings of interference of pain with functioning (all P<0.05) with duloxetine vs placebo. The least squares mean PGI-I score demonstrated significantly greater improvements with duloxetine compared to placebo (P≤0.01). Scores of 1 (‘very much better’) or 2 (‘much better’) were reported by a significantly greater percentage of patients in the duloxetine group compared to the placebo group (53.3 vs 26.8%, respectively; P<0.001). Patients receiving duloxetine demonstrated significantly greater improvements in the SDS global functional impairment score compared to placebo (46.4 vs 31.8%, respectively; P<0.001).
Rosso et al.[82] (2012)	RCT, SB Patients ≥18 years	N=49 6 weeks	Primary: Change in HAM-D-17	Primary: There was no significant difference in HAM-D-17 total score among the treatment groups (P=0.793).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Duloxetine 120 mg/day vs bupropion ER 300 mg/day	of age with MDD who failed to respond to 2 consecutive antidepressant trials with SSRIs		Secondary: CGI-S, GAF	Secondary: There was no significant difference in CGI-S (P=0.653) or GAF (P=0.565) scores among the treatment groups. Compared to baseline, there was a significant improvement in HAM-D-17 and CGI-S total scores with duloxetine and bupropion ER compared to baseline (all P<0.001). The 6-item-HAM-D mean score decreased significantly by week two with duloxetine (from 11.84 to 6.04; P<0.001) and bupropion ER (from 12.05 to 5.52; P<0.001). There was no difference in the success rates (HAM-D response, HAM-D remission) between the treatment groups. Additional information obtained by the CGI-S success rate confirmed this finding.
Nierenberg et al.[83] (2007) Duloxetine 60 mg daily vs escitalopram 10 mg daily vs placebo	AC, DB, PC, RCT Patients ≥18 years of age with MDD	N=547 8 weeks	Primary: Percentage of patients achieving onset criteria at week two (defined as 20% decrease from baseline in HAM-D) Secondary: Not reported	Primary: No significant difference was observed in the probability of patients meeting onset criteria at week two between the duloxetine group and the escitalopram group (P=0.097). Duloxetine and escitalopram both showed significant improvement compared to placebo on primary efficacy analysis at week one and week eight (P≤0.05). Secondary: Not reported
Pigott et al.[84] (2007) <u>Acute Phase</u> Duloxetine 60 mg/day	DB, MC, PC, RCT Patients >18 years of age with MDD	N=684 <u>Acute Phase</u> 8 weeks <u>Extension Phase</u>	Primary: HAM-D_{17}, CGI-S, PGI-I, HAMA, remission rates Secondary: Not reported	Primary: After eight months of treatment, there were no significant differences in efficacy between duloxetine and escitalopram as assessed by mean changes from baseline in the HAM-D_{17} total score and the HAM-D_{17} Maier, anxiety/somatization, and retardation/ somatization subscales. The only HAM-D_{17} subscale with a significant drug difference was the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs escitalopram 10 mg/day vs placebo <u>Extension Phase</u> Duloxetine 60 to 120 mg/day vs escitalopram 10 to 20 mg/day		24 weeks		$HAM\text{-}D_{17}$ sleep subscale, which demonstrated that escitalopram was associated with a significantly greater improvement in insomnia than duloxetine at the eight-month study endpoint. There were no significant differences in efficacy among the treatment groups as assessed by the CGI-S and the PGI-I. After eight months of treatment, there were no significant differences between the treatment groups with regards to anxiety symptoms as measured by the HAMA total score and the HAMA subscales (psychic and somatic). There was no significant difference in remission at eight weeks (duloxetine 40%, escitalopram 33%; P=0.25) or at eight months (duloxetine 70%, escitalopram 75%; P=0.44). Secondary: Not reported
Detke et al.[85] (2004) Duloxetine 40 or 60 mg BID vs paroxetine 20 mg/day vs placebo After acute treatment, patients who had a ≥30% reduction in	DB, PC, RCT Outpatients ≥18 years of age with MDD	N=367 (acute phase) N=273 (continuation phase) 8 weeks of acute treatment plus a 6-month continuation phase	Primary: HAM-D-17 total scores Secondary: HAM-D-17 subscales, MADRS, HAMA, VAS for pain, CGI-S, PGI-I, SSI, SDS, safety	Primary: In the acute phase, patients treated with duloxetine had significantly greater improvement in HAM-D-17 total scores at week eight (P=0.001 and P<0.001) compared to patients treated with placebo. Paroxetine also demonstrated significant superiority over placebo at week eight (P<0.001). In the acute phase, estimated probabilities of response at week eight for patients receiving duloxetine 80 (70%) and 120 mg/day (77%) were significantly more efficacious to that of placebo (47%; P=0.005 and P<0.001). The estimated probability of response for paroxetine-treated patients was also significantly greater compared to placebo-treated patients (P<0.001). In the acute phase, estimated probabilities of remission for patients receiving duloxetine 80 and 120 mg/day, and paroxetine 20 mg/day were significantly more efficacious to patients receiving placebo at week eight. In the continuation phase, patients within each active treatment group demonstrated significant within-group improvement in HAM-D-17 total

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
baseline HAM-D-17 total score were allowed to continue on the same (blinded) treatment for a 6-month continuation phase.				score. In the continuation phase, a log-rank test demonstrated that duloxetine 80 mg/day, duloxetine 120 mg/day, and paroxetine each had a significantly longer time to loss of response compared to placebo (P=0.002, P=0.018, and P=0.002, respectively). Secondary: In the acute phase, duloxetine 80 mg/day, duloxetine 120 mg/day, and paroxetine showed significantly greater improvement on the HAM-D-17 anxiety/somatization, core factor, maier, and retardation subscales compared to placebo. Paroxetine-treated patients showed a significant improvement on the sleep subscale compared to patients receiving placebo. In the acute phase, patients receiving duloxetine 80 mg/day, duloxetine 120 mg/day, or paroxetine 20 mg/day has significantly greater improvements in MADRS (P≤0.001 vs placebo for all, P≤0.05 for duloxetine 120 vs 80 mg/day), HAMA (P≤0.01 for duloxetine 80 mg/day vs placebo, P≤0.001 for duloxetine 120 mg/day and paroxetine vs placebo), CGI-S (P≤0.001 for all comparisons), and PGI-I (P≤0.01 for duloxetine 80 mg/day vs placebo, P≤0.001 for duloxetine 120 mg/day and paroxetine vs placebo, P≤0.05 for duloxetine 80 mg/day vs paroxetine) scales compared to patients receiving placebo. In the acute phase, patients receiving duloxetine or paroxetine showed significantly greater improvement on both SSI 26- and 28-Item Averages compared to placebo-treated patients. Using mean change analysis, in the acute phase patients treated with duloxetine and paroxetine showed significantly greater improvement on the SDS work item, social life item, family life item, and total score compared to patients receiving placebo. In the continuation phase, patients within each active treatment group demonstrated significant within-group improvement in MADRS, HAMA, CGI-S, and PGI-I. Patients receiving placebo exhibited significant within-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				group improvement in HAMA and PGI-I. In the continuation phase, patients receiving duloxetine 120 mg/day showed marginally significant improvement from baseline on the SSI 28-Item Average (P=0.054), while improvement was significant for the Pain Item Average (P=0.034). There were no deaths during the acute treatment phase. One serious adverse event occurred in a patient receiving paroxetine, but was considered to be non-treatment related. The proportion of patients who discontinued the study due to adverse events did not differ significantly across treatment groups (4.2, 3.2, 3.5, and 3.2%; P=1.00). The only adverse event leading to discontinuation in more than one patient within any treatment group was headache (two patients receiving duloxetine 120 mg/day). Treatment-emergent adverse events experienced by ≥5% of patients receiving duloxetine 120 mg/day are constipation, dry mouth, increased sweating, somnolence, nausea, headache, and insomnia. Three patients died during the six-month continuation phase (one patient receiving duloxetine 120 mg/day and placebo died as a result of suicide, while one patient receiving duloxetine 80 mg/day died as a result of pulmonary edema). All three deaths were considered to be non-treatment related. Serious adverse events were reported by one placebo-treated patient, one duloxetine 80 mg/day-treated patient, and four duloxetine 120 mg/day-treated patients. The proportions of patients discontinuing treatment due to an adverse event were similar across groups.
Goldstein et al.[86] (2004) Duloxetine 20 to 40 mg BID vs paroxetine 20 mg daily	DB, PC, RCT Outpatients with depression	N=353 8 weeks	Primary: HAM-D Secondary: Adverse effects	Primary: Duloxetine 80 mg/day was more effective than placebo on mean HAM-D-17 total change by 3.62 points (95% CI, 1.38 to 5.86; P=0.002). Duloxetine 40 mg/day was also significantly more efficacious than placebo by 2.43 points (95% CI, 0.19 to 4.66; P=0.034), while paroxetine was not (1.51 points; 95% CI, -0.55 to 3.56; P=0.150). Duloxetine 80 mg/day was more efficacious than placebo for most other measures, including overall pain severity, and was more efficacious than paroxetine on the HAM-D-17 improvement (by 2.39 points; 95% CI, 0.14

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				to 4.65; P=0.037) and estimated probability of remission (57% for duloxetine 80 mg/day, 34% for paroxetine; P=0.022). Secondary: The only adverse event reported significantly more frequently for duloxetine 80 mg/day than for paroxetine was insomnia (19.8% for duloxetine 80 mg/day, 8.0% for paroxetine; P=0.031).
Perahia et al.[87] (2006) Duloxetine 40 mg BID vs duloxetine 60 mg BID vs paroxetine 20 mg daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with MDD	N=392 8 months	Primary: Mean change from baseline in HAM-D-17 Secondary: Discontinuation of study drug due to adverse drug events	Primary: Patients treated with duloxetine 80 and 120 mg/day had significantly greater improvement in HAM-D-17 total scores at week eight compared to placebo-treated patients (P=0.045 and P=0.014, respectively). Paroxetine was not significantly different from placebo (P=0.089) on mean change on the HAM-D-17. Secondary: The proportion of patients who discontinued the study due to adverse events did not differ significantly (P=0.836) across treatment groups; placebo (2.0%), duloxetine 80 mg/day (4.3%), duloxetine 120 mg/day (3.9%), and paroxetine 20 mg (4.1%).
Goldstein et al.[88](abstract) (2002) Duloxetine, titrated from 20 to 60 mg BID vs placebo	DB, MC, PC, RCT Patients 18 to 75 years of age with MDD	N=173 8 weeks	Primary: HAM-D-17 total score Secondary: MADRS, CGI-S, CGI-I, PGI-I, safety	Primary: Duloxetine was more efficacious to placebo in change in HAM-D-17 total score (P=0.009). Estimated probabilities of response and remission were 64 and 56%, respectively, with duloxetine compared to 52 and 30% with fluoxetine, and 48 and 32% with placebo. Duloxetine was numerically more efficacious to fluoxetine on the primary outcome. Secondary: Duloxetine was numerically more efficacious to fluoxetine on most

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs fluoxetine 20 mg/day				secondary outcomes. Duloxetine was well tolerated; 76% of patients achieved the maximum dose, and insomnia and asthenia were the only adverse events reported significantly more frequently compared to placebo (P<0.05).
Martinez et al.[89] (2012) Duloxetine 30 to 120 mg QD vs generic SSRIs (citalopram 20 to 40 mg/day, fluoxetine 20 to 80 mg/day, paroxetine 20 to 50 mg/day, or sertraline 50 to 200 mg/day at the investigator's discretion)	AC, MC, RCT Adult outpatients with severe MDD	N=750 12 weeks	Primary: Remission at week 12 as measured by QIDS-SR Secondary: Response as measured by QIDS-SR, probability of response and remission as measured by HAM-D_{17}, BPI, SDS	Primary: Remission rates derived from the QIDS-SR at week 12 did not significantly differ between the duloxetine and SSRI treatment groups (36 vs 32%, respectively). The groups did not differ significantly with respect to changes in QIDS-SR scores across 12 weeks of therapy. Secondary: The QIDS-SR estimated probability of response did not differ significantly between duloxetine-treated and SSRI-treated patients (71 vs 64%; P=0.085). On the HAM-D_{17}, patients treated with duloxetine had significantly greater probabilities of response compared to patients treated with SSRIs (73 vs 61%; P=0.001) and remission (53 vs 44%; P=0.034). The NNT for one additional case of remission was 25 for the QIDS-SR, and was 12 for the HAM-D_{17}. The NNT for one additional case of response was 15 for the QIDS-SR, and was 9 for the HAM-D_{17}. Patients treated with duloxetine demonstrated significantly greater mean changes on the HAM-D_{17} total score and HAM-D subscales (anxiety/ somatization, Bech, Maier, and retardation). Improvement in associated painful symptoms was significantly greater with duloxetine compared to SSRIs as measured by the mean change in the BPI 24-hour average pain score in both the pain-enriched cohort of patients (P=0.034) and in the entire study population (P=0.030). Patients receiving duloxetine demonstrated significantly greater improvements on the SDS global functional score (P=0.002), and on each of the individual items that measure work/school (P=0.013), family functioning (P=0.015), and social functioning (P=0.005) compared to SSRIs. Dry mouth and constipation occurred at a significantly greater rate in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				patients treated with duloxetine vs patients treated with SSRIs (P=0.023 and 0.003, respectively). There was no significant difference between duloxetine and the SSRI group in the occurrence of any of the other most commonly reported treatment emergent adverse events.
Mancini et al.[90] (2012) Duloxetine vs placebo	MA (6DB, PC, PG, RCT) Patients with MDD	N=2,496 Short-term (7 to 13 weeks) and the long-term (>24 weeks) endpoint	Primary: SDS total score Secondary: Functional remission (SDS total< 6) rates, VAS	Primary: The between-treatment difference of -2.52 between duloxetine and placebo in the SDS total score at the short-term endpoint was statistically significant in favor of duloxetine vs placebo (95% CI, -3.17, -1.87; P<0.001). Secondary: The endpoint functional remission rates were 39.5% with duloxetine and 28.7% with placebo. Time since first depression episode, antidepressant pretreatment (yes/no), baseline VAS pain (<30/>30 mm), and sex were significant prognostic factors. The effect of duloxetine was maintained at the long-term endpoint.
Van Baardewijk et al.[91] (2005) Duloxetine 40 to 120 mg daily for at least 8 weeks vs venlafaxine ER 75 to 225 mg daily for at least 8 weeks	MA Adults with moderate to severe MDD and a score ≥15 on the HAM-D or ≥18 on the MADRS scale	N=not specified 6 months	Primary: Remission (an improvement in the HAM-D scale to a score <7, or a score ≤10 on the MADRS scale), symptom-free days Secondary: Not reported	Primary: Patients receiving duloxetine and venlafaxine ER experienced similar success rates after six months of treatment, 53 and 57%, respectively (P value not reported). Patients receiving duloxetine and venlafaxine ER experienced similar number of symptom-free days after six months of treatment, 52.72 and 57.03%, respectively (P value not reported). Duloxetine therapy was associated with a greater hospitalization rate compared to venlafaxine ER therapy, 47 and 43%, respectively (P value not reported). Secondary: Not reported
Vis et al.[92] (2005) Duloxetine 40 to 120 mg/day	MA (8 trials) Outpatients >18 years of age with MDD	N=1,754 (efficacy) N=1,791 (safety)	Primary: Remission and response (HAM-D, MADRS) Secondary:	Primary: Both treatment groups demonstrated a significant difference compared to placebo for both remission and response (P<0.001 for all). Secondary: More patients receiving placebo dropped out due to lack of efficacy

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs venlafaxine ER 75 to 225 mg/day vs placebo		8 weeks	Dropout rates and rates of adverse events	compared to patients in the treatment arms (P<0.001 for both drugs). Dropout rates due to adverse reactions were also significant when active drugs were compared to placebo (P value not reported). More patients in the treatment groups than in the placebo groups dropped out due to adverse reactions (venlafaxine ER; P<0.001 and duloxetine; P=0.008).
Perahia et al.[93] (2008) Duloxetine 60 to 120 mg/day vs venlafaxine ER 75 to 225 mg/day	DB, MC, RCT (pooled analysis of 2 trials) Patients >18 years of age with MDD	N=667 12 weeks	Primary: GBR (remission at endpoint using HAM-D-17 ≤7) Secondary: Efficacy	Primary: There were no significant differences in GBR with duloxetine and venlafaxine ER at the end of six weeks of therapy (-1.418 vs -1.079; P=0.217) or 12 weeks (-0.349 vs -0.121; P=0.440). Secondary: Mean changes from baseline to endpoint in the HAM-D-17 total scores were not different between the duloxetine and venlafaxine ER treatment groups. Comparisons of mean change from baseline to endpoint on secondary efficacy measures (HAM-D-17 item 1, HAM-D-17 subscales [core, Maier, anxiety/somatization, retardation and sleep], HAMA total score, CGI-S, and PGI-I) were not significantly different between the treatment groups. Response and remission rates were not significantly different between duloxetine and venlafaxine ER at six weeks (response rate for duloxetine, 51.6%; venlafaxine, 54.5%; remission rate for duloxetine, 31.4%; venlafaxine, 35.2%) or 12 weeks (response rate for duloxetine, 62.6%; venlafaxine, 69.1%; remission rate for duloxetine, 48.1%; venlafaxine, 50.3%). Estimates of remission rates at two, four, eight and 12 weeks were 11.1, 36.6, 53.0, and 71.0% for the duloxetine-treated group and 10.4, 32.1, 51.7, and 67.4% for the venlafaxine-treated group, respectively (P=0.309).
Rush et al.[94] CO-MED (2011)	MC, PC, RCT, SB Patients 18 to 75 years of age with	N=665 7 months	Primary: Symptom remission (QIDS-SR), attrition,	Primary: At 12 weeks, the remission rates were 38.8% for escitalopram plus placebo, 38.9% for bupropion SR plus escitalopram, and 37.7% for venlafaxine ER plus mirtazapine. The response rates were 51.6 to 52.4%.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Escitalopram 10 to 20 mg/day and placebo vs bupropion SR 300 to 400 mg/day and escitalopram 10 to 20 mg/day vs venlafaxine XR 150 to 300 mg/day and mirtazapine 15 to 45 mg/day	MDD		anxiety (IDS-C), functioning, QOL, adverse events Secondary: Not reported	The treatment groups did not differ in the percentage of change in QIDS-SR score or in effects on QOL. At seven months, the treatment groups were not different in terms of remission rate (range, 41.8 to 46.6%), response rate (range, 57.4 to 59.4%), or attrition rate. There was no difference in the percentage of change in QIDS-SR, QOL, or work and social adjustment. The venlafaxine ER plus mirtazapine group had greater side effect frequency and intensity at 12 weeks and greater side effect frequency, intensity, and burden at seven months as compared to escitalopram plus placebo. Secondary: Not reported
Kerber et al.[95] CO-MED (2012) Escitalopram 10 to 20 mg/day plus placebo vs bupropion SR 300 to 400 mg/day plus escitalopram 10 to 20 mg/day vs venlafaxine ER 150 to 300 mg/day plus mirtazapine	Subgroup analysis of CO-MED Patients 18 to 75 years of age with MDD, with and without heart disease	N=665 (6% [n=40] reported having and being treated for heart disease) 7 months	Primary: Symptom remission (QIDS-SR), attrition, anxiety (IDS-C), functioning, QOL, adverse events Secondary: Not reported	Primary: In general, patients with heart disease had fewer problems with treatment side effects at week 12 compared to patients without heart disease. At week 12, there were no significant differences between those with and without heart disease in terms of remission, response, QOL, or functional measures. This pattern was also seen with regard to measures at trial end (week 28). There were no significant differential treatment effects among those with and without heart disease in side effect burden and symptom severity at weeks 12 and 28. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
15 to 45 mg/day				
Morris et al.[96] CO-MED (2012) Escitalopram 10 to 20 mg/day plus placebo vs bupropion SR 300 to 400 mg/day plus escitalopram 10 to 20 mg/day vs venlafaxine ER 150 to 300 mg/day plus mirtazapine 15 to 45 mg/day	Subgroup analysis of CO-MED Patients 18 to 75 years of age with MDD, with and without general medical conditions	N=665 (49.5% reported having no treated general medical conditions, 23.8% reported having 1, 14.8% reported having 2, and 11.9% reported having ≥3) 7 months	Primary: Symptom remission (QIDS-SR), attrition, anxiety (IDS-C), functioning, QOL, adverse events Secondary: Not reported	Primary: No differences in outcomes between antidepressant monotherapy and either of the antidepressant combination therapies, regardless of the number of general medical conditions a patient had. Specifically, within each group having a given number of conditions, the three treatments did not differ significantly with respect to any of the measures of efficacy or tolerability assessed, either at week 12 or 28. Secondary: Not reported
Moore et al.[97] (2005) Escitalopram 20 mg daily vs citalopram 40 mg daily	DB, MC, RCT Outpatients with MDD having an MADRS score of ≥30 at baseline	N=280 8 weeks	Primary: Change from baseline in the MADRS total score, adverse events, response to treatment, remission rate Secondary; Not reported	Primary: Escitalopram group exhibited a greater improvement in the MADRS score compared to the citalopram arm (–22.4 vs –20.3; P<0.05). There were more treatment responders with escitalopram than with citalopram (76.1 vs 61.3%; P<0.01). Remission rate was higher among patients on escitalopram compared to the citalopram group (56.1 vs 43.6%; P<0.05). Tolerability was similar in both treatment groups. Secondary; Not reported
Colonna et al.[98]	DB, RCT	N=357	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2005) Escitalopram 10 mg daily vs citalopram 20 mg daily	Patients with moderate-to-severe MDD	24 weeks	Change from base-line in MADRS Secondary: Change from baseline in CGI-S	No significant difference was observed between groups in the MADRS at week 24. Secondary: Escitalopram patients had significantly better scores on the CGI-S at week 24 compared to citalopram patients.
Burke et al.[99] (2002) Escitalopram 10 mg daily vs escitalopram 20 mg daily vs citalopram 40 mg daily vs placebo	DB, MC, RCT Outpatients 18 to 65 years of age with MDD	N=491 8 weeks	Primary: Change from baseline in the MADRS total score at week eight Secondary: Change from baseline in the MADRS total score at weeks one, two, four, and six, change from baseline in the HAM-D, CGI-S, CGI-I, HAMA, QOL, and CES-D	Primary: Mean changes from baseline for the MADRS score were significantly greater compared to placebo in the two escitalopram groups (P<0.01) and in the citalopram group (P<0.05). There were no significant differences in the mean change of MADRS score from baseline to endpoint between the escitalopram 20 mg daily and citalopram 40 mg daily groups (P=0.09). Secondary: Patients randomized to the two escitalopram groups and the citalopram arm exhibited significantly greater improvement in the HAM-D score from baseline compared to placebo (P<0.01 and P<0.05, respectively). Response to treatment was observed in 50% of escitalopram 10 mg, 51.2% of escitalopram 20 mg, and 45.6% of citalopram 40 mg groups; the difference in response rate was significantly greater than that of placebo group (P<0.01) but not statistically different among the three active groups. There were no significant differences in the mean change of CGI-I, HAM-D, and CGI-S scores from baseline to endpoint between the escitalopram 20 mg daily and citalopram 40 mg daily groups (P=0.09). All three treatment groups exhibited significantly improved HAM-D depressed mood scores from baseline to endpoint (P<0.01). Patients randomized to the escitalopram 10 and 20 mg group exhibited

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				significantly greater improvement in the HAMA score from baseline compared to placebo (P=0.04 and P<0.01, respectively). Mean changes from baseline for the QOL score were significantly greater compared to placebo in the escitalopram 10 mg group (P=0.04) and in the escitalopram 20 mg group (P<0.01). Mean changes from baseline for the CES-D score were significantly greater compared to placebo in the escitalopram 10 mg group (P=0.02) and in the escitalopram 20 mg group (P<0.01). There was no statistically significant difference in the discontinuation rates due to adverse events between the escitalopram 10 mg and placebo groups; however, escitalopram 20 mg and citalopram 40 mg groups had significantly greater discontinuation rates compared to placebo (P<0.05). The rate of adverse effects was not significantly different between the escitalopram 10 mg group and placebo (79 vs 70.5%; P=0.14). Escitalopram 20 mg and citalopram 40 mg groups were associated with significantly greater adverse event rates compared to placebo (85.6 vs 86.4%; P<0.01).
Yevtushenko et al.[100] (2007) Escitalopram 10 mg/day vs citalopram 10 mg/day vs citalopram 20	AC, DB, MC, RCT Patients 25 to 45 years of age with MDD	N=330 6 weeks	Primary: MADRS total score Secondary: MADRS total score in severely depressed patients, MADRS core depression subscale score, CGI-S and CGI-I scores, proportions of patients classified as	Primary: The mean changes in MADRS total score were significantly greater in patients receiving escitalopram than citalopram 10 or 20 mg (-28.70 vs -20.11 and -25.19; both, P 0.001). The difference between the two citalopram groups was also significant (P<0.001). Secondary: In the severely depressed subpopulation, the differences in the mean change in MADRS score between the escitalopram group and the citalopram 10 and 20 mg groups were -9.46 and-3.99, respectively (both, P<0.001). The difference between the citalopram 20 and 10 mg groups was -5.47 (P<0.001). The differences in mean change in MADRS core depression subscale scores between the escitalopram group and citalopram 10 and 20 mg

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day			responders and remitters	groups were -6.00 and -2.48, respectively (both, P<0.001). The difference between the citalopram 20 and 10 mg groups was -3.52 (P<0.001) The mean changes in CGI-S score were -2.60, -1.61, and -2.05 in the escitalopram, citalopram 10 mg, and citalopram 20 mg groups, respectively (all, P<0.001 vs baseline). The differences in mean changes from baseline between the escitalopram and citalopram 10 and 20 mg groups were -0.99 and -0.55, respectively (both, P<0.001). The difference between the citalopram 20 and 10 mg groups was significant at end point (-0.44; P<0.001). Response rates were 95.4 vs 44.3 and 83.3% in the escitalopram vs citalopram 10 and 20 mg groups, respectively (both, P<0.001). Remission rates were 89.8 vs 25.5 and 50.9% in the escitalopram vs citalopram 10 and 20 mg groups, respectively (both, P<0.001).
Lam et al.[101] (2006) Escitalopram 10 to 20 mg daily vs citalopram 20 to 40 mg daily	MA Outpatients with MDD	N=1,321 (3 trials) 8 weeks	Primary: MADRS, response rate Secondary: CGI-I, CGI-S, HAM-D	Primary: No significant difference in response rate between the two treatment groups was seen at week eight. The analysis of pooled data demonstrated that the difference between citalopram and placebo was approximately constant; however, the difference between escitalopram and placebo (P=0.0010) and escitalopram and citalopram (P=0.0012) became greater the more severely depressed the patient was at baseline. Secondary: Similar results were seen in the secondary outcomes.
Gorman et al.[102] (2002) Escitalopram 10 to 20 mg daily vs citalopram 20 to	MA Outpatients with MDD	N=1,321 (3 trials) 8 weeks	Primary: MADRS, CGI-I Secondary; Not reported	Primary: Mean change in MADRS score from baseline at week eight was significantly improved in both treatment groups compared to baseline (P<0.05). Mean change in MADRS score from baseline at week eight was significantly improved in the escitalopram group compared to the citalopram group (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
40 mg daily				Mean change in CGI-I score from baseline at week eight was significantly improved in both treatment groups compared to baseline (P<0.05). No significant difference in CGI-I scores between the two treatment groups was reported at week eight (P>0.05).
Llorca et al.[103] (2005) Escitalopram 10 to 20 mg daily vs citalopram 20 to 40 mg daily vs placebo	MA Patient 18 to 80 years of age with depression	N=506 (3 trials) 8 weeks	Primary: MADRS Secondary: HAM-D, CGI-I, CGI-S	Primary: Mean change from baseline in MADRS total scores was significantly higher in the escitalopram-treated group compared to the citalopram-treated group (P=0.003). Response rates to escitalopram were 56% compared to 41% with citalopram (P=0.007). Secondary: The mean change in HAM-D from baseline between escitalopram and citalopram was in favor of escitalopram at endpoint (P=0.007). On both the CGI-I and CGI-S scales, patients showed a significant improvement at treatment endpoint in favor of escitalopram when compared to citalopram treatment (P=0.01 and P=0.001 for CGI-I and CGI-S, respectively).
Ou et al.[104] (2011) Escitalopram 10 to 20 mg/day vs citalopram 20 to 40 mg/day	DB, MC, RCT Patients 18 to 65 years of age with MDD	N=240 6 weeks	Primary: Change in HAM-D_{17} total score Secondary: Response and remission rates	Primary: At all time-points, there was no significant difference in HAM-D_{17} total score, score change, or rate change among the treatment groups (all P>0.05). At the end of the study, the mean rate change was 62.5% in the escitalopram group and 60.7% in the citalopram group (P=0.653). Secondary: Overall, response rates were 72.17% with escitalopram compared to 74.36% with citalopram (P=0.707). Remission rates were 60.87% with escitalopram compared to 56.41% with citalopram (P=0.982). For severe MDD patients, response rates were 72.50 vs 71.79% with escitalopram and citalopram, respectively (P=0.991). Remission rates were 57.50 and 46.15% with escitalopram and citalopram, respectively (P=0.350).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference in adverse events with escitalopram and citalopram (28.7 vs 29.9%, respectively; P=0.8384). Nausea and other gastrointestinal reactions (including stomach discomfort, burning sensation) were the most frequently reported adverse events. No serious adverse events were observed.
Wade et al.[105] (2007) Escitalopram 20 mg/day vs duloxetine 60 mg/day	DB, RCT Patients 18 to 65 years of age with MDD	N=294 24 weeks	Primary: Mean change in MADRS total score from baseline to week 24 Secondary: MADRS total score, HAM-D_{17}, CGI‑I, CGI‑S, HAMA scores	Primary: The mean change from baseline in MADRS total scores was –23.4 for escitalopram-treated patients and –21.7 for duloxetine treated patients (P=0.055). Secondary: At week eight, the mean change from baseline in MADRS total scores was –19.5 for escitalopram-treated patients and –17.4 for duloxetine-treated patients (P<0.05). There was no significant difference in the mean change from baseline in HAM-D_{17} (7.13 vs 8.47; P=0.096), HAMA (7.73 vs 8.62; P=0.267), CGI-I (1.76 vs 1.99; P=0.077), CGI-S (2.11 vs 2.28; P=0.214) at 24 weeks between escitalopram-treated patients and duloxetine-treated patients.
Khan et al.[106] (2007) Escitalopram 10 to 20 mg daily vs duloxetine 60 mg daily	DB, MC, PG, RCT Patients with MDD	N=278 8 weeks	Primary: Change from base-line to week eight in MADRS scores using the LOCF Secondary: Not reported	Primary: At week eight, a significantly greater decrease in MADRS scores (LOCF) was observed in the escitalopram group compared to the duloxetine group (P<0.05). No significant differences in MADRS scores were observed between groups in the observed case analysis (P=0.79). Secondary: Not reported
Boulenger et al.[107] (2006) Escitalopram 20 mg daily vs	DB, MC, RCT Patients with MDD	N=459 24 weeks	Primary: Change in MADRS score, withdrawal Secondary: HAMA, CGI-S, remitters	Primary: The difference in MADRS scores at 24 weeks compared to baseline was -25.2 for the escitalopram treated patients compared to -23.1 for the paroxetine-treated patients (P=0.0105). Significantly more patients withdrew from the study in the paroxetine group (32%) compared to the escitalopram group (19%; P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
paroxetine 40 mg daily				Secondary: The difference in HAMA scores at 24 weeks compared to baseline was –15.1 for the escitalopram-treated patients compared to –13.2 for the paroxetine-treated patients (P=0.01). The difference in CGI-S scores at 24 weeks compared to baseline was –2.8 for the escitalopram-treated patients compared to –2.6 for the paroxetine-treated patients (P=0.05). After 24 weeks of treatment the proportion of remitters was 75% in the escitalopram group compared to 66.8% in the paroxetine group (P<0.05).
Montgomery et al.[108] (2004) Escitalopram 10 to 20 mg daily vs venlafaxine ER 75 to 150 mg daily	DB, RCT Patients with MDD	N=293 8 weeks	Primary: Change from baseline in MADRS scores Secondary: Not reported	Primary: No significant difference between groups was observed at week eight in MADRS scores. Escitalopram-treated patients achieved remission significantly faster compared to venlafaxine patients in a post-hoc analysis. Secondary: Not reported
Fedgchin et al.[109] (2019) TRANSFORM-1 Esketamine nasal spray 56 mg or 84 mg twice weekly vs placebo	AC, DB, MC, RCT Patients 18 to 64 years of age with recurrent MDD or single-episode MDD (≥2 years), without psychotic features	N=346 4 weeks	Primary: Change from baseline (day 1) to day 28 in MADRS total score Secondary: Onset of clinical response by day 2 (24 hours) that was maintained until day 28, change from baseline in SDS and PHQ-9 total score at day	Primary: Statistical significance was not achieved with esketamine 84 mg compared with placebo (LS means difference [95% CI]: -3.2 [-6.88 to 0.45]; 2-sided P value=0.088). Although esketamine 56 mg could not be formally tested, the LS means difference was -4.1 [-7.67 to -0.49] (2-sided P value=0.027). Secondary: Results of onset of clinical response by day 2, SDS total score, and PHQ-9 total score numerically favored both the esketamine treatment groups over placebo group. The onset of clinical response by day 2 maintained to day 28 was achieved by 12 subjects (10.4%), 10 subjects (8.8%) and 2 subjects (1.8%) in the esketamine 56 mg, esketamine 84 mg and placebo group, respectively. The difference in response rates in the esketamine 56 mg group compared

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			28, proportion or responders and remitters	to placebo was 8.90 (OR=6.47; 95% CI, 1.38 to 60.45) and in the esketamine 84 mg compared to placebo was 6.76 (OR=5.34; 95% CI, 1.09 to 50.91). The difference of LS means for the change in baseline in SDS in the esketamine 56 mg group compared to placebo was -2.5 (95% CI, -5.25 to 0.20) and in the esketamine 84 mg group was -2.2 (95% CI, -4.91 to 0.53). The difference of LS means for the change in baseline in PHQ-9 total in the esketamine 56 mg group compared to placebo was -2.3 (95% CI, -4.34 to -0.31) and in the esketamine 84 mg group was -2.2 (95% CI, -4.26 to -2.0). The proportion of patients who were responders and the proportion in remission at any given timepoint generally increased over the double-blind phase in all 3 treatment groups; at day 28, a total of 54.1%, 53.1%, and 38.9% of patients in the esketamine 56 mg, esketamine 84 mg, and placebo groups, respectively, were responders, and 36.0%, 38.8%, and 30.6%, respectively, were in remission.
Popova et al.[110] (2019) TRANSFORM-2 Esketamine nasal spray 56 mg or 84 mg twice weekly plus a new oral antidepressant once daily vs placebo nasal spray twice weekly plus a new oral antidepressant once daily	DB, flexible-dose, MC, PC, RCT Patients 18 to 64 years of age with a diagnosis of single-episode (≥2 years) or recurrent MDD without psychotic features, a total score ≥34 on IDS-C30 (moderate-to-severe), non-response to ≥2 AD in the current episode of depression (treatment resistant)	N=223 4 weeks	Primary: Mean change in MADRS total score from baseline to day 28 Secondary: Proportion of responders (≥50% reduction from baseline in MADRS total score) at day 28, proportion of patients in remission (MADRS total score ≤12) at day 28, change in SDS	Primary: Patients treated with esketamine nasal spray plus an oral antidepressant demonstrated greater improvements from baseline to endpoint in mean MADRS total score compared to those treated with placebo plus an oral antidepressant (-19.8 vs -15.8; LSMD, -4.0; 95% CI, -7.31 to -0.64; P=0.020). Secondary: At the study endpoint, 69.3% of patients treated with esketamine achieved clinical response compared to 52.0% of patients treated with placebo. In addition, 52.5% of patients treated with esketamine achieved clinical remission compared to 31.0% of patients treated with placebo. The percentage of patients who experienced sustained clinical response (from day two to 28) was 7.9% in those treated with esketamine, compared to 4.6% in the placebo group. The between-group difference was not statistically significant (P=0.321); therefore, endpoints related to SDS (-12.3 vs -8.4; LSMD, -4.0; 95% CI, -6.28 to -1.64), PHQ-9 (-11.8 vs -9.4; LSMD, -2.4; 95% CI, -4.18 to -0.69), and CGI-S (-2 vs -2; OR, 2.8;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			total score from baseline to day 28, change in PHQ-9 total score from baseline to day 28, CGI-S	95% CI, 1.14 to 7.68) could not be formally evaluated.
Daly et al.[111] (2019) SUSTAIN-1 Esketamine nasal spray 56 mg or 84 mg twice weekly plus a new oral antidepressant once daily vs placebo nasal spray twice weekly plus a new oral antidepressant once daily	DB, flexible-dose, MC, RCT, WD Patients 18 to 64 years of age with a diagnosis of single-episode (≥ 2 years) or recurrent MDD without psychotic features, a total score ≥34 on IDS-C30 (moderate-to-severe), non-response to ≥2 AD in the current episode of depression	N=297 16 weeks	Primary: Mean time to relapse in stable remitters (defined as MADRS total score ≥22 for two consecutive assessments separated by five to 15 days, hospitalization for worsening depression, suicide attempt, suicide prevention or completed suicide, or any other clinically relevant event suggestive of relapse) Secondary: Time to relapse in patients with a stable response, change from baseline to the maintenance phase endpoint for PHQ-9, SDS, and CGI-S	Primary: Among stable remitters, 26.7% of patients treated with esketamine plus an oral antidepressant experienced a relapse event compared to 45.3% of patients treated with placebo. Secondary: Treatment with esketamine significantly delayed time to relapse by 51% among patients achieving stable remission compared to placebo (HR, 0.49; 95% CI, 0.29 to 0.84; P=0.003). Among stable responders, 25.8% of patients treated with esketamine plus an oral antidepressant experienced a relapse event, compared to 57.6% of patients treated with placebo. Treatment with esketamine significantly delayed relapse by 70% compared to placebo (HR, 0.30; 95% CI, 0.16 to 0.55; P<0.001). Median time to relapse was 635 days for those treated with esketamine, compared to 88 days for those treated with placebo.
Davey et al.[112]	DB, MC, PC, PG,	N=153	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2019) YoDA-C study Fluoxetine 20 to 40 mg QD* vs placebo* *Given in combination with cognitive behavioral therapy	RCT Patients 15 to 25 years of age with moderate-to severe MDD and scored ≥20 on MADRS	12 weeks	Change in MADRS score at 12 weeks Secondary: QIDS, GAD-7, Suicidal Ideation Questionnaire, Social and Occupational Functioning Assessment Scale and Quality of Life Enjoyment and Satisfaction Questionnaire–Short-Form	After 12 weeks of treatment both groups showed a reduction in MADRS scores (-13.7; 95% CI, -16.0 to -11.4, in the placebo group and -15.1; 95% CI, -17.4 to -12.9, in the fluoxetine group). There was no significant between-group difference in change in MADRS score at 12 weeks. (mean difference: -1.4; 95% CI, -4.7 to 1.8; P=0.39). Secondary: There was no significant between-group difference for changes in self-reported depressive symptoms, measured with the QIDS (-1.0; 95% CI, -2.7 to 0.7; P=0·26). There was evidence of a greater reduction in anxiety symptoms, as measured by the GAD-7, in the fluoxetine group compared with the placebo group (-2.1; 95% CI, -3.9 to -0.3; P=0.02). During the 12 weeks of the trial, there were five suicide attempts in the placebo group and one in the fluoxetine group. There were no significant differences observed between the groups on the Suicidal Ideation Questionnaire. Changes in functioning, as measured using the Social and Occupational Functioning Assessment Scale, and quality of life, as measured using Quality of Life Enjoyment and Satisfaction Questionnaire–Short-Form, did not differ between the groups after 12 weeks of treatment for individuals <18 years of age; however there was evidence of greater improvement in the fluoxetine group compared to the placebo group for individuals >18 years of age.
Fava et al.[113] (2002) Fluoxetine 20 mg daily vs sertraline 50 mg daily	DB, MC, RCT Patients ≥18 years of age with depression	N=284 10 to 16 weeks	Primary: HAM-D_{17} scores Secondary: Improvement in insomnia/sleep disturbances	Primary: As indicated by baseline-to-endpoint improvement on the HAM-D_{17}, there were no statistically significant differences between fluoxetine, sertraline, and paroxetine on all outcome measures (P=0.365). Secondary: Insomnia improvement when using the sleep disturbance factor was similar in all patients with no significant difference between groups (P=0.868).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs paroxetine 20 mg daily				
Thase et al.[114] (2002) Imipramine (mean dosage, 221 mg/day) vs sertraline (mean dosage, 163 mg/day)	DB, SC Patients with chronic major depression who failed to respond to 12 weeks of treatment with either imipramine or sertraline	N=168 12 weeks	Primary: HAM-D, CGI Secondary; Not reported	Primary: The two groups were equal in response rates for completers, 63 and 55% for the sertraline and imipramine groups, respectively (P=0.16). However, in the ITT analysis there was a statistically better outcome for the sertraline group (P=0.03). Those patients going from sertraline to imipramine experienced significant increases in eight adverse events and significant reductions in three adverse events while those patients going from imipramine to sertraline experienced a significant reduction in seven adverse events and no increase in any adverse event. Secondary; Not reported
Le Noury et al.[115] (2015) Study 329 Imipramine (200 to 300 mg/day) vs paroxetine (20 to 40 mg/day) vs placebo	Reanalysis of DB, MC, PC, RCT Adolescents 12 to 18 years of age who met DSM-IV criteria for a current episode of major depression of at least eight weeks' duration	N=275 8 weeks	Primary: HAM-D Secondary: CGI, autonomous functioning checklist, adverse events	Primary: There was no statistical significance (considered at P<0.05) or clinical significance shown for any of the prespecified primary or secondary efficacy variables in either the observed case or last observation carried forward datasets. HAM-D scores decreased by 10.7 (95% CI, 9.1 to 12.3), 9.0 (95% CI, 7.4 to 10.5), and 9.1 (95% CI, 7.5 to 10.7) points (least squares mean) for the paroxetine, imipramine, and placebo groups, respectively. Secondary: There were clinically significant increases in harms, including suicidal ideation and behavior and other serious adverse events in the paroxetine group and cardiovascular problems in the imipramine group.
Le Noury et al.[116] (2016) Study 329	Reanalysis of DB, MC, PC, RCT	N=119 6-month	Primary: Percentage of patients who	Primary: Relapse was not a primary endpoint of the original trial, and cannot be analyzed in a way that would allow a definitive statement about rates of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Imipramine (200 to 300 mg/day) vs paroxetine (20 to 40 mg/day) vs placebo	Adolescents 12 to 18 years of age who met DSM-IV criteria for a current episode of major depression of at least eight weeks' duration	continuation phase of patients who had responded to treatment	relapsed Secondary: Safety	relapse compared to placebo. Of patients entering the continuation phase, 15 of 49 for paroxetine (31%), 12 of 39 for imipramine (31%) and 12 of 31 for placebo (39%) completed as responders. Across the study, 25 patients on paroxetine relapsed (41% of those showing an initial response), 15 on imipramine (26%), and 10 on placebo (21%). Secondary: In the continuation and taper phases combined there were 211 adverse events in the paroxetine group, 147 on imipramine and 100 on placebo. The taper phase had a higher proportion of severe adverse events per week of exposure than the acute phase, with the continuation phase having the fewest events.
Asnis et al.[117] (2013) Levomilnacipran 40 mg QD or levomilnacipran 80 mg QD or levomilnacipran 120 mg QD vs placebo	DB, MC, PC, RCT Patents 18 to 65 years of age, met the diagnostic criteria of MDD per the DSM-IV-TR, current ongoing depressive episode ≥8 weeks in duration, MADRS score ≥30 at baseline, MADRS-SR ≥26 at baseline	N=708 N=506 completed study 8 weeks	Primary: Mean reduction of MADRS score from baseline at week eight (reported as LSMD from placebo) Secondary: Mean reduction of SDS score from baseline at week eight, mean reduction on $HDRS_{17}$ from baseline at week eight, mean change from baseline of CGI-S total score at week eight and mean reduction from baseline of CGI-I total score at week eight (all reported as LSMD	Primary: The LSMD from placebo of MADRS scores for levomilnacipran 40, 80 and 120 mg at week eight were -3.23; P=0.0186, -3.99; P=0.0038 and -4.86; P=0.0005, respectively. Secondary: The LSMD from placebo on the SDS total score for levomilnacipran 40, 80 and 120 mg was -1.4; P>0.05, -2.51; P<0.05, -2.57; P<0.05, respectively. The LSMD from placebo on the $HDRS_{17}$ for levomilnacipran 40, 80 and 120 mg was -1.2; P>0.05; -2.09; P<0.05 and -2.34; P<0.05, respectively. The LSMD from placebo on the CGI-S for levomilnacipran 40, 80 and 120 mg was -.04; P>0.05, -0.43; P<0.01 and -0.35; P<0.05, respectively. The LSMD from placebo on the CGI-I score for levomilnacipran 40, 80 and 120 mg was -0.1; P>0.05, -0.34; P<0.05 and -0.32; P<0.05, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			from placebo)	
Bakish et al.[118] (2013) Levomilnacipran 40 mg QD or levomilnacipran 80 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 75 years of age, met diagnostic criteria per the DSM-IV-TR for recurrent MDD, current ongoing depressive episode 6 weeks to 12 months in duration, 5 or fewer major depressive episodes within the previous 5 years, MADRS score ≥26 at baseline, CGI-S score ≥4 at baseline	N=557 N=441 completed study 8 weeks	Primary: Mean reduction of MADRS score from baseline at week eight (reported as LSMD from placebo) Secondary: Mean reduction of SDS score from baseline at week eight, mean reduction on $HDRS_{17}$ from baseline at week eight and mean reduction from baseline of CGI-S total score at week eight (all reported as LSMD from placebo)	Primary: The LSMD from placebo week eight for levomilnacipran 40 and 80 mg was -3.3; P=0.003 and -3.1; P=0.004, respectively. Secondary: The LSMD from placebo at week eight for levomilnacipran 40 and 80 mg was -1.8; P=0.046 and - 2.7; P=0.003, respectively. The LSMD from placebo on $HDRS_{17}$ scores for levomilnacipran 40 and 80 mg were -2.2; P=0.007 and -1.6; P=0.043. The LSMD from placebo on CGI-S scores for levomilnacipran 40 and 80 mg was -0.3 for both arms with P=0.020 and P=0.015, respectively.
Sambunaris et al.[119] (2013) Levomilnacipran 40 to 120 mg vs placebo	DB, FD, MC, PC, RCT Patients 18 to 80 years of age, met the diagnostic criteria for MDD per the DSM-IV-TR, ongoing major depressive episode of at least 4 weeks in duration, MADRS score ≥30	N=429 N=335 completed study 8 weeks	Primary: Mean reduction of MADRS score from baseline at week eight (reported as LSMD from placebo Secondary: Mean reduction of SDS score from baseline at week eight, mean	Primary: The LSMD from placebo on the MADRS score at week eight was -3.095; P=0.0051 for levomilnacipran 40 to 120 mg. Secondary: The LSMD from placebo on the SDS at week eight was -2.632; P=0.0010 for levomilnacipran 40 to 120 mg. The LSMD from placebo on the $HDRS_{17}$ score for levomilnacipran 40 to 120 mg was -2.146; P=0.0038. Levomilnacipran 40 to 120 mg did not show statistically significant results for the LSMD from placebo on the CGI-I total score at week eight (-0.207; P=0.0881). Levomilnacipran 40 to 120 mg showed a LSMD from placebo on the CGI-S at week eight of -0.352; P=0.0083. The LSMD from placebo on the MEI-SF for levomilnacipran 40 to 120 mg at week eight was 5.048;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	at baseline and MADRS-SR ≥26 at baseline		reduction on $HDRS_{17}$ from baseline at week eight, mean change from baseline of CGI-I total score at week eight, mean reduction from baseline of CGI-S total score at week eight and mean change from baseline on MEI-SF total score at week eight (all reported as LSMD from placebo)	P=0.0382.
Montgomery et al.[120] (2013) Levomilnacipran 75 or 100 mg QD Levomilnacipran dose was increased to 100 mg/day over 12 days. vs placebo	DB, FD, MC, PC, RCT Outpatients 18 to 70 years of age who met DSM-IV criteria for MDD (duration > 1 month) with a HDRS17 score > 22 and SDS score > 10	N=553 10 weeks	Primary: MADRS score change from baseline to week 10 Secondary: HDRS17, SDS, CGI-I, MADRS response (>50% decrease from baseline) and remission (score <10), safety	Primary: Levomilnacipran was significantly "superior" to placebo on MADRS total score change from baseline to week 10 (LSMD, -4.2; 95% CI, -5.7 to -2.6; P<.0001). Secondary: Statistical significance in favor of levomilnacipran was demonstrated on change from baseline to week 10 in HDRS17 total score (LSMD, -3.4; 95% CI, -4.7 to -2.2; P<0.0001) and SDS total score (LSMD, -3.4; 95% CI, -4.6 to -2.2; P<0.0001) and subscales. Significantly more levomilnacipran patients vs placebo patients achieved MADRS response (59.1 vs 42.2%; P<0.0001) and remission (46.4 vs 26.0%; P<0.0001). Levomilnacipran was generally safe and well tolerated; more levomilnacipran patients (9.4%) vs placebo patients (6.5%) discontinued due to adverse events, but more placebo patients vs levomilnacipran patients discontinued overall (24.9 vs 20.2%).
Montgomery et al.[121] (2015)	MA (5 studies) Patients 18 to 80 years of age with	N=2598 8 or 10 weeks	Primary: MADRS total score, treatment response (≥50%	Primary: Significantly greater improvements from baseline in MADRS total score were seen with levomilnacipran ER compared with placebo in four of five studies. The LSMDs between levomilnacipran ER and placebo were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Levomilnacipran ER 40 to 120 mg/day vs placebo	MDD		improvement in MADRS), remission (MADRS score ≤10) Secondary: Not reported	statistically significant in two fixed-dose studies (range, –3.1 to –4.9; P<0.05) and two flexible-dose studies (range, –3.1 to –4.2; P<0.05). In one flexible-dose study, the LSMD from placebo did not reach statistical significance (–1.5; P=0.25). The percentage of patients meeting the MADRS criterion for treatment response was higher with levomilnacipran ER than with placebo. In the overall population, the difference between levomilnacipran ER and placebo response rates was 10.2% (P<0.001). The difference between levomilnacipran ER and placebo in remission rates was 6.2% (P<0.05) in the overall population. Secondary: Not reported
Kornstein et al.[122] (2016) Levomilnacipran ER (40 to 120 mg/ day) vs placebo	Post-hoc analysis of 5 DB, MC, PC, RCTs Patients ≥18 years of age, with a DSM-IV diagnosis of MDD who were in a current major depressive episode; three subgroups were identified, (1) first-episode MDD, defined as all patients (treatment-naïve and previously treated) who entered the study during their first major depressive episode; (2) highly recurrent MDD, defined as all	N=2,598 8 or 10 weeks	Primary: MADRS, HAM-D, SDS scores Secondary: Not reported	Primary: LSMDs between groups indicated significantly greater improvements with levomilnacipran ER versus placebo in MADRS (first-episode, -2.5; highly recurrent, -3.0; chronic, -4.9; all P<0.05) and HAM-D (first-episode, -2.1; highly recurrent, -1.6; chronic, -2.6; all P<0.05) total scores. LSMDs for SDS total score were statistically significant in the first-episode and highly recurrent MDD subgroups (both subgroups, -2.3; P<0.01). MADRS response rate was significantly higher with levomilnacipran ER versus placebo in all three subgroups (first-episode, 44.5% versus 35.0%; highly recurrent, 44.3% versus 33.5%; 36.8% versus 22.0%; all P<0.05). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	patients with ≥3 lifetime depressive episodes; and (3) chronic MDD, defined as all patients with a current episode duration ≥2 years			
Kessler et al.[123] (2018) MIR study Mirtazapine 15 to 30 mg/day vs placebo Given in combination with SSRI or SNRI	MC, PC, PG, RCT Patients 18 years of age or more, had used an SSRI or SNRI antidepressant at an adequate dose for at least six weeks, were adherent to treatment, had a BDI II score of 14 or more and fulfilled the ICD-10 criteria for depression	N=480 Up to 50 weeks	Primary: BDI II score at 12 weeks Secondary: Response, remission, measure of depression using PHQ-9, anxiety symptoms, social and physical functioning, adherence and adverse events	Primary: At 12 weeks, the mean BDI II score in those randomized to the usual care and mirtazapine group was 18.0 (SD=12.3) compared with 19.7 (12.4) in those randomized to usual care and placebo. A small difference in favor of the mirtazapine arm was found after adjustment for baseline BDI II score. There was not a statistically significant difference between the two groups in BDI II score at 12 weeks (adjusted difference in means -1.83, 95% CI, -3.92 to 0.27; P=0.09). Secondary: The adjusted OR (95% CI) between mirtazapine and placebo for response was 1.39 (0.94 to 2.07; P=0.10) and for remission was 1.29 (0.82 to 2.02; P=0.27). The adjusted difference in means (95% CI) between mirtazapine and placebo for GAD-7 was -0.98 (-1.93 to -0.03; P=0.04), PHQ-9 was -1.05 (-2.14 to 0.04; P=0.06), SF-12 (physical) was −1.09 (-2.75 to 0.57; P=0.20) and SF-12 (mental) was 3.91 (1.63 to 6.20; P=0.001). The between group differences in the secondary outcome scores at 12 weeks were in favor of the mirtazapine group. However, the differences were small, and in almost every case (apart from the GAD-7 and the mental health component of the SF-12) the CI for the difference included the null. Adherence to the trial drug was substantially lower in the mirtazapine group compared with placebo group with an adjusted OR (95% CI) of 0.55 (0.34 to 0.89; P=0.01). No between group difference was found for adverse effects using the antidepressant side effect checklist at 12 weeks.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Versiani et al.[124] (2005) Mirtazapine 15 to 60 mg daily vs fluoxetine 20 to 40 mg daily	DB, RCT Patients 18 to 65 years of age with MDD	N=297 8 weeks	Primary: Change from baseline in HAM-D_{17} score Secondary: MADRS, CGI	Primary: No statistically significant differences were noted between the two groups in change from baseline HAM-D_{17} score at any time point. Secondary: Mirtazapine treatment was associated with greater change in MADRS score at day 14 (–10.9 vs –8.5; P=0.006) and the proportion of patients with ≥50% decrease in MADRS score (21.4 vs 10.9%; P=0.031). On the CGI, the proportion of "much/very much improved" patients tended to be greater with mirtazapine (significant at day seven; 9.7 vs 3.4%, P=0.032). No significant between-group differences were observed for the majority of QOL measures. Mirtazapine produced significantly better improvements on "sleeping assessment 1" (14.9±5.2 vs 13.7±5.4; P=0.028) and "sleeping assessment 2" (P=0.013) than fluoxetine. Both agents were generally well tolerated but mirtazapine-treated patients experienced a mean weight gain of 0.8±2.7 kg compared to a mean decrease in weight of 0.4±2.1 kg for fluoxetine-treated patients (P<0.001).
Wheatley et al.[125] (1998) Mirtazapine 15 to 60 mg/day vs fluoxetine 20 to 40 mg/day	DB, MC, RCT Patients with MDD 18 to 75 years of age	N=123 6 weeks	Primary: HAM-D Secondary; Not reported	Primary: The mean HAM-D_{17} scores were not different at week six for the two groups; although at week three (the estimated treatment difference was -3.4 in favor of mirtazapine; 95% CI, –6.1 to –0.76; P=0.006) and week four (the estimated treatment difference was -3.8 in favor of mirtazapine: 95% CI, –6.61 to –1.02; P=0.009), statistical significance was reported for mirtazapine. No other assessment endpoints were statistically different between the two groups at week six.
Blier et al.[126] (2009) Mirtazapine 30 mg	DB, RCT Patients with MDD	N=61 8 weeks	Primary: MADRS, HAM-D_{17}, CGI	Primary: There was a greater improvement on the MADRS at day 28 with combination therapy (P=0.045) when compared to monotherapy (mirtazapine; P=0.046, paroxetine; P=0.02).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
at bedtime (may be increased to 45 mg after 4 weeks) vs paroxetine 20 mg in the morning (may be increased to 30 mg after 4 weeks) vs mirtazapine 30 mg/day plus paroxetine 20 mg/day for 6 weeks After 6 weeks, non-responders on monotherapy had the second trial drug added to their current regimen. Non-responders on combination therapy had the dosage of both drugs increased by 50%.			Secondary; Not reported	There was a greater improvement on the MADRS at days 35 (P=0.006) and 42 (P=0.002) with combination therapy compared to monotherapy (mirtazapine; P=0.003 and 0.001, respectively; paroxetine; P=0.011 and 0.003, respectively). Statistical significance was achieved on the HAM-D_{17} in the combination group at day 35 (P=0.02) when compared to mirtazapine (P=0.005), and at day 42 (P=0.007) when compared to both drugs alone (mirtazapine; P=0.002, paroxetine; P=0.04). Statistical significance was achieved on the CGI in the combination group at day 35 vs mirtazapine (P=0.004) and for both drugs at day 42 (mirtazapine; P=0.002, paroxetine; P=0.04). Four patients remitted by day 42 in the mirtazapine group (19%) and 5 in the paroxetine group (26%) compared to 9 patients remitted in the combination group (43%; P>0.05). At day 42, 10 patients in each of the monotherapy arms received the other drug in combination. The mean scores improved rapidly in both groups with seven and five patients achieving remission in the subsequent two weeks in the mirtazapine and paroxetine groups, respectively. Five patients on the combination had their regimens increased to 45 mg/day of mirtazapine and paroxetine 30 mg/day. Two of these patients achieved remission by day 56. Secondary; Not reported
Behke et al.[127] (2003) Mirtazapine orally	DB, RCT Patients with MDD	N=345 8 weeks	Primary: HAM-D Secondary:	Primary: Mirtazapine was significantly (P<0.05) more effective than sertraline at all assessments during the first two weeks of the study. After this time, HAM-D total scores were similar in both groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
disintegrating tablets 30 to 45 mg/day vs sertraline 50 to 150 mg/day			CSFQ	Secondary: The CSFQ revealed a greater improvement in sexual functioning with mirtazapine than with sertraline at all assessments in both females and males. The differences were not statistically significant.
Guelfi et al.[128] (2001) Mirtazapine 15 to 60 mg/day vs venlafaxine 75 to 375 mg/day	DB, MC, RCT Hospitalized patients with severe depressive episode with melancholic features	N=157 8 weeks	Primary: HAM-D, MADRS Secondary: Adverse effects	Primary: A significant difference favoring mirtazapine was found on the HAM-D Sleep Disturbance factor at all assessment points (P≤0.03). Secondary: A significantly higher percentage of patients treated with venlafaxine (15.3%) than mirtazapine (5.1%) dropped out because of adverse events (P=0.037).
Feighner et al.[129] (1998) Nefazodone 200 mg BID vs placebo	DB, PC, PG Patients that were hospitalized due to depression	N=120 6 weeks	Primary: HAM-D_{17}, CGI-I, MADRS Secondary: Not reported	Primary: Nefazodone treatment resulted in a significant reduction (P<0.01) of the HAM-D_{17} total score compared to placebo from the end of the first treatment week through the end of the study (–12.2 nefazodone vs –7.7 placebo). At the end of the trial, significantly more nefazodone-treated patients (50%) than placebo-treated patients (29%) had responded, as indicated by their CGI-I score (P=0.021) or by a ≥50% reduction in their HAM-D_{17} scores (P=0.017). Significantly more patients treated with nefazodone (36%) than placebo-treated patients (14%) had a HAM-D_{17} score ≤10 at the end of treatment (P=0.004). Significant treatment differences (P<0.01) in favor of nefazodone were also seen in the MADRS; the HAM-D retardation, anxiety, and sleep disturbance factors; and HAM-D item 1 (depressed mood). Patients with dysthymia in addition to major depression also showed significant improvement (P<0.05) when treated with nefazodone, with significant differences in response rates seen as early as week two and through the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				end of the trial. Secondary: Not reported
Dunner et al.[130] (2005) Paroxetine CR 12.5 to 62.5 mg vs placebo	DB, PC, RCT (Pooled analysis) Adults with MDD	N=303 (4 trials) 8 to 12 weeks	Primary: Changes in depressive symptoms according to HAM-D_{17} and CGI-I, patients achieving remission Secondary; Not reported	Primary: Statistically significant improvements in depressive symptoms in favor of paroxetine CR compared to placebo were observed in patients with both severe MDD (HAM-D treatment difference, –4.37; 95% CI, –6.31 to –2.42; P<0.001) and nonsevere MDD (HAM-D_{17} treatment difference, -1.89; 95% CI, –2.91 to –0.87; P<0.001). The odds of CGI-Improvement response were also significantly higher for patients receiving paroxetine CR than those receiving placebo, regardless of baseline depressive symptomatology (severe MDD: OR, 2.42; 95% CI, 1.50 to 3.91; P<0.001, nonsevere MDD: OR, 1.63; 95% CI, 1.21 to 2.19; P<0.002).
Birkenhager et al.[131] (2004) Phenelzine 10 mg BID vs tranylcypromine 10 mg BID	DB, RCT Patients 18 to 65 years of age with depression	N=77 5 weeks	Primary: HAM-D Secondary: Side effects	Primary: Seventeen patients (44%) responded to tranylcypromine and 18 patients (47%) responded to phenelzine (≥50% reduction in HAM-D; P=0.82). The mean reduction in HAM-D score was 10.4 for the tranylcypromine group vs 8.3 for the phenelzine group (P=0.23). No significant differences in response rates were demonstrated between the treatment groups (P=0.97). Secondary: A substantial number of patients experienced severe side effects, mainly dizziness, agitation, and insomnia. The incidence was the same in both samples (21%).
Hedayati et al.[132] (2017) CAST Sertraline 50 to 200 mg/day vs	DB, PC, RCT Patients with MDD and stage 3, 4, or 5 non-dialysis-dependent chronic kidney disease	N=201 12 weeks	Primary: Improvement in QIDS-C16 (score range, 0 to 27; minimal clinically important difference, 2 points)	Primary: The mean change from baseline to study exit in the QIDS-C16 score was −4.1 in the sertraline group and −4.2 in the placebo group (between-group difference, 0.1; 95% CI, −1.1 to 1.3; P=0.82). Secondary: There was no significant between-group difference in change in patient-reported overall health on the Kidney Disease Quality of Life Survey

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo			Secondary: Improvement in QOL; adverse events	(median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0; 95% CI, -10.0 to 0; P=0.61). Nausea or vomiting occurred more frequently in the sertraline vs placebo group (22.7 vs 10.4%, respectively; between-group difference, 12.3%; 95% CI, 1.9 to 22.6%; P=0.03), as well as diarrhea (13.4 vs 3.1%; between-group difference, 10.3%; 95% CI, 2.7 to 17.9%; P=0.02).
Lewis et al.[133] (2019) PANDA study Sertraline 50 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 74 years of age who had depressive symptoms of any severity or duration in the past 2 years, where there was clinical uncertainty about the benefit of an antidepressant	N=653 Up to 11 weeks	Primary: Depressive symptoms at 6 weeks, measured by PHQ-9 scores Secondary: Depressive symptoms and remission, generalized anxiety symptoms and mental and physical health related quality of life	Primary: Mean PHQ-9 scores at 6 weeks were 7.98 (SD=5.63) in patients allocated to sertraline and 8.76 (SD=5.86) in patients allocated to placebo. After adjustment for baseline scores and stratification variables, the adjusted proportional difference between sertraline and placebo was 0.95 (95% CI, 0.85 to 1.07; P=0.41). Secondary: The adjusted proportional difference in PHQ-9 scores across all timepoints was 0.93 (95% CI, 0.86 to 1.01, P=0.11). At 12 weeks, PHQ-9 scores were 13% lower (0.87; 95% CI, 0.79 to 0.97) in the sertraline group. At 6 weeks, GAD-7 scores were 21% lower (adjusted proportional difference=0.79; 95% CI, 0.70 to 0.89) in those allocated to sertraline than in those allocated to placebo. Mental health-related quality of life scores were higher (2.41; 95% CI, 1.14 to 3.96; P=0.00021) in the sertraline group than in the placebo group. There was no evidence observed of a difference in physical health-related quality of life.
Mowla et al.[134] (2016) Sertraline (range 50 to 200 mg/day) vs duloxetine (range 40 to 60 mg/day)	DB, RCT Patients diagnosed according to DSM-V criteria for MDD by a board-certified psychiatrist	N=63 6 weeks	Primary: HAM-D Secondary: Not reported	Primary: The HAM-D total scores for the both groups were reduced at the end of the trial period without any significant difference (P=0.463). The response rates in both groups were around 60%. Depressed mood, anhedonia, suicidality, insomnia (early, middle and late), work and activity and loss of appetite improved in both groups without significant difference. Psychomotor retardation, general somatic symptoms and sexual problems improved more in the duloxetine group. Agitation, anxiety symptoms and hypochondriasis ameliorated better in the sertraline group. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Rossini et al.[135] (2005) Sertraline 150 mg daily vs fluvoxamine 200 mg daily	DB, RCT Patients >59 years of age with MDD	N=88 7 weeks	Primary: Response rate (HAM-D) Secondary; Not reported	Primary: Response rates were 55.6% for sertraline and 71.8% for fluvoxamine. No significant difference in final response rates were observed between treatment groups (P=0.12). Secondary; Not reported
Sheehan et al.[136](2009) Trazodone ER 150 to 375 mg/day vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with MDD, current episode of MDD for a minimum of 1 month, dysphoria for most days over the previous 4 weeks, and a MADRS total score ≥26 at screening and baseline	N=412 8 weeks	Primary: Change from baseline in HAM-D-17 total score Secondary: HAM-D-17 responders, HAM-D-17 remitters, change in HAM-D-17 depressed mood item from baseline, change in MADRS total score from baseline, CGI-I responders, PGI-I responders, change in CGI-S from baseline, CGI-I at last study visit, PGI-I at last study visit, discontinuations due to lack of efficacy, and overall quality of	Primary: The change in the HAM-D-17 total score from baseline decreased by an average of 11.4±8.2 and 9.3±7.9 in the trazodone and placebo groups, which statistically favored treatment with trazodone (P=0.012). Results demonstrated a significantly greater improvement in the mean HAM-D-17 total score in the trazodone group compared to the placebo group by the first week of treatment (day seven of titration: 5.6±5.2 vs 3.9±4.8, respectively; P=0.005). The significantly greater differences were maintained throughout the study. Secondary: The number of HAM-D-17 responders (decrease ≥50% from baseline HAM-D-17 total score) in the trazodone group was significantly greater compared to the placebo group (54.0 vs 41.2%; P=0.003). No difference in the proportion of HAM-D-17 remitters (HAM-D-17 total score ≤7) was observed between treatment groups (35.6 vs 31.9%; P=0.22). The change in the HAM-D-17 depressed mood item from baseline decreased by average of 1.6±1.3 and 1.3±1.2 in the trazodone and placebo groups, which statistically favored treatment with trazodone (P=0.030). The change in MADRS total score from baseline also statistically favored treatment with trazodone (-16.6±11.3 vs -14.1±11.9; P=0.036).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			sleep	No difference in the proportion of CGI-I responders ("much improved" or "very much improved" at last study visit) was observed between treatment groups (53.3 vs 48.6%; P=0.22). No difference in the proportion of PGI-I responders ("much improved" or "very much improved" at last study visit) was observed between treatment groups (51.1 vs 43.7%; P=0.15). The change in the CGI-S from baseline decreased by 1.7±1.4 and 1.4±1.4 in the trazodone and placebo groups, which statistically favored treatment with trazodone (P=0.036). The CGI-I scores at the last study visit were comparable in both treatment groups (P=0.22). The PGI-I scores at the last study visit were comparable in both treatment groups (P=0.084). Four percent of patients in the trazodone group discontinued treatment due to lack of efficacy compared to 4.4% of patients in the placebo group (P>0.99). At the end of the study, patients treated with trazodone had statistically significant improvements compared to placebo in all quality of sleep parameters.
Lenox-Smith et al.[137] (2008) Venlafaxine ER 75 to 300 mg/day vs citalopram 20 to 60 mg/day	DB, MC, RCT Patients 18 to 65 years of age with MDD who had not experienced a treatment response to 8 weeks of monotherapy with an adequate regimen of an SSRI	N=406 12 weeks	Primary: HAM-D_{21} total score Secondary: MADRS, CGI-S, CGI-I	Primary: There was no significant difference between venlafaxine ER and citalopram on the HAM-D_{21} total score (-17.0 vs -16.5, respectively; P=0.4778). Secondary: There were no significant differences between venlafaxine ER and citalopram on the MADRS total scores (P=0.5002) or CGI-S (P=0.3014), or in the analyses of response (P=0.953). Significant differences between treatment groups were observed for one

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				subscale analysis: more venlafaxine ER patients had a CGI-I score of 1 at week 12 (P=0.024).
Bielski et al.[138] (2004) Venlafaxine ER 225 mg/day vs escitalopram 20 mg/day	DB, RCT Patients with MDD	N=195 8 weeks	Primary: MADRS Secondary: Adverse effects	Primary: There were no significant differences in efficacy, remission rates, or response rates between venlafaxine ER and escitalopram. Mean changes from baseline to endpoint in MADRS total score for escitalopram and venlafaxine ER were –15.9 and –13.6, respectively. Remission (MADRS score of ≤10) rates at endpoint were 41.2% for escitalopram and 36.7% for venlafaxine ER. Response (≥50% reduction from baseline MADRS score) rates for the escitalopram and venlafaxine ER groups were 58.8 and 48.0%, respectively. Secondary: More patients in venlafaxine ER group had treatment-emergent adverse effects compared to escitalopram (85.0 vs 68.4%) but this was not statistically significant and may have been due to rapid titration of the venlafaxine dose. Venlafaxine ER had a higher incidence of discontinuation due to adverse events (16.0 vs 4.1%; P<0.01).
Nemeroff et al.[139] (2007) Venlafaxine 75 to 225 mg/day vs fluoxetine 20 to 60 mg/day vs placebo	DB, MC, PC, RCT Outpatients ≥18 years of age with MDD	N=308 6 weeks	Primary: HAM-D Secondary: Not reported	Primary: On the HAM-D, overall differences among treatment groups at week six did not reach significance (P=0.051), though the difference between the venlafaxine and placebo groups was significant (P=0.016). The differences between fluoxetine and placebo (P=0.358) and between venlafaxine and fluoxetine (P=0.130) were not significant. The difference on the HAM-D depressed mood item was significant among treatment groups at week six (P<0.001); both active treatments were significantly more effective than placebo (venlafaxine; P<0.001, fluoxetine; P=0.024). The difference between the active treatments was not statistically significant (P=0.117). Secondary: Not reported
Rudolph et al.[140]	DB, MC, PC, PG,	N=301	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1999) Venlafaxine ER 75 to 225 mg/day vs fluoxetine 20 to 60 mg/day vs placebo	RCT Outpatients ≥18 years of age with MDD	8 weeks	HAM-D, MADRS, CGI Secondary: Not reported	The percentages of patients who achieved full remission of their depression (HAM-D total score ≤7) at the end of treatment were 37, 22, and 18% for the venlafaxine ER, fluoxetine and placebo groups, respectively. The differences in remission rates between venlafaxine ER and the other groups were significant (P<0.05). Venlafaxine ER produced a significant lower mean total score on the MADRS analysis than did fluoxetine (P=0.048). The P value for the statistical test of center by center interaction was not significant, indicating that treatment outcomes did not differ significantly between individual investigational sites. Secondary: Not reported
Benkert et al.[141] (1996) Venlafaxine 150 to 375 mg/day vs imipramine 200 mg/day	DB, PG, RCT Hospitalized patients with major depression and melancholia	N=167 6 weeks	Primary: HAM-D, MADRS Secondary: Not reported	Primary: No differences in the response rates on the HAM-D or MADRS were observed between treatments. Among patients who demonstrated a response on the HAM-D, there was a significantly faster onset of response (P=0.036) and sustained response (P=0.018) in the venlafaxine group. The median time to response on the HAM-D among responders was 14 days with venlafaxine and 21 days with imipramine. However, no differences between treatments were observed among responders on the MADRS. Secondary: Not reported
Kok et al.[142] (2007) Venlafaxine ER 75 to 375 mg/day vs	DB, RCT Inpatients ≥60 years of age with MDD	N=81 12 weeks	Primary: Remission (MADRS ≤10) Secondary: Remission on HAM-D and GDS, response rates	Primary: There was no significant difference in remission between the treatment groups as measured by a reduction in MADRS (venlafaxine, 27.5% vs nortriptyline, 36.6%; P=0.381). Secondary: There was no significant difference in remission rates between the treatment groups as measured by HAM-D and GDS (P=NS).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
nortriptyline 25 to 200 mg/day				There was no significant difference in response rates between the treatment groups as measured by MADRS, HAM-D, GDS, and CGI-I (P=NS).
Richard et al.[143] (2012) Venlafaxine ER, up to a maximum of 225 mg/day vs paroxetine, up to a maximum of 40 mg/day vs placebo	DB, PC, RCT Patients ≥30 years of age with idiopathic PD, without dementia, and depressive disorder or operationally defined subsyndromal depression	N=115 12 weeks	Primary: HAM-D-17 total score Secondary: MADRS, BDI-II, GDS, UPDRS, safety	Primary: Treatment effects relative to placebo, expressed as mean 12-week reduction in HAM-D-17 total score, were 6.2 points (97.5% CI, 2.2 to 10.3; P=0.0007) with paroxetine and 4.2 points (97.5% CI, 0.1 to 8.4; P=0.02) with venlafaxine ER. There was no difference noted between paroxetine and venlafaxine ER (P=0.28). Secondary: Significant beneficial effects of paroxetine and venlafaxine ER relative to placebo were apparent for the secondary outcomes (MADRS, BDI-II, and GDS; P≤0.01 for all comparisons). UPDRS total and motor scores improved in all three treatment groups, but there were no significant group differences in mean response. There was no evidence of treatment-associated worsening of motor function. One hundred patients reported at least one adverse event during the trial: 86, 85, and 90% with paroxetine, venlafaxine ER, and placebo. Insomnia was reported significantly less frequently with paroxetine compared to venlafaxine ER and placebo. There were three serious adverse events.
Mazeh et al.[144] (2007) Venlafaxine 75 to 300 mg/day vs paroxetine 10 to 60 mg/day	RCT, SB Inpatients ≥65 years of age with MDD who did not respond to two adequate pharmacological treatments for depression during the current depressive episode	N=30 6 weeks	Primary: CGI, HAM-D, GDS Secondary: Not reported	Primary: Nine patients treated with venlafaxine (60%) and five patients treated with paroxetine (33%) remitted after eight weeks of treatment. Three patients from each group responded without achieving remission after eight weeks of treatment (20%). Four patients treated with venlafaxine (26.7%) and eight patients treated with paroxetine (53.3%) failed to respond. Mean score changes from baseline to endpoint for paroxetine were: HAM-D=-12.5, CGI=-2.3, and GDS=-3.2. Mean score changes from baseline to endpoint for venlafaxine were: HAM-D=-19.1, CGI=-2.3, and GDS=-6.0

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				in the venlafaxine group. Venlafaxine was more effective than paroxetine on CGI and HAM-D measures (P<0.0003). Secondary: Not reported
DeSilva et al.[145] (2012) Venlafaxine vs an SSRI	MA Published, randomized, DB, head-to-head trials, which compared venlafaxine and an SSRI in the treatment of MDD in adults	N=26 trials Duration varied	Primary: Remission, response, discontinuation Secondary: Not reported	Primary: MA using a random effect model showed that venlafaxine was more efficacious compared to SSRIs in achieving remission (OR, =1.13; 95% CI, 1.0 to 1.28; P=0.05) and response (OR, 1.17; 95% CI, 1.03 to 1.34; P=0.02). Subgroup analysis found that venlafaxine had a significantly better response rate than fluoxetine (OR, 1.28; 95% CI, 1.05 to 1.55; P=0.01). There were no significant differences in response or remission between venlafaxine and other individual SSRIs. There was no significant difference in all cause discontinuation between venlafaxine and SSRIs (OR, 1.10; 95% CI, 0.97 to 1.25; P=0.15). Venlafaxine had significantly higher discontinuation due to adverse events compared to SSRIs (OR, 1.41; 95% CI, 1.10 to 1.79; P=0.006). Secondary: Not reported
Reed et al.[146] (2012) Vilazodone 40 mg QD vs placebo	2 DP, PC, RCT Patients with MDD	N=410 (RCT-1), 481 (RCT-2) 8 weeks	Primary: Change from baseline to end of treatment MADRS total score; mixed-effects repeated-measures analyses were conducted in the PC trials; effectiveness analyses in the	Primary: Vilazodone-treated patients in both short-term studies showed greater improvement from baseline to end of treatment in mean MADRS scores than placebo-treated patients (LSM treatment difference, -3.2; P=0.00 RCT-1 and -2.5; P=0.009 RCT-2). CGI-I mean scores at end of treatment reflected greater improvement with vilazodone compared to placebo in both studies (LSM treatment difference, -0.4; P=0.001 RCT-1 and -0.3; P=0.004 RCT-2). MADRS response rates were significantly greater among patients receiving vilazodone vs those receiving placebo (RCT-1, 40.4 vs 28.1%, respectively; P=0.007 and RCT-2, 43.7 vs 30.3%, respectively; P=0.002). The greater efficacy of vilazodone vs placebo was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			long-term study included mean MADRS score change over time Secondary; Not reported	consistent for the majority of demographic and MDD characteristic subgroups. In the long-term study, the mean MADRS score improved from 29.9 (baseline) to 11.4 (week eight), 8.2 (week 24), and 7.1 (week 52). Secondary; Not reported
Khan et al.[147] (2011) Vilazodone 40 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 70 years of age with MDD (single episode or recurrent)	N=481 8 weeks	Primary: Change in MADRS total score Secondary: MADRS and HDRS-17 response, HDRS-21, HARS, CGI-S, CGI-I scores, CSFQ	Primary: Patients receiving vilazodone showed significantly greater improvements in mean MADRS scores compared to placebo (LSM treatment difference, -2.5; P=0.009). Secondary: Treatment with vilazodone resulted in significant improvements for the HDRS-17 (P=0.026), HDRS-21 (P=0.029), HARS (P=0.037) and CGI-S (P=0.004) scores. CGI-I scores at week eight showed significantly greater global improvement with vilazodone compared to placebo (P=0.004). The MADRS response rate was significantly greater among patients receiving vilazodone compared to placebo (43.7 vs 30.3%, respectively; P=0.002), as was the HDRS-17 response rate (44.2 vs 32.9%; P=0.013). Remission rates for vilazodone were not significantly different than placebo based on MADRS (27.3 vs 20.3%, respectively; P=0.066) or HDRS-17 (24.2 vs 17.7%, respectively; P=0.088). More patients receiving vilazodone (82.1%) experienced a treatment-related adverse event compared to placebo (64.4%). The most frequently reported adverse events with vilazodone compared to placebo were diarrhea (30.6 vs 10.7%), nausea (26.0 vs 5.6%) and headache (12.8 vs 10.3%). Most adverse events were considered mild-to-moderate in nature. Treatment-related effects on sexual function as measured by CSFQ were small and similar among the treatment groups. Effects on weight were similar to placebo.
Rickels et al.[148] (2009)	DB, MC, PC, RCT Patients 18 to 65	N=410 8 weeks	Primary: Change in MADRS total	Primary: The mean change on the MADRS total score was significantly greater with vilazodone compared to placebo (-12.9 vs -9.6, respectively;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Vilazodone 40 mg QD vs placebo	years of age with MDD (single episode or recurrent)		score, HAM-D_{17} total score, and HAM-A total score, CGI-S and CGI-I scores Secondary: Response (≥50% decrease in total score on MADRS, and HAM-D_{17} total scores, or a score of 1 or 2 on the CGI-I)	P=0.001). The difference was evident by week one (P<0.001) and on each subsequent visit (P<0.05). The mean change on the HAM-D_{17} total score was significantly greater with vilazodone compared to placebo (-10.4 vs -8.6, respectively; P=0.022). The difference was evident by week one and on each subsequent visit (P<0.05). The mean score change on the CGI-S was significantly greater with vilazodone compared to placebo (-1.4 vs -1.0, respectively; P=0.001). The mean score change on the CGI-I was significantly improved with vilazodone compared to placebo (2.6 vs 3.0, respectively; P=0.001). The mean change on the HAM-A total score was significantly greater with vilazodone compared to placebo (-6.6 vs -5.1, respectively; P=0.045). Secondary: Response rates were significantly better with vilazodone than with placebo on the MADRS (P=0.007), HAM-D_{17} (P=0.011), and CGI-I (P=0.001). Treatment-emergent adverse events with vilazodone included diarrhea, nausea and somnolence. Most of the adverse events were mild-to-moderate in severity.
Croft et al.[149] (2014) Vilazodone 40 mg/day vs placebo	DB, MC, PC, RCT Patients 18 to 70 years of age with ongoing major depressive episode lasting eight or more weeks and up to 12 months, MADRS total score ≥26	N=505 8 weeks	Primary: MADRS Secondary: CGI-S, sustained response (MADRS total score ≤12 for at least the last two consecutive double-blind visits)	Primary: Statistically significant reductions that were consistent with greater symptom improvement were seen for vilazodone- versus placebo-treated patients (LSMD, –5.117; P<0.00001, effect size=0.54). Secondary: Decrease from baseline to week eight in CGI-S score was statistically greater for vilazodone versus placebo (LSMD, –0.622; P<0.00001, effect size =0.50). The difference in the rate of MADRS sustained response was also statistically significant in favor of vilazodone (27%) versus placebo (17%; P=0.0047).
Mathews et al.[150] (2015)	DB, MC, PC, RCT Patients 18 to 70	N=1133 10 weeks	Primary: MADRS	Primary: Vilazodone treatment (20 and 40 mg/day) compared with placebo was associated with significantly greater reduction in MADRS total scores

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Vilazodone 20 mg/day or vilazodone 40 mg/day vs citalopram 40 mg/day vs placebo	years of age with ongoing major depressive episode lasting eight or more weeks and up to 12 months, MADRS total score ≥26		Secondary: CGI-S, sustained response (MADRS total score ≤12 for at least the last two consecutive double-blind visits), HAMA, adverse events	from baseline to week 10. Statistical significance in favor of both vilazodone groups appeared at week two and was sustained throughout the double-blind period. MADRS mean change from baseline to week 10 was also significantly greater for citalopram versus placebo, demonstrating sensitivity of the study to detect treatment effects in the primary efficacy measure. Secondary: Both vilazodone groups relative to placebo showed significantly greater improvement from baseline in CGI-S scores. Sustained MADRS response rates were numerically higher for all active treatment groups compared with placebo, although the differences did not reach statistical significance. HAMA change from baseline improved over time but did not achieve statistical significance relative to placebo. The most commonly reported adverse events leading to discontinuation was nausea (placebo, n=1; vilazodone 20 mg/day, n=6; vilazodone 40 mg/day, n=3, citalopram, n=4). Adverse events that occurred in at least 5% of patients in either vilazodone group and at twice the rate of placebo were diarrhea, nausea, insomnia, and vomiting (40 mg/day group only).
Henigsberg et al.[151] (2012) Vortioxetine 1 mg QD or vortioxetine 5 mg QD or vortioxetine 10 mg QD	DB, MC, PC, PG, RCT Patients 18 to 75 years of age, had a current MDE per DSM-IV-TR criteria, ambulatory and a baseline MADRS total score ≥26	N=556 (N=505 completed study) 8 weeks	Primary: Change from baseline in HAMD-24 after eight weeks of treatment Secondary: Decrease from baseline on SDS, CGI-I score and decrease from baseline on MADRS	Primary: At eight weeks, all treatment groups had a significantly greater decrease from baseline in HAMD-24 compared to placebo. Vortioxetine 1 mg had a decrease from baseline on the HAMD-24 of -14.82 (P<0.001). Vortioxetine 5 mg had a decrease from baseline of -15.42 (P<0.001), and vortioxetine 10 mg had a decrease from baseline on the HAMD-24 of -16.23 (P<0.001). Secondary: None of the vortioxetine treatment groups had statistically significant decrease from baseline on the SDS as compared to placebo for (P values not reported). Vortioxetine 1, 5 and 10 mg all met the secondary endpoint of CGI-I compared to placebo; 2.37, 2.37 and 2.29 respectively (P<0.001 for all comparators). Vortioxetine 1, 5, and 10 mg all met statistical significance for the endpoint of decrease from baseline on the MADRS total score; -14.89, -15.09 and -15.65, respectively (P<0.001 for all).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				
Mahableshwarkar et al.[152] (2015) Vortioxetine 10 mg QD or vortioxetine 15 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 75 years of age with MDD and a baseline MADRS total score >26 and CGI-S score ≥4	N=1111 8 weeks	Primary: Change from baseline in MADRS total score Secondary: MADRS response (≥50% decrease in the MADRS total score from baseline), MADRS remission (MADRS total score ≤10), CGI-S remission (CGI-S score ≤2), and CGI-I response (CGI-I score ≤2)	Primary: Differences from placebo in mean change from baseline MADRS scores were not statistically significant for the vortioxetine 10 mg or 15 mg groups. Secondary: For all five key secondary efficacy end points, the results were similar between the two vortioxetine groups, and differences from placebo did not reach statistical significance at the 0.025 level.
Jacobsen et al.[153] (2015) Vortioxetine 10 mg QD vs vortioxetine 20 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 75 years of age with MDD and a baseline MADRS total score >26 and CGI-S score ≥4	N=462 8 weeks	Primary: MADRS total score Secondary: Change from baseline in MADRS total score, MADRS responders, mean CGI-I score, change from baseline in MADRS total score in subjects	Primary: The mean difference between vortioxetine 20 mg and placebo for MADRS total score was –3.64 (SE ± 1.161; P=0.002). The difference between vortioxetine 10 mg and placebo in MADRS change from baseline did not reach significance at week eight (P=0.058). Vortioxetine 20 mg separated from placebo at week four and remained separated at weeks six and eight. The vortioxetine 10 mg dose also separated from placebo at weeks four and six but not at week eight. Secondary: MADRS response at eight weeks (≥50% decrease from baseline in MADRS total score) was achieved in 33.8, 39.2, and 28.4% of subjects in the vortioxetine 10 mg, 20 mg, and placebo groups, respectively (P=0.301 [10 mg vs placebo]; P=0.044 [20 mg vs placebo]). Since the difference did not reach the predefined level of statistical significance (0.025), the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			with baseline HARS score ≥20, MADRS remission, and change from baseline in SDS total score	hierarchical testing strategy was stopped, and all subsequent P values (<0.05) were considered nominal and not statistically significant.
Jain et al.[154] (2013) Vortioxetine 5 mg QD vs placebo	DB, PC Patients 18 to 75 years of age with MDD and a baseline MADRS total score >30	N=600 8 weeks	Primary: Change from baseline in HAMD-24 total score at week six compared to placebo Secondary: Response and remission rates, CGI-I, HAMA, MADRS-S total score, adverse events	Primary: There were no significant differences in efficacy measures between subjects in the 5 mg vortioxetine and placebo groups at week six. Secondary: HAMD-24 total score in subjects with baseline HAMA >19 in the 5 mg vortioxetine group was improved at weeks three to six compared to the placebo group (P<0.05). The most common adverse events for the vortioxetine and placebo groups were nausea (19.1 and 9.4%), headache (17.1 and 15.1%) and diarrhoea (11.4 and 7.0%), respectively.
Nishimura et al.[155] (2018) Vortioxetine 5 mg QD vs vortioxetine 10 mg QD vs vortioxetine 20 mg QD	DB, MC, PC, RCT Patients 20 to 64 years of age with a primary diagnosis of MDD, a MADRS total score ≥ 26, a CGI-S score ≥ 4 and had the current major depressive episode for ≥ 3 months at baseline	N=600 8 weeks	Primary: Change from baseline in the MADRS total score at week 8 Secondary: MADRS response, MADRS remission, CGI-I score and change from baseline in SDS total score	Primary: No statistically significant differences in the LS mean change from baseline in the MADRS total scores were observed at week 8 between placebo and any vortioxetine group in the overall population. Nominally significant improvements over placebo were observed for vortioxetine doses of 10 and 20 mg when the primary end-point was evaluated using the mixed model for repeated measures as the secondary analysis. Secondary: Patients treated with vortioxetine 10 and 20 mg had nominally higher MADRS response rates at week 8 (LOCF) than those in the placebo group, resulting in OR of 1.837 (95% CI, 1.158 to 2.914; P =0.0098) for the 10 mg group and 1.604 (95% CI, 1.013 to 2.538; P =0.0437) for the 20 mg group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				Response rates were not significantly different in patients treated with vortioxetine 5 mg and those receiving placebo. Remission rates were not significantly different between placebo and any vortioxetine group. Overall improvement and patient functioning, when assessed with the CGI-I and SDS, respectively, showed numerical improvement with vortioxetine 10 mg QD. At week 8, mean CGI-I scores and mean changes from baseline in the SDS total scores were nominally significantly greater for those treated with vortioxetine 10 mg than those receiving placebo.
Katona et al.[156] (2012) Vortioxetine 5 mg QD or duloxetine 60 mg QD vs placebo QD	AC, DB, MC, PC, PG, RCT Patients ≥65 years of age, with a primary diagnosis of MDD per DSM-IV-TR criteria and a MADRS score ≥26	N=453 (N=392 completed the study) 8 weeks	Primary: Change from baseline in HAMD-24 total score at weeks one, two, four, six, and eight. Secondary: Change in baseline from CGI-I, MADRS total score, HAMA and CGI-S at week eight. Cognitive changes from baseline assessed via the RAVLT and DSST at week eight	Primary: The vortioxetine treatment group did not meet the primary endpoint until week six of the study, and it was not reported when the duloxetine treatment group began to separate from placebo for the primary endpoint. The vortioxetine treatment group began to separate on the HAMD-24 scale from placebo at week six (P=0.024). At week eight, vortioxetine 5 mg had a mean change from baseline in HAMD-24 score of -13.7 (P<0.01), and duloxetine 60 mg had a mean change from baseline on the HAMD-24 of -15.8 (P<0.0001). Secondary: Vortioxetine 5 mg and duloxetine 60 mg both met all secondary endpoints at week eight. A change in CGI-I of -0.56 (P<0.001) was reported for the vortioxetine group, along with a decrease in MADRS total change of -4.29 (P<0.001), a decrease in HAMA scores of -2.35 (P<0.01) and a decrease of CGI-S of -0.60 (P<0.001). Duloxetine showed similar results for these secondary endpoints with a P<0.001 for all of these measures. The cognitive measures also showed positive results for both treatment groups. Vortioxetine 5 mg showed a difference from placebo on the DSST change of 2.79 (P>0.05), and vortioxetine showed a difference from placebo in RAVLT for acquisition change of 1.14 (P<0.05) and delayed recall change of 0.47 (P<0.05). The duloxetine group did not show statistical significance for DSST change with a value of 0.77 (no P value reported). The duloxetine group did show statistical significance on the RAVLT for acquisition of change of 1.41 (P<0.01) and delayed recall

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				change of 0.64 (P<0.01)
Mahableshwarkar et al.[157] (2013) Vortioxetine 2.5 mg QD or vortioxetine 5 mg QD vs duloxetine 60 mg QD vs placebo QD	DB, PC Adult patients with MDD	N=611 8 weeks	Primary: Change from baseline in the HAM-D24 Secondary: Responder rate, CGI-I), and remission rate; adverse events, ASEX	Primary: Both doses of vortioxetine were associated with declines in HAM-D24 total scores compared to placebo but were not statistically significant. At eight weeks, changes from baseline were [mean]: -10.50 (0.76) placebo, -12.04 (0.74) 2.5 mg vortioxetine, and -11.08 (0.74) 5 mg vortioxetine. Secondary: CGI-I and remission rate were not significantly different from placebo. Duloxetine treatment was associated with declines in HAM-D24 total score [-13.47(0.75); P=0.005] as well as significant improvements in secondary outcome measures vs placebo (P<0.05). The most common adverse events for vortioxetine were nausea, dry mouth, and headache. Rates of sexual dysfunction (ASEX) were 51.0, 37.5, 46.9, and 33.3% in the vortioxetine 2.5 mg, vortioxetine 5 mg, duloxetine, and placebo groups, respectively.
Boulenger et al.[158] (2014) Vortioxetine 15 mg QD or vortioxetine 20 mg QD vs duloxetine 60 mg QD	DB, MC, PC, RCT Patients 18 to 75 years of age with MDD, MADRS score ≥26, CGI-S ≥4	N=607 8 weeks	Primary: Change from baseline MADRS total score Secondary: MADRS responders, CGI-I, remission (MADRS ≤10), SDS	Primary: Both doses of vortioxetine improved mean change from baseline in MADRS total score at week eight, with a mean treatment difference to placebo of −5.5 (vortioxetine 15 mg, standard error=1.1, P<0.0001) and −7.1 points (vortioxetine 20 mg, standard error=1.1, P<0.0001). The active reference duloxetine was also significantly superior to placebo (nominal P<0.0001). Secondary: Both doses of vortioxetine were statistically significantly superior to placebo in all the predefined key secondary efficacy analyses, including response and remission based on the MADRS.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo QD				
Mahableshwarkar et al.[159] (2015) Vortioxetine 15 mg QD or vortioxetine 20 mg QD vs duloxetine 60 mg QD vs placebo QD	DB, MC, PC, PG, RCT Patients 18 to 75 years of age with MDD	N=614 8 weeks	Primary: Change from baseline MADRS total score Secondary: HAMA, CGI-I, CGI-S, adverse events, ASEX	Primary: Treatment with vortioxetine 20 mg reduced the MADRS total score at week eight more than placebo (P=0.023). Vortioxetine 15 mg was not significantly different from placebo at week eight (P=0.224). Duloxetine 60 mg separated from placebo (P<0.001) on the primary endpoint, confirming assay sensitivity. Secondary: The key secondary efficacy endpoints did not separate from placebo (P>0.050) with either vortioxetine dose. Discontinuation due to adverse events occurred in 2.5% of patients in the placebo group, 9.5% in the vortioxetine 15-mg group, 9.1% in the vortioxetine 20-mg group, and 6.6% in the duloxetine 60-mg group. Treatment-emergent sexual dysfunction, suicidal ideation or behavior, and discontinuation symptoms were not significantly different between vortioxetine and placebo.
Robinson et al.[160] (2011) Vilazodone 40 mg QD	MC, OL Patients 18 to 70 years of age with MDD	N=616 52 weeks	Primary: Safety, sexual function (CSFQ), effectiveness (MADRS, CGI-S and CGI-I scales) Secondary: Not reported	Primary: A total of 93.8% of patients had ≥1 treatment-emergent adverse events. The most frequent treatment-emergent adverse events were diarrhea (35.7%), nausea (31.6%), and headache (20.0%). The incidence of severe adverse events was 14.9%. The incidence of severe gastrointestinal adverse events was 3.5% and the incidence of severe headache was 1.2%. Mean weight increase was 1.7 kg at week 52. At six months, mean weight change for patients with normal baseline weight was 1.3 kg; for overweight and obese patients, mean weight increases were 1.6 and 1.0 kg, respectively. The mean CSFQ scores at baseline were 46.9 for men and 38.7 for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				women; both scores indicative of sexual dysfunction. The CSFQ mean scores improved and exceeded threshold values for sexual dysfunction at week four for men and week eight for women. Adverse events pertaining to impaired sexual desire or function were decreased libido (4.2%) and anorgasmia including abnormal orgasm (2.3%). Those pertaining to males only were erectile dysfunction (4.2%) and delayed ejaculation (3.1%). There were a total of eight patients who had adverse events of either suicidal ideation or behavior. The mean MADRS scores improved from 29.9 at baseline to 11.4 at week eight (change, -18.5), 8.2 at week 24 (change, -21.7), and 7.1 at one year (change, -22.8). The mean CGI-S improved from 4.3 at baseline to 2.5 at week eight (change, -1.9) and 1.7 at one year (change, -2.6). The CGI-I mean score decreased from 3.5 at week one to 1.9 at week eight and 1.4 at one year. Secondary: Not reported
Baldwin et al.[161] (2012) Vortioxetine 2.5 mg QD or vortioxetine 5 mg QD or vortioxetine 10 mg QD	OL Patients with MDD	N=535 52 weeks	Primary: Safety and tolerability, MADRS Secondary: Not reported	Primary: Adverse events reported by >10% of patients were nausea, headache, and nasopharyngitis. Six patients had eight adverse events related to sexual dysfunction. There were no clinically significant safety findings with respect to mean changes of vital signs, weight, ECG parameters, or clinical laboratory values. Patients entered the ES with a mean MADRS total score of 13.5+8.7. The mean MADRS total score decreased (improved) by approximately 8 points to 5.5+6.0 at week 52. By the end of the study, the proportion of responders had increased from 63 to 94%, as had the proportion in remission (MADRS <10), increasing from 42 to 83%. Patients in remission (n=226) at the start of this study had a relapse rate (MADRS >22) of 9.7%. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cipriani et al.[162] (2009) New-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine)	MA (117 trials) Patients with MMD receiving acute treatment	N=25,928 6 to 12 weeks	Primary: Response (defined as the proportion of patients who had a reduction ≥50% from the baseline score on the HDRS or MADRS, or who scored much improved or very much improved on the CGI at eight weeks) and dropout rates Secondary: Not reported	Primary: *Direct Comparisons* Efficacy favored escitalopram over citalopram; citalopram over reboxetine and paroxetine; mirtazapine over fluoxetine and venlafaxine; sertraline over fluoxetine; and venlafaxine over fluoxetine and fluvoxamine. For dropouts, fluoxetine was better tolerated than reboxetine and citalopram than sertraline. *Multiple-treatments MA* Escitalopram, mirtazapine, sertraline, and venlafaxine were significantly more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine. Reboxetine was significantly less efficacious than all the other 11 antidepressants. Duloxetine and paroxetine were less well tolerated than escitalopram and sertraline; fluvoxamine was less well tolerated than citalopram, escitalopram, and sertraline; venlafaxine was less well tolerated than escitalopram; reboxetine was less well tolerated than many other antidepressants, such as bupropion, citalopram, escitalopram, fluoxetine, and sertraline; and escitalopram and sertraline were better tolerated than duloxetine, fluvoxamine, paroxetine, and reboxetine. Mirtazapine, escitalopram, venlafaxine, and sertraline were more efficacious than fluoxetine, and fluoxetine was more efficacious than reboxetine. Fluoxetine was better tolerated than reboxetine. Mirtazapine, escitalopram, venlafaxine, and sertraline were among the most efficacious treatments, and escitalopram, sertraline, bupropion, and citalopram were better tolerated than the other remaining antidepressants. The cumulative probabilities of being among the four most efficacious treatments were: mirtazapine (24.4%), escitalopram (23.7%), venlafaxine (22.3%), sertraline (20.3%), citalopram (3.4%), milnacipran (2.7%), bupropion (2.0%), duloxetine (0.9%), fluvoxamine (0.7%), paroxetine (0.1%), fluoxetine (0.0%), and reboxetine (0.0%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The cumulative probabilities of being among the four best treatments in terms of acceptability were escitalopram (27.6%), sertraline (21.3%), bupropion (19.3%), citalopram (18.7%), milnacipran (7.1%), mirtazapine (4.4%), fluoxetine (3.4%), venlafaxine (0.9%), duloxetine (0.7%), fluvoxamine (0.4%), paroxetine (0.2%), and reboxetine (0.1%). Secondary: Not reported
Moncrieff et al.[163] (2004) Antidepressants vs placebo	MA Patients with MDD	N=751 (9 trials) Variable duration	Primary: Efficacy Secondary; Not reported	Primary: TCAs were statistically better than active placebo in the pooled analysis (0.39, 95% CI, 0.24 to 0.54). Secondary; Not reported
Walsh et al.[164] (2002) Antidepressants vs placebo	MA Adult outpatients with MDD	N=not specified (75 trials) Variable duration	Primary: HAM-D, CGI Secondary: Not reported	Primary: The mean proportion of patients in the placebo group who responded was 29.7% (range, 12.5 to 51.8). Response was determined by a reduction of at least 50% in their score on the HAM-D and/or CGI rating of markedly or moderately improved. Both the proportion of patients responding to placebo and the proportion responding to medication were significantly positively correlated with the year of publication (for placebo P<0.001; for medication P=0.02). The association between year of publication and response rate was more statistically robust for placebo than medication. Secondary; Not reported
Geddes et al.[165] (2003) Antidepressants vs	MA Studies evaluating relapse prevention of depression	N=4,410 (31 trials) 6 to 36 months	Primary: Proportion of patients relapsing; withdrawal from the trial	Primary: Continuing treatment with antidepressants reduced the odds of relapse by 70% (95% CI, 62 to 78; P<0.00001) compared to treatment discontinuation. The average rate of relapse on placebo was 41% compared to 18% on active treatment. The treatment effect seemed to persist for up to 36 months, although most trials were of 12 months

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo			Secondary: Not reported	duration, and so the evidence on longer-term treatment requires confirmation. Significantly more participants allocated antidepressants withdrew from the trials than did those allocated to placebo (18 vs 15%, respectively; OR, 1.30; 95% CI, 1.07 to 1.59). Secondary: Not reported
Mohamed et al.[166] (2017) VAST-D Switch to bupropion vs augment current treatment with bupropion vs augment with aripiprazole	MC, SB, RCT Veterans Health Administration patients ≥18 years of age with an MDD diagnosis and suboptimal response to a treatment course with a selective-serotonin reuptake inhibitor, serotonin and norepinephrine reuptake inhibitor, or mirtazapine	N=1,522 12 weeks (acute treatment phase), up to 36 weeks (continuation phase)	Primary: Remission during the acute treatment phase (QIDS-Clinician Rated score ≤5 at two consecutive visits) Secondary: Response (≥50% reduction in QIDS-Clinician Rated score or improvement on the CGI-I scale), relapse, and adverse effects	Primary: The primary outcome of remission occurring through week 12 was higher for the augment-aripiprazole group (28.9%) compared with the switch group (22.3%; RR, 1.30; 95% CI, 1.05 to 1.60; P=0.02) but not compared with the augment-bupropion group (26.9%; RR, 1.08; 95% CI, 0.88 to 1.31; P=0.47). Remission with the augment-bupropion group was not significantly different than the switch group (RR, 1.20; 95% CI, 0.97 to 1.50; P=0.09). Secondary: Response based on QIDS-Clinician score was significantly higher for the augment-aripiprazole group (74.3%) than for both the switch group (62.4%; RR, 1.19; 95% CI, 1.09 to 1.29; P<0.001) and the augment-bupropion group (65.6%; RR, 1.13; 95% CI, 1.04 to 1.23; P=0.003), with no significant difference between the augment-bupropion group and the switch group (RR, 1.05; 95% CI, 0.96 to 1.15; P=0.29). Response measured by CGI improvement similarly favored the augment-aripiprazole group (79%) compared with both the switch group (70%; RR, 1.14; 95% CI, 1.06 to 1.22; P<0.001) and the augment-bupropion group (74%; RR, 1.07; 95% CI, 1.00 to 1.14; P=0.07). Among the 396 patients achieving remission in the acute treatment phase, there were no significant differences in the secondary outcome of cumulative relapse: augment-bupropion group vs switch group (HR, 1.36; 95% CI, 0.78 to 2.39; P=0.70); augment-aripiprazole group vs switch group (HR, 1.12; 95% CI, 0.65 to 1.94; P=0.68); or augment-bupropion group vs augment-aripiprazole group (HR, 0.96; 95% CI, 0.58 to 1.59; P=0.87).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Anxiety was more frequent in the two bupropion groups (24.3% in the switch group [n=124] vs 16.6% in the augment-aripiprazole group [n=84]; and 22.5% in augment-bupropion group [n=114]). Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain.
Saveanu et al.[167] (2015) iSPOT-D Escitalopram vs sertraline vs venlafaxine ER Dose adjustments managed by each participant's usual treating clinician according to their usual clinical practice.	MC, PRO, RCT Patients 18 to 65 years of age with diagnosis of nonpsychotic MDD and HDRS-17 score ≥16	N=1008 8 weeks	Primary: HDRS-17 (response rate was defined as a ≥50% decrease in severity from baseline; remission by an HDRS-17 score ≤7) Secondary: Self-reported response and remission on the QIDS-SR16, for which response rate was a ≥50% decrease in severity from baseline to week 8, and remission a score ≤5, functional capacity, adverse events	Primary: Of the 71.6% of patients who completed the full eight weeks and at least one outcome measure at week eight, over 60% of participants met criteria for response, of which 45.4% were in remission. Response and remission rates did not significantly differ between the treatment arms. Secondary: By the QIDS-SR16, 53.3% of participants had responded, of which 37.6% were in remission at week eight. Most domains of function showed improvement on the order of one standard deviation, a clinically meaningful shift over the acute treatment phase. None of the score changes differed significantly between the three treatment arms. Adverse events (any medical symptom or condition occurring or worsening after the baseline visit) were reported by 44.8% of participants, 88.3% (399/452) of whom experienced events likely to be related to the antidepressants. Overall, 3.6% of participants discontinued due to intolerance.
Chuang et al.[168] (2014) Paroxetine (20 mg/day)	OBS, OL Patients 18 to 65 years of age with diagnosis of MDD and HDRS-17 score	N=249 24 weeks	Primary: HDRS-17: response (score decreased more than 50%), remission (score	Primary: There were no significant differences between the three groups in response (P=0.72). There were no significant differences in remission rates between the three groups when the criterion for remission was an HDRS-17 score ≤5. However, Milnacipran was more efficacious than paroxetine in relieving the symptoms of MDD when the remission criterion was an

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs venlafaxine (75 to 225 mg/day) vs milnacipran (100 mg/day)	≥16		≤7 or ≤5, as stated) Secondary: Not reported	HDRS-17 score ≤7, and, using LOCF analysis, paroxetine was more efficacious than venlafaxine when the remission criterion was an HDRS-17 score ≤5. Secondary: Not reported
Thase et al.[169] (1995) Phenelzine (PHZ) vs isocarboxazid (ISO) vs tranylcypromine (TRP) vs placebo	MA Patients with MDD	Review of Medline and Psychological abstracts from 1959 to 1992	Primary: Efficacy Secondary; Not reported	Primary: For outpatients using ITT samples, all three agents appear to be equally effective (PHZ=57.9%±4.0%; ISO=60.1%±7.1%; TRP=52.6%±12.4%). When compared to placebo in outpatients, ISO (41.3%±18.0%) had a larger relative advantage compared to either PHZ (29.5% ±11.1%) or TRP (22.1%±25.4%) in the doses studied. For inpatients, PHZ was somewhat more effective (22.3%±30.7%) than placebo, whereas the ISO-placebo difference was smaller (15.3%±12.6%). Secondary; Not reported
Cipriani et al.[170] (2005) Fluoxetine, sertraline, nortriptyline, amitriptyline, venlafaxine, imipramine, nefazodone,	MA (132 trials) Patients with depression	N=9,311 Duration varied	Primary: Number of patients who responded to treatment (HAM-D, MADRS) Secondary: Tolerability	Primary: On a dichotomous outcome fluoxetine was less effective than sertraline (PetoOR, 1.40; 95% CI, 1.11 to 1.76), mirtazapine (PetoOR, 1.64; 95% CI, 1.01 to 2.65) and venlafaxine (PetoOR, 1.40; 95% CI, 1.15 to 1.70; P values not reported). On a continuous outcome, fluoxetine was less effective than venlafaxine (SMD random effect, 0.11; 95% CI, 0.00 to 0.23; P value not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
citalopram, desipramine, paroxetine, pramipexole, fluvoxamine, trazodone, bupropion, clomipramine, duloxetine, mirtazapine, doxepin				Fluoxetine was better tolerated than TCAs considered as a group (PetoOR, 0.78; 95% CI, 0.68 to 0.89), and was better tolerated in comparison with individual antidepressants, in particular than amitriptyline (PetoOR, 0.64; 95% CI, 0.47 to 0.85) and imipramine (PetoOR, 0.79; 95% CI, 0.63 to 0.99), and among newer antidepressants than pramipexole (PetoOR, 0.20; 95% CI, 0.08 to 0.47; P values not reported).
Stahl et al.[171] (1997) Mirtazapine up to 35 mg daily vs amitriptyline up to 280 mg daily vs placebo up to 7 capsules daily	MA Patients with MDD	N=580 (4 trials) 6 weeks	Primary: HAM-D, HDRS, responder rate (percentages of patients with ≥50% decrease in baseline 17-item HDRS score), remitter rate (patients with a total 17-item HDRS score ≤7), MADRS, CGI Secondary: Change from baseline in the "depressed mood" item on the HDRS scale, anxiety/ somatization factor, sleep disturbance factor, melancholia factor, tolerability	Primary: Compared to placebo, both mirtazapine and amitriptyline therapy significantly improved patient HDRS, MADRS, and CGI scores from baseline (P<0.05). Significantly greater percentages of patients responded to mirtazapine or amitriptyline therapy, assessed with the HDRS criteria, compared to placebo (P<0.05). Significantly greater percentages of patients randomized to mirtazapine or amitriptyline therapy exhibited remission compared to placebo (P<0.05). There were no statistically significant differences between mirtazapine and amitriptyline in any of the primary endpoints. Secondary: Significantly greater improvement from baseline in the "depressed mood" item was seen in the mirtazapine and amitriptyline groups compared to placebo (P<0.05). Significantly greater improvement from baseline in the anxiety/soma-tization, sleep disturbance, and melancholia factors was seen in the mirtazapine and amitriptyline groups compared to placebo (P<0.05). There were no statistically significant differences between mirtazapine and amitriptyline in the "depressed mood", anxiety, somatization, sleep

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				disturbance, or melancholia factors on the HDRS scale. Patients on amitriptyline therapy experienced a significantly higher incidence of restlessness (14.0 vs 2.1%), vertigo (2.1 vs 0), blurred vision (6.2 vs 0.5%), dyspepsia (10.4 vs 0.5%), dry mouth (80.8 vs 34.0%), constipation (31.1 vs 18.0%), palpitations (8.8 vs 3.6%), and tachycardia (4.7 vs 0.5%) compared to patients receiving mirtazapine therapy (P<0.05). Patients on mirtazapine therapy experienced a significantly higher incidence of weight gain compared to the amitriptyline group (14.4 vs 6.7%; P<0.05). Drowsiness and sedation were more common in the active groups compared to the placebo group (P<0.05). Hypotension was more common in the amitriptyline group compared to the placebo (3.6 vs 0.5%; P<0.05). Increased appetite was more common in the mirtazapine group compared to the placebo group (3.6 vs 0; P<0.05).
Bull et al.[172] (2002) Continuation of an SSRI vs discontinuation of an SSRI vs switching of an SSRI	RETRO Adult patients diagnosed with a depressive disorder, taking an SSRI for at least 6 months were interviewed over the phone; prescribing physicians were asked to complete a survey	N=137,401 6 months	Primary: Patient-physician communication about therapy duration and adverse effects, therapy discontinuation or switching of medication within three months of SSRI use, BDI-FS, depression symptoms Secondary;	Primary: While 72% of physicians reported instructing their patients on taking SSRIs for a minimum of 6 months, only 34% of patients acknowledged receiving this information from their physician and 56% reported receiving no instructions at all. Patients instructed to continue therapy for less than 6 months were 3 times more likely to discontinue therapy prematurely compared to those told to continue therapy for a longer duration (OR, 3.12; 95% CI, 1.21 to 8.07; P<0.001). Patients who were informed about adverse effects common with their medication were less likely to discontinue therapy than patients who did not have this discussion with their physician (OR, 0.49; 95% CI, 0.25 to 0.95).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Not reported	Patients who discussed adverse effects with their physicians were more likely to switch medications (RR, 5.60; 95% CI, 2.31 to 13.60). Patients experiencing adverse effects were 3 times more likely to switch their medication (OR, 3.09; 95% CI, 1.30 to 7.31). Less than three follow-up visits, and lack of therapeutic response to medication at three months were also associated with a higher incidence of therapy discontinuation (P=0.002, P<0.001, respectively). Patients who continued to have severe symptoms, based on the BDI-FS scale, were six times more likely to switch their medication (OR, 6.15; 95% CI, 2.11 to 17.89). Secondary; Not reported
Anderson et al.[173] (2000) TCAs vs SSRIs	MA Patients with MDD	N=10,706 (102 trials) Variable duration	Primary: HAM-D, MADRS Secondary: Adverse events	Primary: Efficacy was based on 102 studies (5,533 SSRI patients and 5,173 TCA patients). Efficacy was determined by comparing the mean reduction in depression scores based upon the HAM-D or the MADRS. There was no statistical difference in efficacy between the two groups (effect size, –0.03; 95% CI, –0.09 to 0.03). TCAs did appear more effective for inpatients (–0.23; 95% CI, –0.4 to -0.05). Secondary: SSRIs were better tolerated with discontinuations due to adverse effects significantly greater in the TCA group (12.4 vs 17.3%; P<0.0001).
MacGillivray et al.[174] (2003) TCAs vs SSRIs	MA Patients with MDD	N=2,951 (11 trials) Variable duration	Primary: HAM-D; MADRS Secondary: Tolerability	Primary: Efficacy between SSRI and tricyclics did not differ significantly (standardized weighted mean difference, fixed effects 0.07; 95% CI, –0.02 to 0.15; P<0.11). Secondary: Significantly more patients receiving a tricyclic withdrew from treatment (RR, 0.78; 95% CI, 0.68 to 0.90; P<0.0007) and withdrew specifically because of side effects (RR, 0.73; 0.60 to 0.88; P<0.001).
Steffens et al.[175]	MA	N=not	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1997) TCAs vs SSRIs	Patients with MDD	specified (34 trials) Variable duration	HAM-D Secondary: Frequency of side effects	Overall, the response rate to treatment for patients who completed a trial was 63.2% for SSRIs and 68.2% for TCAs (P=0.038). For the ITT groups, these rates dropped to 48.0 and 48.6% (P=NS), respectively. Significantly more TCA-treated than SSRI-treated patients dropped out due to either lack of efficacy or adverse reactions (30.0 vs 24.7%; P=0.01). Secondary: Patients taking SSRIs experienced more gastrointestinal problems and sexual dysfunction, whereas treatment with TCAs produced significantly more complaints of sedation, dizziness, and anticholinergic symptoms.
Diabetic Neuropathy				
Yan et al.[176] (2010) Duloxetine 60 to 120 mg daily vs placebo	DB, PC, RCT Adult Chinese patients with diabetic peripheral neuropathic pain and BPI 24-hour average pain severity rating ≥4	N=215 12 weeks	Primary: Change from baseline to endpoint in BPI average pain score Secondary: BPI-S and BPI-I, PGI-I, CGI-S, EQ-5D, Athens Insomnia Scale	Primary: Mean change from baseline to endpoint in BPI pain score was not significantly different between treatments (-2.31±0.18 vs -2.69±0.19; P=0.124). Duloxetine-treated patients showed significantly greater pain reduction compared to placebo-treated patients at weeks one, two, and four (P=0.004, P=0.009, and P=0.006), but not at week eight (P=0.125) and 12 (P=0.107). Secondary: Duloxetine-treated patients experienced significant improvement in PGI-I (2.32±0.11 vs 2.64±0.10; P=0.028), CGI-S (-1.24±0.11 vs -0.99±0.11; P=0.036), AUC for pain relief, BPI-S pain right now (-2.72±0.26 vs -1.99±0.25; P=0.012), and BPI-I walking ability (-2.45±0.24 vs -1.82±0.23; P=0.016). Patients receiving duloxetine had numerically higher 30 and 50% response rates on BPI average pain compared to placebo-treated patients. A higher proportion of patients receiving duloxetine (62.5%) met the criteria for sustained response compared to patients receiving placebo (50.5%). All other secondary efficacy measures, including health outcomes measures, were numerically but not significantly improved in patients receiving duloxetine compared to patients receiving placebo.
Armstrong et al.[177] (2007)	3 DB, MC, PC, RCT	N=1,139	Primary: Patient-reported	Primary: Diabetic peripheral neuropathic pain patients treated with duloxetine 60

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Duloxetine 20 or 60 mg QD, or 60 mg BID vs placebo	Patients with diabetic peripheral neuropathic pain	12 weeks	functional outcomes (SF-36, BPI, EQ-5D) Secondary: Not reported	mg QD or BID had greater improvement, compared to placebo, in all SF-36 domains of physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Within treatment group changes among the domain scores ranged from 0.9 to 23.5 points. Duloxetine 60 mg BID showed some advantage over duloxetine 60 mg QD on general health (P=0.02) and mental health (P=0.04) status. Consistent results were seen in the ITT population with the exception that the above indicated advantages of duloxetine 60 mg BID over 60 mg QD in the domains of general and mental health were not significant. Duloxetine 60 mg QD and 60 mg BID were significantly more efficacious to placebo at reducing scores in all BPI-I items thereby indicating improvements in all seven items, with similar results demonstrated for the ITT population. In the analysis of the EQ-5D, patients on duloxetine 60 mg QD (P=0.004) and 60 mg BID (P<0.001) were both significantly better compared to placebo for the trial completers. Results for the ITT analysis were consistent, thus demonstrating the superiority of duloxetine 60 mg QD and BID compared to placebo with regard to changes in all included function and QOL measures. Secondary: Not reported
Kajdasz et al.[178] (2007) Duloxetine 20 or 60 mg QD, or 60 mg BID vs placebo	Post-hoc analysis of 3 DB, MC, PC, RCT Patients with diabetic peripheral neuropathic pain	N=1,139 12 weeks	Primary: Response rate (defined as ≥30 and ≥50% reductions from baseline in weekly mean of the 24-hour average pain severity scores) Secondary: NNH (based on	Primary: NNTs based on 50% reduction for patients receiving duloxetine 60 mg QD and 60 mg BID were 5.2 (95% CI, 3.8 to 8.3) and 4.9 (95% CI, 3.6 to 7.6), respectively, based on LOCF. Similarly, NNTs of 5.3 (95% CI, 3.8 to 8.3) for 60 mg QD and 5.7 (95% CI, 4.1 to 9.7) for 60 mg BID observed based on baseline observation carried forward. Secondary: The NNHs based on discontinuation due to adverse events were 17.5 (95% CI, 10.2 to 58.8) with duloxetine 60 mg QD and 8.8 (95% CI, 6.3 to 14.7) with duloxetine 60 mg BID.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			rates of dis-continuation due to adverse events)	
Lunn et al.[179] (2009) Duloxetine vs placebo or control Only outcomes for painful peripheral neuropathy are reported.	SR (6 RCTs) Patients with painful peripheral neuropathy or chronic pain conditions	N=2,200 ≥8 weeks	Primary: Short term (≤12 weeks) improvement in pain Secondary: Long term (>12 weeks) improvement in pain, improvement in short- and long-term pain ≥30%, improvement in any validated QOL score ≥30%	Primary: Three trials in painful diabetic neuropathy reported data on the primary outcome measure of 50% improvement of pain compared to baseline at <12 weeks. Patients were treated with duloxetine 20, 60, or 120 mg/day. Combining data from all doses from the three trials together, the RR of 50% improvement with any dose was 1.63 (95% CI, 1.35 to 1.97) greater than placebo. The RR of improvement was significantly greater compared to placebo for the 60 and 120 mg/day doses, but not 20 mg/day, for which it was 1.43 (95% CI, 0.98 to 2.09). The RR of improvement with 120 mg/day (1.66; 95% CI, 1.35 to 2.04) was not significantly greater compared to 60 mg/day (1.65; 95% CI, 1.34 to 2.03). The mean improvement in pain at <12 weeks on an 11-point Likert scale was significantly greater compared to placebo with 60 (-1.04; 95% CI, -1.37 to -0.71) and 120 mg/day (-1.16; 95% CI, -1.49 to -0.83) of duloxetine. Secondary: None of the included trials of painful diabetic neuropathy included outcomes >12 weeks. Two trials included data on >30% improvement of pain at ≤12 weeks. The results were similar to those for ≥50% improvement. Relative rates of improvement were significantly greater compared to placebo with duloxetine for the 60 mg/day (1.53; 95% CI, 1.27 to 1.83), 120 mg/day (1.55; 95% CI, 1.30 to 1.86), and for both doses combined (1.54; 95% CI, 1.30 to 1.82). Trials that included QOL information used the SF-36. In painful diabetic neuropathy, the effect of duloxetine 20 mg was not significant on any of the selected SF-36 subscores at up to 12 weeks (relevant physical, mental, and bodily pain subsections). The WMD of improvement on the physical summary component was significantly greater with 60 mg/day (2.51; 95% CI, 1.00 to 4.01) and 120 mg/day (2.80; 95% CI, 1.04 to 4.55). The WMD

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				on the mental summary component was significantly greater only with 120 mg/day (2.23; 95% CI, 0.69 to 3.77). The WMD on the bodily pain subscale showed significantly more improvement compared to placebo with 60 mg/day (5.58; 95% CI, 1.74 to 9.42) and with 120 mg/day (8.19; 95% CI, 4.33 to 12.05). Three trials reported the PGI-C and pain at rest, and two reported the bodily pain index. The WMD for each outcome was significant and similar in magnitude for 60 and 120 mg/day. However, a clinically meaningful differences in the PGI-C is suggested as one point and hence the change associated with 60 mg/day (-0.59; 95% CI, -0.78 to -0.41) may not be clinically significant. The RR for the bodily pain index is significantly reduced by -0.97 (95% CI, -1.38 to -0.57) but this borders on a change considered clinically significant.
Kaur et al.[180] (2011) Duloxetine 20 to 60 mg QD for 6 weeks vs amitriptyline 10 to 50 mg QD at bedtime for 6 weeks	AC, DB, RCT, XO Patients 18 to 75 years of age with type 2 diabetes who had painful diabetic neuropathy for ≥1 month	N=58 14 weeks	Primary: Reduction in the median pain score from baseline Secondary: Assessment of pain by McGill Pain Questionnaire, overall improvement score, 24-point HAM-D, change in sleep pattern, and patient self-evaluation of change in PGI-C scale	Primary: There was a significant improvement in pain at six weeks with both treatments compared to their baseline values (P<0.001 for both). For duloxetine, 59% of patients showed good improvement, 22% showed moderate improvement, and 9% showed mild improvement. For amitriptyline, 55% of patients showed good improvement, 24% showed moderate improvement, and 16% showed mild improvement. Overall pain relief of >30% was observed in 64% of patients receiving duloxetine and 62% of patients receiving amitriptyline. A >50% improvement was seen in 50% of patients receiving duloxetine and 55% of patients receiving placebo. Secondary: There was no significant difference in efficacy among the treatment groups as assessed by the McGill Pain Questionnaire and Likert scale. Significant improvement in sleep and overall well-being was observed with both drugs (P<0.001 for both). Overall, 48% of patients preferred duloxetine compared to 36% of patients who preferred amitriptyline (P=0.18). Based on pain relief and tolerability, 5, 14 and 30% of patients preferred duloxetine 20, 40, and 60 mg, respectively. A total of 5, 22, and 9% of patients preferred amitriptyline

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				10, 25, and 50 mg. The number of mild treatment-emergent adverse effects was higher with duloxetine compared to amitriptyline (P<0.02). The number of moderate to severe treatment emergent adverse event was higher with amitriptyline (P<0.01). Dry mouth was significantly more common with amitriptyline that duloxetine (55 vs 24%, respectively; P<0.01).
Boyle et al.[181] (abstract) (2012) Duloxetine 60 mg/day vs amitriptyline 50 mg/day vs pregabalin 300 mg/day	AC, DB, PG, RCT Patients ≥18 years of age with diabetes (type 1 or type 2) for ≥1 year and neuropathic pain of diabetic origin (≥1 of the following: dysesthesia, burning pain, cold or heat allodynia, shooting or lancinating pains and hyperalgesia affecting both lower extremities at any level below the mid-thighs) and LANSS score >12	N=83 4 weeks	Primary: BPI Secondary: SF-36, sleep, mood and daytime sleepiness	Primary: All three treatments significantly reduced pain compared to placebo. No one treatment was "superior" to the others with regard to pain. Secondary: For sleep, pregabalin improved sleep continuity (P<0.001), whereas duloxetine increased wake and reduced TST (P<0.01 and P<0.001). Despite negative effects on sleep, duloxetine enhanced central nervous system arousal and performance on sensory motor tasks. There were no significant safety findings; however, there were a significantly higher number of adverse events in the pregabalin treatment group.
Tanenberg et al.[182] (2011) Duloxetine 60 mg/day vs pregabalin 300 mg/day	MC, NI, OL, RCT Adult patients with type 1 or 2 with HbA_{1c} ≤12%, and diabetic peripheral neuropathic pain who had been treated with gabapentin (900 mg/day) and had an	N=407 12 weeks	Primary: Reduction from baseline in the weekly mean of the daily 24-hour pain diary ratings at week 12 Secondary: Worst pain and night pain ratings,	Primary: The estimated mean change in the daily pain severity score at 12 weeks was -2.6 for duloxetine and -2.1 for pregabalin, representing an observed 0.49 advantage of duloxetine; therefore, NI was established. Significant superiority vs pregabalin in the mean daily pain diary ratings was observed at weeks, two, three, and five through 11 with duloxetine and with duloxetine plus gabapentin at weeks two and eight, but between-treatment differences at the 12-week end point met NI criteria, not statistical superiority.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs duloxetine 60 mg/day and gabapentin ≥900 mg/day (existing therapy)	inadequate response		Clinician Global Impression of Severity, BPI-S and BPI-I, BDI-II, PGI-I, SDS, response rate	The NI comparison between duloxetine and combination therapy on the differences between end point mean changes in daily pain diary ratings in the ITT patient population was also met. Secondary: Reduction from baseline in BPI average pain and BPI worst pain severity ratings was significantly greater with duloxetine vs pregabalin, but differences between treatments were not significant for the other BPI pain measures, CGI-S, depressive symptoms, or the SDS global measure. Also, no significant between-treatment differences were found among the various response outcomes.
Quilici et al.[183] (2009) Duloxetine vs pregabalin and gabapentin Placebo was used a common comparator.	MA (11 RCTs; duloxetine, 3 trials; pregabalin, 6 trials; gabapentin, 2 trials) Patients with diabetic peripheral neuropathic pain	N=not specified ≥5 to 13 weeks	Primary: Reduction in 24-hour pain severity, response rate (≥50% pain reduction), overall health improvement (PGI-I and PGI-C) Secondary: Not reported	Primary: Direct comparisons All three agents were more efficacious to placebo for all efficacy parameters. For 24-hour pain severity effect values were -1.13 (95% CI, -1.36 to -0.89), -0.90 (95% CI, -1.23 to -0.57), and -1.44 (95% CI, -2.21 to -0.66) with duloxetine, pregabalin, and gabapentin. Corresponding effect values for response rates were 0.86 (95% CI, 0.63 to 1.09; NNT, 5; 95% CI, 3 to 7) and 0.84 (95% CI, 0.52 to 1.16; NNT, 5; 95% CI, 4 to 8) with duloxetine and pregabalin, and for PGI-I/C were -0.76 (95% CI, -1.00 to -0.51) and -1.29 (95% CI, -1.72 to -0.86) with duloxetine and pregabalin. Indirect comparisons For the primary efficacy outcome of 24-hour reduction in pain severity, a difference of -0.248 (95% CI, -0.677 to 0.162) was observed in favor of duloxetine over pregabalin. Duloxetine was not inferior to pregabalin on this outcome. For response rates, the difference between duloxetine and pregabalin was close to zero and not significant. For PGI-I/C outcomes, pregabalin showed an improvement of 0.542 points over duloxetine, a difference that reached significant (95% CI, 0.016 to 1.060). Secondary: Not reported
Wernicke et al.[184] (2007) Duloxetine 60 mg	ES, OL, RCT Adult patients who presented with pain	N=293 52 weeks	Primary: Not reported Secondary:	Primary: Not reported Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
BID vs routine care (gabapentin, amitriptyline, and venlafaxine)	due to bilateral peripheral neuropathy caused by type 1 or 2 diabetes		Health outcomes	There were significant treatment-group differences observed in favor of duloxetine in the SF-36 physical component summary score, and subscale scores of physical functioning, bodily pain, mental health, and vitality. A significant treatment-by-investigator interaction was seen for general health perceptions (P=0.073), mental health (P=0.092), and social functions (P=0.003) subscales. There were no significant treatment-group differences observed on the EQ-5D questionnaire. During the trial, four deaths occurred. Deaths were considered to be unrelated to the study drug or protocol procedures. During the trial, 22 (11.2%) duloxetine vs 16 (16.7%) routine care-treated patients experienced at least one serious adverse event. The most frequently reported serious adverse events for both treatments together were cerebrovascular accident and diabetes, and these events were not considered to be drug-related. Fourteen (4.8%) patients discontinued due to any adverse event; which included 11 and three duloxetine- and routine care-treated patients (P=0.560). A total of 157 (53.6%) patients reported at least one treatment-emergent adverse event, and there were no treatment-group differences in the overall incidence of these events. There was a significant increase in mean uric acid levels in routine care-treated patients compared to duloxetine-treated patients with regard to chemistry/urinalysis. Both treatments experienced a slight increase in HbA_{1c}, with duloxetine-treated patients experiencing a larger increase in the mean change from baseline to endpoint (P<0.001). No significant treatment-group differences were observed in low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride levels. There were no significant treatment-group differences observed in the mean change in the Michigan Neuropathy Screening Instrument score from baseline to endpoint. There were no significant treatment-group differences observed in either

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				subset of patients in the ulnar F-wave, ulnar distal sensory latency, and peroneal compound muscle action potential from baseline to endpoint for all patients. There was a significant increase observed in the peroneal F-wave measure for routine care-treated patients (P=0.05). There were no significant treatment-group differences observed for any of the ophthalmologic exam measures. There was a significant treatment-group difference observed in the mean change in microalbumin/creatinine ratio from baseline to endpoint (P=0.031), with duloxetine-treated patients experiencing a bigger mean decrease compared to routine care-treated patients. There was no significant treatment-group difference observed in the mean change from baseline to endpoint vital signs and weight. One duloxetine-treated patient and one routine care-treated patient met the definition for sustained elevation in SBP, and there were no significant differences between treatments. There were no ECG parameters that were significantly different between treatments. Significantly more routine-care patients had potentially clinically significant Fridericia-corrected QT interval increases (P=0.034).
Raskin et al.[185] (2006) Duloxetine 60 mg BID vs routine care (gabapentin, amitriptyline, and venlafaxine)	ES, OL, RCT Adult patients who presented with pain due to bilateral peripheral neuropathy caused by type 1 or 2 diabetes	N=237 52 weeks	Primary: Not reported Secondary: SF-36, EQ-5D	Primary: Not reported Secondary: No significant treatment-group differences were observed in the SF-36 subscales or in the EQ-5D questionnaire.
Fibromyalgia				
Arnold et al.[186]	DB, PC, RCT	N=308	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2012) Duloxetine 30 mg/day	Patients meeting the criteria for primary fibromyalgia as defined by the American College of Rheumatology	12 weeks	Average pain severity item from the BPI-Modified Short Form, Secondary: PGI-I, FIQ total score and those measuring pain, depression, anxiety, health outcomes, and safety	Duloxetine-treated patients did not have a statistically significant BPI-Modified Short Form average pain severity reduction vs placebo-treated patients (-2.04 vs -1.70; P=0.202). Secondary: There was a significant difference between duloxetine-treated and placebo-treated patients (P<0.05) for the PGI-I endpoint score (2.97 vs 3.35) and the changes in FIQ total score (-14.62 vs -9.75) and the SF-36 mental component score. Discontinuations due to adverse events did not differ significantly between treatment groups; nausea and dry mouth were the only adverse events with a significantly higher incidence with duloxetine vs placebo.
Arnold et al.[187] (2009) Duloxetine 60 to 120 mg/day vs placebo	DB, MC, PC, RCT (pooled analysis of 4 trials) Outpatients ≥18 years of age with fibromyalgia and a score ≥4 on the average pain severity item of the BPI	N=1,332 12 to 15 weeks	Primary: Pain severity (BPI) Secondary: BPI pain interference items, FIQ, CGI-S, PGI-I, HAM-D, SF-36, SDS, MFI	Primary: In both depressed and nondepressed patients, significantly more duloxetine-treated patients achieved ≥30% reduction in BPI average pain score from baseline compared to placebo-treated patients (P<0.001). The treatment-by-MDD status interaction was not significant (P=0.34). In both depressed and nondepressed patients, significantly more duloxetine-treated patients achieved ≥50% reduction in BPI average pain score from baseline compared to placebo-treated patients (P<0.001). The treatment-by-MDD status interaction was not significant (P=0.39). Secondary: For both depressed and nondepressed patients, mean changes from baseline to endpoint on the FIQ, SDS, and CGI-S were significantly greater for duloxetine-treated patients compared to placebo-treated patients (P<0.05). All treatment-by-MDD status interactions were not significant for these assessments (P value not significant). In patients with MDD, significant differences in baseline to endpoint mean changes between duloxetine-treated and placebo-treated patients were observed for the following SF-36 domains: mental component score, mental health score, bodily pain, physical role functioning, social functioning score, and vitality score. In patients without MDD, significant differences in baseline to endpoint mean changes between duloxetine-treated and placebo-treated patients were observed for the following SF-36

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				domains: mental component score, mental health score, general health score, bodily pain, physical functioning, emotional role functioning score, and vitality score. With the exception of the mental health subscale, for all SF-36 domains and composite scales, the treatment-by-MDD status interactions were not significant. In patients with MDD, significant differences in baseline to endpoint mean changes between duloxetine-treated and placebo-treated mental fatigue and reduced motivation; whereas in patients without MDD, the only significant difference between the duloxetine-treated and placebo-treated groups was observed for the mental fatigue score. For all MFI domains, the treatment-by-MDD status interactions were not significant. In the MDD subgroup, the mean improvement on the clinician-rated HAM-D-17 total score from baseline to endpoint was significantly greater for duloxetine-treated patients compared to placebo-treated patients. In patients without MDD, the mean improvement on the HAM-D-17 total score from baseline to endpoint was not significantly different between the treatment groups. The treatment by- MDD status interaction was not significant (P=0.14). For both depressed and nondepressed patients, significantly more duloxetine-treated patients rated themselves as ‘‘much improved’’ or ‘‘very much improved’’ compared to placebo-treated patients (P<0.001). The treatment-by-MDD status interaction was not significant (P=0.45).
Russell et al.[188] (2008) Duloxetine 20 mg/day vs duloxetine 60 mg/day vs	DB, MC, PC, RCT Patients ≥18 years of age with fibromyalgia	N=502 6 months	Primary: Pain severity (BPI), PGI-I Secondary: FIQ, CGI-S, tender-point pain assessments, MFI, HAM-D-17, SDS, SF-36, EQ-5D	Primary: After three months of therapy, patients treated with duloxetine 60 and 120 mg/day experienced significantly greater improvements in average pain severity score compared to patients treated with placebo (-1.99, -2.31, -1.39, respectively; P≤0.05 and P≤0.001 vs placebo, respectively). There was no significant difference in pain severity with duloxetine 20 mg/day. At the six-month endpoint, patients treated with duloxetine experienced greater improvements in average pain severity score compared to patients treated with placebo (duloxetine 20/60 mg/day, -2.22 [P≤0.05]; duloxetine 60 mg/day, -1.98 [P≤0.05]; duloxetine 120 mg/day, -2.26 [P≤0.01]). After three months of therapy, the mean endpoint PGI-I score was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
duloxetine 120 mg/day vs placebo				significantly lower in patients treated with duloxetine 20 and 120 mg/day compared to patients treated with placebo (2.79, 2.93, 3.37, respectively; P≤0.01 and P≤0.05 vs placebo, respectively). There was no significant difference in PGI-I scores with duloxetine 60 mg/day compared to placebo. After six months of therapy, the mean endpoint PGI-I score was significantly lower in the duloxetine 20/60 mg/day (2.79; P≤0.01) and duloxetine 120 mg/day groups (2.93; P≤0.05), but not the duloxetine 60 mg/day group (3.08; P value not significant) compared to the placebo group (3.37). Secondary: After three months of therapy, duloxetine-treated patients demonstrated greater improvements in the CGI-S score (60 and 120 mg; P≤0.01 and P≤0.001, respectively), SF-36 mental component score (120 mg; P≤0.05), and some of the MFI domains (20, 60, 120 mg; P≤0.05, P≤0.01, and P≤0.001) compared to placebo-treated patients. There were no differences between duloxetine and placebo on other secondary efficacy and health outcome measures. After six months of therapy, duloxetine-treated patients demonstrated greater improvements in the CGI-S score (20/60 mg/day; P≤0.05, 60 mg/day; P≤0.01, 120 mg/day; P≤0.001) and MFI mental fatigue domain (20/60 mg/day; P≤0.05, 60 mg/day; P≤0.05, 120 mg/day; P≤0.01). The other efficacy and health outcome measures that achieved significance in the duloxetine treatment groups compared to the placebo group included the MFI physical fatigue domain and EQ-5D (duloxetine 20/60 mg/day) and the MFI physical fatigue, reduced motivation, and reduced activity domains, as well as SF-36 mental component score (duloxetine 120 mg/day). Response rates (defined as a ≥50% improvement from baseline to the three-month endpoint in the average pain severity score) were significantly greater for duloxetine 120 mg/day (40.1%; P=0.003), but not for duloxetine 60 mg/day (34.0%; P=0.067) or for duloxetine 20 mg/day (32.5%; P=0.200) compared to placebo (23.7%). Response rates from baseline to the six-month endpoint were significantly greater for duloxetine 20/60 mg/day (36.4%; P=0.025), duloxetine 60 mg/day

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(32.6%; P=0.045), and duloxetine 120 mg/day (35.9%; P=0.009) compared to placebo (21.6%). In patients diagnosed with MDD at study entry, least squares mean changes in HAM-D-17 total score at six months were -4.8 for placebo, -5.2 for duloxetine 20/ 60 mg/day, -6.9 for duloxetine 60 mg/day, and -7.2 for 120 mg/day. Treatment group differences were not statistically significant when compared to placebo.
Mease et al.[189] (2010) Duloxetine 60 to 120 mg/day	ES Patients ≥18 years of age with fibromyalgia	N=278 6 months	Primary: Safety, efficacy Secondary: Not reported	Primary: Overall study drug compliance during the six-month ES was 81% in Study 1 and 79% in Study 2. The most common adverse events leading to discontinuation were fatigue and insomnia in Study 1, and diarrhea and nausea in Study 2. The most common treatment-emergent adverse events in Study 1 were nausea, dry mouth, and insomnia. The most common treatment-emergent adverse events in Study 2 were dry mouth, nausea, headache, hyperhidrosis, and muscle spasm. The majority of the treatment groups showed small mean change improvements in the BPI average pain severity score over the final six-month period. The placebo/duloxetine groups in both studies showed significant improvement in the PGI-I, as well as improvement in nearly all other efficacy and health outcome measures, including significant improvement in several SF-36 measures. The maintenance of efficacy analysis in Study 2 did not demonstrate statistical significance (90% CI, -0.39 to 0.77; P=0.580). The mean change in the BPI average pain severity score increased by 0.19 point during the extension phase. Secondary: Not reported
Gilron et al.[190] (2016) Pregabalin and	DB, RCT, XO Patients 18 to 70 years of age with	N=41 6 weeks	Primary: Average pain intensity (0 to 10 scale)	Primary: Average pain (mean ± SEM) was as follows: placebo, 5.1 ± 0.3; pregabalin, 5.0 ± 0.3; duloxetine, 4.1 ± 0.3; combination, 3.7 ± 0.3. Pain with combination was lower than placebo (P<0.001) and pregabalin

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
duloxetine vs pregabalin vs duloxetine vs placebo Participants were allowed to continue NSAIDs, acetaminophen, and/or opioids (≤200 mg oral morphine equivalents)	fibromyalgia and daily pain (≥4/10) for at least three months		Secondary: Worst pain intensity over the past 24 hours and average nocturnal pain intensity during sleeping hours, global pain relief, adverse events	(P<0.001). Pain with duloxetine was lower than placebo (P<0.001) and pregabalin (P=0.003). The comparison of combination to duloxetine resulted in a P-value of 0.09. Secondary: Proportions of participants reporting at least moderate global pain relief at maximum tolerated dose were 18.4% on placebo, 38.5% on pregabalin, 41.7% on duloxetine, and 67.7% on combination. The P value for the comparisons were 0.03 between combination and duloxetine; 0.02 between combination and pregabalin; <0.0001 between combination and placebo; 0.04 between duloxetine and placebo; 0.08 between pregabalin and placebo; and 0.82 between duloxetine and pregabalin. Worst pain with combination (4.5 ± 0.3) was lower than placebo (6.0 ± 0.3, P<0.0001) and pregabalin (5.9 ± 0.3, P<0.0001); worst pain with duloxetine (4.8 ± 0.3) was lower than placebo and pregabalin (P<0.0001 and P=0.0002, respectively). Nocturnal pain with combination (3.2 ± 0.4) was lower than placebo (4.4 ± 0.3, P=0.0001) and pregabalin (4.2 ± 0.4, P=0.0007) but failed to reach significance with duloxetine (3.8 ± 0.3, P=0.052); nocturnal pain with duloxetine was lower than placebo (P=0.03). At maximum tolerated dose, drowsiness was more frequent with combination (26.5%) vs duloxetine (5.3%, P=0.02) and also vs placebo (5.3%, P=0.02); insomnia was significantly more frequent with placebo (34.2%) vs combination (11.8%, P=0.03) and also vs pregabalin (7.9%, P=0.01).
Bidari et al.[191] (2019) Duloxetine 30 to 60 mg/day vs pregabalin 75 to 150 mg/day	OL, RCT Women 18 to 65 years of age with a diagnosis of fibromyalgia	N=99 4 weeks	Primary: Mean difference in score change for Widespread Pain Index (WPI) and BDI-II at week four Secondary: Mean difference in change of sub-scores and total	Primary: WPI scores improved with a statistically significant difference between the two treatment arms, favoring duloxetine (Mean difference in score change -2.32, 95% CI, -4.46 to - 0.18; P=0.034). No significant difference was detected for BDI-II between the two treatment arms. Secondary: No significant difference was detected for FIQ-R or SF-12 between the two treatment arms. Most adverse events occurred during the first and second week of the trial. Overall incidence of nausea was significantly higher in the duloxetine arm

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			score for FIQ-R and SF-12 and difference in cumulative incidence of adverse events	compared to the pregabalin arm. Although there was a higher incidence of constipation, dry mouth, headache, insomnia and hot flashes in the duloxetine arm, no statistical significance was detected. Furthermore, some patients in the duloxetine arm experienced blurred vision, decreased appetite, and generalized weakness, while the patients in the pregabalin arm did not report these adverse events. In contrast, higher incidence of dizziness, light headedness, and drowsiness was reported by patients in the pregabalin arm, with no significant difference between the two treatment arms.
Hauser et al.[192] (2013) Duloxetine or milnacipran vs placebo	MA, SR (10 RCTs) Adult patients >18 years of age with clinical diagnosis of fibromyalgia syndrome by any published, recognized and standardized criteria	N=6,038 Study duration had to be >4 weeks	Primary: Reduction in pain (50%), fatigue, sleep problems, disease-related QOL as measured by total score of FIQ, safety Secondary: 30% reduction in pain, depression, anxiety, disability, sexual function, PGI-C or CGI, cognitive disturbances, tenderness	Primary: Duloxetine and milnacipran had a small effect over placebo in reducing pain (SMD, -0.23; 95% CI, -0.29 to -0.18; 6.1% relative improvement; P<0.001). One-hundred and ninety-two participants per 1,000 on placebo reported an at least 50% pain reduction compared to 286 per 1,000 on duloxetine or milnacipran (RR, 1.49; 95% CI, 1.35 to 1.64; NNT, 11; 95% CI, 9 to 15; P<0.0001). Duloxetine and milnacipran did not reduce fatigue substantially (SMD, -0.14; 95% CI, -0.19 to -0.08; 2.5% relative improvement; NNT, 17; 95% CI, 12 to 29; P<0.001), and did not improve QOL substantially (SMD, -0.20; 95% CI, -0.25 to -0.14; 4.6% relative improvement; NNT, 12; 95% CI, 9 to 17; P<0.001) compared to placebo. There were no statistically significant differences between either duloxetine or milnacipran and placebo in reducing sleep problems (SMD, -0.07; 95% CI, -0.16 to 0.03; 2.5% relative improvement; P=0.15). Secondary: Duloxetine and milnacipran had a significant effect over placebo in 30% pain reduction (RR, 1.36; 95% CI, 1.26 to 1.46; P<0.0001). Duloxetine and milnacipran did not reduce depression substantially (SMD, -0.15; 95% CI, -0.21 to -0.10; P<0.001), and did not improve disability substantially (SMD, -0.22; 95% CI, -0.28 to -0.16; P<0.001) compared to placebo. There were no statistically significant differences between either duloxetine or milnacipran and placebo in reducing anxiety (P=0.54). Out of two studies that reported on sexual function, one study lacked data

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				for reporting and the other study found no difference in reducing sexual problems between milnacipran and placebo. Duloxetine and milnacipran did not improve PGI-C substantially (SMD, -0.27; 95% CI, -0.33 to -0.21; P<0.001), did not have a substantial effect on cognitive disturbances (SMD, -0.15; 95% CI, -0.21 to -0.10; P<0.001), and did not substantially raise the tender point pain threshold (SMD, -0.23; 95% CI, -0.35 to -0.12; P<0.001), compared to placebo. Dropout rates due to adverse events were significantly higher in duloxetine or milnacipran groups at 20.6% compared to 10.9% in the placebo groups (RR, 1.83; 95% CI, 1.53 to 2.18; NNH, 11; 95% CI, 9 to 13; P<0.001). There was no statistically significant difference in serious adverse events between either duloxetine or milnacipran and placebo (RR, 0.78; 95% CI, 0.55 to 1.12; P=0.15). The most frequently reported symptoms leading to stopping medication were nausea, dry mouth, constipation, headache, somnolence/dizziness and insomnia.
Hauser et al.[193] (abstract) (2010) Duloxetine, milnacipran or pregabalin vs placebo	MA (17 RCTs) Patients with fibromyalgia syndrome	N=7,739 Not noted (efficacy noted up to 6 months)	Primary: Symptom reduction (pain, fatigue, sleep disturbance, depressed mood, reduced HRQoL) and adverse events Secondary: Not reported	Primary: Duloxetine, milnacipran and pregabalin were superior to placebo for the outcomes noted except for the following: duloxetine for fatigue, milnacipran for sleep disturbance, and pregabalin for depressed mood were not more efficacious to placebo. There were no significant differences between duloxetine, milnacipran, or pregabalin for 30% pain relief per adjusted indirect comparisons. Differences in average symptom reduction were noted as follows: duloxetine and pregabalin were more efficacious to milnacipran in reduction of pain and sleep disturbances; duloxetine was more efficacious to milnacipran and pregabalin in reducing depressed mood; and milnacipran and pregabalin were more efficacious to duloxetine in reducing fatigue. Secondary: Not reported.
Generalized Anxiety Disorder (GAD)				

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rynn et al.[194] (2008) Duloxetine 60 or 120 mg/day vs placebo	DB, PC, RCT Adult patients with GAD	N=327 10 weeks	Primary: HAMA total score Secondary: Response rate (HAMA total score reduction ≥50% from baseline), CGI-I, SDS, safety	Primary: Duloxetine resulted in significantly greater improvement in HAMA total scores compared to placebo (P=0.023); mean decrease for duloxetine was 8.12 (36% improvement from baseline) compared to a mean decrease of 5.89 (25% improvement from baseline). Significant differences between the two treatments were observed at week two of treatment and remained significant at each subsequent visit (P≤0.001). Secondary: Response and sustained improvement rates were significantly greater for duloxetine-treated patients compared to placebo-treated patients (P<0.05). With duloxetine, the response rate was 40% and sustained improvement was 43.7% compared to 32.0 and 33.1% with placebo. There was no difference in the proportion of patients meeting the criteria for remission (28 vs 23%; P=0.27). Duloxetine resulted in a significantly greater functional improvement based on CGI-I scores compared to placebo (2.68 vs 2.97; P=0.04). Duloxetine-treated patients were significantly more improved compared to placebo-treated patients on SDS global functioning (P<0.01), and work, social, and family/home improvement scores (P<0.05). The rate of discontinuation due to an adverse event was significantly higher with duloxetine compared to placebo (P=0.002). The most commonly reported adverse events with duloxetine treatment were nausea, dizziness, and somnolence.
Koponen et al.[195] (2007) Duloxetine 60 or 120 mg/day vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age with GAD of at least moderate severity	N=513 9 weeks	Primary: HAMA total score Secondary: SDS; HAMA psychic and somatic anxiety factor scores; HAMA response, remission, and	Primary: Both doses of duloxetine demonstrated significantly greater improvements in HAMA total scores compared to placebo (P≤0.001 for both). Both doses of duloxetine resulted in mean decreases in HAMA total score that were more than four points greater than the decreases achieved with placebo; the mean change represents a 49% decrease from baseline with duloxetine. Significant differences between duloxetine and placebo were observed as early as two weeks after treatment initiation, and remained significant at each subsequent visit.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			sustained improvement rates, safety	Secondary: Both doses of duloxetine demonstrated significantly greater functional improvements in SDS global and specific domain scores compared to placebo (P≤0.001). Both doses of duloxetine achieved a mean decrease of more than three points greater than the decreases achieved with placebo; the mean change represents a 47% improvement from baseline with duloxetine. Both doses of duloxetine demonstrated significantly greater improvements in HAMA psychic and somatic anxiety factor scores compared to placebo (P≤0.001 for all comparisons). Both doses of duloxetine resulted in significantly greater HAMA response (58, 56, and 31% with duloxetine 60 mg/day, duloxetine 120 mg/day, and placebo; P≤0.001 for both), remission (31, 38, and 19%; P≤0.01 for duloxetine 60 mg/day vs placebo and P≤0.001 for duloxetine 120 mg/day vs placebo), and sustained improvement rates (64, 67, and 43%; P≤0.001 for both) compared to placebo. There were no significant differences between the two doses of duloxetine on any of the efficacy outcome measures. Approximately 20% of patients receiving duloxetine had their dose decreased during the first two weeks of acute treatment. The rate of study discontinuation due to an adverse event was 11.3, 15.3, and 2.3% with duloxetine 60 mg/day, duloxetine 120 mg/day, and placebo (P≤0.001). Overall, nausea was the most frequent adverse event, which resulted in study discontinuation for 6.0 and 2.4% of duloxetine 60- and 120 mg/day-treated patients.
Alaka et al.[196] (2014) Duloxetine 30 to 120 mg/day vs	DB, MC, PC, RCT Patients ≥65 years of age with GAD with at least moderately severe symptoms	N=291 10 weeks	Primary: HAMA total score Secondary: SDS, adverse events	Primary: Patients treated with duloxetine versus placebo had significantly greater baseline-to-endpoint improvement on the HAMA total score (−15.9 vs −11.7; P<0.001). Significance between treatment group differences began as early as week four and continued to study end at week 10. Secondary: Duloxetine demonstrated a greater effect than placebo on mean changes

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				from baseline in SDS global scores (−8.6 vs −5.4; P<0.001). Treatment-emergent adverse events occurred in ≥5% of duloxetine-treated patients and twice the rate than with placebo including constipation (9 vs 4%; P=0.06), dry mouth (7 vs 1%; P=0.02), and somnolence (6 vs 2%; P=0.14).
Davidson et al.[197] (2008) Duloxetine vs placebo All patients received OL duloxetine for 26 weeks. Treatment responders (≥50% reduction in HAMA total score to ≤11 and "much"/"very much improved" ratings for the last 2 visits of the OL phase.	DB, PC, RCT Patients ≥18 years of age with moderate to severe GAD	N=533 (N=887 OL phase) 26 weeks	Primary: Time to relapse (increase in CGI-S rating ≥2 points from randomization to a score ≥4 while meeting criteria for GAD or by discontinuation due to lack of efficacy) Secondary: HAMA total score, HAMA psychic factor score, HAMA somatic factor scores, HADS-A, CGI-I, PGI-I, SDS, EQ-5D VAS, safety	Primary: Significantly more placebo-treated patients (41.8%) met relapse criteria compared to duloxetine-treated patients (13.7%; P≤0.001). Among patients who did relapse, duloxetine-treated patients had a longer time to relapse compared to patients who were switched to placebo (P≤0.001). Secondary: Patients who continued duloxetine maintained the improvements that were demonstrated during the OL phase. Patients who were switched to placebo significantly worsened on each of the secondary outcomes, including HAMA total score, HAMA psychic factor score, HAMA somatic factor scores, and HADS-A (P≤0.001 for all comparisons). The remission rate for duloxetine-treated patients at endpoint was 68.1 and 39.3% for placebo-treated patients (P≤0.001). Patients receiving placebo were rated as overall less improved by the CGI-I and PGI-I mean endpoint scores compared to patients receiving duloxetine (P≤0.001 for both). Patients treated with placebo also had worsening of their role functioning in all SDS domains of work/school, social life, and family/home management compared to patients who continued with duloxetine (P≤0.001). By endpoint, mean SDS global functioning impairment score with placebo had significantly increased into the range indicating mild to moderate impairment (P≤0.001). The switch to placebo was also associated with decreased life satisfaction and poorer perceived health, as measured by changes in EQ-5D VAS scores (P≤0.001 for all comparisons) compared to patients who continued duloxetine.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				During the OL phase, 15 treatment-emergent adverse events occurred at a frequency of ≥5%: nausea (28.3%), headache (18.7%), dry mouth (14.3%), diarrhea (14.2%), dizziness (13.4%), constipation (12.5%), fatigue (11.5%), hyperhidrosis (10.0%), insomnia (9.8%), somnolence (8.2%), decreased appetite (6.1%), upper respiratory tract infection (5.5%), decreased libido (5.4%), vomiting (5.4%), and nasopharyngitis (5.0%). Most adverse events were mild to moderate in severity. During the DB, continuation phase patients experienced discontinuation-emergent adverse events as the study medication was being withdrawn. Compared to patients receiving duloxetine, dizziness was the only adverse event to occur significantly more often with patients receiving placebo (9.9 vs 3.7%; P≤0.05). No significant increases in pulse rate, DBP, or SBP were observed in duloxetine-treated patients compared to placebo-treated patients. Most events were mild to moderate in severity. Discontinuation from study due to adverse events occurred in four and two patients receiving duloxetine and placebo.
Hartford et al.[198] (2007) Duloxetine 60 to 120 mg/day vs venlafaxine ER 75 to 225 mg/day vs placebo	DB, MC, PC, RCT Outpatients ≥18 years of age with GAD	N=487 10 weeks	Primary: HAMA total score Secondary: HAMA psychic anxiety factor score, somatic anxiety factor score, mood item, and tension item; HADS anxiety and depression subscales scores; CGI-I, PGI-I; SDS	Primary: Patients receiving duloxetine or venlafaxine ER experienced greater improvements in anxiety symptom severity (as measured by HAMA) compared to patients receiving placebo (duloxetine; P=0.007 and venlafaxine ER; P<0.001). The mean decrease in the HAMA total scores was 11.8 for duloxetine and 12.4 for venlafaxine ER compared to 9.2 for placebo. Secondary: Patients treated with duloxetine and venlafaxine ER demonstrated greater improvements in HAMA psychic anxiety factor score, HAMA anxious mood, HAMA tension, and HADS anxiety and depression subscales compared to patients treated with placebo (P<0.01 for all comparisons). Patients treated with both duloxetine and venlafaxine ER had greater improvement ratings at endpoint on the CGI-I and PGI-I compared to patients treated with placebo (P<0.01 for all comparisons). Treatment response was seen in 47% of patients receiving duloxetine, 54%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				of patients receiving venlafaxine ER, and 37% of patients receiving placebo (P<0.001 for venlafaxine ER vs placebo). Using the CGI-I endpoint score, the percentage of responders was greater for duloxetine (55.7%; P=0.007) and venlafaxine ER (60.4%; P<0.001) compared to placebo (41.8%). More venlafaxine ER-treated patients met remission criteria (30%) than placebo-treated patients (19%; P<0.05). The difference was not significant for duloxetine compared to placebo (23%; P value not significant). Sustained improvement rates were greater with duloxetine (55%) and venlafaxine ER (54%) compared to placebo (39%; P<0.01). Duloxetine and venlafaxine ER-treated patients experienced greater improvements in their functioning (SDS global improvement score) from baseline to endpoint compared to placebo (duloxetine, -8.03; venlafaxine ER, -7.97; placebo,-5.42; P<0.01).
Nicolini et al.[199] (2009) Duloxetine 20 mg/day vs duloxetine 60 to 120 mg/day vs venlafaxine ER 75 to 225 mg/day vs placebo	DB, MC, PC, RCT Outpatients ≥18 years of age with GAD	N=581 10 weeks	Primary: HAMA total score Secondary: HAMA psychic and somatic factor scores, SDS, HAMA, CGI-I, PGI-I	Primary: For the HAMA total score, all three treatment groups demonstrated significant improvements from baseline compared to treatment with placebo (duloxetine 20 mg/day, -14.7 [P≤0.01]; duloxetine 60 to 120 mg/day, -15.3 [P≤0.001]; venlafaxine ER, -15.5 [P≤0.001]; placebo -11.6). Secondary: For the HAMA psychic factor scores, all three treatment groups demonstrated significant improvements from baseline compared to treatment with placebo (duloxetine 20 mg/day, -8.1 [P≤0.01]; duloxetine 60 to 120 mg/day, -8.7 [P≤0.001]; venlafaxine ER, -8.6 [P≤0.001]; placebo -6.0). For the HAMA somatic factor score, all three treatments led to improvements from baseline compared to placebo (duloxetine 20 mg/day, -6.6 [P=0.07]; duloxetine 60 to 120 mg/day, -6.6 [P≤0.05]; venlafaxine ER, -7.0 [P≤0.01]; placebo -5.5). Response rates were 60% for duloxetine 20 mg/day (P<0.01), 65% for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				duloxetine 60 to 120 mg/day (P<0.001), 61% for venlafaxine ER (P<0.001), and 42% for placebo. Remission rates were 42% for duloxetine 20 mg/day, 44% for duloxetine 60 to 120 mg/day, 44% for venlafaxine ER, and 20% for placebo (P<0.001 for each comparisons vs placebo). Overall improvement ratings at endpoint were greater for duloxetine-treated patients (20 or 60 to120 mg/day) and venlafaxine ER-treated patients compared to placebo-treated patients by the CGI-I scores (P<0.001 for all comparisons). All three treatments demonstrated significant improvement on the mean HADS anxiety subscale scores compared to placebo (duloxetine 20 mg/day, -7.0 points; duloxetine 60 to 120 mg/day, -7.7 points; venlafaxine ER, -6.9 points; placebo, -4.9 points; P<0.001 for all comparisons). All three treatments demonstrated significant improvement on the mean HADS depression subscale score compared to placebo (duloxetine 20 mg/day, -3.3 points; duloxetine 60 to 120 mg/day, -3.5 points; venlafaxine ER, -3.6 points; placebo, -1.9 points; P<0.001 for all comparisons). For the SDS global functioning improvement score, all three treatment groups demonstrated significant improvements from baseline compared to treatment with placebo (duloxetine 20 mg/day group, -8.5 [P<0.05]; duloxetine 60 to 120 mg/day, -8.9 [P<0.01]; venlafaxine ER, -9.1 [P<0.001]; placebo, -6.2).
Davidson et al.[200] (2005) Escitalopram 10 to 20 mg daily	MC, OL Patients who completed an 8-week, DB, PC, lead-in and were diagnosed with GAD were eligible to enter extension trial	N=526 24 weeks	Primary: CGI-I, HAMA core ≤7 Secondary: Safety	Primary: Ninety two percent of the patients were considered responders. Secondary: Adverse events led to study withdrawal in 9.9% of patents. The most frequent adverse events leading to study withdrawal were ejaculations disorder (1.6%), insomnia (1.3%), and nausea (1%). Serious adverse events were reported by 2.1% of patients, including one completed suicide.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Goodman et al.[201] (2005) Escitalopram 10 to 20 mg daily vs placebo	DB, MC, PC Patients 18 to 80 years of age with DSM-IV defined GAD	N=850 8 weeks	Primary: HAMA Secondary: CGI-S, CGI-I	Primary: Escitalopram significantly improved mean HAMA total scores (the primary efficacy measure) relative to placebo with the mean change from baseline to week eight in HAMA total score –10.1±0.3 for escitalopram and –7.6±0.3 for placebo (P<0.001). Secondary: Escitalopram led to statistically significant improvements compared to placebo in both HAMA subscales: psychic anxiety (–5.8+0.2 vs –3.9±0.2; P<0.001; and somatic anxiety (–4.3±0.2 vs –3.7±0.2; P=0.02). At endpoint, 47.5% of escitalopram-treated patients and 28.6% of placebo-treated patients were responders (P<0.001), and 26.4% of escitalopram-treated patients and 14.1% of placebo-treated patients were remitters (P<0.001). CGI-I response rates at endpoint were 52% for escitalopram and 37% for placebo (P<0.001).
Bielski et al.[202] (2005) Escitalopram 10 to 20 mg/day vs paroxetine 20 to 50 mg/day	DB, RCT Patients with GAD	N=121 24 weeks	Primary: Mean change from baseline in the HAMA scores at week 24, treatment-emergent adverse effects Secondary; Not reported	Primary: After 24 weeks of treatment, patients receiving escitalopram had significantly greater improvement in the HAMA scores compared to the paroxetine group (–15.3 vs –13.3; P=0.13). Significantly fewer patients withdrew from escitalopram than paroxetine treatment due to adverse events (6.6 vs 22.6%; P=0.02). Significantly more patients on paroxetine than on escitalopram experienced treatment-related adverse events (88.7 vs 77.0%). The following adverse events were noted to occur more frequently in the paroxetine group compared to the escitalopram-treated patients: insomnia (25.8 vs 14.8%), constipation (14.5% vs 1.6%), ejaculation disorder (30.0 vs 14.8%), anorgasmia (26.2 vs 5.9%), and decreased libido (22.6 vs 4.9%). In contrast, diarrhea and upper respiratory tract infection were reported more frequently with escitalopram than paroxetine (21.3 vs 8.1%, and 14.8

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				vs 4.8%, respectively). Secondary; Not reported
Bose et al.[203] (2008) Escitalopram 10 to 20 mg/day vs venlafaxine ER 75 to 225 mg/day vs placebo	DB, PC, RCT Outpatients 18 to 65 years of age with GAD	N=404 8 weeks	Primary: Change from baseline to week eight in the HAMA total score Secondary: HAMA psychic anxiety subscale, CGI-I, CGI-S, VAS, HADS QOL, SDS	Primary: The mean change in HAMA total score (LOCF) for escitalopram and venlafaxine ER vs placebo was -1.52 (P=0.09) and -2.27 (P=0.01), respectively at week eight. The mean change in HAMA total score for escitalopram and venlafaxine ER vs placebo was -1.92 (P=0.033) and -3.02 (P=0.001), respectively at week eight. Secondary: Neither escitalopram nor venlafaxine produced greater HAMA response or remission than placebo (response: 52.8 and 52.0% for escitalopram and venlafaxine, respectively vs 42.2% for placebo; remission: 31.2% for both escitalopram and venlafaxine vs 23.7% for placebo; P>0.05 vs placebo, LOCF). Both escitalopram and venlafaxine had significantly higher CGI-I response rates than the placebo (escitalopram 60.0%, venlafaxine 65.6%, placebo 45.9%, P<0.05, LOCF). Both groups had higher CGI-S and HADS response rates compared to placebo. There was no significant difference in VAS, QOL or SDS for escitalopram compared to placebo (LOCF). There was no significant difference in VAS or QOL for venlafaxine compared to placebo (LOCF).
Ball et al.[204] (2005) Paroxetine 10 to 40 mg daily vs sertraline 25 to 100 mg daily	DB, FD, PG Patients with GAD	N=55 8 weeks	Primary: HAMA scores as well as responder and remission rates based on the CGI scale Secondary: Improvement in IU-GAM	Primary: Both sertraline and paroxetine groups displayed significant reductions in HAMA scores from baseline to end of treatment (P<0.001). The mean percent reduction in HAMA scores was 57.3% for the paroxetine group and 55.9% for the sertraline group. The percent of treatment responders was 68% in the paroxetine group and 61% in the sertraline group. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Both sertraline and paroxetine groups displayed significant reductions in IU-GAMS scores from baseline to end of treatment (P<0.001). With treatment response defined as a reduction of greater than 50% in IU-GAMS scores from baseline to posttreatment, 40% of the paroxetine group responded compared to 25% of the sertraline group.
Dahl et al.[205] (2005) Sertraline 50 to 150 mg daily vs placebo	MC, RCT Outpatients with GAD	N=373 12 weeks	Primary: Change from baseline to endpoint in HAMA total score of the ITT population Secondary: CGI-S, CGI-I, MADRS, Q-LES-Q	Primary: Sertraline treatment was associated with significant improvement (P<0.001) in the HAMA psychic anxiety factor. Significant separation from placebo in primary endpoint was significant by week 4 for sertraline (52%) compared to placebo (34%; P=0.001). Clinically meaningful improvement (≥30% reduction in psychic symptom severity) was achieved by week four in the majority of patients (P=0001). Secondary: Global improvement was modestly but consistently better correlated with improvement in psychic anxiety. The degree of correlation was similar, regardless of study treatment. QOL was significantly improved in the sertraline group compared to placebo with improvement seen in 51% of patients on sertraline compared to 35% on placebo (P<0.01).
Schmitt et al.[206] (2005) Venlafaxine, paroxetine, imipramine, trazodone, diazepam, sertraline	MA RCTs evaluating antidepressants in GAD	N=2,238 8 to 28 weeks	Primary: Absence of treatment response (defined as absence of sufficient symptoms to meet diagnostic criteria for GAD) Secondary: Acceptability of the treatment as	Primary: Antidepressants (imipramine, venlafaxine, and paroxetine) were found to be more effective when compared to placebo in treating GAD. The calculated NNT for antidepressants as a group in GAD was 5.15. Considering all trials, the pooled RR for nontreatment response was 0.70 (95% CI, 0.62 to 0.79), favoring antidepressant treatment. The calculated NNT was 5.5 (95% CI, 4.1 to 8.4). For imipramine the calculated RR was 0.67 (95% CI, 0.50 to 0.91) and the NNT was 4.0 (95% CI, 2.4 to 13.7).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			measured by the number of people dropping out during the trial	For venlafaxine the calculated RR for nontreatment response was 0.68 (95% CI, 0.46 to 0.99), and the calculated NNT was 5.00 (95% CI, 3.58 to 8.62). For paroxetine the calculated RR was 0.72 (95% CI, 0.56 to 0.92), and the calculated NNT was 6.72 (95% CI, 3.90 to 24.70). For paroxetine vs imipramine the calculated RR was 1.73 (95% CI, 0.31 to 9.57). Secondary: No significant differences were found between antidepressants and placebo with regard to drop out rate. The RR for dropout for any antidepressant was 0.95 (95% CI, 0.84 to 1.09). Similarly, when individual antidepressants were considered, no differences were found between individual treatments and the placebo group: imipramine: RR, 0.71 (95% CI, 0.41 to 1.24); venlafaxine: RR, 0.86 (95% CI, 0.72 to 1.02); sertraline: RR, 0.45 (95% CI, 0.03 to 5.84); paroxetine: RR, 1.15 (95% CI, 0.74 to 1.78); and paroxetine vs imipramine: RR, 1.62 (95% CI, 0.58 to 4.48).
Insomnia				
Roth et al.[207] (2007) Doxepin 1 mg vs doxepin 3 mg vs doxepin 6 mg	DB, PC, RCT, XO Patients 18 to 64 years of age with chronic primary insomnia	N=67 2 nights	Primary: WTDS Secondary: WASO, sleep efficiency, TST, LPS, number of awakenings after sleep onset, WTAS, and sleep architecture	Primary: I. WTDS was significantly reduced with doxepin 3 mg (P<0.0001) and doxepin 6 mg (P<0.0001) compared to placebo. There was no significant difference in WTDS with doxepin 1 mg compared to placebo (P=0.0918). I. I. Secondary: /. WASO was significantly decreased with doxepin (all doses) compared to placebo (1 mg; P=0.0090, 3 mg; P<0.0001, and 6 mg; P<0.0001). /. I. There were no significant differences in NAASO with doxepin (all doses) compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				I. I. There was no significant difference in LPS with doxepin (all doses) compared to placebo. ǩ. ǩ. TST and overall sleep efficiency were significantly increased with doxepin (all doses) compared to placebo (all P≤ 0.0005). I. I. WTAS was significantly reduced with doxepin 6 mg compared to placebo (P=0.0088). There was no significantly difference with doxepin 1 mg (P=0.1421) or doxepin 3 mg (P=0.0697) compared to placebo. WASO was not significantly decreased with doxepin 1 mg (56.4; P=0.8915), doxepin 3 mg (49.4; P=0.8789), or doxepin 6 mg (45.1; P=0.1168) compared to placebo (54.4). Number of awakenings after sleep onset was significantly decreased with doxepin 3 mg (2.8; P=0.0207) compared to placebo (3.2). LSO was significantly decreased with doxepin 6 mg (43.0; P=0.0244), but not significantly decreased with doxepin 1 mg (46.5; P=0.1944) or doxepin 3 mg (45.3; P=0.0905) compared to placebo (49.6). TST was significantly increased with doxepin 6 mg (380.7; P=0.0190), but not with doxepin 1 mg (364.8; P=0.9992) or doxepin 3 mg (380.0; P=0.0562) compared to placebo (364.2). Sleep quality was significantly improved with doxepin 6 mg (0.8; P=0.0071) compared to placebo (0.4). There were no significant differences among doxepin doses for percentage or min of Stage 1 sleep. There was a significant increase in percentage of Stage 2 sleep (3 mg, 57.8%; P=0.0003, 6 mg, 58.7%; P<0.0001; placebo, 54.7%). There was a significant increase in min of Stage 2 sleep (1 mg, 228.5 min; P=0.0008, 3 mg, 240.4 min; P<0.0001, 6 mg, 245.8 min; P<0.0001; placebo, 212.9 min). There was a significant decrease in percentage of REM sleep (3 mg, 18.3%, P=0.0046; 6 mg, 17.8%, P=0.0002; placebo, 20.0%). The number of min spent in REM sleep was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				not significantly different among the doxepin doses. There were no significant differences among doxepin doses for either percentage or min of Stage 3/4 sleep. There were no significant differences among the treatment groups on any of the measures assessing either psychomotor function (DSST) or next-day alertness (VAS). Adverse events were comparable to placebo, with no reported anticholinergic effects, no memory impairment, and no significant hangover/next-day residual effects.
Scharf et al.[208] (2008) Doxepin 1 mg vs doxepin 3 mg vs doxepin 6 mg vs placebo	DB, PC, RCT, XO Elderly patients with primary insomnia	N=76 2 nights	Primary: WTDS Secondary: WASO, TST, sleep efficiency, latency to sleep onset	Primary: Compared to placebo, treatment with doxepin (all doses) led to significant improvements WTDS (P<0.0001). Secondary: Compared to placebo, treatment with doxepin (all doses) led to significant improvements in WASO (P<0.0001). Compared to placebo, treatment with doxepin (all doses) led to significant improvements in TST (P<0.0001). Compared to placebo, treatment with doxepin (all doses) led to significant improvements in overall sleep efficiency (P<0.0001). Sleep efficiency was significantly improved during all thirds of the night with doxepin 3 and 6 mg compared to placebo (P<0.05). Treatment with doxepin 6 mg led to significant improvements in latency to sleep onset compared to placebo (P=0.0181). The incidence of adverse events with doxepin was comparable to placebo.
Krystal et al.[209] (2010) Doxepin 1 mg	DB, PC, RCT Patients ≥65 years of age with primary insomnia	N=240 12 weeks	Primary: WASO on night one Secondary:	Primary: WASO was significantly improved on night one for doxepin 3 mg (P<0.0001) and doxepin 1 mg (P=0.0053) compared to placebo. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs doxepin 3 mg vs placebo			WASO at other time points, LPS, number of awakenings after sleep onset, TST, sleep efficiency, and WTAS, CGI-S, CGI-I	WASO was significantly improved on night 29 (P=0.0005) night 85 (P<0.0001) for doxepin 3 mg, and on night 85 (P=0.0330) for doxepin 1 mg compared to placebo. Mean change from night one to 85 were: placebo, 0.4 (P=0.96); doxepin 1 mg, 3.0 (P=0.57); doxepin 3 mg, 0.9 (P=0.62). TST and overall sleep efficiency were significantly improved on night one (P<0.0001), night 29 (P=0.0161), and night 85 (P=0.0007) for doxepin 3 mg, and on night one (P=0.0119) and night 85 (P=0.0257) for doxepin 1 mg compared to placebo. There was a significant improvement in sTST at weeks one (P=0.0043), four (P=0.0035), and 12 (P=0.0001) for doxepin 3 mg, and at weeks four (P=0.0343) and 12 (P=0.0027) for doxepin 1 mg compared to placebo. Sleep efficiency in the last quarter of the night was significantly increased on night one1 (P<0.0001), night 29 (P=0.0004), and night 85 (P=0.0014) for doxepin 3 mg compared to placebo. For doxepin 1 mg, sleep efficiency in the last quarter of the night was significantly increased on night one (P=0.0011) compared to placebo. Sleep efficiency in hour eight was significantly increased on night one (P<0.0001) and night 29 (P=0.0029) for doxepin 3 mg compared to placebo. For doxepin 1 mg, sleep efficiency in hour eight was significantly increased on night one compared to placebo (P=0.0211). WTAS was significantly decreased on N85 (P=0.0284) for doxepin 3 mg compared to placebo. LPS was not significantly reduced at any time point when compared to placebo. Sleep quality was significantly increased at weeks one (P=0.0039), four (P=0.0049), and 12 (P=0.0100) for doxepin 3 mg, and at weeks four (P=0.0464) and 12 (P=0.0107) for doxepin 1 mg compared to placebo. There was significant improvement after two weeks (P=0.0047), after four

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				weeks (P=0.0356), and after 12 weeks (P=0.0005) on the CGI-S scale score for doxepin 3 mg, and after 12 weeks (P=0.0101) for doxepin 1 mg compared to placebo. There was significant improvement after two weeks (P=0.0060), after four weeks (P=0.0334), and after 12 weeks (P=0.0008) on the CGI-I scale score for doxepin 3 mg, and after 12 weeks (P=0.0082) for doxepin 1 mg compared to placebo. Daytime function ratings were significantly improved on night one for doxepin 3 mg (P=0.0282) and 1 mg (P=0.0192) and on night 85 for doxepin 3 mg (P=0.0028) and 1 mg (P=0.0102) compared to placebo. Sleep stages were preserved compared to placebo, with no apparent evidence of suppression of REM duration. There were no significant differences between placebo and either dose of doxepin on any of the measures assessing objective psychomotor function (DSST) or subjective next-day alertness (VAS) or drowsiness at any time point during the trial. Rates of treatment-emergent adverse events were lower in patients treated with doxepin 1 mg (40%) and doxepin 3 mg (38%) compared to placebo (52%). The most common adverse events were headache and somnolence.
Krystal et al.[210] (2011) Doxepin 3 mg vs doxepin 6 mg vs placebo	DB, PC, RCT Patients 18 to 64 years of age with primary insomnia	N=229 35 days	Primary: WASO on night one Secondary: WASO at other time points, LPS, number of awakenings after sleep onset, TST, sleep efficiency, and	Primary: WASO was significantly improved on night one for doxepin 3 mg (P<0.0001) and doxepin 6 mg (P<0.0001) compared to placebo. Secondary: WASO was significantly improved on night 15 (P=0.0053) and night 29 (P=0.0299) for doxepin 3 mg, and on night 15 (P=0.0023) and night 29 (P=0.0012) for doxepin 6 mg compared to placebo. There were no significant differences between doxepin groups on WASO. TST and sleep efficiency were significantly improved on night one (P<0.0001) and night 29 (P=0.0262) for doxepin 3 mg, and on night one (P<0.0001), night 15 (P=0.0157), and night 29 (P=0.0003) for doxepin 6 mg compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no significant differences in number of awakenings after sleep onset for any dose at any time point. Sleep efficiency in the last quarter of the night was significantly improved on night one (P=0.0008) and night 15 (P=0.0220) for doxepin 3 mg, and on night one (P<0.0001), night 15 (P=0.0239), and night 29 (P=0.0029) for doxepin 6 mg compared to placebo. Sleep efficiency in hour eight was significantly improved on night one (P<0.0001) and night 29 (P=0.0315) for doxepin 3 mg, and on night one (P<0.0001), night 15 (P=0.0162), and night 29 (P=0.0020) for doxepin 6 mg compared placebo. WTAS was significantly improved on night one (P=0.0001) for doxepin 3 mg, and also on night one (P=0.0016) for doxepin 6 mg compared to placebo. LPS was significantly improved on night one (P=0.0047) for doxepin 3 mg, and on night one (P=0.0007) for doxepin 6 mg compared to placebo. There were significant improvements in patient-reported WASO for both doses of doxepin on night one compared to placebo (3 mg; P=0.0003, 6 mg; P=0.0004). There were significant improvements in patient-reported TST for both doses of doxepin at night one compared to placebo (3 mg; P=0.0088, 6 mg; P=0.0135). Sleep quality was significantly improved for both doses of doxepin at night one compared to placebo (3 mg; P=0.0068, 6 mg; P<0.0001). Subjective LSO was significantly improved on night one with doxepin 6 mg compared to placebo (P=0.0492). There was no evidence of tolerance to the sleep maintenance effects. There is evidence to suggest the development of tolerance to the sleep onset effects. There were increases in the duration of stage two sleep for both doses of doxepin, which were significant at most time points. There were no significant differences between the two doxepin groups vs placebo in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				minutes of stage one sleep, stage 3/4 sleep, or REM sleep. Across two nights, rebound insomnia was experienced by 1% of the placebo group, 1% of the doxepin 3 mg group, and 4% of the doxepin 6 mg group.
Roth et al.[211] (2010) Doxepin 6 mg vs placebo	DB, PC, MC, RCT Healthy adults 25 to 55 years of age with normal sleep habits	N=565 Single dose	Primary: LPS Secondary: WASO, TST, WTDS, WTAS, sleep efficiency, and number of awakenings after sleep onset, sleep architecture measurements, DSST, symbol copying test, and VAS	Primary: LPS was significantly lower for doxepin compared to placebo (21 vs 34 minutes, respectively; P<0.0001). Secondary: WASO was significantly lower for doxepin compared to placebo (38 vs 78 minutes, respectively; P<0.0001). WTDS was significantly lower for doxepin compared to placebo (P value not reported). There were no significant differences among the treatment groups in number of awakenings after sleep onset (P value not reported). TST was significantly higher for doxepin compared to placebo (425.2 vs 374.1 minutes, respectively; P<0.0001). Overall sleep efficiency was significantly higher for doxepin compared to placebo (P value not reported). WTAS, sleep efficiency in the final quarter of the night, and sleep efficiency at hours seven and eight were significantly improved for doxepin compared to placebo (all P<0.0001). Doxepin had significantly higher sleep efficiency at each hour compared to placebo (P<0.0001). Subject- reported LSO was significantly lower for doxepin compared to placebo. WASO and sNAASO were significantly lower for doxepin compared to placebo. TST was significantly higher for doxepin compared to placebo. Sleep quality was significantly improved for doxepin compared to placebo. There were no significant differences between doxepin and placebo in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mean change in DSST score from predose to postdose. There were no significant differences in sleepiness with doxepin compared to placebo (symbol copying test; P=0.0228, VAS; P=0.0241). The incidence of adverse events with doxepin was comparable to placebo.
Musculoskeletal Pain				
Skljarevski et al.[212] (2010) Duloxetine 60 mg QD vs placebo	DB, PC, RCT Patients ≥18 years of age with chronic low back pain	N=401 12 weeks	Primary: Reduction of pain severity (BPI 24-hour average pain rating) Secondary: PGI-I, RMDQ-24, CGI-S, BPI-S, BPI-I, response rates, health outcomes (EQ-5D and SF-36)	Primary: There was a significantly greater reduction in the BPI 24-hour average pain in patients treated with duloxetine compared to patients treated with placebo (P≤0.001). Secondary: Duloxetine-treated patients reported significantly greater improvements in PGI-I scores compared to placebo-treated patients (2.88 vs 3.19, respectively; P=0.011). There was no significant difference in RMDQ-24 scores with duloxetine compared to placebo (-2.69 vs -2.22, respectively; P=0.255). There was no significant difference in CGI-S among the treatment groups. There was a significant reduction in all four domains of BPI-S (average pain, worst pain, least pain, and pain right now) pain scores reported with duloxetine compared to placebo. All seven domains of the BPI-I (general activity, mood, walking ability, normal work, relations with others, sleep, enjoyment of life) were significantly better with duloxetine compared to placebo. A greater percentage of patients receiving duloxetine reported ≥50% pain reduction compared to patients receiving placebo (P=0.006). There was no significant difference in the 30% pain response rates among the treatment groups. There were significant differences in changes on four of six mood states on the POMS-Brief Form, along with the total mood disturbance score, between the two treatment groups: tension-anxiety (P≤0.001), anger-hostility (P≤0.001), vigor-activity (P=0.003), confusion-bewilderment

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P=0.006), and total mood disturbance (P≤0.001). Changes in depression-dejection and fatigue-inertia states were not significant. The change in EQ-5D was significantly different between duloxetine and placebo with the United Kingdome index (P≤0.001) and United States index (P=0.002). In the SF-36 domains, the differences between duloxetine and placebo treatments were significant with regard to mental component summary (P=0.010), bodily pain (P=0.016), mental health transformed (P≤0.001), social functioning (P=0.030), and vitality transformed (P=0.022). There was no significant difference among the treatment groups in other domains. The WPAI questionnaire demonstrated a significant difference between the treatment groups with regard to activity impairment (P=0.007). There was no significant difference among the treatment groups in other domains. Significantly more patients in the duloxetine group (15.2%) than patients in the placebo group (5.4%) discontinued because of adverse events (P=0.002). Nausea and dry mouth were the most common treatment-emergent adverse events with rates significantly higher in duloxetine-treated patients.
Skljarevski et al.[213] (2010) Duloxetine 60 to 120 mg QD vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with chronic low back pain	N=236 13 weeks	Primary: Reduction of pain severity (BPI 24-hour average pain rating) Secondary: PGI-I, RMDQ-24, BPI-S, BPI-I, CGI-S, Athens Insomnia Scale response rates, health outcomes (EQ-5D and SF-36), WPAI	Primary: There was a significantly greater reduction in the BPI 24-hour average pain in patients treated with duloxetine compared to patients treated with placebo at all time points (-1.42 vs -0.78, respectively; P=0.016 at week four; -2.06 vs -1.17, respectively; P=0.001 at week seven; and -2.32 vs -1.50, respectively; P=0.004 at week 13). Secondary: Duloxetine-treated patients reported significantly greater improvements in PGI-I scores compared to placebo-treated patients at all time points (3.12 vs 3.51, respectively; P=0.007 at week four; 2.82 vs 3.32, respectively; P=0.001 at week seven; 2.59 vs 3.16, respectively; P=0.001 at week 13). There was a significant difference in RMDQ-24 scores at endpoint with duloxetine compared to placebo (-3.60 vs -1.93, respectively; P=0.009).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The mean changes in pain scores, including BPI-S (worst pain, least pain, and pain right now) items; BPI-I average pain; and weekly mean of the 24-hour average pain, night pain, and worst pain scores from patient diaries were significantly improved with duloxetine compared to placebo. There was no significant difference in the CGI-S and Athens Insomnia Scale scores among the treatment groups. There was no significant difference in response rates with duloxetine compared to placebo (30% response: 53.2 vs 40.0%, respectively; P=0.060 and 50% response: 38.5 vs 27.0%, respectively; P=0.087). The depression and anxiety scores were not significantly changed from baseline to endpoint. The improvement in BPI average pain was because of the direct analgesic effect (80.4%; P=0.012) of duloxetine treatment and not dependent on the improvement in mood (BDI-II total score, 19.2%) or anxiety (HADS-A, 0.3%) symptoms. The United Kingdome and United States indexes of EQ-5D did not change significantly in patients treated with duloxetine compared to patients treated with placebo. Among the eight subscales of SF-36 only bodily pain (P=0.038), general health (P=0.041), and vitality (P=0.040) were significantly improved with duloxetine compared to placebo. In the WPAI, work activity impairment was the only item that significantly (P=0.002) improved with duloxetine compared to placebo. Significantly more patients in the duloxetine group (13.9%) compared to the placebo group (5.8%) discontinued because of adverse events (P=0.047). The most common treatment-emergent adverse events in the duloxetine group included nausea, dry mouth, fatigue, diarrhea, hyperhidrosis, dizziness, and constipation.
Skljarevski et al.[214](2010) Duloxetine 60 to	ES Patients ≥18 years of age with chronic	N=181 41 weeks	Primary: Reduction of pain severity (BPI 24-hour average pain	Primary: For patients who received duloxetine during the initial 13-week trial, pain reduction continued during the extension phase. The mean change in BPI average pain in the extension phase was -0.97 (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
120 mg QD	low back pain		rating) Secondary: Response rates, PGI-I, RMDQ-24, BPI-S, BPI-I, CGI-S, Athens Insomnia Scale response rates, health outcomes (EQ-5D and SF-36)	Secondary: The 30%, 50%, and sustained response rates were ~10% higher for patients who received duloxetine during the initial 13-week trial compared to those who received placebo. A total of 94.8% of PC phase duloxetine responders still met response criteria at the end of the 41-week extension phase. The BPI average pain, worst pain, least pain, pain right now, and average interference all showed significant within-group improvement for both treatment groups. Both treatment groups showed significant improvement on the RMDQ-24 measures, CGI-S measures, and most of the health outcome assessments. No significant change was observed in the BDI total score and HADS depression score. Duloxetine was well tolerated with no new safety findings reported.
Skljarevski et al.[215] (2009) Duloxetine 20, 60, or 120 mg/day vs placebo	DB, MC, PC, RCT Adult patients with non-radicular chronic low back pain	N=404 13 weeks	Primary: Weekly mean 24-hour average pain (duloxetine 60 mg/day vs placebo) Secondary: RMDQ-24, PGI-I, BPI, safety	Primary: Improvement in average weekly pain was significantly greater for duloxetine 60 and 120 mg/day doses beginning at week three, but the significance was lost at weeks 12 and 13, respectively. The mean change from baseline to endpoint in average weekly pain did not differ significantly from placebo for 60 mg/day (P=0.104) or any other duloxetine doses. Analysis of average weekly pain response rates (30% reduction from baseline to end-point) showed a significantly greater percentage of responders with duloxetine 120 mg/day (57.8%) compared to placebo (43.4%; P=0.033), but neither 20 (41.1%) or 60 mg/day (53.6%) differed significantly from placebo (P values not reported). There were no significant differences between any doses in 50% response rates. Secondary: Patients overall improvement (PGI-I) was greater for patients receiving duloxetine 60 mg/day, and improvement in physical functioning (RMDQ-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				24) was greater for patients receiving duloxetine 60 and/or 120 mg/day compared to patients receiving placebo. Patients receiving duloxetine 60 mg/day also demonstrated significant improvement over patients receiving placebo on several measures of pain severity, interference of pain with activities, and sleep. Eight (1.98%) patients experienced at least one serious adverse event (three placebo-treated patients and one duloxetine 20- and 60 mg/day-treated patients, and three duloxetine 120 mg/day-treated patients). Duloxetine 120 mg/day was associated with a significantly higher proportion of treatment-emergent adverse events compare to placebo (P=0.038).
Chappell et al.[216] (2009) Duloxetine 60 to 120 mg QD vs placebo	DB, MC, PC, RCT Patients ≥40 years of age with osteoarthritis of the knee and pain for ≥14 days/month	N=231 13 weeks	Primary: Mean changes in the weekly mean 24-hour average pain score Secondary: Patients' perceived improvement as measured by PGI-I and on the change in patients' functioning as measured by the WOMAC physical functioning subscale, weekly mean of the 24-hour worst pain score, CGI-S, WOMAC pain and stiffness subscales, BPI-S and BPI-I, response to treatments, health	Primary: Duloxetine was more effective than placebo on the primary efficacy measure (weekly mean 24-hour pain scores) beginning at week one and continuing through the treatment period (P<0.05). There was a significant reduction in the average pain score in the duloxetine group compared to the placebo group at each week. The mean change from baseline to endpoint in the 24-hour average pain score also showed a significant benefit for duloxetine over placebo (P=0.006). Analysis of the weekly 24-hour average pain score response rates (30% reduction in score from baseline to endpoint) showed a significant difference between duloxetine (59.3%) and placebo (44.5%; P=0.033). The 50% response rates revealed a similar pattern (duloxetine, 47.2%; placebo, 29.4%; P=0.006). Secondary: There was a significant improvement with duloxetine in most secondary endpoints compared to placebo. Mean changes in BDI-II and HADS-A did not differ significantly between treatment groups. For patients randomly re-assigned to duloxetine at week seven, there was a significant improvement in mean change in the weekly 24-hour average pain score in the duloxetine 120 mg/day group compared to the duloxetine 60 mg/day group (P=0.039). No significant differences were observed between the two duloxetine groups in the Mixed Model Repeated

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			outcomes, safety	Measures analysis of the weekly 24-hour average pain score or the 30% and 50% response rates at endpoint. Adverse event rates did not differ significantly between treatment groups (49.5% for duloxetine and 40.8% for placebo). A total of 45.0% of patients reported ≥1 treatment-emergent adverse events.
Chappell et al.[217] (2010) Duloxetine 60 to 120 mg QD vs placebo	DB, MC, PC, RCT Patients ≥40 years of age with osteoarthritis of the knee and pain for ≥14 days/month	N=256 13 weeks	Primary: BPI 24-hour average pain rating Secondary: Weekly mean 24-hour average pain and worst pain rating, patients' perceived improvement as measured by PGI-I and on the change in patients' functioning as measured by the WOMAC physical functioning subscale, CGI-S, WOMAC pain and stiffness subscales, BPI-S and BPI-I, response to treatments, health outcomes, safety	Primary: There was a significant reduction in the BPI average pain rating with duloxetine compared to placebo at all time points (P≤0.001). The BPI average pain response rates (≥30% pain reduction from baseline to endpoint) were significantly higher with duloxetine (65.3%) compared to placebo (44.1%; P≤0.001). The 50% response rates of BPI average pain did not significantly differ between the treatment groups (duloxetine, 43.8%; placebo, 32.3%; P=0.068). Secondary: The least squares mean changes in the weekly mean 24-hour average pain rating was significantly reduced with duloxetine compared to placebo as early as at week two and remained significant at all time points. The weekly mean 24-hour worst pain ratings were significantly improved with duloxetine compared to placebo. Patients receiving duloxetine experienced greater improvements in many secondary endpoints compared to placebo, including CGI-S, BPI-S items, and BPI-I items (general activity and normal work). The other BPI-I items (mood, walking ability, relations with other people, sleep, enjoyment of life, and average interference) were not significantly different between the two treatment groups. No significant improvement in PGI-I was observed in the duloxetine group compared to the placebo group (P=0.164). The mean changes from baseline to endpoint were improved significantly for WOMAC total score (P=0.004) and physical functioning subscale (P=0.016) in patients treated with duloxetine compared to placebo. The other two WOMAC subscales (pain and stiffness) did not show significant improvement with duloxetine treatment.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Both the United Kingdome and the United States indexes of EQ-5D did not change significantly with either treatment. Physical component summary and three of the subscales of SF-36 were significantly improved with duloxetine compared to placebo. The other SF-36 items (mental component summary, general health, mental health, role-emotional, social functioning, and vitality) were not significantly improved with duloxetine compared to placebo. The frequency of nausea, constipation, and hyperhidrosis were significantly higher in the duloxetine group (P≤0.05). Significantly more duloxetine-treated patients discontinued therapy because of adverse events (P=0.002).
Frakes et al.[218] (2011) Duloxetine 60 to 120 mg QD vs placebo Patients were also required to take an NSAID and PPI.	DB, MC, PC, RCT Patients ≥40 years of age with osteoarthritis of the knee and pain for ≥14 days/month and who were using NSAIDs on most days of the week	N=524 10 weeks	Primary: Weekly mean of the daily average pain rating at week eight Secondary: Endpoint PGI-I, change in WOMAC physical function	Primary: Patients receiving duloxetine experienced significantly greater pain reduction at week eight than those receiving placebo. The estimated mean change was -2.46 for duloxetine compared to -1.55 for placebo (P<0.001). Duloxetine demonstrated greater improvement as early as week one (P<0.01), and at each subsequent week (P<0.001). Secondary: There was no significant difference in the use of acetaminophen as rescue medication for knee pain due to osteoarthritis (P=0.08). The mean PGI-I and the change in the WOMAC physical function scale were significantly different between the duloxetine and placebo groups (P<0.001 for each). Estimated mean improvement in diary-based night pain and worst pain ratings were significantly greater for duloxetine compared to placebo (P<0.001 for each). Duloxetine-treated patients showed greater reductions for each item on the pain and interference ratings on the BPI compared to placebo-treated patients (P<0.001 for each). Mean reductions for the total score and remaining subscale scores (pain

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and stiffness) of the WOMAC were significantly different (P<0.001 for each). Treatment with duloxetine was associated with significantly more nausea, dry mouth, constipation, fatigue and decreased appetite than treatment with placebo (P<0.05). Discontinuation due to adverse events occurred more commonly in the duloxetine group than the placebo group (P=0.03).
Mazza et al.[219] (2010) Escitalopram 20 mg QD vs duloxetine 60 mg QD	RCT Adult patients with non-radicular chronic low back pain	N=85 13 weeks	Primary: Weekly mean of the 24-hour average pain ratings Secondary: CGI-S and the 36-item SF-36	Primary: The mean change in average weekly pain did not differ significantly between the escitalopram group and duloxetine group (P=0.15). The average weekly pain response rates (30% reduction from baseline to end point) showed no significant difference between the two groups (P=0.12). There were no significant differences between groups in 50% response rates. Secondary: Both escitalopram and duloxetine demonstrated significant improvement on CGI-S and SF-36. No patient experienced serious adverse events and the incidence of side effects did not differ significantly between treatment groups.
Obsessive-compulsive Disorder (OCD)				
Alaghband-Rad et al.[220] (2009) Fluoxetine 20 mg/day vs citalopram 20 mg/day	DB, RCT Children 8 to 17 years of age with OCD	N=29 6 weeks	Primary: CY-BOCS total score, CGI-OCD, adverse events Secondary; Not reported	Primary: After three weeks of treatment, obsessive-compulsive symptom severity for both groups decreased to a similar extent using the CY-BOCS total scores. Scores decreased for both obsessions and compulsions. CGI scores did not change significantly from baseline in either group. After six weeks of treatment, obsessive-compulsive symptom severity for both groups decreased to a similar extent using the CY-BOCS total scores. Scores decreased for both obsessions and compulsions (P<0.01). CGI scores did not change significantly from baseline in either group (P=NS). The most frequently reported adverse events were headache (3.4%), tremor (6.8%), insomnia (3.4%), hypomanic episode (3.4%) for fluoxetine. Headache (3.4%), hypomanic episode (3.4%) for citalopram.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary; Not reported
Koran et al.[221] (1996) Fluvoxamine 100 to 300 mg/day vs clomipramine 100 to 250 mg/day	DB, RCT Patients with OCD	N=79 10 weeks	Primary: Y-BOCS, CGI, HAM-D Secondary; Not reported	Primary: The mean reduction in Y-BOCS for the fluvoxamine group was 30.2% and for the clomipramine group 30.0% (P=NS). At the end of treatment, 56% of fluvoxamine patients were classified as responders (≥25% decrease in Y-BOCS score), compared to 54% of clomipramine patients. Both groups showed steady improvement throughout the study; no statistically significant differences were observed between the groups for any efficacy variable at any time. A similar percentage of patients in both groups withdrew because of adverse events. No serious adverse events related to drug occurred with either drug. Insomnia, nervousness, and dyspepsia were more statistically frequent with fluvoxamine; dry mouth and postural hypotension were more frequent with clomipramine. Secondary; Not reported
Mundo et al.[222] (1997) Fluvoxamine 100 to 300 mg daily vs paroxetine 20 to 60 mg daily vs citalopram 20 to 60 mg daily	RCT Patients with OCD	N=30 10 weeks	Primary: NIMH-OC, Y-BOCS, HAM-D, CGI Secondary; Not reported	Primary: No significant differences were noted between the treatment groups. Results performed on NIMH-OC and Y-BOCS obsessions, compulsions, and total scores did not show any significant effect of the variable group (treatment) but only a significant effect of time (NIMH-OC: P=0.000; Y-BOCS obsessions: P=0.000; Y-BOCS compulsions: P=0.000; Y-BOCS total: P=0.000) and no significant effect of their interaction. Similar results were derived from the ANOVA with repeated measures performed on HAM-D total scores (time effect: P=0.000). Secondary; Not reported
Denys et al.[223]	DB, PG, RCT	N=150	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2003) Paroxetine 15 to 60 mg daily vs venlafaxine 75 to 300 mg daily	Patients with OCD	12 weeks	Y-BOCS Secondary; Not reported	Both paroxetine and venlafaxine were efficacious with a mean decrease of 7.8 and 7.2 points, respectively, at the end of the study, as measured by the reduction in total Y-BOCS scores. Analyses of covariance, adjusted for the mean baseline Y-BOCS scores, revealed a highly significant treatment effect over the 12-week trial period for both treatment groups (P=0.001). A significant decrease in total Y-BOCS scores from baseline was found in the venlafaxine group at week three (P=0.008), whereas in the paroxetine group, a significant decrease in total Y-BOCS scores from baseline was evident as of the fifth week of treatment (P=0.018). Significant decreases in total Y-BOCS scores for both medications were observed until week 10, whereas from week 10 till week 12, no further decrease was detected. Secondary; Not reported
Panic Disorder				
Stahl et al.[224] (2003) Citalopram vs escitalopram vs placebo	DB, PC, RCT Patients 18 to 80 years of age diagnosed with panic disorder	N=366 10 weeks	Primary: Frequency of panic attacks at week 10 assessed by the Modified Sheehan Panic and Anticipatory Anxiety Scale Secondary; Not reported	Primary: A significant decrease in the frequency of panic attacks was observed in both the escitalopram and citalopram groups compared to placebo (P<0.05). Secondary; Not reported
Dannon et al.[225] (2007) Citalopram 10 to 40 mg/day vs	OL Adult patients with panic disorder or panic disorder with agoraphobia	N=200 12 months	Primary: Panic Self-Questionnaire, CGI-I Secondary; Not reported	Primary: Following 52 weeks of therapy, the clinical improvements observed were similar between the groups and there were no significant differences in treatment response as measured using the Panic Self-Questionnaire (P=0.13), VAS (P=0.43), or CGI-I (P=NS). There were no significant differences between the panic disorder and the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
fluoxetine 10 to 40 mg/day vs fluvoxamine 50 to 200 mg/day vs paroxetine 10 to 40 mg/day				panic disorder with agoraphobia groups in treatment response as measured at the 12 monthly follow-up visits. Secondary; Not reported
Rampello et al.[226] (2006) Escitalopram vs citalopram	OL Elderly patients diagnosed with panic attacks	N=40 8 weeks	Primary: Weekly rate of panic attacks Secondary: Change from base-line in HAMA, HAMD and Cooper Disability Scale scores	Primary: No significant difference was observed at eight weeks in the weekly rate of panic attacks. Secondary: No significant differences were observed at eight weeks in the HAMA or HAMD, or in the Cooper Disability Scale scores. A significant improvement from baseline in outcome measures was observed in the escitalopram at two weeks and in the citalopram group at four weeks (P<0.001 and P<0.01 respectively).
Van Ameringen et al.[227] (2007) Nefazodone 300 to 600 mg daily vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age with GSP diagnosis confirmed by DSM-IV for more than 1 year	N=105 14 weeks	Primary: Percent of responders at endpoint Secondary: Not reported	Primary: At endpoint, 31.4% of nefazodone-treated patients and 23.5% of placebo-treated patients were considered responders (P=0.38). Secondary: Not reported
Sheehan et al.[228] (2005)	DB, MC, PC, RCT Patients with DSM-	N=889 10weeks	Primary: Patients free of panic attacks in the	Primary: Paroxetine CR was statistically more effective compared to placebo on the primary outcome measure: 63 vs 53%; P<0.005.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Paroxetine CR 25 to 75 mg daily vs placebo	IV panic disorder with or without agoraphobia		two weeks prior to endpoint Secondary: CGI-I, HAMA	 Secondary: Paroxetine CR was statistically more effective compared to placebo in the proportion of patients with improved CGI-I (79 vs 55%; P<0.001). Paroxetine CR was statistically more effective compared to placebo in alleviating general anxiety symptoms as measured by HAMA; P<0.001. Adverse events leading to study withdrawal occurred in 11% of patients in the paroxetine CR group and 6% of patients in the placebo group.
Ballenger et al.[229] (1998) Paroxetine 10 mg daily vs paroxetine 20 mg daily vs paroxetine 40 mg daily	DB, PG, PC, RCT Patients with panic disorder 18 years of age or older	N=278 10 weeks	Primary: Change in panic attacks from baseline, CGI-S Secondary: Marks-Sheehan Phobia Scale, HARS, MASDR	Primary: The percent of patients free of panic attacks were 86% (40 mg), 65.2% (20 mg), and 67.4% (10 mg) (P<0.019 at weeks four and 10). No significant differences were noted between groups in mean change from baseline in number of full panic attacks. No significant differences were reported between groups in percentage of patients with a 50% reduction from baseline in number of full panic attacks. The mean CGI global and severity ratings were 81.2% (40 mg), 75.4% (20 mg), 57.8% (10 mg), 51.5% (placebo) (significantly higher with 40 and 20 mg, P<0.019). Secondary: The mean score for public avoidance on the Marks-Sheehan Phobia Scale declined in all groups (P=NS). Significant improvement in the score on the HARS (total) was observed for the 40 mg paroxetine group (in the end-point but not in the completer analysis). Improvement in depressive symptoms (MADRS) was significantly greater for the 40 mg paroxetine group than for the placebo group at week 10.
Bandelow et al.[230] (2004)	DB, MC, PG, RCT	N=225	Primary: Clinician-rated	Primary: Treatment with sertraline and paroxetine resulted in equivalent levels of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Sertraline 50 to 150 mg daily vs paroxetine 40 to 60 mg daily	Patients with panic disorder between 18 and 65 years of age	12 weeks	PAS Secondary: CGI-I score	improvement on the primary outcome measure from baseline, the PAS total score (P=0.749). The efficacy of sertraline and paroxetine was equivalent (P=0.487) with regard to the PAS across the agoraphobia and non-agoraphobia subtypes. Secondary: Global response (CGI-I score ≤2) was achieved by 82% of the efficacy-evaluable population treated with sertraline compared to 78% of patients treated with paroxetine (P=0.320).
Pollack et al.[231] (2007) Venlafaxine ER 75 mg/day vs venlafaxine ER 225 mg/day vs paroxetine 40 mg/day vs placebo	DB, MC, PC, RCT Outpatients ≥18 years of age with panic disorder (with or without agoraphobia)	N=653 12 weeks	Primary: Percentage of patients free from full-symptom panic attacks at endpoint (LOCF) Secondary: Changes from baseline in the Panic Disorder Severity Scale total score and panic attack frequency	Primary: Each of the active treatment groups had a significantly higher proportion of patients who were free of full-symptom panic attacks than in the placebo group (venlafaxine ER 75 mg, 64.7% [P≤0.001 vs placebo]; venlafaxine ER 225 mg, 70.0% [P≤0.001 vs placebo; P≤0.05 vs paroxetine]; paroxetine, 58.3% [P≤0.05 vs placebo]; placebo, 47.8%). Secondary: All three treatment groups had significantly greater mean reductions in Panic Disorder Severity Scale total score compared to the placebo group at study endpoint. The venlafaxine ER 225 mg group had a significantly lower Panic Disorder Severity Scale total score (4.78 vs 6.26; P<0.05) at endpoint than the paroxetine group. Each of the active treatment groups had significantly more CGI-I responders than the placebo group (venlafaxine ER 75 mg, 81.4%; venlafaxine ER 225 mg, 85.0%; paroxetine, 83.3%; placebo, 59.9%; P<0.001 vs placebo for all comparisons). The percentage of patients who experienced remission was higher in the active treatment groups (venlafaxine ER 225 mg, 50.0%; venlafaxine ER 75 mg, 41.0%; paroxetine 40 mg, 39.3%) than in the placebo group (26.8%).
Posttraumatic Stress Disorder (PTSD)				
Davidson et al.[232] (2005)	OL, RCT Patients 18 to 70	N=123 6 months	Primary: Rate of relapse defined by a	Primary: On the CGI-I, there was a significantly higher number of relapses in the group who received placebo (50%) compared to the group that received

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fluoxetine 10 to 60 mg daily vs placebo	years of age with PTSD		change in CGI-I score that reverted back to no improvement relative to baseline or worse, CGI-I score which increased by at least two points Secondary: CGI-S	fluoxetine (22.2%; P=0.029). Secondary: Differences between the fluoxetine and the placebo group failed to meet significance for CGI-S (P=0.08).
Friedman et al.[233] (2007) Sertraline 250 to 200 mg daily vs placebo	DB, PC, RCT Patients with combat-related PTSD	N=169 12 weeks	Primary: Mean change in CAPS-2 total severity score from baseline to endpoint Secondary: IES, CGI-S	Primary: The adjusted mean changes on the CAPS-2 total severity score for the sertraline and placebo groups were –13.1 and –15.4, respectively; the difference was not statically different (P=0.26). Secondary: The adjusted mean changes for the IES total score were –8.7 and –8.1 for the sertraline and placebo groups, respectively. The difference was not statistically significant (P=0.28). For the CGI-S scale, there was no statically significant difference between treatment groups in changes from baseline to endpoint. The mean changes from baseline to endpoint were –0.5 and –0.6, respectively (P=0.41).
Premenstrual Dysphoric Disorder				
Pearlstein et al.[234] (2005) Paroxetine CR 12.5 mg daily or 25 mg daily vs placebo	DB, MC, PC, RCT Patients 18 to 45 years of age who had regular menstrual cycles with PMDD	N=47 3 menstrual cycles	Primary: VAS-Mood Secondary: VAS-Total	Primary: A statistically significant difference was observed in favor of paroxetine CR 25 mg vs placebo on the VAS-Mood (P<0.001) and for paroxetine CR 12.5 mg vs placebo (P=0.013). Secondary: Paroxetine CR demonstrated greater mean reduction in VAS-Total scores compared to placebo at each time point. At the treatment cycle three last-observation-carried-forward endpoint, statistically significant differences in mean changes were observed in favor of paroxetine CR 25 mg vs placebo (P<0.001) as well as for paroxetine CR 12.5 mg vs placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P=0.011).
Steiner et al.[235] (2005) Paroxetine CR 12.5 mg daily vs paroxetine CR 25 mg daily vs placebo	DB, MC, PC, RCT Patients 18 to 45 years of age who had regular menstrual cycles with PMDD	N=373 3 menstrual cycles	Primary: VAS-Mood Secondary: Change form baseline to treatment cycle three in the sum of the 11VAS symptoms; change from baseline in the SDS total score	Primary: A statistically significant difference was demonstrated in favor of paroxetine CR 25 and 12.5 mg compared to placebo (paroxetine CR 25 mg vs placebo: adjusted mean difference, –10.79 mm; 95% CI, –16.46 to –5.12; P<0.001; paroxetine CR 12.5 mg vs placebo: adjusted mean difference, –7.66 mm; 95% CI, –13.25 to –2.08; P=0.007) for change from baseline in mean luteal phase VAS-Mood score at the treatment cycle three last-observation-carried-forward endpoint. Secondary: The mean change from baseline in the VAS-Total score, (paroxetine CR 25 mg vs placebo, -77.82 mm; P=0.006, paroxetine CR 12.5 mg vs placebo, –73.13 mm; P=0.009) The mean change from baseline in the SDS total score (paroxetine CR 25 mg vs placebo, –2.74 mm; P=0.016, paroxetine CR 12.5 mg vs placebo, –2.33 mm; P=0.028) was greater compared to placebo.
Yonkers et al.[236] (2015) Sertraline 50 to 100 mg/day during the symptomatic interval vs placebo	DB, MC, PC, RCT Women 18 to 48 years of age with menstrual cycles of 21 to 35 days with PMDD	N=252 6 menstrual cycles	Primary: PMTS Secondary: IDS, DRSP, Michelson SSRI Withdrawal Scale	Primary: The difference between the sertraline and placebo groups in rates of change for the PMTS scores was not statistically significant (P=0.06). Secondary: Compared with the placebo group, participants in the sertraline group showed greater improvement in IDS scores over time (P=0.02). The mean changes in the total and Anger/Irritability subscale scores of the DRSP were greater for the sertraline than the placebo groups, with an estimated mean difference for change from baseline to the end point for the total DRSP (1.09; 95% CI, 0.96 to 1.25; P=0.02) and the Anger/Irritability subscale (1.22; 95% CI, 1.05 to 1.41; P<0.01) scores, but no differences were found between conditions in the Depressive Symptoms and Physical Symptoms subscales. Both groups acknowledged fewer and similar symptoms on the Michelson SSRI Withdrawal Symptoms Scale as the trial progressed.
Multiple Diseases				
Wernicke et al.[237] (2007)	MA (42 RCTs)	N=8,504	Primary: Vital signs, ECG	Primary: Patients receiving duloxetine were noted to have statistically significant

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Duloxetine vs placebo	Patients diagnosed with either an MDD, diabetic peripheral neuropathy, fibromyalgia, GAD, or lower urinary tract infection	4 to 12 weeks	findings, cardiovascular side effects of the study drug Secondary: Not reported	changes from baseline in ECG findings compared to patients receiving placebo (P<0.001). However, the differences in ECG findings of patients taking duloxetine were not judged to be of clinical significance. Demographic subgroup analysis suggests that there is no difference in risk of ECG abnormality or vital sign changes between patients ≥65 years of age and a younger population (P value not reported). Although patients receiving duloxetine experienced statistically significant pulse and blood pressure elevations compared to patients receiving placebo (P<0.001), those changes were transient returning to baseline values with sustained therapy. There was no statistically significant difference between placebo and duloxetine groups in sustained blood pressure (P=0.631), SBP (P=0.740), or DBP (P=1.00) measured during three consecutive visits. Patients randomized to duloxetine therapy experienced higher incidences of palpitations (P=0.004), tachycardia (P=0.007), orthostatic hypotension (P=0.004), increased blood pressure (P<0.001), blood total cholesterol (P=0.031), and peripheral coldness (P=0.044) compared to patients randomized to placebo. Secondary: Not reported
Mullins et al.[238] (2005) Sertraline vs paroxetine vs citalopram	RETRO Patients with depression, PTSD, or social anxiety disorder	N=14,933 Data gathered from 1/1/99 to 6/30/02	Primary: Persistence, switching, discontinuation Secondary: Not reported	Primary: Compared to patients receiving sertraline and citalopram, those receiving paroxetine had lower rates of persistence (23.79% for paroxetine vs 25.96% for sertraline [P=0.0093] and 26.56% for citalopram [P=0.0022]) and higher rates of switching (3.55% for paroxetine vs 3.32% for sertraline [P=0.5076] and 2.78% for citalopram [P=0.0359]) and discontinuation (72.66% for paroxetine vs 70.72% for sertraline [P=0.0258] and 70.66% for citalopram [P=0.0334]). Survival curves showed that persistence rates with sertraline and citalopram were significantly greater than with paroxetine (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Stein et al.[239] (2000) SSRIs, MAOIs, benzodiazepines, beta blockers, buspirone, gabapentin, olanzapine	MA Patients with social anxiety disorders	N=5,264 (36 trials) Variable duration	Primary: CGI-I scale Secondary: LSAS	Primary: Summary statistics for responder status (assessed using the CGI from 25 short-term comparisons demonstrated a higher degree of efficacy of various medications over placebo (RR of non-response, 0.63; 95% CI, 0.55 to 0.72). Response to treatment by SSRIs (N=11; RR, 0.67; 95% CI, 0.59 to 0.76), MAOIs (N=3; RR, 0.43; 95% CI, 0.24 to 0.76) supported the value of these agents. However, the SSRIs were significantly more effective than the other agents (P<0.00001). Secondary: LSAS showed a statistically significant difference between medication and placebo (weighed mean difference, –15.56; 95% CI, –17.95 to -13.16), with this effect once again most evident for the SSRIs. Medication was also significantly more effective compared to placebo in reducing symptom clusters, comorbid depressive symptoms, and associated disability. The value of long-term medication treatment in treatment responders was supported by three comparisons from maintenance studies (RR, 0.58; 95% CI, 0.39 to 0.85) and five comparisons from relapse prevention studies (RR, 0.33; 95% CI, 0.22 to 0.49).

Drug abbreviations: BID=twice daily, CR=controlled release, ER=extended release, QD=once daily, SR=sustained release, XR=extended release
Study abbreviations: AC=active control, CI=confidence interval, DB=double-blind, ES=extension study, FD=fixed dose, ITT=intention to treat, LOCF=last observation carried forward, LSM=least square mean, LSMD=least square mean difference, MA=meta-analysis, MC=multicenter, NI=non inferiority, NNH=number needed to harm, NNT=number needed to treat, OBS=observational, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel-group, RCT=randomized controlled trial, RETRO=retrospective, RR=relative risk, SB=single blind, SC=single center, SE=standard error, SMD=standard mean difference, SR=systemic review, XO=cross over
Diagnostic Criteria: DSM-III-R=Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th edition
Miscellaneous abbreviations: ASEX=Arizona Sexual Experience Scale, BAI=Beck Anxiety Inventory, BDI-FS=Beck Depression Inventory Fast Screen, BDI-II=Beck Depression Inventory-II, BPI=brief pain inventory, CAPS-S=Clinician-Administered PTSD Scale, CES-D=Center for Epidemiological Studies-Depression Scale, CGI-I=Clinical Global Impression, Improvement, CGI-S=Clinical Global Impression, Severity, CSFQ=Changes in Sexual Functioning Questionnaire, DBP=diastolic blood pressure, DRSP=Daily Record of Severity of Problems, DSST=digital symbol substitution test, ECG=electrocardiogram, EQ-5D=EuroQoL: 5 Dimensions Questionnaire, FIQ=Fibromyalgia Impact Questionnaire, FIQ=Fibromyalgia Impact Questionnaire-Revised, GAD=Generalized Anxiety Disorder, GAF=Global Assessment of Functioning, GDS=Geriatric Depression Scale, GSP=Generalized Social Phobia, HADS-A=Hospital Anxiety and Depression Scale – Anxiety subscale, HAMA=Hamilton Rating Scale for Anxiety, HAM-D=Hamilton Rating Scale for Depression, HARS=Hamilton Anxiety Rating Scale, HDRS-17=17-item Hamilton Depression Rating Scale, HRQOL=health related quality of life, IDS=Inventory of Depressive Symptomatology-Clinician-Rated, IES=Impact of Event Scale, IU-GAM=Indiana University Generalized Anxiety Measurement Scale, LANSS=Leeds Assessment of Neuropathic Symptoms and Signs, LPS=Latency to Persistent Sleep, LSAS=Liebowitz Social Anxiety Scale, MADRS=Montgomery-Åsberg Depression Rating Scale, MAOIs=Monoamine Oxidase Inhibitors, MDD=major depressive disorder,

MFI=Multidimensional Fatigue Inventory, MHID=Mantel-Haenszel Incidence Difference, MHRD=Mantel-Haenszel Exposure Time-adjusted Rate Difference, MRS=Menopause Rating Scale, NIMH-OC=National Institute of Mental Health-Obsessive-Compulsive Scale, NSAID=nonsteroidal anti-inflammatory drug, OCD=obsessive compulsive disorder, PAS=Panic and Agoraphobia Scale, PGI-C=Patient Global Impression of Change, PGI-I=Patient Global Impressions of Improvement, PMDD=premenstrual dysphoric disorder, PMTS=Premenstrual Tension Scale, PPD=postpartum depression, PPI=proton pump inhibitor, PTSD=Posttraumatic Stress Disorder, QIDS= Quick Inventory of Depressive Symptomatology, QIDS-SR16=16-item Quick Inventory of Depressive Symptomatology–Self-Rated, QOL=Quality of Life, Q-LES-Q=Quality of Life, Enjoyment, and Satisfaction Questionnaire, RAVLT=Rey Auditory Verbal Learning Test, REM=rapid eye movement, RMDQ-24=Roland Morris Disability Questionnaire, SBP=systolic blood pressure, SDS=Sheehan Disability Scale, SF-36=36-item Short-Form Health Status Survey, SNRI=serotonin norepinephrine reuptake inhibitor, SSI=28-item Somatic Symptom Inventory, SSRIs=Selective Serotonin-reuptake Inhibitors, TST=Total Sleep Time, UPDRS=Unified Parkinson's Disease Rating Scale, VAS=Visual Analog Scale, WASO=Wake Time After Sleep Onset, WHO-5=World Health Organization 5-item Well Being Index, WOMAC=Western Ontario and McMaster Universities, WPI=Widespread Pain Index, WTAS=Wake Time After Sleep, WTDS=Wake Time During Sleep, Y-BOCS=Yale-Brown Obsessive-Compulsive Scale

Additional Evidence

Dose Simplification
Claxton et al. evaluated compliance rates with fluoxetine 90 mg once weekly compared to fluoxetine 20 mg once daily in patients who had previously received four weeks of fluoxetine 20 mg once daily.[240] At the end of 12 weeks, compliance significantly declined from 87 to 79% with the once daily fluoxetine; however, the effect on clinical outcomes was not measured. More patients in the once-weekly group discontinued therapy due to lack of efficacy than in the once-daily group, but this difference was not statistically significant.

Stable Therapy
Brent et al. evaluated the efficacy of four treatment strategies in adolescents who continued to have depression despite initial treatment with a selective serotonin-reuptake inhibitor (SSRI).[241] The interventions included switching to a different SSRI, switching to a different SSRI plus cognitive behavioral therapy, switching to venlafaxine, or switching to venlafaxine plus cognitive behavioral therapy. The authors found that switching to a different treatment plus cognitive behavioral therapy was more effective than medication switch alone. A switch to another SSRI was as effective as switching to venlafaxine.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 15. Relative Cost of the Antidepressants

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Monoamine Oxidase Inhibitors				
Isocarboxazid	tablet	Marplan®	$$$$$	N/A
Phenelzine	tablet	Nardil®*	$$	$
Selegiline	transdermal patch	Emsam®	$$$$$	N/A
Tranylcypromine	tablet	N/A	N/A	$$$$
Selective Serotonin- and Norepinephrine-reuptake Inhibitors				
Desvenlafaxine	extended-release tablet	Pristiq®*	$$$$$	$$
Duloxetine	delayed-release capsule	Cymbalta®*, Drizalma Sprinkle®	$$$$$	$
Levomilnacipran	extended-release capsule	Fetzima®	$$$$$	N/A
Venlafaxine	extended-release capsule,	Effexor XR®*	$$$$$	$

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
	extended-release tablet, tablet			
Selective Serotonin-reuptake Inhibitors				
Citalopram	solution, tablet	Celexa®*	$$$$$	$
Escitalopram	solution, tablet	Lexapro®*	$$$$$	$
Fluoxetine	capsule, delayed-release capsule, solution, tablet	Prozac®*, Sarafem®*	$$$$$	$
Fluvoxamine	extended-release capsule, tablet	N/A	N/A	$$$
Paroxetine	capsule, extended-release tablet, suspension, tablet	Brisdelle®*, Paxil®*, Paxil CR®*, Pexeva®	$$$$$	$
Sertraline	oral concentrate, tablet	Zoloft®*	$$$$$	$
Serotonin Modulators				
Nefazodone	tablet	N/A	N/A	$$$
Trazodone	tablet	N/A	N/A	$
Vilazodone	tablet	Viibryd®	$$$$$	N/A
Vortioxetine	tablet	Trintellix®	$$$$$	N/A
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Single Entity Agents				
Amitriptyline	tablet	N/A	N/A	$
Amoxapine	tablet	N/A	N/A	$$$$
Clomipramine	capsule	Anafranil®*	$$$$$	$$$$
Desipramine	tablet	Norpramin®*	$$$$$	$$
Doxepin	capsule, oral concentrate, tablet	Silenor®*	$$$$$	$
Imipramine	capsule, tablet	Tofranil®*	$$$$$	$$
Maprotiline	tablet	N/A	N/A	$$$$
Nortriptyline	capsule, solution	Pamelor®*	$$$$$	$
Protriptyline	tablet	N/A	N/A	$$$$$
Trimipramine	capsule	N/A	N/A	$$$$$
Tricyclics and Other Norepinephrine-reuptake Inhibitors-Combination Products				
Amitriptyline and chlordiazepoxide	tablet	N/A	N/A	$$$$$
Antidepressants, Miscellaneous				
Brexanolone	injection	Zulresso®	$$$$$	N/A
Bupropion	extended-release tablet, sustained-release tablet, tablet	Aplenzin®, Forfivo XL®*, Wellbutrin SR®*, Wellbutrin XL®*	$$$$$	$
Esketamine	nasal spray	Spravato®	$$$$$	N/A
Mirtazapine	orally disintegrating tablet, tablet	Remeron®*	$$$$	$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The antidepressants are approved to treat a variety of mental disorders, including anxiety disorders, depressive disorders, eating disorders (bulimia nervosa), mood disorders, premenstrual dysphoric disorder, and moderate to severe vasomotor symptoms associated with menopause.[1-32] Some of the agents are also approved for the treatment of nonpsychiatric conditions, such as chronic musculoskeletal pain, diabetic peripheral neuropathy, fibromyalgia, insomnia, nocturnal enuresis, and tobacco abuse.[1-32] The antidepressants are categorized into six different American Hospital Formulary Service (AHFS) subclasses, including monoamine oxidase inhibitors (MAOIs), selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs), selective serotonin-reuptake inhibitors (SSRIs), serotonin modulators, tricyclic antidepressants (TCAs), and miscellaneous agents. The agents which make up these subclasses differ with respect to their Food and Drug Administration (FDA)-approved

indications, mechanism of action, pharmacokinetics, adverse events, and drug interactions. The majority of the products are available in a generic formulation, and there is at least one generic product available in each antidepressant subclass. Since the last review, two new chemical entities, brexanolone and esketamine, have been approved. Brexanolone is indicated for the treatment of postpartum depression and is administered intravenously.[30] Esketamine nasal spray is indicated in conjunction with an oral antidepressant for the treatment of adults with treatment-resistant depression or depressive symptoms with major depressive disorder with acute suicidal ideation or behavior[31].

Numerous clinical trials have been conducted with the antidepressants and comparative studies have demonstrated similar efficacy in patients with major depressive disorder.[34,55-175] Guidelines do not give preference to one agent over another. Rather, the selection of an antidepressant should be based on adverse events, tolerability, and patient preference.[34, 35]

Several antidepressants are approved for the treatment of anxiety disorders. The American Psychiatric Association recommends the initial use of either an SNRI or SSRI for the treatment of panic disorder due to their favorable safety and tolerability profiles.[37] The National Institute for Health and Clinical Excellence recommends the use of SSRIs as first-line therapy for the long-term treatment of generalized anxiety disorder.[37] SSRIs are also recommended for the initial treatment of obsessive-compulsive disorder.[39-40] The SNRIs, SSRIs, and TCAs have all been shown to be more effective than placebo for the treatment of anxiety disorders, and comparative studies have demonstrated similar efficacy among the antidepressants.[194-206,220-231] Guidelines do not give preference to one agent over another.[41-47] The choice of treatment should be based on safety, adverse events, drug interactions, prior response to treatment and comorbid conditions.[37-43]

Duloxetine has been approved by the FDA for the treatment of chronic musculoskeletal pain, in addition to depression, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia.[7] It has been shown to be more effective than placebo in patients with chronic low back pain and osteoarthritis of the knee; however, the effects were modest.[212-219]

Antidepressants are most commonly prescribed for postpartum depression according to the same principles for other types of major depressive disorder, despite a limited number of controlled studies. Ongoing patient assessments for efficacy and ongoing need for therapy is advised.[34,36] Based upon clinical trials, the least-squares mean reduction in HAM-D total score at the end of the 60-hour intravenous infusion favored brexanolone compared to placebo.[54] Guidelines currently do not specifically address this new agent. Due to safety concerns, brexanolone carries a boxed warning regarding excessive sedation and loss of consciousness, requiring continuous pulse oximetry monitoring. In addition, brexanolone is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program called Zulresso® REMS due to safety concerns.[30]

Esketamine was evaluated in placebo-controlled trials among adults with major depressive disorder. Results demonstrated that patients treated with esketamine nasal spray plus an oral antidepressant demonstrated greater improvements in mean MADRS score compared to those treated with placebo plus an oral antidepressant, and among remitters, fewer patients treated with esketamine plus and oral antidepressant experienced a relapse compared to patients treated with placebo.[109-11] Esketamine is associated with significant side effects, and carries a boxed warning regarding sedation, dissociation, abuse, and misuse. Due to these risks, esketamine is only available through a restricted Spravato® REMS program.[31]

According to the boxed warning, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents and young adults compared to placebo in short-term studies of major depressive disorder and other psychiatric disorders.[1-32] Short-term studies did not show an increase in the risk of suicidality in adults older than 24 years of age, and there was a reduction in risk in adults 65 years of age and older. Although the MAOIs are an effective treatment option for patients with major depressive disorder, drug interactions, dietary restrictions, and serious adverse events limit their use. It is recommended that MAOIs be reserved for patients who are not responding to other treatment options.[34]

There is insufficient evidence to support that one brand antidepressant is more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand antidepressants within the class reviewed, with the exception of the monoamine oxidase inhibitors, are comparable to each other and to the generics in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use. The monoamine oxidase inhibitors possess an extensive adverse effect profile compared to the other brands and generics in the class (if applicable) and should be managed through the existing medical justification portion of the prior authorization process. In addition, brexanolone for intravenous administration and esketamine nasal spray are both indicated for specific patient populations, have significant side effect profiles, and are only available through restricted access program and; therefore, should also be managed through the existing medical justification portion of the prior authorization process.

XI. Recommendations

No brand antidepressant is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

No brand monoamine oxidase inhibitor is recommended for preferred status, regardless of cost.

XII. References

1. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jul]. Available from: http://online.factsandcomparisons.com.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jul]. Available from: http://www.thomsonhc.com/.
3. Marplan® [package insert]. Parsippany, NJ: Validus Pharmaceuticals, LLC; Nov 2018.
4. Emsam® [package insert]. Morgantown, WV: Somerset Pharmaceuticals; July 2017.
5. Parnate® [package insert]. St. Michael, Barbados: Concordia Pharmaceuticals; January 2018.
6. Pristiq® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; February 2018.
7. Cymbalta® [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2020.
8. Effexor XR® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; November 2019.
9. Fetzima® [package insert]. Irvine, CA: Allergan USA, Inc.; October 2019.
10. Celexa® [package insert]. Irvine, CA: Allergan USA, Inc; December 2018.
11. Lexapro® [package insert]. Irvine, CA: Allergan USA, Inc; January 2019.
12. Prozac® [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2020.
13. Sarafem® [package insert]. Irvine, CA: Allergan USA, Inc; January 2017.
14. Paxil® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; January 2017.
15. Paxil CR® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2019.
16. Pexeva® [package insert]. Roswell, GA: Sebela Pharmaceutical, Inc; April 2020.
17. Zoloft® [package insert]. New York, NY: Pfizer Inc; December 2017.
18. Brisdelle® [package insert]. Roswell, GA: Sebela Pharmaceutical, Inc; March 2018.
19. Viibryd® [package insert]. Irvine, CA: Allergan USA, Inc.; January 2020.
20. Trintellix® [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; July 2019.
21. Anafranil® [package insert]. Hazelwood, MO: Mallinckrodt Inc; Mar 2019.
22. Silenor® [package insert]. Morristown, NJ: Currax Pharmaceuticals, LLC; August 2019.
23. Pamelor® [package insert]. Hazelwood, MO: Mallinckrodt Inc; April 2019.
24. Surmontil® [package insert]. Horsham, PA: Teva Pharmaceuticals; May 2014.
25. Aplenzin® [package insert]. Bridgewater, NJ: Bausch Health US, LLC; May 2020.
26. Wellbutrin® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; November 2019.
27. Wellbutrin SR® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; November 2019.
28. Wellbutrin XL® [package insert]. Bridgewater, NJ: Bausch Health US, LLC; November 2019.
29. Remeron® [package insert]. Whitehouse Station, NJ: Merck & Co.; April 2020.
30. Zulresso® [package insert]. Cambridge (MA): Sage Therapeutics, Inc.; 2019 Jun.
31. Spravato® [package insert]. Titusville (NJ): Janssen Pharmaceuticals.; 2020 Feb.
32. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 Jul]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
33. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
34. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA); 2010 Oct. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed 2020 Aug.
35. National Institute for Clinical Excellence. Depression in adults: recognition and management. National Institute for Clinical Excellence (NICE); October 2009. Available at: http://guidance.nice.org.uk/CG90. Accessed Apr 2018.
36. National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. 2020 February Update [cited 2020 Sep 1]. Available from: https://www.nice.org.uk/guidance/cg192
37. National Institute for Clinical Excellence. Generalized anxiety disorder and panic disorder in adults: management. National Institute for Clinical Excellence (NICE); January 2011 (Updated July 2019). Available at: https://www.nice.org.uk/guidance/. Accessed Sep 2020).
38. Stein M, Goin M, Pollack M, et al. Practice guideline for the treatment of patients with panic disorder, second edition. American Psychiatric Association; 2009. Available at: http://psychiatryonline.org/data/Books/prac/PanicDisorder_2e_PracticeGuideline.pdf.

39. Geller DA, March J, AACAP Committee on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2012; 51(1):98-113.
40. Koran L, Hanna G, Hollander E, Nestadt G, Simpson H; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington (VA): American Psychiatric Association; July 2007. Available at: http://psychiatryonline.org/data/Books/prac/OCDPracticeGuidelineFinal05-04-07.pdf. Accessed Apr 2018.
41. Cohen JA, AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Posttraumatic Stress Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2010;49(4):414-430.
42. Benedek D, Friedman M, Zatzick D, Ursano R. Guideline Watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Psychiatric Association; 2005. Available at: http://psychiatryonline.org/data/Books/prac/AcuteStressDisorder-PTSD_GuidelineWatch.pdf. Accessed Apr 2018.
43. Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B, et al; American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Psychiatric Association; November 2004. Available at: http://psychiatryonline.org/data/Books/prac/ASD_PTSD_Inactivated_04-16-09.pdf. Accessed Apr 2018.
44. Hofmeister S, Bodden S. Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Am Fam Physician. 2016 Aug 1;94(3):236-40.
45. Yager J, Devlin MJ, Halmi KA, et al. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with eating disorders. Arlington, VA: American Psychiatric Association; 2006. Available at: http://psychiatryonline.org/data/Books/prac/EatingDisorders3ePG_04-28-06.pdf. Accessed Apr 2018.
46. Qaseem A, Wilt TJ, McLean RM, Forciea MA, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-530.
47. Kolasinski SL, Neogi T, Hochberg MC et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology. 2020 Feb;72(2):220-33.
48. American Academy of Orthopedic Surgeons: Clinical practice guideline on the treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): 2013 [Guideline on the internet]. Available from: http://www.aaos.org/research/guidelines/OAKguideline.pdf.
49. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 2017;76:318-328.
50. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65.
51. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88.
52. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr;21 Suppl 1:1-87. doi: 10.4158/EP15672.GL.
53. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042.
54. Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomized, placebo controlled, phase 3 trials. Lancet. 2018 Sept;392(10152):1058-1070
55. Koshino Y, Bahk W-M, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. 2013 Aug 27;9:1273-1280.
56. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared to escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-46.

57. Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2009;23:531-8.
58. Weihs KL, Settle EC Jr, Batey SR, et al: Bupropion sustained release vs paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000 Mar;61(3):196-202.
59. Kavoussi RJ, Segraves RT, Hughes AR, et al: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997;58(12):532-537.
60. Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis F, Rivoira E, Taricco B, Bogetto F. Citalopram vs sertraline in late-life non-major clinically significant depression: a 1 year follow-up clinical trial. J Clin Psychiatry 2005;66:360-9.
61. Clayton AH, Reddy S, Focht K, Musgnung J, Fayyad R. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. Journal of Sexual Medicine. 2013 Mar;10(3):768-76.
62. Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. Journal of Clinical Psychiatry. 2013 Feb;74(2):158-66.
63. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients. A double-blind clinical trial desvenlafaxine vs placebo. J Clin Psychopharmacol. 2011;31:569-76.
64. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71(8):1088-96.
65. Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder. Results of a randomized trial. J Clin Psychopharmacol. 2010;30:18-24.
66. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared to placebo in the treatment of major depressive disorder (abstract). CNS Spectr. 2009 Apr;14(4):183-95.
67. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009;14(1):41-50.
68. Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared to placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54.
69. Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RF, Thase ME. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015 May;76(5):562-9.
70. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243-53.
71. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety and tolerability of desvenlafaxine 50 and 100 mg/day in outpatients with major depressive disorder (abstract). Curr Med Res Opin. 2008 Jul;24(7):1877-90.
72. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663-72.
73. Demartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;69:677-88.
74. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacology. 2007;22:338-47.
75. Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. International Clinical Psychopharmacology. 2013 Jul;28(4):206-13.
76. Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, et al. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs. 2011;25(3):227-38.

77. Ferguson J, Tourian KA, Manley AL, Padmanadhan SK, Nichols A. An evaluation of the efficacy, safety, and tolerability of desvenlafaxine in the long-term treatment of elderly outpatients with major depressive disorder. Prim Psychiatry. 2010;17(1):66-73.
78. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11.
79. Acharya N, Rosen AS. Polzer JP, D'Souza DN, Perahia DG, Cavazzoni PA, Baldessarini RJ. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder J Clin Psychopharmacol. 2006; 26(6):587-94.
80. Gaynor PJ, Gopal M, Zheng W, et al. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res Opin 2011;27:1849-58.
81. Gaynor PJ, Gopal M, Zheng W, et al. Duloxetine vs placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Curr Med Res Opin 2011;27:1859-67.
82. Rosso G, Rigardetto S, Bogetto F, et al. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 2012;136:172-6.
83. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM. Duloxetine vs escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007 Feb;23(2):401-16.
84. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine vs escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303-18.
85. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457-70.
86. Goldstein DJ, Lu Y, Detke MJ, et al: duloxetine in the treatment of depression a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389-99.
87. Perahia DG. Wang F. Mallinckrodt CH. Walker DJ. Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry. 2006;21(6):367-78.
88. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial (abstract). J Clin Psychiatry. 2002 Mar;63(3):225-31.
89. Martinez JM, Katon W, Greist JH, et al. A pragmatic 12-week, randomized trial of duloxetine vs generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol 2012;27:17-26.
90. Mancini M, Sheehan DV, Demyttenaere K, Amore M, Deberdt W, Quail D, Sagman D. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. International Clinical Psychopharmacology. 2012 Nov;27(6):298-309.
91. Van Baardewijk M, Vis PMJ, Einarson TR. Cost effectiveness of duloxetine compared to venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin. 2005;21(8):1271-79.
92. Vis PM. van Baardewijk M. Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother. 2005;39(11):1798-807.
93. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34.
94. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689-701.
95. Kerber KB, Wisniewksi SR, Luther JF, Leuchter AF, D'Empaire I, Trivedi MH, et al. Effects of heart disease on depression treatment: results from the COMED study. General Hospital Psychiatry. 2012;34:24-34.
96. Morris DW, Budhwar N, Husain M, Wisniewski SR, Kurian BT, Luther JF, et al. Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med. 2012;10:23-33.
97. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram vs citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 May;20(3):131-7.
98. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) vs citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin. 2005 Oct;21(10):1659-68.
99. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331-36.

100. Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalopram vs citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007;29:2319-32.
101. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry. 2006 Sep;39(5):180-4.
102. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002 Apr;7(4 Suppl 1):40-4.
103. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patient with severe depression: a pooled analysis. Int J Clin Pract. 2005 Mar;59(3):268-75.
104. Ou JJ, Xun GL, Wu RR, et al. Efficacy and safety of escitalopram vs citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology (Berl) 2011;213:639-46.
105. Wade A, Gembert K, Florea I, et al. A comparative study of the efficacy of acute and continuation treatment with escitalopram vs duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14.
106. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig. 2007;27(7):481-92.
107. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006 Jul;22(7):1331-41.
108. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50(1):57-64.
109. Fedgchin M, Trivedi M, Daly EJ et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol.2019 Oct 1;22(10):616-630.
110. Popova V, Daly EJ, Trivedi M et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry.2019 Jun 1;176(6):428-438.
111. Daly EJ, Trivedi MH, Janik A et al. Efficacy of esketamine nasal spray plus oral antidepressant Treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019 Jun 5;76(9):893-903.
112. Davey CG, Chanen AM, Hetrick SE et al. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. Lancet Psychiatry. 2019 Sep;6(9):735-744.
113. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine vs sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22(2):137-47.
114. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatr. 2002;59:233-9.
115. Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015 Sep 16;351:h4320.
116. Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. Int J Risk Saf Med. 2016 Sep 17;28(3):143-61.
117. Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40, 80, or 120 mg in major depressive disorder: A phase 3, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2013 Mar;74(3):242-8.
118. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. Journal of Psychiatry & Neuroscience. 2013 Oct 22 [Epub ahead of print]; 38(6):1-10. PMID: 24144196.
119. Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. Journal of Clinical Psychopharmacology. 2013 Nov 27 [Epub ahead of print]; 34(1):1-10. PMID: 24172209
120. Montgomery, Stuart A, Mansuy, Lucilla, Ruth, Adam, Bose, Anjana, Li, Hua, Li, Dayong. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized,

double-blind, placebo-controlled, proof-of-concept study. Journal of Clinical Psychiatry. 2013 Apr;74(4):363-9.
121. Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 2015 Apr;20(2):148-56.
122. Kornstein SG, Gommoll C, Chen C, Kramer K. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD. J Affect Disord. 2016 Mar 15;193:137-43.
123. Kessler DS, MacNEill SJ, Tallon D et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo-controlled trial (MIR). BMJ. 2018 Oct 31;363:k4218.
124. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ. Comparative Efficacy Antidepressants Study Group**.** Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137-46.
125. Wheatley D, Kremer CME: A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression. J Clin Psychiatry. 1998 Jun;59(6):306-12.
126. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy vs their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19:457-65.
127. Behke K, Søgaard J, Martin S, et al: Mirtazapine orally disintegrating tablet vs sertraline. J Clin Psychopharmacol. 2003 Aug;23:4.
128. Guelfi D, Ansseau M, Timmerman L, et al: Mirtazapine vs venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21:425-31.
129. Feighner J, Targum S, Bennet M et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry. 1998;59(5):246-53.
130. Dunner DL, Lipshitx A, Pitts C, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression; post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther. 2005;27:1901-11.
131. Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine vs phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004;65(11):1505-10.
132. Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, et al. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. JAMA. 2017 Nov 21;318(19):1876-1890.
133. Lewis G, Duffy L, Ades A et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry. 2019 Nov;6(11):903-914.
134. Mowla A, Dastgheib SA, Razeghian Jahromi L. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial. Clin Drug Investig. 2016 Jul;36(7):539-43.
135. Rossini D, Serretti A, Franchini L, Mandelli L, Smeraldi E, Ronchi DD, Zanardi R. Sertraline vs fluvoxamine in the treatment of elderly patients with major depression. J Clin Psychopharmacol 2005;25:471-5.
136. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont) 2009;6:20-33.
137. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release vs citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008;23:113-9.
138. Bielski RJ, Ventura D, Chang C. A double-blind comparison of escitalopram and venlafaxine extended-release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:1190-6.
139. Nemeroff CB, Michael E: A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007;41:351-9.
140. Rudolph RL, Feiger AD: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J. Affective Disorders. 1999:56:171-81.
141. Benkert O, Grunder G, Wetzel H, et al: A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res. 1996:30(6):441-51.
142. Kok RM, Nolen WA, Heeren TJ. Venlafaxine vs nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial. Int J Geriatr Psychiatry 2007;22:1247-54.
143. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229-36.

144. Mazeh D, Shahal B, Aviv A, et al. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007;22:371-5.
145. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine vs specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. International Clinical Psychopharmacology. 2012 Jan;27(1):8-16.
146. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012 Jan;28(1):27-39.
147. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7.
148. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33.
149. Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014 Nov;75(11):e1291-8.
150. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015 Mar;30(2):67-74.
151. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled eight-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder [abstract]. 2012 Jul 1;73(7):953-59.
152. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015 May;76(5):583-91.
153. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015 May;76(5):575-82.
154. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology. 2013 Mar. 16(2):313-21.
155. Nishimura A, Aritomi Y, Sasai K et al. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin Neurosci. 2018.Feb;72(2):64-72.
156. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. 2012 July 1;27(4):215-23.
157. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) vs placebo for 8 weeks in adults with major depressive disorder. Current Medical Research & Opinion. 2013 March 29(3):217-26.S
158. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014 May;29(3):138-49.
159. Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015 Jun;232(12):2061-70.
160. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6.
161. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Current Medical Research & Opinion. 2012 Oct. 28(10):1717-24.
162. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
163. Moncrieff J, Wessely S, Hardy R. Active placebos vs antidepressants for depression. Cochrane Database Syst Rev. 2004;(1):CD003012.
164. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-7.

165. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-61.
166. Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11;318(2):132-145.
167. Saveanu R, Etkin A, Duchemin AM, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015 Feb;61:1-12.
168. Chuang HY, Chang YH, Cheng LY, et al. Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study. Chin J Physiol. 2014 Oct 31;57(5):265-70.
169. Thase ME, Trivedi MH, Rush AJ. MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology. 1995;12(3):185-219.
170. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetine vs other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004185.
171. Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine vs amitriptyline in major depression. Acta Psychiatr Scand. 1997;96(suppl 391):22-30.
172. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002 Sep 18;288(11):1403-09.
173. Anderson IM. Selective serotonin reuptake inhibitors vs tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000 Apr;58(1):19-36.
174. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared to tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326:1014-9.
175. Steffens DC, Ranga K, Krishnan MD, et al. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6:10-8.
176. Yan G, Guang N, Wei-ping J, Zhi-guang Z, Zhang-rong X, Zhi-min L, et al. Duloxetine vs placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J. 2010;123(22):3184-92.
177. Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med. 2007 Jul-Aug;8(5):410-8.
178. Kajdasz DK, Iyengar S, Desaiah D, Backonja MM, Farrar JT, Fishbain DA, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29:2536-46.
179. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.CD007115.
180. Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011;34:818-22.
181. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012 Dec;35(12):2451-8.
182. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011;86:615-26.
183. Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK, et al. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology. 2009;9:6-19.
184. Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Medicine. 2007;8(6):503-13.
185. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, et al. Duloxetine vs routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliative Med. 2006;9(1):29-40.
186. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain. 2012 Nov-Dec;28(9):775-81.

187. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with vs without major depressive disorder. Clin J Pain 2009;25:461-8.
188. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44.
189. Mease PJ, Russell IJ, Kajdasz DK, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2010;39:454-64.
190. Gilron I, Chaparro LE, Tu D, Holden RR, Milev R, Towheed T, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016 Jul;157(7):1532-40.
191. Bidari A, Moazen-Zadeh E, Ghavidel-P B et al. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019 Jun;27(1):149-158.
192. Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013 Jan 31;1:CD010292.
193. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome (abstract). J Pain. 2010 Jun;11(6):505-21.
194. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety. 2008;25:182-9.
195. Koponen H, Allgulander G, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007;9:100-7.
196. Alaka KJ, Noble W, Montejo A, et al. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2014 Sep;29(9):978-86.
197. Davidson JRT, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropschopharmacol. 2008;18:673-81.
198. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-74.
199. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-76.
200. Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2005;66:1441-6.
201. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 87;2005;161-7.
202. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005 Apr;17(2):65-69.
203. Bose A, Korotzer A, Gommoll C, et al. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 2008;25:854-61.
204. Ball S, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66:94-9.
205. Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T. Sertraline in generalized anxiety disorder: efficacy in treatment in psychic and somatic anxiety factors. Acta Psychiatr Sand 2005;111:429-35.
206. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr. 2005 Mar;27(1):18-24.
207. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1, 3 and 6 mg in adults with primary insomnia. Sleep 2007;30: 1555-61
208. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1, 3 and 6 mg in elderly patients with primary insomnia. J Clin Psychiatry 2008; 69:1557-64
209. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61.
210. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011;34:1433-42.

211. Roth T, Heith Durrence H, Jochelson P, et al. Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 2010;11:843-7.
212. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine vs placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-90.
213. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35:E578-85.
214. Skljarevski V, Zhang S, Chappell AS, et al. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med 2010;11:648-57.
215. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, et al. A double-blind, randomized trial of duloxetine vs placebo in the management of chronic low back pain. Eur J Neurol. 2009;16:1041-8.
216. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60.
217. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2010;11:33-41.
218. Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:2361-72.
219. Mazza M, Mazza O, Pazzaglia C, et al. Escitalopram 20 mg vs duloxetine 60 mg for the treatment of chronic low back pain. Expert Opin Pharmacother 2010;11:1049-52.
220. Alaghband-Rad J, Hakimshooshtary M. A randomized controlled clinical trial of citalopram vs fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry 2009;18:131-5.
221. Koran LM, McElroy SL, Davidson JRT, et al. Fluvoxamine vs clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol. 1996;16:121-9.
222. Mundo E, Bianchi L, Bellodi L. Efficacy of Fluvoxamine, paroxetine, and Citalopram in the treatment of obsessive-compulsive disorder: A single-blind study. J Clin Psychopharmacol. 1997;17(4):267-71.
223. Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568-75.
224. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003 Nov;64(11):1322-7.
225. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 2007;30:326-34.
226. Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram vs citalopram. J Clin Psychopharmacol. 2006 Feb;26(1):67-70.
227. Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B. Nefazodone in the treatment of generalized social phobia; a randomized, placebo-controlled trial. J Clin Psychiatry 2007;68:288-95.
228. Sheehan DV, Burnham DB, Iyengar MK, Perea P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005;66:34-40.
229. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36-42.
230. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. Sertraline vs paroxetine in the treatment of panic disorder: An acute, double-blind noninferiority comparison. J Clin Psych. 2004;65(3):405-13.
231. Pollack M, Mangano R, Entsuah R, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007;194:233-42.
232. Davidson JR, Connor KM, Hertzberg MA, Weisler RH, Wislon WH, Payne VM. Maintenance therapy with fluoxetine in posttraumatic stress disorder. J Clin Psychopharmacol 2005;25:166-9.
233. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting. J Clin Psychiatry 2007;61:711-20.
234. Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry. 2005;7:53-60.

235. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee M, Van Erp E. Luteal phase dosing with paroxetine controlled release in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005;193:352-60.
236. Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Oct;72(10):1037-44.
237. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine. Drug Safety.2007;30(5):437-55.
238. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005;25(5):660-7.
239. Stein DJ, Ipser JC, van Balkom AJ. Pharmacotherapy for social anxiety disorder. Cochrane Database Syst Rev. 2000 (4):CD001206. doi: 10.1002/14651858.CD001206.pub2.
240. Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000 Dec;61(12):928-32.
241. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299:901-13.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Cerebral Stimulants/Agents Used for ADHD
Central Alpha-Agonists, AHFS Class 240816
Amphetamine Derivatives AHFS Class 282004
Respiratory and CNS Stimulants, AHFS Class 282032
Central Nervous System Agents, Miscellaneous, AHFS Class 289200
November 4, 2020

I. Overview

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that is often diagnosed during childhood; however, children with ADHD may continue to manifest symptoms into adulthood.[1-2] The key diagnostic feature is a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.[1] There are three subtypes of ADHD, including a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype in which both symptoms are displayed.[1] Untreated (or undertreated) ADHD is associated with adverse sequelae, including conduct disorder, antisocial personality traits, substance abuse, and other comorbidities.[1]

There are several central nervous system agents that are approved for the treatment of ADHD. This includes cerebral stimulants (amphetamines and methylphenidate derivatives), as well as atomoxetine, extended-release clonidine, and extended-release guanfacine.[3-27] The stimulants are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.[4-24] Due to their potential for abuse, the stimulants are classified as Schedule II controlled substances. Atomoxetine, extended-release clonidine, and extended-release guanfacine are not considered controlled substances and have no known potential for abuse or dependence. Their mechanism of action in the treatment of ADHD is unknown. Atomoxetine is a selective norepinephrine reuptake inhibitor, while clonidine and guanfacine are alpha$_2$-adrenergic agonists.[3,25,26]

The cerebral stimulants/agents used for ADHD that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Table 2 classifies the agents based on their duration of action. Many of the products are available in a generic formulation. This class was last reviewed in August 2018.

Table 1. Cerebral Stimulants/Agents Used for ADHD Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Central Alpha-Agonists			
Clonidine	extended-release tablet	N/A	clonidine
Amphetamine Derivatives			
Amphetamine	extended-release orally disintegrating tablet, extended-release suspension, tablet	Adzenys ER®*, Adzenys XR-ODT®, Dyanavel XR®, Evekeo®*	amphetamine
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	extended-release capsule, tablet	Adderall®*, Adderall XR®*, Mydayis ER®	amphetamine-dextroamphetamine
Dextroamphetamine	sustained-release capsule, solution, tablet	Dexedrine®*, ProCentra®*, Zenzedi®*	dextroamphetamine
Lisdexamfetamine	capsule, chewable tablet	Vyvanse®	Vyvanse®
Methamphetamine	tablet	Desoxyn®*	methamphetamine
Respiratory and CNS Stimulants			
Dexmethylphenidate	extended-release capsule, tablet	Focalin®*, Focalin XR®*†	Dexmethylphenidate IR, Focalin XR®*†
Methylphenidate	chewable tablet, extended-release capsule,	Adhansia XR®, Aptensio XR®*, Concerta®*†,	methylphenidate, Concerta®*†, Ritalin®*

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
	extended-release chewable tablet, extended-release orally disintegrating tablet, extended-release solution, extended-release tablet, sustained-release tablet, solution, tablet, transdermal patch	Cotempla XR-ODT®, Daytrana®, Jornay PM®, Methylin®*, Quillichew ER®, Quillivant XR®, Relexxii ER®*, Ritalin®*, Ritalin LA®*	
Central Nervous System Agents, Miscellaneous			
Atomoxetine	capsule	Strattera®*	atomoxetine
Guanfacine	extended-release tablet	Intuniv®*	guanfacine

*Generic is available in at least one dosage form or strength.
†Generic product requires prior authorization.
PDL=Preferred Drug List.

Table 2. Cerebral Stimulants/Agents Used for ADHD Classified by Duration of Action[3-24]

Generic Name(s)	Short-Acting	Intermediate-Acting	Long-Acting
Central Alpha-Agonists			
Clonidine			Kapvay®
Amphetamine Derivatives			
Amphetamine sulfate	Evekeo®*		Adzenys ER®*, Adzenys XR-ODT®, Dyanavel XR®
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	amphetamine aspartate, amphetamine sulfate, and dextroamphetamine, Adderall®*		amphetamine aspartate, amphetamine sulfate, and dextroamphetamine, Adderall XR®*, Mydayis ER®
Dextroamphetamine	dextroamphetamine, ProCentra®*, Zenzedi®*	dextroamphetamine, Dexedrine®*	
Lisdexamfetamine			Vyvanse®
Methamphetamine		methamphetamine, Desoxyn®*	
Respiratory and CNS Stimulants			
Dexmethylphenidate	dexmethylphenidate, Focalin®*		Focalin XR®
Methylphenidate	methylphenidate, Methylin®*, Ritalin®*	methylphenidate SR	methylphenidate, Adhansia XR®, Aptensio XR®*, Concerta®*, Cotempla XR-ODT®, Daytrana®, Jornay PM®, Ritalin LA®*, Quillichew ER®, Quillivant XR®, Relexxii ER®*
Central Nervous System Agents, Miscellaneous			
Atomoxetine			Strattera®*
Guanfacine			Intuniv®*

*Generic is available in at least one dosage form or strength.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the cerebral stimulants/agents used for attention-deficit/hyperactivity disorder (ADHD) are summarized in Table 3.

Table 3. Treatment Guidelines Using the Cerebral Stimulants/Agents Used for ADHD

Clinical Guideline	Recommendation(s)
American Academy of Pediatrics: **Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents (2019)**[30]	Preschool-aged children (four to five years of age) • The primary care clinician should prescribe evidence-based behavioral parent training in behavior management and/or behavioral classroom interventions as the first-line of treatment. • Methylphenidate may be prescribed if the behavior interventions do not provide significant improvement and there is moderate-to-severe continuing disturbance in the child's function. Elementary and middle school-aged children (six to 11 years of age) • The primary care clinician should prescribe Food and Drug Administration (FDA)-approved medications for attention deficit-hyperactivity disorder (ADHD) along with parent training in behavior management and/or behavioral classroom intervention, preferably both. • The evidence is particularly strong for stimulant medications and sufficient but less strong for atomoxetine, extended-release guanfacine, and extended-release clonidine (in that order). Adolescents (12 to 18 years of age) • The primary care clinician should prescribe FDA-approved medications for ADHD with the assent of the adolescent and may prescribe evidence-based training interventions and/or behavioral interventions as treatment for ADHD. General considerations • Stimulant medications are highly effective for most adolescents in reduction of core symptoms of ADHD. • Atomoxetine, extended-release guanfacine and extended-release clonidine reduce core symptoms; however, they have a smaller evidence base than stimulants. • Extended-release guanfacine and extended-release clonidine have evidence to support their use as adjunctive therapy with stimulant medications. • Before beginning medication treatment for adolescents with newly diagnosed ADHD, clinicians should assess these patients for symptoms of substance abuse. • Clinicians should monitor symptoms and prescription-refill requests for signs of misuse or diversion of ADHD medications and consider prescribing medications with no abuse potential, such as atomoxetine, extended-release guanfacine or extended-release clonidine. • Primary care clinicians should titrate doses of medication for ADHD to achieve maximum benefit with minimum adverse effects.
National Institute for Health and Clinical Excellence: **Attention Deficit Hyperactivity Disorder: Diagnosis and Management (2018)**[31] Last updated September 2019	Planning treatment for ADHD in children under five years of age • Offer an ADHD-focused group parent-training program to parents or carers of children under five years with ADHD as first-line treatment. • If after an ADHD-focused group parent-training program, ADHD symptoms across settings are still causing a significant impairment in a child under five years after environmental modifications have been implemented and reviewed, obtain advice from a specialist ADHD service with expertise in managing ADHD in young children. • Do not offer medication for ADHD for any child under five years without a second specialist opinion from an ADHD service with expertise in managing ADHD in young children. Planning treatment for ADHD in children aged five years and over and young people • Give ADHD-focused information and offer additional support as the first approach to parents and carers of all children aged five years and over and young people with ADHD. The support should be group based and ADHD focused. • Consider individual parent-training/education programs for parents and carers of

Clinical Guideline	Recommendation(s)
	children and young people with ADHD when there are particular difficulties for families in attending group sessions (for example, because of disability, needs related to diversity such as language differences, learning disability [intellectual disability], parental ill-health, problems with transport, or where other factors suggest poor prospects for therapeutic engagement) and when a family's needs are too complex to be met by group-based parent-training/education programs. • Offer medication for children aged five years and over and young people if their ADHD symptoms are still causing a persistent significant impairment in at least one domain after their parents have received ADHD-focused information, group-based support has been offered, and environmental modifications have been implemented and reviewed. • Consider a course of cognitive behavioral therapy (CBT) for young people with ADHD who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain, addressing the following areas: o social skills with peers o problem-solving o self-control o active listening skills o dealing with and expressing feelings <u>Planning treatment for ADHD in adults</u> • Offer medication to adults with ADHD if their ADHD symptoms are still causing a significant impairment in at least one domain after environmental modifications have been implemented and reviewed. • Consider non-pharmacological treatment for adults with ADHD who have made an informed choice not to have medication, have difficulty adhering to medication, or have found medication to be ineffective or cannot tolerate it. • Consider non-pharmacological treatment in combination with medication for adults with ADHD who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain. • When non-pharmacological treatment is indicated for adults with ADHD, offer the following as a minimum: a structured supportive psychological intervention focused on ADHD and regular follow‑up either in person or by phone. • Treatment may involve elements of or a full course of CBT. <u>Medication choice – children aged five years and over and young people</u> • Offer methylphenidate (either short or long acting) for children aged five years and over and young people if their ADHD symptoms are still causing a persistent significant impairment in at least one domain after their parents have received ADHD-focused information, group-based support has been offered and environmental modifications have been implemented and reviewed. • Consider switching to lisdexamfetamine for children aged five years and over and young people who have had a six-week trial of methylphenidate at an adequate dose and not derived enough benefit in terms of reduced ADHD symptoms and associated impairment. • Consider dexamphetamine for children aged five years and over and young people whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. • Offer atomoxetine or guanfacine to children aged five years and over and young people if: o they cannot tolerate methylphenidate or lisdexamfetamine or o their symptoms have not responded to separate six-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.

Clinical Guideline	Recommendation(s)
	Medication choice – adults • Offer lisdexamfetamine or methylphenidate as first-line pharmacological treatment for adults with ADHD. • Consider switching to lisdexamfetamine for adults who have had a six-week trial of methylphenidate at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment. • Consider switching to methylphenidate for adults who have had a six-week trial of lisdexamfetamine at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment. • Consider dexamphetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. • Offer atomoxetine to adults if: o they cannot tolerate lisdexamfetamine or methylphenidate or o their symptoms have not responded to separate six-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses. Further medication choices • Obtain a second opinion or refer to a tertiary service if ADHD symptoms in a child aged five years or over, a young person or adult are unresponsive to one or more stimulants and one non-stimulant. • Do not offer any of the following medication for ADHD without advice from a tertiary ADHD service: o guanfacine for adults o clonidine for children with ADHD and sleep disturbance, rages or tics o atypical antipsychotics in addition to stimulants for people with ADHD and coexisting pervasive aggression, rages or irritability Medication choice – people with coexisting conditions • Offer the same medication choices to people with ADHD and anxiety disorder, tic disorder or autism spectrum disorder as other people with ADHD. • For children aged five years and over, young people and adults with ADHD experiencing an acute psychotic or manic episode: o stop any medication for ADHD o consider restarting or starting new ADHD medication after the episode has resolved, taking into account the individual circumstances, risks and benefits of the ADHD medication. Considerations when prescribing ADHD medication • When prescribing stimulants for ADHD, think about modified-release once-daily preparations for the following reasons: o convenience o improving adherence o reducing stigma (because there is no need to take medication at school or in the workplace) o reducing problems of storing and administering controlled drugs at school o the risk of stimulant misuse and diversion with immediate-release preparations o their pharmacokinetic profiles. • Immediate-release preparations may be suitable if more flexible dosing regimens are needed, or during initial titration to determine correct dosing levels. • When prescribing stimulants for ADHD, be aware that effect size, duration of effect and adverse effects vary from person to person. • Think about using immediate- and modified-release preparations of stimulants to

Clinical Guideline	Recommendation(s)
	optimize effect (for example, a modified-release preparation of methylphenidate in the morning and an immediate-release preparation of methylphenidate at another time of the day to extend the duration of effect). • Be cautious about prescribing stimulants for ADHD if there is a risk of diversion for cognitive enhancement or appetite suppression. • Do not offer immediate-release stimulants or modified-release stimulants that can be easily injected or insufflated if there is a risk of stimulant misuse or diversion. • Prescribers should be familiar with the requirements of controlled drug legislation governing the prescription and supply of stimulants. <u>Adherence to treatment</u> • Be aware that the symptoms of ADHD may lead to people having difficulty adhering to treatment plans (for example, remembering to order and collect medication). • Ensure that people are fully informed of the balance of risks and benefits of any treatment for ADHD and check that problems with adherence are not due to misconceptions (for example, tell people that medication does not change personality). • Encourage the person with ADHD to use the following strategies to support adherence to treatment: o being responsible for their own health, including taking their medication as needed o following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, adverse effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) o using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) o taking medication as part of their daily routine (for example, before meals or after brushing teeth) o attending peer support groups (for both the person with ADHD and for the families and carers). • Encourage parents and carers to oversee ADHD medication for children and young people. <u>Review of medication and discontinuation</u> • A healthcare professional with training and expertise in managing ADHD should review ADHD medication at least once a year and discuss with the person with ADHD (and their families and carers as appropriate) whether medication should be continued. The review should include a comprehensive assessment of the: o preference of the child, young person or adult with ADHD (and their family or carers as appropriate) o benefits, including how well the current treatment is working throughout the day o adverse effects o clinical need and whether medication has been optimized o impact on education and employment o effects of missed doses, planned dose reductions and periods of no treatment o effect of medication on existing or new mental health, physical health or neurodevelopmental conditions o need for support and type of support (for example, psychological, educational, social) if medication has been optimized but ADHD symptoms continue to cause a significant impairment. • Encourage people with ADHD to discuss any preferences to stop or change medication and to be involved in any decisions about stopping treatments.

Clinical Guideline	Recommendation(s)
	• Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. If the decision is made to continue medication, the reasons for this should be documented.
British Association of Psychopharmacology: **Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology (2014)**[32]	<u>Treatment recommendations for children and adolescents</u> • All children with severe ADHD (conceptualized as hyperkinetic disorder) should be offered pharmacological treatment. In addition, consider pharmacological treatment for children with moderate symptoms of ADHD who have not responded to psychological interventions. • The treatment of choice for children with severe ADHD or moderate ADHD non-responsive to psychological treatments is psychostimulant medication. • Atomoxetine can be used instead when there is a risk of misuse of psychostimulants by children or the adults supporting the child. • Appropriate child and family-based psychological interventions should be available to all children with ADHD. These interventions should be tailored to the child's needs and not depend on the local availability of services. • Teachers should be given evidence-based information about ADHD. • Patient and parental preferences should be taken into account when designing a psychological intervention for ADHD. • Every effort should be made to facilitate the transition from adolescence to adulthood. This should include education of parents, children, and professionals involved in the care of these children and the development of appropriate services and shared care protocols to enable this transition. • Systems and protocols need to be implemented to allow early re-acces to services for young people who may have dropped out of treatment at an early age, but still have significant symptoms and impairment. <u>Treatment recommendations for adults</u> • Stimulant medications are the first-line drugs in adults with ADHD. • Although amphetamines, methylphenidate and atomoxetine are all effective in adults with ADHD, they cannot be considered equivalent because they have different mechanisms of actions and hazards. • Once methylphenidate, atomoxetine, and amphetamines have all been given a fair trial, third-line medications can be considered. These include bupropion, modafinil, tricyclic antidepressants, guanfacine and clonidine. • Co-administration of psychostimulant and other drugs (mainly atomoxetine) is an option for patients showing a limited or lack of clinical response. There is, however, limited evidence supporting either the efficacy or safety of combination therapy. • Psychological treatments are a complement to pharmacological treatment. • Different approaches have been used but the majority the evidence is for structured treatments employing a cognitive behavioral paradigm. • The use of different methods of delivery (group and individual therapy), different criteria for control groups and different outcome measures limit the generalization of results. <u>Abuse potential</u> • Abuse potential is related to drug action and formulation. Abuse is generally low among patients but it can occur with stimulants. Slow-release preparations of these agents or atomoxetine are preferred for patients with a history of substance abuse, or who are at risk for substance abuse.
American Academy of Sleep Medicine: **Practice Parameters**	• Most of the agents used to treat excessive sleepiness have little effect on cataplexy or other rapid eye movement sleep associated symptoms. Most antidepressants and anticataplectics have little effect on alertness. However,

Clinical Guideline	Recommendation(s)
for the Treatment of Narcolepsy and Other Hypersomnias of Central Origin (2007)[33]	some compounds act on both symptoms. Compounds should be selected depending on the diagnosis and the targeted symptoms. Coadministration of two or more classes of compounds may be needed in some patients to adequately address their symptoms. • Modafinil is effective for treatment of daytime sleepiness due to narcolepsy. • Sodium oxybate is effective for treatment of cataplexy, daytime sleepiness, and disrupted sleep due to narcolepsy. Sodium oxybate may be effective for treatment of hypnagogic hallucinations and sleep paralysis. • Amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are effective for treatment of daytime sleepiness due to narcolepsy. • Selegiline may be an effective treatment for cataplexy and daytime sleepiness. • Tricyclic antidepressants, selective serotonin reuptake inhibitors, and venlafaxine may be effective treatment for cataplexy. • Scheduled naps can be beneficial to combat sleepiness, but seldom suffice as primary therapy for narcolepsy.
European Federation of Neurological Sciences: **Guidelines on Management of Narcolepsy in Adults (2011)[34]**	<u>Excessive daytime sleepiness and irresistible episodes of sleep</u> • Modafinil should be prescribed when excessive daytime sleepiness is present. Modafinil should be dosed as 100 to 400 mg/day, given once in the morning or twice daily. • Sodium oxybate may be used when excessive daytime somnolence coexists with cataplexy and poor sleep. Depressed patients should not receive sodium oxybate. • Sodium oxybate should be initiated with 4.5 g/night, increasing by increments of 1.5 g at four-week intervals and should not be used with other sedatives, respiratory depressants or muscle relaxants. Monitor patients for possible development of sleep-disordered breathing. Adverse effects may limit the dose, and require slower titration. • The optimal response on excessive daytime sleepiness may take up to 12 weeks. • Supplementation with modafinil is generally more successful than sodium oxybate alone. • Methylphenidate may be considered if modafinil is insufficient and sodium oxybate is not recommended. • The short-acting effect of methylphenidate is of interest when modafinil needs to be supplemented at a specific time of the day, or in situations where maximum alertness is required. <u>Cataplexy</u> • First-line pharmacological treatment of cataplexy is sodium oxybate at a starting dose of 4.5 g/night divided into two equal doses of 2.25 g/night. The dose may be increased to a maximum of 9 g/night, divided into two equal doses of 4.5 g/night, by increments of 1.5 g at two-week intervals. • Adverse effects may limit the dose, and require slower titration and the optimal response on excessive daytime sleepiness may take up to 12 weeks. • Antidepressants are recommended as second-line pharmacological treatment. Tricyclic antidepressants, particularly clomipramine (10 to 75 mg), are potent anticataplectic drugs; however, anticholinergic adverse effects are common. • Selective serotonin reuptake inhibitors are slightly less active but have fewer adverse effects. • Venlafaxine is widely used but clinical evidence supporting its use is limited. • Reboxetine and atomoxetine, also lack published clinical evidence. • Given the efficacy of sodium oxybate and antidepressants, the place for other compounds is fairly limited. • There is no accepted behavioral treatment of cataplexy. <u>Poor sleep</u> • Sodium oxybate appears to be the most appropriate to treat poor sleep.

Clinical Guideline	Recommendation(s)
	• Benzodiazepine or non-benzodiazepine hypnotics may be effective in consolidating nocturnal sleep, but objective evidence is lacking over intermediate- or long-term follow-up. • The improvement in poor sleep reported by some patients once established on modafinil is noteworthy. <u>Obstructive sleep apnea/hypopnea syndrome, periodic limb movements in sleep, neuropsychiatric symptoms</u> • Obstructive sleep apnea/hypopnea syndrome should be similarly in narcoleptic patients and general population, although continuous positive airway pressure does not improve excessive daytime sleepiness in most narcolepsy subjects. • There is usually no need to treat periodic limb movements in narcoleptic patients. Antidepressants and psychotherapy should be used in depressed narcoleptic patients as in non-narcoleptic depressed patients.
American Academy of Sleep Medicine: **Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults (2009)**[35]	<u>Weight reduction</u> • Successful dietary weight loss may improve the apnea-hypopnea index in obese obstructive sleep apnea patients. • Dietary weight loss should be combined with a primary treatment for obstructive sleep apnea. • Bariatric surgery may be adjunctive in the treatment of obstructive sleep apnea in obese patients. <u>Pharmacologic agents</u> • Modafinil is recommended for the treatment of residual excessive daytime sleepiness in obstructive sleep apnea patients who have sleepiness despite effective positive airway pressure treatment and who are lacking any other identifiable cause for their sleepiness. • Selective serotonin reuptake inhibitors, protriptyline, methylxanthine derivatives (aminophylline and theophylline), and estrogen therapy are not recommended for treatment of obstructive sleep apnea. <u>Supplemental oxygen</u> • Oxygen supplementation is not recommended as a primary treatment for obstructive sleep apnea. <u>Medical therapies intended to improve nasal patency</u> • Short-acting nasal decongestants are not recommended for treatment of obstructive sleep apnea. • Topical nasal corticosteroids may improve the apnea-hypopnea index in patients with obstructive sleep apnea and concurrent rhinitis, and thus may be a useful adjunct to primary therapies for obstructive sleep apnea. <u>Positional therapies</u> • Positional therapy is an effective secondary therapy or can be a supplement to primary therapies for obstructive sleep apnea in patients who have a low apnea-hypopnea index in the non-supine vs that in the supine position.
American Academy of Sleep Medicine: **Practice Parameters for the Evaluation and Treatment of Extrinsic Circadian Rhythm Sleep Disorders (2015)**[36]	<u>Shift work disorder</u> • Planned napping before or during the night shift is indicated to improve alertness and performance among night shift workers. • Timed light exposure in the work environment and light restriction in the morning, when feasible, is indicated to decrease sleepiness and improve alertness during night shift work. • Administration of melatonin prior to daytime sleep is indicated to promote daytime sleep among night shift workers. • Hypnotic medications may be used to promote daytime sleep among night shift

Clinical Guideline	Recommendation(s)
	workers. Carryover of sedation to the nighttime shift with potential adverse consequences for nighttime performance and safety must be considered. • Modafinil is indicated to enhance alertness during the night shift for shift work disorder. • Caffeine is indicated to enhance alertness during the night shift for shift work disorder.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the cerebral stimulants/agents used for attention deficit-hyperactivity disorder (ADHD) are noted in Table 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 4. FDA-Approved Indications for the Cerebral Stimulants/Agents Used for ADHD[28]

Generic Name(s)	Attention Deficit-Hyperactivity Disorder	Narcolepsy	Exogenous Obesity	Binge Eating Disorder
Central Alpha-Agonists				
Clonidine	✔ *			
Amphetamine Derivatives				
Amphetamine sulfate	✔	✔ †	✔ †§	
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	✔	✔ †		
Dextroamphetamine	✔	✔		
Lisdexamfetamine	✔			✔ ‖
Methamphetamine	✔		✔ §	
Respiratory and CNS Stimulants				
Dexmethylphenidate	✔			
Methylphenidate	✔	✔ †‡		
Central Nervous System Agents, Miscellaneous				
Atomoxetine	✔			
Guanfacine	✔ *			

*As monotherapy and as adjunctive therapy to stimulant medications.
†Immediate-release formulations.
‡Sustained-release formulations.
§As a short-term adjunct in a regimen of weight reduction based on caloric restriction, for patients in whom obesity is refractory to alternative therapy (e.g., repeated diets, group programs, and other drugs).
‖For use in moderate to severe Binge Eating Disorder. Not indicated for weight loss or treatment of obesity.

IV. Pharmacokinetics

The pharmacokinetic parameters of the cerebral stimulants/agents used for attention deficit-hyperactivity disorder (ADHD) are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the Cerebral Stimulants/Agents Used for ADHD[3-29]

Generic Name(s)	Onset (hours)	Duration (hours)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Central Alpha-Agonists							
Clonidine	0.5 to 1.0	6 to 10	89	20 to 40	Liver (50)	Renal (40 to 60)	12 to 16
Amphetamine Derivatives							
Amphetamine	1 to 3	Up to 10	Well absorbed	20	Liver (not reported)	Renal (67 to 73)	7 to 34
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	Not reported	IR: 4 to 6 XR: 10 to 12	Well absorbed	Not reported	Liver (not reported)	Renal (1 to 75)	9 to 14
Dextroamphetamine	2 to 3	IR: 4 to 6 SR: 6 to 8	Well absorbed	Not reported	Liver (not reported)	Renal (17 to 73)	10 to 12
Lisdexamfetamine	Not reported	10	Rapid	Not reported	Blood (not reported)	Renal (96.0) Feces (0.3)	<1
Methamphetamine	Not reported	Not reported	Rapid	Not reported	Liver (not reported)	Renal (62)	4 to 5
Respiratory and CNS Stimulants							
Dexmethylphenidate	1	IR: 5 to 6 XR: 12	22 to 25	12 to 15	Liver (not reported)	Renal (90)	2.0 to 4.5
Methylphenidate	IR: 2 SR: 4 to 7 ER: 1 to 2 XR: 0.5 to 1.0 TD: 2	IR: 3 to 6 SR: 8 ER: 10 to 12 XR: 8 to 12 TD: 10 to 12	10 to 52	10 to 33	Liver (not reported)	Renal (90) Fecal (1 to 3)	3 to 4
Central Nervous System Agents, Miscellaneous							
Atomoxetine	1 week	Not reported	63 to 94	98	Liver (not reported)	Renal (>80) Feces (<17)	5 to 22
Guanfacine	Not reported	Not reported	80	70	Liver (50)	Renal (50)	16

ER=extended-release (osmotic), IR=immediate-release, SR=sustained-release, TD=transdermal, XR=extended-release (non-osmotic)

V. Drug Interactions

Major drug interactions with the cerebral stimulants/agents used for attention deficit-hyperactivity disorder (ADHD) are listed in Table 6.

Table 6. Major Drug Interactions with the Cerebral Stimulants/Agents Used for ADHD[29]

Generic Name(s)	Interaction	Mechanism
Central Alpha-Agonists		
Clonidine	Beta-adrenergic blockers	Withdrawal hypertension may be more severe in patients receiving clonidine and beta-adrenergic blockers. This combination may, on occasion, cause paradoxical hypertension.
Clonidine	Tricyclic antidepressants	The antihypertensive effects of clonidine may be decreased by tricyclic antidepressants. Tricyclic antidepressants may worsen rebound reactions from abrupt clonidine withdrawal.
Clonidine	Non-dihydropyridine calcium channel blockers	Concurrent use of clonidine and non-dihydropyridine calcium channel blockers may result in increased incidence of sinus bradycardia.
Clonidine	Mirtazapine	Concurrent use of mirtazapine and clonidine may result in hypertension, decreased antihypertensive effectiveness.
Clonidine	Tizanidine	The potential for symptomatic additive hypotension exists when tizanidine is coadministered with clonidine.
Amphetamine Derivatives		
Amphetamine derivatives	MAOIs	Toxicity of amphetamines may be increased by MAOIs. Headache, hyperpyrexia, elevated blood pressure and bradycardia may occur. Amphetamines can liberate large quantities of intraneuronal norepinephrine that have accumulated during treatment with MAOIs.
Amphetamine derivatives	Urinary alkalinizers	Interaction may lead to pH-dependent diminished urinary elimination of amphetamines and increases risk of amphetamine toxicity.
Amphetamine derivatives	Thiazide diuretics	Concurrent use of amphetamines and thiazide diuretics may result in increased exposure to amphetamine.
Respiratory and CNS Stimulants		
Methylphenidates	MAOIs	Pharmacologic effects of methylphenidates may be increased. Headache, gastrointestinal symptoms and hypertension may occur. The mechanism of this interaction is not clear. Liberation of intraneuronal catecholamine stores may play a role.
Methylphenidates	Bupropion	Caution is advised with concomitant use of bupropion and methylphenidates, as this may result in an increased risk of seizures, especially in patients with a seizure history. Both agents may lower the seizure threshold.
Central Nervous System Agents, Miscellaneous		
Atomoxetine	MAOIs	Toxic effects may be increased with concurrent administration of atomoxetine and MAOIs. Serious and sometimes fatal reactions have occurred. Pharmacologic effects of atomoxetine and MAOIs may be additive.

Generic Name(s)	Interaction	Mechanism
Atomoxetine	Albuterol	Concurrent use of albuterol and atomoxetine may result in an increase in heart rate and blood pressure.
Guanfacine	Conivaptan	Concurrent use of conivaptan and guanfacine may result in increased guanfacine exposure.

MAOIs=monoamine oxidase inhibitors

VI. Adverse Drug Events

The most common adverse drug events reported with the cerebral stimulants/agents used for attention deficit-hyperactivity disorder (ADHD) are listed in Tables 7 to 10. The boxed warnings for the cerebral stimulants/agents used for ADHD are listed in Tables 11 to 16. Methylphenidate and amphetamines increase dopamine levels in the brain similar to cocaine and methamphetamine. They are classified as Schedule II controlled substances by federal regulation. Long-term abusive use can lead to tolerance and psychological dependence. There is no evidence to suggest that drug abuse results from prescribed stimulants if they are properly monitored.[1,37-39] Methylphenidate is a less potent sympathomimetic amine than mixed amphetamine salts, which may be associated with a lower potential for abuse.[38] The osmotic-release formulation of methylphenidate cannot be crushed and may decrease the potential for abuse. It has also been proposed that transdermal methylphenidate may possess less potential for abuse compared to orally-administered cerebral stimulants. Atomoxetine, clonidine, and guanfacine are not controlled substances.

Table 7. Adverse Drug Events (%) Reported with the Central Alpha-Agonists[3]

Adverse Events	Clonidine
Cardiovascular	
Atrioventricular block	✔
Bradycardia	≤4
Cardiac arrhythmia	✔
Chest pain	✔
Congestive heart failure	✔
Electrocardiogram abnormalities	✔
Orthostatic hypotension	✔
Pallor	✔
Palpitations	1
Reynaud's phenomenon	✔
Syncope	✔
Tachycardia	1
Central Nervous System	
Abnormal sleep-related event	1 to 3
Aggressive behavior	✔
Agitation	✔
Anxiety	✔
Behavioral change	✔
Crying	1 to 3
Delirium	✔
Dizziness	2 to 5
Emotional disorder	3 to 4
Fatigue/lethargy	12 to 15
Fever	✔
Hallucinations	✔
Headache	1 to 11
Insomnia	≤5
Irritability	3 to 6
Malaise	✔
Mental depression	1

Adverse Events	Clonidine
Nervousness	1 to 3
Nightmares	✔
Paresthesia	✔
Restlessness	✔
Sleep terror	3
Somnolence	26 to 33
Tremor	✔
Vivid dreams	✔
Dermatological	
Flushing	✔
Rash	1
Urticaria	✔
Gastrointestinal	
Abdominal pain	≤3
Anorexia	1
Constipation	1 to 6
Diarrhea	≤1
Dry mouth	✔
Nausea	1 to 4
Thirst	1 to 3
Vomiting	✔
Weight gain	<1
Genitourinary	
Dysuria	✔
Enuresis	4
Erectile dysfunction	2 to 3
Gynecomastia	1
Libido decreased	✔
Nocturia	1
Pollakiuria	3
Sexual disturbances	3
Hepatic	
Hepatitis	✔
Liver function test abnormalities	≤1
Musculoskeletal	
Arthralgia	1
Leg cramps	≤1
Myalgia	1
Pain in extremities	✔
Weakness	10
Respiratory	
Asthma	4
Epistaxis	3
Lower respiratory tract infection	2
Nasal congestion	2 to 4
Nasal dryness	✔
Nasopharyngitis	2
Upper respiratory tract infection	2 to 7
Special Senses	
Accommodation difficulties	✔
Blurred vision	✔
Dry eyes	✔
Eye pain	✔
Other	

Adverse Events	Clonidine
Body temperature increase	≤2
Ear infection	✔
Ear pain	4
Flu-like syndrome	≤3
Throat pain	3 to 5
Thrombocytopenic purpura	✔
Viral infection	≤3

✔ Percent not specified.

Table 8. Adverse Drug Events (%) Reported with the Amphetamines[7-12,28]

Adverse Events	Amphetamine	Amphetamine Aspartate/ Amphetamine Sulfate/ Dextroamphetamine	Dextroam-phetamine	Lisdexam-fetamine	Metham-phetamine
Cardiovascular					
Blood pressure increased	-	-	-	3	-
Cardiomyopathy	✔	✔ †	✔	✔	-
Heart rate increased	-	-	✔	2	✔
Hypertension	✔	✔ †	✔	✔	✔
Myocardial infarction	-	✔ *	✔	✔	✔
Palpitations	✔	✔ †, 2 to 4*	✔	✔	✔
Peripheral vascular disease	-	-	✔	-	-
Raynaud's disease	-	-	✔	-	✔
Sudden death	-	✔ *	✔	✔	✔
Tachycardia	✔	✔ †, 6*	✔	✔	✔
Central Nervous System					
Aggressive behavior	-	✔ †*	✔	-	-
Agitation	-	8*	-	3	-
Anxiety	-	8*	-	6	-
Depression	-	✔ †*	-	✔	-
Dizziness	✔	2 to 7*	✔	5	✔
Dyskinesia	✔	✔ †*	✔	✔	-
Dysphoria	✔	✔ †*	✔	✔	✔
Euphoria	✔	✔ †*	✔	✔	✔
Fever	-	5*	-	2	-
Headache	✔	✔ †, 26*	✔	12	✔
Insomnia	✔	12 to 27*	✔	13 to 27	✔
Irritability	-	✔ †*	-	10	-
Labile affect	-	-	-	3	-
Mania	-	-	✔	✔	✔
Nervousness	-	6 to 13*	-	-	-
Overstimulation	✔	✔ †	✔	✔	✔
Psychotic episodes	✔	✔ †	✔	✔	✔
Restlessness	✔	✔ †*	✔	3	✔
Seizures	-	✔ *	-	✔	✔
Somnolence	-	2 to 4*	-	2	-
Speech disorder	-	2 to 4*	-	-	-
Stroke	-	✔ *	✔	✔	✔
Tic exacerbation	✔	✔ †*	✔	2	✔
Tourette's exacerbation	✔	✔ †*	✔	✔	✔
Tremor	✔	✔ †*	✔	2	✔
Twitching	-	2 to 4*	-	-	-
Dermatological					
Diaphoresis	-	2 to 4*	-	-	-
Hyperhidrosis	-	-	-	3	-
Photosensitivity	-	2 to 4*	-	-	-
Rash	-	✔ †*	✔	3	✔
Stevens-Johnson syndrome	-	✔ †*	-	✔	-

Adverse Events	Amphetamine	Amphetamine Aspartate/ Amphetamine Sulfate/ Dextroamphetamine	Dextroam-phetamine	Lisdexam-fetamine	Metham-phetamine
Toxic epidermal necrolysis	-	✔ †*	-	✔	-
Urticaria	✔	✔ †*	✔	✔	✔
Gastrointestinal					
Abdominal pain	-	11 to 14*	-	12	-
Anorexia	✔	-	✔	5	✔
Appetite decreased	-	22 to 36*	-	27 to 39	-
Constipation	✔	✔ †, 2 to 4*	✔	✔	✔
Diarrhea	✔	2 to 6*	✔	7	✔
Dry mouth	✔	2 to 35*	✔	4 to 26	✔
Dyspepsia	-	2 to 4*	-	-	-
Nausea	-	2 to 8*	-	6 to 7	✔
Other gastrointestinal disturbances	✔	-	✔	-	✔
Unpleasant taste	✔	✔ †*	✔	✔	✔
Vomiting	✔	2 to 7*	-	9	✔
Weight loss	✔	4 to 11*	✔	9	✔
Genitourinary					
Changes in libido	✔	2 to 4*	✔	≤2	✔
Impotence	✔	2 to 4*	✔	✔	✔
Prolonged erections	✔	-	-	-	-
Urinary tract infection	-	5*	-	-	-
Other					
Anaphylaxis	-	✔ *	-	✔	-
Angioedema	-	-	-	✔	-
Blurred vision	-	✔ †*	✔	✔	-
Dysmenorrhea	-	2 to 4*	-	-	-
Dyspnea	-	2 to 4*	-	2	-
Growth suppression	-	-	✔	✔	✔
Hypersensitivity reactions	-	-	-	✔	-
Infection	-	2 to 4*	-	-	-
Rhabdomyolysis	✔	-	-	-	-
Tolerance	-	-	-	-	✔
Weakness	-	2 to 6*	-	-	-

†Immediate-release formulation.
*Extended-release formulation.
✔ Percent not specified.
-Event not reported or incidence <1%.

Table 9. Adverse Drug Events (%) Reported with the Respiratory and CNS Stimulants[28]

Adverse Events	Dexmethylphenidate	Methylphenidate
Cardiovascular		
Angina	✔	✔
Cardiac arrhythmia	✔	✔
Chest pain	-	✔
Hypertension	✔	✔
Hypotension	✔	✔
Myocardial infarction	-	✔
Palpitations	✔	✔
Pulse increase/decrease	✔	✔
Raynaud's phenomenon	-	✔
Sudden death	✔	-
Systolic blood pressure increased	-	-
Tachycardia	3	✔
Vasodilation	-	-
Central Nervous System		

Adverse Events	Dexmethylphenidate	Methylphenidate
Aggressive behavior	✔	✔
Agitation	-	-
Anxiety	5 to 11	-
Attention disturbance	-	-
Cerebral arteritis	✔	✔
Cerebral occlusion	✔	✔
Depression	✔	✔
Dizziness	6	✔
Drowsiness	✔	✔
Dyskinesia	✔	✔
Emotional instability	-	6†
Fatigue/lethargy	-	-
Fever	5	✔
Hallucinations	-	✔ †
Headache	25 to 39	✔, 28†
Hyperkinesia	-	-
Hypertonia	-	-
Insomnia	✔	✔, 13 to 30†
Jittery feeling	12	-
Labile affect	-	✔
Mania	-	✔
Migraine	-	-
Nervousness	✔	✔
Neuroleptic malignant syndrome	✔	✔
Overstimulation	-	-
Paresthesia	-	✔
Psychotic episodes	-	-
Restlessness	12	-
Seizures	-	✔ †
Somnolence	-	-
Tic	-	✔, 7†
Tourette's exacerbation	✔	✔
Toxic psychosis	✔	✔
Tremor	-	-
Vertigo	-	-
Dermatological		
Alopecia	-	✔
Application site reaction	-	✔ †
Dermatitis	-	-
Diaphoresis	-	-
Erythema	-	✔
Erythema multiforme	✔	✔
Exfoliative dermatitis	✔	✔
Hair loss	✔	✔
Herpes simplex	-	-
Hyperhidrosis	-	✔
Rash	✔	✔
Stevens-Johnson syndrome	-	-
Toxic epidermal necrolysis	-	✔
Urticaria	✔	✔
Gastrointestinal		
Abdominal pain	15	✔
Anorexia	5 to 7	✔, 5 to 46†

Adverse Events	Dexmethylphenidate	Methylphenidate
Appetite decreased	30	✔, 26†
Bruxism	-	✔
Constipation	-	✔
Diarrhea	-	✔
Dry mouth	7 to 20	✔
Dyspepsia	5 to 9	✔
Flatulence	-	-
Mouth ulceration	-	-
Nausea	9	✔, 12†
Stomach cramps	✔	-
Thirst	-	-
Unpleasant taste	-	-
Vomiting	-	✔, 10†
Weight loss	✔	✔, 9†
Genitourinary		
Abnormal urine	-	-
Erectile disturbance	-	✔
Hematuria	-	-
Libido decreased	-	✔
Polyuria	-	-
Pyuria	-	-
Hematologic		
Agranulocytosis	-	-
Anemia	✔	✔
Eosinophilia	-	-
Leukopenia	✔	✔
Pancytopenia	-	✔
Thrombocytopenic purpura	✔	✔
Hepatic		
Hepatic coma	✔	✔
Liver function test abnormalities	✔	✔
Musculoskeletal		
Arthralgia	✔	✔
Back pain	-	-
Respiratory		
Cough	-	✔
Dyspnea	-	✔
Epistaxis	-	-
Lung disorder	-	-
Nasal congestion	-	✔, 6†
Nasopharyngitis	-	✔, 5†
Pharyngitis	-	✔
Pharyngolaryngeal pain	4 to 7	✔
Respiratory tract infection	-	✔
Rhinitis	-	✔
Sinusitis	-	✔
Special Senses		
Abnormal vision	-	-
Accommodation difficulties	✔	✔
Amblyopia	-	-
Blurred vision	✔	✔
Dry eyes	-	✔
Eye pain	-	-

Adverse Events	Dexmethylphenidate	Methylphenidate
Mydriasis	-	✔
Other		
Accidental injury	-	✔
Allergic contact sensitization	-	✔ †
Anaphylaxis	-	✔ †
Dysmenorrhea	-	✔
Edema	-	-
Flu-like syndrome	-	-
Growth suppression	-	✔
Hypersensitivity reactions	✔	✔
Necrotizing vasculitis	✔	✔
Pain	-	-
Thirst	-	-
Viral infection	-	28†

†Transdermal formulation.
✔ Percent not specified.
- Event not reported or incidence <1%.

Table 10. Adverse Drug Events (%) Reported with the Central Nervous System Agents, Miscellaneous[25-28]

Adverse Events	Atomoxetine	Guanfacine
Cardiovascular		
Atrioventricular block	-	✔
Chest pain	-	-
Diastolic blood pressure increased	4 to 22	-
Flushing	≥2	-
Hypertension	1 to 9	✔
Hypotension	<2	4
Palpitations	3	-
QT prolongation	<1	-
Reynaud's phenomenon	✔	-
Sinus arrhythmia	-	✔
Stroke	✔	-
Systolic blood pressure increased	4 to 13	-
Tachycardia	2 to 24	-
Central Nervous System		
Abnormal dreams	4	-
Aggressive behavior	✔	-
Agitation	✔	✔
Akathisia	✔	-
Anxiety	✔	✔
Ataxia	-	-
Attention disturbance	-	-
Chills	3	-
Confusion	-	-
Crying	2	-
Depression	-	✔
Disorientation	-	-
Dizziness	5 to 6	6 to 8
Early morning awakening	<2	-
Fatigue/lethargy	6 to 9	14
Fever	3	-
Hallucinations	-	✔
Headache	2 to 19	21 to 24
Hostility	✔	-

Adverse Events	Atomoxetine	Guanfacine
Insomnia	2 to 15	12
Irritability	≤ 6	2
Jittery feeling	2	-
Mania	✔	-
Mood swings	1 to 2	-
Nervousness	-	-
Nightmare	-	✔
Panic disorder	✔	-
Paresthesia	4	-
Rigors	3	-
Seizure	-	✔
Sleep disorder	-	-
Sleep disturbance	3	-
Sleep paralysis	-	-
Sleep walking	-	-
Somnolence	4 to 11	18 to 38
Suicidal ideation	✔	-
Syncope	✔	✔
Tremor	2	-
Dermatological		
Dermatitis	2 to 4	-
Diaphoresis	2	-
Flushing	2	-
Hyperhidrosis	4	-
Rash	2	-
Urticaria	✔	-
Endocrine and Metabolic		
Dysmenorrhea	6	-
Hot flushes	8	-
Menstrual disturbances	2 to 3	-
Gastrointestinal		
Abdominal pain	7 to 18	10 to 11
Anorexia	<3	-
Appetite decreased	11 to 16	2
Constipation	1 to 9	3
Diarrhea	4	-
Dry mouth	4 to 21	3
Dyspepsia	4 to 6	✔
Fecal incontinence	-	-
Flatulence	2	-
Nausea	7 to 26	4
Stomach discomfort	-	✔
Vomiting	3 to 11	✔
Weight increase	-	✔
Weight loss	2 to 30	-
Genitourinary		
Dysuria	3	-
Ejaculatory disturbance	3	-
Enuresis	-	✔
Erectile disturbance	9	-
Impotence	3	-
Libido decreased	4	-
Orgasm abnormal	2	-
Prostatitis	2	-

Adverse Events	Atomoxetine	Guanfacine
Urinary incontinence	-	-
Urinary retention	7	-
Hepatic		
Hepatotoxicity	✔	-
Jaundice	✔	-
Hypoesthesia	-	-
Myalgia	-	-
Myasthenia	-	-
Weakness	-	-
Respiratory		
Asthma	-	✔
Bronchitis	-	-
Cough	11	-
Dyspnea	-	-
Nasopharyngitis	-	-
Rhinitis	-	-
Rhinorrhea	4	-
Sinus headache	3	-
Sinusitis	6	-
Upper respiratory infection	-	-
Special Senses		
Amblyopia	-	-
Blurred vision	-	-
Mydriasis	<2	-
Tinnitus	-	-
Other		
Accidental injury	-	-
Allergic contact sensitization	✔	-
Ear infection	3	-
Ear pain	-	-
Flu-like syndrome	✔	-
Hypersensitivity reactions	<1	✔
Influenza	3	-
Pain	-	-
Pallor	-	✔
Thirst	-	-
Viral infection	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 11. Boxed Warning for the Amphetamines[28]

WARNING
Amphetamines have a high potential for abuse and dependence. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse reactions.

Table 12. Boxed Warning for Atomoxetine[28]

WARNING

Suicidal ideation in children and adolescents: Atomoxetine increased the risk of suicidal ideation in short-term studies in children or adolescents with attention deficit hyperactivity disorder (ADHD). Anyone considering the use of atomoxetine in a child or adolescent must balance this risk with the clinical need. Closely monitor patients who are started on therapy for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider. Atomoxetine is approved for ADHD in children and adults. Atomoxetine is not approved for major depressive disorder (MDD). Pooled analysis of short-term (six- to 18-week), placebo-controlled trials of atomoxetine in children and adolescents (12 trials involving more than 2,200 patients, including 11 trials in ADHD and 1 trial in enuresis) has revealed a greater risk of suicidal ideation early during treatment in those receiving atomoxetine compared to placebo. The average risk of suicidal ideation in patients receiving atomoxetine was 0.4% (5/1,357 patients), compared to none in placebo-treated patients (0/851 patients). No suicides occurred in these trials

Table 13. Boxed Warning for Dexmethylphenidate[28]

WARNING
Drug dependence: Give dexmethylphenidate cautiously to patients with a history of drug dependence or alcoholism. Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during drug withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.

Table 14. Boxed Warning for Lisdexamfetamine[28]

WARNING
CNS stimulants (amphetamines and methylphenidate-containing products), including lisdexamfetamine, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Table 15. Boxed Warning for Methamphetamine[28]

WARNING
Methamphetamine has a high potential for abuse. It should thus be tried only in weight reduction programs for patients in whom alternative therapy has been ineffective. Administration of methamphetamine for prolonged periods of time in obesity may lead to drug dependence and must be avoided. Particular attention should be paid to the possibility of subjects obtaining methamphetamine for nontherapeutic use or distribution to others, and the drug should be prescribed or dispensed sparingly. Misuse of methamphetamine may cause sudden death and serious cardiovascular adverse events.

Table 16. Boxed Warning for Methylphenidate[28]

WARNING
CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

VII. Dosing and Administration

The usual dosing regimens for the cerebral stimulants/agents used for attention deficit-hyperactivity disorder (ADHD) are listed in Table 17.

Table 17. Usual Dosing Regimens for the Cerebral Stimulants/Agents Used for ADHD[3-28]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Central Alpha-Agonists			
Clonidine	Safety and efficacy have not been established in adults.	ADHD in patients ≥6 years of age: Tablet (ER): initial, 0.1 mg at bedtime; increase by 0.1 mg/day every seven days until desired response; doses should be administered twice daily; maximum, 0.4 mg/day	Tablet (ER): 0.1 mg
Amphetamines			
Amphetamine	ADHD: ODT: 12.5 mg daily Suspension (Adzenys ER®): 12.5 mg (10 mL) daily Suspension (Dyanavel XR®): Initial, 2.5 mg or 5 mg once daily in the morning, dose may be increased in increments of 2.5 to 10 mg daily every four to seven days; maximum, 20 mg daily Exogenous obesity: Tablet: usual dosage is up to 30 mg daily, taken in divided doses of 5 to 10 mg, 30 to 60 minutes before meals Narcolepsy: Tablet: 5 to 60 mg/day in divided doses	ADHD in children three to five years of age: Tablet: initial, 2.5 mg once daily, daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response ADHD in children six years of age or older: ODT: initial, 6.3 mg once daily in the morning, daily dosage may be raised in increments of 3.1 or 6.3 mg at weekly intervals; maximum, 18.8 mg daily for patients six to 12 years, and 12.5 mg daily for patients 13 to 17 years Suspension (Adzenys ER®): initial, 6.3 mg (5 mL) once daily in the morning, increase in increments of 3.1 mg (2.5 mL) or 6.3 mg (5 mL) at weekly intervals; maximum, 18.8 mg (15 mL) daily for patients 6 to 12 years, and 12.5 mg (10 mL) daily for patients 13 to 17 years Suspension (Dyanavel XR®): Initial, 2.5 mg or 5 mg once daily in the morning, dose may be increased in increments of 2.5 to 10 mg daily every four to seven days; maximum, 20 mg daily Tablet: initial, 5 mg once or twice daily, daily dosage may	ODT (ER): 3.1 mg 6.3 mg 9.4 mg 12.5 mg 15.7 mg 18.8 mg ODT (IR): 5 mg 10 mg 15 mg 20 mg Suspension (ER): 1.25 mg/mL (Adzenys ER®) 2.5 mg/mL (Dyanavel XR®) Tablet: 5 mg 10 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
		be raised in increments of 5 mg at weekly intervals until optimal response Exogenous obesity in children ≥12 years of age: Tablet: usual dosage is up to 30 mg daily, taken in divided doses of 5 to 10 mg, 30 to 60 minutes before meals Narcolepsy in children six to 12 years of age: Tablet: initial, 5 mg daily, daily dose may be raised in increments of 5 mg at weekly intervals until optimal response Narcolepsy in children 12 years of age and older: Tablet: initial, 10 mg once daily, daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response	
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	ADHD: Capsule (ER): 20 mg once daily in the morning Capsule (Mydayis ER®): initial, 12.5 mg daily in the morning, adjust in increments of 12.5 mg no sooner than weekly; maximum, 50 mg daily Tablet: 2.5 to 5 mg once or twice daily; maintenance, up to 40 mg/day Narcolepsy: Tablet: 5 to 60 mg daily in divided doses	ADHD: Capsule (ER), ≥six years of age: 10 mg once daily in the morning; maximum, 30 mg/day Capsule (Mydayis ER®), ≥13 years of age: initial, 12.5 mg daily in the morning, adjust in increments of 12.5 mg no sooner than weekly; maximum, 25 mg daily Tablet, ≥three years of age: 2.5 to 5 mg once or twice daily; maintenance, up to 40 mg/day Narcolepsy in children six to 12 years of age: Tablet: 5 mg once daily; may increase by 5 mg weekly until optimal response Narcolepsy in children 12 years of age and older: Tablet: 10 mg once daily; may increase by 10 mg weekly until optimal response	Capsule (ER): (Adderall XR®) 5 mg 10 mg 15 mg 20 mg 25 mg 30 mg Capsule (ER): (Mydayis ER®) 12.5 mg 25 mg 37.5 mg 50 mg Tablet: 5 mg 7.5 mg 10 mg 12.5 mg 15 mg 20 mg 30 mg
Dextroamphetamine	ADHD:	ADHD in children six years of	Capsule (SR):

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Solution, tablet: initial, 2.5 to 5 mg once or twice daily; maintenance, up to 40 mg/day Capsule (SR): initial, 5 mg once or twice daily; maintenance, up to 40 mg/day Narcolepsy: Capsule (SR), solution, tablet: 5 to 60 mg/day administered in divided doses	age and older: Solution, tablet: initial, 2.5 to 5 mg once or twice daily; maintenance, up to 40 mg/day Capsule (SR): initial, 5 mg once or twice daily; maintenance, up to 40 mg/day ADHD in children three to five years of age: Solution, tablet: initial, 2.5 mg once daily; maintenance, up to 40 mg daily Narcolepsy in adolescents 12 years of age and older: Capsule (SR), solution, tablet: initial, 10 mg once daily; maintenance, 5 to 60 mg/day administered in divided doses Narcolepsy in children six to 12 years of age: Capsule (SR), solution, tablet: initial, 5 mg once daily; maintenance, 5 to 60 mg/day administered in divided doses	(Dexedrine® Spansule) 5 mg 10 mg 15 mg Solution: (Procentra®) 5 mg/5 mL Tablet: (Dexedrine®, Zenzedi®) 2.5 mg 5 mg 7.5 mg 10 mg 15 mg 20 mg 30 mg
Lisdexamfetamine	ADHD: Capsule: initial, 30 mg once daily in the morning; maximum, 70 mg/day Chewable tablet: initial, 30 mg daily in the morning, adjust dose in increments of 10 or 20 mg at weekly intervals; maximum, 70 mg daily Binge eating disorder: Capsule: initial, 30 mg once daily in the morning; maximum, 70 mg/day	ADHD in children six years of age and older: Capsule: initial, 30 mg once daily in the morning; maximum, 70 mg/day Chewable tablet: initial, 30 mg daily in the morning, adjust dose in increments of 10 or 20 mg at weekly intervals; maximum, 70 mg daily	Capsule: 10 mg 20 mg 30 mg 40 mg 50 mg 60 mg 70 mg Chewable tablet: 10 mg 20 mg 30 mg 40 mg 50 mg 60 mg
Methamphetamine	Exogenous obesity: Tablet: 5 mg taken 30 minutes before each meal ADHD: Tablet: initial, 5 mg once or twice daily; maintenance, 20 to 25 mg/day	Exogenous obesity in children 12 years of age and older: Tablet: 5 mg taken 30 minutes before each meal ADHD in children six years of age and older: Tablet: initial, 5 mg once or twice daily; maintenance, 20 to 25 mg/day	Tablet: 5 mg
Respiratory and CNS Stimulants			
Dexmethylphenidate	ADHD:	ADHD in children six years of	Capsule (ER):

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Capsule (ER) (new starts): initial, 5 to 10 mg once daily in the morning; maximum, 40 mg/day Capsule (ER) (patients currently receiving methylphenidate): initial, half the dose of racemic methylphenidate Tablet (new starts): initial, 2.5 mg twice daily; maximum, 10 mg twice daily Tablet (patients currently receiving methylphenidate): initial, half the dose of racemic methylphenidate; maximum, 10 mg twice daily	age and older: Capsule (ER) (new starts): initial, 5 to 10 mg once daily in the morning; maximum, 30 mg/day Capsule (ER) (patients currently receiving methylphenidate): initial, half the dose of racemic methylphenidate Tablet (new starts): initial, 2.5 mg twice daily; maximum, 10 mg twice daily Tablet (patients currently receiving methylphenidate): initial, half the dose of racemic methylphenidate; maximum, 10 mg twice daily	5 mg 10 mg 15 mg 20 mg 25 mg 30 mg 35 mg 40 mg Tablet: 2.5 mg 5 mg 10 mg
Methylphenidate	Treatment of ADHD: Chewable tablet (Methylin®), solution, tablet: 20 to 30 mg/day administered in two or three divided doses Chewable tablet (Quillichew ER®): initial, 20 mg daily in the morning, adjust in increments of 10, 15, or 20 mg; maximum, 60 mg daily Capsule (ER) (new starts): initial, 10 or 20 mg once daily in the morning; maximum, 60 mg/day Capsule (ER) (patients currently receiving methylphenidate): administer equivalent total daily doses Suspension (ER): initial, 20 mg once daily in the morning; maximum, 60 mg/day Tablet (ER) (new starts): initial, 18 to 36 mg/day; maximum, 72 mg/day Tablet (ER) (patients currently receiving methylphenidate): dosing is based on current dose regimen and clinical judgment	ADHD in children six years of age and older: Capsule (ER): initial, 10 mg once daily in the morning; dosage may be increased weekly in increments of 10 mg; maximum, 60 mg daily Chewable tablet (Methylin®), solution, tablet: initial, 5 mg twice daily; maintenance, increase dose gradually Chewable tablet (Quillichew ER®): initial, 20 mg daily in the morning, adjust in increments of 10, 15, or 20 mg; maximum, 60 mg daily ODT: initial, 17.3 mg daily in the morning, may titrate weekly in increments of 8.6 to 17.3 mg; maximum, 51.8 mg Tablet (ER) (new starts): initial, 18 mg once daily in the morning; maximum, 54 (children) and 72 mg/day (adolescents) Tablet (ER) (patients currently receiving methylphenidate): dosing is based on current dose regimen and clinical judgment	Capsule (ER): (Adhansia XR®, Aptensio XR®, Jornay PM®, Ritalin LA®) 10 mg 15 mg 20 mg 25 mg 30 mg 35 mg 40 mg 45 mg 50 mg 55 mg 60 mg 70 mg 80 mg 85 mg 100 mg Suspension (ER): (Quillivant XR®) 25 mg/5 mL Chewable tablet: (Methylin®) 2.5 mg 5 mg 10 mg Chewable tablet (ER): (Quillichew ER ®) 20 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Tablet (ER): may be used in place of tablets when the eight hour dosage of the tablet (ER) corresponds to the titrated eight hour dosage with the tablets Tablet (SR): may be used in place of tablets when the eight hour dosage of the tablet (SR) corresponds to the titrated eight hour dosage with the tablets Transdermal patch: initial, 10 mg; maintenance, titrate to effect <u>Narcolepsy:</u> Chewable tablet (Methylin®), solution, tablet (adults): 20 to 30 mg/day administered in two or three divided doses Tablet (ER): may be used in place of tablets when the eight hour dosage of the tablet (ER) corresponds to the titrated eight hour dosage with the tablets Tablet (SR): may be used in place of tablets when the eight hour dosage of the tablet (SR) corresponds to the titrated eight hour dosage with the tablets	Tablet (ER): may be used in place of tablets when the eight hour dosage of the tablet (ER) corresponds to the titrated eight hour dosage with the tablets Tablet (SR): may be used in place of tablets when the eight hour dosage of the tablet (SR) corresponds to the titrated eight hour dosage with the tablets Transdermal patch: initial, 10 mg; maintenance, titrate to effect <u>Narcolepsy in children six years of age and older:</u> Chewable tablet (Methylin®), solution, tablet: initial, 5 mg twice daily; maintenance, increase dose gradually Tablet (ER): may be used in place of tablets when the eight hour dosage of the tablet (ER) corresponds to the titrated eight hour dosage with the tablets Tablet (SR): may be used in place of tablets when the eight hour dosage of the tablet (SR) corresponds to the titrated eight hour dosage with the tablets	30 mg 40 mg ODT (ER): (Cotempla XR-ODT®) 8.6 mg 17.3 mg 25.9 mg Solution: (Methylin®) 5 mg/5 mL 10 mg/5 mL Tablet (ER): (Concerta®, Relexxii ER®) 10 mg 18 mg 20 mg 27 mg 36 mg 54 mg 72 mg Tablet: (Methylin®, Ritalin®) 5 mg 10 mg 20 mg Tablet (SR): 20 mg Transdermal patch: 10 mg/9 hours 15 mg/9 hours 20 mg/9 hours 30 mg/9 hours
Central Nervous System Agents, Miscellaneous			
Atomoxetine	<u>ADHD:</u> Capsule (>70 kg and adults): initial, 40 mg/day; maintenance, 80 mg/day; maximum, 100 mg/day	<u>ADHD in children six years of age and older:</u> Capsule (≤70 kg): initial, 0.5 mg/kg/day; maintenance, 1.2 mg/kg/day; maximum, 1.4 mg/kg/day Capsule (>70 kg and adults): initial, 40 mg/day; maintenance, 80 mg/day; maximum, 100 mg/day.	Capsule: 10 mg 18 mg 25 mg 40 mg 60 mg 80 mg 100 mg
Guanfacine	<u>ADHD as monotherapy and as adjunctive therapy to stimulant medications:</u>	<u>ADHD as monotherapy and as adjunctive therapy to stimulant medications in children six</u>	Tablet (ER): 1 mg 2 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Tablet (ER): initial, 1 mg once daily; maintenance, 1 to 4 mg/day	years of age and older: Tablet (ER): initial, 1 mg once daily; maintenance, 1 to 4 mg/day	3 mg 4 mg

ADHD=attention deficit hyperactivity disorder, ER=extended-release, ODT=orally disintegrating tablet, SR=sustained-release

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the cerebral stimulants/agents used for attention deficit hyperactivity disorder (ADHD) are summarized in Table 18.

Table 18. Comparative Clinical Trials with the Cerebral Stimulants/Agents Used for ADHD

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Attention Deficit Hyperactivity Disorder				
McCracken et al.[40] (2003) AMP-IR (Adderall®) 10 mg daily vs AMP-XR (Adderall XR®) 10 to 30 mg daily vs placebo	DB, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD (combined or hyperactive-impulsive subtype)	N=51 5 weeks	Primary: SKAMP scales Secondary: Examination of the time course of AMP-XR	Primary: AMP-IR and AMP-XR were judged to have similar efficacy, and both exceeded placebo on attention and deportment SKAMP scales (P<0.0001). Secondary: The AMP-XR group displayed continued efficacy (in SKAMP score improvements) at time points beyond that of the AMP-IR group (i.e., 12 hours post dose).
Pliszka et al.[41] (2000) AMP-IR (Adderall®) 12.5 mg daily vs MPH-IR 25 mg daily vs	DB, PC, PG, RCT Children in grades one through five diagnosed with ADHD	N=58 3 weeks	Primary: CGI-S (parent and teacher) Secondary: Not reported	Primary: More responders were reported with AMP-IR than MPH-IR or placebo on both CGI-S scores (P<0.05). Behavioral effects of AMP-IR appeared to persist longer than with MPH-IR. Fourteen (70%) patients in the AMP-IR group required only a single morning dose, and 17 (85%) patients in the MPH-IR group received two or more doses per day (P=0.003). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				
Pelham et al.[42] (1999) AMP-IR (Adderall®) 7.5 or 12.5 mg twice daily vs MPH-IR (Ritalin®) 10 or 17.5 mg twice daily vs placebo	DB, PC, RCT, XO Children five to 12 years of age diagnosed with ADHD	N=25 6 weeks	Primary: Time course and dose-dependent response information Secondary: Not reported	Primary: Both doses of AMP-IR were generally more efficacious in reducing negative behaviors and improving academic productivity than low-dose MPH-IR (10 mg BID) throughout the course of the entire day. The differences were more pronounced when the effects of MPH-IR were wearing off at midday and late afternoon/early evening (P<0.025). Conversely, AMP-IR 7.5 mg BID and MPH-IR 17.5 mg BID produced equivalent behavioral changes throughout the entire day. The doses of AMP-IR that were assessed produced greater improvement than did the assessed doses of MPH-IR, particularly the lower dose of MPH-IR (P<0.01). Both drugs produced low and comparable levels of clinically significant side effects. Secondary: Not reported
Faraone et al.[43] (2002) AMP-IR (Adderall®) vs MPH-IR	MA (4 trials) Patients diagnosed with ADHD	N=216 3 to 8 weeks	Primary: CGI-S (parent, teacher and investigator) Secondary: Not reported	Primary: Combined results showed slightly greater efficacy with AMP-IR vs MPH-IR in clinician and parent ratings (P<0.05). No statistically significant difference was found in CGI-S scores with teacher ratings (P≥0.26). Secondary: Not reported
Biederman et al.[44] (2002) AMP-XR (Adderall XR®) 10 to 30 mg daily vs	DB, MC, PC, RCT Children six to 12 years of age diagnosed with ADHD (hyperactive-impulsive or	N=584 3 weeks	Primary: CGI-S (teachers and parents) Secondary: Variation in responses based on morning and	Primary: Each AMP-XR treatment group had a statistically significant improvement in both CGI-S teacher and parent scales (P<0.001). Secondary: The CGI-S teacher scores calculated for the morning and afternoon assessments showed all doses of AMP-XR to be more effective than placebo (P<0.001) at each assessment.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	combined subtypes)		afternoon assessments	The CGI-S teacher scores in the AMP-XR group were statistically significantly improved at all time points compared to those in the placebo group (P<0.001).
Goodman et al.[45] (2005) AMP-XR (Adderall XR®) 10 to 60 mg daily	MC, OL, PRO Adults ≥18 years of age diagnosed with ADHD (any subtype)	N=725 10 weeks	Primary: ADHD-RS, CGI-I Secondary: SF-36	Primary: At the end of the study, the mean ADHD-RS scores significantly decreased in the AMP-XR group regardless of dose compared to baseline (P<0.0001). Statistical analysis comparing the individual AMP-XR doses was not performed. At the end of the study, most patients obtained CGI-I ratings of much/very much improved (522/702; 74.4%). Secondary: At the end of the study, the AMP-XR groups reported significant improvements in all quality of life measurements (P<0.0001 for all) measured by the SF-36, including physical functioning and mental health parameters.
Childress et al.[46] (2018) AMP-ER oral suspension 10 to 20 mg/day vs placebo	DB, MC, PC, PG, RCT Children six to 12 years of age diagnosed with ADHD	N=99 6 weeks (5 week, open-label, dose-optimization phase and 1 week randomized, placebo controlled phase)	Primary: Change from pre-dose in the model-adjusted average of SKAMP-combined score at four hours post-dose Secondary: Onset and duration of efficacy	Primary: The change from pre-dose in the model-adjusted average of SKAMP-combined score observed at four hours post-dose was met, with the LS mean treatment difference between AMP-ER oral suspension compared to placebo being -14.8 (95% CI, -17.9 to -11.6; P<0.0001). Secondary: The onset of treatment effect occurred at the earliest time point assessed, one hour post-dose (treatment difference LS mean [SE], -10.2 [1.61], P<0.0001). The duration of efficacy persisted until the final time point at 13 hours post-dose (treatment difference LS mean [SE], -9.2 [1.61], P<0.0001). At each post-dose time point measured throughout the laboratory classroom day, the change from pre-dose SKAMP-combined score was statistically significantly improved following treatment with AMP-ER oral suspension versus placebo.
Biederman et al.[47] (2002) Atomoxetine	2 DB, MC, PC, RCT Females seven to 13	N=51 9 weeks	Primary: ADHD-RS Secondary:	Primary: Atomoxetine significantly decreased ADHD-RS scores compared to placebo (P<0.05) for the entire duration of the study.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
1.2 to 1.8 mg/kg/day vs placebo	years of age diagnosed with ADHD		CPRS-R, CGI-S (parents)	Secondary: Atomoxetine statistically significantly decreased the parent-rated CPRS-R index scores compared to placebo (10.3 vs 1.0; P<0.001). Atomoxetine also statistically significantly decreased the parent-rated CGI-S scores compared to placebo (1.5 vs 0.6; P<0.001).
Durell et al.[48] (2013) Atomoxetine vs placebo	DB, PC, RCT Young adults 18 to 30 years of age with ADHD	N=445 12 weeks	Primary: CAARS-Inv: SV total ADHD symptoms score with adult prompts Secondary: AAQoL-29, CGI-S, Patient Global Impression-Improvement, CAARS self-report, BRIEF-Adult Version Self Report and assessments of depression, anxiety, sleepiness, driving behaviors, social adaptation and substance abuse	Primary: Compared to placebo, treatment with atomoxetine resulted in a greater improvement in CAARS: Inv: SV (-13.6±0.8 vs -9.3±0.8; 95% CI, -6.35 to -2.37; P<0.001). Secondary: Compared to placebo, treatment with atomoxetine resulted in a greater improvement in CGI-S (-1.1±0.1 vs -0.7±0.1; 95% CI, -0.63 to -0.24; P<0.001) and CAARS Self-Report (-11.9±0.8 vs -7.8±0.7; 95% CI, -5.94 to -2.15; P<0.001) but not on the Patient Global Impression-Improvement score. Treatment with atomoxetine was superior to placebo on the AAQoL-29 and BRIEF-Adult Version Self-Report.
Michelson et al.[49] (2001) Atomoxetine 1.2 to 1.8 mg/kg/day vs	MC, OL, PC, RCT Children eight to 18 years of age diagnosed with ADHD	N=297 8 weeks	Primary: ADHD-RS Secondary: CPRS-R, CHQ	Primary: Significant reduction in ADHD-RS was seen in both active groups (P<0.001). No difference was seen between the 1.2 and the 1.8 mg/kg/day treatment arms. Secondary: Atomoxetine 1.2 mg/kg showed significant decreases in all scales of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				CPRS-R (P<0.05). Atomoxetine 1.8 mg/kg showed significant increase in all scales of CHQ (P<0.05).
Kratochvil et al.[50] (2011) Atomoxetine 0.5 to 1.8 mg/kg/day vs placebo	DB, MC, PC, RCT Children five to six years of age diagnosed with ADHD	N=101 8 weeks	Primary: ADHD-RS Secondary: CGI-S, CGI-I	Primary: Atomoxetine significantly reduced mean parent (P<0.009) and teacher (P=0.02) ADHD-RS total score compared to placebo. Secondary: A total of 40% of children treated with atomoxetine and 22% of children who received placebo had CGI-I scores much too very much improved (P=0.1) with no significant differences between groups. A total of 62% of children treated with atomoxetine had CGI-S scores of moderately or severely ill at the end of the study compared to 77% of children who received placebo. Common adverse events included decreased appetite, gastrointestinal upset, and sedation. Most adverse events were considered mild or moderate by the study investigator.
Spencer et al.[51] (2002) Atomoxetine up to 90 mg daily vs placebo	DB, MC, PC, RCT (pooled data) Children seven to 13 years of age diagnosed with ADHD	N=291 9 weeks	Primary: ADHD-RS Secondary: CPRS-R:S, CGI-S	Primary: Significant mean reductions in both active groups in all scales were reported (both studies) for ADHD-RS (P<0.001) and CPRS-R:S (P=0.023 for study one and P<0.001 for study two). Secondary: Atomoxetine displayed a significant mean reduction in CPRS-R:S index over placebo in both studies (study 1: -5.7 vs -2.6; P=0.023 and study 2: -8.8 vs -2.1; P<0.001). Atomoxetine displayed a statistically significant mean change in CGI-S scores over placebo in both studies (study 1: -1.2 vs -0.5; P=0.023 and study 2: -1.5 vs -0.7; P=0.001).
Adler et al.[52] (2014) Atomoxetine 20 to	DB, MC, PC, RCT Patients 18 to 30 years of age with	N=445 12 weeks	Primary: BRIEF-A Secondary:	Primary: Significantly greater mean reductions were seen in the atomoxetine vs placebo group for the BRIEF-A GEC, Behavioral Regulation Index, and Metacognitive Index scores, as well as the Inhibit, Self-Monitor, Working

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
50 mg twice daily vs placebo	ADHD		Not reported	Memory, Plan/Organize and Task Monitor subscale scores (P<0.05), with decreases in scores signifying improvements in executive functioning. Changes in the BRIEF-A Initiate (P=0.051), Organization of Materials (P=0.051), Shift (P=0.090), and Emotional Control (P=0.219) subscale scores were not statistically significant. The validity scales: Inconsistency (P=0.644), Infrequency (P=0.097), and Negativity (P=0.456) were not statistically significant, showing scale validity. Secondary: Not reported
Dittmann et al.[53] (2011) Atomoxetine 0.5 mg/kg/day for seven days, then 1.2 mg/kg/day (fast titration) vs atomoxetine 0.5 mg/kg/day for seven days, then 0.8 mg/kg/day for seven days, then 1.2 mg/kg/day (slow titration) vs placebo	DB, PC, RCT Patients six to 17 years of age ADHD with comorbid ODD or conduct disorder	N=181 9 week	Primary: SNAP-ODD, SNAP-ADHD Secondary: CGI-S	Primary: Treatment with atomoxetine once daily at week nine, using either fast or slow titration to a target dose of 1.2 mg/kg/day, was significantly better compared to placebo in reducing ODD symptoms measured by SNAP-ODD scores (P<0.001). Comparing fast and slow titration separately, the decrease in ODD symptoms severity was significant for both individual titration groups (atomoxetine-fast: 8.6; 95% CI, 7.2 to 9.9; atomoxetine-slow: 9.0; 95% CI, 7.7 to 10.3; and placebo: 12.0; 95% CI, 10.6 to 13.5). Atomoxetine was significantly more effective than placebo in reducing the severity of ADHD symptoms measured by SNAP-ADHD scores. Scores reflecting severity of conduct disorder symptoms, attention-deficit and disruptive behavior, were significantly reduced after nine weeks of atomoxetine treatment. Secondary: CGI-S and individual treatment behaviors showed were significantly reduced after treatment with atomoxetine. The most common adverse events included fatigue, sleep disorders, nausea, and gastrointestinal complaints and were reported the first three weeks of treatment in 60.0% of atomoxetine-fast, 44.3% of atomoxetine-slow, and 18.6% of placebo group study patients.
Hammerness et	OL, PRO	N=34	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
al.[54] (2009) Atomoxetine 0.5 to 1.4 mg/kg/day	Children six to 17 years of age diagnosed with ADHD who had a prior trial of stimulant treatment	6 weeks	ADHD-RS, CGI Secondary: Not reported	There was a significant reduction in ADHD RS symptoms compared to baseline. There was a significant reduction in ADHD-RS symptoms score from baseline to the second week of atomoxetine treatment. There was a significant reduction in ADHD symptoms of inattention (-8.1; P<0.001) and hyperactivity (-5.7; P<0.001) at the end of atomoxetine treatment. A total of 56% of patients met criteria for the a priori definition of response; much or very much improved on the CGI plus >30% reduction in ADHD-RS symptoms. Commonly reported adverse events (>10%) included gastrointestinal problems, headache and sedation. Secondary: Not reported
Adler et al.[55] (2008) Atomoxetine 60 to 120 mg/day	MC, OL Adults diagnosed with ADHD	N=384 4 years	Primary: CAARS-Inv:SV total ADHD symptom score Secondary: CAARS-Self:SV, CGI-ADHD-S, HAM-D-17, HAMA, WRAADDS, SDS	Primary: The mean CAARS-Inv:SV total ADHD symptom scores decreased 30.2% from baseline to endpoint (-8.8; P<0.001). Secondary: Significant decreases were found on the CAARS-Inv:SV subscales, and the CAARS-Self:SV total and subscales (P<0.001). CGI-ADHD-S and WRAADDS scores improved significantly from baseline (-1.1 and -5.0, respectively; P<0.001 for both). SDS total and subscale scores improved 25.3% (-3.8; P<0.001). A slight increase was noted in HAM-D-17 scores (0.8; P=0.004), but this small change is not likely clinically relevant. There was no significant change in HAMA scores (0.4; P=0.216). HR, DBP, SBP increased. Weight loss over the course of the study was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				statistically significant (-0.94 kg; P<0.001).
Wietecha et al.[56](2012) Atomoxetine 40 mg daily titrated to 100 mg daily after two weeks vs placebo	DB, PC, RCT Adults with ADHD having both a spouse/partner and child	N=502 24 weeks	Primary: CAARS-Inv: SV and CGI-S Secondary: Not reported	Primary: Treatment with atomoxetine resulted in a greater improvement in CAARS-Inv: SV (-16.43 vs -8.65; P<0.001) and CGI-S compared to placebo at week 24 (P<0.001). Secondary: Not reported
Biederman et al.[57] (2006) Atomoxetine 0.5 mg to 1.2 mg/kg daily vs AMP-XR (Adderall XR®) 10 to 30 mg daily	DB, FD, MC, RCT Females six to 12 years of age diagnosed with ADHD	N=57 18 days	Primary: SKAMP-A SKAMP-D Academic testing Secondary: Adverse events	Primary: The AMP-XR group experienced significantly greater mean changes in SKAMP-D scores from baseline compared to the atomoxetine group (-0.48 vs -0.04; P<0.001). The AMP-XR group experienced significantly greater mean changes in SKAMP-A scores from baseline compared to the atomoxetine group (-0.45 vs -0.05; P<0.001). Both AMP-XR and atomoxetine groups experienced a significant increase in the mean number of math problems attempted and answered correctly from baseline (P<0.001), but patients in the AMP-XR group attempted a significantly greater number of math problems than those in the atomoxetine group (P=0.04). Secondary: Both AMP-XR and atomoxetine were well tolerated. The number of adverse events was similar in both groups. Most adverse events reported were of mild or moderate severity.
Kemner et al.[58] (2005) Atomoxetine 0.5 mg/kg once daily	MC, OL, PRO, RCT Children six to 12 years of age diagnosed with	N=1,323 3 weeks	Primary: Investigator-related ADHD-RS and CGI-I, performed at weeks one, two, and three; PSQ	Primary: The ADHD-RS change from baseline measured at each time point showed that both treatments were effective. MPH ER produced significantly greater improvements in ADHD-RS scores at weeks, one, two, and three (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs MPH-ER (Concerta®) 18 mg once daily	ADHD		Secondary: Not reported	At week three, rates of treatment response (i.e., ≥25% reduction in ADHD-RS score) were significantly greater with MPH ER than were seen with atomoxetine (P<0.001). Significantly more children treated with MPH ER than with atomoxetine achieved a CGI-I score ≤2 after week three (P<0.001). Parent-rated PSQ scores revealed statistically significantly greater improvements with MPH ER than with atomoxetine. Secondary: Not reported
Newcorn al.[59] (2008) <u>Acute Comparison Trial</u> Atomoxetine 0.8 mg to 1.8 mg/kg/day administered twice daily vs MPH-ER (Concerta®) 18 mg to 54 mg once daily vs placebo <u>XO Trial</u> Atomoxetine	DB, PC, RCT, XO Children six to 16 years of age diagnosed with ADHD (any subtype)	Acute Comparison Trial: N=516 6 weeks XO Trial: N=178 6 weeks	Primary: ADHD-RS Secondary: CGI-S, CPRS, CHQ, and Daily Parent Ratings of Evening and Morning Behavior-Revised	Acute Comparison Trial Primary: The proportion of patients responding to atomoxetine (45%) was significantly higher than the rate for placebo (24%; P=0.003). MPH-ER (56%) was also more effective than placebo (24%; P≤0.001). MPH-ER was found to be more effective than atomoxetine (P=0.02). Secondary: Atomoxetine and MPH-ER produced greater improvements in CGI-S, CPRS and CHQ compared to placebo. MPH-ER also produced greater improvements compared to atomoxetine on CGI-S, CPRS and CHQ (P=0.004, P=0.003, P=0.02, respectively). XO Trial The responses to the two treatments in these patients were as follows: 34% responded to either atomoxetine or MPH-ER, but not both; 44% responded to both treatments; 22% did not respond to either treatment. Of the 70 patients who did not respond to MPH-ER in the initial trial, 43% subsequently responded to atomoxetine in the XO trial. Of the 69 patients who did not respond to atomoxetine in the second trial, 42% had previously responded to MPH-ER. Of the patients classified as MPH-ER, 36% showed significantly worse response on atomoxetine, 18% showed significantly better response on

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
0.8 mg to 1.8 mg/kg/day administered twice daily Patients on MPH-ER were switched to atomoxetine during the XO trial.				atomoxetine, and 46% showed roughly the same response to treatment with atomoxetine. Of the 70 patients classified as MPH-ER nonresponders, 10% showed significantly worse response, 51% showed significantly better response, and 39% showed roughly the same response to treatment with atomoxetine.
Starr et al.[60] (2005) Atomoxetine 0.5 mg/kg once daily vs MPH-ER (Concerta®) 18 mg once daily	OL, RCT African-American children six to 12 years of age diagnosed with ADHD	N=183 3 weeks	Primary: Investigator-related ADHD-RS and CGI-I, performed at weeks one, two, and three; PSQ Secondary: Not reported	Primary: For the ADHD-RS scores, both treatment groups achieved significant improvements from baseline at all time points (P<0.001). Improvements from baseline, defined as ADHD-RS score reductions of ≥30% or ≥50%, were significantly greater in the MPH ER group starting at week three (P<0.03 for ≥30% reduction, P<0.006 for ≥50% reduction). Significantly more children treated with MPH ER than atomoxetine achieved a CGI-I score ≤2 after week three (P<0.01). Parent-rated PSQ scores revealed statistically significantly greater improvements with MPH ER than with atomoxetine. Secondary: Not reported
Wang et al.[61] (2007) Atomoxetine 0.8 mg to 1.8 mg/kg/day vs MPH-IR 0.2 mg to 0.6 mg/kg/day in	DB, MC, RCT Children six to 16 years of age diagnosed with ADHD	N=330 8 weeks	Primary: ADHD-RS Secondary: CPRS-R:S, CGI-S, treatment-emergent adverse events, weight	Primary: Atomoxetine was not significantly different than MPH in improving ADHD symptoms based on ADHD-RS scores (atomoxetine, 77.4%; MPH, 81.5%; P=0.404). Secondary: Both atomoxetine and MPH-IR treatment groups significantly improved CPRS-R:S and CGI-S scores from baseline (P<0.001 for all), the groups were not statistically significant from each other in both measures (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
two divided doses				Treatment-emergent adverse events that occurred significantly more frequently in the atomoxetine group, compared to the MPH group, included anorexia (37.2 vs 25.3%; P=0.024), nausea (20.1 vs 10.2%; P=0.014), somnolence (26.2 vs 3.6%; P<0.001), dizziness (15.2 vs 7.2%; P=0.024) and vomiting (11.6 vs 3.6%; P=0.007), most of which were of mild or moderate severity. Patients in the atomoxetine group experienced a small but significantly greater mean weight loss at the end of eight weeks compared to those in the MPH group (-1.2 vs -0.4 kg; P<0.001).
Kratochvil et al.[62] (2002) Atomoxetine titrated up to 2 mg/kg/day vs MPH-IR titrated up to 60 mg daily	MC, OL Males seven to 15 years of age and females seven to nine year of age diagnosed with ADHD	N=228 10 weeks	Primary: ADHD-RS Secondary: CPRS-R, CGI-S, safety	Primary: Both atomoxetine and MPH-IR were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters but were not statistically different (P=0.66). Secondary: There were no statistically significant differences between treatment groups on all of the CPRS-R and CGI-S outcome measures (P<0.001). Tolerability was also similar between the two drugs with no statistical differences in discontinuations (P=0.18). Statistically significant increases in pulse and BFI were seen with both atomoxetine and MPH-IR (P<0.05).
Sutherland et al.[63] (2012) Atomoxetine 40 mg to 100 mg/day vs atomoxetine 40 mg to 100 mg/day and buspirone 15 mg to 45 mg/day	DB, MC, PC, RCT Men and women 18 to 60 years of age diagnosed with ADHD	N=241 8 weeks	Primary: AISRS Secondary: Not reported	Primary: There was a significantly greater decrease in the AISRS total score for atomoxetine plus buspirone than placebo at weeks one to seven, with an estimated mean difference of -4.80 (P=0.001). There was a greater decrease in the AISRS total score for atomoxetine plus buspirone than for atomoxetine at weeks one to seven, but only statistically significant at week four (P<0.09). The most commonly reported adverse events from both treatment groups included insomnia, dry mouth, headache, and asthenia. Dizziness was most commonly reported for the atomoxetine plus buspirone treatment group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				Discontinuations due to treatment-related adverse events were 15.5% for atomoxetine plus buspirone, 11.3% for atomoxetine and 14.9% for placebo. Secondary: Not reported.
Ni et al.[64] (2013) Atomoxetine titrated up to 1.2 mg/kg/day vs MPH-IR titrated up to 60 mg/day	OL, RCT Patients 18 to 50 years of age diagnosed with ADHD	N=63 8 to 10 weeks	Primary: ASRS, CGI-ADHD-S, AAQoL, WFIS-S and safety Secondary: Not reported	Primary: At visit one (weeks four and five), both the MPH-IR and atomoxetine treatment groups experienced statistically significant reductions from baseline in ASRS scores for inattention (-5.77 and -8.93, respectively; P<0.001 for both) and hyperactivity-impulsivity (-3.69 and -8.11, respectively; P<0.001). The differences between the treatment groups was significant, favoring treatment with atomoxetine (P<0.05). Significant reductions from baseline in ASRS scores were apparent at visit two (eight to 10 weeks) for both the inattention (-9.25 and -10.20, respectively; P<0.001) and hyperactivity-impulsivity subtypes (-6.21 and -7.80, respectively; P<0.001); however, differences between treatment groups were not statistically significant. Both treatment groups experienced improved CGI-ADHD-S scores at all time points compared to baseline values (P<0.001 for all); however, differences between groups were not statistically significant. The mean AAQoL scores significantly increased from baseline to visit one (weeks four and five) and visit two (weeks eight to 10) for both treatment groups. The effect sizes as assessed by Cohen's d ranged from 0.59 to 1.63 (P<0.01). Both treatment groups experienced significant improvements in the severity of functional impairment (WFIS-S) from baseline to visit one (weeks four to five) or (weeks eight to 10). Cohen's d ranged from 0.49 to 1.70 for the MPH-IR group and 0.42 to 1.11 for the atomoxetine group. Differences between the treatment groups were not statistically significant. Decreased appetite, vomiting and palpitation were frequently reported in both treatment groups. There was no significant difference in the occurrence of adverse events between treatment groups. Moreover, there

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				was no significant change in body weight, BP, or HR during the study period (P>0.05 for all). Secondary: Not reported
Sutherland et al.[65] (2012) Atomoxetine 40 to 100 mg daily vs atomoxetine 40 to 100 mg daily plus buspirone 15 to 45 mg daily vs placebo	DB, MC, PC, RCT Patients 18 to 60 years of age diagnosed with ADHD	N=241 8 weeks	Primary: AISRS Secondary: Not reported	Primary: There was a significantly greater decrease in the AISRS total score for atomoxetine plus buspirone than placebo at weeks one to seven, with an estimated mean difference -4.80 (P=0.001). There was a greater decrease in the AISRS total score for atomoxetine plus buspirone than for atomoxetine at weeks one to seven, but only statistically significant at week four (P<0.09). The most commonly reported adverse events from both treatment groups included insomnia, dry mouth, headache, and asthenia. Dizziness was most commonly reported for the atomoxetine plus buspirone treatment group. Discontinuations due to treatment-related adverse events were 15.5% for atomoxetine plus buspirone, 11.3% for atomoxetine, and 14.9% for placebo. Secondary: Not reported
Prasad et al.[66] (2007) Atomoxetine 0.5 mg to 1.8 mg/kg/day vs standard current therapy	MC, OL, RCT Children seven to 15 years of age diagnosed with ADHD	N=201 10 weeks	Primary: CHIP-CE Secondary: ADHD-RS, CGI-S, CGI-I, HSPP, FBIM	Primary: Quality of life greatly improved over the 10 weeks in the atomoxetine group vs the standard current therapy group as demonstrated by the significant increase in CHIP-CE (P<0.001). Secondary: ADHD-RS, CGI-S, and CGI-I scores were significantly improved in the atomoxetine group over the standard current therapy group (P<0.001 for all). The atomoxetine group was significantly better in improving the HSPP Social Acceptance domain over the standard current therapy group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P=0.03), but the groups were not significantly different in the other five HSPP domains (P>0.05). There was not a statistically significant difference between groups in reduction in FBIM scores (P>0.05).
Cheng et al.[67] (2007) Atomoxetine vs placebo	MA (9 trials) Patients diagnosed with ADHD	N=1,828 Variable duration	Primary: ADHD-RS Secondary: CTRS-RS, CPRS-R:S, CGI-S, CHQ	Primary: Atomoxetine significantly improved ADHD-RS scores compared to placebo (P<0.01 for all). Secondary: Atomoxetine significantly improved CTRS-RS, CPRS-R:S, and CGI-S scores compared to placebo (P<0.01 for all). Atomoxetine significantly improved quality of life as measured by the CHQ compared to placebo (P<0.01).
Hazell et al.[68] (2003) Clonidine 0.1 to 0.2 mg/day vs placebo	PC, RCT, TB Children six to 14 years of age with ADHD and co-morbid ODD or conduct disorder	N=67 6 weeks	Primary: CBC (subscales conduct and hyperactive index) Secondary: Not reported	Primary: Significantly more children treated with clonidine than placebo improved on the CBC-Conduct scale (21 of 37 vs 6 of 29; P<0.01) but not the Hyperactive Index (13 of 37 vs 5 of 29; P=0.16). Compared to placebo, clonidine was associated with a greater reduction in standing SBP measured and with transient sedation and dizziness. Study patients treated with clonidine have a greater reduction in a number of unwanted effects associated with psychostimulant treatment compared to placebo. Secondary: Not reported
Jain et al.[69] (2011) Clonidine XR 0.2 mg/day vs	DB, PC, RCT Patients six to 17 years of age diagnosed with ADHD	N=236 8 weeks	Primary: ADHD-RS (total score) Secondary: ADHD-RS (inattention and hyperactivity),	Primary: Improvement from baseline to week five in ADHD-RS total score was significantly greater in both clonidine ER groups vs placebo (P<0.001). A significant improvement in ADHD-RS total score occurred beginning week one for the clonidine ER 0.2 mg/day group (P=0.02) and week two for the clonidine ER 0.4 mg/day group (P<0.0001) as compared to the placebo group and continued throughout the treatment period.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Clonidine 0.4 mg/day vs placebo			CPRS-R:S, CGI-S, CGI-I, PGA, treatment-emergent adverse events	Secondary: A significant improvement in mean change in ADHD-RS inattention score at week five vs baseline was -7.7 for both clonidine ER groups vs -3.4 for the placebo group (P<0.001 for clonidine ER 0.2 mg/day; P<0.006 for clonidine ER 0.4 mg/day). Improvements from baseline to week five in ADHD-RS hyperactivity score were -4.1 in the placebo group, -7.9 in the clonidine ER 0.2-mg/day group, and -8.8 in the clonidine ER 0.4-mg/day group (P<0.0012). Mean improvement in CPRS-R total score was significantly greater than placebo in both clonidine ER groups (P<0.01) at weeks three and five. Improvement in CGI-S and CGI-I from baseline to week five was significantly greater in both treatment groups vs placebo (P<0.0001 for CGI-S and P<0.003 for CGI-I). Significant improvement in PGA score from baseline in both treatment groups vs placebo was observed at week two (P<0.001) and was maintained through week seven (P<0.02) in the clonidine ER 0.2 mg/day group and through week five in the clonidine ER 0.4 mg/day group (P<0.009). The most common treatment-emergent adverse event was mild-to-moderate somnolence. Changes on ECG were minor and due to the pharmacology of clonidine.
Kollins et al.[70] (2011) Clonidine-XR 0.1 mg to 0.4 mg/day and psychostimulant vs	DB, MC, PC, RCT Children and adolescents diagnosed with hyperactive or combined subtype ADHD who had inadequate response to their	N=198 8 weeks	Primary: ADHD-RS (total score) Secondary: ADHD-RS (hyperactivity and inattention), CPRS, CGI-S, CGI-I, PGA	Primary: At week five, study patients in the clonidine ER plus psychostimulant group experienced a greater improvement in ADHD-RS total score compared to patients in the placebo plus psychostimulant group (P=0.009). Secondary: Scores from baseline ADHD-RS hyperactivity and inattention subscale (P=0.014 and P=0.017, respectively), CPRS (P<0.062), CGI-S (P=0.021), CGI-I (P=0.006), and PGA (P=0.001) were significantly improved in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo and psychostimulant	psychostimulant therapy			clonidine ER plus psychostimulant group compared to the placebo plus psychostimulant group. The most commonly treatment-emergent adverse event reported were mild to moderate in severity and included somnolence, headache, fatigue, upper abdominal pain, and nasal congestion.
Wigal et al.[71] (2004) DXM (Focalin®) 2.5 to 10 mg twice daily vs MPH-IR 5 to 20 mg twice daily vs placebo	DB, MC, PC, RCT Children six to 17 years of age diagnosed with ADHD (any subtype)	N=132 4 weeks	Primary: SNAP-T Secondary: SNAP-P, CGI-I Math test performance (clinic and home)	Primary: Both DXM and MPH-IR significantly improved SNAP-T scores compared to placebo (P=0.004 and P=0.0042, respectively) Secondary: The DXM group decreased SNAP-P scores at both 3 and 6 PM assessments compared to placebo (P<0.0001 and P=0.0003 respectively). The MPH-IR group significantly decreased 3 PM SNAP-P assessments compared to the placebo group (P=0.0073) but did not reach statistical significance at the 6 PM assessment (P=0.064). Both DXM and MPH-IR improved CGI-I scores in significantly more patients than the placebo group (67% [P=0.0010] and 49% [P=0.0130] compared to 22%, respectively). Both DXM and MPH-IR significantly improved clinic-based math test scores compared to placebo (P=0.001 and P=0.0041 respectively). DXM significantly improved home-based math test scores compared to placebo (P=0.0236). MPH-IR did not reach statistical significance compared to placebo.
Greenhill et al.[72] (2006) DXM-XR (Focalin XR®) 5 to 30 mg daily vs placebo	DB, MC, PC, RCT Children six to 17 years of age diagnosed with ADHD (any subtype)	N=97 7 weeks	Primary: CADS-T Secondary: CADS-P, CGI-I, CGI-S, CHQ (physical and psychosocial)	Primary: DXM-XR significantly increased CADS-T scores from baseline compared to placebo (16.3 vs 5.7; P<0.001). Secondary: DXM-XR significantly increased CADS-P scores from baseline compared to placebo (17.6 vs 6.5; P<0.001). DXM-XR improved overall CGI-I scores in a greater percent of patients compared to placebo (67.3 vs 13.3%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				DXM-XR significantly improved CGI-S scores in a greater percent of patients than placebo (64.0 vs 11.9%; P<0.001). There was not a statistical difference between DXM-XR and placebo on the mean change in CHQ physical scores. DXM-XR did significantly improve mean CHQ psychosocial scores compared to placebo (11.9 vs 4.3; P<0.001).
Spencer et al.[73] (2007) DXM-XR (Focalin XR®) 20 to 40 mg daily vs placebo	DB, MC, PC, RCT Adults 18 to 60 years of age diagnosed with ADHD (any subtype), childhood onset of symptoms, and a baseline ADHD-RS score ≥24	N=184 5 weeks	Primary: ADHD-RS Secondary: ADHD-RS, CGI-I, CGI-S, CAARS, Q-LES-Q	Primary: All doses of DXM-XR significantly improved ADHD-RS scores from baseline compared to placebo (P<0.05). Secondary: The 20 and 40 mg doses of DXM-XR achieved improved ADHD-RS scores ≥30% and were significant compared to placebo, the 30 mg group did not reach statistical significance. The percent of patients who achieved ≥30% were as follows: DXM-XR 20 mg, 57.9% (P=0.017); DXM-XR 30 mg, 53.7% (P=0.054); DXM-XR 40 mg, 61.1% (P=0.007); and placebo, 34.0%. All doses DXM-XR significantly improved CGI-I scores over placebo (P<0.05 for all). The 20 and 40 mg doses of DXM-XR improved CGI-S scores in a greater percent of patients compared to placebo, but the 30 mg group did not reach statistical significance. The percents of patients were as follows: 20 mg, 68.4% (P=0.09); 30 mg, 61.1% (P value not significant); 40 mg, 64.8% (P=0.031); and placebo, 41.5%. All doses of DXM-XR significantly improved CAARS scores compared to placebo (P<0.05 for all). None of the groups improved Q-LES-Q scores from baseline nor were there significant differences between groups.
Adler et al.[74] (2009)	DB, MC, RCT Patients 18 to 60	N=103 6 months	Primary: Long-term safety and tolerability	Primary: DXM-XR was well tolerated; the most common adverse events were headache (27.6%), insomnia (20.0%), and decreased appetite (17.6%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
DXM-XR (Focalin XR®) 20 to 40 mg/day vs placebo After completion of DB phase, patients could enter an OL extension phase with flexible dosing 20 to 40 mg/day for six months.	years of age diagnosed with ADHD		Secondary: ADHD-RS, CGI-I	Most adverse events were considered mild or moderate by the study investigator. Secondary: Mean improvements in ADHD-RS scores were -10.2 for study patients switched from placebo to DXM-XR and -8.4 for those maintained on DXM-XR. Improvements in CGI-I scores were reported in 95.1% of study patients switched from placebo to DXM-XR and 95.0% of study patients maintained on DXM-XR.
Brams et al.[75] (2012) DXM-XR 20 mg daily vs DXM-XR 30 mg daily vs placebo	DB, RCT, XO Children 6 to 12 years of age with ADHD previously stabilized on MPH (40 mg to 60 mg/day) or DXM (20 mg to 30 mg/day)	N=165 3 weeks	Primary: Change in average SKAMP-combined score from pre-dose to 10, 11 and 12 hours post-dose Secondary: Not reported	Primary: The mean change from pre-dose in SKAMP-combined score was significantly greater in the DXM-XR 30 mg group compared to the DXM-XR 20 mg group (-4.47 vs -2.02; P=0.002). Significantly greater improvement in ADHD symptoms was observed in the DXM-XR 30 mg group compared to the DXM-XR 20 mg group at hours 10 through 12. Secondary: Not reported
Stein et al.[76] (2011) DXM-XR (Focalin XR®) 10 to 30 mg/day	DB, PC, RCT Patients nine to 17 years of age with ADHD	N=56 8 weeks	Primary: ADHD-RS, CGI-I, CGI-S, WFIS, SSERS Secondary:	Primary: There were significant dose-related decreases in total and hyperactive-impulsive symptom scores (P<0.001 and P<0.001, respectively) that did not differ by type of stimulant. There were significant dose-related decreases for Inattention symptoms

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs AMP-XR (Adderall XR®) 10 to 30 mg/day			Not reported	(P<0.001) that were more modest and did not differ by type of stimulant. There were significant dose-related decreases in CGI-S scores (P<0.001) that did not differ by type of stimulant. There were significant effects of dose on the WFIS total score (P=0.008), on the Family (P=0.010), Learning (P=0.002), Social Activities (P=0.018), and Risk Taking (P=0.050) subscales, but not on the Living Skills or Self-Esteem subscales. The most common adverse events were mild to moderate in severity and included decreased appetite and insomnia. Adverse events were more common at higher dose levels for both stimulants. Secondary: Not reported
Muniz et al.[77] (2008) DXM-XR (Focalin XR®) 20 mg/day vs DXM-XR (Focalin XR®) 30 mg/day vs MPH-ER (Concerta®) 36 mg/day vs	DB, MC, RCT Children six to 12 years of age diagnosed with ADHD and stabilized on MPH ≥2 weeks	N=84 10 weeks	Primary: SKAMP Secondary: Not reported	Primary: Mean change in combined SKAMP score at two hours post-dose was significantly larger for MPH-ER 20 vs 36 mg/day (P<0.001). MPH-ER 20 and 30 mg doses have a more rapid onset and a greater effect in the morning relative to MPH-ER 36 and 54 mg doses while MPH-ER 36 and 54 mg had a greater effect at the end of the 12 hour day. All active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing. Secondary: Not reported

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td>MPH-ER (Concerta®)
54 mg/day

vs

placebo</td><td></td><td></td><td></td><td></td></tr>
<tr><td>McCracken et al.[78] (2016)

DXM-XR 5 to 20 mg/day

vs

guanfacine 1 to 3 mg/day

vs

combination of DXM-XR and guanfacine

vs

placebo</td><td>DB, RCT

Children seven to 14 years of age diagnosed with ADHD</td><td>N=207

8 weeks</td><td>Primary:
ADHD-RS-IV

Secondary:
Safety</td><td>Primary:
<table><tr><th>ADHD-RS Total Score</th><th>Estimated Difference</th><th>P-value</th></tr><tr><td>COMB vs Placebo</td><td>−10.66±1.99</td><td><0.0001</td></tr><tr><td>COMB vs GUAN</td><td>−2.67±1.35</td><td>0.049</td></tr><tr><td>COMB vs DXM-XR</td><td>−2.89±1.56</td><td>0.065</td></tr><tr><td>GUAN vs DXM-XR</td><td>−0.21±1.31</td><td>0.87</td></tr><tr><td>GUAN vs Placebo</td><td>−7.99±1.22</td><td><0.0001</td></tr><tr><td>DXM-XR vs Placebo</td><td>−7.77±1.70</td><td><0.0001</td></tr></table>
Secondary:
Overall rates for any treatment-emergent adverse events (mild, moderate, and severe) were high, but did not differ between groups. No serious adverse events occurred during the trial. Discontinuation at any time due to treatment-emergent adverse events was low and equivalent across groups: 1.5% in guanfacine, 1.5% in DXM-XR, and 2.9% in combination. No serious cardiovascular events occurred. Sedation, somnolence, lethargy, and fatigue were greater in both guanfacine groups.</td></tr>
<tr><td>Scahill et al.[79] (2001)

Guanfacine 0.5 mg at bedtime, day four added 0.5 mg in the morning, day eight added 0.5 mg afternoon dose</td><td>DB, PC, PG, RCT

Children seven to 15 years of age diagnosed with ADHD and tic disorder</td><td>N=34

8 weeks</td><td>Primary:
ADHD-RS, CGI-I, CPRS-R (hyperactivity index), YGTSS, CPT

Secondary:
Not reported</td><td>Primary:
Guanfacine was associated with a mean improvement of 37% in the teacher-rated ADHD-RS total score compared to 8% improvement for placebo (P<0.01).

Nine of 17 patients who received guanfacine were rated on the CGI-I as either much improved or very much improved, compared to 0 of 17 patients who received placebo.

The mean CPRS-R on the parent-rated hyperactivity index improved by</td></tr>
</table>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				27% in the guanfacine group and 21% in the placebo group, not a significant difference. Tic severity decreased by 31% in the guanfacine group, compared to 0% in the placebo group (P=0.05). For CPT, commission errors decreased by 22% and omission errors by 17% in the guanfacine group, compared to increases of 29% in commission errors and of 31% in omission errors in the placebo group. No significant adverse events were observed; one study patient taking guanfacine withdrew with sedation. Guanfacine was associated with an insignificant decrease in BP and pulse. Secondary: Not reported
Kollins et al.[80] (2011) Guanfacine ER 1 to 3 mg once daily vs placebo	DB, MC, PC, RCT Patients six to 17 years of age diagnosed with ADHD	N=182 6 weeks	Primary: CANTAB-CRT Secondary: CANTAB-SWM, DSST, PERMP	Primary: There were no significant differences between guanfacine ER and placebo groups on measures of psychomotor functioning or alertness on the CANTAB-CRT (mean difference, 2.5; P=0.8 for CRT, 2.5; P=0.84 for correct responses, 15.5; P=0.30 for movement time, and -8.2; P=0.72 for total time). Secondary: Guanfacine ER treatment was associated with significant improvement in ADHD symptoms (P=0.001) Most sedative adverse events were mild to moderate and occurred during dose titration, decreased with dose maintenance, and resolved during the study period.
Sallee et al.[81] (2009) Guanfacine ER 1 to 4 mg once daily vs	DB, MC, PC, RCT Patients six to 17 years of age with ADHD and a baseline score of 24 on the ADHD-RS-	N=324 9 weeks	Primary: ADHD-RS-IV total score Secondary: CPRS-R, CGI-I, PGA	Primary: The mean reduction in ADHD-RS-IV total scores from baseline to endpoint across all guanfacine ER dose groups was -19.6 compared to -12.2 for the placebo group. The placebo-adjusted mean endpoint changes from baseline were -6.75 (P=0.0041), -5.41 (P=0.0176), -7.34 (P=0.0016), and -7.88 (P=0.0006) in the guanfacine ER 1, 2, 3, and 4 mg groups, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	IV			Placebo-adjusted mean baseline-to-endpoint changes for symptoms of inattentiveness were: -4.2 (P=0.002), -3.0 P=0.02), -3.5 (P=0.007), and -4.0 (P=0.002) for guanfacine ER 1, 2, 3, and 4 mg, respectively. Placebo-adjusted mean baseline-to-endpoint changes for symptoms of hyperactivity/impulsivity were: -2.7 (P=0.028), -2.5 (P=0.03), -3.9 (P=0.001), and -4.0 (P=0.0008) for guanfacine ER 1, 2, 3, and 4 mg, respectively. Secondary: Using placebo-adjusted LSMD in change from baseline at endpoint in CPRS-R total scores, the 4 mg guanfacine ER dose demonstrated significant efficacy at eight hours (-10.2; P=0.004) and 12 hours (-7.5; P=0.04). The 3 mg guanfacine ER dosage group demonstrated significant improvements in CPRS-R results at eight (-11.8; P=0.002), 12 (-9.6; P=0.01), and 14 hours (-9.8; P=0.0156) postdose. The 2 mg guanfacine ER dosage group demonstrated significant improvements in CPRS-R scores at eight hours (-9.0; P=0.01) postdose. For the 1 mg guanfacine ER dosage group, the placebo-adjusted LSMD in CPRS-R at eight, 12, 14, and 24 hours were -12.8 (P=0.0004), -11.4 (P=0.002), -10.4 (P=0.0077), and -8.9 (P=0.02), respectively. Based on CGI-I scores, the percentages of the patients showing clinical improvement were 30% (placebo), 54% (guanfacine ER 1 mg; P=0.007 vs placebo), 43% (guanfacine ER mg; P=0.1404 vs placebo), 55% (guanfacine ER mg; P=0.006 vs placebo), and 56% (guanfacine ER mg; P=0.004 vs placebo). Improvements in PGA scores were 30% (placebo), 51% (guanfacine ER 1 mg; P=0.030 vs placebo), 36% (guanfacine ER 2 mg; P=0.4982 vs placebo), 62% (guanfacine ER mg; P=0.002 vs placebo), and 57% (guanfacine ER 4 mg; P=0.0063 vs placebo). Mild to moderate treatment-emergent adverse events in patients taking guanfacine ER were somnolence, headache, fatigue, sedation, dizziness, irritability, upper abdominal pain, and nausea. There were no significant differences in sleepiness between the patients taking placebo and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				guanfacine ER. Guanfacine ER was not associated with abnormal changes in height or weight. SBP, DBP, and pulse rate decreased as the guanfacine ER dose increased and then increased during dose maintenance and tapering. The range of mean changes from baseline for seated SBP for the placebo group was -1.30 to -0.48 mm Hg and -7.38 to 0.54 mm Hg for the guanfacine ER randomized dose groups.
Sallee et al.[82] (2009) Guanfacine ER 1 to 4 mg once daily	ES, OL Patients six to 17 years of age with ADHD and a baseline score of 24 on the ADHD-RS-IV	N=257 24 months	Primary: ADHD-RS-IV, CPRS-R, CGI-I, CHQ-PF50, CTRS-R, PGA Secondary: Not reported	Primary: Somnolence (30.5%), headache (24.3%), upper respiratory tract infection (17.8%), nasopharyngitis (14.3%), fatigue (13.9%), upper abdominal pain (12.7%) and sedation (11.2%) were the most frequently reported adverse events. The majority of somnolence, sedation, or fatigue events was moderate or mild in severity and resolved by end of treatment. Hypotension was reported in 5.0% of patients. Decreased DBP was found in 3.5% of patients, decreased BP in 2.7% of patients, and decreased SBP in 2.3% of patients. Decreased appetite (13.2%), irritability (13.2%), and pharyngitis (11.3%) were among the most common treatment-emergent adverse events that differed in the subgroup coadministered psychostimulants relative to monotherapy or the overall safety population. Mean changes in ADHD-RS-IV total score from baseline to end point showed significant improvement: overall, -20.1 (P<0.001), and for all guanfacine ER dose groups, -23.8, -22.5, -20.0, and -18.4 for the 1, 2, 3, and 4 mg dose groups, respectively (P<0.001 for each). CPRS-R mean changes from baseline to end point were statistically significant in the overall treatment group (-18.2; P<0.001). The overall mean change from baseline demonstrated significant improvement in CPRS-R scores at each postdose assessment (P<0.001). Investigator-rated CGI-I scores at end point showed that investigators rated the majority of patients very much improved (29.3%) or much improved (28.8%). For the PGA, 59.7% of patients were rated as very much or much

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				improved at end point. Mean changes in CHQ-PF50 Physical Summary Scores from baseline to end point were not statistically significant. CHQ-PF50 Psychosocial Summary Scores demonstrated significant improvement from baseline to end point for the overall full analysis set (P<0.001). Secondary: Not reported
Sallee et al.[83] (2012) Guanfacine ER 1 to 4 mg daily vs placebo	DB, PC, RCT (Post-hoc analysis) Patients 6 to 17 years of age with ADHD	N=631 Variable duration	Primary: Change in ADHD-RS total scores Secondary: Not reported	Primary: For patients with the predominantly inattentive subtype of ADHD, patients treated with guanfacine ER achieved significantly greater mean reductions from baseline in ADHD-RS total scores compared to placebo (P≤0.020). For patients with combined-type ADHD, patients treated with guanfacine ER achieved significantly greater reductions in ADHD-RS total score from baseline compared to placebo at treatment weeks one through five and at study end (P≤0.011). Secondary: Not reported
Connor et al.[84] (2010) Guanfacine ER 1 to 4 mg once daily vs placebo	DB, MC, PC, RCT Patients six to 12 years of age with a diagnosis of ADHD and the presence of oppositional symptoms	N=217 9 weeks	Primary: Change from baseline to endpoint in the oppositional subscale of the CPRS-R:L Secondary: Change in ADHD-RS-IV total score and safety	Primary: The mean change from baseline in the oppositional subscale of the CPRS-R:L was -10.9 for those receiving guanfacine ER and -6.8 for those receiving placebo (P<0.001). The mean percentage reductions from baseline were 56.3% with guanfacine ER and 33.4% with placebo (P<0.001). Secondary: The mean decrease from baseline to endpoint in ADHD-RS-IV total score was 23.8 points for guanfacine ER compared to 11.5 for placebo (P<0.001). The mean percentage reductions from baseline were 56.7% with guanfacine ER and 26.5% with placebo (P<0.001). Adverse events were reported in 84.6% of those receiving guanfacine ER group and 60.3% of those receiving placebo. Treatment-emergent adverse events occurred more frequently with guanfacine ER than with placebo (83.8 vs 57.7%, respectively). The most common treatment-emergent

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				adverse events in the guanfacine ER group were somnolence (50.7%), headache (22.1%), sedation (13.2%), upper abdominal pain (11.8%) and fatigue (11.0%).
Biederman et al.[85] (2008) Guanfacine ER 2 to 4 mg once daily vs placebo	DB, MC, PC, RCT Patients six to 17 years of age with ADHD combined subtype, predominantly inattentive subtype, or predominantly hyperactive-impulsive subtype	N=345 8 weeks	Primary: ADHD-RS-IV total score observed during the last treatment week of the dosage escalation period (weeks one to five) Secondary: CGI-S, CGI-I, PGA, CPRS-R, and CTRS-R observed during the last treatment week of the dosage escalation period (weeks one to five)	Primary: The mean reduction in ADHD-RS-IV score at end point across all guanfacine ER groups was -16.7 compared to -8.9 for placebo. Placebo-adjusted LS mean end point changes from baseline in the guanfacine ER 2, 3, and 4 mg groups were -7.70 (P=0.0002), -7.95 (P=0.0001), and -10.39 (P<0.0001), respectively. Mean changes from baseline in hyperactivity/impulsivity in the placebo and guanfacine ER 2, 3, and 4 mg groups were -3.51, -7.33 (P=0.0002 vs placebo), -7.32 (P=0.0002 vs placebo), and -9.31, (P<0.0001 vs placebo) respectively. Mean changes from baseline in inattentiveness were -4.92, -8.7 (P=0.0011 vs placebo), -9.11 (P=0.0006 vs placebo), and -9.44 (P=0.0002 vs placebo), respectively. Secondary: Significant improvement in CGI-I scores at end point was shown in 25.64, 55.95, 50.00, and 55.56% of patients in the placebo and guanfacine ER 2, 3, and 4 mg groups, respectively. Improvement in CGI-I scores was significant in the guanfacine ER 2 mg group compared to the placebo group by week two (P=0.0194) and in all guanfacine ER groups by week three continuing through week five (P<0.05). Significant improvement in PGA scores at end point was shown in 23.08, 62.12, 50.82, and 66.10% of patients in the placebo and guanfacine ER 2, 3, and 4 mg groups, respectively. On the CPRS-R, placebo-adjusted LS mean day total end point changes from baseline were -6.55 in the 2 mg group (P=0.0448), -7.36 in the 3 mg group (P=0.0242), and -12.70 in the 4 mg group (P<0.0001). On the CTRS-R, placebo-adjusted LS mean day total end point changes from baseline were -11.57 (P<0.0001), -13.48 (P<0.0001), and -12.53 (P<0.0001), for the 2, 3, and 4 mg doses, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The most commonly reported treatment-emergent adverse events were somnolence, fatigue, upper abdominal pain and sedation. The incidence of somnolence in patients who were receiving guanfacine ER 1, 2, 3, and 4 mg doses was 12.7, 11.4, 20.9, and 17.5%, respectively. SBP, DBP, and pulse rate decreased as guanfacine ER dosages increased, then increased as dosages stabilized and tapered down. The greatest mean changes from baseline in SBP and DBP for patients who were receiving guanfacine ER 2, 3, and 4 mg doses were -7.0 mm Hg (week 3) and -3.8 mm Hg (week 2), -7.0 mm Hg (week 3) and -4.7 mm Hg (weeks three and five), and -10.1 mm Hg (week four) and -7.1 mm Hg (week four), respectively. The greatest mean changes from baseline in pulse rate for patients who were receiving guanfacine ER 2, 3, and 4 mg doses were -5.7 beats per minute (week three), -8.1 beats per minute (week three), and -8.0 beats per minute (week four), respectively. Mean changes in height and weight from baseline to end point were not significant across the treatment groups.
Iwanami et al.[86] (2020) Guanfacine ER 2 mg to 6 mg/day vs placebo	DB, PC RCT Adults ≥18 years of age currently diagnosed with ADHD who had a total score ≥24 on the ADHD-RS-IV and a score ≥4 on the CGI-S	N=201 12 weeks (5 weeks dose-optimization, 5 weeks dose-maintenance and 2 weeks dose taper)	Primary: Change from baseline in total score of the ADHD-RS-IV at week 10 Secondary: ADHD-RS-IV subscales, CGI-I, Patient Global Impression-Improvement and treatment-emergent adverse event	Primary: At week 10, the LS mean ±SE change from baseline in ADHD-RS-IV total score was greater with guanfacine ER (-11.55±1.10) than with placebo (-7.27±1.07) with LS mean difference of-4.28 (95% CI, -6.67 to -1.88; P=0.0005). Secondary: There were greater improvements in guanfacine ER compared to placebo for ADHD-RS-IV inattention (-7.39±0.79 vs -4.89±0.76; P=0.0032) and hyperactivity-impulsivity (-3.84±0.54 vs -2.10±0.52; P=0.0021) subscale scores, CGI-I scores (48.1% vs 22.6%; P=0.0007), and Patient Global Impression-Improvement scores (25.3% vs 11.8%; P=0.0283). More patients in the guanfacine ER versus the placebo group reported treatment-emergent adverse events (81.2% vs 62.0%) and discontinued due to treatment-emergent adverse events (19.8% vs 3.0%). The main treatment-emergent adverse event in the guanfacine ER group were somnolence, thirst, blood pressure decrease, nasopharyngitis, postural dizziness and constipation; most treatment-emergent adverse events were mild to moderate in severity.
Newcorn et al.[87] (2016)	DB, MC, randomized-	N=316	Primary: Percentage of	Primary: A significantly smaller proportion of participants failed treatment with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Guanfacine ER vs placebo Participants who met the response criteria in the OL phase, defined as at ≥30% reduction in ADHD-RS-IV total score and a CGI-S score of 1 or 2 at both Weeks 12 and 13, were entered into the 26-week, randomized-withdrawal phase	withdrawal study Children and adolescents (six to 17 years of age) with ADHD and an ADHD-RS-IV score ≥32 and CGI-S score ≥4	7 weeks: OL dose optimization 6 weeks: OL maintenance phase 26 weeks: DB, randomized-withdrawal phase	treatment failures at the end of the randomized-withdrawal phase, defined as ≥50% increase in ADHD-RS-IV total score and a 2 or more point increase in CGI-S score Secondary: Time to treatment failure	guanfacine ER (49.3%) than with placebo (64.9%; difference −15.6, 95% CI, −26.6 to −4.5; P=0.006). Secondary: The median time to treatment failure was 56.0 days (95% CI, 44.0 to 97.0) for the placebo group. The difference in time to treatment failure between the guanfacine ER and placebo groups was statistically significant (P=0.003). The median time to treatment failure in the guanfacine ER group could not be calculated, as less than half the participants failed treatment.
Hervas et al.[88] (2014) Guanfacine ER vs placebo An atomoxetine arm was included to provide reference data against placebo.	DB, MC, PC, PG, RCT Patients six to 17 years of age with a diagnosis of ADHD of at least moderate severity	N=337 10 to 13 weeks: 4 to 7 weeks of dose optimization, 6 weeks of DB maintenance, 2 week tapering, follow up 1 week after last dose	Primary: ADHD-RS Secondary: CGI-I, WFIS-parent report	Primary: The placebo-adjusted difference in LS mean change from baseline in ADHD-RS total score for guanfacine ER was −8.9 (95% CI, −11.9 to −5.8; P<0.001). Secondary: Compared with placebo, the difference in the percentage of patients showing improvement in CGI-I rating was 23.7 (95% CI, 11.1 to 36.4; P<0.001) for guanfacine ER and 12.1 (−0.9 to 25.1; P=0.024) for atomoxetine. The placebo-adjusted difference in LS mean change from baseline in WFIRS-parent report learning and school domain at study end for guanfacine ER was −0.22 (95% CI, −0.36 to −0.08; P=0.003) and for WFIRS-parent score family domain at study end was −0.21 (95% CI, −0.36 to −0.06; P=0.006). The corresponding values for atomoxetine were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				−0.16 (95% CI, −0.31 to −0.02; P=0.026) and −0.09 (95% CI, −0.24 to −0.06; P=0.242), respectively.
Biederman et al.[89] (2008) Guanfacine ER 2 to 4 mg once daily	ES, OL Patients six to 17 years of age with ADHD combined subtype, predominantly inattentive subtype, or predominantly hyperactive-impulsive subtype	N=240 24 months	Primary: Safety Secondary: ADHD-RS-IV, PGA, CHQ-PF50	Primary: Somnolence (30.4%), headache (26.3%), fatigue (14.2%), and sedation (13.3%) were the most frequently reported adverse events. Changes from baseline to endpoint in SBP, DBP, and pulse rate were -0.8 mm Hg, -0.4 mm Hg, and -1.9 beats per minute, respectively. Mean changes in pulse rate and QRS intervals were generally unchanged across study visits. Hypotension was reported in 2.9% of patients and bradycardia was reported in 2.1% of patients. There were no unexpected changes in mean height or weight. Approximately 7.0% of patients reported weight increase possibly or probably related to study drug. Weight decrease was not reported. Appetite increase was reported by 2.1% of patients, appetite decrease by 3.3% of patients, and anorexia by 0.8% of patients. Secondary: The mean ADHD-RS-IV total score was significantly reduced from baseline to endpoint (-18.1; P<0.001 vs baseline). Mean reductions in ADHD-RS-IV scores were significant for both the inattention (-9.5; P<0.001 vs baseline) and the hyperactivity/impulsivity (-8.5; P<0.001 vs baseline) subscales. For PGA scores, 58.6% of patients were ‘improved’ at endpoint compared to baseline of the preceding study. For the CHQ-PF50, physical summary scores did not change significantly from baseline to endpoint overall or in any dose or age group.
Spencer et al.[90] (2009) Guanfacine ER 1	MC, OL Patients six to 17 years of age with	N=75 9 weeks	Primary: ADHD-RS-IV, CPRS-R, CGI-I, CGI-S, CHQ-	Primary: The most common treatment-related adverse events were fatigue (34.7%), headache (33.3%), upper abdominal pain (32.0%), irritability (32.0%), somnolence (18.7%), and insomnia (16.0%). Most adverse events were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg to 4 mg once daily added to existing stimulant therapy	ADHD (combined, predominantly inattentive, or predominantly hyperactive-impulsive subtype) and who were on a stable regimen of either MPH or AMP ≥1 month with suboptimal control of ADHD symptoms		PF50, and PGA Secondary: Not reported	mild to moderate in severity. The incidences of the treatment-emergent adverse events were comparable between both psychostimulant subgroups except for fatigue (28.6% in the guanfacine ER plus MPH subgroup vs 18.2% in the guanfacine ER plus AMP subgroup) and irritability (14.3% in the guanfacine ER plus MPH subgroup vs 33.3% in the guanfacine ER plus AMP subgroup). Twenty patients have a decrease in BP judged to be of clinical interest. Twelve patients exhibited orthostatic BP decreases. None of the patients with BP decreases reported syncope or lightheadedness. At baseline, the mean PDSS score was 15.0. Decreases were observed at visit six (-4.8) and end point (-3.1). During treatment, there was an increase from screening in the number of patients reporting clinically significant dullness, tiredness, and listlessness on the PSERS. There was a decrease in the number of patients with clinically significant loss of appetite and trouble sleeping. The psychostimulant subgroups were generally comparable. Significant decreases from baseline (psychostimulant only) to end point in ADHD-RS-IV total score were observed overall and in both psychostimulant combination subgroups, indicating improvement in ADHD symptoms (overall, -16.1; guanfacine ER plus MPH group, -17.8; guanfacine ER plus AMP group, -13.8; $P<0.0001$ for all). The mean percentage reduction from baseline to end point in ADHD-RS-IV score overall was 56.0%. Improvement was significant for the mean day CPRS-R total score (-19.8; $P<0.0001$), as well as for all three time points (-23.2 at 12 hours postdose, -18.5 at 14 hours postdose, and -17.8 at 24 hours postdose; $P<0.0001$ for all). The percentage of patients showing improvement at end point on the CGI was 73.0%. On the PGA, 84.1% of patients showed improvement.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				No significant improvement occurred at end point in the CHQ-PF50 physical summary score. Mean improvement for the CHQ-PF50 psychosocial score was 10.2 (*P*<0.0001). Secondary: Not reported
Wilens et al.[91] (2012) Guanfacine ER 1 to 4 mg/day in the morning and placebo at bedtime vs placebo in the morning and guanfacine ER 1 mg to 4 mg/day in the afternoon vs placebo Patients continued stable dose of psychostimulant given in the morning.	DB, MC, PC, RCT Children and adolescents six to 17 years of age diagnosed with ADHD	N=461 9 weeks	Primary: ADHD-RS Secondary: CGI-S, CGI-I	Primary: At the end of the study, guanfacine ER treatment groups showed significantly greater improvement from baseline ADHD-RS total scores compared to placebo plus psychostimulant (guanfacine ER in the morning; P=0.002; guanfacine ER in the evening; P<0.001). Secondary: Significant benefits of guanfacine ER treatment compared to placebo plus psychostimulant were observed on the CGI-S (guanfacine ER in the morning; P=0.013, guanfacine ER in the evening; P<0.001) and CGI-I (guanfacine ER in the morning; P=0.024, guanfacine ER in the evening; P=0.003). At study endpoint, small mean decreases in pulse, SBD, and DBP were observed in guanfacine ER treatment groups compared to placebo plus psychostimulant group. The most common treatment-emergent adverse events were mild to moderate in severity and included headache, somnolence and upper respiratory infections.
Cutler et al.[92] (2014) Guanfacine ER 1 to 4 mg/day in the morning and	Post hoc analysis of Wilens et al, 2012 Children and adolescents six to 17 years of age	N=461 9 weeks	Primary: Response (≥40% or ≥50% reduction in ADHD-RS scores), remission (symptomatic:	Primary: With response defined as ≥40% reduction, 69.8% of participants in the guanfacine ER morning group and 70.3% of participants in the guanfacine ER evening group achieved response, vs 57.9% of placebo participants. The percentage of responders in both guanfacine ER groups was higher (P=0.032 for the morning group; P=0.026 for the evening group)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo at bedtime vs placebo in the morning and guanfacine ER 1 mg to 4 mg/day in the afternoon vs placebo Patients continued stable dose of psychostimulant given in the morning.	diagnosed with ADHD		ADHD-RS score ≤18; syndromal: ADHD-RS score ≤18 and CGI-S score ≤2) Secondary: Not reported	compared with placebo. With response defined as ≥50%, response rates were 63.1% for the guanfacine ER morning group, 64.9% for the guanfacine ER evening group, and 43.4% for placebo (P<0.001 for the morning group; P<0.001 for the evening group compared with placebo). At final on-treatment assessment, more participants receiving morning guanfacine ER (61.1%; P=0.010) and evening guanfacine ER (62.2%; P=0.005) achieved symptomatic remission compared with the placebo group (46.1%). Similarly, more participants receiving guanfacine ER (morning group [40.3%; P=0.053] or evening group [46.6%; P=0.002]) achieved syndromal remission compared with participants receiving placebo (29.6%). Secondary: Not reported
Faraone et al.[93] (2010) Guanfacine ER 1 to 4 mg once daily	MA Patients six to 17 years of age with ADHD (combined subtype, predominantly inattentive subtype, or predominantly hyperactive-impulsive subtype)	N=813 6 to 9 weeks	Primary: Predictors of efficacy and sedation using various models Secondary: Not reported	Primary: Actual Dose Model The presence or absence of ADHD symptoms was influenced by the actual doses of medication received by the participants (P=0.006). In participants with residual ADHD symptoms, greater total ADHD-RS symptom scores were significantly related to shorter treatment duration (P<0.001) and higher baseline total ADHD-RS symptom scores (P<0.001). The only significant influence on the frequency of sedation-related adverse events was treatment duration (P=0.034). mg/kg Dose Model: The presence or absence of ADHD symptoms was significantly influenced by the dose of medication received by the participant as expressed in mg/kg (P=0.001). Treatment duration (P<0.001) and baseline total ADHD-RS symptom scores (P<0.001) were predictors of weekly total ADHD-RS symptom scores.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The only significant influence on the frequency of sedation-related adverse events was treatment duration (P=0.034). Titration Rate Dose Model: The presence or absence of ADHD symptoms was significantly influenced by the titrated dose of medication received by the participant (P=0.005). The number of symptoms was significantly influenced by treatment duration (P<0.001) and baseline total ADHD-RS scores (P<0.001). The only significant influence on the frequency of sedation-related adverse events was treatment duration (P=0.034). Secondary: Not reported
Adler et al.[94] (2013) LDX 30 to 70 mg daily vs placebo	DB, PC, RCT Adults 18 to 55 years of age with a primary diagnosis of ADHD and executive function deficits (assessed by baseline BRIEF-A GEC T-scores ≥65)	N=161 10 weeks	Primary: BRIEF-A scales (GEC, index and clinical subscales) Secondary: Not reported	Primary: At week 10 or early termination, treatment with LDX was associated with significantly greater reductions from baseline in mean BRIEF-A GEC T-scores compared to placebo (P<0.0001) and significantly greater reductions from baseline in mean T-scores for both BRIEF-A index scales (metacognition scale) and all nine clinical subscales (P≤0.0056 for all). At week 10 or early termination, patients treated with LDX had mean T-scores for BRIEF-A indices and clinical subscales that were below levels of clinically significant deficits in executive function. The mean GEC T-scores were 57.2 and 68.3 for the LDX and placebo groups, respectively. Secondary: Not reported
Babcock et al.[95] (2012) LDX 30 to 70 mg daily vs	DB, MC, RCT (Post-hoc analysis) Adults with ADHD who remained symptomatic on AMP therapy prior to enrollment in a	N=36 4 weeks	Primary: Mean change in ADHD-RS score from baseline Secondary: Change in CGI-S, CGI-I	Primary: At study end, the change from baseline in mean ADHD-RS scores for LDX-treated patients was similar in the AMP group and the overall study group. The prior AMP non-responders in the placebo group had a change from baseline in ADHD-RS total score of -13.5. In the overall efficacy population, the placebo group experienced a change from baseline of -7.8. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	four-week trial			Mean CGI scores were similar between the prior AMP subgroup and overall efficacy population in the LDX groups. In addition, the percentage of clinical responders and symptomatic remitters was comparable at all time points assessed in both LDX groups.
Biederman et al.[96] (2007) LDX 30 to 70 mg daily vs placebo	DB, MC, PC, RCT Children six to 12 years of age diagnosed with ADHD and with an ADHD-RS score ≥28	N=209 4 weeks	Primary: ADHD-RS Secondary: CPRS-R, CGI-S, CGI-I	Primary: ADHD-RS scores were significantly greater with each of the three LDX doses compared to placebo (P<0.001). The greatest efficacy was seen in the 70 mg group with a mean ADHD-RS change of -4.91 from baseline between the 30 and 70 mg groups (P<0.05). Secondary: Each LDX group significantly improved CPRS-R scores throughout the day compared to the placebo group (P<0.01 for all). Mean CGI-S scale scores significantly improved from baseline to treatment end point for all LDX groups compared to the placebo group (P<0.001 for all). CGI-I ratings were either "very much improved" or "much improved" in ≥70% of patients in the LDX groups compared to 18% of patients in the placebo group (P<0.001 for all).
Biederman et al.[97] (2007) LDX 30 to 70 mg daily vs placebo (AMP-XR 10 to 30 mg was used as a control arm)	DB, MC, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD	N=52 12 weeks	Primary: SKAMP scale Secondary: PERMP, CGI-I	Primary: SKAMP scores significantly improved in both the LDX and AMP-XR groups compared to the placebo group (P<0.0001 for both). Secondary: PERMP scores for both the LDX and AMP-XR groups significantly decreased compared to the placebo group (P<0.0001 for both). The CGI-I scores significantly improved in the both LDX and AMP-XR groups compared to the placebo group (P<0.0001).
Brams et al.[98] (2012)	DB, RCT Withdrawal study	N=116	Primary: Proportion of	Primary: At study end, 8.9% of patients in the LDX group and 75.0% of patients in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
LDX 30 to 70 mg daily vs placebo	Adults 18 to 55 years of age with baseline ADHD-RS with adult prompt total scores <22 and CGI-S ratings of 1, 2 or 3	6 weeks	patients with symptom relapse (≥50% increase in ADHD-RS score and ≥2 rating-point increase in CGI-S score) Secondary: Not reported	the placebo group experienced symptom relapse (P<0.0001), with most patients showing relapse after one and two weeks of the randomized withdrawal period. Secondary: Not reported
Coghill et al.[99] (2013) LDX 30 to 70 mg daily vs MPH-ER (Concerta®) 18 to 54 mg daily vs placebo	DB, MC, PC, PG, RCT Children and adolescents six to 17 years of age diagnosed with ADHD	N=336 7 weeks	Primary: ADHD-RS Secondary: CGI-I	Primary: The LS mean change from baseline in ADHD-RS total score was significantly greater for patients treated with LDX (-24.3±1.2) and MPH-ER (-18.7±1.1) compared to placebo (-5.7±1.1; P<0.001 for both). The LS mean change from baseline in ADHD-RS total score was significantly greater with LDX or MPH-ER compared to placebo at every time point evaluated (P<0.001 for all visits). Effect sizes based on the difference in LS mean change in ADHD-RS total score from baseline to endpoint were 1.80 and 1.26 for LDX and MPH-ER, respectively. The decreases in both the ADHD-RS hyperactivity/impulsivity and inattention subscale scores from baseline were also significantly greater for patients treated with LDX or MPH-ER compared to placebo. The LS mean change from baseline to endpoint in hyperactivity/impulsivity was significantly greater with LDX compared to placebo (-8.7; 95% CI -10.3 to -7.2; P<0.001) as was the change in inattention score (-9.9; 95% CI, -11.5 to -8.3; P<0.001). The LS mean change from baseline to endpoint significantly favored MPH-ER compared to placebo for hyperactivity/impulsivity (-6.0; 95% CI, -7.5 to -4.5; P<0.001) and inattention (-7.0; 95% CI, -8.6 to -5.4; P<0.001) scores. Secondary: The proportions of patients with a CGI-I rating of 'very much improved' or 'much improved' after seven weeks of treatment were 78 and 61% for patients treated with LDX or MPH-ER, respectively, compared to 14% of patients treated with placebo (P<0.001 for both).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Findling et al.[100] (2011) LDX 30 to 70 mg daily vs placebo	DB, PC, RCT Adolescents 13 to 17 years of age diagnosed with ADHD	N=314 4 weeks	Primary: ADHD-RS Secondary: CGI-I, YQOL-R, treatment-emergent adverse events	Primary: Differences in ADHD-RS total scores favored all LDX doses compared to placebo at all weeks (P<0.0076). Secondary: Patients were rated much or very much improved at the end of the study with all doses of LDX (69.1%) compared to placebo (39.5%; P<0.0001). YQOL-R scores at the end of the study indicated improvement with LDX treatment, but did not result in significant differences compared to placebo. The most common treatment-emergent adverse events for all combined LDX doses included decreased appetite, headache, insomnia, decreased weight, and irritability. The severity of treatment-emergent adverse events was generally mild or moderate Clinically insignificant mean increases in pulse, BP and ECG changes were noted with LDX.
Findling et al.[101] (2008) LDX 30 to 70 mg daily	MC, OL, SA Children six to 12 years of age diagnosed with ADHD	N=274 12 months	Primary: ADHD-RS Secondary: CGI-S	Primary: Mean ADHD-RS total score improved by 27.2 points (P<0.001). Mean ADHD-RS inattentive subscale score improved by 13.4 points (P<0.001). Mean ADHD-RS hyperactivity score improved by 13.8 points (P<0.001). After improvements during the first four weeks, improvements in ADHD-RS scores were maintained throughout eleven months of treatment. Secondary: Improvement in scale scores seen in >80% of study patients at endpoint and >95% of completers at 12 months were rated as improved. Adverse event included insomnia and vomiting and considered mild or moderate by the study investigator. There were no clinical meaningful changes in BP or electrocardiographic parameters.
Jain et al.[102] (2013)	OL, PC, RCT, SA, XO	N=150	Primary: Study 1	Study 1 Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
LDX 20 to 70 mg daily vs placebo	(Post-hoc analysis) Children 6 to 12 years of age with ADHD and baseline ADHD-RS IV total score ≥28 who had received MPH within six months of study enrollment	Variable duration	Change in ADHD-RS total score from baseline Study 2 Mean SKAMP-D subscore over the course of a laboratory school day Secondary: Study 1 CGI-S, EESC, BRIEF-Parent form Study 2 SKAMP-A, PERMP math scores, ADHD-RS and CGI scores	Of patients treated with LDX, the mean change from baseline in ADHD-RS total score was similar for the overall study population and the prior MPH group, with a 64.9% improvement observed in the prior MPH group. Secondary: Of patients treated with LDX, the mean change in BRIEF scores from baseline were similar for the overall study population and the prior MPH group. The mean change in CGI-I scores, EESC total scores and the BRIEF index subscale scores from baseline were similar between the overall study population and the prior MPH group. In addition, the BRIEF index subscale scores were normalized at endpoint. The rates of symptomatic remission were similar between the overall study population and the prior MPH group; however, the prior MPH group had numerically lower remission rates compared to the overall group. A clinical response was achieved in 89.6% and 86.7% of the overall population and the prior MPH group, respectively. Study 2 Primary: Improvements in SKAMP-D subscores were similar for both the overall study population and the prior MPH group. For both groups, SKAMP-D scores were improved at all post-dose time points from 1.5 hours to 13 hours with LDX vs placebo ($P \leq 0.0046$ and $P \leq 0.0284$ for all time points in the overall study population and prior MPH group, respectively). Secondary: Improvements in SKAMP-A scores were similar in the overall study population and prior MPH group from 1.5 hours to 13 hours post-dose with LDX vs placebo ($P<0.0001$ and $P \leq 0.0114$ for all time points in the overall study population and prior MPH group, respectively). The PERMP-A and PERMP-C scores were improved to a similar degree in both the overall study population and the prior MPH group at all post-dose time points from 1.5 to 13.0 hours with LDX vs placebo ($P<0.0001$ for all time points in the overall study population and prior MPH group, respectively, for both PERMP-A and PERMP-C). The change from baseline in mean ADHD-RS total scores for the overall

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				study population and the prior MPH groups were similar when taking LDX and placebo during the XO phase (57.1 and 18.1% for patients who had previously received MPH in the LDX group and the placebo group, respectively). At visit five during the XO period, mean CGI-I scores were 1.7 and 3.5 for patients taking LDX and placebo, respectively, for the overall study population and 1.7 and 3.7, respectively, for the prior MPH group who had received ≥1 mg/kg/day of MPH.
Mattingly et al.[103] (2013) LDX 30 to 70 mg daily vs placebo	Post-hoc analysis of Weisler et al. Adults aged 18 to 55 years of age diagnosed with ADHD who had completed ≥2 weeks of treatment with LDX	N=345 12 months	Primary: ADHD-RS-IV Secondary: Not reported	Primary: Baseline ADHD-RS-IV total scores were lower in the predominantly inattention and hyperactivity/impulsivity symptom cluster subgroups. LDX decreased ADHD-RS-IV total scores in all predominant symptom cluster subgroups. Mean percent reduction from baseline to endpoint was 55.9, 71.0, and 62.6% for the predominantly inattention, hyperactivity/impulsivity, and combined symptom cluster subgroups, respectively, and was 61.1% for the overall population. At trial end, 285/345 patients were classified as clinical responders (ADHD-RS-IV total score decrease of ≥30% from baseline and CGI-I score of one or two). Of the 93 patients with predominantly inattention symptom cluster at baseline, 74 were classified as clinical responders at trial end. All 13 patients who had predominantly hyperactivity/impulsivity symptom cluster at baseline were classified as clinical responders at endpoint. At endpoint, 236 of patients who had combined type ADHD at baseline, 196 were classified as clinical responders. Secondary: Not reported
Weisler et al.[104] (2009) LDX 30 to 70 mg daily	DB, PC, RCT, SA Adults aged 18 to 55 years of age diagnosed with ADHD	N=349 12 months	Primary: ADHD-RS Secondary: CGI-S, CGI-I	Primary: Mean ADHD-RS total scores improved at week one of treatment and sustained throughout the eleven month treatment period (P<0.001). Mean ADHD-RS total scores improved by 24.8 points from baseline to study endpoint (P<0.001). Secondary: All study patients rated as moderately ill with a mean CGI-S of 4.8 with improvement in their mean score of 1.7 at endpoint.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				At weeks one, two, three, and four, the proportion of study patients rated as improved on the CGI-I was 43.9, 68.3, 83.4 and 89.1%, respectively. At month 12, 92.6% were improved on the CGI-I. Common adverse events included upper respiratory tract infection, insomnia, headache, dry mouth, decreased appetite and irritability. Most adverse events were considered mild or moderate by the study investigator. Small but statistically significant increases in pulse and BP noted at treatment endpoint.
Dittmann et al.[105] (2013) LDX 30 to 70 mg/day vs atomoxetine 40 to 100 mg/day (or weight-based dosing if patient <70 kg)	AC, DB, RCT Patients aged six to 17 years of age with an ADHD-RS-IV total score ≥28 and an inadequate response to MPH treatment	N=262 9 weeks	Primary: Days to first clinical response (defined as CGI-I score of 1 or 2) Secondary: Proportion of responders at each study visit and the change from baseline in ADHD-RS-IV and CGI-Severity scores	Primary: The median time to first clinical response was shorter for patients receiving LDX (12.0 days; 95% CI, 8.0 to 16.0) than those receiving atomoxetine (21.0 days; 95% CI, 15.0 to 23.0; P=0.001). Secondary: Significantly greater proportions of patients receiving LDX than of those receiving atomoxetine responded to treatment at each study visit (all P<0.01). By visit nine, 81.7% (95% CI, 75.0 to 88.5) of patients receiving LDX had responded compared with 63.6% (55.4 to 71.8) of those receiving atomoxetine (P=0.001). The proportion of patients with a decrease of at least one category from baseline in CGI-S score was greater in the LDX treatment group than in the atomoxetine treatment group by visit four (LDX, 92.3%; 95% CI, 87.5 to 97.1; atomoxetine, 81.3%; 95% CI, 74.4 to 88.2; P<0.05) and by visit nine (LDX, 92.3%; 95% CI, 87.5 to 97.1; ATX, 79.7%; 95% CI, 72.6 to 86.8; P<0.01). Reductions from baseline in mean ADHD-RS-IV total scores were observed in both treatment groups; by visit nine, the mean ADHD-RS-IV total score was 16.3 in the LDX group and 22.5in the atomoxetine group. Treatment-emergent adverse events were reported by 71.9 and 70.9% of patients receiving LDX and atomoxetine, respectively.
Wigal et al.[106] (2011) MPH-ER (Concerta®)	DB, PC, RCT Children nine to 12 years of age diagnosed with	N=78 5 months	Primary: PERMP, SKAMP, TOVA, Finger Windows forward and backward	Primary: MPH-ER significantly improved performance on the number of problems attempted and number of problems correctly answered on the PERMP compared to placebo (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
18 to 54 mg daily vs placebo	ADHD		subtest Secondary: Not reported	MPH-ER significantly improved performance on inattention, deportment, and total ratings of the SKAMP measure (P<0.001) as compared to placebo. Children taking MPH-ER had statistically significantly better scores than children taking placebo on response time (P<0.000). MPH-ER significantly improved performance on memory as compared to placebo. Most common adverse effects included decreased appetite, upper abdominal pain, headache and irritability. Most adverse events were considered mild or moderate by the study investigator. Secondary: Not reported
Casas et al.[107] (2011) MPH-ER (Concerta®) 54 mg to 72 mg/day vs placebo	DB, MC, PC, RCT Men and women 18 to 65 years of age diagnosed with ADHD	N=279 13 weeks	Primary: CAARS-Inv: SV Secondary: CGI-S, CGI-C, CAARS-Self: SV, SDS, AIMA-A	Primary: Improvements in CAARS-Inv:SV were significantly greater with MPH-ER 72 mg compared to placebo (P=0.0024). There was no significant difference between MPH-ER 54 mg and placebo. Secondary: Mean improvement in CGI-S score was significantly greater with MPH-ER 72 mg than placebo (P<0.001); however, there was no significant difference with MPH-ER 54 mg compared to placebo. Median improvement in CGI-C score was significantly greater with MPH-ER 72 mg (2.0) compared to placebo (3.0; P=0.0018); however, there was no significant difference with MPH-ER 54 mg (2.5) compared to placebo. CAARS-Self:SV scores decreased significantly compared to placebo in both MPH-ER treatment groups (P<0.05). There was no significant change in SDS score from baseline in either treatment group. Significant benefit compared to placebo was observed on several AIM-A

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				subscales, which included performance and daily functioning, communication and relationships, living with ADHD and general well-being. The most common adverse events with MPH-ER were mild to moderate in severity and included headache, decreased appetite, dry mouth and nausea.
Wigal et al.[108] (2017) MPH-ER chewable tablet 20 to 60 mg daily vs placebo	DB, PC, RCT Children six to 12 years of age diagnosed with ADHD	N=90 1 week (after 6-week dose-optimization)	Primary: Average of all the postdose SKAMP-Combined scores assessed during visit nine (the classroom study day) Secondary: Onset and duration of clinical efficacy; safety	Primary: Treatment with MPH-ER chewable tablet was associated with a statistically significant reduction in ADHD symptoms compared with placebo based on the primary efficacy endpoint (12.1 vs 19.1, respectively; P<0.001). Secondary: There were significant differences in SKAMP-Combined scores between MPH-ER and placebo from two hours postdose and continuing through eight hours postdose after adjusting for the prespecified fixed-sequence testing procedure (P<0.001 at two, four, and eight hours postdose). The 10-hour comparison did not reach statistical significance (P=0.133), and all subsequent comparisons in the fixed sequence (12-, 13-, and 0.75-hour time points) were considered nonsignificant. The only treatment-emergent adverse event reported by more than one subject receiving MPH-ER in the double-blind period was upper respiratory tract infection, reported by three (7%) subjects in each treatment group. No severe adverse events or serious adverse events were reported, and no deaths occurred at any time during the study.
Childress et al.[109] (2017) MPH-ER ODT 20 to 60 mg daily vs placebo	DB, MC, PC, RCT Children six to 12 years of age diagnosed with ADHD	N=87 1 weeks (after 5-week dose-optimization and stabilization)	Primary: SKAMP-Combined postdose score averaged across the seven postdose measurements over the classroom day Secondary: Onset and duration	Primary: The postdose SKAMP-Combined scores averaged over the classroom testing day for participants on MPH XR-ODT (LS mean, 14.3; 95% CI, 12.2 to 16.4) were significantly lower (improved) than for participants on placebo (LS mean, 25.3; 95% CI, 23.0 to 27.6; P<0.0001). The LS means difference was −11.0 (95% CI, −13.9 to −8.2). Secondary: The onset and duration of efficacy were assessed by comparing the SKAMP-Combined scores for participants on MPH XR-ODT versus placebo at one, three, five, seven, 10, 12, and 13 hours postdose on the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			of effect; safety	classroom study day. The MPH XR-ODT-treated group demonstrated significantly lower scores than placebo at one hour postdose (LS means difference, −10.7; 95% CI, −13.6 to −7.9; P<0.0001). The difference between the two groups continued to be statistically significant at each assessment through 12 hours postdose (P<0.0001 at three, five, and seven hours; P=0.0024 at 10 hours; and P=0.0262 at 12 hours). The most common (occurred in >5% of the participants) adverse events during the open-label dose optimization/stabilization periods were decreased appetite, upper abdominal pain, headache, insomnia, upper respiratory tract infection, affect lability, irritability, cough, and vomiting. The only adverse event that occurred in >5% of participants during the double-blind period was upper respiratory tract infection.
Goodman et al.[110] (2017) MPH OROS 18 to 72 mg daily vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age with a diagnosis of ADHD and a baseline AISRS score >24	N=357 6 weeks	Primary: Change from baseline to end point (week 6 or study discontinuation) in the investigator-rated AISRS, with remission defined as an AISRS score of <18 Secondary: CGI-S, CGI-I, adverse events	Primary: The mean AISRS score at baseline was 37.8 for the OROS methylphenidate group and 37.0 for the placebo group. At end point, subjects receiving MPH OROS had a greater change from baseline (−17.1) than placebo subjects (−11.7). Treatment difference was larger for the MPH OROS–treated group with a LS mean difference of −5.0 (−16.9 and −12.0, respectively; P<0.001]. Remission (i.e., AISRS score of <18) was attained by a significantly greater percentage of MPH OROS–treated than placebo-treated subjects (45.0 vs 30.8%; P=0.0008). Secondary: In the investigator-rated assessments, OROS methylphenidate–treated subjects exhibited greater illness improvement (CGI-I; P<0.001) and a greater decrease in illness severity (CGI-S; P<0.001) compared to placebo treated-subjects. Any treatment-emergent adverse event occurred in 72.4% of the MPH OROS patients and 49.7% of placebo patients. Severe events were reported in six subjects treated with OROS methylphenidate (3.4%; anxiety, restlessness, tension headache, fatigue, nervousness and feeling jittery, and gastroenteritis) and in three placebo-treated subjects (1.7%; headache and fatigue, insomnia, and increased blood pressure). One placebo-treated subject experienced a serious adverse event of suicidal ideation.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Wigal et al.[111] (2013) MPH-ER suspension (Quillivant XR®) 20 to 60 mg daily vs placebo	DB, MC, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD	N=45 2 weeks	Primary: SKAMP combined score Secondary: Onset of action and duration of clinical effect, subscale scores for SKAMP, PERMP, CGI-S and CGI-I	Primary: Children treated with MPH-ER suspension experienced a statistically significant improvement in SKAMP combined score at four hours post-dose compared to children treated with placebo. The LS mean SKAMP combined score was 7.12 in children receiving MPH-ER suspension compared to 19.58 in children receiving placebo (LS mean difference, -12.46; P<0.0001). Secondary: There were statistically significant improvements from baseline with MPH-ER suspension compared to placebo at each time point tested (45 minutes, two, four, eight, 10 and 12 hours), with the onset of action at 45 minutes post-dose and a duration of effect continuing to be significant compared to placebo at 12 hours post-dose. The results of the remaining secondary endpoints were not presented in this study.
Wigal et al.[112] (2015) MPH-ER (Aptensio XR®) 10, 15, 20, or 40 mg once daily vs placebo	DB, MC, PC, RCT Children and adolescents six to 18 years of age with ADHD	N=221 Four study phases: (1) 4-week screening/ baseline; (2) 1-week, DB treatment; (3) 11-week, OL, dose-optimization period; (4) 30-day follow-up call	Primary: Change from baseline to end of DB treatment in ADHD-RS-IV total score Secondary: Changes in ADHD-RS-IV subscales and CGI-I at the end of the DB treatment phase	Primary: The mean decrease in ADHD-RS-IV total score from baseline was -5.0 in the placebo group and -9.1, -10.2, -12.0, and -12.6 in the MPH-ER 10, 15, 20, and 40 mg groups, respectively. The 20 and 40 mg doses were statistically different (P=0.0145 and P=0.0011, respectively) from placebo. Secondary: Subset analyses that examined the decrease in ADHD-RS-IV total score over the DB period revealed no difference among treatment groups for all sites, all age groups, and all races. Females responded differently than males (P=0.0238); there was a significant difference among treatments for males but not for females, partly because only one-third of subjects were females and partly because some females who received placebo had considerable improvement during the DB phase. CGI-I scores at the end of the DB phase also showed more improvement as the dose of MPH-ER increased. Pairwise difference from placebo was significant for both the 20 mg (P=0.0311) and 40 mg (P=0.0072) doses but not for the 10 mg (P=0.7391) or the 15 mg (P=0.5518) doses.
Matthijssen et al.[113]	DB, MC, PC, randomized	N=94	Primary: ADHD-RS	Primary: The mean ADHD-RS scores at baseline for the continuation and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2019) MPH-ER 36 mg or 54 mg/day (continue same maintenance dose) vs placebo (gradual withdrawal over three weeks, then four weeks of placebo)	discontinuation study Children eight to 18 years of age who had been using MPH as prescribed in clinical practice in any dosage or form for two years or longer	7 weeks	Secondary: CGI-I and CTRS-RS	discontinuation groups, respectively, were 21.4 (SD=9.7) and 19.6 (SD=8.9). After seven weeks, the mean scores were 21.9 (SD=10.8) and 24.7 (SD=11.4), with a significant between-group difference in change over time of -4.6 (95% CI, -8.7 to -0.56) in favor of the group that continued MPH-ER treatment. The ADHD-RS inattention subscale also deteriorated significantly more in the discontinuation placebo group. Secondary: The CGI-I scores indicated worsening in overall functioning in 19 of the 47 patients (40.4%) in the discontinuation placebo group, compared with seven of the 47 patients (15.9%) in the continuation group, with a significant between-group difference (χ^2=6.7, degrees of freedom=1, P=0.01). The analyses for the CTRS-RS showed significant differences with regard to the ADHD index (P<0.001) and the hyperactivity subscale score (P=0.001). The mean change from baseline was significantly larger among patients assigned to the discontinuation group than among those receiving MPH-ER, with medium effect sizes.
Wilens et al.[114] (2004) MPH-ER (Concerta®) 18 to 54 mg daily	MC, OS, PRO Children six to 13 years of age diagnosed with ADHD	N=432 1 year	Primary: HR and BP after one year Secondary: Not reported	Primary: Compared to baseline, MPH-ER was associated with minor clinical, although statistically significant, DBP elevations (1.5 mm Hg; P<0.001), SBP elevations (3.3 mm Hg; P<0.001) and HR (3.9 beats per minute; P<0.0001) at the 12-month end point. Secondary: Not reported
Mattos et al.[115] (2012) MPH-ER (Concerta®) 18 mg to 72 mg/day	MC, OL Men and women 18 to 65 years of age diagnosed with ADHD	N=60 12 weeks	Primary: ASRS, AAQoL, STAI, HAMD, CGI-I Secondary: Not reported	Primary: ADHD symptom severity improved with the ASRS scores (total score, inattention and hyperactivity) significantly reduced from baseline to weeks four, eight, and 12 (P<0.001). AAQoL subscales (P<0.001), as well as AAQoL total score (P<0.001), significantly improved from baseline to week 12. A significant reduction in STAI, CGI-I, and HAMD, scores were observed (P<0.0001). The most common adverse events included appetite changes (25%), dry

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mouth (16.7%), headache (11.7%), irritability (5%) and insomnia (5%). Adverse events were mild to moderate in severity as reported by the study investigators. Secondary: Not reported
Cox et al.[116] (2006) MPH-ER (Concerta®) 36 mg once daily on days one to five, then 72 mg once daily on days 6 to 17 vs AMP-XR (Adderall XR®) 15 mg once daily on days one to five, then 30 mg once daily on days 6 to 17 vs placebo	DB, PC, RCT, XO Adolescents 16 to 19 years of age diagnosed with ADHD and licensed to drive	N=35 21 to 38 days	Primary: IDS, assessed using an Atari Research Driving Simulator on days 10 and 17; subjective ratings of driving performance by participants and investigators Secondary: Not reported	Primary: Overall IDS values were significantly better than with placebo with MPH-ER (P<0.001), but not with AMP-ER (P=0.24). Simulator-rated driving performance as indicated by IDS was also significantly better in the MPH-ER group than in those receiving AMP-ER (P=0.03). MPH-ER was significantly better than placebo in the categories off-road excursions (P=0.02), speeding (P=0.01), SD speed (P=0.02), and time at a stop sign deciding where to turn (P=0.003). AMP-ER was significantly better than placebo in the category of inappropriate braking (P=0.04). Subjective ratings of driving performance by participants and investigators rated MPH-ER as better for driving performance (P=0.008). Secondary: Not reported
Yang et al.[117] (2011) MPH-ER 18 mg to 54 mg/day	RCT, SB Children and adolescents seven to 14 years of age diagnosed with ADHD	N=142 4 to 6 weeks	Primary: RCFT, Digit span, Stroop color word test Secondary: Not reported	Primary: Both MPH-ER and atomoxetine significantly improved visual memory, verbal memory, and word inference time. Visual and verbal memory was not significantly different from the control group at post-treatment assessment (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs atomoxetine 0.5 mg to 1.4 mg/kg/day				Although word interference time was more improved than the control group, there was no statistically significant difference (P>0.05). Secondary: Not reported
Su et al.[118] (2016) MPH OROS 18 to 54 mg daily vs atomoxetine 0.5 mg to 1.4 mg/kg/day	RCT Chinese children and adolescents, six to 16 years of age, diagnosed with ADHD	N=237 4 weeks (maintenance period) 1 year (adherence)	Primary: Investigator-rated ADHD Rating Scale-IV Secondary: CGI-ADHD-S. adherence	Primary: The ADHD-RS-IV total scores were significantly lower at each post-treatment assessment (the ends of the week one, titration period, and maintenance period) compared with pretreatment for both OROS MPH and atomoxetine (P<0.001). The difference between the two medication groups was not significant. Secondary: The CGI-ADHD-S scores were significantly lower at each post-treatment assessment compared with pretreatment for both OROS MPH and atomoxetine (P<0.001). The difference between the two medication groups was not significant. Adherence rates to both medications were low. Subjects were adherent to OROS MPH treatment for a mean of 20.66 weeks, as compared with a mean of 10.92 weeks for atomoxetine during one year (P<0.001). For both medications, adverse effects and lack of efficacy were the primary reasons reported. At one year follow-up, 78.2% of the total patients were not compliant with OROS MPH treatment; in 31.9% and 20.2% of patients this was because of adverse effects and lack of efficacy, respectively. For those assigned to the atomoxetine group, 96.6% of patients were not compliant; in 36.4% and 33.9% of patients this was because of adverse effects and lack of efficacy, respectively.
Wolraich et al.[119] (2001) MPH-ER (Concerta®) 18 to 54 mg daily vs	DB, PC, PG, RCT Children six to 12 years of age diagnosed with ADHD (any subtype)	N=282 28 days	Primary: Iowa Conners I/O and O/D rating scale (parents and teachers) Secondary: SNAP-IV scores (teachers and	Primary: Both MPH-ER and MPH-IR demonstrated a statistically significant improvement in the Iowa Conners I/O and O/D rating scale scores compared to placebo at week one and at the end of the study (P<0.001). There was no significant difference in the mean Iowa Conners scale scores between the MPH-ER and MPH-IR groups at week one (P=0.838) or at the end of the study (P=0.539).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
MPH-IR 5 to 15 mg three times daily vs placebo			parents), CGI-I scores (investigators), global assessment of efficacy (parents and teachers)	Secondary: Teacher and parent SNAP-IV scores were significantly better for patients in the MPH-ER and MPH-IR groups than for those in the placebo group (P<0.001). There was not a significant difference in SNAP-IV scores between the MPH-ER and MPH-IR groups. CGI-I scores significantly improved in the MPH-ER and MPH-IR groups compared to the placebo group (P<0.001). Both the parent and teacher global assessment of efficacy scores were significantly higher with the MPH-ER and MPH-IR groups than the placebo group (P<0.001).
Pelham et al.[120] (2001) MPH-ER (Concerta®) 18 to 54 mg daily vs MPH-IR 5 to 15 mg three times daily vs placebo	DB, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD (any subtype) who were taking MPH prior to study entry	N=68 1 week	Primary: Iowa Conners I/O and O/D rating scales (teacher and parents), SKAMP scale (teacher) Secondary: Not reported	Primary: MPH-ER and MPH-IR were better than placebo in the Iowa Conners I/O and O/D rating scale scores from teachers and parents (P<0.05). MPH-ER scored significantly better than MPH-IR in the parent Iowa Conners I/O rating scales (P<0.05). In the SKAMP scales, MPH-ER and MPH-IR were similar in efficacy, but both were significantly better than placebo. Secondary: Not reported
Gau et al.[121] (2006) MPH-ER (Concerta®) 18 to 36 mg daily	OL, RCT Children six to 15 years of age diagnosed with ADHD (any subtype) who were	N=64 28 days	Primary: CTRS-RS, CPRS-RS, SKAMP-A, SKAMP-D Secondary: SAICA, CGI	Primary: Each of the four groups displayed a significant decrease in all measures of CTRS-RS, CPRS-RS, SKAMP-A, SKAMP-D at each of the follow-up visits (P<0.001 for all) compared to baseline, but there were no significant differences between the groups (P>0.05 for all). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs MPH-IR 5 to 10 mg three times daily	taking MPH (10 to 40 mg/day)			Patients in both the MPH-XR and MPH-IR groups experienced significant improvements from baseline in academic performance and less severe problems at school (P<0.05). Patients in the MPH-XR group also significantly improved from baseline in attitude toward their teachers, school social interaction, and relationships with peers and siblings (P<0.05). The MPH-XR group had a significantly greater number of patients being very much or much improved (84.4%) than the MPH-IR group (56.3%) (P=0.014) based on the CGI score.
Lopez et al.[122] (2003) MPH-ER (Concerta®) 18 to 36 mg daily vs MPH-XR (Ritalin LA®) 20 mg daily vs placebo	DB, PC, RCT Children six to 12 years of age diagnosed with ADHD who were previously stabilize on MPH (equivalent dose of 10 mg BID)	N=36 28 days	Primary: SKAMP scales Secondary: Not reported	Primary: Both MPH-ER and MPH-XR statistically improved SKAMP scale scores compared to placebo (P<0.001). Secondary: Not reported
Swanson et al.[123] (2004) MPH-ER (Concerta®) 18 to 54 mg daily vs MPH-XR	DB, MC, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD (inattentive type, hyperactive-impulsive type, or combined type)	N=184 7 weeks	Primary: SKAMP scales, PERMP Secondary: Not reported	Primary: MPH-ER and MPH-XR demonstrated similar efficacy, and both were better than placebo in SKAMP and PERMP scores (P<0.016). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(Metadate CD®) 20 to 60 mg daily vs placebo	being treated with MPH in doses of 10 to 60 mg/day			
Silva et al.[124] (2005) MPH-ER (Concerta®) 18 mg vs MPH-ER (Concerta®) 36 mg vs MPH ER 20 mg vs MPH ER 40 mg vs placebo All medications were dosed once per study day (six consecutive Saturdays).	MC, RCT, SB, XO Children six to 12 years of age diagnosed with ADHD and stabilized on MPH (20 to 40 mg/day)	N=54 6 weeks	Primary: SKAMP-A rating subscale Secondary: SKAMP-D and SKAMP-C rating subscales and written math tests	Primary: All doses of the study medications significantly improved SKAMP-A scores from baseline at all time points, compared to placebo (P<0.038). ER-MPH 20 and 40 mg showed significantly greater differences from predose on the SKAMP-A than did MPH ER, 36 mg at two hours postdose, and also when scores were integrated over zero to four hours (P=0.022 for the 20 mg dose and P=0.001 for the 40 mg dose), but showed no significant improvement over eight to 12 hours. Secondary: Single morning doses of ER-MPH and MPH ER were effective in improving SKAMP-D scores and academic productivity for the majority of the 12-hour classroom session.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients continued their regular ADHD medications on Sunday through Thursday of the study weeks, with no medications allowed on Friday.				
Jahromi et al.[125] (2009) MPH-IR 0.125 mg/kg/dose twice daily for one week (low dose) vs MPH-IR 0.25 mg/kg/dose twice daily for one week (medium dose) vs MPH-IR 0.50 mg/kg/dose twice daily for one week (high dose) vs placebo for one week	DB, RCT, XO Children five to 13 years of age with PDD and hyperactivity	N=33 4 weeks	Primary: JAMES, Caregiver-Child Interaction measure (competing demands and clean-up task) captured social communication, self-regulation and affective behavior Secondary: Not reported	Primary: Significant positive effect of MPH was seen on social communication (P<0.05); comparing each of the three MPH doses of MPH compared to placebo, the low dose showed significant improvement compared to placebo (P<0.05); no significant differences found between placebo and the medium or high doses. No significant improvement in self-regulation for the competing demands task when comparing best dose MPH to placebo (P=0.09); significant improvement in self-regulation behaviors comparing low dose MPH (P<0.05) and medium dose effect (P<0.01) compared to placebo; no improvement found in high dose MPH over placebo. No significant improvement in self-regulation behaviors for the clean-up task for any of the three dose levels of MPH compared to placebo, or between placebo and the best dose of MPH (P>0.05). Significant improvement in affective behavior for the competing demands task when comparing medium MPH dose (P <0.05) and high MPH dose compared to placebo (P<0.05); no improvement found in best dose of MPH compared to placebo (P=0.09); or low dose (P=0.07). No significant improvement on affective behavior for the clean-up task and any MPH dose (P>0.05). Secondary: Not reported
Spencer et al.[126]	PG, RCT, SB	N=61	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2011) MPH-IR three times daily vs MPH-ER once daily (OROS-MPH)	Patients 19 to 60 years of age diagnosed with ADHD who were on stable therapy with MPH-IR	6 weeks	AISRS Secondary: Not reported	MPH-IR responders randomized to MPH-IR or MPH-ER had no effect on AISRS score at the study endpoint (11.2 vs 10.7; P=0.80). Study patients stabilized on MPH-IR and switched to MPH-ER remained satisfied over 71% of the time. MPH-IR treatment group missed significantly more doses than the MPH-ER treatment group (7.3 vs 3.3; P=0.02). Secondary: Not reported
Efron et al.[127] (1997) MPH-IR 0.3 mg/kg/dose twice daily vs DEX-IR 0.15 mg/kg/dose twice daily Patients received one drug for two weeks then crossed over to the other stimulant for two weeks.	DB, RCT, XO Children five to 15 years of age diagnosed with ADHD	N=125 4 weeks	Primary: SERS Secondary: Not reported	Primary: There was a statistically significant decrease in the mean number of side effects in the MPH-IR group vs the DEX-IR group (8.19 vs 7.19; P=0.03) based on the results of the SERS questionnaire which assess the 17 most common side effects of stimulants including trouble sleeping, decreased appetite and anxiousness. Mean severity of side effects statistically significantly improved in the MPH-IR group compared to the DEX-IR group (3.24 vs 3.73; P<0.01). A majority of parents rated their children as improved compared to their "usual selves" in both of the treatment groups (68.8% in the DEX-IR groups and 72% in the MPH-IR). Secondary: Not reported
Pelham et al.[128] (1990) MPH-IR 10 mg twice daily vs	DB, PC, RCT, XO Males eight to 13 years of age diagnosed with ADHD	N=22 8 weeks	Primary: Evaluated social behavior during activities, classroom performance, and performance on a	Primary: Each of the active treatment groups were more effective than placebo on most measures of social behavior from the medication assessment (P<0.05). DEX-SR and pemoline tended to produce the most consistent effects.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
MPH-SR (Ritalin SR®) 20 mg daily vs DEX-SR (Dexedrine®) 10 mg daily vs pemoline 56.25 mg daily vs placebo			continuous performance task Secondary: Not reported	The continuous performance task results showed that all four medications had an effect within two hours, and the effects lasted for nine hours vs placebo (P<0.025). Secondary: Not reported
Palumbo et al.[129] (2008) MPH-IR 5 mg to 60 mg/day vs clonidine 0.05 mg to 0.6 mg/day vs MPH-IR and clonidine vs	DB, MC, PC, RCT Children seven to 12 years of age diagnosed with ADHD	N=122 16 weeks	Primary: CASQ-T Secondary: CASQ-P, CGAS	Primary: For CASQ-T, clonidine did not improve ADHD symptoms. Study patients treated with MPH showed significant improvement compared to those not treated with MPH. Secondary: Study patients treated with clonidine had greater improvements on the CASQ-P and CGAS, but a higher rate of sedation compared to patients not treated with clonidine.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				
Huss et al.[130] (2014) MPH-LA 40 mg/day vs MPH-LA 60 mg/day vs MPH-LA 80 mg/day vs placebo	DB, MC, PC, RCT Adult patients 18 to 60 years of age with a diagnosis of ADHD	N=725 40 weeks (9 week double-blind dose-confirmation phase; 5 week real-life dose-optimization phase; 6 month double-blind maintenance of effect phase)	Primary: ADHD-RS, SHS, percentage of treatment failures Secondary: CGI-I, CGI-S, CAARS- observer, ASRS	Primary: Improvement from baseline in ADHD-RS (P<0.0001 for all comparisons) and SDS (40 mg, P=0.0003; 60 mg, P=0.0176; 80 mg, P<0.0001) total scores was significantly greater vs placebo for all MPH-LA doses. Treatment failure rate was significantly lower with MPH-LA (21.3%) versus placebo (49.6%) during the six-month maintenance of effect phase. By the end of the nine-week double-blind dose-confirmation phase, improvement from baseline in ADHD-RS total score for all MPH-LA dose levels was significantly greater than placebo (all comparisons: P<0.0001). Similarly, functional improvement, as assessed by change from baseline in the SDS total score, was significantly greater for all MPH-LA dose levels compared to placebo (40 mg, P=0.0003; 60 mg, P=0.0176; 80 mg, P<0.0001). During the six-month double-blind maintenance of effect phase, significantly less patients treated with MPH-LA were required to discontinue the study due to treatment failure (21.3%, n=75) compared to those treated with placebo (49.6%, n=57). Patients treated with placebo had more than three times higher chance of being required to discontinue the study due to treatment failure compared to patients treated with MPH-LA (OR, 0.3; 95% CI, 0.2 to 0.4). Secondary: The percentage of patients with improvement on the CGI-I scale for all three MPH-LA dose levels was significantly higher compared to placebo. Similarly, the percentage of patients with improvement for all three MPH-LA dose levels on CGI-S was significantly higher compared to the placebo group. Consistent results were seen for the observer-rated CAARS and self-rated ASRS: improvement from baseline for all dose levels of MPH-LA was significantly greater than placebo.
Ginsberg et al.[131] (2014) MPH-LA (40 to 80 mg/day)	ES (of Huss et al, 2014), OL Adult patients 18 to 60 years of age with	N=298 1 year (6 month double-blind	Primary: Safety Secondary: Efficacy (ADHD-	Primary: Overall, the incidence of adverse events was comparable between patients receiving placebo (79.3%) and those receiving MPH-LA (81.0%) during the maintenance of effect phase of the core study. The incidence of adverse events occurring in the extension study was 69.8%. Incidence of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	a diagnosis of ADHD	maintenance of effect phase and 6 month extension)	RS, SDS, CGI-I, CGI-S)	adverse events was comparable between MPH-LA mean daily dosage groups (69.4; 75.0; and 65.1% in the ≤40, >40 to 60, and >60 mg dosage groups, respectively). Secondary: The mean improvement in total score of ADHD-RS from the maintenance of effect phase baseline to the end of the extension study was 0.9. The mean improvement in SDS total score from the maintenance of effect phase baseline to the end of the extension study was 1.4. A total of 91 (31.4%) patients showed improvement in CGI-S score from the maintenance of effect phase baseline to the end of the extension study (MPH-LA, 32.1%; placebo, 29.5%). The mean improvement in total score of ADHD-RS and SDS from extension baseline to the end of the study was 7.2 and 4.8, respectively. Overall, 69.4% of patients showed improvement in CGI-I rating (MPH-LA, 65.3%; placebo, 80.2%), and 52.1% of patients showed improvement in CGI-S scale (MPH-LA, 42.9%; placebo, 76.9%) from the extension study baseline to the end of the study.
Greenhill et al.[132] (2002) MPH-XR (Metadate CD®) 20 to 60 mg daily vs placebo	DB, MC, PC, RCT Children six to 16 years of age diagnosed with ADHD	N=321 3 weeks	Primary: CGI-S (teacher) Secondary: CGI-S (parents), CGI-I scores, adverse events	Primary: CGI-S teacher scores significantly improved in the MPH-XR group (12.7±7.2 to 4.9±4.7) compared to the placebo group (11.5±7.3 to 10.3±6.9; P<0.001). Secondary: CGI-S parent scores significantly improved from 13.6±6.6 to 7.4±5.9 with MPH-XR vs 12.9±7.6 to 10.1±6.7 with placebo (P<0.001 for both scales). Eighty-one percent of the patients in the MPH-XR group compared to 50% of the patients in the placebo group were classified as responders based on their CGI-I scores (P<0.001). In the MPH-XR group, 52% of children reported at least one adverse event vs 38% from the placebo group (P=0.014). The rate of anorexia was more significant in the MPH-XR group vs the placebo group (9.7 vs 2.5%; P=0.007).
McGough et al.[133]	OL, RCT (first five	N=80	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2006) MPH transdermal system 10 to 27 mg daily vs standard current therapy	weeks) then DB, PC Children six to 12 years of age diagnosed with ADHD	7 weeks	Evaluate time course effects of MPH transdermal patch vs placebo transdermal patch via SKAMP-A, SKAMP-D, PERMP, ADHD-RS-IV, CPRS-R, CGI-I, and PGA rating scales Secondary: Acute efficacy and tolerability of MPH transdermal patch	Mean SKAMP-D scores were improved with MPH transdermal patch vs placebo (mean score, 3.2 vs 8.0) and at all time points assessed including 12 hours post-application (P<0.01). Mean (SKAMP-A) scores were improved with MPH transdermal patch vs placebo (6.2±0.50 vs 9.9±0.50, respectively; P<0.0001). PERMP scale results: Mean number of math problems attempted and math problems correct were significantly higher with MPH transdermal patch vs placebo (113.8 vs 86.2 and 109.4 vs 80.7, respectively; P<0.0001). Across the double-blind period, mean scores for the ADHD-RS-IV and CPRS-R scales were significantly improved with MPH transdermal patch vs placebo (P<0.0001). Those in the MPH transdermal patch group (79.8%) were more likely to be deemed improved on clinician rated CGI-I scores vs those in the placebo group (79.85 and 11.6%, respectively; P<0.0001). Statistically significant differences were observed with PGA ratings; 71.1% of MPH transdermal patch participants and 15.8% of placebo participants were rated as improved (P<0.0001). Secondary: More treatment-emergent adverse events were recorded with MPH transdermal patch therapy (39 events, 24 participants) vs placebo therapy (25 events, 18 participants). The most common treatment-related adverse events were decreased appetite, anorexia, headache, insomnia, and upper abdominal pain, all reported by less than 5% of study participants.
Pelham et al.[134] (2005) MPH transdermal patches: 6.25 cm^2 (0.45 mg/hour),	DB, DR, MC, RCT Children seven to 12 years of age diagnosed with ADHD	N=36 8 days	Primary: MPH transdermal patch efficacy and influence of exposure time on morning effects	Primary: All doses of MPH transdermal patches were significantly improved vs placebo on measures of social behavior in recreational settings, classroom functioning, and parent ratings of evening behavior (P<0.05). Beneficial effects of MPH transdermal patches were observed at all time

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
12.5 cm^2 (0.9 mg/hour) and 25 cm^2 (1.8 mg/hour), worn for at least 12 hours daily Each participant received single applications of MPH transdermal patches 6.25 cm^2, 12.5 cm^2 or 25 cm^2 patches or placebo in a random order on separate days and at two time points (6:00 AM or 7:00 AM).			Secondary: Not reported	points after application of the patch and were still seen for three hours after the patch had been removed (i.e., throughout the 12-hour assessment). Incidence of skin rash was reported as 40 to 50%. Secondary: Not reported
Pelham et al.[135] (2005) MPH transdermal patches: 12.5 cm^2, 25 cm^2 and 37.5 cm^2 plus behavior modification Each participant had two days on each treatment without concomitant plus behavior modification and four days on each treatment with plus behavior	DR, RCT Children aged six to 12 years diagnosed with ADHD	N=27 6 weeks	Primary: Proportion that reached individual target goals in Daily Report Card scores Secondary: Not reported	Primary: The percentage of individualized target criteria met by children in their Daily Report Card assessment was significantly (P<0.05 for all) higher with MPH transdermal patch 12.5, 25, and 37.5 cm^2 vs placebo, both without behavior modification (41.9, 63.1, and 66.2 vs 20.8%) and with behavior modification (73.7, 87.5, and 86.2 vs 54.7%; all P<0.05). Response rates were higher in the MPH transdermal patches 25 cm^2 group than in the 12.5 cm^2 group, both with and without behavior modification (P<0.05 for both); increasing the size of the patch to 37.5 cm^2 added no further advantage. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
modification.				
Faraone et al.[136] (2009) MPH transdermal patches 10 to 30 mg daily worn for nine hours per day or MPH-ER (Concerta®) 18 to 54 mg daily vs placebo	DB, MC, PC, RCT Children six to 12 years of age diagnosed with ADHD (predominantly hyperactive-impulsive, predominantly inattentive, or combined type)	N=268 5 weeks	Primary: CSHQ Secondary: Not reported	Primary: No significant difference in the severity of sleep problems was observed among the treatment and placebo groups (P≥0.233). No significant differences in the numbers of sleep problems were observed between MPH transdermal patch/MPH-ER and placebo (P≥0.554). There was no significant effect of MPH dosage on sleep problems (P=0.135). The effects of each MPH treatment and the various doses of these treatments on each CSHQ subscale were identical to the effects observed for the total CSHQ scale. Secondary: Not reported
Findling et al.[137] (2008) MPH transdermal system 10 to 30 mg daily or OROS-MPH 18 to 54 mg daily vs placebo	DB, PC, RCT Children six to 12 years of age diagnosed with ADHD	N=282 7 weeks	Primary: ADHD-RS Secondary: CTRS-R, CPRS-R, CGI-S, CGI-I	Primary: Mean total ADHD-RS scores were similar between MPH transdermal patch, MPH-ER, and placebo at baseline (43.0, 43.8, and 41.9, respectively), but not at endpoint (18.8, 21.8, and 32.1, respectively). Mean change from baseline in ADHD-RS scores was greater in study patients receiving MPH transdermal patch and MPH-ER compared to patients receiving placebo (P<0.001). There was a two-fold improvement of ADHD symptoms in active treatments compared to placebo from baseline to study endpoint. Secondary: MPH transdermal patch and MPH-ER showed improvements over placebo in mean total parent and teacher scores from baseline to endpoint. More study patients receiving MPH transdermal patch and MPH-ER compared to placebo were rated as improved by clinicians and parents (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Adverse events included decreased appetite, nausea, vomiting and insomnia. Most adverse events were considered mild or moderate by the study investigator.
Chou et al.[138] (2012) MPH-ER (Concerta®) 18, 36, or 54 mg once daily	OS Children six to 19 years of age with ADHD who have received MPH-IR for ≥1 month	N=521 10 weeks (six weeks forced-titration phase to achieve remission, followed by a four week maintenance phase)	Primary: Symptomatic remission Secondary: Changes in efficacy and satisfaction, safety	Primary: Using the forced-titration of MPH-ER dosage to increase the dosage during the first six weeks, the remission rate significantly increased with time from 4.8% (at baseline), 25% (week two), 44.2% (week four), 58.8% (week six), up to 59.6% (week 10) among 507 ITT patients. Among 439 patients who completed the 10 week follow-up assessments, 290 (66.1%) patients achieved symptomatic remission (95% CI, 61.6 to 70.5). The non-remission group had higher mean daily doses compared to the remission group from visit two to trial end. Secondary: Among the 439 patients who completed the treatment, there was a significant decrease in the total score and three sub-scores of the Chinese SNAP-IV (P<0.001), CGI-ADHD-S (P<0.001), and CGI-ADHD-I (P<0.001) as intra-individual comparison from the baseline to each visit through the trial period. Among the items on the Barkley SERS, poor appetite was the only one exacerbated on visit three, but improved on later visits. The other side effects gradually decreased in intensity throughout the trial period, and the difference from baseline reached significance from visit three to trial end. At trial end, there was a decrease in both mean body weight (-0.85 kg) and mean respiratory rate (-0.44/minute), and an increase in mean pulse rate (5.09 beats per minute) in comparison with baseline with significance (P<0.001). Five percent of patients withdrew from the trial because of adverse events, and these patients mostly left due to poor appetite and insomnia. Three patients experienced at least one serious adverse event that was not deemed to be treatment-related.
Faraone et al.[139] (2006)	MA (29 trials) Patients diagnosed	N=2,988 Variable	Primary: Effect sizes	Primary: All of the drugs groups produced a significant measure of effect compared to the placebo group (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
AMP-IR, AMP-XR, atomoxetine, bupropion, DEX-IR, DEX-ER, DEX-IR, modafinil, MPH-ER, MPH-IR, MPH-XR, MPH transdermal patches, pemoline	with ADHD	duration	Secondary: Not reported	The effect sizes for non-stimulant medications were significantly less than those for immediate-release stimulants (P<0.0001) or long-acting stimulants (P=0.0008). The two classes of stimulant medications (short acting and long acting) did not differ significantly from one another (P=0.14). Secondary: Not reported
Schelleman et al.[140] (2011) ADHD medications vs nonusers	RETRO Children three to 17 years of age who were dispensed a prescription for an AMP, atomoxetine, or MPH	N=241,417 Variable duration	Primary: Sudden cardiac death, or ventricular arrhythmia, stroke, MI Secondary: All-cause death	Primary and Secondary: No statistically significant difference between incident users and nonusers was observed in the rate of validated sudden death or ventricular arrhythmia (HR, 1.6; 95% CI, 0.19 to 13.60) or all-cause death (HR, 0.76; 95% CI, 0.52 to 1.12). None of the strokes identified during exposed time to ADHD medications were validated. No MIs were identified in study patients who used ADHD medication. No statistically significant difference between prevalent users and nonusers was observed for validated sudden death or ventricular arrhythmia (HR, 1.43; 95% CI, 0.31 to 6.61); stroke (HR, 0.89; 95% CI, 0.11 to 7.11); stroke/MI (HR, 0.72; 95% CI, 0.09 to 5.57); or all-cause death (HR, 0.77; 95% CI, 0.56 to 1.07).
Olfson et al.[141] (2012) AMP and MPH vs nonusers	RETRO Patients six to 21 years of age diagnosed with ADHD who were prescribed AMP or MPH	N=171,126 Variable duration	Primary: Cardiac events (inpatient diagnosis of chest pain, cardiac dysrhythmia or transient cerebral ischemia) and	Primary: There were 0.92 new cardiac events and 3.08 new cardiac symptoms per 1,000,000 days of current stimulant use. Current stimulant use compared to no stimulant use was not associated with less severe cardiovascular event (adjusted OR, 0.69; 95% CI, 0.42 to 1.12).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			cardiac symptoms (tachycardia, palpitations, or syncope) Secondary: Not reported	Past stimulant use compared to no stimulant use was not associated with less severe cardiovascular event (adjusted OR, 1.18; 95% CI, 0.83 to 1.66). The adjusted ORs for cardiac symptoms were 1.18 (95% CI, 0.89 to 1.59) for current and 0.93 (95% CI, 0.71 to 1.21) for past stimulant use when compared to no stimulant use. Current and past stimulant use was not associated with cardiac symptoms. No significant differences were observed in risks of cardiovascular events (adjusted OR, 2.14; 95% CI, 0.82 to 5.63) or symptoms (adjusted OR, 1.08; 95% CI, 0.66 to 1.79) for current MPH use compared to AMP use. Secondary: Not reported
Schelleman et al.[142] (2012) AMP, atomoxetine, MPH	RETRO Patients three to 17 years of age with a prescription for an AMP, atomoxetine, or MPH	N=219,954 Variable duration	Primary: Sudden death, ventricular arrhythmia, stroke, MI Secondary: Not reported	Primary: No significant difference between incident users and nonusers was observed in the rate of sudden death or ventricular arrhythmia (HR, 1.60; 95% CI, 0.19 to 3.60) or all-cause death (HR, 0.76; 95% CI, 0.52 to 1.12). None of the strokes identified during exposed time to ADHD medications were validated. No MIs were identified in ADHD medication users. No significant difference between prevalent users and nonusers was observed (HR for validated sudden death or ventricular arrhythmia, 1.43; 95% CI, 0.31 to 6.61; stroke, 0.89; 95% CI, 0.11 to 7.11; stroke/MI, 0.72; 95% CI, 0.09 to 5.57; and all-cause death, 0.77; 95% CI, 0.56 to 1.07). Secondary: Not reported
Hanwella et al.[143] (2011) Atomoxetine	MA (five trials) Children and adolescents six to 16 years of age	N=2,762 Variable duration	Primary: ADHD-RS Secondary: Not reported	Primary: The MA did not find a significant difference in efficacy between MPH and atomoxetine when comparing SMD in ADHD-RS scores (SMD, 0.09; 95% CI, -0.08 to 0.26).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs MPH	diagnosed with ADHD			There was no significant difference in response rates between the two medications (RR, 0.93; 95% CI, 0.76 to 1.14). Treatment effects between the formulations of MPH showed a significant SMD in ADHD-RS favoring OROS-MPH (SMD, 0.32; 95% CI, 0.12 to 0.53). MPH-IR was not superior to atomoxetine (SMD, -0.04; 95% CI, -0.19 to 0.12). There was no significant difference in acceptability between atomoxetine and MPH (RR, 1.22; 95% CI, 0.87 to 1.71). Secondary: Not reported
Bloch et al.[144] (2009) ADHD medications	MA (11 trials) Children diagnosed with ADHD and Tourette's	N=77 Variable duration	Primary: ADHD severity (ADHD-RS, CADS-P, CADS-T, CTRS-R) and tic severity (YGTSS, STSSS, HMVTS, and GTSS) Secondary: Not reported	Primary: MPH, α-2 agonists, desipramine, and atomoxetine demonstrated efficacy in improving ADHD symptoms in children with co-morbid tics. α-2 agonists and atomoxetine significantly improved co-morbid tic symptoms. There was evidence that supratherapeutic doses of DXM worsened tics; however, there was no evidence that MPH worsened tic severity in the short term. Secondary: Not reported
Binge Eating Disorder				
McElroy et al.[145] (2015) LDX 30 mg/day vs LDX 50 mg/day vs LDX 70 mg/day	DB, PC, PG, RCT Adults 18 to 55 years of age with moderate to severe binge eating disorder, as indicated by at least three binge eating days per week for the two weeks before the baseline visit	N=260 11 weeks	Primary: Number of binge eating days per week Secondary: Number of binge eating episodes per week, one-week binge eating response status, four-week cessation from	Primary: The mean (SD) changes from baseline to week 11 or early termination in nontransformed binge eating days per week for the placebo and the 30, 50, and 70 mg treatment groups were −3.3 (2.04), −3.5 (1.95), −4.1 (1.52), and −4.1 (1.57), respectively. The primary efficacy end point was significantly decreased in the 50 and 70 mg treatment groups but not in the 30 mg treatment group compared with the placebo group. Secondary: The LS mean change from baseline to week 11 of binge eating episodes per week was significantly decreased for the 50 and 70 mg treatment groups. At week 11 or early termination, the one-week response status was improved in the 50 and 70 mg treatment groups compared with the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			binge eating, CGI-I	placebo group, and the four-week binge eating cessation response status was improved in the 50 and 70 mg treatment groups compared with the placebo group. Greater proportions of participants receiving lisdexamfetamine were rated improved (CGI-I rating, one or two) compared with those receiving placebo at week 11 or early termination.
Hudson et al.[146] (2017) LDX 50 or 70 mg/day vs placebo	DB, MC, randomized withdrawal study Adults 18 to 55 years of age meeting DSM-IV-R binge-eating disorder criteria with moderate to severe binge eating disorder (≥3 binge-eating days per week for 14 days before OL baseline; CGI-S scores ≥4 [moderate severity] at screening and OL baseline)	N=275 LDX responders 26 weeks	Primary: Time to relapse (≥2 binge-eating days per week for 2 consecutive weeks and ≥2-point CGI-S score increases from randomized withdrawal baseline) Secondary: Binge-eating days per week, CGI-S scores, and Yale-Brown Obsessive Compulsive Scale modified for Binge Eating scores	Primary: The observed percentage of participants meeting relapse criteria was 32.1% with placebo and 3.7% with lisdexamfetamine (P<0.001). Secondary: The LS mean treatment difference for the change from randomized withdrawal baseline in binge-eating days per week indicated that there was an increase for placebo compared with LDX (−0.61; 95% CI, −0.81 to −0.42; nominal P<0.001). CGI-S score distributions differed between treatment groups (nominal P<0.001), with placebo scores skewed toward more severe illness than LDX scores. The LS mean treatment difference for the change from randomized withdrawal baseline indicated that there were total score increases for placebo compared with LDX on the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating (−5.6; 95% CI, −7.2 to −3.9; nominal P<0.001).
Gasior et al.[147] (2017) LDX 50 or 70 mg/day	ES, MC, OL Adults 18 to 55 years of age meeting DSM-IV-R binge-eating disorder criteria who completed one of three antecedent studies	N=604 52 weeks (4 week dose optimization and 48 week dose maintenance)	Primary: Adverse events Secondary: CGI-I, Eating Disorder Examination Questionnaire	Primary: Most participants reported treatment-emergent adverse events (84.5%), and most of the reported treatment-emergent adverse events were of mild or moderate intensity. There were no deaths during the study. Cholecystitis was the only serious adverse event reported in more than one participant (n=3). A detailed review of these events did not suggest a direct association with LDX, and none was considered to be related to LDX by the investigator. The only serious adverse events considered to be related to LDX by the investigator were coincident events of supraventricular tachycardia (mild intensity) and acute coronary syndrome (moderate intensity) reported in one participant who indicated that a double dose of 50-mg LDX may have been taken on the day of the events.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The most frequently reported treatment-emergent adverse events (occurring in ≥10% of participants) were dry mouth (27.2%), headache (13.2%), insomnia (12.4%), and upper respiratory tract infection (11.4%). Secondary: During the study, more than half of the participants in the full analysis set were categorized as improved on the CGI-I. At week 52/end-of-treatment, 89.8% (536/597) of the participants were categorized as improved on the CGI-I, with most participants having scores of one ("very much improved," 67.0%). At week 52/end-of-treatment, four participants exhibited worsening on the CGI-I ("minimally worse," n=3; "much worse," n=1). Mean Eating Disorder Examination Questionnaire global and subscale scores and the number of binge eating days for the past 28 days at weeks 52 and 52/end-of-treatment were numerically lower than those at baseline.

Drug regimen abbreviations: AMP=mixed amphetamine salts, DEX=dextroamphetamine, DXM=dexmethylphenidate, ER=extended release, IR=immediate release, LDX=lisdexamfetamine, MPH=methylphenidate, ODT=orally disintegrating tablet, OROS=osmotic-release oral system, SR=sustained release, XR=extended release
Study abbreviations: CI=confidence interval, DB=double blind, DR=dosing ranging, ES=extension study, FD=fixed dose, HR=hazard ratio, MA=meta-analysis, MC=multi-center, OL=open-label, OR=odds ratio, OS=observational study, PC=placebo-controlled, PG=parallel-group, PRO=prospective trial, RCT=randomized controlled trial, RETRO=retrospective, RR=relative risk, SA=single arm, SB=single blind, TB=triple blind, XO=crossover design
Other abbreviations: AAQoL=Adult ADHD quality of life scale, ADHD=attention deficit hyperactivity disorder, ADHD-RS=ADHD rating scale, AIM-A=ADHD impact module-adult, AISRS=Adult ADHD investigator system symptom report scale, ASRS=Adult self-rating scale, BFI=Brief Fatigue Inventory, BP=blood pressure, BRIEF=Behavior Rating Inventory of Executive Function, BRIEF-A=Behavior Rating Inventory of Executive Function-Adult Version, CAARS=Conner's adult ADHD rating scale, CAARS-Inv:SV=Conners' Adult ADHD Rating Scale–Investigator Rated: Screening Version, CAARS-Self:SV=Conners' Adult ADHD Rating Scale–Self Rated: Screening Version, CADS-P=Conners ADHD/DSM IV scale-parent version, CADS-T=Conners ADHD/DSM IV scale-teacher version, CANTAB-CRT=Cambridge Neuropsychological Test Automated Battery-Choice Reaction Time, CANTAB-SWM=Cambridge Neuropsychological Test Automated Battery-Working Memory and Strategy Performance, CASQ-P=Conner's abbreviated symptom questionnaire for parents, CASQ-T=Conner's abbreviated symptom questionnaire for teachers, CBC=Conner's behavior checklist, CGAS=Children's Global Assessment Scale, CGI=clinical global impression CGI-C=clinical global impression of change, CGI-I=clinical global impression of improvement, CGI-S=clinical global impression of severity, CHIP-CE=Child Health and Illness Profile-Child Edition, CPRS=Conners parent rating scale, CHQ=child health questionnaire, CHQ-PF50=Child Health Questionnaire-Parent Form, CPRS=Conners parent rating scale, CPRS-R=Conners parent rating scale—revised, CPRS-R:S=Conners parent rating scale: short form, CPRS-R:L=Conners' parent rating scale-revised: long form, CPT=Continuous performance test, CSHQ=Children's Sleep Habits Questionnaire, CTRS-R=Conners teacher rating scale–revised, CTRS-R: S=Conners teacher rating scale-revised: short form, DBP=diastolic blood pressure, DSST=Digit Symbol Substitution Task/Coding Test, EESC=Expression and Emotion Scale for Children, FBIM=Family Burden of Illness Module, HAMA=Hamilton Anxiety Rating Scale, GEC=global executive composite, GTSS=Global tic severity scale, $HAMD_{17}$=Hamilton 17-item Depression Rating scale, HMVTS=Hopkins motor/vocal tic scale, HR=heart rate, HSPP=Harter Self-Perception Profile, I/O=inattention/overactivity, JAMES=Joint Attention Measure from the ESCs (Early and Social Communication Scale), LS=least square, MI=myocardial infarction, O/D=oppositional/defiance, ODD=oppositional defiant disorder, PDD=pervasive developmental disorders, PERMP=permanent product measure of performance, PGA=parent global assessment, PSQ=parental satisfaction questionnaire, Q-LES-Q=quality of life, enjoyment, and satisfaction questionnaire, SAICA=Social Adjustment Scale for Children and Adolescents, SBP=systolic blood pressure, SD=standard deviation, SDS=Sheehan disability scale, SE=standard error, SF-36=36-item Short Form Health Survey, SERS=side effect ratings scale, SKAMP=Swanson, Kotkin, Agler, M-Flynn, and Pelham, SKAMP-A=SKAMP-Attention, SKAMP-D=SKAMP-Deportment, SMD=standard mean difference, SNAP=Swanson, Nolan and Pelham, SNAP-ODD=Swanson, Nolan and Pelham-oppositional defiant disorder, SNAP-P=Swanson, Nolan and Pelham-parent rating scale, SNAP-T=Swanson, Nolan and Pelham-teacher rating scale, SSERS=Stimulant Side Effects Rating Scale, STAI=State and trait anxiety inventory, STSSS=Shapiro Tourette syndrome severity scale, TOVA=test of variables of attention, WFIS=Weiss Functional Impairment Scale, WRAADDS=Wender-Reimherr Adult Attention-Deficit Disorder Scale, YGTSS=Yale global tic severity scale, YQOL-R=Youth quality of life-research version

Additional Evidence

Dose Simplification
Once-daily formulations increase patient compliance and eliminate the need for medication use during school. Prescribing immediate-release stimulants that require dosing during school hours can be problematic, especially with controlled drugs which have the potential for abuse. A few studies have compared immediate-release formulations with extended-release products. Lage et al. evaluated a pharmacy claims database to assess medication compliance among patients who took methylphenidate three times daily compared to those taking an extended-release product (Concerta®).[145] The investigators found better compliance in patients taking the extended-release product, less likelihood of switching medications, and a lower probability of discontinuing the medication. The use of the extended-release product was associated with a lower rate of emergency-room visits and fewer physician visits.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 19. Relative Cost of the Cerebral Stimulants/Agents Used for Attention-Deficit/Hyperactivity Disorder

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Central Alpha-Agonists				
Clonidine	extended-release tablet	N/A	N/A	$$
Amphetamine Derivatives				
Amphetamine	extended-release orally disintegrating tablet, extended-release suspension, tablet	Adzenys ER®*, Adzenys XR-ODT®, Dyanavel XR®, Evekeo®*	$$$$$	$$$$$
Amphetamine aspartate, amphetamine sulfate, and dextroamphetamine	extended-release capsule, tablet	Adderall®*, Adderall XR®*, Mydayis ER®	$$$$$	$$ to $$$$$

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Dextroamphetamine	sustained-release capsule, solution, tablet	Dexedrine®*, ProCentra®*, Zenzedi®*	$$$$$	$$
Lisdexamfetamine	capsule, chewable tablet	Vyvanse®	$$$$$	N/A
Methamphetamine	tablet	Desoxyn®*	$$$$$	$$$$$
Respiratory and CNS Stimulants				
Dexmethylphenidate	extended-release capsule, tablet	Focalin®*, Focalin XR®*	$$$$$	$$
Methylphenidate	chewable tablet, extended-release capsule, extended-release chewable tablet, extended-release orally disintegrating tablet, extended-release solution, extended-release tablet, sustained-release tablet, solution, tablet, transdermal patch	Adhansia XR®, Aptensio XR®*, Concerta®*, Cotempla XR-ODT®, Daytrana®, Jornay PM®, Methylin®*, Quillichew ER®, Quillivant XR®, Relexxii ER®*, Ritalin®*, Ritalin LA®*	$$$$$	$$
Central Nervous System Agents, Miscellaneous				
Atomoxetine	capsule	Strattera®*	$$$$$	$$$
Guanfacine	extended-release tablet	Intuniv®*	$$$$$	$$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The central nervous system agents that are included in this review are approved to treat attention deficit hyperactivity disorder (ADHD).[3-27] The cerebral stimulants are classified as Schedule II (amphetamines and methylphenidate derivatives) controlled substances. Atomoxetine, extended-release clonidine, and extended-release guanfacine are not cerebral stimulants; therefore, they are not classified as controlled substances. There is at least one short-acting, intermediate-acting, and long-acting central nervous system agent available in a generic formulation. Only lisdexamfetamine is not available in a generic formulation.

Guidelines recommend the use of an agent approved by the Food and Drug Administration (FDA) for the initial pharmacologic treatment of ADHD and they do not give preference to one agent over another.[30-32] The central nervous system agents have been shown to be effective for the treatment of ADHD in numerous clinical trials.[40-147] Although comparative trials have been conducted, it is difficult to interpret the results of these studies due to design flaws (small sample size, short duration, crossover design, variable outcomes, etc.).[41-43,57-62,64,71,76,116-123,127-129,137] Extended-release clonidine and extended-release guanfacine are approved for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulants.[2,28,70,78,90,91]

There are several factors to take into consideration when selecting a pharmacologic agent for the treatment of children and adolescents with ADHD. This includes the presence of comorbid conditions, patient/family preference, storage/administration at school, history of substance abuse, drug diversion, pharmacokinetics, and adverse events.[2,30-31] The advantage of a once-daily formulation is that the medication does not need to be taken during school hours, as is the case with the immediate-release formulations. Administration of medications during school hours, especially Schedule II controlled substances, can be difficult since the medication must be administered by a licensed school nurse. Atomoxetine, extended-release clonidine, and extended-release guanfacine are not controlled substances, which may be preferable to the stimulants in certain situations.

There is insufficient evidence to support that one brand cerebral stimulant/agent used for ADHD is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand cerebral stimulant/agent used for ADHD within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand cerebral stimulant/agent used for ADHD is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
2. Krull K. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. In: UpToDate, Torchia, M (Ed), UpToDate, Waltham, MA, 2020 [cited 2020 Jun 26]. Available from: http://www.utdol.com/utd/index.do.
3. Kapvay® [package insert]. St. Michael, Barbados: Concordia Pharmaceuticals Inc.; February 2020.
4. Adzenys ER® [package insert]. Grand Prairie, TX: Neos Therapeutics; September 2017.
5. Adzenys XR ODT® [package insert]. Grand Prairie, TX: Neos Therapeutics; January 2017.
6. Dyanavel XR® [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; February 2019.
7. Evekeo® [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; September 2016.
8. Adderall XR® [package insert]. Lexington, MA: Shire US, Inc.; July 2019.
9. Mydayis ER® [package insert]. Lexington, MA: Shire USA, Inc.; September 2019.
10. Dexedrine® [package insert]. Hayward, CA: Impax Specialty Pharma; February 2018.
11. Vyvanse® [package insert]. Lexington, MA: Shire US, Inc.; January 2018.
12. Desoxyn® [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc.; March 2019.
13. Focalin® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; November 2019.
14. Focalin XR® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; November 2019.
15. Aptensio XR® [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; June 2019.
16. Concerta® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2017.
17. Cotempla XR ODT® [package insert]. Grand Prairie, TX: Neos Therapeutics; June 2017.
18. Daytrana® [package insert]. Miami, FL: Noven Therapeutics, LLC; October 2019.
19. Metadate CD® [package insert]. Smyrna, GA: UCB, Inc.; January 2017.
20. Methylin® [package insert]. Florham Park, NJ: Shionogi Inc.; January 2017.
21. Ritalin®, Ritalin-SR® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; November 2019.
22. Ritalin LA® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; November 2019.
23. Quillichew ER® [package insert]. New York, NY: Pfizer Inc.; March 2017.
24. Quillivant XR® [package insert]. New York, NY: Pfizer Inc.; January 2017.
25. Strattera® [package insert]. Indianapolis, IN: Eli Lilly and Company; February 2020.
26. Intuniv® [package insert]. Lexington, MA: Shire US, Inc.; December 2019.
27. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2-2- [cited 2020 Jun]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
28. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jun]. Available from: http://online.factsandcomparisons.com.
29. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jun]. Available from: http://www.thomsonhc.com/.
30. American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. October 2019, 144 (4) e20192528.
31. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management [guideline on the Internet]. London (UK). March 2018. Available at: https://www.nice.org.uk/guidance/ng87/. Accessed June 2020.
32. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2014. 1-25. DOI: 10.1177/0269881113519509.
33. American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705-11.
34. European Federation of Neurological Sciences. Management of narcolepsy in adults. [guideline on the internet]. Vienna, Austria: European Federation of Neurological Societies; 2011 [cited 2020 Jun 26].Available from: http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2011_Management_of_narcolepsy_in_adults.pdf.
35. American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-76.

36. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleepwake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015. J Clin Sleep Med 2015;11(10):1199 – 1236.
37. Searight HR, Burke JM, Rottneck F. Adult ADHD: Evaluation and treatment in family medicine. Am Fam Physician. 2000;62:2077-86,2091-2.
38. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of the pharmacology, animal, and clinical studies. J Atten Disord. 2002;6(1):S65-71.
39. Barkley RA, Fisher M, Smallish L et al. Does the treatment of attention deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111:97-109.
40. McCracken JT, Biederman J, Greenhill LL et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLL381 (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychology. 2003;426(6):673-83.
41. Pliszka SR, Browne RG, Olvera RL et al. A double-blind, placebo controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(5):619-26.
42. Pelham WE, Aronof HR, Midlam JL et al. A comparison of Ritalin and Adderall; efficacy and time course in children with attention hyperactivity deficit disorder. Pediatrics. 1999;103:e43.
43. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22(5):468-73.
44. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double blind, placebo controlled parallel group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-66.
45. Goodman DW, Ginsberg L, Weisler, RH, Cutler AJ, Hodgkins P. An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD. CNS Spectr. 2005;10(Suppl 20):26-34.
46. Childress AC, Wigal SB, Brams MN, Turnbow JM, Pincus Y, Belden HW et al. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children With Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):306-313.
47. Biederman J, Heiligenstein JH, Faries DE et al. Atomoxetine ADHD Study Group. Efficacy of atomoxetine vs placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(6):e75.
48. Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2013 Feb;33(1):45-54.
49. Michelson D, Adler L, Spencer T et al. Atomoxetine in the treatment of children and adolescents with attention deficit, hyperactivity disorder: A randomized, placebo controlled, dose response study. Pediatrics. 2001;108(5):e83.
50. Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127:e862-8.
51. Spencer T, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7.
52. Adler LA, Clemow DB, Williams DW, Durell TM. Atomoxetine effects on executive function as measured by the BRIEF-A in young adults with ADHD: a randomized, double-blind, placebo-controlled study. PLoS One. 2014 Aug 22;9(8):e104175.
53. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine vs placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol. 2011;21:97-110.
54. Hammerness P, Doyle R, Kotarski M, et al. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry. 2009;18:493-8.
55. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12:248-53.
56. Wietecha L, Young J, Ruff D, Dunn D, Findling RL, Saylor K. Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning. Clin Neuropharmacol. 2012 Juen;35(3):125-33.

57. Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther. 2006; 28(2):280–93.
58. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared to atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005 Sep-Oct;22(5):498-512.
59. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721-30.
60. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate vs atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005 Oct;97(10 Suppl):11S-16S.
61. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. Atomoxetine vs methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 Mar;41(3):222-30.Clin Ther. 2006 Feb;28(2):280-93.
62. Kratochvil CJ, Heiligenstein JH, Dittmann R. et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-84.
63. Sutherland SM, Adler LA, Chen C, Smith MD, Feltner DE. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry. 2012 Jan 10.
64. Ni HC, Lin YJ, Gau SS M D Ph D, Huang HC, Yang LK. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD. J Atten Disord. 2013 Mar 8. [Epub ahead of print].
65. Sutherland SM, Adler LA, Chen C, Smith MD, Feltner DE. An eight-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry. 2012 Apr;73(4):445-50.
66. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; The SUNBEAM Study Group. A multi-centre, randomised, open-label study of atomoxetine compared to standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007 Feb;23(2):379-94.
67. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. 2007;194:197-209.
68. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42:886-94.
69. Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:171-9.
70. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406-13.
71. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Adolesc Psychiatry. 2004;43(11):1406-14.
72. Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):817-23.
73. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:1380-7.
74. Adler LA, Spencer T, McGough JJ, et al. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord. 2009;12:449-59.
75. Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, et al. A randomized, double-blind study of 30 vs 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2012 Oct;32(5):637-44.
76. Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581-8.

77. Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R. Efficacy and safety of extended-release dexmethylphenidate compared to d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18:248-56.
78. McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, et al. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):657-666.e1.
79. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067-74.
80. Kollins SH, López FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:111-20.
81. Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:155-65.
82. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:215-26.
83. Sallee FR, Kollins SH, Wigal TL. Efficacy of guanfacine extended-release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 June;22(3):206-14.
84. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged six to 12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755-68.
85. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:e73-84.
86. Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2020 Apr 14;81(3):19m12979.
87. Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016 Jun;57(6):717-28.
88. Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014 Dec;24(12):1861-72.
89. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13:1047-55.
90. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:501-10.
91. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:74-85.
92. Cutler AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct;53(10):1092-101.
93. Faraone SV, Glatt SJ. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. J Atten Disord. 2010;13:532-8.
94. Alder LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(7):694-702.
95. Babcock T, Dirks B, Adeyi B, Scheckner B. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacology and Toxicology. 2012;13:18.

96. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, randomized, multicenter, double-blind, parallel-group study. Clin Ther. 2007;29:450–63.
97. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-6.
98. Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornweel MC, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977-83.
99. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013 Jan 14. [Epub ahead of print].
100. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395-405.
101. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spect. 2008;13:614-20.
102. Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, et al. Efficacy and safety of lisdexamfetamine dimesylate in children with attention deficit/hyperactivity disorder and recent methylphenidate use. Adv Ther. 2013;30:472-86.
103. Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, et al. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2013;13:39.
104. Weisler R, Young J, Mattingly G et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr. 2009;14:573-85.
105. Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013 Dec;27(12):1081-92.
106. Wigal SB, Wigal T, Schuck S, et al. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:121-31.
107. Casas M, Rösler M, Sandra Kooij JJ, et al. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry. 2011 Nov 22. [Epub ahead of print].
108. Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, et al. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699.
109. Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):66-74.
110. Goodman DW, Starr HL, Ma YW, Rostain AL, Ascher S, Armstrong RB. Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. J Clin Psychiatry. 2017 Jan;78(1):105-114.
111. Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared to placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013 Feb;23(1):3-10.
112. Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. CNS Drugs. 2015 Apr;29(4):331-40.
113. Matthijssen AFM, Dietrich A, Bierens M, Deters RK, van de Loo-Neus GHH, van den Hoofdakker BJ et al. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. Am J Psychiatry. 2019 Sep 1;176(9):754-762.

114. Wilens TE. Biederman J. Lerner M. Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. Journal of Clinical Psychopharmacology. 2004;24(1):36-41.
115. Mattos P, Louzã MR, Palmini AL, et al. A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study. J Atten Disord. 2012 Feb 14. [Epub ahead of print].
116. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate vs mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006 Sep;118(3):e704-10.
117. Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. Int J Neuropsychopharmacol. 2011 Oct 21:1-12. [Epub ahead of print].
118. Su Y, Yang L, Stein MA, Cao Q, Wang Y. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up. J Child Adolesc Psychopharmacol. 2016 May;26(4):362-71.
119. Wolraich ML, Greenhill LL, Pelham W et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:883-92.
120. Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta - methylphenidate vs three times daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:e105.
121. Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006 Aug;16(4):441-55.
122. Lopez F, Silva R, Pestreich L et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs. 2003;5(8):545-55.
123. Swanson JM, Wigal SB, Wigal T et al. A comparison of one-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs study). Pediatrics. 2004;113:e206-16.
124. Silva R, Muniz R, Pestreich LK, Brams M, Childress A, Lopez FA. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol. 2005 Aug;15(4):637-54.
125. Jahromi LB, Kasari CL, McCracken JT, Lee LS, Aman MG, McDougle CJ, Scahill L, Tierney E, Arnold LE, Vitiello B, Ritz L, Witwer A, Kustan E, Ghuman J, Posey DJ. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39:395-404.
126. Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011;15:286-94.
127. Efron D, Jarman F, Barker M. Efficacy of methylphenidate and dextroamphetamine in children with attention hyperactivity disorder: a double blind crossover trial. Pediatrics. 1997;100:662-8.
128. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics. 1990;86:226-37.
129. Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: 1. Efficacy and tolerability of outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:180-8.
130. Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther. 2014 Jan;31(1):44-65.
131. Ginsberg Y, Arngrim T, Philipsen A, et al. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. CNS Drugs. 2014 Oct;28(10):951-62.
132. Greenhill LL, Findling RL, Swanson JM et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:e39.
133. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system. J of Att Dis. 2006;9(3):476-85.

134. Pelham WE, Manos MJ, Ezzell CE, Tresco KE, et al. A dose-ranging study of methylphenidate transdermal system in children with ADHD. J Am Acad Adolesc. 2005;44(6):522-9.
135. Pelham WE, Burrows-MacLean L, Gnagy EM, Fabiano GA, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacology. 2005;13:111-26.
136. Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan;12(4):308-15.
137. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:149-59.
138. Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, et al. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25.
139. Faraone SV, Bierderman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8(4):4.
140. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102-10.
141. Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:147-56.
142. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169:178-85.
143. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.
144. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884-93.
145. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235-46.
146. Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):903-910.
147. Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder. J Clin Psychopharmacol. 2017 Jun;37(3):315-322.
148. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adol Psychopharmacol. 2004;14(4):575-81.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Wakefulness Promoting Agents
AHFS Class 282080
November 4, 2020

I. Overview

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and intermittent manifestations of rapid eye movement sleep during wakefulness.[1] Obstructive sleep apnea is the most common form of breathing-related sleep disorder, which is caused by obstruction of the airway.[2] Individuals with obstructive sleep apnea often suffer from excessive daytime sleepiness, as well as other serious health conditions (e.g., depression, hypertension, and cardiovascular/cerebrovascular disease).[3] Circadian rhythm sleep disorder consists of a persistent/recurrent pattern of sleep interruption. The shift work type occurs in individuals who work non-standard hours (e.g., night work, early morning work, and rotating schedules), and is characterized by excessive sleepiness and/or insomnia.[2,4]

Modafinil and armodafinil (the longer half-life enantiomer of modafinil) are wakefulness promoting agents approved to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.[5,6] The exact mechanism by which these two agents improve wakefulness is unknown; however, their actions are similar to other sympathomimetic agents. They have been shown to produce psychoactive and euphoric effects similar to stimulants, as well as alterations in mood, perception, thinking, and feelings.[5,6] As a result, these agents are classified as Schedule IV controlled substances.

Sodium oxybate is gamma-hydroxybutyric acid, a known drug of abuse.[7] It is classified as a miscellaneous central nervous system agent but included within this review as it is approved for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The exact mechanism by which sodium oxybate reduces cataplexy and excessive daytime sleepiness in patients with narcolepsy is unknown. It is classified as a Schedule III controlled substance; however, non-medical uses of sodium oxybate are classified under Schedule I.

Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved in adult patients with excessive daytime sleepiness associated with narcolepsy or excessive daytime sleepiness associated with obstructive sleep apnea in combination with continuous positive airway pressure therapy. The mechanism by which solriamfetol exerts its therapeutic effect is unknown. Solriamfetol is classified as a Schedule IV controlled substance.[8]

Pitolisant is a histamine H3 receptor antagonist/inverse agonist approved for excessive daytime sleepiness associated with narcolepsy. The mechanism by which pitolisant exerts its therapeutic effect in narcolepsy is unknown but believed to be mediated through its H3 activity. Pitolisant is the only approved agent in this class that is not a controlled substance based on the potential for abuse or dependence.[9]

The wakefulness promoting agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. In terms of duration of action, modafinil, armodafinil, pitolisant and solriamfetol are all long-acting agents while sodium oxybate is a short-acting agent.[5-9] Armodafinil and modafinil are currently available generically. The agents in this class were last reviewed in August 2018.

Table 1. Wakefulness Promoting Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Armodafinil	tablet	Nuvigil®*	armodafinil
Modafinil	tablet	Provigil®*	modafinil
Pitolisant	tablet	Wakix®	none
Sodium oxybate	oral solution	Xyrem®	none
Solriamfetol	tablet	Sunosi®	none

*Generic is available in at least one dosage form or strength.
†Generic product requires prior authorization.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the wakefulness promoting agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Wakefulness Promoting Agents

Clinical Guideline	Recommendation(s)
American Academy of Sleep Medicine: **Practice Parameters for the Treatment of Narcolepsy and Other Hypersomnias of Central Origin (2007)[1]**	• Most of the agents used to treat excessive sleepiness have little effect on cataplexy or other rapid eye movement sleep associated symptoms. Most antidepressants and anticataplectics have little effect on alertness. However, some compounds act on both symptoms. Compounds should be selected depending on the diagnosis and the targeted symptoms. Coadministration of two or more classes of compounds may be needed in some patients to adequately address their symptoms. • Modafinil is effective for treatment of daytime sleepiness due to narcolepsy. • Sodium oxybate is effective for treatment of cataplexy, daytime sleepiness, and disrupted sleep due to narcolepsy. Sodium oxybate may be effective for treatment of hypnagogic hallucinations and sleep paralysis. • Amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are effective for treatment of daytime sleepiness due to narcolepsy. • Selegiline may be an effective treatment for cataplexy and daytime sleepiness. • Tricyclic antidepressants, selective serotonin reuptake inhibitors, and venlafaxine may be effective treatment for cataplexy. • Scheduled naps can be beneficial to combat sleepiness, but seldom suffice as primary therapy for narcolepsy.
European Federation of Neurological Sciences: **Guidelines on Management of Narcolepsy in Adults (2011)[10]**	<u>Excessive daytime sleepiness and irresistible episodes of sleep</u> • Modafinil should be prescribed when excessive daytime sleepiness is present. Modafinil should be dosed as 100 to 400 mg/day, given once in the morning or twice daily. • Sodium oxybate may be used when excessive daytime somnolence coexists with cataplexy and poor sleep. Depressed patients should not receive sodium oxybate. • Sodium oxybate should be initiated with 4.5 g/night, increasing by increments of 1.5 g at four-week intervals and should not be used with other sedatives, respiratory depressants or muscle relaxants. Monitor patients for possible development of sleep-disordered breathing. Adverse effects may limit the dose, and require slower titration. • The optimal response on excessive daytime sleepiness may take up to 12 weeks. • Supplementation with modafinil is generally more successful than sodium oxybate alone. • Methylphenidate may be considered if modafinil is insufficient and sodium oxybate is not recommended. • The short-acting effect of methylphenidate is of interest when modafinil needs to be supplemented at a specific time of the day, or in situations where maximum alertness is required. <u>Cataplexy</u> • First-line pharmacological treatment of cataplexy is sodium oxybate at a starting dose of 4.5 g/night divided into two equal doses of 2.25 g/night. The dose may be increased to a maximum of 9 g/night, divided into two equal doses of 4.5 g/night, by increments of 1.5 g at two-week intervals. • Adverse effects may limit the dose, and require slower titration and the optimal response on excessive daytime sleepiness may take up to 12 weeks. • Antidepressants are recommended as second-line pharmacological treatment. Tricyclic antidepressants, particularly clomipramine (10 to 75 mg), are potent anticataplectic drugs; however, anticholinergic adverse effects are common. • Selective serotonin reuptake inhibitors are slightly less active but have fewer

Clinical Guideline	Recommendation(s)
	adverse effects. • Venlafaxine is widely used but clinical evidence supporting its use is limited. • Reboxetine and atomoxetine, also lack published clinical evidence. • Given the efficacy of sodium oxybate and antidepressants, the place for other compounds is fairly limited. • There is no accepted behavioral treatment of cataplexy. <u>Poor sleep</u> • Sodium oxybate appears to be the most appropriate to treat poor sleep. • Benzodiazepine or non-benzodiazepine hypnotics may be effective in consolidating nocturnal sleep, but objective evidence is lacking over intermediate- or long-term follow-up. • The improvement in poor sleep reported by some patients once established on modafinil is noteworthy. <u>Obstructive sleep apnea/hypopnea syndrome, periodic limb movements in sleep, neuropsychiatric symptoms</u> • Obstructive sleep apnea/hypopnea syndrome should be similarly in narcoleptic patients and general population, although continuous positive airway pressure does not improve excessive daytime sleepiness in most narcolepsy subjects. • There is usually no need to treat periodic limb movements in narcoleptic patients. Antidepressants and psychotherapy should be used in depressed narcoleptic patients as in non-narcoleptic depressed patients.
American Academy of Sleep Medicine: **Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults (2009)**[3]	<u>Weight reduction</u> • Successful dietary weight loss may improve the apnea-hypopnea index in obese obstructive sleep apnea patients. • Dietary weight loss should be combined with a primary treatment for obstructive sleep apnea. • Bariatric surgery may be adjunctive in the treatment of obstructive sleep apnea in obese patients. <u>Pharmacologic agents</u> • Modafinil is recommended for the treatment of residual excessive daytime sleepiness in obstructive sleep apnea patients who have sleepiness despite effective positive airway pressure treatment and who are lacking any other identifiable cause for their sleepiness. • Selective serotonin reuptake inhibitors, protriptyline, methylxanthine derivatives (aminophylline and theophylline), and estrogen therapy are not recommended for treatment of obstructive sleep apnea. <u>Supplemental oxygen</u> • Oxygen supplementation is not recommended as a primary treatment for obstructive sleep apnea. <u>Medical therapies intended to improve nasal patency</u> • Short-acting nasal decongestants are not recommended for treatment of obstructive sleep apnea. • Topical nasal corticosteroids may improve the apnea-hypopnea index in patients with obstructive sleep apnea and concurrent rhinitis, and thus may be a useful adjunct to primary therapies for obstructive sleep apnea. <u>Positional therapies</u> • Positional therapy is an effective secondary therapy or can be a supplement to primary therapies for obstructive sleep apnea in patients who have a low apnea-hypopnea index in the non-supine vs that in the supine position. vs

Clinical Guideline	Recommendation(s)
American Academy of Sleep Medicine: **Practice Parameters for the Evaluation and Treatment of Extrinsic Circadian Rhythm Sleep Disorders (2015)[4]**	Shift work disorder • Planned napping before or during the night shift is indicated to improve alertness and performance among night shift workers. • Timed light exposure in the work environment and light restriction in the morning, when feasible, is indicated to decrease sleepiness and improve alertness during night shift work. • Administration of melatonin prior to daytime sleep is indicated to promote daytime sleep among night shift workers. • Hypnotic medications may be used to promote daytime sleep among night shift workers. Carryover of sedation to the nighttime shift with potential adverse consequences for nighttime performance and safety must be considered. • Modafinil is indicated to enhance alertness during the night shift for shift work disorder. • Caffeine is indicated to enhance alertness during the night shift for shift work disorder.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the wakefulness promoting agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Wakefulness Promoting Agents[5-9,11-12]

Generic Name(s)	Improve Wakefulness in Adult Patients with Excessive Sleepiness Associated with Narcolepsy	Improve Wakefulness in Adult Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea	Improve Wakefulness in Adult Patients with Excessive Sleepiness Associated with Shift Work Disorder	Treatment of Cataplexy in Narcolepsy	Treatment of Excessive Daytime Sleepiness in Narcolepsy
Armodafinil	✔	✔	✔		
Modafinil	✔	✔	✔		
Pitolisant					✔
Sodium oxybate				✔	✔
Solriamfetol	✔	✔			

IV. Pharmacokinetics

The pharmacokinetic parameters of the wakefulness promoting agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Wakefulness Promoting Agents[12]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Armodafinil	Rapid	60	Liver (not reported)	Renal (not reported)	15
Modafinil	Rapid	60	Liver (90)	Renal (80) Feces (1)	15
Pitolisant	Not reported	91 to 96	Liver (not reported)	Renal (90) Feces (2.3)	20
Sodium oxybate	88	<1	Liver	Renal (1 to 5)	<1

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
			(not reported)		
Solriamfetol	95	13.3 to 19.4	Minimal (not reported)	Renal (not reported)	7.1

V. Drug Interactions

Major drug interactions with the wakefulness promoting agents are listed in Table 5.

Table 5. Major Drug Interactions with the Wakefulness Promoting Agents[12]

Generic Name(s)	Interaction	Mechanism
Modafinil	Hormonal contraceptives	Concurrent use of modafinil and hormonal contraceptives may result in decreased plasma levels of hormonal contraceptives.
Modafinil	Tolvaptan	Concurrent use of modafinil and tolvaptan may result in decreased tolvaptan plasma concentrations.
Modafinil	Enzalutamide	Concurrent use of enzalutamide and modafinil may result in decreased enzalutamide plasma concentrations; decreased modafinil plasma concentrations.
Modafinil	Citalopram	Concurrent use of citalopram and modafinil may result in increased citalopram exposure and risk of QT interval prolongation.
Modafinil	Ifosfamide	Concurrent use of ifosfamide and modafinil may result in increased neurotoxic and nephrotoxic effects.
Pitolisant	Strong CYP2D6 inhibitors (i.e., paroxetine, fluoxetine, bupropion)	Concurrent use increases pitolisant exposure by 2.2-fold. Reduce pitolisant dose by half if used concomitantly.
Pitolisant	Strong CYP3A4 inducers (i.e., rifampin, carbamazepine)	Concurrent use decreases pitolisant exposure by 50%. Assess for loss of efficacy after initiation of a strong CYP3A4 inducer. Dose may be doubled for patients using 8.9 or 17.8 mg. If concomitant dosing of a strong CYP3A4 inducer is discontinued, decrease pitolisant dosage by half. No recommendations regarding patients stabilized on 35.6 mg.
Pitolisant	Centrally acting H1 antagonist (i.e., pheniramine maleate, diphenhydramine, imipramine, promethazine, clomipramine, mirtazapine)	Concurrent use of H1 antagonists that cross the blood brain barrio may reduce the effectiveness of pitolisant. Avoid concomitant use.
Pitolisant	QT prolonging agents (i.e., quinidine, procainamide, disopyramide, amiodarone, sotalol, ziprasidone, chlorpromazine, thioridazine, moxifloxacin)	Concurrent use of drugs that prolong the QT interval may add to the QT effects of pitolisant and increase the risk of cardiac arrhythmia. Avoid concomitant use.
Pitolisant	CYP3A4 substrates (i.e., midazolam, hormonal contraceptives, cyclosporine)	Concurrent use with certain sensitive CYP3A4 substrates may result in reduced effectiveness of the substrates. The effectiveness of hormonal contraceptives may be reduced for 21 days after discontinuation of therapy. Non-hormonal contraceptives should be used.
Sodium oxybate	Barbiturates	Concurrent use of sodium oxybate and barbiturates may result in an increase in sleep duration and central nervous system depression.

Generic Name(s)	Interaction	Mechanism
Sodium oxybate	Benzodiazepines	Concurrent use of sodium oxybate and benzodiazepines may result in an increase in sleep duration and central nervous system depression.
Sodium oxybate	Central nervous system depressants	Concurrent use of sodium oxybate and central nervous system depressants may result in an increase in sleep duration and central nervous system depression.
Sodium oxybate	Opioid analgesics	Concurrent use of sodium oxybate and opioid analgesics may result in additive respiratory depression.
Sodium oxybate	Sedative hypnotics	Concurrent use of sodium oxybate and sedative hypnotics may result in increased central nervous system depression.
Sodium oxybate	Selected antiepileptics (topiramate, perampanel, difenoxin)	Concurrent use of sodium oxybate and selected antiepileptics may result in increased central nervous system depression.
Sodium oxybate	Selected antipsychotics (loxapine, thioridazine, chlorpromazine)	Concurrent use of sodium oxybate and selected antipsychotics may result in increased central nervous system depression.
Sodium oxybate	Skeletal muscle relaxants	Concurrent use of sodium oxybate and skeletal muscle relaxants may result in increased central nervous system depression.
Sodium oxybate	Buspirone	Concurrent use of sodium oxybate and buspirone may result in an increase in sleep duration and central nervous system depression.
Solriamfetol	Monoamine oxidase inhibitors	Concurrent use may increase the risk of hypersensitivity reactions or hypertensive crisis. Concomitant use or use of a monoamine oxidase inhibitor within the preceding 14 days is contraindicated.
Solriamfetol	Drugs that increase blood pressure and/or heart rate	Concurrent use has not been evaluated and should be used with caution.
Solriamfetol	Dopaminergic drugs	Concurrent use has may result in pharmacodynamic interactions which have not been evaluated with solriamfetol and should be used with caution.

VI. Adverse Drug Events

The most common adverse drug events reported with the wakefulness promoting agents are listed in Table 6. The boxed warning for sodium oxybate is listed in Table 7. Sodium oxybate is a known drug of abuse and has been associated with central nervous system-related adverse reactions, including confusion, respiratory depression, profound decreases in consciousness, and death. As such, sodium oxybate is classified as a Schedule III controlled substance by federal regulation and is available through a centralized pharmacy. Modafinil and armodafinil may produce psychoactive and euphoric effects similar to stimulants and are therefore classified as Schedule IV controlled substances by federal regulation. Solriamfetol also has potential for abuse as a study demonstrated that solriamfetol produced Drug Liking scores similar to or lower than phentermine. As such, solriamfetol is also classified as a Schedule IV controlled substance by federal regulation. Pitolisant is not a controlled substance.

Table 6. Adverse Drug Events (%) Reported with the Wakefulness Promoting Agents [5-9,11]

Adverse Events	Armodafinil	Modafinil	Pitolisant	Sodium Oxybate	Solriamfetol
Cardiovascular					
Angina	-	-	-	-	-
Cardiac arrhythmia	-	-	-	-	-
Chest discomfort	-	-	-	-	2
Chest pain	-	3	-	-	
Heart rate increase	-	-	3	-	-
Hypertension	-	3	-	✔	-

Adverse Events	Armodafinil	Modafinil	Pitolisant	Sodium Oxybate	Solriamfetol
Hypotension	-	-	-	-	-
Myocardial infarction	-	-	-	-	-
Palpitations	2	2	-	-	2 to 3
Pulse increase/decrease	1	-	-	-	-
Raynaud's phenomenon	-	-	-	-	-
Sudden death	-	-	-	-	-
Systolic blood pressure increased	✔	-	-	-	-
Tachycardia	-	2	-	-	-
Vasodilation	-	2	-	-	-
Central Nervous System					
Abnormal dreams	-	-	-	-	-
Aggressive behavior	-	-	-	-	-
Agitation	1	1	-	-	-
Anxiety	4	5 to 21	5	1 to 2	4 to 6
Ataxia	-	-	-	-	-
Attention disturbance	1	-	-	0 to 4	-
Cerebral arteritis	-	-	-	-	-
Cerebral occlusion	-	-	-	-	-
Chills	-	-	-	-	-
Confusion	-	-	-	3 to 17	-
Depression	1 to 3	2	-	-	-
Disorientation	-	-	-	1 to 3	-
Dizziness	3 to 8	5	-	9 to 15	2
Drowsiness	-	-	-	-	-
Dyskinesia	-	1	-	-	-
Emotional instability	-	-	-	-	-
Fatigue/lethargy	2	-	-	-	-
Fever	1	-	-	-	-
Hallucinations	-	-	3	-	-
Headache	14 to 23	34	18	✔	16
Hyperkinesia	-	1	-	-	-
Hypertonia	-	1	-	-	-
Insomnia	4 to 6	3 to 21	6	-	5
Irritability	-	-	3	0 to 3	3
Jittery feeling	-	-	-	-	3
Labile affect	-	-	-	-	-
Mania	-	✔	-	-	-
Migraine	1	-	-	-	-
Nervousness	1	7	-	-	-
Neuroleptic malignant syndrome	-	-	-	-	-
Nightmare	-	-	-	-	-
Overstimulation	-	1	-	-	-
Paresthesia	1	2	-	1 to 3	-
Psychotic episodes	-	✔	-	-	-
Restlessness	-	-	-	-	-
Seizures	-	-	-	-	-
Sleep disorder	-	-	-	-	-
Sleep disturbance	-	-	3	-	-
Sleep paralysis	-	-	-	1 to 3	-
Sleep walking	-	-	-	0 to 3	-
Somnolence	-	2	-	1 to 8	-
Suicidal ideation	-	-	-	-	-

Adverse Events	Armodafinil	Modafinil	Pitolisant	Sodium Oxybate	Solriamfetol
Syncope	-	-	-	-	-
Tic	-	-	-	-	-
Tourette's exacerbation	-	-	-	-	-
Toxic psychosis	-	-	-	-	-
Tremor	1	1	-	0 to 5	-
Vertigo	-	1	-	-	-
Dermatological					
Alopecia	-	-	-	-	-
Application site reaction	-	-	-	-	-
Dermatitis	1	-	-	-	-
Diaphoresis	-	1	-	-	-
Erythema	-	-	-	-	-
Erythema multiforme	-	✔	-	-	-
Exfoliative dermatitis	-	-	-	-	-
Hair loss	-	-	-	-	-
Herpes simplex	-	1	-	-	-
Hyperhidrosis	1	-	-	1 to 3	2
Rash	1 to 4	<1	2	-	-
Stevens-Johnson syndrome	✔	✔	-	-	-
Toxic epidermal necrolysis	-	-	-	-	-
Urticaria	-	-	-	-	-
Gastrointestinal					
Abdominal pain	2	-	3	1 to 3	3
Anorexia	1	4	-	-	-
Appetite decreased	1	-	3	✔	6 to 9
Bruxism	-	-	-	-	-
Constipation	1	2	-	-	3
Diarrhea	3 to 5	6	-	3 to 4	4
Dry mouth	2 to 7	4	2	1 to 2	4
Dyspepsia	2	5	-	-	-
Flatulence	-	1	-	-	-
Mouth ulceration	-	1	-	-	-
Nausea	7 to 14	11	6	8 to 20	7 to 8
Stomach cramps	-	-	-	-	-
Thirst	-	1	-	-	-
Unpleasant taste	-	1	-	-	-
Vomiting	1	-	-	2 to 11	-
Weight increase	-	-	-	-	-
Weight loss	-	-	-	✔	-
Genitourinary					
Abnormal urine	-	1	-	-	-
Enuresis	-	-	-	3 to 7	-
Erectile disturbance	-	-	-	-	-
Hematuria	-	1	-	-	-
Libido decreased	-	-	-	-	-
Polyuria	1	-	-	-	-
Pyuria	-	1	-	-	-
Urinary incontinence	-	-	-	-	-
Hematologic					
Agranulocytosis	-	✔	-	-	-
Anemia	-	-	-	-	-
Eosinophilia	-	1	-	-	-
Leukopenia	-	-	-	-	-
Pancytopenia	✔	-	-	-	-

Adverse Events	Armodafinil	Modafinil	Pitolisant	Sodium Oxybate	Solriamfetol
Thrombocytopenic purpura	-	-	-	-	-
Hepatic					
Hepatic coma	-	-	-	-	-
Liver function test abnormalities	✔	2	-	-	-
Musculoskeletal					
Arthralgia	-	-	-	✔	-
Back pain	-	6	-	-	-
Cataplexy	-	-	2	1 to 2	-
Hypoesthesia	-	-	-	-	-
Muscle spasms	-	-	-	<1 to 2	-
Musculoskeletal pain	-	-	5	-	-
Pain in extremity	-	-	-	1 to 3	-
Weakness	-	-	-	-	-
Respiratory					
Bronchitis	-	-	-	-	-
Cough	-	-	-	-	-
Dyspnea	1	-	-	-	-
Epistaxis	-	1	-	-	-
Lung disorder	-	2	-	-	-
Nasal congestion	-	-	-	-	-
Pharyngitis	-	4	-	-	-
Pharyngolaryngeal pain	-	-	-	-	-
Rhinitis	-	7	-	-	-
Sinusitis	-	-	-	-	-
Upper respiratory tract infection	-	-	5	-	-
Special Senses					
Abnormal vision	-	1	-	-	-
Accommodation difficulties	-	1	-	-	-
Amblyopia	-	1	-	-	-
Blurred vision	-	1	-	✔	-
Dry eyes	-	-	-	-	-
Eye pain	-	1	-	-	-
Mydriasis	-	-	-	-	-
Tinnitus	-	-	-	-	-
Other					
Accidental injury	-	-	-	-	-
Anaphylaxis	✔	✔	-	-	-
Ear pain	-	-	-	-	-
Edema	-	1	-	0 to 3	-
Feeling drunk	-	-	-	0 to 3	-
Flu-like syndrome	1	4	-	-	-
Growth suppression	-	-	-	-	-
Hypersensitivity reactions	-	✔	-	-	-
Pain	1	-	-	<1 to 3	-
Thirst	1	-	-	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 7. Boxed Warning for Sodium Oxybate[7]

WARNING
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and MISUSE AND ABUSE

WARNING

Xyrem® (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses obtundation and clinically significant respiratory depression occurred in Xyrem®-treated patients. Almost all of the patients who received Xyrem® during clinical trials in narcolepsy were receiving central nervous system stimulants.

Xyrem® (sodium oxybate) is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.

Because of the risks of CNS depression, abuse, and misuse, Xyrem® is available only through a restricted distribution program called the Xyrem Success Program®, using a centralized pharmacy. Prescribers and patients must enroll in the program. For further information go to www.XYREM.com or call 1-866-XYREM88® (1-866-997-3688).

VII. Dosing and Administration

The usual dosing regimens for the wakefulness promoting agents are listed in Table 8.

Table 8. Usual Dosing Regimens for the Wakefulness Promoting Agents[5-9,11]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Armodafinil	Improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy: Table: 150 mg to 250 mg once daily in the morning Improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea: Tablet: 150 mg to 250 mg once daily in the morning Improve wakefulness in adult patients with excessive sleepiness associated with shift work disorder: Tablet: 150 mg daily given one hour prior to start of work shift	Safety and efficacy in children have not been established.	Tablet: 50 mg 150 mg 200 mg 250 mg
Modafinil	Improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy: Tablet: 200 mg once daily in the morning Improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea: Tablet: 200 mg once daily in the morning Improve wakefulness in adult patients with excessive sleepiness associated with shift work disorder: Tablet: 200 mg as a single dose one hour prior to start of work shift	Safety and efficacy in children have not been established.	Tablet: 100 mg 200 mg
Pitolisant	Excessive daytime sleepiness associated with narcolepsy: Tablet: initial, 8.9 mg (two 4.45 mg tablets) once daily for one week then 17.8 mg once daily; may	Safety and efficacy in children have not been established.	Tablet: 4.45 mg 17.8 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	increase to 35.6 mg (two 17.8 mg tablets) once daily after one week; maximum, 35.6 mg once daily		
Sodium oxybate	Cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy: Oral solution: initial, 4.5 g per night in two divided doses; first dose to be given at bedtime after the patient is in bed and second dose to be given 2.5 to four hours later; dose may be increased or adjusted in two-week intervals; maximum, 9 g per day	Cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy in patients 7 years of age and older: Oral solution: initial, ≤1 to 2.25 g twice nightly; maximum 3 to 4.5 g twice nightly; recommended starting pediatric dosage, titration regimen and maximum total nightly dosage are based on body weight; first dose to be given at bedtime and second dose to be given 2.5 to four hours later	Oral solution: 500 mg/mL
Solriamfetol	Excessive daytime sleepiness associated with narcolepsy: Tablet: initial, 75 mg once daily; maintenance, 75 mg to 150 mg once daily; maximum, 150 mg once daily Excessive daytime sleepiness associated with obstructive sleep apnea: Tablet: initial, 37.5 mg once daily; maintenance, 37.5 mg to 150 mg once daily; maximum, 150 mg once daily	Safety and efficacy in children have not been established.	Tablet: 75 mg 150 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the wakefulness promoting agents are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Wakefulness Promoting Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Narcolepsy				
Harsh et al.[13] (2006) Armodafinil 150 to 250 mg once daily vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age diagnosed with narcolepsy	N=196 12 weeks	Primary: MWT 0900-1500 sleep latency, CGI-C Secondary: MWT 1500-1900 sleep latency, CGI-C, CDR, ESS, BFI	Primary: Mean MWT 0900–1500 sleep latency increased 1.3, 2.6, and 1.9 minutes from baseline in the 150 mg, 250 mg, and armodafinil combined groups, respectively, and decreased 1.9 minutes from baseline in the placebo group (P<0.01 for all comparisons). Secondary: Mean MWT 1500–1900 sleep latency increased 1.5, 1.6, and 1.6 minutes in the 150 mg, 250 mg, and armodafinil combined groups, respectively, and decreased 1.2 minutes from baseline in the placebo group. The differences for the armodafinil combined group vs placebo and the 150 mg group vs the placebo group were significant (P<0.05 for both comparisons). The proportion of patients with at least minimal improvement in their CGI-C rating was significantly higher for the armodafinil 150 mg, 250 mg, and combined groups compared to the placebo group (P<0.0001 for all comparisons). The proportion of patients rated as minimally, much, and very much improved on the CGI-C from baseline to final visit was 21, 33, and 16%, respectively, for armodafinil 150 mg; 20, 35, and 18%, respectively, for armodafinil 250 mg; 20, 34, and 17%, respectively, for the armodafinil combined group; and 17, 12, and 3%, respectively, for placebo. Power of attention was significantly improved in the armodafinil 150 mg/day and armodafinil combined groups compared to placebo at the final visit (P<0.05). There were not significant effects on mean continuity of attention between the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Armodafinil demonstrated significantly greater improvements in quality of episodic secondary memory compared to placebo at the final visit (P<0.05). Armodafinil 250 mg and the combined group demonstrated significantly greater improvement in speed of memory compared to placebo at the final visit (P<0.05). Differences in the change from baseline on the ESS were statistically significant in favor of each armodafinil group compared to placebo at weeks eight (P<0.01 for all comparisons) and 12 (P<0.01) and at the final visit (150 mg/day, -4.1; P=0.0044, 250 mg/day, -3.8; P=0.0015, and combined group, -3.9; P=0.0006). At the final visit, 21% of patients in the armodafinil 150 mg/day group (P=0.0312) and 28% of patients in the armodafinil 250 mg/day group (P=0.0023) had an ESS score <10, compared to only 7% of patients in the placebo group. Improvements in global fatigue were significantly greater with armodafinil compared to placebo at the final visit (150 mg/day, -1.5; P=0.0007; 250 mg/day, -1.3; P=0.0018; combined group, -1.4; P=0.0002; placebo, -0.3). Headache, nausea, dizziness, and decreased appetite were the most commonly reported adverse events with armodafinil.
U.S. Modafinil in Narcolepsy Group[14] (1998) Modafinil 200 to 400 mg daily vs placebo	DB, MC, PC, RCT Adults 18 to 68 years of age diagnosed with narcolepsy	N=283 9 weeks	Primary: ESS Secondary: MSLT, MWT, CGI-C	Primary: Both modafinil treatment groups reduced mean ESS scores and subjective sleepiness at each time point (weeks three, six, and nine) compared to the placebo group (P<0.001). The two modafinil groups did not differ from each other. Secondary: Mean sleep latency for MSLT significantly increased in both modafinil groups compared to the placebo group (P<0.001). Modafinil groups did not differ from each other. Mean sleep latencies for MWT significantly increased in each of the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				modafinil groups compared to the placebo group (P<0.001). The two modafinil groups did not differ from each other. There were significantly more patients with improved CGI-C scores in each of the modafinil groups compared to the placebo group (P<0.005), but the number of patients did not differ between modafinil groups.
U.S. Modafinil in Narcolepsy Group[15] (2000) Modafinil 200 to 400 mg daily vs placebo	DB, MC, PC, RCT Adults 17 to 67 years of age diagnosed with narcolepsy	N=271 9 weeks	Primary: MWT, CGI-C Secondary: MSLT, ESS	Primary: MWT improved for both modafinil groups vs the placebo group (P<0.001) at each follow-up visit (weeks three, six, nine). The percent of patients with improvement in CGI-C scores at week nine were as follows: modafinil 200 mg, 58%; modafinil 400 mg, 61%; and placebo, 38% (P<0.03). Secondary: MSLT increased by 5.1 minutes with modafinil 400 mg vs 3.5 minutes with placebo (P<0.001). The impact of the 200 mg modafinil dose was not significant. Mean ESS scores were reduced by both treatment groups (P<0.001) vs the placebo group.
Broughton et al.[16] (1997) Modafinil 200 to 400 mg daily vs placebo	MC, PC, RCT, XO Patients 27 to 59 years of age diagnosed with narcolepsy	N=75 6 weeks	Primary: MWT results, patient assessed sleepiness Secondary: ESS	Primary: MWT (sleep latency) increased by 40% with modafinil 200 mg (P<0.002) and by 54% with modafinil 400 mg (P<0.001) compared to placebo. There was not a significant difference between modafinil groups. Both modafinil groups significantly decreased the patient assessed mean number of involuntary sleep and somnolence episodes by 24% in the 200 mg group and 26% in the 400 mg group as compared to the placebo group (P<0.013 and P<0.007). Secondary: ESS was significantly decreased in modafinil 200 mg (P<0.018) and modafinil 400 mg (P<0.0009) groups compared to the placebo group.
Billiard et al.[17] (1994)	DB, MC, PC, RCT, XO	N=50	Primary: Results of sleep	Primary: In the patient sleep logs, the number of episodes of sleepiness and duration

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Modafinil 100 mg in the morning and 200 mg at noon (or vice versa) vs placebo	Patients 27 to 54 years of age diagnosed with narcolepsy	12 weeks	logs, CGI Secondary: MWT	of daytime total sleep time were significantly reduced in the modafinil groups compared to the placebo group (P=0.05, P=0.0002). The CGI scores were not statistically significantly different between the modafinil group and the placebo group (P=0.19). Secondary: MWT scores were significantly improved in the modafinil group compared to the placebo group (P<0.05).
Boivin et al.[18] (1993) Modafinil 200 mg in morning and 100 mg at noon vs placebo	DB, PC, RCT, XO Patients 31 to 61 years of age with a history of EDS, cataplexy, at least two sleep onset REM periods and MSLT less than five minutes	N=10 12 weeks	Primary: Subjectively assessed sleepiness, FCRTT, PLM, nocturnal sleep organization Secondary: Not reported	Primary: Subjective sleepiness was significantly reduced in the modafinil group compared to the placebo group (P<0.05) based on home questionnaires. Modafinil significantly reduced the number of gaps and % of error at the FCRTT (P<0.05), but did not significantly reduce the mean reaction time over placebo (P=0.08). Modafinil did not statistically significantly decrease PLMs over placebo (P=0.06). Modafinil did not display negative effects on any of the nocturnal sleep parameters measured (P value not significant). Secondary: Not reported
Thorpy et al.[19] (2003) Modafinil 200 to 400 mg/day	OL, RCT Adults 17 to 65 years of age diagnosed with narcolepsy who had been receiving MPH for EDS for a month	N=40 5 weeks	Primary: ESS, tolerability Secondary: Not reported	Primary: Mean ESS scores were <12 for all groups at the end of the study: 11.3 in the no-washout group, 8.2 for in the washout group, and 10.1 in the taper-down/titrate-up group. Headache was the most frequently reported adverse event during therapy, experienced by 42% of patients in the no-washout group, 36% of patients in the washout group, and 21% of patients in the taper/titrate group. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Dauvilliers et al.[20] (2013) Pitolisant hydrochloride QD (10, 20, or 40 mg) or modafinil QD (100, 200, 400 mg) vs placebo	AC, DB, MC, PC, PG, RCT Patents 18 years of age with a diagnosis of narcolepsy, mean sleep latency ≤8 minutes with two or more sleep onset rapid eye movement periods, and ESS score ≥14	N=94 8 weeks	Primary: Change in ESS score from baseline to week eight Secondary: Change from baseline to week eight in MWT, SART-NO GO, SART-GO, SART total, CGI-C, EQ-5D, and patient's global opinion of their treatment, and symptoms of cataplexy	Primary: The mean change in ESS scores from baseline to week eight was -3.4 (18.9 to 15.6) for placebo, -5.8 (17.8 to 12.0) for pitolisant and -6.9 (18.5 to 11.6) for modafinil. There was a statistically significant difference for pitolisant when compared to placebo (mean difference, -3.0; 95% CI, -5.6 to -0.4; P=0.024). When compared to modafinil, pitolisant was shown to be non-inferior (mean difference, 0.12; 95% CI, -2.5 to 2.7; P=0.25). Secondary: The mean change in MWT from baseline to week eight was 0.88 (8.4 to 7.6) for placebo, 1.32 (7.4 to 9.7) for pitolisant and 1.72 (8.8 to 15.1) for modafinil. There was a statistically significant difference for pitolisant when compared to placebo (mean difference, 1.47; 95% CI, 1.01 to 2.14; P=0.044). When compared to modafinil, pitolisant was shown to be non-inferior (mean difference, 0.173; 95% CI, 0.52 to 1.13; P=0.173). Mean change in SART-NO GO from baseline to week eight was 1.0 (8.0 to 8.1) for placebo, 0.82 (9.2 to 7.5) for pitolisant and 0.84 (8.5 to 7.1) for modafinil. There was a statistically significant difference for pitolisant when compared to placebo (mean difference, 0.81; 95% CI, 0.67 to 0.99; P=0.038). When compared to modafinil, pitolisant was shown to be non-inferior (mean difference, 0.97; 95% CI, 0.81 to 1.17; P=0.765). Mean change in SART-GO from baseline to week 8 was 0.76 (3.5 to 2.7) for placebo, 0.6 (3.5 to 2.1) for pitolisant and 0.79 (3.2 to 2.5) for modafinil. There was no statistically significant difference between pitolisant and either placebo or modafinil (P=0.176 and P=0.141, respectively). Mean change in SART-total from baseline to week eight was 1.0 (11.5 to 11.4) for placebo, 0.8 (12.5 to 10.0) for pitolisant and 0.89 (11.6 to 10.4) for modafinil. There was no statistically significant difference between pitolisant and either placebo or modafinil (P=0.053 and P=0.370, respectively). The proportion of patients for EDS improvement as assessed by the CGI-C after eight weeks of treatment was 56% (14/25) in the placebo group,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				35% (19/26) in the pitolisant group and 86% (24/28) in the modafinil group (P values not reported). The proportion of patients that were cataplexy improvement as assessed by CGI-C after eight weeks of treatment was 24% (6/25) in the placebo group, 35% (9/26) in the pitolisant group and 29% (8/28) in the modafinil group (P values not reported). EQ-5D score changed from 64 to 70.2 in the placebo group, from 65.3 to 73.8 in the pitolisant group and from 58.7 to 72.6 in the modafinil group (P values not reported). The proportion of patients who considered themselves globally improved was 56% (14/25) in the placebo group, 81% (24/28) in the pitolisant group and 86% (24/28) in the modafinil group (P values not reported).
U.S. Xyrem Multicenter Study Group[21] (2004) <u>Phase One (Two weeks)</u> Continue sodium oxybate at the dose previously prescribed. <u>Phase Two (Two weeks)</u> Continue sodium oxybate treatment at previously prescribed dose vs	DB treatment withdrawal study design (alternative to conventional DB, PC, RCT) Patients ≥16 years of age with narcolepsy or symptoms of narcolepsy who were previously stabilized on sodium oxybate 3 to 9 g/day	N=55 4 weeks	Primary: Cataplexy attacks, treatment-emergent adverse events Secondary: Not reported	Primary: During the two-week DB phase, the abrupt cessation of sodium oxybate therapy in the placebo study patients resulted in a significant increase in the number of cataplexy attacks (median, 21; P<0.001) compared to patients who remained on sodium oxybate (median, 0). Cataplexy attacks returned gradually with placebo study patients reporting a median of 4.2 and 11.7 cataplexy attacks during the first and second weeks, respectively. There were no symptoms of withdrawal reported by the study investigators. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
conversion to placebo				
Xyrem International Study Group[22] (2005) Sodium oxybate 4.5 to 9 g/day administered at bedtime vs placebo	DB, MC, PC, RCT Patients ≥16 years of age with narcolepsy or symptoms of narcolepsy	N=228 8 weeks	Primary: ESS, MWT, CGI-C Secondary: Not reported	Primary: Study patients displayed dose related decreases in median ESS scores and frequency of weekly inadvertent naps, which were significant at the 6 and 9 g doses (P<0.001 for each). Study patients treated with 9 g of sodium oxybate nightly displayed a significant median increase of >10 minutes in the MWT (P<0.001). Improvements in EDS were incremental in those study patients who received concomitant stimulants alone. Significant improvements in the CGI-C were observed for each group treated with sodium oxybate (P≤0.001). The most common adverse events were mild to moderate and included nausea, dizziness, and enuresis, which seemed to be dose related. Other adverse events less common included feeling drunk, contusion, back pain, muscle cramp, somnolence, disturbance in attention, dysarthria, tremor, disorientation, sleepwalking, dyspnea, and snoring. Secondary: Not reported
Xyrem International Study Group[23] (2005) Sodium oxybate 4.5 to 9 g/day administered at bedtime vs placebo	DB, MC, PC, RCT Patients ≥16 years of age with narcolepsy or symptoms of narcolepsy	N=228 8 weeks	Primary: Narcolepsy symptoms, medication use, adverse events Secondary: Not reported	Primary: Compared to placebo, nightly doses of 4.5, 6, and 9 g of sodium oxybate for eight weeks resulted in significant decreases in weekly cataplexy attacks of 57.0 (P=0.003), 65.0 (P=0.002), and 84.7% (P<0.001), respectively. The decrease in cataplexy at the 4.5 g dose was significant compared to placebo at eight weeks of treatment (P=0.003). The reduction in the number of weekly cataplexy attacks was dependent on the length of time study patients received treatment and the amount of medication received. The weekly increase in sodium oxybate dose was associated with fewer adverse events than previously reported in double-blind sodium oxybate

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				studies using fixed doses. The most common adverse events included nausea and dizziness, which demonstrated a clear dose–response relationship. Although greater than 5% of study patients reported emesis, this adverse event was not significantly different than placebo-treated patients. Secondary: Not reported
Black et al.[24] (2010) Sodium oxybate 4.5 to 9 g/day administered at bedtime vs placebo	DB, PC, PG, RCT Patients ≥16 years of age with narcolepsy or symptoms of narcolepsy	N=228 8 weeks	Primary: Sleep architecture, narcolepsy symptoms and adverse events Secondary: Not reported	Primary: Following four (P<0.001) and eight weeks (P<0.001) of sodium oxybate treatment, study patients demonstrated significant dose-related increases in the duration of stage three and four sleep, reaching a median increase of 52.5 minutes in patients receiving 9 g nightly. Compared to placebo-treated patients, delta power was significantly increased in all treatment dose groups. Stage one sleep and the frequency of nocturnal awakenings were each significantly decreased at the 6 and 9 g/night doses. The changes in nocturnal sleep coincided with significant decreases in the severity and frequency of narcolepsy symptoms. The most common adverse events included nausea, headache, dizziness, nasopharyngitis, and enuresis with a statistically significant difference in nausea and dizziness compared to placebo. Adverse events were mild to moderate in severity and appeared to be dose-related as documented by study investigators. Secondary: Not reported
Weaver et al.[25] (2006) Sodium oxybate	DB, MC, RCT Patients 16 to 75 years of age with	N=285 4 weeks	Primary: FOSQ Secondary:	Primary: The nightly administration of sodium oxybate showed statistically significant dose-related improvements in functional status and quality of life as evidenced by the total FOSQ (P<0.001), as well as in the activity

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
4.5 to 9 g/day in two divided doses taken at bedtime and again 2.5 to 4 hours later vs placebo	narcolepsy who were experiencing cataplexy and EDS with recurrent episodes for ≥3 months		Not reported	level (P<0.001), vigilance (P<0.001), general productivity (P=0.002), and social outcomes (P<0.001) subscales. Effect sizes escalated from small effects for the 6 g per day dose of sodium oxybate to large effects for the 9 g/day dose. Secondary: Not reported
Wang et al.[26] (2009) Sodium oxybate	RETRO Patients receiving sodium oxybate	N=~26,000 68 months	Primary: Occurrence of abuse/misuse of sodium oxybate Secondary: Not reported	Primary: During the study period, 3,781 adverse event reports were reported to the manufacturer worldwide. Overall, there were no new significant safety findings from the postmarketing adverse event profile compared to what was reported in clinical trials described in the product prescribing information. Of those 26,000 patients, 0.2% reported ≥1 of the events studied. These included 10 cases (0.039%) meeting DSM-IV abuse criteria, four cases (0.016%) meeting DSM-IV dependence criteria, eight cases (0.031%, including three of the previous four) with withdrawal symptoms reported after discontinuation of sodium oxybate, two confirmed cases (0.008%) of sodium oxybate–facilitated sexual assault, eight cases (0.031%) of overdose with suicidal intent, 21 deaths (0.08%) in patients receiving sodium oxybate treatment with one death known to be related to sodium oxybate, and three cases (0.01%) of traffic accidents involving drivers taking sodium oxybate. During the study period, approximately 600,000 bottles of sodium oxybate were distributed, and five incidents (0.0009%) of diversion were reported. Secondary: Not reported
Mamelak et al.[27] (2015) Sodium oxybate 3	MC, OL Patients ≥16 years of age with a history	N=202 12 weeks	Primary: Adverse events Secondary:	Primary: In total, 56% of patients reported adverse events. Nine patients discontinued due to a variety of adverse events that included psychosis, migraine headache, dizziness, nausea, anxiety, fatigue, insomnia,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to 9 g/night (titrated to clinical effect)	of narcolepsy with cataplexy who were sodium oxybate-naïve or had participated in one of three randomized clinical trials of sodium oxybate and had not been titrated to adequate clinical effect		NSAQ	abdominal pain, shortness of breath, and depression. Five patients had serious adverse events, and two of these were serious adverse events were considered treatment related: headache in a patient taking 7.5 g/night who continued with study participation, and psychosis in a patient taking 9 g/night who discontinued treatment. The most common adverse events were nausea (10%), headache (7%), and dizziness (5%). Secondary: Based on the response criterion of "much improved" or "somewhat improved" relative to baseline for overall symptoms on the NSAQ, 92% of all patients were rated as treatment responders at week six, and 90% were responders at week 12. The response rate among patients across treatment doses was similar at the two time points. At week six, 54% of all patients reported being "much improved," and 60% at week 12.
Plazzie et al.[28] (2018) EXPRESS study Sodium oxybate, continuation of stable dose or titration to optimal dose vs placebo	DB, MC, PC, randomized withdrawal trial Patients 7 to 16 years of age with a primary diagnosis of narcolepsy with cataplexy and were either being treated with sodium oxybate or were sodium oxybate-naive at entry	N=63 Up to one year (3 to 10 week titration period, 2 week stable-dose period, DB randomized withdrawal period and OL sodium oxybate treatment safety period)	Primary: Change in weekly number of cataplexy attacks from the last 2 weeks of the stable-dose period (baseline) to the 2 weeks of the DB treatment period Secondary: Change in CGI-C for cataplexy severity and in ESS for Children and Adolescents from the end of the stable-dose period to the end of double-blind treatment period	Primary: Participants who were withdrawn from sodium oxybate treatment and randomly assigned to placebo during the DB treatment period had a significant increase in the number of weekly cataplexy attacks compared with participants who were randomly assigned to continue treatment with sodium oxybate. The median change from baseline in the weekly number of cataplexy attacks was 12.7 (Q1, Q3=3.4, 19.8) for participants randomly assigned to placebo and 0.3 (-1.0, 2.5) for participants randomly assigned to continue treatment with sodium oxybate (P<0.0001). Secondary: Participants who received placebo were rated as having worse cataplexy severity than were participants continuing sodium oxybate treatment. The mean change in CGI-C score for cataplexy severity for the placebo group was -1.5 (SD=1.2) versus -0.4 (SD=1.1) for the sodium oxybate group (P=0.0006). The median change from baseline in ESS for Children and Adolescents scores was greater in the placebo group (3.0 [Q1, Q3=1.0, 5.0]), indicating increased sleepiness, compared with the sodium oxybate group (0.0 [-1.0, 2.0]; P=0.0004).
Thorpy et al.[29]	DB, MC, PC, PG,	N=236	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2019) TONES 2 Solriamfetol 75 mg QD or solriamfetol 150 mg QD (75 mg QD on day one to three) or solriamfetol 300 mg QD (150 mg QD on day one to three) vs placebo	RCT Patents 18 to 75 years of age with a diagnosis of type 1 or type 2 narcolepsy according to the ICSD-3 or DSM-5, mean sleep latency <25 minutes on the first four trials of a 5-trial MWT, baseline ESS score ≥10, usual nightly total sleep time ≥6 hours, and a BMI between 18 and 45 kg/m^2	12 weeks	Change in MWT mean sleep latency on the first four trials of the MWT from baseline to week 12 and change in ESS score from baseline to week 12 Secondary: Proportion of patients who reported improvement on the PGI-C at week 12; change in sleep latency on each of the five MWT trials; change in mean sleep latency from baseline to week four; change in ESS from baseline to weeks one, four, and eight; percentage of patients who reported improvement on PGI-C at weeks one, four, and eight; and the percentage of patients who reported improvement on	The treatment difference in least squares mean change in MWT from baseline to week 12 when compared to placebo was 2.67 (95% CI, -1.04 to 6.28; P=0.1595) for solriamfetol 75 mg, 7.65 (95% CI, 3.99 to 11.31; P<0.0001) for solriamfetol 150 mg, and 10.14 (95% CI, 6.39 to 13.90; P<0.0001). There were significant differences in the solriamfetol 150 mg and 300 mg groups when compared to placebo. The treatment difference in least square mean change in ESS score from baseline to week 12 when compared to placebo was -2.2 (95% CI, -4.0 to -0.3; P=0.0211) for solriamfetol 75 mg, -3.8 (95% CI, -5.6 to -2.0; P<0.0001) for solriamfetol 150 mg, and -4.7 (95% CI, -6.6 to -2.9; P<0.0001). Secondary: The proportion of patients reporting an improvement on PGI-C at week 12 was 39.7% for placebo, 67.8% for solriamfetol 75 mg, 78.2% for solriamfetol 150 mg and 84.7% for solriamfetol 300 mg. When compared to placebo, there was a statistically significant difference in favor of the solriamfetol 75 mg (P<0.05), solriamfetol 150 mg (P<0.0001) and solriamfetol 300 mg (P<0.0001). Treatment difference in the proportion of patients who. The degrees of improvement were not reported. The proportion of patients who reported improvement on PGI-C at weeks one, four and eight was 53.4%, 53.4% and 44.8% for placebo, respectively; 71.2%, 71.2% and 66.1% for solriamfetol 75 mg, respectively; 84.9%, 89.1%, 83.6% for solriamfetol 150 mg, respectively; and 84.7%, 88.1%, 88.1% and 84.7% for solriamfetol 300 mg, respectively. When compared with placebo there were statistically significant differences between all solriamfetol groups at all time points (P<0.05 or P<0.0001). The degrees of improvement were not reported. The least square mean changes from baseline to week four in MWT mean sleep latency was 2.2 for placebo, 4.7 for solriamfetol 75 mg, 9.2 for solriamfetol 150 mg and 13.1 for solriamfetol 300 mg. When compared to placebo there was a statistically significant difference in favor of solriamfetol 150 mg (treatment difference 7.0; P<0.0001) and solriamfetol 300 mg (treatment difference 10.9; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			the CGI-C at weeks 1, 4, 8 and 12.	The least square mean changes from baseline in ESS at weeks one, four and eight were -2.7, -2.2, and -2.1 for placebo; -3.2, -3.3, and -3.4 for solriamfetol 75 mg; -5.5, -5.6, -5.2 for solriamfetol 150 mg; -6.7, -5.6, -6.4 for solriamfetol 300 mg. When compared to placebo there were no statistically significant differences for solriamfetol 75 mg. When compared to placebo, were statistically significant differences for solriamfetol 150 mg at weeks one, four and eight (P<0.05, P<0.0001, P<0.05) and solriamfetol 300 mg at weeks one, four and eight (P<0.0001 for all time points). The proportion of patients with reported improvement on CGI-C at weeks one, four and eight and 12 was 50.0%, 55.2%, 48.3% and 41.4% for placebo, respectively; 67.8%, 67.8%, 66.1% and 69.5 for solriamfetol 75 mg, respectively; 81.8%, 90.9%, 90.9%, and 83.6% for solriamfetol 150 mg, respectively; and 88.1%, 89.8%, 89.8% and 83.1% for solriamfetol 300 mg, respectively. When solriamfetol 75 mg is compared to placebo, there was a statistically significant difference only at week 12 (P<0.05). When solriamfetol 150 mg and 300 mg were compared to placebo, there were statistically significant differences between groups at all time points (P<0.05 or P<0.0001). The degrees of improvement were not reported. Least square mean changes in sleep latency on each of the 5 MWT trials was statistically significant begging at one hour post-dose and maintained through nine hours post-dose (P<0.05 or P<0.001 for various time points). There was no significant difference between placebo or solriamfetol 75 mg at any time point.
Black et al.[30] (2006) Sodium oxybate 6 to 9 g/day vs modafinil 200 to 600 mg/day	DB, MC, PC, RCT Patients ≥18 years of age with narcolepsy taking 200 to 600 mg of modafinil daily for the treatment of EDS	N=270 8 weeks	Primary: MWT Secondary: ESS, CGI-C	Primary: Following the switch from modafinil to placebo, the mean average daytime sleep latency on the MWT decreased from 9.74 minutes at baseline to 6.87 minutes after eight weeks (P<0.001). In the sodium oxybate group, there was no decrease in sleep latency, suggesting that this medication was as efficacious in treating EDS as previously administered modafinil. In the sodium oxybate plus modafinil group, there was an increase in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs sodium oxybate 6 to 9 g/day and modafinil 200 to 600 mg/day vs placebo				daytime sleep latency from 10.43 to 13.15 minutes (P<0.001), suggesting that this combination of drugs produced an additive effect. Secondary: The sodium oxybate group showed a decrease in median average EES scores, from 15 to 12 (P<0.001). The sodium oxybate plus modafinil group showed a decreased in median average EES scores from 15 to 11 (P<0.001). Treatment with sodium oxybate, alone (P=0.002) and together with modafinil (P=0.023), showed significant overall clinical improvements as compared to the placebo-treated study patients. The placebo and the modafinil-treated study patients demonstrated no significant change in symptoms.
Black et al.[31] (2009) Sodium oxybate 6 g/day vs modafinil 200 to 600 mg/day vs sodium oxybate 6 g/day and modafinil 200 to 600 mg/day vs placebo	DB, PC, RCT Patients ≥18 years of age with narcolepsy taking modafinil 200 to 600 mg/day for the treatment of EDS	N=278 8 weeks	Primary: Sleep architecture, MWT Secondary: Not reported	Primary: Following eight weeks of treatment, there was no significant change in total sleep time for any group. Significant changes in total non-REM sleep among patients receiving sodium oxybate and sodium oxybate plus modafinil included a median increase in Stage three and four sleep (43.5 and 24.25 minutes, respectively; P<0.001 for each) and delta power (P<0.001 for each) and significant decrease in the number of nocturnal awakenings in sodium oxybate (P=0.008) and sodium plus modafinil (P=0.014) treated study patients. No significant changes in PSG parameters were noted in patients treated with placebo or modafinil alone. Patients who had been randomized to placebo demonstrated a significant decrease in MWT sleep latency at eight weeks (P<0.001) once they had been switched to placebo following stable chronic modafinil treatment. A slight worsening of EDS indicated by increased ESS scores, was noted in placebo-treated patients (P=0.011) after stopping baseline modafinil,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and ESS scores continued unchanged in the group that was randomized to continue modafinil treatment. Sodium oxybate-treated patients and sodium oxybate plus modafinil-treated patients experienced significant improvements in ESS scores (P<0.001 for each). There was no change in ESS scores in the group maintained on modafinil alone. Secondary: Not reported
Obstructive Sleep Apnea				
Hirshkowitz et al.[32] (2007) Armodafinil 150 mg/day vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age with a diagnosis of OSA/hypopnea syndrome who complained of residual excessive sleepiness during CPAP therapy	N=263 12 weeks	Primary: MWT, CGI-C Secondary: CDR, ESS, BFI	Primary: Armodafinil significantly improved wakefulness compared to placebo. The mean MWT sleep latency increased from baseline by 2.3 minutes in the armodafinil group and decreased by 1.3 minutes in the placebo group (P=0.0003). Armodafinil significantly improved MWT sleep latency compared to placebo at each visit (P<0.01 for all). The proportion of patients with at least ‘‘minimal improvement’’ on the CGI-C scale was greater for armodafinil than placebo (71 vs 53%; P=0.0069). Secondary: As assessed on the CDR, armodafinil significantly improved the quality of episodic secondary memory compared to placebo. The quality of episodic secondary memory increased by 7.6 points from baseline to the final visit for patients in the armodafinil group and decreased by 7.0 points for those in the placebo group (P=0.0102). The mean change from baseline in ESS total score was significantly greater for patients receiving armodafinil than for those receiving placebo (P<0.01 for all). As assessed on the BFI, armodafinil significantly reduced global fatigue and worst fatigue in the past 24 hours at weeks four and 12 and at the final

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				visit compared to placebo (P<0.05 for all).
Roth et al.[33] (2006) Armodafinil 150 to 250 mg/day vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age with a diagnosis of moderate OSA/ hypopnea syndrome and residual excessive sleepiness despite effective, regular, and stable use of CPAP treatment	N=395 12 weeks	Primary: MWT, CGI-C Secondary: ESS, CDR, BFI	Primary: The mean changes in MWT sleep latency across the first four tests were significantly greater in the armodafinil 150 mg/day, 250 mg/day, and combined groups compared to the placebo group at the final visit (P<0.001 for all). There was no difference between the two modafinil doses. The proportions of patients who had at least minimal improvement on the CGI-C were significantly greater in the armodafinil 150 mg/day, 250 mg/day, and combined groups compared to the placebo group (P<0.001 for all). There was no difference between the two modafinil doses. Secondary: The mean change in ESS total score was significantly greater in the armodafinil combined group compared to the placebo group at the final visit (P<0.001). Mean changes in global fatigue scores were significantly greater in the armodafinil combined group compared to the placebo group at all visits (P<0.05 for all). The mean change in score for worst fatigue during the past 24 hours was statistically greater in the armodafinil combined group compared to placebo at week eight (P<0.05). Mean changes in quality of episodic secondary memory score were significantly greater with armodafinil 150 and 250 mg/day compared to placebo at week four (both, P<0.05) and with armodafinil 250 mg/day vs placebo at week eight (P<0.01). No significant differences in speed of memory or power of attention were found between the armodafinil combined and placebo groups across the first four or last three sessions at any assessment. At weekeight8, mean changes in continuity of attention across the first four sessions were significantly greater in the armodafinil 150 mg/day, 250 mg/day, and combined groups compared to the placebo group (P<0.05

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				for all). The most frequently reported adverse event was headache, occurring in 17.6% of patients in the armodafinil combined group and 8.5% of patients in the placebo group (P<0.05). The severity of adverse events was generally mild or moderate in patients receiving armodafinil (58.4%) or placebo (46.9%).
Krystal et al.[34] (2010) Armodafinil 200 mg/day vs placebo	DB, PC, PG, RCT Patients 18 to 65 years of age diagnosed with obstructive sleep apnea	N=249 18 months	Primary: CGI-C as related to sleepiness, mean change from baseline in MWT to mean sleep latency at final visit Secondary: ESS	Primary: The proportion of patients with least minimal improvement on CGI-C was significantly greater in the armodafinil group compared to the placebo group (69 vs 53%; P=0.012). Mean MWT sleep latency was increased following armodafinil (2.6 minutes) compared to placebo (1.1 minutes), but was not statistically significant (P=0.30). Secondary: Mean ESS scores were significantly reduced in study patients treated with armodafinil compared to patients treated with placebo (-6.3 vs -4.8; P=0.003). The most common adverse effects included headache, dry mouth and insomnia. Most adverse events were considered mild or moderate by the study investigator.
Black et al.[35] (2005) Modafinil 200 to 400 mg/day vs placebo	DB, MC, PC, RCT Adults 18 to 70 years of age with OSA/ hypopnea syndrome and having residual excessive sleepiness during CPAP therapy	N=305 12 weeks	Primary: MWT, ESS Secondary: CGI-C, FOSQ	Primary: Modafinil significantly improved mean sleep latency on the MWT compared to placebo (P<0.001). Modafinil significantly decreased the ESS scores compared to placebo (P<0.001). There were no significant differences in MWT or ESS scores seen between the two modafinil treatment groups (P>0.15 for each). Secondary: At the end of the study, modafinil had significant improvements in CGI-C compared to placebo (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Modafinil improved mean FOSQ scores compared to placebo (P<0.02) for vigilance, general productivity, and activity level.
Weaver et al.[36] (2009) Modafinil 200 to 400 mg/day vs placebo	2 DB, MC, PC, RCT (Pooled analysis) Patients 24 to 76 years of age diagnosed with OSA and residual excessive sleepiness associated with CPAP	N=480 4 to 12 weeks	Primary: FOSQ Secondary: Not reported	Primary: After treatment with modafinil, there were greater improvements from baseline in the total FOSQ score (P<0.0001) as well as activity level (P=0.002), productivity level (P=0.007), intimacy and sexual relationships (P=0.01) and vigilance (P<0.001) compared to treatment with placebo. A greater proportion of patients who received modafinil were considered responders compared to patients who received placebo (45 vs 25%; P<0.001). Analysis based on the individual FOSQ questions demonstrated that 18 of the 30 questions increased at least one point for significantly more patients who received modafinil (P<0.05). Secondary: Not reported
Williams et al.[37] (2010) Modafinil 200 mg/day vs placebo	DB, RCT, XO Men diagnosed with OSA who were modafinil-naïve	N=21 2 days	Primary: Driving simulation, subjective sleepiness Secondary: Not reported	Primary: During CPAP withdrawal, severe sleep-disordered breathing was evident and administration of modafinil improved simulated driving performance (steering variability; P<0.0001, mean reaction time; P<0.0002, lapses on a current task; P<0.01), psychomotor vigilance task (mean one/reaction time and lapses, both P<0.0002), and subjective sleepiness (P<0.01). Secondary: Not reported
Schweizer et al.[38] (2019) TONES 3 Solriamfetol 37.5 mg QD or	DB, MC, PC, PG, RCT Patients 18 to 75 years of age with a diagnosis of EDS associated with OSA according to the ICSD-3, current	N=474 12 weeks	Primary: Change from baseline to week 12 in mean sleep latency derived from the first four trials of a five-trial 40-minute MWT and change from	Primary: The LS mean difference in change from baseline to week 12 for sleep latency derived from MWT when compared to placebo was 4.5 (95% CI, 1.2 to 7.9; P=0.0086) for solriamfetol 37.5 mg, 8.9 (95% CI, 5.6 to 12.1; P<0.0001) for solriamfetol 75 mg, 10.7 (95% CI, 8.1 to 13.4; P<0.0001) for solriamfetol 150 mg, and 12.8 (95% CI, 10.0 to 15.6; P<0.0001) for solriamfetol 300 mg. The LS mean difference in change from baseline to week 12 for ESS when

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
solriamfetol 75 mg QD or solriamfetol 150 mg QD (75 mg QD on days 1 to 3) or solriamfetol 300 mg QD (150 mg QD on days 1 to 3) vs placebo	or previous use of a primary OSA therapy including PAP, mandibular advancement device or surgical intervention to treat underlying obstruction or have been tried to use a primary OSA therapy for at least one month with at least one documented adjustment to therapy, ESS score ≥10, baseline sleep latency <30 minutes for the first four of a five-trial 40-minute MWT, and usual nightly sleep time greater than or equal to six hours		baseline to week 12 in ESS score Secondary: Change from baseline to week 12 in sleep latency for each of the five individual MWT trials, proportion of patients reporting any improvement on the PGI-C at week 12, proportion of patients with any improvement on the CGI-C at week 12	compared to placebo was -1.9 (95% CI, -3.4 to -0.3; P=0.0161) for solriamfetol 37.5 mg, -1.7 (95% CI, -3.2 to -0.2; P=0.0233) for solriamfetol 75 mg, -4.5 (95% CI, -5.7 to -3.2; P<0.0001) for solriamfetol 150 mg, and -4.7 (95% CI, -5.9 to -3.4; P<0.0001) for solriamfetol 300 mg. Secondary: The difference in the proportion of patients reporting any improvement on the PGI-C when compared to placebo was 6.2% (95% CI, -9.7 to 22.2; P=0.4447) for solriamfetol 37.5 mg, 23.3% (95% CI, 8.6 to 38.0; P=0.0035) for solriamfetol 75 mg, 40.5% (95% CI, 29.8 to 51.3; P<0.0001) for solriamfetol 150 mg and 39.6% (95% CI, 28.7 to 50.4; P<0.0001) for solriamfetol 300 mg. There was a statistically significant difference in favor of the solriamfetol 75 mg, 150 mg and 300 mg groups when compared to placebo. Change from baseline in sleep latency on each of the five individual MWT trials at week 12 was significantly greater with solriamfetol 75-, 150-, and 300-mg doses compared with placebo from one to nine hours after dosing (P<0.05 or P<0.0001). The 37.5-mg dose showed a significant difference relative to placebo for trial 2 only (P<0.05), based on the prespecified testing sequence. The proportion of patients with reported improvement on CGI-C at week 12 was 49.1%, 58.9%, 70.7%, 90.5% and 88.7% for the placebo and solriamfetol 37.5 mg, 75 mg, 150 mg and 300 mg groups, respectively. When compared to placebo, there was a statistically significant difference between the solriamfetol 75 mg group (P<0.05) and solriamfetol 150 and 300 mg groups (P<0.0001 for both). There was no significant difference between placebo and solriamfetol 37.5 mg. The following secondary and exploratory endpoints were not noted, but results were not included: 10-item functional outcomes of sleep questionnaire, work productivity and activity impairment questionnaire: specific health problems, 36-item short form health survey version two, five-dimension five-level EuroQoL, and change in primary OSA therapy use.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Strollo et al.[39] (2018) TONES 4 Solriamfetol (75, 150 or 300 mg) QD vs placebo	MC, PC, RCT, Withdrawal Patients 18 to 75 years of age with OSA who had current or prior primary OSA therapy, BMI 18 to <45 kg/m2, baseline ESS score ≥10, mean sleep latency <30 minutes on the first four trials of a five-trial, 40-minute MWT, and usual nightly sleep time ≥6 hours	N=174 6 weeks	Primary: Change from week four to week six in MWT mean sleep latency and ESS score Secondary: Proportion of patients who reported worsening of their condition on the PGI-C from week four to week six, proportion of patients who worsened from week four to week six by CGI-C	Primary: The LS mean changes in MWT mean sleep latency from week four to week six were -1.0 for solriamfetol and -12.1 for placebo, representing a statistically significant difference in favor of placebo (treatment difference, 11.2 minutes; 95% CI, 7.8 to 14.6; P<0.0001). The LS mean changes in ESS score from week four to week six were 4.5 for placebo and -0.1 for solriamfetol resulting a statistically significant difference in favor of placebo (treatment difference, -4.6; 95% CI, −6.4 to −2.8; P<0.0001). Secondary: The proportion of patients who reported worsening of during the withdrawal phase (weeks four to six) on the ePGI-C was 50.0% for patients randomized to placebo and 20.0% for patients who remained on solriamfetol (treatment difference, -30.0%; 95% CI, -46.0 to -14.0; P<0.001). The proportion of patients who worsened from week four to week six by CGI-C was 59.0% of patients randomized to placebo and 21.7% who continued solriamfetol (treatment difference, -37.3%; 95% CI, -53.50 to -21.19; P<0.0001).
Shift Work Sleep Disorder				
Czeisler et al.[40] (2009) Armodafinil 150 mg daily administered 30 to 60 minutes before the start of work shift vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age who exhibited signs and symptoms of SWD of moderate or greater severity, as documented by a CGI-S rating of four or higher for sleepiness on work nights, including the commute to and	N=254 12 weeks	Primary: MSLT, CGI-C Secondary: KSS, CDR	Primary: Armodafinil improved mean nighttime sleep latency (2 to 8 AM) by 3.1 to 5.3 minutes compared to an increase of 0.4 to 2.8 minutes at in patients receiving placebo at the final visit (P<0.001). Of the patients who received armodafinil, 79% were rated as improved in the CGI-C ratings compared to 59% of the patients who received placebo at the final visit (P=0.001). Secondary: Patient-reported levels of sleepiness during the night shift on the KSS were reduced with armodafinil compared to placebo at all visits. Armodafinil improved most items assessed in the electronic diaries,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	from work			including the maximum level of sleepiness during the night shift and commute home, and mean number of mistakes, accidents, or near misses compared to placebo. Armodafinil significantly improved the mean score for the quality of episodic secondary memory factor compared to placebo at each visit (P<0.001 at weeks four and eight; P=0.002 at week 12; P<0.001 at final visit) and during the first four tests on the final night shift (P=0.002 at 12:30 AM; P<0.001 at 2:30 AM; P=0.02 at 4:30 AM; P=0.006 at 6:30 AM). Armodafinil significantly improved speed of memory from baseline compared to placebo at week eight (armodafinil, -240.9 milliseconds; placebo, -6.5 milliseconds; P=0.02) and week 12 (armodafinil, -307.7 milliseconds; placebo, -115.2 milliseconds; P=0.01). However, this was not significant at the final visit (armodafinil, -257.2 milliseconds; placebo. -140.4 milliseconds; P=0.09). Armodafinil significantly improved mean power of attention at each study visit (P=0.005 at week four; P=0.006 at week eight; P=0.005 at week 12; P=0.001 at final visit) and during the first four tests on the final night shift compared to placebo (P=0.002 at 12:30 AM; P=0.006 at 2:30 AM; P=0.004 at 4:30 AM; P=0.03 at 6:30 AM). Continuity of attention improved at the final visit in patients who received armodafinil compared to those who received placebo (P<0.001). Adverse events included headache, nausea, nasopharyngitis and anxiety. Most adverse events were considered mild or moderate by the investigator.
Tembe et al.[41] (2011) Armodafinil 150 mg administered one hour prior to night shift	DB, MC, RCT Patients 18 to 60 years of age suffering from excessive sleepiness associated with SWD	N=211 12 weeks	Primary: Proportion of patients showing ≥2 grades of improvement (responder) based on SSS in both groups	Primary: Responder rates with armodafinil (72.12%) and modafinil (74.29%) were comparable (P=0.76). Secondary: Armodafinil and modafinil significantly improved mean sleepiness grades as compared to baseline (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs modafinil 200 mg administered one hour prior to night shift			Secondary: Improvement in mean SSS grades, compliance, patients' as well as physicians' global assessment for efficacy and safety	At the end of therapy, compliance in both modafinil group (99.31%) and armodafinil group (99.13%) was found to be comparable (P=0.63). Both physicians' and patients' assessment of efficacy was comparable among the treatment groups. Adverse events were similar with modafinil (40.57%) and armodafinil (42.87%; P=0.78). The most commonly treatment-emergent adverse events reported were mild to moderate in severity and included headache, nausea, and dry mouth.
Erman et al. (abstract)[42] (2012) Armodafinil 150 mg administered one hour prior to night shift vs placebo	DB, MC, PC, PG, RCT Patients 18 to 65 years of age suffering from excessive sleepiness associated with SWD	N=383 6 weeks	Primary: SDS-M and FOSQ-10 Secondary: Not reported	Primary: Patients treated with armodafinil experienced significantly greater improvements in SDS-M composite scores at final visit compared to patients treated with placebo (-6.8 vs -4.5, respectively; P=0.0027). Patients in the armodafinil treatment group demonstrated a greater improvement in total FOSQ-10 score from baseline to six weeks compared to placebo (3.6 vs 2.7; P=0.0351); however, there was no difference between treatments at the final visit (3.4 vs 2.7; P=0.0775). Secondary: Not reported
Erman et al.[43] (2011) Armodafinil 150 mg administered one hour prior to night shift vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age suffering from excessive sleepiness associated with SWD	N=383 6 weeks	Primary: CGI-C Secondary: GAF and KSS	Primary: Significantly more patients treated with armodafinil experienced an improvement in CGI-C compared to placebo at three weeks (78 vs 51%; P<0.0001) and at six weeks (80 vs 56%; P<0.0001). Similarly, more patients treated with armodafinil experienced an improvement in late-in-shift CGI-C at the final visit compared to placebo (77 vs 57%; P<0.0001). At the final visit, most patients in the armodafinil group were categorized as 'much improved' (33%) or 'very much improved' (24%) on the late-in-shift CGI-C rating scale. For patients treated with placebo, 38% had 'no change' in their condition compared to only 19% of patients in the armodafinil group. Secondary: The mean (±SD) improvement from baseline in GAF score at the final

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				visit was significantly greater in the armodafinil group compared to the placebo group (9.4 vs 5.0; P<0.0001). Improvements in GAF scores were also significantly greater for armodafinil-treated patients at three weeks (6.9 vs 3.7; P<0.0001) and six weeks (9.8 vs 4.9; P<0.0001) compared to patients treated with placebo. A higher proportion of patients treated with armodafinil had GAF scores greater than 70 ("normal function") at each visit, with almost twice as many patients receiving armodafinil reaching GAF scores greater than 70 at final visit compared to placebo (51 vs 28%; P value not reported). The improvements in KSS scores from baseline to the final visit were significantly greater for armodafinil-treated patients compared to patients receiving placebo (-2.8 vs -1.8; P<0.0001). The KSS scores were also significantly improved in the armodafinil group compared to the placebo group at three weeks (-2.6 vs -1.6; P<0.0001) and six weeks (-2.9 vs -1.8; P<0.0001).
Czeisler et al.[44] (2005) Modafinil 200 mg daily administered 30 to 60 minutes before the start of work shift vs placebo	DB, MC, PC, RCT Adults 18 to 60 years of age diagnosed with SWD and worked each month at least five night shifts for ≤12 hours, with ≥6 hours or worked between 10 PM and 8 AM and at least three shifts occurring consecutively	N=204 3 months	Primary: MSLT, CGI-C, Psychomotor Vigilance Test Secondary: Not reported	Primary: The modafinil group produced a significant increase in overall mean MSLT from 2.1 minutes at baseline to 3.8 minutes at endpoint compared to the placebo change of 2.04 to 2.37 minutes (P=0.002). The modafinil group significantly improved the CGI-C test scores with 74% of the patients rated as at least minimally improved compared to 36% in the placebo group (P<0.001). The modafinil group produced a significant decrease in mean number of lapses of attention during the Psychomotor Vigilance Test from baseline vs the placebo group (P=0.005). Secondary: Not reported
Miscellaneous				
Black et al.[45] (2010) Armodafinil 100 to 250 mg/day	DB, MC, OL Men and women 18 to 65 years of age with a diagnosis of	N=743 ≥12 months	Primary: Tolerability and efficacy (CGI-C, ESS, BFI)	Primary: Discontinuations due to adverse events occurred in 13% of study patients during the initial study period. Most adverse events were mild to moderate in severity and included

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(OSA) or 100 to 250 mg/night 30 minutes to one hour before night shift but no later than 23:00 (SWD)	OSA, SWD, or narcolepsy		Secondary: Not reported	headache (25%), nasopharyngitis (17%), and insomnia (14%). Small increases were observed in BP (3.6/2.3 mm Hg), HR (6.7 beats per minute) across all study patient groups with most of the changes occurring by month three. Greater improvement, compared to baseline, on the CGI-C was reported in the three study groups (75 to 92%) at the final visit with the SWD group reporting the greatest improvement. Study patients reported significant improvement at the final visit by 65% with treated OSA (95% CI, 60.2 to 68.9), 88% with SWD (95% CI, 81.3 to 93.9), and 62% with narcolepsy (95% CI, 54.2 to 69.8). Armodafinil improved wakefulness, measured by the ESS, in the treated OSA and narcolepsy groups, at all follow-up visits compared to baseline. The level of fatigue and its impact on daily activities was consistently reduced from baseline, at all visits, in each of the study groups, measured by BFI scores. Secondary: Not reported
Schwartz et al.[46] (2010) Armodafinil 100 to 250 mg/day (OSA and narcolepsy) or 100 to 250 mg/day 30 minutes to one hour before the start of night shift but no later than 23:00 (SWD)	MC, OL Patients 18 to 65 years of age who had a complaint of excessive sleepiness associated with OSA, SWD, or narcolepsy	N=328 12 months	Primary: CGI, ESS, adverse events Secondary: Not reported	Primary: At the final visit, 80% (95% CI, 74.1 to 86.7) of patients with OSA and 84% (95% CI, 72.7 to 94.8) of patients with narcolepsy were rated with the CGI-I scale as at least minimally improved with regard to overall clinical condition. Armodafinil improved EES scores in study patients treated with OSA (-7.3; 95% CI, -8.39 to -6.30) and narcolepsy (-4.7; 95% CI, -7.41 to -1.93). A total of 98% (95% CI, 95.2 to 100.0) of patients with SWD were rated as improved with regard to sleepiness during night shifts, including the commute to and from work. Across the diagnosis groups, the most commonly occurring adverse event

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				was headache (14 to 24%). The adverse event was mild to moderate in severity as noted by the study investigators. Secondary: Not reported
Jean-Pierre et al.[47] (2010) Modafinil 200 mg/day vs placebo	DB, MC, PC, RCT Patients ≥18 years of age diagnosed with cancer with a survival expectancy >6 months	N=877 4.5 years	Primary: BFI question 3, ESS, POMS-DD Secondary: Not reported	Primary: Patients with severe fatigue at baseline benefited from modafinil (P=0.033) whereas patients with mild (P=0.09) to moderate (P=0.41) fatigue did not benefit from modafinil as compared to placebo. Daytime sleepiness improved significantly in the modafinil group (P=0.002). Modafinil had no statistically significant effect on depression (P>0.05). Secondary: Not reported
Orlikowski et al.[48] (2009) Modafinil 300 mg/day vs placebo	DB, MC, PC, RCT Patients ≥18 years of age diagnosed with myotonic muscular dystrophy type one experiencing hypersomnia	N=28 2.5 years	Primary: MWT Secondary: MSLT, ESS, global assessment (patient and physician), HAMD, SF-36	Primary: At four weeks, the mean MWT score was 16.4 minutes in the modafinil group and 15.8 minutes in the placebo group (P=0.71). Secondary: There were no significant differences between the treatment groups in MSLT latency, ESS or treatment efficacy scores. There were no significant differences between the groups in disturbances of personality and mood or quality-of-life. A total of eight patients reported at least one adverse event, including digestive, neurologic and skin symptoms. The adverse events were considered mild or moderate by the study investigator.

Study abbreviations: DB=double blind, CI=confidence interval, MC=multi-center, OL=open-label, PC=placebo-controlled, PG=parallel-group, RCT=randomized controlled trial, RETRO=retrospective, SD=standard deviation, XO=crossover design

Other abbreviations: BFI=Brief Fatigue Inventory, CDR=Cognitive Drug Research, CGI-C=clinical global impression of change, CGI-S=clinical global impression of severity, CPAP=continuous positive airway pressure, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, EDS=excessive daytime sleepiness, EQ-5D=European quality-of-life questionnaire, ESS=Epworth sleep scale, FCRTT=four-choice reaction time test, FOSQ=Functional outcomes of sleep questionnaire, GAF=Global Assessment of Functioning, $HAMD_{17}$=Hamilton 17-item Depression Rating scale, ICSD-3=International Classification of Sleep Disorders Third Edition, KSS=Karolinska Sleepiness Scale, MPH=methylphenidate, MSLT=multiple sleep latency test, MWT=maintenance of wakefulness test, NSAQ=Narcolepsy Symptom Assessment Questionnaire, OSA=obstructive sleep apnea, PGI-C=Patient Global Impression of Change, PLM=periodic leg movements, POMS-DD=depression-dejection subscale of profile of mood states, PSG=Polysomnogram, REM=rapid eye movement, SART=Sustained attention to response task, SDS-M=modified Sheehan Disability Scale, SF-36=36-item Short Form Health Survey, SSS=Stanford sleepiness score, SWD=shift work disorder

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 10. Relative Cost of the Wakefulness Promoting Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Armodafinil	tablet	Nuvigil®*	$$$$$	$$$
Modafinil	tablet	Provigil®*	$$$$$	$$
Pitolisant	tablet	Wakix®	$$$$$	N/A
Sodium oxybate	oral solution	Xyrem®	$$$$$	N/A
Solriamfetol	tablet	Sunosi®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available

X. Conclusions

The central nervous system agents that are included in this review are approved to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.[5-9, 11-12] Armodafinil, modafinil and solriamfetol are Schedule IV controlled substances. Sodium oxybate is a central nervous system depressant and is classified as a Schedule III controlled substance. Pitolisant is the only agent in this review that is not a controlled substance. Armodafinil, modafinil, pitolisant and solriamfetol are long-acting agents while sodium oxybate is a short-acting agent. Armodafinil and modafinil are available in generic formulations.[5-9]

The American Academy of Sleep Medicine guidelines for the treatment of narcolepsy state that amphetamines, methylphenidate, modafinil, and sodium oxybate are all effective for the treatment of narcolepsy.[1] Modafinil is also recommended as one of several initial treatment options for individuals with excessive sleepiness due to obstructive sleep apnea and shift work sleep disorder.[3,4] Armodafinil is not specifically addressed in the available guidelines. Armodafinil, modafinil, pitolisant, solriamfetol and sodium oxybate have been shown to be more effective than placebo in patients with narcolepsy, obstructive sleep apnea, and shift work sleep disorder[13-24,28-40,42-44]

There is insufficient evidence to support that one brand wakefulness promoting agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand wakefulness promoting agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand wakefulness promoting agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705-11.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
3. American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-76.
4. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleepwake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015. J Clin Sleep Med 2015;11(10):1199 – 1236.
5. Nuvigil® [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; February 2017.
6. Provigil® [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; January 2015.
7. Xyrem® [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; October 2018.
8. Sunosi® [package insert]. Palo Alto (CA): Jazz Pharmaceuticals, Inc.; 2019 Jun.
9. Wakix® [package insert]. Plymouth Meeting (PA): Harmony Biosciences, LLC; 2019 Nov.
10. European Federation of Neurological Sciences. Management of narcolepsy in adults. [guideline on the internet]. Vienna, Austria: European Federation of Neurological Societies; 2011 [cited 2018 Feb 21]. Available from: http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2011_Management_of_narcolepsy_in_adults.pdf.
11. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 July]. Available from: http://online.factsandcomparisons.com.
12. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 July]. Available from: http://www.thomsonhc.com/.
13. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22:761-74.
14. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998 Jan;43(1):88-97.
15. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000 Mar 14;54(5):1166-75.
16. Broughton RJ, Felming JAE, George CFP, et al. Randomized, double blind, placebo controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444-51.
17. Billiard M, Besset A, Montplaisir J, et al. Modafinil: A double-blind multicenter study. Sleep. 1994;17(8):S107-112.
18. Boivin DB, Montplasir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmaco. 1993;16:46-53.
19. Thorpy MJ, Schwartz JR, Kovacevic-Ristanovic R, Hayduk R. Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open label safety study. Psychopharmacology. 2003;167:380-5.
20. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013 Nov;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4. Epub 2013 Oct 7.
21. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119-23.
22. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1:391-7.
23. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6:415-21.
24. Black J, Pardi D, Hornfeldt CS, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596-602.
25. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep. 2006;29:1189-94.

26. Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5:365-71.
27. Mamelak M, Swick T, Emsellem H, Montplaisir J, Lai C, Black J. A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy. Sleep Med. 2015 Jan;16(1):52-8.
28. Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J et al. Treatment of Paediatric Narcolepsy With Sodium Oxybate: A Double-Blind, Placebo-Controlled, Randomised-Withdrawal Multicentre Study and Open-Label Investigation. Lancet Child Adolesc Health. 2018 Jul;2(7):483-494.
29. Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019 Mar;85(3):359-370. doi: 10.1002/ana.25423.
30. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939-46.
31. Black J, Pardi D, Hornfeldt CS, et al. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10:829-35.
32. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007;101:616-27.
33. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28:689-706.
34. Krystal AD, Harsh JR, Yang RR et al. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. J Clin Psychiatry. 2010;71:32-40.
35. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;28(4):464-71.
36. Weaver TE, Chasens ER, Arora S. Modafinil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment. J Clin Sleep Med. 2009;5:499-505.
37. Williams SC, Marshall NS, Kennerson M, et al. Modafinil effects during acute continuous positive airway pressure withdrawal: a randomized crossover double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2010;181:825-31.
38. Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, et al. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431. doi: 10.1164/rccm.201806-1100OC.
39. Strollo PJ Jr, Hedner J, Collop N, Lorch DG Jr, Chen D, Carter LP, et al. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. Chest. 2019 Feb;155(2):364-374. doi: 10.1016/j.chest.2018.11.005. Epub 2018 Nov 22.
40. Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009;84:958-72.
41. Tembe DV, Dhavale A, Desai H et al. Armodafinil vs Modafinil in Patients of Excessive Sleepiness Associated with Shift Work Sleep Disorder: A Randomized Double Blind Multicentric Clinical Trial. Neurol Res Int. 2011;2011:514351. Epub 2011 Jun 1.
42. Erman MK, Yang R, Seiden DJ. The effect of armodafinil on patient-reported functioning and quality of life in patients with excessive sleepiness associated with shift work disorder: a randomized, double-blind, placebo-controlled trial. Prim Care Companion CNS Disord. 2012;14(4).
43. Erman MK, Seiden DJ, Yang R, Dammerman R. Efficacy and tolerability of armodafinil: effect on clinical condition late in the shift and overall functioning of patients with excessive sleepiness associated with shift work disorder. J Occup Environ Med. 2011 Dec;53(12):1460-5.
44. Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, et al. Modafinil for excessive sleepiness associated with Shift-Work Sleep disorder. N Engl J Med. 2005;353:476-86.
45. Black JE, Hull SG, Tiller J, et al. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6:458-66.
46. Schwartz JR, Khan A, McCall WV, et al. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. J Clin Sleep Med. 2010;6:450-7.
47. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy:

a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116:3513-20.

48. Orlikowski D, Chevret S, Quera-Salva MA, et al. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized double-blind, placebo-controlled, 4-week trial. Clin Ther. 2009;31:1795-73.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Anxiolytics, Sedatives, and Hypnotics – Barbiturates
AHFS Class 282404
November 4, 2020

I. Overview

The barbiturates are approved for the treatment of insomnia and for the induction of sedation. Some of the agents are also approved for use as an adjunct to anesthesia, as well as for the treatment of seizure disorders. The barbiturates affect the gamma-aminobutyric acid system and cause reversible depression of all excitable tissues, especially the central nervous system. They depress the sensory cortex, decrease motor activity, and alter cerebellar function. Depression of the central nervous system may range from sedation to general anesthesia.[1-5]

The use of barbiturates is associated with abuse and psychological/physical dependence.[1-5] Individuals who have psychological dependence may increase the dosage or decrease the dosing interval. This behavior may result in a fatal overdose. Tolerance to the sedative-hypnotic effects occurs rapidly, and these agents lose their effectiveness for sleep induction/maintenance after two weeks.[1-6] Complex behaviors such as "sleep driving", as well as other behaviors, have been reported in patients who are not fully awake after taking a sedative-hypnotic.[1,2,5] Despite their extensive use in the past, the use of barbiturates has largely been replaced by benzodiazepines.

The barbiturates that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Phenobarbital is available in a generic formulation. This class was last reviewed in August 2018.

Table 1. Barbiturates Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Amobarbital	injection	Amytal Sodium®	none
Pentobarbital	injection	N/A	none
Phenobarbital	elixir, injection, tablet	N/A	phenobarbital
Secobarbital	capsule	Seconal Sodium®	none

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the barbiturates are summarized in Table 2.

Table 2. Treatment Guidelines Using the Barbiturates

Clinical Guideline	Recommendation(s)
American Academy of Sleep Medicine: **Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults (2008)**[7]	• The primary treatment goals are to improve sleep quality/quantity and to improve insomnia related daytime impairments. • Short-term hypnotic treatment should be supplemented with behavioral and cognitive therapies when possible. • When pharmacotherapy is utilized, the choice of a specific pharmacological agent should be directed by: symptom pattern, treatment goals, past treatment responses, patient preference, availability of other treatments, comorbid conditions, contraindications, concurrent medication interactions, and side effects. • For patients with primary insomnia, when pharmacologic treatment is utilized alone or in combination therapy, the recommended general sequence of medication trials is: o Short-intermediate acting benzodiazepine receptor agonists or ramelteon. o Alternate short-intermediate acting benzodiazepine receptor agonists or ramelteon if the initial agent has been unsuccessful. o Sedating antidepressants, especially when used in conjunction with

Clinical Guideline	Recommendation(s)
	treating comorbid depression/anxiety. Examples of these include trazodone, amitriptyline, doxepin, and mirtazapine. o Combined benzodiazepine receptor agonists or ramelteon and sedating antidepressant. o Other sedating agents. Examples include anti-epilepsy medications (gabapentin, tiagabine) and atypical antipsychotics (quetiapine and olanzapine). These medications may only be suitable for patients with comorbid insomnia who may benefit from the primary action of these drugs as well as from the sedating effect. • Over-the-counter antihistamine or antihistamine/analgesic type drugs (over-the-counter "sleep aids"), as well as herbal and nutritional substances (e.g., valerian and melatonin), are not recommended in the treatment of chronic insomnia due to the relative lack of efficacy and safety data. • Older approved drugs for insomnia including barbiturates, barbiturate-type drugs and chloral hydrate are not recommended for the treatment of insomnia. • Pharmacological treatment should be accompanied by patient education regarding treatment goals, safety concerns, potential side effects and drug interactions, other treatment modalities (cognitive and behavioral treatments), potential for dosage escalation, and rebound insomnia. • Patients should be followed on a regular basis, every few weeks in the initial period of treatment when possible, to assess for effectiveness, possible side effects, and the need for ongoing medication. • Efforts should be made to employ the lowest effective maintenance dosage of medication and to taper medication when conditions allow. Medication tapering and discontinuation are facilitated by cognitive behavioral therapy for insomnia. • Chronic hypnotic medication may be indicated for long-term use in those with severe or refractory insomnia or chronic comorbid illness. Whenever possible, patients should receive an adequate trial of cognitive behavioral treatment during long-term pharmacotherapy. • Long-term prescribing should be accompanied by consistent follow-up, ongoing assessment of effectiveness, monitoring for adverse effects, and evaluation for new onset or exacerbation of existing comorbid disorders. • Long-term administration may be nightly, intermittent (e.g., three nights per week), or as needed.
American Academy of Sleep Medicine: **Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults (2017)[8]**	<u>Recommendations for treating sleep onset insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically. • Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 14 minutes greater, compared to placebo (95% CI, 3 to 24 minute reduction). o Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo. • Ramelteon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 6 to 12 minute reduction). o Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 37 minutes greater, compared to placebo (95% CI, 21 to 53 minute reduction). o Quality of Sleep: Small improvement in quality of sleep, compared to placebo.

Clinical Guideline	Recommendation(s)
	• Triazolam is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 4 to 22 minute reduction). o Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. • Zaleplon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 10 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). o Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was five to 12 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). o Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Recommendations for treating sleep maintenance insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically. • Doxepin is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 26 to 32 minutes longer, compared to placebo (95% CI, 18 to 40 minute improvement). o Wake After Sleep Onset: Mean reduction was 22 to 23 minutes greater, compared to placebo (95% CI, 14 to 30 minute reduction). o Quality of Sleep: Small-to-Moderate improvement in quality of sleep, compared to placebo. • Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 28 to 57 minutes longer, compared to placebo (95% CI, 18 to 76 minute improvement). o Wake After Sleep Onset: Mean reduction was 10 to 14 minutes greater, compared to placebo (95% CI, 2 to 18 minute reduction). o Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo. • Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 99 minutes longer, compared to placebo (95% CI, 63 to 135 minute improvement). o Wake After Sleep Onset: Not reported. o Quality of Sleep: Small improvement in quality of sleep, compared to placebo. • Suvorexant is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 10 minutes longer, compared to placebo (95% CI, 2 to 19 minute improvement). o Wake After Sleep Onset: Mean reduction was 16 to 28 minutes greater, compared to placebo (95% CI, 7 to 43 minute reduction). o Quality of Sleep: Not reported. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 29 minutes longer, compared to placebo (95% CI, 11 to 47 minute improvement).

Clinical Guideline	Recommendation(s)
	○ Wake After Sleep Onset: Mean reduction was 25 minutes greater, compared to placebo (95% CI, 18 to 33 minute reduction). ○ Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Not recommended for treating insomnia</u> • The following drugs are not recommended for the treatment of sleep onset or sleep maintenance insomnia (versus no treatment) in adults: Diphenhydramine, Melatonin, Tiagabine, Trazodone, L-tryptophan, Valerian.
American College of Physicians: **Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline (2016)[9]**	• It is recommended that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. ○ CBT-I consists of a combination of treatments that include cognitive therapy around sleep, behavioral interventions (such as sleep restriction and stimulus control), and education (such as sleep hygiene). • It is recommended that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom CBT-I alone was unsuccessful. ○ Low-quality evidence showed that both eszopiclone and zolpidem improved global outcomes in the general population, and low- to moderate-quality evidence showed that eszopiclone, zolpidem, and doxepin improved sleep outcomes, such as sleep onset latency, total sleep time, and wake after sleep onset. ○ Moderate-quality evidence showed that suvorexant improved treatment response and sleep outcomes in mixed general and adult populations. ○ Low-quality evidence showed no statistically significant difference between ramelteon and placebo for sleep outcomes in the general population. ○ Evidence was insufficient for melatonin in the general population and in older adults. ○ Benzodiazepines, although widely used, were not addressed in this guideline because few studies met the inclusion criteria of the systematic review (insufficient evidence). ○ Evidence on harms was limited from randomized controlled trials that met the inclusion criteria for the review, which mostly reported on study withdrawals. However, observational studies have shown that hypnotic drugs may be associated with infrequent but serious adverse effects, such as dementia, serious injury, and fractures. ○ Evidence is insufficient to evaluate the balance of the benefits and harms of long-term use of pharmacologic treatments in adults with chronic insomnia disorder. The FDA has approved pharmacologic therapy for short-term use (four to five weeks), and patients should not continue using the drugs for extended periods. ○ The FDA also recommends that patients with insomnia that does not remit within seven to 10 days of treatment should be further evaluated. ○ There was insufficient evidence overall on the comparative effectiveness and safety of the various pharmacologic treatments.
International League Against Epilepsy: **Updated International League Against Epilepsy Evidence Review of Antiepileptic Drug Efficacy**	<u>Adults with partial onset seizures</u> • Carbamazepine, levetiracetam, phenytoin, and zonisamide are established treatments as initial monotherapy for adults with newly diagnosed or untreated partial-onset seizures. Valproic acid is probably effective and gabapentin, lamotrigine, oxcarbazepine, phenobarbital, topiramate and vigabatrin are possibly effective for partial onset seizures. Clonazepam and primidone are potentially efficacious/effective. <u>Children with partial-onset seizures</u>

Clinical Guideline	Recommendation(s)
and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes (2013)[10]	• Oxcarbazepine is established as initial monotherapy for children with newly diagnosed or untreated partial-onset seizures. Carbamazepine, phenobarbital, phenytoin, topiramate, valproic acid and vigabatrin may be effective and clobazam, clonazepam, lamotrigine and zonisamide are potentially efficacious/ effective. Elderly adults with partial-onset seizures • Gabapentin and lamotrigine are effective as initial monotherapy for elderly adults with newly diagnosed or untreated partial-onset seizures. Carbamazepine may be effective and topiramate and valproic acid are potentially efficacious/effective. Adults with generalized-onset tonic-clonic seizures • Carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate and valproic acid are possibly effective as initial monotherapy for adults with newly diagnosed or untreated generalized-onset tonic-clonic seizures. Gabapentin, levetiracetam and vigabatrin are potentially efficacious/effective. Carbamazepine and phenytoin may precipitate or aggravate generalized-onset tonic-clonic seizures. Children with generalized-onset tonic-clonic seizures • Carbamazepine, phenobarbital, phenytoin, topiramate and valproic acid are possibly effective for children with newly diagnosed or untreated generalized onset tonic-clonic seizures. Oxcarbazepine is potentially efficacious/effective. Carbamazepine and phenytoin may precipitate or aggravate generalized-onset tonic-clonic seizures. Children with absence seizures • Ethosuximide and valproic acid are established treatments for children with newly diagnosed or untreated absence seizures. Lamotrigine is possibly efficacious/ effective as initial monotherapy. Gabapentin is inefficacious/ineffective for children with absence seizures. • Based on scattered reports, the following antiepileptic drugs may precipitate or aggravate absence seizures: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, tiagabine and vigabatrin. No conclusion can be made about levetiracetam efficacy/effectiveness for absence seizures since the failed class III placebo-controlled trial was uninformative. Children with benign childhood epilepsy with centrotemporal spikes • Carbamazepine and valproic acid are possibly effective as initial monotherapy for children with benign childhood epilepsy with centrotemporal spikes. Gabapentin, levetiracetam, oxcarbazepine, and sulthiame* are potentially efficacious/effective. Juvenile myoclonic epilepsy • Topiramate and valproic acid are potentially efficacious/effective for patients with newly diagnosed juvenile myoclonic epilepsy. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, tiagabine and vigabatrin may precipitate or aggravate absence seizures, myoclonic seizures, and in some cases generalized tonic-clonic seizures. There has been a report that lamotrigine may exacerbate seizures in juvenile myoclonic epilepsy.
National Institute for Clinical Excellence: **Epilepsies: Diagnosis and Management (2012)[11]**	General information about pharmacological treatment • Valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless alternative treatments are not suitable. • Valproate must not be used in pregnant women. • The anti-epileptic drug (AED) treatment strategy should be individualized

Clinical Guideline	Recommendation(s)
Updated February 2020	according to the seizure type, epilepsy syndrome, co-medication and co-morbidity, the child, young person or adult's lifestyle, and the preferences of the person and their family and/or carers as appropriate. • The diagnosis of epilepsy needs to be critically evaluated if events continue despite an optimal dose of a first-line AED. • It is recommended that children, young people and adults should be treated with a single AED (monotherapy) wherever possible. If the initial treatment is unsuccessful, then monotherapy using another drug can be tried. • It is recommended that combination therapy (adjunctive or 'add-on' therapy) should only be considered when attempts at monotherapy with AEDs have not resulted in seizure freedom. • If using carbamazepine, offer controlled-release carbamazepine preparations. Treatment of focal seizures • First-line treatment in children, young people, and adults with newly diagnosed focal seizures: carbamazepine or lamotrigine. • If carbamazepine or lamotrigine are unsuitable or not tolerated for newly diagnosed focal seizures: o Offer levetiracetam or oxcarbazepine to women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years). If the first of these AEDs tried is ineffective, offer the other one. o Do not offer sodium valproate to women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years) with focal seizures, unless other options are ineffective or not tolerated and the pregnancy prevention programme is in place. o Offer levetiracetam, oxcarbazepine or sodium valproate to boys, men and women who are not of childbearing potential. If the first AED tried is ineffective, offer an alternative from these AEDs. • Consider adjunctive treatment if a second well-tolerated antiepileptic is ineffective. • For refractory focal seizures, offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, or topiramate as adjunctive treatment to boys, men, women and girls of childbearing potential with focal seizures if first-line treatments are ineffective or not tolerated. Sodium valproate is also an option for adjunctive treatment to boys, men and women who are not of childbearing potential. • For refractory focal seizures, if adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist. Other antiepileptics that may be considered by a specialist are eslicarbazepine acetate*, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. • Carefully consider the risk–benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. Treatment of generalized tonic-clonic seizures • First-line treatment in children, young people, and adults (except women and girls of childbearing potential) with newly diagnosed focal seizures: sodium valproate. • Offer lamotrigine if sodium valproate is unsuitable. • Consider carbamazepine and oxcarbazepine. • Offer clobazam, lamotrigine, levetiracetam, or topiramate as adjunctive treatment to women and girls if first-line treatments are ineffective or not tolerated. Sodium valproate is an additional option as adjunctive treatment to boys, men and women who are not of childbearing potential. • If there are absence or myoclonic seizures, or if juvenile myoclonic epilepsy is

Clinical Guideline	Recommendation(s)
	suspected, do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin. Treatment of absence seizures • First-line treatment in children, young people, and adults with absence seizures: ethosuximide or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). If there is a high risk of generalized tonic-clonic seizures, offer sodium valproate first, unless it is unsuitable. • Offer lamotrigine if ethosuximide and sodium valproate are unsuitable, ineffective, or not tolerated. • If two first-line antiepileptics are ineffective, consider a combination of two of these three antiepileptics as adjunctive treatment: ethosuximide, lamotrigine, or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam, levetiracetam, topiramate or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of myoclonic seizures • First-line treatment in children, young people, and adults with myoclonic seizures: valproate, unless unsuitable (do not offer sodium valproate to women and girls of childbearing potential). • Consider levetiracetam or topiramate if sodium valproate is unsuitable or not tolerated. • Offer levetiracetam, sodium valproate, or topiramate as adjunctive treatment to patients if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist or consider clobazam, clonazepam, piracetam*, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of atonic or tonic seizures • First-line treatment in children, young people, and adults with tonic or atonic seizure: sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). • Offer lamotrigine as adjunctive treatment if sodium valproate is unsuitable, ineffective, or not tolerated. • Discuss with a tertiary epilepsy specialist if adjunctive treatment is ineffective or not tolerated. Other antiepileptics that may be considered by the tertiary epilepsy specialist are rufinamide and topiramate. • Do not offer carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin. Treatment of infantile spasms • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when an infant presents with infantile spasms. • Offer a steroid or vigabatrin as first-line treatment to infants with infantile spasms that are not due to tuberous sclerosis. • Offer vigabatrin as first-line treatment to infant with infantile spasms due to tuberous sclerosis. If vigabatrin is ineffective, offer a steroid.

Clinical Guideline	Recommendation(s)
	Treatment of Dravet syndrome • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when a child presents with suspected Dravet syndrome. • Consider topiramate for women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years). • Consider sodium valproate or topiramate for boys, men and women who are not of childbearing potential. • Discuss with a tertiary epilepsy specialist if first-line treatments are ineffective or not tolerated, and consider clobazam or stiripentol as adjunctive treatment. • Do not offer carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of Lennox-Gastaut Syndrome • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when a child presents with suspected Lennox-Gastaut syndrome. • Offer sodium valproate as first-line treatment to children with Lennox-Gastaut syndrome (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine as adjunctive treatment if first-line treatments are unsuitable, ineffective, or not tolerated. • Discuss with a tertiary epilepsy specialist if adjunctive treatment is ineffective or not tolerated. Other antiepileptics that may be considered by the tertiary epilepsy specialist are rufinamide and topiramate. • Do not offer carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin. • Only offer felbamate in centers providing tertiary epilepsy specialist care and when treatment with all of the antiepileptics listed above have proved ineffective or not tolerated. Treatment of benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) • Discuss with the child or young person, and their family and/or caretakers, whether antiepileptic drug treatment is indicated. • Offer carbamazepine or lamotrigine as first-line treatment to children and young people. • Offer levetiracetam, oxcarbazepine, or sodium valproate if first-line treatments are unsuitable or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). If the first antiepileptic drug tried is ineffective, offer an alternative from the five antiepileptics noted above. • Consider adjunctive treatment if a second well-tolerated antiepileptic drug is ineffective. • Offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist. Other antiepileptic drugs that may be considered are eslicarbazepine acetate*, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Treatment of idiopathic generalized epilepsy • First-line treatment in children, young people, and adults with idiopathic

Clinical Guideline	Recommendation(s)
	generalized epilepsy: sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine if sodium valproate is unsuitable or not tolerated. • Consider topiramate. • Offer lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. <u>Treatment of juvenile myoclonic epilepsy</u> • First-line treatment in children, young people, and adults with juvenile myoclonic epilepsy: sodium valproate(do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Consider lamotrigine, levetiracetam, or topiramate if sodium valproate is unsuitable or not tolerated. • Offer lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. <u>Treatment of epilepsy with generalized tonic-clonic seizures only</u> • First-line treatment in children, young people, and adults with epilepsy with generalized tonic-clonic seizures only: lamotrigine, sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Consider carbamazepine or oxcarbazepine. • Offer clobazam, lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). <u>Treatment of childhood absence epilepsy, juvenile absence epilepsy, or other absence epilepsy syndromes</u> • First-line treatment in children, young people, and adults: ethosuximide, sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine if first-line treatments are unsuitable, ineffective, or not tolerated. • If two first-line antiepileptic drugs are ineffective, consider a combination of two of these three antiepileptic drugs adjunctive treatment: ethosuximide, lamotrigine, or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a

Clinical Guideline	Recommendation(s)
	tertiary epilepsy specialist and consider clobazam, clonazepam, levetiracetam, topiramate, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin.
American Academy of Neurology: **Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society (2012)**[12] Reaffirmed 2018	• To date, there is insufficient evidence to support the use of agents other than adrenocorticotropic hormone, and vigabatrin. • Low-dose adrenocorticotropic hormone should be considered as an alternative to high-dose adrenocorticotropic hormone for treatment of infantile spasms. • Adrenocorticotropic hormone or vigabatrin may be offered for short-term treatment of infantile spasms. Evidence suggests that adrenocorticotropic hormone may be offered over vigabatrin. • There is insufficient evidence to recommend the use of dexamethasone, prednisolone and methylprednisolone as being as effective as adrenocorticotropic hormone for short-term treatment of infantile spasms. • The data is insufficient to recommend other therapies (valproic acid, vitamin B6, nitrazepam, levetiracetam, zonisamide, topiramate, the ketogenic diet, or novel/combination therapies) for the treatment of infantile spasms. • Hormonal therapy (adrenocorticotropic hormone or prednisolone) may be considered for use in preference to vigabatrin in infants with cryptogenic infantile spasms, to possibly improve developmental outcome. • A shorter lag time to treatment of infantile spasms with either hormonal therapy or vigabatrin may be considered to improve long-term cognitive outcomes.
Infantile Spasms Working Group: **Infantile Spasms: A U.S. Consensus Report (2010)**[13]	• To improve outcomes in infantile spasms, the goals include early recognition and diagnosis, short-term treatment with a first-line therapy, timely electroencephalography evaluation to assess treatment effectiveness and prompt treatment modification if indicated. • Effective treatment should produce both cessation of spasms and resolution of hypsarrhythmia on electroencephalography. • The dose of the chosen first-line agent should be adjusted to achieve the maximum effective dose in as short amount of time as clinically indicated. • There is insufficient evidence to recommend the best approach in events of relapse. Possible treatment options include using the previously effective agent and dose, using the previously effective agent at the maximum dose or using a new agent. • Adrenocorticotropic hormone is considered first-line therapy for infantile spasms. There is insufficient evidence to recommend the optimal dose and duration of treatment, although short duration is preferable to avoid adverse events. Treatment with the maximum dose of adrenocorticotropic hormone should be continued for two weeks followed by taper and evaluation of treatment response. • Vigabatrin is considered first-line therapy for infantile spasms, especially in patients with comorbid tuberous sclerosis complex. Vigabatrin should be initiated at 50 mg/kg/day and increased up to 100 to 150 mg/kg/day if indicated. Efficacy should be assessed within two weeks following dose titration. Responders to treatment may continue therapy for six to nine months, with continued ophthalmic evaluation. • No recommendations can be given with regard to oral corticosteroids in the treatment of infantile spasms. • Ketogenic diet may be considered as second-line therapy when first-line therapies fail or are inappropriate. • Patients with refractory spasms, concomitant partial seizures or focal abnormalities on the electroencephalography may be evaluated for surgery.
European Federation of Neurological Societies:	<u>Initial pharmacological treatment for generalized convulsive status epilepticus and non-convulsive status epilepticus</u> • The preferred treatment is intravenous administration of lorazepam 0.1 mg/kg;

Clinical Guideline	Recommendation(s)
Guideline on the Management of Status Epilepticus (2010)[14]	however, depending on the patients' general medical condition, treatment can be started at a lower dose of 4 mg, to be repeated if seizures continue for >10 minutes after first injection. • If lorazepam is not available, diazepam 10 mg (route of administration not specified) directly followed by phenytoin (15 to 18 mg/kg) or equivalent fosphenytoin. • General management of refractory status epilepticus includes treatment in an intensive care unit. Pharmacological treatment for refractory generalized convulsive status epilepticus and subtle status epilepticus • Immediate infusions of anesthetic doses of midazolam, propofol or barbiturates are recommended due to the progressive risk of brain and systemic damage. • If midazolam is given, seizure suppression is recommended. This goal should be maintained for at least 24 hours. Simultaneous initiation of the chronic medication the patient with be treated with in the future should be initiated. • For elderly patients in whom intubation and artificial ventilation would not be justified, further non-anesthetizing anticonvulsants may be tried. Pharmacological treatment for refractory non-convulsive status epilepticus • Due to poor evidence and lack of any head-to-head trials, no recommendations can be made regarding which of the non-anaesthetizing anticonvulsants should be the drug of choice. • Recommendations include phenobarbital, valproic acid and levetiracetam. • If treatment regimen includes the administration of anesthetics, use the same protocol as refractory generalized convulsive status epilepticus.
American Epilepsy Society/ American Academy of Neurology: **Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults (2016)[15]**	Initial therapy phase (five to 20 minutes) • A benzodiazepine (specifically intramuscular (IM) midazolam, intravenous (IV) lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and tolerability. • Although IV phenobarbital is established as efficacious and well tolerated as initial therapy, its slower rate of administration, compared with the three recommended benzodiazepines above, positions it as an alternative initial therapy rather than a drug of first choice. • For pre-hospital settings or where the three first-line benzodiazepine options are not available, rectal diazepam, intranasal midazolam, and buccal midazolam are reasonable initial therapy alternatives. Second therapy phase (begins when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response or lack of response to the second therapy should be apparent) • Reasonable options include fosphenytoin, valproic acid, and levetiracetam. There is no clear evidence that any one of these options is better than the others. Third therapy phase (begins when seizure duration reaches 40 minutes) • There is no clear evidence to guide therapy in this phase. • If second therapy fails to stop the seizures, treatment considerations should include repeating second-line therapy or anesthetic doses of either thiopental, midazolam, pentobarbital, or propofol (all with continuous EEG monitoring). •
American Academy of Neurology/ American Epilepsy Society: **Efficacy and Tolerability of the New Antiepileptic**	• Lamotrigine use should be considered to decrease seizure frequency. • Lamotrigine use should be considered, and gabapentin use may be considered to decrease seizure frequency in patients aged ≥60 years. • Levetiracetam use may be considered to decrease seizure frequency. • Zonisamide use may be considered to decrease seizure frequency. • Vigabatrin use appears to be less efficacious than immediate-release carbamazepine use and may not be offered; furthermore, toxicity profile precludes

<table>
<tr><th>Clinical Guideline</th><th>Recommendation(s)</th></tr>
<tr><td>Drugs I: Treatment of New Onset Epilepsy (2018)[16]</td><td>vigabatrin use as first-line therapy.
• Pregabalin use at 150 mg/day is possibly less efficacious than lamotrigine use at 100 mg/day.
• Evidence is insufficient to consider gabapentin, oxcarbazepine, or topiramate instead of carbamazepine.
• Evidence is insufficient to consider topiramate instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic seizures, or generalized epilepsy presenting with generalized tonic-clonic seizures.
• Data are lacking to support or refute use of third-generation antiepileptic drugs, clobazam, felbamate, or vigabatrin in treating new-onset epilepsy.
• Data are lacking to support or refute use of newer antiepileptic drugs in treating unclassified generalized tonic-clonic seizures.</td></tr>
<tr><td>American Academy of Neurology/ American Epilepsy Society: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment of Refractory Epilepsy (2018)[17]</td><td>Summary of guidelines on the use of antiepileptic drugs (AEDs) in treatment-resistant epilepsy, based on Level A and B recommendations
<table>
<tr><th>AED</th><th>Adjunctive focal adult</th><th>Focal mono-therapy</th><th>Idiopathic generalized epilepsy</th><th>Lennox-Gastaut syndrome</th><th>Adjunctive focal pediatric</th></tr>
<tr><td>Gabapentin</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr>
<tr><td>Lamotrigine</td><td>Yes</td><td>Yes</td><td>Yes (only in childhood absence epilepsy</td><td>Yes</td><td>Yes</td></tr>
<tr><td>Levetiracetam</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
<tr><td>Oxcarbazepine</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr>
<tr><td>Tiagabine</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
<tr><td>Topiramate</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr>
<tr><td>Zonisamide</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
</table>
• For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin and perampanel are established as effective to reduce seizure frequency. Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Vigabatrin and rufinamide should be considered established as effective for decreasing seizure frequency in TRAFE but are not first-line agents (retinopathy risk with vigabatrin and modest benefit with rufinamide). Ezogabine use should be considered to decrease seizure frequency in this population but carries a serious risk of skin and retinal discoloration. Clobazam and extended-release oxcarbazepine use may be considered to decrease seizure frequency in TRAFE.
• Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE. Data are insufficient to recommend the use of second- and the other third-generation AEDs as monotherapy in TRAFE.
• For add-on therapy for generalized epilepsy, immediate-release and extended-release lamotrigine use should be considered as add-on therapy to decrease seizure frequency in treating adults with treatment-resistant generalized tonic-clonic seizures secondary to generalized epilepsy. Levetiracetam use should be considered to decrease seizure frequency as add-on therapy for treatment-resistant generalized tonic-clonic seizures and for treatment-resistant juvenile myoclonic epilepsy.
• For Lennox-Gastaut syndrome, rufinamide use should be considered established as effective to decrease seizure frequency as add-on therapy, and clobazam use should be considered.
• For add-on therapy for treatment-resistant focal epilepsy, levetiracetam use should be considered to decrease seizure frequency (for ages one month to 16 years), zonisamide use should be considered to decrease seizure frequency (for ages six to 17 years), and oxcarbazepine use should be considered to decrease seizure</td></tr>
</table>

Clinical Guideline	Recommendation(s)
	frequency (for ages one month to four years). Data are unavailable on the efficacy of clobazam, eslicarbazepine, lacosamide, perampanel, pregabalin, rufinamide, tiagabine, or vigabatrin as add-on therapy for the treatment of these children or adolescents.

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the barbiturates are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Barbiturates[1-5]

Indication	Amobarbital	Pentobarbital	Phenobarbital	Seco-barbital
Anesthesia				
Preanesthetic	✔	✔	✔ *	✔
Anticonvulsant				
Anticonvulsant in the emergency control of certain acute convulsive episodes		✔	✔ *	
Long-term anticonvulsant for the treatment of generalized tonic-clonic and cortical focal seizures			✔ *	
Treatment of generalized and partial seizures			✔ *†	
Sedative-Hypnotic				
Short-term treatment of insomnia	✔	✔	✔ *	✔
Sedation	✔	✔	✔ *†	

*Parenteral formulation.
†Oral formulation.

IV. Pharmacokinetics

The pharmacokinetic parameters of the barbiturates are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Barbiturates[2]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life
Amobarbital	Not reported	Not reported	Liver	Renal Feces (4 to 5)	8 to 42 hours
Pentobarbital	Not reported	Not reported	Liver	Renal Feces (less common)	15 to 50 hours
Phenobarbital	>95	20 to 60	Liver	Renal (21)	1.5 to 4.9 days
Secobarbital	90	52 to 57	Liver	Renal	19 to 34 hours

V. Drug Interactions

Major drug interactions with the barbiturates are listed in Table 5.

Table 5. Major Drug Interactions with the Barbiturates[2]

Generic Name(s)	Interaction	Mechanism
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Anticoagulants	Barbiturates reduce the effects of anticoagulants through increased metabolic clearance of anticoagulants, probably caused by induction of hepatic microsomal enzymes.
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Benzodiazepines	Concurrent use of barbiturates and benzodiazepines may result in additive respiratory depression.
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Butalbital	Concurrent use of barbiturates and butalbital may result in additive respiratory depression.
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Centrally acting muscle relaxants	Concurrent use of barbiturates and centrally acting muscle relaxants may result in additive respiratory depression.
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Chloral hydrate	Concurrent use of barbiturates and chloral hydrate may result in additive respiratory depression.
Barbiturates (amobarbital, pentobarbital, phenobarbital, secobarbital)	Sodium oxybate	Concurrent use of sodium oxybate and barbiturates may result in an increase in sleep duration and central nervous system depression.
Barbiturates (phenobarbital)	Hepatitis C virus protease inhibitors	Plasma concentrations and pharmacologic effects of hepatitis C virus protease inhibitors may be decreased by phenobarbital. Induction of CYP3A4 by phenobarbital may increase the metabolic elimination of hepatitis C virus protease inhibitors.
Barbiturates (phenobarbital)	Lurasidone	Plasma concentrations and pharmacologic effects of lurasidone may be decreased by phenobarbital. Induction of CYP3A4 by phenobarbital may increase the metabolic elimination of lurasidone.
Barbiturates (phenobarbital)	Praziquantel	Praziquantel plasma concentrations may be decreased by phenobarbital. The antiparasitic effect of praziquantel may be decreased. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of praziquantel.
Barbiturates (phenobarbital)	Ranolazine	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by phenobarbital. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of ranolazine.
Barbiturates (phenobarbital)	Rilpivirine	Plasma concentrations and pharmacologic effects of rilpivirine may be reduced by phenobarbital possibly resulting in loss of virologic response or resistance. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of rilpivirine.
Barbiturates (phenobarbital)	Voriconazole	Plasma concentrations and pharmacologic effects of Voriconazole may be decreased by phenobarbital. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of voriconazole.
Barbiturates (amobarbital, phenobarbital, secobarbital)	Clozapine	Clozapine plasma concentrations may be reduced, possibly through induction of hepatic metabolism of clozapine, decreasing the pharmacologic effects.
Barbiturates (amobarbital, phenobarbital, secobarbital)	Methoxyflurane	Barbiturates appear to stimulate degradation of methoxyflurane, perhaps to nephrotoxic metabolites. Enhanced renal toxicity may occur.

Generic Name(s)	Interaction	Mechanism
Barbiturates (amobarbital, phenobarbital, secobarbital)	Tacrolimus	Plasma concentrations and pharmacologic effects of tacrolimus may be decreased, due to increased hepatic metabolism of tacrolimus via CYP3A4.
Barbiturates (amobarbital, phenobarbital, secobarbital)	Ulipristal	Plasma concentrations and pharmacologic effects of ulipristal may be decreased by barbiturates. Coadministration of butabarbital with ulipristal may reduce the efficacy of ulipristal.
Barbiturates (pentobarbital)	Tolvaptan	Plasma concentrations of tolvaptan may be decreased by pentobarbital.
Barbiturates (phenobarbital)	Epothilones	The pharmacologic effects of epothilones may be decreased by strong CYP3A4 inducers, such as phenobarbital. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of epothilones.
Barbiturates (phenobarbital)	Human immunodeficiency virus protease inhibitors	Plasma concentrations and pharmacologic effects of human immunodeficiency virus protease inhibitors may be decreased by phenobarbital. Induction of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of human immunodeficiency virus protease inhibitors.
Barbiturates (phenobarbital)	Mammalian target of rapamycin inhibitors	Induction of CYP34A isoenzymes by phenobarbital may increase the metabolic elimination and decrease pharmacological of mammalian target of rapamycin inhibitors.
Barbiturates (phenobarbital)	Non-nucleoside reverse transcriptase inhibitors	Induction of CYP34A isoenzymes by phenobarbital may increase the metabolic elimination and decrease pharmacological of non-nucleoside reverse transcriptase inhibitors.
Barbiturates (phenobarbital)	Tyrosine kinase receptor inhibitors	Induction of CYP34A isoenzymes by phenobarbital may increase the metabolic elimination of tyrosine kinase receptor inhibitors. Concomitant use is not recommended.
Barbiturates (amobarbital, phenobarbital, secobarbital)	Vasopressin receptor antagonists	Plasma concentrations and pharmacologic effects of vasopressin receptor antagonists may be decreased by barbiturates. Induction of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of vasopressin receptor antagonists.
Barbiturates (phenobarbital)	Deferasirox	Plasma concentrations and pharmacologic effects of deferasirox may be decreased by phenobarbital. Induction of UDP-glucuronosyltransferase by phenobarbital may increase the metabolic elimination of deferasirox.
Barbiturates (phenobarbital)	Dronedarone	Plasma concentrations and pharmacologic effects of dronedarone may be decreased by phenobarbital. Induction of cytochrome P450 3A4 isoenzymes by phenobarbital may increase the metabolic elimination of dronedarone.
Barbiturates (phenobarbital)	Maraviroc	Induction of CYP3A4 isoenzymes by long-acting barbiturates may increase the metabolic elimination of maraviroc and decrease its pharmacologic effects.
Barbiturates (phenobarbital)	Mifepristone	Plasma concentrations and pharmacologic effects of mifepristone may be decreased by phenobarbital. Induction of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of mifepristone.
Barbiturates (phenobarbital)	Roflumilast	Plasma concentrations and pharmacologic effects of roflumilast may be decreased by phenobarbital. Induction

Generic Name(s)	Interaction	Mechanism
		of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of roflumilast.
Barbiturates (phenobarbital)	Ticagrelor	Plasma concentrations and pharmacologic effects of ticagrelor may be decreased by phenobarbital. Induction of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of ticagrelor.
Barbiturates (phenobarbital)	Vandetanib	Plasma concentrations and pharmacologic effects of vandetanib may be decreased by phenobarbital. Induction of CYP3A4 isoenzymes by barbiturates may increase the metabolic elimination of vandetanib.

VI. Adverse Drug Events

The most common adverse drug events reported with the barbiturates are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Barbiturates[1-5]

Adverse Events	Amobarbital	Pentobarbital	Phenobarbital	Secobarbital
Cardiovascular				
Bradycardia	✔	-	✔	-
Hypotension	✔	-	✔	✔
Syncope	✔	-	✔	-
Central Nervous System				
Abnormal thinking	✔	-	-	-
Agitation	✔	-	✔	-
Anxiety	✔	-	✔	-
Ataxia	✔	-	✔	-
Confusion	✔	-	✔	✔
Central nervous system depression	✔	-	✔	✔
Central nervous system excitation	-	-	✔	-
Complex sleep-related activities	-	-	-	✔
Depression	-	-	-	✔
Dizziness	✔	-	✔	✔
Drowsiness	-	-	✔	✔
Excitement	-	-	-	✔
Faint feeling	-	-	-	✔
Fever	✔	-	-	✔
Hallucinations	✔	-	✔	✔
Hangover effect	-	-	✔	✔
Headache	✔	-	✔	✔
Hyperkinesia	✔	-	✔	-
Impaired judgment	-	-	✔	-
Insomnia	✔	-	✔	✔
Lethargy	-	-	✔	-
Lightheadedness	-	-	-	✔
Nervousness	✔	-	✔	✔
Nightmares	✔	-	✔	✔
Psychiatric disturbances	✔	-	-	-
Somnolence	✔	✔	✔	-
Dermatological				
Exfoliative dermatitis	-	-	✔	✔
Injection site reaction	✔	-	-	-
Rash	-	-	✔	✔
Stevens-Johnson syndrome	-	-	✔	✔

Adverse Events	Amobarbital	Pentobarbital	Phenobarbital	Secobarbital
Urticaria	-	-	-	✔
Gastrointestinal				
Constipation	✔	-	✔	✔
Nausea	✔	-	✔	✔
Vomiting	✔	-	✔	✔
Hematologic				
Agranulocytosis	-	-	✔	✔
Megaloblastic anemia	✔	-	✔	✔
Thrombocytopenia	-	-	✔	✔
Thrombophlebitis	-	-	✔	✔
Respiratory				
Apnea	✔	-	✔	✔
Atelectasis	✔	-	-	-
Hypoventilation	✔	-	✔	-
Laryngospasm	-	-	✔	✔
Respiratory depression	-	-	✔	✔
Other				
Anaphylaxis	-	-	-	✔
Angioedema	✔	-	-	✔
Dependence	-	-	-	-
Gangrene	-	-	✔	-
Hypersensitivity reaction	✔	-	-	-
Liver damage	✔	-	-	-
Oliguria	-	-	✔	-
Pain at injection site	-	-	✔	✔

✔ Percent not specified.
- Event not reported or incidence <1%.

VII. Dosing and Administration

The usual dosing regimens for the barbiturates are listed in Table 7.

Table 7. Usual Dosing Regimens for the Barbiturates[1-5]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Amobarbital	Preanesthetic: Injection: 65 to 500 mg administered intramuscularly or intravenously two to three times daily Hypnotic (short-term treatment of insomnia): Injection: 65 to 200 mg administered intramuscularly or intravenously at bedtime Sedative (sedation): Injection: 30 to 50 mg administered intramuscularly or intravenously two to three times daily	Preanesthetic: Injection: 65 to 500 mg administered intravenously Hypnotic (short-term treatment of insomnia): Injection: six to 12 years of age, 65 to 500 mg administered intravenously Sedative (sedation): Injection: six years of age and older, 30 to 50 mg administered intramuscularly or intravenously two to three times daily	Injection: 500 mg
Pentobarbital	Anesthesia, short-term treatment of insomnia, sedation, and seizure in the emergency control of certain acute	Anesthesia, short-term treatment of insomnia, sedation, and seizure in the	Injection: 50 mg/mL

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	convulsive episodes: Injection: 150 to 200 mg administered intramuscularly as a single injection; There is no average intravenous dosage; a commonly used dosage for a 70 kg adult is 100 mg intravenously initially, maximum rate of 50 mg/min; after 1 minute may give additional small doses at 1 minute intervals if necessary up to total of 200 to 500 mg.	emergency control of certain acute convulsive episodes: Injection: 2 to 6 mg/kg administered intramuscularly; maximum 100 mg per dose.	
Phenobarbital	Acute convulsions: Injection: 20 to 320 mg intramuscularly or intravenously, repeated in six hours as necessary, maximum 600 mg/24 hours Anticonvulsant: Elixir: 60 to 200 mg/day Tablet: 50 to 100 mg two or three times daily Hypnotic (short-term treatment of insomnia): Elixir: 100 to 200 mg/day at bedtime, up to maximum 400 mg in 24 hours Injection, tablet: 100 to 320 mg at bedtime, up to maximum 600 mg in 24 hours for injection and 400 mg in 24 hours for tablet Preanesthetic: Injection: 100 to 200 mg intramuscularly 60 to 90 minutes before surgery Sedative (sedation): Elixir, tablet: 30 to120 mg/day in two to three divided doses, up to maximum 400 mg in 24 hours Injection: 30 to 120 mg/day in two to three divided doses intramuscularly or intravenously	Anticonvulsant: Elixir: 3 to 6 mg/kg/day Injection: 4 to 6 mg/kg/day for seven to 10 days to blood level of 10 to 15 µg/mL or 10 to 15 mg/kg/day intramuscularly or intravenously Tablet: 15 to 50 mg two or three times daily Preanesthetic: Injection: 1 to 3 mg/kg intramuscularly or intravenously 60 to 90 minutes prior to procedure Sedative (sedation): Tablet: 6 mg/kg/day in three divided doses Status epilepticus: Injection: 15 to 20 mg/kg intravenously over 10 to 15 minutes	Elixir: 20 mg/5 mL Injection: 50 mg/mL 65 mg/mL 130 mg/mL Tablet: 15 mg 16.2 mg 30 mg 32.4 mg 60 mg 64.8 mg 97.2 mg 100 mg
Secobarbital	Hypnotic (short-term treatment of insomnia): Capsule: 100 mg at bedtime Preanesthetic: Capsule: 200 to 300 mg one to two hours before surgery	Preanesthetic: Capsule: 2 to 6 mg/kg one to two hours before surgery, maximum dose of 100 mg	Capsule: 100 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the barbiturates are summarized in Table 8. Although the barbiturates have been available for decades, there are few clinical trials available that directly compare the various agents.

Table 8. Comparative Clinical Trials with the Barbiturates

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Alcohol Detoxification				
Mariani et al.[18] (2006) Phenobarbital 60 mg QID for one day, 60 mg TID for one day, 60 mg BID for one day then 60 mg QD for one day vs gabapentin 2,400 mg on day one (titrated), 600 mg TID for one day, 600 mg BID for one day, then 600 mg QD for one day	OL, RCT Patients 18 to 60 years of age who were admitted for inpatient alcohol detoxification	N=27 4 days	Primary: Treatment failure and severity of withdrawal symptoms Secondary: Not reported	Primary: There was no significant difference in the number of patients completing treatment among the phenobarbital treatment group compared to the gabapentin group (62 vs 71%; P<0.70). Rescue medication was required in 38% of the phenobarbital group and this proportion did not differ significantly from the gabapentin group (57%; P<0.45). The results of each withdrawal-symptom rating scale and the number of hours of sleep per night did not differ significantly between treatment groups. No withdrawal seizures or symptoms of alcohol withdrawal delirium were demonstrated in either treatment group. Secondary: Not reported
Insomnia				
Okawa et al.[19] (1978) Secobarbital 100 mg vs	DB, RCT, XO (two trials) Patients 18 to 60 years of age with a history of insomnia and two of the following: onset of	N=76 2 nights	Primary: Patient preference questionnaire, success (defined as sleep onset in 30 minutes or less and sleep duration of six hours or more),	Primary: One trial compared triazolam to placebo and involved 19 patients. Sixteen patients preferred triazolam over placebo and three expressed no preference (P<0.001). Triazolam demonstrated greater efficacy over placebo in overall sleep (P<0.001), onset (P<0.001), duration (P<0.002) and number of awakenings (P<0.002). Triazolam was determined to be significantly more successful in 15 of 19 patients (P<0.004). No difference in next-morning alertness was noted between the two study groups. Seven

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
triazolam 0.5 mg vs placebo	sleep longer than 30 minutes, duration of sleep six hours or less, or experiencing three or more awakenings		adverse effects Secondary: Not reported	patients receiving active treatment experienced mild-to-moderate adverse effects, with dizziness, drowsiness and headache as the most frequently reported. In comparison, three of the patients in the placebo group experienced mild-to-moderate side effects. The second trial was a combined study of 57 patients comparing triazolam and secobarbital. The results of the patient preference questionnaire were analyzed and showed a significant preference for triazolam (41 patients) over secobarbital (10 patients), with six having no preference for either agent (P<0.001). Significant improvement was seen with triazolam compared to secobarbital (P<0.001) in sleep onset, duration of sleep and number of awakenings. Feelings of alertness the next morning did not differ between treatment groups. Success was established in 73% of triazolam treated patients whereas only 30% of the secobarbital treated patients were determined successful (P<0.001). Thirteen patients in the secobarbital group reported adverse effects ranging from drowsiness and restlessness to dry mouth. More patients on triazolam reported side effects. Secondary: Not reported
Seizures				
Arya et al.[20] (2013) Antiepileptic drugs as monotherapy and adjunctive therapy	SR RCTs, SRs and MAs for pediatric population with partial onset or focal seizures classified based on monotherapy and add-on therapy criteria modified from updated International League Against Epilepsy guidelines and American	46 trials Variable duration	Primary: Complete seizure freedom during the observed unit time using 50% responder rate (the proportion of patients experiencing a reduction of ≥50% in seizure frequency during the treatment phase compared to the baseline phase), retention of	Primary: The only antiepileptic drug with Class I evidence for efficacy as initial monotherapy for partial-onset seizures in children is oxcarbazepine. Carbamazepine, clobazam, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, vigabatrin and zonisamide have Class III evidence of efficacy for monotherapy of partial-onset seizures in children. Gabapentin, lamotrigine, levetiracetam, oxcarbazepine and topiramate have Class I evidence of efficacy for treatment of partial-onset seizures in children. The efficacy of phenobarbital monotherapy in children with partial-onset seizures was from open-label trials and as a result, the status of phenobarbital as monotherapy remains undefined. There is no systematic evidence for the efficacy or tolerability of phenobarbital as adjunctive

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	Academy of Neurology/ American Epilepsy Society report		patients on study medication Secondary: Not reported	therapy in children with refractory partial-onset seizures. Secondary: Not reported
Nolan SJ et al.[21] (2013) Phenobarbitone vs phenytoin	SR Adults and children with partial onset seizures or generalized tonic-clonic seizures with or without other generalized seizure types	N=599 (4 trials) Variable duration	Primary: Time to treatment withdrawal (a HR>1 indicates a clinical advantage for phenytoin) Secondary: Time to 12-month seizure-free period (remission), six-month remission and first seizure post randomization; for all outcomes, a HR>1 indicates a clinical advantage for phenytoin	Primary: Phenobarbitone was more likely to be withdrawn than phenytoin based on the overall pooled HR that was calculated using fixed effects and adjusted for seizure type (HR, 1.62; 95% CI, 1.23 to 2.14; P=0.0007). Substantial heterogeneity was present between the trials and when this was accounted for with random effects, the test for interaction between treatment effect and epilepsy type was not significant (Chi^2=1.92; P=0.17). Secondary: The pooled HR for time to 12-month remission was 0.90 (95% CI, 0.69 to 1.18). The pooled HR for time to six-month remission was 0.92 (95% CI, 0.73 to 1.16). The pooled HR for time to first seizure was 0.85 (95% CI, 0.68 to 1.05).
Malamiri et al.[22] (2012) Phenobarbital 20 mg/kg (loading dose) followed by 5 mg/kg divided in two doses and given 12 hours and 24 hours after the loading dose (maintenance dose)	RCT Children two years of age and older (range three to 16 years) with convulsive status epilepticus and acute prolonged seizures who had experienced convulsions while attending	N=60 24 hours	Primary: Termination of all convulsive activity within 20 minutes of starting anticonvulsant infusion, without respiratory depression or hypotension and without another convulsion within one hour	Primary: Twenty-seven out of thirty patients (90%) in the valproate group had their seizures controlled in less than 20 minutes after beginning infusion. Twenty-three out of thirty patients (77%) in the phenobarbital group had their seizures controlled in less than 20 minutes after beginning infusion. There was no statistically significant difference found between the two groups (Fischer Exact Test; P=0.189). Secondary: Termination of seizures within 20 minutes and no seizure recurrence within 24 hours after termination of seizure was 77% in the valproate group (23 out of 30 participants). Termination of seizures within 20 minutes and no seizure recurrence within 24 hours after termination of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs sodium valproate 20 mg/kg diluted in 20 mL saline (loading dose) followed by continuous infusion of 1 mg/kg per hour, given 60 minutes after the bolus dose (maintenance dose)	emergency rooms and whose seizures were not controlled by a bolus of intravenous diazepam 0.2 mg/kg within five minutes		Secondary: Freedom from seizures for 24 hours after seizure termination, adverse effects	seizure was 37% in the phenobarbital group (11 out of 30 participants); (Fisher Exact Test; P=0.004). The overall occurrence of clinical adverse effects was 74% in the phenobarbital group and 24% in the valproate group (Fisher Exact Test; P<0.001). Seven patients in the valproate group had adverse effects: three reported lethargy, three reported vomiting, and one developed significant hypotension requiring vasopressor infusion. Seventeen patients in the phenobarbital group had adverse effects: 17 reported lethargy, four had vomiting, and one developed respiratory depression requiring bag and mask ventilation.
Su et al.[23] (2016) Phenobarbital 20 mg/kg (loading dose) followed by IV dose of 100 mg every 6 hours vs valproate 30 mg/kg (loading dose) followed by a continuous infusion at a rate of 1 to 2 mg/kg per hour	PRO, RCT Adults ≥18 years of age with generalized convulsive status epilepticus who initially received treatment with diazepam (0.2 mg/kg IV, twice) and did not respond to diazepam treatment	N=73 Variable duration	Primary: Number of patients with effective seizure control, defined as a cessation of clinical and electroencephalo-graphic seizure activity within 10 to 20 min of loading dose administration Secondary: Relapse rates, adverse events	Primary: Intravenous phenobarbital was successful in 81.1% (30/37) of patients with generalized convulsive status epilepticus, and intravenous valproate was successful in 44.4% (16/36) of patients (P<0.05). Secondary: Relapse of status epilepticus within 24 h occurred in 6.7 and 31.3% of patients in the phenobarbital and valproate groups, respectively (P<0.05). Relapse of nonconvulsive status epilepticus within 24 h did not reach statistical significance (20.0 vs 31.3%). More severe adverse events were seen in the phenobarbital group (13.5 vs 0%; P=0.04), in which six patients had transient depressed respiration and two (5.4%) needed ventilation; five patients developed hypotension and two (5.4%) required vasopressor support. Moreover, two patients developed gastric motility insufficiency, two showed a transient transaminase increase, and one developed bone marrow suppression. After phenobarbital withdrawal, the patients returned to normal levels within one month. In contrast, in the valproate group, no patients showed hypotension or hypoventilation, and six showed transient hyperammonemia without hepatic injury or hyperammonemia encephalopathy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Painter et al.[24] (1999) Phenobarbital 25 µg/mL vs phenytoin 3 µg/mL	RCT, SB Neonates with seizures	N=59 5 years	Primary: Complete seizure control determined by electro-encephalography Secondary: Not reported	Primary: Phenobarbital controlled seizures completely in 43% of patients, while phenytoin controlled seizures in 45% of patients (P=1.00). Secondary: Not reported
Smith et al.[25] (2003) Phenobarbital vs carbamazepine	MA Children or adults with partial-onset seizures or generalized-onset tonic-clonic seizures	N=684 (4 trials) Variable duration	Primary: Time to withdrawal, time to 12-month remission, time to first seizure Secondary: Not reported	Primary: Time to withdrawal was significantly improved with carbamazepine over phenobarbital (HR, 1.63; 95% CI, 1.23 to 2.15). There was no significant difference between treatment groups for the time to 12-month remission and time to first seizure (HR, 0.87; 95% CI, 0.65 to 1.17 and HR, 0.85; 95% CI, 0.68 to 1.05 respectively). Further analysis of each type of seizure indicated that phenobarbital provided statistical benefit over carbamazepine for time to first partial-onset seizure, whereas carbamazepine demonstrated benefit over phenobarbital in patients for time to first generalized-onset tonic-clonic seizures. Secondary: Not reported
Nolan et al.[26] (2015) Phenobarbital vs carbamazepine	MA Children or adults with newly onset partial or generalized epilepsy	N=836 (6 trials) Variable duration	Primary: Time to withdrawal Secondary: Time to 12-month remission, time to first seizure	Primary: Time to withdrawal was significantly improved with carbamazepine over phenobarbital (HR, 1.49; 95% CI, 1.15 to 1.94). Secondary: There was no significant difference between treatment groups for the time to 12-month remission and time to first seizure (HR, 0.93; 95% CI, 0.72 to 1.19 and HR, 0.86; 95% CI, 0.71 to 1.04 respectively).
Treiman et al.[27] (1998) Phenobarbital 15	DB, MC, RCT Adults with overt or subtle generalized	N=518 5 years	Primary: Success (defined as cessation of all motor and	Primary: For treatment success in overt status epilepticus, a significant difference overall in the frequency of success was found, reported as: lorazepam, 64.9%; phenobarbital, 58.2%; diazepam/phenytoin, 55.8%; and phenytoin,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/kg vs diazepam 0.15 mg/kg, followed by phenytoin 18 mg/kg vs lorazepam 0.1 mg/kg vs phenytoin 18 mg/kg	convulsive status epilepticus		electrical seizure activity within 20 minutes of start of drug infusion and no recurrence of seizure activity within the next 40 minutes), side effects, outcomes 30 days posttreatment Secondary: Not reported	43.6% (P<0.02 between all groups). For subtle status epilepticus, no significant differences were seen between treatment groups (P<0.18). Lorazepam showed significantly higher frequency of treatment success compared to phenytoin in a pairwise comparison of patients with overt status epilepticus (P<0.002). Pairwise comparisons among other individual treatments showed no significant differences. There were no significant differences among any of the treatment groups with respect to adverse effects or 30-day posttreatment outcomes. Secondary: Not reported
Yasiry et al.[28] (2014) Phenobarbital vs lacosamide vs levetiracetam vs phenytoin vs	MA Patients with status epilepticus who have been resistant to initial therapy with benzodiazepines	N=Not reported (22 trials) Variable duration	Primary: Cessation of seizure activity Secondary: Not reported	Primary: Efficacy of levetiracetam was 68.5% (95% CI, 56.2 to 78.7), phenobarbital 73.6% (95% CI, 58.3 to 84.8), phenytoin 50.2% (95% CI, 34.2 to 66.1) and valproate 75.7% (95% CI, 63.7 to 84.8). Lacosamide studies were excluded from the meta-analysis due to insufficient data. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
valproate				
Sedation				
Kienstra et al[29] (2004) Pentobarbital 1.25 mg/kg to 2.5 mg/kg per titration protocol vs etomidate 0.1 mg/kg to 0.2 mg/kg per titration protocol	DB, PRO, RCT Children six months to six years of age requiring sedation for a head or neck computed tomography scan with American Society of Anesthesiologists physical status class I or II	N=57 1 day	Primary: Efficacy (success rate to complete the procedure with sedation) Secondary: Induction time, sedation time, total examination time	Primary: The success rate for the etomidate group was 57% (N=7) at total doses of up to 0.3 mg/kg and 76% (N=17) at total doses of up to 0.4 mg/kg compared to a success rate of 97% (N=33) for pentobarbital at a total dose of up to 5 mg/kg. The success rate for pentobarbital was significantly greater than the final etomidate group with a difference in proportions of 20.5% (95% CI, 1.9% to 44.4%; P=0.04). Secondary: Patients receiving etomidate had a significantly shorter induction time with a difference of means of 2.1 minutes (95% CI, 0.35 to 3.86; P=0.020), sedation time with a difference of means of 31.3 minutes (95% CI, 24.0 to 38.5; P<0.001), and total examination time with a difference of means of 53.1 minutes (95% CI, 40.8 to 65.3; P<0.001).
Moro-Sutherland et al[30] (2000) Midazolam IV per titration protocol vs pentobarbital IV per titration protocol	PRO, RCT Children six months to six years of age requiring sedation for a head computed tomography scan with American Society of Anesthesiologists physical status class I or II	N=55 1 day	Primary: Efficacy (success rate to complete the procedure with sedation) Secondary: Induction time, sedation time	Primary: In the pentobarbital group, 97% (N=28) of patients were successfully scanned with good sedation compared to 11% (N=3) of patients in the midazolam group. Among the midazolam group an additional 8% (N=2) of patients had the scan completed despite incomplete sedation. Of the 21 patients (81%) given IV midazolam who were unsuccessfully sedated, 16 (61%) were subsequently sedated with the addition of IV pentobarbital to complete the imaging. Secondary: The mean level of sedation in the pentobarbital group was 5 on the Ramsay Scale (range, 4 to 6; SD±0.56). The mean induction time with pentobarbital was six minutes (range, 1 to 15 minutes; SD±4.1) and the mean sedation time was 86 minutes (range, 20 to 300 minutes; SD±69.2). The average induction and sedation times were not calculated for the midazolam group given only three patients were adequately sedated.
Malviya et al[31] (2004)	PRO, RCT Children two to 12	N=70 1 day	Primary: Sedation scores (University of	Primary: Sedation scores were higher for the pentobarbital group compared to the chloral hydrate group, although were similar following the procedure and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Pentobarbital 2 mg/kg IV in incremental doses titrated to a maximum of 5 mg/kg or 150 mg vs chloral hydrate 75 mg/kg to a maximum of 2 g PO as a single dose Note: midazolam in 0.05 mg/kg increments (incremental doses not to exceed 1 mg; total dose not to exceed 0.1 mg/kg) to augment sedation as deemed appropriate by nurse administrator for procedure completion.	years of age with American Society of Anesthesiologists physical status class I to III scheduled for sedation for magnetic resonance image scan		Michigan Sedation Scale) Secondary: Time to procedure onset, duration of procedure, minutes to discharge, percent requiring midazolam augmentation, adverse events	at discharge. Secondary: The mean time to procedure onset (±SD) was 9 (±6) minutes in the pentobarbital group and 28 (±14) minutes in the chloral hydrate group (P<0.05). The mean time of procedure duration (±SD) was 40 (±14) minutes in the pentobarbital group and 45 (±23) minutes in the chloral hydrate group. The mean time to procedure discharge (±SD) was 33 (±34) minutes in the pentobarbital group and 31 (±19) minutes in the chloral hydrate group. The percentage of patients requiring midazolam augmentation was 9% (N=3) in the pentobarbital group and 37% (N=13) in the chloral hydrate group (P<0.05). A total of five patients in the pentobarbital group experienced a paradoxical reaction (i.e., marked irritability, thrashing, and kicking). While the incidence of adverse events was similar in the two groups, the time to return to baseline activity was significantly longer in children who received pentobarbital (P=0.04). A total of 66% (N=21) of pentobarbital-treated patients did not return to baseline activity for more than eight hours versus 47% (N=15) of chloral hydrate-treated patients (P=NS). There were no differences in the incidence of agitation or restlessness between groups.
Miscellaneous				
Gerhardt et al.[32] (2011) Secobarbital 100 mg for one to two doses post-discharge	DB, PC, RCT Patients 18 to 65 years of age who presented to the emergency department with a migraine (with or	N=50 1 day	Primary: Change in perceived headache pain using a 100 mm visual analog scale Secondary:	Primary: The average change in reported headache pain for the placebo group was an increase of 3 mm (95% CI, −13 to 19 mm) at 24 hours after emergency department discharge. In the secobarbital group, the average change in reported headache pain was a decrease of 25 mm (95% CI, −13 to −38; P=0.01 vs placebo). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	without aura); patients underwent standard treatment in the emergency department (intravenous fluids, antiemetics, ketorolac, and opiate rescue therapy as required)		Difference in self-reported headache resolution rate	A total of 94% of patients receiving secobarbital self-reported partial or complete headache resolution (95 CI, 81 to 100) compared to 50% of patients receiving placebo (95% CI, 24 to 76; P=0.012). This translated to a number needed to treat of 2.3 patients treated with secobarbital to affect one additional partial or complete headache resolution.

Drug regimen abbreviations: BID=twice daily, QD=once daily, QID=four times daily, TID=three times daily
Study abbreviations: DB=double-blind, MA=meta-analysis, MC=multicenter, OL=open-label, PC=placebo-controlled, PRO=prospective, RCT=randomized controlled trial, SB=single-blind, SD=standard deviation, SR=systematic review, XO=crossover
Other abbreviations: CI=confidence interval, HR=hazard ratio, IV=intravenous, PO=by mouth

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Barbiturates

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Amobarbital	injection	Amytal sodium®	$$$$$	N/A
Pentobarbital	injection	N/A	N/A	$$$$$
Phenobarbital	elixir, injection, tablet	N/A	N/A	$$
Secobarbital	capsule	Seconal sodium®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available

X. Conclusions

The barbiturates are approved for the treatment of insomnia and for the induction of sedation. Some of the agents are also approved for use as an adjunct to anesthesia, as well as for the treatment of seizure disorders. Pentobarbital and phenobarbital are available in a generic formulation.[1-6]

Currently, there are no clinical guidelines that recommend the use of a barbiturate as first-line therapy for any condition in an outpatient setting.[8-17] There are few clinical trials available that directly compare the various agents. Studies suggest that the barbiturates are not as effective as other sedative-hypnotic agents.[18-32]

The use of barbiturates is associated with abuse and psychological/physical dependence. Individuals who have psychological dependence may increase the dosage or decrease the dosing interval. This behavior may result in a fatal overdose. Tolerance to the sedative-hypnotic effects occurs rapidly, and these agents lose their effectiveness

for sleep induction/maintenance after two weeks.[1-6] The use of barbiturates has been largely replaced by benzodiazepines.

There is insufficient evidence to support that one brand barbiturate is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand barbiturates within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand barbiturate is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jun]. Available from: http://online.factsandcomparisons.com.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Sep]. Available from: http://www.thomsonhc.com/.
3. Amytal Sodium® [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals, LLC; 2017 Apr.
4. Seconal Sodium® [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals, LLC; 2015 Nov.
5. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 Sep]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
6. Becker W, Starrels JL. Prescription drug misuse: Epidemiology, prevention, identification, and management. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun].
7. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008 Oct;4(5):487-504.
8. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.
9. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33.
10. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63.
11. National Institute for Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London, UK: 2012 Jan [cited 2020 July]. Available from: http://www.nice.org.uk.
12. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, et al. Evidence-based guideline update: medical treatment of infantile spasms: report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Available at: http://www.neurology.org/content/78/24/1974.full.html.
13. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010 Oct;51(10):2175-89.
14. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol. 2010;17:348-55.
15. Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.
16. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology Jul 2018, 91 (2) 74-81; DOI: 10.1212/WNL.0000000000005755.
17. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology Jul 2018, 91 (2) 82-90; DOI: 10.1212/WNL.0000000000005756.
18. Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006 Jan-Feb;15(1):76-84.
19. Okawa KK, Allens GS. A clinical comparison of triazolam with placebo and with secobarbital in insomniac patients. J Int Med Res. 1978;6(4):343-7.
20. Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs. 2013 Apr;27(4):273-86.
21. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone vs phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013 Jan 31;1:CD002217.

22. Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate vs phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012 Sep;16(5):536-41.
23. Su Y, Liu G, Tian F, Ren G, Jiang M, Chun B, et al. Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China. CNS Drugs. 2016 Dec;30(12):1201-1207.
24. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared to phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999 Aug;341(7):485-9.
25. Smith CT, Marson AG, Williamson PR. Carbamazepine vs phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904.
26. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2015 Jul 23;7:CD001904.
27. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998 Sep;339(12):792-8.
28. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014 Mar;23(3):167-74.
29. Kienstra AJ, Ward MA, Sasan F, Hunter J, Morriss MC, Macias CG. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. Pediatr Emerg Care. 2004;20(8):499-506.
30. Moro-Sutherland DM, Algren JT, Louis PT, Kozinetz CA, Shook JE. Comparison of intravenous midazolam with pentobarbital for sedation for head computed tomography imaging. Acad Emerg Med. 2000;7(12):1370-5.
31. Malviya S, Voepel-Lewis T, Tait AR, Reynolds PI, Gujar SK, Gebarski SS. Pentobarbital vs chloral hydrate for sedation of children undergoing MRI: efficacy and recovery characteristics. Paediatr Anaesth. 2004;14(7):589-95.
32. Gerhardt RT, Hermstad E, Crawford DM, Rayfield J, Plaff J, Hunter CJ. Postdischarge secobarbital after ED migraine treatment decreases pain and improves resolution. Am J Emerg Med. 2011 Jan;29(1):86-90.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Anxiolytics, Sedatives, and Hypnotics – Benzodiazepines
AHFS Class 282408
November 4, 2020

I. Overview

The benzodiazepines are approved for the treatment of anxiety disorders and insomnia.[1-12] Anxiety disorders include generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and social phobia.[13] The agents approved for the treatment of anxiety include alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, lorazepam, and oxazepam.

The benzodiazepines that are approved solely for the treatment of insomnia include estazolam, flurazepam, temazepam, and triazolam.[1-12] The key diagnostic feature of primary insomnia is difficulty initiating or maintaining sleep for at least three months, which causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.[13] Insomnia may be considered either an acute or chronic disorder (especially if associated with underlying illnesses).

Some of the benzodiazepines are also approved for the treatment of seizure disorders (monotherapy, adjunctive therapy, Lennox-Gastaut syndrome, and status epilepticus) and for the management of acute alcohol withdrawal. Midazolam is a unique product compared to the other benzodiazepines; it is used for the induction/maintenance of general anesthesia and as a sedative (e.g., preoperative, prior to diagnostic/radiologic procedures, and intensive care unit sedation).[1-12]

Benzodiazepines potentiate the effects of gamma-aminobutyric acid and other inhibitory neurotransmitters.[1-12] Within the body there are three major benzodiazepine receptor subtypes. Benzodiazepine receptor subtype-1 is located throughout the central nervous system and is thought to mediate the anxiolytic, sedative and anticonvulsant properties of the benzodiazepines. Benzodiazepine receptor subtype-2 is located in the cortex, hippocampus, striatum, and spinal cord and is believed to mediate muscle relaxation, central nervous system depression, as well as psychomotor impairment. Depression of the central nervous system may range from mild impairment of task performance to hypnosis.[1,2] Benzodiazepine receptor subtype-3 is located throughout the body and glial cells, and is believed to contribute to tolerance and withdrawal when activated.[1,2] The benzodiazepines are mechanistically similar; however, they differ with regards to their pharmacokinetic properties. This includes onset, duration of action, and metabolism. Benzodiazepines with an active parent compound and rapid onset of action may produce euphoria and are more likely to be abused.[14-15] On September 23, 2020, the FDA released a publication to address labeling changes to the benzodiazepine class to improve the safe use of these agents. This action by the FDA is part of ongoing efforts to promote the public health by minimizing risks associated with inappropriate use of controlled substances. The update requires class-wide labeling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions to help improve their safe use. Beyond requiring an update to the Boxed Warning, other required changes to the prescribing information encompass the Warnings and Precautions, Drug Abuse and Dependence, and Patient Counseling Information sections. Revisions to the patient Medication Guide will also be mandated to educate patients and caregivers about the associated risks of these therapies.[16]

The benzodiazepines that are included in this review are listed in Table 1. Prior to January 1, 2014, benzodiazepines were an excludable/optional drug class in accordance with the Omnibus Budget Reconciliation Act of 1990 (OBRA 90). This review encompasses all dosage forms and strengths, regardless of coverage status. All of the benzodiazepines are available in a generic formulation. This class was last reviewed in August 2018.

Table 1. Benzodiazepines Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Alprazolam	extended-release tablet, oral concentrate, orally disintegrating tablet, tablet	Xanax®*, Xanax XR®*	alprazolam, alprazolam ER
Chlordiazepoxide	capsule	N/A	chlordiazepoxide

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Clonazepam	orally disintegrating tablet, tablet	Klonopin®*	clonazepam
Clorazepate	tablet	Tranxene T-Tab®*	clorazepate
Diazepam	injection, oral concentrate, oral solution, rectal gel, tablet	Diastat®*, Diastat AcuDial®*	Diastat®*†, Diastat AcuDial®*†, diazepam (excluding rectal gel)
Estazolam	tablet	N/A	estazolam
Flurazepam	capsule	N/A	flurazepam
Lorazepam	injection, oral concentrate, tablet	Ativan®*	lorazepam
Midazolam	injection, oral syrup	N/A	midazolam
Oxazepam	capsule	N/A	oxazepam
Temazepam	capsule	Restoril®*	temazepam
Triazolam	tablet	Halcion®*	triazolam

*Generic is available in at least one dosage form or strength.
†Generic product requires prior authorization.
PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the benzodiazepines are summarized in Table 2.

Table 2. Treatment Guidelines Using the Benzodiazepines

Clinical Guideline	Recommendation(s)

National Institute for Clinical Excellence: **Generalized Anxiety Disorder and Panic Disorder in Adults: management (2011)**[17]
 	
Last updated July 2019
	Stepped care for people with generalized anxiety disorder (GAD)
	• If a person with GAD chooses drug treatment, offer a selective serotonin reuptake inhibitor (SSRI), specifically sertraline.
	• If sertraline is ineffective, offer an alternative SSRI or a serotonin–noradrenaline reuptake inhibitor (SNRI), taking into account the following factors:
	  ○ Tendency to produce a withdrawal syndrome (especially with paroxetine and venlafaxine).
	  ○ The side-effect profile and the potential for drug interactions.
	  ○ The risk of suicide and likelihood of toxicity in overdose (especially with venlafaxine).
	  ○ The person's prior experience of treatment with individual drugs (particularly adherence, effectiveness, side effects, experience of withdrawal syndrome and the person's preference).
	• If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin.
	• Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises.
	• Do not offer an antipsychotic for the treatment of GAD in primary care.
	
	Panic disorder general considerations
	• Benzodiazepines are associated with a less effective outcome in the long term and should not be prescribed for panic disorder.
	• Sedating antihistamines or antipsychotics should not be prescribed for panic disorder.
	• Interventions with evidence for the longest duration of effect are listed in descending order, where preference of the patient should be taken into account:
	  ○ Psychological therapy (i.e., cognitive behavioral therapy, structured problem solving, psychoeducation).
	  ○ Pharmacological therapy (antidepressant therapy).
	  ○ Self-help interventions (i.e., bibliotherapy, support groups, exercise, cognitive behavioral therapy via a computer interface).

Clinical Guideline	Recommendation(s)
	• Antidepressants should be the only pharmacologic intervention used in the longer term. • The classes of antidepressants that have an evidence base for effectiveness are the SSRIs, SNRIs and tricyclic antidepressants (TCAs). • Unless otherwise indicated, an SSRI (e.g., paroxetine, fluvoxamine, citalopram) licensed for panic disorder should be offered. If an SSRI is not suitable or there is no improvement after a 12-week course and if further medication is appropriate, imipramine or clomipramine may be considered. • If the patient is showing improvement, the medication should be continued for at least six months after optimal dose is reached, after which the dose may be tapered slowly over an extended period of time to minimize the risk of discontinuation/withdrawal symptoms.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Panic Disorder, Second Edition (2009)[18]**	• SSRIs, SNRIs, TCAs, and benzodiazepines have demonstrated efficacy in numerous controlled trials and are recommended for treatment of panic disorder. • Because SSRIs, SNRIs, TCAs, and benzodiazepines appear roughly comparable in their efficacy for panic disorder, selecting a medication involves considerations of side effects, pharmacological properties, potential drug interactions, prior treatment history, and comorbid medical and psychiatric conditions. • The relatively favorable safety and side effect profile of SSRIs and SNRIs makes them the best initial choice for many patients with panic disorder. • There is no evidence of differential efficacy between the SSRIs, although differences in the side-effect profile (e.g., potential for weight gain, discontinuation-related symptoms), half-life, propensity for drug interactions, and availability of generic formulations may be clinically relevant. They are safer than TCAs and monoamine oxidase inhibitors. They are rarely lethal in overdose and have few serious effects on cardiovascular function. • Venlafaxine extended release has been shown to be effective for panic disorder. It is generally well tolerated and has a side effect profile similar to the SSRIs. No systematic data are currently available supporting the use of duloxetine, in panic disorder, although its mechanism of action suggests it might be an effective agent. • Although TCAs are effective, the side effects and greater toxicity in overdose limit their acceptability to patients and clinical utility. Given the equivalency of TCAs in treating depression, there is little reason to expect other TCAs to work less well for panic disorder. TCAs that are more noradrenergic (e.g., desipramine, maprotiline) may be less effective than agents that are more serotonergic. • SSRIs, SNRIs, and TCAs are all preferable to benzodiazepines as monotherapies for patients with comorbid depression or substance use disorders. Benzodiazepines may be especially useful adjunctively with antidepressants to treat residual anxiety symptoms. • Benzodiazepines may be preferred for patients with very distressing or impairing symptoms in whom rapid symptom control is critical. The benefit of more rapid response to benzodiazepines must be balanced against the possibilities of troublesome side effects and physiological dependence that may lead to difficulty discontinuing the medication. • MAOIs appear effective for panic disorder but, because of their safety profile, they are generally reserved for patients who have failed to respond to several first-line treatments. • Neither trazodone nor nefazodone can be recommended as a first-line treatment for panic disorder. There is minimal support for the use of trazodone in panic disorder and it appears less effective than imipramine and alprazolam. There are a few small, uncontrolled studies showing benefits of nefazodone in some patients with panic disorder; however, its use has been limited by concerns about

Clinical Guideline	Recommendation(s)
	liver toxicity. • Bupropion was effective in one small trial and ineffective in another. It cannot be recommended as a first line treatment for panic disorder. • Other medications with less empirical data may be considered as monotherapies or adjunctive treatments for panic disorder when patients have failed to respond to several standard treatments or based on other individual circumstances.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder (2012)[19]**	• The psychiatric assessment of children and adolescents should routinely screen for the presence of obsessions and/or compulsions or repetitive behaviors. • If screening suggests obsessive-compulsive symptoms, clinicians should fully evaluate the child using the DSM-IV-TR criteria and scalar assessment. • A complete psychiatric evaluation should be performed, including information from all available sources and compromising standard elements of history and a mental state examination, with attention to the presence of commonly occurring comorbid psychiatric disorders. • It is possible that three out of four children with obsessive-compulsive disorder (OCD) meet criteria for at least one comorbid diagnosis, and these children have lower response rates to CBT than children without comorbid diagnoses. • Identification of MDD and bipolar disorder is very important before initiating treatment with a SSRI. • Comorbid eating disorders are infrequent in younger children; however, comorbid eating disorders become more prevalent in adolescents. • A full medical, developmental, family and school history should be included with the psychiatric history and examination. • CBT is the first-line treatment for mild to moderate OCD in children, whenever possible. • For moderate to severe OCD, medication is indicated in addition to CBT. • Serotonin reuptake inhibitors (SRIs) are the first-line medications recommended for OCD in children, including clomipramine (a TCA) and certain SSRIs (fluoxetine, fluvoxamine, paroxetine and sertraline). • There is no SRI that is proven to be more efficacious over another. • The modality of assigned treatment should be guided by empirical evidence on the moderators and predictors of treatment response. • Multimodal treatment with CBT and medication is recommended if CBT fails to achieve a clinical response after several months or in more severe cases. • Medication augmentation strategies are reserved for treatment-resistant cases in which impairments are deemed moderate in at least one important domain of function despite adequate monotherapy. • Adding clomipramine to an SSRI is a useful medication augmentation strategy. • Augmenting with an atypical neuroleptic is also a strategy employed by experts (e.g. haloperidol and risperidone combined) based on studies in adults with OCD; however, controlled data for the use of atypical antipsychotics in children with OCD does not exist. • A minimum of two adequate SSRI trials or an SSRI and clomipramine trial is recommended before atypical augmentation. • Empirically validated medication and psychosocial treatments for comorbid disorders should be considered.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder (2007; 2013 update)[20]**	<u>General considerations</u> • OCD is a chronic illness which typically waxes and wanes. • Patients who have symptoms interfering with daily functioning should be treated. • Clinical remission and recovery may not always occur and will not occur rapidly. • Goals of treatment include improving symptoms, patient functioning, and quality of life. <u>Initial treatment options</u>

Clinical Guideline	Recommendation(s)
	• The choice of treatment depends on the patient's ability to comply with therapy, whether psychotherapy, pharmacotherapy, or both. • First-line treatments include cognitive-behavioral therapy, SRIs, or a combination of the two. The choice depends on past treatment history, comorbid psychiatric conditions, severity of symptoms, and functional limitations. • Cognitive-behavioral therapy or SRI therapy may be used alone or in combination, and combination therapy may be considered in patients who do not respond fully to monotherapy, those with severe symptoms, those with comorbid psychiatric illnesses for which an SRI is indicated, or in patients who wish to limit SRI exposure. • All SRIs appear to be equally effective, though patients may respond to agents differently. • Prescribers should consider the safety, side effects, FDA warnings, drug interactions, past response to treatment, and comorbid medical conditions when choosing a medication for treatment. • Most patients do not experience a significant improvement until four to six weeks after treatment initiation, and some may ultimately respond after as many as 10 to 12 weeks. • Patients not responding after 10 to 12 weeks may respond to a higher dose of the same medication. <u>Changing treatments and pursuing sequential treatment trials</u> • Augmentation strategies may be preferred to switching strategies in patients who have a partial response to the initial treatment. • Augmentation of SRIs with trials of different antipsychotic medications or with cognitive-behavioral therapy or augmentation of cognitive-behavioral therapy with an SRI. • Patients who do not respond to their first SRI may have their medication switched to a different SRI. A switch to venlafaxine is less likely to produce an adequate response. • For patients who have not benefitted from their first SSRI trial, a switch to mirtazapine can be considered. • After first- and second-line treatments and well-supported augmentation strategies have been exhausted, less well-supported treatment strategies may be considered. These include augmenting SRIs with clomipramine, buspirone, pindolol, riluzole, or once- weekly oral morphine sulfate. • Evidence for beneficial effects of benzodiazepines as monotherapy for OCD is limited to case reports with clonazepam and alprazolam. Modest doses of benzodiazepines may relieve anxiety and distress in OCD without directly diminishing the frequency or duration of obsessions or compulsions. Given their limited evidence for efficacy, benzodiazepines cannot be recommended as monotherapy for OCD, except in those rare individuals who are unable or unwilling to take standard anti-OCD medications.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents with Posttraumatic Stress Disorder (2010)[21]**	• The psychiatric evaluation of children and adolescents should routinely include questions about traumatic experiences and posttraumatic stress disorder (PTSD) symptoms. • If the evaluation indicates symptoms of PTSD, the clinician should formally determine if PTSD is present, the severity of PTSD symptoms and the degree of functional impairment. Caregivers should be included in the formal evaluation. • A differential diagnosis should be conducted in order to rule out diagnoses with symptoms that can mimic PTSD symptoms. • The treatment plan should be comprehensive in approach and should consider the severity of symptoms and impairment, as well as comorbid psychiatric conditions. • Trauma-focused psychotherapies should be considered first-line in children and

Clinical Guideline	Recommendation(s)
	adolescents with PTSD, including psychoanalytic, attachment and cognitive behavioral treatment models. • SSRIs can be considered for treatment of children and adolescents with PTSD. • The effect of SSRIs in children with PTSD may be more consistent with a placebo effect. • Other medications such as clonidine and propranolol may be useful in decreasing symptoms of hyperarousal, and anticonvulsants may beneficial in treating PTSD symptoms other than avoidance. • Benzodiazepines have not been found to be beneficial in treating PTSD symptoms. • School-based accommodations are recommended for children with PTSD, especially in children with school-based trauma, such as bullying. • The use of restrictive, "rebirthing," binding or other coercive therapies are not recommended. • Screening for PTSD in the school or community should be conducted after traumatic events that affect significant numbers of children.

American Psychological Association: **Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (2017)**[22]	• For adults with PTSD, psychotherapies are strongly recommended.
	• For adults with PTSD, offer one of the following (listed alphabetically):
	  ○ Fluoxetine
	  ○ Paroxetine
	  ○ Sertraline
	  ○ Venlafaxine
	• There is insufficient evidence to recommend for or against the following medications for treatment of adults with PTSD:
	  ○ Risperidone
	  ○ Topiramate

Department of Veterans Affairs/ Department of Defense: **The Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2017)**[23]	<u>Treatment selection</u> • Individual, manualized trauma-focused psychotherapy is recommended over other pharmacologic and nonpharmacologic interventions for the primary treatment of PTSD. • When individual trauma-focused psychotherapy is not readily available or not preferred, pharmacotherapy or individual non-trauma-focused psychotherapy is recommended. With respect to pharmacotherapy and nontrauma-focused psychotherapy, there is insufficient evidence to recommend one over the other. <u>Pharmacotherapy</u> • Sertraline, paroxetine, fluoxetine, or venlafaxine is recommended as monotherapy for PTSD for patients diagnosed with PTSD who choose not to engage in or are unable to access trauma-focused psychotherapy. • Nefazodone, imipramine, or phenelzine is suggested as monotherapy for the treatment of PTSD if recommended pharmacotherapy, trauma-focused psychotherapy, or non-trauma-focused psychotherapy are ineffective, unavailable, or not in accordance with patient preference and tolerance. (NOTE: Nefazodone and phenelzine have potentially serious toxicities and should be managed carefully.) • Treatment of PTSD with quetiapine, olanzapine, and other atypical antipsychotics (except for risperidone, which is a Strong Against), citalopram, amitriptyline, lamotrigine, or topiramate as monotherapy are NOT suggested due to the lack of strong evidence for their efficacy and/or known adverse effect profiles and associated risks. • Treating PTSD with divalproex, tiagabine, guanfacine, risperidone, benzodiazepines, ketamine, hydrocortisone, or D-cycloserine are NOT recommended as monotherapy due to the lack of strong evidence for their efficacy and/or known adverse effect profiles and associated risks. • Treating PTSD with cannabis or cannabis derivatives is NOT recommended due

Clinical Guideline	Recommendation(s)
	to the lack of evidence for their efficacy, known adverse effects, and associated risks. • There is insufficient evidence to recommend for or against monotherapy or augmentation therapy for the treatment of PTSD with eszopiclone, escitalopram, bupropion, desipramine, doxepin, D-serine, duloxetine, desvenlafaxine, fluvoxamine, levomilnacipran, mirtazapine, nortriptyline, trazodone, vilazodone, vortioxetine, buspirone, hydroxyzine, cyproheptadine, zaleplon, and zolpidem. Augmentation therapy • The use of topiramate, baclofen, or pregabalin is NOT suggested as augmentation treatment of PTSD due to insufficient data and/or known adverse effect profiles and associated risks. • Combining exposure therapy with D-cycloserine is NOT suggested in the treatment of PTSD outside of the research setting. • Using atypical antipsychotics, benzodiazepines, and divalproex is NOT recommended as augmentation therapy for the treatment of PTSD due to low quality evidence or the absence of studies and their association with known adverse effects. • There is insufficient evidence to recommend the combination of exposure therapy with hydrocortisone outside of the research setting. • There is insufficient evidence to recommend for or against the use of mirtazapine in combination with sertraline for the treatment of PTSD. Prazosin • For global symptoms of PTSD, the use of prazosin is NOT suggested as mono- or augmentation therapy. • For nightmares associated with PTSD, there is insufficient evidence to recommend for or against the use of prazosin as mono- or augmentation therapy. Combination therapy • In partial- or non-responders to psychotherapy, there is insufficient evidence to recommend for or against augmentation with pharmacotherapy. • In partial- or non-responders to pharmacotherapy, there is insufficient evidence to recommend for or against augmentation with psychotherapy. • There is insufficient evidence to recommend for or against starting patients with PTSD on combination pharmacotherapy and psychotherapy.

American Academy of Sleep Medicine: **Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults (2008)**[24]	• The primary treatment goals are to improve sleep quality/quantity and to improve insomnia related daytime impairments.
	• Short-term hypnotic treatment should be supplemented with behavioral and cognitive therapies when possible.
	• When pharmacotherapy is utilized, the choice of a specific pharmacological agent should be directed by: symptom pattern, treatment goals, past treatment responses, patient preference, availability of other treatments, comorbid conditions, contraindications, concurrent medication interactions, and side effects.
	• For patients with primary insomnia, when pharmacologic treatment is utilized alone or in combination therapy, the recommended general sequence of medication trials is:
	  ○ Short-intermediate acting benzodiazepine receptor agonists or ramelteon.
	  ○ Alternate short-intermediate acting benzodiazepine receptor agonists or ramelteon if the initial agent has been unsuccessful.
	  ○ Sedating antidepressants, especially when used in conjunction with treating comorbid depression/anxiety. Examples of these include trazodone, amitriptyline, doxepin, and mirtazapine.

Clinical Guideline	Recommendation(s)
	○ Combined benzodiazepine receptor agonists or ramelteon and sedating antidepressant. ○ Other sedating agents. Examples include anti-epilepsy medications (gabapentin, tiagabine) and atypical antipsychotics (quetiapine and olanzapine). These medications may only be suitable for patients with comorbid insomnia who may benefit from the primary action of these drugs as well as from the sedating effect. • Over-the-counter antihistamine or antihistamine/analgesic type drugs (over-the-counter "sleep aids"), as well as herbal and nutritional substances (e.g., valerian and melatonin), are not recommended in the treatment of chronic insomnia due to the relative lack of efficacy and safety data. • Older approved drugs for insomnia including barbiturates, barbiturate-type drugs and chloral hydrate are not recommended for the treatment of insomnia. • Pharmacological treatment should be accompanied by patient education regarding treatment goals, safety concerns, potential side effects and drug interactions, other treatment modalities (cognitive and behavioral treatments), potential for dosage escalation, and rebound insomnia. • Patients should be followed on a regular basis, every few weeks in the initial period of treatment when possible, to assess for effectiveness, possible side effects, and the need for ongoing medication. • Efforts should be made to employ the lowest effective maintenance dosage of medication and to taper medication when conditions allow. Medication tapering and discontinuation are facilitated by cognitive behavioral therapy for insomnia. • Chronic hypnotic medication may be indicated for long-term use in those with severe or refractory insomnia or chronic comorbid illness. Whenever possible, patients should receive an adequate trial of cognitive behavioral treatment during long-term pharmacotherapy. • Long-term prescribing should be accompanied by consistent follow-up, ongoing assessment of effectiveness, monitoring for adverse effects, and evaluation for new onset or exacerbation of existing comorbid disorders. • Long-term administration may be nightly, intermittent (e.g., three nights per week), or as needed.
American Academy of Sleep Medicine: **Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults (2017)**[25]	<u>Recommendations for treating sleep onset insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically. • Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Sleep Latency: Mean reduction was 14 minutes greater, compared to placebo (95% CI, 3 to 24 minute reduction). ○ Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo. • Ramelteon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. ○ Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 6 to 12 minute reduction). ○ Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Sleep Latency: Mean reduction was 37 minutes greater, compared to placebo (95% CI, 21 to 53 minute reduction). ○ Quality of Sleep: Small improvement in quality of sleep, compared to placebo. • Triazolam is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults.

Clinical Guideline	Recommendation(s)
	○ Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 4 to 22 minute reduction). ○ Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. • Zaleplon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. ○ Sleep Latency: Mean reduction was 10 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). ○ Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Sleep Latency: Mean reduction was five to 12 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). ○ Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Recommendations for treating sleep maintenance insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically. • Doxepin is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. ○ Total Sleep Time: Mean improvement was 26 to 32 minutes longer, compared to placebo (95% CI, 18 to 40 minute improvement). ○ Wake After Sleep Onset: Mean reduction was 22 to 23 minutes greater, compared to placebo (95% CI, 14 to 30 minute reduction). ○ Quality of Sleep: Small-to-Moderate improvement in quality of sleep, compared to placebo. • Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Total Sleep Time: Mean improvement was 28 to 57 minutes longer, compared to placebo (95% CI, 18 to 76 minute improvement). ○ Wake After Sleep Onset: Mean reduction was 10 to 14 minutes greater, compared to placebo (95% CI, 2 to 18 minute reduction). ○ Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo. • Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Total Sleep Time: Mean improvement was 99 minutes longer, compared to placebo (95% CI, 63 to 135 minute improvement). ○ Wake After Sleep Onset: Not reported. ○ Quality of Sleep: Small improvement in quality of sleep, compared to placebo. • Suvorexant is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. ○ Total Sleep Time: Mean improvement was 10 minutes longer, compared to placebo (95% CI, 2 to 19 minute improvement). ○ Wake After Sleep Onset: Mean reduction was 16 to 28 minutes greater, compared to placebo (95% CI, 7 to 43 minute reduction). ○ Quality of Sleep: Not reported. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ○ Total Sleep Time: Mean improvement was 29 minutes longer, compared to placebo (95% CI, 11 to 47 minute improvement). ○ Wake After Sleep Onset: Mean reduction was 25 minutes greater, compared to placebo (95% CI, 18 to 33 minute reduction).

Clinical Guideline	Recommendation(s)
	○ Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Not recommended for treating insomnia</u> • The following drugs are not recommended for the treatment of sleep onset or sleep maintenance insomnia (versus no treatment) in adults: Diphenhydramine, Melatonin, Tiagabine, Trazodone, L-tryptophan, Valerian.
American College of Physicians: **Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline (2016)[26]**	• It is recommended that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. ○ CBT-I consists of a combination of treatments that include cognitive therapy around sleep, behavioral interventions (such as sleep restriction and stimulus control), and education (such as sleep hygiene). • It is recommended that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom CBT-I alone was unsuccessful. ○ Low-quality evidence showed that both eszopiclone and zolpidem improved global outcomes in the general population, and low- to moderate-quality evidence showed that eszopiclone, zolpidem, and doxepin improved sleep outcomes, such as sleep onset latency, total sleep time, and wake after sleep onset. ○ Moderate-quality evidence showed that suvorexant improved treatment response and sleep outcomes in mixed general and adult populations. ○ Low-quality evidence showed no statistically significant difference between ramelteon and placebo for sleep outcomes in the general population. ○ Evidence was insufficient for melatonin in the general population and in older adults. ○ Benzodiazepines, although widely used, were not addressed in this guideline because few studies met the inclusion criteria of the systematic review (insufficient evidence). ○ Evidence on harms was limited from randomized controlled trials that met the inclusion criteria for the review, which mostly reported on study withdrawals. However, observational studies have shown that hypnotic drugs may be associated with infrequent but serious adverse effects, such as dementia, serious injury, and fractures. ○ Evidence is insufficient to evaluate the balance of the benefits and harms of long-term use of pharmacologic treatments in adults with chronic insomnia disorder. The FDA has approved pharmacologic therapy for short-term use (four to five weeks), and patients should not continue using the drugs for extended periods. ○ The FDA also recommends that patients with insomnia that does not remit within seven to 10 days of treatment should be further evaluated. ○ There was insufficient evidence overall on the comparative effectiveness and safety of the various pharmacologic treatments.
International League Against Epilepsy: **Updated International League Against Epilepsy Evidence Review of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic**	<u>Adults with partial onset seizures</u> • Carbamazepine, levetiracetam, phenytoin, and zonisamide are established treatments as initial monotherapy for adults with newly diagnosed or untreated partial-onset seizures. Valproic acid is probably effective and gabapentin, lamotrigine, oxcarbazepine, phenobarbital, topiramate and vigabatrin are possibly effective for partial onset seizures. Clonazepam and primidone are potentially efficacious/effective. <u>Children with partial-onset seizures</u> • Oxcarbazepine is established as initial monotherapy for children with newly diagnosed or untreated partial-onset seizures. Carbamazepine, phenobarbital,

Clinical Guideline	Recommendation(s)
Seizures and Syndromes (2013)[27]	phenytoin, topiramate, valproic acid and vigabatrin may be effective and clobazam, clonazepam, lamotrigine and zonisamide are potentially efficacious/ effective. Elderly adults with partial-onset seizures • Gabapentin and lamotrigine are effective as initial monotherapy for elderly adults with newly diagnosed or untreated partial-onset seizures. Carbamazepine may be effective and topiramate and valproic acid are potentially efficacious/effective. Adults with generalized-onset tonic-clonic seizures • Carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate and valproic acid are possibly effective as initial monotherapy for adults with newly diagnosed or untreated generalized-onset tonic-clonic seizures. Gabapentin, levetiracetam and vigabatrin are potentially efficacious/effective. Carbamazepine and phenytoin may precipitate or aggravate generalized-onset tonic-clonic seizures. Children with generalized-onset tonic-clonic seizures • Carbamazepine, phenobarbital, phenytoin, topiramate and valproic acid are possibly effective for children with newly diagnosed or untreated generalized onset tonic-clonic seizures. Oxcarbazepine is potentially efficacious/effective. Carbamazepine and phenytoin may precipitate or aggravate generalized-onset tonic-clonic seizures. Children with absence seizures • Ethosuximide and valproic acid are established treatments for children with newly diagnosed or untreated absence seizures. Lamotrigine is possibly efficacious/effective as initial monotherapy. Gabapentin is inefficacious/ineffective for children with absence seizures. • Based on scattered reports, the following antiepileptic drugs may precipitate or aggravate absence seizures: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, tiagabine and vigabatrin. No conclusion can be made about levetiracetam efficacy/effectiveness for absence seizures since the failed class III placebo-controlled trial was uninformative. Children with benign childhood epilepsy with centrotemporal spikes • Carbamazepine and valproic acid are possibly effective as initial monotherapy for children with benign childhood epilepsy with centrotemporal spikes. Gabapentin, levetiracetam, oxcarbazepine, and sulthiame* are potentially efficacious/effective. Juvenile myoclonic epilepsy • Topiramate and valproic acid are potentially efficacious/effective for patients with newly diagnosed juvenile myoclonic epilepsy. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, tiagabine and vigabatrin may precipitate or aggravate absence seizures, myoclonic seizures, and in some cases generalized tonic-clonic seizures. There has been a report that lamotrigine may exacerbate seizures in juvenile myoclonic epilepsy.
National Institute for Clinical Excellence: **Epilepsies: Diagnosis and Management (2012)**[28] Updated February 2020	General information about pharmacological treatment • Valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless alternative treatments are not suitable. • Valproate must not be used in pregnant women. • The anti-epileptic drug (AED) treatment strategy should be individualized according to the seizure type, epilepsy syndrome, co-medication and co-

Clinical Guideline	Recommendation(s)
	morbidity, the child, young person or adult's lifestyle, and the preferences of the person and their family and/or carers as appropriate. • The diagnosis of epilepsy needs to be critically evaluated if events continue despite an optimal dose of a first-line AED. • It is recommended that children, young people and adults should be treated with a single AED (monotherapy) wherever possible. If the initial treatment is unsuccessful, then monotherapy using another drug can be tried. • It is recommended that combination therapy (adjunctive or 'add-on' therapy) should only be considered when attempts at monotherapy with AEDs have not resulted in seizure freedom. • If using carbamazepine, offer controlled-release carbamazepine preparations. Treatment of focal seizures • First-line treatment in children, young people, and adults with newly diagnosed focal seizures: carbamazepine or lamotrigine. • If carbamazepine or lamotrigine are unsuitable or not tolerated for newly diagnosed focal seizures: o Offer levetiracetam or oxcarbazepine to women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years). If the first of these AEDs tried is ineffective, offer the other one. o Do not offer sodium valproate to women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years) with focal seizures, unless other options are ineffective or not tolerated and the pregnancy prevention programme is in place. o Offer levetiracetam, oxcarbazepine or sodium valproate to boys, men and women who are not of childbearing potential. If the first AED tried is ineffective, offer an alternative from these AEDs. • Consider adjunctive treatment if a second well-tolerated antiepileptic is ineffective. • For refractory focal seizures, offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, or topiramate as adjunctive treatment to boys, men, women and girls of childbearing potential with focal seizures if first-line treatments are ineffective or not tolerated. Sodium valproate is also an option for adjunctive treatment to boys, men and women who are not of childbearing potential. • For refractory focal seizures, if adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist. Other antiepileptics that may be considered by a specialist are eslicarbazepine acetate*, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. • Carefully consider the risk–benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. Treatment of generalized tonic-clonic seizures • First-line treatment in children, young people, and adults (except women and girls of childbearing potential) with newly diagnosed focal seizures: sodium valproate. • Offer lamotrigine if sodium valproate is unsuitable. • Consider carbamazepine and oxcarbazepine. • Offer clobazam, lamotrigine, levetiracetam, or topiramate as adjunctive treatment to women and girls if first-line treatments are ineffective or not tolerated. Sodium valproate is an additional option as adjunctive treatment to boys, men and women who are not of childbearing potential.

Clinical Guideline	Recommendation(s)
	• If there are absence or myoclonic seizures, or if juvenile myoclonic epilepsy is suspected, do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin. Treatment of absence seizures • First-line treatment in children, young people, and adults with absence seizures: ethosuximide or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). If there is a high risk of generalized tonic-clonic seizures, offer sodium valproate first, unless it is unsuitable. • Offer lamotrigine if ethosuximide and sodium valproate are unsuitable, ineffective, or not tolerated. • If two first-line antiepileptics are ineffective, consider a combination of two of these three antiepileptics as adjunctive treatment: ethosuximide, lamotrigine, or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam, levetiracetam, topiramate or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of myoclonic seizures • First-line treatment in children, young people, and adults with myoclonic seizures: valproate, unless unsuitable (do not offer sodium valproate to women and girls of childbearing potential). • Consider levetiracetam or topiramate if sodium valproate is unsuitable or not tolerated. • Offer levetiracetam, sodium valproate, or topiramate as adjunctive treatment to patients if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist or consider clobazam, clonazepam, piracetam*, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of atonic or tonic seizures • First-line treatment in children, young people, and adults with tonic or atonic seizure: sodium valproate (do not offer sodium valproate to women and girls of childbearing potential). • Offer lamotrigine as adjunctive treatment if sodium valproate is unsuitable, ineffective, or not tolerated. • Discuss with a tertiary epilepsy specialist if adjunctive treatment is ineffective or not tolerated. Other antiepileptics that may be considered by the tertiary epilepsy specialist are rufinamide and topiramate. • Do not offer carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin. Treatment of infantile spasms • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when an infant presents with infantile spasms. • Offer a steroid or vigabatrin as first-line treatment to infants with infantile spasms that are not due to tuberous sclerosis. • Offer vigabatrin as first-line treatment to infant with infantile spasms due to tuberous sclerosis. If vigabatrin is ineffective, offer a steroid.

Clinical Guideline	Recommendation(s)
	Treatment of Dravet syndrome • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when a child presents with suspected Dravet syndrome. • Consider topiramate for women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years). • Consider sodium valproate or topiramate for boys, men and women who are not of childbearing potential. • Discuss with a tertiary epilepsy specialist if first-line treatments are ineffective or not tolerated, and consider clobazam or stiripentol as adjunctive treatment. • Do not offer carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. Treatment of Lennox-Gastaut Syndrome • Discuss with, or refer to, a tertiary pediatric epilepsy specialist when a child presents with suspected Lennox-Gastaut syndrome. • Offer sodium valproate as first-line treatment to children with Lennox-Gastaut syndrome (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine as adjunctive treatment if first-line treatments are unsuitable, ineffective, or not tolerated. • Discuss with a tertiary epilepsy specialist if adjunctive treatment is ineffective or not tolerated. Other antiepileptics that may be considered by the tertiary epilepsy specialist are rufinamide and topiramate. • Do not offer carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin. • Only offer felbamate in centers providing tertiary epilepsy specialist care and when treatment with all of the antiepileptics listed above have proved ineffective or not tolerated. Treatment of benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) • Discuss with the child or young person, and their family and/or caretakers, whether antiepileptic drug treatment is indicated. • Offer carbamazepine or lamotrigine as first-line treatment to children and young people. • Offer levetiracetam, oxcarbazepine, or sodium valproate if first-line treatments are unsuitable or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). If the first antiepileptic drug tried is ineffective, offer an alternative from the five antiepileptics noted above. • Consider adjunctive treatment if a second well-tolerated antiepileptic drug is ineffective. • Offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist. Other antiepileptic drugs that may be considered are eslicarbazepine acetate*, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Treatment of idiopathic generalized epilepsy

Clinical Guideline	Recommendation(s)
	• First-line treatment in children, young people, and adults with idiopathic generalized epilepsy: sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine if sodium valproate is unsuitable or not tolerated. • Consider topiramate. • Offer lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. <u>Treatment of juvenile myoclonic epilepsy</u> • First-line treatment in children, young people, and adults with juvenile myoclonic epilepsy: sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Consider lamotrigine, levetiracetam, or topiramate if sodium valproate is unsuitable or not tolerated. • Offer lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin. <u>Treatment of epilepsy with generalized tonic-clonic seizures only</u> • First-line treatment in children, young people, and adults with epilepsy with generalized tonic-clonic seizures only: lamotrigine, sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Consider carbamazepine or oxcarbazepine. • Offer clobazam, lamotrigine, levetiracetam, sodium valproate, or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). <u>Treatment of childhood absence epilepsy, juvenile absence epilepsy, or other absence epilepsy syndromes</u> • First-line treatment in children, young people, and adults: ethosuximide, sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years). • Offer lamotrigine if first-line treatments are unsuitable, ineffective, or not tolerated. • If two first-line antiepileptic drugs are ineffective, consider a combination of two of these three antiepileptic drugs adjunctive treatment: ethosuximide, lamotrigine, or sodium valproate (do not offer sodium valproate to women and girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years).

Clinical Guideline	Recommendation(s)
	• If adjunctive treatment is ineffective or not tolerated, discuss with, or refer to, a tertiary epilepsy specialist and consider clobazam, clonazepam, levetiracetam, topiramate, or zonisamide. • Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin.
American Academy of Neurology: **Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society (2012)**[29] Reaffirmed 2018	• To date, there is insufficient evidence to support the use of agents other than adrenocorticotropic hormone, and vigabatrin. • Low-dose adrenocorticotropic hormone should be considered as an alternative to high-dose adrenocorticotropic hormone for treatment of infantile spasms. • Adrenocorticotropic hormone or vigabatrin may be offered for short-term treatment of infantile spasms. Evidence suggests that adrenocorticotropic hormone may be offered over vigabatrin. • There is insufficient evidence to recommend the use of dexamethasone, prednisolone and methylprednisolone as being as effective as adrenocorticotropic hormone for short-term treatment of infantile spasms. • The data is insufficient to recommend other therapies (valproic acid, vitamin B6, nitrazepam, levetiracetam, zonisamide, topiramate, the ketogenic diet, or novel/combination therapies) for the treatment of infantile spasms. • Hormonal therapy (adrenocorticotropic hormone or prednisolone) may be considered for use in preference to vigabatrin in infants with cryptogenic infantile spasms, to possibly improve developmental outcome. • A shorter lag time to treatment of infantile spasms with either hormonal therapy or vigabatrin may be considered to improve long-term cognitive outcomes.
Infantile Spasms Working Group: **Infantile Spasms: A U.S. Consensus Report (2010)**[30]	• To improve outcomes in infantile spasms, the goals include early recognition and diagnosis, short-term treatment with a first-line therapy, timely electroencephalography evaluation to assess treatment effectiveness and prompt treatment modification if indicated. • Effective treatment should produce both cessation of spasms and resolution of hypsarrhythmia on electroencephalography. • The dose of the chosen first-line agent should be adjusted to achieve the maximum effective dose in as short amount of time as clinically indicated. • There is insufficient evidence to recommend the best approach in events of relapse. Possible treatment options include using the previously effective agent and dose, using the previously effective agent at the maximum dose or using a new agent. • Adrenocorticotropic hormone is considered first-line therapy for infantile spasms. There is insufficient evidence to recommend the optimal dose and duration of treatment, although short duration is preferable to avoid adverse events. Treatment with the maximum dose of adrenocorticotropic hormone should be continued for two weeks followed by taper and evaluation of treatment response. • Vigabatrin is considered first-line therapy for infantile spasms, especially in patients with comorbid tuberous sclerosis complex. Vigabatrin should be initiated at 50 mg/kg/day and increased up to 100 to 150 mg/kg/day if indicated. Efficacy should be assessed within two weeks following dose titration. Responders to treatment may continue therapy for six to nine months, with continued ophthalmic evaluation. • No recommendations can be given with regard to oral corticosteroids in the treatment of infantile spasms. • Ketogenic diet may be considered as second-line therapy when first-line therapies fail or are inappropriate. • Patients with refractory spasms, concomitant partial seizures or focal abnormalities on the electroencephalography may be evaluated for surgery.
European Federation of Neurological	Initial pharmacological treatment for generalized convulsive status epilepticus and non-convulsive status epilepticus

Clinical Guideline	Recommendation(s)
Societies: **Guideline on the Management of Status Epilepticus (2010)**[31]	• The preferred treatment is intravenous administration of lorazepam 0.1 mg/kg; however, depending on the patients' general medical condition, treatment can be started at a lower dose of 4 mg, to be repeated if seizures continue for >10 minutes after first injection. • If lorazepam is not available, diazepam 10 mg (route of administration not specified) directly followed by phenytoin (15 to 18 mg/kg) or equivalent fosphenytoin. • General management of refractory status epilepticus includes treatment in an intensive care unit. Pharmacological treatment for refractory generalized convulsive status epilepticus and subtle status epilepticus • Immediate infusions of anesthetic doses of midazolam, propofol or barbiturates are recommended due to the progressive risk of brain and systemic damage. • If midazolam is given, seizure suppression is recommended. This goal should be maintained for at least 24 hours. Simultaneous initiation of the chronic medication the patient with be treated with in the future should be initiated. • For elderly patients in whom intubation and artificial ventilation would not be justified, further non-anesthetizing anticonvulsants may be tried. Pharmacological treatment for refractory non-convulsive status epilepticus • Due to poor evidence and lack of any head-to-head trials, no recommendations can be made regarding which of the non-anaesthetizing anticonvulsants should be the drug of choice. • Recommendations include phenobarbital, valproic acid and levetiracetam. • If treatment regimen includes the administration of anesthetics, use the same protocol as refractory generalized convulsive status epilepticus.
American Epilepsy Society/ American Academy of Neurology: **Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults (2016)**[32]	Initial therapy phase (five to 20 minutes) • A benzodiazepine (specifically intramuscular (IM) midazolam, intravenous (IV) lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and tolerability. • Although IV phenobarbital is established as efficacious and well tolerated as initial therapy, its slower rate of administration, compared with the three recommended benzodiazepines above, positions it as an alternative initial therapy rather than a drug of first choice. • For pre-hospital settings or where the three first-line benzodiazepine options are not available, rectal diazepam, intranasal midazolam, and buccal midazolam are reasonable initial therapy alternatives. Second therapy phase (begins when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response or lack of response to the second therapy should be apparent) • Reasonable options include fosphenytoin, valproic acid, and levetiracetam. There is no clear evidence that any one of these options is better than the others. Third therapy phase (begins when seizure duration reaches 40 minutes) • There is no clear evidence to guide therapy in this phase. • If second therapy fails to stop the seizures, treatment considerations should include repeating second-line therapy or anesthetic doses of either thiopental, midazolam, pentobarbital, or propofol (all with continuous EEG monitoring). •
American Academy of Neurology/ American Epilepsy Society: **Efficacy and Tolerability of the New Antiepileptic**	• Lamotrigine use should be considered to decrease seizure frequency. • Lamotrigine use should be considered, and gabapentin use may be considered to decrease seizure frequency in patients aged ≥60 years. • Levetiracetam use may be considered to decrease seizure frequency. • Zonisamide use may be considered to decrease seizure frequency. • Vigabatrin use appears to be less efficacious than immediate-release

<table>
<tr><th>Clinical Guideline</th><th>Recommendation(s)</th></tr>
<tr><td>Drugs I: Treatment of New Onset Epilepsy (2018)[33]</td><td>carbamazepine use and may not be offered; furthermore, toxicity profile precludes vigabatrin use as first-line therapy.
• Pregabalin use at 150 mg/day is possibly less efficacious than lamotrigine use at 100 mg/day.
• Evidence is insufficient to consider gabapentin, oxcarbazepine, or topiramate instead of carbamazepine.
• Evidence is insufficient to consider topiramate instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic seizures, or generalized epilepsy presenting with generalized tonic-clonic seizures.
• Data are lacking to support or refute use of third-generation antiepileptic drugs, clobazam, felbamate, or vigabatrin in treating new-onset epilepsy.
• Data are lacking to support or refute use of newer antiepileptic drugs in treating unclassified generalized tonic-clonic seizures.</td></tr>
<tr><td>American Academy of Neurology/ American Epilepsy Society: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment of Refractory Epilepsy (2018)[34]</td><td>Summary of guidelines on the use of antiepileptic drugs (AEDs) in treatment-resistant epilepsy, based on Level A and B recommendations
<table>
<tr><th>AED</th><th>Adjunctive focal adult</th><th>Focal mono-therapy</th><th>Idiopathic generalized epilepsy</th><th>Lennox-Gastaut syndrome</th><th>Adjunctive focal pediatric</th></tr>
<tr><td>Gabapentin</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr>
<tr><td>Lamotrigine</td><td>Yes</td><td>Yes</td><td>Yes (only in childhood absence epilepsy</td><td>Yes</td><td>Yes</td></tr>
<tr><td>Levetiracetam</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
<tr><td>Oxcarbazepine</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr>
<tr><td>Tiagabine</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
<tr><td>Topiramate</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr>
<tr><td>Zonisamide</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></tr>
</table>
• For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin and perampanel are established as effective to reduce seizure frequency. Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Vigabatrin and rufinamide should be considered established as effective for decreasing seizure frequency in TRAFE but are not first-line agents (retinopathy risk with vigabatrin and modest benefit with rufinamide). Ezogabine use should be considered to decrease seizure frequency in this population but carries a serious risk of skin and retinal discoloration. Clobazam and extended-release oxcarbazepine use may be considered to decrease seizure frequency in TRAFE.
• Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE. Data are insufficient to recommend the use of second- and the other third-generation AEDs as monotherapy in TRAFE.
• For add-on therapy for generalized epilepsy, immediate-release and extended-release lamotrigine use should be considered as add-on therapy to decrease seizure frequency in treating adults with treatment-resistant generalized tonic-clonic seizures secondary to generalized epilepsy. Levetiracetam use should be considered to decrease seizure frequency as add-on therapy for treatment-resistant generalized tonic-clonic seizures and for treatment-resistant juvenile myoclonic epilepsy.
• For Lennox-Gastaut syndrome, rufinamide use should be considered established as effective to decrease seizure frequency as add-on therapy, and clobazam use should be considered.
• For add-on therapy for treatment-resistant focal epilepsy, levetiracetam use should be considered to decrease seizure frequency (for ages one month to 16 years), zonisamide use should be considered to decrease seizure frequency (for</td></tr>
</table>

Clinical Guideline	Recommendation(s)
	ages six to 17 years), and oxcarbazepine use should be considered to decrease seizure frequency (for ages one month to four years). Data are unavailable on the efficacy of clobazam, eslicarbazepine, lacosamide, perampanel, pregabalin, rufinamide, tiagabine, or vigabatrin as add-on therapy for the treatment of these children or adolescents.
National Institute for Health and Clinical Excellence: **Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence (2011)**[35] **Reaffirmed 2015**	Drug regimens for assisted withdrawal • Prescribe and administer medication for assisted withdrawal within a standard clinical protocol. The preferred medication for assisted withdrawal is a benzodiazepine (chlordiazepoxide or diazepam). • Gradually reduce the dose of the benzodiazepine over seven to 10 days to avoid alcohol withdrawal recurring. • When managing alcohol withdrawal in the community, avoid giving people who misuse alcohol large quantities of medication to take home to prevent overdose or diversion (the drug being taken by someone other than the person it was prescribed for). Prescribe for installment dispensing, with no more than two days' medication supplied at any time. • Do not offer clomethiazole for community-based assisted withdrawal because of the risk of overdose and misuse. Interventions for moderate and severe alcohol dependence after successful withdrawal • After a successful withdrawal for people with moderate and severe alcohol dependence, consider offering acamprosate or oral naltrexone in combination with an individual psychological intervention. • After a successful withdrawal for people with moderate and severe alcohol dependence, consider offering disulfiram in combination with a psychological intervention to service users who have a goal of abstinence but for whom acamprosate and oral naltrexone are not suitable, or prefer disulfiram and understand the relative risks of taking the drug. Treatment for acute alcohol withdrawal • Offer pharmacotherapy to treat the symptoms of acute alcohol withdrawal. • Consider offering a benzodiazepine or carbamazepine. • Clomethiazole may be offered as an alternative to a benzodiazepine or carbamazepine. However, it should be used with caution, in inpatient settings only and according to the summary of product characteristics. Management of delirium tremens • Lorazepam is considered a first-line treatment option. • If symptoms persist or oral medication is declined, give parenteral lorazepam or haloperidol. Management of alcohol withdrawal seizures • In people with alcohol withdrawal seizures, consider offering a quick-acting benzodiazepine (e.g., lorazepam) to reduce the likelihood of further seizures. • Do not offer phenytoin to treat alcohol withdrawal seizures.

American Psychiatric Association: **Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder (2018)**[36]	Selection of a Pharmacotherapy
	• Naltrexone or acamprosate should be offered to patients with moderate to severe alcohol use disorder who
	  ○ have a goal of reducing alcohol consumption or achieving abstinence,
	  ○ prefer pharmacotherapy or have not responded to nonpharmacological treatments alone, and
	  ○ have no contraindications to the use of these medications.
	• Disulfiram may be offered to patients with moderate to severe alcohol use disorder who

Clinical Guideline	Recommendation(s)
	○ have a goal of achieving abstinence, ○ prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate, ○ are capable of understanding the risks of alcohol consumption while taking disulfiram, and ○ have no contraindications to the use of this medication. • Topiramate or gabapentin may be offered to patients with moderate to severe alcohol use disorder who ○ have a goal of reducing alcohol consumption or achieving abstinence, ○ prefer topiramate or gabapentin or are intolerant to or have not responded to naltrexone and acamprosate, and ○ have no contraindications to the use of these medications. <u>Recommendations Against Use of Specific Medications</u> • Antidepressant medications should not be used for treatment of alcohol use disorder unless there is evidence of a co-occurring disorder for which an antidepressant is an indicated treatment. • In individuals with alcohol use disorder, benzodiazepines should not be used unless treating acute alcohol withdrawal or unless a co-occurring disorder exists for which a benzodiazepine is an indicated treatment. • For pregnant or breastfeeding women with alcohol use disorder, pharmacological treatments should not be used unless treating acute alcohol withdrawal with benzodiazepines or unless a co-occurring disorder exists that warrants pharmacological treatment. • Acamprosate should not be used by patients who have severe renal impairment. • For individuals with mild to moderate renal impairment, acamprosate should not be used as a first-line treatment and, if used, the dose of acamprosate be reduced compared with recommended doses in individuals with normal renal function. • Naltrexone should not be used by patients who have acute hepatitis or hepatic failure. • Naltrexone should not be used as a treatment for alcohol use disorder by individuals who use opioids or who have an anticipated need for opioids. <u>Treatment of Alcohol Use Disorder and Co-occurring Opioid Use Disorder</u> • In patients with alcohol use disorder and co-occurring opioid use disorder, naltrexone should be prescribed to individuals who ○ wish to abstain from opioid use and either abstain from or reduce alcohol use and ○ are able to abstain from opioid use for a clinically appropriate time prior to naltrexone initiation.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the benzodiazepines are noted in Tables 3 to 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Benzodiazepines (Drugs A to E)[1-12]

Indication	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Anxiety Disorders						
Management of anxiety disorders	✔ *†	✔		✔	✔ *‡	
Short-term relief of symptoms of anxiety	✔ *	✔		✔	✔ *‡	
Treatment of panic disorder, with or without agoraphobia	✔ *†§		✔			
Premedication for relief of anxiety and tension in patients who are to undergo surgical procedures					✔ ‡	
Premedication for the relief of anxiety and tension prior to cardioversion and to diminish the patient's recall of the procedure					✔ ‡	
Preoperative apprehension/anxiety		✔				
Sedative-Hypnotic						
Short-term management of insomnia						✔
Seizure Disorders						
Adjunct in partial seizures				✔		
Adjunct in status epilepticus and severe recurrent seizures					✔ ‡	
Adjunctive in convulsive disorders					✔ *	
Management of patients with absence seizures who failed succinimides			✔			
Management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity					✔ ‖	
Monotherapy or adjunctive treatment of Lennox-Gastaut syndrome, akinetic and myoclonic seizures			✔			
Miscellaneous						
Acute alcohol withdrawal		✔		✔	✔ *‡	
Adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, and stiff-man syndrome					✔ *‡	

*Immediate-release formulation (tablet, concentrate and/or solution).

†Orally disintegrating tablet formulation.
‡Injection formulation.
§Extended-release formulation.
‖Rectal formulation.

Table 4. FDA-Approved Indications for the Benzodiazepines (Drugs F to T)[1-12]

Indication	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Anesthesia						
Induction of anesthesia, before administration of other anesthetic agents			✔ *			
Preanesthetic medication, producing sedation, relief of anxiety, and a decreased ability to recall events related to the day of surgery		✔ *				
Preoperative sedation/anxiolysis/amnesia			✔ *			
Sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures			✔ *†			
Sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting			✔ *			
Anxiety Disorders						
Management of anxiety disorders		✔ †		✔		
Short-term relief of symptoms of anxiety		✔ †		✔		
Sedative-Hypnotic						
Short-term management of insomnia	✔				✔	✔
Seizure Disorders						
Treatment of status epilepticus		✔ *				
Miscellaneous						
Acute alcohol withdrawal				✔		

*Injection formulation.
†Oral formulation(s).

IV. Pharmacokinetics

The pharmacokinetic parameters of the benzodiazepines are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the Benzodiazepines[2]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Alprazolam	90	80	Liver	Renal (80) Feces (7)	ER: 10.7 to 15.8 IR: 6.3 to 26.9 ODT: 7.9 to 19.2
Chlordiazepoxide	Nearly complete	90 to 98	Liver	Renal (1 to 2)	10 to 48
Clonazepam	90	85	Liver	Renal (<1)	30 to 40
Clorazepate	91	97 to 98	Liver	Renal (62 to 67) Feces (15 to 19)	2.29
Diazepam	Oral: >90 Rectal: 90	95 to 99	Liver	Renal (75)	up to 48
Estazolam	Not reported	93	Not reported	Renal Feces (4)	10 to 24
Flurazepam	Not reported	97	Liver	Renal	2.3
Lorazepam	90 to 93	85 to 91	Liver (75)	Renal (88) Feces (7)	12
Midazolam	36	97	Liver	Renal (45 to 57)	1.8 to 6.4
Oxazepam	93	86 to 99	Liver	Renal (50)	2.8 to 8.6
Temazepam	Well absorbed	96	Not reported	Renal (80 to 90)	3.5 to 18.4
Triazolam	Well absorbed	89 to 94	Liver	Renal (80) Feces (9)	2.3

ER=extended-release, IR=immediate-release, ODT=orally disintegrating tablet

V. Drug Interactions

Major drug interactions with the benzodiazepines are listed in Table 6.

Table 6. Major Drug Interactions with the Benzodiazepines[2]

Generic Name(s)	Interaction	Mechanism
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Barbiturates	Concurrent use of triazolam and barbiturates may result in additive respiratory depression.
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Centrally acting muscle relaxants	Concurrent use of benzodiazepines and centrally acting muscle relaxants may result in additive respiratory depression.
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Flumazenil	Concurrent use of flumazenil and benzodiazepines may result in precipitation of seizures.
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Mirtazapine	Concurrent use of mirtazapine and benzodiazepines may result in increased risk of CNS depression.

Generic Name(s)	Interaction	Mechanism
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Sodium oxybate	Concurrent use of sodium oxybate and benzodiazepines may result in an increase in sleep duration and central nervous system depression.
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Tapentadol	Concurrent use of tapentadol and sedatives may result in an increase in central nervous system and respiratory depression.
Benzodiazepines (alprazolam, clorazepate, diazepam, estazolam, flurazepam, midazolam, triazolam)	Protease inhibitors	Concurrent use may lead to severe sedation and respiratory depression due to inhibition of hepatic metabolism.
Benzodiazepines (alprazolam, diazepam, midazolam, triazolam)	Azole antifungals	Increased and prolonged serum levels, central nervous system depression, and psychomotor impairment have been reported with benzodiazepines undergoing oxidative metabolism.
Benzodiazepines (diazepam)	Hydantoins	Serum hydantoin concentrations may be increased and phenytoin may increase the clearance of certain benzodiazepines.
Benzodiazepines (clonazepam, clorazepate, diazepam, estazolam, flurazepam, midazolam, triazolam)	Nefazodone	Nefazodone may increase the pharmacologic effects of certain benzodiazepines due to CYP3A4 inhibition and decreased metabolic elimination. Impaired psychomotor performance and increased sedation may result from elevated benzodiazepine plasma concentrations.
Benzodiazepines (clonazepam, clorazepate, diazepam, estazolam, flurazepam, midazolam)	Rifamycins	Pharmacologic effects of certain benzodiazepines may be decreased by rifamycins due to CYP3A4 induction and increased metabolic elimination.
Benzodiazepines (alprazolam, clonazepam)	Carbamazepine	The pharmacologic effects of certain benzodiazepines may be decreased due to CYP3A4 induction by carbamazepine.
Benzodiazepines (diazepam, estazolam, midazolam)	Macrolides and ketolides	Central nervous system depression and prolonged sedation have been reported with the concurrent use of benzodiazepines and macrolides/ketolides.
Benzodiazepines (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam)	Opioid analgesics	Concurrent use of opioid analgesics and benzodiazepines may result in additive respiratory depression
Benzodiazepines (midazolam)	Vasopressin receptor antagonists	Plasma concentrations of midazolam may be increased by vasopressin receptor antagonists.
Benzodiazepines (midazolam)	Delavirdine	Inhibition of CYP3A4 by delavirdine may decrease the metabolic elimination of certain benzodiazepines. Plasma concentrations and pharmacologic effects of certain benzodiazepines may be increased by delavirdine. Adverse effects, including the potential for serious cardiac arrhythmias, may result.
Benzodiazepines (alprazolam, clonazepam, midazolam, triazolam)	Idelalisib	Concurrent use of idelalisib and triazolam may result in increased triazolam concentrations.
Benzodiazepines (alprazolam, midazolam, triazolam)	Cobicistat	Concurrent use of cobicistat and triazolam may result in increased triazolam plasma concentrations

Generic Name(s)	Interaction	Mechanism
		and increased risk for serious adverse effects including, prolonged or increased sedation or respiratory depression.

VI. Adverse Drug Events

The most common adverse drug events reported with the benzodiazepines are listed in Tables 7 to 8. The boxed warnings for midazolam are listed in Tables 9 to 11. The benzodiazepines share a number of similar adverse drug events. The most common adverse events are central nervous system-related, including ataxia, confusion, drowsiness, dizziness, and lightheadedness.[1-12] Long-acting benzodiazepines, or benzodiazepines with active metabolites, may have a higher incidence of residual daytime sedation and cognitive/psychomotor impairment. This may be more pronounced in elderly patients or patients with impaired elimination of benzodiazepines. Complex behaviors such as "sleep driving", as well as other behaviors, have been reported in patients who are not fully awake after taking a sedative-hypnotic.[1,2]

Misuse and dependence are a concern with the use of benzodiazepines. The risk of dependence increases with long-term therapy, high daily dose, use of high potency and rapid-onset benzodiazepines, history of substance abuse, chronic physical illness, chronic sleep disorders, and dysthymic or personality disorders.[37,38] Withdrawal symptoms may occur when benzodiazepines are discontinued, especially if therapy is abruptly stopped. Symptoms may include relapse of anxiety disorder or rebound/withdrawal syndromes. Withdrawal may occur within hours of discontinuation of a short-acting benzodiazepine or as late as one to two weeks with the use of long-acting agents. Factors that can predict the severity of withdrawal symptoms include long-term therapy, high daily dose, short benzodiazepine half-life, rapid taper rate, and concomitant substance abuse.[37,39]

Table 7. Adverse Drug Events (%) Reported with the Benzodiazepines (Drugs A to E)[1-12]

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Cardiovascular						
Chest pain	1 to 10	-	-	-	-	-
Flushing	-	-	-	-	-	1 to 10
Hypotension	1 to 10	1 to 10	-	✔	✔	-
Palpitations	1 to 10	-	✔	-	-	1 to 10
Syncope	<10	-	-	-	-	-
Tachycardia	1 to 10	-	-	-	-	-
Vasodilation	-	-	-	-	✔	-
Central Nervous System						
Agitation	1 to 10	-	-	-	-	1 to 10
Akathisia	1 to 10	1 to 10	-	-	-	-
Amnesia	<1	-	✔	-	✔	1 to 10
Anxiety	-	-	-	✔	-	1 to 10
Apathy	-	-	-	-	-	1 to 10
Ataxia	>10	>10	✔	✔	✔	-
Attention disturbance	1 to 10	-	-	-	-	-
Behavior changes	-	-	✔	-	-	-
Cognitive disorder	>10	-	-	-	-	-
Coma	-	-	✔	-	-	-
Complex sleep-related behavior	-	-	-	-	-	<1
Confusion	1 to 10	1 to 10	✔	✔	✔	1 to 10

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Coordination abnormal	>10	-	✔	-	-	1 to 10
Depersonalization	1 to 10	-	-	-	-	-
Depression	>10	-	✔	✔	✔	-
Derealization	1 to 10	-	-	-	-	-
Disinhibition	1 to 10	-	-	-	-	-
Disorientation	1 to 10	-	-	-	-	-
Dizziness	>10	1 to 10	✔	✔	-	1 to 10
Dream abnormalities	1 to 10	-	-	-	-	-
Drowsiness	>10	>10	✔	✔	✔	-
Dysdiadochokinesia	-	-	✔	-	-	-
Emotional lability	-	-	✔	-	-	1 to 10
Euphoria	-	-	-	-	-	1 to 10
Fatigue	>10	>10	✔	✔	✔	-
Fear	1 to 10	-	-	-	-	-
Fever	-	-	✔	-	-	<1
Hallucinations	1 to 10	-	✔	-	-	-
Hangover effect	-	-	-	-	-	1 to 10
Headache	1 to 10	-	✔	✔	✔	-
Hemiparesis	-	-	✔	-	-	-
Homicidal ideation	<1	-	-	-	-	-
Hostility	-	-	-	-	-	1 to 10
Hypersomnia	1 to 10	-	-	-	-	-
Hypoesthesia	1 to 10	-	-	-	-	-
Hypokinesia	-	-	-	-	-	1 to 10
Hypomania	<1	-	-	-	-	-
Hypotonia	-	-	✔	-	-	-
Hysteria	-	-	✔	-	-	-
Insomnia	1 to 10	-	✔	✔	-	-
Intellectual ability reduced	-	-	✔	-	-	-
Irritability	>10	>10	-	✔	-	-
Lethargy	1 to 10	-	-	-	-	-
Lightheadedness	>10	>10	-	✔	-	-
Malaise	1 to 10	-	-	-	-	-
Mania	<1	-	-	-	-	-
Memory impairment	>10	-	✔	✔	-	-
Mental impairment	1 to 10	>10	-	-	-	-
Nervousness	1 to 10	-	✔	✔	-	-

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Nightmares	1 to 10	-	-	-	-	-
Paradoxical reactions	-	-	✔	-	✔	-
Paresthesia	1 to 10	-	-	-	-	1 to 10
Psychosis	-	-	✔	-	-	-
Restlessness	1 to 10	-	-	-	-	-
Sedation	>10	-	-	-	-	-
Seizure	1 to 10	-	✔	-	-	1 to 10
Sleep disturbances	-	-	-	-	-	1 to 10
Slurred speech	-	-	✔	✔	✔	-
Somnolence	>10	-	✔	-	-	>10
Stupor	-	-	-	-	-	1 to 10
Suicidal ideation/attempts	<1	-	✔	-	-	-
Talkativeness	1 to 10	-	-	-	-	-
Tremor	1 to 10	1 to 10	✔	✔	✔	1 to 10
Vasomotor disturbances	2	-	-	-	-	-
Vertigo	1 to 10	-	✔	-	✔	-
Dermatological						
Alopecia	-	-	✔	-	-	-
Dermatitis	1 to 10	1 to 10	-	-	-	1 to 10
Hirsutism	-	-	✔	-	-	-
Photosensitivity	-	1 to 10	-	-	-	-
Pruritus	-	-	-	-	-	1 to 10
Rash	1 to 10	>10	✔	✔	✔	1 to 10
Stevens-Johnson Syndrome	<1	-	-	-	-	-
Urticaria	-	-	-	-	-	1 to 10
Gastrointestinal						
Abdominal pain	1 to 10	-	✔	-	-	-
Anorexia	1 to 10	-	✔	-	-	-
Appetite increased/decreased	>10	>10	✔	✔	-	-
Change in appetite	-	-	-	-	-	1 to 10
Constipation	>10	-	✔	✔	✔	1 to 10
Dehydration	-	-	✔	-	-	-
Diarrhea	1 to 10	-	✔	✔	✔	-
Dyspepsia	1 to 10	-	-	-	-	-
Dysphagia	-	-	-	-	-	-
Encopresis	-	-	✔	-	-	-
Flatulence	-	-	-	-	-	1 to 10

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Gastritis	-	-	✔	-	-	1 to 10
Gingival soreness	-	-	✔	-	-	-
Nausea	1 to 10	-	✔	✔	✔	-
Salivation decreased	-	>10	-	✔	-	-
Salivation increased	1 to 10	1 to 10	-	-	✔	-
Taste alteration	-	-	-	-	-	1 to 10
Tongue coated	-	-	✔	-	-	-
Vomiting	1 to 10	-	-	✔	-	-
Xerostomia	>10	>10	✔	✔	✔	1 to 10
Genitourinary						
Colpitis	-	-	✔	-	-	-
Dysmenorrhea	1 to 10	-	✔	-	-	-
Dysuria	-	-	✔	-	-	-
Ejaculation delayed	-	-	✔	-	-	-
Enuresis	-	-	✔	-	-	-
Impotence	-	-	✔	-	-	-
Incontinence	1 to 10	1 to 10	-	-	✔	-
Libido decreased	>10	>10	✔	✔	✔	-
Libido increased	1 to 10	1 to 10	✔	-	✔	-
Menstrual disorders	1 to 10	>10	-	-	-	1 to 10
Micturition difficulty	>10	>10	-	-	-	1 to 10
Micturition frequency	-	-	✔	-	-	1 to 10
Nocturia	-	-	✔	-	-	-
Sexual dysfunction	1 to 10	1 to 10	-	-	-	-
Urinary retention	-	-	✔	-	✔	-
Urinary tract infection	-	-	✔	-	-	-
Vaginal discharge/itching	-	-	-	-	-	1 to 10
Hematologic						
Anemia	-	-	✔	-	-	-
Eosinophilia	-	-	✔	-	-	-
Leukopenia	-	-	✔	-	-	-
Neutropenia	-	-	-	-	✔	-
Thrombocytopenia	-	-	✔	-	-	-
Hepatic						
Alkaline phosphatase increased	-	-	✔	-	-	-
Bilirubin increased	1 to 10	-	-	-	-	-
Hepatic failure	<1	-	-	-	-	-

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Hepatitis	<1	-	-	-	-	-
Hepatomegaly	-	-	✔	-	-	-
Jaundice	<10	-	-	✔	✔	-
Liver enzymes increased	<10	-	✔	✔	-	-
Musculoskeletal						
Arthralgia	1 to 10	-	✔	-	-	-
Back pain	1 to 10	-	✔	-	-	-
Choreiform movements	-	-	✔	-	-	-
Dysarthria	>10	>10	✔	-	✔	-
Dyskinesia	1 to 10	-	-	-	-	-
Dystonia	1 to 10	-	-	-	-	-
Muscle cramps	1 to 10	1 to 10	-	-	-	-
Muscle pain	-	-	✔	-	-	-
Muscle spasm	-	-	-	-	-	<1
Muscle twitching	1 to 10	-	-	-	-	-
Muscle weakness	-	-	✔	-	-	-
Myalgia	1 to 10	-	✔	-	-	<1
Neck pain	-	-	-	-	-	<1
Rigidity	-	1 to 10	-	-	-	-
Weakness	1 to 10	-	-	-	✔	>10
Respiratory						
Allergic rhinitis	1 to 10	-	-	-	-	-
Apnea	-	-	-	-	✔	-
Asthma	-	-	-	-	✔	1 to 10
Bronchitis	-	-	✔	-	-	-
Chest congestion	-	-	✔	-	-	-
Cough	-	-	✔	-	-	1 to 10
Dyspnea	1 to 10	-	-	-	-	1 to 10
Hypersecretions	-	-	✔	-	-	-
Hyperventilation	1 to 10	-	-	-	-	-
Nasal congestion	>10	1 to 10	-	-	-	-
Pharyngitis	-	-	✔	-	-	-
Respiratory depression	-	-	✔	-	✔	-
Respiratory tract infection	-	-	✔	-	-	-
Rhinitis	-	-	✔	-	-	1 to 10
Rhinorrhea	-	-	✔	-	-	-
Shortness of breath	-	-	✔	-	-	-

Adverse Events	Alprazolam	Chlordiazepoxide	Clonazepam	Clorazepate	Diazepam	Estazolam
Sinusitis	-	-	✔	-	-	1 to 10
Upper respiratory infection	1 to 10	-	-	-	-	-
Special Senses						
Blurred vision	1 to 10	-	✔	✔	✔	-
Diplopia	-	-	-	✔	✔	-
Eye movements abnormal	-	-	✔	-	-	-
Eye pain/swelling	-	-	-	-	-	1 to 10
Nystagmus	-	-	✔	-	-	-
Other						
Allergic reaction	-	-	✔	-	-	<1
Anaphylaxis	-	-	-	-	-	<1
Angioedema	<1	-	-	-	-	<1
Aphonia	-	-	✔	-	-	-
Chills	-	-	-	-	-	<1
Diaphoresis	1 to 10	-	-	-	-	1 to 10
Drug dependence	-	-	-	-	-	<1
Edema	-	-	✔	-	-	-
Falls	<1	-	-	-	-	-
Galactorrhea	<1	-	-	-	-	-
Gynecomastia	<1	-	-	-	-	-
Hyperprolactinemia	<1	-	-	-	-	-
Lymphadenopathy	-	-	✔	-	-	-
Pain with injection	-	-	-	-	✔	-
Peripheral edema	<1	-	-	-	-	-
Sleep apnea syndrome	<1	-	-	-	-	-
Tinnitus	<1	1 to 10	-	-	-	-
Weight changes	>10	>10	✔	-	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 8. Adverse Drug Events (%) Reported with the Benzodiazepines (Drugs F to T)[1-12]

Adverse Events	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Cardiovascular						
Bigeminy	-	-	<1	-	-	-
Chest pain	✔	-	-	-	-	<1
Hypotension	✔	1 to 10	1 to 10	-	-	-
Palpitations	✔	-	-	-	-	-

Adverse Events	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Syncope	-	-	-	✔	-	-
Tachycardia	-	-	-	-	-	<1
Central Nervous System						
Abnormal thinking	-	-	-	-	-	-
Agitation	-	-	<1	-	-	-
Akathisia	-	1 to 10	-	-	-	-
Amnesia	-	1 to 10	<1	-	<1	<1
Anxiety	-	-	-	-	1 to 10	-
Apathy	-	-	-	-	-	-
Apprehension	✔	-	-	-	-	-
Ataxia	✔	1 to 10	-	✔	<1	5
Coma	✔	-	-	-	-	-
Complex sleep-related behavior	-	-	-	-	<1	<1
Confusion	✔	1 to 10	-	-	1 to 10	<1
Delirium	-	-	<1	-	-	-
Depression	✔	1 to 10	-	-	-	<1
Disinhibition	-	<1	-	-	-	-
Disorientation	-	1 to 10	-	-	-	-
Dizziness	✔	1 to 10	-	✔	1 to 10	8
Dream abnormalities	-	-	-	-	-	<1
Drowsiness	✔	-	1 to 10	✔	1 to 10	14
Dysesthesia	-	-	-	-	-	<1
Dystonia	-	-	-	-	-	-
Euphoria	✔	<1	<1	-	1 to 10	<1
Faintness	✔	-	-	-	-	-
Fatigue	-	<1	-	-	1 to 10	<1
Hallucinations	✔	-	<1	-	-	-
Hangover effect	✔	-	-	-	1 to 10	-
Headache	✔	1 to 10	1 to 10	✔	1 to 10	10
Hyperkinesia	-	-	-	-	-	-
Hypokinesia	-	-	-	-	-	-
Incoordination	-	-	-	-	-	-
Irritability	✔	-	-	-	-	-
Lethargy	-	-	-	-	1 to 10	-
Lightheadedness	✔	-	-	-	-	5
Malaise	-	-	-	-	-	-
Memory impairment	✔	-	-	✔	-	<1

Adverse Events	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Nervousness	✔	-	-	-	-	5
Nightmares	-	-	-	-	-	<1
Over sedation	-	-	1 to 10	-	-	-
Paradoxical reaction	✔	-	1 to 10	✔	<1	<1
Paranoid reaction	-	-	-	-	-	-
Paresthesia	-	-	-	-	-	<1
Restlessness	✔	-	-	-	-	-
Sedation	-	>10	-	-	-	<1
Seizure	-	<1	1 to 10	-	-	-
Sleep disturbances	-	-	-	-	-	-
Slurred speech	✔	-	-	-	-	<1
Speech disorder	-	-	-	-	-	-
Staggering	✔	-	-	-	-	-
Stimulation	-	-	-	-	-	-
Suicidal ideation	-	<1	-	-	-	-
Talkativeness	✔	-	-	-	-	-
Tremor	-	-	-	✔	-	-
Vertigo	-	<1	-	✔	1 to 10	-
Dermatological						
Dermatitis	-	1 to 10	-	-	-	<1
Flushing	✔	-	-	-	-	-
Pruritus	✔	-	-	-	-	-
Rash	✔	1 to 10	<1	✔	1 to 10	-
Gastrointestinal						
Abdominal pain	-	-	-	-	-	-
Anorexia	-	-	-	-	-	-
Appetite increased/decreased	✔	1 to 10	-	-	-	-
Bitter taste	✔	-	-	-	-	-
Constipation	✔	-	-	-	-	-
Cramps	-	-	-	-	-	<1
Diarrhea	✔	-	-	-	1 to 10	-
Dyspepsia	-	-	-	-	-	-
Gastrointestinal pain	✔	-	-	-	-	-
Heartburn	✔	-	-	-	-	-
Hiccups	-	-	1 to 10	-	-	-
Nausea	✔	1 to 10	1 to 10	-	-	5
Salivation increased	✔	<1	-	-	-	-

Adverse Events	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Taste alteration	-	-	-	-	-	-
Upset stomach	✔	-	-	-	-	-
Vomiting	✔	-	1 to 10	-	<1	5
Weight changes	✔	1 to 10	-	-	-	-
Xerostomia	✔	-	-	-	-	<1
Genitourinary						
Impotence	-	-	-	-	-	-
Incontinence	-	-	-	✔	-	-
Libido changes	-	-	-	✔	1 to 10	<1
Decreased libido	-	-	-	-	-	-
Menstrual irregularities	-	<1	-	✔	-	-
Urinary retention	-	-	-	-	-	-
Hematologic						
Blood dyscrasias	-	<1	-	✔	<1	-
Granulocytopenia	✔	-	-	-	-	-
Leukopenia	✔	-	-	✔	-	-
Hepatic						
Aspartate aminotransferase increased	✔	-	-	-	-	-
Alkaline phosphatase increased	✔	-	-	-	-	-
Alanine aminotransferase increased	✔	-	-	-	-	-
Bilirubin increased	✔	-	-	-	-	-
Hepatic dysfunction	-	-	-	✔	-	-
Jaundice	✔	-	-	✔	-	-
Musculoskeletal						
Asthenia	-	<1	-	-	-	-
Dysarthria	✔	-	-	✔	1 to 10	<1
Joint pain	✔	-	-	-	-	-
Muscle spasticity	-	-	-	-	-	-
Myoclonic jerks	-	-	1 to 10	-	-	-
Weakness	✔	1 to 10	-	-	1 to 10	<1
Respiratory						
Apnea	✔	1 to 10	-	-	-	-
Bronchospasm	-	-	<1	-	-	-
Cough	-	-	1 to 10	-	-	-
Dyspnea	✔	-	-	-	-	-
Hyperventilation	-	1 to 10	-	-	-	-
Laryngospasm	-	-	<1	-	-	-

Adverse Events	Flurazepam	Lorazepam	Midazolam	Oxazepam	Temazepam	Triazolam
Nasal congestion	-	1 to 10	-	-	-	-
Respiratory rate decreased	-	-	>10	-	-	-
Tidal volume decreased	-	-	>10	-	-	-
Special Senses						
Abnormal vision	-	-	-	-	-	-
Blurred vision	✔	-	-	✔	1 to 10	-
Cataract	-	-	-	-	-	-
Difficulty focusing	✔	-	-	-	-	-
Diplopia	-	-	-	✔	-	-
Eyes burning	✔	-	-	-	-	-
Nystagmus	-	-	1 to 10	-	-	-
Visual disturbances	-	1 to 10	-	-	-	<1
Other						
Anaphylaxis	-	-	-	-	<1	<1
Angioedema	-	-	-	-	<1	<1
Diaphoresis	✔	-	-	-	1 to 10	-
Drug dependence	✔	<1	1 to 10	✔	<1	-
Edema	-	-	-	✔	-	-
Falling	✔	-	-	-	-	-
Injection site reaction	-	-	1 to 10	-	-	-
Pain	✔	-	-	-	-	<1

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 9. Boxed Warning for Benzodiazepines[1]

WARNING
Risks from concomitant use with opioids: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Table 10. Boxed Warning for Midazolam Injection[1]

WARNING
Adults and pediatrics: Intravenous midazolam hydrochloride has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Intravenous midazolam hydrochloride should be used only in hospital or ambulatory care settings, including physicians' and dental offices, that provide for continuous monitoring of respiratory and cardiac function (i.e., pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be ensured. Patients should be continuously monitored with some means of detection for early signs of hypoventilation, airway obstruction, or apnea (i.e., pulse oximetry). Hypoventilation, airway obstruction, and apnea can lead to hypoxia or cardiac arrest unless effective countermeasures are taken immediately. The immediate availability of specific reversal agents (flumazenil) is highly recommended. Vital signs should continue to be monitored during the recovery period. For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure. The initial dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients and in patients receiving concomitant narcotics or other central nervous system depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional two or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam hydrochloride for sedation/anxiolysis/amnesia is age, procedure, and route dependent. Neonates: Midazolam hydrochloride should not be administered by rapid injection in the neonatal population. Rapid injection should be avoided in the neonatal population. Midazolam hydrochloride administered rapidly as an intravenous injection (less than two minutes) has been associated with severe hypotension in neonates, particularly when the patient has also received fentanyl. Likewise, severe hypotension has been observed in neonates receiving a continuous infusion of midazolam who then receive a rapid intravenous injection of fentanyl. Seizures have been reported in several neonates following rapid intravenous administration.

Table 11. Boxed Warning for Midazolam Syrup[1]

WARNING
Midazolam syrup has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. Midazolam syrup has been associated with reports of respiratory depression, airway obstruction, desaturation, hypoxia, and apnea, most often when used concomitantly with other central nervous system depressants (e.g., opioids). Midazolam syrup should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, that can provide for continuous monitoring of respiratory and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for ventilation and intubation, and personnel trained in their use and skilled in airway management should be ensured. For deeply sedated patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.

VII. Dosing and Administration

The usual dosing regimens for the benzodiazepines are listed in Table 12.

Table 12. Usual Dosing Regimens for the Benzodiazepines[1-12]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Alprazolam	Management of anxiety disorders, short-term relief of symptoms of anxiety: Oral concentrate (IR), orally disintegrating tablet (IR), tablet (IR): initial, 0.25 to 0.5 mg orally three times daily; may be increased to achieve a maximum therapeutic effect at every three to four days; maximum, 4 mg/day Treatment of panic disorder, with or without agoraphobia: Oral concentrate (IR), orally disintegrating tablet (IR), tablet (IR): initial, 0.5 mg orally three times daily; may increase dosage up to 1 mg every three to four days; usual dosage range is 1 to 10 mg/day Tablet (ER): initial, 0.5 to 1 mg orally in the morning; may increase dosage by up to 1 mg/day every three to four days; usual dosage range is 3 to 6 mg/day; maximum, 10 mg/day	Safety and efficacy in children have not been established.	Oral concentrate (IR): 1 mg/mL Orally disintegrating tablet (IR): 0.25 mg 0.5 mg 1 mg 2 mg Tablet (ER): 0.5 mg 1 mg 2 mg 3 mg Tablet (IR): 0.25 mg 0.5 mg 1 mg 2 mg
Chlordiazepoxide	Acute alcohol withdrawal: Capsule: initial, 25 to 100 mg, followed by repeated doses as needed; maximum, 300 mg/day Management of anxiety disorders, short-term relief of symptoms of anxiety: Capsule: mild-to-moderate symptoms, 5 or 10 mg three to four times daily; severe symptoms, 20 or 25 mg three to four times daily Preoperative apprehension/ anxiety: Capsule: 5 to 10 mg three to four times daily on days preceding surgery	Management of anxiety disorders, short-term relief of symptoms of anxiety ≥6 years of age: Capsule: 5 mg two to four times daily; may be increased to 10 mg two to three times daily	Capsule: 5 mg 10 mg 25 mg
Clonazepam	Treatment of panic disorder,	Management of patients with	Orally disintegrating

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	with or without agoraphobia: Orally disintegrating tablet, tablet: initial, 0.25 mg twice daily; increase by 0.125 to 0.25 mg twice daily every three days; maximum, 4 mg/day Management of patients with absence seizures who failed succinimides, monotherapy or adjunctive treatment of Lennox-Gastaut syndrome, akinetic and myoclonic seizures: Orally disintegrating tablet, tablet: initial, 1.5 mg/day divided into three doses; increase daily by 0.5 to 1 mg/day every three days; maximum, 20 mg/day	absence seizures who failed succinimides, monotherapy or adjunctive treatment of Lennox-Gastaut syndrome, akinetic and myoclonic seizures: Orally disintegrating tablet, tablet: ≤10 years of age (≤30 kg), 0.01 to 0.03 mg/kg/day divided two to three times daily; increase by 0.25 to 0.5 mg/day every three days; maximum, 0.2 mg/kg/day; >10 years of age (>30 kg): Initial, 1.5 mg/day divided into three doses; increase by 0.5 to 1 mg/day every three days; maximum, 20 mg/day	tablet: 0.125 mg 0.25 mg 0.5 mg 1 mg 2 mg Tablet: 0.5 mg 1 mg 2 mg
Clorazepate	Acute alcohol withdrawal: Tablet: day one: 30 mg initially, then 30 to 60 mg in divided doses for the remainder of the day; say two: 45 to 90 mg/day in divided doses; day three: 22.5 to 45 mg/day in divided doses; day four: 15 to 30 mg/day in divided doses; day five and thereafter: 7.5 to 15 mg/day in divided doses until the patient's condition is stable; maximum, 90 mg/day Management of anxiety disorders, short-term relief of symptoms of anxiety: Tablet: 15 to 60 mg/day in divided doses; usual daily dose is 30 mg/day; may be administered in a single dose at bedtime. Adjunct in partial seizures: Tablet: 7.5 mg three times daily; may increase dose by 7.5 mg/week; maximum, 90 mg/day	Adjunct in partial seizures: Tablet: nine to 12 years of age, 7.5 mg twice daily; increase by 7.5 mg/week; maximum, 60 mg/day; >12 years of age: 7.5 mg three times daily; increase by 7.5 mg/week; maximum, 90 mg/day	Tablet 3.75 mg 7.5 mg 15 mg
Diazepam	Acute alcohol withdrawal: Injection: initial, 10 mg IM/IV, then 5 to 10 mg in three to four hours, if necessary Oral concentrate, oral solution, tablet: 10 mg three to four times during the first 24 hours,	Management of anxiety disorders, short-term relief of symptoms of anxiety: Oral concentrate, oral solution, tablet: ≥6 months of age, 1 to 2.5 mg three to four times daily; increase gradually as needed and	Injection: 5 mg/mL Oral concentrate: 5 mg/mL Rectal gel: 2.5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	reducing to 5 mg three to four times daily as needed Management of anxiety disorders, short-term relief of symptoms of anxiety: Injection: moderate symptoms: Initial, 2 to 5 mg IM/IV; repeat in three to four hours, if necessary; severe symptoms: initial, 5 to 10 mg IM/IV; repeat in three to four hours, if necessary Oral: 2 to 10 mg two to four times daily Premedication for the relief of anxiety and tension prior to cardioversion and to diminish the patient's recall of the procedure: Injection: 5 to 15 mg IV five to 10 minutes prior to the procedure Premedication for relief of anxiety and tension in patients who are to undergo surgical procedures (endoscopic procedure): Injection: 10 to 20 mg IV immediately prior to procedure or five to 10 mg IM 30 minutes prior to procedure Premedication for relief of anxiety and tension in patients who are to undergo surgical procedures: Injection: 10 mg IM (preferred route) before surgery Adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, and stiff-man syndrome: Injection: initial, 5 to 10 mg IM/IV, then 5 to 10 mg in three to four hours, if necessary. Oral: 2 to 10 mg three to four times daily	tolerated Adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, and stiff-man syndrome: Injection: 30 days to five years of age, 1 to 2 mg IM/IV, repeated every three to four hours, if necessary ≥5 years of age, 5 to 10 mg IM/IV, repeated every three to four hours, if necessary Oral concentrate, oral solution, tablet: ≥6 months of age, 1 to 2.5 mg three to four times daily; increase gradually as needed and tolerated Adjunctive in convulsive disorders: Oral concentrate, oral solution, tablet: ≥6 months of age: 1 to 2.5 mg three to four times daily; increase gradually as needed and tolerated Rectal gel: two to five years of age, 0.5 mg/kg; may repeat in four to 12 hours; six to 11 years of age, 0.3 mg/kg; may repeat in four to 12 hours; ≥12 years of age, 0.2 mg/kg; may repeat in four to 12 hours Adjunct in status epilepticus and severe recurrent seizures: Injection: 30 days to five years of age: 0.2 to 0.5 mg (IV preferred) every two to five minutes; maximum, 5 mg; ≥5 years of age: 1 mg (IV preferred) every two to five minutes; maximum, 10 mg	5-7.5-10 mg 12.5-15-17.5-20 mg Oral solution: 5 mg/5 mL Tablet: 2 mg 5 mg 10 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Adjunctive in convulsive disorders: Oral: 2 to 10 mg two to four times daily Rectal gel: 0.2 mg/kg; may repeat in four4 to 12 hours Adjunct in status epilepticus and severe recurrent seizures: Injection: initial, 5 to 10 mg (IV preferred); may be repeated at 10 to 15 minute intervals; maximum, 30 mg		
Estazolam	Short-term management of insomnia: Tablet: 1 to 2 mg at bedtime	Safety and efficacy in children have not been established.	Tablet: 1 mg 2 mg
Flurazepam	Short-term management of insomnia: Capsule: 15 to 30 mg at bedtime	Safety and efficacy in children have not been established.	Capsule: 15 mg 30 mg
Lorazepam	Management of anxiety disorders, short-term relief of symptoms of anxiety: Oral concentrate, tablet: 2 to 3 mg/day divided into two to three daily doses Preanesthetic medication, producing sedation, relief of anxiety, and a decreased ability to recall events related to the day of surgery: Injection: 0.05 mg/kg IM two to three hours before procedure; maximum, 4 mg; 0.044 mg/kg or 2 mg IV (whichever is less); maximum, 0.05 mg/kg or 4 mg Treatment of status epilepticus: Injection: 4 mg IV; may repeat dose in 10 to 15 minutes if needed	Safety and efficacy in children have not been established.	Injection: 2 mg/mL 4 mg/mL Oral concentrate: 2 mg/mL Tablet: 0.5 mg 1 mg 2 mg
Midazolam	Induction of anesthesia, before administration of other anesthetic agents: Injection: un-premedicated patients, 0.3 to 0.35 mg/kg IV; premedicated patients, 0.15 to 0.35 mg/kg IV Sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures (amnesia	Preoperative sedation/anxiolysis/amnesia: Injection: non-neonatal: 0.1 to 0.15 mg/kg IM, six months to five years of age, 0.05 to 0.1 mg/kg IV; six to 12 years of age, 0.025 to 0.05 mg/kg IV; 12 to 16 years of age: refer to adult dosing Syrup: 0.25 to 1 mg/kg; maximum, 20 mg	Injection: 1 mg/mL 5 mg/mL Syrup: 2 mg/mL

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	maintenance): Injection: incremental injections of approximately 25% of the induction dose should be given in response to signs of lightening of anesthesia and repeated as necessary Preoperative sedation/ anxiolysis/amnesia: Injection: 0.07 to 0.08 mg/kg IM administered up to one hour before surgery; IV dosage must be individualized and titrated; some patients may respond to as little as 1 mg; no more than 2.5 mg should be given over a period of at least two minutes Sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures (continuous infusion): Injection: 0.01 to 0.05 mg/kg IV loading dose, followed by a continuous IV infusion at a rate of 0.02 to 0.10 mg/kg/hr	Sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting: Injection: <32 weeks, continuous IV infusion at a rate of 0.03 mg/kg/hr; ≥32 weeks, continuous IV infusion at a rate of 0.06 mg/kg/hour; non-neonatal, 0.05 to 0.2 mg/kg IV loading dose, followed by a continuous IV infusion at a rate of 0.06 to 0.12 mg/kg/hr	
Oxazepam	Acute alcohol withdrawal: Capsule: 15 to 30 mg three to four times daily Management of anxiety disorders, short-term relief of symptoms of anxiety: Capsule: mild-to-moderate symptoms: 10 to 15 mg three to four times daily; severe symptoms: 15 to 30 mg three to four times daily	Safety and efficacy in children <6 years of age have not been established. Absolute dosage for patients six to 12 years of age is not established. Management of anxiety disorders, short-term relief of symptoms of anxiety: Capsule: mild-to-moderate symptoms: 10 to 15 mg three to four times daily; severe symptoms: 15 to 30 mg three to four times daily	Capsule: 10 mg 15 mg 30 mg
Temazepam	Short-term management of insomnia: Capsule: 7.5 to 30 mg at bedtime	Safety and efficacy in children have not been established.	Capsule: 7.5 mg 15 mg 22.5 mg 30 mg
Triazolam	Short-term management of insomnia: Tablet: 0.125 to 0.25 mg at bedtime; maximum, 0.5 mg	Safety and efficacy in children have not been established.	Tablet: 0.125 mg 0.25 mg

ER=extended-release, IM=intramuscular, IR=immediate-release, IV=intravenous

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the benzodiazepines are summarized in Table 13.

Table 13. Comparative Clinical Trials with the Benzodiazepines

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Alcohol Withdrawal				
Holbrook et al.[40] (1999) Benzodiazepines (chlordiazepoxide, diazepam, oxazepam, lorazepam) vs alternative active treatments (bromocriptine, carbamazepine, chlorpromazine, clonidine, doxepin, ethanol, hydroxyzine, paraldehyde, propranolol, thiamine) vs placebo	MA Patients being treated for acute alcohol withdrawal	N=1,286 (11 trials) Variable duration	Primary: Improvement of withdrawal symptoms, therapeutic success (CIWA-Ar score $\leq$10), adverse events, dropout rates Secondary: Not reported	Primary: In three studies with a similar outcome measures, the benzodiazepines were rated as more efficacious compared to placebo in relieving the symptoms of alcohol withdrawal within the first two days of withdrawal (OR, 3.28; 95% CI, 1.30 to 8.28). There were no significant differences in efficacy between individual benzodiazepines. In the nine trials that compared benzodiazepines with alternative active agents, there was no evidence of better efficacy of any alternative agent over a benzodiazepine. Three studies reported the number of adverse events and found no significant difference between benzodiazepines and the alternative treatments examined (OR, 0.67; 95% CI, 0.34 to 1.32). Data on study dropout rates were combined from five trials and indicated that fewer patients in the benzodiazepines group compared to the alternative treatment group dropped out within the first seven days of treatment (OR, 0.68; 95% CI, 0.47 to 0.97). Secondary: Not reported
Ntais et al.[41] (2005) Benzodiazepines alone or in	MA Patients with alcohol dependence who experienced	N=4,051 Variable duration	Primary: Severity of overall alcohol withdrawal syndrome, alcohol withdrawal	Primary: Compared to placebo, there was a benefit with the benzodiazepines against alcohol withdrawal seizures (P=0.01). Benzodiazepines had similar success rates as other drugs and offered a

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
combination with other agents vs alternate benzodiazepines vs other agents (e.g., anticonvulsants) vs placebo	alcohol withdrawal		seizures, alcohol withdrawal delirium Secondary: Adverse events, discontinuation due to adverse events, withdrawal rate, mortality	benefit for seizure control against non-anticonvulsants (P=0.02), but not against anticonvulsants (95% CI, 0.46 to 8.65). Data on other comparisons were limited preventing informative quantitative synthesis for the various outcomes. Secondary: Compared to placebo, the number of withdrawals per arm tended to be less common among patients receiving benzodiazepine (P=0.22). No patients discontinued due to side effects in the benzodiazepine group and one patient discontinued treatment for this reason in the placebo group. No patients died in either the benzodiazepine groups or placebo groups. In those studies that compared benzodiazepines to other agents, there were no between-group differences in number of withdrawals per arm (P=0.54 for comparison with other drugs and P=0.75 for comparison with anticonvulsants). Two out of 901 benzodiazepine-treated patients died compared to five out of 1,275 patients receiving other agents. Patients receiving benzodiazepines had a higher incidence of side effects compared to patients receiving other agents (P=0.16) or anticonvulsants (P=0.47), though NS.
Kumar et al.[42] (2009) Lorazepam 8 mg/day (2 mg in the morning, 2 mg in the afternoon, 4 mg at night) for 2 days; the dose was reduced by 2 mg/day every 2 days vs	DB, RCT Male inpatients in a state of moderately severe, uncomplicated alcohol withdrawal	N=100 12 days	Primary: Withdrawal severity and changes in the CIWA-Ar scale Secondary: Not reported	Primary: There was no significant difference in withdrawal severity between patients receiving lorazepam or chlordiazepoxide at baseline or at any time during the study. Using an 11-item alcohol-withdrawal checklist, irritability (2.9 vs 0.4%; P<0.001), dizziness (0.9 vs 0.0%; P<0.001), and brisk reflexes (0.8 vs 0.2%; P<0.02) were more common with lorazepam than with chlordiazepoxide. Palpitations were more common with chlordiazepoxide than with lorazepam (0.9 vs 0.0%, respectively; P<0.001). The incidence of the remaining items (depressed mood, impaired concentration, anorexia, insomnia, fever, and gait ataxia) did not differ between the two groups. There were no symptoms of benzodiazepine withdrawal recorded during

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
chlordiazepoxide 80 mg/day (20 mg in the morning, 20 mg in the afternoon, 40 mg at night) for 2 days; the dose was reduced by 20 mg per day every 2 days Dosing was down-titrated to zero across 8 treatment days.				the last four days of the study, nor were there impairing adverse events reported during this period. Secondary: Not reported
Caputo et al.[43] (2014) GATE 1 Oxazepam vs sodium oxybate	DB, MC, RCT Alcohol-dependent outpatients 21 to 75 years of age affected by uncomplicated AWS with CIWA-Ar score ≥10	N=126 10 days	Primary: Reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline Secondary: Not reported	Primary: A significant decrease of the mean total CIWA-Ar score from the baseline to the end of the study was found both in the sodium oxybate group (adjusted mean change from baseline of −15.62 ± 0.38; ANCOVA model P<0.0001) and in the oxazepam group (adjusted mean change from baseline of −16.27 ± 0.38; ANCOVA model P<0.0001), with no significant differences between the two treatments (ANCOVA model: estimated point 0.65 (95 % CI, −0.37 to 1.66) P=0.210). Secondary: Not reported
Anxiety Disorders				
Martin et al.[44] (2007) Alprazolam, diazepam, lorazepam vs	MA Patients with generalized anxiety disorder	N=2,326 (23 trials) 2 to 24 weeks	Primary: Withdrawals for any reason and withdrawals due to adverse events Secondary: Withdrawals due to lack of efficacy	Primary: The RR of withdrawal for any reason was 0.78 (95% CI, 0.62 to 1.00; P=0.05) in favor of benzodiazepines. The RR of withdrawal due to adverse events was 1.54 (95% CI, 1.17 to 2.03; P=0.002) indicating an increased risk for the benzodiazepine group. Secondary: The RR of withdrawal due to lack of efficacy was 0.29 (95% CI, 0.18 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				0.45; P<0.00001) in favor of benzodiazepines.
Moylan et al.[45] (2011) Alprazolam vs benzodiazepines	MA Patients ≥18 years of age with panic disorder or agoraphobia with panic attacks	N=631 (8 trials) Variable duration	Primary: PAF, HAM-A, proportion of panic attack-free patients, adverse events Secondary: Not reported	Primary: There was no significant difference in mean PAF improvement between alprazolam and other benzodiazepines (WMD in PAF of 0.6 panic attacks/week; 95% CI, -0.3 to 1.6). There was no difference in mean HAM-A improvement between alprazolam and other benzodiazepines (WMD, 0.8 points; 95% CI, -0.5 to 2.1). There was no significant difference between alprazolam and other benzodiazepines in the proportion of panic-attack free patients (RR, 1.1; 95% CI, 0.9 to 1.4). The most commonly reported adverse effect was sedation. There was no significant difference in the dropout rates due to adverse effects. There was no clinically significant difference in tolerability between alprazolam and comparative benzodiazepine. Secondary: Not reported
Mitte et al.[46] (2005) Benzodiazepines vs azapirones vs placebo	MA Patients with generalized anxiety disorder	N=12,053 (48 trials) Variable duration	Primary: Anxiety (HAM-A), depression (HAM-D) Secondary: Not reported	Primary: Active treatment reduced both anxiety and depression symptoms better than placebo. There were no significant differences in efficacy between the benzodiazepines and azapirones (P=NS). Significantly fewer patients in the benzodiazepine group dropped out of the study (20.5 vs 30.7%; P<0.05). Secondary: Not reported
Blanco et al.[47] (2003) Benzodiazepines,	MA Patients with social anxiety disorder	N=2,954 (23 trials) 6 to 20 weeks	Primary: Outcome data on the LSAS or a categorical	Primary: In terms of LSAS, no statistical difference was detected between medications or medication groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
SSRIs, MAOIs, RIMAs, β-blockers, gabapentin, buspirone vs placebo			measure of status Secondary: CGI score	Secondary: In terms of responders, effect sizes of each medication group were: benzodiazepines (16.61), brofaromine (6.96), phenelzine (4.10), gabapentin (3.78), SSRIs (3.22), atenolol (1.36), and moclobemide (1.27). No statistical differences were detected between these medications or medication groups.
van Balkom et al.[48] (1997) Benzodiazepines vs antidepressants vs psychological panic management vs exposure in vivo vs placebo	MA Patients with panic disorder (with or without agoraphobia)	N=5,011 (106 trials) Variable duration	Primary: Panic, agoraphobia, depression, and general anxiety Secondary: Not reported	Primary: Antidepressants, psychological panic management and antidepressants/ exposure in vivo demonstrated significant improvement in the reduction of panic, agoraphobia, depression, and anxiety compared to a control conditions. High-potency benzodiazepines showed significant improvement in panic, agoraphobia, and anxiety compared to control conditions. There were no significant differences between the treatments for panic disorder. Antidepressant test groups had significant improvements compared to other treatments except exposure in vivo in agoraphobia. A significantly greater improvement was noted in antidepressant/exposure in vivo compared to exposure in vivo alone and psychological panic management/exposure in vivo in treatment of depression and anxiety. Secondary: Not reported
Chessick et al.[49] (2006) Benzodiazepines vs	MA Patients with generalized anxiety disorder	N=5,908 (36 trials) 4 to 14 weeks	Primary: HAM-A, patient acceptability Secondary: Not reported	Primary: Using the HAM-A, lorazepam (WMD, 1.1; 95% CI, 0.29 to 1.91; P=0.008) and alprazolam (WMD, 1.1; 95% CI, 0.28 to 1.92; P=0.009) were more effective than buspirone, but diazepam was comparable in efficacy to buspirone (WMD, -0.20; 95% CI, -7.45 to 7.05; P=0.96).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
azapirones The MA also compared the azapirones to hydroxyzine, kava kava, placebo, venlafaxine and psychotherapy, but only the results from studies comparing the azapirones to the benzodiazepines are reported in this review.				Significantly fewer participants dropped out on benzodiazepine therapy compared to buspirone (RR, 1.24; 95% CI, 1.01 to 1.52; P=0.04). Patients receiving buspirone reported less drowsiness (P<0.00001), fatigue (P=0.00001), nervousness (P=0.0006), depression (P<0.00001), insomnia (P=0.01) and sleep problems (P=0.02) compared to benzodiazepines. Patients receiving benzodiazepines reported less nausea (P=0.03) and dizziness (P=0.02) compared to buspirone. In the trial that discontinued either diazepam or buspirone at either six or 12 weeks, neither group had worsening symptoms of anxiety but those on diazepam did show withdrawal symptoms at six weeks compared to those on buspirone (P<0.001). In the one extension trial with a taper off, 25% of patients on ipsapirone showed rebound anxiety symptoms compared to 40% of patients on lorazepam (P<0.001). Secondary: Not reported
Insomnia				
Holbrook et al.[50] (2000) Benzodiazepines vs zopiclone, diphenhydramine, glutethimide, promethazine, cognitive behavioral therapy, placebo	MA Patients with insomnia	N=2,672 (45 trials) 1 day to 6 weeks	Primary: Sleep latency, total sleep duration, adverse effects, dropout rates, cognitive function decline Secondary: Not reported	Primary: Using sleep records, benzodiazepines demonstrated a decrease in sleep latency by 4.2 minutes compared to placebo (95% CI, -0.7 to 9.2). Benzodiazepines demonstrated a significant increase in sleep duration compared to placebo by 61.8 minutes (95% CI, 37.4 to 86.2). Benzodiazepines were more likely to be associated with complaints of daytime drowsiness (OR, 2.4; 95% CI, 1.8 to 3.4) and dizziness/ lightheadedness (OR, 2.6; 95% CI, 0.7 to 10.3) compared to placebo. No difference was observed in dropout rates between the two groups. Pooled results from three trials indicated there was no significant difference between benzodiazepines and zopiclone in sleep latency, but benzodiazepine therapy may lead to a longer sleep by 23.1 minutes (95% CI, 5.6 to 40.6). There was no significant difference in adverse events among the treatment

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				groups (OR, 1.5; 95% CI, 0.8 to 2.9). Comparisons between benzodiazepines and antihistamines did not detect any significant differences on sleep outcomes. Triazolam was found to be more effective in reducing sleep latency early in one trial, but efficacy decreased by the second week of treatment. Behavioral therapy efficacy was maintained throughout the nine-week follow-up. Secondary: Not reported
Smith et al.[51] (2002) Benzodiazepines or benzodiazepine receptor agonists vs behavioral treatment vs placebo	MA Patients with primary insomnia for ≥1 month	N=470 (21 trials) 1 to 10 weeks	Primary: Sleep latency, TST, number of awakenings, wake time after sleep onset, and sleep quality before and after treatment Secondary: Not reported	Primary: Sleep latency was reduced by 30% with pharmacological treatment compared to 43% with behavioral interventions. Pharmacotherapy increased TST by 12% compared to 6% with behavior therapy. Both pharmacotherapy and behavior therapy reduced number of awakenings per night by one. Wake time after sleep onset was reduced by 46% with pharmacotherapy and by 56% with behavior therapy. Pharmacotherapy improved sleep quality by 20% compared to 28% with behavior therapy. Overall, there were no differences in TST, number of awakenings, wake time after sleep onset, and sleep quality between benzodiazepine receptor agonists and behavioral therapy. The behavioral therapy group had a greater reduction in latency to sleep onset than the group that took the benzodiazepine receptor agonists (95% CI, 0.17 to 1.04). Secondary: Not reported
Nowell et al.[52]	MA	N=1,894	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1997) Benzodiazepines or benzodiazepine receptor agonists vs placebo	Adults <65 years of age with chronic insomnia	(22 trials) 4 to 35 days	Sleep latency, TST, number of awakenings, sleep quality Secondary: Not reported	Zolpidem and benzodiazepines were significantly more effective than placebo with regards to sleep latency, TST, number of awakenings and sleep quality (P<0.001). Secondary: Not reported
Buscemi et al.[53] (2007) Benzodiazepines, non-benzodiazepines, antidepressants vs placebo	MA Adults with chronic insomnia	105 trials 1 night to 6 months	Primary: Sleep latency, WASO, sleep efficiency, sleep quality, TST, adverse events Secondary: Not reported	Primary: Sleep latency assessed by PSG was significantly decreased for benzodiazepines (WMD, -10.0 minutes; 95% CI, -16.6 to -3.4), non-benzodiazepines (WMD, -12.8 minutes; 95% CI, -16.9 to -8.8) and antidepressants (WMD, -7.0 minutes; 95% CI, -10.7 to -3.3). Sleep latency assessed by sleep diaries was also significantly improved for benzodiazepines (WMD, -19.6 minutes; 95% CI, -23.9 to -15.3), non-benzodiazepines (WMD, -17.0 minutes; 95% CI, -20.0 to -14.0) and antidepressants (WMD, -12.2 minutes; 95% CI, -22.3 to -2.2). MA for WASO, sleep efficiency, sleep quality and TST measured by PSG and sleep diary were statistically significant and favored benzodiazepines and non-benzodiazepines vs placebo with the exception of PSG studies measuring WASO and TST, which were marginally nonsignificant. In contrast, PSG results significantly favored antidepressants vs placebo, but sleep diary results were fewer and non-significantly favored antidepressants for WASO and non-significantly favored placebo for TST. Indirect comparisons between benzodiazepines and non-benzodiazepines resulted in no significant difference in sleep latency; however, benzodiazepines were associated with more adverse events. Indirect comparisons between benzodiazepines and antidepressants resulted in no significant difference in sleep latency or adverse events. Indirect comparisons between non-benzodiazepines and antidepressants resulted in a significantly greater sleep latency assessed by PSG but not by

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				sleep diary for non-benzodiazepines. There was no significant difference in adverse events. All drug groups had a statistically significant higher risk of harm compared to placebo, although the most commonly reported adverse events were minor. The adverse events most commonly reported in these studies were headache, drowsiness, dizziness and nausea. Secondary: Not reported
Glass et al.[54] (2008) Temazepam 15 mg for 2 weeks vs diphenhydramine 50 mg for 2 weeks vs placebo for 2 weeks	DB, PC, RCT, XO Elderly patients ≥70 years of age with primary insomnia	N=20 6 weeks	Primary: Subjective assessments of sleep recorded on sleep diaries Secondary: Morning-after psychomotor impairment (using the DSST and the MTT); morning-after memory impairment (using free-recall)	Primary: There was a significant difference in sleep quality scores with temazepam compared to diphenhydramine and placebo (both P<0.05). There was a significant difference in sleep-onset latency and TST with temazepam compared to placebo (P<0.05). There was a significant difference in the number of awakenings with diphenhydramine and temazepam compared to placebo (both P<0.05). Secondary: There were no changes in the DSST or the MTT scores with any treatment. No treatment effects could be detected on the memory assessment performed.
Piccione et al.[55] (1980) Triazolam 0.25 mg vs triazolam 0.50 mg vs	DB, XO Elderly patients >60 years of age with insomnia	N=27 5 days	Primary: Efficacy (questionnaire with subjective estimates of sleep latency, TST, number of awakenings, overall quality of sleep), side effects	Primary: The patients' global evaluation of effectiveness indicated that triazolam 0.25 and 0.50 mg improved sleep more than placebo (both P<0.05), while chloral hydrate 250 and 500 mg were not better than placebo. Triazolam 0.50 mg, but not 0.25 mg, was significantly better than chloral hydrate 250 mg (P<0.01) and 500 mg (P<0.05) in the global evaluation of effectiveness. There was no significant difference in sleep latency, TST and number of awakenings between placebo and either dose of chloral hydrate.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
chloral hydrate 250 mg vs chloral hydrate 500 mg vs placebo			Secondary: Not reported	Triazolam 0.25 mg significantly decreased sleep latency and increased TST compared to placebo (both P<0.05). Triazolam 0.50 mg significantly decreased the number of awakenings compared to placebo (P<0.01). Patients estimated their TST to be longer following the use of triazolam 0.25 mg as compared to chloral hydrate 250 or 500 mg (both P<0.05). There were no significant differences in reported side effects between the active treatments and placebo. Secondary: Not reported
Okawa et al.[56] (1978) Secobarbital 100 mg vs triazolam 0.5 mg vs placebo	DB, RCT, XO (two trials) Patients 18 to 60 years of age with a history of insomnia and two of the following: onset of sleep longer than 30 minutes, duration of sleep six hours or less, or experiencing three or more awakenings	N=76 2 nights	Primary: Patient preference questionnaire, success (defined as sleep onset in 30 minutes or less and sleep duration of six hours or more), adverse effects Secondary: Not reported	Primary: One trial compared triazolam to placebo and involved 19 patients. Sixteen patients preferred triazolam over placebo and three expressed no preference (P<0.001). Triazolam demonstrated greater efficacy over placebo in overall sleep (P<0.001), onset (P<0.001), duration (P<0.002) and number of awakenings (P<0.002). Triazolam was determined to be significantly more successful in 15 of 19 patients (P<0.004). No difference in next-morning alertness was noted between the two study groups. Seven patients receiving active treatment experienced mild-to-moderate adverse effects, with dizziness, drowsiness and headache as the most frequently reported. In comparison, three of the patients in the placebo group experienced mild-to-moderate side effects. The second trial was a combined study of 57 patients comparing triazolam and secobarbital. The results of the patient preference questionnaire were analyzed and showed a significant preference for triazolam (41 patients) over secobarbital (10 patients), with six having no preference for either agent (P<0.001). Significant improvement was seen with triazolam compared to secobarbital (P<0.001) in sleep onset, duration of sleep and number of awakenings. Feelings of alertness the next morning did not differ between treatment groups. Success was established in 73% of triazolam treated patients whereas only 30% of the secobarbital treated patients were determined successful (P<0.001). Thirteen patients in the secobarbital group reported adverse effects ranging from drowsiness and restlessness to dry mouth. More patients on triazolam reported side effects.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Seizures				
Conry et al.[57] (2014) Clobazam adjunctive therapy	ES, OL Patients 2 to 60 years of age from two RCTs taking clobazam as adjunctive therapy for Lennox-Gastaut syndrome	N=267 2 to 6 years	Primary: Changes in rates of drop seizures and total seizures Secondary: Responder rates (≥50, ≥75, or 100% decreases in seizure frequency vs baseline), sustained efficacy over time, and global evaluations; safety	Primary: The high median percentage decrease from baseline in average weekly rate of drop seizures (85 to 91%) was maintained through year five. The median percentage decrease in total seizures was also maintained, with an 85% reduction from baseline in those patients who had reached year five. Secondary: The percentages of patients with decreases of ≥50, ≥75, or 100% in their average weekly seizure rates from the previous blinded study baseline were consistent over the five-year trial span for both drop and total seizures. Over five years, 62 to 69% achieved at least a 75% reduction in drop seizures, and 50 to 65% attained a 75% or more reduction in total seizures while treated with clobazam. The majority of patients were assessed by both their physicians and caregivers as "very much improved" or "much improved" after one, two, and three years of treatment. During the open-label study, 60% of patients experienced ≥1 treatment-related adverse event. The most common adverse events during the open label extension were upper respiratory tract infection (28%) and pyrexia (19%). The upper respiratory tract infection and pneumonia events occurred predominantly in pediatric patients.
Isojarvi et al.[58] (2016) Clobazam: low dosage (target of 0.25 mg/kg/day [maximum 10 mg/day]), medium dosage (target of 0.5 mg/kg/day [maximum 20 mg/day]), and high	Post-hoc analysis of a DB, MC, PC, RCT Patients 2 to 60 years of age with a diagnosis of Lennox-Gastaut syndrome who were receiving stable doses of 1 to 3 AEDs (except	N=217 12 weeks	Primary: Seizure-related injuries Secondary: Adverse events	Primary: Patients receiving clobazam experienced significantly fewer seizure-related injuries than those receiving placebo (P<0.05). Compared with placebo (27.1%), the rates of seizure-related injuries were statistically significantly lower for the medium- (4.8%, P<0.001) and high-dosage (10.2%, P<0.03) clobazam groups, but not for the low-dosage clobazam group (12.1%). Secondary: A total of 32 patients experienced 53 adverse events that were considered to be seizure-related, of which 50 (94.3%) were mild or moderate in intensity. All severe seizure-related adverse events occurred in the placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
dosage (target of 1.0 mg/kg/day [maximum 40 mg/day]) vs placebo	benzodiazepines) for ≥30 days and were experiencing ≥2 drop seizures per week			group, with three patients experiencing one severe adverse event each (fall, contusion, or jaw fracture). In all treatment groups, all but one of the injuries were not serious, and most resolved by study end. The single serious adverse event (jaw fracture, which required surgery) occurred in a placebo-treated patient; this was the only seizure-related injury that required hospitalization.
Pavlidou et al.[59] (2006) Diazepam 0.33 mg/kg every 8 hours rectally for 1 day, followed by every 12 hours on day 2 vs no treatment	PRO, RCT Children 6 months to 3 years of age who experienced a first febrile seizure	N=139 3 years	Primary: Recurrence rates Secondary: Not reported	Primary: The 36-month recurrence rates in the no treatment group compared to the diazepam group were: 83 vs 38% (high-risk patients; P=0.005), 55 vs 35% (intermediate-risk patients; P=0.341), and 46 vs 33% (low-risk patients; P=0.412). Secondary: Not reported
Treiman et al.[60] (1998) Phenobarbital 15 mg/kg vs diazepam 0.15 mg/kg, followed by phenytoin 18 mg/kg vs lorazepam 0.1	DB, MC, RCT Adults with overt or subtle generalized convulsive status epilepticus	N=518 5 years	Primary: Success (defined as cessation of all motor and electrical seizure activity within 20 minutes of start of drug infusion and no recurrence of seizure activity within the next 40 minutes), side effects, outcomes 30 days posttreatment	Primary: For treatment success in overt status epilepticus, a significant difference overall in the frequency of success was found, reported as: lorazepam, 64.9%; phenobarbital, 58.2%; diazepam/phenytoin, 55.8%; and phenytoin, 43.6% (P<0.02 between all groups). For subtle status epilepticus, no significant differences were seen between treatment groups (P<0.18). Lorazepam showed significantly higher frequency of treatment success compared to phenytoin in a pairwise comparison of patients with overt status epilepticus (P<0.002). Pairwise comparisons among other individual treatments showed no significant differences. There were no significant differences among any of the treatment groups with respect to adverse effects or 30-day posttreatment outcomes. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/kg vs phenytoin 18 mg/kg			Secondary: Not reported	Not reported
Appleton et al.[61] (2002) Lorazepam intravenous or rectally (dose not specified) vs diazepam intravenous or rectally (dose not specified)	MA Children 1 month to 16 years of age with acute tonic-clonic convulsions	N=102 1 year	Primary: Efficacy (cessation of the presenting convulsion, seizure recurrence within 24 hours of initial termination, need for additional drugs), safety (adverse events, admission to intensive care unit) Secondary: Not reported	Primary: Administration of one to two intravenous doses stopped the convulsion in 70% of lorazepam-treated patients compared to 65% of patients receiving intravenous diazepam (RR, 1.09; 95% CI, 0.77 to 1.54). A single dose of rectal lorazepam stopped the convulsion in all children (6/6), compared to 6/19 children treated with rectal diazepam (RR, 3.17; 95% CI, 1.63 to 6.14). Approximately 22% of intravenous lorazepam-treated children and 35% of intravenous diazepam-treated children experienced a further convulsion within 24 hours after presentation (RR, 0.63; 95% CI, 0.27 to 1.46). Approximately 4% of patients receiving intravenous lorazepam compared to 15% of patients receiving intravenous diazepam required additional antiepileptic drugs to terminate the presenting seizure (RR, 0.25; 95% CI, 0.03 to 2.03). The incidence of respiratory depression occurring in the lorazepam-treated group was 4% compared to 21% in the diazepam-treated group (RR, 0.18; 95% CI, 0.02 to 1.37). Secondary: Not reported
Chamberlain et al.[62] (2014) Lorazepam 0.1 mg/kg intravenous vs	DB, RCT Patients 3 months <18 years of age with convulsive status epilepticus	N=273 4 hours	Primary: Cessation of status epilepticus by 10 minutes without recurrence within 30 minutes, assisted ventilation	Primary: Cessation of status epilepticus for 10 minutes without recurrence within 30 minutes occurred in 101 of 140 (72.1%) in the diazepam group and 97 of 133 (72.9%) in the lorazepam group, with an absolute efficacy difference of 0.8% (95% CI, −11.4 to 9.8%). Twenty-six patients in each group required assisted ventilation (16.0 in the diazepam vs 17.6% in the lorazepam groups; absolute risk difference, 1.6%; 95% CI, −9.9 to 6.8%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
diazepam 0.2 mg/kg intravenous Half of the treatment dose repeated at five minutes if necessary. If status epilepticus continued at 12 minutes, fosphenytoin was administered.			Secondary: Rates of seizure recurrence and sedation	Secondary: The rates of recurrent generalized convulsions within 60 minutes, excluding patients who failed the primary outcome, were 10.9% for diazepam and 10.3% for lorazepam and the rates of recurrence within four hours were 38.6 and 39.2%, respectively. The only statistically significant difference between treatment groups in any of the secondary outcomes was in the incidence of sedation, which occurred in 81 of 162 diazepam patients (50%) and 99 of 148 lorazepam patients (66.9%) (absolute risk difference, 16.9%; 95% CI, 6.1 to 27.7%).
Prasad et al.[63] (2014) Lorazepam intravenous vs diazepam intravenous or rectally vs phenytoin intravenous vs placebo	MA Patients with status epilepticus	N=2755 (18 studies) Variable duration	Primary: Efficacy and safety Secondary: Not reported	Primary: Intravenous diazepam demonstrated a greater reduction than placebo in the risk of non-cessation of seizures (RR, 0.73; 95% CI, 0.57 to 0.92), requirement for ventilatory support (RR, 0.39; 95% CI, 0.16 to 0.94), or continuation of status epilepticus requiring use of a different drug or general anaesthesia (RR, 0.73; 95% CI, 0.57 to 0.92). Intravenous lorazepam demonstrated a lower risk than placebo for non-cessation of seizures (RR, 0.52; 95% CI, 0.38 to 0.71) and for risk of continuation of status epilepticus requiring a different drug or general anaesthesia (RR, 0.52; 95% CI, 0.38 to 0.71). Intravenous lorazepam demonstrated a greater reduction than intravenous diazepam for the risk of non-cessation of seizures (RR, 0.64; 95% CI, 0.45 to 0.90) and had a lower risk for continuation of status epilepticus requiring a different drug or general anaesthesia (RR, 0.63; 95% CI, 0.45 to 0.88). Intravenous lorazepam demonstrated a greater reduction than intravenous phenytoin for risk of non-cessation of seizures (RR, 0.62; 95% CI, 0.45 to 0.86). Diazepam gel demonstrated a greater reduction than placebo gel in the risk of non-cessation of seizures (RR, 0.43; 95% CI, 0.30 to 0.62). Secondary: Not reported
Miscellaneous				
Leufkens et al.[64]	DB, PC, XO	N=18	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2007) Alprazolam XR 1 mg vs alprazolam IR 1 mg vs placebo	Healthy individuals 20 to 45 years of age	Up to 5.5 hours after administration	Comparison of effects on actual driving ability (as assessed in a standard on-the-road driving test) measured by SDLP in centimeters) Secondary: Comparison of effects on cognitive and psychomotor functioning related to driving in a controlled laboratory setting	Both drug formulations significantly increased SDLP (P<0.001 for both IR and XR). However, mean SDLP after alprazolam XR was significantly lower than alprazolam IR (23.44 vs 27.68 cm, respectively; P<0.001). SDLP increased with approximately 8 cm in the IR group and 4 cm in the XR group as compared to placebo (19.5 cm with placebo; P<0.001 for both comparisons). No overall differences were found between placebo and either formulation of alprazolam in terms of mean speed and speed variability. Ten driving tests were terminated prematurely due to patients being too drowsy to continue (7/18 rides in the IR group and 3/18 rides in the XR group). Secondary: In terms of the divided attention task, performance was significantly impaired at 1 (P<0.001), 2.5 (P<0.001), and 5.5 hours (P<0.01) after administration of alprazolam IR 1 mg. The effects of the XR preparation were less severe than the IR formulation at one hour (P<0.05) and at 2.5 hours (P<0.5) but no longer at 5.5 hours postdose. A significant impairment on target detection by alprazolam IR compared to placebo was noted for all times of measurement (P<0.05). Alprazolam XR did not differ significantly from placebo one hour postdose; however, there was a significant difference at 2.5 and 5.5 hours (P<0.05 for both). In terms of the stop signal task, relative to placebo, the go reaction time was significantly longer after alprazolam IR (P<0.001) but not after alprazolam XR. In terms of the word learning test, placebo-drug comparisons demonstrated a significant impairing effect of alprazolam IR at one hour after administration but not with alprazolam XR.
Hindmarch et al.[65] (2006) Flurazepam 30 mg vs	DB, RCT, XO Healthy volunteers ≥65 years of age	N=24 Single dose treatment	Primary: Psychometric tests performed 8 hours after study medication (CFF, CRT, word recall,	Primary: There were no significant differences in psychometric tests between the zolpidem modified release treatment groups and placebo (P>0.05). Psychometric performance was significantly impaired with flurazepam compared to placebo for all tests with the exception of the DSST (P=0.0526).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
zolpidem modified release 6.25 mg vs zolpidem modified release 12.5 mg vs placebo			CTT, DSST), subjective evaluation of sleep (LSEQ), safety, pharmacokinetics (zolpidem modified release only) Secondary: Not reported	Ease of falling asleep and sleep quality were significantly improved with both doses of zolpidem modified release and with flurazepam (all P<0.05). Neither zolpidem modified release, nor flurazepam, modified perception of well-being on awakening. The frequency of adverse events was similar in all four treatment conditions. None of the adverse events was serious or led to withdrawal from the study. The plasma concentration ratio was 1.96 between the two doses of zolpidem modified release, which is consistent with dose linearity. Secondary: Not reported
Johnson et al.[66] (2006) Triazolam 0.25, 0.5 or 0.75 mg vs ramelteon 16, 80 or 160 mg vs placebo	DB, XO Adults with a history of sedative abuse	N=14 18 days	Primary: Subject-rated measures (drug liking, street value, pharmacological classification), observer-rated measures (sedation, impairment), motor and cognitive performance (balance task, DSST, word recall) Secondary: Not reported	Primary: Triazolam showed dose-related effects on subject-rated, observer-rated, and motor and cognitive performance measures. Compared to placebo, all doses of ramelteon showed no significant effect on any of the subjective effect measures, including those related to potential for abuse (all P>0.05). In the pharmacological classification, 79% of patients identified the highest dose of ramelteon as placebo. Compared to placebo, ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure (all P>0.05). Secondary: Not reported

Study abbreviations**:** CI=confidence interval, DB=double-blind, ES=extension study, MA=meta-analysis, MC=multi-center, NS=not significant, OL=open label, PC=placebo controlled, PRO=prospective trial, OR=odds ratio, RETRO=retrospective trial, RCT=randomized controlled trial, RR=relative risk, XO=crossover, WMD=weighted mean difference
Other abbreviations: AWS=alcohol withdrawal syndrome, CGI=Clinical Global Impression, CIWA-Ar=Clinical Institute Withdrawal Assessment of Alcohol Scale, CRT=choice reaction time, CPS=complex partial seizures, DSST=digit symbol substitution task, HAM-A=Hamilton Rating Scale for Anxiety, HAM-D=Hamilton Rating Scale for Depression, IR=immediate-release, LSAS=Lebowitz Social Anxiety Scale, LSEQ=Leeds sleep evaluation questionnaire, MAOI=monoamine oxidase inhibitor, MTT=manual tracking task, PAF=panic attack frequency, PSG=polysomnogram, RIMA=reversible inhibitor of monoamine-oxidase-A, SDLP=Standard Deviation of Lateral Position, SSRI=Selective serotonin reuptake inhibitor, XR=extended-release, TST=total sleep time, WASO=wake after sleep onset

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 14. Relative Cost of the Benzodiazepines

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Alprazolam	extended-release tablet, oral concentrate, orally disintegrating tablet, tablet	Xanax®*, Xanax XR®*	$$$$$	$
Chlordiazepoxide	capsule	N/A	N/A	$
Clonazepam	orally disintegrating tablet, tablet	Klonopin®*	$$$$	$$
Clorazepate	tablet	Tranxene T-Tab®*	$$$$$	$$$$
Diazepam	injection, oral concentrate, oral solution, rectal gel, tablet	Diastat®*, Diastat AcuDial®*	$$$$$	$
Estazolam	tablet	N/A	N/A	$$$$
Flurazepam	capsule	N/A	N/A	$$$
Lorazepam	injection, oral concentrate, tablet	Ativan®*	$$$$$	$
Midazolam	injection, oral syrup	N/A	N/A	$
Oxazepam	capsule	N/A	N/A	$$
Temazepam	capsule	Restoril®*	$$$$$	$
Triazolam	tablet	Halcion®*	$$$$$	$

*Generic is available in at least one dosage form or strength.
N/A=Not available

X. Conclusions

The benzodiazepines are approved for the treatment of anxiety disorders and for the short-term treatment of insomnia. In addition, some of the agents are approved for the treatment of seizure disorders, acute alcohol withdrawal, as muscle relaxants, and for the induction/maintenance of general anesthesia.[1-12] The benzodiazepines are mechanistically similar; however, they differ with regards to their pharmacokinetic properties (e.g., onset and duration of action).[15,17] All of the benzodiazepines are available in a generic formulation.

The benzodiazepines that are approved for the treatment of anxiety include alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, lorazepam, and oxazepam. The American Psychiatric Association recommends the initial use of either a serotonin-norepinephrine reuptake inhibitor (SNRI) or a selective serotonin reuptake inhibitor (SSRI) for the treatment of panic disorder due to their favorable safety and tolerability profiles.[19] However, benzodiazepines may be preferred for patients with very distressing or impairing symptoms in whom rapid symptom control is critical. They can be used concurrently with antidepressants to help control symptoms until the antidepressant takes effect, which is then followed by a slow tapering of the benzodiazepine.[19] For the long-term treatment of generalized anxiety disorder, the National Institute for Health and Clinical Excellence recommends the use of an SSRI as first-line therapy. Benzodiazepines should only be used as a short-term measure during crises.[17] Benzodiazepines have been shown to be more effective than placebo, and have demonstrated similar efficacy compared to agents in other classes for the treatment of anxiety disorders.[19,45,47-50] Guidelines do not give preference to one particular benzodiazepine over another. The risk of adverse events and physiological dependence must be considered when using the benzodiazepines.[16,19] Benzodiazepines are not recommended as monotherapy for the treatment of obsessive-compulsive disorder or posttraumatic stress disorder.[20-24]

Several benzodiazepines are approved for the short-term treatment of insomnia, including estazolam, flurazepam, temazepam, and triazolam. The American Academy of Sleep Medicine recommends the use of a short/intermediate-acting benzodiazepine, benzodiazepine receptor agonist, or ramelteon for the initial treatment of insomnia.[25] They do not give preference to one agent over another. Symptom pattern, treatment goals, past treatment responses, patient preference, comorbid conditions, contraindications, drug interactions, and adverse events should be considered when selecting a specific agent.[25] The frequency and severity of adverse events may be lower with benzodiazepine receptor agonists (e.g., eszopiclone, zaleplon, and zolpidem) due to their shorter half-lives.[27] Hypnotic treatments should be combined with behavioral and cognitive therapies.[25] Patients should be followed every few weeks during the initial treatment period to assess for effectiveness, adverse events, and the need for ongoing medication. Chronic use of hypnotic medications may be necessary in those individuals with severe/refractory insomnia or for those with chronic comorbid illnesses.[25] Results from clinical trials demonstrate that the benzodiazepines are effective for the short-term treatment of insomnia.[25-27, 51, 53-56]

Benzodiazepines may also be used for the treatment of seizure disorders, either as monotherapy or adjunctive therapy. It should be noted that other antiepileptic drugs are not currently included in the Preferred Drug Program. Diazepam is available in a rectal gel formulation, which is approved for the management of selected, refractory, patients with epilepsy who require intermittent use of diazepam to control bouts of increased seizure activity.[7]

In August 2016, the FDA announced class-wide changes to drug labeling was being required for the opioid and benzodiazepine classes because of serious risks associated with using these medications at the same time. The benzodiazepines now include a boxed warning in their labeling stating that concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing of these drugs should be reserved for use in patients for whom alternative treatment options are inadequate.[1-12] Subsequently, on September 23, 2020, the FDA released a publication to address labeling changes to the benzodiazepine class to improve the safe use of these agents. This action by the FDA is part of ongoing efforts to promote the public health by minimizing risks associated with inappropriate use of controlled substances. The update requires class-wide labeling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions to help improve their safe use. In addition to the Boxed Warning update, other required changes to the prescribing information encompass the Warnings and Precautions, Drug Abuse and Dependence, and Patient Counseling Information sections. Revisions to the patient Medication Guide will also be mandated to educate patients and caregivers about the associated risks of these therapies.[16]

There is insufficient evidence to support that one brand benzodiazepine is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all benzodiazepines within the class reviewed, with the exception of diazepam rectal gel, are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use. Diazepam rectal gel provides a beneficial route of administration compared to other agents in this class. Therefore, patients should be allowed approval for this agent through the medical justification portion of the prior authorization process.

XI. Recommendations

No brand benzodiazepine is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jul]. Available from: http://online.factsandcomparisons.com.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jul]. Available from: http://www.thomsonhc.com/.
3. Xanax® [package insert]. New York (NY): Pfizer, Inc.; 2016 Sep.
4. Xanax® XR [package insert]. New York (NY): Pfizer, Inc.; 2016 Sep.
5. Klonopin® [package insert]. South San Francisco (CA): Genentech USA, Inc.; 2017 Oct.
6. Tranxene T-Tab® [package insert]. Lebanon (NJ): Recordati Rare Diseases, Inc.; 2016 Sep.
7. Diastat® [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals North America; 2016 Dec.
8. Ativan® tablets [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals, LLC; 2016 Sep.
9. Ativan® injection [package insert]. Eatontown (NJ): West-Ward Pharmaceuticals; 2017 Apr.
10. Restoril® [package insert]. Hazelwood (MO): Mallinckrodt, Inc.; 2018 Dec.
11. Halcion® [package insert]. New York (NY): Pfizer, Inc.; 2019 Oct.
12. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 Jul]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
14. Becker W, Starrels JL. Prescription drug misuse: Epidemiology, prevention, identification, and management. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 July]. Available from: http://www.utdol.com/utd/index.do.
15. Winkelman JW. Overview of the treatment of insomnia in adults. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 July]. Available from: http://www.utdol.com/utd/index.do.
16. FDA Requiring Labeling Changes for Benzodiazepines [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2020 Sep 23 [cited 2020 Sep 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-benzodiazepines.
17. National Institute for Clinical Excellence. Generalized anxiety disorder and panic disorder in adults: management. National Institute for Clinical Excellence (NICE); 2011 Jan [cited 2020 July]. Available at: http://www.nice.org.uk/.
18. Stein M, Goin M, Pollack M, et al. Practice guideline for the treatment of patients with panic disorder, second edition. American Psychiatric Association; 2009 [cited 2020 July]. Available at: http://psychiatryonline.org/.
19. Geller DA, March J, AACAP Committee on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2012; 51(1):98-113.
20. Koran L, Hanna G, Hollander E, Nestadt G, Simpson H; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington (VA): American Psychiatric Association; 2007 Jul [cited 2018 Feb 22]. Available at: http://psychiatryonline.org/.
21. Cohen JA, AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Posttraumatic Stress Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2010;49(4):414-430.
22. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. February 2017. Available from https://www.apa.org/ptsd-guideline/ptsd.pdf.
23. The Management of Posttraumatic Stress Disorder Work Group. VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 3.0 – 2017. Available from https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal082917.pdf.
24. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008 Oct;4(5):487-504.
25. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.
26. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33.

27. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63.
28. National Institute for Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London, UK: 2012 Jan [cited 2020 July]. Available from: http://www.nice.org.uk.
29. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, et al. Evidence-based guideline update: medical treatment of infantile spasms: report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Available at: http://www.neurology.org/content/78/24/1974.full.html.
30. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010 Oct;51(10):2175-89.
31. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol. 2010;17:348-55.
32. Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.
33. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology Jul 2018, 91 (2) 74-81; DOI: 10.1212/WNL.0000000000005755.
34. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology Jul 2018, 91 (2) 82-90; DOI: 10.1212/WNL.0000000000005756.
35. National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders. Diagnosis, assessment and management of harmful drinking and alcohol dependence. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Feb [cited 2016 Feb 22]. 54 p. (Clinical guideline; no. 115). Available at: http://www.nice.org.uk/nicemedia/live/12995/48991/48991.pdf.
36. The American Psychiatric Association. Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. 2018. https://doi.org/10.1176/appi.books.9781615371969.
37. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry. 1991 Sep;52 Suppl:38-41.
38. Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol. 1999;19(Suppl 2):2S-11S.
39. Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(Suppl 2):12S-6S.
40. Holbrook A, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ. 1999 Mar 9;160(5):649-55.
41. Ntais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005063.
42. Kumar CN, Andrade C, Murthy P, et al. A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. J Stud Alcohol Drugs. 2009;70:467-74.
43. Caputo F, Skala K, Mirijello A, et al. Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. CNS Drugs. 2014 Aug;28(8):743-52.
44. Martin JL, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21:774-82.
45. Moylan S, Staples J, Ward SA, et al. The efficacy and safety of alprazolam vs other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011;31:647-52.
46. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005 Apr;25(2):141-50.
47. Blanco C, Schneier F, Schmidt A, Blanco-Jerez C, Marshall R, Sanchez-Lacay A et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40.

48. van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997 Aug;185(8):510-6.
49. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006 Jul 19;3:CD006115.
50. Holbrook A, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000 Jan 25;162(2):225-33.
51. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002 Jan;159(1):5-11.
52. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia. A meta-analysis of treatment efficacy. JAMA. 1997 Dec 24/31;278(24):2170-7.
53. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007 Sep;22(9):1335-50.
54. Glass JR, Sproule BA, Herrmann N, et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28:182-8.
55. Piccione P, Zorick F, Lutz T, Grissom T, Kramer M, Roth T. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res. 1980;8(5):361-7.
56. Okawa KK, Allens G. A clinical comparison of triazolam with placebo and with secobarbital in insomniac patients. J Int Med Res. 1978;6(4):343-7.
57. Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014 Apr;55(4):558-67.
58. Isojarvi J, Lee D, Peng G, Sperling MR. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia. 2016 Jun;57(6):e113-6.
59. Pavlidou E, Tzitiridou M, Panteliadis. Effectiveness of intermittent diazepam prophylaxis in febrile seizures: Long-term prospective controlled study. J Child Neurol. 2006;21:1036-40.
60. Treiman D, Meyers P, Walton N, Collins J, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998 Sep 17;339(12):792-8.
61. Appleton R, Martland T, Phillips B. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2002;(4):CD001905.
62. Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014 Apr 23-30;311(16):1652-60.
63. Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014 Sep 10;9:CD003723.
64. Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology. 2007;191:951-9.
65. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol. 2006;62(5):538-45.
66. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psych. 2006 Oct;63:1149-57.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Anxiolytics, Sedatives, and Hypnotics – Miscellaneous
AHFS Class 282492
November 4, 2020

I. Overview

The miscellaneous anxiolytics, sedatives, and hypnotics are used primarily for the treatment of anxiety disorders and insomnia. Anxiety disorders include generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and social phobia.[1] The agents approved for the treatment of anxiety include buspirone, hydroxyzine, and meprobamate.[2-14] The exact mechanism of action of buspirone is unknown. It lacks anticonvulsant, muscle relaxant, or sedative properties, which are seen with other agents. The anxiolytic effects of hydroxyzine may be due to a suppression of activity in key regions of the subcortical area of the central nervous system. Meprobamate has been shown to have effects at multiple sites in the central nervous system, including the thalamus and limbic system.[2-14]

The key diagnostic feature of primary insomnia is difficulty initiating or maintaining sleep for at least three months, which causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.[1] Insomnia may be classified as episodic (symptoms last at least one month but less than three months), persistent (lasting three months or longer) or recurrent (two or more) episodes within the space of one year).[1] Eszopiclone, zaleplon, and zolpidem are approved for the treatment of insomnia.[4-14] These agents are considered benzodiazepine receptor agonists; however, they are more selective than traditional benzodiazepines and bind to the $GABA_A$ receptor complex. Compared to the benzodiazepines, they have a more rapid onset, shorter duration of action, and a lower risk of tolerance, dependence, and abuse. They are classified as Schedule IV controlled substances by federal regulation.[2-14] Ramelteon is a melatonin receptor agonist, which is also approved for the treatment of insomnia.[9] It is more selective for the melatonin type 1 (MT_1) and type 2 (MT_2) receptors as compared to the type 3 (MT_3) receptor in the suprachiasmatic nucleus of the hypothalamus.[9] The MT_1 and MT_2 receptors are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle. Ramelteon is not a controlled substance. Discontinuation after chronic administration did not produce withdrawal signs and it does not appear to produce physical dependence.[9] Suvorexant (Belsomra®) was Food and Drug Administration (FDA) approved in 2014 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Suvorexant is a selective antagonist of orexin receptors (OX1R and OX2R). Orexin A and orexin B are neuropeptides that promote wakefulness. Blocking the binding of orexin to the orexin receptors is thought to suppress wakefulness.[10] Lemborexant (Dayvigo®) was FDA approved in 2019 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Lemborexant is a competitive orexin receptor antagonist that binds to both OX1R and OX2R with stronger inhibition effect to OX2R.[11] Both suvorexant and lemborexant are Schedule IV controlled substances, producing similar effects as zolpidem in an abuse liability study.[10,11]

Some of the miscellaneous agents are also approved for the management of acute alcohol withdrawal, for use as a sedative (e.g., preoperative, prior to procedures, and in intubated or mechanically ventilated patients), for the management of nausea/vomiting from surgical/diagnostic procedures, and for the treatment of pruritus. Dexmedetomidine is a selective $alpha_2$-adrenergic agonist with sedative properties.[14] Droperidol is a butyrophenone antipsychotic. The antiemetic effect is due to the blockade of dopamine stimulation of the chemoreceptor trigger zone.[2,3] Other effects include alpha-adrenergic blockade, peripheral vascular dilation, and reduction of the pressor effect of epinephrine.

Hetlioz® (tasimelteon) was FDA approved for treatment of Non-24-Hour Sleep-Wake Disorder (non-24) in 2014.[13] Tasimelteon is a melatonin receptor agonist with effects at the MT_1 and MT_2 receptors. Although the precise mechanism of tasimelteon in non-24 is unknown, these receptors are thought to be involved in the control of circadian rhythms.[13] This is the first FDA approval of a treatment for non-24, a chronic circadian rhythm disorder which occurs almost exclusively in persons who are completely blind, and the effectiveness of tasimelteon was evaluated in this population.[15]

In January 2013, the FDA released new recommendations that the dose of zolpidem be lowered due to new data suggesting that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. Women appear to be more susceptible, as they eliminate zolpidem more slowly than men.[16] The FDA required the manufacturers of Ambien®, Ambien CR®, and Edluar® to lower the recommended dose. The recommended dose of zolpidem for women should be lowered from 10 to 5 mg for immediate-release products (Ambien®, Edluar®) and from 12.5 to 6.25 mg for extended-release products (Ambien CR®). For men, the labeling should recommend that health care professionals consider prescribing the lower doses—5 mg for immediate-release products and 6.25 mg for extended-release products.[16] In May 2014, a similar safety communication was issued for eszopiclone, based on data that the 2 and 3 mg doses may be associated with impairment of driving skills, memory, and coordination lasting more than 11 hours without subjective awareness in some patients. A starting dose of 1 mg is now recommended in all patients.[17]

In April 2019, the FDA released a safety announcement advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. A boxed warning is now required for eszopiclone, zaleplon, and zolpidem.[18]

The miscellaneous anxiolytics, sedatives, and hypnotics that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation, with the exception of suvorexant and tasimelteon. This class was last reviewed in August 2018.

Table 1. Miscellaneous Anxiolytics, Sedatives, and Hypnotics Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Buspirone	tablet	N/A	buspirone
Dexmedetomidine	injection	Precedex®*	dexmedetomidine
Droperidol	injection	N/A	droperidol
Eszopiclone	tablet	Lunesta®*	eszopiclone
Hydroxyzine	capsule, injection, solution, tablet	Vistaril®*	hydroxyzine
Lemborexant	tablet	Dayvigo®	none
Meprobamate	tablet	N/A	meprobamate
Ramelteon	tablet	Rozerem®*	none
Suvorexant	tablet	Belsomra®	none
Tasimelteon	capsule	Hetlioz®	none
Zaleplon	capsule	N/A	zaleplon
Zolpidem	extended-release tablet, sublingual tablet, tablet	Ambien®*, Ambien CR®*, Edluar®	zolpidem

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.
N/A=Not available.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the miscellaneous anxiolytics, sedatives, and hypnotics are summarized in Table 2.

Table 2. Treatment Guidelines Using the Miscellaneous Anxiolytics, Sedatives, and Hypnotics

Clinical Guideline	Recommendation(s)
National Institute for Clinical Excellence: **Generalized Anxiety Disorder and Panic Disorder in Adults: management (2011)**[19]	Stepped care for people with generalized anxiety disorder (GAD) • If a person with GAD chooses drug treatment, offer a selective serotonin reuptake inhibitor (SSRI), specifically sertraline. • If sertraline is ineffective, offer an alternative SSRI or a serotonin–noradrenaline reuptake inhibitor (SNRI), taking into account the following factors: ○ Tendency to produce a withdrawal syndrome (especially with paroxetine and venlafaxine). ○ The side-effect profile and the potential for drug interactions.

Clinical Guideline	Recommendation(s)
Last updated July 2019	○ The risk of suicide and likelihood of toxicity in overdose (especially with venlafaxine). ○ The person's prior experience of treatment with individual drugs (particularly adherence, effectiveness, side effects, experience of withdrawal syndrome and the person's preference). • If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin. • Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises. • Do not offer an antipsychotic for the treatment of GAD in primary care. <u>Panic disorder general considerations</u> • Benzodiazepines are associated with a less effective outcome in the long term and should not be prescribed for panic disorder. • Sedating antihistamines or antipsychotics should not be prescribed for panic disorder. • Interventions with evidence for the longest duration of effect are listed in descending order, where preference of the patient should be taken into account: ○ Psychological therapy (i.e., cognitive behavioral therapy, structured problem solving, psychoeducation). ○ Pharmacological therapy (antidepressant therapy). ○ Self-help interventions (i.e., bibliotherapy, support groups, exercise, cognitive behavioral therapy via a computer interface). • Antidepressants should be the only pharmacologic intervention used in the longer term. • The classes of antidepressants that have an evidence base for effectiveness are the SSRIs, SNRIs and tricyclic antidepressants (TCAs). • Unless otherwise indicated, an SSRI (e.g., paroxetine, fluvoxamine, citalopram) licensed for panic disorder should be offered. If an SSRI is not suitable or there is no improvement after a 12-week course and if further medication is appropriate, imipramine or clomipramine may be considered. • If the patient is showing improvement, the medication should be continued for at least six months after optimal dose is reached, after which the dose may be tapered slowly over an extended period of time to minimize the risk of discontinuation/withdrawal symptoms.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Panic Disorder, Second Edition (2009)[20]**	• SSRIs, SNRIs, TCAs, and benzodiazepines have demonstrated efficacy in numerous controlled trials and are recommended for treatment of panic disorder. • Because SSRIs, SNRIs, TCAs, and benzodiazepines appear roughly comparable in their efficacy for panic disorder, selecting a medication involves considerations of side effects, pharmacological properties, potential drug interactions, prior treatment history, and comorbid medical and psychiatric conditions. • The relatively favorable safety and side effect profile of SSRIs and SNRIs makes them the best initial choice for many patients with panic disorder. • There is no evidence of differential efficacy between the SSRIs, although differences in the side-effect profile (e.g., potential for weight gain, discontinuation-related symptoms), half-life, propensity for drug interactions, and availability of generic formulations may be clinically relevant. They are safer than TCAs and monoamine oxidase inhibitors (MAOI). They are rarely lethal in overdose and have few serious effects on cardiovascular function. • Venlafaxine extended release has been shown to be effective for panic disorder. It is generally well tolerated and has a side effect profile similar to the SSRIs. No systematic data are currently available supporting the use of duloxetine, in panic disorder, although its mechanism of action suggests it might be an effective agent. • Although TCAs are effective, the side effects and greater toxicity in overdose limit their acceptability to patients and clinical utility. Given the equivalency of TCAs in treating depression, there is little reason to expect other TCAs to work

Clinical Guideline	Recommendation(s)
	less well for panic disorder. TCAs that are more noradrenergic (e.g., desipramine, maprotiline) may be less effective than agents that are more serotonergic. • SSRIs, SNRIs, and TCAs are all preferable to benzodiazepines as monotherapies for patients with comorbid depression or substance use disorders. Benzodiazepines may be especially useful adjunctively with antidepressants to treat residual anxiety symptoms. • Benzodiazepines may be preferred for patients with very distressing or impairing symptoms in whom rapid symptom control is critical. The benefit of more rapid response to benzodiazepines must be balanced against the possibilities of troublesome side effects and physiological dependence that may lead to difficulty discontinuing the medication. • MAOIs appear effective for panic disorder but, because of their safety profile, they are generally reserved for patients who have failed to respond to several first-line treatments. • Neither trazodone nor nefazodone can be recommended as a first-line treatment for panic disorder. There is minimal support for the use of trazodone in panic disorder and it appears less effective than imipramine and alprazolam. There are a few small, uncontrolled studies showing benefits of nefazodone in some patients with panic disorder; however, its use has been limited by concerns about liver toxicity. • Bupropion was effective in one small trial and ineffective in another. It cannot be recommended as a first line treatment for panic disorder. • Other medications with less empirical data may be considered as monotherapies or adjunctive treatments for panic disorder when patients have failed to respond to several standard treatments or based on other individual circumstances.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder (2012)**[21]	• The psychiatric assessment of children and adolescents should routinely screen for the presence of obsessions and/or compulsions or repetitive behaviors. • If screening suggests obsessive-compulsive symptoms, clinicians should fully evaluate the child using the Diagnostic and Statistical Manual of Mental Disorders-IV-TR criteria and scalar assessment. • A complete psychiatric evaluation should be performed, including information from all available sources and compromising standard elements of history and a mental state examination, with attention to the presence of commonly occurring comorbid psychiatric disorders. • It is possible that three out of four children with obsessive-compulsive disorder (OCD) meet criteria for at least one comorbid diagnosis, and these children have lower response rates to cognitive behavioral therapy than children without comorbid diagnoses. • Identification of major depressive disorder and bipolar disorder is very important before initiating treatment with a SSRI. • Comorbid eating disorders are infrequent in younger children; however, comorbid eating disorders become more prevalent in adolescents. • A full medical, developmental, family and school history should be included with the psychiatric history and examination. • Cognitive behavioral therapy is the first-line treatment for mild to moderate OCD in children, whenever possible. • For moderate to severe OCD, medication is indicated in addition to cognitive behavioral therapy. • Serotonin reuptake inhibitors (SRIs) are the first-line medications recommended for OCD in children, including clomipramine (a TCA) and certain SSRIs (fluoxetine, fluvoxamine, paroxetine and sertraline). • There is no SRI that is proven to be more efficacious over another. • The modality of assigned treatment should be guided by empirical evidence on the moderators and predictors of treatment response. • Multimodal treatment with cognitive behavioral therapy and medication is

Clinical Guideline	Recommendation(s)
	recommended if cognitive behavioral therapy fails to achieve a clinical response after several months or in more severe cases. • Medication augmentation strategies are reserved for treatment-resistant cases in which impairments are deemed moderate in at least one important domain of function despite adequate monotherapy. • Adding clomipramine to an SSRI is a useful medication augmentation strategy. • Augmenting with an atypical neuroleptic is also a strategy employed by experts (e.g. haloperidol and risperidone combined) based on studies in adults with OCD; however, controlled data for the use of atypical antipsychotics in children with OCD does not exist. • A minimum of two adequate SSRI trials or an SSRI and clomipramine trial is recommended before atypical augmentation. • Empirically validated medication and psychosocial treatments for comorbid disorders should be considered.
American Psychiatric Association: **Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder (2007; 2013 update)**[22]	<u>General considerations</u> • OCD is a chronic illness which typically waxes and wanes. • Patients who have symptoms interfering with daily functioning should be treated. • Clinical remission and recovery may not always occur and will not occur rapidly. • Goals of treatment include improving symptoms, patient functioning, and quality of life. <u>Initial treatment options</u> • The choice of treatment depends on the patient's ability to comply with therapy, whether psychotherapy, pharmacotherapy, or both. • First-line treatments include cognitive-behavioral therapy, SRIs, or a combination of the two. The choice depends on past treatment history, comorbid psychiatric conditions, severity of symptoms, and functional limitations. • Cognitive-behavioral therapy or SRI therapy may be used alone or in combination, and combination therapy may be considered in patients who do not respond fully to monotherapy, those with severe symptoms, those with comorbid psychiatric illnesses for which an SRI is indicated, or in patients who wish to limit SRI exposure. • All SRIs appear to be equally effective, though patients may respond to agents differently. • Prescribers should consider the safety, side effects, Food and Drug Administration (FDA) warnings, drug interactions, past response to treatment, and comorbid medical conditions when choosing a medication for treatment. • Most patients do not experience a significant improvement until four to six weeks after treatment initiation, and some may ultimately respond after as many as 10 to 12 weeks. • Patients not responding after 10 to 12 weeks may respond to a higher dose of the same medication. <u>Changing treatments and pursuing sequential treatment trials</u> • Augmentation strategies may be preferred to switching strategies in patients who have a partial response to the initial treatment. • Augmentation of SRIs with trials of different antipsychotic medications or with cognitive-behavioral therapy or augmentation of cognitive-behavioral therapy with an SRI. • Patients who do not respond to their first SRI may have their medication switched to a different SRI. A switch to venlafaxine is less likely to produce an adequate response. • For patients who have not benefitted from their first SSRI trial, a switch to mirtazapine can be considered. • After first- and second-line treatments and well-supported augmentation strategies

Clinical Guideline	Recommendation(s)
	have been exhausted, less well-supported treatment strategies may be considered. These include augmenting SRIs with clomipramine, buspirone, pindolol, riluzole, or once- weekly oral morphine sulfate. • Evidence for beneficial effects of benzodiazepines as monotherapy for OCD is limited to case reports with clonazepam and alprazolam. Modest doses of benzodiazepines may relieve anxiety and distress in OCD without directly diminishing the frequency or duration of obsessions or compulsions. Given their limited evidence for efficacy, benzodiazepines cannot be recommended as monotherapy for OCD, except in those rare individuals who are unable or unwilling to take standard anti-OCD medications.
American Academy of Child and Adolescent Psychiatry: **Practice Parameter for the Assessment and Treatment of Children and Adolescents with Posttraumatic Stress Disorder (2010)**[23]	• The psychiatric evaluation of children and adolescents should routinely include questions about traumatic experiences and posttraumatic stress disorder (PTSD) symptoms. • If the evaluation indicates symptoms of PTSD, the clinician should formally determine if PTSD is present, the severity of PTSD symptoms and the degree of functional impairment. Caregivers should be included in the formal evaluation. • A differential diagnosis should be conducted in order to rule out diagnoses with symptoms that can mimic PTSD symptoms. • The treatment plan should be comprehensive in approach and should consider the severity of symptoms and impairment, as well as comorbid psychiatric conditions. • Trauma-focused psychotherapies should be considered first-line in children and adolescents with PTSD, including psychoanalytic, attachment and cognitive behavioral treatment models. • SSRIs can be considered for treatment of children and adolescents with PTSD. • The effect of SSRIs in children with PTSD may be more consistent with a placebo effect. • Other medications such as clonidine and propranolol may be useful in decreasing symptoms of hyperarousal, and anticonvulsants may beneficial in treating PTSD symptoms other than avoidance. • Benzodiazepines have not been found to be beneficial in treating PTSD symptoms. • School-based accommodations are recommended for children with PTSD, especially in children with school-based trauma, such as bullying. • The use of restrictive, “rebirthing,” binding or other coercive therapies are not recommended. • Screening for PTSD in the school or community should be conducted after traumatic events that affect significant numbers of children.

American Psychological Association: **Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (2017)**[24]	• For adults with PTSD, psychotherapies are strongly recommended.
	• For adults with PTSD, offer one of the following (listed alphabetically):
	  ○ Fluoxetine
	  ○ Paroxetine
	  ○ Sertraline
	  ○ Venlafaxine
	• There is insufficient evidence to recommend for or against the following medications for treatment of adults with PTSD:
	  ○ Risperidone
	  ○ Topiramate

Department of Veterans Affairs/ Department of Defense: **The Management of Posttraumatic Stress Disorder and Acute Stress**	Treatment selection • Individual, manualized trauma-focused psychotherapy is recommended over other pharmacologic and nonpharmacologic interventions for the primary treatment of PTSD. • When individual trauma-focused psychotherapy is not readily available or not preferred, pharmacotherapy or individual non-trauma-focused psychotherapy is recommended. With respect to pharmacotherapy and nontrauma-focused psychotherapy, there is insufficient evidence to recommend one over the other.

Clinical Guideline	Recommendation(s)
Disorder (2017)[25]	Pharmacotherapy • Sertraline, paroxetine, fluoxetine, or venlafaxine is recommended as monotherapy for PTSD for patients diagnosed with PTSD who choose not to engage in or are unable to access trauma-focused psychotherapy. • Nefazodone, imipramine, or phenelzine is suggested as monotherapy for the treatment of PTSD if recommended pharmacotherapy, trauma-focused psychotherapy, or non-trauma-focused psychotherapy are ineffective, unavailable, or not in accordance with patient preference and tolerance. (NOTE: Nefazodone and phenelzine have potentially serious toxicities and should be managed carefully.) • Treatment of PTSD with quetiapine, olanzapine, and other atypical antipsychotics (except for risperidone, which is a Strong Against), citalopram, amitriptyline, lamotrigine, or topiramate as monotherapy are NOT suggested due to the lack of strong evidence for their efficacy and/or known adverse effect profiles and associated risks. • Treating PTSD with divalproex, tiagabine, guanfacine, risperidone, benzodiazepines, ketamine, hydrocortisone, or D-cycloserine are NOT recommended as monotherapy due to the lack of strong evidence for their efficacy and/or known adverse effect profiles and associated risks. • Treating PTSD with cannabis or cannabis derivatives is NOT recommended due to the lack of evidence for their efficacy, known adverse effects, and associated risks. • There is insufficient evidence to recommend for or against monotherapy or augmentation therapy for the treatment of PTSD with eszopiclone, escitalopram, bupropion, desipramine, doxepin, D-serine, duloxetine, desvenlafaxine, fluvoxamine, levomilnacipran, mirtazapine, nortriptyline, trazodone, vilazodone, vortioxetine, buspirone, hydroxyzine, cyproheptadine, zaleplon, and zolpidem. Augmentation therapy • The use of topiramate, baclofen, or pregabalin is NOT suggested as augmentation treatment of PTSD due to insufficient data and/or known adverse effect profiles and associated risks. • Combining exposure therapy with D-cycloserine is NOT suggested in the treatment of PTSD outside of the research setting. • Using atypical antipsychotics, benzodiazepines, and divalproex is NOT recommended as augmentation therapy for the treatment of PTSD due to low quality evidence or the absence of studies and their association with known adverse effects. • There is insufficient evidence to recommend the combination of exposure therapy with hydrocortisone outside of the research setting. • There is insufficient evidence to recommend for or against the use of mirtazapine in combination with sertraline for the treatment of PTSD. Prazosin • For global symptoms of PTSD, the use of prazosin is NOT suggested as mono- or augmentation therapy. • For nightmares associated with PTSD, there is insufficient evidence to recommend for or against the use of prazosin as mono- or augmentation therapy. Combination therapy • In partial- or non-responders to psychotherapy, there is insufficient evidence to recommend for or against augmentation with pharmacotherapy. • In partial- or non-responders to pharmacotherapy, there is insufficient evidence to recommend for or against augmentation with psychotherapy.

Clinical Guideline	Recommendation(s)
	• There is insufficient evidence to recommend for or against starting patients with PTSD on combination pharmacotherapy and psychotherapy.
American Academy of Sleep Medicine: **Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults (2008)**[26]	• The primary treatment goals are to improve sleep quality/quantity and to improve insomnia related daytime impairments. • Short-term hypnotic treatment should be supplemented with behavioral and cognitive therapies when possible. • When pharmacotherapy is utilized, the choice of a specific pharmacological agent should be directed by: symptom pattern, treatment goals, past treatment responses, patient preference, availability of other treatments, comorbid conditions, contraindications, concurrent medication interactions, and side effects. • For patients with primary insomnia, when pharmacologic treatment is utilized alone or in combination therapy, the recommended general sequence of medication trials is: o Short-intermediate acting benzodiazepine receptor agonists or ramelteon. o Alternate short-intermediate acting benzodiazepine receptor agonists or ramelteon if the initial agent has been unsuccessful. o Sedating antidepressants, especially when used in conjunction with treating comorbid depression/anxiety. Examples of these include trazodone, amitriptyline, doxepin, and mirtazapine. o Combined benzodiazepine receptor agonists or ramelteon and sedating antidepressant. o Other sedating agents. Examples include anti-epilepsy medications (gabapentin, tiagabine) and atypical antipsychotics (quetiapine and olanzapine). These medications may only be suitable for patients with comorbid insomnia who may benefit from the primary action of these drugs as well as from the sedating effect. • Over-the-counter antihistamine or antihistamine/analgesic type drugs (over-the-counter "sleep aids"), as well as herbal and nutritional substances (e.g., valerian and melatonin), are not recommended in the treatment of chronic insomnia due to the relative lack of efficacy and safety data. • Older approved drugs for insomnia including barbiturates, barbiturate-type drugs and chloral hydrate are not recommended for the treatment of insomnia. • Pharmacological treatment should be accompanied by patient education regarding treatment goals, safety concerns, potential side effects and drug interactions, other treatment modalities (cognitive and behavioral treatments), potential for dosage escalation, and rebound insomnia. • Patients should be followed on a regular basis, every few weeks in the initial period of treatment when possible, to assess for effectiveness, possible side effects, and the need for ongoing medication. • Efforts should be made to employ the lowest effective maintenance dosage of medication and to taper medication when conditions allow. Medication tapering and discontinuation are facilitated by cognitive behavioral therapy for insomnia. • Chronic hypnotic medication may be indicated for long-term use in those with severe or refractory insomnia or chronic comorbid illness. Whenever possible, patients should receive an adequate trial of cognitive behavioral treatment during long-term pharmacotherapy. • Long-term prescribing should be accompanied by consistent follow-up, ongoing assessment of effectiveness, monitoring for adverse effects, and evaluation for new onset or exacerbation of existing comorbid disorders. • Long-term administration may be nightly, intermittent (e.g., three nights per week), or as needed.
American Academy of Sleep Medicine: **Clinical Practice Guideline for the**	<u>Recommendations for treating sleep onset insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically.

Clinical Guideline	Recommendation(s)
Pharmacologic Treatment of Chronic Insomnia in Adults (2017)[27]	• Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 14 minutes greater, compared to placebo (95% CI, 3 to 24 minute reduction). o Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo. • Ramelteon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 6 to 12 minute reduction). o Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 37 minutes greater, compared to placebo (95% CI, 21 to 53 minute reduction). o Quality of Sleep: Small improvement in quality of sleep, compared to placebo. • Triazolam is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was nine minutes greater, compared to placebo (95% CI, 4 to 22 minute reduction). o Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. • Zaleplon is recommended as a treatment for sleep onset insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was 10 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). o Quality of Sleep: No improvement in quality of sleep, compared to placebo. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Sleep Latency: Mean reduction was five to 12 minutes greater, compared to placebo (95% CI, 0 to 19 minute reduction). o Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Recommendations for treating sleep maintenance insomnia</u> • Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences. Recommendations are listed alphabetically. • Doxepin is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 26 to 32 minutes longer, compared to placebo (95% CI, 18 to 40 minute improvement). o Wake After Sleep Onset: Mean reduction was 22 to 23 minutes greater, compared to placebo (95% CI, 14 to 30 minute reduction). o Quality of Sleep: Small-to-Moderate improvement in quality of sleep, compared to placebo. • Eszopiclone is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 28 to 57 minutes longer, compared to placebo (95% CI, 18 to 76 minute improvement). o Wake After Sleep Onset: Mean reduction was 10 to 14 minutes greater, compared to placebo (95% CI, 2 to 18 minute reduction). o Quality of Sleep: moderate-to-large improvement in quality of sleep, compared to placebo.

Clinical Guideline	Recommendation(s)
	• Temazepam is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 99 minutes longer, compared to placebo (95% CI, 63 to 135 minute improvement). o Wake After Sleep Onset: Not reported. o Quality of Sleep: Small improvement in quality of sleep, compared to placebo. • Suvorexant is recommended as a treatment for sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 10 minutes longer, compared to placebo (95% CI, 2 to 19 minute improvement). o Wake After Sleep Onset: Mean reduction was 16 to 28 minutes greater, compared to placebo (95% CI, 7 to 43 minute reduction). o Quality of Sleep: Not reported. • Zolpidem is recommended as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. o Total Sleep Time: Mean improvement was 29 minutes longer, compared to placebo (95% CI, 11 to 47 minute improvement). o Wake After Sleep Onset: Mean reduction was 25 minutes greater, compared to placebo (95% CI, 18 to 33 minute reduction). o Quality of Sleep: Moderate improvement in quality of sleep, compared to placebo. <u>Not recommended for treating insomnia</u> • The following drugs are not recommended for the treatment of sleep onset or sleep maintenance insomnia (versus no treatment) in adults: Diphenhydramine, Melatonin, Tiagabine, Trazodone, L-tryptophan, Valerian.
American College of Physicians: **Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline (2016)**[28]	• It is recommended that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. o CBT-I consists of a combination of treatments that include cognitive therapy around sleep, behavioral interventions (such as sleep restriction and stimulus control), and education (such as sleep hygiene). • It is recommended that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom CBT-I alone was unsuccessful. o Low-quality evidence showed that both eszopiclone and zolpidem improved global outcomes in the general population, and low- to moderate-quality evidence showed that eszopiclone, zolpidem, and doxepin improved sleep outcomes, such as sleep onset latency, total sleep time, and wake after sleep onset. o Moderate-quality evidence showed that suvorexant improved treatment response and sleep outcomes in mixed general and adult populations. o Low-quality evidence showed no statistically significant difference between ramelteon and placebo for sleep outcomes in the general population. o Evidence was insufficient for melatonin in the general population and in older adults. o Benzodiazepines, although widely used, were not addressed in this guideline because few studies met the inclusion criteria of the systematic review (insufficient evidence). o Evidence on harms was limited from randomized controlled trials that met the inclusion criteria for the review, which mostly reported on study withdrawals. However, observational studies have shown that hypnotic drugs may be associated with infrequent but serious adverse effects, such as dementia, serious injury, and fractures. o Evidence is insufficient to evaluate the balance of the benefits and harms of

Clinical Guideline	Recommendation(s)
	long-term use of pharmacologic treatments in adults with chronic insomnia disorder. The FDA has approved pharmacologic therapy for short-term use (four to five weeks), and patients should not continue using the drugs for extended periods. o The FDA also recommends that patients with insomnia that does not remit within seven to 10 days of treatment should be further evaluated. o There was insufficient evidence overall on the comparative effectiveness and safety of the various pharmacologic treatments.
American Society for Gastrointestinal Endoscopy: **Sedation and Anesthesia in Gastrointestinal Endoscopy (2018)**[29]	• All patients undergoing endoscopic procedures should be evaluated to assess their risk of sedation related to pre-existing medical conditions. • The combination of an opioid and benzodiazepine is a safe and effective regimen for achieving minimal to moderate sedation for upper endoscopy and colonoscopy in patients without risk factors for sedation-related adverse events. • Using an appropriate adjunctive agent (e.g., diphenhydramine, promethazine, or droperidol) is suggested in combination with conventional sedative drugs in select clinical circumstances. • Providers should undergo specific training in the administration of endoscopic sedation and possess the skills necessary for the diagnosis and management of sedation-related adverse events, including rescue from a level of sedation deeper than that intended. • The routine monitoring of blood pressure, oxygen saturation, and heart rate in addition to clinical observation for changes in cardiopulmonary status is recommended during all endoscopic procedures using sedation. Supplemental oxygen administration should be considered for moderate sedation and should be administered during deep sedation. Supplemental oxygen should be administered if hypoxemia is anticipated or develops. • Capnography monitoring should be considered for patients undergoing endoscopy targeting deep sedation. • Anesthesia provider–administered sedation should be considered for complex endoscopic procedures or patients with multiple medical comorbidities or at risk for airway compromise. • Endoscopists should use propofol-based sedation (endoscopist-directed or anesthesia-provider administered) when it is expected to improve patient safety, comfort, procedural efficiency, and/or successful procedure completion.
Society for Ambulatory Anesthesia: **Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (2014)**[30]	<u>Prevention of postoperative nausea and vomiting (PONV) in adults</u> • The efficacy of dexamethasone 4 mg intravenous, ondansetron 4 mg intravenous and droperidol 1.25 mg intravenous for the prevention of postoperative nausea and vomiting appears to be similar. • Ondansetron, dolasetron, granisetron, and tropisetron are most effective in the prophylaxis of PONV when given at the end of surgery, although; some data on dolasetron suggest timing may have little effect on efficacy. Palonosetron is typically given at the start of surgery. • Aprepitant is similar to ondansetron in achieving complete response (no vomiting and no use of rescue antiemetic) for 24 hours after surgery. However, aprepitant was significantly more effective than ondansetron for preventing vomiting at 24 and 48 hours after surgery and in reducing nausea severity in the first 48 hours after surgery. It also has a greater antiemetic effect compared with ondansetron. • Systematic reviews have demonstrated that 5-HT_3 receptor antagonists in combination with dexamethasone or droperidol are more effective than monotherapy with any of the agents. • Droperidol in combination with dexamethasone is more effective than either agent as monotherapy. • Combinations that include metoclopramide have not been shown to be more effective than monotherapy.

Clinical Guideline	Recommendation(s)
	Prevention of postoperative nausea and vomiting in children • Children are at increased risk of postoperative nausea and vomiting compared to adults. • Children at moderate to high risk for postoperative nausea and vomiting should receive combination therapy with two to three prophylactic agents from different classes. • Ondansetron has been studied extensively in pediatric patients and is approved for patients as young one month of age. • There is now good evidence to suggest that 5-HT_3 antagonists and dexamethasone are the most effective antiemetics in the prophylaxis of pediatric postoperative nausea Treatment of PONV in patients who failed or did not receive prophylaxis • If prophylactic therapy fails, an agent from a different pharmacologic class should be selected for treatment. • If no prophylactic therapy was given, first-line treatment should include a low-dose 5-HT_3 antagonist.
National Institute for Health and Clinical Excellence: **Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence (2011)**[31] **Reaffirmed 2015**	Drug regimens for assisted withdrawal • Prescribe and administer medication for assisted withdrawal within a standard clinical protocol. The preferred medication for assisted withdrawal is a benzodiazepine (chlordiazepoxide or diazepam). • Gradually reduce the dose of the benzodiazepine over seven to 10 days to avoid alcohol withdrawal recurring. • When managing alcohol withdrawal in the community, avoid giving people who misuse alcohol large quantities of medication to take home to prevent overdose or diversion (the drug being taken by someone other than the person it was prescribed for). Prescribe for installment dispensing, with no more than two days' medication supplied at any time. • Do not offer clomethiazole for community-based assisted withdrawal because of the risk of overdose and misuse. Interventions for moderate and severe alcohol dependence after successful withdrawal • After a successful withdrawal for people with moderate and severe alcohol dependence, consider offering acamprosate or oral naltrexone in combination with an individual psychological intervention. • After a successful withdrawal for people with moderate and severe alcohol dependence, consider offering disulfiram in combination with a psychological intervention to service users who have a goal of abstinence but for whom acamprosate and oral naltrexone are not suitable, or prefer disulfiram and understand the relative risks of taking the drug. Treatment for acute alcohol withdrawal • Offer pharmacotherapy to treat the symptoms of acute alcohol withdrawal. • Consider offering a benzodiazepine or carbamazepine. • Clomethiazole may be offered as an alternative to a benzodiazepine or carbamazepine. However, it should be used with caution, in inpatient settings only and according to the summary of product characteristics. Management of delirium tremens • Lorazepam is considered a first-line treatment option. • If symptoms persist or oral medication is declined, give parenteral lorazepam or haloperidol. Management of alcohol withdrawal seizures

Clinical Guideline	Recommendation(s)
	• In people with alcohol withdrawal seizures, consider offering a quick-acting benzodiazepine (e.g., lorazepam) to reduce the likelihood of further seizures. • Do not offer phenytoin to treat alcohol withdrawal seizures.

American Psychiatric Association: **Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder (2018)**[32]	Selection of a Pharmacotherapy
	• Naltrexone or acamprosate should be offered to patients with moderate to severe alcohol use disorder who
	  ○ have a goal of reducing alcohol consumption or achieving abstinence,
	  ○ prefer pharmacotherapy or have not responded to nonpharmacological treatments alone, and
	  ○ have no contraindications to the use of these medications.
	• Disulfiram may be offered to patients with moderate to severe alcohol use disorder who
	  ○ have a goal of achieving abstinence,
	  ○ prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate,
	  ○ are capable of understanding the risks of alcohol consumption while taking disulfiram, and
	  ○ have no contraindications to the use of this medication.
	• Topiramate or gabapentin may be offered to patients with moderate to severe alcohol use disorder who
	  ○ have a goal of reducing alcohol consumption or achieving abstinence,
	  ○ prefer topiramate or gabapentin or are intolerant to or have not responded to naltrexone and acamprosate, and
	  ○ have no contraindications to the use of these medications.
	
	Recommendations Against Use of Specific Medications
	• Antidepressant medications should not be used for treatment of alcohol use disorder unless there is evidence of a co-occurring disorder for which an antidepressant is an indicated treatment.
	• In individuals with alcohol use disorder, benzodiazepines should not be used unless treating acute alcohol withdrawal or unless a co-occurring disorder exists for which a benzodiazepine is an indicated treatment.
	• For pregnant or breastfeeding women with alcohol use disorder, pharmacological treatments should not be used unless treating acute alcohol withdrawal with benzodiazepines or unless a co-occurring disorder exists that warrants pharmacological treatment.
	• Acamprosate should not be used by patients who have severe renal impairment.
	• For individuals with mild to moderate renal impairment, acamprosate should not be used as a first-line treatment and, if used, the dose of acamprosate be reduced compared with recommended doses in individuals with normal renal function.
	• Naltrexone should not be used by patients who have acute hepatitis or hepatic failure.
	• Naltrexone should not be used as a treatment for alcohol use disorder by individuals who use opioids or who have an anticipated need for opioids.
	
	Treatment of Alcohol Use Disorder and Co-occurring Opioid Use Disorder
	• In patients with alcohol use disorder and co-occurring opioid use disorder, naltrexone should be prescribed to individuals who
	  ○ wish to abstain from opioid use and either abstain from or reduce alcohol use and
	  ○ are able to abstain from opioid use for a clinically appropriate time prior to naltrexone initiation.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the miscellaneous anxiolytics, sedatives, and hypnotics are noted in Tables 3 and 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Miscellaneous Anxiolytics, Sedatives, and Hypnotics (Drugs B-L)[2-14]

Indication	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Anxiety Disorders						
Management of generalized anxiety disorders	✔					
Short-term relief of symptoms of anxiety	✔					
Symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested					✔	
Sedative-Hypnotic						
Sedation when used as premedication and following general anesthesia					✔	
Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting; administer by continuous infusion not to exceed 24 hours		✔				
Sedation of non-intubated patients prior to and/or during surgical and other procedures		✔				
Treatment of insomnia (shown to decrease sleep latency and improve sleep maintenance)				✔		✔
Miscellaneous						
Management of pruritus caused by allergic conditions such as chronic urticaria and atopic or contact dermatoses and in histamine-mediated pruritus					✔	
To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures			✔			

Table 4. FDA-Approved Indications for the Miscellaneous Anxiolytics, Sedatives, and Hypnotics (Drugs M-Z)[2-14]

Indication	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Anxiety Disorders						
Management of anxiety disorders	✔					
Short-term relief of symptoms of anxiety	✔					
Sedative-Hypnotic						

Indication	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Short-term treatment of insomnia (shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies; it has not been shown to increase total sleep time or decrease the number of awakenings; the clinical trials performed in support of efficacy ranged from a single night to five weeks in duration; the final formal assessments of sleep latency were performed at the end of treatment)					✔	
Short-term treatment of insomnia characterized by difficulties with sleep initiation (shown to decrease sleep latency for up to 35 days in controlled clinical studies)						✔ *
Insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep (not indicated for the treatment of middle-of-the night awakening when the patient has fewer than four hours of bedtime remaining before the planned time of waking)						✔ †
Treatment of insomnia characterized by difficulty with sleep onset		✔				
Insomnia characterized by difficulties with sleep onset and/or sleep maintenance			✔			✔ ‡
Miscellaneous						
Treatment of Non-24-Hour Sleep-Wake Disorder				✔		

*Immediate-release formulations (sublingual tablet [Edluar®] and tablet).
†Immediate-release formulations (sublingual tablet [Intermezzo®]).
‡Extended-release formulation.

IV. Pharmacokinetics

The pharmacokinetic parameters of the miscellaneous anxiolytics, sedatives, and hypnotics are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the Miscellaneous Anxiolytics, Sedatives, and Hypnotics[3]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Buspirone	Variable	86	Liver	Renal (29 to 63) Feces (18 to 38)	2 to 3
Dexmedetomidine	SubQ: 81	94	Liver	Renal (95) Feces (4)	2.0 to 2.7
Droperidol	Complete	Extensive	Liver	Renal (75) Feces (22)	2
Eszopiclone	Rapidly absorbed	Not reported	Liver	Renal	5 to 6
Hydroxyzine	Rapidly absorbed orally	Not reported	Liver	Not reported	3 to 20
Lemborexant	Not reported	94	Liver	Renal (29.1) Feces (57.4)	17 to 19
Meprobamate	Well absorbed	0 to 30	Liver	Renal (10 to 20)	9 to 11
Ramelteon	1.8	82	Liver	Renal (84) Feces (4)	1.0 to 2.6
Suvorexant	82	>99	Liver	Renal (23) Feces (66)	12
Tasimelteon	38.3	90	Liver	Renal (80) Feces (4)	1.3
Zaleplon	30	60	Liver	Renal (71) Feces (17)	1
Zolpidem	70	93	Liver	Renal (<1)	2.5 to 3.0

V. Drug Interactions

Major drug interactions with the miscellaneous anxiolytics, sedatives, and hypnotics are listed in Table 6.

Table 6. Major Drug Interactions with the Miscellaneous Anxiolytics, Sedatives, and Hypnotics[3]

Generic Name(s)	Interaction	Mechanism
Buspirone	Linezolid	Serotonin syndrome (e.g., agitation, altered consciousness, ataxia, myoclonus, overactive, reflexes, shivering) may occur in some patients. Unless patients are carefully observed for signs and symptoms of serotonin syndrome, do not coadminister.
Buspirone	Tranylcypromine	Concurrent use of buspirone and tranylcypromine may result in hypertensive crisis.
Buspirone	Phenelzine	Concurrent use of phenelzine and buspirone may result in hypertensive crisis.
Buspirone	Isocarboxazid	Concurrent use of isocarboxazid and buspirone may result in hypertensive crisis.
Buspirone	Monoamine oxidase inhibitors	Concurrent use of buspirone and monoamine oxidase inhibitors may result in hypertensive crisis.
Buspirone	Clozapine	Concurrent use of clozapine and buspirone may result in an increased risk of gastrointestinal bleeding and hyperglycemia.
Buspirone	Procarbazine	Concurrent use of buspirone and procarbazine may result in hypertensive crisis.
Buspirone, dexmedetomidine, droperidol,	CNS Depressants	Concurrent use may result in increased risk of respiratory and CNS depression.

Generic Name(s)	Interaction	Mechanism
eszopiclone, hydroxyzine, meprobamate, ramelteon, suvorexant, zaleplon, zolpidem		
Droperidol	Ziprasidone	The combination of ziprasidone and droperidol may have cause additive prolongation of the QT interval.
Droperidol	Neuroleptics (molindone, clozapine, perphenazine, trifluprom azine, remoxipride, acetophenazine, bromperidol, tiapride, pipamperone)	Concurrent use of droperidol and neuroleptics may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Fluoroquinolones	Concurrent use of droperidol and fluoroquinolones may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Tricyclic antidepressants, monoamine oxidase inhibitors, phenothiazines	Concurrent use of droperidol and tricyclic antidepressants may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Class I and III antiarrhythmics	Concurrent use of droperidol and antiarrhythmic agents may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Diuretics	Concurrent use of droperidol and diuretics may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Laxatives	Concurrent use of droperidol and laxatives may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Antimalarials	Concurrent use of droperidol and antimalarials may result in an increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest).
Droperidol	Calcium channel blockers	Concurrent use of droperidol and calcium channel blockers may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Droperidol	Tyrosine kinase inhibitors	Concurrent use of droperidol and tyrosine kinase inhibitors may result in an increased risk of QT interval prolongation.
Eszopiclone, zaleplon	Ketoconazole	Concurrent use of eszopiclone or zaleplon and ketoconazole may result in increased plasma concentrations of eszopiclone or zaleplon.
Eszopiclone	Selected strong CYP3A4 inhibitors (nelfinavir, saquinavir, delavirdine, lopinavir, tipranavir, posaconazole, boceprevir, telaprevir,	Concurrent use of eszopiclone and selected strong CYP3A4 inhibitors may result in increased plasma concentrations of eszopiclone.

Generic Name(s)	Interaction	Mechanism
	cobicistat, atazanavir)	
Hydroxyzine	QT prolonging agents	Concurrent use of hydroxyzine and QT prolonging agents may result in increased risk of QT interval prolongation.
Lemborexant	Strong, moderate, and weak CYP3A inhibitors (e.g., itraconazole, clarithromycin, verapamil, etc.)	Concurrent use with a strong, moderate, or weak CYP3A inhibitor increases lemborexant AUC and Cmax which may increase the risk of lemborexant adverse reactions.
Lemborexant	Strong and moderate CYP3A inducers (e.g., rifampin, carbamazepine, efavirenz, bosentan, modafinil, etc.)	Concurrent use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce lemborexant efficacy.
Lemborexant	CYP2B6 substrates (e.g., bupropion, methadone, etc.)	Concurrent use of lemborexant decreases the AUC of drugs that are CYP2B6 substrates, which may result in reduced efficacy for these concomitant medications.
Ramelteon	Fluvoxamine	Plasma concentrations of ramelteon may be increased by coadministration of fluvoxamine. Inhibition of CYP1A2 by fluvoxamine may decrease the metabolic elimination of ramelteon/zolpidem.
Suvorexant	CYP3A4 inhibitors	Concurrent use of suvorexant and selected CYP3A4 inhibitors may result in increased plasma concentrations of suvorexant.
Tasimelteon	Selected strong CYP1A2 inhibitors (abiraterone, ciprofloxacin, enoxacin, fluvoxamine)	Concurrent use of tasimelteon and selected strong CYP1A2 inhibitors may result in increased tasimelteon exposure and increased risk of tasimelteon adverse events.
Tasimelteon	Selected strong CYP1A2 inducers (phenytoin, carbamazepine, primidone, phenobarbital, rifampin, rifabutin, fosphenytoin, St john's wort, rifapentine, enzalutamide)	Concurrent use of tasimelteon and selected strong CYP3A4 inducers may result in decreased tasimelteon exposure with reduced tasimelteon efficacy.
Zolpidem	Human immunodeficiency virus protease inhibitors	Inhibition of CYP3A4 by protease inhibitors may decrease the metabolic elimination and increase plasma concentrations of eszopiclone and zolpidem.
Zolpidem	Carbamazepine	Concurrent use of carbamazepine and zolpidem may result in decreased zolpidem plasma concentrations.
Zolpidem	Ciprofloxacin	Concurrent use of ciprofloxacin and zolpidem may result in increased zolpidem plasma concentrations.

VI. Adverse Drug Events

The most common adverse drug events reported with the miscellaneous anxiolytics, sedatives, and hypnotics are listed in Tables 7 and 8. The boxed warnings are listed in Tables 9 and 10. Meprobamate, eszopiclone, suvorexant, zaleplon, and zolpidem are classified as Schedule IV controlled substances by federal regulation because of their abuse potential. The risk of abuse and dependence increases with the dose, duration of treatment, and concomitant use of other psychoactive drugs. The risk is also greater for patients who have a history of alcohol/drug abuse or psychiatric disorders.

Table 7. Adverse Drug Events (%) Reported with the Miscellaneous Anxiolytics, Sedatives, and Hypnotics (A to L)[2]

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Cardiovascular						
Arrhythmia	-	✔	-	-	-	-
Atrial fibrillation	-	2 to 9	-	-	-	-
Atrioventricular block	-	✔	-	-	-	-
Bradycardia	<1	5 to 42	-	-	-	-
Cardiac arrest	-	✔	✔	-	-	-
Cardiomyopathy	<1	-	-	-	-	-
Chest pain	≥1	-	-	1 to 10	-	-
Extrasystoles	-	✔	-	-	-	-
Heart block	-	✔	-	-	-	-
Heart failure	<1	-	-	-	-	-
Hypertension	<1	✔	✔	<1	-	-
Hypotension	<1	24 to 56	✔	-	-	-
Hypovolemia	-	3	-	-	-	-
Myocardial infarction	<1	✔	-	-	-	-
Peripheral edema	-	3 to 7	-	1 to 10	-	-
QTc prolongation	-	-	✔	-	-	-
Supraventricular tachycardia	-	✔	-	-	-	-
Syncope	<1	-	-	-	-	-
T-wave inversion	-	✔	-	-	-	-
Tachycardia	-	25	✔	-	-	-
Torsades de pointes	-	-	✔	-	-	-
Ventricular arrhythmia	-	✔	-	-	-	-
Ventricular tachycardia	-	✔	✔	-	-	-
Central Nervous System						
Abnormal gait	-	-	-	<1	-	-
Agitation	-	✔	-	<1	-	-
Anger	2	-	-	-	-	-
Anxiety	-	5 to 9	✔	1 to 3	-	-
Ataxia	<1	-	-	<1	-	-
Cerebrovascular attack	<1	-	-	-	-	-
Chills	-	-	✔	-	-	-

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Complex sleep-related activities	-	-	-	<1	-	-
Confusion	2	✔	-	≤3	-	-
Delirium	-	✔	-	-	-	-
Depression	-	-	✔	1 to 4	-	-
Dizziness	12	✔	✔	5 to 7	✔	-
Dream disturbances	≥1	-	-	1 to 3	-	-
Drowsiness	10	-	✔	-	✔	-
Dysphoria	-	-	✔	-	-	-
Emotional lability	-	-	-	<1	-	-
Euphoria	-	-	-	<1	-	-
Excitement	2	-	-	-	-	-
Extrapyramidal symptoms	<1	-	✔	-	-	-
Fever	-	✔	-	<1	-	-
Hallucinations	<1	✔	✔	1 to 3	✔	-
Headache	6	✔	-	15 to 21	✔	4.5 to 5.9
Hostility	-	-	-	<1	-	-
Hyperactivity	-	-	✔	-	-	-
Illusion	-	✔	-	-	-	-
Incoordination	1	-	-	-	-	-
Involuntary movements	-	-	-	-	✔	-
Lightheadedness	3	-	-	-	-	-
Memory impairment	-	-	-	<1	-	-
Malaise	-	-	-	<1	-	-
Migraine	-	-	-	1 to 10	-	-
Nervousness	5	-	-	≤5	✔	-
Neuralgia	-	✔	-	≤3	-	-
Neuritis	-	✔	-	<1	-	-
Neuroleptic malignant syndrome	-	-	✔	-	-	-
Neuropathy	-	-	-	<1	-	-
Neurosis	-	-	-	<1	-	-
Nightmare or abnormal dreams	-	-	-	-	-	0.9 to 2.2
Numbness	2	-	-	-	-	-
Paresthesia	1	-	-	<1	✔	-
Parkinsonism	<1	-	-	-	-	-
Personality disorders	<1	-	-	-	-	-
Psychosis	<1	-	-	-	-	-
Restlessness	-	-	✔	-	-	-
Seizure	<1	✔	-	-	✔	-
Somnolence	-	-	-	8 to 10	-	6.9 to 9.6
Speech disorder	-	✔	-	-	-	-
Suicidal ideation	<1	-	-	-	-	-

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Tremor	1	-	-	<1	✔	-
Vertigo	-	-	-	<1	-	-
Dermatological						
Alopecia	-	-	-	<1	-	-
Contact dermatitis	-	-	-	<1	-	-
Ecchymosis	<1	-	-	-	-	-
Eczema	-	-	-	<1	-	-
Erythema multiforme	-	-	-	<1	-	-
Maculopapular rash	-	-	-	<1	-	-
Photosensitivity reaction	-	-	-	<1	-	-
Pruritus	-	-	-	1 to 4	✔	-
Rash	1	-	-	3 to 4	✔	-
Urticaria	-	-	-	<1	✔	-
Vesiculobullous rash	-	-	-	<1	-	-
Endocrine and Metabolic						
Acidosis	-	✔	-	-	-	-
Breast enlargement	-	-	-	<1	-	-
Breast neoplasm	-	-	-	<1	-	-
Cholelithiasis	-	-	-	<1	-	-
Galactorrhea	<1	-	-	-	-	-
Gout	-	-	-	<1	-	-
Gynecomastia	-	-	-	≤3	-	-
Mastitis	-	-	-	<1	-	-
Thyroid abnormality	<1	-	-	-	-	-
Gastrointestinal						
Abdominal pain	-	✔	-	-	-	-
Anorexia	<1	-	-	<1	-	-
Colitis	-	-	-	<1	-	-
Dehydration	-	-	-	<1	-	-
Diarrhea	2	✔	-	2 to 4	-	-
Dysgeusia	-	-	-	8 to 34	-	-
Dyspepsia	-	-	-	2 to 6	-	-
Dysphagia	-	-	-	<1	-	-
Gastrointestinal ulcer	-	-	-	<1	-	-
Irritable colon	<1	-	-	-	-	-
Melena	-	-	-	<1	-	-
Nausea	8	3 to 11	-	4 to 5	-	-
Rectal hemorrhage	<1	-	-	<1	-	-
Thirst	-	✔	-	-	-	-
Tongue edema	-	-	-	<1	-	-
Ulcerative stomatitis	-	-	-	<1	-	-

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Vomiting	-	✔	-	≤3	-	-
Xerostomia	-	3 to 4	-	3 to 7	✔	-
Genitourinary						
Amenorrhea	-	-	-	<1	-	-
Cystitis	-	-	-	<1	-	-
Dysmenorrhea	-	-	-	≤3	-	-
Dysuria	-	-	-	<1	-	-
Enuresis	<1	-	-	-	-	-
Hematuria	-	-	-	<1	-	-
Kidney calculus	-	-	-	<1	-	-
Kidney pain	-	-	-	<1	-	-
Libido decreased	-	-	-	≤3	-	-
Menorrhagia	-	-	-	<1	-	-
Menstrual irregularities	<1	-	-	-	-	-
Oliguria	-	✔	-	<1	-	-
Pelvic inflammatory disease	<1	-	-	-	-	-
Pyelonephritis	-	-	-	<1	-	-
Urethritis	-	-	-	<1	-	-
Urinary frequency	-	-	-	<1	-	-
Urinary incontinence	-	-	-	<1	-	-
Urinary retention	-	1	-	-	-	-
Urinary tract infection	-	-	-	≤3	-	-
Vaginal hemorrhage	-	-	-	<1	-	-
Vaginitis	-	-	-	<1	-	-
Vulvovaginal dryness	-	-	-	-	-	-
Hematologic						
Anemia	-	✔	-	-	-	-
Eosinophilia	<1	-	-	-	-	-
Leukopenia	<1	-	-	-	-	-
Thrombocytopenia	<1	-	-	-	-	-
Thrombophlebitis	-	-	-	<1	-	-
Hepatic						
Alkaline phosphatase increased	-	✔	-	-	-	-
Alanine transaminase increased	-	✔	-	-	-	-
Aspartate aminotransferase increased	-	✔	-	-	-	-
Gamma-glutamyl transpeptidase increased	-	✔	-	-	-	-
Hepatic impairment	-	✔	-	-	-	-
Hepatitis	-	-	-	<1	-	-
Hepatomegaly	-	-	-	<1	-	-
Hyperbilirubinemia	-	✔	-	-	-	-

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Liver damage	-	-	-	<1	-	-
Transaminases increased	<1	-	-	-	-	-
Laboratory Test Abnormalities						
Blood urea nitrogen increased	-	✔	-	-	-	-
Hypercholesterolemia	-	-	-	<1	-	-
Hyperkalemia	-	✔	-	-	-	-
Hypocalcemia	-	1	-	-	-	-
Hypoglycemia	-	✔	-	-	-	-
Hypokalemia	-	-	-	<1	-	-
Musculoskeletal						
Cogwheel rigidity	<1	-	-	-	-	-
Dyskinesia	<1	-	-	-	-	-
Dystonia	<1	-	-	-	-	-
Muscle spasms	<1	-	-	-	-	-
Myasthenia	-	-	-	<1	-	-
Myopathy	-	-	-	<1	-	-
Neck rigidity	-	-	-	<1	-	-
Restless leg syndrome	<1	-	-	-	-	-
Rigors	-	✔	-	-	-	-
Weakness	2	-	-	-	-	-
Respiratory						
Apnea	-	✔	-	-	-	-
Asthma	-	-	-	<1	-	-
Bronchitis	-	-	-	<1	-	-
Bronchospasm	-	✔	✔	-	-	-
Dyspnea	<1	✔	-	<1	-	-
Epistaxis	<1	-	-	<1	-	-
Hypercapnia	-	✔	-	-	-	-
Hyperventilation	<1	-	-	-	-	-
Hypoventilation	-	✔	-	-	-	-
Hypoxia	-	✔	-	-	-	-
Laryngospasm	-	-	✔	-	-	-
Nasal congestion	≥1	-	-	-	-	-
Pleural effusion	-	2	-	-	-	-
Pulmonary congestion	-	✔	-	-	-	-
Respiratory acidosis	-	✔	-	-	-	-
Respiratory depression	-	37	-	-	✔	-
Throat irritation	≥1	-	-	-	-	-
Upper respiratory tract infection	-	-	-	-	-	-
Wheezing	-	≤1	-	-	-	-
Special Senses						

Adverse Events	Buspirone	Dexmedetomidine	Droperidol	Eszopiclone	Hydroxyzine	Lemborexant
Blurred vision	2	-	-	-	✔	-
Conjunctivitis	<1	-	-	<1	-	-
Dry eyes	-	-	-	<1	-	-
Mydriasis	-	-	-	<1	-	-
Nystagmus	-	-	-	<1	-	-
Photophobia	-	-	-	<1	-	-
Photopsia	-	✔	-	-	-	-
Tinnitus	≥1	-	-	<1	-	-
Vestibular disorder	-	-	-	<1	-	-
Visual disturbance	<1	✔	-	-	-	-
Other						
Accidental injury	-	-	-	≤3	-	-
Allergic reaction	<1	-	-	<1	✔	-
Anaphylaxis	-	-	✔	<1	-	-
Angioedema	<1	-	-	<1	-	-
Diaphoresis	1	✔	-	<1	-	-
Edema	<1	-	-	<1	-	-
Facial edema	-	-	-	<1	-	-
Heat stroke	-	-	-	<1	-	-
Hemorrhage	-	✔	-	-	-	-
Herpes zoster	-	-	-	<1	-	-
Infection	-	-	-	5 to 10	-	-
Pain	1	✔	-	4 to 5	-	-
Serotonin syndrome	<1	-	-	-	-	-
Shivering	-	-	✔	-	-	-
Twitching	-	-	-	<1	-	-
Viral infection	-	-	-	3	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 8. Adverse Drug Events (%) Reported with the Miscellaneous Anxiolytics, Sedatives, and Hypnotics (M to Z)[2]

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Cardiovascular						
Angina	-	-	-	-	<1	-
Arrhythmia	✔	-	-	-	-	-
Bigeminy	-	-	-	-	<1	-
Bundle branch block	-	-	-	-	<1	-
Cardiospasm	-	-	-	-	<1	-
Chest pain	-	-	-	-	≥1	1 to 10
Electrocardiogram changes	✔	-	-	-	-	-

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Hypertension	-	-	-	-	<1	<1
Hypotension	-	-	-	-	<1	<1
Hypotensive crisis	✔	-	-	-	-	-
Palpitation	✔	-	-	-	<1	1 to 10
Pericardial effusion	-	-	-	-	<1	-
Peripheral edema	✔	-	-	-	≤1	-
Syncope	✔	-	-	-	<1	<1
Tachycardia	✔	-	-	-	-	<1
Vasodilation	-	-	-	-	<1	-
Ventricular extrasystoles	-	-	-	-	<1	-
Ventricular tachycardia	-	-	-	-	<1	-
Central Nervous System						
Abnormal dreams	-	-	2	10	-	-
Abnormal thinking	-	-	✔	-	≥1	-
Agitation	-	-	-	-	-	<1
Amnesia	-	-	✔	-	2 to 4	1 to 10
Anxiety	-	-	✔	-	≤1	1 to 10
Apathy	-	-	-	-	-	1 to 10
Ataxia	✔	-	-	-	<1	1 to 10
Attention disturbance	-	-	-	-	-	1 to 10
Burning sensation	-	-	-	-	-	1 to 10
Cerebrovascular attack	-	-	-	-	<1	<1
Chills	✔	-	-	-	-	-
Central nervous system stimulation	-	-	-	-	<1	-
Cognition decreased	-	-	-	-	-	<1
Complex sleep-related activities	-	✔	-	-	<1	<1
Concentration decreased	-	-	-	-	-	<1
Confusion	-	-	-	-	≤1	1 to 10
Delusions	-	-	-	-	<1	-
Depersonalization	-	-	-	-	<1 to 2	1 to 10
Depression	-	2	-	-	≥1	1 to 10
Disinhibition	-	-	-	-	-	1 to 10
Disorientation	-	-	-	-	-	1 to 10
Dizziness	✔	4 to 5	3	-	7 to 9	1 to 12
Dream disturbances	-	-	-	-	-	1 to 10
Drowsiness	✔	-	2 to 12	-	-	1 to 10
Drugged feeling	-	-	-	-	-	1 to 10
Emotional lability	-	-	-	-	-	<1
Euphoria	✔	-	-	-	-	1 to 10
Excitement	✔	-	-	-	-	-
Fatigue	-	3 to 4	-	-	-	1 to 10

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Fever	✔	-	-	-	≥1	1 to 10
Hallucinations	-	-	✔	-	≤1	1 to 10
Headache	✔	-	7	17	30 to 42	3 to 19
Hypoesthesia	-	-	-	-	<1 to 2	1 to 10
Illusion	-	-	-	-	-	<1
Insomnia	-	3	-	-	-	1 to 10
Lethargy	-	-	-	-	-	1 to 10
Lightheadedness	-	-	-	-	-	1 to 10
Memory impairment	-	-	-	-	-	1 to 10
Malaise	-	-	-	-	<1 to 2	-
Migraine	-	-	-	-	≥1	<1
Mood disorder	-	-	-	-	-	1 to 10
Nervousness	-	-	-	-	≥1	-
Overstimulation	✔	-	-	-	-	-
Paresthesia	✔	-	-	-	3	<1 to 10
Sleep disorder	-	-	-	-	-	1 to 10
Somnolence	-	3 to 5	-	-	5 to 6	6 to 15
Speech disorder	✔	-	-	-	-	<1
Stress	-	-	-	-	-	1 to 10
Stupor	-	-	-	-	-	<1
Suicidal ideation	-	-	✔	-	-	-
Temperature regulation altered	-	-	-	-	-	1 to 10
Tremor	-	-	-	-	2	1 to 10
Vertigo	✔	-	-	-	≤1	1 to 10
Dermatological						
Alopecia	-	-	-	-	<1	-
Contact dermatitis	✔	-	-	-	-	-
Ecchymosis	✔	-	-	-	<1	-
Erythema multiforme	✔	-	-	-	-	-
Petechiae	✔	-	-	-	-	-
Photosensitivity reaction	-	-	-	-	≤1	-
Pruritus	-	-	-	-	≥1	<1
Purpura	✔	-	-	-	<1	-
Rash	✔	-	-	-	≥1	1 to 10
Stevens-Johnson syndrome	✔	-	-	-	-	-
Urticaria	-	-	-	-	-	1 to 10
Wrinkling	-	-	-	-	-	1 to 10
Endocrine and Metabolic						
Cholelithiasis	-	-	-	-	<1	-
Cyanosis	-	-	-	-	<1	-
Diabetes mellitus	-	-	-	-	<1	-

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Goiter	-	-	-	-	<1	-
Ketosis	-	-	-	-	<1	-
Gastrointestinal						
Abdominal pain	-	-	-	-	6	1 to 10
Anorexia	-	-	-	-	<1 to 2	-
Appetite disorder	-	-	-	-	-	1 to 10
Bleeding gums	-	-	-	-	<1	-
Colitis	-	-	-	-	≤1	-
Constipation	-	-	-	-	≥1	1 to 10
Dehydration	-	-	-	-	-	-
Diarrhea	✔	-	2	-	-	1 to 10
Dysgeusia	-	2	-	-	≥1	-
Dyspepsia	-	-	-	-	≥1	1 to 10
Dysphagia	-	-	-	-	-	<1
Flatulence	-	-	-	-	-	1 to 10
Gastroenteritis	-	-	-	-	<1	1 to 10
Gastroesophageal reflux	-	-	-	-	-	1 to 10
Gastrointestinal ulcer	-	-	-	-	<1	-
Hiccup	-	-	-	-	-	1 to 10
Intestinal obstruction	-	-	-	-	<1	-
Nausea	✔	3	-	-	6 to 8	1 to 10
Proctitis	✔	-	-	-	-	-
Rectal hemorrhage	-	-	-	-	<1	-
Stomatitis	✔	-	-	-	-	-
Tongue edema	-	-	-	-	<1	-
Ulcerative stomatitis	-	-	-	-	<1	-
Vomiting	✔	-	-	-	-	1 to 10
Xerostomia	-	-	2	-	≥1	1 to 10
Genitourinary						
Anuria	✔	-	-	-	-	-
Cystitis	-	-	-	-	-	<1
Dysmenorrhea	-	-	-	-	3 to 4	-
Dysuria	-	-	-	-	<1	1 to 10
Hematuria	-	-	-	-	<1	-
Impotence	-	-	-	-	<1	-
Incontinence	-	-	-	-	<1	<1
Menorrhagia	-	-	-	-	-	1 to 10
Oliguria	✔	-	-	-	-	-
Renal failure	-	-	-	-	-	<1
Urinary retention	-	-	-	-	<1	-
Urinary tract infection	-	-	-	7	-	1 to 10

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Vaginitis	-	-	-	-	-	<1
Vulvovaginal dryness	-	-	-	-	-	1 to 10
Hematologic						
Agranulocytosis	✔	-	-	-	-	-
Anemia	-	-	-	-	<1	<1
Aplastic anemia	✔	-	-	-	-	-
Eosinophilia	✔	-	-	-	<1	-
Leukocytosis	-	-	-	-	<1	-
Leukopenia	✔	-	-	-	-	<1
Lymphadenopathy	-	-	-	-	<1	<1
Lymphocytosis	-	-	-	-	<1	-
Porphyria exacerbation	✔	-	-	-	-	-
Thrombocytopenic purpura	✔	-	-	-	-	-
Thrombophlebitis	-	-	-	-	<1	-
Hepatic						
Abnormal hepatic function	-	-	-	-	-	<1
Alanine transaminase increased	-	-	-	10	<1	-
Aspartate aminotransferase increased	-	-	-	-	<1	-
Hyperbilirubinemia	-	-	-	-	<1	-
Liver function tests abnormal	-	-	-	-	<1	-
Laboratory Test Abnormalities						
Cortisol decreased	-	1	-	-	-	-
Hypercholesterolemia	-	-	✔	-	-	-
Hyperglycemia	-	-	-	-	<1	<1
Hyperuricemia	-	-	-	-	<1	-
Hypoglycemia	-	-	-	-	<1	-
Hypothyroidism	-	-	-	-	<1	-
Prolactin increased	-	✔	-	-	-	-
Testosterone decreased	-	✔	-	-	-	-
Musculoskeletal						
Arthralgia	-	2	-	-	≥1	1 to 10
Arthritis	-	-	-	-	≥1	-
Back pain	-	-	-	-	≥1	1 to 10
Balance disorder	-	-	-	-	-	1 to 10
Dysarthria	-	-	-	-	<1	-
Dystonia	-	-	-	-	<1	-
Hypertonia	-	-	-	-	1	-
Involuntary muscle contractions	-	-	-	-	-	1 to 10
Myalgia	-	2	-	-	≥1	1 to 10
Myasthenia	-	-	-	-	<1	-
Myositis	-	-	-	-	<1	-

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Neck pain	-	-	-	-	-	1 to 10
Osteoporosis	-	-	-	-	<1	-
Psychomotor retardation	-	-	-	-	-	1 to 10
Weakness	✔	-	✔	-	5 to 7	1 to 10
Respiratory						
Bronchitis	-	-	-	-	≥1	-
Bronchospasm	✔	-	-	-	-	-
Cough	-	-	2	-	-	-
Dyspnea	-	-	-	-	-	<1
Epistaxis	-	-	-	-	≤1	-
Pharyngitis	-	-	-	-	-	1 to 10
Pulmonary embolus	-	-	-	-	<1	-
Sinusitis	-	-	-	-	-	1 to 10
Throat irritation	-	-	-	-	-	1 to 10
Upper respiratory tract infection	-	3	2	7	-	1 to 10
Special Senses						
Accommodation impaired	✔	-	-	-	-	-
Asthenopia	-	-	-	-	-	1 to 10
Blurred vision	-	-	-	-	-	1 to 10
Conjunctivitis	-	-	-	-	≥1	-
Depth perception altered	-	-	-	-	-	1 to 10
Diplopia	-	-	-	-	-	1 to 10
Ear pain	-	-	-	-	≤1	-
Eye pain	-	-	-	-	3 to 4	-
Eye redness	-	-	-	-	-	1 to 10
Glaucoma	-	-	-	-	<1	-
Hyperacusis	-	-	-	-	1 to 2	-
Parosmia	-	-	-	-	1 to 2	-
Photophobia	-	-	-	-	<1	-
Ptosis	-	-	-	-	<1	-
Scleritis	-	-	-	-	-	<1
Tinnitus	-	-	-	-	-	1 to 10
Visual disturbance	-	-	-	-	<1 to 2	1 to 10
Other						
Allergic reaction	-	-	-	-	-	1 to 10
Anaphylaxis	✔	✔	-	-	<1	<1
Angioedema	-	✔	-	-	<1	<1
Angioneurotic edema	✔	-	-	-	-	-
Binge eating	-	-	-	-	-	1 to 10
Diaphoresis	-	-	-	-	-	<1
Drug dependence	-	-	✔	-	-	-

Adverse Events	Meprobamate	Ramelteon	Suvorexant	Tasimelteon	Zaleplon	Zolpidem
Edema	-	-	-	-	-	<1
Facial paralysis	-	-	-	-	<1	-
Falling	-	-	-	-	-	<1
Flu-like syndrome	-	-	-	-	-	1 to 10
Hypersensitivity	✔	-	-	-	-	-
Influenza	-	1	-	-	-	-
Lactose intolerance	-	-	-	-	<1	-
Somnambulism	-	-	-	-	-	<1
Thrombosis	-	-	-	-	-	<1

✔ Percent not specified.
- Event not reported or incidence <1%.

Table 9. Boxed Warning for Droperidol[2]

WARNING
Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation, and some cases have been fatal. Due to its potential for serious proarrhythmic effects and death, reserve droperidol for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Cases of QT prolongation and serious arrhythmias (e.g., torsade de pointes) have been reported in patients treated with droperidol. Based on these reports, all patients should undergo a 12-lead electrocardiogram prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, do not administer droperidol. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, perform electrocardiogram monitoring prior to treatment and continue for two to three hours after completing treatment to monitor for arrhythmias. Droperidol is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome. Administer droperidol with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). Other risk factors may include age greater than 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and intravenous opiates. Initiate droperidol at a low dose and adjust upward, with caution, as needed to achieve the desired effect.

Table 10. Boxed Warning for Eszopiclone, Zaleplon, and Zolpidem[2]

WARNING
Complex sleep behaviors including sleepwalking, sleep-driving, and engaging in other activities while not fully awake may occur following use of these agents. Some of these events may result in serious injuries, including death. Discontinue immediately if a patient experiences a complex sleep behavior

VII. Dosing and Administration

The usual dosing regimens for the miscellaneous anxiolytics, sedatives, and hypnotics are listed in Table 11.

Table 11. Usual Dosing Regimens for the Miscellaneous Anxiolytics, Sedatives, and Hypnotics[2-14]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Buspirone	Management of anxiety disorders; short-term relief of symptoms of anxiety: Tablet: 5 to 7.5 mg twice daily; increase by 5 mg/day every two to three days as needed; maximum, 60 mg/day	Safety and efficacy in children have not been established.	Tablet: 5 mg 7.5 mg 10 mg 15 mg 30 mg
Dexmedetomidine	Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting; administer by continuous infusion not to exceed 24 hours: Injection: 1 µg/kg intravenous over 10 minutes, then 0.2 to 0.7	Safety and efficacy in children have not been established.	Injection: 80 µg/20 mL 200 µg/2 mL 200 µg/50 mL 400 µg/4 mL 400 µg/100 mL 1,000 µg/10 mL

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	µg/kg/hour Sedation of non-intubated patients prior to and/or during surgical and other procedures: Injection: 1 µg/kg intravenous over 10 minutes, then 0.2 to 1.0 µg/kg/hour		
Droperidol	To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures: Injection: 2.5 mg; additional 1.25 mg doses may be given to achieve desired effect	To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures in patients two to 12 years of age: Injection: 0.1 mg/kg To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures in patients >12 years of age: Injection: 2.5 mg	Injection: 2.5 mg/mL
Eszopiclone	Treatment of insomnia: Tablet: 1 mg immediately before bedtime; maximum, 3 mg	Safety and efficacy in children have not been established.	Tablet: 1 mg 2 mg 3 mg
Hydroxyzine	Symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: Injection: 50 to 100 mg intramuscular stat, then every four to six hours as needed Capsule, syrup, tablet: 50 to 100 mg four times daily Management of pruritus caused by allergic conditions such as chronic urticaria and atopic or contact dermatoses and in histamine-mediated pruritus: Capsule, syrup, tablet: 25 mg three to four times per day Sedation when used as premedication and following general anesthesia: Injection: 25 to 100 mg intramuscular Capsule, syrup, tablet: 50 to 100 mg	Symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested in patients ≥6 years of age: Capsule, syrup, tablet: 50 to 100 mg daily in divided doses Symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested in patients <6 years of age: Capsule, syrup, tablet: 50 mg daily in divided doses Management of pruritus caused by allergic conditions such as chronic urticaria and atopic or contact dermatoses and in histamine-mediated	Capsule: 25 mg 50 mg 100 mg Oral solution: 10 mg/5 mL 50 mg/25 mL Tablet: 10 mg 25 mg 50 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
		pruritus in patients ≥6 years of age: Capsule, syrup, tablet: 50 to 100 mg daily in divided doses Management of pruritus caused by allergic conditions such as chronic urticaria and atopic or contact dermatoses and in histamine-mediated pruritus in patients <6 years of age: Capsule, syrup, tablet: 50 mg daily in divided doses Sedation when used as premedication and following general anesthesia: Injection: 0.5 mg/lb Capsule, syrup, tablet: 0.6 mg/kg	
Lemborexant	Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance: Tablet: 5 mg taken no more than once per night, immediately before going to bed with at least seven hours before planned time of awakening; maximum, 10 mg once per night	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg
Meprobamate	Management of anxiety disorders, short-term relief of symptoms of anxiety: Tablet: 1,200 to 1,600 mg/day in three to four doses; maximum, 2,400 mg	Management of anxiety disorders, short-term relief of symptoms of anxiety in patients six to 12 years of age: Tablet: 200 to 600 mg/day in two to three divided doses	Tablet: 200 mg 400 mg
Ramelteon	Treatment of insomnia characterized by difficulty with sleep onset: Tablet: 8 mg within 30 minutes of going to bed; maximum, 8 mg	Safety and efficacy in children have not been established.	Tablet: 8 mg
Suvorexant	Insomnia characterized by difficulties with sleep onset and/or sleep maintenance: Tablet: 10 mg taken no more than once per night and within 30 minutes of going to bed, with ≥7 hours remaining before awakening; maximum, 20 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg 15 mg 20 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Tasimelteon	Treatment of Non-24-Hour Sleep-Wake Disorder: Capsule: 20 mg taken before bedtime, at the same time every night	Safety and efficacy in children have not been established.	Capsule: 20 mg
Zaleplon	Short-term treatment of insomnia: Capsule: 10 mg immediately before bedtime; maximum, 20 mg	Safety and efficacy in children have not been established.	Capsule: 5 mg 10 mg
Zolpidem	Short-term treatment of insomnia characterized by difficulties with sleep initiation: Immediate release sublingual tablet (Edluar®), tablet: 5 mg for women and 5 or 10 mg for men, immediately before bedtime with at least seven to eight hours remaining before the planned time of awakening Insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep: Immediate release sublingual tablet (Intermezzo®): 1.75 mg for women and 3.5 mg for men, taken only once per night if needed; take only if four hours of bedtime remain before the planned time of waking Insomnia characterized by difficulties with sleep onset and/or sleep maintenance: Extended release tablet: 6.25 mg for women, and 6.25 or 12.5 mg for men, immediately before bedtime with at least seven to eight hours remaining before the planned time of awakening	Safety and efficacy in children have not been established.	Extended release tablet (Ambien CR®): 6.25 mg 12.5 mg Immediate release tablet (Ambien®): 5 mg 10 mg Sublingual tablet: 1.75 mg (Intermezzo®) 3.5 mg (Intermezzo®) 5 mg (Edluar®) 10 mg (Edluar®)

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the miscellaneous anxiolytics, sedatives, and hypnotics are summarized in Table 12.

Table 12. Comparative Clinical Trials with the Miscellaneous Anxiolytics, Sedatives, and Hypnotics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Anxiety				
Gammans et al.[33] (1992) Buspirone 10 to 60 mg/day vs placebo	MA Adult outpatients with generalized anxiety disorder	N=509 (8 trials) 4 weeks	Primary: HAM-A score, HAM-D score, CGI score to determine responders Secondary: Not reported	Primary: Overall, patients treated with buspirone demonstrated significant (P<0.001) improvement over baseline in total HAM-A scores compared to placebo. Significantly more buspirone-treated patients (54%) were classified as responders than placebo-treated patients (28%) (P<0.001). Patients with GAD and concurrent depressive symptoms exhibited significantly greater improvement with buspirone compared to placebo (P<0.01 to P<0.03 depending upon the parameter measured and severity of depressive symptoms). Weekly ratings indicated that buspirone produced a progressively increasing anxiolytic response relative to placebo throughout the four-week DB treatment period in patients with GAD and coexisting depressive symptoms (P<0.05 at week one for HAM-D and P<0.05 at week two for HAM-A). Secondary: Not reported
Lader et al.[34] (1998) Buspirone 20 mg/day vs hydroxyzine 50 mg/day	DB, MC, PC, RCT Adult outpatients with GAD	N=244 6 weeks	Primary: HAM-A scores Secondary: CGI, MADRS, HAD Scale, FARD, Tyrer Withdrawal Symptom Scale	Primary: Hydroxyzine (P<0.02), but not buspirone (P=NS), significantly improved HAM-A scores over placebo after 28 days of treatment. HAM-A scores were not significantly different between hydroxyzine and buspirone. Secondary: Significantly (P<0.02) more patients on hydroxyzine improved CGI scores than placebo. There was no significant difference between buspirone and placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				With respect to the MADRS, both buspirone and hydroxyzine patients were significantly better than placebo (P<0.001). HAD scores for both depression (P<0.01 for buspirone, P<0.02 for hydroxyzine) and anxiety (P<0.001 for both buspirone and hydroxyzine) were significantly better with the active drugs compared to placebo. The FARD total scores (P<0.001 for both buspirone and hydroxyzine) were also significantly better than placebo. There was no rebound with respect to HAM-A or other efficacy variables following placebo substitution at day 28. Both the buspirone and hydroxyzine patients continued to improve. No significant withdrawal symptoms for either active drug were detected on the Tyrer Scale. Both active treatments were well tolerated. The only side effects affecting more than 5% of the exposed patients were headache and migraine (6.1%) in the buspirone-treated patients (0% in hydroxyzine and 2.5% in placebo patients) and somnolence in the hydroxyzine group (9.9%) as compared to 4.9% in the buspirone and none in the placebo group.
Llorca et al.[35] (2002) Hydroxyzine 50 mg/day or bromazepam* 6 mg/day vs placebo	DB, MC, PG, RCT Adult outpatients with GAD	N=334 18 weeks	Primary: HAM-A scores Secondary: Responder and remission rates, change in CGI-S scale score and HAD scale score, maintenance of treatment efficacy, evaluation of rebound and withdrawal symptoms, safety	Primary: Mean change in HAM-A scores from baseline was significantly greater for hydroxyzine (-12.16) compared to placebo (-9.64; P=0.019). Bromazepam was also significantly more effective than placebo in decreasing HAM-A scores (P<0.03). Secondary: Results at endpoint for percentage of responders (P=0.003), remission rates (P=0.028), change in CGI-S scale score (P=0.001), HAD scale score (P=0.008), and maintenance of efficacy (P=0.022) on day 84 also confirmed the efficacy of hydroxyzine over placebo. The study showed no statistically significant difference between hydroxyzine and bromazepam; however, the study was not designed or powered to detect differences between these two active treatments. Efficacy was significantly maintained vs placebo in 86.5% of patients in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				the hydroxyzine group (P=0.022) and in 88.1% of patients in the bromazepam group (P=0.010) until day 84. In the placebo, hydroxyzine, and bromazepam groups, only 10.1%, 14.7% and 14.0% of patients, respectively, experienced at least one adverse event considered to be related to treatment. Safety results were comparable in the 3 groups with the exception of drowsiness, which was reported most frequently in the bromazepam group (7.9%), followed by hydroxyzine (3.9%) and then placebo (1.8%). There were no statistically significant differences between each treatment group with regards to rebound effect. Differences in withdrawal symptoms that reached statistical significance were the following: hydroxyzine induced more sweating than placebo (P=0.048) and bromazepam induced more sleep disturbances than placebo (P=0.002).
Blanco et al.[36] (2003) Benzodiazepines, SSRIs, MAOIs, RIMAs, β-blockers, gabapentin, buspirone vs placebo	MA Patients with social anxiety disorder	N=2,954 (23 trials) 6 to 20 weeks	Primary: Outcome data on the LSAS or a categorical measure of status Secondary: CGI score	Primary: In terms of LSAS, no statistical difference was detected between medications or medication groups. Secondary: In terms of responders, effect sizes of each medication group were: benzodiazepines (16.61), brofaromine (6.96), phenelzine (4.10), gabapentin (3.78), SSRIs (3.22), atenolol (1.36), and moclobemide (1.27). No statistical differences were detected between these medications or medication groups.
Insomnia				
Zammit et al.[37] (2004) Eszopiclone 2 to 3 mg vs	DB, MC, PC, RCT Adults 21 to 64 years of age with chronic primary insomnia	N=308 6 weeks	Primary: Efficacy (PSG and patient reports), next day residual effects (DSST), tolerance, rebound insomnia, safety	Primary: Eszopiclone 2 and 3 mg had significantly less time to sleep onset ($P \leq 0.001$ and $P \leq 0.0001$, respectively), more TST ($P \leq 0.01$ and $P \leq 0.0001$), better SE ($P \leq 0.001$ and $P \leq 0.0001$), and enhanced quality and depth of sleep (both $P<0.05$) across the DB period compared to placebo. Eszopiclone 3 mg ($P \leq 0.01$) but not 2 mg significantly improved sleep maintenance compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo			Secondary: Not reported	Median DSST scores showed no decrement in psychomotor performance relative to baseline and did not differ from placebo in either eszopiclone group. There was no evidence of tolerance or rebound insomnia after therapy discontinuation. Treatment was well tolerated; unpleasant taste was the most common adverse event reported with eszopiclone. Secondary: Not reported
Krystal et al.[38] (2003) Eszopiclone 3 mg vs placebo	DB, MC, PC, RCT Adults with chronic insomnia	N=788 6 months	Primary: SL, WASO, NAW, TST, quality of sleep, next-day ratings of ability to function, daytime alertness, sense of physical well-being, safety Secondary: Not reported	Primary: At the first week and each month for the study duration, eszopiclone produced significant and sustained improvements in SL, WASO, NAW, number of nights awakened per week, TST, and quality of sleep compared to placebo (all $P \leq 0.003$). Monthly ratings of next-day function, alertness, and sense of physical well-being were also significantly better with the use of eszopiclone than with placebo (all $P \leq 0.002$). There was no evidence of tolerance and the most common adverse events were unpleasant taste and headache. Secondary: Not reported
Walsh et al.[39] (2007) Eszopiclone 3 mg vs placebo	DB, MC, PC, RCT Adults 21 to 64 years of age with primary insomnia	N=830 26 weeks	Primary: Patient-reported sleep measures (SL, WASO, TST, NAW, sleep quality, daytime alertness, ability to concentrate, physical well-	Primary: Patient-reported sleep and daytime function improved more with eszopiclone than with placebo at all months ($P<0.001$). Eszopiclone reduced ISI scores to below clinically meaningful levels for 50% of patients (vs 19% of patients with placebo; $P<0.05$) at six months. Lower mean scores on the FSS and the ESS were observed in the eszopiclone group relative to placebo for each month and the month one to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			being, and ability to function), ISI, FSS, ESS, Medical Outcomes Study SF-36, Work Limitations Questionnaire, safety (assessments performed at baseline, treatment months one to six, and two weeks after discontinuation of treatment) Secondary: Not reported	six average (P<0.05). SF-36 domains of Physical Functioning, Vitality, and Social Functioning were improved with eszopiclone vs placebo for the month one to six average (P<0.05). Similarly, improvements were observed for all domains of the Work Limitations Questionnaire with eszopiclone vs placebo for the month one to six average (P<0.05). There was no evidence of rebound insomnia after discontinuation of eszopiclone as SL, WASO and TST remained significantly improved from baseline (all P<0.001). There were no between-treatment differences observed during the discontinuation period except for a significantly greater SL on the first night after discontinuation with eszopiclone vs placebo (45 vs 30 minutes; P=0.015). No significant group differences were observed in mean Benzodiazepine Withdrawal Symptom Questionnaire scores (3.0 with eszopiclone and 2.3 with placebo; P=0.12), or overall adverse event rates (15.2% for eszopiclone and 11.1% for placebo; P value not reported). Unpleasant taste (19.7 vs 1.1%; P<0.001), somnolence (8.8 vs 3.2%; P=0.0029), and myalgia (6.0 vs 2.9; P=0.047) were reported in significantly more patients receiving eszopiclone than those receiving placebo. Secondary: Not reported
Joffe et al.[40] (2009) Eszopiclone 3 mg for 4 weeks vs placebo for 4 weeks Each treatment	DB, PC, RCT, XO Perimenopausal and postmenopausal women 40 to 65 years of age with sleep-onset and/or sleep-maintenance insomnia co-occurring with hot flashes and depressive and/or	N=59 11 weeks Each treatment period was separated by a 2-week washout period	Primary: Changes in the ISI scale Secondary: Diary-based sleep parameters (WASO, SE, sleep-onset latency, TST, NAW); number of hot flashes/night sweats, depressive	Primary: The ISI score was reduced by 8.7 more points with eszopiclone than with placebo (P<0.0001). The ISI score was 7 or less after four weeks of treatment in 87% of women on eszopiclone and in 34% of women on placebo. Secondary: SL was reduced by 17.8 more minutes with eszopiclone than with placebo (P=0.04). For both treatment periods together, WASO was reduced by 37.7 minutes more with eszopiclone than placebo (P=0.05), SE improved by 14.6% more with eszopiclone than with placebo (P=0.01), and TST increased by 66.5 minutes more with eszopiclone than with placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
period was separated by a 2-week washout period.	anxiety symptoms		symptoms (via MADRS), anxiety symptoms (assessed via BAI), MENQOL, and functional impairment, safety	(P=0.01). Among patients with anxiety symptoms at baseline, BAI scores were reduced by a mean of 1.5 more with eszopiclone than with placebo (P=0.03). Quality of life (P=0.0002) and functional disability (P=0.09) improved more on eszopiclone than on placebo. Among those with depressive symptoms at baseline, MADRS scores were reduced by a mean of 7.4 more points with eszopiclone than with placebo (P=0.0004). Compared to placebo, eszopiclone had a significant effect on depressive symptoms during the second (P=0.003), but not first, treatment period. There was a significant reduction in nighttime hot flashes with eszopiclone compared to placebo (reduction by 1.5 nighttime hot flashes; P=0.047), but the effect on daytime symptoms was not different. Compared to placebo, eszopiclone had a significant effect on nighttime hot flashes during the second (P=0.0006), but not first, treatment period. Overall, the treatment was well tolerated. The only adverse event occurring in >5% of the population was metallic taste on eszopiclone (25%).
Scharf et al.[41] (2005) Eszopiclone 1 to 2 mg vs placebo	DB, MC, PC, RCT Community-dwelling elderly patients (mean age 72.3 years) with primary insomnia	N=231 2 weeks	Primary: Patient-reported efficacy (SL, TST) Secondary: WASO, NAW, number and length of naps, quality of sleep, depth of sleep, ratings of daytime alertness, sense of physical well-being, morning sleepiness, ability	Primary: Patients treated with eszopiclone 1 and 2 mg had a significantly shorter SL compared to placebo (P<0.05 and P=0.0034, respectively). The eszopiclone 2-mg group (P=0.0003) but not the 1-mg group (P>0.1) had significantly longer TST compared to placebo. Secondary: Compared to placebo, patients receiving eszopiclone 2 mg had significantly less WASO but similar NAW per night (P>0.1). Patients receiving eszopiclone 2 mg had significantly fewer (P=0.028) and shorter in duration (P=0.011) daytime naps, higher ratings of sleep quality (P=0.0006) and depth (P=0.0015), better daytime alertness (P=0.022) and sense of physical well-being (P=0.047) compared to patients receiving

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			to function, quality of life (Q-LES-Q), safety	placebo. The differences between eszopiclone 2 mg and placebo were marginally significant for morning sleepiness (P=0.055) and ability to function (P=0.058). Duration of nap was significantly shorter in the eszopiclone 1-mg group compared to the placebo group (P<0.05); however, there were no other significant differences in any other secondary efficacy endpoints. Compared to placebo, the eszopiclone 2-mg group had significantly higher quality of life scores on five of the 16 Q-LES-Q domains (physical health, mood, household activities, leisure time activities and medications; P<0.05). The differences between eszopiclone 2 mg and placebo were marginally significant for the Q-LES-Q global score (P=0.064). There were no significant differences between eszopiclone 1 mg and placebo for any of the Q-LES-Q dimensions. Eszopiclone was well tolerated with unpleasant taste reported as the most frequent treatment-related adverse event.
Ancoli-Israel et al.[42] (2010) Eszopiclone 2 mg vs placebo	DB, MC, PC, RCT Patients 65 to 85 years of age with primary insomnia	N=388 12 weeks Treatment was followed by a two week, SB run out period	Primary: Change from baseline sTST Secondary: Change from baseline in sSL and WASO	Primary: After 12 weeks, the mean sTST was 360.08 minutes with eszopiclone compared to 297.86 minutes at baseline (mean change of 63.24 minutes). This was significantly greater than placebo (P<0.0001). Secondary: There was a greater improvement in sSL with eszopiclone compared to placebo (mean decrease of 24.62 vs 19.92 minutes; respectively; P=0.0014). Patients receiving eszopiclone experienced a greater decrease in WASO compared to those receiving placebo (mean decrease of 36.4 vs 14.8 minutes; P<0.0001). The reported NAW per night was reduced (P≤0.01), and the quality (P<0.001) and depth of sleep (P≤0.001) was improved at all time points with eszopiclone compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was a significantly greater decrease in naps per week over the first three weeks of treatment with eszopiclone (1.2 naps per week decrease) vs placebo (0.4 naps per week; P=0.006), but not at subsequent time points. Similar results were obtained for total nap time per week. Patients receiving eszopiclone had significantly greater improvements in ISI total scores than those receiving placebo at all time points (all P<0.001). The percentage of patients with ISI total scores categorized as "no insomnia" and "sub-threshold insomnia" was greater in the eszopiclone group (78.0% at week 12) than in the placebo group (61.1%; P<0.05). Changes in self-reported daytime alertness, ability to function, ability to concentrate, and sense of physical well-being were significantly increased with eszopiclone compared to placebo at all times points (all P≤0.001). Patients receiving eszopiclone had significant improvements in the vitality scale of the SF-36 at week six (P=0.04) and week 12 (P=0.008), and in the general health scale at week 12 (P=0.009) compared to placebo. There were no significant differences on the other SF-36 individual scale scores, or on the mental or physical component summary scores among the treatment groups. On the SDS, there were significant improvements observed in the eszopiclone group compared to the placebo group for the social life and family life/home responsibilities items (both P≤0.03) at week six, but not at week 12. There was no significant difference on the work/school item at either time point. The overall incidence of adverse events was 59.3% for eszopiclone and 50.5% for placebo. The most common adverse events reported in the eszopiclone group were headache (13.9 vs 12.4% for placebo), unpleasant taste (12.4 vs 1.5% for placebo), and nasopharyngitis (5.7 vs 6.2% for placebo).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Lettieri et al.[43] (2009) Eszopiclone 3 mg 30 minutes prior to PSG (premedication) vs placebo 30 minutes prior to PSG (premedication)	DB, PC, RCT Patients 18 to 64 years of age with newly diagnosed obstructive sleep apnea who were initiating CPAP	N=117 4 to 6 weeks	Primary: CPAP compliance during the initial four to six weeks of therapy Secondary: CPAP titration quality as assessed by WASO), TST, total arousal index, SL, SE, AHI	Primary: CPAP was used on a higher percentage of nights in the eszopiclone group than in the placebo group (75.9 vs 60.1%, respectively; P=0.005). Eszopiclone was associated with more hours of use per night during nights used (4.8 vs 3.9 hours, respectively; P=0.03) and for more hours per night for all nights of the study period (4.0 vs 2.9 hours, respectively; P=0.03). The percentage of days with >4 hours of use also was greater among the eszopiclone group (59.2 vs 37.0%, respectively; P=0.007). Good compliance (>4 hours of use per night on >70% of nights) was observed in more patients pretreated with eszopiclone than with placebo (53.1 vs 27.1%, respectively; P=0.009). Secondary: Premedication with eszopiclone improved the quality of CPAP titration PSG compared to placebo as evidenced by shortened SL (19.4 vs 31.8 minutes, respectively; P=0.08), improved SE (87.8 vs 80.1%, respectively; P=0.002), expanded TST (350.9 vs 319.7 minutes, respectively; P=0.007), and decreased WASO (39.3 vs 59.9 minutes, respectively; P=0.009). The residual AHI tended to be lower following eszopiclone premedication (6.4 vs 12.8 events/hour, respectively; P=0.08).
Lettieri et al.[44] (2009) Eszopiclone 3 mg for 2 weeks vs placebo for 2 weeks To promote adherence with CPAP, OL use of	DB, PC, RCT Patients 18 to 64 years of age with newly diagnosed obstructive sleep apnea who were initiating CPAP	N=160 24 weeks	Primary: Adherence to CPAP at week 24 Secondary: Rate of CPAP discontinuation and OL use of sedative-hypnotic agents	Primary: Patients receiving eszopiclone used CPAP for 64.4% of nights compared to 45.2% of nights in those receiving placebo (P=0.003). In the eszopiclone and placebo groups, CPAP was used for 3.57 vs 2.42 hours per night, respectively for all study nights (P=0.005) and for 4.05 vs 3.02 hours per night, respectively for nights when CPAP was used (P=0.019). Secondary: The mean duration of regular use of CPAP was 13.3 weeks for the placebo group and 17.6 weeks for the eszopiclone group (P=0.005). The mean time to discontinuation of CPAP for the placebo and eszopiclone groups was 17.2 and 19.7 weeks, respectively (P=0.033).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
sedative-hypnotic agents was allowed after the first 4 weeks of treatment.				A total of 24.7% of patients requested OL non-benzodiazepines. This request was more frequent among those receiving placebo than eszopiclone (31% vs 19%; P=0.084). The mean duration of hypnotic use (9.7 days) was similar for both groups. Adverse events were reported in 7.1% of patients and did not differ between the groups.
Menza et al.[45] (2010) Eszopiclone 2 to 3 mg vs placebo	DB, MC, PC, PG, RCT Patients 35 to 85 years of age with Parkinson's disease and sleep maintenance insomnia or SL insomnia, as well as clinically significant daytime distress or impairment secondary to insomnia	N=30 6 weeks	Primary: Patient-reported TST Secondary: WASO, NAW and SII, quality of sleep, quality of life (assessed via PDQ-8), motor function (assessed via UPDRS), severity and change (assessed via CGI), ability to function, daytime alertness, fatigue severity (assessed via FSS), caregiver quality of life and depression (assessed via MCBI and CES-D)	Primary: There was no significant difference in the improvement seen in TST among the groups (66.5 minutes with eszopiclone vs 47.0 minutes with placebo; P=0.1099). Secondary: There were significant differences in NAW (P=0.035), quality of sleep (P=0.018), and CGI-improvement in sleep (P=0.035) among the groups. There was no significant difference in WASO (P=0.071). There were no differences in the UPDRS motor, activities of daily living, therapeutic complications, mood or Schwab subscales. There were no significant differences in SL, FSS, SII, PDQ-8, Ability to Function Scale, the MCBI caregiver burden, the CES-D, or the Daytime Alertness Scale. Overall, 30% of patients reported adverse events; 33% of patients receiving eszopiclone and 27% of patients receiving placebo.
Pollack et al.[46] (2011) Eszopiclone 3 mg for 3 weeks	DB, PC, RCT, XO Patients 18 to 64 years of age with PTSD with associated sleep	N=24 7 weeks	Primary: Changes in scores on the SPRINT and PSQI scales Secondary:	Primary: Eszopiclone was associated with significant improvement in PTSD symptomatology as measured by the SPRINT compared to placebo (P=0.032). Eszopiclone was associated with a significantly greater reduction in PSQI

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo for 3 weeks Each treatment period was separated by a 1-week washout period.	disturbance		CAPS, SL and TST	score compared to placebo (P=0.011). Secondary: In phase 1, the CAPS was also significantly reduced with eszopiclone compared to placebo (P=0.003). SL was significantly reduced with eszopiclone compared to placebo (P=0.044). There was no significant difference in TST among the treatment groups (P=0.061). Adverse events with eszopiclone were of mild to moderate severity, with the most common comprising unpleasant taste (32%), sedation (16%), and headaches (12%).
McCall et al.[47] (2010) Eszopiclone 3 mg vs placebo All patients started with one week of OL fluoxetine; patients experiencing insomnia after this period were randomized to 8 weeks of eszopiclone or placebo in addition to the OL fluoxetine.	DB, PC, RCT Patients 18 to 70 years of age with depression and insomnia	N=60 8 weeks	Primary: DLRF subscale of the Basis-32 Secondary: Safety	Primary: Final DLRF scores were better (lower) in the eszopiclone group than in the placebo group (0.81±0.64 vs 1.2±0.72). Secondary: The only meaningful adverse event reported, was unpleasant taste, and it occurred in 46% of patients treated with eszopiclone.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rosenberg et al.[48] (2005) Eszopiclone 1, 2, 3 or 3.5 mg vs placebo	DB, PC, RCT Healthy adult volunteers with transient insomnia	N=436 1 night	Primary: Efficacy and next-morning effects evaluated by PSG, DSST and self-report Secondary: Not reported	Primary: Patients treated with eszopiclone had significantly less PSG LPS (all doses except 1 mg; P≤0.0001), WASO (all doses; P≤0.05) and NAW (3 and 3.5 mg doses; P<0.005), and greater SE (all doses; P≤0.02) compared to placebo. Self-reported efficacy results were similar to PSG. Self-reported morning sleepiness scores were significantly better for eszopiclone 3 and 3.5 mg compared to placebo (P<0.05). Treatment was well tolerated by patients, and the most common treatment-related adverse event was unpleasant taste. Secondary: Not reported
Krystal et al.[49] (2012) Eszopiclone 3 mg vs placebo	Post hoc analysis of a 6-month PC, RCT Patients diagnosed with chronic primary insomnia	N=195 6 months	Primary: Determination of the distribution of baseline WASO; continuous analysis of the relationship between baseline WASO severity and drug-placebo difference at month one and six; and categorical efficacy analyses of subgroups delimited by the following WASO thresholds: 0, 30, 45, 60, and 90 minutes Secondary:	Primary: The baseline WASO distribution was: <30 minutes, 32.2%; >0 to <45 minutes, 41.5%; >30 to <90 minutes, 33.0%; >45 to <90 minutes, 23.7%; >90 minutes, 22.6%. A relationship between greater baseline WASO severity and a significantly greater drug-placebo difference in efficacy for WASO was evident. Eszopiclone was found to have significant sleep maintenance efficacy at each time point across the entire range of WASO severity studied. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Not reported	
Rosenberg et al.[50] SUNRISE-1 (2019) Lemborexant 5 mg QHS or lemborexant 10 mg QHS vs zolpidem tartrate ER 6.25 mg QHS vs placebo	AC, DB, DD, MC, PC, PG, RCT Males ≥65 and females ≥55 years of age with a diagnosis of insomnia based on DSM-5, history of sWASO ≥60 minutes at least three nights per week in the previous four weeks, regular time spent in bed (between seven and nine hours), evidence of sleep maintenance insomnia, ISI score ≥13	N=1,006 4 weeks	Primary: Change from baseline for mean LPS on Days 29/30 as measured by PSG Secondary: Change from baseline for SE and WASO on Days 29/30, change from baseline for mean WASO in the second half of the night (WASO2H) on Days 29/30, safety	Primary: Treatment with both lemborexant 5 mg and 10 mg demonstrated significantly greater mean decreases from baseline in LPS on Days 29/30 compared to placebo (-19.5 and -21.5 vs -7.9 minutes, respectively). Treatment with zolpidem ER demonstrated a mean decrease from baseline in LPS on Days 29/30 compared to placebo (-7.5 vs -7.9 minutes, respectively). Secondary: Treatment with lemborexant 5 mg and 10 mg demonstrated significantly greater increases from baseline in SE (measured by PSG) at one month compared to placebo (12.9 and 14.1 vs 5.4%, respectively), as well as WASO (measured by PSG) at one month of treatment compared to placebo (-43.9 and -46.4 vs -18.6 minutes, respectively). The mean increase from baseline in SE was 9.1% for the zolpidem ER group and the mean decrease from baseline in WASO was -36.5 minutes. Treatment with lemborexant 5 mg and 10 mg demonstrated significantly greater decreases from baseline in WASO2H at one month (-27.2 and -28.8 vs -8.9 minutes, respectively). The mean decrease was -21.4 minutes in the zolpidem ER group. Treatment with lemborexant 5 mg and 10 mg demonstrated significantly greater decreases from baseline in sSOL at one month compared to placebo (-25.2 and -24.8 vs -8.1). The mean decrease was -17.0 in the zolpidem ER group. The overall incidence of treatment-emergent adverse events was similar among treatment groups. Non-serious adverse events were deemed to be mild or moderate in severity. A total of six individuals (four in the zolpidem group and two in the lemborexant 5 mg group) reported eight serious adverse; none were deemed to be treatment-related. Sleep paralysis was reported by one individual in the lemborexant 5 mg group and three in the lemborexant 10 mg group, although all were reported as mild in severity.
Kärppä et al.[51]	DB, MC, PC, PG,	N=971	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
SUNRISE-2 (2020) Lemborexant 5 mg QHS or lemborexant 10 mg QHS vs placebo	RCT Adults ≥18 years of age with a diagnosis of insomnia based on DSM-5, history of sSOL ≥30 minutes and/or sWASO ≥60 minutes on at least three nights per week in the previous four weeks, regular time spent in bed (between seven and nine hours), ISI score ≥15	52 weeks	Change from baseline in sSOL at month six Secondary: Change from baseline in sSE and sWASO at month six compared to placebo	Treatment with lemborexant 5 mg and 10 mg demonstrated significantly greater decreases from baseline in median sSOL compared to placebo at month six (-21.81 and -28.21 vs -11.43 minutes, respectively; P<0.0001 for both strengths). Secondary: Treatment with lemborexant 5 mg and 10 mg demonstrated significantly greater increases from baseline at month six compared to placebo in both sSE (LSM, 14.19 and 14.31 vs 9.64%; P=0.0001 for 5 mg group and <0.0001 for 10 mg group) and sWASO (LSM, -46.75 and -41.95 vs -29.28; P=0.0005 [5 mg] and P=0.0105 [10 mg]). A greater proportion of sleep onset responders was seen with lemborexant 5 mg and 10 mg compared with placebo at month six (31.2 and 30.1 vs 17.7%, respectively; P<0.001 [both strengths]). A greater proportion of sleep maintenance responders was seen with lemborexant 5 mg and 10 mg compared with placebo at month six (35.0 and 30.0 vs 20.4%, respectively; P<0.001 [5 mg] and P<0.05 [10 mg]). Both lemborexant 5 mg and 10 mg demonstrated significant greater increases from baseline in sTST compared with placebo at month six (LSM, 69.95 and 74.08 vs 51.40 minutes, respectively; P=0.0034 [5 mg] and P=0.0004 [10 mg], respectively).
Uchimura et al.[52] (abstract) (2011) Ramelteon 4 and 8 mg vs placebo	DB, PC, RCT Japanese adults with chronic insomnia	N=1,130 Duration not reported	Primary: Not reported Secondary: Not reported	Primary: Not reported Secondary: Not reported There was no statistically significant difference between ramelteon and placebo in the change in subjective SL (P value not reported). Significant improvement was observed in the change in subjective TST with ramelteon 8 mg at week one (P value not reported). Post hoc analyses indicated that treatment with ramelteon 8 mg resulted in a reduction in subjective SL in individuals with smaller fluctuations

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(within ±30 minutes) of subjective SL at baseline, in those with a shorter (<1 year) history of insomnia, and in individuals who had not used benzodiazepines (P value not reported). Ramelteon was safe and well tolerated up to 16 mg nightly.
Kohsaka et al.[53] (abstract) (2011) Ramelteon 4, 8, 16, or 32 mg vs placebo	DB, PC, XO Japanese patients with chronic insomnia	N=65 Each dose was given for two nights over five study periods	Primary: Not reported Secondary: Not reported	Primary: Not reported Secondary: Not reported Ramelteon 8 and 32 mg significantly shortened the mean LPS when compared to placebo (P value not reported). Overall changes in sleep architecture were modest (<3% changes vs placebo; P value not reported), with increases in stage 1 and decreases in stage 3/4. When compared to SL data from a similarly designed United States study, there was no evidence of any ethnic differences in the efficacy of ramelteon between Japanese and United States patients. Overall, ramelteon 8 mg showed the most favorable balance between sleep-promoting effects and tolerability (P value not reported). Ramelteon was well tolerated, the most common adverse effect was somnolence, which was similar to placebo at doses up to 8 mg, but increased with higher doses (P value not reported). Next-day residual effects occurred no more frequently with ramelteon at any dose than with placebo (P value not reported).
Wang-Weigand et al.[54] (2011) Ramelteon 8 mg vs placebo	PC, RCT Adults 18 to 64 years of age with chronic insomnia	N=552 Nightly treatment for 3 weeks with a one week, placebo run-out period to assess rebound insomnia	Primary: Patient reported SL at week three Secondary: Patient reported SL at week one and two, patient reported TST, patient reported WASO, patient	Primary and secondary: There was a reduction in the average patient reported SL (as measured by the PSQ-IVRS) at weeks one, two, and three, when compared to placebo; however, none of these reductions reached statistical significance (P value not reported). There were no significant differences seen between ramelteon and placebo at any time point regarding the following patient-reported parameters: TST, WASO, NAW, or sleep quality (P value not reported). There was no evidence of rebound insomnia detected during the placebo run-out period for the groups that had received placebo or ramelteon.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			reported NAW, and sleep quality (all assessed each week), safety	Headache and somnolence occurred in more than 3% of subjects in either group. Overall, the proportion of subjects with any treatment-related adverse events was similar between the ramelteon and placebo-groups (16.5 vs 15.4%, respectively; P-value not reported).
Wang-Weigand et al.[55] (2009) Ramelteon 8 mg vs placebo	DB, PC, RCT (pooled analysis of 4 trials) Patients 18 to 83 years of age with chronic insomnia	N=1,122 Duration varied among included trials	Primary: LS mean LPS for nights one and two for each included trial Secondary: Safety	Primary: At nights one and two, mean LPS was 43.3 minutes for the placebo group and 30.2 minutes, resulting in a between-group difference of 13.1 minutes (P<0.001). Secondary: The total number of adverse events was similar for ramelteon 8 mg (209 [36.5%]) and placebo (192 [34.3%]) (P value not reported). The most common adverse events were headache and somnolence.
Zammit et al.[56] (2009) Ramelteon 8 or 16 mg vs placebo	DB, MC, PC, RCT, SD Healthy patients 18 to 64 years of age	N=289 1 night	Primary: LPS assessed by PSG Secondary: PSG assessed endpoints include TST, WASO, and NAW after persistent sleep onset; subjective measures include SL, TST, WASO, NAW after persistent sleep onset, and overall sleep quality, safety	Primary: Treatment with ramelteon 8 mg resulted in a significant decrease in LS mean LPS when compared to placebo (12.2 vs 19.7 minutes; P=0.004). Treatment with ramelteon 16 mg resulted in a numeric decrease in LS mean LPS when compared to placebo; however, this decrease did not reach statistical significance (14.8 vs 19.7 minutes; P=0.065). Secondary: Treatment with ramelteon 8 and 16 mg resulted in significant increases in the LS mean TST when compared to placebo (8 mg: 436.8 vs 419.7 minutes; P=0.009 and 16 mg: 433.1 vs 419.7 minutes; P=0.043). There were no significant changes in any other objective or subjective measures of sleep. A total of 31 subjects (10.7%) reported at least one adverse event during the study. The incidence rates were 12.4, 13.3, and 6.4% for the placebo, ramelteon 8 and 16 mg groups, respectively. Most adverse events were mild or moderate in severity and the most commonly reported adverse event was somnolence.
Erman et al.[57] (2006) Ramelteon 4 to 32 mg	DB, MC, PC, RCT, 5-period XO Men and non-pregnant, non-	N=107	Primary: Mean LPS Secondary: TST, WASO,	Primary: All tested doses of ramelteon resulted in statistically significant reductions in LPS compared to placebo (P<0.001). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	lactating women 18 to 64 years of age with chronic insomnia		percentage of sleep time in each sleep stage, subjective sleep quality, next-day performance and alertness, safety	All tested doses of ramelteon resulted in statistically significant increases in TST compared to placebo (P=0.001). No significant differences in WASO (P=0.470), percentage of time spent in the different sleep stages and subjective sleep quality (P=0.525) were reported between the ramelteon groups and the placebo group. There were no differences between the placebo group and any ramelteon dose group on next-day performance and alertness (P values not reported). The safety of ramelteon at each dose was similar to that of placebo and the most commonly reported adverse events were headache, somnolence, and sore throat.
Mayer et al.[58] (2009) Ramelteon 8 mg vs placebo	DB, PC, RCT Patients ≥18 years of age with chronic primary insomnia	N=451 6 months	Primary: LPS (measured by PSG) Secondary: TST (measured by PSG), total time spent in each sleep stage, latency to REM, self-reported efficacy	Primary: Greater reductions in LPS occurred with ramelteon compared to placebo (P<0.05 for each time point). A greater change from baseline occurred with ramelteon (54 to 56%) compared to placebo (30 to 47%). Secondary A greater increase in TST occurred with ramelteon (381.1 minutes) compared to placebo (365.7 minutes) at week one (P<0.001), but not at any other time points. There were no significant changes in percent of time spent in Stage 1 or REM sleep with ramelteon vs placebo. There was a significant increase in percent of time spent in Stage 2 sleep and a significant decrease in time spent in Stage 3/4 with ramelteon compared to placebo (P values not reported). There was a greater reduction in subjective SL with ramelteon compared to placebo at week one, as well as months one and five (P<0.05). There

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				were no significant reductions at other time points between the treatment groups. There were no significant differences between ramelteon and placebo at any time point on the following measures: subjective TST, subjective NAW and sleep quality. No significant differences in sWASO was observed between ramelteon (90.89 minutes) and placebo (79.54 minutes) at any time point except month six (P=0.036). There were no significant differences on measures of morning level of alertness and ability to concentrate, or immediate/delayed morning recall between the treatment groups. No rebound insomnia was observed during the placebo run-out period. There were no differences between the treatment groups with regards to measures of withdrawal during the placebo run-out period.
Uchiyama et al.[59] (2011) Ramelteon 8 mg vs placebo	DB, MC, PC, RCT Japanese patients 20 to 85 years of age with primary insomnia	N=1,605 2 weeks	Primary: Mean patient-reported SL during week one of treatment Secondary: Mean SL during week two of treatment, mean patient-reported TST for week one and for week two, patient's global impression of treatment, rebound insomnia, and safety	Primary: The mean SL was reduced in week one in both the ramelteon and placebo groups (-15.98 and -11.73 minutes, respectively; P=0.0010). Secondary: The mean SL decreased further in week two in both groups; however, the difference between the groups of -2.36 minutes in favor of ramelteon did not achieve statistical significance (P=0.1093). Ramelteon increased TST significantly more than placebo at week one (difference in LS mean, 4.2 minutes; P=0.0484), but not at week two (2.4 minutes; P=0.2378). The mean NAW reported by patients in the ramelteon group was significantly less than that in the placebo group at week two (difference in LS mean of -0.07; P=0.0469) but not for week 1 (-0.04; P=0.2592). The mean sleep quality score with ramelteon was significantly smaller than that with placebo for week one (difference in LS mean, -0.12;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				P=0.0174), but not week two (-0.06; P=0.2059). There was no evidence of rebound insomnia with ramelteon during the run-out period. The mean total score for patients' global impression of treatment improved significantly with ramelteon compared to placebo at the end of week one (1.52 vs 1.59; P=0.0041) and week two (1.45 vs 1.53; P=0.0028). The proportion of patients scoring individual items as ''improved'' was significantly higher for ramelteon than placebo at weeks one and two for time to fall asleep (week one, 53.1 vs 44.3%; P=0.0100, week two, 58.3 vs 52.5%; P=0.0434), TST (week one, 42.0 vs 34.0%; P=0.0121, week two, 47.6 vs 38.8%; P=0.0031), sleep quality (week one, 56.4 vs 48.2%; P=0.0115, week two, 62.5 vs 56.1%; P=0.0463), and usefulness of treatment (week one, 58.2 vs 47.6%; P=0.0008, week two, 64.6 vs 56.8%; P=0.0123), but not for daytime distress (week one, 33.4 vs 31.9%; P=0.9116, week two, 42.7 vs 37.7%; P=0.0881). A total of 26.4% of patients in the ramelteon group and 20.5% of patients in the placebo group reported at least one treatment-emergent adverse event. All events were mild or moderate in severity. The most common adverse event leading to discontinuation was nasopharyngitis.
Uchiyama et al.[60] (2011) Ramelteon 4 to 16 mg	MC, SB Japanese patients 20 to 85 years of age with primary insomnia	N=222 24 weeks	Primary: Adverse events, residual effects, rebound insomnia, withdrawal symptoms, and dependence Secondary: Subjective SL and TST	Primary: During the study, 77.4% of patients reported adverse events. The most frequent reported adverse events were nasopharyngitis, inflammation of upper respiratory tract, eczema, elevated γ-glutamyltransferase, laryngopharyngitis, and headache. Endocrine adverse events that were considered drug-related included metrorrhagia, dysmenorrhea, polymenorrhea, increased estradiol, increased cortisol, and decreased cortisol. The mean change in next-morning residual scores significantly improved from baseline with ramelteon (P<0.05). The mean change from baseline in SL at week 24 and the placebo run-out period using the full analysis set with 8 mg were -30.4 and -28.6 minutes in the group continuously treated with ramelteon, which confirms the lack

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				of rebound insomnia. Ramelteon was not associated with withdrawal symptoms and there was no evidence of dependence. Secondary: Mean subjective SL decreased significantly during the study. In the group that continuously received ramelteon 8 mg, it decreased from a baseline of 70.5 to 54.4 minutes after one week (P<0.0001) and 33.8 minutes after 20 weeks (P<0.0001), then plateaued until the end of the study. The mean subjective TST was 5.52 hours at baseline, increasing to 5.78 hours at week one (P<0.0001) and 6.30 hours at week 20 (P<0.0001), and remained stable until the end of the study.
Gooneratne et al.[61] (2010) Ramelteon 8 mg vs placebo	DB, PC, RCT Patients ≥60 years of age with obstructive sleep apnea and insomnia symptoms	N=21 4 weeks	Primary: Objective change in SOL using PSG Secondary: PSQI, (ISI, FOSQ, quality of life (SF-36)	Primary: Using PSG, there was a 10.7 minute decrease in SOL in the ramelteon arm compared to a 17.8 minute increase in the placebo arm (difference, 28.5 minutes; P=0.008). For self-reported SOL, there was no significant difference among the two study arms (−1.3 minutes; P=0.9). Neither objective nor subjective SE differed significantly between study arms. Secondary: There were no significant differences in the PSQI, ISI, FOSQ, or SF-36 among the treatment groups. The adverse events reported with ramelteon were diarrhea, skin ulcer, sinusitis, and fracture after being hit by a bicyclist. For placebo, the adverse events were abdominal pain and nausea. All adverse events were thought to be unrelated to study drug treatments, and none were serious adverse events.
Liu et al.[62] (2012) Ramelteon	MA Patients with chronic insomnia	N=8 trials Duration varied	Primary: Subjective and polysomnographic SL, TST and latency to REM	Primary: There were significant improvements in all outcomes (subjective and polysomnographic SL, TST and latency to REM), except for the percentage of REM.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			Secondary: Not reported	By subgroup analysis, subjective SL was reduced only in the patients 18 to 64 years of age. For the safety, ramelteon was not associated with higher risk ratio of any frequent adverse events comparing with control. Secondary: Not reported
Dobkin et al.[63] (2009) Ramelteon 8 mg	OL, PRO Patient population not specified	N=20 6 weeks	Primary: Patient reported LPS Secondary: Patient reported endpoints include TST, WASO, total number of nighttime awakenings, SE, and number of hot flashes/ night sweats; other secondary endpoints include sleep impairment (assessed via the SII), daytime functioning, daytime alertness, quality of life (assessed via the MENQOL), mood (assessed via the BDI), CGI-S, and CGI-I, safety	Primary: Treatment with ramelteon resulted in improvements in LPS at week six when compared to baseline (24.0±15.0 vs 46.2±19.8 minutes; P<0.001). The average improvement across all participants was 22 minutes. Secondary: Treatment with ramelteon 8 mg resulted in improvements at week six when compared to baseline in the following parameters: TST (420±38 vs 336±62 minutes; P<0.001), SE (0.91±0.06 vs 0.80±0.10; P<0.001), night time awakenings (1.86±1.53 vs 2.32±1.36; P<0.05), and hot flashes (1.52±1.32 vs 2.31±1.95; P<0.05). There were no significant improvements in WASO at any time period throughout the study when compared to baseline. Significant improvements were observed in patient reported sleep quality (P<0.001), daytime dysfunction (P<0.01), daytime alertness (P<0.001), SII scores (P<0.001), MENQOL scores (P<0.01), BDI scores (P<0.001), and anxiety (P<0.001). At the end of this trial, 55% of women were considered “responders” according to the CGI-I scale. Insomnia severity, assessed by the CGI-S, also improved over baseline (3.14 vs 4.65; P<0.001). Of the subjects treated with ramelteon in this trial, 40% reported side effects. The most frequently reported side effects included headaches, daytime fatigue/fogginess, dry mouth, lightheadedness, and dizziness. Most side effects were mild and transient.
Richardson et al.[64] (2009)	OL, PRO	N=1,213	Primary: Adverse events,	Primary: There were no noteworthy changes in vital signs, physical examinations,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ramelteon 8 or 16 mg Subjects >65 years of age received 8 mg/day, subjects 18 to 64 years of age received 16 mg/day.	Adults with primary insomnia	48 weeks	changes in vital signs, laboratory values, 12-ECG, and results of physical examination Secondary: Safety	clinical chemistry, hematology, or urinalysis values. There were also no ECG changes to suggest adverse cardiac effects. Consistent statistically significant (P≤0.05) decreases in free thyroxine and free testosterone (in older men) were detected. Duration of menses increased by approximately one day. In both groups, those older and younger than 65, subjective SL and TST improved by month one and was sustained during the one-year period. At six months and one year, CGI indices were improved. During the placebo run-out period, SL did increase but did not return to baseline. Secondary: A total of 69.8% of patients reported at least one adverse event. There was no difference in adverse event incidence between those older and younger than 65 (P value not reported). The overall incidence of adverse events was similar at six months and one year.
Gross et al.[65] (2009) Ramelteon 8 mg All patients continued to take their antidepressant; dose reductions were permitted at any time but no dose increases were permitted during the study period.	OL, PRO Patients 18 to 80 years of age with GAD and related insomnia	N=27 10 weeks	Primary: CGI-I, CGI-S, daytime sleepiness (assessed via ESS), HAMA, and patient reported sleep diaries Secondary: Safety	Primary: The addition of ramelteon 8 mg resulted in significant improvement over baseline in the following study parameters: time to fall asleep (34.67±29.26 vs 77.52±47.73 minutes; P<0.001), TST (7.52±1.22 vs 5.02±0.96 hours; P<0.001), CGI-S Insomnia (1.67±0.73 vs 4.30±0.47; P<0.001), CGI-I Insomnia (1.59±0.64 vs 3.85±0.36; P<0.001), HAMA (3.96±2.97 vs 8.26±2.94; P<0.001), ESS (5.48±3.27 vs 11.56±2.14; P<0.001), CGI-S Anxiety (1.25±0.64 vs 2.85±0.66; P<0.001), CGI-I Anxiety (1.41±0.50 vs 2.33±0.78; P<0.001). Secondary: The most common adverse events regarding ramelteon use were headache upon stopping ramelteon (7.4%), daytime tiredness (3.7%), and depression (3.7%). All side effects were reported as transient.
Roth et al.[66] (2006) Ramelteon 4 mg	DB, PC, RCT Patients 64 to 93 years of age with	N=829 5 weeks	Primary: SL at week one Secondary:	Primary: Significant reductions in SL at week one were reported with both ramelteon 4 mg (70.2 vs 78.5 minutes; P=0.008) and 8 mg (70.2 vs 78.5 minutes; P=0.008) compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ramelteon 8 mg vs placebo	chronic primary insomnia		TST at weeks one, three and five; reductions in SL at weeks three and five; sleep diaries; rebound insomnia and withdrawal effects during the seven-day placebo run out	Secondary: Patients continued to report reduced SL at week three with ramelteon 8 mg (P=0.003) and at week five with ramelteon 4 and 8 mg (P=0.028 and P<0.001, respectively) compared to placebo. Patient-reported TST at weeks one and three was significantly longer compared to placebo for ramelteon 4 mg (324.6 vs 313.9 minutes; P=0.004 and 336.0 vs 324.3 minutes; P=0.007, respectively). TST for ramelteon 4 mg at five weeks and for ramelteon 8 mg at weeks one, three and five were longer than placebo but did not reach statistical significance (P values >0.05). Analyses of other sleep parameters obtained via sleep diaries (e.g., NAW, ease of falling back asleep after an awakening and sleep quality) yielded no statistically significant differences among groups at weeks one, three and five. There was no evidence of significant rebound insomnia or withdrawal effects following treatment discontinuation. Incidence of adverse events was 51.5, 54.8 and 58.0% of patients in the placebo, 4 and 8 mg ramelteon groups, respectively.
Roth et al.[67] (2005) Ramelteon 16 mg vs ramelteon 64 mg vs placebo Doses were given	DB, PC, MC, RCT Healthy adult volunteers with transient insomnia (35 to 60 years of age with total sleep duration 6.5 to 8.5 hours, a usual SL of 30 minutes or less, a habitual bedtime between 8:30 PM and midnight)	N =375	Primary: Mean LPS as measured by PSG Secondary: TST, WASO, percentage of sleep time in each sleep stage, NAW, residual effects assessed by DSST and post-sleep questionnaire, safety	Primary: Participants who had received either ramelteon dosage had significantly shorter LPS relative to placebo (both P<0.001). Secondary: Participants who had received ramelteon 16 or 64 mg had significantly longer TST compared to participants who had received placebo (P=0.007 and P=0.033, respectively). There were no significant differences between the ramelteon groups and placebo with regard to WASO, percentage of sleep time in each sleep stage, and NAW. No significant differences in DSST scores were reported among the

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td>30 minutes before bedtime.</td><td></td><td></td><td></td><td>groups, but ramelteon 64 mg was associated with statistically significant declines in subjective levels of alertness (P=0.020) and ability to concentrate (P=0.043) compared to placebo.

No serious adverse events were reported.</td></tr>
<tr><td>Michelson et al.[68] (2014)

Suvorexant 30 mg nightly for elderly patients and 40 mg nightly for non-elderly patients

vs

placebo</td><td>DB, PC, RCT

Patients ≥18 years of age with primary insomnia</td><td>N=779

1 year</td><td>Primary:
Safety and tolerability

Secondary:
sTST, sTSO</td><td>Primary:
Similar proportions of patients treated with suvorexant or placebo discontinued because of adverse events. The most common adverse events that were increased for suvorexant versus placebo were somnolence, fatigue, and dry mouth. Somnolence was the adverse event with the highest incidence for discontinuations, (suvorexant 20/521 [4%] vs placebo 2/258 [1%]). Somnolence was most common in the first three months (57/527 [11%] for suvorexant vs 6/258 [2%] for placebo) and was less commonly reported by the second three months (11/425 [3%] for suvorexant vs 1/254 [<1%] for placebo). There were no clinically meaningful differences between groups in vital signs or laboratory values.

Secondary:
Over the first month, the suvorexant group showed significant improvements in sTST and sTSO compared with the placebo group. The improvements were maintained throughout the one-year phase.</td></tr>
<tr><td>Herring et al.[69] (2016)

Suvorexant 15 mg nightly for elderly patients and 20 mg nightly for non-elderly patients

vs

placebo</td><td>Pooled analysis from 2 identical DB, PC, RCTs

Non-elderly (18 to 64 years of age) and elderly (≥ 65 years of age) patients with insomnia</td><td>N=493 suvorexant; N=767 placebo

3 months</td><td>Primary:
Change from baseline in sleep diary and PSG measures of sleep maintenance (sTST, WASO) and sleep onset (sTSO, LPS)

Secondary:
Safety</td><td>Primary:
Change from baseline in sleep diary and PSG measures of sleep maintenance
<table>
<tr><th></th><th>Month 1</th><th>Month 1 P-value (vs placebo)</th><th>Month 3</th><th>Month 3 P-value (vs placebo)</th></tr>
<tr><td colspan="5">Diary measures</td></tr>
<tr><td>sTST, minutes</td><td>18.4</td><td>P<0.001</td><td>16.0</td><td>P<0.001</td></tr>
<tr><td>sTSO, minutes</td><td>-5.6</td><td>P<0.05</td><td>-5.9</td><td>P<0.001</td></tr>
<tr><td>sWASO, minutes</td><td>-6.6</td><td>P<0.01</td><td>-4.7</td><td>P<0.05</td></tr>
<tr><td colspan="5">PSG measures</td></tr>
<tr><td>LPS, minutes</td><td>-9.1</td><td>P<0.001</td><td>-4.6</td><td>NS</td></tr>
<tr><td>WASO, minutes</td><td>-25.4</td><td>P<0.001</td><td>-23.1</td><td>P<0.001</td></tr>
<tr><td>TST, minutes</td><td>34.7</td><td>P<0.001</td><td>27.5</td><td>P<0.001</td></tr>
</table>
Secondary:
Patients treated with suvorexant had generally similar incidences of any</td></tr>
</table>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				adverse events or discontinuations due to adverse events compared with placebo. The proportion of patients with serious adverse events was similar among the treatment groups. The proportion of patients that had drug-related adverse events was somewhat higher with suvorexant, but none of the drug-related adverse events were serious. The most common adverse event that was increased for suvorexant versus placebo was next-day somnolence (6.7 vs 3.3%). Somnolence rarely resulted in discontinuation and was mostly mild or moderate in severity.
Scharf et al.[70] (1994) Zolpidem 10 to 15 mg vs placebo	DB, MC, PC, PG, RCT Adults with chronic insomnia	N=75 5 weeks	Primary: LPS, SE, sleep maintenance, sleep quality, effects on sleep stages, residual drug effects, safety Secondary: Not reported	Primary: Zolpidem had a significant (P<0.05) effect on LPS and SE from weeks two through five in the 10-mg group and at weeks two through six in the 15-mg group. Polysomnographic measures of sleep maintenance were not significantly different among the three treatment groups (P>0.05). Patients receiving zolpidem 15 mg reported significantly better quality of sleep than those receiving the 10 mg dose at week two and placebo at week five. Stages 1, 2, and 3 to 4 sleep were not significantly affected by either the 10- or 15-mg doses of zolpidem compared to placebo. However, there were significant (P<0.05) decreases in REM sleep at weeks three and four with zolpidem 15 mg compared to placebo. There was no evidence of residual effect with zolpidem 10 or 15 mg. There was no evidence of tolerance at either dose. The only significant treatment difference was in the percent of time in Stage 3 to 4 sleep (P<0.05 for both zolpidem doses compared to placebo). There were no significant treatment differences between the 10-mg zolpidem group and the placebo group in LPS, SE, WTDS or sleep quality during the post treatment period when zolpidem was discontinued. The 15-mg zolpidem group did not differ significantly from the placebo group on LPS or SE on the first night post treatment, but did result in a significantly greater WTDS and poorer quality of sleep (P<0.05 compared to placebo)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				during the first night post treatment. Comparison of the subsequent two nights post treatment showed no significant differences between zolpidem 15 mg and placebo on any of these variables. Overall, the incidence of treatment emergent adverse events in the zolpidem groups was similar to those in the placebo group. While none of the adverse events were severe, two patients in the 15-mg zolpidem group withdrew from the study: one patient experienced drowsiness, dizziness, and nausea; and one patient experienced visual disturbance and over sedation. The 15-mg zolpidem dosage provided no clinical advantage over the 10 mg zolpidem dosage. Secondary: Not reported
Roehrs et al.[71] (2011) Zolpidem 10 mg vs placebo	DB, PC, RCT Patients 21 to 70 years of age with primary insomnia	N=33 12 months	Primary: Number of zolpidem or placebo choices made, total number of zolpidem or placebo capsules chosen, and given a placebo or zolpidem choice on a given night, the nightly number of capsules taken Secondary: Not reported	Primary: On weekly telephone interviews, patients reported taking 73 to 89% of the single nightly capsules each month while at home. The groups did not differ in the average percentage of capsules used over the 12 months (placebo, 81% vs zolpidem, 84%). Over the three one-week laboratory self-administration assessments, the zolpidem group selected zolpidem (80.3%) more often than placebo (P<0.020). The placebo group showed no color preference, choosing the red capsule 51% of opportunities and the blue capsule 49% of opportunities. Overall, the zolpidem group self-administered more zolpidem capsules than placebo capsules (P<0.001). In the zolpidem group, the total number of capsules chosen, whether placebo or zolpidem, did not differ over months one, four, and 12. The total number of placebo capsules self-administered by the placebo group increased significantly during month four and month 12 compared to month one (P<0.02). Within the zolpidem group, the nightly number of placebo vs zolpidem capsules self-administered each month did not differ. On average, the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				zolpidem group self-administered a 9.1 mg dose nightly in month one, a 9.4 mg dose in month four, and a 9.4 mg dose in month 12. In the placebo group, the nightly number of capsules increased over time (P<0.02). The percent of patients increasing the dose did not differ between the zolpidem and placebo groups and did not change from month four to month 12. A significantly greater percent of patients receiving zolpidem compared to placebo decreased the dose they self-administered in month four and month 12 compared to month one (P<0.001). The self-administration rates did not differ when at the laboratory vs at home for patients receiving zolpidem. These rates also did not differ over the three assessments. Secondary: Not reported
Roth et al.[72] (1995) Zolpidem 5, 7.5, 10, 15, 20 mg vs placebo Statistical analyses were primarily performed between zolpidem 7.5 and 10 mg and placebo.	DB, PC, PG, RCT Healthy adult volunteers with transient insomnia	N=462 SD	Primary: SL, sleep duration, SE (TST divided by time in bed) NAW (sleep maintenance), effect on sleep stages, next day psychomotor performance and alertness (DSST, Symbol Copying Tests, Visual Analog Scales on the Morning Questionnaire) Secondary: Not reported	Primary: Compared to placebo, zolpidem 7.5 and 10 mg significantly decreased SL, increased sleep duration and efficiency, and reduced the NAW (all P<0.05). Subjective quality of sleep was also rated significantly better with both doses of zolpidem compared to placebo (both P<0.001). Increasing the dose above 10 mg did not result in a corresponding increase in hypnotic efficacy. Treatment with zolpidem had no effect on stage 1, stage 2 and stages 3 to 4 sleep. Significantly less REM sleep was reported in the zolpidem groups compared to the placebo group (both P<0.001). Zolpidem 7.5 or 10 mg had no significant effect on next day psychomotor performance and alertness. No statistically significant differences in the overall side effects were found between zolpidem doses of 7.5 mg (4.9%) or 10 mg (6.7%) and placebo (7.8%). Higher doses of zolpidem were associated with more side effects (17.6% with 15 mg [P=0.069 vs placebo] and 31.4% with 20 mg [P<0.001 vs placebo]).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Randall et al.[73] (2012) Zolpidem 5 or 10 mg vs placebo	DB, PC, RCT Adults 23 to 70 years of age with chronic primary insomnia	N=91 8 months	Primary: Polysomnographic sleep parameters and morning subject assessments of sleep on two nights in months one and eight Secondary: Not reported	Primary: Relative to placebo, zolpidem significantly increased overall TST and SE, reduced SL and wake after sleep onset when assessed at months one and eight. Overall, subjective evaluations of efficacy were not shown among treatment groups. Secondary: Not reported
Krystal et al.[74] (2008) Zolpidem ER 12.5 mg vs placebo Treatments were taken 3 to 7 nights per week.	DB, MC, PC, RCT Patients 18 to 64 years of age with chronic primary insomnia	N=1,025 26 weeks	Primary: Score on the PGI, Item 1, (aid to sleep) at week 12 of the treatment period in the ITT population Secondary: Scores on CGI-I, PGI, PMQ, TST, WASO, SOL, quality of sleep, and NAW in the ITT population	Primary: At week 12, PGI, Item 1 (aid to sleep) was scored as favorable (i.e., "helped me sleep") by 89.8% of zolpidem patients vs 51.4% of placebo patients (P<0.0001). Secondary: The percentage of patients who reported a treatment benefit on the PGI (Items 1 to 4) was higher in the zolpidem ER group compared to placebo at each four-week interval during the 24-week treatment period (all P<0.0001). The percentage of patients who obtained a positive evaluation on the CGI-I scale was greater in the zolpidem ER group compared to the placebo group at all four-week intervals during the 24-week treatment period (all P<0.0001). At every time point, results on the PMQ were greater for patients in the zolpidem ER group compared to the placebo group for the TST (P<0.0001), WASO (P<0.0001), SOL (P≤0.0014), quality of sleep (P<0.0001), and NAW (month one; P=0.0515, months two to six; P<0.0001). Patients in the zolpidem ER group demonstrated improvements in their

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				ability to concentrate in the morning at each month throughout the treatment period, as compared to those in the placebo group (months one to five; P<0.0001, month six; P=0.0014). Patients in the zolpidem ER group had sustained reductions in their level of sleepiness in the morning compared to placebo at each month throughout the treatment period (P<0.0001). The most common adverse events occurring at a higher frequency in the zolpidem extended-release group than in the placebo group were headache, anxiety, somnolence, dizziness, fatigue, disturbance inattention, irritability, nausea, and sinusitis.
Fava et al.[75] (2011) Zolpidem ER 12.5 mg vs placebo Patients were also receiving OL escitalopram 10 mg daily.	DB, MC, PC, PG, RCT Patients 21 to 64 years of age with major depressive disorder and associated insomnia	N=358 24 weeks Two phases were included Phase 1 was 8 weeks; responders (≥50% in 17-item $HDRS_{17}$) at week 8 continued to receive an additional 16 weeks of therapy in phase 2	Primary: Change from baseline in subjective TST Secondary: Subjective LSO, NAW, WASO, sleep quality, sleep-related next-day functioning, $HDRS_{17}$ SIS score, PGI-IT, CGI-I, CGI-S, MGH-CPFQ, Q-LES-Q, safety	Primary: Phase 1 During phase 1, treatment with zolpidem ER led to significantly greater improvements in TST when compared to treatment with placebo (P<0.0001). Phase 2 During phase 2, treatment with zolpidem ER led to improvements in TST that were significant at weeks 12 and 16 (P<0.05 for both), but not at weeks 20 and 24 (P value not reported). Secondary: Phase 1 Treatment with zolpidem ER led to significantly greater improvement in TST at each assessment. The LSM difference between the treatment groups in the change from baseline TST ranged from 37.9 to 45.5 minutes (P<0.0001 for all comparisons). The group receiving zolpidem ER had a TST of approximately seven hours at week eight, compared to approximately five hours at baseline (P<0.0001 vs placebo for improvement over baseline). Treatment with zolpidem ER led to significantly greater improvements in WASO, LSO, NAW, and sleep quality when compared to treatment with placebo (P<0.001 for all comparisons at all time points). Total improvement in insomnia-only $HDRS_{17}$ was also significantly greater in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				the group receiving zolpidem ER compared to those receiving placebo (P<0.001 for all time points). Treatment with zolpidem ER also produced favorable results on all domains of the SIS, except mental fatigue, when compared to treatment with placebo at week eight (P<0.05). There were no significant differences at week eight between the two groups on the improvement in functioning and quality of life on the Q-LES-Q; however, at week eight, there were greater improvements seen in the MGH-CPFQ total score, wakefulness/alertness, energy, memory/recall, and mental acuity in those patients receiving zolpidem ER compared to those receiving placebo (P<0.05). There were no significant improvements found with zolpidem ER compared to placebo on motivation/enthusiasm, attention focus/sustain, or ability to find words, at week eight. Treatment with zolpidem ER was also associated with greater improvements than placebo in some aspects of sleep-related next-day functioning, including morning energy, sleep impact on daily activities, and morning concentration ability. Decreases seen in the $HDRS_{17}$ scores at week eight were comparable between the two treatment groups; at the end of phase 1 58.4 and 63.7% of patients in the placebo and zolpidem ER groups, respectively, met the criteria for depression treatment response. PGI-IT scores were superior in the group receiving zolpidem ER compared to those in the placebo group (P<0.001) and both CGI-S and CGI-I scores were comparable between the groups throughout phase 1. Phase 2 During phase 2, treatment with zolpidem ER continued to show significantly greater improvement at each visit in the NAW and sleep quality, when compared to treatment with placebo (P value not reported). For WASO, treatment with zolpidem ER resulted in significant improvements over treatment with placebo at weeks 16 and 20 and there were no significant differences between the treatment groups in LSO during phase 2 (P value not reported). The $HDRS_{17}$ total score of insomnia-only items demonstrated significantly greater improvement in the zolpidem ER group throughout phase 2 (P<0.05 for all time points).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Treatment with zolpidem ER was associated with significant differences on all of the SIS domain scores at week 24, except mental fatigue (P<0.05). There were no differences between the groups in any of the MGH-CPFQ subscales at week 24 (P-value not reported). Treatment with zolpidem ER resulted in improvements over placebo on the physical health/activities and medication satisfaction subscales of Q-LES-Q (P<0.05); however, treatment with placebo resulted in improvements over zolpidem ER on the school/course work subscale (P<0.05). Both groups experienced improvements in depression treatment remission and depression symptoms; however, these improvements were not significantly different between groups (P value not reported). PGI-IT scores indicated insomnia treatment was rated higher with zolpidem ER compared to placebo (P<0.001). Ratings of severity and mental illness by clinicians were comparable between the two groups throughout phase 2. A greater percentage of patients treated with zolpidem ER experienced at least one adverse event during phase 1 when compared to patients treated with placebo (72.9 vs 66.3%; P value not reported). The most common adverse events that occurred more frequently in the group receiving zolpidem ER, compared to the placebo group, include nausea, somnolence, dry mouth, dizziness, fatigue, upper respiratory tract infection, and decreased libido. During phase 2, 57.3% of zolpidem ER-treated patients and 60% of placebo-treated patients experienced an adverse event (P value not reported). The most frequently reported events among both treatment groups include headache, diarrhea, and nasopharyngitis.
Fava et al.[76] (2009) Zolpidem ER 12.5 mg	DB, MC, PC, PG, RCT Patients 21 to 64 years of age with	N=383 8 weeks	Primary: Change from baseline to week eight in subjective TST	Primary: At week eight, the mean TST increased from baseline by 106 minutes in the group receiving zolpidem ER and by 68.2 minutes in the placebo group (LSM in the change from baseline between groups 39.4 minutes, 90% CI, 24.81 to 53.99; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo All patients received OL escitalopram 10 mg/day.	insomnia and comorbid GAD		Secondary: Subjective SOL, NAW, WASO, sleep quality, HAMA, BAI, SIS, MGH-CPFQ, SDS, safety	Secondary: From week one through week eight, mean TST was significantly greater in the group receiving zolpidem ER when compared to those receiving placebo (P<0.0001). Significant improvements in SOL, WASO, NAW, and quality of sleep were observed throughout the treatment period with zolpidem ER vs placebo based on the difference in LSM change from baseline (P<0.0001 for all comparisons). Significant improvements were also seen with MSQ measures of sleep-related next-day symptoms, including morning energy, morning concentration, and impact of sleep on daily activities (P<0.0001 for all comparisons). The change from baseline in PGI-IT for the zolpidem ER-treated group was significantly greater when compared to the placebo-treated group (P<0.0001 for all comparisons). At week two, there was a significant difference in favor of treatment with zolpidem ER on all seven items of the SIS (P<0.0001 for six comparisons; P<0.01 for one comparison). This improvement was sustained to week eight on four of the seven items: daily activities (P=0.107), emotional impact (P<0.0001), energy/fatigue (P<0.001), and satisfaction with sleep (P<0.0001). Between group differences in the total MGH-CPFQ score were significant at week four but not at week eight (P=0.0586). There were statistically significant differences between groups at one or both of the time points for three of seven items. There was statistically significantly greater improvement in the zolpidem ER group on three items (motivation, wakefulness/alertness, and energy) at week four (P<0.05) and on two items (wakefulness/alertness and energy) at week eight (P<0.01). The mean HAMA total scores decreased for both groups throughout the study. At week eight, HAMA total scores for both the group receiving zolpidem ER and the group receiving placebo showed comparable reductions (-13.3 vs -12.5, respectively; P=0.4095). Rates of treatment response in the group receiving zolpidem ER and the group receiving placebo were similar at week eight (63.4 vs 64.2%, respectively; P=0.8564).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Both treatment groups demonstrated at least a 40% reduction in the BAI at week one and continued to improve throughout the study. By week six, there was a difference in favor of the placebo group that as also present at week eight. There were no significant differences in Q-LES-Q between groups at week eight and there were no significant differences between groups in SDS scores at any time point measured. Treatment-emergent adverse events that occurred in at least 10% of patients and either group but with a higher incidence in the group receiving zolpidem ER included dizziness, nausea, and fatigue. Six patients receiving zolpidem ER experienced seven events of non-global amnesia between two and 59 days of taking the study medication. One patient in each group experienced one serious adverse event. Laboratory values, vital signs, and physical examination findings revealed no meaningful changes or clinically relevant differences between groups.
Erman et al.[77] (2008) zolpidem ER 12.5 mg vs placebo Zolpidem ER or placebo was to be taken nightly or at least 3 times per week.	DB, PC, RCT (subset analysis) Adults under 65 years of age with chronic insomnia	N=1,012 24 weeks	Primary: Change from baseline to week 12 in the Time Management and Output scales of the WLQ Secondary: Change from baseline to week four and to week 24 in the Time Management and Output scales of the WLQ, or premature discontinuation	Primary: At week 12, treatment with zolpidem ER 12.5 resulted in a 4.86 point reduction in the Output Scale (95% CI, -8.37 to -1.36; P=0.0066) and a 7.29 point reduction in the Time Management Scale (95% CI, -10.77 to -3.81; P<0.0001) vs placebo. Secondary: At week four, scores for the Output Scale and the Time Management Scale were significantly lower than at baseline (P value not reported). The decrease was significantly greater with zolpidem ER than for placebo for both the Output Scale (-9.59 vs -2.16; P<0.0001) and the Time Management Scale (-12.22 vs -3.85; P<0.0001).
Roth et al.[78] (2013)	DB, MC, PC, PG, RCT	N=295	Primary: LSO after MOTN,	Primary: Zolpidem SL tablets significantly (P<0.0001) decreased LSO over four

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Zolpidem SL tablets 3.5 mg vs placebo	Adults with primary insomnia and difficulty returning to sleep after MOTN	28 nights	adverse events Secondary: Not reported	weeks (baseline, 68.1 minutes; zolpidem SL tablets, 38.2 minutes) compared to placebo (baseline, 69.4 minutes; placebo, 56.4 minutes). Ratings of morning sleepiness/alertness significantly (P=0.0041) favored the zolpidem SL tablets group on nights medication was taken but not on other nights. Participants in the zolpidem SL tablets group took the study drug on 62% of nights during the four weeks; members of the placebo group took study medication on 64% of nights. Adverse events were generally mild and at the same rate (19.3% of participants) in both groups. There were no treatment-related serious adverse events, and one adverse event-related study discontinuation from the placebo group. Dosing/week did not increase across the study. Secondary: Not reported
Roth et al.[79] (2008) Zolpidem 1.75 or 3.5 mg SL vs placebo Subjects were awakened 4 hours after lights out, dosed with zolpidem SL or placebo, kept awake for 30 minutes, and then returned to bed for 30 minutes.	DB, PC, XO Adults with insomnia characterized by difficulty returning to sleep following MOTN awakenings	N=82 3 2-night treatment periods Each treatment period consisted of 2 consecutive nights of dosing separated by a washout of 5 to 12 days.	Primary: LPS following MOTN comparing zolpidem SL 3.5 mg to placebo Secondary: TST, SE, sleep quality, subjective SOL, subjective TST, and mean LPS for zolpidem SL 1.75 compared to placebo (all assessed after MOTN); according to the statistical analysis plan, if any test of a secondary endpoint did not attain	Primary: Treatment with zolpidem SL 3.5 mg resulted in a significant improvement in LPS after MOTN compared to treatment with placebo (9.69 vs 28.12 minutes; P<0.001 vs placebo, P<0.001 vs zolpidem SL 1.75 mg). Secondary: Treatment with zolpidem SL 1.75 mg resulted in a significant improvement in LPS after MOTN compared to treatment with placebo (16.89 vs 28.12 minutes; P<0.001). Treatment with zolpidem SL 1.75 mg resulted in improvements in the following parameters: TST after MOTN (197.80 vs 183.12 minutes; P<0.001), subjective SOL after MOTN (28.58 vs 40.43 minutes; P<0.001), and subjective TST after MOTN (162.36 vs 148.61 minutes; P<0.011). Treatment with zolpidem SL 3.5 mg resulted in improvements in the following parameters: TST after MOTN (208.99 vs 183.12 minutes; P<0.001 vs placebo, P=0.005 vs zolpidem SL 1.75 mg), subjective SOL after MOTN (25.23 vs 40.43 minutes; P<0.001), and subjective TST after MOTN (172.51 vs 148.61 minutes; P<0.011). The endpoints of WASO after MOTN and NAW after MOTN failed to reach significance for either dose of zolpidem SL compared to placebo. Treatment with zolpidem SL 3.5 mg resulted in the greater improvement

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			statistical significance, then inferential analyses of secondary endpoints would cease and no further inferential assessment of remaining secondary endpoints would be made, safety	in sleep quality compared to treatment with placebo (P<0.001) and compared to treatment with zolpidem SL 1.75 mg (P=0.018). Sleep quality ratings in the group receiving zolpidem SL 1.75 mg were not significantly different than the group receiving placebo. No serious adverse events occurred and no subject discontinued the study due to an adverse event. Out of the 82 included subjects, 14 reported an adverse event. All adverse events were mild in severity and transient.
Staner et al.[80] (2010) Zolpidem 10 mg SL tablet vs zolpidem 10 mg tablet	DB, MC, RCT, XO Patients 18 to 65 years of age with primary insomnia	N=70 SD	Primary: LPS, SOL, time spent in sleep stage 1 Secondary: TST, WASO, SE index, total time spent awake, time spent in stage 2, time spent in slow wave sleep; time spent in REM sleep; REM SL, LSEQ, DSST, CFF Test	Primary: Zolpidem SL shortened the LPS by about 34% or 10.3 minutes (P=0.001), SOL with about 8.6 minutes (P<0.01) and time spent in sleep stage 1with about 7.4 minutes (P<0.01) compared to zolpidem. Secondary: There were no significant differences on in TST and WASO among the treatment groups. The TST was 432 minutes for zolpidem SL and 425 minutes for zolpidem. WASO was 31 and 30 minutes for zolpidem SL and zolpidem, respectively. There was a significant difference in SE index (P<0.05) and total time spent awake (P<0.05), favoring zolpidem SL. No differences were found between the treatments for the sleep architecture parameters time spent in sleep stage 1, slow wave sleep, REM and REM SL. The difference found for time spent in stage 2 reached statistical significance (P<0.05), favoring zolpidem SL. There were no significant differences in LSEQ scores among the treatment groups. There were no significant differences in the way patients rated their subjective feelings of alertness, contentedness and calmness on the visual analog scale. There were no significant differences in DSST between the two treatments. CFF Test results indicated that, during the descending

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				runs, patients had a lower flicker fusion threshold after zolpidem SL than after zolpidem (P<0.05). There were no between-treatment differences for the ascending runs. Both routes of administration were well tolerated with a similar overall incidence of adverse events. The most common adverse events with zolpidem SL were somnolence and dysgeusia. Nausea, dysgeusia, somnolence and dizziness were the most common adverse events with zolpidem.
Valente et al.[81] (2013) Zolpidem 5 and 10 mg SL vs zolpidem 10 mg oral	DB, DD, OL, RCT Healthy volunteers	N=58 Duration not specified	Primary: PSG and post-sleep questionnaires Secondary: Not reported	Primary: A significant main treatment effect was evident considering the SOL and persistent SL. An earlier sleep onset was induced by SL zolpidem 10 mg (SOL; P<0.004 and persistent SL; P<0.006) and SL zolpidem 5 mg (SOL; P<0.025 and persistent SL; P<0.046) compared to oral zolpidem 10 mg. Subjects that received SL zolpidem 10 mg reported an earlier sleep onset (latency to sleep and latency until persistent sleep) when compared to subjects from other groups (P<0.005). Secondary: Not reported
Staner et al.[82] (2009) Zolpidem 5 mg SL tablet vs zolpidem 10 mg SL tablet vs zolpidem 10 mg tablet	OL, RCT, XO Healthy volunteers in a post-nap model of insomnia	N=21 SD	Primary: LPS, SOL, latency to stage 1, TST, SE, awakening after sleep onset, REM SL, stage 4 duration Secondary: Not reported	Primary: For zolpidem 10 mg SL tablets, LPS was significantly decreased by 6.11 minutes as compared to zolpidem 10 mg tablets (P<0.05). Zolpidem 10 mg SL tablets decreased SOL by 5.81 minutes as compared to zolpidem 10 mg tablets (P<0.05). Zolpidem 10 mg SL tablets decreased latency to stage 1 by 6.17 minutes as compared to zolpidem 10 mg tablets (P<0.05). Similar differences were demonstrated for sleep initiation parameters between zolpidem 5 and 10 mg SL tablets (7.28 minute difference for LPS, 6.69 minute difference for SOL and 6.06 minute difference for latency to stage 1; all P<0.05). There were no significant differences in the three sleep initiation parameters between zolpidem 5 and 10 mg SL tablets.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no significant differences between the three treatments for sleep maintenance parameters, including TST, SE or awakening after sleep onset. There were no differences in sleep maintenance between zolpidem 5 and 10 mg SL tablets. Significant treatment effects were evidenced for REM SL and stage 4 duration. Both REM SL and stage 4 duration were similar with zolpidem 5 and 10 mg SL tablets. Both parameters were significantly shorter in patients receiving zolpidem 5 mg SL tablets compared to zolpidem 10 mg tablets (REM SL, -19.22 minutes; P<0.01, stage 4 duration, -11.89 minutes; P<0.01). There were no differences in sleep architecture between zolpidem 5 and 10 mg SL tablets. No differences were detected in subjective sleep parameters as indicated by a lack of significant treatment effect on any of the LSEQ variables. Next-day residual effects were comparable between treatments. Vigilance, psychomotor performances, attention and concentration were comparable between treatments. The most frequent adverse events were somnolence, headache and fatigue. All were of moderate or mild intensity and resolved spontaneously. Secondary: Not reported
Castro et al.[83] (2020) Zolpidem 5 mg SL tablet vs zolpidem 10 mg tablet Treatments administered at	DD, RCT Adults 20 to 64 years of age with insomnia who reported nocturnal awakenings predominantly before 3:00 a.m. and who had not used psychoactive drugs in the 30 preceding days	N=67 3 months	Primary: Clinical improvement Secondary: Adverse events	Primary: There was clinical improvement in 37 (55%) participants after completing the protocol: 23 (68%) in the sublingual group and 14 (42%) in the oral group (P=0.05). Most of these participants (n=23) improved after week six. Additionally, 11 (16%) participants presented early improvement followed by symptom recurrence, and there was no clinical improvement in 19 (28%) participants. Both treatments decreased middle-of-the-night awakenings by an average of -3.1±2.3 days/week and increased total sleep time by 1.5 hours. Changes in sleep quality and insomnia severity scores were also favorable and comparable between groups: variation depended on continuation of treatment. Regarding PSG findings, sleep latency decreased more in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
bedtime, and "as needed" following middle-of-the-night awakenings				sublingual group than the oral group (-14±42 vs 10±29 min; P=0.03). Secondary: The investigators registered 152 adverse events, 58 (38%) unrelated to the study medication, 69 (45%) possibly related, and 25 (16%) probably/certainly related. Headache, sleepiness, and dizziness were the most likely events to be treatment related. The proportion of patients with adverse events did not differ between groups, but the number of treatment-related adverse events leading to discontinuation was higher in the oral group than the sublingual group (29%, n=24 vs 13%, n=9; two-sided P=0.02).
Beaulieu-Bonneau et al.[84] (2017) Initial six-week acute treatment with CBT, delivered alone (CBT; N=80) or combined with zolpidem 10 mg nightly (COMB; N=80) This was followed by a six-month extended treatment during which those receiving CBT initially were further randomized to extended monthly CBT sessions (CBT–CBT) or no additional	RCT Adults ≥30 years of age with chronic insomnia	N=160 24 months	Primary: ISI, sleep diary measures (SOL, WASO, TST, and SE) at 12 and 24 months Secondary: Not reported	Primary: For ISI total scores, there was a significant treatment condition effect at the 6-month follow-up (P<0.001), with post hoc tests revealing significantly lower ISI scores in the COMB-taper group than in the other groups (from 8.7 to 9.0). There were no significant between-group differences at the 12-month follow-up (P=0.17), and the simple main effect failed to reach significance at 24-month follow-up (P=0.09). There was no significant group effect for any of the four sleep diary variables (P>0.18) at 12-months. At the 24-month follow-up, a significant treatment effect was found for WASO and SE, with post hoc tests revealing a similar pattern as the one observed at the 6-month follow-up, i.e., a significantly shorter WASO and a higher SE in the COMB-taper condition compared to the other three conditions (WASO: 46.2 vs. 59.7 to 71.7 min, SE: 86.9 vs. 81.2 to 83.7%). The treatment group effect was not significant for SOL or TST at the 24-month follow-up. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
treatment (CBT-no tx), and those receiving combined treatment initially were randomized to extended monthly CBT while zolpidem medication was tapered (COMB-taper) or extended CBT combined with medication as needed (COMB-prn; 10 pills per month)				
Elie et al.[85] (1999) Zaleplon 5 to 20 mg or zolpidem 10 mg vs placebo	DB, MC, PC, RCT Adults with primary insomnia or insomnia associated with mild nonpsychotic psychiatric disorders	N=615 4 weeks	Primary: Patient's assessment of SL Secondary: Patient's assessment of sleep duration, sleep quality, NAW, rebound insomnia, withdrawal effects, safety	Primary: Median SL was significantly lower with zaleplon 10 and 20 mg than with placebo during all four weeks of treatment, and with zaleplon 5 mg and zolpidem 10 mg for the first three weeks. Secondary: Zaleplon 20 mg significantly ($P<0.05$) increased sleep duration compared to placebo in all but week three of the study, while zolpidem 10 mg significantly ($P<0.05$) increased sleep duration at all time points. Mean scores for sleep quality were significantly ($P<0.05$) better than with placebo during week one with zaleplon 10 mg and 20 mg, and for all weeks with zolpidem 10 mg. No significant differences were observed in NAW between the placebo and active treatment groups. The number of patients treated with zaleplon showing rebound insomnia was not significantly different from placebo on the first night after discontinuation of four weeks of treatment. Significant differences in SL

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P<0.05) and NAW (P<0.01) were noted in patients treated with zolpidem 10 mg. On the second night after discontinuation of treatment, there were significantly more patients (P<0.05) showing rebound insomnia for the NAW with zaleplon 10 and 20 mg than with placebo, and on the third night there were significantly fewer patients (P<0.05) showing rebound for the NAW with zaleplon 20 mg. There was no evidence of withdrawal symptoms after discontinuation of four weeks of zaleplon treatment. Significantly more patients who had received zolpidem than placebo reported withdrawal effects on the first night after treatment was discontinued; however, there was no statistically significant difference on the second or third night between the two groups. The frequency of adverse events in the active treatment groups did not differ significantly from that in the placebo group. The study did not report any direct comparisons between the zaleplon.
Huedo et al.[86] (2012) Eszopiclone, zaleplon, or zolpidem vs placebo	MA DB, PG, PC, RCTs of eszopiclone, zaleplon, or zolpidem	N=4,378 Duration varied	Primary: Polysomnographic and subjective SL Secondary: Waking after sleep onset, NAW, TST, SE, and subjective sleep quality	Primary: Significant improvements (reductions) in primary outcomes were documented: polysomnographic SL (weighted standardized mean difference; 95% CI, -0.57 to -0.16) and subjective SL (-0.33, -0.62 to -0.04) compared to placebo. Analyses of weighted mean raw differences showed that the active agents decreased polysomnographic SL by 22 minutes (-33 to -11 minutes) compared to placebo. Secondary: No significant results were identified in the secondary outcomes.
Uchimura et al.[87] (2012) Eszopiclone 1, 2, and 3 mg vs	DB, PC, RCT, XO Japanese patients with primary insomnia	N=72 10 nights	Primary: Sleep measures from PSG and subjective patient reports Secondary: Not reported	Primary: All active treatments produced significant improvement in objective and subjective SL compared to placebo (P<0.05 for all comparisons); linear dose-response relationships were observed for eszopiclone. PSG-determined WASO, SE, and NAW, and patient-reported measures of WASO, NAW, sleep quality, sleep depth, and daytime functioning significantly improved following treatment with eszopiclone 2 mg and 3

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
zolpidem 10 mg vs placebo				mg and zolpidem 10 mg vs placebo (P<0.05). Eszopiclone at all doses increased TST and stage 2 sleep time (P<0.001 for both comparisons), but did not alter REM or slow-wave sleep. Eszopiclone was generally well tolerated; the most frequently reported adverse event was mild dysgeusia. Secondary: Not reported
Pinto et al.[88] (2016) Eszopiclone 3 mg vs zopiclone 7.5 mg	DB, DD, NI, RCT Patients 20 to 64 years of age	N=199 4 weeks	Primary: ISI after four weeks of treatment Secondary: PSG measures including TST, SE, and SL	Primary: No significant differences were observed between groups regarding ISI values (P=0.588). The primary efficacy analysis demonstrated the non-inferiority of eszopiclone over zopiclone. Secondary: At the end of the study, a significant difference between the zopiclone and eszopiclone groups regarding TST was found (P=0.039), with a longer duration observed in the latter. A difference between the groups (P=0.018) was also observed for SE, indicating greater values in the eszopiclone group (mean sleep efficiency of 90% for eszopiclone vs 86% for zopiclone). However, there was no difference between the two groups regarding SL (P=0.151) and time awake (P=0.097).
Erman et al.[89] (2008) Eszopiclone 1 mg for 2 nights vs eszopiclone 2 mg for 2 nights vs eszopiclone 2.5 mg for 2 nights	MC, RCT, XO Patients 21 to 64 years of age with primary insomnia; with a 3 to 7 day washout between XO treatments	N=65 2 nights for each treatment	Primary: LPS Secondary: SE, WASO, WTDS, NAW, and patient-reported variables	Primary: All active treatments reduced median LPS by 42 to 55% compared to placebo (P<0.05). The median LPS was 13.1 minutes for eszopiclone 3 mg and zolpidem 10 mg. The median LPS was 29.0, 16.8, 15.5, and 13.8 minutes for the placebo, eszopiclone 1, 2, and 2.5 mg dose groups, respectively. The two highest doses of eszopiclone (2.5 and 3 mg) and zolpidem demonstrated significantly lower LPS when compared to eszopiclone 1 mg (P<0.05). Secondary: Significant differences were found between all active treatments in SE compared to placebo (P<0.05). Eszopiclone 2, 2.5, and 3 mg, and zolpidem 10 mg demonstrated significantly higher SE when compared to eszopiclone 1 mg (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs eszopiclone 3 mg for 2 nights vs zolpidem 10 mg for 2 nights vs placebo for 2 nights There was a 3 to 7 day washout between XO treatments				Treatment with eszopiclone 3 mg resulted in significant differences compared to treatment with placebo for WASO, WTDS, and NAW. Eszopiclone 2.5 mg demonstrated significant differences compared to placebo for WASO and WTDS. Neither of the lower doses of eszopiclone nor zolpidem 10 mg was different from placebo for WASO or WTDS. Comparisons of eszopiclone 3 mg and zolpidem 10 mg were not significantly different for WASO (P=0.12), for WTDS (P=0.07), or for NAW (P=0.10). Treatment with eszopiclone 2 and 3 mg and zolpidem 10 mg showed improvements in patient-reported measures of sleep relative to placebo. Both doses of eszopiclone and zolpidem 10 mg significantly improved sSL, sTST, quality of sleep, and depth of sleep relative to placebo (P<0.05). Eszopiclone 2 and 3 mg and zolpidem 10 mg were significantly different from placebo for subject reported NAW and sWASO (P<0.05). Morning sleepiness was significantly less with eszopiclone 3 mg compared to placebo (P<0.05). Evening ratings of daytime alertness were significantly increased with eszopiclone 2 mg and with zolpidem 10 mg compared to placebo (P<0.05), and daytime ability to function was significantly improved for eszopiclone 2 and 3 mg and zolpidem 10 mg compared to placebo (P<0.05). The most common adverse events were headache, unpleasant taste, somnolence, dizziness, and nausea. The overall rate of central nervous system adverse events was 7.9% for placebo, 6.2 to 12.5% for the eszopiclone groups, and 23.4% for zolpidem 10 mg.
Zammit et al.[90] (2009) Ramelteon 8 mg vs zolpidem 10 mg vs	DB, MC, PC, XO Adults over the age of 65 with self-reported chronic insomnia	N=33 Each study drug was taken for one night each with a 4 to 10 day washout period between	Primary: SOT composite score Secondary: Equilibrium scores on the SOT, SOT ratios, SQTT scores, and memory tests,	Primary: There were no differences between placebo and ramelteon on the SOT (P=0.837). Secondary: There were no significant differences between placebo and ramelteon on turn time (P=0.776) or turn sway (P=0.982). Treatment with zolpidem, the positive control, did result in significant impairments on the SOT, turn time, and turn sway (P<0.001 for all). Immediate and delayed memory recall were not significantly different with ramelteon (P=0.683 and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo Subjects were administered the study drug 30 minutes prior to bedtime and were awakened 2 hours after dosing to evaluate balance.		treatments.	safety	P=0.650, respectively); however, immediate recall declined significantly with zolpidem (P=0.002). Adverse events were infrequent and none were serious. The same proportion of subjects in the ramelteon and placebo groups reported adverse events (21.2%) compared to 39.4% of subjects in the zolpidem group. Adverse events that occurred in at least two subjects in any group include dizziness, headache, nausea, and somnolence.
Huang et al.[91] (2011) Zaleplon 10 mg vs zolpidem 10 mg	AC, DB, RCT Patients 20 to 65 years of age with primary insomnia	N=48 2 weeks	Primary: Change in subjective SL from baseline to week two Secondary: Sleep duration, NAW, sleep quality and incidence of rebound insomnia	Primary: There was a significant reduction in subjective SL in the zaleplon group (reduced from 63.0 minutes to 31.6 minutes; P<0.05) and zolpidem group (reduced from 61.9 minutes to 30.0 minutes; P<0.05). There was no significant difference between the zaleplon group and zolpidem group in SL (P=0.084). Secondary: There was no significant difference in sleep duration, NAW, or sleep quality among the groups. None of the patients experienced rebound insomnia. The most frequently reported adverse effects were headache, dizziness, anxiety and urinary tract infection. There was no significant difference in the frequency of each adverse effect between the zaleplon and zolpidem groups.
Dunbar et al.[92] (2004) Zaleplon 5 to 20 mg vs zolpidem 5 to 10 mg	MA Patients 16 to 85 years of age with insomnia	N=1,539 (6 trials)	Primary: SOL, TST, quality of sleep, adverse events, rebound insomnia Secondary: Not reported	Primary: Of the two studies that directly compared SOL, one study reported a significantly shorter SL with zaleplon (P<0.001), whereas the other study reported results in favor of zolpidem (P=0.03). Of the two studies that directly compared TST, one study reported that sleep duration was significantly less in the zaleplon group (290.7 vs 308.6 minutes for zolpidem; P=0.05) but another study found no difference (eight hours for zaleplon vs 8.3 hours on zolpidem).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
		4 weeks		Patients on zaleplon were less likely to experience an improvement in sleep quality than those on zolpidem (OR, 0.66; 95% CI, 0.51 to 0.87). There was no statistically significant difference in the frequency of treatment-emergent adverse events (OR, 0.86; 95% CI, 0.62 to 1.20). One study reported that patients taking zaleplon were less likely to suffer withdrawal symptoms on the first night of the placebo run-out phase than those on zolpidem (1.5 and 7.1% respectively; P=0.01). Combined results from two trials noted that patients receiving zaleplon were less likely to experience rebound insomnia compared to those on zolpidem (SL OR, 0.27; 95% CI, 0.17 to 0.44, sleep duration OR, 0.25; 95% CI, 0.15 to 0.41, and NAW OR, 0.34; 95% CI, 0.18 to 0.61). In a XO study, 62.3% of patients favored zolpidem compared to 37.7% of patients who favored zaleplon (P=0.08). Secondary: Not reported
Zammit et al.[93] (2006) Zaleplon 10 mg for 2 nights vs zolpidem 10 mg for 2 nights vs placebo for	DB, PC, RCT, XO Patients 18 to 65 years of age with primary sleep-maintenance insomnia	N=37	Primary: LPS and TST, daytime SL Secondary: Not reported	Primary: LPS after the administration of zaleplon 10 mg, zolpidem 10 mg, and placebo was 14.9, 11.7, and 42.2 minutes, respectively (overall P<0.001), which made the LPS with active agents shorter by approximately 27 and 31 minutes (P<0.001 for both comparisons). TST was significantly longer with zaleplon 10 mg and zolpidem 10 mg than placebo by approximately 22 and 30 minutes, respectively (overall P<0.001). Daytime SL was not significantly different between the zaleplon 10 mg and placebo groups (P>0.136); however, it was shorter with zolpidem 10 mg compared to placebo (overall P<0.001) when tested at four (P<0.001), five (P<0.001), and seven (P<0.05) hours, respectively, after dose administration. There was no significant difference between the zaleplon 10 mg and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Each treatment period was separated by a 5- or 12-day washout period.				placebo in patients' subjective level of alertness or ability to concentrate. Patients reported significantly less alertness after the SLT performed at four hours after dosing with zolpidem 10 mg compared to placebo (overall P=0.005). Daytime subjective reports of ability to concentrate following zolpidem 10 mg were significantly worse than following placebo when tested after the SLT at four, five, and six hours after treatment (overall P<0.05). Secondary: Not reported
Danjou et al.[94] (1999) Zaleplon 10 mg vs zolpidem 10 mg vs placebo	DB, XO Healthy volunteers, mean age 29.5 years	N=36 13 days	Primary: Subjective and objective measurements of residual effects when study drug was given five, four, three, or two hours before morning awakening, tests included DSST, CFF threshold, CRT, Memory Test, Sternberg Memory Scanning Task, LARS, LSEQ, adverse events Secondary: Not reported	Primary: No residual effects were demonstrated after zaleplon 10 mg, when administered as little as two hours before waking, on either subjective or objective assessments. Zolpidem 10 mg showed significant residual effects on DSST and memory after administration up to five hours before waking and CRT, CFF threshold and Sternberg Memory Scanning Task after administration up to four hours before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. There were no serious adverse experiences during the study; all adverse events were mild-to-moderate. Overall, the number of subjects who reported any adverse experience after administration of study drug was similar for zaleplon and placebo (11 and 33% regardless of the time of drug administration) but was significantly higher following zolpidem (56 to 72%) when zolpidem was administered two, three, four, and five hours before awakening (P values not reported). Secondary: Not reported
Verster et al.[95] (2002) Zaleplon 10 mg	DB, XO Healthy volunteers with mean age 24.0	N=30 SD with at least a 5-day	Primary: Driving ability (standard deviation of the lateral	Primary: Zaleplon 10 and 20 mg did not significantly impair driving ability four hours after middle-of-the-night administration (significant difference defined as P<0.0125).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs zaleplon 20 mg vs zolpidem 10 mg vs zolpidem 20 mg vs placebo This was a 2-part study with the first part evaluating the effect of ethanol and the second part evaluating the effects of zaleplon and zolpidem. Only the second part of the study was reported in this review.	years	washout period	position, standard deviation of speed, memory, psychomotor performance) (subjects given study medication five hours after going to bed and awakened three hours after dose, driving test performed four hours after awakened, memory and psychomotor tests performed six hours after awakened) Secondary: Not reported	Relative to placebo, after zolpidem 10 mg, standard deviation of the lateral position (amount of weaving of the car) was significantly elevated but the magnitude of the difference was small and not likely to be of clinical importance (difference, 2.87 cm; P<0.005). Standard deviation of speed (speed variability) was not significantly different for zolpidem 10 mg than placebo (P=0.256). Zolpidem 20 mg significantly increased SDLP and speed variability (both P<0.001). Memory and psychomotor test performances were unaffected after both doses of zaleplon and zolpidem 10 mg. Zolpidem 20 mg significantly impaired performance on psychomotor and memory tests. (Note: the recommended dose for zolpidem is 10 mg immediately before bedtime.) Secondary: Not reported
Piccione et al.[96] (1980) Triazolam 0.25 mg vs	DB, XO Elderly patients >60 years of age with insomnia	N=27 5 days	Primary: Efficacy (questionnaire with subjective estimates of SL, TST, NAW, overall quality of	Primary: The patients' global evaluation of effectiveness indicated that triazolam 0.25 and 0.50 mg improved sleep more than placebo (both P<0.05), while chloral hydrate 250 and 500 mg were not better than placebo. Triazolam 0.50 mg, but not 0.25 mg, was significantly better than chloral hydrate 250 mg (P<0.01) and 500 mg (P<0.05) in the global evaluation of effectiveness.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
triazolam 0.50 mg vs chloral hydrate 250 mg vs chloral hydrate 500 mg vs placebo			sleep), side effects Secondary: Not reported	There was no significant difference in SL, TST and NAW between placebo and either dose of chloral hydrate. Triazolam 0.25 mg significantly decreased SL and increased TST compared to placebo (both P<0.05). Triazolam 0.50 mg significantly decreased the NAW compared to placebo (P<0.01). Patients estimated their TST to be longer following the use of triazolam 0.25 mg as compared to chloral hydrate 250 or 500 mg (both P<0.05). There were no significant differences in reported side effects between the active treatments and placebo. Secondary: Not reported
Johnson et al.[97] (2006) Triazolam 0.25, 0.5 or 0.75 mg vs ramelteon 16, 80 or 160 mg vs placebo	DB, XO Adults with a history of sedative abuse	N=14 18 days	Primary: Subject-rated measures (drug liking, street value, pharmacological classification), observer-rated measures (sedation, impairment), motor and cognitive performance (balance task, DSST, word recall) Secondary: Not reported	Primary: Triazolam showed dose-related effects on subject-rated, observer-rated, and motor and cognitive performance measures. Compared to placebo, all doses of ramelteon showed no significant effect on any of the subjective effect measures, including those related to potential for abuse (all P>0.05). In the pharmacological classification, 79% of patients identified the highest dose of ramelteon as placebo. Compared to placebo, ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure (all P>0.05). Secondary: Not reported
Hindmarch et al.[98] (2006) Flurazepam 30 mg	DB, RCT, XO Healthy volunteers ≥65 years of age	N=24 SD treatment	Primary: Psychometric tests performed 8 hours after study	Primary: There were no significant differences in psychometric tests between the zolpidem modified release treatment groups and placebo (P>0.05). Psychometric performance was significantly impaired with flurazepam

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs zolpidem modified release 6.25 mg vs zolpidem modified release 12.5 mg vs placebo			medication (CFF, CRT, word recall, CTT, DSST), subjective evaluation of sleep (LSEQ), safety, pharmacokinetics (zolpidem modified release only) Secondary: Not reported	compared to placebo for all tests with the exception of the DSST (P=0.0526). Ease of falling asleep and sleep quality were significantly improved with both doses of zolpidem modified release and with flurazepam (all P<0.05). Neither zolpidem modified release, nor flurazepam, modified perception of well-being on awakening. The frequency of adverse events was similar in all four treatment conditions. None of the adverse events was serious or led to withdrawal from the study. The plasma concentration ratio was 1.96 between the two doses of zolpidem modified release, which is consistent with dose linearity. Secondary: Not reported
Holbrook et al.[99] (2000) Benzodiazepines vs zopiclone, diphenhydramine, glutethimide, promethazine, cognitive behavioral therapy, placebo	MA Patients with insomnia	N=2,672 (45 trials) 6 weeks	Primary: SL, total sleep duration, adverse effects, dropout rates, cognitive function decline Secondary: Not reported	Primary: Using sleep records, benzodiazepines demonstrated a decrease in SL by 4.2 minutes compared to placebo (95% CI, -0.7 to 9.2). Benzodiazepines demonstrated a significant increase in sleep duration compared to placebo by 61.8 minutes (95% CI, 37.4 to 86.2). Benzodiazepines were more likely to be associated with complaints of daytime drowsiness (OR, 2.4; 95% CI, 1.8 to 3.4) and dizziness/ lightheadedness (OR, 2.6; 95% CI, 0.7 to 10.3) compared to placebo. No difference was observed in dropout rates between the two groups. Pooled results from three trials indicated there was no significant difference between benzodiazepines and zopiclone in SL, but benzodiazepine therapy may lead to a longer sleep by 23.1 minutes (95% CI, 5.6 to 40.6). There was no significant difference in adverse events among the treatment groups (OR, 1.5; 95% CI, 0.8 to 2.9).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Comparisons between benzodiazepines and antihistamines did not detect any significant differences on sleep outcomes. Triazolam was found to be more effective in reducing SL early in one trial, but efficacy decreased by the second week of treatment. Behavioral therapy efficacy was maintained throughout the nine-week follow-up. Secondary: Not reported
Buscemi et al.[100] (2007) Benzodiazepines, non-benzodiazepines, antidepressants vs placebo	MA Adults with chronic insomnia	105 trials 1 night to 6 months	Primary: SL, WASO, SE, sleep quality, TST, adverse events Secondary: Not reported	Primary: SL assessed by PSG was significantly decreased for benzodiazepines (WMD, -10.0 minutes; 95% CI, -16.6 to -3.4), non-benzodiazepines (WMD, -12.8 minutes; 95% CI, -16.9 to -8.8) and antidepressants (WMD, -7.0 minutes; 95% CI, -10.7 to -3.3). SL assessed by sleep diaries was also significantly improved for benzodiazepines (WMD, -19.6 minutes; 95% CI, -23.9 to -15.3), non-benzodiazepines (WMD, -17.0 minutes; 95% CI, -20.0 to -14.0) and antidepressants (WMD, -12.2 minutes; 95% CI, -22.3 to -2.2). MA for WASO, SE, sleep quality and TST measured by PSG and sleep diary were statistically significant and favored benzodiazepines and non-benzodiazepines vs placebo with the exception of PSG studies measuring WASO and TST, which were marginally nonsignificant. In contrast, PSG results significantly favored antidepressants vs placebo, but sleep diary results were fewer and non-significantly favored antidepressants for WASO and non-significantly favored placebo for TST. Indirect comparisons between benzodiazepines and non-benzodiazepines resulted in no significant difference in SL; however, benzodiazepines were associated with more adverse events. Indirect comparisons between benzodiazepines and antidepressants resulted in no significant difference in SL or adverse events. Indirect comparisons between non-benzodiazepines and antidepressants

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				resulted in a significantly greater SL assessed by PSG but not by sleep diary for non-benzodiazepines. There was no significant difference in adverse events. All drug groups had a statistically significant higher risk of harm compared to placebo, although the most commonly reported adverse events were minor. The adverse events most commonly reported in these studies were headache, drowsiness, dizziness and nausea. Secondary: Not reported
Smith et al.[101] (2002) Benzodiazepines or benzodiazepine receptor agonists vs behavioral treatment vs placebo	MA Patients with primary insomnia for ≥1 month	N=470 (21 trials)	Primary: SL, TST, NAW, WASO, and sleep quality before and after treatment Secondary: Not reported	Primary: SL was reduced by 30% with pharmacological treatment compared to 43% with behavioral interventions. Pharmacotherapy increased TST by 12% compared to 6% with behavior therapy. Both pharmacotherapy and behavior therapy reduced NAW per night by one. WASO was reduced by 46% with pharmacotherapy and by 56% with behavior therapy. Pharmacotherapy improved sleep quality by 20% compared to 28% with behavior therapy. Overall, there were no differences in TST, NAW, WASO, and sleep quality between benzodiazepine receptor agonists and behavioral therapy. The behavioral therapy group had a greater reduction in LSO than the group that took the benzodiazepine receptor agonists (95% CI, 0.17 to 1.04). Secondary: Not reported
Nowell et al.[102] (1997)	MA	N=1,894 (22 trials)	Primary: SL, TST, NAW,	Primary: Zolpidem and benzodiazepines were significantly more effective than

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Benzodiazepines or benzodiazepine receptor agonists vs placebo	Adults <65 years of age with chronic insomnia	4 to 35 days	sleep quality Secondary: Not reported	placebo with regards to SL, TST, NAW and sleep quality (P<0.001). Secondary: Not reported
Post-Operative Nausea and Vomiting				
Schaub et al.[103] (2012) Droperidol vs placebo (or no treatment)	MA RCTs testing prophylactic droperidol in adults undergoing general anaesthesia and reporting on post-operative nausea and vomiting	N=25 trails Duration varied	Primary: Prevention of nausea and vomiting; adverse events Secondary: Not reported	Primary: For the prevention of early nausea (within six hours postoperatively), the RR was 0.45 (95% CI, 0.35 to 0.58) and the number needed to treat was 7, 4, and 2 for low, medium and high baseline risk. For the prevention of early vomiting the RR was 0.65 (95% CI, 0.57 to 0.74), and the number needed to treat was 11, 6, and 4 respectively. For the prevention of late nausea (within 24 hours) the RR was 0.74 (95% CI, 0.62 to 0.87) and the number needed to treat was 15, 8, and 5 respectively. For the prevention of late vomiting the RR was 0.61 (95% CI, 0.47 to 0.80) and the number needed to treat was 10, 5, and 3 respectively. Droperidol decreased the risk of headache but increased the risk of restlessness. There were no differences in the incidences of sedation or dizziness. Two patients receiving droperidol 0.625 mg had extrapyramidal symptoms. Cardiac toxicity data were not reported. Secondary: Not reported
Atsuta et al.[104] (2017) Droperidol 1.25 mg	DB, RCT Patients 20 to 80 years of age scheduled to undergo elective	N=186 72 hours	Primary: Overall and cumulative incidence of vomiting	Primary: The overall incidence of vomiting for 72 hours post-craniotomy was significantly lower in the fosaprepitant group (12.8%) than in the droperidol group (38%; P<0.001; RR, 0.336; 95% CI, 0.186 to 0.605). The cumulative incidence of vomiting was significantly lower in the fosaprepitant group than in the droperidol group (HR, 0.30; 95% CI, 0.16

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs fosaprepitant 150 mg Dexamethasone 9.9 mg was given to all patients, except those with diabetes	craniotomy		Secondary: Overall and cumulative incidence of PONV, incidence of vomiting, frequency of vomiting, nausea score, and use of rescue antiemetic use	to 0.56; P<0.001). Secondary: There was no significant difference between the groups in the overall incidence of PONV for 72 hours (44.7% for fosaprepitant vs 54.3% for droperidol; P=0.24). There were no significant differences in nausea score or antiemetic use between the two groups, although the nausea score and nausea incidence were lower in the fosaprepitant group at 6 to 24 hours.
Non-24-hour sleep-wake disorder				
Lockley et al.[105] (2015) SET and RESET Tasimelteon 20 mg one hour prior to bedtime vs placebo	DB, MC, PC, RCT Totally blind patients 18 to 75 years of age with non-24 hour sleep-wake disorder	*SET:* N=84 6 months *RESET:* N=20 20 weeks	*SET:* Primary: Proportion of entrained patients (patients having an internal circadian period of ≤24.1 hours and CI including 24.0 hours); proportion of patients who had a clinical response (entrainment at month one or month seven plus clinical improvement, measured by the Non-24 Clinical Response Scale) Secondary: Not reported	*SET:* Primary: Circadian entrainment occurred in eight (20%) of 40 patients in the tasimelteon group compared with one (3%) of 38 patients in the placebo group at month one (difference 17%; 95% CI, 3.2 to 31.6; P=0.0171). Nine (24%) of 38 patients showed a clinical response, compared with none of 34 in the placebo group (difference 24%; 95% CI, 8.4 to 39.0; P=0.0028). Secondary: Not reported *RESET:* Primary: Nine (90%) of ten patients in the tasimelteon group maintained entrainment, whereas only two (20%) of ten patients withdrawn to placebo maintained entrainment (difference 70%; 95% CI, 26.4 to 100.0; P=0.0026). Secondary: No deaths were reported in either study, and discontinuation rates due to adverse events were comparable between the tasimelteon (3 [6%] of 52 patients) and placebo (2 [4%] of 52 patients) treatment courses.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			RESET: Primary: Proportion of non-entrained patients Secondary: Safety	
Sedation				
Fraser et al.[106] (2013) Dexmedetomidine or propofol vs benzodiazepine	MA RCTs consisting of critically ill, mechanically ventilated adults requiring sedation regimen	N=1,235 Duration varied	Primary: Duration of intensive care unit length of stay, duration of mechanical ventilation, delirium prevalence, and/or short-term mortality Secondary: Not reported	Primary: Compared to a benzodiazepine sedative strategy, a nonbenzodiazepine sedative strategy was associated with a shorter intensive care unit length of stay (difference, 1.62 days; 95% CI, 0.68 to 2.55; P=0.0007) and duration of mechanical ventilation (difference, 1.9 days; 95% CI, 1.70 to 2.09; P<0.00001) but a similar prevalence of delirium (risk ratio, 0.83; 95% CI, 0.61 to 1.11; P=0.19) and short-term mortality rate (risk ratio, 0.98; 95% CI, 0.76 to 1.27; P=0.88). Secondary: Not reported

Drug regimen abbreviations: ER=extended release, SL=sublingual
Study abbreviations: AC=active control, CI=confidence interval, DB=double-blind, DD=double dummy, ITT=intent to treat, LS=least square, LSM=least squares mean, MA=meta-analysis, MC=multicenter, NS=not significant, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized controlled trial, RR=relative risk, SB=single-blind, SD=single dose, XO=crossover, WMD=weighted mean difference
Miscellaneous abbreviations: AHI=apnea hypopnea index, BAI=Beck Anxiety Inventory, CAPS=Clinician Administered PTSD Scale, CBT=cognitive-behavioral therapy, CES-D=Center for Epidemiologic Studies Depression Scale, CFF=Critical Flicker Fusion, CGI=Clinical Global Impression, CGI-I=Clinical Global Impression-Improvement, CGI-S=Clinical Global Impressions-Severity, CPAP=Continuous positive airway pressure, CRT=Choice Reaction Time, CTT=Continuous Tracking Test, DLRF=Daily Living and Role Functioning, DSM-5=Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSST=Digit-Symbol Substitution Test, ECG=electrocardiogram, ESS=Epworth Sleepiness Scale, FARD=Ferreri Anxiety Rating Diagram, FOSQ=Functional Outcomes of Sleepiness Questionnaire, FSS=Fatigue Severity Scale, HAD=Hospital Anxiety and Depression, HAMA=Hamilton Rating Scale for Anxiety, HAM-D=Hamilton Rating Scale for Depression, $HDRS_{17}$=Hamilton Depression Rating Scale 17-item, ISI=Insomnia Severity Index, LPS=latency to persistent sleep, LSAS=Liebowitz Social Anxiety Scale, LSEQ=Leeds Sleep Evaluation Questionnaire, LSO=latency to sleep onset, MADRS=Montgomery-Åsberg Depression Rating Scale, MAOI=monoamine oxidase inhibitors, MCBI=Multidimensional Caregiver Burden Inventory, MENQOL=Menopause-Related Quality of Life, MGH-CFPQ=Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, MOTN=middle-of-the-night awakening, NAW=number of awakenings, PDQ-8=Parkinson Disease Questionnaire Short Form, PGI=Patient Global Impression, PGI-IT= Patient Global Impression of Insomnia Treatment, PMQ=Patient Morning Questionnaire, PSG=polysomnography, PSQI=Pittsburg Sleep Quality Index, PSQ-IVRS=Post-Sleep Questionnaire Interactive Voice Response System, PTSD=posttraumatic stress disorder, Q-LES-Q=Quality of Life Enjoyment and Satisfaction Questionnaire, REM=rapid eye movement, RIMA=reversible inhibitors of monoamine oxidase-A, SDS=Sheehan Disability Scale, sSE=subjective sleep efficiency, SE=sleep efficiency, SF-36=Short Form-36, SII=Sleep Impairment Index, SIS=Sleep Impact Scale, SL=sleep latency, sSOL= subjective sleep onset latency, SOL=sleep onset latency, SOT=Sensory Organization Test, SPRINT=Short PTSD Rating Interview, SQTT=Step Quick Turn Test, SSRI=selective serotonin-reuptake inhibitor, sTSO=subjective time to sleep onset, sTST=subject reported total sleep time, sWASO=subjective wake time after sleep onset, TST=total sleep time, WASO=wake time after sleep onset, WLQ=Work Life Questionnaire, WTDS=wake time during sleep

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 13. Relative Cost of the Miscellaneous Anxiolytics, Sedatives, and Hypnotics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Buspirone	tablet	N/A	N/A	$
Dexmedetomidine	injection	Precedex®*	$$$$$	$$$$$
Droperidol	injection	N/A	N/A	$
Eszopiclone	tablet	Lunesta®*	$$$$$	$
Hydroxyzine	capsule, solution, tablet	Vistaril®*	$$$$$	$
Lemborexant	tablet	Dayvigo®	$$$$$	N/A
Meprobamate	tablet	N/A	N/A	$$$$$
Ramelteon	tablet	Rozerem®*	$$$	$$$
Suvorexant	tablet	Belsomra®	$$$$$	N/A
Tasimelteon	capsule	Hetlioz®	$$$$$	N/A
Zaleplon	capsule	N/A	N/A	$$$
Zolpidem	extended-release tablet, sublingual tablet, tablet	Ambien®*, Ambien CR®*, Edluar®	$$$$$	$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The miscellaneous anxiolytics, sedatives, and hypnotics are used primarily for the treatment of anxiety disorders and insomnia. In addition, some agents are approved for the treatment of acute alcohol withdrawal, management

of procedural nausea/vomiting, treatment of Non-24-Hour Sleep-Wake Disorder (non-24), as well as treatment of pruritus. All of the products are available in a generic formulation, with the exception of suvorexant and tasimelteon.

The agents that are approved for the treatment of anxiety disorders include buspirone, hydroxyzine, and meprobamate.[2-3] The American Psychiatric Association recommends the initial use of either a serotonin-norepinephrine reuptake inhibitor (SNRI) or a selective serotonin reuptake inhibitor (SSRI) for the treatment of panic disorder due to their favorable safety and tolerability profiles.[20] Buspirone and sedating antihistamines are not effective as monotherapy for the treatment of panic disorder.[19-20] For the long-term treatment of generalized anxiety disorder, the National Institute for Health and Clinical Excellence recommends the use of an SSRI as first-line therapy.[19] Sedating antihistamines are one of several options for the short-term, immediate treatment of generalized anxiety disorder.[19] Buspirone is not recommended for the initial treatment of obsessive-compulsive disorder or posttraumatic stress disorder.[21-25] The available guidelines do not provide any recommendations regarding the use of meprobamate for the treatment of anxiety disorders.[19-25]

Eszopiclone, lemborexant ramelteon, suvorexant, zaleplon, and zolpidem are approved for the treatment of insomnia.[2-14] The American Academy of Sleep Medicine recommends the use of a short/intermediate-acting benzodiazepine, benzodiazepine receptor agonist, or ramelteon for the initial treatment of insomnia.[26] They do not give preference to one agent over another. Symptom pattern, treatment goals, past treatment responses, patient preference, comorbid conditions, contraindications, drug interactions and adverse events should be considered when selecting a specific agent.[26,27] The American College of Physicians recommends that all adult patients receive cognitive behavioral therapy for insomnia as the initial treatment for chronic insomnia disorder. If cognitive behavioral therapy alone is unsuccessful, a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, should be used to decide whether to add pharmacological therapy. This guideline found insufficient evidence overall on the comparative effectiveness and safety of the various pharmacologic treatments to recommend certain therapies over others.[28] The frequency and severity of adverse events may be lower with benzodiazepine receptor agonists (e.g., eszopiclone, zaleplon, and zolpidem) and ramelteon than benzodiazepines due to their shorter half-lives.[26,28] Hypnotic treatments should be combined with behavioral and cognitive therapies.[27] Patients should be followed every few weeks during the initial treatment period to assess for effectiveness, adverse events and the need for ongoing medication. Chronic use of hypnotic medications may be necessary in those individuals with severe/refractory insomnia or for those with chronic comorbid illnesses.[27] Results from clinical trials demonstrate that these agents are effective for the treatment of insomnia. Relatively few studies were found in the medical literature directly comparing the efficacy and safety of these agents.

Tasimelteon is the first FDA-approved treatment for non-24, a chronic circadian rhythm disorder which occurs almost exclusively in persons who are completely blind.[13,15] Tasimelteon was reviewed under priority review and received orphan-product designation because it is intended to treat a rare disease.[15] There are currently no guidelines incorporating the use of tasimelteon.

There is insufficient evidence to support that one brand miscellaneous anxiolytic, sedative, or hypnotic agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand miscellaneous anxiolytic, sedative, or hypnotic agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand miscellaneous anxiolytic, sedative, or hypnotic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
2. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Sept]. Available from: http://online.factsandcomparisons.com.
3. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Sept]. Available from: http://www.thomsonhc.com/.
4. Lunesta® [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; Aug 2019.
5. Ambien® [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; Aug 2019.
6. Edluar® [package insert]. Somerset, NJ: Meda Pharmaceuticals, Inc.; Aug 2019.
7. Ambien CR® [package insert]. Bridgewater, NJ: Sanofi-Aventis US; Aug 2019.
8. Intermezzo® [package insert]. Stamford, CT: Purdue Pharma L.P.; September 2015.
9. Rozerem® [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; Dec 2018.
10. Belsomra® [package insert]. Whitehouse Station, NJ: Merk & Co., Inc.; Mar 2020.
11. Dayvigo® [package insert]. Woodcliff Lake (NJ): Eisai Inc.; 2020 Apr.
12. Precedex® [package insert]. Lake Forest, IL: Hospira; Feb 2020.
13. Hetlioz® [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; Oct 2019.
14. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 July]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
15. FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2014 Jan 31 [cited 2016 Feb]. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384092.htm.
16. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2013 Jan 1 [cited 2014 Mar 21]. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html.
17. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2014 May 15 [cited 2016 Feb]. Available from: http://www.fda.gov/drugs/drugsafety/ucm397260.htm.
18. FDA Drug Safety Communication: FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2019 Apr 30 [cited 2020 July]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia.
19. National Institute for Clinical Excellence. Generalized anxiety disorder and panic disorder in adults: management. National Institute for Clinical Excellence (NICE); January 2011. Available at: http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf. Accessed Jul 2020.
20. Stein M, Goin M, Pollack M, et al. Practice guideline for the treatment of patients with panic disorder, second edition. American Psychiatric Association; 2009. Available at: http://psychiatryonline.org/data/Books/prac/PanicDisorder_2e_PracticeGuideline.pdf. Accessed June 2020.
21. Geller DA, March J, AACAP Committee on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2012; 51(1):98-113.
22. Koran L, Hanna G, Hollander E, Nestadt G, Simpson H; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington (VA): American Psychiatric Association; July 2007. Available at: http://psychiatryonline.org/data/Books/prac/OCDPracticeGuidelineFinal05-04-07.pdf. Accessed February 2018.
23. Cohen JA, AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Posttraumatic Stress Disorder. American Academy of Child and Adolescent Psychiatry (AACAP). J Am Acad Child Adolesc Psychiatry 2010;49(4):414-30.
24. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. February 2017. Available from https://www.apa.org/ptsd-guideline/ptsd.pdf.

25. The Management of Posttraumatic Stress Disorder Work Group. VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 3.0 – 2017. Available from https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal082917.pdf.
26. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. American Academy of Sleep Medicine (AASM). J Clin Sleep Med. 2008;4:487-504.
27. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.
28. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33..
29. ASGE Standards of Practice Committee. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2018 Feb;87(2):327-337..
30. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113.
31. National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders. Diagnosis, assessment and management of harmful drinking and alcohol dependence. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Feb. 54 p. (Clinical guideline; no. 115). Available at: http://www.nice.org.uk/nicemedia/live/12995/48991/48991.pdf. Accessed February 2016.
32. The American Psychiatric Association. Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. 2018. https://doi.org/10.1176/appi.books.9781615371969.
33. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology. 1992;25(4):193-201.
34. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology. 1998 Oct;139(4):402-6.
35. Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002 Nov;63(11):1020-7.
36. Blanco C, Schneier F, Schmidt A, Blanco-Jerez C, Marshall R, Sanchez-Lacay A et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40.
37. Zammit G, McNabb L, Caron J, Amato D, Roth T. Efficacy and safety of eszopiclone across 6 weeks of treatment for primary insomnia. Curr Med Res Opin. 2004 Dec;20(12):1979-91.
38. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003 Nov 1;26(7):793-9.
39. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein F, Roth T. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007:30(8):959-68.
40. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010;202:171.e1-171.e11.
41. Scharf M, Erman M, Rosengerg R, Seiden D, McCall WV, Amato D, Wessel TC. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720-7.
42. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33:225-34.
43. Lettieri CJ, Collen JF, Eliasson AH, et al. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial. Chest. 2009;136:1263-8.
44. Lettieri CJ, Shah AA, Holley AB, et al. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009;151:696-702.
45. Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25:1708-14.
46. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:892-7.

47. McCall WV, Blocker JN, D'Agostino R, Kimball J, Boggs N, Lasater B, et al. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med. 2010;6(4):322-9.
48. Rosenberg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med. 2005;6:15-22.
49. Krystal AD. Huang H. Zummo J. Grinnell T. Marshall RD. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. Sleep Medicine. 2012 Jun;13(6):691-6.
50. Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Network Open. 2019 Dec 2;2(12):e1918254. doi:10.1001/jamanetworkopen.2019.18254
51. Karppa M, Yardley J, Pinner K et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020 Sep 14;43(9):1-11. doi: 10.1093/sleep/zsaa123.
52. Uchimura N, Ogawa A, Hamamura M, Hashimoto T, Nagata H, Uchiyama M. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study [abstract]. Expert Rev Neurother. 2011;11(2):215-24.
53. Kohsaka M, Kanemura T, Taniguci M, Kuwahara H, Mikami A, Kamikawa K, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia [abstract]. Expert Rev Neurother. 2011;11(10):1389-97.
54. Wang-Weigand S, Watissee M, Roth T. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia. Sleep Medicine. 2011;12:920-3.
55. Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res and Opin. 2009;25(5):1209-13.
56. Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Medicine. 2009;10:55-9.
57. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17-24.
58. Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32:351-60.
59. Uchiyama M, Hamamura M, Kuwano T, et al. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med. 2011;12:119-26.
60. Uchiyama M, Hamamura M, Kuwano T, et al. Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med. 2011;12:127-33.
61. Gooneratne NS, Gehrman P, Gurubhagavatula I, et al. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med. 2010;6:572-80.
62. Liu J. Wang LN. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. International Journal of Clinical Practice. 2012 Sep;66(9):867-73.
63. Dobkin RD, Menza M, Bienfait KL, Allen LA, Marin H, Gara MA. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int. 2009;15(1):13-8.
64. Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a one-year, open-label study. J Clin Psychiatry. 2009;70(4):467-76.
65. Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med. 2009;5(1):28-33.
66. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006 Jun;7(4):312-8.
67. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28(3):303-7.
68. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 May;13(5):461-71.

69. Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, et al. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. J Clin Sleep Med. 2016 Sep 15;12(9):1215-25.
70. Scharf M, Roth T, Vogel G, Walsh J. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994 May;55(5):192-9.
71. Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep. 2011;34:207-12.
72. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995 May;18(4):246-51.
73. Randall S. Roehrs TA. Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012 Nov;35(11):1551-7.
74. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31:79-90.
75. Fava M, Asnis GM, Shirvastava RK, Lydiard B, Bastani B, Sheehan DV, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011;72(7):914-28.
76. Fava M, Asnis GM, Shrivastava R, Lydiard B, Bastani B, Sheehan D, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:222-30.
77. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a six month randomized, placebo-controlled trial. Sleep. 2008;31(10):1371-8.
78. Roth T. Krystal A. Steinberg FJ. Singh NN. Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013 Feb;36(2):189-96.
79. Roth T, Hull SG, Lankford A, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle of the night awakenings. Sleep. 2008;31(9):1277-84.
80. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin. 2010;26:1423-31.
81. Valente KD. Hasan R. Tavares SM. Gattaz WF. Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers. Sleep Medicine. 2013 Jan.;14(1):20-3.
82. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med. 2009;10:616-20.
83. Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D. Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial. Braz J Psychiatry. 2020;42(2):175-184. doi:10.1590/1516-4446-2019-0389.
84. Beaulieu-Bonneau S, Ivers H, Guay B, Morin CM. Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep. 2017 Mar 1;40(3).
85. Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999 Aug;60(8):536-44.
86. Huedo-Medina TB. Kirsch I. Middlemass J. Klonizakis M. Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
87. Uchimura N. Kamijo A. Kuwahara H. Uchiyama M. Shimizu T. Chiba S. Inoue Y. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Medicine. 2012 Dec;13(10):1247-53.
88. Pinto LR Jr, Bittencourt LR, Treptow EC, Braga LR, Tufik S. Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (Sao Paulo). 2016 Jan;71(1):5-9.
89. Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med. 2008;4:229-34.

90. Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle of the night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5(1):34-40.
91. Huang YS, Hsu SC, Liu SI, et al. A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon vs zolpidem in shortening sleep latency in primary insomnia. Chang Gung Med J 2011;34:50-6.
92. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2004:19:305-22.
93. Zammit G, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med. 2006;2:417-23.
94. Danjou P, Paty I, Fruncillo R, Worthington P, Unruh M, Cevallos W, Martin P. A comparison of the residual effects of zaleplon and zolpidem following administration five to two hours before awakening. Br J Clin Pharmacol. 1999;48:367-74.
95. Verster JC, Volkerts ER, Schreuder AHCML, Eijken EJE, van Heuckelum JHG, Veldhuijzen DS, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002 Dec;22(6):576-83.
96. Piccione P, Zorick F, Lutz T, Grissom T, Kramer M, Roth T. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res. 1980;8(5):361-7.
97. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psych. 2006 Oct;63:1149-57.
98. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol. 2006;62(5):538-45.
99. Holbrook A, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000 Jan 25;162(2):225-33.
100. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007 Sep;22(9):1335-50.
101. Smith M, Perlis M, Park A, Smith M, Pennington J, Giles D, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002 Jan;159(1):5-11.
102. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia. A meta-analysis of treatment efficacy. JAMA. 1997 Dec 24/31;278(24):2170-7.4.
103. Schaub I. Lysakowski C. Elia N. Tramer MR. Low-dose droperidol (<1 mg or <15 mug kg-1) for the prevention of postoperative nausea and vomiting in adults: quantitative systematic review of randomized controlled trials. European Journal of Anaesthesiology. 2012 Jun;29(6):286-94.
104. Atsuta J, Inoue S, Tanaka Y, Abe K, Nakase H, Kawaguchi M. Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study. J Anesth. 2017 Feb;31(1):82-88.
105. Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015 Oct 31;386(10005):1754-64.
106. Fraser GL. Devlin JW. Worby CP. Alhazzani W. Barr J. Dasta JF. Kress JP. Davidson JE. Spencer FA. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Critical Care Medicine. 2013 Sep;41(9 Suppl 1):S30-8.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Genitourinary Smooth Muscle Relaxants
AHFS Class 861204 – Antimuscarinics
November 4, 2020

I. Overview

Urinary incontinence is the involuntary leakage of urine, which may be classified as urgency, stress, overflow, or mixed incontinence.[1] Urgency incontinence is accompanied by a sense of urgency, while stress incontinence generally occurs with effort, exertion, sneezing, or coughing. Overflow incontinence is associated with dribbling and/or continuous leakage due to incomplete bladder emptying.[1] Overactive bladder is a functional disorder characterized by urinary urgency, daytime frequency (>8 voids during the daytime), nocturia (>1 void at night), with or without incontinence.[2,3] Urinary incontinence and overactive bladder may be due to lower urinary tract dysfunction or secondary to non-genitourinary disorders. The most common cause of overactive bladder is overactivity of the bladder's detrusor muscle. Symptoms may be assessed by patient history, the use of validated questionnaires, and/or bladder diaries. Clinical testing (e.g., bladder stress test, postvoid residual volume testing, urine flow rate, and urodynamic testing) may help identify the pathology, but are not always necessary for diagnosis or initiation of therapy.[1,2] Urinary incontinence and overactive bladder cause both physical and psychological morbidity, as well as adversely impact quality of life.[1] Initial treatment options include lifestyle modifications (weight loss and dietary changes) and behavioral therapy (bladder training, physical therapy, and toileting assistance).[2,4] Pharmacologic therapy is typically trialed if initial treatment is ineffective.[2,4] Neurogenic lower urinary tract disorder is caused by a lesion at any level of the nervous system.[5,6] The lesion interferes with the normal nerve pathways associated with urination. Early diagnosis and treatment of neurogenic lower urinary tract disorder is essential for both congenital and acquired disorders as irreversible changes may occur.[6]

Normal voiding is dependent on acetylcholine-induced stimulation of muscarinic receptors on bladder smooth muscle. There are five muscarinic receptor subtypes, of which M1, M2, and M3 mediate bladder contractility. Muscarinic receptors are also found in the gastrointestinal tract, salivary glands, and tear ducts. Antimuscarinic drugs increase bladder capacity, decrease urgency, and are useful for the treatment of urge incontinence.[4,7-18] Darifenacin, fesoterodine, solifenacin, tolterodine, and trospium are muscarinic receptor antagonists. Flavoxate is an antispasmodic which exerts its effects directly on muscle and counteracts the smooth muscle spasm of the urinary tract. Oxybutynin has a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Some antimuscarinic agents claim to have greater affinity for specific receptor subtypes that mediate bladder contractility, but the clinical significance of this is unclear. The most common adverse effects associated with the use of antimuscarinic agents include dry mouth, blurred vision, abdominal discomfort, drowsiness, nausea, and dizziness. These agents may also cause confusion or cognitive impairment in the elderly.[4]

The genitourinary smooth muscle relaxants that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Darifenacin, flavoxate, oxybutynin, solifenacin, tolterodine, and trospium are available in a generic formulation. This class was last reviewed in August 2018.

Table 1. Genitourinary Smooth Muscle Relaxants Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Darifenacin	extended-release tablet	Enablex®*	darifenacin
Fesoterodine	extended-release tablet	Toviaz®	Toviaz®
Flavoxate	tablet	N/A	flavoxate
Oxybutynin	extended-release tablet, syrup, tablet, transdermal gel, transdermal patch	Ditropan XL®*, Gelnique®, Oxytrol®	oxybutynin, Oxytrol®
Solifenacin	tablet	VESIcare®*	solifenacin
Tolterodine	extended-release capsule, tablet	Detrol®*, Detrol LA®*	tolterodine
Trospium	extended-release capsule, tablet	N/A	trospium

*Generic is available in at least one dosage form or strength.
N/A=Not available, PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the genitourinary smooth muscle relaxants are summarized in Table 2.

Table 2. Treatment Guidelines Using the Genitourinary Smooth Muscle Relaxants

Clinical Guideline	Recommendation(s)
National Institute for Health and Clinical Excellence: **Urinary Incontinence and Pelvic Organ Prolapse in Women: Management (2019)**[19] Last updated June 2019	Behavioral therapy • Bladder training should be offered for a minimum of six weeks as first-line treatment to women with urge or mixed urinary incontinence. • If women do not achieve satisfactory benefit from bladder training, the combination of an overactive bladder medicine with bladder training should be considered if frequency is a troublesome symptom. • Do not offer transcutaneous sacral nerve stimulation, transcutaneous posterior tibial nerve stimulation, or percutaneous posterior tibial nerve stimulation to women with urinary incontinence. Pharmacologic therapy • Before starting treatment with a medicine for overactive bladder, the following should be explained to the woman: the likelihood of the medicine being successful; the common adverse effects associated with the medicine; that some adverse effects of anticholinergic medicines, such as dry mouth and constipation, may indicate that the medicine is starting to have an effect; that she may not see substantial benefits until she has been taking the medicine for at least four weeks and that her symptoms may continue to improve over time; and that the long-term effects of anticholinergic medicines for overactive bladder on cognitive function are uncertain. • When offering anticholinergic medicines to treat overactive bladder, the following should be taken into consideration of the woman's: coexisting conditions (such as poor bladder emptying, cognitive impairment or dementia); current use of other medicines that affect total anticholinergic load; and risk of adverse effects, including cognitive impairment. • Flavoxate, propantheline and imipramine should not be offered for the treatment of urinary incontinence or overactive bladder in women. • Immediate-release oxybutynin should not be offered to older women who may be at higher risk of a sudden deterioration in their physical or mental health. • Anticholinergic medicine with the lowest acquisition cost should be offered to treat overactive bladder or mixed urinary incontinence in women. • If the first medicine for overactive bladder or mixed urinary incontinence is not effective or well-tolerated, another medicine with a low acquisition cost should be offered. • A transdermal overactive bladder treatment should be offered to women unable to tolerate oral medicines. • The use of desmopressin may be considered to reduce nocturia in women with urinary incontinence or overactive bladder who find it a troublesome symptom. • Duloxetine is not recommended as a first-line treatment for women with predominant stress urinary incontinence. Duloxetine should not routinely be used as a second-line treatment for women with stress urinary incontinence, although it may be offered as second-line therapy if women prefer pharmacological to surgical treatment or are not suitable for surgical treatment. • Systemic hormone replacement therapy is not recommended for the treatment of urinary incontinence. • Intravaginal estrogens are recommended for the treatment of overactive bladder symptoms in postmenopausal women with vaginal atrophy.

Clinical Guideline	Recommendation(s)
	• Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects. ○ People currently receiving mirabegron that is not recommended for them should be able to continue treatment until they and their clinician consider it appropriate to stop. Complementary therapy • Complementary therapies are not recommended for the treatment of urinary incontinence or overactive bladder.
European Association of Urology: **Guidelines on Urinary Incontinence (2018)**[20]	Antimuscarinic drugs • There is limited evidence that one antimuscarinic drug is superior to an alternative antimuscarinic drug for cure or improvement of urgency urinary incontinence. • Higher doses of antimuscarinic drugs are more effective to cure or improve urgency urinary incontinence, but with a higher risk of side effects. • Once daily (extended release) formulations are associated with lower rates of adverse events compared to immediate release ones, although similar discontinuation rates are reported in clinical trials. • Dose escalation of antimuscarinic drugs may be appropriate in selected patients to improve treatment effect although higher rates of adverse events can be expected. • Transdermal oxybutynin (patch) is associated with lower rates of dry mouth than oral antimuscarinic drugs, but has a high rate of withdrawal due to skin reaction. • Offer antimuscarinic drugs for adults with urgency urinary incontinence who failed conservative treatment. • Consider extended release formulations in patients who do not tolerate immediate release antimuscarinics. • If antimuscarinic treatment proves ineffective, consider dose escalation or offering an alternative treatment. • Consider using transdermal oxybutynin if oral antimuscarinic agents cannot be tolerated due to dry mouth. • Offer and encourage early review (of efficacy and side effects) of patients on antimuscarinic medication for urgency urinary incontinence. • Adherence to antimuscarinic treatment is low and decreases over time because of lack of efficacy, adverse events and/or cost. • Most patients will stop antimuscarinic agents within the first three months. Antimuscarinic and β-3 agonist agents, the elderly and cognition • Antimuscarinic drugs are effective in elderly patients. • Mirabegron has been shown to efficacious and safe in elderly patients. • In older people, the cognitive impact of drugs which have anticholinergic effects is cumulative and increases with length of exposure. • Oxybutynin may worsen cognitive function in elderly patients. • Solifenacin, darifenacin, fesoterodine and trospium have been shown not to cause cognitive dysfunction in elderly people in short-term studies. Additional recommendations for antimuscarinic drugs in the elderly • In older people being treated for urinary incontinence, every effort should be made to employ nonpharmacological treatments first. • Long-term antimuscarinic treatment should be used with caution in elderly patients especially those who are at risk of, or have, cognitive dysfunction. • When prescribing antimuscarinic for urgency urinary incontinence, consider the total antimuscarinic load in older people on multiple drugs. • Consider the use of Mirabegron in elderly patients if additional antimuscarinic load is to be avoided.

Clinical Guideline	Recommendation(s)
	Mirabegron • Mirabegron is better than placebo and as efficacious as antimuscarinics for improvement of urgency urinary incontinence symptoms. • Adverse event rates with mirabegron are similar to placebo. • Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron than dose escalation of solifenacin. • In patients with urgency urinary incontinence and an inadequate response to conservative treatments, offer mirabegron unless they have uncontrolled hypertension. Drugs for stress urinary incontinence • Duloxetine, 40 mg twice daily improves stress urinary incontinence in women. • Duloxetine causes significant gastrointestinal and central nervous system (CNS) side effects leading to a high rate of treatment discontinuation, although these symptoms are limited to the first weeks of treatment. • Duloxetine can be used with caution to treat women with symptoms of stress urinary incontinence. • Duloxetine should be initiated using dose titration because of high adverse event rates. Estrogen • Vaginal oestrogen therapy for vulvovaginal atrophy should be prescribed long-term. In women with a history of breast cancer, the treating oncologist needs to be consulted. Monitoring for hyponatremia • Consider offering desmopressin to patients requiring occasional short-term relief from daytime urinary incontinence and inform them that this drug is not licensed for this indication. • Monitor plasma sodium levels in patients on desmopressin. Drug treatment in mixed urinary incontinence • Offer antimuscarinic drugs or β-3 agonists to patients with urgency-predominant mixed urinary incontinence. Drug therapy • Duloxetine, either alone or combined with conservative treatment, can hasten recovery of continence but does not improve continence rate following prostate surgery. Compression devices in males • Consider offering duloxetine to hasten recovery of continence after prostate surgery but inform the patient about the possible adverse events.
American Urological Association: **Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: American Urological Association/ Society of Urodynamics, Female Pelvic Medicine &**	Diagnosis • Overactive bladder is a symptom complex that is not generally life threatening. • The clinician should engage in a diagnostic process to document symptoms and signs that characterize overactive bladder and exclude other disorders that could be the cause of the patient's symptoms. • After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice. First line treatment • Behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) should be offered as first line therapy. • Behavioral therapies can also be combined with pharmacologic management.

Clinical Guideline	Recommendation(s)
Urogenital Reconstruction Guideline (2012); Amended (2014, 2019)[21]	Second line treatment • Clinicians should offer oral antimuscarinics or oral β3-adrenoceptor agonists as second line therapy. • If extended-release and immediate-release formulations are available, the extended-release should be preferred over the immediate-release given formulation due to lower rates of dry mouth. Transdermal oxybutynin is also an option. • If a patient experiences inadequate symptom control and/or unacceptable adverse drug events with one agent then a dose modification or a different antimuscarinic medication or β3-adrenoceptor agonist may be tried. • May consider combination therapy with an anti-muscarinic and β3-adrenoceptor agonist for patients refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists. • Anti-muscarinics should be avoided in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist and should also be used with extreme caution in patients with impaired gastric emptying or a history of urinary retention. • Manage constipation and dry mouth before abandoning effective anti-muscarinic therapy. Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics. • Use caution in prescribing anti-muscarinics in patients who are using other medications with anti-cholinergic properties. • Use caution in prescribing anti-muscarinics or β3-adrenoceptor agonists in the frail patient. • Patients who are refractory to behavioral and pharmacologic therapy should be evaluated by an appropriate specialist if they desire additional therapy. Third line treatment • Clinicians may offer intradetrusor onabotulinumtoxinA as a third-line option in the carefully selected patients who has been refractory to first and second line overactive bladder treatments. The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary. • Clinicians can also offer peripheral tibial nerve stimulation as third-line treatment. • Clinicians may offer sacral neuromodulation as third line treatment in a carefully selected patient population characterized by server refractory overactive bladder symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure. • Patients should persist with new treatments for an adequate trial in order to determine whether the therapy is efficacious and tolerable. Combination therapeutic approaches should be assembled methodically, with the addition of new therapies occurring only when the relative efficacy of the preceding therapy is known. Therapies that do not demonstrate efficacy after an adequate trial should be ceased.
National Institute for Health and Clinical Excellence: **Urinary Incontinence in Neurological Disease (2012)**[22]	Behavioral treatment • For patients with neurogenic lower urinary tract dysfunction, behavioral management programs should be considered (e.g., timed voiding, bladder retraining or habit retraining). • When choosing a behavioral management program, take into account that prompted voiding and habit retraining are particularly suitable for people with cognitive impairment. Antimuscarinics • Antimuscarinic drugs should be offered to patients with spinal cord disease (e.g.,

Clinical Guideline	Recommendation(s)
	spinal cord injury or multiple sclerosis) who have symptoms of overactive bladder such as increased frequency, urgency and incontinence. • In patients with conditions affecting the brain (e.g., cerebral palsy, head injury or stroke) with symptoms of an overactive bladder, antimuscarinic drugs should be considered. • Antimuscarinic drug treatment should be considered in patients with urodynamic investigations showing impaired bladder storage. • Residual urine volume should be monitored in patients not using intermittent or indwelling catheterization after beginning treatment. • Antimuscarinic treatment can reduce bladder emptying, which may increase the risk of urinary tract infections and may precipitate or exacerbate constipation. Antimuscarinics known to cross the blood-brain barrier (e.g. oxybutynin) have the potential to cause central nervous system related adverse effects (e.g., confusion). Botulinum toxin A • Bladder wall injection with botulinum toxin A should be offered to adult patients with spinal cord diseases (e.g., spinal cord injury or multiple sclerosis) and symptoms of overactive bladder and an inadequate response to or poorly tolerated antimuscarinic drugs. • Bladder wall injection with botulinum toxin A may be considered for children and young people with spinal cord disease and symptoms of overactive bladder for who antimuscarinic drugs were ineffective or poorly tolerated. • Bladder wall injection with botulinum toxin A may be considered in adults with spinal cord disease with urodynamic investigations showing impaired bladder storage for whom antimuscarinic drugs were ineffective or poorly tolerated. • Consider bladder wall injection with botulinum toxin A for children and young people with spinal cord disease with urodynamic investigations showing impaired bladder storage and for whom antimuscarinic drugs were ineffective or poorly tolerated. • A catheterization regimen is needed in most people with neurogenic lower urinary tract dysfunction after botulinum toxin A treatment. The patient must be able and willing to manage such a regimen should urinary retention develop after the treatment. • Monitor residual urine volume in patients who are not using a catheterization regimen during treatment with botulinum toxin A. • Monitor upper urinary tract in patients at risk of renal complications (e.g., those with high intravesical pressures on filling cystometry) during treatment. • People should be offered repeated botulinum toxin A injections and have prompt access to repeat injections when symptoms return.
International Scientific Committee: **Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence (2018)**[23]	Initial management of urinary incontinence in children • For children with mono-symptomatic nocturnal enuresis, initial treatment should include: o Parental and child counselling and motivation o Review of bladder diary with attention to night-time polyuria o Age appropriate education and demystification or explanation o Counselling, timed voiding, behavior modification and bowel management when necessary o Antimuscarinics may be used if the child has overactive bladder symptoms Initial management of urinary incontinence in men • For men with stress, urgency or mixed urgency/stress incontinence, initial treatment should include: o Lifestyle interventions. o Supervised pelvic floor muscle training for men with post-radical

Clinical Guideline	Recommendation(s)
	prostatectomy stress urinary incontinence. o Scheduled voiding regimes for overactive bladder. o Antimuscarinic/beta 3 agonist drugs for overactive bladder symptoms with or without urgency incontinence if the patient has no evidence of significant post-void residual urine. o Alpha adrenergic antagonists (α-blockers) can be added if it is thought that there may also be bladder outlet obstruction. Initial management of urinary incontinence in women • For women with stress, urgency or mixed urgency/stress incontinence, initial treatment should include: o Advice on caffeine reduction for overactive bladder and weight reduction. o Supervised pelvic floor muscle training and vaginal cones training for women with stress incontinence. o Supervised bladder training for overactive bladder. o If estrogen deficiency and/or urinary tract infection is found, the patient should be treated at initial assessment and then reassessed after a suitable interval. o Antimuscarinics/beta-3 agonist for overactive bladder symptoms with or without urgency incontinence. o Duloxetine may be considered for stress urinary incontinence. Initial management of neurogenic urinary incontinence • Conservative treatment modalities (often in combination): o Intermittent catheterization. o Behavioral treatment. o Timed voiding. o Continence products. o Antimuscarinics. o Alpha-1-adrenergic blockers. o Oral cannabinoid agonists (MS) o Beta-3-agonist alone or as an add-on to antimuscarinics o Bladder expression. o Triggered voiding. o Indwelling catheter. Management of urinary incontinence in frail older persons • Initial treatment should be individualized and influenced by goals of care, treatment preferences, and estimated remaining life expectancy, as well as the most likely clinical diagnosis. • In some frail elders the only possible outcome may be contained urinary incontinence (managed with pads), especially for persons with minimal mobility (require assistance of >2 persons to transfer), advanced dementia (unable to state their name), and/or nocturnal urinary incontinence. • Conservative and behavioral therapy for urinary incontinence include lifestyle changes, bladder training for more fit alert patients, and prompted voiding for frailer, more impaired patients. • For select cognitively intact patients, pelvic muscle exercises may be considered. Antimuscarinics may be added to conservative therapy of urgency urinary incontinence. Alpha-blockers may be cautiously considered in frail men with suspected prostatic outlet obstruction. All drugs should be started at the lowest dose and titrated with regular review until either care goals are met or adverse effects are intolerable. • DDAVP (vasopressin) has a high risk of severe hyponatremia in frail persons and should not be used outside specialist centers or without very careful monitoring

Clinical Guideline	Recommendation(s)
	and long-term follow-up.
Neurogenic Bladder Society: **Clinical Guidelines for Overactive Bladder (2009)**[2]	Behavioral therapy • Behavioral therapy can include lifestyle guidance, bladder training, physical therapy and toileting assistance. • Behavioral therapy is minimally invasive with no adverse reactions and combination therapy with other forms of treatment is also possible. • Behavioral therapy should be considered as the first-line choice for initial treatment of overactive bladder. • The efficacy of combined behavioral therapy and drug therapy over monotherapy has yet to be determined, but it is the recommended treatment approach. Drug therapy • Drug therapy forms the basis of treatment for overactive bladder. • The drugs for which efficacy and safety have been investigated are the antimuscarinic agents. These are most commonly used for the treatment of overactive bladder. • When using antimuscarinic drugs, it is necessary to consider adverse reactions due to blockade of the systemic muscarine receptors Antimuscarinic drugs • Oxybutynin has a direct relaxing effect and paralyzing effect on smooth muscle in addition to its antimuscarinic activity. It has been extensively evaluated and its efficacy has been well demonstrated. The incidence of adverse reactions associated with its antimuscarinic activity is higher than that of other antimuscarinic drugs. It is recommended that treatment is started from a low dose and titrated gradually to determine the optimal dose. Oxybutynin can pass through the blood-brain barrier potentially causing central nervous system adverse events (cognitive impairment, etc.). Caution is required in elderly patients. • Tolterodine has no selectivity for muscarinic receptor subtypes, is well distributed to and has a high binding affinity for the bladder, and as compared to the salivary glands, is highly selective for the bladder. It has been extensively evaluated and there is substantial evidence for efficacy and safety in overactive bladder patients, including the elderly and patients with severe overactive bladder. • Solifenacin is highly selective for the muscarinic receptor M3, and is more highly selective for the bladder than for the salivary glands. It has been shown to be effective for urgency, frequency, and urge urinary incontinence in overactive bladder. • Flavoxate has no antimuscarinic activity, but appears to have a moderate calcium antagonistic action, inhibitory effect on phosphodiesterase, and a local relaxant effect on smooth muscle. Flavoxate has been observed to have almost no adverse reactions, but its efficacy has not been adequately evaluated. • Darifenacin is high selectivity for the M3 receptor subtype, and it has shown a higher selectivity for the bladder than the salivary glands in animal studies. Concern has been raised about adverse reactions involving the salivary glands and gastrointestinal tract, in which M3 receptors are numerous. Antidepressants • Several types of tricyclic antidepressants are indicated for enuresis or nocturnal enuresis, with imipramine being the most commonly used drug. Imipramine appears to be useful for nocturnal enuresis in children, but its usefulness as a therapeutic agent for overactive bladder is yet to be adequately evaluated. Botulinum Toxin • Botulinum toxin is believed to inhibit bladder contraction by blocking the release of acetylcholine from cholinergic nerves, primarily by causing chemical

Clinical Guideline	Recommendation(s)
	denervation. • Injection of botulinum toxin into the bladder wall is believed to be a promising therapeutic method for overactive bladder, but its usefulness is yet to be adequately explored. <u>Efficacy of drug therapy for overactive bladder symptoms in benign prostatic hyperplasia patients</u> • α_1-blockers are first-line drug therapy for overactive bladder symptoms in benign prostatic hyperplasia patients, but their long-term efficacy in patients without lower urinary tract obstruction has yet to be proven. • Randomized controlled studies to demonstrate the efficacy and safety of antimuscarinic drugs for overactive bladder symptoms associated with benign prostatic hyperplasia have yet to be performed. • Despite the fact that antimuscarinic drugs may be effective in some benign prostatic hyperplasia patients with overactive bladder symptoms, there is ample risk of causing acute urinary retention or chronic urinary retention. • The therapeutic positioning of antimuscarinic drugs for men with lower urinary tract symptoms is uncertain, and they are contraindicated in patients with severe lower urinary tract obstruction or urinary retention. • It remains uncertain whether combination therapy with an α_1-blocker and an antimuscarinic drug is superior to α_1-blocker monotherapy in benign prostatic hyperplasia patients with overactive bladder symptoms. <u>Practical guidelines for drug therapy for overactive bladder: Rules for treatment with anticholinergic drugs, classified by sex and age</u> • Overactive bladder in women: o Antimuscarinic drugs can be administered immediately. o If voiding symptoms, as well as overactive bladder symptoms, are present, antimuscarinic drugs should be administered with caution. o Since overactive bladder and impaired detrusor contractility may both be present in elderly women (80 years or older) in particular, patients should be referred to a urological specialist if voiding symptoms are severe or if residual urine is copious (50 mL or more). • Overactive bladder in men under 50 years of age: o For overactive bladder in relatively young men, it is recommended that patients be evaluated by a urological specialist at least once, as there may be an underlying comorbid neurological disease or urological disease. • Overactive bladder in men aged 50 years or older: o Because there is a high probability of overactive bladder as a complication of benign prostatic hyperplasia, give top priority to starting an α_1-blocker if voiding symptoms are confirmed. o If there is no improvement in overactive bladder symptoms, an antimuscarinic drug can be coadministered. However, since there is not adequate evidence regarding this combination, the patient should also be referred to a urological specialist.
American College of Obstetricians and Gynecologists: **Practice Bulletin: Urinary Incontinence in Women (2015)**[24] Reaffirmed 2018	• Behavioral therapy (e.g., bladder training and prompted voiding) and pelvic floor muscle exercises improve symptoms of stress, urgency, and mixed urinary incontinence and may be recommended as an initial, noninvasive treatment in many women. • Moderate weight loss can improve urinary incontinence symptoms in overweight and obese women. • Pelvic floor muscle exercises appear to be an effective treatment for adult women with stress, urgency, or mixed incontinence and can be recommended as a noninvasive treatment for many women. • Current evidenced-based medical treatments typically are reserved for urgency

Clinical Guideline	Recommendation(s)
	urinary incontinence. Medical therapies for treatment of stress urinary incontinence are less effective and generally are not recommended. Available medical treatments for urgency urinary incontinence include antimuscarinic agents (also known as anticholinergic agents), β-agonists, onabotulinumtoxinA, and estrogen. • The antimuscarinic medications have been shown to have a small beneficial effect as therapy for urgency incontinence. Numerous antimuscarinic agents are available, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium, that have similar efficacy and safety profiles; however, conclusions regarding comparative effectiveness and safety are limited by the lack of high-quality evidence from head-to-head trials between specific agents. • Antimuscarinic medications also were associated with significant discontinuation rates because of bothersome adverse effects, with dry mouth as the most frequently reported adverse event. • Compared with antimuscarinic treatment, intravesical onabotulinumtoxinA results in similar reduction of incontinence episodes, and more patients report complete resolution of incontinence. Thus, intradetrusor onabotulinumtoxinA may be a treatment option for overactive bladder in appropriate patients, and consideration of its use requires shared decision making between the patient and physician. • Systemic estrogen therapy, with or without progesterone, does not appear to be effective in the prevention or treatment of urinary incontinence; several large trials of hormone therapy have found an increased occurrence of stress incontinence in users of hormone therapy (estrogen alone or combined with progesterone). Locally administered (vaginal) estrogen, however, may be of some benefit in decreasing urinary incontinence.
European Association of Urology/European Society for Pediatric Urology: **Guidelines on Pediatric Urology: Management of Neurogenic Bladder in Children (2020)**[5]	Early management with clean intermittent catheterization Starting intermittent catheterization (IC) soon after birth and closure of the defect by the neurosurgeon in all infants has shown to decrease renal complications and the need for later augmentation. Medical therapy • Antimuscarinic/anticholinergic medication reduces/prevents detrusor overactivity and lowers intravesical pressure. • Oxybutynin is the most frequently used in children with neurogenic bladder with a success rate of up to 93%. • Tolterodine, solifenacin, trospium chloride and propiverine and their combinations can be also used in children. • Early prophylactic treatment with anticholinergics showed a lower rate of renal deterioration as well as a lower rate of progression to bladder augmentation. Beta-3 agonists like mirabegron may be also an alternative agent and may be effective in patients with neurogenic bladders. Up to date, there is almost no experience with this drug, therefore there are no recommendation that can be made. Alpha-adrenergic antagonists may facilitate emptying in children with neurogenic bladder. Botulinum toxin injections • Injection of botulinum toxin into the detrusor is an alternative treatment option for neurogenic bladders, which are refractory to antimuscarinics. The use of botulinum toxin in adults prompted its use in children and even though it has been shown to have beneficial effects on clinical and urodynamic variables. • Although the evidence is too low to recommend its routine use in decreasing outlet resistance, injection of botulinum toxin in the urethral sphincter has been shown to be effective in decreasing urethral resistance and improving voiding.
European Association of Urology: **Guidelines on Neuro-Urology**	Treatment goals • The primary goals for the treatment of neurogenic lower urinary tract dysfunction are: o Protection of the upper urinary tract.

Clinical Guideline	Recommendation(s)
(2020)[6]	○ Achievement (or maintenance) of urinary continence. ○ Improvement of the patient's quality of life. ○ Restoration of lower urinary tract function. • Other considerations include the patient's disability, cost-effectiveness, technical complexity, and possible complications. Assisted bladder emptying • Incomplete bladder emptying is a risk factor for urinary tract infections, for developing high intravesical pressure during the filling phase, and for incontinence. • Methods to improve the voiding process should be practiced in patients with neurogenic lower urinary tract dysfunction and include the following: bladder expression, triggered reflex voiding and external appliances Neuro-urological rehabilitation • Bladder rehabilitation aims to re-establish bladder function in patients with neurogenic lower urinary tract dysfunction. • Peripheral temporary electrostimulation suppresses neurogenic detrusor over activity during acute stimulation and it has demonstrated sustained effects in patients with neurogenic bladder due to multiple sclerosis. In multiple sclerosis patients, a combined approach of pelvic floor muscle training with neuromuscular electrostimulation and biofeedback was more efficacious to electrostimulation alone in achieving a substantial reduction in lower urinary tract dysfunction. • Biofeedback can be used for supporting the alleviation of neuro-urological symptoms. • Intravesical electrostimulation may increase bladder capacity; improve bladder compliance as well as the sensation of bladder filling in patients with incomplete spinal cord injuries or meningomyelocele. • Bladder rehabilitation techniques are mainly based on electrical or magnetic stimulation; however, there is a lack of well-designed studies. Drug treatment • An optimal medical treatment for neurogenic lower urinary tract dysfunction is not available, and currently a combination of treatment modalities is the best therapeutic approach To prevent urinary tract damage and improve long-term outcomes. • Antimuscarinic drugs are first-line in the treatment of neurogenic detrusor overactivity (NDO). They increase bladder capacity and reduce episodes of urinary incontinence secondary to NDO by the inhibition of parasympathetic pathways. • Outcomes for neurogenic detrusor overactivity can be maximized by considering a combination or using higher doses of antimuscarinic agents. However, antimuscarinics have a high incidence of adverse events which may lead to discontinuation of therapy. • Alternative routes of administration (i.e., transdermal or intravesical) of antimuscarinic agents may be used to help reduce adverse effects. • Oxybutynin, tolterodine, trospium, and propiverine are established, effective, and well-tolerated treatment choices. • Darifenacin and solifenacin have been evaluated in NDO secondary to spinal cord injury and multiple sclerosis and had results similar to other antimuscarinic drugs. • Fesoterodine has also been introduced; to date there has been no published clinical evidence for its use in the treatment of neuro-urological disorders. • The role of mirabegron in neuro-urological patients is still unclear. • In patients with detrusor underactivity, cholinergic drugs (bethanechol chloride and distigmine bromide) may enhance detrusor contractility and promote bladder

Clinical Guideline	Recommendation(s)
	emptying, but are not used in clinical practice due to a lack of clinical evidence. • Alpha-blockers have been used successfully on occasion for decreasing bladder outlet resistance. External appliances • Social continence may be achieved by collecting the urine when incontinence cannot be resolved by any other methods. • Condom catheters with urine collection devices are a practical method for men. Incontinence pads may also offer a reliable solution. Minimal invasive treatment • Intermittent catheterization is the preferred management for neurourological patients who cannot effectively empty their bladders. • Botulinum toxin injection in the detrusor can be used to reduce neurogenic detrusor overactivity in multiple sclerosis or spinal cord injury patients if antimuscarinic therapy is ineffective. Therapy causes a long-lasting chemical denervation that lasts approximately nine months. • Antimuscarinics can be administered intravesically to reduce detrusor over activity. This route of administration may decrease adverse effects and a greater amount is sequestered in the bladder.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the genitourinary smooth muscle relaxants are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Genitourinary Smooth Muscle Relaxants: Antimuscarinics[7-18]

Indication	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin	Solifenacin	Tolterodine	Trospium
Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency	✔	✔		✔ *†	✔	✔	✔
For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis			✔				
Relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)				✔ ‡			
Treatment of pediatric patients aged six years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida)				✔ †			

*Transdermal formulations.
† Extended-release oral formulation.
‡Immediate-release oral formulation.

IV. Pharmacokinetics

The pharmacokinetic parameters of the genitourinary smooth muscle relaxants are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Genitourinary Smooth Muscle Relaxants: Antimuscarinics[8]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Darifenacin	15 to 25	98	Liver; Intestinal wall	Renal (60) Feces (40)	13 to 19
Fesoterodine	52	50	Liver	Renal (70) Feces (7)	4 to 7
Flavoxate	Not reported	Not reported	Not reported	Renal (57)	Not reported
Oxybutynin	IR: 6 ER: 156 to 187 (compared to IR)	>99	Liver; Intestinal wall	Renal (<0.1)	Gel: 30 ER: 13.2 IR: 2.0 to 3.0 Patch: 7 to 8
Solifenacin	90	98	Liver	Renal (3 to 6) Feces (22.5)	40 to 68
Tolterodine	IR: 77	Not reported	Liver	Renal (77) Feces (17)	1.9 to 3.7
Trospium	IR: 9.6	IR: 50 to 85 ER:48 to 78	Liver	Renal (5.8) Feces (85.2)	IR: 18.3 ER: 35

ER=extended-release formulation, IR=immediate-release formulation

V. Drug Interactions

Major drug interactions with the genitourinary smooth muscle relaxants are listed in Table 5.

Table 5. Major Drug Interactions with the Genitourinary Smooth Muscle Relaxants: Antimuscarinics[8]

Generic Name(s)	Interaction	Mechanism
Genitourinary smooth muscle relaxants (darifenacin, solifenacin)	Thioridazine	Coadministration may have additive effects on the prolongation of the QT interval.
Genitourinary smooth muscle relaxants (darifenacin, fesoterodine, flavoxate, oxybutynin, solifenacin, tolterodine, trospium)	Potassium preparations	Antimuscarinic agents may slow gastrointestinal motility and cause delay in tablet passage through the gastrointestinal tract.
Genitourinary smooth muscle relaxants (fesoterodine, solifenacin, tolterodine)	Imidazoles	Inhibition of cytochrome P450 3A4 by imidazoles may decrease the metabolic elimination of genitourinary smooth muscle relaxants. Plasma concentrations and pharmacologic effects of genitourinary smooth muscle relaxants may be increased.
Genitourinary smooth muscle relaxants (fesoterodine, solifenacin, tolterodine)	Macrolides	Inhibition of cytochrome P450 3A4 by macrolides may decrease the metabolic elimination of genitourinary smooth muscle relaxants. Plasma concentrations and pharmacologic effects of genitourinary smooth muscle relaxants may be increased.
Genitourinary smooth muscle relaxants (fesoterodine, solifenacin, tolterodine)	Protease inhibitors	Inhibition of cytochrome P450 3A4 by protease inhibitors may decrease the metabolic elimination of genitourinary smooth muscle relaxants. Plasma concentrations and pharmacologic effects of genitourinary smooth muscle relaxants may be increased.

Generic Name(s)	Interaction	Mechanism
Genitourinary smooth muscle relaxants (solifenacin, tolterodine)	Nefazodone	Inhibition of cytochrome P450 3A4 by nefazodone may decrease the metabolic elimination of genitourinary smooth muscle relaxants. Plasma concentrations and pharmacologic effects of genitourinary smooth muscle relaxants may be increased.
Genitourinary smooth muscle relaxants (darifenacin)	Desipramine, imipramine	Concurrent use may result in increased desipramine/imipramine exposure and potentially increased adverse effects. Probable mechanism is the competitive inhibition of CYP2D6-mediated desipramine/imipramine metabolism.
Genitourinary smooth muscle relaxants (darifenacin)	Flecainide	Concurrent use of darifenacin and flecainide may result in increased flecainide exposure with an increased risk of cardiac arrhythmias.

VI. Adverse Drug Events

The most common adverse drug events reported with the genitourinary smooth muscle relaxants are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Genitourinary Smooth Muscle Relaxants: Antimuscarinics[7-18]

Adverse Events	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin (Oral)	Oxybutynin (Transdermal)	Solifenacin	Tolterodine	Trospium
Cardiovascular								
Arrhythmia	-	-	-	1 to 5		-	-	<1
Atrial fibrillation	✔	-	-	-	-	-	-	-
Chest pain	-	✔	-	1 to 5	✔ §	-	2	✔
Hypertension	≥1	-	-	1 to 5	-	≤1	-	✔
Hypotension	-	-	-	1 to 5	-	-	-	-
Myocarditis	-	-	-	-	✔ §	-	-	-
Palpitations	✔	✔	✔	1 to 5	-	-	✔	✔
Peripheral edema	≥1	1	-	1 to 5	-	-	✔	-
QT_c prolongation	-	✔	-	1 to 5	-	✔	-	-
Supraventricular tachycardia	-	-	-	-	-	-	-	✔
Syncope	-	-	-	-	-	-	-	✔
T-wave inversion	-	-	-	-	-	-	-	✔
Tachycardia	✔	✔	✔	1 to 5	✔ §	-	✔	1 to 2
Torsade de pointes	-	-	-	-	-	✔	-	-
Central Nervous System								
Agitation	-	-	-	1 to 5	-	-	-	-
Anxiety	-	-	-	-	-	-	1†	-
Confusion	✔	-	✔	-	-	✔	✔	-
Delirium	✔	-	-	-	-	-	-	✔
Depression	-	-	-	1 to 5	-	≤1	-	-
Disorientation	-	-	-	-	-	-	✔	-
Dizziness	1 to 2	-	-	4 to17	2 to 3‡	≤1	2†, 5γ	-
Drowsiness	-	-	✔	6 to 14	-	-	-	-
Dysphonia	✔	-	-	✔	-	-	-	-
Fatigue	-	-	✔	1 to 5	2‡	1 to 2	2†, 4γ	2
Hallucinations	✔	-	-	1 to 5	✔ §	✔	✔	✔
Headache	7	-	✔	6 to 10	2‡	3 to 6	7†, 6γ	4 to 7
Heat prostration	-	✔	-	-	-	-	-	-
Hyperpyrexia	-	-	✔	-	-	-	-	-
Insomnia	-	1	-	1 to 6	-	-	-	-

Adverse Events	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin (Oral)	Oxybutynin (Transdermal)	Solifenacin	Tolterodine	Trospium
Memory impairment	-	-	-	1 to 5	-	-	✔	-
Nervousness	-	-	✔	1 to 7	-	-	-	-
Psychotic disorder	-	-	-	1 to 5	-	-	-	-
Seizure	-	-	-	1 to 5	-	-	-	-
Somnolence	✔	-	✔	2 to 14	-	-	3	✔
Vertigo	-	-	✔	-	-	-	5γ	-
Dermatological								
Application site reaction	-	-	-	-	5‡, 17§	-	-	-
Dermatitis	-	-	-	-	5‡	-	-	-
Dry skin	≥1	-	-	1 to 5	-	-	1γ	✔
Erythema	-	-	-	✔	5‡, 6 to 8§	✔	-	-
Flushing	-	-	-	1 to 5	-	-	-	-
Irritation	-	-	-	-	5‡	-	-	-
Papules	-	-	-	-	5‡	-	-	-
Pruritus	≥1	-	-	1 to 5	1 to 5‡, 14§	✔	-	-
Rash	≥1	≤1	✔	1 to 5	3§	✔	-	✔
Stevens-Johnson syndrome	-	-	-	-	-	-	✔	✔
Sweating decreased	-	-	-	1 to 5	✔ §	-	-	-
Urticaria	-	-	✔	-	-	✔	-	-
Vesicles	-	-	-	-	3§	-	-	-
Gastrointestinal								
Abdominal pain	2 to 4	1	-	1 to 5	-	1 to 2	4†, 5γ	1 to 3
Anorexia	-	-	-	✔	-	-	-	-
Aptyalism	-	-	-	1 to 5	-	-	-	-
Constipation	15 to 21	4 to 6	✔	7 to 15	1‡, 3§	5 to 13	6†, 7γ	9 to 10
Diarrhea	1 to 2	-	-	1 to 9	3§	-	✔	-
Diverticulitis	-	<1	-	-	-	-	-	-
Dysgeusia	-	-	-	1 to 5	-	-	-	-
Dyspepsia	3 to 8	2	-	5 to 7	-	1 to 4	3†, 4γ	1 to 2
Dysphagia	-	-	-	1 to 5	-	-	-	-
Eructation	-	-	-	1 to 5	-	-	-	-
Fecal impaction	-	-	-	-	-	✔	-	-
Feces hard	-	-	-	-	-	-	-	✔
Flatulence	-	-	-	1 to 5	-	-	-	1 to 2
Gastritis	-	-	-	-	-	-	-	✔
Gastroenteritis	-	<1	-	-	2‡	-	-	-

Adverse Events	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin (Oral)	Oxybutynin (Transdermal)	Solifenacin	Tolterodine	Trospium
Gastrointestinal obstruction	-	-	-	-	-	✔	-	-
Gastroesophageal reflux disease	✔	-	-	1 to 5	-	-	-	-
Gastrointestinal motility decreased	-	-	-	1 to 5	-	-	-	-
Hoarseness	-	-	-	1 to 5	-	-	-	-
Irritable bowel syndrome	-	<1	-	-	-	-	-	-
Loose stools	-	-	-	1 to 5	-	-	-	-
Nausea	2 to 4	1 to 2	✔	2 to 12	-	2 to 3	-	≤1
Taste abnormality	-	-	-	1 to 5	-	-	-	✔
Thirst	-	-	-	1 to 5	-	-	-	-
Tongue coated	-	-	-	1 to 5	-	-	-	-
Vomiting	≥1	-	✔	1 to 5	-	≤1	-	✔
Weight gain	≥1	-	-	-	-	-	1	-
Xerostomia	19 to 35	19 to 35	✔	29 to 71	7 to 8‡, 4 to 10§	11 to 28	23†, 35γ	10 to 22
Genitourinary								
Cystitis	-	-	-	1 to 5	-	-	-	-
Dysuria	-	1 to 2	✔	1 to 5	2§	-	1†, 2γ	-
Impotence	-	-	-	1 to 5	✔ §	-	-	-
Pollakiuria	-	-	-	1 to 5	-	-	-	-
Urinary retention	✔	1 to 2	-	6	-	≤1	-	≤1
Urinary tract infection	4 to 5	2 to 4	-	5 to 7	7‡	3 to 5	-	1 to 7
Vaginitis	≥1	-	-	-	-	-	-	-
Hepatic								
Alanine transaminase increased	✔	≤1	-	-	-	-	-	-
Gamma-glutamyl transferase increased	-	≤1	-	-	-	-	-	-
Musculoskeletal								
Arthralgia	≥1	-	-	1 to 5	-	-	2	-
Back pain	≥1	1 to 2	-	1 to 5	-	-	-	✔
Rhabdomyolysis	-	-	-	-	-	-	-	✔
Weakness	<3	-	-	3 to 7	-	-	-	-
Respiratory								
Asthma	-	-	-	1 to 5	-	-	-	-
Bronchitis	≥1	-	-	1 to 5	-	-	-	-
Cough	-	1 to 2	-	1 to 5	-	≤1	-	-
Dry throat	-	1 to 2	✔	1 to 5	-	-	-	-
Nasal congestion	-	-	-	1 to 5	-	-	-	-

Adverse Events	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin (Oral)	Oxybutynin (Transdermal)	Solifenacin	Tolterodine	Trospium
Nasal dryness	-	-	-	1 to 5	-	-	-	1
Nasopharyngitis	-	-	-	1 to 5	3‡	-	-	3
Pharyngitis	≥1	-	-	-	-	-	-	-
Rhinitis	≥1	-	-	2 to 6	-	-	-	-
Sinus congestion	-	-	-	1 to 5	-	-	-	-
Sinus headache	-	-	-	1 to 5	-	-	-	-
Sinusitis	≥1	-	-	1 to 5	-	-	2†	-
Upper respiratory tract infection	-	2 to 3	-	1 to 5	-	-	-	-
Special Senses								
Abnormal vision	≥1	-	-	-	-	-	1†, 2γ	-
Blurred vision	-	✔	✔	1 to 10	-	4 to 5	-	1
Cycloplegia	-	-	-	1 to 5	✔ §	-	-	-
Dry eyes	1.5 to 2.0	1 to 4	-	3 to 6	-	≤2	3	1 to 2
Eye irritation	-	-	-	1 to 5	-	-	-	-
Intraocular pressure increased	✔	-	✔	-	-	-	-	-
Keratoconjunctivitis sicca	-	-	-	1 to 5	-	-	-	-
Mydriasis	-	-	-	1 to 5	-	-	-	-
Vision changes	-	-	✔	-	3§	-	-	-
Other								
Anaphylactoid reactions	-	-	-	-	-	-	✔	-
Anaphylaxis	-	-	-	-	-	✔	-	✔
Angioedema	✔	-	-	✔	-	-	✔	-
Angioneurotic edema	-	-	-	✔	-	✔	-	✔
Edema	-	-	-	1 to 5	-	≤1	-	-
Extremity pain	-	-	-	1 to 5	-	-	-	-
Flank pain	-	-	-	1 to 5	-	-	-	-
Flu-like syndrome	1 to 3	-	-	-	-	-	3	-
Fungal infection	-	-	-	1 to 5	-	-	-	-
Hyperglycemia	-	-	-	1 to 5	-	-	-	-
Hyperkalemia	✔	-	-	-	-	-	-	-
Hypersensitivity	✔	-	-	-	-	✔	✔	-
Infection	-	-	-	-	-	-	1	-
Influenza	-	-	-	-	-	≤2	-	2
Lactation suppression	-	-	-	1 to 5	✔ §	-	-	-
Leukopenia	-	-	✔	-	-	-	-	-
Pain	≥1	-	-	1 to 7	-	-	-	-

Adverse Events	Darifenacin	Fesoterodine	Flavoxate	Oxybutynin (Oral)	Oxybutynin (Transdermal)	Solifenacin	Tolterodine	Trospium
Pharyngolaryngeal pain	-	-	-	1 to 5	-	-	-	-
Renal impairment	✔	-	-	-	-	-	-	-

✔ Percent not specified.
- Event not reported or incidence <1%.
†Extended-release formulation.
‡Transdermal gel formulation.
§Transdermal patch formulation.
γ Immediate-release formulation.

VII. Dosing and Administration

The usual dosing regimens for the genitourinary smooth muscle relaxants are listed in Table 7.

Table 7. Usual Dosing Regimens for the Genitourinary Smooth Muscle Relaxants: Antimuscarinics[7-18]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Darifenacin	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Tablet (ER): 7.5 to 15 mg once daily	Safety and efficacy in children have not been established.	Tablet (ER): 7.5 mg 15 mg
Fesoterodine	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Tablet (ER): 4 to 8 mg once daily	Safety and efficacy in children have not been established.	Tablet (ER): 4 mg 8 mg
Flavoxate	For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis: Tablet: 100 to 200 mg three or four times/day	For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis in patients ≥12 years of age: Tablet: 100 to 200 mg three or four times/day	Tablet: 100 mg
Oxybutynin	Relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria): Tablet/syrup (IR): 5 mg two to three times/day; maximum, 5 mg four times/day Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Tablet (ER): 5 to 10 mg once daily; maximum, 30 mg/day Transdermal gel in 10% packets: the contents of one sachet should be applied once daily Transdermal patch: one 3.9 mg/day system applied twice weekly (every three to four days)	Relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients ≥5 years of age: Tablet/syrup (IR): 5 mg twice daily; maximum, 5 mg three times daily Treatment of pediatric patients aged six years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida): Tablet (ER): 5 mg once daily; maximum, 20 mg/day	Syrup: 5 mg/5 mL Tablet (ER): 5 mg 10 mg 15 mg Tablet (IR): 5 mg Transdermal gel: 10% Transdermal patch: 3.9 mg/24 hours
Solifenacin	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Tablet: 5 to 10 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Tolterodine	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Capsule (ER): 4 mg once daily Tablet (IR): 2 mg twice daily	Safety and efficacy in children have not been established.	Capsule (ER): 2 mg 4 mg Tablet (IR): 1 mg 2 mg
Trospium	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Capsule (ER): 60 mg once daily Tablet (IR): 20 mg twice daily	Safety and efficacy in children have not been established.	Capsule (ER): 60 mg Tablet (IR): 20 mg

ER=extended-release, IR=immediate-release

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the genitourinary smooth muscle relaxants are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Genitourinary Smooth Muscle Relaxants: Antimuscarinics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Buser et al.[25] (2008) Available antimuscarinic drugs at the time of the analysis, excluding drugs with less direct antimuscarinic effects (e.g., flavoxate)	MA Trials evaluating safety and efficacy in patients being treated for OAB	Efficacy comparison: N=38,662 (76 trials) Safety comparison: N=39,919 (90 trials)	Primary: Perception of cure or improvement, urgency episodes per 24 hours, leakage episodes per 24 hours, urgency incontinence episodes per 24 hours, micturitions per 24 hours, and nocturia episodes per 24 hours and safety outcomes Secondary: Not reported	Primary: 40 mg/day trospium chloride, 100 mg/g per day oxybutynin topical gel and 4 mg/day fesoterodine had the best efficacy, while higher dosages of orally administered oxybutynin and propiverine had the least favorable relationship of efficacy and adverse events. Secondary: Not reported
Chapple et al.[26] (2005) Darifenacin ER 7.5 to 15 mg once daily vs placebo	DB, PG, MC, RCT (Pooled analysis) Men and women ≥18 years of age with symptoms of OAB for ≥6 months, 5 to 50 episodes of incontinence/week, and a high voiding frequency (a mean of ≥8 voids/24 hours) and urgency	N=1,059 (3 trials) 12 weeks	Primary: Median change in the number of incontinence episodes/week Secondary: Number of significant leaks/week, voiding frequency, bladder capacity, frequency and severity of	Primary: The median change in weekly incontinence episodes from baseline was -8.8 (-68.4%) for darifenacin 7.5 mg and -10.6 (-76.8%) for darifenacin 15 mg compared to placebo (-53.8 and -58.3%; P=0.004 and P<0.001 vs placebo, respectively). Secondary: There was a decrease in the number of significant leaks (P<0.001), voiding frequency (P<0.001), number/severity of urgency episodes (P<0.001), and an increase in bladder capacity (P<0.001) with both doses of darifenacin compared to placebo. There was no difference in the number of nocturnal awakenings/week caused by OAB between the darifenacin and placebo groups (P=0.13 and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	(a mean of ≥1 episode/24 hours)		urgency, number of nocturnal awakenings caused by OAB, responder rates, proportion of patients experiencing three or more dry days/week, or at least seven consecutive dry days, in the last two weeks of study treatment, adverse events	P=0.06 for darifenacin 7.5 and 15 mg, respectively). The proportion of patients who achieved a ≥70% reduction from baseline in the number of incontinent episodes/week was 48% for 7.5 mg and 57% for 15 mg darifenacin, compared to 33 and 39% of patients in the placebo group (P<0.001). The proportion of patients who achieved a ≥90% reduction from baseline was 27 and 28% of patients in each of these groups, respectively, compared to 17% of patients in the placebo group (P<0.005). The OR for improvement compared to placebo were consistent for both doses across all responder rates analyzed (OR, 1.8 to 1.9 for 7.5 mg and 1.8 to 2.2 for 15 mg darifenacin; P<0.005). Responder rates for the reduction in urgency episodes also showed significant differences from placebo (P<0.05) for both doses of darifenacin at all levels of response (≥30%, ≥50%, ≥70%, ≥90%). The proportion of patients who attained a normal voiding frequency (<8 voids/day) after 12 weeks of treatment was significantly greater with both doses of darifenacin (7.5 mg, 34%; P=0.029 vs placebo; and 15 mg, 35%; P=0.007 vs placebo) than in the corresponding placebo groups (27 and 28%, respectively). Twenty-four percent of patients treated with darifenacin 15 mg were 'dry' for at least seven days, compared to 16% in the corresponding placebo group (P=0.011). More patients (55 and 61%) had ≥3 dry days/week in the darifenacin 7.5 and 15 mg groups, respectively, than in those taking placebo (43 and 48%, respectively; both P<0.001). The overall incidence of any cause was 54% with darifenacin 7.5 mg and 65.6% with 15 mg darifenacin compared to 48.7% with placebo. The most common all-cause adverse events were dry mouth and constipation, most of which were mild to moderate. The incidence of nervous system adverse events reported by patients taking 7.5 or 15 mg of darifenacin was comparable to placebo. The most common nervous system adverse events were central nervous system-related: dizziness (darifenacin 7.5 mg, 0.9%; 15 mg, 2.1%; vs placebo 1.3%) and somnolence (0.3 and 0.9% vs 0.8%, respectively). The incidence of all-cause cardiovascular adverse events

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				with darifenacin 7.5 mg (6.2%) or 15 mg (3.6%) was also comparable with that of placebo (2.3%).
Foote et al.[27] (2005) Darifenacin ER 7.5 to 15 mg once daily vs placebo	DB, MC, RCT (Pooled analysis) Men and women ≥65 years of age with symptoms of OAB for ≥6 months, 5 to 50 episodes of incontinence/week, and a high voiding frequency (a mean of ≥8 voids/24 hours) and urgency (a mean of ≥1 episode/24 hours)	N=317 (3 trials) 12 weeks	Primary: Median change in the number of incontinence episodes/week Secondary: Number of micturitions/24 hours, bladder capacity, number of urgency episodes per 24 hours, and adverse events	Primary: At week 12, the median reduction in the number of incontinence episodes/week was significantly greater for darifenacin 7.5 mg (-11.2; -66.7%) and darifenacin 15 mg (-10.8; 75.9%) compared to placebo (-4.8; -34.8 and -6.8; 44.8%, respectively; P<0.001). Secondary: There was a significant decrease in the frequency of micturition/24 hours (P<0.001) and urgency episodes (P<0.001), and increased bladder capacity (P<0.001) with both doses of darifenacin compared to placebo. Adverse events were reported by 53.6, 69.1 and 50.9% of patients treated with 7.5 mg darifenacin, 15 mg darifenacin or placebo. The most common treatment-related adverse events, dry mouth, constipation and dyspepsia. The incidence of nervous system and cardiovascular adverse events during darifenacin therapy was similar to that with placebo, and did not increase with increasing dose of darifenacin.
Haab et al.[28] (2006) Darifenacin ER 7.5 to 15 mg once daily	ES, MC, OL Men and women ≥65 years of age who had completed one of two RCTs (feeder studies) who had previously had symptoms of OAB for ≥6 months, 5 to 50 episodes of incontinence/week, and a high voiding frequency (a mean of ≥8 voids/24 hours) and urgency (a mean of ≥1 episode/24 hours)	N=716 2 years	Primary: Safety, tolerability and efficacy Secondary: Not reported	Primary: All-causality adverse events were reported by 80% of patients at some time during the two-year extension and resulted in discontinuation in 8.9% of patients. The most commonly reported adverse events were dry mouth and constipation (23.3 and 20.9%, respectively). There were no relevant changes in any bowel-habit variables from feeder-study end to ES end in the overall group. There were few treatment-related cardiovascular and nervous system adverse events; 0.4, 0.3 and 0.3% of patients reported hypertension, arrhythmias and tachycardia, respectively, while 0.4% of patients each reported hypertonia, somnolence and paresthesia. Abnormal vision was reported in 0.6% of patients. No patient developed treatment-related glaucoma or reported worsening of a pre-existing glaucomatous condition.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				After 24 months of treatment with darifenacin, the median change from baseline of the feeder studies in incontinence episodes/week was -11.0 (84.4%), voids/24 hours was -1.4 (-13.9%), urgency episodes/24 hours was -3.9 (-56.4%), severity of urgency was -15.4 (-28.8%), nocturnal awakenings for OAB/week was -1.5 (-14.3%), and significant leaks/week was -4.7 (-100%). All variables were P<0.001 vs feeder study baseline. Overall, 62.3% of patients achieved a ≥70% reduction in incontinence episodes and 43.8% achieved a ≥90% reduction at two years. Secondary: Not reported
Hill et al.[29] (2007) Darifenacin ER 7.5 to 15 mg once daily	ES, MC, OL Men and women ≥18 years of age who had completed one of two RCTs (feeder studies) who had previously had symptoms of OAB for ≥6 months, 5 to 50 episodes of incontinence/week, and a high voiding frequency (a mean of ≥8 voids/24 hours) and urgency (a mean of ≥1 episode/24 hours)	N=214 2 years	Primary: Safety, tolerability and efficacy Secondary: Not reported	Primary: Dry mouth and constipation were the most common treatment-related (adverse events) adverse events in this older patient population (23.4 and 22.4%, respectively) and were associated with low discontinuation rates (2.3 and 4.2%, respectively). Treatment-related cardiovascular and peripheral/central nervous system adverse events were infrequently reported (1.4 and 3.3%, respectively). After 24 months of treatment with darifenacin, the median change from baseline of the feeder studies in incontinence episodes/week was -11.0 (83.7%), voids/24 hours was -1.2 (-12.4%), urgency episodes/24 hours was -3.7 (-52.0%), severity of urgency was -12.6 (-23.3%), nocturnal awakenings for OAB/week was -1.4 (-10.9%), and significant leaks/week was -4.9 (-100%). All variables were P<0.001 vs feeder study baseline. There were high proportions of responders by all definitions (≥50, ≥70 or ≥90% reductions in incontinence episodes/week), with 74.1%, 60.0% and 44.4%, patients age ≥65 years of age achieving these response levels at 24 months, respectively. Thirty-four percent of older patients experienced normalization of micturition (<8 micturitions/day) after three months of darifenacin treatment and this effect was maintained in approximately the same number of patients at the end of the two-year study (33.8%). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
But et al.[30] (2012) Darifenacin 7.5 mg once daily vs solifenacin 5 mg once daily	MC, OL, RCT Female patients with idiopathic OAB, defined as urgency intensity and urgency urinary incontinence of ≥3 on the UPS and frequency of ≥1 urgency episodes per day who have not received any anticholinergic drugs for at least 6 months	N=100 3 months	Primary: OAB symptoms Secondary: Changes in dose throughout the study, QOL scores, objective assessment of treatment improvement and safety evaluations.	Primary: Analyses of OAB symptoms at baseline were generally similar between the two treatment groups, although urgency (bothersome) scores were higher in the darifenacin group, and frequency scores were higher in the solifenacin group. Following one and three months of treatment, all measured OAB symptoms decreased, with no statistically significant treatment differences being seen between the groups. Nocturia decreased to a greater extent in the solifenacin group at one month and this group also used less incontinence pads than those in the darifenacin group at three months. Secondary: The majority of patients in the solifenacin group who completed the study maintained the same dose post-study (21/25 patients). However, in the darifenacin group only 11 patients who completed then maintained the same dose (11/24 patients). Patients treated with solifenacin indicated a greater improvement in QOL compared to patients treated with darifenacin. Overall patient subjective and objective assessment of treatment improvement was higher for solifenacin compared to darifenacin, with the difference again being statistically significant in favor of solifenacin (P=0.01). Adverse events of dry mouth, constipation, blurred vision, headache, dizziness, concentration problems, memory problems, and insomnia were solicited at the one month and three month assessments, as well as at baseline. Solifenacin showed statistically a decreased incidence of dry mouth after three months of treatment compared to the darifenacin group.
Zinner et al.[31] (2005) Darifenacin ER 15 to 30 mg once daily	DB, PC, RCT, XO Patients 18 to 85 years of age with urge incontinence with ≥4 significant	N=76 2 weeks	Primary: Incontinence episodes/week, urgency episodes/day, severity of urgency	Primary: The mean number of incontinence episodes/week decreased from 20.4 to 10.93 with solifenacin 15 mg (P<0.05 vs placebo), 8.82 with solifenacin 30 mg (P<0.05 vs placebo), 9.45 with oxybutynin (P<0.05 vs placebo), and 14.64 with placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs oxybutynin IR 5 mg three times daily vs placebo	incontinent episodes/week (defined as leakage that would normally require a change of clothing or absorbent pad) and urinary frequency ≥8 voids/24 hours		episodes, and micturitions/day Secondary: Not reported	The mean number of urgency episodes/day decreased from 9.3 to 7.95 with solifenacin 15 mg (P<0.05 vs placebo), 7.59 with solifenacin 30 mg (P<0.05 vs placebo), 8.12 with oxybutynin (P<0.05 vs placebo), and 8.71 with placebo. The mean severity of urgency episodes decreased from 2.00 to 1.93 with solifenacin 15 mg (P<0.05 vs placebo), 1.84 with solifenacin 30 mg (P<0.05 vs placebo), 1.89 with oxybutynin (P<0.05 vs placebo), and 2.03 with placebo. The number of micturitions/day decreased from 10.4 to 9.93 with solifenacin 15 mg (P=NS vs placebo), 8.85 with solifenacin 30 mg (P<0.05 vs placebo), 9.24 with oxybutynin (P=NS vs placebo), and 9.62 with placebo. Dry mouth occurred in a similar percentage of patients receiving darifenacin 30 mg and oxybutynin, which was significantly higher than treatment with placebo or darifenacin 15 mg (P<0.05). There was no significant difference between darifenacin 15 mg and placebo. Constipation occurred more frequently with darifenacin and oxybutynin than placebo. There was no significant difference between darifenacin 15 mg and oxybutynin. Blurred vision and dizziness occurred in 3.3 and 1.6% of patients receiving oxybutynin, respectively. Secondary: Not reported
Chapple et al.[32] (2005) <u>Cohort 1</u> Darifenacin IR 2.5 mg three times daily for 7 days vs oxybutynin 2.5 mg	DB, RCT, XO Patients 18 to 75 years of age with detrusor overactivity within the previous 6 months (either idiopathic or neurogenic with ≥2 associated	N=65 7 days	Primary: Urodynamic parameters, salivary flow, tolerability and safety Secondary: Not reported	Primary: All urodynamic pressure parameters significantly decreased from baseline after seven days' therapy with each treatment. No significant differences between treatments were observed for any dose of darifenacin vs oxybutynin. There were no differences between treatments in responder rates for any of the ambulatory urodynamic parameters. Reduction in salivary flow was significantly less with darifenacin ER (15 and 30 mg) than with oxybutynin (5 mg three times daily). Salivary flow

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
three times daily for 7 days Cohort 2 Darifenacin ER 15 mg once daily for 7 days vs oxybutynin 5 mg three times daily for 7 days Cohort 3 Darifenacin ER 30 mg once daily for 7 days vs oxybutynin 5 mg three times daily for 7 days	symptoms (average of ≥7 micturitions per day, ≥7 episodes of urgency/week, ≥1 urge incontinence episode/week necessitating change of clothing or pads)			was comparable for darifenacin IR (2.5 mg three times daily) and oxybutynin (2.5 mg three times daily). The mean maximum decrease in salivary flow from baseline to day seven was significantly greater with oxybutynin 5 mg three times daily than with darifenacin ER 15 mg (P<0.01). There were no differences in mean heart rate for darifenacin and oxybutynin on day seven. There were no significant differences with darifenacin and oxybutynin for visual nearpoint. The most common adverse events were dry mouth and constipation, which were generally mild or moderate in severity. Dry mouth was reported more frequently in oxybutynin-treated patients than in darifenacin-treated patients. Secondary: Not reported
Wyndaele et al.[33] (2009) Fesoterodine ER 4 to 8 mg once daily	MC, OL Men and women ≥18 years of age with self-reported OAB symptoms for ≥3 months, mean micturition frequency of ≥8 micturitions/24 hours, mean number of urgency episodes ≥3/24 hours, and	N=516 12 weeks	Primary: Number of micturitions, number of UUI episodes, number of micturition-related urgency episodes/24 hours, and the percentage of patients reporting treatment satisfaction at week 12 (‘very	Primary: The change from baseline to week 12 in the number of micturitions was -3.0 (-22%; P<0.0001), -1.7 for the number of UUI episodes (-100%; P<0.0001), and -5.0 for urgency episodes (-57%; P<0.0001). At 12 weeks, 80% of patients who responded to the TSQ reported being satisfied with fesoterodine treatment, with 38.4% of patients being ‘very satisfied’ and 41.4% of patients being ‘somewhat satisfied’. Secondary: The change from baseline to week 12 in the number of nocturnal micturitions was -0.8 (-31%; P<0.0001), -3.5 for severe urgency episodes (-94%; P<0.0001), and -15.2 for frequency-urgency sum/24 hours

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	treated with tolterodine or tolterodine ER for OAB within 2 years who reported being 'somewhat dissatisfied' or 'very dissatisfied' with tolterodine treatment on the TSQ		satisfied' or 'somewhat satisfied' on the TSQ) Secondary: Change from baseline to week 12 in nocturnal micturitions, severe micturition-related urgency episodes, frequency-urgency sum/24 hours, change from baseline in PPBC, UPS and OAB-q scores at week 12	(P<0.0001). Mean PPBC scores improved from 4.9 at baseline to 3.1 at week 12 (P<0.0001). Mean UPS scores improved from 1.8 at baseline to 2.4 at week 12 (P<0.0001). The mean change in OAB-q Symptom Bother score (29-point improvement) from baseline to week 12 was statistically significant (P<0.0001). Mean changes in total HRQOL (26-point improvement) and all four HRQOL domain (Concern, 29-point improvement; Coping, 31-point improvement; Sleep, 25-point improvement; Social Interaction, 17-point improvement) scores were also significant at 12 weeks, compared to baseline (P<0.0001). The improvements for all scales and domains were above the minimally important difference of 10 points, indicating that these changes were clinically meaningful. Dry mouth (23%) and constipation (5%) were the most frequently reported adverse events.
Nitti et al.[34] (2007) Fesoterodine ER 4 to 8 mg once daily vs placebo	DB, MC, PC, RCT Men and women ≥18 years of age with OAB syndrome for ≥6 months, urinary frequency (≥8 micturitions/24 hours) and urinary urgency (≥6 episodes during the 3-day diary period) or UUI	N=836 12 weeks	Primary: Number of micturitions/24 hours, number of UUI episodes/24 hours and treatment response Secondary: Mean volume voided/micturition, daytime micturitions, nocturnal micturitions,	Primary: The mean change from baseline in the number of micturitions/24 hours was significantly improved with fesoterodine 4 mg (-1.61, -14.9%; P<0.001) and fesoterodine 8 mg (-2.09, -16%; P<0.001) compared to placebo (-1.08, -6.9%). The mean change from baseline in the number of UUI episodes/24 hours was significantly improved with fesoterodine 4 mg (-1.65, -67.4%; P<0.001) and fesoterodine 8 mg (-2.28, -81.8%; P<0.001) compared to placebo (-0.96, -40%). Subject-reported treatment response rates with fesoterodine 4 mg (64%) and fesoterodine 8 mg (74%) were significantly higher than those with placebo (45%) at study end point (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			urgency episodes/24 hours and continent days/week	Secondary: Fesoterodine 4 mg showed significant improvements in the mean change from baseline compared to placebo for the number of nocturnal micturitions (P<0.05), urgency episodes (P<0.001) and continent days/week (P<0.001). Fesoterodine 8 mg was significantly better than placebo for MVV/micturition, number of urgency episodes, number of daytime micturitions and continent days/week (each P<0.001). Treatment-emergent adverse events occurred in 55, 61 and 69% of patients receiving placebo, and 4 and 8 mg fesoterodine, respectively. Dry mouth was the most commonly reported adverse event. It was usually mild to moderate in severity and it occurred in 7, 16 and 36% of patients receiving placebo, and 4 and 8 mg fesoterodine, respectively.
Chapple et al.[35] (2014) EIGHT Fesoterodine 4 mg once daily vs fesoterodine 8 mg once daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with OAB symptoms including UUI	N=1955 12 weeks	Primary: Change from baseline to week 12 in UUI episodes per 24 hours Secondary: Changes in micturitions and urgency episodes per 24 hours, patient reported outcomes	Primary: Fesoterodine 8 mg treatment resulted in significantly greater improvements in the change from baseline in UUI episodes/24 hours at week 12 compared with placebo (P<0.001) and compared with fesoterodine 4 mg (P=0.011). Secondary: Patients receiving fesoterodine 8 mg also had significantly greater improvements in micturition frequency and urgency episodes/24 h than patients receiving placebo (both P<0.001) or fesoterodine 4 mg (both P<0.001). Improvements in scores on the PPBC, UPS, and all OAB-q scales and domains at week 12 were significantly greater with fesoterodine 8 mg compared with placebo (all P<0.001) and fesoterodine 4 mg (all P<0.01).
Chapple et al.[36] (2007) Fesoterodine ER 4 to 8 mg once daily	AC, DB, PC, RCT Men and women ≥18 years of age with a medical history of OAB symptoms with	N=1,135 12 weeks	Primary: Micturitions/24 hours and treatment response Secondary: Mean volume	Primary: The mean number of micturitions/24 hours was significantly reduced from baseline in patients receiving tolterodine (-1.73, -13.8%; P=0.001 vs placebo), fesoterodine 4 mg (-1.76, -16.7%; P<0.001 vs placebo), and fesoterodine 8 mg (-1.88, -18.6%; P<0.001 vs placebo). Treatment with tolterodine resulted in significantly greater proportion of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tolterodine ER 4 mg once daily vs placebo	urinary urgency for ≥6 months, ≥8 micturitions/24 hours, and either ≥6 urgency episodes or ≥3 UUI/24 hours, and self-reported perception of moderate problems using a Likert scale		voided/micturition, daytime micturitions/24 hours, nocturnal micturitions/24 hours, urgency episodes/24 hours, continent days/week, adverse events	patients who responded to treatment compared to placebo (P<0.001). The proportion of patients reporting a positive treatment response was significantly greater among patients receiving tolterodine (72%; P<0.001) fesoterodine 4 mg (75%; P<0.001) and fesoterodine 8 mg (79%; P<0.001) compared to placebo (53%). The mean reduction from baseline in UUI episodes/24 hours was significantly greater for patients receiving tolterodine (-1.74, -70%; P=0.008 vs placebo), fesoterodine 4 mg (-1.95, -80%; P=0.001 vs placebo), and fesoterodine 8 mg (-2.22, -87.5%; P<0.001 vs placebo). Secondary: Active treatment significantly increased MVV from baseline (P≤0.002) compared to placebo. The increases in MVV were 2.5, 3.0, and 3.6 times greater than placebo in the patients receiving tolterodine, fesoterodine 4 mg, or fesoterodine 8 mg, respectively. The mean number of daytime micturitions/24 hours was significantly reduced from baseline in patients receiving tolterodine (-1.35, -13.6%; P=0.003), fesoterodine 4 mg (-1.37, -14.3%; P=0.001), and fesoterodine 8 mg (-1.48, -16.9%; P<0.001) compared to placebo (-0.60, -9.5%). The mean number of nocturnal micturitions/24 hours did not differ significantly from placebo in patients receiving tolterodine (-0.40, -25%; P=0.815), fesoterodine 4 mg (-0.39, -28.6%; P=0.982), and fesoterodine 8 mg (-0.39, -23.1%; P<0.896). The mean number of urgency episodes/24 hours was significantly reduced from baseline in patients receiving tolterodine (-2.03, -16%; P=0.004), fesoterodine 4 mg (-1.88, -17.6%; P=0.002), and fesoterodine 8 mg (-2.36, -19.1%; P<0.001) compared to placebo (-1.07, -11.1%). Significant improvements in change from baseline compared to placebo in number of continent days/week were observed in patients receiving fesoterodine 4 or 8 mg. The most frequent adverse event was dry mouth, which was mild to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				moderate in most patients; however, 3% of patients receiving fesoterodine 8 mg reported severe dry mouth.
Chapple et al.[37] (2008) Fesoterodine ER 4 to 8 mg once daily vs tolterodine ER 4 mg once daily vs placebo Only the results of fesoterodine ER 8 mg vs tolterodine ER 4 mg are reported.	AC, DB, PC, RCT (Post-hoc analysis) Men and women ≥18 years of age with a medical history of OAB symptoms with urinary urgency for ≥6 months, ≥8 micturitions/24 hours, and either ≥6 urgency episodes or ≥3 UUI/24 hours, and self-reported perception of moderate problems using a Likert scale	N=1,135 12 weeks	Primary: Number of micturitions/24 hours and treatment response Secondary: Mean volume voided/micturition, urgency episodes/24 hours, continent days/week, HRQOL (KHQ and ICIQ-SF), adverse events	Primary: There was no significant difference in the number of micturitions/24 hours or rate of treatment response reported with tolterodine 4 or fesoterodine 8 mg. Fesoterodine 8 mg led to a significant improvement in UUI episodes/24 hours compared to tolterodine 4 mg in 'incontinent patients' (P<0.001). Secondary: Fesoterodine 8 mg led to a significant improvement in MVV/void in 'all patients' and 'incontinent patients' compared to tolterodine (P<0.05). Fesoterodine 8 mg led to a significant improvement in continent days/week (P<0.05) and severe urgency episodes/24 hours (P<0.05) in 'incontinent patients' compared to tolterodine 4 mg. There was no significant difference in the median percent change in number of urgency episodes/24 hours reported in 'all patients' and 'incontinent patients' with fesoterodine 8 mg or tolterodine 4 mg. Scores from the KHQ and ICIQ-SF showed a significant improvement in HRQOL for the groups treated with fesoterodine 8 mg and tolterodine 4 vs placebo. The fesoterodine 8 mg dose produced significant improvements on eight of the nine domains assessed compared to placebo. Tolterodine-treated patients reported significant improvements in six of nine KHQ domains compared to placebo. Both fesoterodine 8 mg and tolterodine 4 mg treatment resulted in a ≥5-point improvement from baseline (which constitutes a meaningful change for the patient) for all domains except General Health. A major improvement in the severity of bladder-related problems from baseline to the end of treatment was reported by 39% of fesoterodine 8 mg and 34% of tolterodine 4 patients (P=0.01 for both groups vs placebo), compared to 25% on placebo. Adverse events reported in ≥2% of patients in the active-treatment groups and occurring more frequently than placebo included dry mouth,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				constipation, dry eye, dry throat, and elevated levels of alanine aminotransferase. More patients treated with fesoterodine 8 mg had dry mouth than those receiving tolterodine 4 mg or placebo. Most cases of dry mouth were mild or moderate; 3% of patients on fesoterodine 8 mg reported severe dry mouth. More patients on fesoterodine 8 mg reported constipation than those receiving tolterodine 4 or placebo; most cases were mild to moderate. Overall, 3.2% of patients discontinued the study prematurely because of an adverse event: placebo, 2%; tolterodine 4 mg, 3%; fesoterodine 8 mg, 5%.
Ginsberg et al.[38] (2013) Fesoterodine ER 4 mg once daily for 1 week, then 8 mg once daily vs tolterodine ER 4 mg once daily vs placebo	DB, DD, RCT Men and women ≥18 years of age with a medical history of OAB symptoms with self-reported symptoms ≥3 months in 3-day baseline diaries and had ≥8 micturitions and ≥1 UUI episode per 24 hours	N=4,129 Two 12-week studies	Primary: Change from baseline to week 12 in UUI episodes Secondary: Changes from baseline in three-day bladder diary variables, scores from the PPBC, UPS, and OAB-q, diary-dry rate, proportion of subjects with >0 UUI episodes according to baseline diary and no UUI episodes according to post-baseline diary and safety evaluations	Primary: At week 12, women showed significantly greater improvement with fesoterodine than with ER tolterodine (-1.9 vs -1.7; P≤0.007) and placebo (-1.9 vs -1.6; P≤0.001) in UUI episodes. In men, there were no significant differences in improvement in UUI episodes between any treatment groups at week 12 (-1.4 for all groups; P>0.05 for both comparisons). Secondary: At week 12, women showed significantly greater improvement with fesoterodine 8 mg than with ER tolterodine 4 mg and placebo in micturition frequency, urgency episodes, and all other diary endpoints (except nocturnal micturitions vs ER tolterodine), and also in scores on the PPBC, UPS, and all OAB-q scales and domains (all P<0.005). Improvements in men were significantly greater with fesoterodine than with ER tolterodine for severe urgency and the OAB-q Symptom Bother domain and were also significantly greater with fesoterodine than with placebo for micturition frequency, urgency episodes, severe urgency episodes, PPBC responses and scores on all OAB-q scales and domains at week 12 (all P<0.04). The most frequently reported treatment-emergent adverse events in both genders were dry mouth (women: fesoterodine, 29%; ER tolterodine, 15%; placebo, 6%; men: fesoterodine, 21%; ER tolterodine, 13%; placebo, 5%) and constipation (women: fesoterodine, 5%; ER tolterodine, 4%; placebo, 2%; men: fesoterodine, 5%; ER tolterodine, 3%; placebo, 1%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Van Kerrebroeck et al.[39] (2010) Fesoterodine ER 4 to 8 mg once daily	ES, OL Men and women ≥18 years of age with a medical history of OAB symptoms with urinary urgency for ≥6 months, ≥8 micturitions/24 hours, and either ≥6 urgency episodes or ≥3 UUI/24 hours, and self-reported perception of moderate problems using a Likert scale	N=417 24 to 32 months	Primary: Safety and tolerability Secondary: Bladder diary variables and PROs	Primary: A total of 161 patients (39%) discontinued treatment before or at the 24-month study visit. Primary reasons for discontinuation were adverse events (n=47), withdrawal of consent (n=46), and insufficient clinical response (n=36). A total of 264 patients (63%) received fesoterodine for ≥24 months during the DB and the OL extension phases. Patients received the higher fesoterodine 8 mg dose for an average of 80% of their respective treatment days during OL extension. A total of 315 patients (76%) experienced at least one treatment emergent adverse event, of which 219 cases were related to fesoterodine. The most common treatment emergent adverse events were dry mouth (34%), constipation (7%), and UTI (15%). Overall, ≥88% of patients rated treatment tolerance with fesoterodine "good" or "excellent" at months four, 12, and 24. Secondary: Compared to OL baseline, there were significant mean improvements in all diary variables throughout the 24-month extension (all P<0.001). Diary variables included UUI episodes per 24 hours, micturitions per 24 hours, urgency episodes per 24 hours, and MVV per micturition. There were significant improvements in all KHQ domains (P≤0.002), except for general health perception at months 12 and 24. Changes in mean scores typically exceeded the minimally important difference of 5. There were significant mean improvements in ICIQ-SF scores at months four, 12, and 24 (P<0.0001 for all). In the overall population, patient-reported treatment satisfaction was 97% at month 24.
Scarpero et al.[40] (2011)	ES, OL (Pooled analysis)	N=890 (2 trials)	Primary: Safety and tolerability	Primary: Overall, 55% of men (n=102) and 50% of women (n=349) discontinued treatment within the first 24 months of the OL extension. The most

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fesoterodine ER 4 to 8 mg once daily	Men and women ≥18 years of age with OAB syndrome for ≥6 months, urinary frequency (≥8 micturitions/24 hours) and urinary urgency (≥6 episodes during the 3-day diary period) or UUI	24 to 36 months	Secondary: Bladder diary entries (number of UUI episodes, micturitions, and urgency episodes	common reasons for discontinuation in men and women were insufficient clinical response (16 and 13%), adverse events (16 and 12%), and withdrawal of consent (14 and 13%). Both men and women were treated with the higher 8 mg dose for the majority of days on OL fesoterodine (89 and 83%). A total of 539 women (77%) and 140 men (76%) experienced ≥1 treatment emergent adverse event. A total of 351 women (50%) and 86 men (47%) experienced ≥1 treatment emergent adverse event that were determined to be related to fesoterodine. The most commonly reported treatment emergent adverse events in men were dry mouth (24%) and constipation (6%), compared to dry mouth (32%) and UTI (18%) in women. The majority of men and women (≥92 and ≥91%, respectively) reported "good" or "excellent" treatment tolerance at months four, 12, and 24. Secondary: Among women, improvements in all diary variables (mean UUI episodes per 24 hours, micturitions per 24 hours, urgency episodes per 24 hours, and MVV per micturition) were significant at each time point during OL treatment compared to both DB baseline (P<0.0001) and OL baseline (P<0.0001). Among men, improvements in all diary variables were significant at each time point during OL treatment compared to DB baseline (P<0.05). Improvements in micturitions and urgency episodes per 24 hours were significant at months one, four, eight, and 12 compared to OL baseline (P<0.05). At month 24, there were no statistically significant differences from OL baseline for any diary variable.
Kelleher et al.[41] (2008) Fesoterodine ER 4 to 8 mg once daily	DB, MC, PC, RCT (Pooled analysis) Men and women ≥18 years of age with OAB	N=1,971 (2 trials) 12 weeks	Primary: Treatment-related effects on HRQOL using the KHQ (disease-specific questionnaire to	Primary: The fesoterodine 8 mg group had statistically significant improvements over placebo in eight of nine KHQ domains. Fesoterodine 4 mg and tolterodine showed statistically significant improvements over placebo in seven of nine domains of the KHQ. Fesoterodine 8 mg led to better results than 4 mg in two domains (Emotions and Severity/Coping; P<0.05). There

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tolterodine ER 4 mg once daily vs placebo	syndrome for ≥6 months		assess LUTS), ICIQ-SF (questionnaire to evaluate patients with UI including urinary frequency, urine leakage and perceived impact of these symptoms on patients' daily lives) and a six-point Likert Scale used by patients to rate the severity of problems related to their bladder condition, and treatment response Secondary: Not reported	were no significant differences between fesoterodine 8 mg and tolterodine 4 mg. In all treatment groups, all but one KHQ domain (General Health) showed improvements meaningful to the patient (i.e., changes of ≥5 points from baseline). All active-treatment groups reported a significant improvement in the ICIQ-SF score vs placebo (P<0.001). There were no significant differences between active treatment groups. Baseline scores for the six-point Likert scale were 3.6, which indicates moderate to severe problems. At the end of the study, the scores were 2.3 to 2.8, which indicate minor problems. The percentage of patients reporting scores of 1 to 3 was <1% at baseline and increased after 12 weeks. There was also a similar change in scores with placebo. A major improvement in bladder condition (i.e., ≥2-point change) was reported by 33% of patients on fesoterodine 4 mg, 38% on fesoterodine 8 mg, and 34% on tolterodine compared to 21% on placebo (P<0.001). The percentage of patients reporting a positive treatment response was significantly higher in those receiving fesoterodine than those receiving placebo. There were significant differences between the doses in favor of fesoterodine 8 mg at two weeks and 12 weeks. Secondary: Not reported
Herschorn et al.[42] (2010) Fesoterodine ER 4 to 8 mg once daily vs tolterodine ER 4 mg once daily	DB, MC, PC, RCT Men and women ≥18 years of age with symptoms of OAB for ≥3 months	N=1,697 12 weeks	Primary: Changes from baseline to week 12 in UUI episodes Secondary: Total and nocturnal voids, urgency episodes, severe urgency episodes, frequency-urgency sum per 24 hours,	Primary: The mean reduction in the number of UUI episodes/24 hours was significantly greater in the fesoterodine group than in the tolterodine group (P=0.017) and placebo group (P<0.001). The median percentage reduction in UUI episodes was 100% for fesoterodine. Tolterodine ER also produced a significantly greater improvement in UUI episodes than placebo (P=0.011). The diary-dry rate at week 12 was significantly greater for patients receiving fesoterodine than for those receiving tolterodine ER (64 vs 57.2%; P=0.015) or placebo (45%; P<0.001). The difference between tolterodine ER and placebo in diary-dry rate was also significant

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			and MVV per void, UPS, OAB-q, and PPBC	(P<0.001). Secondary: Fesoterodine produced a significantly greater increase in MVV per void than tolterodine ER (P=0.005) or placebo (P<0.001). Compared to placebo, fesoterodine also significantly reduced voids, urgency episodes, severe urgency episodes, and frequency-urgency sum per 24 hour (all P<0.001 vs placebo). Fesoterodine did not significantly improve nocturnal voids (P=0.327). Compared to tolterodine ER, total voiding, urgency episodes, severe urgency episodes, and frequency-urgency sum per 24 hours were not statistically different. Compared to placebo, tolterodine ER significantly improved total voids, urgency episodes, severe urgency episodes, and frequency-sum per 24 hours (all P<0.001). The categorical change in PPBC score was significantly more favorable in the fesoterodine group than in patients on placebo (P<0.001) and tolterodine ER (P<0.001). The change between tolterodine ER and placebo was also significant (P<0.001). The categorical change in UPS was significantly more favorable for fesoterodine than placebo (P<0.001) and tolterodine (P=0.014). The difference between tolterodine ER and placebo was NS. Improvements in the OAB-q scores were significantly greater in the fesoterodine than the placebo group on the Symptom Brother scale, total HRQOL scale, and all four HRQOL domains (all P<0.001). In a post-hoc analysis, improvements with fesoterodine were also significantly greater than tolterodine ER on the Symptom Bother (P<0.001) and total HRQOL (P=0.006) scales and the Concern (P=0.008), Coping (P=0.002), and Social Interaction (P=0.019) domains. Six patients (2%) receiving placebo, 28 (4%) receiving tolterodine ER, and 42 (6%) receiving fesoterodine discontinued treatment due to treatment-emergent adverse effects. The most frequent treatment emergent adverse event in the fesoterodine and tolterodine groups were dry mouth (28 vs 16%), headache (6 vs 3%), and constipation (5 vs 4%). Sixteen (2%) of patients in the fesoterodine group had a non-fatal serious adverse events during treatment, two of which were considered related to fesoterodine. One patient with BPH developed urinary retention requiring catheterization.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Kaplan et al.[43] (2011) Fesoterodine ER 4 to 8 mg once daily vs tolterodine ER 4 mg once daily vs placebo	DB, PC, PG, RCT Men and women ≥18 years of age who have self-reported OAB symptoms for ≥3 months and had a mean of at least one UUI episode and ≥8 micturitions per 24 hours in 3-day bladder diary	N=2,417 12 weeks	Primary: Change in UUI episodes from baseline to week 12 Secondary: Change from baseline in micturitions, nocturnal micturitions, urgency episodes, severe urgency episodes, frequency-urgency sum per 24 hours, three-day diary-dry rate, and MVV per micturition	Primary: The median percentage reduction in UUI episodes at week 12 was 100% in all groups; however, the treatment differences between the fesoterodine group and the tolterodine ER group (P=0.0093) and placebo (P=0.0001) were significant. Additionally, the difference between groups was shown as early as week four. Secondary: At week 12, fesoterodine 8 mg had significantly greater mean improvements than patients receiving tolterodine ER for micturitions (P=0.0016), urgency episodes (P<0.0001), severe urgency episodes (P<0.0001), and frequency-urgency sum (P<0.0001). Compared to tolterodine, fesoterodine did not improve nocturnal micturition or MVV. Fesoterodine also significantly improved all diary endpoints compared to placebo at week 12 (all P<0.02). Tolterodine ER significantly improved UUI episodes (P=0.0228), MVV (P=0.0021), and micturitions (P=0.0407) compared to placebo at week 12. The three-day diary-dry rate at week 12 was significantly better in the fesoterodine group vs tolterodine ER and placebo (P=0.0169 and P=0.0003). PPBC, UPS, and OAB-q scores were better at week 12 with fesoterodine compared to both tolterodine ER and placebo. These changes were also better for tolterodine ER compared to placebo. The most frequent treatment emergent adverse events in all groups were dry mouth, constipation, and headache.
Herschorn et al.[44] (2017) SYNERGY Solifenacin 5 mg plus mirabegron 25 mg (combined S5 + M25 group)	DB, MC, RCT Patients aged ≥18 years with wet OAB (urgency, urinary frequency and urinary incontinence) for ≥3	N=3,398 18 weeks (4-week placebo run-in, 12-week DB treatment	Primary: Change from baseline to end of treatment in the mean number of urinary incontinence episodes/24 h and	Primary: Although the combined S5 + M50 group significantly reduced urinary incontinence episodes compared to solifenacin 5 mg, with a mean (SE) adjusted difference of −0.20 (0.12) urinary incontinence episodes/24 hours (95% CI, −0.44 to 0.04, P=0.033), statistical “superiority” versus mirabegron 50 mg was not demonstrated (mean adjusted difference, −0.23 UI episodes/24 hours; 95% CI, −0.47 to 0.01; P=0.052). Therefore, the primary objective for the combined S5 + M50 therapy was not met.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs solifenacin 5 mg plus mirabegron 50 mg (combined S5 + M50 group) vs solifenacin 5 mg vs mirabegron 25 mg vs mirabegron 50 mg vs placebo	months who recorded on average ≥8 micturitions/24 h, ≥1 urgency episode/24 h, and ≥3 urinary incontinence episodes over the 7-day micturition diary	period, 2-week placebo run-out period)	micturitions/24 h, assessed using a 7-day electronic micturition diary Secondary: Change from baseline in the mean volume voided/micturition, change from baseline in mean number of urinary incontinence episodes/24 h, micturitions/24 h, urgency episodes/24 h, UUI episodes/24 h and nocturia episodes/24 h; the percentage of patients (responders) achieving zero urinary incontinence episodes/24 h in the last 7 days prior to each visit, micturition frequency normalization (<8 episodes/24 h), and the number of UUI episodes and nocturia episodes	Because the null hypothesis for this test was not rejected, the subsequent hypotheses for mean number of micturitions/24 h and the MVV/micturition could not be tested. Also, no hypothesis testing could be performed for the combined S5 + M25 group. Urinary incontinence episodes decreased vs baseline for all treatment arms. The mean adjusted change from baseline to end of treatment was greater in the combined therapy groups vs monotherapies and placebo. Secondary: For micturitions/24 hours, adjusted change from baseline was greater in the combined therapy groups vs monotherapies (combined S5 + M50 group, nominal P values 0.006 and <0.001 versus solifenacin 5 mg and mirabegron 50 mg, respectively; combined S5 + M25 group, nominal P values 0.040 and 0.001 versus solifenacin 5 mg and mirabegron 25 mg, respectively). All active treatment groups had greater improvements in the mean numbers of micturitions/24 hours versus placebo, with effect sizes for the combined therapy groups (combined S5 + M25 group: -0.85 micturitions/24 h; combined S5 + M50 group: -0.95 micturitions/24 h) higher than with mirabegron monotherapy (25 mg: -0.36; 50 mg: -0.39 micturitions/24 h) and solifenacin 5 mg (-0.56 micturitions/24 h). The combined S5 + M50 group was statistically significantly improved compared to both monotherapies at end of treatment for UUI episodes, urgency episodes, and nocturia, with effect sizes that appeared to be additive. The combined S5 + M25 group demonstrated statistically significant improvement compared to mirabegron 25 mg for the same variables, except for nocturia. In responder analyses at the end of treatment, odds ratios in favor of both combined therapies vs monotherapies were shown for the proportion of patients with zero urinary incontinence episodes and those achieving micturition frequency normalization. There was a slightly increased frequency of treatment-emergent adverse events in the combined therapy groups vs monotherapies and placebo. Most of the treatment-emergent adverse events were mild or moderate in severity. There were slightly higher frequencies of dry mouth, constipation, and dyspepsia in the combined therapy groups versus monotherapies.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			in the 7-day diary; safety	
Drake et al.[45] (2016) BESIDE Solifenacin 5 mg and mirabegron 50 mg (combination) vs solifenacin 5 mg vs solifenacin 10 mg	DB, MC, RCT Adult OAB patients remaining incontinent despite daily solifenacin 5mg during 4-wk single-blind run-in	N=2,174 12 weeks	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes/24 hours Secondary: Change from baseline to end of treatment in the mean number of micturitions/24 hours, number of incontinence episodes; safety	Primary: The adjusted change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours was greater with combination (−1.80) versus solifenacin 5 mg (−1.53; P=0.001) and versus solifenacin 10 mg (−1.67; P=0.008). Secondary: At end of treatment, reductions in mean daily micturitions and in three-day incontinence episodes were significantly greater with combination versus solifenacin 5 mg (P<0.001). Combination was noninferior to solifenacin 10 mg for both key secondary end points and superior to solifenacin 10 mg for the reduction in micturition frequency. Significant differences in favor of the combination were evident as early as week four versus solifenacin 5 mg and week eight versus solifenacin 10 mg. The incidence of treatment-emergent adverse events was lowest with solifenacin 5 mg (33.1%), highest with solifenacin 10 mg (39.4%), and 35.9% with combination; dry mouth and constipation were the most common treatment-emergent adverse events. Incidence of dry mouth was lower with combination (5.9%) versus solifenacin 10 mg (9.5%) and similar to solifenacin 5 mg (5.6%).
Gratzke et al.[46] (2019) SYNERGY II Solifenacin succinate 5 mg plus mirabegron 50 mg combination therapy vs solifenacin 5 mg	DB, MC, PG, RCT Patients completed either BESIDE or SYNERGY study or male or female and ≥18 years of age with symptoms of wet OAB (urinary frequency and urgency with incontinence) for ≥3 months	N=1,829 12 months	Primary: Safety, measured as treatment emergent adverse events Secondary: Change from baseline to the end of treatment in the mean number of incontinence episodes per 24 hours and	Primary: Overall, 856 patients (47%) experienced ≥1 treatment emergent adverse events. Treatment emergent adverse events frequency was slightly higher in the combination group (combination, 49%; mirabegron, 41%; solifenacin, 44%). Across all groups, the majority of the treatment emergent adverse events were mild or moderate in severity (mild, 24%; moderate, 19%; severe, 4.0%). There were no clinically relevant differences across groups in the frequency of treatment emergent adverse events leading to permanent treatment discontinuation (difference vs combination −0.2% for mirabegron and 0.4% for solifenacin). Serious treatment emergent adverse events were reported by 67 patients (3.7%); one was considered possibly treatment-related (mirabegron group, atrial fibrillation). Dry mouth was the most common treatment emergent

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
monotherapy vs mirabegron 50 mg monotherapy			micturitions per 24 hours	adverse events (combination, 6.1%; solifenacin, 5.9%; mirabegron, 3.9%). Secondary: Combination therapy was statistically superior to both monotherapies in terms of change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours (adjusted mean difference: mirabegron, -0.5; 95% CI, -0.7 to -0.2; P<0.001; solifenacin, -0.1; 95% CI, -0.4 to 0.1; P=0.002) and the mean number of micturitions per 24 hours (adjusted mean difference: mirabegron, -0.5; 95% CI, -0.8 to -0.2; P<0.001; solifenacin, -0.4; 95% CI, -0.7 to -0.1; P=0.004).
Inoue M et al.[47] (2019) Solifenacin 5 mg once daily for four weeks followed by mirabegron 50 mg once daily for four weeks (group S) vs mirabegron 50 mg once daily for 4 weeks followed by solifenacin 5 mg once daily for 4 weeks (group M)	PRO, RCT, XO Female patients ≥20 years, an OABSS of 3 or higher and urgency once or more per week	N=47 8 weeks	Primary: Efficacy outcomes including change in OABSS, IPSS and VAS Secondary: Not reported	Primary: The IPSS was significantly improved after the patients received solifenacin (P value not reported). After they received mirabegron, the IPSS was also improved, but not significantly. The OABSS was significantly improved in both groups after treatment. There were no significant differences between the two groups. In group M, the OABSS after eight weeks was significantly improved compared to that after four weeks. On the other hand, in group S, it was not significantly improved. In group M, the VAS values for urgency and incontinence were significantly improved after treatment. In addition, the VAS values for urgency and incontinence after eight weeks were significantly improved compared to those after four weeks. In group S, on the other hand, they were not significantly improved.
Chapple et al.[48] (2013) Mirabegron 100 mg once daily vs mirabegron 50 mg	DB, MC, RCT Patients ≥18 years of age with OAB symptoms for ≥3 months and with an average baseline micturition frequency of ≥8	N=2,444 12 months	Primary: Incidence and severity of treatment-emergent adverse events, vital signs and laboratory tests Secondary:	Primary: The incidence of treatment-emergent adverse events was similar among patients treated with mirabegron 50 mg (59.7%), 100 mg (61.3%) or tolterodine ER (62.6%). Most events were categorized as mild or moderate in severity. The most frequent treatment-related adverse events included hypertension, dry mouth, constipation, and headache, occurring at a similar incidence across all treatment groups, except for dry mouth, which was highest in the tolterodine group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
once daily vs tolterodine ER 4 mg once daily	micturitions/24 hours and ≥3 urgency episodes with or without incontinence during the 3-day micturition diary period		Change from baseline in micturition frequency and urgency frequency at one, three, six, nine and 12 months; OAB-q, PPBC and VAS scores, proportion of treatment responders (≥50% decrease from baseline in the incontinence episodes/24 hours or those with zero incontinence episodes at final visit)	Discontinuations resulting from adverse events were similar between treatment groups, with 6.4, 5.9 and 6.0% of patients treated with mirabegron 50 mg, 100 mg and tolterodine ER 4 mg, discontinuing treatment, respectively. Urinary retention occurred in one patient each in the mirabegron 50 mg and 100 mg group compared to three patients treated with tolterodine ER. Urinary retention requiring catheterization was reported in one patient receiving mirabegron 100 mg and tolterodine ER. There was a higher incidence of cardiac arrhythmias with tolterodine ER 4 mg (6.0%) compared to mirabegron 50 mg (3.9%) and 100 mg (4.1%). Mean changes from baseline in systolic blood pressure with mirabegron 50 mg, 100 mg and tolterodine were 0.2, 0.4 and -0.5 mm Hg for morning measurements and -0.3, 0.1 and 0.0 mm Hg for evening measurements, respectively. The mean changes in diastolic blood pressure were -0.3, 0.4, and 0.1 mm Hg, respectively for morning measurements and 0.0, 0.1 and 0.6 mm Hg, respectively for evening measurements. There was a higher incidence of neoplasm (benign, malignant and unspecified including cysts and polyps) in the mirabegron 100 mg group (1.3%) compared to the 50 mg group (0.1%) and tolterodine ER 4 mg (0.5%). Secondary: There were similar improvements between treatments with regard to the mean number of micturitions/24 hours (-1.27 for mirabegron 50 mg, -1.41 for mirabegron 100 mg and -1.39 for tolterodine ER 4 mg; P values not reported). Improvements in the mean number of incontinence episodes/24 hours (-1.01 for mirabegron 50 mg, -1.24 for mirabegron 100 mg and -1.26 for tolterodine ER 4 mg) and MVV (17.5 mL for mirabegron 50 mg, 21.5 mL for mirabegron 100 mg and 18.1 mL for tolterodine ER 4 mg) were similar among treatment groups (P values not reported). At the final visit, the proportion of treatment responders (≥50% reduction from baseline in the mean number of incontinence episodes/24 hours was 63.7, 66.3 and 66.8% for patients treated with mirabegron 50 mg, 100 mg

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and tolterodine ER, respectively; P values not reported). The proportion of patients who reported zero incontinence episodes at the final visit was 43.4, 45.8 and 45.1%, respectively; P values not reported). Both doses of mirabegron showed numerical improvements on the other secondary efficacy variables including OAB-q symptom bother and QOL, treatment satisfaction, number of nocturia episodes and PPBC.
Khullar et al.[49] (2013) SCORPIO Mirabegron 100 mg once daily vs mirabegron 50 mg once daily vs tolterodine SR 4 mg once daily vs placebo	AC, DB, MC, PC, PG, RCT Patients ≥18 years of age, with OAB symptoms for ≥3 months and an average baseline micturition frequency of ≥8 micturitions/24 hours and ≥3 urgency episodes with or without incontinence during the 3-day micturition diary period	N=1,978 12 weeks	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours, change from baseline to end of treatment in the mean number of micturitions per 24 hours Secondary: Change from baseline to end of treatment in the mean VVPM, change from baseline to week four in the mean number of incontinence episodes per 24 hours, change from baseline to week 4 in the mean number of micturitions per 24	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours was -1.46 in the mirabegron 100 mg group, -1.57 in the mirabegron 50 mg group, -1.27 in the tolterodine SR group and -1.17 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) but not in the tolterodine SR group (P value not reported). Change from baseline to end of treatment in the mean number of micturitions per 24 hours was -1.77 in the mirabegron 100 mg group, -1.93 in the mirabegron 50 mg group, -1.59 in the tolterodine SR group and -1.34 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) but not in the tolterodine SR group (P value not reported). Secondary: Change from baseline to end of treatment in the mean VVPM was 25.6 mL in the mirabegron 100 mg group, 24.2 mL in the mirabegron 50 mg group, 25.0 mL in the tolterodine SR group and 12.3 mL in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to week four in the mean number of incontinence episodes per 24 hours was -1.03 in the mirabegron 100 mg group, -1.04 in the mirabegron 50 mg group, -1.00 in the tolterodine SR group and -0.65 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			hours, change from baseline to final visit in mean level of urgency, change from baseline to final visit in mean number of urgency incontinence episodes per 24 hours, change from baseline to final visit in grade 3 or 4 urgency episodes per 24 hours, change from baseline to final visit in mean number of nocturia episodes, safety	group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to week four in the mean number of micturitions per 24 hours was -1.29 in the mirabegron 100 mg group, -1.16 in the mirabegron 50 mg group, -1.10 in the tolterodine SR group and -0.77 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to final visit in mean level of urgency was -0.30 in the mirabegron 100 mg group, -0.31 in the mirabegron 50 mg group, -0.29 in the tolterodine SR group and -0.22 in the placebo group (P values not reported). Change from baseline to final visit in mean number of urgency incontinence episodes per 24 hours was -1.33 in the mirabegron 100 mg group, -1.46 in the mirabegron 50 mg group, -1.18 in the tolterodine SR group and -1.11 in the placebo group (P values not reported). Change from baseline to final visit in grade 3 or 4 urgency episodes per 24 hours was -1.96 in the mirabegron 100 mg group, -2.25 in the mirabegron 50 mg group, -2.07 in the tolterodine SR group and -1.65 in the placebo group (P values not reported). Change from baseline to final visit in mean number of nocturia episodes was -0.56 in the mirabegron 100 mg group, -0.41 in the mirabegron 50 mg group, -0.50 in the tolterodine SR group and -0.45 in the placebo group (P values not reported). Mirabegron and tolterodine SR were well tolerated and the incidence of adverse events was similar across all groups. Adverse events reported in ≥2% of the placebo, mirabegron 50 mg group, mirabegron 100 mg and tolterodine SR group respectively included hypertension (7.7 vs 5.9 vs 5.4 vs 8.1%), nasopharyngitis (1.6 vs 2.8 vs 2.8 vs 2.8%), dry mouth (2.6 vs 2.8 vs 2.8 vs 10.1%), headache (2.8 vs 3.7 vs 1.8 vs 3.6%), influenza (1.6 vs 2.2 vs 2.0 vs 1.4%), UTI (1.4 vs 1.4 vs 1.8 vs 2.0%), constipation (1.4 vs 1.6 vs 1.6 vs 2.0%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Yamaguchi et al.[50] (2014) mirabegron 50 mg once daily vs placebo once daily vs tolterodine 4 mg once daily (as an active comparator)	AC, DB, PC, RCT Patients ≥20 years of age experiencing OAB symptoms for ≥24 weeks	N=1139 12 weeks	Primary: Change in the mean number of micturitions/24 h from baseline Secondary: Micturition variables related to urgency and/or incontinence and quality-of-life domain scores on KHQ, adverse events	Primary: Mirabegron 50 mg was associated with a significantly greater change from baseline in the mean number of micturitions/24 h compared with placebo (P<0.001). Secondary: The mean [SD] change from baseline to final assessment for the secondary efficacy variables showed significant improvements for mirabegron vs placebo for number of urgency episodes/24 h (–1.85 [2.555] vs –1.37 [3.191]; P=0.025); number of incontinence episodes/24 h (–1.12 [1.475] vs –0.66 [1.861]; P=0.003); number of urgency incontinence episodes/24 h (–1.01 [1.338] vs –0.60 [1.745]; P=0.008); and volume voided/micturition (24.300 [35.4767] vs 9.715 [29.0864] mL; P<0.001); but not for number of nocturia episodes (–0.44 [0.933] vs –0.36 [1.062]; P=0.277). The percentage of subjects with zero incontinence episodes at the final assessment in the placebo, mirabegron, and tolterodine groups was 39.4, 50.8, and 48.8%, respectively. Treatment with mirabegron for 12 weeks was associated with significant improvements compared with placebo in seven of the nine quality-of-life domain scores in the KHQ. The overall incidence of treatment-related AEs was similar in the mirabegron (24.5%) and placebo (24.0%) groups, but higher in the tolterodine group (34.9%).
Staskin et al.[51] (2009) Oxybutynin 10% topical gel 1 g applied once daily vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age with OAB, urge or mixed urinary incontinence with predominance of UUI episodes as well as ≥8 daily urinary voids and ≥4 daily UUI episodes	N=789 12 weeks	Primary: Change in mean number of daily incontinence episodes Secondary: Mean change in urinary frequency, urinary volume per void, number of nocturia episodes, proportion of patients achieving complete urinary continence and	Primary: Patients receiving oxybutynin topical gel reported a significantly greater decrease in the mean number of daily incontinence episodes compared to patients receiving placebo (-3.0 vs -2.5; P<0.0001). Secondary: Oxybutynin topical gel was associated with a significant improvement in the mean number of episodes of urinary frequency (-2.7 vs -2.0; P=0.0017) and voided urinary volume compared to placebo (21.0 vs 3.8 mL; P=0.0018). The difference between groups in the number of nocturia episodes did not reach statistical significance (-0.75 daily for oxybutynin topical gel compared to -0.65 daily for placebo; P=0.1372). Complete urinary continence was demonstrated in 27.8% patients receiving oxybutynin topical gel patients compared to 17.3% of patients randomized to placebo (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			safety	Compared to placebo, oxybutynin topical gel was associated with a higher incidence of dry mouth (6.9 vs 2.8%; P=0.0060) and application site dermatitis (1.8 vs 0.3%; P=0.0358).
Goldfischer et al.[52] (2013) Oxybutynin 3% topical gel 84 g applied once daily vs Oxybutynin 3% topical gel 56 g applied once daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with symptoms of urgency and/or mixed UI and a predominance of urgency incontinence for ≥3 months and who had a history of at least 1 to 2 urinary urgency episodes and ≥8 voids per day; were treatment-naive or had a previous beneficial response to anticholinergic treatment; and, if on anticholinergic medication or any pharmacologic treatment for OAB at screening, were willing to undergo a 2-week washout period.	N=626 12 weeks	Primary: Change from baseline to week 12 in mean number of weekly UI episodes Secondary: Change from baseline to week 12 in daily urinary frequency, average urinary void volume per void, daily UI episodes and change from baseline to week one in these analyses and safety endpoints	Primary: At 12 weeks, the 84 and 56 mg/day arms achieved significantly greater improvement vs placebo in weekly UI episodes (mean change from baseline: -20.4 and -16.4 vs -18.1; P<0.05 and P=0.04, respectively). Secondary: At 12 weeks, the 84 mg/day arm achieved significantly greater improvement vs placebo in daily urinary frequency (-2.6 vs -1.9; P=0.001) and urinary void volume (32.7 vs 9.8; P<0.0001). For oxybutynin gel 56 mg/day, the changes from baseline in these secondary endpoints were not significantly different from placebo. The 84-mg/day arm also reduced the number of daily UI episodes from baseline by a mean of 2.9 episodes, and significant changes from baseline in weekly and daily UI episodes, daily urinary frequency, and urinary void volume were achieved within one week after the start of treatment. The most common treatment-emergent adverse events (>2% of patients) that occurred significantly more often in patients receiving oxybutynin gel than in those receiving placebo, were dry mouth and application site erythema.
Anderson et al.[53] (1999) Oxybutynin ER	AC, DB, MC, RCT Community dwelling men and	N=97 Not specified	Primary: Urge incontinence episodes/week	Primary: The mean number of weekly urge incontinence episodes decreased from 27.4 to 4.8 in the ER group and from 23.4 to 3.1 in the IR group (P=0.6). The percentage reduction in weekly urge incontinence episodes was 84%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
5 to 30 mg daily vs oxybutynin IR 5 mg 1 to 4 times/day	women with urge incontinence or mixed incontinence with a primary urge component who had at least 6 urge incontinence episodes a week when not taking medication (who had previously responded to oxybutynin)		Secondary: Proportion of participants achieving elimination of urge incontinence episodes, number of incontinence episodes, proportion of those achieving continence, adverse events	in the ER group and 88% in the IR group (P=0.71). Secondary: Of the participants, 52% in the ER group and 51% in the IR group had no urge incontinence episodes at the end of treatment (P=0.7). Total incontinence (urge, stress and other) episodes decreased from 29.3 to 6.0 in the ER group and from 26.3 to 3.8 in the IR group from baseline to the end of the study (P=0.6). The percentage reduction in any incontinence episodes was 82% in the ER group and 88% in the IR group (P=0.5). The proportions of patients who were totally continent was 41% in the ER group and 40% in the IR group (P=0.9). Normal void frequency increased 54% in the ER group and 17% in the IR group (P<0.001). At least one anticholinergic event occurred in 87% of patients in the ER group and 94% of patients in the IR group. The most common anticholinergic event in both groups was dry mouth (68% of the ER group and 87% of the IR group; P=0.04). Fewer participants reported moderate or severe dry mouth with ER oxybutynin (25 vs 46%; P=0.03). There was no significant difference among the treatment groups for other anticholinergic adverse events. There were few reports of moderate to severe dry mouth at the 5 mg dose, and there was a trend in both groups toward increasing frequency of dry mouth as doses increased.
Barkin et al.[54] (2004) Oxybutynin ER 15 mg daily vs oxybutynin IR 5 mg three times daily	DB, MC, PG, RCT Men and women >18 years of age with UUI who demonstrated >7 UI episodes/week and >8 voids/day	N=123 9 weeks	Primary: Void frequency, UI episodes, treatment-related changes in QOL as assessed by the IIQ and UDI, and adverse events Secondary: Not reported	Primary: The mean number of incontinence episodes/week decreased from 24.3 to 10.4 in the ER group (P<0.001 vs baseline) and from 23.0 to 6.1 in the IR group (P<0.001 vs baseline). There was no significant difference among the treatment groups (P=0.404). The mean voluntary micturition episodes/day decreased from 11.4 to 9.6 in the ER group (P<0.001 vs baseline) and from 11.0 to 8.6 in the IR group (P<0.001 vs baseline). There was no significant difference among the treatment groups (P=0.286).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference among the treatment groups in mean urine voided/micturition (P=0.533), incidence of urgency (P=0.116), or severity of urgency (P=0.255). There was a significant reduction from baseline in the mean number of pads/day in the ER group (2.3. to 1.7; P<0.001); however, there was no change from baseline in the IR group (2.4 to 1.9; P=NS). Patients in both treatment groups demonstrated significant improvements from baseline in mean IIQ scores (ER; P<0.001, IR; P<0.001) and mean UDI scores (ER; P<0.001, IR; P<0.001). There were no significant differences among the treatment groups. The most frequently reported adverse events in the ER and IR oxybutynin groups were dry mouth (68 and 72%, respectively) and dry throat (31 and 37%, respectively). There was no significant difference in the incidence of moderate and severe dry mouth among the treatment groups (ER, 26% and IR, 42%). More patients in the ER group rated their medication tolerable compared to the IR group (P=0.020). More patients discontinued treatment in the IR oxybutynin group than in the ER oxybutynin group (P=0.047), primarily due to adverse events. Secondary: Not reported
Birns et al.[55] (2000) Oxybutynin ER 10 mg once daily vs oxybutynin IR 5 mg twice daily	DB, MC, PC, RCT Patients 18 to 76 years of age with detrusor instability or detrusor hyperreflexia whose symptoms were stabilized on conventional oral oxybutynin tablets (5 mg twice daily)	N=130 6 weeks	Primary: Proportion of patients with daytime continence at completion of the study Secondary: Percentage of patients with nighttime continence, median	Primary: At the completion of the study, 53% of patients receiving oxybutynin ER were continent during the day compared to 58% of patients receiving oxybutynin IR (P=0.62). Secondary: There was no significant difference between the treatment groups in the percentage of patients with nighttime continence at the completion of the study or the median change in the number of voluntary daytime voids, voluntary nighttime voids, daytime episodes of incontinence and nighttime episodes of incontinence from the week preceding treatment to the completion of the study.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	for 2 weeks		change in the number of voluntary daytime voids, voluntary nighttime voids, daytime episodes of incontinence and nighttime episodes of incontinence from the week preceding treatment to the completion of the study, adverse events	Dry mouth and vision abnormalities were more common in patients receiving oxybutynin ER than in those receiving oxybutynin IR; however, this was NS (P=NS).
Versi et al.[56] (2000) Oxybutynin ER 5 to 20 mg/day vs oxybutynin IR 5 to 20 mg/day	DB, MC, PG, RCT Patients with 7 to 45 urge incontinence episodes/week and ≥4 days of incontinence/week who had previously responded to treatment with antimuscarinic drugs	N=226 Duration not specified	Primary: Number of incontinence episodes and total incontinence episodes Secondary: Not reported	Primary: Urge incontinence episodes decreased from 18.6 to 2.9/week with oxybutynin ER (83% reduction; P<0.001) and from 19.8 to 4.4/week with oxybutynin IR from baseline (76% reduction; P<0.001). There was no significant difference between the treatment groups (P=0.36). Total incontinence episodes decreased from 20.2 to 3.5/week with oxybutynin ER (81% reduction; P<0.001) and from 22.4 to 5.4/week with oxybutynin IR from baseline (75% reduction; P<0.001). There was no significant difference between the treatment groups (P=0.41). There was no significant difference in anticholinergic adverse events among the treatment groups. Dry mouth occurred in 47.7% and 59.1% of patients receiving oxybutynin ER and IR, respectively. Secondary: Not reported
Nilsson et al.[57] (1997) Oxybutynin ER 10 mg daily for 60	XO Female patients 37 to 65 years of age with symptoms of	N=17 120 days	Primary: Frequency of voluntary voiding, the maximal volume of	Primary: The frequency of voids/24 hour was reduced by 23% with oxybutynin ER and by 24% with oxybutynin IR (P=0.51). Treatment with oxybutynin ER resulted in a 28% reduction in the total

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
days vs oxybutynin IR 5 mg twice daily for 60 days	urge incontinence and detrusor instability		urine/single void, and the total volume of voluntarily voided urine/24 hour Secondary: Not reported	weight of pads compared to a 21% reduction with oxybutynin IR (P=0.80). The total volume of voluntary voided urine/day increased by 15% with both treatments (P=0.75), and the maximal volume of urine/void increased by 26% and 34% with oxybutynin ER and oxybutynin IR, respectively (P=0.95). There were no significant differences in adverse events among the treatment groups, including dry mouth (P=0.41), headache (P=1.00), dyspepsia (P=0.26), or vision abnormality (P=0.32). Secondary: Not reported
Appell et al.[58] (2001) Oxybutynin ER 10 mg daily vs tolterodine IR 2 mg twice daily	DB, PG, MC, RCT Participants with OAB who had between 7 and 50 episodes of urge incontinence/week and 10 or more voids/24 hours	N=378 12 weeks	Primary: Number of urge incontinence episodes/week, number of total incontinence episodes/week and micturition frequency episodes/week Secondary: Not reported	Primary: The number of urge incontinence episodes/week decreased from 25.6 to 6.1 in the oxybutynin group and from 24.1 to 7.8 in the tolterodine group (P=0.03). The number of total incontinence episodes/week decreased from 28.6 to 7.1 in the oxybutynin group and from 27.0 to 9.3 in the tolterodine group (P=0.02). Micturition frequency episodes/week decreased from 91.8 to 67.1 in the oxybutynin group and from 91.6 to 71.5 in the tolterodine group (P=0.02). Both drugs improved symptoms of OAB significantly from baseline to the end of the study as assessed by the three main outcome measures (P<0.001). Overall, 92.6 and 95.3% of the patients in the oxybutynin and tolterodine groups, respectively, had fewer incontinence episodes at the end of the study period compared to baseline. The incidence of dry mouth was similar among the treatment groups (28.1% for oxybutynin and 33.2% for tolterodine; P=0.32). Moderate to severe dry mouth was also similar among the treatment groups (10.2% for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				oxybutynin and 10.9% for tolterodine; P=0.87). Other adverse events were similar among the treatment groups. Overall, the discontinuation rates for adverse events were 7.6% in the oxybutynin group and 7.8% in the tolterodine group (P=0.99). Secondary: Not reported
Sand et al.[59] (2004) Oxybutynin ER 10 mg once daily vs tolterodine IR 2 mg twice daily	DB, RCT Women with urge or mixed incontinence (≥7 and ≤50 urge incontinence episodes/week and ≥10 voids/24 hours)	N=315 12 weeks	Primary: Number of urge incontinence episodes, total incontinence, micturition frequency, tolerability Secondary: Not reported	Primary: The number of urge incontinence episodes decreased from 28.1 to 6.2/week in the oxybutynin ER group compared to a reduction from 28.9 to 8.5/week in the tolterodine IR group (P=0.038). Total incontinence episodes decreased from 25.2 to 7.3/week in the oxybutynin ER group compared to a reduction from 25.1 to 10.1/week in the tolterodine IR group (P=0.030). Micturition frequency decreased from 91.7 to 68.0/week in the oxybutynin ER group compared to a reduction from 91.6 to 71.2/week in the tolterodine IR group (P=0.272). There was no significant difference in dry mouth, central nervous system events or other adverse events among the treatment groups. Secondary: Not reported
Diokno et al.[60] (2003) Oxybutynin ER 10 mg daily vs tolterodine ER 4 mg daily	AC, DB, MC, RCT Women ≥18 years of age with OAB who documented 21-60 UUI episodes/week and ≥10 voids/day	N=790 12 weeks	Primary: Mean weekly UUI episodes, weekly total incontinence episodes and weekly micturition frequency, adverse events Secondary: Not reported	Primary: The mean weekly episodes of UUI decreased from 37.1 to 10.8 in the oxybutynin group and from 36.7 to 11.2 in the tolterodine group (P=0.28). The mean number of total incontinence episodes decreased from 43.4 to 12.3 in the oxybutynin group and from 42.4 to 13.8 in the tolterodine group (P=0.08). Patients receiving oxybutynin had a greater decrease in the mean weekly micturition frequency compared to tolterodine participants (P=0.003). The proportion of participants who reported total dryness (no incontinence

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				episodes) in their last seven-day 24-hour voiding diary was 23.0% in the oxybutynin group compared to 16.8% in the tolterodine group (P=0.03). The proportion of participants who reported no UUI episodes at the last assessment was 26.7% in the oxybutynin group compared to 20.9% in the tolterodine group (P=0.06). Dry mouth was more common in the oxybutynin group than in the tolterodine group (29.7 vs 22.3%, respectively; P=0.02). Most reports of dry mouth events were mild. Other anticholinergic adverse events (constipation, impaired urination-retention, and blurred vision) and central nervous system adverse effects (dizziness, somnolence, depression, and confusion) occurred at similar frequencies in each group. Adverse events led to discontinuation of study medication by 20 patients receiving oxybutynin and 19 receiving tolterodine. Secondary: Not reported
Reinberg et al.[61] (2003) Oxybutynin ER 5 mg/day vs tolterodine ER 2 mg/day vs tolterodine IR 2 mg/day	OL Pediatric patients with a history of non-neurogenic diurnal urinary incontinence and symptoms of OAB	N=132 Duration not specified	Primary: Urinary frequency, incontinence and safety Secondary: Not reported	Primary: Oxybutynin ER led to a greater reduction in urinary frequency compared to tolterodine IR (P<0.01). Both oxybutynin ER and tolterodine ER were significantly better than tolterodine IR in improving symptoms of diurnal incontinence and urinary frequency (P<0.01 and P<0.05, respectively). Oxybutynin ER was significantly more effective than tolterodine ER in completely resolving diurnal incontinence (P<0.05). There were no significant differences in the peripheral or central nervous system anticholinergic side effects among the treatment groups. Secondary: Not reported
Nelken et al.[62] (2011)	PRO, RCT Women who had	N=59 12 weeks	Primary: Change from baseline in number	Primary: After 12 weeks, both groups had a significant decrease in the number of daily voids (14.7 to 11.7 for oxybutynin [P=0.003] and 14.9 to 10.4 for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Oxybutynin IR 5 mg twice daily vs estradiol vaginal ring 7.5 µg/day	≥10 voids in a 24 hour period, as recorded in a 72 hour voiding diary, and were postmenopausal		of daily voiding episodes Secondary: Change in vaginal pH levels, vaginal maturation index, and QOL scores, as assessed by the UDI-6 and the IIQ-7	estradiol ring [P<0.001]). The difference between groups was not statistically significant. Secondary: There was a significant decrease in UDI-6 (12.1 to 9.4 for oxybutynin [P=0.003] and 11.4 to 7.8 for estradiol [P<0.001]) and IIQ-7 (14.7 to 11.3 for oxybutynin [P=0.02] and 13.2 to 8.1 for estradiol [P<0.001]) scores in both treatment groups. Mean vaginal pH levels in the oxybutynin group remained unchanged after 12 weeks of treatment, but those who received the estradiol ring had a significant decrease in mean pH (6 to 4.9; P=0.002). Mean maturation index did not significantly change in the oxybutynin group, whereas mean maturation index increased significantly after 12 weeks of therapy with an estradiol ring (24.3 to 70.1; P<0.001). Dry mouth, constipation, and blurry vision occurred significantly more in patients who received oxybutynin, whereas more women in the estradiol group reported vaginal discharge.
Davila et al.[63] (2001) Oxybutynin transdermal 2 to 4 patches applied twice weekly vs oxybutynin IR 5 to 7.5 mg orally two or three times daily	DB, MC, PC, RCT Patients ≥18 years of age with a history of urge or mixed urinary incontinence with a predominance of urge symptoms who had symptomatic improvement during a minimum of 6 weeks of oral oxybutynin	N=76 6 weeks	Primary: Average number of daily incontinence episodes, patient-completed VAS for efficacy, dry mouth on an anticholinergic symptoms questionnaire, cystometric comparisons Secondary: Not reported	Primary: The average daily incontinence episodes were reduced by approximately five episodes in both groups (P<0.0001), with no significant difference between transdermal and oral therapy. The change in the mean VAS score for each group was 5.8 vs 6.0 cm for the transdermal and oral groups, respectively (P<0.0001). The difference in mean VAS score between transdermal and oral therapy was 0.1 cm (P=0.9). Dry mouth occurred in 38% of patients in the transdermal group compared to 94% of patients in the oral group (P<0.001). Blurred vision, dizziness, drowsiness, palpitations, nausea and impotence were comparable between the groups. Average bladder volume at first detrusor contraction increased by 66 mL in the transdermal (P<0.0055) and 45 mL in the oral groups (P=0.1428).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference among the transdermal and oral groups (P=0.57). Average maximum cystometric capacity increased 53 and 51 mL in the transdermal (P<0.0011) and the oral (P<0.0538) groups, respectively. Post-void residual volume increased by an average of 13 and 16 mL in the oral and transdermal groups, respectively (P=NS). The most frequent treatment related adverse events were dry mouth, constipation, somnolence, dizziness, blurred vision and impaired urination, which occurred more frequently in the oral group. Secondary: Not reported
Dmochowski et al.[64] (2003) Oxybutynin transdermal delivery system (OXY-TDS) 3.9 mg/day applied twice weekly vs tolterodine ER (TOL-LA) 4 mg daily vs placebo	DB, RCT Patients ≥18 years of age who were receiving pharmacologic treatment for OAB and who had a beneficial response to the pre-study treatment	N=361 12 weeks	Primary: Change from baseline in the number of incontinence episodes/day, average daily urinary frequency, average urinary volume/void, and changes in the QOL instruments Secondary: Not reported	Primary: There was a significant reduction in the number of urinary incontinence episodes/day in patients treated with OXY-TDS compared to placebo (median change -3 vs -2, respectively; P=0.0137). There was a significant reduction in the number of urinary incontinence episodes/day in patients treated with TOL-LA compared to placebo (median change -3 vs -2, respectively; P=0.0011). There was no significant difference between OXY-TDS and TOL-LA in the reduction of incontinent episodes (P=0.2167). The reduction in incontinence episodes corresponded to a 75% improvement in the OXY-TDS group, 75% in the TOL-LA group, and 50% in the placebo group. Complete continence was achieved by 39% of patients in the OXY-TDS group, 38% of patients in the TOL-LA group, and 22% of patients in the placebo group (both, P=0.014 vs placebo). The mean decrease in average daily urinary frequency was -1.9 micturitions/day with OXY-TDS (P=0.1010 vs placebo) -2.2 micturitions/day with TOL-LA (P=0.0025 vs placebo), and -1.4 micturitions/day with placebo. There was no significant difference

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				between OXY-TDS and TOL-LA (P=0.2761). The median increases in average urinary volume/void was 24 mL with OXY-TDS (P=0.0010 vs placebo), 29 mL with TOL-LA (P=0.0017 vs placebo) and 5.5 mL in the placebo group. There was no significant difference between OXY-TDS and TOL-LA (P=0.7690). The patients' Global Assessment of Disease State scores were significantly improved with OXY-TDS (P=0.0106) and TOL-LA (P=0.0001) compared to placebo. There was no significant difference between OXY-TDS and TOL-LA (P=0.1861). The total IIQ scores improved significantly with OXY-TDS (P=0.0018) and TOL-LA (P=0.0045) compared to placebo. Significant improvements in irritative symptoms of the UDI questionnaire were also observed with OXY-TDS (P=0.0156) and TOL-LA (P=0.0010) compared to placebo. The most common treatment-related adverse events in the OXY-TDS group were application site reactions, including erythema (8.3%) and pruritus (14.0%). Dry mouth (4.1 vs 1.7% with placebo; P=0.2678) and constipation (3.3%) were also reported. Adverse events led to treatment discontinuation in 10.7% of patients receiving OXY-TDS. Anticholinergic adverse events were the most common treatment-related events in the TOL-LA group (13.0%). Dry mouth occurred at a greater rate with TOL-LA (7.3%) than placebo (1.7%; P=0.0379). Constipation occurred in 5.7% of TOL-LA patients. Adverse events led to treatment discontinuation in 1.6% of patients receiving TOL-LA. Secondary: Not reported
Metello et al.[65] (2007) Solifenacin 5 mg once daily	OL Women ≥18 years of age with OAB symptoms (≥8 voids/24 hours and ≥1 incontinence	N=40 30 days	Primary: Patient self-assessment of improvement after 30 days using the USS in both treatment groups	Primary: After 30 days of therapy, treatment with solifenacin led to a significant improvement in USS scores when assessed in all patients (P<0.001). There was no significant difference in USS scores among patients who were drug naïve compared to those who had previously failed trospium. Overall 16% of patients experienced no improvement, 13.5% had mild

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	episode/24 hours) for ≥3 months who had either not received any previous medication or who had been previously unsuccessfully treated with trospium		Secondary: Reduction of the daily number of voids and urgency or involuntary leakage episodes	improvement and 69.5% had great improvement. Secondary: Treatment with solifenacin resulted in a significant reduction in urgency episodes, involuntary leakage episodes, and number of voids/24 hours when assessed in all patients (P<0.001). There was no significant difference in these endpoints among patients who were drug naïve compared to those who had previously failed trospium. Overall, 16% of patients had no improvement in the number of involuntary leakage episodes, 11% of patients had mild improvement and 73% of patients had great improvement. For daily urgency episodes, 13.5% of patients had no improvement, 27.0% had a mild reduction, and 59.0% had a great reduction.
Chancellor et al.[66] (2008) Solifenacin 5 to 10 mg once daily	MC, OL Patients ≥18 years of age with symptoms of OAB for ≥3 months who had been treated with tolterodine ER 4 mg for ≥4 weeks, and wished to switch therapy because of a lack of sufficient subjective improvement in urgency (≥3 urgency episodes/24 hours)	N=441 12 weeks	Primary: Change in urgency episodes compared to pre-washout (when patients were receiving tolterodine ER 4 mg) Secondary: Change in micturitions, incontinence episodes, nocturia episodes, and nocturnal voids compared to pre-washout and post-washout; PRO using the PPBC and the OAB-q was also assessed	Primary: The mean change in the number of urgency episodes/24 hours was −3.4 from pre-washout to study end (P<0.001). The median percent change was -75%. Secondary: The mean change in micturitions, incontinence episodes, nocturia episodes, and nocturnal voids from pre-washout to study end was –1.6, –1.9, –0.7, and –0.8, respectively (all, P<0.001). The median percent change from pre-washout was –15.0% for the number of micturitions, –96.4% for incontinence episodes, –40.8% for nocturia episodes, and –40.0% for nocturnal voids. The median change in micturitions, incontinence episodes, nocturia episodes, and nocturnal voids from post-washout to study end was –2.0 (-19.5%), –2.0 (-100%), –0.7 (-43.7%), and –0.7 (-40.0%), respectively (all, P<0.001). The mean PPBC score decreased from pre-washout by 1.2 points (95% CI, –1.3 to –1.1; P<0.001) and from post-washout by 1.2 points (95% CI, –1.3 to –1.0; P<0.001). Patients had significant improvements on the OAB-q at study end

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				compared to both pre-washout and post-washout (all, P<0.001). The mean changes in OAB-q scores at study end relative to pre-washout and post-washout were –27.4 and –29.5, respectively, for symptom bother; 23.1 and 27.9 for coping; 25.2 and 29.7 for concern; 21.9 and 24.5 for sleep; 11.1 and 15.0 for social interaction; and 21.1 and 25.2 for total HRQOL. The most common adverse events were dry mouth (17.5%), constipation (11.6%), and blurred vision (2.3%).
Zinner et al.[67] (2008) Solifenacin 5 to 10 mg once daily	MC, OL Patients ≥18 years of age with OAB symptoms for ≥3 months who were previously treated with tolterodine ER 4 mg/day for ≥4 weeks, and who wished to switch to solifenacin due to lack of sufficient improvement in urgency episodes while receiving tolterodine (≥3 urgency episodes/24 hours)	N=441 12 weeks	Primary: WPAI-SHP, HUI, and a resource utilization questionnaire administered at pre-washout and week 12 Secondary: Not reported	Primary: Patients reported significantly fewer physician office visits (0.2 vs 1.2; P<0.0001), UTIs (0.1 vs 0.2; P<0.0001), and pads/diapers (7.9 vs 10.7/week; P=0.0009) with solifenacin compared to the pre-washout period. There were no significant differences in the numbers of skin rashes or falls reported at end of the study compared to pre-washout. Patients reported using fluid management as a behavioral management strategy on fewer days with solifenacin compared to when they were taking tolterodine ER 4 mg/day (14.2 vs 18.0 days; P=0.0381). There were no significant differences in other behavioral management strategies. Based on the WPAI-SHP, patients who were working reported a reduction in percent of work time missed (0.2 vs 2.1%; P=0.0017), a reduction in percent of impairment while working (11.3 vs 22.9%; P<0.0001), a reduction in percent of overall work impairment (11.9 vs 24.0%; P<0.0001), and a reduction in percent of activity impairment (18.4 vs 31.6%; P<0.0001) after 12 weeks of therapy with solifenacin. There was no significant difference in the health utility score between pre-washout and end of study based on the HUI 2/3. Secondary: Not reported
Wong et al.[68] (2009)	OL Women with OAB	N=9 12 weeks	Primary: Daytime frequency,	Primary: The mean number of daytime micturitions was reduced from 11.4 to 7.3 with solifenacin (P=0.0002).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Solifenacin 5 to 10 mg once daily	who had previously taken oxybutynin IR without benefit or developed intolerable adverse effects		nocturia, number of incontinence episodes, average urinary voided volume, and quality-of-life (OAB-q short form symptom bother) Secondary: Not reported	The mean number of nocturia episodes was reduced from 2.8 to 0.9 with solifenacin (P=0.0004). The total number of incontinence episodes/day was reduced from 4.9 to 1.9 with solifenacin (P=0.02). The mean micturition volumes were increased from 160 to 280 ml with solifenacin (P=0.002). The symptom severity domain of the OAB-q showed a value of 60.8% at baseline and 32.0% at 12 weeks with solifenacin (P=0.001). The HRQOL domain of the OAB-q showed a value of 45.5% at baseline and 73.3% at 12 weeks with solifenacin (P=0.0006). Secondary: Not reported
Garely et al.[69] (2006) Solifenacin 5 to 10 mg once daily	MC, OL Patients ≥18 years of age with OAB (urgency, urge urinary incontinence, frequency, and/or nocturia for ≥3 months)	N=2,225 12 weeks	Primary: PPBC scale, OAB-q, and a VAS for the degree of bother caused by individual OAB symptoms Secondary: Not reported	Primary: The mean PPBC scale score decreased significantly to 2.9 (mean change, -1.4; 95% CI, -1.49 to -1.38; P<0.001), which corresponded to a perception of "some minor problems" associated with their bladder condition. There were significant improvements in all of the OAB-q scoring domains (symptom severity, coping, concern, sleep, social interaction, and overall HRQoL) with solifenacin (all subscales, P<0.001). Significant improvements in urinary urgency, urge urinary incontinence, frequency, or nocturia were observed with solifenacin on the VAS. For urinary urgency, 88.2% of patients indicated less bothersome symptoms; for urge urinary incontinence, 89.4% of patients indicated less bothersome symptoms; for frequency, 88.3% of patients indicated frequency was less bothersome; for nocturia, 87.5% of patients indicated that nocturia was less bothersome. Anticholinergic adverse events occurred as follows: dry mouth (21.4%), constipation (13.3%), headache (3.4%), blurred vision (2.6%), nausea

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(1.8%), dyspepsia (1.5%), and dry eyes (1.3%). A total of 9.7% of patients discontinued treatment due to an adverse event. The most frequently reported treatment-emergent adverse events that resulted in discontinuation were dry mouth (1.9%) and constipation (1.9%). Secondary: Not reported
Haab et al.[70] (2005) Solifenacin 5 to 10 mg once daily	ES, OL Patients ≥18 years of age with symptoms of OAB (≥8 micturitions/24 hours and either ≥1 urgency episode/24 hours or ≥1 incontinence episode/24 hours) for >3 months	N=1,633 40 weeks	Primary: Safety and tolerability Secondary: Efficacy	Primary: Dry mouth occurred in 10% of patients receiving solifenacin 5 mg and 17% of patients receiving solifenacin 10 mg. The discontinuation rate due to dry mouth was 0.4%. After 40 weeks, 85% of patients indicated satisfaction with solifenacin tolerability, and 99% of patients rated solifenacin tolerability as either ‘‘satisfactory’’ or ‘‘acceptable.’’ Secondary: The mean number of urgency episodes/24 hours decreased by 63%. For patients with ≥1 episode of urgency/24 hours at baseline, 40% had no symptomatic urgency at end point. The mean number of incontinence episodes/24 hours decreased by 66%. For patients with ≥1 episode of incontinence at baseline, 58% were continent at end point. The mean number of micturitions/24 hours decreased by 2.97 (23%) with solifenacin. A total of 39% of patients had <8 micturitions/24 hours by study end. The mean number of nocturia episodes/24 hours decreased by 32% and the mean volume voided/micturition increased by 31%.
Bolduc et al.[71] (2010) Solifenacin 0.15 to 0.25 mg/kg once daily	OL, PRO Children with OAB (neurogenic and non-neurogenic) who failed intensive	N=72 ≥3 months	Primary: Efficacy for continence, safety and tolerability Secondary:	Primary: Subjective continence improved in all cases. Patients/parents rated improvement as 100% (complete dryness in 24 patients, >90% improvement in 42 patients, and a 50 to 89% decrease in six patients). MVV and cystometric bladder capacity improved without deterioration in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	medical and behavioral therapy		Not reported	compliance (P<0.001). Maximum detrusor contraction pressure decreased overall as well (P<0.0001). There were no significant differences in response in neurogenic vs non-neurogenic cases. The mean PPBC score at baseline was 4.9 (mod-severe problems), which significantly improved to 1.8 (minor problems) at study end (P<0.0001). No adverse events were reported in 50 patients (70%). The most common adverse event was dry mouth (n=14). Secondary: Not reported
Chapple et al.[72] (2006) Solifenacin 5 to 10 mg once daily vs placebo	DB, MC, PC, RCT (Pooled analysis) Patients ≥18 years of age with OAB (≥8 micturitions/24 hours, and either a mean of ≥1 incontinence episode/24 hours or a mean of ≥1 urgency episode/24 hours)	N=2,848 (4 trials) 12 weeks	Primary: Urgency episodes (mean absolute values and median percentage values), incontinence episodes, micturition frequency, nocturia episodes/24 hours, and volume voided/micturition Secondary: Not reported	Primary: Treatment with solifenacin 5 and 10 mg resulted in a -2.9 (-66.1%) and -3.4 (-70.0%) reduction in urgency episodes, respectively, compared to a -2.0 (-40.0%) reduction with placebo (P<0.001). Treatment with solifenacin 5 and 10 mg resulted in a -1.5 (-100%) and -1.8 (-100%) reduction in incontinence episodes, respectively compared to a -1.1 (-63.6%) reduction with placebo (P<0.001). The frequency of micturition was significantly reduced with solifenacin 5 mg (-2.3; -19.4%) and 10 mg (-2.7; -22.5%) compared to placebo (-1.4; -12.0%; P<0.001). The number of nocturia episodes were significantly reduced with solifenacin 5 mg (-0.6; -35.5%) and 10 mg (-0.6; -36.4%) compared to placebo (-0.4; -25.0%; P<0.05 and P<0.001 for solifenacin 5 and 10 mg, respectively). The volume voided/micturition increased significantly with solifenacin 5 mg (32.3 mL; 19.0%) and 10 mg (42.5 mL; 25.7%) compared to placebo (8.5 mL; 3.1%; P<0.001). The most common adverse events were dry mouth, constipation, and blurred vision. The incidence of dry mouth was higher in the 10 mg solifenacin group compared to the 5 mg group. The numbers of patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				discontinuing treatment due to adverse events were as follows: 4.4, 2.8, and 6.8% with placebo, solifenacin 5 mg and solifenacin 10 mg. Secondary: Not reported
Abrams et al.[73] (2005) Solifenacin 5 to 10 mg once daily vs placebo	DB, MC, PC, RCT (Pooled analysis) Subgroup of patients >18 years of age with symptoms of OAB (≥8 micturitions/24 hours or ≥1 urgency episode/24 hours) who did not experience incontinence episodes at baseline	N=975 (4 trials) 12 weeks	Primary: Urgency episodes, micturition frequency, and nocturia episodes/24 hours, and volume voided/micturition Secondary: Not reported	Primary: The mean change from baseline in urgency episodes/24 hours (-3.2, -3.2, -2.1), micturition frequency/24 hours (-2.6, -2.8, -1.6), and volume voided/micturition (24.9 mL, 33.9 mL, 7.0 mL) were significantly greater with solifenacin 5 and 10 mg than placebo, respectively (all P<0.001). The mean change from baseline in nocturia episodes/24 hours was significantly greater for solifenacin 10 mg than placebo (P<0.01). The percentage of patients with resolution of urgency (36.6, 32.9, 24.6%) and normalization of micturitions (29, 34.7, 18.5%) was significantly greater with solifenacin 5 mg and solifenacin 10 mg compared to placebo, respectively (P<0.05 to P<0.001). The percentage of patients with resolution of nocturia (14.1, 20.9, 12.8%) was significantly greater with solifenacin 10 mg compared to placebo (P<0.01). Dry mouth was reported in 3.6, 10.8, and 24.4% of patients receiving placebo, 5 mg solifenacin, and 10 mg solifenacin, respectively. The incidence of constipation was 1.3, 4.0, and 12.2% with placebo, 5 mg, and 10 mg, respectively. Discontinuations due to adverse events for the solifenacin 5 mg group (2.8%) and solifenacin 10 mg group (7.8%) were comparable with or less than that of the placebo group (6.2%). Secondary: Not reported
Millard et al.[74] (2006) Solifenacin 5 to 10 mg once daily vs	DB, MC, PC, RCT (Pooled analysis) Subgroup of patients ≥18 years of age with severe OAB (>3 incontinence	N=2,848 (4 trials) 12 weeks	Primary: Responder rates, urgency episodes, incontinence episodes, micturition, frequency, nocturia episodes/24 hours,	Primary: For those with >3 incontinence episodes/24 hours, the percentage of patients who were continent at study end point was significantly higher with solifenacin 5 mg (28.4%; P<0.01) and 10 mg (30.5%; P<0.001) compared to placebo (15.3%). The mean change in the number of episodes of incontinence and urgency, the frequency of micturitions and volume voided/micturition was significantly greater with solifenacin 5 mg (P<0.01) and 10 mg (P<0.001) than with placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	episodes/24 hour, >8 urgency episodes/24 hours, or >13 micturition episodes/24 hours)		and volume voided/micturition Secondary: Not reported	For those with >8 urgency episodes/24 hours, the percentage of patients with resolution of urgency at study end point was significantly higher with solifenacin 5 mg (12.4%; P<0.01) and 10 mg (13.9%; P<0.001) compared to placebo (4.6%). The mean change in the number of episodes of incontinence and urgency, the frequency of micturitions and volume voided/micturition was significantly greater with solifenacin 10 mg compared to placebo (P<0.001). For solifenacin 5 mg, the mean change for all efficacy parameters was significantly greater than placebo (P<0.05; except micturition frequency/24 hours). For those with >13 micturitions/24 hours, the percentage of patients who achieved normalization of micturition frequency (<8 micturitions/24 hours) at study end point was significantly higher with solifenacin 10 mg (13.3%; P<0.001) compared to placebo (4.0%). There was no significant difference between solifenacin 5 mg and placebo. The mean change in the number of episodes of incontinence and urgency, the frequency of micturitions and volume voided/micturition was significantly greater with solifenacin 5 mg (P<0.05) and 10 mg (P<0.001) compared to placebo. The incidence of adverse events was comparable among the treatment groups. Dry mouth, constipation, UTI, blurred vision, and nausea occurred at a higher incidence with solifenacin 5 or 10 mg than with placebo. Discontinuations due to adverse events occurred in 4.1, 7.5, and 4.8% of patients in the solifenacin 5 and 10 mg and placebo groups, respectively. Secondary: Not reported
Wagg et al.[75] (2006) Solifenacin 5 to 10 mg once daily vs placebo	DB, MC, PC, RCT (Pooled analysis) Subgroup of patients ≥65years of age with OAB (≥8 micturitions/24 hours, and either a mean of ≥1	N=1,554 (5 trials) 12 to 40 weeks	Primary: Urgency episodes (mean absolute values and median percentage values), incontinence episodes, micturition frequency, nocturia	Primary: In the 12-weeks studies, elderly patients had significantly greater decreases in the mean number of incontinence episodes/24 hours with solifenacin 5 and 10 mg compared to placebo (P=0.013 and P<0.001, respectively). The median change in the number of incontinence episodes/24 hours was -1.0 (-92.4%) and -1.5 (-91.9%) with solifenacin 5 and 10 mg, respectively, and -0.7 (-50%) with placebo (P<0.001 for 10 mg dose). There was no significant difference between solifenacin 5 mg and placebo. A greater percentage of elderly patients who were incontinent at

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	incontinence episode/24 hours or a mean of ≥1 urgency episode/24 hours)		episodes/24 hours, and volume voided/micturition Secondary: Not reported	baseline were continent with solifenacin 5 and 10 mg (49.1 and 47.3%, respectively) compared to placebo (28.9%; P<0.001). In 12-week studies, elderly patients had significantly greater decreases in the mean number of urgency episodes/24 hours with solifenacin 5 and 10 mg compared to placebo (P<0.001). The median change in the number of urgency episodes was -2.3 (-76.1%) and -2.7 (-66.7%) with solifenacin 5 and 10 mg, respectively, and -1.5 (-33.3%) with placebo (P<0.001 for 10 mg dose). A greater percentage of elderly patients with urgency at baseline had resolution of urgency with solifenacin 5 and 10 mg (34.6 and 24.9%, respectively) compared to placebo (16.9%; P<0.001 for 5 mg and P<0.01 for 10 mg). In 12-week studies, elderly patients had significantly greater decreases in the mean number of micturitions/24 hours with solifenacin 5 and 10 mg compared to placebo (P<0.001). The median change in the number of micturitions was -2.0 (-18.3%) and -2.3 (-22%) with solifenacin 5 and 10 mg, respectively, and -1.0 (-10.3%) with placebo (P=0.008 for the 5 mg dose and P<0.001 for the 10 mg dose. In 12-week studies, elderly patients had a significantly greater increase in the mean volume voided/micturition with solifenacin 5 and 10 mg compared to placebo (P<0.001).The median change in volume voided/micturition was 27.2 (17.8%) and 40.1 (28.5%) with solifenacin 5 and 10 mg, respectively, and 6.2 (3.7%) with placebo (P<0.001). During the 40-week extension trial, elderly patients maintained improvements in the number of incontinence episodes/24 hours, urgency episodes/24 hours, and number of micturitions/24 hours, and experienced an increase in the volume voided/micturition compared to baseline. A total of 59.5% of elderly patients were continent and 37.8% reported resolution of urgency at the end of the study period. During the 12-week trials, the most commonly reported adverse events were dry mouth, constipation, and UTI. Rates of discontinuation were 5.5% in the placebo group, 4.7% in the solifenacin 5 mg group, and 9.3% in the solifenacin 10 mg group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				During the 40-week extension, the most common adverse events were dry mouth, constipation, and UTI. A total of 9.2% of patients discontinued therapy due to any type of adverse event. Secondary: Not reported
Kelleher et al.[76] (2005) Solifenacin 5 to 10 mg once daily vs placebo	DB, MC, PC, RCT (Pooled analysis) Patients ≥18 years of age with symptoms of OAB (≥8 micturitions/24 hours and either ≥1 urgency episode/24 hours or ≥1 incontinence episode/24 hours) for >3 months	N=3,237 (3 trials) 12 to 40 weeks	Primary: QOL data using the KHQ Secondary: Not reported	Primary: In the 12-weeks studies, there was a significant improvement in all QOL domains (except personal relationships) with solifenacin compared to placebo (P<0.05 to P<0.001). In the 40-week ES, there was a significant improvement in all QOL domains with solifenacin (17% for the general health perception and 35 to 48% for all the other domains). Secondary: Not reported
Herschorn et al.[77] (2010) Solifenacin 5 mg once daily vs oxybutynin IR 5 mg three times daily	DB, MC, RCT Patients ≥18 years of age with OAB symptoms (>1 urgency episode per 24 hours and ≥8 micturitions per 24 hours for ≥3 months)	N=132 8 weeks	Primary: Incidence and severity of dry mouth reported after direct questioning Secondary: Three-day diary changes in urgency, frequency, incontinence, nocturia, voided volume, PPBC, and the OAB-q	Primary: Significantly fewer patients on solifenacin reported dry mouth after direct questioning compared to oxybutynin IR (35 vs 83%; 95% CI, 33 to 62; P<0.0001). Additionally, in those reporting dry mouth, solifenacin was associated with significantly lower severity than that of oxybutynin IR (P=0.001). Secondary: Patients in both groups showed improvement in bladder diary documented urgency, incontinence, frequency, nocturia, and VVPM from baseline to end of treatment. PPBC and OAB-q scores also significantly improved with both groups. Overall adverse events were significantly fewer with solifenacin than with oxybutynin IR (72 vs 92%; P=0.003). Besides dry mouth, the incidence of other adverse events was 59% for solifenacin and 70% for oxybutynin (P=0.17).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Fewer patients that received solifenacin withdrew from the study due to dry mouth compared to oxybutynin IR (3 vs 19%; P=0.003).
Herschorn et al.[78] (2011) Solifenacin 5 mg once daily vs oxybutynin IR 5 mg three times daily	DB, MC, RCT (Subgroup analysis) Patients ≥18 years of age with OAB symptoms (>1 urgency episode per 24 hours and ≥8 micturitions per 24 hours for ≥3 months)	N=132 8 weeks	Primary: Adverse events in patients ≤ 65 years of age and in those >65 years of age Secondary: Not reported	Primary: In both age groups, solifenacin 5 mg/day was associated with numerically fewer episodes of dry mouth compared to oxybutynin IR. Patients receiving oxybutynin IR were >8 times more likely to have dry mouth than those receiving solifenacin, regardless of age (OR, 8.88; 95% CI, 3.91 to 20.17). Additionally, oxybutynin IR caused more severe dry mouth compared to solifenacin. The incidence and severity of other adverse events with solifenacin were similar between age groups. Discontinuation of oxybutynin IR treatment occurred more often than solifenacin, irrespective of age. Although the numbers were low, there was a higher incidence of constipation and fatigue in patients >65 years who received solifenacin compared to oxybutynin IR. Secondary: Not reported
Amarenco et al.[79] (2017) SONIC Solifenacin 5 mg, 10 mg vs placebo vs oxybutynin hydrochloride 15 mg	DB, MC, PRO, RCT Patients 18 to 65 years of age with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury	N=189 4 weeks	Primary: Change in maximum cystometric capacity from baseline Secondary: Change from baseline in urodynamic variables as measured by cystometry, and patient-reported outcomes	Primary: Mean increase from baseline to end of treatment in maximum cystometric capacity was 134.2 mL with solifenacin 10 mg versus 5.4 mL with placebo (P<0.001). Maximum cystometric capacity was also significantly improved with solifenacin 5 mg and oxybutynin versus placebo, with increases of 77.8 and 165.4 mL, respectively (P=0.007 and P<0.001 vs placebo). Secondary: Improvements in secondary urodynamic variables were greater with solifenacin and oxybutynin compared with placebo. Compared with placebo, all active treatment groups showed reductions in patient perception of bladder condition from baseline to end of treatment, but these were statistically significant only for solifenacin 10 mg versus placebo (–0.6 vs –0.1; P=0.041). Of the I-QoL subscales, changes in "avoidance and limiting behavior" reached statistical significance for both solifenacin doses versus placebo (5 mg, P=0.014; 10 mg, P=0.030),

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				whereas oxybutynin had no significant effect on any I-QoL subscore compared with placebo.
Hsiao et al.[80] (2011) Solifenacin 5 mg once daily vs tolterodine ER 4 mg once daily	OL, RCT Women ≥18 years who had ≥3 month history of OAB symptoms (including urgency, urinary frequency, nocturia or urge incontinence) and a mean of ≥8 micturitions per 24 hours	N=48 12 weeks	Primary: Changes in total voided volume, VVPM, and the episodes of micturition, urgency, incontinence and nocturia in 24 hours Secondary: Not reported	Primary: In the solifenacin group, there was a decrease in the PPBC and the micturition, urgency and incontinence episodes per 24 hours and the VVPM increased at most follow-up visits. In the tolterodine group, there was a decrease in the PPBC and the nocturia episodes per 24 hours, but the heart rate increased at most follow-up visits. There were no between- or within-group differences in the changes of the number of episodes of micturition, urgency, incontinence, nocturia or total voided volume per 24 hours or VVPM at weeks four, eight or 12. Compared to baseline, the volume voided was significantly increased after solifenacin treatment (P=0.04). The strong desire to void and pad test result improved after tolterodine treatment (P=0.02 and P=0.03, respectively). At 12 weeks, there were no between-group differences in changes of urodynamic data and pad test results. Changes in the heart rate differed significantly between these two groups at visit two (solifenacin vs tolterodine ER, -4.3; 95% CI, -7.2 to -1.3 vs 3.8; 95% CI, 0.3 to 7.3; P=0.02 and visit three (-3.2; 95% CI, -7.4 to 1.0 vs 4.8; 95% CI, 1.2 to 8.3; P=0.03). There was no difference in the number of patients who experienced adverse events between groups (P=0.23). Ten patients in the solifenacin group experienced adverse events, including dry mouth (n=7), constipation (n=3), palpitations (n=1), dizziness (n=1) and fatigue (n=1). Five patients in the tolterodine group experienced adverse events, including dry mouth (n=3), constipation (n=1), and palpitations (n=1). Secondary: Not reported
Armstrong et al.[81] (2007) Oxybutynin XL 10	MA of 2 studies Present study is a MA of the OPERA	N=1,168 12 weeks	Primary: Adverse events Secondary:	Primary: Gastrointestinal adverse events occurred in 41.8, 36.3 and 45.1% of patients receiving oxybutynin XL, tolterodine LA and tolterodine IR therapy, respectively (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg once daily vs tolterodine LA 4 mg once daily vs tolterodine IR 2 mg twice daily	and OBJECT studies (Appell et al and Diokno et al)		Not reported	The most common adverse event was dry mouth, occurring in 29.3, 22.3 and 33.2% of patients receiving oxybutynin XL, tolterodine LA and tolterodine IR therapy, respectively (P value not reported). The incidence of nervous system adverse events in the oxybutynin XL, tolterodine LA, and tolterodine IR groups was comparable (10.2 vs 8.3 vs 10.9%, respectively; P value not reported). Most adverse events were mild or moderate in intensity. Severe drug-related adverse events occurred in 4.3, 1.5 and 2.6% of patients in the oxybutynin XL, tolterodine LA and tolterodine IR groups, respectively. The most common adverse event resulting in early discontinuation from the study was dry mouth, with 1.2, 1.0 and 1.6% of patients discontinuing treatment with oxybutynin XL, tolterodine LA and tolterodine IR, respectively (P value not reported). Secondary: Not reported
Madhuvrata et al.[82] (2012) Fesoterodine 4 to 8 mg once daily vs oxybutynin IR 2.5 to 5 mg twice daily to four times daily vs oxybutynin XL 5 to 20 mg once	MA of 86 studies Patients with a symptomatic diagnosis of OAB syndrome with or without a urodynamic diagnosis of detrusor overactivity	N=31,249 Up to 52 weeks	Primary: Condition-specific QOL and psychosocial measures Secondary: Patient observations, quantification of symptoms, clinician's measures, socioeconomics	Primary: There was no significant difference between tolterodine and oxybutynin with regard to QOL (SMD, -0.00; 95% CI, -0.18 to 0.18). The results from three studies reported a statistically significant improvement in QOL for patients treated with solifenacin compared to tolterodine (SMD, -0.12; 95% CI, -0.23 to -0.01). Treatment with fesoterodine was associated with a significant improvement in QOL compared to tolterodine LA (SMD, -0.20; 95% CI, -0.27 to -0.14). Secondary: There was no statistically significant difference between tolterodine and oxybutynin with regard to the proportion of patients reporting a symptomatic cure or improvement (RR, 1.01; 95% CI, 0.93 to 1.11), fewer

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
daily vs tolterodine IR 1 to 2 mg twice daily vs tolterodine LA 2 to 4 mg once daily vs trospium IR 20 mg twice daily vs solifenacin 5 to 10 mg once daily vs placebo				leakage episodes or voids over 24 hours (WMD, 0.33; 95% CI, -0.08 to 0.73). There was no difference in patient reported cure or improvement between patients receiving oxybutynin or trospium (RR, 1.00; 95% CI, 0.90 to 1.11). Moreover, there was no significant difference between the treatments with regard to cystometric capacity or residual bladder volume. Trospium was associated with fewer treatment withdrawals (RR, 0.66; 95% CI, 0.48 to 0.91) and a lower risk of dry mouth compared to oxybutynin (RR, 0.64; 95% CI, 0. 52 to 0.77). Compared to oxybutynin, tolterodine was associated with significantly lower rates of withdrawal due to adverse events (RR, 0.52; 95% CI, 0.40 to 0.66) and a lower incidence of dry mouth (RR, 0.65; 95% CI, 0.60 to 0.71). Treatment with solifenacin was associated with a higher patient report of cure or improvement compared to tolterodine (RR, 1.25; 95% CI, 1.13 to 1.39). There was a statistically significant reduction in the number of leakage episodes/24 hours (WMD, -0.30; 95% CI, -0.53 to -0.08 and urgency episodes/24 hours with solifenacin compared to tolterodine (WMD, -0.43; 95% CI, -0.74 to -0.13). Withdrawal rates due to adverse events and the incidence of dry mouth were similar between solifenacin and tolterodine; however, following the exclusion of one study with tolterodine LA, dry mouth rates were significantly lower with solifenacin compared to tolterodine LA (RR, 0.69; 95% CI, 0.51 to 0.94). Fesoterodine treatment was associated with a higher rate of patient reported cure or improvement compared to tolterodine LA (RR, 1.11; 95% CI, 1.06 to 1.16). Compared to tolterodine LA, patients taking fesoterodine reported significant reductions in leakage episodes (WMD, -0.19; 95% CI, -0.30 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				-0.09), frequency (WMD, -0.27; 95% CI, -0.47 to -0.06) and urgency episodes/24 hours (WMD, -0.44; 95%CI, -0.72 to -0.16). Patients receiving treatment with fesoterodine had a higher risk of withdrawal due to adverse event compared to tolterodine LA treatment (RR, 1.45; 95% CI, 1.07 to 1.98) and higher risk of dry mouth (RR, 1.80; 95% CI, 1.58 to 2.05). Similar improvements in leakage episodes and micturitions/24 hours were reported for 1, 2 and 4 mg doses of tolterodine IR administered twice daily. There was a higher incidence of dry mouth with both the 2 and 4 mg doses relative to the lower doses of tolterodine IR. Fesoterodine 8 mg was associated with a greater clinical efficacy (patient reported cure, leakage episodes, micturition/24 hours) compared to the 4 mg fesoterodine. There was no difference in efficacy between the 4 mg and 12 mg doses, although higher dose was associated with a greater incidence of dry mouth. The 8 mg strength was also associated with a higher risk of dry mouth compared to fesoterodine 4 mg. Both tolterodine LA and oxybutynin XL were associated with a lower risk of dry mouth compared to their respective IR formulations; however, no significant differences in cure, improvement, leakage episodes, micturitions/24 hours, or withdrawal events were reported between. There was a lower risk of dry mouth with tolterodine LA compared to oxybutynin XL (RR, 0.75; 95% CI, 0.59 to 0.95). There was no difference in the incidence of dry mouth between transdermal oxybutynin and tolterodine LA, although there was a higher withdrawal rate with transdermal oxybutynin due to a skin reaction at the transdermal patch site at 12 weeks.
Ho et al.[83] (2010) Solifenacin 5 mg once daily	OL, PRO, RCT Male or female patients ≥18 years of age with OAB symptoms (urinary	N=75 12 weeks	Primary: Change from baseline to endpoint for the mean number of micturitions per 24	Primary: Compared to baseline, both treatment groups showed significant improvements in reducing mean micturition numbers per 24 hours from week four. At week 12, the mean changes were not significantly different between solifenacin and tolterodine (-2.56 vs -2.44; P=0.58).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tolterodine ER 4 mg once daily	frequency, urgency, or urge incontinence) ≥3 months, who experienced frequency (defined as ≥8 micturitions per 24 hours)		hours Secondary: Change from baseline to endpoint for MVV per micturition, mean urgency episode per 24 hours, mean incontinence per 24 hours, PPBC, patient and physician assessment of treatment benefit	Secondary: Both groups significantly improved urgency and incontinence episodes per 24 hours. At week 12, the mean changes from baseline were not significant for urgency episodes between solifenacin and tolterodine (-1.7 vs -1.15; P=0.37), nor were the mean changes for incontinence episodes (-2.79 vs -4.67; P=0.28). A significant increase in MVV per micturition was only observed in the solifenacin group (27.61±51.74 mL). PPBC was significantly improved with both groups compared to baseline. At week 12, the mean changes from baseline were -1.4 and -1.4 in the solifenacin and tolterodine groups, respectively. The difference between solifenacin and tolterodine was not statistically significant. Patient and physician assessment of treatment benefit showed that improvements were made in both groups compared to baseline, but not between each other. The most common adverse events for solifenacin and tolterodine were dry mouth (18.0 vs 8.3%; P=0.31) and constipation (12.8 vs 2.8%; P=0.2).
Chapple et al.[84] (2005) Solifenacin 5 to 10 mg once daily vs tolterodine ER 4 mg once daily	DB, MC, RCT Patients ≥18 years of age with OAB symptoms (≥8 micturitions/24 hours, ≥1 incontinence episode/24 hours, or ≥1 urgency episode/24 hours) for ≥3 months	N=1,200 12 weeks	Primary: Micturition frequency Secondary: Urgency episodes, urge incontinence, total incontinence, nocturia, proportion of patients who experienced a 50% reduction in incontinence episodes, pad usage, and QOL	Primary: The mean number of micturitions was reduced with solifenacin (-2.45) compared to treatment with tolterodine (-2.24; P=0.004 for non-inferiority). Secondary: Treatment with solifenacin led to a reduction in the number of urgency episodes/24 hours (-2.85) compared to treatment with tolterodine (-2.42; P<0.05). Treatment with solifenacin led to a reduction in the number of urge incontinence episodes/24 hours (-1.42) compared to treatment with tolterodine (-0.83; P<0.01). Treatment with solifenacin led to a reduction in the number of total incontinence episodes/24 hours (-1.60) compared to treatment with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			using a six-point categorical scale to assess perception of bladder condition	tolterodine (-1.11; P<0.01). There was no significant difference in nocturia among the treatment groups (P=0.730). Approximately 74% of patients receiving solifenacin who were incontinent at baseline experienced ≥50% reduction in incontinence episodes compared to 67% of patients receiving tolterodine (P=0.021). The percentage of patients who were incontinent at baseline who became continent at study end point was 59% (solifenacin) and 49% (tolterodine; P=0.006). The mean volume voided/micturition increased with solifenacin (38 mL) compared to tolterodine (31 mL; P=0.010). Solifenacin decreased the number of incontinence pads used compared to tolterodine (P=0.0023). Patient-reported perception of bladder condition was significantly improved with solifenacin compared to tolterodine (P=0.006). Approximately 5.9% of patients receiving solifenacin and 7.3% of patients receiving tolterodine discontinued treatment (for any reason); 1.2% and 2.0% discontinued therapy due to insufficient therapeutic response with solifenacin and tolterodine, respectively. The most common adverse events were dry mouth, constipation and blurred vision. The percentage of patients discontinuing treatment due to adverse events was similar between the treatment groups (3.5% of patients receiving solifenacin and 3.0% of patients receiving tolterodine). A total of 1.2 and 2.0% of patients discontinued therapy due to an insufficient therapeutic response with solifenacin and tolterodine, respectively.
Chapple et al.[85] (2004) Solifenacin 2.5 to 20 mg once daily	DB, PC, RCT Patients 18 to 80 years of age with OAB and urodynamic	N=225 6 weeks	Primary: Number of voids/24 hours Secondary: Volume voided/	Primary: The mean change in number of voids/24 hours was significantly lower with solifenacin 5 mg (-2.21), 10 mg (-2.47) and 20 mg (-2.75) compared to placebo (-1.03; all P<0.05). There was no significant difference with tolterodine (-1.79) compared to placebo (P=NS).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tolterodine IR 2 mg twice daily vs placebo	evidence of detrusor overactivity (>8 voids/24 hours and >3 episodes of incontinence or urgency)		void; incontinence episodes/24 hours; urgency episodes/24 hours; and total sum score of Contilife items 1 to 27, sum scores of the five Contilife domains (i.e., daily activities, effort, self-image, emotional consequences, and sexuality), and overall Contilife QOL score	Secondary: The mean volume voided/void was significantly greater for solifenacin 5 mg, 10 and 20 mg than for placebo (all P<0.01). There was no significant difference with tolterodine compared to placebo. There was no significant difference in the mean number of incontinence episodes/24 hours with solifenacin or tolterodine compared to placebo. There was no significant difference in the number of urgency episodes/24 hours with solifenacin or tolterodine compared to placebo. Treatment with solifenacin led to significant improvements over baseline based on the results of the Contilife sum score QOL analysis compared to placebo. There was no significant difference with tolterodine compared to placebo. Treatment with solifenacin led to significant improvements in the daily life activities (all groups; P<0.01), self-image (10 and 20 mg; P<0.05), emotional consequences (5, 10 and 20 mg; P<0.05) and sexuality (10 and 20 mg; P<0.05) compared to placebo. Tolterodine resulted in significant improvements in the daily life activities domain only compared to placebo (P<0.05). Solifenacin 10 and 20 mg and tolterodine produced significant improvements over placebo in the Contilife overall QOL score (P<0.05). The most frequently reported adverse event was dry mouth, followed by constipation and blurred vision. The frequency of dry mouth was highest among patients receiving solifenacin 20 mg (38%), tolterodine 2 mg (24%) and solifenacin 5 and 10 mg (14% each). Constipation was reported in 19% of patients taking solifenacin 20 mg.
Chapple et al.[86] (2004) Solifenacin 5 to 10 mg once daily	DB, MC, RCT Patients ≥18 years of age with symptoms of OAB (including urgency,	N=1,081 12 weeks	Primary: Urgency episodes, all incontinence episodes, urge incontinence episodes, voids/24	Primary: There was a significant decrease in the mean number of urgency episodes/24 hours with solifenacin 5 and 10 mg (-52% and -55%, respectively) compared to placebo (-33%; both P<0.001). There was no significant difference in urgency episodes/24 hours between tolterodine (-38%) and placebo (P=0.0511). Direct comparison of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tolterodine IR 2 mg twice daily vs placebo	urge incontinence, or frequency) for ≥3 months (≥8 voids/24 hours, ≥3 episodes of urgency and/or ≥3 episodes of incontinence)		hours and voided volume/void Secondary: Not reported	solifenacin 5 and 10 mg with tolterodine resulted in estimated differences of - 0.791 and - 1.015 (95% CI, -1.434 to -0.148, and -1.659 to -0.370), respectively. There was a significant decrease in urge incontinence episodes/24 hours with solifenacin 5 mg (-1.41; P=0.002) and 10 mg (-1.36; P=0.0028) compared to placebo (-0.62). There was no significant difference in urge incontinence episodes/24 hours between tolterodine (-0.91) and placebo (P=0.2390). There was no significant difference in urge incontinence episodes/24 hours between solifenacin and tolterodine (5 mg, -0.487; 95% CI, -0.988 to 0.014 and 10 mg, -0.436; 95% CI, -0.921 to 0.048). There was a significant decrease in all incontinence episodes/24 hours with solifenacin 5 mg (-1.42; P=0.008) and 10 mg (-1.45; P=0.0038) compared to placebo (-0.76). There was no significant difference in all incontinence episodes/24 hours between tolterodine (-1.14) and placebo (P=0.1122). There was no significant difference in all incontinence episodes/24 hours between solifenacin and tolterodine (5 mg, -0.276; 95% CI, -0.761 to 0.208 and 10 mg, -0.316; 95% CI, -0.786 to 0.164). There was a significant decrease in mean number of voids/24 hours with solifenacin 5 mg (-2.19, -17%; P<0.001), solifenacin 10 mg (-2.61, -20%; P<0.001) and tolterodine (- 1.88, -15%; P=0.0145) compared to placebo (-1.20, - 8%). Direct comparison of solifenacin 5 and 10 mg with tolterodine resulted in estimated differences of -0.312 and -0.737 (95% CI -0.844 to 0.219, and -1.269 to -0.204). There was a significant increase in mean volume voided/void with solifenacin 5 mg (32.9 mL, +25.1%), solifenacin 10 mg (39.2 mL, +29.0%), and tolterodine (24.4 mL, +20.3%) compared to placebo (7.4 mL; all, P<0.001). There was no significant difference in mean volume voided/void between solifenacin and tolterodine (5 mg, 8.4 mL; 95% CI, 0.496 to 16.34 and 10 mg, 14.8 mL; 95% CI, 6.855 to 22.72). The percentages of patients discontinuing treatment for an adverse event were 3.7% in the placebo group, 3.2% in the solifenacin 5 mg group, 2.6% in the solifenacin 10 mg group, and 1.9% in the tolterodine group. The

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				incidence of dry mouth was lowest with solifenacin 5 mg (14%). Constipation was reported in 7.2 and 7.8% of patients treated with solifenacin 5 and 10 mg, respectively, in 2.6% of patients treated with tolterodine and in 1.9% of placebo patients. Blurred vision was reported in 3.6% of patients receiving solifenacin 5 mg, 5.6% receiving solifenacin 10 mg, 1.5% receiving tolterodine, and 2.6% receiving placebo. Secondary: Not reported
Yamaguchi et al.[87] (2011) Solifenacin 2.5 mg plus tamsulosin 0.2 mg once daily (TAM+SOL 2.5) vs solifenacin 5 mg plus tamsulosin 0.2 mg once daily (TAM+SOL 5) vs tamsulosin 0.2 mg once daily plus placebo (TAM+PBO)	DB, MC, PC, RCT Men ≥50 years of age with LUTS and residual OAB symptoms despite treatment with tamsulosin for ≥6 weeks, ≥2 urgency episodes per 24 hours in a 3-day bladder diary, Qmax ≥5 mL/s, and PVR volume <50 mL	N=638 12 weeks	Primary: Mean change in urgency episodes per 24 hours Secondary: Mean changes in micturitions, nocturia episodes, urgency incontinence episodes, IPSS, IPSS-QOL, and OABSS	Primary: The mean number of urgency episodes per 24 hours decreased by 2.2 and 2.4 episodes in the TAM+SOL 2.5 and TAM+SOL 5 groups, respectively. TAM+SOL 5 showed a significant improvement in urgency episodes compared to TAM+PBO (P=0.049). Secondary: The number of micturitions per 24 hours was reduced by 1.27 episodes in the TAM+SOL 2.5 group and by 1.06 episodes in TAM+SOL 5 groups, and both of these were significantly better than TAM+PBO (0.22 episodes; P<0.01). Compared to TAM+PBO, TAM+SOL 2.5 and TAM+SOL 5 did not significantly reduce the number of nocturia episodes and urgency incontinence. IPSS storage symptom score was significantly improved in both solifenacin groups compared to placebo. IPSS total score, voiding symptom score, post-micturition symptom score, or QOL were no significantly better compared to placebo. For OABSS, both solifenacin groups significantly improved the total score, daytime frequency score, urgency score, and urgency incontinence score compared to placebo. The most common adverse events were dry mouth (6.2% for TAM+SOL 2.5 vs 11.3% for TAM+SOL 5), constipation (3.8% for TAM+SOL 2.5 vs 10.3% for TAM+SOL 5), increase in PVR ≥50 mL (2.9% for TAM+SOL

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				2.5 vs 6.1% for TAM+SOL 5), abdominal discomfort (2.4% for TAM+SOL 2.5 vs 1.9% for TAM+SOL 5), and creatinine phosphokinase increase (1.9% for TAM+SOL 2.5 vs 2.3% for TAM+SOL 5). A total of four patients in TAM+SOL 5 had urinary retention requiring temporary cauterization.
Kreder et al.[88] (2002) Tolterodine ER 4 mg once daily	ES, OL Patients ≥18 years of age with urinary frequency (≥8 micturitions/24 hours), urge incontinence (≥5 incontinence episodes/week) and urgency for ≥6 months	N=1,077 12 months	Primary: Safety and tolerability Secondary: Efficacy	Primary: The most common adverse events were autonomic nervous system disorders (13.2%), gastrointestinal disorders (11.4%), general body disorders (14.5%), respiratory disorders (9.8%), urinary disorders (9.1%) and musculoskeletal disorders (6.0%). The most frequently report adverse event was dry mouth, which occurred in 12.9% of patients. Approximately 10% of patients withdrew from the study due to adverse events. The most common adverse events leading to withdrawal were dry mouth (1.8%), headache (0.8%), abdominal pain (0.8%), dizziness (0.7%), UTI (0.7%), dyspepsia (0.6%), constipation (0.6%), xerophthalmia (0.5%), and micturition disorders (0.5%). Secondary: The number of urge incontinence episodes/week was significantly decreased with tolterodine compared to baseline (median change, -83%). The number of micturitions/24 hours significantly decreased with tolterodine compared to baseline (median change, -21%). The change in volume voided/micturition significantly increased with tolterodine compared to baseline (median change, 25%). Approximately 75% of patients who received tolterodine perceived improvement after 12 months of therapy.
Takei et al.[89] (2005) Tolterodine ER	ES, OL Japanese patients ≥20 years of age	N=188 12 months	Primary: Safety and tolerability	Primary: The most common adverse event was dry mouth (33.5%). The incidence decreased during the course of the OL extension (24.5% during the first three months vs 4.3% during the six to 12-month periods).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
4 mg once daily	with OAB symptoms including urinary urgency, urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥5 episodes/week) for ≥6 months		Secondary: Efficacy	Approximately 23% of patients withdrew prematurely due to adverse events (10.0%), lack of efficacy (8.0%), consent withdrawal (3.7%), lost to follow-up (0.5%) and protocol violation (0.5%). Secondary: The number of incontinence episodes/week was decreased with tolterodine (mean change, -77.2%). The number of micturitions/24 hours significantly decreased with tolterodine (mean change, -21.3%; P<0.0001). The change in volume voided/micturition significantly increased with tolterodine (mean change, 19.6%; P<0.0001).
Choo et al.[90] (2008) Tolterodine ER 4 mg once daily	OL Patients ≥18 years of age with OAB who had urinary frequency (≥8 micturitions/24 hours) and urgency (≥2 episodes/24 hours) with or without urgency incontinence	N=60 12 weeks	Primary: Rate of PGA by a visual analogue scale Secondary: Changes in symptom severity, voiding diary and PPBC, and willingness to continue treatment	Primary: The median rate of PGA was: frequency (60%; 95% CI, 46.9 to 63.6), urgency (60%; 95% CI, 46.2 to 64.9), urge incontinence (80%; 95% CI, 34.2 to 80.0), nocturia (50%; 95% CI, 39.4 to 57.6) and tenesmus (30%; 95% CI, 25.4 to 52.2). Secondary: The median percentage reduction in symptom severity was as follows: frequency (45%; 95% CI, 36.2 to 54.4), urgency (55%; 95% CI, 40.1 to 60.4), urgency incontinence (71%; 95% CI, 39.2 to 76.8), nocturia (52%; 95% CI, 40.2 to 59.7) and tenesmus (26%; 95% CI, 16.9 to 50.4). Patients reported that the most troublesome symptoms were daytime frequency (50.0%), nocturia (17.9%), urgency incontinence (16.1%), urgency (10.7%) and tenesmus (5.4%). Frequency (-2.7), urgency (-4.2), urgency incontinence (-1.0), and nocturia (-0.7) were significantly reduced with tolterodine (all, P<0.01). The mean voided volume significantly increased with tolterodine (32 mL; P=0.05). Approximately 90% of patients experienced an improvement of at least one point in their bladder condition, and 62.5% reported improvements of at least two points on the PPBC questionnaire.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				A total of 73.2% of patients wished to continue treatment after receiving three months of treatment. The most common adverse events were dry mouth (21.7%), constipation or indigestion (10.0%), headache (5.0%), UTI (3.3%) and peripheral edema (1.7%).
Van Kerrebroeck et al.[91] (2001) Tolterodine ER 4 mg once daily vs tolterodine IR 2 mg twice daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥5 incontinence episodes/week) for ≥6 months	N=1,529 12 weeks	Primary: Incontinence episodes/week, number of micturition/24 hours, volume voided/micturition, and the number of pads used/24 hours Secondary: Not reported	Primary: The mean change in incontinence episodes/week was significantly better with tolterodine ER (-11.8; P=0.0001) and tolterodine IR (-10.6; P=0.0005) compared to placebo (-6.9). The median percentage reductions in incontinence episodes/week were: tolterodine ER, 71%; tolterodine IR, 60%; and placebo, 33%. Tolterodine ER was 18% more effective than tolterodine IR (P<0.05). The mean change in number of micturitions/24 hours was significantly better with tolterodine ER (-1.8; P=0.0047) and tolterodine IR (-1.7; P=0.0079) compared to placebo (-1.2). The mean change in volume voided/micturition was significantly greater with tolterodine ER (34 mL; P=0.0001) and tolterodine IR (29 mL; P=0.0001) compared to placebo (14 mL). The mean change in number of pads used/24 hours was significantly lower with tolterodine ER (-0.5; P=0.0145) and tolterodine IR (-0.5; P=0.0035) compared to placebo (-0.2). The most common adverse events in all treatment groups were dry mouth, constipation, and headache. With the exception of dry mouth, the incidence of adverse events was comparable between active treatment and placebo. The rate of dry mouth was 23, 30, and 8% for tolterodine ER, tolterodine IR, and placebo, respectively. Patients receiving tolterodine ER had 23% less dry mouth than those taking tolterodine IR (P=0.02). Discontinuation rates due to adverse events were similar in all the treatment groups (tolterodine ER, 5%; tolterodine IR, 5%; placebo, 6%). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Swift et al.[92] (2003) Tolterodine ER 4 mg once daily vs tolterodine IR 2 mg twice daily vs placebo	DB, MC, PC, RCT (Subgroup analysis) Women ≥18 years of age with urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥5 incontinence episodes/week) for ≥6 months	N=1,235 12 weeks	Primary: Incontinence episodes/week, number of micturition/24 hours, volume voided/micturition, and the number of pads used/24 hours Secondary: Not reported	Primary: The mean change in incontinence episodes/week was significantly better with tolterodine ER (-11.8; P=0.001) and tolterodine IR (-10.1; P=0.001) compared to placebo (-7.2). The difference between tolterodine ER and tolterodine IR was significant (P=0.036). The median percentage reductions in incontinence episodes/week were: tolterodine ER, 71%; tolterodine IR, 57%; and placebo, 33%. The mean change in number of micturitions/24 hours was significantly better with tolterodine ER (-1.9; P=0.001) and tolterodine IR (-1.7; P=0.005) compared to placebo (-1.2). There was no significant difference between tolterodine ER and tolterodine IR. The mean change in volume voided/micturition was significantly greater with tolterodine ER (37.9 ml; P=0.001) and tolterodine IR (32.5 mL; P=0.001) compared to placebo (13.3 mL). There was no significant difference between tolterodine ER and tolterodine IR. The mean change in number of pads used/24 hours was significantly lower with tolterodine ER (-0.6; P=0.001) and tolterodine IR (-0.5; P=0.001) compared to placebo (-0.2). There was no significant difference between tolterodine ER and tolterodine IR. Dry mouth, constipation, headache and UTI were the most common adverse events in all treatment groups. With the exception of dry mouth, the incidence of adverse events was comparable between active treatment and placebo. There was no significant difference in dry mouth with tolterodine ER or tolterodine IR (P=0.06). Discontinuation rates due to adverse events were similar in all the treatment groups (tolterodine ER, 5%; tolterodine IR, 5%; placebo, 6%). Secondary: Not reported
Homma et al.[93] (2003)	AC, DB, PC, RCT,	N=608	Primary: Incontinence	Primary: The number of incontinence episodes/24 hours was significantly decreased

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Tolterodine ER 4 mg once daily vs oxybutynin IR 3 mg three times daily vs placebo	Patients ≥20 years of age with OAB and symptoms of urinary urgency, urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥5 episodes/week) for ≥6 months	12 weeks	episodes/week Secondary: Voids/24 hours and mean volume voided/void, median number of incontinence pads used/24 hours, patient perception of bladder condition, patient perception of urgency, and QOL using the KHQ	with tolterodine (median -78.6%; P=0.0027) and oxybutynin (median -76.5%; P=0.0168) compared to placebo (-46.4%). There was no significant difference between tolterodine and oxybutynin (P=0.4469). Secondary: The number of voids/24 hours decreased with tolterodine (-2.0; P<0.001) and oxybutynin (-2.1; P=0.0114) compared to placebo (-1.1). There was no significant difference among the treatment groups (P=0.3132). The volume voided/void increased significantly with tolterodine (17.2 mL; P=0.0086) and oxybutynin (22.3 mL; P<0.001) compared to placebo (6.6 mL). The number of pads used/24 hours was not significantly different among the treatment groups. Approximately 72% of patients treated with tolterodine and 73% treated with oxybutynin perceived improvement after 12 weeks of treatment compared to 59% of patients treated with placebo. The difference between tolterodine and placebo was NS (P=0.515). There was no significant difference between tolterodine and oxybutynin (P=0.9394). Significantly more patients reporting at least some benefit with tolterodine (79%; P=0.0091; little benefit 36%; much benefit, 42%) and oxybutynin (81%; P<0.001; little benefit 29%; much benefit 53%) than with placebo (66%; little benefit 40%; much benefit 25%). There was no significant difference between tolterodine and oxybutynin in the assessment of treatment benefit (P=0.2240). Treatment with tolterodine and oxybutynin resulted in significantly greater mean reductions in both the incontinence impact domain and role limitation domain scores (KHQ questionnaire) compared to placebo. There was no significant difference between the improvements with tolterodine and oxybutynin for either domain. Tolterodine and oxybutynin were associated with improvements in other KHO domains, including physical limitations, social limitations, personal relationships, sleep/energy, severity measures, and the severity of urinary symptoms compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				placebo. The differences in improvements between tolterodine and oxybutynin were NS for any of these domains. Dry mouth was the most common adverse event reported with tolterodine (33.5%), oxybutynin (53.7%) and placebo (9.8%). Dry mouth was more common in patients receiving oxybutynin than tolterodine (P<0.001). Other adverse events occurring in >5% of patients were constipation, abdominal pain/tenderness, dyspepsia, difficulty in voiding and headache. Eye disorders occurred in significantly more patients receiving oxybutynin than tolterodine (P<0.0383). The incidence of nervous system disorders was lower in the tolterodine group (8.4%) than in the oxybutynin group (12.7%) or placebo group (11.5%). More patients on oxybutynin withdrew due to adverse events compared to tolterodine (P<0.001).
Sussman et al.[94] (2002) Trial 1 Tolterodine ER 2 to 4 mg once daily Trial 2 Oxybutynin ER 5 to 10 mg once daily	OL, RCT Patients ≥18 years of age with OAB and symptoms of urinary frequency and urgency with or without urge incontinence	Trial 1 N=669 8 weeks Trial 2 N=620 8 weeks	Primary: Patient perception of bladder condition and patient assessment of treatment benefit Secondary: Physician assessment of treatment benefit	Primary: Seventy percent of patients in the tolterodine 4 mg group perceived an improvement in their bladder condition compared to 60% in the tolterodine 2 mg group, 59% in the oxybutynin 5 mg group, and 60% in the oxybutynin10 mg group (all P<0.01 vs tolterodine 4 mg). There was a greater percentage of patients who reported an improved bladder condition with tolterodine 4 mg compared to oxybutynin 10 mg (77 vs 65%; P<0.01) in those whose perception of bladder condition was moderate to severe at baseline. There was no significant difference in the perception of their bladder condition among treatment-naïve patients (P=0.11) and those who had received prior antimuscarinic therapy (P=0.11). Secondary: There was no significant difference in patient assessment or physician's assessment of treatment benefit between tolterodine and oxybutynin. Dry mouth was dose-dependent in both trials (tolterodine 2 mg vs tolterodine 4 mg; P=0.09; oxybutynin 5 mg vs oxybutynin 10 mg; P=0.05). Patients treated with tolterodine 4 mg reported a significantly

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				lower severity of dry mouth compared to oxybutynin 10 mg (P=0.03).
Chung et al.[95] (2010) Tolterodine ER 4 mg once daily and dutasteride 0.5 mg once daily	OL Men ≥45 years of age on dutasteride 0.5 mg for at least 6 months who failed alpha-blocker therapy, prostate >30 g, an IPSS ≥12, IPSS QOL item ≥3, ≥8 voids per 24 hours, ≥3 urgency episodes per 24 hours with or without urgency incontinence, and self-rated bladder condition on patient perception of bladder condition of hours at least "some moderate bother"	N=51 12 weeks	Primary: Change in frequency, nocturnal OAB micturition, IPSS, Qmax, change in PVR, adverse events, and episodes of urinary retention requiring a catheter Secondary: Not reported	Primary: Tolterodine ER significantly reduced frequency and urgency. Specifically, tolterodine reduced 24 hours micturition frequency (-3.2; P<0.02), OAB episodes (19.2%; P<0.03), severe OAB episodes (71.4%; P<0.05), and nighttime voiding (-0.9; P<0.003). Patients reported a reduction in 24 hours frequency from baseline 11.9 episodes to 10.2 episodes after three months of dutasteride, which further decreased to 8.7 after 12 weeks of tolterodine ER. IPSS decreased with the initial addition of dutasteride (19.3 to 14.3) and further decreased with the addition of tolterodine ER (7.1; P<0.001). There were no significant decreases in Qmax with the addition of tolterodine ER and tolterodine ER did not significantly increase PVR. Additionally, zero patients required catheterization. Four patients (7.5%) experienced dry mouth, one patient (2%) had constipation, and sexual function decreased in two patients (3.9%). Secondary: Not reported
Chung et al.[96] (2011) Tolterodine ER 4 mg once daily plus doxazosin 4 mg and/or dutasteride 0.5 mg once daily vs doxazosin 4 mg	OS, PRO, RCT Male patients ≥70 years of age with an IPSS score >8 and a storage subscore of >5, QOL index score >3, total prostate volume >20 mL, Qmax <15 mL/second, and with urodynamic confirmed	N=153 12 months	Primary: Improvement in IPSS subscores (voiding and storage) at 12 months Secondary: Change in PVR volume, and QOL-I	Primary: The mean IPSS-voiding (8.5 to 2.88 with tolterodine [P<0.001], 9.83 to 4.78 without tolterodine [P<0.001]), IPSS-storage (9.44 to 5.18 with tolterodine [P<0.001], 8.34 to 6.92 without tolterodine [P<0.001]), and IPSS-total (18.1 to 8.06 with tolterodine [P<0.001], 18.2 to 11.7 without tolterodine [P<0.001]) improved similarly in both groups by 12 months follow-up. The patients receiving tolterodine ER experienced a better reduction of IPSS-storage symptoms (4.26 vs 1.42; P<0.001). Secondary: The change of PVR in the patients who received tolterodine ER did not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and/or dutasteride 0.5 mg once daily	BPH/BOO			differ significantly from those who did not (15.2 vs 8.9 mL; P=0.69). QoL-I also improved in both groups, but change was not significantly different from each other (1.62 vs 1.46; P=0.551). Both groups demonstrated a significant improvement in Qmax compared to baseline, but there was not a significant difference between the two groups (P=0.275). Intolerable dry mouth, constipation, and dizziness were the most commonly reported adverse events and numerically occurred more in patients who received tolterodine ER.
Abrams et al.[97] (2001) Tolterodine IR 2 mg twice daily	ES, OL Patients ≥18 years of age with urinary frequency (≥8 micturitions/24 hours), urgency, and/or urge incontinence (≥1 incontinence episode/24 hours)	N=714 12 months	Primary: Number of micturitions/24 hours, number of urge incontinence episodes/24 hours, mean urine volume voided/micturition, safety Secondary: Not reported	Primary: The number of micturitions/24 hours significantly decreased with tolterodine (-2.4; P=0.0001; mean change, -20%). The number of urge incontinence episodes/24 hours significantly decreased with tolterodine (-1.3; P=0.0001; median change, -74%). The change in volume voided/micturition significantly increased with tolterodine (33 mL; P=0.0001; mean change, 18%). Approximately 69% of patients who received tolterodine perceived improvement after 12 months of therapy. The most frequently occurring adverse events were autonomic nervous system disorders (46%), general body disorders (22%), gastrointestinal disorders (22%) and urinary disorders (18%). The most frequently report adverse event was dry mouth, which occurred in 41% of patients (27% mild, 10% moderate, 3% severe). The most common adverse events leading to withdrawal were adverse events (15%), withdrawal of consent (13%), lost to follow-up (4%) and other (6%). A total of 34 (5%) patients withdrawing from the study due to dry mouth.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Appell et al.[98] (2001) Tolterodine IR 2 mg twice daily	ES, OL Patients ≥18 years of age with OAB, increased urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥1 incontinence episode/24 hours) or urinary frequency	N=854 9 months	Primary: Safety and tolerability Secondary: Efficacy	Primary: The most frequently reported adverse events were autonomic nervous system disorders (31%), gastrointestinal disorders (24%) and general body disorders (26%). The most frequently report adverse event was dry mouth, which occurred in 28% of patients (19% mild, 7% moderate, 2% severe). Of those patients enrolled in the OL trial, 30% did not complete nine months of therapy. The most common reasons for withdrawal were adverse events (9%), lack of efficacy (6%), lot to follow-up (6%) and withdrawal of consent (4%). Secondary: The number of micturitions/24 hours significantly decreased with tolterodine (-2.5; P=0.0001; median change, -22%). The number of urge incontinence episodes/24 hours significantly decreased with tolterodine (-2.0; P=0.0001; median change, -76%). The change in volume voided/micturition significantly increased with tolterodine (40 mL; P=0.0001; median change, 22%). Approximately 65% of patients who received tolterodine perceived improvement after nine months of therapy. Secondary: Not reported
Kilic et al.[99] (2006) Tolterodine IR 1 mg twice daily vs	PRO, RCT Children with detrusor instability (most with symptoms of nocturnal enuresis	N=60 ≥6 months	Primary: Urodynamic investigations before and after treatment, episodes of UUI, and adverse events	Primary: The tolterodine group had a significant increase in the bladder capacity from 148.5 to 239.33 mL; P<0.001, an increase in compliance from 4.6 to 12.57; P<0.001, and a decrease in the maximum detrusor pressure from 79.43 to 40.4 cm H_20; P<0.001. In the oxybutynin group, a significant increase in bladder capacity from

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
oxybutynin IR 0.4 mg/kg three times daily	associated with daytime incontinence, frequency, urgency, and/or small bladder volume)		Secondary: Not reported	154.67 to 255.23 mL; P<0.001, an increase in compliance from 5.13 to 13.07; P<0.001, and a decrease in the maximum detrusor pressure from 85.47 to 39.43 cm H_20; P<0.001, were found. Increase in the bladder capacity and compliance during cystometry and reduction in the maximal bladder pressure over the period were similar for tolterodine and oxybutynin groups. While there was not a statistically significant difference between the groups, both had a significant reduction in detrusor instability after six months (100 to 30.0% for tolterodine and 100 to 23.3% for oxybutynin). Clinical response was also similar between tolterodine and oxybutynin (73.3% for tolterodine and 80.0% for oxybutynin; P>0.05). Adverse events were significantly lower in the tolterodine group compared to the oxybutynin group (13 vs 27 events; P=0.027). Eight patients in the oxybutynin group were crossed over to tolterodine due to adverse effects. Secondary: Not reported
Appell et al.[100] (1997) Tolterodine IR 1 to 2 mg twice daily vs oxybutynin IR 5 mg three times daily vs placebo	DB, MC, PC, RCT (Pooled analysis) Patients ≥18 years of age with OAB, increased urinary frequency (≥8 micturitions/24 hours) and urge incontinence (≥1 incontinence episode/24 hours) or urinary frequency	N=1,120 (4 trials) 12 weeks	Primary: Number of micturitions/24 hours, number of incontinence episodes/24 hours, and mean urinary volume voided/micturition Secondary: Not reported	Primary: The number of micturitions/24 hours significantly decreased with tolterodine 1 mg (P<0.001), tolterodine 2 mg (P<0.001), and oxybutynin (P<0.01) compared to placebo. There was no significant difference between tolterodine 2 mg and oxybutynin. The number of incontinence episodes/24 hours significantly decreased with tolterodine (1 and 2 mg) and oxybutynin compared to placebo (P<0.05). There was no significant difference between tolterodine 2 mg and oxybutynin. The change in volume voided/micturition significantly increased with tolterodine (1 and 2 mg) and oxybutynin compared to placebo (P<0.001). Approximately 39% of patients who received placebo, 41% treated with tolterodine 1 mg, 52% treated with tolterodine 2 mg (P=0.003 vs placebo),

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and 50% treated with oxybutynin (P=0.017 vs placebo) perceived improvement after 12 weeks of treatment. Dry mouth was the most common adverse event (16% of the placebo group, 24% of the tolterodine 1 mg group, 40% of the tolterodine 2 mg group, and 78% of the oxybutynin group). The percentage of patients reporting dry mouth was significantly higher in the oxybutynin group than in the tolterodine or placebo groups (all, P<0.001). The percentage of patients reporting moderate or severe dry mouth was higher in the oxybutynin group (60%) compared to the tolterodine 1 mg group (4%), tolterodine 2 mg group (17%), and placebo group (6%; all, P<0.001). Other commonly reported adverse events included headache, dyspepsia, dizziness, and UTI. Dyspepsia was reported at a higher rate with oxybutynin (11%) than with tolterodine2 mg (6%; P=0.006). The proportion of patients who withdrew because of adverse events was higher in the oxybutynin group than in either of the tolterodine groups or the placebo group (all, P<0.001). Secondary: Not reported
Lee et al.[101] (2002) Tolterodine IR 2 mg twice daily vs oxybutynin IR 5 mg twice daily	DB, MC, PG, RCT Patients ≥18 years of age with OAB and symptoms of urinary urgency and frequency (≥8 micturitions/24 hour) for ≥6 months	N=228 8 weeks	Primary: Number of micturition/24 hours and incontinence episodes/24 hours Secondary: Not reported	Primary: The number of micturitions/24 hours decreased with tolterodine (-2.6) and oxybutynin (-1.8) compared to baseline. There was no significant difference among the treatment groups (P=0.14). In patients who were incontinent at baseline, the number of incontinence episodes/24 hours decreased with tolterodine (-2.2) and oxybutynin (-1.4). There was no significant difference among the treatment groups (P=0.10). Overall, 45% of patients who received tolterodine and 46% of patients who received oxybutynin reported 'much' benefit. There was no significant difference among the groups. The most frequently reported adverse events were autonomic nervous system disorders, gastrointestinal disorders, and urinary disorders. Dry mouth was the most commonly reported adverse event and was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				significantly higher with oxybutynin than tolterodine (P=0.001). There was a higher frequency of moderate-to-severe dry mouth with oxybutynin (28%) than tolterodine (9%). Secondary: Not reported
Malone-Lee et al.[102] (2001) Tolterodine IR 2 mg twice daily vs oxybutynin IR 5 mg twice daily	DB, MC, RCT Patients ≥50 years of age with OAB, increased urinary frequency (≥8 micturitions/24 hours), and symptoms of urgency and/or urge incontinence (≥1 episode/24 hours)	N=379 10 weeks	Primary: Number of micturition/24 hours, incontinence episodes/24 hours and volume voided/micturition Secondary: Not reported	Primary: The number of micturitions/24 hours decreased with tolterodine (-1.7) and oxybutynin (-1.7). There was no significant difference among the treatment groups (P=0.97). The number of incontinence episodes/24 hours decreased with tolterodine (-1.3) and oxybutynin (-1.8). There was no significant difference among the treatment groups (P=0.065). The change in volume voided/micturition increased with tolterodine (33 mL) and oxybutynin (34 mL). There was no significant difference among the treatment groups (P=0.90). Approximately 45% of patients treated with tolterodine and 41% treated with oxybutynin perceived improvement after 12 weeks of treatment. There was no significant difference among the treatment groups. Autonomic nervous system disorders and gastrointestinal problems were the most commonly reported adverse events. A higher percentage of patients experienced dry mouth with oxybutynin (61%) than with tolterodine (37%). Severe dry mouth was more common in the oxybutynin group (15%) than in the tolterodine group (4%). The proportion of patients who withdrew because of adverse events was similar in the oxybutynin group (15%) and in the tolterodine group (15%). Secondary: Not reported
Abrams et al.[103] (1998)	DB, MC, PC, RCT Patients ≥18 years	N=293 12 weeks	Primary: Number of micturition/24	Primary: The mean change in number of micturitions/24 hours was significantly lower with tolterodine (-2.7; P=0.0022) compared to placebo (-1.6). There

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Tolterodine IR 2 mg twice daily vs oxybutynin IR 5 mg three times daily vs placebo	of age with OAB, increased urinary frequency (≥8 micturitions/24 hours), and symptoms of urgency and/or urge incontinence (≥1 episode/24 hours) for ≥6 months		hours, incontinence episodes/24 hours and volume voided/micturition Secondary: Not reported	was no difference between oxybutynin (-2.3) and placebo (P=0.068). There was also no significant difference between tolterodine and oxybutynin (95% CI, -1.1 to 0.1). The number of incontinence episodes/24 hours significantly decreased with oxybutynin (-1.7; P=0.023) compared to placebo (-0.9). There was no difference between tolterodine (-1.3) and placebo (P=0.22). There was also no significant difference between tolterodine and oxybutynin (95% CI, -0.2 to 1.0). The change in volume voided/micturition significantly increased with tolterodine (38 mL) and oxybutynin (47 mL) compared to placebo (6 mL; P<0.001). Approximately 47% of patients who received placebo, 50% treated with tolterodine, and 49% treated with oxybutynin perceived improvement after 12 weeks of treatment. There was no significant difference among the groups. Dry mouth was the most common adverse event. It was reported at a significantly higher rate with both tolterodine (50%) and oxybutynin (86%) than placebo (21%; P<0.001). It was also more common with oxybutynin than tolterodine (P<0.001). The proportion of patients who withdrew because of adverse events was higher in the oxybutynin group (17%) than in the tolterodine (8%) or placebo (12%) groups. Secondary: Not reported
Drutz et al.[104] (1999) Tolterodine IR 2 mg twice daily vs	DB, MC, PC, RCT Patients ≥18 years of age with OAB, increased urinary frequency (≥8 micturitions/24	N=277 12 weeks	Primary: Number of micturition/24 hours, incontinence episodes/24 hours and volume voided/micturition	Primary: The number of micturitions/24 hours significantly decreased with tolterodine (-2.0; P=0.036) compared to placebo (-1.1). There was no difference between oxybutynin (-2.0) and placebo (P=0.066). There was also no significant difference between tolterodine and oxybutynin (95% CI, -0.8 to 0.8).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
oxybutynin IR 5 mg three times daily vs placebo	hours), and symptoms of urgency and/or urge incontinence (≥1 episode/24 hours)		Secondary: Not reported	The number of incontinence episodes/24 hours was not significantly different with tolterodine (-1.7; P=0.063) or oxybutynin (-1.7; P=0.10) compared to placebo (-1.0). There was no significant difference between tolterodine and oxybutynin (95% CI, -0.7 to 0.7). The change in volume voided/micturition significantly increased with tolterodine (34 mL; P=0.0075) and oxybutynin (50 mL; P=0.0001) compared to placebo (12 mL). Dry mouth was the most common adverse event (15% of the placebo group, 30% of the tolterodine group, and 69% of the oxybutynin group). The percentage of patients reporting dry mouth was significantly higher in the oxybutynin group than in the tolterodine group (P<0.001). The percentage of patients reporting moderate or severe dry mouth was higher in the oxybutynin group (44%) compared to the tolterodine group (9%), and placebo group (7%). Other more commonly reported adverse events with oxybutynin were headache (10%) and dizziness (11%). Headache occurred in 15% of patients receiving tolterodine. The proportion of patients who withdrew because of adverse events was higher in the oxybutynin group (31%) than in the tolterodine (13%) or placebo (14%) groups. Secondary: Not reported
Leung et al.[105] (2002) Tolterodine IR 2 mg twice daily vs oxybutynin IR 5 mg three times daily	DB, MC, RCT Women ≥18 years of age with OAB, increased urinary frequency (≥8 micturitions/24 hours), and symptoms of urgency and/or urge incontinence (≥1 episode/24 hours)	N=106 10 weeks	Primary: Tolerability Secondary: Efficacy	Primary: The median drug compliance rate was 87.5% with oxybutynin and 75% in with tolterodine (P=0.778). Adverse events occurred in 49.1% of patients treated with oxybutynin and 60.4% of patients treated with tolterodine (P=0.329). The proportion of patients who withdrew was 15.1% with oxybutynin and 17.0% with tolterodine (P=1.0). Secondary: There was no significant difference in frequency of micturition (P=0.965),

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				urgency episodes (P=0.672), incontinence episodes (P=0.993), or pad use (P=0.665) among the treatment groups.
Giannitsas et al.[106] (2004) Tolterodine IR 2 mg twice daily for 6 weeks vs oxybutynin IR 5 mg three times daily for 6 weeks	OL, RCT, XO Patients ≥18 years of age with OAB who were categorized according to the characteristics of the first overactive detrusor contraction during filling cystometrogram: high volume–low pressure (grade-group I), high volume–high pressure (grade-group II), low volume–low pressure (grade-group III) and low volume–high pressure (grade-group IV)	N=128 12 weeks	Primary: Volume voided/micturition, number of micturition/24 hours, incontinence episodes/24 hours, and other urodynamic parameters in the total population and individual severity groups Secondary: Not reported	Primary: <u>Total Study Population</u> The mean volume voided/micturition was significantly increased with tolterodine (40.6 mL) and oxybutynin (43.8 mL) and there was no significant difference among the treatment groups. The mean change in number of micturitions/24 hours was -0.9 with tolterodine and -0.8 with oxybutynin (which reached statistical significance only with tolterodine). There was an increase in the 24 hour volume of urine with both treatments; however it was only statistically significant with oxybutynin. Overactivity index was significantly decreased with tolterodine and oxybutynin; there was no significant difference among the treatment groups. There was a significant increase in bladder volume at first desire to void with tolterodine and oxybutynin, which was significantly higher with oxybutynin. The volume at first overactive detrusor contraction and maximum cystometric capacity were significantly increased with tolterodine and oxybutynin; there was no significant difference among the treatment groups. There was no significant change in pressure of first overactive contraction with tolterodine or oxybutynin. <u>Low volume–High pressure Overactivity (Group IV)</u> The mean volume voided/micturition was significantly increased with tolterodine (39.7 mL) and oxybutynin (54.2 mL) and there was no significant difference among the treatment groups. The mean change in number of micturitions/24 hours was -0.9 with tolterodine and -1.0 with oxybutynin; there was no significant difference among the treatment groups. There was an increase in the 24 hour volume of urine with both treatments; however it was only statistically significant with oxybutynin.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Overactivity index was significantly decreased with oxybutynin. Volume at first desire to void was significantly increased with oxybutynin and volume at first overactive contraction was significantly increased with tolterodine. There was no significant change in pressure of first overactive contraction with tolterodine or oxybutynin. Low volume–Low pressure Overactivity (Group III) The mean volume voided/micturition was significantly increased with tolterodine (48.8 mL) and oxybutynin (43.1 mL) and there was no significant difference among the treatment groups. There were no significant changes in the rest of voiding diary parameters in this group. Overactivity index was significantly reduced with tolterodine only. Volume at first desire to void was increased significantly with tolterodine and oxybutynin; there was no significant difference among the treatment groups. There were no significant changes for pressure of first overactive contraction and cystometric capacity with tolterodine or oxybutynin. High volume–High pressure Overactivity (Group II) Changes in clinical parameters did not reach statistical significance. Overactivity index was reduced by tolterodine and oxybutynin; there was no significant difference among the treatment groups. Oxybutynin achieved an increase in volume at first desire to void and volume at first overactive contraction. There were no significant changes in max cystometric capacity and pressure of first overactive contraction. High volume–Low pressure Overactivity (Group I) The small number of patients in this group did not allow for statistical analyses to be performed. Secondary: Not reported
Harvey et al.[107] (2001)	MA	4 trials	Primary: Incontinent	Primary: The mean change in number of micturitions/24 hours was not significantly

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Tolterodine IR 1 to 2 mg twice daily vs oxybutynin IR 2.5 to 5 mg three times daily	Patients ≥18 years of age with OAB, increased urinary frequency (≥8 micturitions/24 hours), and symptoms of urgency and/or urge incontinence (≥1 episode/24 hours)	12 weeks	episodes/24 hours, quantity of pad used/24-hour period, micturitions/24 hours, and voided volume/micturition Secondary: Adverse events	different between tolterodine and oxybutynin (WMD, 0.00; 95% CI, -0.38 to 0.38). The number of incontinence episodes/24 hours significantly favored oxybutynin compared to tolterodine (WMD, 0.41; 95% CI, 0.04 to 0.77). The change in volume voided/micturition significantly favored oxybutynin (–8.24 mL; 95% CI, –14.11 to –2.38). This translates to an average increase in the volume voided/micturition of more than 8 mL among patients using oxybutynin compared to patients using tolterodine. Secondary: Dry mouth was significantly lower with tolterodine than oxybutynin (RR, 0.54; 95% CI, 0.48 to 0.61), including moderate to severe dry mouth (RR, 0.33; 95% CI, 0.24 to 0.45). There were fewer patients who withdrew from studies due to dry mouth with tolterodine compared to oxybutynin (RR, 0.63; 95% CI, 0.46 to 0.88).
Staskin et al.[108] (2004) Trospium 20 mg twice daily vs placebo	DB, MC, PC, RCT Patients with OAB	N=658 12 weeks	Primary: Central nervous system adverse effects and daytime sleepiness using the SSS Secondary: Not reported	Primary: After 12 weeks of treatment, 2.5% of patients receiving placebo and 1.5% of patients receiving trospium exhibited a clinically significant increase (3 points or greater) from baseline in their SSS scores. There was no significant difference between the treatment groups. In a subgroup analysis based on age (<65 and ≥65 years of age; <75 and ≥75 years of age), there was no significant difference in SSS scores among the treatment groups. Approximately 5.8% of patients receiving trospium and 5.2% of patients receiving placebo reported at least one central nervous system adverse event. Somnolence was reported by 0.3% of patients receiving trospium and 0.6% of patients receiving placebo. Sedation was reported by 0.3% of patients receiving placebo and no patients reported sedation with trospium. Secondary: Not reported
Halaska et al.[109] (2003)	AC, DB, MC, RCT	N=358	Primary: Safety and efficacy	Primary: Blood chemistry, nitrogenous metabolites, uric acid, and sodium and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Trospium (TCl) 20 mg twice daily vs oxybutynin IR (OXY) 5 mg twice daily	Patients ≥18 years of age with urge syndrome, urge incontinence, urge incontinence as one component of mixed incontinence, or urge incontinence due to a neurological condition (detrusor hyperreflexia)	52 weeks	Secondary: Not reported	potassium were not adversely affected by either treatment. Systolic and diastolic blood pressure were unaffected by the treatments. A pulse rate of >100 beats/min was noted in 27 patients treated with TCl (10.1%) as compared to six patients in the OXY group (6.7%). In the TCl group at 26 and 52 weeks of treatment, 49 and 63% of the trial physicians assessed tolerability as very good, respectively. In the OXY group, the assessment by the trial physicians at the same points showed very good tolerability in 36 and 42% of patients, respectively. Appraisal by the patients led to similar results. Adverse events were observed in 64.8% of patients in the TCl group and 76.7% of patients in the OXY group. Dry mouth was the most common adverse event and was reported by 33% of patients treated with TCl and 50% of those treated with OXY. UTI was reported by 12% of patients receiving TCl and 11% of patients receiving OXY. For the adverse events taken as a whole, the differences between TCl and OXY were significant with regards to time to event (P<0.01). There was also a significant difference between the two treatment groups in favor of TCl for the overall total of adverse events having probable or possible connections with the trial medication (P=0.02), for all gastrointestinal adverse events with this classification (P=0.02) and for dryness of the mouth (P<0.01). When the number of adverse events is viewed in relation to the total number of patients treated and the duration of treatment, the risk of occurrence of an adverse event/patient/week is 0.027 for TCl and 0.045 for OXY (RR, 0.6 in favor of TCl). Patients treated with TCl showed increases in maximum cystometric bladder capacity of 92 mL at 26 weeks and 115 mL at 52 weeks. The OXY group showed increases of 117 and 119.4 mL respectively. The changes from baseline were significant in both treatment arms (P=0.001). There was no significant difference between the treatment groups. The increase in volume at the first unstable contraction was 46.0 mL with TCl and 36.7 mL with OXY. There was no significant difference between the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference between the treatment groups in the volume at the first sensation to void, as well as of other urodynamic parameters. The frequency of micturition in the TCl group decreased by 1.2 micturitions/day at two weeks, 2.9 micturitions/day at 26 weeks and 3.5 micturitions/day at 52 weeks. In frequency of micturitions in the OXY group decreased by 1.5 micturitions/day at two weeks, 3.4 micturitions/day at 26 weeks and 4.2 micturitions/day at 52 weeks. Episodes of urgency in the TCl group decreased by 1.6 at two weeks, 3.2 at six weeks and 3.5 at 52 weeks. In the OXY group, episodes of urgency decreased by 1.7 at 2 weeks, 3.2 at 26 weeks and 3.6 at 52 weeks. After 52 weeks of treatment, 29 and 17% of the physicians considered the therapeutic outcome for the TCl and OXY groups as ‘‘cure’’, respectively. The results were similar with regards to patient assessments. Secondary: Not reported
Madersbacher et al.[110] (1995) Trospium (TCl) 20 mg twice daily vs oxybutynin IR (Oxy) 5 mg three times daily	DB, MC, RCT Patients with detrusor hyperreflexia	N=95 2 weeks	Primary: Maximum bladder capacity and maximum voiding detrusor pressure during micturition Secondary: Bladder compliance, residual urine, adverse events	Primary: Maximum bladder capacity in the TCl group increased significantly by 96.6 mL (P<0.001). In the Oxy group, maximum bladder capacity increased by 163.0 mL (P<0.001). There was no significant difference between the treatment groups (P=0.057). Maximum detrusor pressure during micturition decreased by 35.4 cmH_20 (P<0.001) in the TCl group and 38 cmH_20 (P<0.001) in the Oxy group. There was no significant difference between the treatment groups (P=0.63). Secondary: Bladder compliance increased by 16.96 mL/cm H_20 (P<0.001) in the TCl group and by 22.56 mL/cmH_20 in the Oxy group (P<0.001). There was no significant difference between the treatment groups (P=0.43).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Residual urine increased by 76.45 mL in the TC1 group and 114.08 in the Oxy group. There was no significant difference between the treatment groups (P=0.19). There was no significant difference between the treatment groups with regards to the frequency of hyper-reflexive waves (P=0.16). There were no significant changes in blood pressure among the treatment groups. The rate of adverse events was similar in both groups. Dry mouth occurred in 54% of patients in the TCl group and 56% of patients in the Oxy group. The severity grading showed that dryness of the mouth deteriorated to 'severe' in 4% of patients receiving TC1 and 23% of patients receiving Oxy. Withdrawal from the trial occurred more frequently in patients taking Oxy (16%) than in those taking TCl (6%). The Oxy patients withdrew earlier (after an average of 7.1 days) than the TCl patients (after an average of 14.3 days).
Zinner et al.[111] (2011) Trospium ER 60 mg once daily	ES, OL Patients ≥18 years of age with symptoms of OAB for ≥6 months who met the following criteria: urinary frequency ≥30 toilet voids per 3 days, ≥1 severe urgency severity rating per 3 days, and ≥3 UUI episodes per 3 days	N=944 48 weeks	Primary: Changes in the mean number of toilet voids per day and UUI episodes per day Secondary: Urgency severity associated with toilet voids, voided volume per void, daily urgency frequency associated with toilet voids, OAB-PGA, KHQ, and OAB-q	Primary: There were reductions from baseline in the number of daily toilet voids and UUI episodes in both the placebo-to-trospium and trospium-to-trospium groups. The mean change in number of toilet voids per day was -3.2 (-24.5%) in the placebo-to-trospium group and -3.4 (-25.5%) in the trospium-to-trospium group at week 48. The median change in the number of UUI episodes per day was -2.3 in both groups (-85.7%). Secondary: Urgency severity associated with toilet voids, voided volume per void, and daily urgency frequency associated with toilet voids all improved in both groups. Significant improvements in OAB-PGA findings were present with both groups. Patients in the placebo-to-trospium and trospium-to-trospium groups reported improvements from baseline in individual questions addressing toilet void frequency (84.1 and 85.1%, respectively), UUI (79.9 and 82.6%, respectively), and urgency severity (79.2 and 81.6%, respectively). Overall OAB symptoms improved in approximately 84% of patients.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				KHQ and OAB-q demonstrated improvements with both groups at week 48. Overall, 552 patients (58.5%) experienced ≥1 treatment emergent adverse events, of which 197 were considered at least possibly related to study medication. Dry mouth (n=60) and constipation (n=59) were the most common adverse events reported.
Bolduc et al.[112] (2009) Combination antimuscarinic therapy (oxybutynin 10 to 30 mg, tolterodine ER 4 mg, and/or solifenacin 5 to 10 mg)	OL, PRO Children with OAB, persistent incontinence and a partial urodynamic response to an optimal dose of a well-tolerated, ER antimuscarinic drug	N=33 ≥6 months	Primary: Efficacy for continence Secondary: Safety and tolerability	Primary: Continence improved in all cases. A total of 17 (52%), 14 (42%), and two patients (6%) rated 100% improvement (complete dryness), a >90% decrease in incontinence episodes and a 50 to 89% decrease, respectively. MVV in three-day diaries improved from 165 to 330 mL. Cystometric bladder capacity improved from 192 to 380 mL without any deterioration in compliance and maximum detrusor contraction pressure decreased from 77 to 18 cm H_20 (P<0.01). Secondary: Overall, 12 patients (36%) reported no adverse effects, 16 (48%) reported mild adverse effects (dry mouth, constipation, blurred vision, and headache), and 5 (15%) had a moderate adverse effect (dry mouth). No patients discontinued therapy due to adverse effects.
Chapple et al.[113] (2008) Darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium	MA Patients ≥18 years of age with OAB	73 trials ≥2 weeks	Primary: Incontinence episodes/day, number of micturitions/day, urgency episodes/day, volume voided/micturition, proportion of patients returning to continence, proportion of patients undergoing global	Primary: Antimuscarinic agents were significantly more effective than placebo with regards to the mean change in the number of incontinence episodes/day. Pooled differences in mean changes ranged from 0.4 to 1.1 incontinence episodes per day. Tolterodine 2 mg IR was not more effective than placebo; however, the 4 mg ER/IR formulations were more effective than placebo. There were no significant differences among the antimuscarinic agents with the exception of fesoterodine 8 mg/day. One study found that this agent was more effective than tolterodine ER 4 mg/day (P=0.03). Antimuscarinic agents were significantly more effective than placebo with regards to the mean change in the number of micturitions/day. Pooled differences in mean changes ranged from 0.5 to 1.3 episodes per day. Three trials favoring solifenacin 10 mg/day over tolterodine IR 4 mg/day (P=0.01). Four trials favored solifenacin 10 mg/day over solifenacin 5

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			improvements in their storage LUTS Secondary: Tolerability, safety, and HRQOL	mg/day (P=0.02). Otherwise, there were no significant differences among the antimuscarinic agents. Fesoterodine, propiverine, solifenacin, and tolterodine were significantly more effective than placebo with regards to the mean change in the number of urgency episodes/day (when this outcome was reported). Pooled differences in mean changes ranged from 0.64 to 1.56 episodes per day. Some trial data favored solifenacin 10 mg/day over tolterodine IR 4 mg/day (P<0.01) and solifenacin 5 mg/day over tolterodine IR 4 mg/day (P=0.01). Otherwise, there were no significant differences among the antimuscarinic agents. Antimuscarinic agents were significantly more effective than placebo with regards to the mean change in the volume voided/micturition (when this outcome was reported). Differences in pooled mean changes were 13 to 40 ml. Solifenacin 10 mg/day was favored over tolterodine IR 4 mg/day (P<0.01); solifenacin 10 mg/day was favored over solifenacin 5 mg/day (P<0.01); fesoterodine 8 mg/day was favored over tolterodine ER 4 mg/day (P=0.03); and oxybutynin IR 15 mg/day was favored over tolterodine IR 4 mg/day (P<0.01). The proportions of patients who had improvements in their bladder condition was significantly higher for fesoterodine 4 and 8 mg/day than for placebo (P=0.01and P=0.01, respectively). Otherwise, there were no significant differences among the antimuscarinic agents. Secondary: Compared to placebo, treatment with oxybutynin IR (15 and 7.5 to 10 mg/day) was associated with significantly higher risk of withdrawal due to any cause (P=0.04 and P<0.01, respectively). Otherwise, there was no significant difference in the proportions of patients who withdrew for any causes between active treatments and placebo. Oxybutynin IR 7.5 to 10 mg/day was associated with a significantly greater risk of withdrawal due to any cause than oxybutynin ER 5 mg/day (P=0.03); oxybutynin IR 7.5 to 10 mg/day was associated with a greater risk of withdrawal than tolterodine ER 4 mg/day (P<0.01) and tolterodine IR 4 mg/day (P=0.04); oxybutynin IR 15 mg/day was associated with a greater risk of withdrawal

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				than tolterodine IR 4 mg/day P<0.01) and oxybutynin ER 15 mg/day (P=0.04). Tolterodine ER 4 mg/day was associated with a significantly lower risk of withdrawal due to an adverse event than placebo (P=0.02). Formulations associated with a significantly higher risk of withdrawal due to adverse events than placebo were as follows: oxybutynin IR 7.5 to 10 mg/day (P=0.01), oxybutynin IR 15 mg/day (P<0.01), and solifenacin 10 mg/day (P=0.04). Tolterodine ER 4 mg/day was associated with lower risk of withdrawal due to an adverse event compared to oxybutynin transdermal delivery system 3.9 mg/day (P=0.01) and oxybutynin IR 15 mg/day (P<0.01); tolterodine IR 4 mg/day was associated with a lower risk than oxybutynin IR 15 mg/day (P<0.01); and oxybutynin ER 5 mg/day was associated with a lower risk than oxybutynin ER 15 mg/day (P=0.04). Otherwise, there were no significant differences among the antimuscarinic agents. Every antimuscarinic agent was associated with a significantly greater risk of adverse events than placebo, except tolterodine IR 2 mg/day (P=0.97) and oxybutynin transdermal delivery system 3.9 mg/day (P=0.07). The pooled RR for any adverse event in comparison to placebo varied between 1.13 and 2.00. The risk of adverse events was significantly lower with tolterodine IR 2 mg/day than with oxybutynin ER 5 mg/day (P<0.01) and lower with tolterodine IR 4 mg/day than with oxybutynin IR 7.5 to 10 mg/day (P<0.01) and oxybutynin IR 15 mg/day (P<0.01). There was a higher risk of adverse events with fesoterodine 8 mg/day than with fesoterodine 4 mg/day (P=0.04) and tolterodine ER 4 mg/day (P=0.04). There was a higher risk of adverse events with oxybutynin IR 7.5 to 10 mg/day than with trospium 40 mg/day (P=0.02). Dry mouth was the most frequently reported adverse event and occurred in 29.6% of patients receiving antimuscarinic therapy compared to 7.9% of patients receiving placebo. The following adverse events were reported at statistically significantly higher levels in first-named active treatments than in second-named active treatments: blurred vision (solifenacin 10 mg/day vs solifenacin 5 mg/day, solifenacin 10 mg/day vs tolterodine IR 4 mg/day); constipation (solifenacin 5 mg/day vs tolterodine ER and IR 4

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mg/day, darifenacin 15 mg/day vs tolterodine IR 4 mg/day); fatigue (tolterodine ER 4 mg/day vs fesoterodine 4 or 8 mg/day); nausea (oxybutynin IR 15 mg/day vs oxybutynin ER 15 mg/day); and vomiting (tolterodine ER 4 mg/day vs oxybutynin ER 7.5 to 10 mg/day). Significant differences in HRQOL were reported for darifenacin, fesoterodine, oxybutynin transdermal delivery system, solifenacin, tolterodine ER and IR, and trospium compared to placebo.
Hay-Smith et al.[114] (2009) Darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium	MA Patients with OAB with or without a urodynamic diagnosis of detrusor overactivity	N=11,332 (49 trials) Variable duration	Primary: QOL, patient's observations, symptoms, objective measurements, adverse events Secondary: Not reported	Primary: <u>Oxybutynin vs tolterodine (10 studies)</u> There was no significant difference between the groups in the proportion of people reporting cure/improvement (47% with tolterodine vs 44% with oxybutynin; RR, 1.06; 95% CI 0.89 to 1.26). There was no significant difference between IR tolterodine and ER oxybutynin with regards to the change in the number of leakage episodes/24 hours (WMD, -0.15; 95% CI, -0.47 to 0.16). There was no significant difference between IR tolterodine and ER oxybutynin with regards to the change in micturitions/24 hours (WMD, -0.25; 95% CI, -0.61 to 0.10). There were fewer withdrawals with tolterodine therapy (7%) compared to treatment with oxybutynin (12%; RR, 0.57; 95% CI, 0.43 to 0.75). Dry mouth was significantly lower with tolterodine than oxybutynin (RR, 0.60; 95% CI, 0.54 to 0.66). <u>Oxybutynin vs trospium (four studies)</u> Two trials reported on maximum cystometric capacity and residual volume and there was no significant difference between the groups. Dry mouth was significantly lower with trospium than oxybutynin (RR, 0.74; 95% CI, 0.59 to 0.93). <u>ER vs IR oxybutynin (four trials)</u> There was no significant difference in patient's perception of improvement (one trial).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference between the groups in the number of leakage episodes/24 hours. There was a lower maximum cystometric capacity and larger volume at first contraction in the ER formulations; however, only volume at first contraction was significant. There was no significant difference in residual volume measured using ultrasound. There was no significant difference in withdrawals due to adverse events between IR and ER groups. Dry mouth was significantly lower with the ER preparations (RR, 0.77; 95% CI, 0.66 to 0.91). <u>ER vs IR tolterodine (one trial)</u> There was no significant difference between the ER and IR formulations with regards to leakage episodes or micturitions/24 hours. There was no significant difference in withdrawals due to adverse events. There were fewer reports of dry mouth for those using the ER preparation. <u>ER oxybutynin vs IR tolterodine (one trial)</u> There was no significant difference in the number of leakage episodes/24 hours. There was a significant difference in favor of oxybutynin for the number of micturitions/24 hours. There was no significant difference in the number of withdrawals due to adverse events among the treatment groups. There was no significant difference in the rate of dry mouth among the treatment groups. <u>ER tolterodine vs IR oxybutynin (one trial)</u> The risk of dry mouth was less for those taking ER tolterodine compared to oxybutynin IR. <u>Tolterodine ER vs oxybutynin ER (two trials)</u> There was no significant difference in change in leakage episodes or

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				micturitions/24 hours (one trial). There was no statistically significant difference between the groups in withdrawals due to adverse events. There was no significant difference in the rate of dry mouth among the treatment groups; however, there was clinical heterogeneity noted among the studies. One study found significantly fewer reports of dry mouth with oral ER tolterodine than oral ER oxybutynin. There was no difference in risk of dry mouth between oral ER tolterodine and transdermal ER oxybutynin. Secondary: Not reported
Maman et al.[115] (2014) Darifenacin, fesoterodine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium	MA Patients ≥18 years of age with a diagnosis of OAB, may be referred to as detrusor overactivity or urinary urgency	N=27,309 (44 trials) Variable duration	Primary: Efficacy outcomes including micturition frequency, incontinence and urgency urinary incontinence; safety outcomes including dry mouth, constipation and blurred vision Secondary: Not reported	Primary: The results from 26 studies (22,040 patients) showed that the effect of mirabegron 50 mg did not differ significantly in terms of micturition frequency from other treatments, except solifenacin 10 mg, which was more effective (mean difference vs mirabegron 50 mg of -0.584). The estimated mean difference of tolterodine compared to mirabegron was not significant (0.157 micturition episodes per day). The results from 17 studies (13,101 patients) showed improvement with mirabegron 50 mg in the daily number of incontinence episodes per 24 hours from baseline to end of study was not significantly different from improvements with tolterodine 4 mg, oxybutynin 10 mg, darifenacin 7.5 mg and 15 mg and fesoterodine 4 mg and 8 mg. Mirabegron 50 mg was statistically superior to placebo with a mean difference estimated at 0.493 incontinence episodes per day. The results of 18 studies (16,044 patients) showed that mirabegron 50 mg was significantly less efficacious than solifenacin 10 mg in terms of urgency urinary incontinence (mean difference vs mirabegron 50 mg of -0.422 urgency incontinence episodes per day) and did not differ significantly from other antimuscarinics. All 44 trials (27,309 patients) reported a similar incidence of dry mouth

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				with mirabegron 50 mg to placebo (OR, 1.344). All antimuscarinics were associated with a significantly higher risk of dry mouth compared with mirabegron 50 mg. The OR for the occurrence of dry mouth with antimuscarinics compared with mirabegron 50 mg ranged from 5.213 with solifenacin 5 mg to 40.702 with oxybutynin IR 15 mg. Data of 41 studies (25,257 patients) reported incidence of constipation associated with mirabegron 50 mg was comparable with placebo (OR, 0.732). Other antimuscarinics except darifenacin 15 mg, fesoterodine 8 mg, solifenacin 5 mg, solifenacin 10 mg and trospium 60 mg had similar incidences of constipation. The 25 studies (14,348 patients) available reported blurred vision being relatively rare and no significant difference in risk of developing blurred vision was found between treatments arms. Secondary: Not reported

Drug regimen abbreviations: ER=extended-release, IR=immediate-release, LA=long acting, SR=sustained-release, XL=extended release
Study abbreviations: AC=active control, CI=confidence interval, DD=double-dummy, DB=double-blind, ES=extension study, MA=meta-analysis, MC=multicenter, NS=not significant, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized controlled trial, RR=relative risk, XO=crossover
Miscellaneous abbreviations: BPH=benign prostatic hyperplasia, BOO=bladder outlet obstruction, HRQOL=health-related quality of life, ICIQ-SF=International Consultation on Incontinence Questionnaire–Short Form, IIQ=incontinence impact questioner, IPSS=international prostate symptoms score, IPSS-QOL=international prostate symptoms score quality of life, KHQ=King's Health Questionnaire, LUTS=lower urinary tract symptoms, MVV=mean voided volume per void, OAB=overactive bladder, OAB-PGA=Overactive Bladder Patient Global Assessment questionnaire, OAB-q=Overactive Bladder Questionnaire, OABSS=Overactive Bladder Symptom Scores, PPBC=Patient Perception of Bladder Condition Questionnaire, PGA=patient global assessment, PRO=patient reported outcome, PVR=postvoid residual, Qmax=maximum flow rate, QOL=quality of life, QOL-I=Quality of Life Index, SMD=standard mean difference, SSS=Stanford Sleepiness Scale, TSQ=Treatment Satisfaction Questionnaire, UDI=urogenital distress inventory, UPS=Urgency Perception Scale, URI=upper respiratory infection, USS=Urinary Sensation Scale, UTI=urinary tract infection, UUI=urgency urinary incontinence, VAS=visual analog scale, VVPM=volume voided per micturition, WMD=weighted mean difference

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Genitourinary Smooth Muscle Relaxants: Antimuscarinics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Darifenacin	extended-release tablet	Enablex®*	$$$$$	$$$
Fesoterodine	extended-release tablet	Toviaz®	$$$$$	N/A
Flavoxate	tablet	N/A	N/A	$$
Oxybutynin	extended-release tablet, syrup, tablet, transdermal gel, transdermal patch	Ditropan XL®*, Gelnique®, Oxytrol®	$$$$$	$
Solifenacin	tablet	Vesicare®*	$$$$$	$
Tolterodine	extended-release capsule, tablet	Detrol®*, Detrol LA®*	$$$$$	$$
Trospium	extended-release capsule, tablet	N/A	N/A	$$$

*Generic is available in at least one dosage form or strength.
N/A=Not available

X. Conclusions

Urinary incontinence and overactive bladder cause both physical and psychological morbidity, as well as adversely impact quality of life.[1] Initial treatment options include lifestyle modifications (weight loss and dietary changes) and behavioral therapy (bladder training, physical therapy, and toileting assistance). Pharmacologic therapy is typically trialed if initial treatment is ineffective.[2,4] Antimuscarinic drugs increase bladder capacity,

decrease urgency, and are useful for the treatment of urge incontinence.[4] Darifenacin, flavoxate, oxybutynin, solidenacin, tolterodine, and trospium are available in a generic formulation.

Several guidelines provide recommendations on the use of the genitourinary smooth muscle relaxants for the treatment of urinary incontinence and overactive bladder. Antimuscarinic agents are the primary treatment for patients with overactive bladder symptoms (with or without urge incontinence), in addition to lifestyle modifications and behavioral therapy.[2,19-24] In general, the guidelines do not identify a single preferred agent for initial therapy. However, several recent guidelines provide general recommendations.[20-21,24] For example, two guidelines from the American Urological Association and the European Association of Urology favor the use of extended-release preparations.[20-21] In addition, guidelines from the National Institute of Health and Clinical Excellence recommend immediate-release oxybutynin, immediate-release tolterodine, or once-daily darifenacin as initial therapy.[19] Several guidelines also recommend the use of transdermal oxybutynin if anticholinergic side effects are experienced with initial therapy.[20-21,24]

In clinical trials, the genitourinary smooth muscle relaxants have been shown to modestly improve urinary symptoms, including frequency, urgency, nocturia, and incontinence episodes.[25-115] The majority of the studies were six to 12 weeks in duration; however, a few long-term (up to 36 months), open-label, non-comparative studies have also been conducted. There were relatively few active-controlled studies found in the medical literature with flavoxate, darifenacin, fesoterodine, solifenacin, or trospium. The majority of the active-controlled studies compared oxybutynin and tolterodine. Several studies have demonstrated similar efficacy with the genitourinary smooth muscle relaxants for most, but not all, of the outcomes assessed. In general, studies directly comparing immediate-release and extended-release formulations of the same drug found no differences in efficacy.[53-57,63,92] Studies directly comparing immediate-release formulations of different drugs, as well as studies directly comparing extended-release formulations of different drugs, also demonstrated similar efficacy.[26,29,37,42,60-61,80,83,99-106,109-110] Few studies have demonstrated greater efficacy with one genitourinary smooth muscle relaxant over another.[25,38,43,49,59-60,77,82,86,94] The use of the genitourinary smooth muscle relaxants for the treatment of urinary incontinence and overactive bladder has also been associated with an improvement in quality of life.[37,41,54,76,85-86,93]

Adverse events occur frequently with the genitourinary smooth muscle relaxants due to their antimuscarinic effects, which often leads to discontinuation of therapy. The most common adverse events include dry mouth, blurred vision, abdominal discomfort, drowsiness, nausea, and dizziness. These agents may also cause confusion or memory impairment in the elderly.[4] The incidence of adverse events varies among the agents and depends upon the formulation used (extended-release, immediate-release, or transdermal). Adverse events tend to be higher with the immediate-release formulations compared to extended-release formulations. In general, dry mouth occurs at a higher rate with oral oxybutynin than with the other agents.

There is insufficient evidence to support that one brand genitourinary smooth muscle relaxant: antimuscarinic is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand genitourinary smooth muscle relaxants: antimuscarinics within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand genitourinary smooth muscle relaxant: antimuscarinic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Lukacz ES. Evaluation of females with urinary incontinence. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun 21]. Available from: http://www.utdol.com/utd/index.do.
2. Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Neurogenic Bladder Society. Int J Urol. 2009;16:126-42.
3. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37-49.
4. Lukacz ES. Treatment of urinary incontinence in females. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2-2- [cited 2020 Jun 21]. Available from: http://www.utdol.com/utd/index.do.
5. Radmayr C, Bogaert G, Dogan HS, Kočvara R, Nijman JM, Stein R, et al. European Association of Urology/European Society for Paediatric Urology 2020 guidelines on paediatric urology: management of neurogenic bladder in children. Available at: http://uroweb.org/guideline/paediatric-urology. Accessed June 2020.
6. Blok B, Padilla-Fernández, Pannek J, Castro Diaz D, del Popolo G, et al. European Association of Urology Guidelines on Neuro-Urology 2020. Available at: http://uroweb.org/guideline/neuro-urology. Accessed June 2020 .
7. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jun 21]. Available from: http://online.factsandcomparisons.com.
8. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jun 21]. Available from: http://www.thomsonhc.com/.
9. *Enablex® [package insert]. Rockaway, NJ: Warner Chilcot, U.S., LLC; March 2012.*
10. *Toviaz® [package insert]. New York, NY: Pfizer, Inc.; November 2017.*
11. *Ditropan XL® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September 2019.*
12. *Gelnique® 10% transdermal gel [package insert]*. Irvine, CA: Allergan USA, Inc.; October 2017.
13. *Oxytrol® [package insert]*. Irvine, CA: Allergan USA, Inc.; October 2017.
14. *Vesicare® [package insert]*. Deerfield, Illinois: Astellas Pharma US, Inc.; May 2020.
15. *Detrol® [package insert]. New York, NY: Pfizer, Inc.; August 2012.*
16. *Detrol LA® [package insert]. New York, NY: Pfizer, Inc.; July 2018.*
17. *Gelnique 3%® transdermal gel [package insert]*. Corona, CA: Watson Pharmaceuticals, Inc.; July 2015.
18. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 Jun 21]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
19. National Institute for Health and Clinical Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. London (UK): National Institute for Health and Clinical Excellence (NICE); 2019 Apr. Available at: https://www.nice.org.uk/guidance/ng123. Accessed June 2020.
20. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al., et al. European Association of Urology (EAU) Guidelines on Urinary Incontinence. Available at http://uroweb.org/guideline/urinary-incontinence/. Accessed June 2020.
21. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Linthicum (MD): American Urological Association Education and Research, Inc.; 2019 Apr.
22. National Institute for Health and Clinical Excellence (NICE). Urinary Incontinence in Neurological Disease. NICE clinical guideline 148. London (England): 2012. [cited 2020 Jun 21]. Available from: https://www.nice.org.uk/guidance/cg148.
23. Abrams P, Andersson KE, Birder L, et al. Sixth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2018 Sep;37(7):2271-2272.
24. Practice Bulletin No. 155: Urinary Incontinence in Women (Joint with the American Urogynecologic Society) (Obstet Gynecol 2015;126:e66–81).
25. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012 Dec;62(6):1040-60. doi: 10.1016/j.eururo.2012.08.060.
26. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95:993-1001.

27. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471-7.
28. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. Br J Urol Int. 2006;98:1025-32.
29. Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin. 2007;23:2697-704.
30. But I, Goldstajn MS, Oresković S. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study. Coll Anthropol. 2012 Dec;36(4):1347-53.
31. Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30:1214-9.
32. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol. 2005;48:102-9.
33. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63:560-7.
34. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety, and tolerability of fesoterodine in patients with overactive bladder. J Urol. 2007;178:2488–94.
35. Chapple C, Schneider T, Haab F, et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int. 2014 Sep;114(3):418-26.
36. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in patients with overactive bladder. Eur Urol. 2007;52:1204–12.
37. Chapple CR, Van Kerrebroeck PE, Jünemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102:1128-32.
38. Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, et al. Efficacy of fesoterodine compared to extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.
39. Van Kerrebroeck PE, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract. 2010;64:584-93.
40. Scarpero H, Sand PK, Kelleher CJ, et al. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011;27:921-30.
41. Kelleher CJ, Tubaro A, Wang JT, K et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102:56-61.
42. Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily vs 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010;183:1892-8.
43. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011;107:1432-40.
44. Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017 Oct;120(4):562-575.
45. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145.
46. Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D et al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared With Monotherapy in Patients With Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509.
47. Inoue M, Yokoyama T. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. Acta Med Okayama. 2019 Oct;73(5):387-392.
48. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013 Feb;63(2):296-305.

49. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016.
50. Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014 Jun;113(6):951-60.
51. Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr;181(4):1764-72.
52. Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2013 Oct 16. doi: 10.1002/nau.22504.
53. Anderson RU, Mobley D, Blank B, et al. Once daily controlled vs immediate release oxybutynin chloride for urge urinary incontinence. J Urol. 1999;161:1809-12.
54. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther. 2004;26:1026-36.
55. Birns J, Lukkari E, Malone-Lee JG, et al. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. 2000;85:793-8.
56. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000;95:718-21.
57. Nilsson CG, Lukkari E, Haarala M, et al. Comparison of a 10 mg controlled release oxybutynin tablet with a 5 mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn. 1997;16:533-42.
58. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358-63.
59. Sand PK, Miklos J, Ritter H, et al. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15:243-8.
60. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687-95.
61. Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169:317-9.
62. Nelken RS, Ozel BZ, Leegant AR, et al. Randomized trial of estradiol vaginal ring vs oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962-6.
63. Davila GW, Daugherty CA, Sanders SW, et al. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140-5.
64. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine vs placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237-42.
65. Metello J, Nogueira B, Torgal M, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1021-5.
66. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008;30:1766-81.
67. Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin. 2008;24:1583-91.
68. Wong C, Duggan P. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. J Obstet Gynaecol. 2009;29:31-4.
69. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28:1935-46.
70. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47:376-84.

71. Bolduc S, Moore K, Nadeau G, et al. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010;184 (4 Suppl):1668-73.
72. Chapple CR, Cardozo L, Steers WD, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006;60:959-66.
73. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol. 2005;48:483-7.
74. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin. 2006;22:41-8.
75. Wagg A, Wyndaele JJ, Sieber P, et al. Efficacy and tolerability of solifenacin in elderly patients with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4:14-24.
76. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005;95:81-5.
77. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105:58-66.
78. Herschorn S, Pommerville P, Stothers L, et al. Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011;27:375-82.
79. Amarenco G, Sutory M, Zachoval R, Agarwal M, Del Popolo G, Tretter R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
80. Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin vs tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011;37:1084-91.
81. Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007;39(4):1069-77
82. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429.
83. Ho CH, Chang TC, Lin HH, et al. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc. 2010;109:702-8.
84. Chapple C, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.
85. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303-10.
86. Chapple CR, Araño P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93:71-7.
87. Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology. 2011;78:126-33.
88. Kreder K, Mayne C, Jonas U, et al. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002;41:588-95.
89. Takei M, Homma Y. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol. 2005;12:456-64.
90. Choo MS, Doo CK, Lee KS, et al. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract. 2008;62:191-6.
91. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414-21.
92. Swift S, Garely A, Dimpfl T, et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:50-4.
93. Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92:741-7.

94. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177-84.
95. Chung DE, Te AE, Staskin DR, et al. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010;75:1144-8.
96. Chung SD, Chang HC, Chiu B, et al. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia. Neurourol Urodyn. 2011;30:568-71.
97. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging. 2001;18:551-60.
98. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol. 2001;19:141-7.
99. Kilic N, Akgoz S, Sen N, et al. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol. 2006;13:105-08.
100. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50 (6A Suppl):90-6.
101. Lee JG, Hong JY, Choo MS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol. 2002;9:247-52.
102. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165:1452-6.
103. Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801-10.
104. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10:283-9.
105. Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int. 2002;90:375-80.
106. Giannitsas K, Perimenis P, Athanasopoulos A, et al. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol. 2004;46:776-82.
107. Harvey MA, Baker K, Wells GA. Tolterodine vs oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol. 2001;185:56-61.
108. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004;5:423-6.
109. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392-9.
110. Madersbacher H, Stöhrer M, Richter R, et al. Trospium chloride vs oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452-6.
111. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared to oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23:248-52.
112. Bolduc S, Moore K, Lebel S, et al. Double anticholinergic therapy for refractory overactive bladder. J Urol. 2009;182(4 suppl):2033-8.
113. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543-62.
114. Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2009; (3); Cochrane AN: CD005429.
115. Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755-765.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Genitourinary Smooth Muscle Relaxants
AHFS Class 861208 – Selective Beta-3-Adrenergic Agonists
November 4, 2020

I. Overview

Urinary incontinence is the involuntary leakage of urine, which may be classified as urgency, stress, overflow, or mixed incontinence.[1] Urgency incontinence is accompanied by a sense of urgency, while stress incontinence generally occurs with effort, exertion, sneezing, or coughing. Overflow incontinence is associated with dribbling and/or continuous leakage due to incomplete bladder emptying.[1] Overactive bladder is a functional disorder characterized by urinary urgency, daytime frequency (>8 voids during the daytime), nocturia (>1 void at night), with or without incontinence.[2,3] Urinary incontinence and overactive bladder may be due to lower urinary tract dysfunction or secondary to non-genitourinary disorders. The most common cause of overactive bladder is overactivity of the bladder's detrusor muscle. Symptoms may be assessed by patient history, the use of validated questionnaires, and/or bladder diaries. Clinical testing (e.g., bladder stress test, postvoid residual volume testing, urine flow rate, and urodynamic testing) may help identify the pathology, but are not always necessary for diagnosis or initiation of therapy.[1,2] Urinary incontinence and overactive bladder cause both physical and psychological morbidity, as well as adversely impact quality of life.[1] Initial treatment options include lifestyle modifications (weight loss and dietary changes) and behavioral therapy (bladder training, physical therapy, and toileting assistance).[2,4] Pharmacologic therapy is typically trialed if initial treatment is ineffective.[2,4] Neurogenic lower urinary tract disorder is caused by a lesion at any level of the nervous system.[5,6] The lesion interferes with the normal nerve pathways associated with urination. Early diagnosis and treatment of neurogenic lower urinary tract disorder is essential for both congenital and acquired disorders as irreversible changes may occur.[6]

Mirabegron is the first beta-3 adrenergic receptor agonist to be approved for the treatment of overactive bladder. Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle which increases bladder capacity. Because it acts via the beta-3 adrenergic receptor rather than through muscarinic cholinergic receptors, mirabegron may have a better tolerability profile compared to other urinary antispasmodics.[7-9]

The selective beta-3-adrenergic agonists that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Mirabegron was previously included in the Genitourinary Smooth Muscle Relaxants review. Mirabegron is not available in a generic formulation. This agent was last reviewed in August 2018.

Table 1. Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Mirabegron	extended-release tablet	Myrbetriq®	none

*Generic is available in at least one dosage form or strength.
N/A=Not available, PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the genitourinary smooth muscle relaxants are summarized in Table 2.

Table 2. Treatment Guidelines Using the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists

Clinical Guideline	Recommendation(s)
National Institute for Health and Clinical Excellence: **Urinary**	Behavioral therapy • Bladder training should be offered for a minimum of six weeks as first-line treatment to women with urge or mixed urinary incontinence. • If women do not achieve satisfactory benefit from bladder training, the

Clinical Guideline	Recommendation(s)
Incontinence and Pelvic Organ Prolapse in Women: Management (2019)[19] Last updated Jun 2019	combination of an overactive bladder medicine with bladder training should be considered if frequency is a troublesome symptom. • Do not offer transcutaneous sacral nerve stimulation, transcutaneous posterior tibial nerve stimulation, or percutaneous posterior tibial nerve stimulation to women with urinary incontinence. <u>Pharmacologic therapy</u> • Before starting treatment with a medicine for overactive bladder, the following should be explained to the woman: the likelihood of the medicine being successful; the common adverse effects associated with the medicine; that some adverse effects of anticholinergic medicines, such as dry mouth and constipation, may indicate that the medicine is starting to have an effect; that she may not see substantial benefits until she has been taking the medicine for at least four weeks and that her symptoms may continue to improve over time; and that the long-term effects of anticholinergic medicines for overactive bladder on cognitive function are uncertain. • When offering anticholinergic medicines to treat overactive bladder, the following should be taken into consideration of the woman's: coexisting conditions (such as poor bladder emptying, cognitive impairment or dementia); current use of other medicines that affect total anticholinergic load; and risk of adverse effects, including cognitive impairment. • Flavoxate, propantheline and imipramine should not be offered for the treatment of urinary incontinence or overactive bladder in women. • Immediate-release oxybutynin should not be offered to older women who may be at higher risk of a sudden deterioration in their physical or mental health. • Anticholinergic medicine with the lowest acquisition cost should be offered to treat overactive bladder or mixed urinary incontinence in women. • If the first medicine for overactive bladder or mixed urinary incontinence is not effective or well-tolerated, another medicine with a low acquisition cost should be offered. • A transdermal overactive bladder treatment should be offered to women unable to tolerate oral medicines. • The use of desmopressin may be considered to reduce nocturia in women with urinary incontinence or overactive bladder who find it a troublesome symptom. • Duloxetine is not recommended as a first-line treatment for women with predominant stress urinary incontinence. Duloxetine should not routinely be used as a second-line treatment for women with stress urinary incontinence, although it may be offered as second-line therapy if women prefer pharmacological to surgical treatment or are not suitable for surgical treatment. • Systemic hormone replacement therapy is not recommended for the treatment of urinary incontinence. • Intravaginal estrogens are recommended for the treatment of overactive bladder symptoms in postmenopausal women with vaginal atrophy. • Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects. ○ People currently receiving mirabegron that is not recommended for them should be able to continue treatment until they and their clinician consider it appropriate to stop. <u>Complementary therapy</u> • Complementary therapies are not recommended for the treatment of urinary incontinence or overactive bladder.
European Association of Urology:	<u>Antimuscarinic drugs</u> • There is limited evidence that one antimuscarinic drug is superior to an alternative

Clinical Guideline	Recommendation(s)
Guidelines on Urinary Incontinence (2018)[11]	antimuscarinic drug for cure or improvement of urgency urinary incontinence. • Higher doses of antimuscarinic drugs are more effective to cure or improve urgency urinary incontinence, but with a higher risk of side effects. • Once daily (extended release) formulations are associated with lower rates of adverse events compared to immediate release ones, although similar discontinuation rates are reported in clinical trials. • Dose escalation of antimuscarinic drugs may be appropriate in selected patients to improve treatment effect although higher rates of adverse events can be expected. • Transdermal oxybutynin (patch) is associated with lower rates of dry mouth than oral antimuscarinic drugs, but has a high rate of withdrawal due to skin reaction. • Offer antimuscarinic drugs for adults with urgency urinary incontinence who failed conservative treatment. • Consider extended release formulations in patients who do not tolerate immediate release antimuscarinics. • If antimuscarinic treatment proves ineffective, consider dose escalation or offering an alternative treatment. • Consider using transdermal oxybutynin if oral antimuscarinic agents cannot be tolerated due to dry mouth. • Offer and encourage early review (of efficacy and side effects) of patients on antimuscarinic medication for urgency urinary incontinence. • Adherence to antimuscarinic treatment is low and decreases over time because of lack of efficacy, adverse events and/or cost. • Most patients will stop antimuscarinic agents within the first three months. <u>Antimuscarinic and β-3 agonist agents, the elderly and cognition</u> • Antimuscarinic drugs are effective in elderly patients. • Mirabegron has been shown to efficacious and safe in elderly patients. • In older people, the cognitive impact of drugs which have anticholinergic effects is cumulative and increases with length of exposure. • Oxybutynin may worsen cognitive function in elderly patients. • Solifenacin, darifenacin, fesoterodine and trospium have been shown not to cause cognitive dysfunction in elderly people in short-term studies. <u>Additional recommendations for antimuscarinic drugs in the elderly</u> • In older people being treated for urinary incontinence, every effort should be made to employ nonpharmacological treatments first. • Long-term antimuscarinic treatment should be used with caution in elderly patients especially those who are at risk of, or have, cognitive dysfunction. • When prescribing antimuscarinic for urgency urinary incontinence, consider the total antimuscarinic load in older people on multiple drugs. • Consider the use of Mirabegron in elderly patients if additional antimuscarinic load is to be avoided. <u>Mirabegron</u> • Mirabegron is better than placebo and as efficacious as antimuscarinics for improvement of urgency urinary incontinence symptoms. • Adverse event rates with mirabegron are similar to placebo. • Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron than dose escalation of solifenacin. • In patients with urgency urinary incontinence and an inadequate response to conservative treatments, offer mirabegron unless they have uncontrolled hypertension. <u>Drugs for stress urinary incontinence</u> • Duloxetine, 40 mg twice daily improves stress urinary incontinence in women.

Clinical Guideline	Recommendation(s)
	• Duloxetine causes significant gastrointestinal and central nervous system (CNS) side effects leading to a high rate of treatment discontinuation, although these symptoms are limited to the first weeks of treatment. • Duloxetine can be used with caution to treat women with symptoms of stress urinary incontinence. • Duloxetine should be initiated using dose titration because of high adverse event rates. Estrogen • Vaginal oestrogen therapy for vulvovaginal atrophy should be prescribed long-term. In women with a history of breast cancer, the treating oncologist needs to be consulted. Monitoring for hyponatremia • Consider offering desmopressin to patients requiring occasional short-term relief from daytime urinary incontinence and inform them that this drug is not licensed for this indication. • Monitor plasma sodium levels in patients on desmopressin. Drug treatment in mixed urinary incontinence • Offer antimuscarinic drugs or β-3 agonists to patients with urgency-predominant mixed urinary incontinence. Drug therapy • Duloxetine, either alone or combined with conservative treatment, can hasten recovery of continence but does not improve continence rate following prostate surgery. Compression devices in males • Consider offering duloxetine to hasten recovery of continence after prostate surgery but inform the patient about the possible adverse events.
American Urological Association: **Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: American Urological Association/ Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline (2012); Amended (2014, 2019)**[21]	Diagnosis • Overactive bladder is a symptom complex that is not generally life threatening. • The clinician should engage in a diagnostic process to document symptoms and signs that characterize overactive bladder and exclude other disorders that could be the cause of the patient's symptoms. • After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice. First line treatment • Behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) should be offered as first line therapy. • Behavioral therapies can also be combined with pharmacologic management. Second line treatment • Clinicians should offer oral antimuscarinics or oral beta-3-adrenoceptor agonists as second line therapy. • If extended-release and immediate-release formulations are available, the extended-release should be preferred over the immediate-release given formulation due to lower rates of dry mouth. Transdermal oxybutynin is also an option. • If a patient experiences inadequate symptom control and/or unacceptable adverse drug events with one agent, then a dose modification or a different antimuscarinic medication or β3-adrenoceptor agonist may be tried. • May consider combination therapy with an anti-muscarinic and β3-adrenoceptor

Clinical Guideline	Recommendation(s)
	agonist for patients refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists. • Anti-muscarinics should be avoided in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist and should also be used with extreme caution in patients with impaired gastric emptying or a history of urinary retention. • Manage constipation and dry mouth before abandoning effective anti-muscarinic therapy. Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics. • Use caution in prescribing anti-muscarinics in patients who are using other medications with anti-cholinergic properties. • Use caution in prescribing anti-muscarinics or β3-adrenoceptor agonists in the frail patient. • Patients who are refractory to behavioral and pharmacologic therapy should be evaluated by an appropriate specialist if they desire additional therapy. Third line treatment • Clinicians may offer intradetrusor onabotulinumtoxinA as a third-line option in the carefully selected patients who has been refractory to first and second line overactive bladder treatments. The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary. • Clinicians can also offer peripheral tibial nerve stimulation as third-line treatment. • Clinicians may offer sacral neuromodulation as third line treatment in a carefully selected patient population characterized by server refractory overactive bladder symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure. • Patients should persist with new treatments for an adequate trial in order to determine whether the therapy is efficacious and tolerable. Combination therapeutic approaches should be assembled methodically, with the addition of new therapies occurring only when the relative efficacy of the preceding therapy is known. Therapies that do not demonstrate efficacy after an adequate trial should be ceased.
National Institute for Health and Clinical Excellence: **Urinary Incontinence in Neurological Disease (2012)**[13]	Behavioral treatment • For patients with neurogenic lower urinary tract dysfunction, behavioral management programs should be considered (e.g., timed voiding, bladder retraining or habit retraining). • When choosing a behavioral management program, take into account that prompted voiding and habit retraining are particularly suitable for people with cognitive impairment. Antimuscarinics • Antimuscarinic drugs should be offered to patients with spinal cord disease (e.g., spinal cord injury or multiple sclerosis) who have symptoms of overactive bladder such as increased frequency, urgency and incontinence. • In patients with conditions affecting the brain (e.g., cerebral palsy, head injury or stroke) with symptoms of an overactive bladder, antimuscarinic drugs should be considered. • Antimuscarinic drug treatment should be considered in patients with urodynamic investigations showing impaired bladder storage. • Residual urine volume should be monitored in patients not using intermittent or indwelling catheterization after beginning treatment. • Antimuscarinic treatment can reduce bladder emptying, which may increase the risk of urinary tract infections and may precipitate or exacerbate constipation. Antimuscarinics known to cross the blood-brain barrier (e.g. oxybutynin) have the

Clinical Guideline	Recommendation(s)
	potential to cause central nervous system related adverse effects (e.g., confusion). Botulinum toxin A • Bladder wall injection with botulinum toxin A should be offered to adult patients with spinal cord diseases (e.g., spinal cord injury or multiple sclerosis) and symptoms of overactive bladder and an inadequate response to or poorly tolerated antimuscarinic drugs. • Bladder wall injection with botulinum toxin A may be considered for children and young people with spinal cord disease and symptoms of overactive bladder for who antimuscarinic drugs were ineffective or poorly tolerated. • Bladder wall injection with botulinum toxin A may be considered in adults with spinal cord disease with urodynamic investigations showing impaired bladder storage for whom antimuscarinic drugs were ineffective or poorly tolerated. • Consider bladder wall injection with botulinum toxin A for children and young people with spinal cord disease with urodynamic investigations showing impaired bladder storage and for whom antimuscarinic drugs were ineffective or poorly tolerated. • A catheterization regimen is needed in most people with neurogenic lower urinary tract dysfunction after botulinum toxin A treatment. The patient must be able and willing to manage such a regimen should urinary retention develop after the treatment. • Monitor residual urine volume in patients who are not using a catheterization regimen during treatment with botulinum toxin A. • Monitor upper urinary tract in patients at risk of renal complications (e.g., those with high intravesical pressures on filling cystometry) during treatment. • People should be offered repeated botulinum toxin A injections and have prompt access to repeat injections when symptoms return.
International Scientific Committee: **Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence (2018)**[23]	Initial management of urinary incontinence in children • For children with mono-symptomatic nocturnal enuresis, initial treatment should include: o Parental and child counselling and motivation o Review of bladder diary with attention to night-time polyuria o Age appropriate education and demystification or explanation o Counselling, timed voiding, behavior modification and bowel management when necessary o Antimuscarinics may be used if the child has overactive bladder symptoms Initial management of urinary incontinence in men • For men with stress, urgency or mixed urgency/stress incontinence, initial treatment should include: o Lifestyle interventions. o Supervised pelvic floor muscle training for men with post-radical prostatectomy stress urinary incontinence. o Scheduled voiding regimes for overactive bladder. o Antimuscarinic/beta 3 agonist drugs for overactive bladder symptoms with or without urgency incontinence if the patient has no evidence of significant post-void residual urine. o Alpha adrenergic antagonists (α-blockers) can be added if it is thought that there may also be bladder outlet obstruction. Initial management of urinary incontinence in women • For women with stress, urgency or mixed urgency/stress incontinence, initial treatment should include: o Advice on caffeine reduction for overactive bladder and weight

Clinical Guideline	Recommendation(s)
	reduction. o Supervised pelvic floor muscle training and vaginal cones training for women with stress incontinence. o Supervised bladder training for overactive bladder. o If estrogen deficiency and/or urinary tract infection is found, the patient should be treated at initial assessment and then reassessed after a suitable interval. o Antimuscarinics/beta 3 agonist for overactive bladder symptoms with or without urgency incontinence. o Duloxetine may be considered for stress urinary incontinence. Initial management of neurogenic urinary incontinence • Conservative treatment modalities (often in combination): o Intermittent catheterization. o Behavioral treatment. o Timed voiding. o Continence products. o Antimuscarinics. o Alpha-1-adrenergic blockers. o Oral cannabinoid agonists (MS) o Beta-3-agonist alone or as an add-on to antimuscarinics o Bladder expression. o Triggered voiding. o Indwelling catheter. Management of urinary incontinence in frail older persons • Initial treatment should be individualized and influenced by goals of care, treatment preferences, and estimated remaining life expectancy, as well as the most likely clinical diagnosis. • In some frail elders the only possible outcome may be contained urinary incontinence (managed with pads), especially for persons with minimal mobility (require assistance of >2 persons to transfer), advanced dementia (unable to state their name), and/or nocturnal urinary incontinence. • Conservative and behavioral therapy for urinary incontinence include lifestyle changes, bladder training for more fit alert patients, and prompted voiding for frailer, more impaired patients. • For select cognitively intact patients, pelvic muscle exercises may be considered. Antimuscarinics may be added to conservative therapy of urgency urinary incontinence. • Alpha-blockers may be cautiously considered in frail men with suspected prostatic outlet obstruction. All drugs should be started at the lowest dose and titrated with regular review until either care goals are met or adverse effects are intolerable. • DDAVP (vasopressin) has a high risk of severe hyponatremia in frail persons and should not be used outside specialist centers or without very careful monitoring and long term follow-up.
Neurogenic Bladder Society: **Clinical Guidelines for Overactive Bladder (2009)[2]**	Behavioral therapy • Behavioral therapy can include lifestyle guidance, bladder training, physical therapy and toileting assistance. • Behavioral therapy is minimally invasive with no adverse reactions and combination therapy with other forms of treatment is also possible. • Behavioral therapy should be considered as the first-line choice for initial treatment of overactive bladder. • The efficacy of combined behavioral therapy and drug therapy over monotherapy has yet to be determined, but it is the recommended treatment approach.

Clinical Guideline	Recommendation(s)
	Drug therapy • Drug therapy forms the basis of treatment for overactive bladder. • The drugs for which efficacy and safety have been investigated are the antimuscarinic agents. These are most commonly used for the treatment of overactive bladder. • When using antimuscarinic drugs, it is necessary to consider adverse reactions due to blockade of the systemic muscarine receptors Antimuscarinic drugs • Oxybutynin has a direct relaxing effect and paralyzing effect on smooth muscle in addition to its antimuscarinic activity. It has been extensively evaluated and its efficacy has been well demonstrated. The incidence of adverse reactions associated with its antimuscarinic activity is higher than that of other antimuscarinic drugs. It is recommended that treatment is started from a low dose and titrated gradually to determine the optimal dose. Oxybutynin can pass through the blood-brain barrier potentially causing central nervous system adverse events (cognitive impairment, etc.). Caution is required in elderly patients. • Tolterodine has no selectivity for muscarinic receptor subtypes, is well distributed to and has a high binding affinity for the bladder, and as compared to the salivary glands, is highly selective for the bladder. It has been extensively evaluated and there is substantial evidence for efficacy and safety in overactive bladder patients, including the elderly and patients with severe overactive bladder. • Solifenacin is highly selective for the muscarinic receptor M3, and is more highly selective for the bladder than for the salivary glands. It has been shown to be effective for urgency, frequency, and urge urinary incontinence in overactive bladder. • Flavoxate has no antimuscarinic activity, but appears to have a moderate calcium antagonistic action, inhibitory effect on phosphodiesterase, and a local relaxant effect on smooth muscle. Flavoxate has been observed to have almost no adverse reactions, but its efficacy has not been adequately evaluated. • Darifenacin is high selectivity for the M3 receptor subtype, and it has shown a higher selectivity for the bladder than the salivary glands in animal studies. Concern has been raised about adverse reactions involving the salivary glands and gastrointestinal tract, in which M3 receptors are numerous. Antidepressants • Several types of tricyclic antidepressants are indicated for enuresis or nocturnal enuresis, with imipramine being the most commonly used drug. Imipramine appears to be useful for nocturnal enuresis in children, but its usefulness as a therapeutic agent for overactive bladder is yet to be adequately evaluated. Botulinum Toxin • Botulinum toxin is believed to inhibit bladder contraction by blocking the release of acetylcholine from cholinergic nerves, primarily by causing chemical denervation. • Injection of botulinum toxin into the bladder wall is believed to be a promising therapeutic method for overactive bladder, but its usefulness is yet to be adequately explored. Efficacy of drug therapy for overactive bladder symptoms in benign prostatic hyperplasia patients • α_1-blockers are first-line drug therapy for overactive bladder symptoms in benign prostatic hyperplasia patients, but their long-term efficacy in patients without lower urinary tract obstruction has yet to be proven. • Randomized controlled studies to demonstrate the efficacy and safety of

Clinical Guideline	Recommendation(s)
	antimuscarinic drugs for overactive bladder symptoms associated with benign prostatic hyperplasia have yet to be performed. • Despite the fact that antimuscarinic drugs may be effective in some benign prostatic hyperplasia patients with overactive bladder symptoms, there is ample risk of causing acute urinary retention or chronic urinary retention. • The therapeutic positioning of antimuscarinic drugs for men with lower urinary tract symptoms is uncertain, and they are contraindicated in patients with severe lower urinary tract obstruction or urinary retention. • It remains uncertain whether combination therapy with an α_1-blocker and an antimuscarinic drug is superior to α_1-blocker monotherapy in benign prostatic hyperplasia patients with overactive bladder symptoms. <u>Practical guidelines for drug therapy for overactive bladder: Rules for treatment with anticholinergic drugs, classified by sex and age</u> • Overactive bladder in women: o Antimuscarinic drugs can be administered immediately. o If voiding symptoms, as well as overactive bladder symptoms, are present, antimuscarinic drugs should be administered with caution. o Since overactive bladder and impaired detrusor contractility may both be present in elderly women (80 years or older) in particular, patients should be referred to a urological specialist if voiding symptoms are severe or if residual urine is copious (50 mL or more). • Overactive bladder in men under 50 years of age: o For overactive bladder in relatively young men, it is recommended that patients be evaluated by a urological specialist at least once, as there may be an underlying comorbid neurological disease or urological disease. • Overactive bladder in men aged 50 years or older: o Because there is a high probability of overactive bladder as a complication of benign prostatic hyperplasia, give top priority to starting an α_1-blocker if voiding symptoms are confirmed. o If there is no improvement in overactive bladder symptoms, an antimuscarinic drug can be coadministered. However, since there is not adequate evidence regarding this combination, the patient should also be referred to a urological specialist.
American College of Obstetricians and Gynecologists: **Practice Bulletin: Urinary Incontinence in Women (2015)**[15] Reaffirmed 2018	• Behavioral therapy (e.g., bladder training and prompted voiding) and pelvic floor muscle exercises improve symptoms of stress, urgency, and mixed urinary incontinence and may be recommended as an initial, noninvasive treatment in many women. • Moderate weight loss can improve urinary incontinence symptoms in overweight and obese women. • Pelvic floor muscle exercises appear to be an effective treatment for adult women with stress, urgency, or mixed incontinence and can be recommended as a noninvasive treatment for many women. • Current evidenced-based medical treatments typically are reserved for urgency urinary incontinence. Medical therapies for treatment of stress urinary incontinence are less effective and generally are not recommended. Available medical treatments for urgency urinary incontinence include antimuscarinic agents (also known as anticholinergic agents), β-agonists, onabotulinumtoxinA, and estrogen. • The antimuscarinic medications have been shown to have a small beneficial effect as therapy for urgency incontinence. Numerous antimuscarinic agents are available, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium, that have similar efficacy and safety profiles; however, conclusions regarding comparative effectiveness and safety are limited by the lack of high-quality evidence from head-to-head trials between specific agents.

Clinical Guideline	Recommendation(s)
	• Antimuscarinic medications also were associated with significant discontinuation rates because of bothersome adverse effects, with dry mouth as the most frequently reported adverse event. • Compared with antimuscarinic treatment, intravesical onabotulinumtoxinA results in similar reduction of incontinence episodes, and more patients report complete resolution of incontinence. Thus, intradetrusor onabotulinumtoxinA may be a treatment option for overactive bladder in appropriate patients, and consideration of its use requires shared decision making between the patient and physician. • Systemic estrogen therapy, with or without progesterone, does not appear to be effective in the prevention or treatment of urinary incontinence; several large trials of hormone therapy have found an increased occurrence of stress incontinence in users of hormone therapy (estrogen alone or combined with progesterone). Locally administered (vaginal) estrogen, however, may be of some benefit in decreasing urinary incontinence.
European Association of Urology/European Society for Pediatric Urology: **Guidelines on Pediatric Urology: Management of Neurogenic Bladder in Children (2020)**[5]	Early management with clean intermittent catheterization Starting intermittent catheterization (IC) soon after birth and closure of the defect by the neurosurgeon in all infants has shown to decrease renal complications and the need for later augmentation. Medical therapy • Antimuscarinic/anticholinergic medication reduces/prevents detrusor overactivity and lowers intravesical pressure. • Oxybutynin is the most frequently used in children with neurogenic bladder with a success rate of up to 93%. • Tolterodine, solifenacin, trospium chloride and propiverine and their combinations can be also used in children. • Early prophylactic treatment with anticholinergics showed a lower rate of renal deterioration as well as a lower rate of progression to bladder augmentation. Beta-3 agonists like mirabegron may be also an alternative agent and may be effective in patients with neurogenic bladders. Up to date, there is almost no experience with this drug, therefore there are no recommendation that can be made. Alpha-adrenergic antagonists may facilitate emptying in children with neurogenic bladder. Botulinum toxin injections • Injection of botulinum toxin into the detrusor is an alternative treatment option for neurogenic bladders, which are refractory to antimuscarinics. The use of botulinum toxin in adults prompted its use in children and even though it has been shown to have beneficial effects on clinical and urodynamic variables. • Although the evidence is too low to recommend its routine use in decreasing outlet resistance, injection of botulinum toxin in the urethral sphincter has been shown to be effective in decreasing urethral resistance and improving voiding.
European Association of Urology: **Guidelines on Neuro-Urology (2020)**[6]	Treatment goals • The primary goals for the treatment of neurogenic lower urinary tract dysfunction are: o Protection of the upper urinary tract. o Achievement (or maintenance) of urinary continence. o Improvement of the patient's quality of life. o Restoration of lower urinary tract function. • Other considerations include the patient's disability, cost-effectiveness, technical complexity, and possible complications. Assisted bladder emptying • Incomplete bladder emptying is a risk factor for urinary tract infections, for developing high intravesical pressure during the filling phase, and for incontinence. • Methods to improve the voiding process should be practiced in patients with

Clinical Guideline	Recommendation(s)
	neurogenic lower urinary tract dysfunction and include the following: bladder expression, triggered reflex voiding and external appliances Neuro-urological rehabilitation • Bladder rehabilitation aims to re-establish bladder function in patients with neurogenic lower urinary tract dysfunction. • Peripheral temporary electrostimulation suppresses neurogenic detrusor over activity during acute stimulation and it has demonstrated sustained effects in patients with neurogenic bladder due to multiple sclerosis. In multiple sclerosis patients, a combined approach of pelvic floor muscle training with neuromuscular electrostimulation and biofeedback was more efficacious to electrostimulation alone in achieving a substantial reduction in lower urinary tract dysfunction. • Biofeedback can be used for supporting the alleviation of neuro-urological symptoms. • Intravesical electrostimulation may increase bladder capacity; improve bladder compliance as well as the sensation of bladder filling in patients with incomplete spinal cord injuries or meningomyelocele. • Bladder rehabilitation techniques are mainly based on electrical or magnetic stimulation; however, there is a lack of well-designed studies. Drug treatment • An optimal medical treatment for neurogenic lower urinary tract dysfunction is not available, and currently a combination of treatment modalities is the best therapeutic approach To prevent urinary tract damage and improve long-term outcomes. • Antimuscarinic drugs are first-line in the treatment of neurogenic detrusor overactivity (NDO). They increase bladder capacity and reduce episodes of urinary incontinence secondary to NDO by the inhibition of parasympathetic pathways. • Outcomes for neurogenic detrusor overactivity can be maximized by considering a combination or using higher doses of antimuscarinic agents. However, antimuscarinics have a high incidence of adverse events which may lead to discontinuation of therapy. • Alternative routes of administration (i.e., transdermal or intravesical) of antimuscarinic agents may be used to help reduce adverse effects. • Oxybutynin, tolterodine, trospium, and propiverine are established, effective, and well-tolerated treatment choices. • Darifenacin and solifenacin have been evaluated in NDO secondary to spinal cord injury and multiple sclerosis and had results similar to other antimuscarinic drugs. • Fesoterodine has also been introduced; to date there has been no published clinical evidence for its use in the treatment of neuro-urological disorders. • The role of mirabegron in neuro-urological patients is still unclear. • In patients with detrusor underactivity, cholinergic drugs (bethanechol chloride and distigmine bromide) may enhance detrusor contractility and promote bladder emptying, but are not used in clinical practice due to a lack of clinical evidence. • Alpha-blockers have been used successfully on occasion for decreasing bladder outlet resistance. External appliances • Social continence may be achieved by collecting the urine when incontinence cannot be resolved by any other methods. • Condom catheters with urine collection devices are a practical method for men. Incontinence pads may also offer a reliable solution. Minimal invasive treatment

Clinical Guideline	Recommendation(s)
	• Intermittent catheterization is the preferred management for neurourological patients who cannot effectively empty their bladders. • Botulinum toxin injection in the detrusor can be used to reduce neurogenic detrusor overactivity in multiple sclerosis or spinal cord injury patients if antimuscarinic therapy is ineffective. Therapy causes a long-lasting chemical denervation that lasts approximately nine months. • Antimuscarinics can be administered intravesically to reduce detrusor over activity. This route of administration may decrease adverse effects and a greater amount is sequestered in the bladder.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the genitourinary smooth muscle relaxants are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists[9]

Indication	Mirabegron
Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (alone or in combination with solifenacin)	✔

IV. Pharmacokinetics

The pharmacokinetic parameters of the genitourinary smooth muscle relaxants are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists[8]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Mirabegron	29 to 35	71	Liver	Renal (6 to 12)	50

V. Drug Interactions

Major drug interactions with the genitourinary smooth muscle relaxants are listed in Table 5.

Table 5. Major Drug Interactions with the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists[8]

Generic Name(s)	Interaction	Mechanism
Mirabegron	Thioridazine	Coadministration may have additive effects on the prolongation of the QT interval.
Mirabegron	Propafenone	Concurrent use of mirabegron and propafenone may result in increased propafenone exposure due to inhibition of CYP2D6- and CYP3A4-mediated propafenone metabolism by mirabegron.

VI. Adverse Drug Events

The most common adverse drug events reported with the genitourinary smooth muscle relaxants are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists[7]

Adverse Events	Mirabegron
Cardiovascular	
Hypertension	9 to 11
Tachycardia	2
Central nervous system	
Dizziness	3
Headache	4
Gastrointestinal	
Abdominal pain	1
Constipation	2 to 3
Diarrhea	2
Xerostomia	3
Genitourinary	
Cystitis	2
Urinary tract infection	3 to 6
Vaginitis	✔
Respiratory	
Nasopharyngitis	4
Sinusitis	3
Other	
Angioedema	-
Arthralgia	2
Influenza	3
Pain	3

✔ Percent not specified.
- Event not reported or incidence <1%.

VII. Dosing and Administration

The usual dosing regimens for the genitourinary smooth muscle relaxants are listed in Table 7.

Table 7. Usual Dosing Regimens for the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists[7]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Mirabegron	Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency: Tablet (ER): 25 to 50 mg once daily	Safety and efficacy in children have not been established.	Tablet (ER): 25 mg 50 mg

ER=extended-release, IR=immediate-release

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the genitourinary smooth muscle relaxants are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Nitti et al.[16] (2013) Mirabegron 100 mg once daily vs mirabegron 50 mg once daily vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age, with OAB symptoms for ≥3 months and with an average baseline micturition frequency of ≥8 micturitions/24 hours and ≥3 urgency episodes with or without incontinence during the 3-day micturition diary period	N=1,328 12 weeks	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours, change from baseline to end of treatment in the mean number of micturitions per 24 hours Secondary: Change from baseline to end of treatment in the mean VVPM, change from baseline to week four in the mean number of incontinence episodes per 24 hours, change from baseline to week four in the mean number of micturitions per 24 hours, change from baseline to final	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours was -1.63 in the mirabegron 100 mg group, -1.47 in the mirabegron 50 mg group and -1.13 in the placebo group. When compared to placebo the change from baseline was statistically significant in both the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to end of treatment in the mean number of micturitions per 24 hours was -1.75 in the mirabegron 100 mg group, -1.66 in the mirabegron 50 mg group, and -1.05 in the placebo group. When compared to placebo the change from baseline was statistically significant in both the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Secondary: Change from baseline to end of treatment in the mean VVPM was 18.0 mL in the mirabegron 100 mg group, 18.2 mL in the mirabegron 50 mg group, and 7 mL in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to week 4 in the mean number of incontinence episodes per 24 hours was -1.18 in the mirabegron 100 mg group, -1.20 in the mirabegron 50 mg group, and -0.72 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to week 4 in the mean number of micturitions per 24 hours was -1.37 in the mirabegron 100 mg group, -1.19 in the mirabegron 50 mg group, and -0.77 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			visit in mean level of urgency, change from baseline to final visit in mean number of urgency incontinence episodes per 24 hours, change from baseline to final visit in grade 3 or 4 urgency episodes per 24 hours, change from baseline to final visit in mean number of nocturia episodes, safety	Change from baseline to final visit in mean level of urgency was -0.21 in the mirabegron 100 mg group, -0.19 in the mirabegron 50 mg group, and -0.08 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to final visit in mean number of urgency incontinence episodes per 24 hours was -1.45 in the mirabegron 100 mg group, -1.32 in the mirabegron 50 mg group and -0.89 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to final visit in grade 3 or 4 urgency episodes per 24 hours was -1.76 in the mirabegron 100 mg group, -1.57 in the mirabegron 50 mg group, and -0.82 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Change from baseline to final visit in mean number of nocturia episodes was -0.57 in the mirabegron 100 mg and mirabegron 50 mg group compared to -0.38 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05). Mirabegron was well tolerated and the incidence of adverse events was similar across all groups. Adverse events reported in the placebo group, mirabegron 50 mg group and mirabegron 100 mg respectively were hypertension (6.6 vs 6.1 vs 4.9%), UTI (1.8 vs 2.7 vs 3.7), headache (2.0 vs 3.2 vs 3.0%), nasopharyngitis (2.9 vs 3.4 vs 2.5%), URI (2.6 vs 2.7 vs 2.1%), diarrhea (1.3 vs 2.3 vs 2.3%), sinusitis (2.2 vs 2.0 vs 2.1%), dry mouth (1.5 vs 0.5 vs 2.1%), constipation (1.8 vs 1.4 vs 1.6%). Serious adverse events were reported in 2.0, 2.5 and 3.2% of patients in the placebo group, mirabegron 50 mg group and mirabegron 100 mg respectively. Treatment discontinuation due to adverse events was reported in 3.8, 4.1 and 4.4% of patients in the placebo group, mirabegron

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				50 mg group and mirabegron 100 mg respectively.
Shin DG et al.[17] (2018) MIRACLE Mirabegron 50 mg or placebo (Mirabegron 50 mg given to both groups during extension phase)	DB, PC, PG, MC, RCT Male patients ≥20 years of age with symptoms of OAB persistent for at least 12 weeks, an average of 8 or more 24 hour micturition episodes according to a 3-day voiding diary and those with a score of 2 or greater in the urgency score section (Q3) of the OABSS	N=464 12 weeks plus 14 weeks extension	Primary: Change in the mean number of 24 hour micturition episodes from baseline to 12 weeks Secondary: Changes in the following mean scores from baseline to 12 and 26 weeks of medication: Q3, urgency incontinence score (Q4), total sum of the OABSS score, urgency score (Q4), storage subscore (sum of Q2, Q4, and Q7), and QOL score on the IPSS test	Primary: The mean number of 24 hour micturition episodes significantly reduced by -1.61±2.20 in the mirabegron group and by -1.45±2.54 in the placebo group (P<0.001 in both). The overall reduction in the mean number of 24 hour micturition episodes itself was not significantly different between the two groups (P=0.06). Secondary: Significantly greater changes from baseline to 12 weeks were observed in total OABSS, OABSS urgency incontinence score (Q4), IPSS storage subscore (Q2 + Q4 + Q7), and IPSS urgency score (Q4) in the mirabegron group (P=0.01 for all). However, when mirabegron 50 mg was given to both groups from the 12 to the 26 week point, the changes in all of the investigated parameters from baseline to 26 weeks were similar between the groups. Additionally, the mirabegron group had a significantly larger proportion of patients with a mean of <8 episodes of micturition per 24 hours at the 12 week point than did the placebo group (42.90% vs 27.27%, respectively; P=0.001).
Liao CH et al.[18] (2019) Mirabegron 25 mg daily for 12 weeks (M25 group) vs mirabegron 25 mg daily for 4 weeks +	AC, RCT Patients who previously received antimuscarinic agents and if a drug-free period longer than two weeks was recorded prior to initiating the mirabegron therapy	N=242 12 weeks	Primary: Percentage of patients without urgency or with a reduction of ≥2 in daily urgency episodes after treatment Secondary: OABSS and other	Primary: Both groups showed similar numbers of patients who reached the primary endpoint after treatment (M25: 64.6%; M50: 64.9%; P=0.554). Secondary: All OABSS in both groups improved significantly at four and 12 weeks. Patients in the M50 group had significantly more patients with a reduction of ≥2 in daily urgency episodes (60.9%) than the M25 group (34.5%) for those with residual daily urgency episodes ≥2 after 25 mg mirabegron for four weeks (P=0.034). The M50 group also had a higher number of patients with a reduction of ≥1 in UUI (87.5% vs. 37.5%; P=0.021) for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
50 mg daily for eight weeks (M50 group)			voiding parameters	those with residual daily UUI episodes ≥1. The OABSS, patient perception of intensity of urgency scale, IPSS storage subscore, patient perception of bladder condition, and QOL index in both groups improved significantly at four and 12 weeks after treatment. However, both groups showed no significant difference in the changes of parameters from baseline to 12 weeks. According to the voiding diary, episodes of daytime micturition, nocturia, urgency, and UUI improved after 12 weeks in both groups, but dose escalation to 50 mg further improved the daily urgency and UUI episodes from four to 12 weeks after the initial mirabegron 25 mg treatment. Patients who remained on mirabegron 25 mg had similar urgency and UUI episodes from week four to12.
Herschorn et al.[19] (2017) SYNERGY Solifenacin 5 mg plus mirabegron 25 mg (combined S5 + M25 group) vs solifenacin 5 mg plus mirabegron 50 mg (combined S5 + M50 group) vs solifenacin 5 mg vs mirabegron 25 mg	DB, MC, RCT Patients aged ≥18 years with wet OAB (urgency, urinary frequency and urinary incontinence) for ≥3 months who recorded on average ≥8 micturitions/24 h, ≥1 urgency episode/24 h, and ≥3 urinary incontinence episodes over the 7-day micturition diary	N=3,398 18 weeks (4-week placebo run-in, 12-week DB treatment period, 2-week placebo run-out period)	Primary: Change from baseline to end of treatment in the mean number of urinary incontinence episodes/24 h and micturitions/24 h, assessed using a 7-day electronic micturition diary Secondary: Change from baseline in the mean volume voided/micturition, change from baseline in mean number of urinary incontinence episodes/24 h, micturitions/24 h,	Primary: Although the combined S5 + M50 group significantly reduced urinary incontinence episodes compared to solifenacin 5 mg, with a mean (SE) adjusted difference of −0.20 (0.12) urinary incontinence episodes/24 hours (95% CI, −0.44 to 0.04, P=0.033), statistical “superiority” versus mirabegron 50 mg was not demonstrated (mean adjusted difference, −0.23 UI episodes/24 hours; 95% CI, −0.47 to 0.01; P=0.052). Therefore, the primary objective for the combined S5 + M50 therapy was not met. Because the null hypothesis for this test was not rejected, the subsequent hypotheses for mean number of micturitions/24 h and the MVV/micturition could not be tested. Also, no hypothesis testing could be performed for the combined S5 + M25 group. Urinary incontinence episodes decreased vs baseline for all treatment arms. The mean adjusted change from baseline to end of treatment was greater in the combined therapy groups vs monotherapies and placebo. Secondary: For micturitions/24 hours, adjusted change from baseline was greater in the combined therapy groups vs monotherapies (combined S5 + M50 group, nominal P values 0.006 and <0.001 versus solifenacin 5 mg and mirabegron 50 mg, respectively; combined S5 + M25 group, nominal P values 0.040 and 0.001 versus solifenacin 5 mg and mirabegron 25 mg, respectively). All active treatment groups had greater improvements in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs mirabegron 50 mg vs placebo			urgency episodes/24 h, UUI episodes/24 h and nocturia episodes/24 h; the percentage of patients (responders) achieving zero urinary incontinence episodes/24 h in the last 7 days prior to each visit, micturition frequency normalization (<8 episodes/24 h), and the number of UUI episodes and nocturia episodes in the 7-day diary; safety	mean numbers of micturitions/24 hours versus placebo, with effect sizes for the combined therapy groups (combined S5 + M25 group: -0.85 micturitions/24 h; combined S5 + M50 group: -0.95 micturitions/24 h) higher than with mirabegron monotherapy (25 mg: -0.36; 50 mg: -0.39 micturitions/24 h) and solifenacin 5 mg (-0.56 micturitions/24 h). The combined S5 + M50 group was statistically significantly improved compared to both monotherapies at end of treatment for UUI episodes, urgency episodes, and nocturia, with effect sizes that appeared to be additive. The combined S5 + M25 group demonstrated statistically significant improvement compared to mirabegron 25 mg for the same variables, except for nocturia. In responder analyses at the end of treatment, odds ratios in favor of both combined therapies vs monotherapies were shown for the proportion of patients with zero urinary incontinence episodes and those achieving micturition frequency normalization. There was a slightly increased frequency of treatment-emergent adverse events in the combined therapy groups vs monotherapies and placebo. Most of the treatment-emergent adverse events were mild or moderate in severity. There were slightly higher frequencies of dry mouth, constipation, and dyspepsia in the combined therapy groups versus monotherapies.
Drake et al.[20] (2016) BESIDE Solifenacin 5 mg and mirabegron 50 mg (combination) vs solifenacin 5 mg vs	DB, MC, RCT Adult OAB patients remaining incontinent despite daily solifenacin 5mg during 4-wk single-blind run-in	N=2,174 12 weeks	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes/24 hours Secondary: Change from baseline to end of treatment in the mean number of micturitions/24	Primary: The adjusted change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours was greater with combination (−1.80) versus solifenacin 5 mg (−1.53; P=0.001) and versus solifenacin 10 mg (−1.67; P=0.008). Secondary: At end of treatment, reductions in mean daily micturitions and in three-day incontinence episodes were significantly greater with combination versus solifenacin 5 mg (P<0.001). Combination was noninferior to solifenacin 10 mg for both key secondary end points and superior to solifenacin 10 mg for the reduction in micturition frequency. Significant differences in favor of the combination were evident as early as week four versus solifenacin 5 mg and week eight versus solifenacin 10 mg.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
solifenacin 10 mg			hours, number of incontinence episodes; safety	The incidence of treatment-emergent adverse events was lowest with solifenacin 5 mg (33.1%), highest with solifenacin 10 mg (39.4%), and 35.9% with combination; dry mouth and constipation were the most common treatment-emergent adverse events. Incidence of dry mouth was lower with combination (5.9%) versus solifenacin 10 mg (9.5%) and similar to solifenacin 5 mg (5.6%).
Gratzke et al.[21] (2019) SYNERGY II Solifenacin succinate 5 mg plus mirabegron 50 mg combination therapy vs solifenacin 5 mg monotherapy vs mirabegron 50 mg monotherapy	DB, MC, PG, RCT Patients completed either BESIDE or SYNERGY study or male or female and ≥18 years of age with symptoms of wet OAB (urinary frequency and urgency with incontinence) for ≥3 months	N=1,829 12 months	Primary: Safety, measured as treatment emergent adverse events Secondary: Change from baseline to the end of treatment in the mean number of incontinence episodes per 24 hours and micturitions per 24 hours	Primary: Overall, 856 patients (47%) experienced ≥1 treatment emergent adverse events. Treatment emergent adverse events frequency was slightly higher in the combination group (combination, 49%; mirabegron, 41%; solifenacin, 44%). Across all groups, the majority of the treatment emergent adverse events were mild or moderate in severity (mild, 24%, moderate, 19%, severe, 4%). There were no clinically relevant differences across groups in the frequency of treatment emergent adverse events leading to permanent treatment discontinuation (difference vs combination -0.2% for mirabegron and 0.4% for solifenacin). Serious treatment emergent adverse events were reported by 67 patients (3.7%); one was considered possibly treatment-related (mirabegron group, atrial fibrillation). Dry mouth was the most common treatment emergent adverse events (combination, 6.1%; solifenacin, 5.9%; mirabegron, 3.9%). Secondary: Combination therapy was statistically superior to both monotherapies in terms of change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours (adjusted mean difference: mirabegron, -0.5; 95% CI, -0.7 to -0.2; P<0.001; solifenacin, -0.1; 95% CI, -0.4 to 0.1; P=0.002) and the mean number of micturitions per 24 hours (adjusted mean difference: mirabegron, -0.5; 95% CI, -0.8 to -0.2; P<0.001; solifenacin, -0.4; 95% CI, -0.7 to -0.1; P=0.004).
Inoue M et al.[22] (2019) Solifenacin 5 mg once daily for 4 weeks followed by	PRO, RCT, XO Female patients ≥20 years, an OABSS of 3 or higher and urgency once or	N=47 8 weeks	Primary: Efficacy outcomes including change in OABSS, IPSS and VAS	Primary: The IPSS was significantly improved after the subjects received solifenacin (P value not reported). After they received mirabegron, the IPSS was also improved, but not significantly. The OABSS was significantly improved in both groups after treatment.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mirabegron 50 mg once daily for 4 weeks (group S) vs mirabegron 50 mg once daily for 4 weeks followed by solifenacin 5 mg once daily for 4 weeks (group M)	more per week		Secondary: Not reported	There were no significant differences between the two groups. In group M, the OABSS after eight weeks was significantly improved compared to that after four weeks. On the other hand, in group S, it was not significantly improved. In group M, the VAS values for urgency and incontinence were significantly improved after treatment. In addition, the VAS values for urgency and incontinence after eight weeks were significantly improved compared to those after four weeks. In group S, on the other hand, they were not significantly improved.
Chapple et al.[23] (2013) Mirabegron 100 mg once daily vs mirabegron 50 mg once daily vs tolterodine ER 4 mg once daily	DB, MC, RCT Patients ≥18 years of age with OAB symptoms for ≥3 months and with an average baseline micturition frequency of ≥8 micturitions/24 hours and ≥3 urgency episodes with or without incontinence during the 3-day micturition diary period	N=2,444 12 months	Primary: Incidence and severity of treatment-emergent adverse events, vital signs and laboratory tests Secondary: Change from baseline in micturition frequency and urgency frequency at one, three, six, nine and 12 months; OAB-q, PPBC and VAS scores, proportion of treatment responders (≥50% decrease from baseline in the incontinence episodes/24 hours	Primary: The incidence of treatment-emergent adverse events was similar among patients treated with mirabegron 50 mg (59.7%), 100 mg (61.3%) or tolterodine ER (62.6%). Most events were categorized as mild or moderate in severity. The most frequent treatment-related adverse events included hypertension, dry mouth, constipation, and headache, occurring at a similar incidence across all treatment groups, except for dry mouth, which was highest in the tolterodine group. Discontinuations resulting from adverse events were similar between treatment groups, with 6.4, 5.9 and 6.0% of patients treated with mirabegron 50 mg, 100 mg and tolterodine ER 4 mg, discontinuing treatment, respectively. Urinary retention occurred in one patient each in the mirabegron 50 mg and 100 mg group compared to three patients treated with tolterodine ER. Urinary retention requiring catheterization was reported in one patient receiving mirabegron 100 mg and tolterodine ER. There was a higher incidence of cardiac arrhythmias with tolterodine ER 4 mg (6.0%) compared to mirabegron 50 mg (3.9%) and 100 mg (4.1%). Mean changes from baseline in systolic blood pressure with mirabegron 50 mg, 100 mg and tolterodine were 0.2, 0.4 and -0.5 mm Hg for morning measurements and -0.3, 0.1 and 0.0 mm Hg for evening measurements, respectively. The mean changes in diastolic blood pressure were -0.3, 0.4,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			or those with zero incontinence episodes at final visit)	and 0.1 mm Hg, respectively for morning measurements and 0.0, 0.1 and 0.6 mm Hg, respectively for evening measurements. There was a higher incidence of neoplasm (benign, malignant and unspecified including cysts and polyps) in the mirabegron 100 mg group (1.3%) compared to the 50 mg group (0.1%) and tolterodine ER 4 mg (0.5%). Secondary: There were similar improvements between treatments with regard to the mean number of micturitions/24 hours (-1.27 for mirabegron 50 mg, -1.41 for mirabegron 100 mg and -1.39 for tolterodine ER 4 mg; P values not reported). Improvements in the mean number of incontinence episodes/24 hours (-1.01 for mirabegron 50 mg, -1.24 for mirabegron 100 mg and -1.26 for tolterodine ER 4 mg) and MVV (17.5 mL for mirabegron 50 mg, 21.5 mL for mirabegron 100 mg and 18.1 mL for tolterodine ER 4 mg) were similar among treatment groups (P values not reported). At the final visit, the proportion of treatment responders (≥50% reduction from baseline in the mean number of incontinence episodes/24 hours was 63.7, 66.3 and 66.8% for patients treated with mirabegron 50 mg, 100 mg and tolterodine ER, respectively; P values not reported). The proportion of patients who reported zero incontinence episodes at the final visit was 43.4, 45.8 and 45.1%, respectively; P values not reported). Both doses of mirabegron showed numerical improvements on the other secondary efficacy variables including OAB-q symptom bother and QOL, treatment satisfaction, number of nocturia episodes and PPBC.
Khullar et al.[24] (2013) SCORPIO Mirabegron 100 mg once daily vs	AC, DB, MC, PC, PG, RCT Patients ≥18 years of age, with OAB symptoms for ≥3 months and an average baseline micturition	N=1,978 12 weeks	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes/24 hrs, change from baseline to end of	Primary: Change from baseline to end of treatment in the mean number of incontinence episodes per 24 hours was -1.46 in the mirabegron 100 mg group, -1.57 in the mirabegron 50 mg group, -1.27 in the tolterodine SR group and -1.17 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) but not in the tolterodine SR group (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mirabegron 50 mg once daily vs tolterodine SR 4 mg once daily vs placebo	frequency of ≥8 micturitions/24 hours and ≥3 urgency episodes with or without incontinence during the 3-day micturition diary period		treatment in the mean number of micturitions/24 hrs Secondary: Change from baseline to end of treatment in the mean VVPM, change from baseline to week four in the mean number of incontinence episodes/24 hrs, change from baseline to week 4 in the mean number of micturitions/24 hrs, change from baseline to final visit in mean level of urgency, change from baseline to final visit in mean number of urgency incontinence episodes/24 hrs, change from baseline to final visit in grade 3 or 4 urgency episodes/ 24 hrs, change from baseline to final visit in mean number of nocturia	Change from baseline to end of treatment in the mean number of micturitions per 24 hours was -1.77 in the mirabegron 100 mg group, -1.93 in the mirabegron 50 mg group, -1.59 in the tolterodine SR group and -1.34 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) but not in the tolterodine SR group (P value not reported). Secondary: Change from baseline to end of treatment in the mean VVPM was 25.6 mL in the mirabegron 100 mg group, 24.2 mL in the mirabegron 50 mg group, 25.0 mL in the tolterodine SR group and 12.3 mL in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to week four in the mean number of incontinence episodes per 24 hours was -1.03 in the mirabegron 100 mg group, -1.04 in the mirabegron 50 mg group, -1.00 in the tolterodine SR group and -0.65 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to week four in the mean number of micturitions per 24 hours was -1.29 in the mirabegron 100 mg group, -1.16 in the mirabegron 50 mg group, -1.10 in the tolterodine SR group and -0.77 in the placebo group. When compared to placebo the change from baseline was statistically significant in the mirabegron 100 mg (P<0.05) and 50 group (P<0.05) and tolterodine SR group (P<0.05). Change from baseline to final visit in mean level of urgency was -0.30 in the mirabegron 100 mg group, -0.31 in the mirabegron 50 mg group, -0.29 in the tolterodine SR group and -0.22 in the placebo group (P values not reported). Change from baseline to final visit in mean number of urgency incontinence episodes per 24 hours was -1.33 in the mirabegron 100 mg

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			episodes, safety	group, -1.46 in the mirabegron 50 mg group, -1.18 in the tolterodine SR group and -1.11 in the placebo group (P values not reported). Change from baseline to final visit in grade 3 or 4 urgency episodes per 24 hours was -1.96 in the mirabegron 100 mg group, -2.25 in the mirabegron 50 mg group, -2.07 in the tolterodine SR group and -1.65 in the placebo group (P values not reported). Change from baseline to final visit in mean number of nocturia episodes was -0.56 in the mirabegron 100 mg group, -0.41 in the mirabegron 50 mg group, -0.50 in the tolterodine SR group and -0.45 in the placebo group (P values not reported). Mirabegron and tolterodine SR were well tolerated and the incidence of adverse events was similar across all groups. Adverse events reported in ≥2% of the placebo, mirabegron 50 mg group, mirabegron 100 mg and tolterodine SR group respectively included hypertension (7.7 vs 5.9 vs 5.4 vs 8.1%), nasopharyngitis (1.6 vs 2.8 vs 2.8 vs 2.8%), dry mouth (2.6 vs 2.8 vs 2.8 vs 10.1%), headache (2.8 vs 3.7 vs 1.8 vs 3.6%), influenza (1.6 vs 2.2 vs 2.0 vs 1.4%), UTI (1.4 vs 1.4 vs 1.8 vs 2.0%), constipation (1.4 vs 1.6 vs 1.6 vs 2.0%).
Yamaguchi et al.[25] (2014) mirabegron 50 mg once daily vs placebo once daily vs tolterodine 4 mg once daily (as an active comparator)	AC, DB, PC, RCT Patients ≥20 years of age experiencing OAB symptoms for ≥24 weeks	N=1139 12 weeks	Primary: Change in the mean number of micturitions/24 h from baseline Secondary: Micturition variables related to urgency and/or incontinence and quality-of-life domain scores on KHQ, adverse events	Primary: Mirabegron 50 mg was associated with a significantly greater change from baseline in the mean number of micturitions/24 h compared with placebo (P<0.001). Secondary: The mean [SD] change from baseline to final assessment for the secondary efficacy variables showed significant improvements for mirabegron vs placebo for number of urgency episodes/24 h (–1.85 [2.555] vs –1.37 [3.191]; P=0.025); number of incontinence episodes/24 h (–1.12 [1.475] vs –0.66 [1.861]; P=0.003); number of urgency incontinence episodes/24 h (–1.01 [1.338] vs –0.60 [1.745]; P=0.008); and volume voided/micturition (24.300 [35.4767] vs 9.715 [29.0864] mL; P<0.001); but not for number of nocturia episodes (–0.44 [0.933] vs –0.36 [1.062]; P=0.277). The percentage of subjects with zero incontinence episodes at the final assessment in the placebo, mirabegron, and tolterodine groups was 39.4,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				50.8, and 48.8%, respectively. Treatment with mirabegron for 12 weeks was associated with significant improvements compared with placebo in seven of the nine quality-of-life domain scores in the KHQ. The overall incidence of treatment-related AEs was similar in the mirabegron (24.5%) and placebo (24.0%) groups, but higher in the tolterodine group (34.9%).
Chapple et al.[26] (2015) Mirabegron 50 mg once daily vs placebo	Pooled post hoc analysis Patients with OAB and incontinent at baseline	N=1740 (3 trials) 12 weeks	Primary: Mean change from baseline to final visit (end of treatment) in mean number of incontinence episodes/24 h and mean number of micturitions/24 h Secondary: Mean number of urgency incontinence episodes/24 h, mean number of urgency episodes/ 24 h, and level of urgency	Primary: Mirabegron 50 mg resulted in statistically significant improvements from baseline to final visit relative to placebo in mean number of incontinence episodes per 24 h and mean number of micturitions per 24 h (P<0.001). Secondary: Mirabegron 50 mg resulted in statistically significant improvements from baseline to final visit relative to placebo in mean number of urgency episodes per 24 h and mean volume voided per micturition (P<0.001).
Maman et al.[27] (2014) Darifenacin, fesoterodine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium	MA Patients ≥18 years of age with a diagnosis of OAB, may be referred to as detrusor overactivity or urinary urgency	N=27,309 (44 trials) Variable duration	Primary: Efficacy outcomes including micturition frequency, incontinence and urgency urinary incontinence; safety outcomes including dry mouth, constipation and	Primary: The results from 26 studies (22,040 patients) showed that the effect of mirabegron 50 mg did not differ significantly in terms of micturition frequency from other treatments, except solifenacin 10 mg, which was more effective (mean difference vs mirabegron 50 mg of -0.584). The estimated mean difference of tolterodine compared to mirabegron was not significant (0.157 micturition episodes per day). The results from 17 studies (13,101 patients) showed improvement with mirabegron 50 mg in the daily number of incontinence episodes per 24 hours from baseline to end of study was not significantly different from improvements with tolterodine 4 mg, oxybutynin 10 mg, darifenacin 7.5

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			blurred vision Secondary: Not reported	mg and 15 mg and fesoterodine 4 mg and 8 mg. Mirabegron 50 mg was statistically superior to placebo with a mean difference estimated at 0.493 incontinence episodes per day. The results of 18 studies (16,044 patients) showed that mirabegron 50 mg was significantly less efficacious than solifenacin 10 mg in terms of urgency urinary incontinence (mean difference vs mirabegron 50 mg of -0.422 urgency incontinence episodes per day) and did not differ significantly from other antimuscarinics. All 44 trials (27,309 patients) reported a similar incidence of dry mouth with mirabegron 50 mg to placebo (OR, 1.344). All antimuscarinics were associated with a significantly higher risk of dry mouth compared with mirabegron 50 mg. The OR for the occurrence of dry mouth with antimuscarinics compared with mirabegron 50 mg ranged from 5.213 with solifenacin 5 mg to 40.702 with oxybutynin IR 15 mg. Data of 41 studies (25,257 patients) reported incidence of constipation associated with mirabegron 50 mg was comparable with placebo (OR, 0.732). Other antimuscarinics except darifenacin 15 mg, fesoterodine 8 mg, solifenacin 5 mg, solifenacin 10 mg and trospium 60 mg had similar incidences of constipation. The 25 studies (14,348 patients) available reported blurred vision being relatively rare and no significant difference in risk of developing blurred vision was found between treatments arms. Secondary: Not reported

Drug regimen abbreviations: ER=extended-release, IR=immediate-release, LA=long acting, SR=sustained-release, XL=extended release
Study abbreviations: AC=active control, CI=confidence interval, DD=double-dummy, DB=double-blind, ES=extension study, MA=meta-analysis, MC=multicenter, NS=not significant, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized controlled trial, RR=relative risk, XO=crossover
Miscellaneous abbreviations: BPH=benign prostatic hyperplasia, BOO=bladder outlet obstruction, HRQOL=health-related quality of life, ICIQ-SF=International Consultation on Incontinence Questionnaire–Short Form, IIQ=incontinence impact questioner, IPSS=international prostate symptoms score, IPSS-QOL=international prostate symptoms score quality of life, KHQ=King's Health Questionnaire, LUTS=lower urinary tract symptoms, MVV=mean voided volume per void, OAB=overactive bladder, OAB-PGA=Overactive Bladder Patient Global Assessment questionnaire, OAB-q=Overactive Bladder Questionnaire, OABSS=Overactive Bladder Symptom Scores, PPBC=Patient Perception of Bladder Condition Questionnaire, PGA=patient global assessment, PRO=patient reported outcome, PVR=postvoid residual, Qmax=maximum flow rate, QOL=quality of life, QOL-I=Quality of Life Index, SMD=standard mean difference, SSS=Stanford Sleepiness Scale, TSQ=Treatment Satisfaction Questionnaire, UDI=urogenital distress inventory, UPS=Urgency Perception Scale, URI=upper respiratory infection, USS=Urinary Sensation Scale, UTI=urinary tract infection, UUI=urgency urinary incontinence, VAS=visual analog scale, VVPM=volume voided per micturition, WMD=weighted mean difference

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Mirabegron	extended-release tablet	Myrbetriq®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available

X. Conclusions

Urinary incontinence and overactive bladder cause both physical and psychological morbidity, as well as adversely impact quality of life.[1] Initial treatment options include lifestyle modifications (weight loss and dietary changes) and behavioral therapy (bladder training, physical therapy, and toileting assistance). Pharmacologic therapy is typically trialed if initial treatment is ineffective.[2,4] Antimuscarinic drugs increase bladder capacity, decrease urgency, and are useful for the treatment of urge incontinence.[4] Beta-3 adrenergic receptor agonists increase bladder capacity via relaxation of the detrusor smooth muscle. This novel mechanism may improve tolerability compared to antimuscarinic agents.[4,9]

Mirabegron is a β-3 adrenergic receptor agonist. Based on this mechanism of action, a potential advantage of mirabegron compared to the other agents is the low incidence of any anticholinergic adverse events; however, the agent is associated with an increased incidence of hypertension.[9] In clinical studies, the agent demonstrated safety and efficacy in reducing overactive bladder symptoms with an adverse event profile similar to placebo.[16-17,19-21,23-27] The consensus recommendations for overactive bladder are from the 2014 American Urological Association guideline, which indicates that first line treatment consists of behavioral therapies (e.g., bladder training, bladder

control strategies). Antimuscarinic agents or β-3 adrenergic receptor agonists are recommended as second line and no specific agent is indicated as a preferred.[12] The European Association of Urology's Guidelines on Urinary Incontinence (2018) suggest considering the use of mirabegron in elderly patients if additional antimuscarinic load is to be avoided. They also state that mirabegron is better than placebo and as efficacious as antimuscarinics for improvement of urgency urinary incontinence symptoms, with adverse event rates similar to placebo. Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron than dose escalation of solifenacin. In patients with urgency urinary incontinence and an inadequate response to conservative treatments, offer mirabegron unless they have uncontrolled hypertension.[11]

There is insufficient evidence to support that one brand genitourinary smooth muscle relaxant: beta-3 agonist is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand genitourinary smooth muscle relaxants: beta-3 agonists within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand genitourinary smooth muscle relaxant: beta-3 agonist is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Lukacz ES. Evaluation of females with urinary incontinence. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun 21]. Available from: http://www.utdol.com/utd/index.do.
2. Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Neurogenic Bladder Society. Int J Urol. 2009;16:126-42.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
4. Lukacz ES. Treatment of urinary incontinence in females. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jun 21]. Available from: http://www.utdol.com/utd/index.do.
5. Radmayr C, Bogaert G, Dogan HS, Kočvara R, Nijman JM, Stein R, et al. European Association of Urology/European Society for Paediatric Urology 2020 guidelines on paediatric urology: management of neurogenic bladder in children. Available at: http://uroweb.org/guideline/paediatric-urology. Accessed June 2020.
6. Blok B, Padilla-Fernández, Pannek J, Castro Diaz D, del Popolo G, et al. European Association of Urology Guidelines on Neuro-Urology 2020. Available at: http://uroweb.org/guideline/neuro-urology. Accessed June 2020.
7. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 Jun 21]. Available from: http://online.factsandcomparisons.com.
8. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 Jun 21]. Available from: http://www.thomsonhc.com/.
9. Myrbetriq® [package insert]. Northbrook (IL): Astellas Pharma US, Inc; April 2018.
10. National Institute for Health and Clinical Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. London (UK): National Institute for Health and Clinical Excellence (NICE); 2019 Apr. Available at: https://www.nice.org.uk/guidance/ng123. Accessed June 2020.
11. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al., et al. European Association of Urology (EAU) Guidelines on Urinary Incontinence. Available at http://uroweb.org/guideline/urinary-incontinence/. Accessed June 2020.
12. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Linthicum (MD): American Urological Association Education and Research, Inc.; 2019 Apr.
13. National Institute for Health and Clinical Excellence (NICE). Urinary Incontinence in Neurological Disease. NICE clinical guideline 148. London (England): 2012. [cited 2020 Jun 21]. Available from: https://www.nice.org.uk/guidance/cg148.
14. Abrams P, Andersson KE, Birder L, et al. Sixth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2018 Sep;37(7):2271-2272.
15. Practice Bulletin No. 155: Urinary Incontinence in Women (Joint with the American Urogynecologic Society) (Obstet Gynecol 2015;126:e66–81).
16. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S.. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013 Apr;189(4):1388-95. doi: 10.1016/j.juro.2012.10.017.
17. Shin DG, Kim HW, Yoon SJ, Song, SH, Kim YH, Lee YG et al. Mirabegron as a Treatment for Overactive Bladder Symptoms in Men (MIRACLE Study): Efficacy and Safety Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Comparison Phase IV Study. Neurourol Urodyn. 2019 Jan;38(1):295-304.
18. Liao CH, Kuo HC. Mirabegron Escalation to 50 Mg Further Improves Daily Urgency and Urgency Urinary Incontinence in Asian Patients With Overactive Bladder. J Formos Med Assoc.2019 Mar;118(3):700-706.
19. Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017 Oct;120(4):562-575.
20. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145.

21. Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D et al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared With Monotherapy in Patients With Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509.
22. Inoue M, Yokoyama T. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. Acta Med Okayama. 2019 Oct;73(5):387-392.
23. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013 Feb;63(2):296-305.
24. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016.
25. Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014 Jun;113(6):951-60.
26. Chapple C, Khullar V, Nitti VW, et al. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015 Jan;67(1):11-4.
27. Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755-765.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Disease-Modifying Antirheumatic Agents
AHFS Class 923600
November 4, 2020

I. Overview

The disease-modifying antirheumatic drugs (DMARDs) are used for a variety of inflammatory and immunologic conditions which include: rheumatoid arthritis, neonatal-onset multisystem inflammatory disease, psoriatic arthritis, plaque psoriasis, juvenile/systemic idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, and oral ulcers associated with Behcet's Disease. These agents achieve their therapeutic effect via several different mechanisms of action. The majority of oral and injectable agents inhibit the effect of proinflammatory cytokines, specifically interleukins or tumor necrosis factor (TNF)-α. Interleukin (IL) inhibitors include anakinra (Kineret®), sarilumab (Kevzara®), and tocilizumab (Actemra®); while the TNF-α inhibitors are adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®, Simponi ARIA®), and infliximab (Remicade®, Inflectra®, Renflexis®, Avsola®). Abatacept (Orencia®) is a T-cell activation inhibitor, apremilast (Otezla®) is a phosohodiesterase-4 (PDE-4) inhibitor, leflunomide (Arava®) is a pyrimidine synthesis inhibitor, and tofacitinib (Xeljanz®), baricitinib (Olumiant®), and upadacitinib (Rinvoq®) are Janus kinase inhibitors.[1-20]

The interleukins (ILs) that are targeted by immunomodulator agents are IL-1 (1α and/or 1β), IL-6, IL-12, IL-17A, or IL-23. IL-1 plays an important role in the inflammatory process as a proinflammatory mediator along with TNF-α. IL-1 is also associated with cartilage breakdown as well as stimulation of bone resorption. Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) and blocks the effect of both IL-1α and IL-1β at its receptor.[3,19,20] IL-6 is a chemical messenger that has been associated with the inflammatory process as well as other diverse processes such as T-cell activation, immunoglobulin secretion induction, hepatic acute phase protein synthesis initiation, and hematopoietic precursor cell proliferation and differentiation stimulation. Sarilumab binds to both soluble and membrane-bound IL-6 receptors and has been shown to inhibit IL-6-mediated signaling through these receptors.[14,19,20] Tocilizumab is a humanized monoclonal antibody that competes with IL-6 for binding to IL-6 receptor which can be found in the serum or membrane-bound.[15,19,20]

TNF-α is another proinflammatory mediator that is released by lymphocytes. Working together with IL-1 and other cytokines and growth factors, they induce certain gene expression and protein synthesis.[19,20] Adalimumab, golimumab, and infliximab are monoclonal antibodies that bind to both membrane-bound TNF-α and soluble TNF-α, preventing its binding to the TNF receptors. Certolizumab pegol, an antibody-binding fragment modified with polyethylene glycol (pegylated), acts in a similar fashion. Certolizumab pegol binds to membrane bound and soluble TNF-α preventing its binding to the TNF receptor. Neither of these drugs have affinity for TNF-β, which utilizes that same receptor.[2,5,7-11,19,20] Etanercept is a fusion protein that that contains the ligand binding site of the p75 TNF receptor. As etanercept mimics the TNF receptor, it has affinity for and binds both TNF-α and TNF-β. These agents have been found to be similar with respect to adverse events and interacting medications.[6,19,20]

Abatacept is the only T-cell activation inhibitor in this class of drugs. Abatacept binds to CD80 and CD86 preventing CD28 activation, which is required for the costimulatory signal necessary for full activation of the T-cell.[1,19,20] Apremilast is an oral small-molecule inhibitor of PDE-4 specific for cyclic adenosine monophosphate (cAMP). Cyclic AMP is an intracellular second messenger that controls a network of pro-inflammatory and anti-inflammatory mediators. PDE-4 inhibition results in increased intracellular cAMP levels, which is thought to restore a balance of pro- and anti-inflammatory signals.[4,19,20] Leflunomide inhibits dihydroorotate dehydrogenase, leading to antiproliferative activity which includes the inhibition of T-cell proliferation and reduction of production of autoantibodies by B cells.[13,19,20] Tofacitinib, baricitinib, and upadacitinib are oral Janus kinase inhibitors. They are synthetic chemical compound that interfere with specific signal-transduction pathways. Through their broad effect on multiple cytokine pathways, Janus kinas inhibitors may reduce tissue inflammation and joint damage in rheumatoid arthritis.[16-20]

Because many of the DMARDs are biologic agents made from living organisms and are extremely difficult to duplicate, regulations to approve generic versions of these agents have been difficult to create. Currently, none of the injectable agents in this class are available generically. However, Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to or interchangeable with an FDA-approved biological product.[22] A biosimilar product is defined as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. Currently, the FDA has approved 28 biosimilar products and no interchangeable biologic products.[22]

The disease-modifying antirheumatic agents that are included in this review are listed in Table 1. Leflunomide is the only product available in a generic formulation. Xeljanz XR® was reviewed in February 2017. Adalimumab, etanercept, and infliximab are available in multiple biosimilar formulations. This class was last reviewed in August 2018.

Table 1. Disease-Modifying Antirheumatic Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Abatacept	injection	Orencia®	none
Adalimumab	injection	Humira®	Humira®CC
Anakinra	injection	Kineret®	none
Apremilast	tablet	Otezla®	none
Baricitinib	tablet	Olumiant®	none
Certolizumab pegol	injection	Cimzia®	Cimzia®CC
Etanercept	injection	Enbrel®	Enbrel®CC
Golimumab	injection	Simponi®, Simponi Aria®	none
Infliximab	injection	Avsola®^, Inflectra®^, Remicade®, Renflexis®^	none
Leflunomide	tablet	Arava®*	leflunomide
Sarilumab	injection	Kevzara®	none
Tocilizumab	injection	Actemra®	none
Tofacitinib	extended-release tablet, tablet	Xeljanz®, Xeljanz XR®	none
Upadacitinib	extended-release tablet	Rinvoq®	none

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List
^Biosimilar product.
CCDenotes agent is preferred with clinical criteria in place.

II. *Evidence*-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the disease-modifying antirheumatic agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Disease-Modifying Antirheumatic Agents

Clinical Guideline	Recommendation(s)

Assessment of Spondyloarthritis International Society/European League Against Rheumatism: **2016 Update of the Assessment of Spondyloarthritis International Society/European League Against**	• Treatment of axial spondyloarthritis (axSpA) should be tailored according to:
	  ○ Current manifestations of the disease (axial, peripheral, extra-articular symptoms and signs).
	  ○ Patient characteristics (comorbidities and psychosocial factors).
	• Disease monitoring of patients with axSpA should include: patient-reported outcomes, clinical findings, laboratory tests, and imaging, all with the appropriate instruments and relevant to the clinical presentation. The frequency of monitoring should be decided on an individual basis depending on symptoms, severity, and treatment.
	• Treatment should be guided according to a predefined treatment target.
	• Patients should be educated about axSpA and encouraged to exercise on a regular basis and stop smoking; physical therapy should be considered.

Clinical Guideline	Recommendation(s)
Rheumatism Recommendations for the Management of Axial Spondyloarthritis (2017)[23]	• Nonsteroidal anti-inflammatory drugs (NSAIDs) up to the maximum dose, are recommended as first line drug treatment for patients suffering from pain and stiffness, taking risks and benefits into account. Continuous treatment with an NSAID is preferred for patients who respond well to NSAIDs if symptomatic otherwise. • Analgesics, such as paracetamol and opioid-(like) drugs, might be considered for residual pain after previously recommended treatments have failed, are contraindicated, and/or poorly tolerated. • Patients with purely axial disease should normally not be treated with conventional synthetic disease-modifying antirheumatic drug (DMARD); sulfasalazine may be considered in patients with peripheral arthritis. Biological DMARDS should be considered in patients with persistently high disease activity despite conventional treatments; current practice is to start with tumor necrosis factor inhibitor (TNFi) therapy. • If TNFi therapy fails, switching to another TNFi or interleukin-17 inhibitor therapy should be considered. • If a patient is in sustained remission, tapering of a biological DMARD can be considered. • Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent of age. Spinal corrective osteotomy in specialized centers may be considered in patients with severe disabling deformity. • If a significant change in the course of the disease occurs, causes other than inflammation, such as a spinal fracture, should be considered and appropriate evaluation, including imaging, should be performed.
American College of Rheumatology/ Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network: **Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (2019)**[24]	<u>Recommendations for adults with active ankylosing spondylitis (AS)</u> • Treatment with NSAIDs is recommended over no treatment with NSAIDs. Continuous treatment with NSAIDs is recommended over on-demand treatment with NSAIDs. No particular NSAID is recommended as a preferred choice. • In adults with active AS despite treatment with NSAIDs: o Treatment with sulfasalazine, methotrexate or tofacitinib is recommended over no treatment with these medications. Sulfasalazine or methotrexate should be considered only in patients with prominent peripheral arthritis or when TNFi are not available. o Treatment with TNFi is recommended over treatment with tofacitinib o TNFi treatment is recommended over no treatment with TNFi. No TNF-α inhibitor is recommended as preferred. o Treatment with secukinumab or ixekizumab is recommended over no treatment with secukinumab or ixekizumab. o Treatment with TNFi is recommended over treatment with secukinumab or ixekizumab. o Treatment with secukinumab or ixekizumab is recommended over treatment with tofacitinib. o For those patients who have contraindications to TNFi, treatment with secukinumab or ixekizumab is recommended over treatment with sulfasalazine, methotrexate or tofacitinib. • In adults with active AS despite treatment with the first TNFi used: o Treatment with secukinumab or ixekizumab is recommended over treatment with a different TNFi in patients with primary nonresponse to TNFi. o Treatment with a different TNFi is recommended over treatment with a non- TNFi biologic agent in patients with secondary nonresponse to TNFi. o Switching to treatment with a biosimilar of the first TNFi is strongly not recommended. o Addition of sulfasalazine or methotrexate in favor of treatment with a new biologic is not recommended.

Clinical Guideline	Recommendation(s)
	• In adults with active AS, treatment with systemic glucocorticoids is strongly not recommended. • In adults with AS and isolated active sacroiliitis despite treatment with NSAIDs, treatment with locally administered parenteral glucocorticoids is recommended over no treatment with local glucocorticoids. • In adults with AS with stable axial disease and active enthesitis despite treatment with NSAIDs, treatment with locally administered parenteral glucocorticoids is recommended over no treatment with local glucocorticoids. Peri-tendon injections of Achilles, patellar, and quadriceps tendons should be avoided. • In adults with stable axial disease and active peripheral arthritis despite treatment with NSAIDs, treatment with locally administered parenteral glucocorticoids is recommended over no treatment with local glucocorticoids. • Treatment with physical therapy is recommended over no treatment with physical therapy. Active physical therapy interventions are recommended over passive physical therapy interventions. Land-based physical therapy interventions are recommended over aquatic therapy interventions. <u>Recommendations for adults with stable AS</u> • On-demand treatment with NSAIDS is recommended over continuous treatment with NSAIDs. • In adults receiving treatment with TNFi and NSAIDs, continuing treatment with TNFi alone is recommended compared to continuing both treatments. • In adults receiving treatment with TNFi and conventional synthetic antirheumatic drug, continuing treatment with TNFi alone is recommended over continuing both treatments. • In adults receiving treatment with a biologic, discontinuation of the biologic or tapering of the biologic dose as a standard approach is not recommended. • In adults receiving treatment with an originator TNFi, continuing treatment with the originator TNFi is recommended over mandated switching to its biosimilar. • Treatment with physical therapy over no treatment with physical therapy is recommended. <u>Recommendations for adults with active or stable AS</u> • In adults receiving treatment with TNFi, co-treatment with low-dose methotrexate is not recommended. <u>Recommendations for adults with active nonradiographic axSpA</u> • Treatment with NSAIDs is recommended over no treatment or on-demand treatment with NSAIDs. No particular NSAID is recommended as the preferred choice • In adults with nonradiographic axSpA despite treatment with NSAIDs: o Treatment with sulfasalazine, methotrexate or tofacitinib is recommended over no treatment with these medications. o Treatment with TNFi is recommended over no treatment with TNFi. No particular TNFi is recommended as the preferred choice. o Treatment with TNFi is recommended over treatment with tofacitinib. o Treatment with secukinumab or ixekizumab is recommended over no treatment with secukinumab or ixekizumab. o Treatment with TNFi is recommended over treatment with secukinumab or ixekizumab. o Treatment with secukinumab or ixekizumab is recommended over treatment with tofacitinib. o For those patients who have contraindications to TNFi, treatment with secukinumab or ixekizumab is recommended over treatment with

Clinical Guideline	Recommendation(s)
	sulfasalazine, methotrexate or tofacitinib. • In adults with primary nonresponse to the first TNFi used, switching to secukinumab or ixekizumab is recommend over switching to a different TNFi. • In adults with secondary nonresponse to the first TNFi used, switching to a different TNFi is recommended over switching to a non-TNFi biologic. • In adults with nonradiographic axSpA despite treatment with the first TNFi used: o Switching to treatment with a biosimilar of the first TNFi is strongly not recommended. o Addition of sulfasalazine or methotrexate in favor of treatment with a new biologic is not recommended in favor of treatment with a different biologic. • Treatment with systemic glucocorticoids is strongly not recommended. • In adults with isolated active sacroiliitis despite treatment with NSAIDs, treatment with local glucocorticoids is recommended over no treatment with local glucocorticoids. • In adults with active enthesitis despite treatment with NSAIDs, treatment with locally administered parenteral glucocorticoids is recommended over no treatment with local glucocorticoids. Peri-tendon injections of Achilles, patellar, and quadriceps tendons should be avoided. • In adults with active peripheral arthritis despite treatment with NSAIDs, using treatment with locally administered parenteral glucocorticoids is recommended over no treatment with local glucocorticoids. • Treatment with physical therapy is recommended over no treatment with physical therapy. Active physical therapy interventions are recommended over passive physical therapy interventions. Land-based physical therapy interventions are recommended over aquatic therapy interventions. <u>Recommendations for adults with stable nonradiographic axSpA</u> • On-demand treatment with NSAIDS is recommended over continuous treatment with NSAIDs. • In adults receiving treatment with TNFi and NSAIDs, continuing treatment with TNFi alone is recommended compared to continuing both treatments. • In adults receiving treatment with TNFi and conventional synthetic antirheumatic drug, continuing treatment with TNFi alone is recommended over continuing both treatments. • In adults receiving treatment with a biologic, discontinuation of the biologic or tapering of the biologic dose as a standard approach is not recommended. • In adults receiving treatment with an originator TNFi, continuation of treatment with the originator TNFi is recommended over mandated switching to its biosimilar. <u>Recommendations for adults with active or stable nonradiographic axSpA</u> • In adults receiving treatment with TNFi, co-treatment with low-dose methotrexate is not recommended.
Assessment of Spondyloarthritis International Society: **2010 Update of the International Assessment of Spondyloarthritis International Society Recommendations for the Use of Anti-Tumor Necrosis Factor**	• All patients should have had adequate therapeutic trials of at least two NSAIDs. An adequate therapeutic trial is defined as at least two NSAIDs over a four-week period in total at a maximum recommended dose unless contraindicated. • Patients with pure axial manifestations do not have to take DMARDs before TNF-α inhibitor treatment can be started. • Patients with symptomatic peripheral arthritis should have an insufficient response to at least one local corticosteroid injection if appropriate, and should normally have had an adequate therapeutic trial of a DMARD, preferably sulfasalazine. • Patients with symptomatic enthesitis must have failed appropriate local treatment.

Clinical Guideline	Recommendation(s)
Agents in Patients with Axial Spondyloarthritis (2010)[25]	

National Institute for Health and Clinical Excellence: **TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (2016)[26]**	• Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab are recommended, within their marketing authorizations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, NSAIDs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their clinician consider it appropriate to stop.
	• Adalimumab, certolizumab pegol, and etanercept are recommended, within their marketing authorizations, as options for treating severe non‑radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, NSAIDs.
	• The choice of treatment should be made after discussion between the clinician and the patient about the advantages and disadvantages of the treatments available. This may include considering associated conditions such as extra‑articular manifestations. If more than one treatment is suitable, the least expensive (taking into account administration costs and patient access schemes) should be chosen.
	• The response to adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab treatment should be assessed 12 weeks after the start of treatment. Treatment should only be continued if there is clear evidence of response, defined as:
	  ○ a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre‑treatment value or by 2 or more units and
	  ○ a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.
	• Treatment with another TNF-α inhibitor is recommended for people who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-α inhibitor, or whose disease has stopped responding after an initial response.
	• When using BASDAI and spinal pain VAS scores, healthcare professionals should take into account any physical, sensory, or learning disabilities, or communication difficulties that could affect the responses to the questionnaires and make any adjustments they consider appropriate.

European League Against Rheumatism: **Recommendations For the Management of Behcet's Syndrome: 2018 Update (2018)[27]**	Mucocutaneous involvement • Topical measures such as steroids should be used for the treatment of oral and genital ulcers. Colchicine should be tried first for the prevention of recurrent mucocutaneous lesions especially when the dominant lesion is erythema nodosum or genital ulcer. Papulopustular or acne-like lesions are treated with topical or systemic measures as used in acne vulgaris. • Leg ulcers in Behcet's Syndrome (BS) might be caused by venous stasis or obliterative vasculitis. Treatment should be planned with the help of a dermatologist and vascular surgeon. • Drugs such as azathioprine, thalidomide, interferon-alpha, TNFi or apremilast should be considered in selected cases. Uveitis • Management of uveitis of BS requires close collaboration with ophthalmologists with the ultimate aim of inducing and maintaining remission. • Any patient with BS and inflammatory eye disease affecting the posterior segment should be on a treatment regime such as azathioprine, cyclosporine-A,

Clinical Guideline	Recommendation(s)
	interferon alpha or monoclonal anti-TNF antibodies. Systemic glucocorticoids should be used only in combination with azathioprine or other systemic immunosuppressives. • Patients presenting with an initial or recurrent episode of acute sight-threatening uveitis should be treated with high-dose glucocorticoids, infliximab or interferon alpha. Intravitreal glucocorticoid injection is an option in patients with unilateral exacerbation as an adjunct to systemic treatment. • In patients with isolated anterior uveitis, systemic immunosuppressives could be considered for those with poor prognostic factors such as young age, male sex and early disease onset. Venous thrombosis • For the management of acute deep vein thrombosis in BS, glucocorticoids and immunosuppressives such as azathioprine, cyclophosphamide or cyclosporine-A are recommended. • Monoclonal anti-TNF antibodies could be considered in refractory patients. • Anticoagulants may be added, provided the risk of bleeding in general is low and coexistent pulmonary artery aneurysms are ruled out. Arterial involvement • For the management of pulmonary artery aneurysms, high-dose glucocorticoids and cyclophosphamide are recommended. Monoclonal anti-TNF antibodies should be considered in refractory cases. For patients who have or who are at high risk of major bleeding, embolization should be preferred to open surgery. • For both aortic and peripheral artery aneurysms, medical treatment with cyclophosphamide and corticosteroids is necessary before intervention to repair. • Surgery or stenting should not be delayed if the patient is symptomatic. Gastrointestinal involvement • Gastrointestinal involvement of BS should be confirmed by endoscopy and/or imaging. NSAID ulcers, inflammatory bowel disease and infections such as tuberculosis should be ruled out. • Urgent surgical consultation is necessary in cases of perforation, major bleeding and obstruction. • Glucocorticoids should be considered during acute exacerbations together with disease-modifying agents such as 5-ASA or azathioprine. For severe and/or refractory patients, monoclonal anti-TNF antibodies and/or thalidomide should be considered. Nervous system involvement • Acute attacks of parenchymal involvement should be treated with high-dose glucocorticoids followed by slow tapering, together with immunosuppressives such as azathioprine. Cyclosporine should be avoided. Monoclonal anti-TNF antibodies should be considered in severe disease as first-line or in refractory patients. • The first episode of cerebral venous thrombosis should be treated with high-dose glucocorticoids followed by tapering. Anticoagulants may be added for a short duration. Screening is needed for vascular disease at an extracranial site. Joint involvement • Colchicine should be the initial treatment in BS patients with acute arthritis. Acute monoarticular disease can be treated with intra-articular glucocorticoids. Azathioprine, interferon-alpha or TNFi should be considered in recurrent and chronic cases.
American College of	Mild-to-moderately severe disease/low-risk disease

Clinical Guideline	Recommendation(s)
Gastroenterology: **Management of Crohn's Disease in Adults (2018)**[28]	• Sulfasalazine is effective for treating symptoms of colonic Crohn's disease that is mild to moderately active (conditional recommendation, low level of evidence). • Oral mesalamine has not consistently been demonstrated to be effective compared with placebo for induction of remission and achieving mucosal healing in patients with active Crohn's disease and should not be used to treat patients with active Crohn's disease (strong recommendation, moderate level of evidence). • Controlled ileal release budesonide at a dose of 9 mg once daily is effective and should be used for induction of symptomatic remission for patients with mild-to-moderate ileocecal Crohn's disease (strong recommendation, low level of evidence). • Metronidazole is not more effective than placebo as therapy for luminal inflammatory Crohn's disease and should not be used as primary therapy (conditional recommendation, low level of evidence). • Ciprofloxacin has shown similar efficacy to mesalamine in active luminal Crohn's disease but has not been shown to be more effective than placebo to induce remission in Crohn's disease and should not be used as therapy for luminal inflammatory Crohn's disease (conditional recommendation, very low level of evidence). • Antimycobacterial therapy has not been shown to be effective for induction or for maintenance of remission or mucosal healing in patients with Crohn's disease and should not be used as primary therapy (conditional recommendation, low level of evidence). • For patients with low risk of progression, treatment of active symptoms with anti-diarrheals, other non-specific medications, and dietary manipulation, along with careful observation for inadequate symptom relief, worsening inflammation, or disease progression, is acceptable (strong recommendation, very low level of evidence). <u>Moderate-to-severe disease/moderate-to-high-risk disease</u> • Oral corticosteroids are effective and can be used for short-term use in alleviating signs and symptoms of moderate to severely active Crohn's disease (strong recommendation, moderate level of evidence). • Conventional corticosteroids do not consistently achieve mucosal healing and should be used sparingly (weak recommendation, low level of evidence). • Azathioprine (at doses of 1.5 to 2.5 mg/kg/day) and 6-mercaptopurine (at doses of 0.75 to 1.5 mg/kg day) are not more effective than placebo to induce short-term symptomatic remission and should not be used in this manner (strong recommendation, low level of evidence). • Thiopurines (azathioprine, 6-mercaptopurine) are effective and should be considered for use for steroid sparing in Crohn's disease (strong recommendation, low level of evidence). • Azathioprine and 6-mercaptourine are effective therapies and should be considered for treatment of patients with Crohn's disease for maintenance of remission (strong recommendation, moderate level of evidence). • Thiopurine methyltransferase (TPMT) testing should be considered before initial use of azathioprine or 6-mercaptopurine to treat patients with Crohn's disease (strong recommendation, low level of evidence). • Methotrexate (up to 25 mg once weekly IM or SC) is effective and should be considered for use in alleviating signs and symptoms in patients with steroid-dependent Crohn's disease and for maintaining remission (conditional recommendation, low level of evidence). • Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) should be used to treat Crohn's disease that is resistant to treatment with corticosteroids (strong

Clinical Guideline	Recommendation(s)
	recommendation, moderate level of evidence). • Anti-TNF agents should be given for Crohn's disease refractory to thiopurines or methotrexate (strong recommendation, moderate level of evidence). • Combination therapy of infliximab with immunomodulators (thiopurines) is more effective than treatment with either immunomodulators alone or infliximab alone in patients who are naive to those agents (strong recommendation, high level of evidence). • For patients with moderately to severely active Crohn's disease and objective evidence of active disease, anti-integrin therapy (with vedolizumab) with or without an immunomodulator is more effective than placebo and should be considered to be used for induction of symptomatic remission in patients with Crohn's disease (strong recommendation, high level of evidence). • Natalizumab is more effective than placebo and should be considered to be used for induction of symptomatic response and remission in patients with active Crohn's disease (strong recommendation, high level of evidence). • Natalizumab should be used for maintenance of natalizumab-induced remission of Crohn's disease only if serum antibody to John Cunningham (JC) virus is negative. Testing for anti-JC virus antibody should be repeated every 6 months and treatment stopped if the result is positive. (strong recommendation, moderate level of evidence). • Ustekinumab should be given for moderate-to-severe Crohn's disease patients who failed previous treatment with corticosteroids, thiopurines, methotrexate, or anti-TNF inhibitors or who have had no prior exposure to anti-TNF inhibitors (strong recommendation, high level of evidence). • Cyclosporine, mycophenolate mofetil, and tacrolimus should not be used for Crohn's disease (strong recommendation, moderate level of evidence). <u>Severe/fulminant disease</u> • Intravenous corticosteroids should be used to treat severe or fulminant Crohn's disease (conditional recommendation, moderate level of evidence). • Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) can be considered to treat severely active Crohn's disease (strong recommendation, moderate level of evidence). • Infliximab may be administered to treat fulminant Crohn's disease (conditional recommendation, low level of evidence). <u>Perianal/fistulizing disease</u> • Infliximab is effective and should be considered in treating perianal fistulas in Crohn's disease (strong recommendation, moderate level of evidence). • Infliximab may be effective and should be considered in treating enterocutaneous and rectovaginal fistulas in Crohn's disease (strong recommendation, moderate level of evidence). • Adalimumab and certolizumab pegol may be effective and should be considered in treating perianal fistulas in Crohn's disease (strong recommendation, low level of evidence). • Thiopurines (azathioprine, 6-mercaptopurine) may be effective and should be considered in treating fistulizing Crohn's disease (strong recommendation, low level of evidence). • Tacrolimus can be administered for short-term treatment of perianal and cutaneous fistulas in Crohn's disease (strong recommendation, moderate level of evidence). • Antibiotics (imidazoles) may be effective and should be considered in treating simple perianal fistulas (strong recommendation, moderate level of evidence). • The addition of antibiotics to infliximab is more effective than infliximab alone and should be considered in treating perianal fistulas (strong recommendation,

Clinical Guideline	Recommendation(s)
	moderate level of evidence). • Drainage of abscesses (surgically or percutaneously) should be undertaken before treatment of fistulizing Crohn's disease with anti-TNF agents (conditional recommendation, very low level of evidence). • Placement of setons increases the efficacy of infliximab and should be considered in treating perianal fistulas (strong recommendation, moderate level of evidence). Maintenance Therapy of Luminal Crohn's Disease • Once remission is induced with corticosteroids, a thiopurine or methotrexate should be considered (strong recommendation, moderate level of evidence). • Patients who are steroid dependent should be started on thiopurines or methotrexate with or without anti-TNF therapy (strong recommendation, moderate level of evidence). • Oral 5-aminosalicylic acid has not been demonstrated to be effective for maintenance of medically induced remission in patients with Crohn's disease, and is not recommended for long-term treatment (strong recommendation, moderate level of evidence). • Corticosteroids are not effective for maintenance of medically induced remission in Crohn's disease and should not be used for long-term treatment (strong recommendation, moderate level of evidence). • Budesonide should not be used to maintain remission of Crohn's disease beyond 4 months (strong recommendation, moderate level of evidence). • Anti-TNF therapy, specifically infliximab, adalimumab, and certolizumab pegol, should be used to maintain remission of anti-TNF-induced remission (strong recommendation, high level of evidence). • Anti-TNF monotherapy is effective at maintaining anti-TNF induced remission, but because of the potential for immunogenicity and loss of response, combination with azathioprine/6-mercaptopurine or methotrexate should be considered (strong recommendation, moderate level of evidence). • Vedolizumab should be used for maintenance of remission of vedolizumab-induced remission of Crohn's disease (conditional recommendation, moderate level of evidence). • Natalizumab should be considered for maintaining remission of natalizumab-induced remission of Crohn's disease patients only if John Cunningham (JC) virus is negative (conditional recommendation, moderate level of evidence). • Ustekinumab should be use for maintenance of remission of ustekinumab-induced response of Crohn's disease (conditional recommendation, moderate level of evidence). Postoperative Crohn's Disease • All patients who have Crohn's disease should quit smoking (conditional recommendation, very low level of evidence). • Mesalamine is of limited benefit in preventing postoperative Crohn's disease, but in addition to no treatment is an option for patients with an isolated ileal resection and no risk factors for recurrence (conditional recommendation, moderate level of evidence). • Imidazole antibiotics (metronidazole and ornidazole) at doses between 1 and 2 g/day can be used after small intestinal resection in Crohn's disease patients to prevent recurrence (conditional recommendation, low level of evidence). • Thiopurines may be used to prevent clinical and endoscopic recurrence and are more effective than mesalamine or placebo. However, they are not effective at preventing severe endoscopic recurrence (strong recommendation, moderate level of evidence). • In high-risk patients, anti-TNF agents should be started within four weeks of

Clinical Guideline	Recommendation(s)
	surgery in order to prevent postoperative Crohn's disease recurrence (conditional recommendation, low level of evidence). • Although data are lacking in postoperative Crohn's disease, anti-TNF therapy should be combined with an immunomodulator to decrease immunogenicity and decrease loss of response (conditional recommendation, very low level of evidence).
National Institute for Health and Clinical Excellence: **Crohn's Disease Management (2019)**[29]	Monotherapy • Offer monotherapy with a conventional glucocorticosteroid (prednisolone, methylprednisolone or intravenous hydrocortisone) to induce remission in people with a first presentation or a single inflammatory exacerbation of Crohn's disease in a 12-month period. • Consider enteral nutrition as an alternative to a conventional glucocorticosteroid to induce remission for: o Children in whom there is concern about growth or side effects. o Young people in whom there is concern about growth. • In people with one or more of distal ileal, ileocecal or right-sided colonic disease who decline, cannot tolerate or in whom a conventional glucocorticosteroid is contraindicated, consider budesonide for a first presentation or a single inflammatory exacerbation in a 12-month period. • In people who decline, cannot tolerate or in whom glucocorticosteroid treatment is contraindicated, consider 5-aminosalicylate (5-ASA) treatment for a first presentation or a single inflammatory exacerbation in a 12-month period. • Do not offer budesonide or 5-ASA treatment for severe presentations or exacerbations. • Do not offer azathioprine, mercaptopurine or methotrexate as monotherapy to induce remission. Combination therapy • Consider adding azathioprine or mercaptopurine to a conventional glucocorticosteroid or budesonide to induce remission of Crohn's disease if: o There are two or more inflammatory exacerbations in a 12-month period, or o The glucocorticosteroid dose cannot be tapered. • Assess thiopurine methyltransferase (TPMT) activity before offering azathioprine or mercaptopurine. Do not offer azathioprine or mercaptopurine if TPMT activity is deficient (very low or absent). Consider azathioprine or mercaptopurine at a lower dose if TPMT activity is below normal but not deficient (according to local laboratory reference values). • Consider adding methotrexate to a conventional glucocorticosteroid or budesonide to induce remission in people who cannot tolerate azathioprine or mercaptopurine, or in whom TPMT activity is deficient, if: o There are two or more inflammatory exacerbations in a 12-month period, or o The glucocorticosteroid dose cannot be tapered. • Monitor the effects of azathioprine, mercaptopurine and methotrexate. Monitor for neutropenia in people taking azathioprine or mercaptopurine even if they have normal TPMT activity. Infliximab and adalimumab • Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy. • Infliximab or adalimumab should be given as a planned course of treatment

Clinical Guideline	Recommendation(s)
	until treatment failure (including the need for surgery), or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed to determine whether ongoing treatment is still clinically appropriate. • Treatment as described should normally be started with the less expensive drug. This may need to be varied for individuals because of differences in the method of administration and treatment schedules. • Options of monotherapy with one of these drugs or combined therapy should be discussed when starting infliximab or adalimumab. • Infliximab is recommended as a treatment option for people with active fistulizing Crohn's disease whose disease has not responded to conventional therapy (including antibiotics, drainage and immunosuppressive treatments), or who are intolerant of or have contraindications to conventional therapy. • Infliximab should be given as a planned course of treatment until treatment failure (including the need for surgery) or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed to determine whether ongoing treatment is still clinically appropriate. • Treatment with infliximab or adalimumab should only be continued if there is clear evidence of ongoing active disease as determined by clinical symptoms, biological markers and investigation, including endoscopy if necessary. Specialists should discuss the risks and benefits of continued treatment with patients and consider a trial withdrawal from treatment for all patients who are in stable clinical remission. People who continue treatment with infliximab or adalimumab should have their disease reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate. People whose disease relapses after treatment is stopped should have the option to start treatment again. • Infliximab is recommended for the treatment of people aged 6 to 17 years with severe active Crohn's disease whose disease has not responded to conventional therapy (including corticosteroids, immunomodulators and primary nutrition therapy), or who are intolerant of or have contraindications to conventional therapy. The need to continue treatment should be reviewed at least every 12 months. • Treatment with infliximab or adalimumab should only be started and reviewed by clinicians with experience of TNFi and of managing Crohn's disease. <u>Remission maintenance</u> • For patients that choose maintenance therapy, offer azathioprine or mercaptopurine as monotherapy to maintain remission when previously used with a conventional glucocorticosteroid or budesonide to induce remission or to maintain remission in patients not previously treated with these medications. • Consider methotrexate to maintain remission only in patients who: o Needed methotrexate to induce remission. o Did not tolerate azathioprine or mercaptopurine for maintenance. o Contraindicated to azathioprine or mercaptopurine. • Do not offer conventional glucocorticosteroids or budesonide to maintain remission. <u>Remission maintenance following surgery</u> • To maintain remission in people with ileocolonic Crohn’s disease who have had complete macroscopic resection within the last three months, consider azathioprine in combination with up to three months post-operative metronidazole. Azathioprine alone should be considered for patients who cannot tolerate metronidazole. • Effects of azathioprine and metronidazole should be monitored, including

Clinical Guideline	Recommendation(s)
	neutropenia in patients taking azathioprine even if they have normal TPMT. • Biologics should not be offered to maintain remission after complete macroscopic resection of ileocolonic Crohn's disease. For patients who have had surgery and started taking biologics already, continue with their current treatment until both they and their healthcare professional agree it is appropriate to change.
American College of Rheumatology/Arthritis Foundation: **Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-systemic Polyarthritis, Sacroiliitis and Enthesitis (2019)**[30]	Recommendations for children and adolescents with JIA and polyarthritis • NSAIDs are recommended as adjunct therapy • Using methotrexate is recommended over leflunomide or sulfasalazine • Using subcutaneous methotrexate is recommended over oral methotrexate. • Intraarticular glucocorticoids are recommended as adjunct therapy. • Triamcinolone hexacetonide is strongly recommended over triamcinolone acetonide for intraarticular glucocorticoid injections. • Bridging therapy with a limited course of oral glucocorticoids (<3 months) during initiation or escalation of therapy in patients with high or moderate disease activity is recommended. Bridging therapy with a limited course of oral glucocorticoids is not recommended in patients with low disease activity. • Chronic low-dose glucocorticoid is strongly not recommended, irrespective of risk factors or disease activity. • Initiating treatment with biologic (etanercept, adalimumab, golimumab, abatacept, or tocilizumab) combination therapy with a DMARD is recommended over biologic monotherapy. • Combination therapy with a DMARD is strongly recommended for infliximab. • In all patients with JIA and active polyarthritis, initial therapy with a DMARD is strongly recommended over NSAID monotherapy. Using methotrexate monotherapy as initial therapy is conditionally recommended over triple DMARD therapy. • In patients without risk factors, initial therapy with a DMARD is recommended over a biologic. • In patients with risk factors, initial therapy with a DMARD is recommended over a biologic, recognizing that there are situations where initial therapy that includes a biologic may be preferred. Initial biologic therapy may be considered for patients with risk factors and involvement of high-risk joints (e.g., cervical spine, wrist, or hip), high disease activity, and/or those judged by their physician to be at high risk of disabling joint damage. • For subsequent therapy in patients receiving DMARD and/or biologic with low disease activity, escalating therapy is conditionally recommended over no escalation of therapy. Escalation of therapy may include: Intraarticular glucocorticoid injection(s), optimization of DMARD dose, trial of methotrexate if not done, and adding or changing biologic. • For subsequent therapy in patients receiving DMARD monotherapy with moderate/high disease activity, adding a biologic to original DMARD is recommended over changing to a second DMARD. Adding a biologic is recommended over changing to a triple DMARD therapy. • For subsequent therapy in patients receiving first TNFi with or without DMARD therapy with moderate/high disease activity, switching to a non-TNFi biologic (tocilizumab or abatacept) is recommended over switching to a second TNFi. A second TNFi may be appropriate for patients with good initial response to their first TNFi (i.e., secondary failure). • For subsequent therapy in patients receiving second biologic with moderate/high disease activity, using TNFi, abatacept, or tocilizumab (depending on prior biologics received) is recommended over rituximab.
American College of Rheumatology: **Recommendations for**	General considerations • Recommendations for the treatment of juvenile idiopathic arthritis (JIA) are divided into five treatment groups that were developed by the core expert panel

Clinical Guideline	Recommendation(s)
the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features (2011)[31]	responsible for the literature review in the recommendation development. The treatment groups are as follows: history of arthritis of four or fewer joints, history of arthritis of five or more joints, active sacroiliac arthritis, systemic arthritis with active systemic features (and without active arthritis) and systemic arthritis with active arthritis (and without active systemic features). • Glucocorticoid joint injections for active arthritis are recommended regardless of concurrent therapy (no DMARD, nonbiologic DMARD, biologic DMARD) or JIA treatment group. Due to its "superior" efficacy, triamcinolone hexacetonide should be used. • When initiating a TNF-α inhibitor (etanercept or adalimumab), continuation of methotrexate is recommended for patients that had a partial previous response. <u>History of arthritis in four or fewer joints</u> • For patients with low disease activity, no joint contractures and without features of poor prognosis, initiation of therapy with NSAID monotherapy is recommended as a treatment option. Therapy with an NSAID without additional therapy is not recommended longer than two months. • For all patients regardless of disease activity level, prognostic features or joint contractures, initiation of intra-articular joint injections (with or without additional therapy is recommended. • For patients with high disease activity and poor prognostic features, methotrexate is recommended as initial treatment (without prior therapy). For patients with high disease activity without poor prognostic features or with moderate disease activity and poor prognostic features, methotrexate is recommended after initial joint injection. For patients with low disease activity and poor prognostic features or moderate disease activity without poor prognostic features, methotrexate is recommended after repeated joint injections. • For patients with enthesitis-related arthritis category of JIA with moderate or high disease activity with and without poor prognostic features, sulfasalazine is recommended after glucocorticoid injections or an adequate trial of NSAIDs. • Initiation of a TNF-α inhibitor is recommended for patients with moderate or high disease activity with poor prognostic features after receiving glucocorticoid joint injections and three months of methotrexate at maximum tolerated dose. Initiation of a TNF-α inhibitor is also recommended in patients with high disease activity without poor prognostic features after receiving glucocorticoid joint injections and six months of methotrexate. For patients with enthesitis-related arthritis category of JIA and moderate or high disease activity, regardless of prognostic features, TNF-α inhibitors are recommended after receiving glucocorticoid joint injections and an adequate trial of sulfasalazine (without prior methotrexate). <u>History of arthritis of five or more joints</u> • Initial treatment with methotrexate is recommended in patients with high disease activity with or without poor prognostic features and in patients with moderate disease activity and poor prognostic features. For patients with low disease activity and poor prognostic features, methotrexate therapy is recommended after one month of therapy with NSAIDs. In patients with moderate disease activity without poor prognostic features, methotrexate is recommended after one to two months of therapy with NSAIDs. • Leflunomide is a treatment alternative to methotrexate as initial therapy in patients with high disease activity and poor prognostic features. In patients with high disease activity without poor prognostic features or moderate disease activity with poor prognostic features, leflunomide is a treatment alternative after a brief trial with NSAIDs. • For patients with moderate or high disease activity, regardless of prognostic

Clinical Guideline	Recommendation(s)
	features, TNF-α inhibitors are recommended after receiving methotrexate or leflunomide for three months at the maximum tolerated typical doses. For patients with low disease activity with or without poor prognostic features, TNF-α inhibitors are recommended after receiving methotrexate or leflunomide for six months. • For patients with moderate or high disease activity regardless of prognostic features, switching from one TNF-α inhibitor to another is recommended as a treatment option after receiving four months of therapy with current TNF-α inhibitor. • Abatacept is recommended as a treatment option after receiving four months of therapy with a TNF-α inhibitor in patients with high disease activity regardless of prognostic features or moderate disease activity and poor prognostic features. For patients with moderate or high disease activity regardless of prognostic features or patients with low disease activity with features of poor prognosis, abatacept is recommended as a treatment option after receiving more than one TNF-α inhibitor sequentially. • Switching to a TNF-α inhibitor is recommended as a treatment option in patients that received abatacept for three months and have high disease activity with poor prognostic features and in patients that received abatacept for six months and have moderate to high disease activity with or without features of poor prognosis. <u>Active sacroiliac arthritis</u> • For patients with high disease activity and features of poor prognosis, TNF-α inhibitors are recommended after receiving an adequate trial of NSAIDs. • A TNF-α inhibitor is recommended in patients with high disease activity regardless of prognostic features or moderate disease activity with features of poor prognosis that have received three months of methotrexate, or in patients with moderate disease without poor prognosis that received six months of methotrexate. • A TNF-α inhibitor is recommended in patients with moderate or high disease activity regardless of prognostic features that have received three months of sulfasalazine, or in patients with low disease with poor prognosis that received six months of sulfasalazine. <u>Systemic arthritis with active systemic features</u> • NSAID monotherapy is appropriate during clinical evaluation for possible systemic arthritis. NSAID monotherapy is not recommended for patients with active fever and physician global assessment of overall disease activity ≥7 of 10. In patients with active fever, continuation of NSAID monotherapy longer than one month is not appropriate. • Initial therapy with systemic glucocorticoids (with or without additional concurrent therapy) is recommended for patients with active fever and physician global assessment of seven or greater. For all patients with active fever, systemic glucocorticoids are recommended following up to two weeks of NSAIDs. • Anakinra is recommended for all patients with active fever and poor prognostic features, regardless of current therapy. For patients that sustain or develop fever while receiving systemic glucocorticoid, anakinra is recommended. <u>Systemic arthritis with active arthritis</u> • NSAID monotherapy (with or without glucocorticoid joint injections) for up to one month is recommended for patients with low disease activity without features of poor prognosis. • For all patients with active arthritis, regardless of prognostic features, methotrexate is recommended after one month or less of NSAID monotherapy

Clinical Guideline	Recommendation(s)
	(with or without glucocorticoid injections). • After three months of methotrexate, anakinra is recommended for patients with moderate or high disease activity with or without poor prognostic features. Anakinra is recommended for patients with high or moderate disease activity, regardless of prognostic features, and have received methotrexate and a TNF-α inhibitor or methotrexate and abatacept. Initiation of anakinra later in the disease course may be less appropriate compared to nearer to the onset of disease. • For patients with moderate or high disease activity with or without poor prognosis features, TNF-α inhibitors are recommended after receiving three months of methotrexate. Switching from anakinra to TNF-α inhibitors may be appropriate for patients with moderate to high disease activity regardless of prognostic features. • Abatacept is recommended for patients that received methotrexate and a TNF-α inhibitor and have high disease activity regardless of prognostic features or moderate disease activity and poor prognostic features.
American College of Rheumatology: **2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications (2013)**[32]	<u>Initial treatment of systemic JIA with active systemic features and varying degrees of synovitis</u> • Anakinra is recommended as one initial treatment option for patients with a physician global assessment (MD global) ≥5 irrespective of the active joint count (AJC), or an MD global <5 and an AJC >0. • Systemic glucocorticoid monotherapy (oral or intravenous) is recommended for a maximum period of two weeks for patients with an MD global <5 and an AJC >4 and for all patients with an MD global ≥5 irrespective of the AJC. • Initiating NSAID monotherapy in a patient without prior treatment is recommended as one approach for patients with an MD global <5 irrespective of the AJC. <u>Treatment of systemic JIA with active systemic features and varying degrees of synovitis in patients with continued disease activity</u> • Use of abatacept is recommended only in patients with an MD global ≥5 and an AJC >4 after a trial of both an IL-1 inhibitor and tocilizumab (sequentially). • Use of abatacept for patients with an AJC of zero irrespective of the MD global is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially), in which case it is uncertain. • Use of abatacept for patients with an MD global <5 and an AJC >0 or an MD global ≥5 and an AJC <4 is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially) or a DMARD plus either an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Use of abatacept for patients with an MD global ≥5 and an AJC >4 is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially), in which case it is appropriate, or patients who had tried a DMARD plus either an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Anakinra is recommended for patients with continued disease activity after treatment with glucocorticoid monotherapy or NSAID monotherapy. • Use of a calcineurin inhibitor is recommended only for patients with an MD global ≥5 and an AJC of zero after a trial of both an IL-1 inhibitor and tocilizumab (sequentially). • Use of a calcineurin inhibitor for patients with an MD global <5 and an AJC of zero is inappropriate, with the exception of patients who received either an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Use of a calcineurin inhibitor for patients with an MD global ≥5 and an AJC of zero is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially), in which case it is appropriate, or

Clinical Guideline	Recommendation(s)
	patients who had tried an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Use of a calcineurin inhibitor for patients with an AJC >0 irrespective of the MD global is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially) or an alternate DMARD plus either an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Canakinumab is recommended for patients with continued disease activity after treatment with glucocorticoid monotherapy, methotrexate or leflunomide, anakinra, or tocilizumab irrespective of the MD global and AJC. • Canakinumab is also recommended for patients with an MD global ≥5 irrespective of the AJC, despite prior NSAID monotherapy. • Glucocorticoid monotherapy is recommended as a treatment option after failure of NSAID monotherapy for patients with an MD global <5 and an AJC >0 and for patients with an MD global ≥5 irrespective of the AJC. Adjunct glucocorticoid therapy at any point is appropriate to consider. • Intraarticular glucocorticoid injection is recommended as adjunct therapy at any time. • Methotrexate or leflunomide is recommended for patients with an MD global <5 and an AJC >0 after treatment with glucocorticoid monotherapy, an IL-1 inhibitor, or tocilizumab. Methotrexate or leflunomide is recommended for patients with an MD global ≥5 and an AJC >0, only after a trial of an IL-1 inhibitor or tocilizumab. • Initiation of a TNF-α inhibitor is recommended for patients with an AJC >4 irrespective of the MD global after a trial of an IL-1 inhibitor or tocilizumab. Initiation of a TNF-α inhibitor is recommended for patients with an AJC >0 irrespective of the MD global after a trial of both an IL-1 inhibitor and tocilizumab (sequentially). • Use of a TNF-α inhibitor for patients with an MD global <5 and an AJC of zero is inappropriate, with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially) or a DMARD plus either an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Use of a TNF-α inhibitor for patients with an MD global ≥5 and an AJC of zero is inappropriate, with the exception of patients who had tried an IL-1 inhibitor or tocilizumab, in which case it is uncertain. • Tocilizumab is recommended as a treatment option for patients with continued disease activity following glucocorticoid monotherapy, methotrexate or leflunomide, or anakinra irrespective of the MD global and AJC. • Tocilizumab is also recommended for patients with an MD global ≥5 irrespective of the AJC despite prior NSAID monotherapy. <u>Initial treatment of systemic JIA without active systemic features and varying degrees of synovitis</u> • Intraarticular glucocorticoid injection is recommended as an initial treatment for patients with an AJC ≤4. The utility of repeating injections in the same joint(s) as the only intervention is uncertain. • Initiation of methotrexate or leflunomide is recommended for patients with an AJC >4. • Initiation of NSAID monotherapy in a patient without prior treatment for a maximum period of one month is recommended as one treatment approach for patients with an AJC >0. Continuing NSAID monotherapy for longer than two months for patients with continued disease activity is inappropriate. <u>Treatment of systemic JIA without active systemic features and varying degrees of synovitis in patients with continued disease activity</u> • Use of abatacept is recommended for patients with an AJC >0 after treatment

Clinical Guideline	Recommendation(s)
	with methotrexate or leflunomide, anakinra, or tocilizumab. • Anakinra is recommended as a treatment option for patients with an AJC >4 following failed intraarticular injection or NSAID monotherapy. Use of anakinra is also recommended for patients with an AJC >0 following treatment with methotrexate or leflunomide. • Initiation of canakinumab is recommended for patients with an AJC >4 only after a trial of a DMARD plus anakinra or tocilizumab, a DMARD plus a TNF-α inhibitor, or abatacept. • Use of methotrexate or leflunomide is recommended as a treatment option for an AJC >0 following treatment with intraarticular injection, NSAID monotherapy, an IL-1 inhibitor, or tocilizumab. • Initiation of a TNF-α inhibitor is recommended for patients with an AJC >0 after treatment with methotrexate or leflunomide, anakinra, or tocilizumab. • Initiation of tocilizumab is recommended for an AJC >0 following treatment with anakinra or methotrexate or leflunomide. <u>Initial treatment of systemic JIA with features concerning for macrophage activation syndrome (MAS)</u> • Use of anakinra is recommended as one treatment option for patients with features concerning for MAS. • Use of a calcineurin inhibitor is recommended as one therapeutic option for patients with features concerning for MAS. • Use of systemic glucocorticoid monotherapy (administered by oral or intravenous route) is also recommended as a therapeutic option for patients with features concerning for MAS. • Continuing glucocorticoid monotherapy for longer than two weeks is inappropriate.
European League Against Rheumatism: **Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies (2012)**[33]	<u>Recommendations for treatment</u> • In patients with psoriatic arthritis, NSAIDs may be used to relieve musculoskeletal signs and symptoms. • In patients with active disease (particularly those with many swollen joints, structural damage in the presence of inflammation, high erythrocyte sedimentation rate/C-reactive protein and/or clinically relevant extraarticular manifestations), treatment with DMARDs, such as methotrexate, sulfasalazine, leflunomide, should be considered at an early stage. • In patients with active psoriatic arthritis and clinically relevant psoriasis, a DMARD that also improves psoriasis, such as methotrexate, should be preferred. • Local corticosteroid injections should be considered as adjunctive therapy in psoriatic arthritis; systemic steroids at the lowest effective dose may be used with caution. • In patients with active arthritis and an inadequate response to at least one synthetic DMARD, such as methotrexate, therapy with a TNF-α inhibitor should be commenced. • In patients with active enthesitis and/or dactylitis and insufficient response to NSAIDs or steroid injections, a TNF-α inhibitor may be considered. • In patients with predominantly axial disease that is active and has insufficient response to NSAIDs, a TNF-α inhibitor should be considered. • A TNF-α inhibitor might be considered for a very active patient treatment naïve to DMARDs (particularly those with many swollen joints, structural damage in the presence of inflammation, and/ or clinically relevant extra-articular manifestations, especially extensive skin involvement). • In patients who fail to respond adequately to one TNF-α inhibitor, switching to another TNF-α inhibitor should be considered. • When adjusting therapy, factors apart from disease activity, such as

Clinical Guideline	Recommendation(s)
	comorbidities and safety issues, should be taken into account.
European League Against Rheumatism: **Recommendations For The Management Of Psoriatic Arthritis With Pharmacological Therapies: 2015 Update (2015)**[34]	• Treatment of patients with psoriatic arthritis should aim at the best care and must be based on a shared decision between the patient and the rheumatologist, considering efficacy, safety and costs. • The primary goal of treating patients with psoriatic arthritis is to maximize health-related quality of life, through control of symptoms, prevention of structural damage, normalization of function and social participation; abrogation of inflammation is an important component to achieve these goals. • Treatment should be aimed at reaching the target of remission or, alternatively, minimal/low disease activity, by regular monitoring and appropriate adjustment of therapy. • In patients with psoriatic arthritis, NSAIDs may be used to relieve musculoskeletal signs and symptoms. • In patients with peripheral arthritis, particularly in those with many swollen joints, structural damage in the presence of inflammation, high ESR/CRP and/or clinically relevant extra-articular manifestations, conventional synthetic DMARDs should be considered at an early stage, with methotrexate preferred in those with relevant skin involvement. • Local injections of glucocorticoids should be considered as adjunctive therapy in psoriatic arthritis; systemic glucocorticoids may be used with caution at the lowest effective dose. • In patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, therapy with a biological DMARD, usually a TNF-α inhibitor, should be commenced. • In patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, in whom TNF-α inhibitor are not appropriate, biological DMARDs targeting IL12/23 or IL17 pathways may be considered. • In patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, in whom biological DMARDs are not appropriate, a targeted synthetic DMARD such as a PDE4-inhibitor may be considered. • In patients with active enthesitis and/or dactylitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a biological DMARD should be considered, which according to current practice is a TNF-α inhibitor. • In patients with predominantly axial disease that is active and has insufficient response to NSAIDs, therapy with a biological DMARD should be considered, which according to current practice is a TNF-α inhibitor. • In patients who fail to respond adequately to a biological DMARD, switching to another biological DMARD should be considered, including switching between TNF-α inhibitors.
European League Against Rheumatism: **Recommendations For The Management Of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update (2019)**[35]	• Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy. • NSAIDs may be used to relieve musculoskeletal signs and symptoms. • Local injections of glucocorticoids should be considered as adjunctive therapy in psoriatic arthritis; systemic glucocorticoids may be used with caution at the lowest effective dose. • In patients with polyarthritis, a conventional synthetic DMARD should be initiated rapidly, with methotrexate preferred in those with relevant skin involvement. • In patients with monoarthritis or oligoarthritis, particularly with poor prognostic factors such as structural damage, high erythrocyte sedimentation rate/C reactive protein, dactylitis or nail involvement, a conventional synthetic DMARD should be considered. • In patients with peripheral arthritis and an inadequate response to at least one

Clinical Guideline	Recommendation(s)
	conventional synthetic DMARD, therapy with a biological DMARD should be commenced; when there is relevant skin involvement, an interleukin-17 inhibitor or interleukin-12/23 inhibitor may be preferred. • In patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD and at least one DMARD, or when a biological DMARD is not appropriate, a JAK inhibitor may be considered. • In patients with mild disease and an inadequate response to at least one conventional synthetic DMARD†, in whom neither a biological DMARD nor a JAK inhibitor is appropriate*, a phosphodiesterase-4 inhibitor may be considered. • In patients with unequivocal enthesitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a biological DMARD should be considered. • In patients with predominantly axial disease which is active and has insufficient response to NSAIDs, therapy with a biological DMARD should be considered, which according to current practice is a TNFi; when there is relevant skin involvement, interleukin-17 inhibitor may be preferred. • In patients who fail to respond adequately to, or are intolerant of a biological DMARD, switching to another biological DMARD or targeted synthetic DMARD should be considered, including one switch within a class. • In patients in sustained remission, cautious tapering of DMARDs may be considered.
National Psoriasis Foundation: **Consensus Guidelines for the Management of Plaque Psoriasis (2012)**[36]	<u>Oral therapies</u> • Acitretin is the only antipsoriatic retinoid available for systemic use in the United States. The use of acitretin is limited due to its slow onset of action and persistence of residual plaque psoriasis even when plaque thinning is noted. The combination of acitretin with topical calcipotriene or biological therapy or phototherapy may increase rates of clearance. Acitretin is especially useful in patients with severely sun-damaged skin, in which it may suppress actinic keratoses and even invasive malignant neoplasms. • Although it can be effective in the long term, continuous use of cyclosporine is associated with cumulative renal toxic effects, hypertension and hyperglycemia. Cyclosporine should normally be reserved for intermittent use of no longer than 12 weeks as a short-term treatment agent to control a flare of psoriasis, after which therapy is switched for long-term maintenance. When used in this intermittent fashion, a course of cyclosporine treatment can induce an average decrease of more than 75% in psoriasis severity. • Methotrexate is directly anti-inflammatory because of its effects on T-cell gene expression patterns. Compared to cyclosporine, methotrexate has a more modest effect on psoriasis severity, but can be used continuously for many years with durable benefits. A major safety issue with methotrexate is the cumulative toxic effects to the liver. <u>Biologic agents</u> • Adalimumab may be used as first-line systemic treatment of plaque psoriasis and has a higher efficacy and lower rate of adverse effects compared to methotrexate. • Etanercept is commonly used as a first-line systemic drug for chronic plaque psoriasis. • Infliximab is administered via intravenous infusion, is a fast-acting drug that is often used as a second- or third-line biological for chronic plaque psoriasis • Ustekinumab is associated with favorable results when compared to etanercept in terms of efficacy and safety. It may be used as first-line systemic treatment for chronic plaque psoriasis. • Alefacept is generally used for intermittent use. There is little evidence to

Clinical Guideline	Recommendation(s)
	support use to achieve full clearance, and it is often used in combination regimens. It may be used as first-line systemic drug for chronic plaque psoriasis.
American Academy of Dermatology: **Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis, Sections 2, 3, and 4 (2008-2009)**[37-39]	Topical therapies • Approximately 80% of patients are affected with mild to moderate psoriasis with the majority of cases able to be successfully treated with topical agents. • Topical agents are also used adjunctively to either ultraviolet light or systemic medications for resistant lesions in patients with more severe disease. • Treatment needs vary depending on body location of disease, characteristics of the psoriasis being treated including lesion thickness, degree of erythema and amount of scaling, as well as patient preferences. • Topical corticosteroids are the cornerstone of treatment for the majority of patients with psoriasis. • Other topical agents include anthralin, coal tar, nonmedicated topical moisturizers, pimecrolimus, salicylic acid, tacrolimus, tazarotene, vitamin D analogues, and combination products. • Salicylic acid is a topical keratolytic agent that has been used for many years and has no specific FDA indication. • There are no placebo-controlled trials verifying the safety and efficacy of salicylic acid however the agent is typically used in combination with other topical therapies. Systemic therapies • Although biologics are often less toxic and not teratogenic, traditional systemic therapies (acitretin, cyclosporine, methotrexate) are still used more often due to oral route of administration and low cost. • Used more than 50 years ago, methotrexate is most commonly prescribed for severe, recalcitrant, disabling psoriasis when used in a weekly, single low-dose regimen for its effect on the immune system; concurrent folate supplementation may be warranted. • Though highly effective and known for its rapid effects, cyclosporine is associated with nephrotoxicity and hypertension; its use is restricted to one and two years in the United States and United Kingdom, respectively. • When used in conjunction with ultraviolet radiation B or psoralen and ultraviolet radiation A phototherapy or biologics, acitretin is effective for psoriasis and the treatment of choice in human immunodeficiency virus-positive patients with severe psoriasis due to its lack of significant immunosuppression; effects are dose-dependent and response is observed after three to six months. • Agents not FDA-indicated but used in psoriasis with limited supporting evidence include: azathioprine, fumarates (not approved in the United States), leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus, and 6-thioguanine. Biologics • Three TNF-α inhibitors are FDA-approved for the treatment of psoriatic arthritis; adalimumab, etanercept, and infliximab (please note that the publication of these guidelines was before FDA-approval of golimumab). • Psoriatic arthritis is an inflammatory seronegative spondyloarthropathy associated with psoriasis that if left untreated can lead to persistent inflammation with progressive joint damage that can result in severe physical limitations and disability. • NSAIDs and/or intra-articular injections of corticosteroids may be appropriate treatment options in patients with milder, localized disease. • Patients with moderate to severe psoriatic arthritis that is more extensive or aggressive in nature or that significantly impacts quality of life should be treated with methotrexate, TNF-α inhibitors, or both. These treatment options are

Clinical Guideline	Recommendation(s)
	considered the standard of care. • Other DMARDs which may be used in the treatment of psoriatic arthritis include leflunomide and sulfasalazine. Antimalarials, cyclosporine, and gold are used less frequently due to the evidence for their efficacy being less convincing than for leflunomide, methotrexate, and sulfasalazine. • Although expensive, there are potential long-term cost savings and benefits associated with the use of biologics in the treatment of psoriatic arthritis, including reduced need for joint replacement surgery; reduced demands on medical, nursing, and therapy services; reduced needs for concomitant medicines; reduced demands on social services and careers; improved quality of life; improved prospect of remaining in the work force; and increased life expectancy. • Because the clinical trial efficacy data (primary endpoint of American College of Rheumatology 20% improvement) with all three FDA-approved TNF-α inhibitors are roughly equivalent, the choice of which agent to use is an individual one with the degree and severity of cutaneous involvement an important consideration. • Adalimumab and infliximab both demonstrated significant benefit for the treatment of psoriatic arthritis in clinical trials, while etanercept demonstrated significant improvements in signs and symptoms of psoriatic arthritis.
American Academy of Dermatology/National Psoriasis Foundation: **Joint Guidelines of Care for the Management and Treatment of Psoriasis with Biologics (2019)**[40]	Biologics • Four TNFis are FDA-approved for the treatment of moderate-to-severe psoriasis: adalimumab, etanercept, infliximab, and certolizumab. • Seven interleukin antagonists are FDA-approved for the treatment of moderate-to-severe psoriasis: ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab. • Etanercept and adalimumab are recommended as monotherapy, and can be combined with topical therapies, acitretin, methotrexate, apremilast, cyclosporine, and phototherapy to augment efficacy. • Infliximab is recommended as monotherapy, and can be combined with topical therapies, acitretin, methotrexate, and apremilast to augment efficacy. • Ustekinumab is recommended as monotherapy, and can be combined with topical therapies, acitretin, methotrexate, apremilast, cyclosporine, and phototherapy to augment efficacy. Ustekinumab is less effective than TNF-α inhibitors for psoriatic arthritis. • Secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab are recommended as monotherapy. • All biologics may lose efficacy in patients who initially respond favorably to medication (secondary failure). • The necessity of repeating loading doses depends on disease severity and how many doses were missed. Retreatment after discontinuation may result in a small percentage of patients not being able to recapture previous robust level of response. • If clinically needed, all therapies may be switched with a different biologic agent with the possibility of improved efficacy, safety, and/or tolerability. • Etanercept is the only biologic approved for plaque psoriasis in children aged 4 to 17 years, whereas ustekinumab is approved for plaque psoriasis in adolescents aged 12 to 17 years.
American Academy of Dermatology/National Psoriasis Foundation: **Joint Guidelines of Care for the Management and Treatment of Psoriasis**	• Methotrexate is recommended for the treatment of moderate to severe psoriasis in adults. • Methotrexate is less effective than adalimumab and infliximab for cutaneous psoriasis. • Methotrexate is efficacious for treatment of psoriatic arthritis (peripheral arthritis, but not for axial involvement); in psoriatic arthritis, the efficacy of methotrexate is lower than TNFi.

Clinical Guideline	Recommendation(s)
with Systemic Nonbiologic Therapies (2020)[41]	• Methotrexate can be administered orally or subcutaneously. • Apremilast is recommended for the treatment of moderate to severe psoriasis in adults. • Cyclosporine is recommended for patients with severe, recalcitrant psoriasis. • Cyclosporine can be recommended for the treatment of erythrodermic, generalized pustular, and/or palmoplantar psoriasis. • Cyclosporine can be recommended as short-term interventional therapy in patients who flare up while on a pre-existing systemic therapy. • Acitretin can be recommended as monotherapy for plaque psoriasis. • Acitretin can be recommended for treatment of erythrodermic, pustular, and palmar plantar psoriasis. • Tofacitinib can be considered for treatment of moderate to severe psoriasis but is not currently FDA approved for that indication. • Dimethyl fumarate is approved in the United States for treatment of relapsing forms of multiple sclerosis. It can be recommended for psoriasis. • Although rarely necessary for psoriasis, systemic immunosuppressants and antimetabolites, including hydroxyurea, mycophenolate mofetil, azathioprine, leflunomide, tacrolimus, and thioguanine, may have value for this disease in certain instances.
American College of Rheumatology: **2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2015)[42]**	Recommendations for Early RA Patients • Using a treat-to-target strategy rather than a non-targeted approach, regardless of disease activity level is strongly recommended. The ideal target should be low disease activity or remission, as determined by the clinician and the patient. In some cases, another target may be chosen because risk tolerance by patients or comorbidities may mitigate the usual choices. • For DMARD-naïve patients with early, symptomatic RA, DMARD monotherapy over double or triple DMARD therapy in patients with low disease activity is strongly recommended and DMARD monotherapy over double or triple DMARD therapy in patients with moderate or high disease activity is conditionally recommended. Methotrexate should be the preferred initial therapy for most patients with early RA with active disease. • For patients with moderate or high disease activity despite DMARD therapy (with or without glucocorticoids), treatment with a combination of DMARDs or a TNF-α inhibitor or a non-TNF biologic, with or without methotrexate (MTX) in no particular order of preference, rather than continuing DMARD monotherapy alone is strongly recommend. Biologic therapy should be used in combination with MTX over biologic monotherapy, when possible, due to superior efficacy. • For patients with moderate or high disease activity despite any of the above DMARD or biologic therapies, adding low-dose glucocorticoids (defined as ≤10 mg/day of prednisone or equivalent) is conditionally recommended. Low-dose glucocorticoids may also be used in patients who need a bridge until realizing the benefits of DMARD therapy. The risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and the duration of therapy is short. • For patients experiencing a flare of RA, adding short-term glucocorticoids (less than three months of treatment) at the lowest possible dose for the shortest possible duration, to provide a favorable benefit-risk ratio for the patient is conditionally recommended. Recommendations for Established RA Patients • Using a treat-to-target strategy rather than a non-targeted approach, regardless of disease activity level is strongly recommended. • For DMARD-naïve patients with low disease activity, using DMARD monotherapy over a TNF-α inhibitor is strongly recommended. For DMARD-

Clinical Guideline	Recommendation(s)
	naïve patients with moderate or high disease activity, DMARD monotherapy over double or triple DMARD therapy and DMARD monotherapy over tofacitinib is conditionally recommend. In general, MTX should be the preferred initial therapy for most patients with established RA with active disease. • For patients with moderate or high disease activity despite DMARD monotherapy including methotrexate, using combination DMARDs or adding a TNF-α inhibitor or a non-TNF biologic or tofacitinib (all choices with or without methotrexate) in no particular order of preference, rather than continuing DMARD monotherapy alone is strongly recommended. Biologic therapy should be used in combination with MTX over biologic monotherapy, when possible, due to its superior efficacy. *For all scenarios for established RA below, treatment may be with or without MTX:* • For moderate or high disease activity despite TNF-α inhibitor therapy in patients currently not on a DMARD, it is strongly recommended that one or two DMARDs be added to TNF-α inhibitor therapy rather than continuing TNF-α inhibitor therapy alone. • If disease activity is moderate or high despite single TNF-α inhibitor biologic therapy, it is conditionally recommended to use a non-TNF biologic. • If disease activity is moderate or high despite non-TNF biologic therapy, using another non-TNF biologic is conditionally recommended. However, if a patient has failed multiple non-TNF biologics and they are TNF-α inhibitor - naïve with moderate or high disease activity, treatment with a TNF-α inhibitor is conditionally recommended. • For patients with moderate or high disease activity despite prior treatment with at least one TNF-α inhibitor and at least one non-TNF-biologic (sequentially, not combined), first treating with another non-TNF biologic is conditionally recommended. However, when a non-TNF biologic is not an option (e.g., patient declines non-TNF biologic therapy due to inefficacy or side effects), treatment with tofacitinib is conditionally recommended. • If disease activity is moderate or high despite the use of multiple (two or more) TNF-α inhibitor therapies (in sequence, not concurrently), non-TNF biologic therapy is conditionally recommended and then conditionally treating with tofacitinib when a non-TNF biologic is not an option. • If disease activity is moderate or high despite any of the above DMARD or biologic therapies, adding low-dose glucocorticoids is conditionally recommended. • If patients with established RA experience an RA flare while on DMARD, TNF-α inhibitor, or non-TNF biologic therapy, it is conditionally recommended to add short-term glucocorticoids (less than three months of treatment) at the lowest possible dose and for shortest possible duration to provide the best benefit-risk ratio for the patient. • In patients with established RA and low disease activity but not remission, continuing DMARD therapy, TNF-α inhibitor, non-TNF biologic or tofacitinib rather than discontinuing respective medication is strongly recommended. • In patients with established RA currently in remission, tapering DMARD therapy, TNF-α inhibitor, non-TNF biologic, or tofacitinib is conditionally recommended. • It is strongly recommended not to discontinue all therapies in patients with established RA in disease remission. Recommendations for RA patients with high-risk comorbidities • In patients with established RA with moderate or high disease activity and New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), using combination DMARD therapy, a non-TNF biologic, or

Clinical Guideline	Recommendation(s)
	tofacitinib rather than a TNF-α inhibitor is conditionally recommended. If patients in this population are treated with a TNF-α inhibitor and their CHF worsens while on the TNF-α inhibitor, it is conditionally recommended to switch to combination DMARD therapy, a non-TNF biologic, or tofacitinib rather than a different TNF-α inhibitor. • In patients with established RA with moderate or high disease activity and evidence of active hepatitis B infection (hepatitis surface antigen positive > 6 months), who are receiving or have received effective antiviral treatment, treating them the same as patients without this condition is strongly recommended. For patients with chronic hepatitis B who are untreated, referral for antiviral therapy is appropriate prior to immunosuppressive therapy. • In patients with established RA with moderate or high disease activity and evidence of chronic hepatitis C virus (HCV) infection, who are receiving or have received effective antiviral treatment, treating them the same as the patients without this condition is conditionally recommended. If the same patient is not requiring or receiving antiviral treatment for their hepatitis C, using DMARD therapy rather than TNF-α inhibitor is conditionally recommended. • In patients with established RA and moderate or high disease activity and a history of previously treated or untreated skin cancer (melanoma or non-melanoma), the use of DMARD therapy over biologics or tofacitinib is conditionally recommended. • In patients with established RA with moderate or high disease activity and a history of a previously treated lymphoproliferative disorder, using rituximab rather than a TNF-α inhibitor is strongly recommended and using combination DMARD therapy, abatacept, or tocilizumab rather than TNF-α inhibitor is conditionally recommended. • In patients with established RA with moderate or high disease activity and previously treated solid organ cancer, it is conditionally recommended that they be treated for RA just as one would treat an RA patient without a history of solid organ cancer. • In patients with established RA with moderate or high disease activity and previous serious infection(s), using combination DMARD therapy or abatacept rather than TNF-α inhibitor is conditionally recommended. Recommendations for the Use of Vaccines in RA patients on DMARD and/or biologic therapy • In early or established RA patients aged 50 and over, giving the herpes zoster vaccine before the patient receives biologic therapy or tofacitinib for their RA is conditionally recommended. • In early or established RA patients who are currently receiving biologics, it is conditionally recommended that live attenuated vaccines such as the herpes zoster (shingles) vaccine not be given. • In patients with early or established RA who are currently receiving biologics, using appropriately indicated killed/inactivated vaccines is strongly recommended.
European League Against Rheumatism: **Management Of Rheumatoid Arthritis With Synthetic And Biological Disease-Modifying Antirheumatic Drugs: 2019 Update**	• Treatment of rheumatoid arthritis must be based on a shared decision between the patient and the rheumatologist. • Treatment decisions are based on disease activity and other patient factors, such as progression of structural damage, comorbidities and safety issues. • Patients require access to multiple drugs with different modes of action to address the heterogeneity of rheumatoid arthritis; they may require multiple successive therapies throughout life. • Rheumatoid arthritis incurs high individual, societal and medical costs, all of

Clinical Guideline	Recommendation(s)
(2020)[43]	which should be considered in its management. • Therapy with DMARDs should be started as soon as the diagnosis of rheumatoid arthritis is made. • Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient. • Monitoring should be frequent in active disease (every one to three months); if there is no improvement by at most three months after the start of treatment or the target has not been reached by six months, therapy should be adjusted. • Methotrexate should be part of the first treatment strategy. • In patients with a contraindication to methotrexate (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy. • Short-term glucocorticoids should be considered when initiating or changing conventional synthetic DMARDs, in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible. • If the treatment target is not achieved with the first conventional synthetic DMARD strategy, in the absence of poor prognostic factors, other conventional synthetic DMARDs should be considered. • If the treatment target is not achieved with the first conventional synthetic DMARD strategy, when poor prognostic factors are present, addition of a biological DMARD or a targeted synthetic DMARD should be considered. • Biological DMARDs and targeted synthetic DMARDs should be combined with a conventional synthetic DMARD; in patients who cannot use conventional synthetic DMARDs as comedication, IL-6 pathway inhibitors and targeted synthetic DMARDs may have some advantages compared with other biological DMARDs. • If a biological DMARD or targeted synthetic DMARD has failed, treatment with another biological DMARD or a targeted synthetic DMARD should be considered; if one TNF-inhibitor therapy has failed, patients may receive another TNF-inhibitor or an agent with another mode of action. • If a patient is in persistent remission after having tapered glucocorticoids, tapering of biological DMARDs or targeted synthetic DMARDs can be considered, especially if this treatment is combined with a conventional synthetic DMARD. • If a patient is in persistent remission, tapering the csDMARD could be considered. Terminology: conventional synthetic DMARDs (methotrexate, leflunomide, sulfasalazine); biological DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar DMARDs) and targeted synthetic DMARDs (Janus kinase inhibitors, tofacitinib, baricitinib).
National Institute for Health and Clinical Excellence: **Rheumatoid Arthritis in Adults: Management (2018)[44]**	• In people with newly diagnosed active rheumatoid arthritis, conventional DMARD monotherapy using oral methotrexate, leflunomide or sulfasalazine as first-line treatment as soon as possible, ideally within three months of the onset of persistent symptoms. Hydroxychloroquine can be considered as an alternative to oral methotrexate, leflunomide or sulfasalazine for mild or palindromic disease. Dose can be escalated as tolerated. • Short-term bridging treatment with glucocorticoids (oral, intramuscular or intra-articular) can be considered when starting a new conventional DMARD. • Additional conventional DMARDs (oral methotrexate, leflunomide, sulfasalazine or hydroxychloroquine) in combination in a step-up strategy should be offered when the treatment target (remission or low disease activity) has not been achieved despite dose escalation.

Clinical Guideline	Recommendation(s)
	• Offer short-term treatment with glucocorticoids for managing flares in people with recent onset or established disease, to rapidly decrease inflammation. • In people with established rheumatoid arthritis, only continue long-term treatment with glucocorticoids when the long-term complications of glucocorticoid therapy have been fully discussed, and all other treatment options (including biological drugs and targeted synthetic DMARDs) have been offered. • On the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of rheumatoid arthritis, except in the context of a controlled, long-term clinical study. • Patients currently receiving anakinra for rheumatoid arthritis may suffer loss of wellbeing if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop. • Do not offer the combination of TNF-α inhibitor therapy and anakinra for rheumatoid arthritis. • Oral NSAIDs or COX-2 inhibitors should be considered when control of pain or stiffness is inadequate. Potential gastrointestinal, liver and cardio-renal toxicity, and the person's risk factors, including age and pregnancy should be considered. • When treating symptoms of rheumatoid arthritis with oral NSAIDS, offer the lowest effective dose for the shortest possible time, offer a proton pump inhibitor and review risk factors for adverse events regularly. • If a person with rheumatoid arthritis needs to take low-dose aspirin, healthcare professionals should consider other treatments adding an NSAID (with a proton pump inhibitor) if pain relief is ineffective or insufficient.

National Institute for Health and Clinical Excellence: **Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (2016)**[45]	• Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis, only if:
	  ○ disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
	  ○ disease has not responded to intensive therapy with a combination of conventional DMARDs and
	  ○ the companies provide certolizumab pegol, golimumab, abatacept, and tocilizumab as agreed in their patient access schemes.
	• Adalimumab, etanercept, certolizumab pegol, or tocilizumab can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria above are met.
	• Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at six months after starting therapy.
	• After initial response within six months, withdraw treatment if a moderate EULAR response is not maintained.
	• Start treatment with the least expensive drug (taking into account administration costs, dose needed and product price per dose). This may need to be varied for some people because of differences in the mode of administration and treatment schedules.
	• People whose treatment with adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab, or abatacept is not recommended in this NICE guidance, but was started before this guidance was published, should be able to continue treatment until they and their clinician consider it appropriate to stop.

American College of Gastroenterology, Practice Parameters Committee: **Ulcerative Colitis**	<u>Management of mild-moderate distal colitis</u> • Topical mesalamine agents are “superior” to topical steroids or oral aminosalicylates. • The combination of oral and topical agents is “superior” to each agent used alone.

Clinical Guideline	Recommendation(s)
Practice Guidelines in Adults (2010)[46]	• Mesalamine enemas or suppositories may still be effective in patients refractory to oral aminosalicylates or to topical corticosteroids. One meta-analysis demonstrated topical mesalamine to be "superior" to oral aminosalicylates in achieving clinical improvement in patients with mild-moderate distal colitis. • Patients who are refractory to the above therapies may require oral prednisone 40 to 60 mg daily or infliximab with an induction regimen of 5 mg/kg at weeks zero, two and six. • Oral therapy effective for achieving and maintaining remission include aminosalicylates, balsalazide, mesalamine, olsalazine and sulfasalazine. <u>Maintenance of remission in distal disease</u> • Balsalazide, mesalamine and sulfasalazine are effective in maintaining remission; combination oral and topical mesalamine is more effective than oral mesalamine alone. • Mesalamine suppositories are effective for maintenance of remission in patients with proctitis and mesalamine enemas are effective in patients with distal colitis. • Topical corticosteroids, including budesonide, have not been proven effective at maintaining remission. • When patients fail to maintain remission with the above therapies, thiopurines (6-mercaptopurine or azathioprine) and infliximab may be effective. <u>Management of mild-moderate extensive colitis: active disease</u> • Oral sulfasalazine is considered first line. • Reserve oral steroids for patients refractory to oral aminosalicylates or patients who require rapid improvement. • 6-mercaptopurine or azathioprine can be used for patients refractory to oral prednisone and are acutely ill, requiring intravenous therapy. • Infliximab is effective in patients who are steroid refractory or steroid dependent despite the use of thiopurine at adequate doses or who are intolerant to these medications. <u>Maintenance of remission for mild-moderate extensive colitis</u> • Balsalazide, mesalamine, olsalazine and sulfasalazine are effective in reducing the number of relapses. • 6-mercaptopurine or azathioprine can be used for steroid sparing in steroid dependent patients and have been shown to effectively maintain remission in patients not adequately sustained on aminosalicylates. • Infliximab effectively maintains remission in patient who responded to the infliximab induction regimen. <u>Management of severe colitis</u> • If a patient is refractory to maximum oral treatment of aminosalicylates, oral prednisone, and topical medications may be treated with infliximab if urgent hospitalization is not required. • Patients that show signs of toxicity should be hospitalized to receive intravenous steroids. • Failure to significantly improve within three to five days indicates need for intravenous cyclosporine (or colectomy - weaker evidence). • Infliximab may also be used to avoid colectomy in patients failing intravenous steroids; however, long-term efficacy in this setting is unknown.
American College of Gastroenterology: **Ulcerative Colitis in Adults**	<u>Induction of remission in mildly active ulcerative colitis (UC)</u> • In patients with mildly active ulcerative proctitis, rectal 5-ASA therapies are recommended. • In patients with mildly active left-sided colitis, rectal 5-ASA enemas are

Clinical Guideline	Recommendation(s)
(2019)[47]	recommended over rectal steroids for induction of remission • In patients with mildly active left-sided UC, rectal 5-ASA enemas are recommended combined with oral 5-ASA compared with oral 5-ASA therapy alone for induction of remission • In patients with mildly active left-sided UC who are intolerant or nonresponsive to oral and rectal 5-ASA at appropriate doses oral budesonide MMX is recommended for induction of remission • In patients with mildly active extensive colitis, oral 5-ASA is recommended to induce remission. • In patients with UC of any extent who fail to respond to 5-ASA therapy, oral systemic corticosteroids are recommended to induce remission. • In patients with mildly active UC who fail to reach remission with appropriately dosed 5-ASA changing to an alternate 5-ASA formulation to induce remission is not recommended. Alternative therapeutic classes should be considered (conditional recommendation, low quality of evidence). • In patients with mildly active UC of any extent, using a low dose of 5-ASA compared with a higher dose is recommended, as there is no difference in the remission rate. • In patients with mildly to moderately active UC not responding to oral 5-ASA, the addition of budesonide MMX to induce remission is recommended. • In patients with mildly to moderately active UC of any extent using 5-ASA to induce remission, either once-daily or more frequently dosed oral 5-ASA is recommended based on patient preference to optimize adherence. <u>Maintenance of remission in patients with previously mildly active UC</u> • In patients with mildly active ulcerative proctitis, rectal 5-ASA is recommended. • In patients with mildly active left-sided or extensive UC, oral 5-ASA therapy is recommended. • Use of systemic corticosteroids for maintenance of remission in patients with UC is not recommended. <u>Induction of remission in moderately to severely active UC</u> • In patients with moderately active UC, oral budesonide MMX is recommended for induction of remission. • In patients with moderately to severely active UC of any extent, oral systemic corticosteroids are recommended to induce remission. • In patients with moderately to severely active UC, monotherapy with thiopurines or methotrexate is not recommended for induction of remission. • In patients with moderately to severely active UC, anti-TNF therapy using adalimumab, golimumab, or infliximab for induction of remission is recommended. • In patients with moderately to severely active UC who have failed 5-ASA therapy and in whom anti-TNF therapy is used for induction of remission, using 5-ASA for added clinical efficacy is not recommended. • When infliximab is used as induction therapy for patients with moderately to severely active UC, combination therapy with a thiopurine is recommended. • In patients with moderately to severely active UC, vedolizumab is recommended for induction of remission. • In patients with moderately to severely active UC who have previously failed anti-TNF therapy, vedolizumab is recommended for induction of remission. • In patients with moderately to severely active UC, tofacitinib is recommended to induce remission. • In patients with moderately to severely active UC who have previously failed anti-TNF therapy, tofacitinib is recommended for induction of remission.

Clinical Guideline	Recommendation(s)
	• In patients with moderately to severely active UC who are responders to anti-TNF therapy and now losing response, measuring serum drug levels and antibodies is recommended to assess the reason for loss of response. Maintenance of remission in patients with previously moderately to severely active UC • In patients with previously moderately to severely active UC who have achieved remission but previously failed 5-ASA therapy and are now on anti-TNF therapy, using concomitant 5-ASA for efficacy of maintenance of remission is not recommended • Use of systemic corticosteroids for maintenance of remission in patients with UC is not recommended. • For patients with previously moderately to severely active UC now in remission due to corticosteroid induction, thiopurines for maintenance of remission is recommended compared with no treatment or corticosteroids • In patients with previously moderately to severely active UC now in remission, using methotrexate for maintenance of remission is not recommended. • Continuation of anti-TNF therapy using adalimumab, golimumab, or infliximab is recommended to maintain remission after anti-TNF induction in patients with previously moderately to severely active UC. • Continuation of vedolizumab to maintain remission is recommended in patients with previously moderately to severely active UC now in remission after vedolizumab induction. • Continuation of tofacitinib for maintenance of remission is recommended in patients with previously moderately to severely active UC now in remission after induction with tofacitinib.

European Academy of Dermatology and Venereology: **European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa (2015)**[48]	Adjuvant Therapy
	• It is recommended that adjuvant therapy is offered to patients in the form of general measures and specific help with bandaging lesions in order to improve the patients' quality of life.
	• Cigarette smoking and obesity have to be avoided.
	• Bandages used must be customized due to the anatomical variation, and should be absorbent, nonirritant. They should keep the surface dry and absorb smell. Dedicated hidradenitis suppurativa (HS)-bandages are not currently available.
	• Psychosocial support measures in HS may be of considerable benefit to the patients.
	
	Medical Therapy (non-antibiotic topical therapies)
	• Exfoliants and Peels
	  ○ Topical resorcinol 15% twice daily had good effect compared to previous experience in treating recurrent lesions in patients with Hurley stage I or II HS.
	  ○ Systemic toxicity following topical use of resorcinol is extremely rare, but physicians must be aware of the potential risk.
	• Other Therapies
	  ○ The use of adapalene or azelaic acid may occasionally be beneficial, but must currently be considered experimental. No formal studies have been conducted.
	
	Medical Therapy (topical antibiotics)
	• Clindamycin is the only antibiotic that has been studied as a topical agent.
	  ○ Studied in localized Hurley Stage I or mild stage II disease.
	  ○ Clindamycin lotion three times a day for three months (or prolonged if clinically indicated).
	  ○ A significant improvement was observed with clindamycin than to

Clinical Guideline	Recommendation(s)
	placebo using of a disease score constructed for the study. Medical Therapy (systemic antibiotics) • Systemic treatment is indicated when more severe or widely spread lesions are present. • Tetracycline o More widely spread Hurley stage I or mild stage II disease. o Tetracycline 500 mg three times a day for four months (or prolonged if clinically indicated). o Resulted in an approximately 30% reduction in disease severity. • Clindamycin-Rifampicin o Any stage active inflammatory HS. o Clindamycin 300 mg three times a day plus rifampicin 600 mg daily for 10 weeks. o All [three] studies conclude the treatment to be beneficial. • Other antibiotics o Rifampicin-moxifloxacin-metronidazole, either alone or proceeded by systemic ceftriaxone for 12 weeks. Patients had treatment resistant stage II and III disease. Combination therapy was effective in half (28/58) the patients. ▪ Patients who showed response after 12 weeks of initial treatment were treated for an additional 12 weeks using a combination of moxifloxacin and rifampicin. Intensive treatment led to complete response in 16/28 patients. o A range of other topical and systemic antibiotics have been suggested in case reports and in expert opinion, but none have been systematically evaluated even at the level of open prospective case-series. Medical Therapy (anti-inflammatory therapy) • Intralesional corticosteroids o Rapid reduction in inflammation associated with acute flares and for management of recalcitrant nodules and sinus tracts. o Utilized as both monotherapy and an adjunct to systemic therapies. o When effective, clinical response (flattening, resolution or spontaneous discharge of nodules) is seen within 48 to 72 hours. o Therapy is contraindicated if clinical suspicion of bacterial infection exists. o Triamcinolone acetonide 5 to 10 mg/mL is recommended • Systemic corticosteroids o There are limited data on the use of corticosteroids in HS. o Short and long-term therapy can result in rebound flare on withdrawal. o Short-term, rapidly tapering therapy can provide benefit in reduction in inflammation associated with acute flares. o In the event of clinical relapse on dose reduction, introduction of a second line anti-inflammatory or immunosuppressive agent is recommended. o Routine long-term use is not currently recommended. o Systemic corticosteroid dose and duration should be kept to a minimum to limit long-term complications. o A dose of 0.5 to 0.7 mg/kg oral prednisolone is recommended for short-term use for acute flares; the dose should be rapidly tapered to stop over weeks. o Limited case reports and one case series describe response to the corticosteroid agents hydrocortisone, dexamethasone and prednisolone, as short-term monotherapy and long-term combination therapy.

Clinical Guideline	Recommendation(s)
	▪ Short-term systemic hydrocortisone monotherapy (60 to 80 mg daily; 15 to 56 days) provided sustained remission at 12 months. ▪ Use of prolonged prednisolone monotherapy (60 mg reduced to 25 mg daily; duration not specified) in severe disease resulted in 65% improvement in one case. ▪ Prolonged prednisolone combination therapy (20 mg da to stop over 27 weeks) with antimicrobials followed by isotretinoin resulted in sustained clinical response in one case. • Dapsone o Reserved for patients with mild to moderate disease (Hurley stage I or II) in which standard first or second line agents fail. o Recommended dose is 25 to 200 mg/day. Higher doses are limited by adverse events. o Reported duration and response is variable; the minimum recommended duration of therapy is three months. o When effective, rapid relapse may occur on therapy withdrawal. o There are no data on maximum duration of therapy (reported range three to 48 months). • Ciclosporin A (cyclosporin) o Reserved to cases where failure of response to standard first, second and third line therapies. o Daily doses of two to six mg/kg have been used for variable duration (six weeks to seven months). o Beneficial response to ciclosporin A is reported in four cases. o Combination ciclosporin A (three mg/kg daily for four months) with tapering corticosteroids (two months) resulted in four months of remission in one case. • Hormones o There are indications that antiandrogens, such as cyproterone acetate, and estrogens improve HS, while progestogens induce or worsen a pre-existing HS due to their androgenic properties. o Indication and contraindication: Female patients with menstrual abnormalities, signs of hyperandrogenism or upper normal or high serum levels of dehydroepiandrosterone, androstenedione and/or sexual hormone-binding protein. o All reported patients improved but no evidence-based data exist. <u>Medical Therapy (Biologics)</u> • Used for the treatment of moderate to severe HS. o Improved quality of patient life. o Studied in adalimumab and infliximab, however, adalimumab is considered more tolerable. • Adalimumab o Recommended doses: ▪ To condition for a curative surgical procedure: 160 mg on day zero and possibly 80 mg one week later. ▪ Long-term therapy: 40 mg once weekly. o There are different rates of response to adalimumab reported in case series and in a current, prospective controlled study. • Infliximab o Recommended doses: ▪ To condition for a curative surgical procedure: 5 mg/kg. ▪ Long-term therapy: 5 mg/kg on day zero, two and six then every eight weeks. o Response rates are varied.

Clinical Guideline	Recommendation(s)

	• Etanercept and ustekinumab have also been studied in case reports.
	
	<u>Medical Therapy (retinoids)</u>
	• Isotretinoin
	  o Not recommended in the treatment of HS.
	  o If given early enough in the treatment of HS, isotretinoin may potentially prevent an affected pilosebaceous unit from being occluded by ductal hyper cornification. However, its usage in HS is often disappointing and the literature data are inconsistent.
	• Acitretin/Etretinate
	  o Acitretin usage in early HS stages (Hurley I or mild II) is reasonable and could also be advocated in the chronic stages of HS with recurrent abscesses with sinus tracts (even interconnected) and/or scarring.
	  o The response rate was high.
	
	<u>Medical Therapy (analgesics)</u>
	• Non-steroidal anti-inflammatory drugs (NSAIDs)
	  o No clinical evidence exists on the use of NSAIDs in the amelioration of pain and inflammation in HS.
	  o Their anecdotal use in the usual dosage schemas may be justified for the amelioration of acute pain related to HS.
	• Opiates
	  o No clinical evidence exists for the use of opioids in the amelioration of pain in HS.
	  o Their use should be restricted and limited to cases where all other painkillers have failed.
	  o Codeine should be the first treatment option for this drug class.
	
	<u>Medical Therapy (miscellaneous and experimental therapies)</u>
	• Zinc gluconate
	  o Maintenance treatment in Hurley stage I and II disease.
	  o High dose (90 mg/day) is recommended
	  o Response rate in one study of 22 patients resulted in complete remission in eight patients and partial remission in 14 patients.
	• Intramuscular gamma-globulin
	  o Not recommended due to limited data (one report)
	• Colchicine
	  o Not recommended due to poor efficacy.
	• Botulinum toxin
	  o Experimental treatment in Hurley stage I or II disease.
	  o Limited data from two case reports; both had good effect with one case resulting in six months of remission.
	
	<u>Therapeutic Conclusion</u>
	• It is recommended that HS is treated based on the subjective impact and objective severity of the disease.
	• Locally recurring lesions can be treated surgically, whereas medical treatment either as monotherapy or in combination with surgery is more appropriate for widely spread lesions.
	• Medical therapy may include antibiotics and immunosuppressants.
	• HS treatment algorithm:
	  o Adjuvant therapy should be utilized for all disease severities:
	  ▪ Pain management
	  ▪ Treatment of superinfections
	  ▪ Weight loss and tobacco abstinence

Clinical Guideline	Recommendation(s)
	○ As disease severity increases, provide surgical interventions: ▪ Less severe disease: deroofing, LASERs, local excision ▪ More severe disease: wide surgical excision ○ As disease severity increases, medication therapy should include: ▪ Stage I or II (localized): topical clindamycin ▪ More severe: provide systemic treatment with 1) clindamycin + rifampicine/tetracycline or 2) acitretin ▪ Most severe: provide systemic treatment with anti-TNF biologics adalimumab or infliximab

III. Indications

The Food and Drug Administration (FDA)-approved indications for the disease-modifying antirheumatic agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Disease-Modifying Antirheumatic Agents[1-19]

Indications	Abatacept	Adalimumab	Anakinra	Apremilast	Baricitinib	Certolizumab pegol	Etanercept	Golimumab	Infliximab	Leflunomide	Sarilumab	Tocilizumab	Tofacitinib	Upadacitinib
Ankylosing Spondylitis		✔				✔	✔	✔	✔					
Crohn's Disease		✔				✔			✔					
CRS												✔		
Giant Cell Arteritis												✔		
Hidradenitis Suppurativa		✔												
JIA	✔	✔					✔					✔		
NOMID			✔											
Non-radiographic axSpA						✔								
Oral Ulcers Associated with Behcet's Disease				✔										
Plaque Psoriasis		✔		✔		✔	✔		✔					
Psoriatic Arthritis	✔	✔		✔		✔	✔	✔	✔				✔	
Rheumatoid Arthritis	✔	✔	✔		✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Ulcerative Colitis		✔						✔	✔				✔	
Uveitis		✔												

axSpA=axial spondyloarthritis, CRS=cytokine release syndrome, JIA=juvenile Idiopathic Arthritis, NOMID=Neonatal-Onset Multisystem Inflammatory Disease

IV. Pharmacokinetics

The pharmacokinetic parameters of the disease-modifying antirheumatic agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Disease-Modifying Antirheumatic Agents[20]

Generic Name(s)	Bioavailability (%)	Time to Peak Concentration	Half-Life
Abatacept	100 (intravenous); 78.6 (subcutaneous)	Not reported	13.0 to 14.3 days
Adalimumab	64	131±56 hours	10 to 20 days
Anakinra	95	3 to 7 hours	4 to 6 hours
Apremilast	73	2.5 hours	6 to 9 hours
Baricitinib	80	1 hour	12 hours
Certolizumab	80	54 to 171 hours	14 days
Etanercept	58	69±34 hours	102±30 hours
Golimumab	100 (intravenous); 53 (subcutaneous)	48 to 144 hours (subcutaneous)	14 days
Infliximab	100	Not reported	8 to 10 days
Leflunomide	80	6 to 12 hours	4 to 28 days
Sarilumab	Not reported	2 to 4 days	2 to 4 days
Tocilizumab	100 (intravenous); 80 (subcutaneous)	Not reported	11 to 23 days
Tofacitinib	74	0.5 to 1.0 hour	IR: 3 hours XR: 6 hours
Upadacitinib	Not reported	2 to 4 hours	8 to 14 hours

V. Drug Interactions

Major drug interactions with the disease-modifying antirheumatic agents are listed in Table 5.

Table 5. Major Drug Interactions with the Disease-Modifying Antirheumatic Agents[20]

Generic Name(s)	Interaction	Mechanism
Abatacept, adalimumab, anakinra, baricitinib, certolizumab, etanercept, golimumab, infliximab, leflunomide, sarilumab, tocilizumab, tofacitinib, upadacitinib	Live vaccines	Concomitant use may result in an increased risk of secondary transmission of infection by the live vaccine.
Abatacept, adalimumab, anakinra, etanercept, infliximab, golimumab	Other DMARDs	Concurrent use of may result in an increased risk of infections.
Interleukin-receptor blockers	Other biologic immunomodulators	Concurrent use may increase the risk of infections.
Interleukin-receptor blockers	CYP450 substrates with a narrow therapeutic index	Increased cytokine levels (interleukins) suppress the effect of CYP450 and should be normalized with interleukin-receptor blocking agents. Monitor effect of agents that may have metabolism increased.
Apremilast	CYP3A strong inducers (e.g., rifampin)	Concurrent use of apremilast and strong CYP3A4 inducers may result in decreased apremilast exposure.
Baricitinib	OAT3 Strong inhibitors	Concurrent use may increase baricitinib exposure.

Generic Name(s)	Interaction	Mechanism
	(e.g., probenecid)	
Tumor Necrosis Factor Blocking Agents	Other biologic immunomodulators	Concurrent use may increase the risk of infections.
Etanercept	Cyclophosphamide	Concurrent administration may result in a higher incidence of developing noncutaneous solid malignancies.
Infliximab	Tocilizumab	Concurrent use may increase immunosuppression and the risk of infections.
Leflunomide	Methotrexate	Concurrent use of leflunomide and methotrexate may result in increased risk of hepatotoxicity and bone marrow toxicity.
Leflunomide	Warfarin	Concurrent use of leflunomide and warfarin may result in increased risk of bleeding.
Tofacitinib	Biological DMARDs	Concurrent use may increase the risk of serious infections. Coadministration should be avoided.
Tofacitinib	CYP2C19 potent and CYP3A moderate inhibitors (e.g., fluconazole)	Concurrent use may elevate tofacitinib concentrations, increasing the pharmacologic effects and risk of adverse reactions; the dose of tofacitinib should be reduced to 5 mg once daily.
Tofacitinib	CYP3A strong inhibitors (e.g., ketoconazole)	Concurrent use may elevate tofacitinib concentrations, increasing the pharmacologic effects and risk of adverse reactions; the dose of tofacitinib should be reduced to 5 mg once daily.
Tofacitinib	CYP3A strong inducers (e.g., rifampin)	Concurrent use may reduce tofacitinib concentrations, decreasing the clinical response. Coadminister with caution. Close clinical monitoring is warranted.
Infliximab, tofacitinib	Immunosuppressants (e.g., azathioprine, cyclosporine, tacrolimus)	Concurrent use may increase the risk of added immunosuppression and serious infections. Coadministration of tofacitinib with potent immunosuppressants should be avoided.
Upadacitinib	CYP3A4 strong inhibitors (e.g., ketoconazole)	Concurrent use may increase upadacitinib exposure; upadacitinib should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors.
Upadacitinib	CYP3A4 strong inducers (e.g., rifampin)	Concurrent use may decrease upadacitinib exposure, which may lead to reduced therapeutic effect of upadacitinib. Coadministration is not recommended.

DMARD=disease-modifying antirheumatic drug

VI. Adverse Drug Events

The most common adverse drug events reported with the disease-modifying antirheumatic agents are listed in Table 6. The boxed warnings for the disease-modifying antirheumatic agents are listed in Tables 7 to 14.

Table 6. Adverse Drug Events (%) Reported with the Disease-Modifying Antirheumatic Agents[1-19]

Adverse Event	Abatacept	Adalimumab	Anakinra*	Apremilast	Baricitinib	Certolizumab	Etanercept	Golimumab†	Infliximab	Leflunomide	Sarilumab	Tocilizumab	Tofacitinib	Upadacitinib
Gastrointestinal														
Abdominal pain	-	7	5	4	-	-	5 to 10	-	12	5 to 6	-	-	-	-
Diarrhea	-	-	7	8 to 17	-	-	8 to 16	-	12	17 to 27	-	-	-	-
Dyspepsia	6	-	-	3	-	-	4 to 11	-	10	5 to 6	-	-	-	-
Gastroenteritis	-	-	-	-	-	-	-	-	-	3	-	-	-	-
Nausea	≥10	9	8	7 to 17	3	-	9 to 15	-	21	9 to 13	-	-	-	4
Vomiting	-	-	14‡	≤4	-	-	3 to 5	-	-	5 to 5	-	-	-	-
Laboratory Tests														
Abnormal hepatic test	-	8	-	-	-	-	-	-	-	5 to 10	-	3 to 6	-	-
Alkaline phosphatase increased	-	5	-	-	-	-	-	-	-	2 to 4	5	-	-	-
Hematuria	-	5	-	-	-	-	-	-	-	-	-	-	-	-
Hypercholesterolemia	-	6	-	-	-	-	-	-	-	-	-	-	-	-
Hyperglycemia	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Hyperthyroidism	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Hyperlipidemia	-	7	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Hypokalemia	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Neutropenia	-	-	-	-	-	-	-	-	-	-	≤10	-	-	-
Respiratory														
Bronchitis	5 to 13	-	-	1	-	3	-	-	10	5 to 8	-	-	-	-
Coughing	8	-	-	-	-	-	5 to 6	-	12	3 to 5	-	-	-	2
Flu syndrome	-	7	-	-	-	-	-	-	14	≤4	-	-	-	-
Nasopharyngitis	12	-	-	3	-	5	-	-	-	-	-	4 to 7	-	-
Non-upper respiratory infection	-	-	-	-	-	-	21 to 54	-	-	-	-	-	-	-
Pharyngitis	-	-	11.6‡	-	-	3	6 to 7	-	-	2 to 3	-	-	-	-
Respiratory disorder	-	-	-	-	-	-	5	-	-	-	-	-	-	-
Rhinitis	-	-	-	-	-	-	12 to 16	-	-	2 to 5	-	-	-	-
Sinusitis	5 to 13	11	7	1	-	-	3 to 5	-	14	1 to 2	-	-	-	-
Upper respiratory	≥10	17	14	4 to 9	15 to 16	6	38 to 65	13§ to 16	32	15 to 27	-	6 to 8	-	14

Adverse Event	Abatacept	Adalimumab	Anakinra*	Apremilast	Baricitinib	Certolizumab	Etanercept	Golimumab†	Infliximab	Leflunomide	Sarilumab	Tocilizumab	Tofacitinib	Upadacitinib
infection														
Skin														
Acne	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Eczema	-	-	-	-	-	-	-	-	-	2 to 3	-	-	-	-
Folliculitis	-	-	-	1	-	-	-	-	-	-	-	-	-	-
Pruritus	-	-	-	-	-	-	-	-	7	4 to 6	-	-	-	-
Rash	-	12	-	-	-	3	3 to 13	-	10	10 to 12	-	-	-	-
Other														
Accidental injury	-	10	-	-	-	-	-	-	-	5 to 7	-	-	-	-
Alopecia	-	-	-	-	-	-	1 to 6	-	-	9 to 17	-	-	-	-
Angina pectoris	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Anxiety	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Arthralgia	-	-	6, 11.6‡	-	-	-	-	-	-	≤4	-	-	-	-
Asthenia	-	-	-	-	-	-	5 to 11	-	-	-	-	-	-	-
Back pain	7	6	-	2	-	4	-	-	8	5 to 8	-	-	-	-
Body pain	-	-	-	-	-	-	-	-	8	-	-	-	-	-
Chest pain	-	-	-	-	-	-	-	-	-	1 to 4	-	-	-	-
Depression	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Dizziness	9	-	-	-	-	-	7 to 8	-	-	-	-	-	-	-
Fatigue	-	-	-	3	-	3	-	-	9	-	-	-	-	-
Fever	-	-	11.6‡	-	-	3	2 to 3	-	7	1 to 3	-	-	-	-
Flu like symptoms	-	-	6	-	-	-	-	-	-	-	-	-	-	-
Headache	18	12	12, 14‡	5 to 6	-	5	17 to 24	-	18	7 to 13	-	5 to 7	-	-
Herpes simplex	-	-	-	-	1 to 2	-	-	-	-	-	-	-	-	-
Herpes zoster	-	-	-	-	1	-	-	-	-	-	-	-	-	-
Hypertension	7	5	-	-	-	5	-	-	7	9 to 10	-	4 to 6	-	-
Infections (overall)	-	-	-	-	-	-	-	-	-	-	-	20	-	-
Injection site pain	-	12	-	-	-	-	-	-	-	-	-	-	-	-
Injection site reaction	-	8	16‡, 71	-	-	-	37 to 43	6	-	-	6 to 7	7.1‖ to 10.1‖	-	-
Insomnia	-	-	-	2	-	-	-	-	-	1 to 3	-	-	-	-
Moniliasis	-	-	-	-	-	-	-	-	5	-	-	-	-	-
Mouth ulcer	-	-	-	-	-	-	2 to 6	-	-	3 to 5	-	-	-	-
Muscle Pain	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Neuralgia	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Pain	-	-	-	-	-	-	-	-	-	1 to 4	-	-	-	-

Adverse Event	Abatacept	Adalimumab	Anakinra*	Apremilast	Baricitinib	Certolizumab	Etanercept	Golimumab†	Infliximab	Leflunomide	Sarilumab	Tocilizumab	Tofacitinib	Upadacitinib
Palpitations	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Paresthesia	-	-	-	-	-	-	-	-	-	2 to 4	-	-	-	-
Peripheral edema	-	-	-	-	-	-	2 to 8	-	-	-	-	-	-	-
Pyrexia	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Synovitis	-	-	-	-	-	-	-	-	-	2 to 4	-	-	-	-
Tachycardia	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Urinary tract infection	6	8	-	-	-	-	-	-	8	5	3	-	-	-
Vasculitis	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Vertigo	-	-	-	-	-	-	-	-	-	1 to 3	-	-	-	-
Viral infection	-	-	-	-	-	-	-	5	-	-	-	-	-	-
Weight Gain	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weight Loss	-	-	-	10 to 12	-	-	-	-	-	2 to 4	-	-	-	-
Worsening of rheumatoid arthritis	-	-	19	-	-	-	-	-	-	-	-	-	-	-

-Event not reported or incidence <1%.
*Unless otherwise specified, adverse reaction observed in patients treated for rheumatoid arthritis.
†With or without disease modifying antirheumatic agents. Unless otherwise specified, adverse reaction observed in patients treated with subcutaneous formulation.
‡Neonatal-onset multisystem inflammatory disease during the first six months of therapy.
§Intravenous formulation (Simponi Aria®) only.
‖Subcutaneous formulation only.

Table 7. Boxed Warning for Adalimumab and Infliximab[17]

WARNING
Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with tumor necrosis factor blockers including Humira® and Remicade®. These cases have had a very aggressive disease course and have been fatal. All reported Remicade® cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority was in adolescent and young adult males. All of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with Humira® or Remicade® at or prior to diagnosis.

Table 8. Boxed Warning for Leflunomide[17]

WARNING
Embryo-fetal toxicity: Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level. Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during leflunomide treatment and during an accelerated drug elimination procedure after leflunomide treatment. Stop leflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant. Hepatotoxicity: Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Concomitant use of leflunomide with other potentially hepatotoxic drugs may increase the risk of liver injury. Patients with preexisting acute or chronic liver disease, or those with serum ALT greater than 2 times the upper limit of normal (ULN) before initiating treatment, are at increased risk and should not be treated with leflunomide. Monitor ALT levels at least monthly for 6 months after starting leflunomide, and thereafter every 6 to 8 weeks. If leflunomide-induced liver injury is suspected, stop leflunomide treatment, start an accelerated drug elimination procedure, and monitor liver tests weekly until normalized.

Table 9. Boxed Warning for Tocilizumab[17]

WARNING
Serious Infections Patients treated with Actemra® are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Actemra® until the infection is controlled. Reported infections include: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before Actemra® use and during therapy. Treatment for latent infection should be initiated prior to Actemra® use. • Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. • Bacterial, viral and other infections due to opportunistic pathogens. The risks and benefits of treatment with Actemra® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Actemra®, including the possible development of tuberculosis in patients who tested negative for infection prior to initiating therapy.

Table 10. Boxed Warning for adalimumab, certolizumab pegol, etanercept, golimumab, infliximab[17]

WARNING
Serious Infections Patients treated with Cimzia®, Enbrel®, Humira®, Remicade® or Simponi® are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

WARNING

Cimzia®, Enbrel®, Humira®, Remicade® and Simponi® should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

- Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Cimzia®, Enbrel®, Remicade®, or Simponi® use and during therapy. Treatment for latent infection should be initiated prior to Cimzia®, Enbrel®, Humira®, Remicade®, or Simponi® use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Cimzia®, Enbrel®, Humira®, Remicade®, or Simponi® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Cimzia®, Enbrel®, Humira®, Remicade® or Simponi®, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Malignancy
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor blockers, of which Cimzia®, Enbrel®, Humira®, Remicade® or Simponi® are members.

Table 11. Boxed Warning for Tofacitinib[17]

WARNING

Serious Infections
Patients treated with Xeljanz® are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

If a serious infection develops, interrupt Xeljanz® until the infection is controlled. Reported infections include:

- Active tuberculosis, which may present with pulmonary or extrapulmonary disease.
- Patients should be tested for latent tuberculosis before Xeljanz® use and during therapy.
- Treatment for latent infection should be initiated prior to Xeljanz® use.
- Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral, and other infections due to opportunistic pathogens.

The risks and benefits of treatment with Xeljanz® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Xeljanz®, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Malignancies
Lymphoma and other malignancies have been observed in patients treated with Xeljanz®. Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with Xeljanz® and concomitant immunosuppressive medications.

Table 12. Boxed Warning for Sarilumab[17]

WARNING

WARNING
Risk of serious infections Patients treated with sarilumab are at increased risk for developing serious infections that may lead to hospitalization or death. Opportunistic infections have also been reported in patients receiving sarilumab. Most patients who developed infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid use of sarilumab in patients with an active infection. Reported infections include: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before sarilumab use and during therapy. Treatment for latent infection should be initiated prior to sarilumab use. • Invasive fungal infections, such as candidiasis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. • Bacterial, viral and other infections due to opportunistic pathogens. Closely monitor patients for signs and symptoms of infection during treatment with sarilumab. If a serious infection develops, interrupt sarilumab until the infection is controlled. Consider the risks and benefits of treatment with sarilumab prior to initiating therapy in patients with chronic or recurrent infection.

Table 13. Boxed Warning for Baricitinib[17]

WARNING
Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving baricitinib. If a serious infection develops, interrupt baricitinib until the infection is controlled. Prior to starting baricitinib, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting baricitinib. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with baricitinib. Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, some fatal, have occurred in patients treated with baricitinib. Patients with symptoms of thrombosis should be evaluated promptly.

Table 14. Boxed Warning for Upadacitinib[17]

WARNING
Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving upadacitinib. If a serious infection develops, interrupt upadacitinib until the infection is controlled. Prior to starting upadacitinib, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting upadacitinib. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with upadacitinib. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.

VII. Dosing and Administration

The usual dosing regimens for the disease-modifying antirheumatic agents are listed in Table 15.

Table 15. Usual Dosing Regimens for the Disease-Modifying Antirheumatic Agents[1-19]

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
Abatacept	Psoriatic arthritis, rheumatoid arthritis: Prefilled syringe and single use vial: initial (<60 kg), 500 mg IV over 30 minutes at weeks zero, two and four; (60 to 100 kg), 750 mg IV over 30 minutes at weeks zero, two and four; (>100 kg), 1,000 mg IV over 30 minutes at weeks zero, two and four; maintenance (<60 kg), 500 mg IV over 30 minutes every four weeks; (60 to 100 kg), 750 mg IV over 30 minutes every four weeks; (>100 kg), 1,000 mg IV over 30 minutes every four weeks; or initial (<60 kg), 500 mg IV over 30 minutes followed by 125 mg SC within 24 hours; (60 to 100 kg), 750 mg IV over 30 minutes followed by 125 mg SC within 24 hours; (>100 kg), 1,000 mg IV over 30 minutes followed by 125 mg SC within 24 hours; maintenance, 125 mg SC once weekly	Juvenile idiopathic arthritis (two to 17 years of age): Single use vial: initial, (<75 kg),10 mg/kg IV over 30 minutes at weeks zero, two and four; (≥75 kg), follow adult dosing not to exceed 1,000 mg/dose; maintenance (<75 kg), 10 mg/kg IV over 30 minutes every four weeks; (≥75 kg), follow adult dosing not to exceed 1,000 mg/dose Prefilled syringe: 10 to <25 kg, 50 mg SC once weekly; 25 kg to <50 kg, 87.5 mg SC once weekly; ≥50 kg, 125 mg SC once weekly	Prefilled syringe: 50 mg/0.4 mL 87.5 mg/0.7 mL 125 mg/mL Vial: 250 mg
Adalimumab	Ankylosing spondylitis, psoriatic arthritis: Prefilled pen and syringe, single use vial: initial/maintenance, 40 mg SC every other week Crohn's disease, ulcerative colitis: Prefilled pen and syringe, single use vial: initial, 160 mg SC at week zero (may administer as four injections in one day or two injections daily for two consecutive days), followed by 80 mg SC during week two (day 15); maintenance, 40 mg SC every other week starting at week four (day 29) Hidradenitis Suppurativa: Prefilled pen and syringe, single use vial: 160 mg (four 40 mg injections) on day one, then 80 mg (two 40 mg injections) on day 15, then 40 mg weekly starting on day 29 Plaque psoriasis, uveitis: Prefilled pen and syringe, single use vial: initial, 80 mg SC; maintenance, 40 mg SC every other week starting one week after the initial dose Rheumatoid arthritis: Prefilled pen and syringe, single use vial: initial/maintenance, 40 mg SC every other week; may increase to 40 mg SC every week in patients not receiving concomitant	Crohn's disease (six to 17 years of age): 17 to <40 kg, 80 mg (two 40 mg injections) on day one, then 40 mg on day 15, then 20 mg every other week; ≥40 kg, 160 mg (four 40 mg injections) on day one, then two 40 mg injections on day 15, then 40 mg every other week Juvenile idiopathic arthritis (two to 17 years of age): 10 to <15 kg, 10 mg every other week; 15 to <30 kg, 20 mg SC every other week; ≥30 kg, 40 mg SC every other week (Dose has not been established for patients with a weight of <10 kg)	Prefilled pen: 40 mg/0.4 mL 40 mg/0.8 mL 80 mg/0.8 mL Prefilled syringe: 10 mg/0.1 mL 10 mg/0.2 mL 20 mg/0.2 mL 20 mg/0.4 mL 40 mg/0.4 mL 40 mg/0.8 mL 80 mg/0.8 mL

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
	methotrexate		
Anakinra	NOMID: Prefilled syringe: initial: 1 to 2 mg/kg daily; maintenance, dose can be individually adjusted to a maximum of 8 mg/kg daily Rheumatoid arthritis: Prefilled syringe: initial, 100 mg SC daily; maintenance, 100 mg SC daily	NOMID: Prefilled syringe: initial: 1 to 2 mg/kg SC daily; maintenance, 3 to 4 mg/kg SC daily	Prefilled syringe: 100 mg/0.67 mL
Apremilast	Oral ulcers associated with Behcet's Disease, plaque psoriasis, psoriatic arthritis: Tablet: initial, 10 mg in the morning on day one; 10 mg twice daily on day two; 10 mg in the morning and 20 mg in the evening on day three; 20 mg twice daily on day four; 20 mg in the morning and 30 mg in the evening on day five; maintenance, 30 mg twice daily starting on day six	Safety and efficacy in the pediatric population have not been established.	Dose pack: 10 mg (4)-20 mg (4)-30 mg (47) Tablet: 30 mg
Baricitinib	Moderate to severe rheumatoid arthritis: Tablet: 2 mg by mouth once daily	Safety and efficacy in the pediatric population have not been established.	Tablet: 1 mg 2 mg
Certolizumab	Ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis: Prefilled syringe and vial: initial, 400 mg SC (as two SC injections of 200 mg) once and then repeat at weeks two and four; maintenance, 200 mg SC once every other week or 400 mg (as two SC injections of 200 mg) every four weeks Crohn's disease: Prefilled syringe and vial: initial, 400 mg SC (as two SC injections of 200 mg) once, repeat at weeks two and four; maintenance, 400 mg SC (as two SC injections of 200 mg) once every four weeks Plaque psoriasis: Prefilled syringe and vial: initial and maintenance, 400 mg SC (as two SC injections of 200 mg) every other week; for some patients (with body weight ≤ 90 kg), 400 mg SC (as two SC injections of 200 mg) once, repeat at weeks two and four; maintenance, 200 mg every other week may be considered	Safety and efficacy in the pediatric population have not been established.	Prefilled syringe: 200 mg/mL Vial: 200 mg
Etanercept	Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis: Prefilled autoinjector and syringe and vial: initial/maintenance, 50 mg SC weekly Plaque psoriasis: Prefilled autoinjector and syringe and vial: initial, 50 mg SC twice weekly for three months; maintenance, 50 mg SC weekly	Juvenile idiopathic arthritis, plaque psoriasis (two to 17 years of age): Prefilled autoinjector and syringe and vial: initial and maintenance (<63 kg), 0.8 mg/kg SC weekly;	Prefilled "SureClick" autoinjector: 50 mg/mL Prefilled syringes: 25 mg/0.5 mL 50 mg/mL

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
		(≥63 kg), 50 mg SC weekly	Vial: 25 mg
Golimumab	Ankylosing spondylitis, psoriatic arthritis: Prefilled autoinjector and syringe: initial, 50 mg SC once monthly; maintenance, 50 mg SC once monthly Vial (Simponi Aria®): initial, 2 mg/kg IV over 30 minutes at weeks zero and four; maintenance, 2 mg/kg IV over 30 minutes every eight weeks; all in combination with methotrexate Rheumatoid arthritis: Prefilled autoinjector and syringe: initial, 50 mg SC once monthly in combination with methotrexate; maintenance, 50 mg SC once monthly in combination with methotrexate Vial (Simponi Aria®): initial, 2 mg/kg IV over 30 minutes at weeks zero and four; maintenance, 2 mg/kg IV over 30 minutes every eight weeks; all in combination with methotrexate Ulcerative colitis: Prefilled autoinjector and syringe: initial, 200 mg SC once, followed by 100 mg SC at week two; maintenance, 100 mg SC once every four weeks	Safety and efficacy in the pediatric population have not been established.	Prefilled "SmartJect" autoinjector: 50 mg/0.5 mL 100 mg/mL Prefilled syringe: 50 mg/0.5 mL 100 mg/mL Single use vial (Simponi Aria®): 50 mg/4 mL
Infliximab	Ankylosing spondylitis: Vial: initial, 5 mg/kg IV over two hours at weeks zero, two, and six; maintenance, 5 mg/kg IV over two hours every six weeks Crohn's disease: Vial: initial, 5 mg/kg IV over two hours at weeks zero, two, and six; maintenance, 5 mg/kg IV over two hours every eight weeks; may be increased to 10 mg/kg in patients who respond and then lose response Plaque psoriasis, psoriatic arthritis, ulcerative colitis: Vial: initial, 5 mg/kg IV over two hours at weeks zero, two, and six; maintenance, 5 mg/kg IV over two hours every eight weeks Rheumatoid arthritis: Vial: initial, 3 mg/kg IV over two hours at weeks zero, two, and six; maintenance, 3 mg/kg IV over two hours every eight weeks; may be increased to 10 mg/kg IV over two hours every eight weeks or 3 mg/kg IV over two hours every four weeks if incomplete	Crohn's disease, ulcerative colitis (six years of age and older): Vial: initial, 5 mg/kg IV over two hours at weeks zero, two and six; maintenance, 5 mg/kg IV over two hours every eight weeks	Single use vial: 100 mg

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
	response; all in combination with methotrexate		
Leflunomide	Rheumatoid arthritis: Tablet: Use a loading dose of 100 mg once daily for three days only if the patient is not high risk for leflunomide-associated hepatotoxicity (e.g., taking concomitant methotrexate) or myelosuppression (e.g., taking concomitant immunosuppressants); maintenance, 20 mg once daily	Safety and efficacy in the pediatric population have not been established.	Tablet: 10 mg 20 mg
Sarilumab	Rheumatoid arthritis: Prefilled syringe: initial and maintenance, 200 mg SC every two weeks; do not initiate if ANC is less than 2,000/mm^3, platelets are less than 150,000/mm^3, or if ALT or AST are greater than 1.5 times ULN	Safety and efficacy in the pediatric population have not been established.	Prefilled syringe: 150 mg/1.14 mL 200 mg/1.14 mL
Tocilizumab	Cytokine release syndrome (due to chimeric antigen receptor T-cell therapy): Vial: 8 mg/kg IV for patients ≥30 kg; 12 mg/kg for patients <30 kg; maximum, 800 mg per dose; if clinical improvement does not occur after the first dose, up to three additional doses may be administered (with at least an 8-hour interval between consecutive doses) Giant cell arteritis: Prefilled syringe: 162 mg SC every week (in combination with a tapering course of glucocorticoids) Rheumatoid arthritis: Prefilled syringe: initial and maintenance (<100 kg), 162 mg SC every other week, followed by 162 mg SC every week; (≥100 kg), 162 mg SC every week Vial: initial, 4 mg/kg IV every four weeks as a 60 minute infusion; maintenance, dose may be increased to 8 mg/kg IV every four weeks; maximum, 800 mg/infusion	Cytokine release syndrome (due to chimeric antigen receptor T-cell therapy) in patients two years of age and older: Vial: 8 mg/kg IV for patients ≥30 kg; 12 mg/kg for patients <30 kg; maximum, 800 mg per dose; if clinical improvement does not occur after the first dose, up to three additional doses may be administered (with at least an 8-hour interval between consecutive doses) Polyarticular juvenile idiopathic arthritis (two years of age and older): Vial: initial and maintenance (<30 kg), 10 mg/kg IV every four weeks as a 60 minute infusion; (≥30 kg), 8 mg/kg IV every four weeks as a 60 minute infusion Systemic juvenile idiopathic arthritis (two years of age and older): Vial: initial and maintenance (<30 kg), 12 mg/kg IV every	Prefilled syringe: 162 mg/0.9 mL Single use vial: 80 mg/4 mL 200 mg/10 mL 400 mg/20 mL

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
		two weeks as a 60 minute infusion; (≥30 kg), 8 mg/kg IV every two weeks as a 60 minute infusion	
Tofacitinib	Psoriatic arthritis, rheumatoid arthritis: Tablet: 5 mg by mouth twice daily XR tablet: 11 mg once daily Ulcerative colitis: Tablet: 10 mg twice daily for at least eight weeks; followed by 5 or 10 mg twice daily, depending on therapeutic response	Safety and efficacy in the pediatric population have not been established.	Extended-release tablet: 11 mg 22 mg Tablet: 5 mg 10 mg
Upadacitinib	Moderate-to-severe rheumatoid arthritis: Tablet: 15 mg by mouth once daily	Safety and efficacy in the pediatric population have not been established.	Extended-release tablet: 15 mg

IV=intravenously, SC=subcutaneously
JIA=juvenile Idiopathic Arthritis, NOMID=Neonatal-Onset Multisystem Inflammatory Disease

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the disease-modifying antirheumatic agents are summarized in Table 16.

Table 16. Comparative Clinical Trials with the Disease-Modifying Antirheumatic Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Axial Spondyloarthritis (Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis)				
van der Heijde et al.[49] (2006) Adalimumab 40 mg every other week vs placebo Patients were allowed to continue MTX, NSAIDs, prednisone or prednisone equivalent and SSZ.	DB, MC, RCT Patients ≥18 years of age with a diagnosis of AS based on the modified New York criteria with active disease BASDAI score ≥4, a total back pain score ≥4 by VAS (VAS, 0 to 10 cm) or a duration of morning stiffness ≥1 hour	N=315 24 weeks	Primary: ASAS 20 response at week 12 Secondary: ASAS 20 response at week 24, measures of disease activity, spinal mobility and function, and ASAS partial remission	Primary: An ASAS 20 response was attained in 58% of participants taking adalimumab vs 21% of participants taking placebo at week 12 (P<0.001). Secondary: A significantly greater ASAS 20 response was also noted at week 24 with adalimumab vs placebo (52 vs 18%; P<0.001). Adalimumab, compared to placebo, resulted in a significant improvement in other measures of disease activity such as a 50% improvement in BASDAI at week 12 (45 vs 16%; P<0.001) which was sustained through week 24 (42 vs 15%; P<0.001). ASAS 5/6 and ASAS 40 responses were attained in 49 vs 13% and 40 vs 13% of adalimumab vs placebo patients at week 12 (P<0.001) and 45 vs 12% and 39 vs 13% at week 24 (P<0.001), respectively. Partial remission was achieved in 21 vs 4% at week 12 and 22 vs 6% at week 24 in the adalimumab and placebo groups, respectively (P<0.001).
Landewe et al.[50] (2013) RAPID-axSpA Certolizumab 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (CZP 200 mg) vs	DB, MC, PC, PG, RCT Patients ≥18 years of age with a diagnosis of AS based on the ASAS criteria, with active disease BASDAI score ≥4, spinal pain ≥4, CRP>7.9 mg/L and/or sacroiliitis on	N=325 24 weeks	Primary: ASAS 20 response at week 12 Secondary: ASAS 20 response at week 24, change from baseline in BASFI, BASDAI, and BASMI linear at week 12 and 24	Primary: A greater proportion of patients treated with CZP 200 mg every two weeks (57.7%) and CZP 400 mg every four weeks (63.6%) achieved ASAS 20 response at week 12 compared to placebo (38.3%; P=0.004 and P<0.001, respectively). Secondary: The difference in ASAS 20 response was sustained through week 24 in both CZP treatment groups (P<0.001). Improvements in BASFI scores from baseline were greater in patients treated with CZP 200 mg every two weeks and CZP 400 mg every four

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
certolizumab 400 mg at weeks 0, 2, and 4 then 400 mg every 2 weeks (CZP 400 mg) vs placebo Patients receiving placebo who did not achieve an ASAS 20 response at weeks 14 and 16 were randomized to active treatment at week 16. Concurrent DMARDs (SSZ and MTX) were allowed.	MRI, chronic back pain ≥3 months, inadequate response or intolerance to ≥1 NSAID or ≥2 weeks each for ≥2 NSAIDs in the last ≥30 days			weeks compared to placebo at 12 weeks (-2.0 and -2.0 vs -0.5; P<0.001) and at 24 weeks (-2.2 and -2.2 vs -0.4; P<0.001 for both comparisons), respectively. Improvements in BASDAI scores from baseline were greater in patients treated with CZP 200 mg every two weeks and CZP 400 mg every four weeks compared to placebo at 12 weeks (-2.8 and -2.8 vs -1.2; P<0.001) and at 24 weeks (-3.1 and -3.0 vs -1.1; P<0.001 for both comparisons), respectively. Improvements in BASMI linear scores from baseline were greater in patients treated with CZP 200 mg every two weeks and CZP 400 mg every four weeks compared to placebo at 12 weeks (-0.6 and -0.5 vs -0.1; P<0.001 and P<0.05, respectively) and at 24 weeks (-0.5 and -0.5 vs -0.1; P<0.001 for both comparisons), respectively.
Van der Heijde et al.[51] (2017) RAPID-axSpA extension study Certolizumab pegol 200 mg every 2 weeks or certolizumab pegol 400 mg every 4 weeks Placebo-controlled	OL, extension study Patients ≥18 years of age with chronic back pain of ≥3 months and fulfilling the ASAS criteria for axSpA with active disease	N=218 4 years	Primary: ASAS 20, ASAS 40, ASDAS, BASDAI, BASFI and BASMI scores and remission. Secondary: Not reported	Primary: At week 204 of certolizumab pegol-randomized patients, ASAS 20 and ASAS 40 responses were achieved by 54.1 (44.0%) and 83.7 (68.1%), respectively, showing sustained efficacy from week 24. Responses were comparable between the AS and nr-axSpA subpopulations Responses were maintained across the continuous disease activity outcomes BASDAI and ASDAS, and in measures of spinal mobility (BASMI-linear) and function (BASFI). Although AS patients tended to have higher BASFI scores than nr-axSpA patients at baseline (mean at baseline: AS: 5.6; nr-axSpA: 5.0) and week 204 [AS: 3.0; nr-axSpA: 2.2], the mean change from baseline was similar [week 204: AS: -2.6; nr-axSpA: -2.7].

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to week 24, dose-blind to week 48 and OL to week 204				The proportion of certolizumab pegol -randomized patients in remission, as ASDAS-ID and BASDAI <2 with normal CRP (LOCF), was sustained from week 24 (30.3% for both measures) to week 204 (32.1 and 33.0%, respectively. Partial remission, as ASAS-PR, was achieved by 30.3% of certolizumab pegol-randomized patients at week 24 and 23.4% at week 204 (NRI); 32.4 and 36.5%, respectively, Secondary: Not reported
Gorman et al.[52] (2002) Etanercept 25 mg twice a week vs placebo Patients were allowed to continue stable doses of DMARDs, NSAIDs, and oral corticosteroids.	DB, RCT Patients ≥18 years of age with active inflammatory AS based on the modified New York criteria, despite accepted treatments	N=40 4 months	Primary: Measures of morning stiffness, spinal pain, functioning, patient's global assessment of disease activity, and joint swelling Secondary: Physician's global assessment of disease activity, measures of spinal mobility, scores for enthesitis and peripheral-joint tenderness, ESR and CRP levels, and adverse events	Primary: A response to treatment was detected in 80% of individuals receiving etanercept as opposed to 30% of individuals receiving placebo (P=0.004). Primary endpoints were reported as follows for the etanercept and placebo groups, respectively: duration of morning stiffness, 25.0±78.9 vs 60.0±65.0 minutes (P<0.001); scores for nocturnal spinal pain (0=none to 100=most severe), 15.0±24.3 vs 38.0±27.8 (P<0.001); mean swollen joint scores (0=none to 3=severe), 1.6±3.8 vs 3.7±7.6 (P=0.17); patient's global assessment of disease activity (0=none to 5=very severe), 2.0±0.6 vs 3.0±0.9 (P<0.001); and the BASFI scores (0=none to 10=severe limitations), 2.2±2.1 vs 3.1±3.0 (P<0.001). Secondary: Differences in a number of secondary outcomes did reach statistical significance among those taking etanercept compared to those taking placebo including, physician's global assessment of disease activity (23.0±10.6; P<0.001), chest expansion (3.5±1.9 vs 2.9±1.7 cm; P=0.006), Modified Newcastle Enthesis Index, which is a measure of 17 enthesis on a four point pain scale (0.0±3.0 vs 1.5±8.0; P=0.001), ESR level (8.5±12.8 vs 16.5±18.7 mm/hour; P<0.001) and CRP level (0.7±1.1 vs 2.0±2.8 mg/dL; P=0.003). Injection site reactions and minor infections were the most commonly reported adverse events. The incidence in overall adverse events or specific events did not differ significantly.
Calin et al.[53] (2004)	DB, MC, RCT	N=84	Primary: ASAS 20 response	Primary: ASAS 20 response was found in 60.0% of etanercept patients compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Etanercept 25 mg twice a week vs placebo Patients were allowed to continue stable doses of DMARDs (HCQ, MTX, or SSZ) one NSAID, and oral corticosteroids (≤10 mg prednisone).	Patients 18 to 70 years of age with active AS based on the modified New York criteria	12 weeks	Secondary: ASAS 50 response, ASAS 70 response, individual components of ASAS, BASDAI, acute phase reactants, spinal mobility tests, and safety	23.1% of placebo patients at 12 weeks (P<0.001). Secondary: The etanercept group was associated with the higher rates of ASAS 50 and 70 responses (48.9 and 24.4%) compared to placebo (10.3 and 10.3%) at week 12. However, only the differences in ASAS 50 response reached statistical significance at this assessment point (P<0.001). ASAS 70 response was significantly different between groups up until week eight (28.9% with etanercept vs 7.7% with placebo; P<0.05). The changes in the individual ASAS components were reported as follows for etanercept and placebo: spinal inflammation, 43.3 vs 15.9% (P=0.003); nocturnal and total pain, 43.1 vs 6.2% (P=0.000); patient's global assessment, 37.0 vs 12.6% (P=0.11); functional impairment (BASFI), 35.4 vs 3.4% (P=0.000); BASDAI composite score, 43.6 vs 13.6% (P=0.001); and BASDAI fatigue score, 42.6 vs -4.9% (P=0.000). Injection site reactions occurred more frequently with etanercept compared to placebo (33 vs 15%; P<0.05).
Davis et al.[54] (2008) Etanercept 25 mg twice weekly until week 72, then 50 mg once weekly Stable doses of corticosteroids and NSAIDs were required 2 weeks prior to enrollment; stable doses of HCQ, MTX, or SSZ were required if deemed necessary.	ES, OL Patients 18 to 70 years of age with active AS based on the modified New York criteria	N=257 Up to 192 weeks	Primary: Safety (adverse events, serious adverse events, infections, serious infections, and death) and efficacy (ASAS 20 response, ASAS 5/6 response, and partial remission rates) Secondary: Not reported	Primary: After up to 192 weeks of treatment, the most common adverse events were injection site reactions, headache and diarrhea; no deaths were reported. For etanercept treatment the exposure adjusted serious event rate/patient year was 0.08, the exposure adjusted infection rate/patient year was 1.10, and the exposure adjusted serious infection rate/patient year was 0.02. Injection site reactions were reported in 22.2% of patients, which lead to the withdrawal of 0.4% of patients. A total of 71% of patients were considered ASAS 20 responders at week 96 and 81% of patients were considered responders at week 192. ASAS 5/6 response rates were 61% at week 96 and 60% at week 144. Partial remission response rates were 41% at week 96 and 44% at week 192.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Placebo patients who switched to etanercept in the OL extension showed similar rates of efficacy maintenance. Secondary: Not reported
Braun et al.[55] (2011) ASCEND Etanercept 50 mg once weekly vs SSZ titrated to 3 g daily in divided doses	DB, MC, RCT Patients ≥18 years of age with active AS (diagnosed according to modified New York criteria) who failed treatment with ≥1 NSAID taken for ≥3 months at the maximum recommended dose and were determined to be candidates for SSZ therapy by the investigators	N=566 16 weeks	Primary: Proportion of patients achieving ASAS 20 response at week 16 Secondary: Proportion of patients achieving ASAS 20 response at weeks two, four, eight and 12; proportion of patients achieving ASAS 40 response and ASAS 5/6 response at all time points	Primary: At week 16, significantly greater proportion of patients in the etanercept group achieved ASAS 20 response compared to the SSZ group (75.9 vs 52.9%; P<0.0001). Secondary: Significantly greater proportion of patients in the etanercept group achieved ASAS 20 response at week two compared to patients in the SSZ group; this difference was maintained throughout the time points (P<0.0001 for all). Significantly greater proportion of patients in the etanercept group achieved ASAS 40 and ASAS 5/6 responses compared to patients in the SSZ group at all time points (P<0.0001 for all). At week 16, a greater proportion of patients achieved ASAS 40 and ASAS 5/6 responses in the etanercept group compared to the SSZ group (59.8 vs 32.6%; P<0.0001 and 45.5 vs 21.2%; P<0.0001, respectively). The rates of adverse events and serious adverse events were similar between the two groups.
Inman et al.[56] (2008) Golimumab 50 mg once every 4 weeks vs golimumab 100 mg once every 4 weeks vs	DB, MC, PC, RCT Patients ≥18 years of age with a diagnosis of AS and no evidence of active TB and/or no evidence of latent TB on screening	N=356 24 weeks	Primary: ASAS 20 response at week 14 Secondary: Not reported	Primary: Treatment with golimumab with or without a DMARD, compared to placebo with or without a DMARD, resulted in a significant improvement in signs and symptoms as demonstrated by ASAS 20 response at week 14 (59 vs 22%; P≤0.001). All individual components of the ASAS response criteria were significantly improved in the golimumab 50 mg group compared to the placebo group at week 14. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo Patients who were on stable doses of HCQ, MTX, NSAID, oral corticosteroid and/or SSZ were permitted in the study.				
Braun et al.[57] (2002) Infliximab 5 mg/kg at weeks 0, 2 and 6 vs placebo Concurrent use of NSAIDs not exceeding the baseline dose was allowed.	DB, MC, PC, RCT Adult patients (mean age of 40) with AS based on the modified New York criteria with BASDAI score ≥4 and spinal pain score ≥4	N=70 12 weeks	Primary: Improvement from baseline in BASDAI by 50% at week 12 Secondary: Improvement from baseline in spinal pain, BASFI, BASMI, SF-36, CRP, and ESR	Primary: A greater proportion of patients achieved a 50% improvement in BASDAI at week 12 in the infliximab group (53%; 95% CI, 37 to 69) compared to the placebo group (9%; 95% CI, 3 to 22). The difference between the groups was significant starting at week two and continuing through until week 12 (P<0.0001). Secondary: At week 12, the infliximab group had a significant mean improvement from baseline in spinal pain (P<0.0001), BASFI (P<0.0023), BASMI (P<0.0001), CRP (P<0.0001), and ESR (P<0.0001); while there was no significant difference in the placebo group. At 12 weeks, there were significant improvements from baseline in the physical component and mental component of the SF-36 in the infliximab group (P<0.0001); however, only the improvement in the physical component was significantly greater compared to the placebo group (P<0.0001). A greater proportion of patients reported infections in the infliximab group (51%) compared to the placebo group (35%; difference, 16%; 95% CI, -7 to 40; P=0.227). A greater proportion of patients in the infliximab group experienced serious adverse events and were withdrawn from the study compared to the placebo group (3 vs 0; P=0.239).
van der Heijde et al.[58] (2005) ASSERT	MC, PC, RCT Adult patients (median age of 40) with AS based on	N=279 24 weeks	Primary: Proportion of patients with ASAS 20 at week 24	Primary: After 24 weeks, significantly greater proportion of patients were ASAS 20 responders in the infliximab group (61.2%) compared to the placebo group (19.2%; P<0.001). The difference was significant at week two and continued to week 24.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Infliximab 5 mg/kg at weeks 0, 2, 6, 12 and 18 vs placebo Concurrent NSAIDs, acetaminophen or tramadol were allowed during the study.	the modified New York criteria for at least three months with a BASDAI score ≥4, spinal pain assessment score ≥4 on a VAS and a normal chest radiograph within three months, and negative TB screening		Secondary: ASAS 40 response, ASAS partial remission, ASAS 5/6, disease activity (BASDAI, night pain, patient's global assessment and CRP), physical function (BASFI), range of motion (BASMI), other musculoskeletal assessments (swollen joint count and degree of tenderness) and quality of life (SF-36)	Secondary: Over the 24-week study period, significantly greater proportion of patients were ASAS 40 responders in the infliximab group compared to the placebo group (P<0.001). At 24 weeks 47% of patients were ASAS 40 responders in the infliximab group compared to 12% in the placebo group (P<0.001). Significantly greater proportion of patients treated with infliximab achieved ASAS 5/6 (49%) compared to placebo treated patients (8%; P<0.001). Significantly greater proportion of patients achieved a partial ASAS response in the infliximab group (22.4%) compared to the placebo group (1.3%; P<0.001). The median improvement in all measures of disease activity (BASDAI, night pain, patient's global assessment and CRP) was significantly greater in the infliximab treated patients compared to placebo treated patients (P<0.001). The patients in the infliximab group had a significantly greater median improvement in BASFI compared to patients in the placebo group (P<0.001). There was a significantly greater median improvement in BASMI in the infliximab group compared to the placebo group (P=0.019). The infliximab treated patients had a significantly greater median improvement in swollen joint count compared to the placebo treated patients (P=0.019). There was a significantly greater improvement in the physical component of the SF-36 in the infliximab group compared to the placebo group (P<0.001); there was no significant difference in the mental component (P=0.547). Compared to patients in the placebo group, a greater proportion of patients in the infliximab group experienced at least on adverse event (82.2 vs 72.0%), reported at least one infection (42.6 vs 36.0%) and had severe adverse reactions (3.5 vs 2.7%). Of the adverse events that occurred in at least 5% of patients in either group, the rates of pharyngitis, rhinitis, and increased liver enzymes were greater in the infliximab group.
Machado et al.[59] (2013) Infliximab	MA RCTs of patients with AS based on the modified New	N=2,820 (18 trials) 6 to 104 weeks	Primary: Proportion of patients with ASAS 20 at 12- or 14 weeks and at 30	Primary: Patients treated with TNF-blockers were more likely to achieve ASAS 20 response after 12 or 14 weeks (RR, 2.21; 95% CI, 1.91 to 2.56) and 24 weeks (RR, 2.68; 95% CI, 2.06 to 3.48) compared to controls.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs etanercept vs adalimumab vs golimumab vs certolizumab vs control Concurrent use of stable doses of other medications was allowed.	York criteria		weeks of follow-up Secondary: ASAS 40 response, ASAS 5/6, ASAS partial remission, BASDAI, BASDAI 50, BASFI, and BASMI, withdraws and safety outcomes at 12 or 14 weeks and 30 weeks of follow-up	Treatment with golimumab was associated with the highest RR for ASAS 20 response after 12 or 14 weeks (RR, 2.74; 95% CI, 1.78 to 4.22), followed by adalimumab (RR, 2.33; 95% CI, 1.45 to 3.74), etanercept (RR, 2.13; 95% CI, 1.75 to 2.58), and infliximab (RR, 1.82; 95% CI, 1.16 to 2.58) compared to controls. Treatment with infliximab was associated with the highest RR for ASAS 20 response after 24 weeks (RR, 3.18; 95% CI, 1.99 to 5.08), followed by etanercept (RR, 2.53; 95% CI, 1.80 to 3.57) and adalimumab (RR, 2.15; 95% CI, 0.96 to 4.83) compared to controls. Secondary: Patients treated with TNF-blockers were more likely to achieve ASAS 40 response after 12 or 14 weeks (RR, 2.77; 95% CI, 2.05 to 3.75) and 24 weeks (RR, 3.32; 95% CI, 2.44 to 4.51) compared to controls. Patients treated with TNF-blockers were more likely to achieve ASAS 5/6 response after 12 or 14 weeks (RR, 3.52; 95% CI, 2.17 to 5.71) and 24 weeks (RR, 4.25; 95% CI, 2.80 to 6.46) compared to controls. Patients treated with TNF-blockers were more likely to achieve partial remission after 12 or 14 weeks (RR, 4.79; 95% CI, 2.46 to 9.34) and 24 weeks (RR, 4.43; 95% CI, 2.62 to 7.49) compared to controls. Patients treated with TNF-blockers achieved greater improvements in the disease activity (BASDAI) after 12 weeks (mean difference, -1.64; 95% CI, -2.06 to -1.22) and after 30 weeks (mean difference, -1.79; 95% CI, -2.27 to 1.31) compared to controls. Patients treated with TNF-blockers were more likely to achieve BASDAI 50 response at 12 or 14 weeks (RR, 2.87; 95% CI, 2.23 to 3.69) and at 24 weeks (RR, 3.39; 95% CI, 2.46 to 4.67) compared to controls. Patients treated with TNF-blockers achieved greater improvements in physical function (BASFI) at 12 weeks (mean difference, -1.39; 95% CI, -1.59 to -1.19) and at 24 weeks (mean difference, -1.52; 95% CI, -1.72 to -1.31) compared to controls.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Patients treated with TNF-blockers achieved greater improvements in vertebral mobility (BASMI) at 12 weeks (mean difference, -0.53; 95% CI, -0.72 to -0.35) and at 24 weeks (mean difference, -0.60; 95% CI, -0.87 to -0.33) compared to controls. Meta-analysis of safety outcomes and withdraws did not indicate statistically significant differences between treatment and control groups after 12 or 30 weeks (P value not reported).
Deodhar et al[60] (2019) Certolizumab pegol 400 mg at weeks 0, two and four followed by 200 mg every two weeks vs placebo Given in addition to nonbiologic background medication	DB, MC, PC, PG, RCT Patients ≥18 years of age with a diagnosis of adult-onset axSpA, have ≥12 months of symptom duration, have active disease at screening and baseline despite treatment with nonbiologic background medication and have objective signs of inflammation (patients with radiographic sacroiliitis excluded)	N=317 52 weeks	Primary: Proportion of patients achieving major improvement (i.e., a ≥2.0-point decrease in the score from baseline or achievement of the lowest possible score [0.6]) in the ASDAS at week 52 Secondary: Achievement of ASAS 40 at weeks 12 and 52	Primary: At week 52, major improvement in ASDAS was achieved in 47.2% (75/159) of certolizumab pegol plus nonbiologic background medication patients, which was greater (P<0.0001) than the 7.0% (11/158) of placebo plus nonbiologic background medication patients in whom major improvement in ASDAS was achieved. Secondary: At week 12, 47.8% (76/159) of certolizumab pegol plus nonbiologic background medication patients had achieved an ASAS 40 response, compared to 11.4% (18 of 158) of placebo plus nonbiologic background medication patients (P<0.0001). By week 52, 56.6% (90/159) of certolizumab pegol plus nonbiologic background medication patients and 15.8% (25/158) of placebo plus nonbiologic background medication patients had achieved an ASAS 40 response (P<0.0001).
Crohn's Disease				
Ma et al.[61] (2009) Adalimumab	SR OL and RCT cohort studies of patients with CD who had either lost response,	N=1,810 (15 trials) 8 weeks to 4 years	Primary: Short-term and long-term efficacy Secondary: Adverse events	Primary: Short-term clinical response or remission was evaluated in nine trials. Forty-one to 83% of patients achieved a clinical response at four weeks, while 12 to 67% of participants attained clinical remission. Long-term remission rates ranged from 31 to 82% at six months and 19 to 68% at one year.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	were intolerant or refractory to infliximab			Secondary: Serious adverse events were reported in 0 to 19% of patients and included sepsis, cellulitis, and fungal pneumonia.
Lofberg et al.[62] (2012) CARE Adalimumab 160 mg at week zero, followed by 80 mg at week two, followed by 40 mg every other week At week 12 or later, patients who experienced a disease flare or did not respond to treatment could increase the adalimumab dose to 40 mg weekly.	MC, OL Patients 18 to 75 years of age with a radiologic or endoscopic diagnosis of CD for ≥4 months and a HBI >7 points at screening	N=945 20 weeks	Primary: Remission rates, proportion of patients free of EIM at week 20 Secondary: Fistula healing, remission rates based on concomitant therapies and adverse events	Primary: The proportion of patients in remission who received adalimumab was 43% at week four (95% CI, 40 to 46) and increased to 52% (95% CI, 49 to 55) at week 20. There was a significantly higher remission rate at week 20 among adalimumab-treated patients who were also infliximab naïve compared to patients exposed to infliximab (62 vs 42; P<0.001). A shorter disease duration (less than two years and between two and five years) was associated with higher rates of clinical remission at week four compared to a disease duration longer than five years (50, 52, and 38%, respectively; P<0.001); however the remission rates at 20 weeks were not significantly different (58, 56, and 50%, respectively; P=0.136). Overall, 53% of patients had at least one EIM at baseline, compared to 30% at week 20. Of these, 79% had resolution of at least one EIM and 51% were free of EIM signs and symptoms following 20 weeks of adalimumab treatment. The EIM resolution rates were similar across adalimumab-treated patients regardless of prior infliximab use (P=0.100) and prior infliximab response and those who discontinued treatment for other reasons (P=0.625). Secondary: Complete fistula healing occurred in 26% of patients at week 20. Fistula closure rates were numerically higher in the infliximab-naïve group at week 20 (33%) compared to the infliximab-experienced group (22%); however, the difference was not significant (P=0.275). Fistula healing rates were similar in nonresponders to infliximab compared to those who discontinued infliximab for other reasons (19 vs 23%; P=0.973). Of patients taking corticosteroids at baseline, 37% were able to discontinue them by week 20; Eleven percent and 14% of patients achieved a steroid-free remission at weeks 12 and 20, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Seven percent of patients taking immunosuppressants at baseline were able to discontinue them at week 20. There were similar rates of clinical remission at week 20 between patients taking and not taking steroids at baseline (52% in both groups; P=0.976). By week 20, the rates of clinical remission were 55 and 49%, respectively, in patients who were and were not taking immunosuppressants at baseline (P=0.052). Adverse events occurred in 80% of patients and 11% of patients who discontinued treatment due to adverse events. Serious adverse events were reported in 19% of patients. The adverse events profiles were similar among patients who were exposed to infliximab previously and those who were treatment naïve. The most common adverse event categories were "gastrointestinal disorders" and "CD'' indicating a worsening of patient's underlying disease.
Faubion et al.[63] (2017) IMAgINE 2 Adalimumab 40 mg every week or every other week if ≥40 kg or 20 mg every week or every other week if <40 kg	ES, MC, OL Patients 6 to 17 years of age with a diagnosis of CD who successfully completed IMAgINE 1 through week 52 and achieved clinical response at any time point during the study	N=100 240 weeks	Primary: PDCAI remission (≤10) and response (decrease ≥15 from IMAgINE 1 baseline) Secondary: Corticosteroid-free remission, safety	Primary: Remission and response were achieved by 41% and 48% of patients who entered IMAgINE 2, respectively. Secondary: Corticosteroid-free remission rates in IMAgINE 2 among patients who used corticosteroids at IMAgINE 1 baseline increased from 40.5% (15/37) at enrollment into IMAgINE 2 to 63.2% (12/19, observed analysis) at week 240 of IMAgINE 2. Discontinuation of corticosteroid use increased from week 12 (86.5% [32/37]) through week 240 of IMAgINE 2 (100% [19/19], observed analysis). Serious adverse events (48%) and adverse events leading to discontinuation (32%) of study drug were primarily due to worsening or flare of CD. The most frequently reported adverse events were CD (55%), headache (27%), upper respiratory tract infection (22%), nasopharyngitis (21%), and diarrhea (19%).
Watanabe et al.[64] (2012) (Induction study)	2 DB, MC, PC, RCT Patients 15 to 75 years of age, with	N=90 (induction) N=83	Primary: Induction study Proportion of patients in	Primary: Induction A greater proportion of patients treated with ADA 160/80 and ADA 80/40 achieved a clinical remission by week four compared to placebo (33 and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Adalimumab 160 mg at week zero, followed by 80 mg at week two (ADA 160/80 group) vs adalimumab 80 mg at week zero, followed by 40 mg at week two (ADA 80/40 group) vs placebo (Maintenance study) adalimumab 40 mg every other week vs placebo Patients achieving a Clinical Response 70 (decrease from baseline in CDAI ≥70 points at week four) entered the blinded maintenance trial.	moderate to severely active CD, CDAI score 220 to 450 for >4 months and a diagnosis of ileal, colonic or ileocolonic CD confirmed by endoscopy or radiologic evaluation	(maintenance) 56 weeks (4 weeks induction study and 52 week maintenance study)	clinical remission (CDAI <150) at week four Maintenance Clinical remission (CDAI <150) at week 52 Secondary: Induction study Proportion of patients in clinical remission at week two and with CR-100 or CR-70 (CDAI decrease ≥100 or ≥70) at week four, changes from baseline in CDAI and IOIBD at week two and week four and changes in SF-36 MCS and PCS, and IBDQ scores in each treatment group at week four Maintenance Proportion of patients in clinical remission, (CDAI decrease ≥100 or ≥70) every four weeks,	18 vs 12%, respectively; P value not reported). Maintenance By week 52, a significantly greater proportion of patients treated with adalimumab 40 mg achieved a clinical remission compared to placebo (P<0.05). Secondary: Induction At week two, clinical remission rates were higher with ADA 160/80 and ADA 80/40 compared to placebo (18 and 15 vs 4%, respectively; P value not reported). At week four, significantly greater proportion of patients receiving ADA 160/80 or ADA 80/40 experienced a CR-100 (50 and 46 vs 17%, respectively; P<0.05 for both) compared to placebo. At week four, significantly greater proportion of patients receiving ADA 160/80 experienced a CR-70 (70 vs 30%; P=0.0062); however, the improvement with the ADA 80/40 was not statistically significant. The changes in CDAI from baseline to week two and four, respectively, were, -75.9 and -101.3 in the ADA 160/80 group, -74.4 and -81.3 in the ADA 80/40 group, and -27.2 and -37.5 in the placebo group. The mean changes in IOIBD score from baseline to week two and week four, respectively, were -1.2 and -1.5 in the ADA 160/80 group, -0.7 and -0.8 in the ADA 80/40 group, and -0.4 and -0.5 in the placebo group. ADA 160/80 or ADA 80/40 significantly improved SF-36 MCS from baseline to week four compared to placebo. (6.2 and 5.5 vs -1.6, respectively; P<0.05 for both). There were no statistically significant differences in SF-36 PCS and IBDQ between patients receiving ADA 160/80 compared to patients receiving placebo. Maintenance Adalimumab therapy was more effective compared to placebo at each of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			changes from baseline of the induction to week 52 in CDAI, IOIBD, SF-36 MCS and PCS scores, and IBDQ	the four-week evaluations throughout the 52-week trial compared to placebo with regard to CR-100 (P≤0.05) and CR-70 (P≤0.01). Adalimumab was more effective compared to placebo with regard to maintaining clinical remission at weeks eight, 36, 36, 40, 48 and 52 (P<0.05). The mean changes in CDAI from baseline of the induction trial to week zero and week 52, respectively, were -147.7 and -83.7 in the adalimumab-treated patients and -139.0 and -9.1 in the placebo-treated patients. The mean changes in IOIBD from baseline to week zero and week 52, respectively, were -2.0 and -0.8 in adalimumab-treated patients and -1.2 and -0.2 in placebo-treated patients, respectively. Adalimumab 40 mg was associated with statistically significant improvements in SF-36 MCS and IBDQ compared to placebo at eight weeks (12.0 vs 2.0; P=0.03 and 34.8 vs 8.3; P=0.05, respectively); however, the changes were not significantly different at 52 weeks.
Shao et al.[65] (2009) Certolizumab vs placebo	MA DB, RCTs in patients with moderate to severe CD	N=1,040 (3 trials) 12 to 26 weeks	Primary: Clinical response (a decrease ≥100 points from baseline in CDAI score) and clinical remission (CDAI score ≤150 points) at week four Secondary: Safety	Primary: Certolizumab was associated with an increased rate of induction of clinical response (RR, 1.36; 95% CI, 1.10 to 1.68; P=0.004) and remission (RR, 1.95; 95% CI, 1.41 to 2.70; P<0.0001) compared to placebo. Secondary: Only infection was reported more frequently with certolizumab compared to placebo (60.6 vs 40.7%).
Targan et al.[66] (1997) Infliximab 5 mg/kg vs	DB, MC, PC, RCT Adult patients with CD for six months with CDAI scores 220 to 400 and previously receiving	N=108 12 weeks	Primary: Decrease from baseline in CDAI ≥70 points at four weeks without a change in concomitant	Primary: At week four, the primary endpoint was reached in 81, 50, 64 and 17% in the 5 mg/kg, 10 mg/kg, 20 mg/kg and placebo groups, respectively. The overall response of the infliximab groups was significantly higher (65%) compared to the placebo group (P<0.001). At week two, 61% of the infliximab treated patients had a response

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
infliximab 10 mg/kg vs infliximab 20 mg/kg vs placebo	mesalamine (for ≥8 weeks and a stable dose for four weeks), corticosteroids (maximum of 40 mg/day for ≥8 weeks and a stable dose for two weeks), mercaptopurine or azathioprine (for ≥6 months and stable dose for eight weeks)		medications Secondary: Not reported	compared to 17% of the placebo treated patients (P<0.001). A greater proportion of patients was in remission (CDAI score <150) in the infliximab group at two weeks (27%) compared to the placebo group (4%; P=0.06). At week four, 33% of the infliximab treated patients were in remission compared to 4% of the placebo treated patients (P<0.005). The response rate remained significantly higher in the infliximab treated patients through the 12 weeks of the study (41%) compared to placebo treated patients (12%; P=0.008); however, the remission rate was not significantly different at 12 weeks (24 vs 8%; P=0.31). Secondary: Not reported
Present et al.[67] (1999) Infliximab 5 mg/kg at weeks 0, 2 and 6 vs infliximab 10 mg/kg at weeks 0, 2 and 6 vs placebo	DB, MC, PC, RCT Patients 18 to 65 years of age with ≥1 confirmed draining abdominal or perianal fistulas of ≥3 months as a complication of CD	N=94 18 weeks	Primary: Reduction ≥50% from baseline in number of draining fistulas at two or more consecutive study visits Secondary: Proportion of patients with a complete response (absence of any draining fistula at two consecutive visits), length of time to beginning of response, and duration of response	Primary: There were significantly greater response rates in the infliximab 5 (68%) and 10 mg/kg (56%) groups compared to the placebo group (26%; P=0.002 and P=0.02, respectively). The response rates were not significantly different between the two infliximab groups. Secondary: A greater proportion of patients in the infliximab 5 (55%) and 10 mg/kg (38%) groups had complete response compared to the placebo group (13%; P=0.001 and P=0.04, respectively). In the infliximab group, the median time to the onset of response was two weeks compared to six weeks in the placebo group. The duration of response was approximately three months in patients that reached the primary endpoint. The most frequently reported adverse events in the infliximab group were headache, abscess, upper respiratory tract infection and fatigue.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hyams et al.[68] (2007) REACH Infliximab 5 mg/kg at weeks 0, 2 and 6; those responding to therapy received continued therapy every 8 weeks at weeks 14, 22, 30, 38 and 36 or every 12 weeks at weeks 18, 30 and 42 vs infliximab 5 mg/kg at weeks 0, 2 and 6; those responding to therapy received continued therapy every 12 weeks at weeks 18, 30 and 42	OL, MC, RCT Patients 6 to 17 years of age with a PCDAI >30 at baseline and who initiated immunomodulator therapy (azathioprine, mercaptopurine or MTX) ≥8 weeks before screening and at stable dose for two weeks	N=112 46 weeks	Primary: Clinical response at week 10 (decrease from baseline to week 10 in PCDAI ≥15 points and total PCDAI no more than 30) Secondary: Maintenance of clinical response and remission (PCDAI ≤10)	Primary: At week 10, 88.4% of patients responded to the induction regimen (95% CI, 82.5 to 58.9). Secondary: At week 10, 58.6% of patients were in clinical remission (95% CI, 49.8 to 68.0). At week 54, 63.4 and 55.8% of patients treated with infliximab every eight weeks achieved clinical response and clinical remission, respectively, compared to 33.3 and 23.5% of patients treated with infliximab every 12 weeks (P=0.002 and P<0.001, respectively). At week 10, there was a significant decrease in PCDAI score compared to baseline that continued at weeks 30 and 54 (all P<0.001). There was a significant decrease in corticosteroid use at week 10 compared to baseline that continued at weeks 30 to 54 (all P<0.001). Adverse events were similar between the two groups. Infection was the most common adverse event in both treatment groups.
Van Assche et al.[69] (2012) SWITCH Adalimumab 80 mg at week zero and 40 mg every other week Patients not randomized to adalimumab continued prior	OL, PRO, RCT Patients ≥18 years with luminal CD treated with infliximab maintenance therapy started for ≥6 months with a complete clinical response (PGA assessment of signs and symptoms, but	N=73 54 weeks	Primary: Proportion of patients in the adalimumab group preferring adalimumab over infliximab and proportion of patients who needed rescue therapy with short courses of steroids or	Primary: There was a statistically significant increase in the preference of adalimumab over infliximab for patients who changed from infliximab to adalimumab therapy at all evaluation points (P<0.05), except week 56 (P=0.08). Dose intensification or early treatment termination occurred significantly more frequently over 54 weeks in patients switched to adalimumab (47%) compared to those who continued infliximab (16%; P=0.003). Significantly more patients initiating adalimumab therapy discontinued therapy due to loss of response or intolerance compared those who continued infliximab therapy (28 vs 2%; P<0.01). Of note, the patient who

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
infliximab at 5 mg/kg at their regularly scheduled interval. Patients with a disease flare were able to intensify treatment as follows: adalimumab 40 mg every week and in the infliximab group, a decrease of the dosing interval with two-week decrements.	the CDAI at baseline <200) with stable infliximab dosing intervals of ≥6 weeks		intensified anti-TNF dosing or who had to stop the assigned anti-TNF agent Secondary: Proportion of patients with an injection- or infusion-related reaction and proportion of patients with an increase in the CDAI of >100 above baseline and IBDQ	discontinued infliximab was successfully treated with adalimumab and eight of the 10 patients who stopped adalimumab treatment returned to infliximab therapy. The reasons for early discontinuation of treatment were loss of tolerance in six of 10 patients on adalimumab and in the one patient receiving infliximab. Four other patients in the adalimumab group stopped for loss of efficacy. Refractory eczema with fatigue or arthralgias (n=2), general malaise and diarrhea following injections (n=2) and fatigue plus inability to comply with injections (n=2) led to adalimumab intolerance and an infusion reaction to infliximab intolerance. Secondary: There was no difference in the change from baseline in CDAI at time of early termination in the adalimumab group (184 vs 78; P=0.10). Dose intensification occurred in 27.7% of patients in the adalimumab group, three of which later stopped adalimumab for loss of response, and in and 13.5% of patients in the infliximab group (P=0.20). The median time to dose intensification was not significantly different between the adalimumab and infliximab treatment arms (24 vs 32 weeks; P=0.64). An increase in CDAI ≥100 points was observed in 18.9% of patients in the infliximab group and in 27.7% of patients in the adalimumab group while on the initially assigned treatment. Median IBDQ values at baseline and at week 56 were comparable in both groups and the medians stayed well in the range compatible with disease remission throughout the trial.
Behm et al.[70] (2008) Adalimumab, certolizumab, or infliximab vs placebo	SR RCTs including patients ≥18 years of age with CD who had a clinical response or clinical remission with a TNF-α blocker, or patients with CD in	N=3,586 (9 trials) Duration varied	Primary: Clinical remission, clinical response, and steroid-sparing effects Secondary: Not reported	Primary: Adalimumab demonstrated the ability to maintain clinical remission and clinical response (RR, 2.69; 95% CI, 1.88 to 3.86; P<0.00001), while also having a steroid-sparing effect (data specific to clinical remission and steroid-sparing effect not reported). Certolizumab was shown to maintain both clinical remission (RR, 1.68; 95% CI, 1.30 to 2.16; P=0.000072) and clinical response (RR, 1.74; 95% CI, 1.41 to 2.13; P<0.00001) compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	remission but unable to wean corticosteroids, who were then randomized to maintenance of remission with a TNF-α blocker or placebo			Infliximab was more effective than placebo at maintaining fistula healing (RR, 1.87; 95% CI, 1.15 to 3.04; P=0.012), clinical remission (RR, 2.50; 95% CI, 1.64 to 3.80; P=0.000019), clinical response (RR, 1.66; 95% CI, 1.00 to 2.76; P=0.0046, and achieved a steroid sparing effect (RR, 3.13; 95% CI, 1.25 to 7.81; P=0.014). Secondary: Not reported
Giant-Cell Arteritis				
Stone et al.[71] (2017) GiACTA Tocilizumab 162 mg SC weekly plus a 26-week prednisone taper vs tocilizumab 162 mg SC every other week plus a 26-week prednisone taper vs placebo plus a 26-week prednisone taper vs placebo plus a 52-week prednisone taper	DB, PC, RCT Patients ≥50 years of age who had active giant-cell arteritis within six weeks before baseline and who had a history of an elevated erythrocyte sedimentation rate attributable to giant-cell arteritis	N=251 52 weeks	Primary: Rate of sustained glucocorticoid-free remission at week 52 between each tocilizumab group and the placebo group with the 26-week taper Secondary: Rate of sustained glucocorticoid-free remission at week 52 between each tocilizumab group and the placebo group with the 52-week taper, cumulative prednisone dose, SF-36, safety	Primary: A total of 56% of the patients in the group that received tocilizumab weekly and 53% of those in the group that received tocilizumab every other week had sustained remission at 52 weeks, as compared with 14% of the patients in the placebo group that underwent the 26-week taper (P<0.001 for the comparison of each tocilizumab group with placebo). Secondary: A total of 56% of the patients in the group that received tocilizumab weekly and 53% of those in the group that received tocilizumab every other week had sustained remission at 52 weeks, as compared with 18% of those in the placebo group that underwent the 52-week taper (P<0.001 for the comparison of each tocilizumab group with placebo). The total median cumulative prednisone dose over the 52-week period was 1862 mg (95% CI, 1582 to 1942) in the group that received tocilizumab weekly and 1862 mg (95% CI, 1568 to 2240) in the group that received tocilizumab every other week, as compared with 3296 mg (95% CI, 2730 to 4024) in the placebo group that underwent the 26-week taper and 3818 mg (95% CI, 2818 to 4426) in the placebo group that underwent the 52-week taper (P<0.001 for all comparisons of tocilizumab with placebo). The mean increase (indicating clinical improvement) from baseline to week 52 in the SF-36 physical component summary score was 4.10 in the group that received tocilizumab weekly and 2.76 in the group that received tocilizumab every other week, whereas scores decreased (indicating a worse condition) in the two placebo groups (−0.28 in the placebo group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
All patients received a prednisone taper				with the 26-week taper and −1.49 in the placebo group with the 52-week taper). The difference between the group that received tocilizumab weekly and the placebo group that underwent the 52-week taper was 5.59 points (99% CI, 0.86 to 10.32; P=0.002). However, the differences between the group that received tocilizumab every other week and each placebo group with respect to the SF-36 physical component summary score did not reach statistical significance. The percentages of patients with adverse events were similar in all the trial groups, but fewer patients reported serious adverse events in the group that received tocilizumab weekly (15%) or every other week (14%) than in the placebo group that underwent the 26-week taper (22%) or the placebo group that underwent the 52-week taper (25%).
Hidradenitis Suppurativa				
Kimball et al.[72] (2016) PIONEER I and II Adalimumab 40 mg weekly vs placebo	2 DB, MC, PC, RCTs Men and women who had not received previous anti–TNF-α treatment were eligible if they had moderate-to-severe hidradenitis suppurativa (total abscess and inflammatory-nodule count, ≥3) at baseline and an inadequate response to oral antibiotic treatment. In PIONEER I, patients receiving oral antibiotic agents for hidradenitis	N=633 36 weeks	Primary: Proportion of patients with a clinical response at week 12, defined according to the Hidradenitis Suppurativa Clinical Response measure as at least a 50% reduction from baseline in the total abscess and inflammatory-nodule count, with no increase in the abscess or draining-fistula count Secondary: Total abscess and inflammatory-	Primary: A higher proportion of patients in the adalimumab group than in the placebo group met the primary efficacy end point of a clinical response at week 12 (PIONEER I: 41.8 v. 26.0%, P=0.003; PIONEER II: 58.9 versus 27.6%, P<0.001). Responses to adalimumab were similar regardless of whether baseline antibiotic therapy was continued (in PIONEER II) and regardless of the baseline Hurley stage. Secondary: Adalimumab treatment resulted in greater improvements than placebo in PIONEER II (P=0.01 for total abscess and inflammatory-nodule count of 0, 1, or 2 for patients with Hurley stage II disease at baseline, P<0.001 for 30% reduction from baseline in the score for skin pain, and P<0.001 for mean improvement in the modified Sartorius score) but did not have a significant effect in PIONEER I.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	suppurativa were required to stop treatment for at least 28 days before baseline; in PIONEER II, patients were allowed to continue treatment with antibiotics (tetracycline class) in stable doses.		nodule count of 0, 1, or 2; ≥30% reduction and at least a 1-unit reduction from baseline in the pain score; change from baseline in the modified Sartorius score	
Juvenile Idiopathic/Rheumatoid Arthritis				
Ruperto et al.[73] (2008) Abatacept 10 mg/kg every 28 days vs placebo	DB, MC, PC, RCT (OL lead in period) Patients 6 to 17 years of age with JIA with at least 5 active joints and active disease and who had inadequate response to or intolerance to ≥1 DMARD	N=122 (RCT); 190 (OL lead in period) 6 months (4-month OL lead in)	Primary: Time to flare Secondary: Proportion of patients with a disease flare, changes in baseline in each of six core response variables, and assessment of safety and tolerability	Primary: In the placebo group, the median time to flare was six months; however, insufficient events occurred in the abatacept group to assess median time to flare (P=0.0002). Secondary: There was a significantly greater proportion of patients that experienced a flare in the placebo group compared to the abatacept group (53 vs 12%; P=0.0003). The HR for patients in the abatacept group to experience a flare compared to the placebo group was 0.31 (95% CI, 0.16 to 0.59). After six months or at the time of first flare, 82% of the abatacept group and 69% of the placebo group improved by ≥30% as measured by ACR (P=0.1712), 77% of the abatacept group and 52% of the placebo group improved by ≥50% as measured by ACR (P=0.0071), 53% of the abatacept group and 31% of the placebo group improved by ≥70% as measured by ACR and 40% of the abatacept group and 16% of the placebo group improved by ≥90% as measured by ACR. In the abatacept group, 30% had inactive disease compared to 11% in the placebo group (P=0.0195). Adverse events were similar between the groups.
Lovell et al.[74] (2015)	OL (long-term extension of above	N=153	Primary: Safety	Primary: The overall incidence rates of adverse events and serious adverse events

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Abatacept 10 mg/kg every 28 days	study) Patients 6 to 17 years of age with JIA with at least five active joints and active disease and who had inadequate response to or intolerance to ≥1 DMARD	5 to 7 years	Secondary: ACR Pedi responses, CHAQ	reported in the cumulative study period, corresponding to a mean ±SD maximum total exposure of 62.1 ± 20.9 months, were 209.11 (95% CI, 179.11 to 242.70) and 5.62 (95% CI, 3.92 to 7.82) events per 100 patient-years of exposure, respectively. Secondary: ACR Pedi 30 responses, Pedi 70 responses, and clinically inactive disease status were maintained throughout the long-term extension phase in patients who continued to receive therapy. Improvements in the Child Health Questionnaire physical and psychosocial summary scores were maintained over time.
Lovell et al.[75] (2008) Adalimumab 24 mg/m^2 (maximum of 40 mg) every other week with or without MTX vs placebo Patients were stratified according to MTX use and received OL adalimumab 24 mg/m^2 (maximum of 40 mg) every other week for 16 weeks. The patients with an ACR Pedi 30 response at week 16	DB, MC, OL, RCT Patients 4 to 17 years of age with active JRA who had previously received treatment with NSAIDs	N=171 48 weeks	Primary: Rate of disease flare in patients not receiving MTX Secondary: ACR Pedi 30, 50, 70, and 90 responses at week 48, and safety	Primary: Among patients not receiving MTX, flares occurred in 43% receiving adalimumab and 71% receiving placebo (P=0.03). In patients receiving MTX, flares occurred in 37 and 65% in the adalimumab and placebo groups, respectively (P=0.02). Secondary: In patients receiving MTX, ACR Pedi 30, 50, 70, and 90 responses were reported in 63 vs 38% (P=0.03), 63 vs 35% (P=0.03), 63 vs 27% (P=0.002) and 42 vs 27% (P=0.17) in the adalimumab and placebo groups, respectively. In patients not receiving MTX therapy, ACR Pedi 30, 50, 70, and 90 responses were reported in 57 vs 32% (P=0.06), 53 vs 32% (P=0.10), 47 vs 29% (P=0.16) and 30 vs 18% (P=0.28) in the adalimumab and placebo groups, respectively. The most frequently noted adverse events were mild to moderate in nature and included infections and injection site reactions. There were seven cases of serious infection reported with adalimumab use.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
were then randomly assigned to receive adalimumab or placebo.				
Lovell et al.[76] (2000) Etanercept 0.4 mg/kg twice weekly vs placebo All patients received etanercept 0.4 mg/kg twice weekly for up to 3 months in the OL part of the study; the patients whose condition improved were then randomly assigned to either etanercept or placebo. Concurrent analgesics, NSAIDs, or oral corticosteroids (≤10 mg/day of prednisone or equivalent) were allowed.	DB, MC, OL, RCT Patients 4 to 17 years of age with active polyarticular JRA despite treatment with NSAIDs and MTX ≥10 mg/m^2/week	N=69 7 months	Primary: Rate of disease flare Secondary: Median time to flare, safety	Primary: Seventy-four percent (51/69) of patients demonstrated improvement and were included in the DB part of the trial. The rate of disease flare was significantly higher in the placebo group compared to the etanercept group (81 vs 28%; P=0.003). Secondary: The median time to flare was reported as 116 days in the active treatment arm compared to 28 days with placebo (P<0.001). During the OL segment of the study the adverse events most often reported included injection-site reaction, upper respiratory tract infections, headache, rhinitis and gastrointestinal side effects. There were no differences noted between groups during the latter part of the study.
Lovell et al.[77] (2006)	Ongoing ES, MC, OL by Lovell et al[22] (updated efficacy	N=58 Median of 4	Primary: JRA 30% DOI	Primary: Thirty-two patients were available for efficacy analysis after four years with 94% meeting the JRA 30% DOI.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Etanercept 0.4 mg/kg (maximum of 25 mg) twice weekly Intra-articular and soft-tissue injections of corticosteroids were permitted after 12 continuous weeks of etanercept. MTX could be added to treatment after one year. Concurrent analgesics, NSAIDs, or oral corticosteroids (≤10 mg/day of prednisone or equivalent) were allowed.	and safety results from the study)	years	Secondary: JRA 50% DOI, JRA 70% DOI, an articular severity score (0 to 926), assessment of pain (Likert scale, 0 to 10), CRP levels, safety	Secondary: Approximately 94 and 78% of participants met the JRA 50% DOI and JRA 70% DOI, respectively. At four years, the median CRP level was lowered to 0.1 mg/dL from 3.4 mg/dL at baseline, the median articular severity score was decreased to 18 from 88 at baseline, and the median patient's assessment of pain score was lowered to 0.9 from 3.6 at baseline. Duration of morning stiffness was only assessed through one year and was reported as 5 minutes at month 12 (from 53 minutes at baseline). After four years, there were five reports of serious adverse events and 0.03 serious infections (requiring intravenous antibiotics or hospitalizations)/ patient year.
Horneff et al.[78] (2004) Etanercept 0.4 mg/kg twice weekly Combination treatment with MTX or oral corticosteroids was permitted.	MC, OL Patients 4 to 17 years of age with active idiopathic juvenile arthritis despite treatment with MTX	N=322 Up to 48 months, median of 12 months	Primary: Change in indices of disease activity, 30, 50, and 70% improvement in idiopathic juvenile arthritis Secondary: Safety	Primary: At 12 months, the mean number of tender joints, swollen joints, and joints with limited range of movement were reduced to 1.7 (SD, 3.5), 2.6 (SD, 4.7), and 7.1 (SD, 8.9) from a baseline of 9.1 (SD, 9.5), 8.4 (SD, 9.0), and 11.8 (SD, 11.8), respectively. The duration of morning stiffness was decreased to 7 (SD, 23) minutes from 45 (SD, 65) minutes and CHAQ scores (on a scale of 0=best to 3=worst) were decreased to 0.4 (SD, 0.6) from 1.0 (SD, 0.8). Patient's and PGA scores (on a scale of 0=best to 100=worst) were reduced to 16 (SD, 18) and 20 (SD, 23) from 56 (SD, 27) and 67 (SD, 25), respectively. At last report (30 months) a 30, 50, and 70% improvement was noted in approximately 60, 48, and 28% of patients remaining on etanercept, respectively. Significant improvements in all indices of disease activity were detected at all points of time (months one,

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td></td><td></td><td></td><td></td><td>three, six, 12, 18, 24, and 30; P<0.0001 with the exception of swollen joint count at 30 months; P<0.0005 and duration of morning stiffness; P<0.001).

Secondary:
There were 20 reports of infection or infection related events. Discontinuation of treatment was reported in 53 patients, of which 11 cases were secondary to adverse events.</td></tr>
<tr><td>Hissink Muller et al.[79]
(2017)
BeSt-for-kids

Etanercept and MTX combination (arm 3)

vs

DMARD-monotherapy (SSZ or MTX) (arm 1)

vs

MTX / prednisolone-bridging (arm 2)</td><td>MC, SB, RCT

Patients 2 to 16 years of age diagnosed as DMARD-naive JIA, either rheumatoid factor negative polyarticular, oligoarticular JIA, or juvenile psoriatic arthritis, in need of systemic DMARD therapy according to treating physician</td><td>N=94

3 months</td><td>Primary:
Percentage inactive disease, adjusted ACR Pedi30, 50 and 70 and Juvenile Arthritis Disease Activity Score after six and 12 weeks of treatment

Secondary:
Adverse effects</td><td>Primary:
<table>
<tr><th></th><th>Etanercept + MTX</th><th>DMARD monotherapy</th><th>MTX + prednisone</th><th>P-value</th></tr>
<tr><td>Inactive disease 6-weeks (%)</td><td>3</td><td>0</td><td>13</td><td>0.25</td></tr>
<tr><td>Inactive disease 3-months (%)</td><td>17</td><td>25</td><td>9</td><td>Not reported</td></tr>
<tr><td>aACR Pedi 30 6-weeks (%)</td><td>57</td><td>47</td><td>56</td><td>0.68</td></tr>
<tr><td>aACR Pedi 30 3-months (%)</td><td>73</td><td>50</td><td>53</td><td>0.13</td></tr>
<tr><td>aACR Pedi 50 6-weeks (%)</td><td>37</td><td>28</td><td>44</td><td>0.56</td></tr>
<tr><td>aACR Pedi 50 3-months (%)</td><td>53</td><td>31</td><td>38</td><td>0.19</td></tr>
<tr><td>aACR Pedi 70 6-weeks (%)</td><td>20</td><td>9</td><td>25</td><td>0.25</td></tr>
<tr><td>aACR Pedi 70 3-months (%)</td><td>47</td><td>25</td><td>19</td><td>0.04</td></tr>
<tr><td>JADAS 6-weeks (median)</td><td>12.4</td><td>13.9</td><td>9.6</td><td>0.12</td></tr>
<tr><td>JADAS 3-months (median)</td><td>8.2</td><td>9.0</td><td>11.5</td><td>0.25</td></tr>
</table>

Secondary:
Gastrointestinal symptoms were most frequently reported and were observed 7/32 (22%), 14/32 (44%) and 9/30 (28%) in arm 1, 2 and 3, respectively. Second most reported were mild infectious complications (25% in arm 1, 19% in arm 2 and 43% in arm 3) with eight upper respiratory tract infections documented in arm 3.</td></tr>
<tr><td>De Benedetti et al.[80]</td><td>PC, RCT</td><td>N=112</td><td>Primary:</td><td>Primary:</td></tr>
</table>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2010) TENDER (abstract) Tocilizumab 8 mg/kg every 2 weeks for patients ≥30 kg or 12 mg/kg every 2 weeks for patients <30 kg vs placebo	Patients 2 to 17 years of age with active systemic JIA for ≥6 months with an inadequate response to NSAIDs and corticosteroids	12 weeks	Proportion of patients with JRA ACR 30 response plus absence of fever at week 12 Secondary: Not reported	At week 12, significantly greater proportion of patients treated with tocilizumab achieved JRA 30 response plus absence of fever (85%) compared to patients treated with placebo (24%; P<0.0001). Significantly greater proportion of patients in the tocilizumab group achieved JRA ACR 50, JRA ACR 70, and JRA ACR 90 responses compared to patients in the placebo group (P<0.0001). Secondary: Not reported
Brunner et al.[81] (2012) CHERISH (abstract) Tocilizumab 8 mg/kg every 4 weeks for patients ≥30 kg vs 8 mg/kg every 4 weeks for patients <30 kg vs 10 mg/kg every 4 weeks for patients <30 kg vs	DB, PC, RCT (OL lead in period) Patients 2 to 17 years of age with active polyarticular JIA for ≥6 months who failed MTX	N=166 24 weeks	Primary: Proportion of patients with JIA ACR 30 flare relative to week 16 Secondary: Proportion of patients with JIA ACR 30, ACR 50, and ACR 70 responses	Primary: Tocilizumab treated patients experienced significantly fewer JIA ACR 30 flare at week 40 compared to patients treated with placebo (25.6 vs 48.1%; P<0.0024). Secondary: At week 40, significantly greater proportion of patients in the tocilizumab group achieved JRA ACR 30 (74.4 vs 54.3%; P=0.0084), JRA ACR 50 (73.2 vs 51.9%; P=0.0050), and JRA ACR 70 (64.6 vs 42.0%; P=0.0032) response compared to patients in the placebo group. The degree of improvement was lower for these endpoints in the tocilizumab 8 mg/kg (<30 kg body weight) group compared to the other two tocilizumab groups (10 mg/kg for patients weighing <30 kg and 8 mg/kg for patients weighing ≥30 kg).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				
Psoriasis				
Saurat et al.[82] (2008) CHAMPION Adalimumab 80 mg at week 0, then 40 mg every other week from week 1 through week 15 vs MTX 7.5 mg at week 0, then increased to 10 mg weekly at week 2, then increase to 15 mg weekly at week 4; at week 8, patients not achieving PASI 50 had the dose of MTX increased to 15 mg weekly; at week 12, patients not achieving PASI 50 at week 12 and 8 had the dose of MTX increased to 25 mg weekly vs placebo	DB, DD, MC, RCT Patients ≥18 years of age with moderate to severe psoriasis (>10% of BSA and PASI ≥10), plaque psoriasis for >1 year, stable plaque psoriasis for >2 months, that are candidates for systemic therapy of phototherapy, with plaque psoriasis despite treatment with topical agents and treatment naïve to TNF-antagonists and MTX	N=271 16 weeks	Primary: Proportion of patients achieving PASI 75 at week 16 relative to baseline Secondary: Proportion of patients achieving PASI 50, PASI 90, PASI 100, and PGA	Primary: At 16 weeks, significantly more patients in the adalimumab group (79.6%) achieved PASI 75 compared to the MTX group (35.5%; RD, 43.7%; 95% CI, 30.8 to 56.7; P<0.001) and placebo group (18.9%; RD, 60.5%; 95% CI, 44.5 to 76.6; P<0.001). The difference in treatment groups was seen starting at two weeks for adalimumab vs MTX (P<0.05) and at four weeks for adalimumab vs placebo (P<0.001). Secondary: At week 16, PASI 100 was achieved in significantly more patients in the adalimumab group (16.7%) compared to the MTX group (7.3%; P<0.04) and the placebo group (1.9%; P<0.001).Significantly more patients achieved PASI 50, PASI 90 and a PGA of clear or minimal in the adalimumab group compared to the MTX and placebo groups (P<0.001 for all). Rates of reported infectious adverse events were not significantly different between the groups (P value not reported). Total adverse events and serious adverse events were similar.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Papp et al.[83] (2017) Adalimumab 0.8 mg/kg or 0.4 mg/kg SC at week 0, then every other week starting at week one vs methotrexate once weekly by mouth (0.1 to 0.4 mg/kg)	DB, MC, RCT Patients 4 to <18 years of age with severe plaque psoriasis who had not responded to topical therapy	N=114 16 weeks	Primary: PASI75 and clear or minimal PGA score Secondary: PASI90, PASI100, change from baseline in children's dermatology life quality index and Pediatric quality of life inventory scores	Primary: At week 16, the proportion of patients who achieved PASI75 was higher in the adalimumab 0.8 mg/kg group (58%) than in the methotrexate group (32%; P=0.027); 44% of patients in the adalimumab 0.4 mg/kg group achieved PASI75. PASI75 response to adalimumab 0.8 mg/kg was rapid; a significant difference compared with methotrexate was reached by week four (P=0.002). The proportion of patients who achieved PGA score of 0 or 1 after 16 weeks was higher in the adalimumab 0.8 mg/kg group (61%) than in the methotrexate group (41%; P=0.083) or in the adalimumab 0.4 mg/kg group (41%); however, the difference between the adalimumab 0.8 mg/kg and methotrexate groups did not reach significance. Secondary: The proportion of patients who achieved PASI90 at week 16 was higher in the adalimumab 0.8 mg/kg group than in the methotrexate group (P=0.466). A higher, but not significant, proportion of patients achieved PASI100 in the adalimumab 0.8 mg/kg group than in the methotrexate group (P=0.056). The mean decrease (improvement) in children's dermatology life quality index score from baseline was numerically, but not significantly, higher in patients in the adalimumab 0.8 mg/kg group than in patients in the methotrexate group (P=0.304). The mean increase (improvement) from baseline in Pediatric quality of life inventory score was higher in patients in the adalimumab 0.8 mg/kg group than in patients in the methotrexate group (P=0.005).
Strober et al.[84] (2017) UNVEIL Apremilast 30 mg twice daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with moderate plaque psoriasis (5 to 10% BSA involvement and sPGA score of 2 on a 6-point scale) who were naïve to systemic and biologic therapy	N=221 16 weeks	Primary: Mean percentage change from baseline in PGAxBSA at week 16 Secondary: Quality of life measures	Primary: At week 16, the mean percentage change from baseline in PGAxBSA score was greater with apremilast (-48.1%) vs placebo (-10.2%; P<0.0001). Secondary: Mean percentage change from baseline in PASI score was greater with apremilast (-40.72%) versus placebo (-3.87%; P<0.0001). DLQI scores were improved with apremilast (-4.8) vs placebo (-2.4; P=0.0008). Mean improvements in the Treatment Satisfaction Questionnaire for Medication, version II, were greater with apremilast versus placebo for global satisfaction (63.2 vs 48.7; P<0.0001) and treatment effectiveness (57.3 vs 38.8; P<0.0001). Most adverse events were mild or moderate; most

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				common were diarrhea, headache, nausea, upper respiratory tract infection, decreased appetite, and vomiting.
Reich et al.[85] (2017) LIBERATE Apremilast 30 mg BID vs etanercept 50 mg weekly vs placebo through Week 16; thereafter, all patients continued on or switched to apremilast through Week 104. This study was not designed for apremilast vs etanercept comparisons.	DB, PC, RCT Biologic-naive patients ≥18 years of age with moderate-to-severe plaque psoriasis	N=250 104 weeks (outcomes assessed through week 52)	Primary: Achievement of PASI-75 at Week 16 with apremilast vs placebo Secondary: Achievement of PASI-75 at Week 16 with etanercept vs placebo and improvements in other clinical endpoints vs placebo at Week 16	Primary: At week 16, PASI75 was achieved by more patients receiving apremilast (39.8%) versus placebo (11.9%, P<0.0001). Secondary: At Week 16, PASI75 response was achieved by significantly more patients receiving etanercept (48.2%) versus placebo (11.9%, P<0.0001). Significant improvements were achieved with apremilast (vs placebo) at Week 16 for the following secondary endpoints: sPGA score of 0 (clear) or 1 (almost clear) (P=0.0005), percentage change from baseline in the psoriasis affected BSA (P=0.0002), PASI-50 response (P=0.0008), change from baseline in DLQI total score and Lattice System Physician's Global Assessment score of 0 (clear) or 1 (almost clear) (P=0.0011).
Bagel et al.[86] (2012) Etanercept 50 mg twice- weekly for 12 weeks followed by	DB, MC, PC, RCT Patients ≥18 years of age with stable moderate-to-severe plaque psoriasis	N=124 24 weeks	Primary: Percentage change in PSSI score at week 12 Secondary:	Primary: At week 12, Group A experienced a significantly greater mean improvement in PSSI score compared to Group B (86.8 vs 20.4%; P<0.001) with significant improvements as early as week four of treatment.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
etanercept 50 mg weekly plus placebo weekly for 12 additional weeks (Group A) vs placebo twice-weekly for 12 weeks followed by etanercept 50 mg twice- weekly for 12 additional weeks (Group B) Patients discontinued the use of background therapies.	covering ≥10% of BSA for ≥6 months and PASI scores ≥10 and ≥30% of SSA affected, with PSSI scores ≥15		Percentage change in the PSSI score at week 24 for Group B patients, the proportion of patients achieving PSSI 75 improvement at week 12, patient satisfaction with treatment at week 12, and safety	Secondary: At week 24, both Group A and Group B experienced improvements in PSSI scores from baseline (90.6 vs 79.1%, respectively; P value not reported). A significantly greater proportion of patients in Group A compared to Group B experienced a PSSI 75 at week 12 (86 vs 11%; P<0.0001). Significantly more etanercept-treated patients were either satisfied or very satisfied at week 12 compared to placebo (P<0.0001). At week 24, after etanercept treatment, Group B patients' satisfaction increased significantly over their first 12 weeks on placebo (P<0.0001). More than two thirds of Group A patients continued to be satisfied or very satisfied at week 24. The rates of adverse events were comparable between groups, both at week 12 (etanercept vs placebo) and week 24 (etanercept 50 mg twice-weekly vs once-weekly). No serious adverse events were reported at week 12; however, by week 24, three patients had reported serious events. The most commonly reported adverse events were upper respiratory tract infection, injection site reactions, headache, sinus congestion, cough, and ear infection.
Paller et al.[87] (2016) Etanercept once weekly at 0.8 mg/kg (maximum 50 mg)	ES, OL Patients 4 to 17 years of age with moderate to severe plaque psoriasis	N=182 5 years	Primary: Incidence of adverse events Secondary: PASI75, PASI90, clear/almost clear on PGA	Primary: The most commonly reported adverse events were upper respiratory tract infection (37.6%), nasopharyngitis (26.0%), and headache (21.5%). Injection-site reactions were reported by 16 (8.8%) patients. Only one serious adverse event (cellulitis) was considered by the investigator to be related to the investigational product. Secondary: The percentages of patients achieving PASI75 and PASI90 responses from baseline in the parent study remained relatively constant at approximately 60 to 70% and 30 to 40%, respectively, at week 96 through week 264. Similarly, the percentage of patients who achieved sPGA status of clear/almost clear (score 0/1) remained relatively constant at approximately 40 to 50% from week 96 through week 264.
Bachelez et al.[88] (2015)	DD, MC, NI, PC, RCT	N=1101	Primary: Proportion of	Primary: A PASI75 response at week 12 was achieved by 130 (39.5%) of 329

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Etanercept 50 mg twice weekly vs tofacitinib 5 mg twice daily vs tofacitinib 10 mg twice daily vs placebo	Adult patients with chronic stable plaque psoriasis (for ≥12 months) who were candidates for systemic or phototherapy and had a PASI score of ≥12 and a PGA of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy	12 weeks	patients at week 12 with at least a 75% reduction in the PASI score from baseline and the proportion of patients achieving a PGA score of "clear" or "almost clear" Secondary: Proportion of patients with a 50% reduction and 90% reduction in PASI score, reduction in itch severity item score, decrease in DLQI	patients in the tofacitinib 5 mg group, 210 (63.6%) of 330 in the tofacitinib 10 mg group, 197 (58.8%) of 335 in the etanercept group, and six (5.6%) of 107 in the placebo group. The proportions of PGA responders at week 12 were 155 (47.1%) in the tofacitinib 5 mg group, 225 (68.2%) in the tofacitinib 10 mg group, 222 (66.3%) in the etanercept group, and 16 (15.0%) in the placebo group. For both coprimary endpoints, tofacitinib 10 mg twice daily was non-inferior to etanercept and was superior to placebo, whereas tofacitinib 5 mg twice daily did not meet the non-inferiority criteria versus etanercept but met the superiority criteria versus placebo. Secondary: PASI50 and PASI90 response rates over time, and the corresponding differences between treatment groups, were similar to those based on the PASI75 outcome. Decreased in itch severity score with active treatments were greater than the clinically important difference of 1.64. At week 12, a clinically meaningful improvement in DLQI score (a reduction by five points or more) was achieved by 66.3% of patients in the tofacitinib 10 mg group, 78.2% of patients in the tofacitinib 5 mg group, 74.7% of patients in the etanercept group, and 31.8% of patients in the placebo group, in patients with a baseline score of five or higher (P<0.0001 for each active treatment vs placebo).
Griffiths et al.[89] (2010) Etanercept 50 mg twice weekly vs ustekinumab 45 mg at weeks 0 and 4	MC, PG, RCT Patients ≥18 years of age, with a diagnosis of plaque psoriasis for ≥6 months, were candidates for phototherapy or systemic therapy,	N=903 12 weeks	Primary: PASI 75 at week 12 Secondary: Physician's global assessment score of 0 or 1, PASI 90, difference between PASI at week 12	Primary: A greater number of patients achieved PASI 75 in the ustekinumab 45 mg group (67.5%) and ustekinumab 90 mg group (73.8%) than in the etanercept group (56.8%; P=0.01 vs ustekinumab 45 mg; P<0.001 vs ustekinumab 90 mg). Secondary: A larger proportion of ustekinumab patients met criteria for cleared or minimal on a physician's global assessment (score of 0 or 1) compared to etanercept patients (65.1% on ustekinumab 45 mg and 70.6% on

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ustekinumab 90 mg at weeks 0 and 4 Patients without a response to etanercept at week 12, received ustekinumab 90 mg at weeks 16 and 20; patients without a response to ustekinumab at week 12 received one additional study dose at week 16.	had a baseline PASI score ≥12, had a score ≥3 on physician's global assessment, had ≥10% BSA involvement, and had inadequate response, intolerance, or contraindication to ≥1 conventional systemic agent (i.e., MTX, cyclosporine, or psoralen plus ultraviolet A) and no previous treatment with etanercept or ustekinumab		and 12 weeks after retreatment	ustekinumab 90 mg vs 49.0% on etanercept; P<0.001 for each comparison vs etanercept). PASI 90 was achieved by 36.4% of ustekinumab 45 mg patients, 44.7% of ustekinumab 90 mg patients and 23.1% of etanercept patients (P<0.001, for each comparison vs etanercept). Of the patients that crossed over to ustekinumab from etanercept, 48.9% achieved a PASI 75, 23.4% achieved PASI 90, 40.4% achieved cleared or minimal on the physician's global assessment. Of patients that received retreatment with ustekinumab, 84.4% had a physician's global assessment score of 0 to 2. The most commonly occurring adverse event in the etanercept group was injection site erythema (14.7%) and was reported more often than in the two ustekinumab groups combined (0.7%). At least one serious adverse effect was reported in 1.9, 1.2 and 1.2% of patients in the ustekinumab 45 mg, 90 mg and etanercept groups, respectively.
Schmitt et al.[90] (2008) Adalimumab, cyclosporine, efalizumab*, etanercept, or infliximab vs placebo	MA RCTs in patients with moderate to severe psoriasis	16 trials Duration varied	Primary: PASI 75 Secondary: Tolerability	Primary: Compared to placebo a greater proportion of patients receiving adalimumab (RD, 64%; 95% CI, 61 to 68; P<0.00001), cyclosporine (RD, 33%; 95% CI, 13 to 52; P<0.0009), efalizumab (RD, 24%; 95% CI, 19 to 30; P<0.00001), etanercept 50 mg twice weekly (RD, 44%; 95% CI, 40 to 48; P<0.00001) and etanercept 25 mg twice weekly (RD, 30%; 95% CI, 25 to 35; P<0.00001) achieved PASI 75 response. The infliximab group had the greatest response (RD, 77%; 95% CI, 72 to 81; P<0.00001). Secondary: Average monthly rates of serious adverse events were 0.5% with adalimumab, 2.3% with cyclosporine, 1.2% with efalizumab, 0.6% with etanercept 50 mg twice weekly and 1.1% with infliximab. This outcome was not reported in with etanercept 25 mg twice weekly. Withdrawals due to adverse events occurred on average in 0.3% of adalimumab-treated patients, 16.1% of cyclosporine-treated patients, 1.2% of efalizumab-treated patients, 0.5% of patients on the lower dose of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				etanercept and 0.4% of patients on the higher dose of etanercept and 1.3% of infliximab-treated individuals/month.
Langley et al.[91] (2014) ERASURE and FIXTURE ERASURE: secukinumab 300 mg vs secukinumab 150 mg vs placebo FIXTURE: secukinumab 300 mg vs secukinumab 150 mg vs etanercept vs placebo	DB, DD, MC, PC, PG, RCT (FIXTURE also AC) Patients 18 years of age or older with moderate-to-severe plaque psoriasis for at least six months and poorly controlled with topical treatments, phototherapy, systemic therapy or a combination of those therapies, score ≥12 on the PASI scale, 3 or 4 on the modified investigator global assessment, and 10% or more involvement in body surface area	N=2,044 (ERASURE: 737 FIXTURE: 1,306) 52 weeks	Primary: Proportion of patients that had a PASI75 and a score of 0 or 1 in the investigator's global assessment at week 12. Secondary: PASI90 at week 12, maintenance of PASI75 and a 0 or 1 response on the investigator's global assessment from week 12 to week 52, and PASI100 at week 12, , improvement in DLQI, improvement in pain/itching/ scaling	Primary: ERASURE A greater proportion of patients who received secukinumab 300 mg (200/245 [81.6%]) and secukinumab 150 mg (174/243 [71.6%]) had a PASI75 response at week 12 compared to placebo (11/246 [4.5%]; P<0.001 for both comparisons). Additionally, a greater proportion of patients who received secukinumab 300 mg (160/245 [65.3%]) and secukinumab 150 mg (125/244 [51.2%]) had a response of 0 or 1 on the modified investigator's global assessment at week 12 compared to placebo (6/246 [2.4%]; P<0.001 for both comparisons). FIXTURE The proportion of patients who had a PASI75 response at week 12 was 77.1% (249/323), 67.0% (219/327), 44.0% (142/323), and 4.9% (16/324) for secukinumab 300 mg, secukinumab 150 mg, etanercept, and placebo respectively. Both secukinumab 300 mg and 150 mg had a statistically significant greater proportion of patient who achieved PASI75 at week 12 compared with etanercept and placebo (P<0.001 for each secukinumab dose when compared to either etanercept or placebo). The proportion of patients who had a 0 or 1 response on the modified investigator's global assessment at week 12 was 62.5% (202/323), 51.1% (167/327), 27.2% (88/323), and 2.8% (9/324) for secukinumab 300 mg, secukinumab 150 mg, etanercept, and placebo respectively. Both secukinumab 300 mg and 150 mg had a statistically significant greater proportion of patient who had a 0 or 1 response on the modified investigator's global assessment at week 12 compared with etanercept and placebo (P<0.001 for each secukinumab dose when compared to either etanercept or placebo). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
All drugs were dosed once weekly at baseline and at weeks one, two and three, then every four weeks starting from week four.				ERASURE A greater proportion of patients who received secukinumab 300 mg (145/245 [59.2%]) and secukinumab 150 mg (95/243 [39.1%]) had a PASI90 response at week 12 compared to placebo (3/246 [1.2%]; P<0.001 for both comparisons). PASI75 was maintained from week 12 to 52 for 80.5% (161/200) and 72.4% (126/174) of patients in the secukinumab 300 mg and 150 mg groups respectively. A 0 or 1 response on the modified investigator's global assessment was maintained from week 12 to 52 for 74.4% (119/160) and 59.2% (74/125) of patients in the secukinumab 300 mg and 150 mg groups respectively. PASI100 at week 12 was reached by 28.6%, 12.8% and 0.8% of patients in the secukinumab 300 mg, secukinumab 150 mg, and placebo groups respectively. There was a statistically significant greater proportion of patients who achieved PASI100 in both the secukinumab groups compared to placebo (P<0.001 for both comparisons). Patients in both secukinumab groups reported significant improvements in DLQI, itching, pain and scaling by week 12 compared to etanercept and placebo groups (P values not reported). FIXTURE A greater proportion of patients who received secukinumab 300 mg (175/323 [54.2%]) and secukinumab 150 mg (137/327 [41.9%]) had a PASI90 response at week 12 compared to placebo (5/324 [1.5%]; P<0.001 for both comparisons). Additionally both secukinumab groups had a significantly higher proportion of patients that achieved PASI90 at week 12 compared with the etanercept group (67/323 [20.7%]; P<0.001 for both comparisons). PASI75 was maintained from week 12 to 52 for 84.3% (210/249), 82.2% (180/219), and 72.5% (103/142) of patients in the secukinumab 300 mg, secukinumab 150 mg, and etanercept groups respectively. When compared

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				to etanercept, both secukinumab 300 mg and secukinumab 150 mg had a statistically significant greater proportion of patients that maintained PASI75 from week 12 to 52 (P<0.001 and P=0.009 for the 300 mg and 150 mg dose respectively). A 0 or 1 response on the modified investigator's global assessment was maintained from week 12 to 52 for 79.7% (161/202), 67.7% (113/167), and 56.8% (50/88) of patients in the secukinumab 300 mg, secukinumab 150 mg, and etanercept groups respectively. When compared to etanercept, both secukinumab 300 mg and secukinumab 150 mg had a statistically significant greater proportion of patients that maintained 0 or 1 response on the modified investigator's global assessment from week 12 to 52 (P<0.001 and P=0.002 for the 300 mg and 150 mg dose respectively). PASI100 at week 12 was reached by 24.1%, 14.4%, 4.3% and 0% of patients in the secukinumab 300 mg, secukinumab 150 mg, etanercept, and placebo groups respectively. There was a statistically significant greater proportion of patients who achieved PASI100 in both the secukinumab groups compared to etanercept (P<0.001 for both comparisons). There was no comparison done with placebo as no patients achieved PASI100 at week 12. Patients in both secukinumab groups reported significant improvements in DLQI, itching, pain and scaling by week 12 compared to placebo groups (P values not reported).
Psoriatic Arthritis				
Mease et al.[92] (2017) Abatacept 125 mg SC weekly vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with a diagnosis of psoriatic arthritis with a minimum of both three swollen and three tender joints, active plaque	N=424 24 weeks	Primary: ACR20 at week 24 Secondary: Proportions of patients with an HAQ-DI response (reduction from baseline, ≥0.35), an ACR20 response in	Primary: Abatacept treatment resulted in a significantly higher proportion of patients achieving an ACR20 response at week 24 versus placebo (39.4 vs 22.3%; P<0.001). Secondary: Although abatacept numerically increased HAQ-DI response rates at week 24, this was not statistically significant (31.0 vs 23.7%; P=0.097). The benefits of abatacept were seen in ACR20 responses regardless of TNF inhibitor exposure and in other musculoskeletal manifestations, but

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	psoriasis, and inadequate response or intolerance to ≥1 non-biologic DMARD		the TNFi-naïve and TNFi-exposed subgroups and a radiographic non-progression (change from baseline score, ≤0)	significance could not be attributed due to ranking below HAQ-DI response in hierarchical testing.
Genovese et al.[93] (2007) Adalimumab 40 mg every other week vs placebo Patients who completed a 12 week blinded phase could elect to receive OL therapy.	DB, MC, RCT Patients with moderately to severely active PsA with an inadequate response to DMARD therapy	N=100 24 weeks	Primary: ACR 20 response at week 12 Secondary: ACR 50 response, ACR 70 response, PsARC scores, assessments of disability, psoriatic lesions, and quality of life	Primary: At week 12, an ACR 20 response was achieved by 39% of adalimumab patients vs 16% of placebo patients (P=0.012). Secondary: ACR 50 and ACR 70 responses were also achieved by significantly more patients on adalimumab (25 and 14%, respectively) compared to patients on placebo at week 12 (2 and 0%, respectively; P=0.001 for ACR 50 and P=0.013 for ACR 70). A PsARC response was achieved by 51% of adalimumab patients vs 24% of placebo patients (P=0.007). At week 12, measures of skin lesions (-3.7 units with adalimumab vs -0.3 units with placebo; P≤0.001) and disability were statistically significantly improved with adalimumab. Adalimumab use was associated with significant mean improvements from baseline in components of quality of life assessments such as physical functioning (P=0.027), bodily pain (P=0.007), general health (P=0.017) and mental health (P=0.009). OL adalimumab provided continued improvement for adalimumab patients and initiated rapid improvement for placebo patients, with ACR 20 response rates of 65 and 57%, respectively, observed at week 24. Serious adverse events occurred at a similar frequency during therapy with placebo (4.1%), blinded adalimumab (2.0%), and OL adalimumab (3.1%). Adalimumab use was not associated with serious infections.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Mease et al.[94] (2005) Adalimumab 40 mg every other week vs placebo Stable doses of MTX were allowed and corticosteroid or DMARD rescue therapy was permitted in patients without at least a 20% reduction in swollen and tender joints by week 12.	DB, MC, PG, RCT Patients ≥18 years of age with moderately to severely active PsA with active psoriatic skin lesions or a documented history of psoriasis and a history of inadequate response to NSAIDs	N=315 24 weeks	Primary: ACR 20 response at 12 weeks, change in mTSS at week 24 Secondary: ACR 20 response at 24 weeks, ACR 50 and ACR 70 response at weeks 12 and 24, measures of joint disease, disability, quality of life, and severity of skin disease in patients with psoriasis involving at least 3% of BSA	Primary: At week 12, 58% of the adalimumab treated patients achieved an ACR 20 response, compared to 14% of the placebo-treated patients (P<0.001). The mean change in the mTSS of radiographic structural damage was -0.2 in patients receiving adalimumab and 1.0 in those receiving placebo (P<0.001). Secondary: ACR 20 response at 24 weeks was 57% with adalimumab and 15% with placebo (P<0.001). An ACR 50 response was detected in 36% of adalimumab-treated individuals at 12 weeks and 39% of adalimumab-treated individuals at week 24 compared to 4 and 6% of those on placebo, respectively (P<0.001 for both outcomes). An ACR 70 response was found in 20% in the adalimumab arm and 1% in the placebo arm at 12 weeks and 23 and 1% at 24 weeks (P<0.001). PsARC response was achieved with adalimumab in 62% at 12 weeks and 60% at 24 weeks compared to 26 and 23% on placebo, respectively (P value not reported). Among the 69 adalimumab treated patients evaluated with the PASI, 59% achieved a PASI 75 improvement response at 24 weeks, compared to 1% of placebo-treated patients (P<0.001). Disability and quality of life measures were also significantly improved with adalimumab treatment compared to placebo treatment (P<0.001 for changes in both HAQ-DI and SF-36 PCS scores at weeks 12 and 24). Changes in SF-36 MCS scores were not statistically significant between groups at both week 12 (P=0.708) and week 24 (P=0.288). The rates of overall and serious adverse events were similar among groups.
Kavanaugh et al.[95]	PC, RCT	N=504	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
PALACE 1 (2014) Apremilast 20 mg BID vs apremilast 30 mg BID vs placebo	Patients ≥18 years of age with a diagnosis of psoriatic arthritis with a minimum of both three swollen and three tender joints, despite prior treatment with traditional DMARDs and/or biologic treatment or concurrent treatment with traditional DMARDs	24 weeks	Proportion of patients achieving ACR20 at week 16 Secondary: Change from baseline to week 16 in HAQ-DI, safety	At week 16, significantly more patients receiving apremilast 20 mg BID (31.3%; P=0.0140) and 30 mg BID (39.8%; P=0.0001) achieved an ACR20 response versus placebo (19.4%). Secondary: At week 16, apremilast was associated with significantly greater reductions (improvements) in HAQ-DI compared with placebo. During the 24 weeks, the adverse events occurring in ≥5% of any treatment group included diarrhea, nausea, headache, and upper respiratory tract infection. Discontinuations due to adverse events were comparable across groups (placebo: 4.8%; apremilast 20 mg BID: 6.0%; apremilast 30 mg BID: 7.1%).
Papp et al.[96] (2013) Apremilast 20 mg QD vs apremilast 20 mg BID vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age with a six-month history or longer of moderate to severe plaque psoriasis with a PASI score ≥10 and BSA involvement ≥10%	N=260 12 weeks	Primary: PSAI75 Secondary: Change from baseline in PASI, BSA involvement, and PGA, adverse events	Primary: At week 12, a significantly greater proportion of subjects receiving apremilast 20 mg BID achieved PASI75 vs those receiving placebo [21/86 (24.4%) subjects vs. 9/87 (10.3%); P=0.023]. A similar proportion of subjects receiving apremilast 20 mg QD and placebo achieved a PASI75 score at week 12 (10.3% in each group). Secondary: A statistically significantly greater proportion of subjects receiving apremilast 20 mg BID achieved PASI50 vs placebo (P<0.001). Although a greater proportion of subjects receiving apremilast 20 mg BID achieved PASI90 vs placebo, the difference was not statistically significant (P=0.113). A significantly greater mean per cent reduction in PASI score was achieved with apremilast 20 mg QD and 20 mg BID than with placebo [17.4% with placebo; 30.3% with apremilast 20 mg QD (P=0.021); 52.1% with apremilast 20 mg BID (P<0.001)] at week 12. Mean change from baseline in overall static PGA and BSA was only significant in the apremilast 20 mg BID group. The percentage of subjects reporting one or more treatment emergence

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				adverse events was 59.8% with placebo, 67.8% with apremilast 20 mg QD and 54.1% with apremilast 20 mg BID.
Schett et al.[97] (2012) Apremilast 20 mg BID vs apremilast 40 mg QD vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with symptomatic PsA for ≥6 months with ≥3 swollen joints and ≥3 tender joints, and to have discontinued treatment with immunosuppressants other than methotrexate for an adequate washout period	N=204 12 weeks	Primary: ACR20 Secondary: Safety	Primary: A significantly greater proportion of patients achieved an ACR20 response at week 12 among the group receiving apremilast 20 mg twice per day (43.5%) and the group receiving apremilast 40 mg once per day (35.8%), when compared with those receiving placebo (11.8%) (P<0.001 and P=0.002, respectively). In patients achieving an ACR20 response, the median time to response was four weeks. Secondary: The percentage of patients affected by ≥1 adverse event was similar across treatment groups. No significant laboratory abnormalities were observed, and no opportunistic infections were reported.
Cutolo et al.[98] (2016) PALACE 2 Apremilast 20 mg BID vs apremilast 30 mg BID vs placebo Patients whose swollen joint count and tender joint	DB, PC, RCT Patients ≥18 years of age with a diagnosis of psoriatic arthritis with a minimum of both three swollen and three tender joints, despite prior treatment with traditional DMARDs and/or biologic treatment or concurrent treatment with traditional DMARDs	N=484 24 weeks	Primary: Proportion of patients achieving ACR20 at week 16 Secondary: Change from baseline to week 16 in HAQ-DI, safety	Primary: ACR20 at Week 16 was achieved by more patients receiving apremilast 20 mg (37.4%; P=0.0002) and 30 mg (32.1%; P=0.0060) versus placebo (18.9%). Secondary: At Week 16, mean change from baseline in HAQ-DI score was greater with apremilast 20 mg (−0.17, P=0.032) and 30 mg (−0.23, P=0.0042) versus placebo (−0.07). Clinically meaningful improvements in signs and symptoms of PsA, physical function, and psoriasis were observed with apremilast through Week 52. The most common adverse events were diarrhea, nausea, headache, and upper respiratory tract infection.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
count had not improved by ≥20% at Week 16 were defined as nonresponders and re-randomized (1:1) to apremilast 20 mg or 30 mg if initially randomized to placebo; if initially randomized to apremilast, treatment continued without a dose change. At Week 24, all patients who were still receiving placebo were re-randomized to apremilast 20 mg or 30 mg.				
Edwards et al.[99] (2016) PALACE 3 Apremilast 20 mg BID vs apremilast 30 mg BID vs placebo	DB, PC, RCT Patients ≥18 years of age with a diagnosis of PsA with a minimum of both three swollen and three tender joints, despite prior treatment with traditional DMARDs and/or biologic treatment or concurrent treatment with traditional DMARDs	N=505 52 weeks	Primary: Proportion of patients achieving ACR20 at week 16 Secondary: Change from baseline to week 16 in HAQ-DI, safety	Primary: At week 16, significantly more apremilast 20 mg and 30 mg patients achieved an ACR20 response versus placebo (placebo: 18%; 20 mg: 28%, P=0.0295; 30 mg: 41%, P<0.0001) Secondary: Apremilast 30 mg was associated with a significant improvement in the HAQ-DI score versus placebo at week 16. Mean change from baseline in the HAQ-DI score at week 16 was −0.20 with apremilast 30 mg versus −0.07 with placebo (P=0.0073). Mean change in the HAQ-DI score with apremilast 20 mg (−0.13) did not reach statistical significance versus placebo. At week 52, observed improvements in these measures demonstrated sustained response with continued apremilast treatment. Most adverse events were mild to moderate in severity; the most common were diarrhoea, nausea, headache and upper respiratory tract infection.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rescue therapy with apremilast was designated at week 16 for placebo patients not achieving 20% improvement in swollen and tender joint counts; at week 24, the remaining placebo patients were then randomized to apremilast 20 or 30 mg twice daily				
Kavanaugh et al.[100] (2019) Extension study of PALACE I, II and III Apremilast 20 mg or 30 mg BID	OL, extension study Patients ≥18 years of age with active PsA for ≥ 6 months and three or more swollen joints and three or more tender joints despite prior treatment with DMARDs	N=1,493 5 years	Primary: Rates of patients achieving ACR 20, ACR 50 and ACR 70 responses Secondary: Changes from baseline in swollen joint count and tender joint count, Maastricht Ankylosing Spondylitis Enthesitis Score, proportions of patients achieving a dactylitis count of 0 among those with dactylitis at baseline and change in physical	Primary: Of patients receiving apremilast 30 mg BID, 55.3% achieved an ACR 20 response at week 52; at week 260, 67.2% of patients who continued apremilast treatment achieved an ACR 20 response. At week 260, 44.4% and 27.4% achieved ACR 50 and ACR 70 responses, respectively. Secondary: Mean swollen joint count and tender joint count improved by 63.3% and 49.8% at week 52, with improvements reaching 82.3% and 72.7%, respectively, with continued treatment at week 260. Among patients with enthesitis or dactylitis at baseline, mean changes in Maastricht Ankylosing Spondylitis Enthesitis Score and dactylitis at week 260 were -2.9 and -2.8, respectively. The proportions of those achieving a Maastricht Ankylosing Spondylitis Enthesitis Score of 0 or a dactylitis count of 0 increased over 52 weeks and were maintained through week 260 with continued apremilast 30 mg treatment. Improvements in physical function were maintained through week 260 in patients who continued receiving apremilast 30 mg BID, including mean change in HAQ-DI and the proportion achieving a minimal clinically important difference of ≥0.35 in the HAQ-DI score.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			function and skin involvement	Among patients involving ≥3% of the body surface area at baseline, the proportion of patients achieving PASI-75 response was generally maintained with continued treatment, with 43.6% of patients having a PASI-75 response at week 260.
Nash et al.[101] (2018) Apremilast 30 mg BID vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age with a documented diagnosis of active PsA for ≥3 months, met Classification Criteria for Psoriatic Arthritis and have at least three swollen and three tender joints, CRP of ≥0.2 mg/dL and be biological DMARD-naïve	N=219 52 weeks	Primary: ACR 20 response at 16 weeks Secondary: 28-joint DAS, morning stiffness duration and severity and physical function assessments	Primary: The ACR 20 response rate at week 16 was significantly greater in patients receiving apremilast versus placebo (38.2% [42/110] vs 20.2% [22/109]; P=0.004) with response observed at week 2 (16.4% [18/110] vs 6.4% [7/109]); P=0.025). Secondary: At week 16, apremilast-treated patients demonstrated a significant reduction from baseline in 28-joint DAS score versus placebo (P<0.0001). Reductions continued through week 24 (-1.26 vs -0.76; P=0.005). Improvements in morning stiffness duration were observed with apremilast versus placebo at week 16 (P=0.005) and week 24 (median per cent change: -33.3% vs 0.0%; P=0.001). More apremilast-treated patients showed improvement in morning stiffness severity at week 16 (P=0.015) continuing to week 24 (40.0% vs 20.2%; P=0.002). Apremilast-treated patients experienced improvements in physical disability, as assessed by various outcomes for physical function. Clinically meaningful and significant improvements were observed in physical function, as indicated by decreases in HAQ-DI score at week 16 with apremilast versus placebo (-0.21 vs -0.06; P=0.023). Decreases were observed beginning at week 2 (P=0.040). The improvements seen with apremilast continued through week 24, with a mean reduction of -0.27; however, the mean change did not reach statistical significance compared to placebo (-0.27 vs -0.17; P=0.168).
Mease et al.[102] and van der Heijde et al.[103] (2013) RAPID-PsA	DB, MC, PC, RCT Patients ≥18 years of age with adult-onset active PsA for ≥6 months despite	N=409 24 weeks	Primary: ACR 20 response at week 12, change from baseline in mTSS at week 24	Primary: A greater proportion of patients treated with CZP 200 mg every two weeks (58.0%) and CZP 400 mg every four weeks (51.9%) achieved an ACR 20 response at week 12 compared to placebo (24.3%; P<0.001 for both comparisons).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Certolizumab 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (CZP 200 mg) vs certolizumab 400 mg at weeks 0, 2, and 4 then 400 mg every 2 weeks (CZP 400 mg) vs placebo Concurrent MTX (up to 25 mg/week), SSZ (up to 3 g/day), leflunomide (up to 20 mg/day) at stable doses or oral corticosteroids (≤10 mg/day prednisone or equivalent) were allowed.	treatment with ≥1 DMARD		Secondary: ACR 20 at week 24, HAQ-DI at week 24, PASI 75 (in patients with least 3% body surface area psoriatic skin involvement) at week 24, and change from baseline in mTSS at week 24	Secondary: A greater proportion of patients treated with CZP 200 mg every two weeks (63.8%) and CZP 400 mg every four weeks (56.3%) achieved an ACR 20 response at week 24 compared to placebo (23.5%; P<0.001 for both comparisons). At week 24, improvements in HAQ-DI scores from baseline were greater in patients treated with CZP compared to placebo (combined CZP groups: -0.50 vs -0.19; P<0.001). In patients with least 3% body surface area psoriatic skin involvement at baseline, a greater proportion of patients treated with CZP 200 mg every two weeks (62.2%) and CZP 400 mg every four weeks (60.5%) achieved PASI 75 at week 24 compared to placebo (15.1%; P<0.001 for both comparisons). Prespecified imputation analysis led to an estimated mean mTSS change from baseline that was not statistically different between CZP and placebo groups (combined CZP groups: 18.3 vs 28.9; P≥0.05). Post hoc analysis using the median mTSS of the entire population to impute missing values in patients with fewer than two analyzable mTSS suggested that patients treated with CZP had reduced radiographic progression compared to placebo patients (combined CZP groups: 0.06 vs 0.28; P=0.007).
Mease et al.[104] (2000) Etanercept 25 mg twice weekly vs placebo	DB, RCT Patients 18 to 70 years of age with active PsA despite NSAID therapy	N=60 12 weeks	Primary: PsARC, PASI 75 at 12 weeks Secondary: ACR 20 response, ACR 50 response, ACR 70 response, PASI 75, and	Primary: Eighty-seven percent of etanercept treated patients met the PsARC, compared to 23% of placebo-controlled patients (P<0.0001). PASI 75 improvement was detected in 26% of etanercept-treated patients vs none of placebo treated patients (P=0.0154). Secondary: The ACR 20 was achieved by 73% of etanercept-treated patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients on stable doses of corticosteroids (equal to ≤10 mg/day of prednisone) or MTX were permitted to continue therapy.			improvement in target psoriasis lesions	compared to 13% of placebo-treated patients (P<0.0001), while approximately 48 and 5% achieved an ACR 50 response and 12% and 0% achieved an ACR 70 response, respectively (P=0.0001 for ACR 50; P value not reported for ACR 70). Of the 19 patients in each treatment group who could be assessed for psoriasis, 26% of etanercept-treated patients achieved a 75% improvement in PASI, compared to none of the placebo-treated patients (P=0.0154). Median target lesion improvements were 50 and 0%, for etanercept and placebo, respectively (P=0.0004). There were no significant differences detected in the rate of adverse events between groups.
Mease et al.[105] (2004) Etanercept 25 mg twice weekly vs placebo Patients who completed a 24 week blinded phase could elect to receive OL therapy in a 48 week extension. Patients on stable doses of corticosteroids (equal to ≤10 mg/day of	DB, MC, RCT Patients 18 to 70 years of age with active PsA despite NSAID therapy	N=205 72 weeks	Primary: ACR 20 response Secondary: ACR 50 response, ACR 70 response, change in mTSS, PsARC, PASI 75, SF-36 Health Survey, HAQ, and safety	Primary: At 12 weeks, 59% of etanercept patients met the ACR 20 improvement criteria for joint response, compared to 15% of placebo patients (P<0.0001), and results were sustained at 24 and 48 weeks. Secondary: At 24 weeks, ACR 50 and ACR 70 responses were achieved in approximately 40 and 15% of etanercept patients and 5 and 1% of placebo patients, respectively (P values not reported). The mean annualized rate of change in the mTSS with etanercept was -0.03 unit, compared to 1.00 unit with placebo (P<0.0001). A PsARC response was achieved by 72 and 70% of etanercept patients at weeks 12 and 24, respectively vs 31 and 23% of placebo patients (P values not reported). At 24 weeks, 23% of etanercept patients eligible for psoriasis evaluation achieved at least 75% improvement in the PASI, compared to 3% of placebo patients (P=0.001). SF-36 PCS scores improved more often with etanercept compared to placebo, but SF-36 MCS scores did not differ significantly between

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
prednisone) or MTX were permitted to continue therapy.				groups. HAQ scores at 24 weeks were significantly improved with etanercept (54%) over placebo (6%; P<0.0001). Injection site reactions occurred at a greater rate with etanercept than placebo (36 vs 9%; P<0.001).
Mease et al.[106] (2019) SEAM-PsA Etanercept 50 mg SC once weekly vs methotrexate 20 mg PO once weekly vs etanercept 50 mg SC and methotrexate 20 mg PO once weekly At or after 24 weeks, patients with an inadequate response to treatment received rescue therapy with etanercept plus methotrexate until week 48	DB, MC, RCT Patients ≥18 years of age with active PsA who were naive to treatment with etanercept and other biologic agents, and had no prior use of methotrexate for PsA	N=851 48 weeks	Primary: ACR 20 response at week 24 Secondary Minimal Disease Activity response, ACR 50 and ACR 70 responses at week 24	Primary: The proportion of patients achieving an ACR 20 response at week 24 was significantly greater among those receiving etanercept monotherapy compared with those receiving methotrexate monotherapy (173/284 [60.9%] versus 144/284 [50.7%]; adjusted P=0.029) and significantly greater among those receiving combination therapy compared with those receiving methotrexate monotherapy (184/283 [65.0%] versus 144/284 [50.7%]; adjusted P=0.005). Secondary: The proportion of patients achieving a Minimal Disease Activity response at week 24 was significantly greater among patients receiving etanercept monotherapy compared with those receiving methotrexate monotherapy (102/284 [35.9%] versus 6/2845 [22.9%]; adjusted P=0.005) and significantly greater among those receiving combination therapy compared with those receiving methotrexate monotherapy (101/283 [35.7%] versus 65/284 [22.9%]; adjusted P=0.005). The proportion of patients achieving an ACR 50 response at week 24 was greater for the etanercept monotherapy group compared with the methotrexate monotherapy group (114/257 [44.4%] versus 77/252 [30.6%]; unadjusted P =0.006) and for the combination therapy group compared with the methotrexate monotherapy group (117/256 [45.7%] versus 77/252 [30.6%]; unadjusted P<0.001). The proportion of patients achieving an ACR 70 response at week 24 was greater with etanercept monotherapy compared with methotrexate monotherapy (75/257 [29.2%] versus 35/253 [13.8%]; unadjusted P<0.001) and greater with combination therapy compared with methotrexate monotherapy (71/256 [27.7%] versus 35/253 [13.8%];

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				unadjusted P<0.001).
Kavanaugh et al.[107] (2009) GO-REVEAL Golimumab 50 mg SC once every 4 weeks vs golimumab SC 100 mg once every 4 weeks vs placebo Patients who had used or were currently using MTX, an NSAID, an oral corticosteroid, or a systemic or topical psoriasis treatment were enrolled.	MC, PC, RCT Patients ≥18 years of age with a diagnosis of PsA and active PsA despite current or previous DMARD or NSAID therapy and no evidence of active TB and/or no evidence of latent TB on screening	N=405 24 weeks	Primary: ACR 20 response at week 14 Secondary: Not reported	Primary: Golimumab 50 mg with or without MTX compared to placebo with or without MTX, resulted in a significant improvement in signs and symptoms as demonstrated by ACR 20 response at week 14 (51 vs 9%; P<0.001). Similar ACR 20 responses at week 14 were observed in patients with different PsA subtypes. ACR responses observed in the golimumab treated groups were similar in patients receiving and not receiving concomitant MTX. Secondary: Not reported
Antoni et al.[108] (2005) IMPACT 2 Infliximab 5 mg/kg at weeks 0, 2, 6, 14 and 22 vs	DB, MC, PC, PG, RCT Patients ≥18 year of age with active PsA for ≥6 months, inadequate response to current or previous DMARDs	N=200 24 weeks	Primary: ACR 20 response at week 14 Secondary: PsARC, PASI 75, duration of morning stiffness, dactylitis in hands	Primary: At week 14, there was significantly more patients in the infliximab group that achieved an ACR 20 response (58%) compared to the placebo group (11%; P<0.001). This difference continued through week 24 (54 vs 16%; P<0.001). Secondary: A significantly greater percentage of patients in the infliximab treated group had improvement in PsARC (77%) compared to the placebo group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	or NSAIDs, ≥1 qualifying lesion and negative serum RF		and feet, and presence or absence of enthesopathy in the feet and SF-36	(27%; P<0.001) at week 14 and continued through week 24 (70 vs 32%; P<0.001). At weeks 14 and 24, fewer patients in the infliximab group had digits with dactylitis (18 and 12%) compared to the placebo group (30 and 34%; P=0.025 and P<0.001, respectively). Fewer patients in the infliximab group had enthesopathy compared to the placebo group at week 14 (22 vs 34%; P=0.016) and week 24 (20 vs 37%; P=0.002). A significantly higher proportion of patients achieved PASI 75 in the infliximab group compared to the placebo group at weeks 14 and 24 (64 vs 2%; P<0.001 and 60 vs 1%; P<0.001, respectively). At week 14, the physical and mental components of the SF-36 were significantly improved in the infliximab group compared to the placebo group (both P<0.001). There was also significant improvement at week 24 in the physical and mental components of the SF-36 in the infliximab group compared to the placebo group (P<0.001 and P=0.047, respectively). Adverse events were similar between the groups. There were a higher proportion of patients who discontinued treatment due to adverse events in the infliximab group compared to the placebo group (4 vs 1%). There were a greater number of patients in the infliximab group that had increased ALT compared to the placebo group (1 vs 6%).
Baranauskaite et al.[109] (2012) RESPOND Infliximab 5 mg/kg infusions at weeks 0, 2, 6 and 14 plus MTX 15 mg/week	MC, OL, PC, PRO Patients ≥18 years of age who were treatment naïve and had active psoriasis in combination with peripheral articular disease with ≥1 of the	N=115 16 weeks	Primary: Proportion of patients achieving an ACR 20 response at week 16 Secondary: Proportions of patients with ACR	Primary: In the ITT analysis, an ACR 20 response at week 16 was achieved by significantly more patients treated with infliximab plus MTX compared to patients treated with MTX alone (86.3 vs 66.7%; P=0.021). Secondary: The ACR 50 (72.5 vs 39.6%; P=0.0009) and ACR 70 (49.0 vs 18.8%; P=0.0015) response rates at week 16 were also significantly higher in the infliximab plus MTX group at 16 weeks compared to those receiving MTX alone.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs MTX 15 mg/week The use of NSAIDs and oral steroids (maximum dose 10 mg/day of prednisone or equivalent) was allowed if the dose was stable within four weeks before screening and kept stable throughout the study.	following for three or more months before screening: distal interphalangeal joint involvement; polyarticular arthritis in the absence of rheumatoid nodules; arthritis mutilans; or asymmetric peripheral arthritis		50 and ACR 70 responses, PASI 75 in patients whose baseline PASI was 2.5 or greater, EULAR response, DAS28 scores, number of digits with dactylitis, Maastricht AS enthesitis score, fatigue scores, and duration of morning stiffness and safety	In patients with a PASI ≥2.5 or at baseline, a PASI 75 response at week 16 occurred in 97.1% of patients receiving infliximab plus MTX compared to 54.3% of patients receiving MTX alone (P<0.0001). By week 16, the mean reduction in PASI score was 93.3% for patients treated with infliximab plus MTX compared to 67.4% of patients treated with MTX alone (P=0.0029). The mean DAS28 at week 16 improved by 56.5% in the infliximab plus MTX patients compared to 29.7% of patients receiving MTX alone (P<0.0001). The EULAR response at week 16 was achieved in 98% of patients receiving infliximab plus MTX compared to 72.9% of those receiving MTX alone (P<0.0001). A median reduction of two digits with dactylitis was observed at week 16 in the patients treated with infliximab plus MTX, while no reduction was observed in the MTX monotherapy group (P=0.0006). Patients treated with infliximab plus MTX experienced a median reduction of two sites with enthesitis at week 16 compared to a reduction of one site in the MTX alone group (P=0.082). A significantly greater reduction from baseline in fatigue scores occurred in the infliximab plus MTX group compared to the MTX monotherapy group at week 16 (70.8 vs 44.0%, respectively; P=0.0003). At week 16, the median change in the duration of morning stiffness was -0.92 hour with combination treatment vs -0.50 hour with MTX alone (P=0.0015). The incidence of adverse events was higher in patients receiving infliximab plus MTX compared to MTX alone. Most adverse events were mild or moderate in severity. One adverse event in each group was considered

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				severe: increased transaminases in the infliximab plus MTX group and renal colic in the MTX-alone group. Treatment related adverse events were reported in 45.6% of the infliximab plus MTX group and 24.1% in the MTX alone group. The most frequent treatment-related adverse event involved hepatic enzyme increases.
Mease et al.[110] (2017) Tofacitinib 5 mg orally twice daily vs tofacitinib 10 mg orally twice daily vs adalimumab 40 mg dose administered SC once every two weeks vs placebo with a blinded switch to the 5 mg tofacitinib dose at three months vs placebo with a blinded switch to the 10 mg tofacitinib dose at three months	AC, DB, RCT Patients ≥18 years of age with active PsA who previously had an inadequate response to conventional synthetic DMARDs Patients were required to receive a stable background dose of a single conventional synthetic DMARD (methotrexate, sulfasalazine, or leflunomide)	N=422 12 months	Primary: ACR20 and HAQ-DI at month three Secondary: ACR50, ACR70, PASI75 at month three	Primary: At three months, the rate of ACR20 response was 50% in the 5 mg tofacitinib group and 61% in the 10 mg tofacitinib group, as compared with 33% in the placebo group (P=0.01 for the comparison of the 5 mg tofacitinib dose with placebo; P<0.001 for the comparison of the 10 mg dose with placebo). The mean change from baseline in the HAQ-DI score was −0.35 in the 5 mg tofacitinib group and −0.40 in the 10 mg tofacitinib group, as compared with −0.18 in the placebo group (P=0.006 for the comparison of the 5 mg dose with placebo; P<0.001 for the comparison of the 10 mg dose with placebo). Adalimumab resulted in an ACR20 response rate of 52% and in a mean change in the HAQ-DI score of −0.38. Secondary: At month three, the rates of ACR50 response were significantly higher in each tofacitinib group (28% in the 5 mg tofacitinib group and 40% in the 10 mg tofacitinib group) than in the placebo group (10%; P<0.001 for both comparisons), as were the rates of ACR70 response (17% in the 5 mg tofacitinib group and 14% in the 10 mg tofacitinib group, vs 5% in the placebo group; P=0.004 for the comparison of the 5 mg dose with placebo; P=0.02 for the comparison of the 10 mg dose with placebo), and improvements were observed across all ACR components. Adalimumab resulted in an ACR50 response rate of 33% and an ACR70 response rate of 19%. Sequential hierarchical testing of the key secondary end points at month three showed a significantly higher rate of PASI75 response in each tofacitinib group than in the placebo group (P<0.001 for both comparisons).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Gladman et al.[111] (2017) OPAL Beyond Tofacitinib 5 mg orally twice daily vs tofacitinib 10 mg orally twice daily vs placebo, with a switch to 5 mg of tofacitinib twice daily at three months vs placebo, with a switch to 10 mg of tofacitinib twice	DB, MC, PC, RCT Patients ≥18 years of age with a diagnosis of psoriatic arthritis at least six months previously, active plaque psoriasis at baseline, and an inadequate response to at least one TNF inhibitor Patients were required to receive a stable background dose of a single conventional synthetic DMARD (methotrexate, sulfasalazine, or leflunomide)	N=395 6 months	Primary: ACR20 and HAQ-DI at month three Secondary: ACR50, ACR70, PASI75 at month three	Primary: At three months, the rates of ACR20 response were 50% with the 5 mg dose of tofacitinib and 47% with the 10 mg dose of tofacitinib, as compared with 24% with placebo (P<0.001 for both comparisons), and the corresponding mean changes in HAQ-DI score from baseline were −0.39 and −0.35, as compared with −0.14 (P<0.001 for both comparisons). Secondary: The 5 mg and 10 mg doses of tofacitinib yielded a higher response rate than placebo at three months with respect to the ACR50 (P=0.003 and P=0.007, respectively), but not the ACR70. The 10 mg dose of tofacitinib, but not the 5 mg dose, showed a higher rate than placebo with respect to PASI75 response at three months (P<0.001).
Rheumatoid Arthritis				
Westhovens et al.[112] (2009) Abatacept intravenous ~10 mg/kg on days 1, 15 and 29 then every four weeks plus MTX 15 mg/weekly	DB, MC, PC, RCT Patients ≥18 years of age with RA for ≤2 years and ≥12 tender and 10 swollen joints, CRP ≥0.45 mg/dL, RF and/or anti-CCP2 seropositivity	N=509 24 months	Primary: Remission rates (DAS28 <2.6) and structural damage at year one (Genant-modified Sharp scoring system maximum score of 290)	Primary: A significantly higher proportion of patients in the abatacept group achieved DAS28-defined remission compared to the placebo group after one year of treatment (41.4 vs 23.3%, respectively; P<0.001). The mean change in structural damage at year one, measured using the Genant-modified Sharp scoring system total scores, was significantly lower in patients treated with abatacept compared to patients treated with placebo (0.63 vs 1.06, respectively; P=0.040).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo plus MTX 15 mg/weekly	and radiographic evidence of bone erosion of the hands/wrists/feet; patients were either MTX-naive or had previous exposure of 10 mg/week or less for three weeks or less, with none administered		Secondary: ACR 50 responses, MCR (ACR 70 maintained for >6 consecutive months); DAS28 scores, erosion score (maximum possible 145) and joint-space narrowing score (JSN; maximum possible 145), physical function (improvement of >0.3 units from baseline in the; HAQ-DI), SF-36 scores, proportion of patients achieving ACR 70 and ACR 90 responses, and the proportion of patients without radiographic progression and safety	Secondary: A higher proportion of patients treated with abatacept achieved an ACR 50 (57.4 vs 42.3%; P<0.001), ACR 70 (42.6 vs 27.3%; P<0.001) and ACR 90 (16.4 vs 6.7%; P=0.001) compared to patients treated with placebo after one year of treatment. After one year of abatacept therapy, 27.3% of patients achieved an MCR (ACR 70 maintained for more than six consecutive months) compared to 11.9% of patients receiving placebo alone (P<0.001). Following one year of abatacept treatment, disease activity was significantly reduced compared to patients receiving placebo (-3.22 vs -2.49; P<0.001). Patients treated with abatacept achieved significantly greater improvements from baseline in total score and erosion score compared to patients randomized to the placebo group (P=0.040 and P=0.033, respectively). The changes from baseline in JSN scores were similar between the abatacept and placebo groups (P=0.246). The proportion of patients with no radiographic progression in the abatacept group at one year was 61.2% (95% CI, 55.0 to 67.3) compared to the group receiving placebo 52.9% (95% CI, 46.6 to 59.2), with an estimated difference of 8.3% (95% CI, 21.0 to 17.5). A significantly greater proportion of patients in the abatacept group compared to the placebo group experienced a change from baseline in HAQ-DI score ≥0.3 units following one year of therapy (71.9 vs 62.1%; P=0.024). Abatacept treatment was associated with statistically significant improvements in the mental and physical components of the SF-36 questionnaire compared to the placebo group (P<0.05 for both). The most frequently reported adverse events in the abatacept group were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				nausea, upper respiratory tract infection and headache. Six deaths were reported; two (0.8%) in the abatacept group and four (1.6%) in the placebo Of the two deaths in the abatacept group, one patient had pneumonia and severe gastrointestinal bleeding and the other had an acute myocardial infarction. The most frequent infections in patients treated with abatacept and placebo respectively, were upper respiratory tract infection in 26 (10.2%) and 26 (10.3%) patients, nasopharyngitis in 21 (8.2%) and 26 (10.3%) patients and influenza in 19 (7.4%) and 23 (9.1%) patients. Serious infections occurred in five (2.0%) abatacept-treated patients (pneumonia, gastroenteritis, cellulitis, pseudomonal lung infection and postoperative wound infection, one patient each) and five (2.0%) patients receiving placebo (pneumonia, three patients; gastroenteritis, one patient; and breast cellulitis and staphylococcal infection, both in the same patient). No patients in the abatacept group discontinued due to an infection. In the abatacept treatment group, autoimmune disorders were reported in six patients compared to five patients in the placebo group. Sixteen patients in the abatacept treatment group experienced infusion related reaction compared to five patients receiving placebo.
Genovese et al.[113] (2011) ACQUIRE Abatacept subcutaneous 125 mg days 1 and 8 then weekly (intravenous loading dose of ~10 mg/kg was also administered on day 1) vs	DB, DD, MC, RCT Patients with RA (defined by ACR 1987 criteria) and functional class I, II and III (defined by ACR 1991 revised criteria) that had an inadequate response to ≥3 months of MTX therapy (≥15 mg/week), with ≥10 swollen joints, ≥12 tender joints and CRP ≥0.8 mg/dL	N=1,457 6 months	Primary: Proportion of patients achieving ACR 20 at six months Secondary: Proportion of patients achieving ACR 50 and ACR 70	Primary: The proportion of patients achieving ACR 20 with abatacept subcutaneous (76.0%; 95% CI, 72.9 to 79.2) and abatacept intravenous (75.8%; 95% CI, 72.6 to 79.0) was not significantly different (estimated between group difference, 0.3%; 95% CI, -4.2 to 4.8). Secondary: The proportion of patients achieving ACR 50 with abatacept subcutaneous and abatacept intravenous (51.5 vs 50.3%) was not significantly different. The proportion of patients achieving ACR 70 with abatacept subcutaneous and abatacept intravenous (26.4 vs 25.1%) was not significantly different. Adverse events were also similar between the groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
abatacept intravenous ~10 mg/kg on days 1, 15 and 29 then every 4 weeks				
Genovese et al.[114] (2018) ACQUIRE extension study Abatacept SC 125 mg weekly	OL, extension study All patients who completed the 6-month DB period from ACQUIRE study	N=1,372 5 years (including initial 6 month DB period)	Primary: Safety, tolerability and efficacy at 5 years Secondary: Not reported	Primary; During long term extension five-year period, 97 (7.1%) patients discontinued treatment because of an adverse event. Incidence rate (IR; event/100 patient-years of exposure; based on long term extension data, 95% CI) for adverse events of interest were the following: serious adverse events 7.73 (6.96 to 8.58), infection 38.60 (36.24 to 41.12), serious infection 1.68 (1.35 to 2.07), malignancies 1.09 (0.84 to 1.42), and autoimmune disorders 1.33 (1.05 to 1.69) and were stable over time. Immunogenicity was assessed in 1,365 patients; during the long-term extension period, a total of 316 (23.2%) patients were positive for anti-abatacept antibodies. No association between immunogenicity and either worsening of abatacept safety or loss of efficacy was noted. Efficacy in the long-term extension was consistent with the DB period and was maintained to the end of the study. As-observed ACR 20, 50, and 70 responses at Day 169 were 80.1% (1,087/1,357), 53.2% (724/1,362), and 27.2% (371/13,62), and at Day 1,821 were 84.6% (356/421), 65.5% (277/423), and 44.9% (191/425), respectively. Secondary: Not reported
Keystone et al.[115] (2012) ATTUNE Abatacept 125 mg subcutaneously once weekly	OL Patients ≥18 years of age with active RA previously refractory to either MTX or anti-TNFs who had received ≥4 years of intravenous abatacept in either	N=128 12 months	Primary: Safety at three months Secondary: Immunogenicity at three months, and efficacy at 12 months	Primary: Up to month three, adverse events occurred in 39.8% of patients; no individual adverse events were reported in ≥5% of patients. One adverse event (musculoskeletal pain) led to discontinuation. Overall, 75.6% of patients experienced an adverse event during the cumulative period. After month three, 12 further adverse events were reported, of which three led to discontinuation (breast cancer, sarcoidosis and brain neoplasm). No deaths were reported in the study or during follow-up.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	of two previous RCTs			Infections reported up to month three (more than one patient) included nasopharyngitis (n=4), urinary tract infection (n=3), bronchitis (n=2), gastroenteritis (n=2), sinusitis (n=2) and upper respiratory tract infection (n=2). No serious infections, malignancies or autoimmune events were reported during the first three months. Serious infections, malignancies or autoimmune events occurring after month three were as follows: one serious infection (pneumonia)), two malignancies (breast and uterine cancer) and two autoimmune events occurred (sarcoidosis and erythema nodosum). Secondary: Eight patients were seropositive based on ELISA through month three. Of these eight, six were already positive prior to enrolment. All seropositive patients continued treatment. Adverse events experienced by the seropositive patients were not consistent with immune-mediated toxicities, except for one patient who developed sarcoidosis and discontinued treatment. None of these patients had an abatacept-induced seropositive result based on the ECL assay. At baseline, mean DAS28 and HAQ-DI scores in the overall population were 3.39 and 0.94, respectively. Improvements in disease activity and physical function achieved during intravenous treatment were maintained through month 12 of subcutaneous treatment.
Haraoui et al.[116] (2011) CanACT Adalimumab 40 mg subcutaneously every other week	MC, OL, PRO Patients ≥18 years of age with RA diagnosed according to the 1987 revised ACR criteria with active disease, (≥5 swollen joints (of 66 joints evaluated) and one of the following: positive RF, ≥1 joint erosions present	N=879 12 weeks	Primary: Mean change in DAS28 Secondary: Proportion of patients achieving clinical remission (DAS28 <2.6) and low-disease activity (DAS28 <3.2) at week 12, proportion	Primary: Patients treated with adalimumab achieved significantly lower DAS28 scores at week 12 compared to baseline (4.2 vs 6.1; P<0.001). Secondary: Following 12 weeks of treatment with adalimumab, 15.3 and 28.9% of patients achieved clinical remission (DAS28 <2.6) and low-disease activity (DAS28 <3.2), respectively (P values not reported). At week 12, 25.9% of patients treated with adalimumab were considered EULAR responders to treatment. The proportion of patients who experienced an ACR 20, ACR 50 and ACR 70 response at 12 weeks was 58.4, 30.6 and 12.7%, respectively (P

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	on x-ray, or a HAQ-DI score ≥1 and an unsatisfactory responses or intolerance to prior antirheumatic therapies		achieving EULAR-moderate and good response, ACR 20, ACR 50, and ACR 70) responses at weeks four, eight, and 12, mean changes in ACR core components [tender joint count, swollen joint count, ESR, physician and patient assessments, and HAQ-DI	values not reported). At week eight, the proportion of patients who experienced an ACR 20, ACR 50 and ACR 70 response was 52.2, 21.7 and 7.2%, respectively (P values not reported). At week four, the proportion of patients who experienced an ACR 20, ACR 50 and ACR 70 response, was 37.6, 10.6 and 2.4%, respectively (P values not reported). Patients treated with adalimumab experienced a decrease in the number of tender joints at week 12 compared to baseline (6.8 vs 19.9; P value not reported) and the number of swollen joints was reduced from 13.2 at baseline to 6.4 after 12 weeks (P value not reported). As measured on a VAS, patient's assessment of pain decreased from a 66.2 at baseline to 37.3 following adalimumab therapy. Patients' assessment of disease activity decreased from 65.1 at baseline to 37.4 at follow up. Similarly physician assessment of disease activity decreased from 63.6 at baseline to 29.0 (P values not reported). The mean HAQ-DI score improved by an average of 0.5 units from 1.5 at baseline to 1.0 after 12 weeks of adalimumab treatment. In addition, the ESR decreased from a mean of 30.3 mm/h at baseline to 20.0 mm/h at 12 weeks (P<0.001). Adverse events were reported in 43.4% of patients treated with adalimumab. Most adverse events were mild to moderate in intensity. The most commonly reported adverse events were injection site reactions (9.9%), headache (5.2%), injection site erythema (3.5%), nausea (3%) and rash (2.8%). Of the treatment-emergent adverse events considered by the investigator to be related to study drug, injection site reaction and headache were the most frequently reported (≥5% of patients).
Keystone et al.[117] (2013) Adalimumab 40 mg	ES, OL Patients ≥18 years of age with RA	N=202 10 years	Primary: ACR 20, ACR 50, ACR 70, DAS28-CRP <3.2, clinical	Primary: At year 10, 64.2, 49.0, and 17.6% of patients achieved ACR 50, ACR 70, and ACR 90 responses, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
subcutaneous injection every other week vs placebo All patients received concurrent MTX therapy.	(defined by ACR 1987 criteria) despite ≥3 months of MTX (12.5 to 25 mg/week), tender joint count ≥9 out of 68, swollen joint count ≥6 out of 66, CRP ≥1 mg/L, and positive for RF or at least one bony erosion		remission (DAS 28-CRP <2.6 or SDAI ≤3.3), SDAI, HAQ-DI score, and mTSS at 10 years Secondary: Not reported	Mean DAS28-CRP was 2.6, with 74.1% achieving DAS28-CRP <3.2 at year 10. The proportions of patients achieving DAS28-CRP and SDAI clinical remission states were 59.0 and 33.2%, respectively. From baseline to year 10, mean HAQ-DI was reduced by 50%, with 42.2% of patients achieving HAQ-DI <0.5 or normal functionality. Mean change from baseline to year 10 in mTSS was 2.8 units (annual progression rate of approximately 0.3 units/year), suggesting minimal radiographic progression over 10 years. Secondary: Not reported
Genovese et al.[118] (2016) RA-BEACON Baricitinib 4 mg PO daily vs baricitinib 2 mg PO daily vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with IR to ≥1 prior TNF blocker, 6/68 tender joints and 6/66 swollen joints, and hsCRP≥3.6 mg/L without prior biologic DMARD use in one month prior to randomization	N= 527 24 weeks	Primary: Proportion of patients achieving ACR20 at week 12 Secondary: Proportion of patients achieving: DAS28-CRP score ≤3.2 and <2.6, SDAI remission ≤3.3, ACR20/50/70 response rate	Primary: At 12 weeks, there was a greater proportion of patients treated with baricitinib achieving ACR20 at 55% for baricitinib 4 mg, 49% for baricitinib 2 mg, and 27% for placebo (P≤0.001 for both baricitinib groups). Secondary: There was a greater proportion of patients in the baricitinib groups who achieved improvement in DAS28-CRP (16% and 11% vs 4%), ACR50 response rate (28% and 20% vs 8%), and ACR70 response rate (11% and 13% vs 2%) at week 12 compared to placebo (P≤0.01).
Dougados et al.[119] (2016) RA-BUILD Baricitinib 4 mg PO daily plus	DB, MC, PC, RCT Patients ≥18 years of age with IR to ≥1 prior conventional DMARD, ≥3	N= 684 24 weeks	Primary: Proportion of patients achieving ACR20 at week 12 Secondary:	Primary: At 12 weeks, there was a greater proportion of patients treated with baricitinib achieving ACR20 at 62% for baricitinib 4 mg, 66% for baricitinib 2 mg, and 40% for placebo (P≤0.001 for both baricitinib groups).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
conventional DMARD vs baricitinib 2 mg PO daily plus conventional DMARD vs placebo plus conventional DMARD	erosions, 6/68 tender joints and 6/66 swollen joints, and hsCRP≥3.6 mg/L without prior biologic DMARD use		Proportion of patients achieving: DAS28-CRP score ≤3.2 and <2.6, SDAI remission ≤3.3, ACR50/70 response rate	Secondary: There was a greater proportion of patients in the baricitinib groups who achieved improvement in DAS28-CRP (26% and 26% vs 9%), SDAI remission (9% and 9% vs 1%), ACR50 response rate (33% and 34% vs 13%), and ACR70 response rate (18% and 18% vs 3%) at week 12 compared to placebo (P≤0.001 for both baricitinib groups).
Taylor et al.[120] (2017) RA-BEAM Baricitinib 4 mg PO daily vs adalimumab 40 mg SQ every two weeks vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with IR to MTX, RF and ACPA positive, ≥3 erosions, 6/68 tender joints and 6/66 swollen joints, and hsCRP≥6 mg/L without prior biologic DMARD use	N= 1,307 52 weeks	Primary: Proportion of patients achieving ACR20 at week 12 Secondary: Proportion of patients achieving: DAS28-CRP score ≤3.2 and <2.6, SDAI remission ≤3.3, ACR20/50/70 response rate	Primary: At 12 weeks, there was a greater proportion of patients treated with baricitinib achieving ACR20 compared to placebo at 70% for baricitinib and 40% for placebo (P≤0.001). Secondary: There was a greater proportion of patients in the baricitinib group who achieved improvement in DAS28-CRP (24% vs 4%), SDAI remission (8% vs 2%), ACR50 response rate (45% vs 17%), and ACR70 response rate (19% vs 5%) at week 12 compared to placebo (P≤0.001). There was a greater proportion of patients in the baricitinib group who achieved DAS28-CRP ≤3.2 (44% versus 35%) and ACR50 response rate (45% versus 35%) at week 12 compared to adalimumab (P≤0.01). Additionally, there was a greater proportion of patients treated with baricitinib who achieved SDAI ≤11 (42% versus 35%) and ACR70 response rate (19% versus 13%) at week 12 compared to adalimumab (P≤0.05).
Fleischmann et al.[121] (2017) RA-BEGIN	DB, MC, AC, RCT Patients ≥18 years of age with early	N=584 52 weeks	Primary: Noninferiority comparison based on proportion of	Primary: At 24 weeks, there was a greater proportion of patients achieving ACR20 compared to methotrexate at 77% for baricitinib and 62% for methotrexate (P≤0.001 for noninferiority and P≤0.01 for superiority).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Baricitinib 4 mg PO daily vs baricitinib 4 mg PO daily plus MTX vs MTX	active RA, RF or ACPA positive, 6/68 tender joints and 6/66 swollen joints, and limited MTX treatment up to three weeks		patients achieving ACR20 at week 24 Secondary: Proportion of patients achieving: DAS28-CRP score ≤3.2 and <2.6, improvements in HAQ-DI score, SDAI remission ≤3.3, ACR50/70 response rate	Secondary: There was a greater proportion of patients in the baricitinib monotherapy and baricitinib with MTX groups who achieved improvement in DAS28-CRP (40% vs 24%), HAQ-DI score (77% vs 66%), SDAI remission (22% vs 10%), ACR50 response rate (60% vs 43%), and ACR70 response rate (42% vs 21%) at week 24 compared to MTX (P≤0.05 for all comparisons). There was a greater proportion of patients in the baricitinib monotherapy and baricitinib with MTX groups who achieved improvement in DAS28-CRP (44% vs 24%), HAQ-DI score (65% vs 43%), SDAI remission (25% vs 13%), ACR50 response rate (57% vs 38%), and ACR70 response rate (42% vs 25%) at week 52 compared to MTX (P≤0.05 for all comparisons).
Keystone et al.[122] (2008) RAPID 1 Certolizumab 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks plus MTX (CZP 200 mg) vs certolizumab 400 mg at weeks 0, 2, and 4 then 400 mg every 2 weeks plus MTX (CZP 400 mg) vs placebo plus MTX Patients were randomized 2:2:1.	DB, MC, PG, RCT Patients ≥18 years of age with a diagnosis of RA (defined by ACR 1987 criteria), for ≥6 months and up to 15 years with active disease despite treatment with MTX	N=982 52 weeks	Primary: ACR 20 at 24 weeks, mean change from baseline in mTSS at 52 weeks Secondary: Mean change from baseline in mTSS at 24 weeks, HAQ-DI, ACR 20 at 52 weeks, ACR 50, and ACR 70 at 24 weeks	Primary: A significantly greater number of ACR 20 responders at 24 weeks were found in the CZP 200 mg group (58.8%) and CZP 400 mg group (60.8%) compared to the placebo group (13.6%; P<0.001). There was no significant difference detected between the two CZP regimens. mTSS were significantly lower with CZP 200 mg (0.4 Sharp units) and 400 mg (0.2 Sharp units) vs placebo (2.8 Sharp units; P<0.001). Secondary: Active treatment was associated with reduced mTSS at 24 weeks compared to placebo (0.2 Sharp units for 200 and 400 mg vs 1.3 Sharp units for placebo; P<0.001). The HAQ-DI score at 52 weeks was -0.60 with CZP 200 mg, -0.63 with CZP 400 mg and -0.18 with placebo (P<0.001). ACR 20 response remained significantly higher with CZP 200 mg over 52 weeks (P<0.001 vs placebo). A significantly greater proportion of individuals achieved ACR 50 and ACR 70 with CZP 200 mg (37.1 and 21.4%) and CZP 400 mg (39.9 and 20.6%) compared to placebo (7.6 and 3.0%; P<0.001) at week 24. Infections and infestations occurred in 56.4% of CZP 200 mg patients,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Concurrent analgesics, NSAIDs or COX2 inhibitors, or oral corticosteroids (≤10 mg/day of prednisone or equivalent) were allowed.				58.4% of CZP 400 mg patients and 56.9% of placebo patients with serious infections occurring in 5.3, 7.3 and 2.2% of CZP 200 mg, 400 mg and placebo patients, respectively. The most frequent adverse events reported included headache, hypertension and back pain.
Smolen et al.[123] (2009) RAPID 2 Certolizumab 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks plus MTX (CZP 200 mg) vs certolizumab 400 mg at weeks 0, 2, and 4 then 400 mg every 2 weeks plus MTX (CZP 400 mg) vs placebo plus MTX Patients were randomized 2:2:1. Concurrent analgesics, NSAIDs	DB, MC, RCT Patients ≥18 years of age with a diagnosis of RA (defined by ACR 1987 criteria) for ≥6 months and up to 15 years with active disease despite treatment with MTX	N=619 24 weeks	Primary: ACR 20 at 24 weeks Secondary: ACR 50, ACR 70, mTSS, SF-36 Health Survey and individual ACR core set variables, and safety	Primary: ACR 20 was attained by significantly more individuals receiving CZP 200 mg (57.3%) and CZP 400 mg (57.6%) compared to placebo (8.7%; P≤0.001). Secondary: ACR 50 and ACR 70 were achieved in a significantly greater number of patients in the CZP 200 mg group (32.5 and 15.9%, respectively) and CZP 400 mg group (33.1 and 10.6%, respectively) vs placebo (3.1 and 0.8%, respectively; P≤0.01). CZP 200 mg (0.2; 95% CI, -1.0 to 0.6) and CZP 400 mg (-0.4 mg; 95% CI, -0.7 to -0.1) were associated with a significantly lower change in mTSS than placebo (1.2; 95% CI, 0.5 to 2.0; P≤0.01 compared to CZP 200 mg; P≤0.001 compared to CZP 400 mg). Active treatment resulted in greater improvements in SF-36 scores vs placebo (P<0.001) and ACR core components vs placebo (P<0.001). Serious infection was reported in 3.2% of CZP 200 mg patients, 2.4% of CZP 400 mg patients and 0% of placebo patients. Tuberculosis was reported in five patients receiving certolizumab.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
or COX2 inhibitors, or oral corticosteroids (≤10 mg/day of prednisone or equivalent) were allowed.				
Fleischmann et al.[124] (2009) FAST4WARD Certolizumab 400 mg every 4 weeks vs placebo Concurrent analgesics, NSAIDs, or oral corticosteroids (≤10 mg/day of prednisone or equivalent) were allowed.	DB, MC, RCT Patients 18 to 75 years of age with adult onset RA (defined by ACR 1987 criteria) for ≥6 months, with active disease and failed at least one prior DMARD	N=220 24 weeks	Primary: ACR 20 at 24 weeks Secondary: ACR 50, ACR 70, ACR component scores, DAS 28, patient reported outcomes, and safety	Primary: ACR 20 achievement at 24 weeks was significantly higher with certolizumab (45.5%) than placebo (9.3%; P<0.001). Secondary: A significantly greater proportion of ACR 50 and ACR 70 responders were found in the active treatment group vs the placebo group (22.7 vs 3.7%; P<0.001 and 5.5 vs 0%; P≤0.05, respectively). A significant improvement in all ACR components was also detected among patients on certolizumab vs placebo (P≤0.05). A significantly greater change in DAS 28 was also reported with active treatment (-1.5 vs -0.6 for placebo; P<0.001). Patients reported significant improvements in physical function with certolizumab as measured by HAQ-DI (P<0.001), arthritis pain (P≤0.05) and fatigue (P<0.001). Headache, nasopharyngitis, upper respiratory tract infections, diarrhea and sinusitis occurred in at least 5% of certolizumab patients. There were no reports of tuberculosis or opportunistic infections throughout the study.
Weinblatt et al.[125] (2012) REALISTIC Certolizumab 400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks	DB, MC, RCT Patients ≥18 years of age with adult onset RA (defined by ACR 1987 criteria) for ≥3 months, with active disease and failed at	N=1063 12 weeks	Primary: ACR 20 at 12 weeks Secondary: ACR 50, ACR 70, DAS 28, and ACR component scores	Primary: ACR 20 achievement at 12 weeks was significantly higher with certolizumab (51.1%) than placebo (25.9%; P < 0.001). Secondary: A significantly greater proportion of ACR 50 and ACR 70 responders were found in the active treatment group vs the placebo group (26.6 vs 9.9%; P<0.001 and 13.0 vs 2.8%; P<0.001, respectively). A significant improvement in all ACR components was also detected among patients on

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	least one prior DMARD			certolizumab vs placebo (P≤0.05). At 12 weeks, 81.1% of patients on certolizumab achieved a DAS28 improvement of at least 1.2 vs 56.5% with placebo (P<0.001). The most common AEs reported were nausea, upper respiratory tract infections, flare of RA and headaches. Injection and infusion-site reactions occurred in 5.8% of certolizumab patients and 1.0% placebo patients.
Emery et al.[126] (2017) C-EARLY Certolizumab pegol 400 mg SC at weeks 0, 2, 4, then 200 mg every 2 weeks + dose-optimized MTX (CZP+MTX) vs placebo + dose-optimized MTX (PBO+MTX)	DB, MC PC, RCT Patients ≥18 years of age with moderate-to-severe, active, progressive RA with poor prognostic who were DMARD-naïve and had ≤1 year of active RA	N=879 52 weeks	Primary: Proportion of patients with sustained remission (DAS28-ESR <2.6 at both weeks 40 and 52) Secondary: Proportion of patients with sustained low disease activity (DAS28-ESR ≤3.2 at both weeks 40 and 52); hierarchical testing procedure were ACR50 response, change from baseline in HAQ-DI and change from baseline in mTSS, all at Week 52	Primary: Sustained remission was achieved by 28.9% CZP+MTX patients versus 15.0% PBO+MTX patients (P<0.001). Secondary: Sustained low disease activity was achieved by 43.8% CZP+MTX patients versus 28.6% in the PBO+MTX group (P<0.001). All secondary endpoints showed statistically significant differences for CZP+MTX versus PBO+MTX at Week 52, respectively: more patients achieved ACR50 response (61.8 vs 52.6%, P=0.023), greater improvements in physical function (change from baseline in HAQ-DI: −1.00 vs −0.82, P<0.001; HAQ-DI normative function: 48.1 vs 35.7%, P=0.002) and significant inhibition of radiographic progression (change from baseline in mTSS: 0.2 vs 1.8, P<0.001).
Tanaka et al.[127] (2012) GO-FORTH	DB, MC, PC, RCT Patients 20 to 75 years of age with	N=269 24 weeks	Primary: Proportion of patients achieving ACR 20 at week 14	Primary: There was a significantly higher proportion of patients achieving an ACR 20 in the golimumab 50 and 100 mg groups compared to the placebo group (74.7 and 72.1 vs 27.3%; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Golimumab 50 mg once every four weeks and MTX (Group 3) vs golimumab 100 mg once every four weeks and MTX (Group 2) vs placebo and MTX (Group 1)	RA (diagnosed with ACR 1987criteria) with RA for ≥3 months and were receiving 6 to 8 mg/week oral MTX for RA for ≥3 months before study and active RA (≥4/66 swollen joints and ≥4/68 tender joints at screening/ baseline) and ≥2 of the following criteria at screening/ baseline: CRP >1.5 mg/dL, ESR by the Westergren method of >28 mm/hour, morning stiffness lasting ≥30 minute, radiographic evidence of bone erosion, or anti-cyclic citrullinated peptide antibody-positive or rheumatoid factor-positive		Secondary: Proportion of patients achieving an ACR 50 and ACR 70 response, ACR-N Index of Improvement, DAS28(ESR) response DAS28(ESR) remission (score <2.6), HAQ-DI, and safety	Secondary: Similarly, more patients in the golimumab 50 and 100 mg groups achieved an ACR 50 compared to the placebo group (43.0 and 37.9 vs 9.1%; P≤0.005). More patients receiving golimumab 50 or 100 mg achieved an ACR 70 compared to patients receiving placebo (22.1 and 13.8 vs 2.3%; P≤0.005). The ACR-N index of improvement was significantly higher in patients receiving golimumab 50 mg (30%) and golimumab 100 mg (25.85%) compared to placebo (20.00; P<0.001 for both). Significantly more patients in the golimumab 50 mg and 100 mg treatment groups achieved DAS28(ESR) scores for response to treatment compared to placebo (79.5 and 85.5 vs 37.6%; P<0.0001). A higher proportion of patients receiving golimumab 50 mg or 100 mg achieved DAS28(ESR) for remission compared to placebo at 14 weeks (31.4 and 18.4 vs 3.4%; P<0.0001). Patients randomized to golimumab 100 mg and 50 mg treatment groups experienced statistically significant improvements in HAQ-DI scores compared to placebo at 14 weeks (0.32 and 0.39 vs 0.07; P<0.0001). By week 16, 72.7, 75.6 and 78.2% of patients receiving placebo, golimumab 100 mg and 50 mg, respectively, had adverse events. Infections were the most common adverse event in the placebo (39.8%), golimumab 100 mg (38.4%) and golimumab 50 mg (33.3%) treatment groups at week 24. Serious adverse events were relatively uncommon through week 16, occurring in one patient (1.1%) in receiving placebo (intervertebral disc protrusion), one patient (1.2%) in the golimumab 100 mg group (ileus) and two patients receiving golimumab 50 mg (2.3%). By week 24, 11 (5.5%) of the 201 patients treated with golimumab 50 mg or 100 mg had discontinued golimumab due to the following adverse events: infection (n=2), skin disorders (n=2), liver function abnormality

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(n=2), injury (n=2), bone neoplasm (n=1), aortic dissection (n=1), gastrointestinal disorder (n=1) and elevated blood pressure (n=1 in combination with skin disorder).
Emery et al.[128] (2009) Golimumab 100 mg once every 4 weeks and placebo vs golimumab 50 mg once every 4 weeks and MTX vs golimumab 100 mg once every 4 weeks and MTX vs placebo and MTX	DB, PC, RCT MTX naïve patients ≥18 years of age with a diagnosis of active RA for ≥3 months and not previously treated with a TNF-blocker	N=637 24 weeks	Primary: ACR 50 response at week 24 Secondary: ACR 20, 70, 90 responses at week 24	Primary: The golimumab monotherapy group was not statistically different from the MTX monotherapy group in ACR response (P=0.053). However, post-hoc modified intent-to-treat analysis (excluding three untreated patients) of the ACR 50 response showed statistically significant difference between the two groups (P=0.049). Secondary: The combined golimumab and MTX groups had greater proportion of patients achieve an ACR 20 response at week 24 compared to placebo and MTX groups (P=0.028 for both groups). ACR 70 response was not significant and ACR 90 response was significant for the golimumab 50 mg and MTX groups.
Keystone et al.[129] (2009) GO-FORWARD Golimumab 100 mg once every 4 weeks and placebo vs golimumab 50 mg once every 4 weeks	DB, MC, PC, RCT Patients ≥18 years of age with a diagnosis of active RA for ≥3 months despite stable dose of ≥15 mg/week of MTX and not previously treated with a TNF-blocker	N=444 24 weeks	Primary: ACR 20 response at week 14, change from baseline in HAQ at week 24 Secondary: ACR 50, 70, 90 responses and ACR-N EULAR response, remission according to DAS	Primary: At week 14, an ACR 20 response was achieved by 33.1% of placebo and MTX-treated patients, 44.4% of golimumab 100 mg and placebo-treated patients (P=0.059), 55.1% of golimumab 50 mg and MTX-treated patients (P=0.001), and 56.2% of golimumab 100 mg and MTX-treated patients (P<0.001). At week 24, the median improvements from baseline in the HAQ-DI scores were -0.13 (P=0.240), -0.38 (P=0.001), and -0.50 (P<0.001), respectively. Secondary: ACR 50 and ACR-N response was significant for all the groups except placebo and MTX; ACR 70 was significant for all the groups except the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and MTX vs golimumab 100 mg once every 4 weeks and MTX vs placebo and MTX			28, and sustained remission (DAS 28 remission at week 14 and maintained through week 24)	placebo and MTX and golimumab and placebo groups; ACR 90 was not significant for any of the groups. Greater proportion of patients in the golimumab and MTX groups achieved significant EULAR response. At week 24, clinical remission was achieved by 6.0% of placebo and MTX-treated patients, 12.0% (P=0.087) of golimumab 100 mg and placebo-treated patients, 20.2% (P=0.001) of golimumab 50 mg and MTX-treated patients, and 22.5% (P<0.001) of golimumab 100 mg and MTX-treated patients, respectively. Sustained remission was achieved by 0.8%, 6.3% (P=0.018), 10.2% (P=0.001), and 11.9% (P<0.001), respectively.
Keystone et al.[130] (2016) GO-FORWARD Golimumab 100 mg once every four weeks and placebo vs golimumab 50 mg once every four weeks and MTX vs golimumab 100 mg once every four weeks and MTX vs placebo and MTX	DB, MC, PC, RCT Patients ≥18 years of age with a diagnosis of active RA for ≥3 months despite stable dose of ≥15 mg/week of MTX and not previously treated with a TNF-blocker	N=444 5 years	Primary: Adverse events Secondary: ACR and DAS28-CRP scores, HAQ-DI	Primary: Among all patients, 29.5% discontinued study agent through Week 252; of these, 14.4% discontinued because of an adverse event, including worsening of RA (n=6, 1.4%), and 25 (5.6%) discontinued because of unsatisfactory therapeutic effect. Among all golimumab-treated patients, the most common types of adverse event were infections/infestations (80.4%), musculoskeletal and connective tissue disorders (48.4%), and gastrointestinal disorders (46.3%) through Week 268. Common adverse events included upper respiratory tract infection (n=143, 32.9%), bronchitis (n=74, 17.1%), nasopharyngitis (n=74, 17.1%), and cough (n=73, 16.8%). Forty golimumab-treated patients (9.2%) reported ≥1 injection site reaction; none were considered to be serious or severe. A total of 172 (39.6%) golimumab-treated patients had ≥1 serious adverse event, with pneumonia and sepsis being among the most common (n=7, 1.6% for both). The incidence of serious infections was 4.01 (95% CI, 3.14 to 5.05). Secondary: Among all patients, 63.1% had an ACR20, 40.8% had an ACR50, and 24.1% had an ACR70 at Week 256, with no appreciable differences among treatment groups. ACR20 and ACR50 rates were maintained over time through Week 256. At Week 256, 78.2% of all patients had a good or moderate DAS28-CRP response. About 36% of patients were in DAS28-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients with inadequate response could enter early escape at Week 16 to a golimumab + MTX group, and all remaining placebo + MTX patients crossed over to golimumab 50 mg + MTX at Week 24				CRP remission, while 21% met either the SDAI or CDAI remission criteria. Mean improvements from baseline to Week 256 in HAQ-DI ranged from 0.34 to 0.52, with an overall mean (SD) improvement of 0.44 (0.71). Among all patients, 61.0% had an improvement in HAQ-DI ≥0.25 and 36.3% achieved a normal HAQ-DI score (≤0.5) at Week 256 compared with 12.6% who had a normal HAQ-DI score at baseline.
Smolen et al.[131] (2009) GO-AFTER Golimumab 50 mg once every 4 weeks vs golimumab 100 mg once every 4 weeks vs placebo Patients were allowed to continue stable doses of concomitant HCQ, MTX, or SSZ during the trial.	DB, PC, RCT Patients ≥18 years of age with a diagnosis of active RA for ≥3 months previously treated with ≥1 dose of a TNF-blocker without a serious adverse reaction	N=461 24 weeks	Primary: ACR 20 response at week 14 Secondary: ACR 50 response at week 14, DAS 28 response at week 14, ACR 20 response at week 24, and improvement from baseline in HAQ scores at week 24	Primary: Golimumab 50 and 100 mg were significantly better than placebo in improving signs and symptoms of RA according to ACR 20 (35.3 and 37.9 vs 18.1%, respectively; P<0.001). ACR 20 responders at week 14 among patients who discontinued previous TNF-blocker therapy due to lack of efficacy included 35.7 and 42.7% of patients in the golimumab 50 and 100 mg groups, respectively, compared to 17.7% of patients in the placebo group (P=0.006, golimumab 50 mg vs placebo; P<0.001, golimumab 100 mg vs placebo). Secondary: ACR 50 response at week 14 was significant for the golimumab-treated groups compared to the placebo group. DAS 28 response was significant for golimumab 50 and 100 mg groups compared to placebo (56.2 and 59.5 vs 30.3%, respectively; P<0.001). ACR 20 response at week 24 was significant for the golimumab-treated groups compared to the placebo group. At week 24, golimumab improved physical function and fatigue according to HAQ and FACIT-F scores, respectively.
Smolen et al.[132] 2012 (GO-AFTER Extension)	DB, MC, PC, RCT Patients ≥18 years of age with a	N=459 160 weeks	Primary: ACR 20 Secondary:	Primary: At week 160, 62.7, 66.7 and 56.8% of patients achieved ACR20 response and 59, 65 and 64% had HAQ improvement ≥0.25 unit in Groups 1, 2 and 3, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Golimumab 50 mg once every 4 weeks (Group 1) vs golimumab 50 mg once every 4 weeks. Dose could be increased to 100 mg if <20% improvement in both tender and swollen joint counts at week 16 of the original study occurred. (Group 2) vs golimumab 100 mg once every 4 weeks (Group 3)	diagnosis of active RA for ≥3 months previously treated with ≥1 dose of a TNF-blocker without a serious adverse reaction		ACR 50/70,DAS 28, SDAI, and HAQ score	Secondary: At week 160, 17.3, 14.8 and 23.5% of patients achieved ACR70 response Groups 1, 2 and 3, respectively. DAS 28 response for groups 1, 2 and 3, response was 71.8, 83.8 and 71.4%, respectively. Remission as measured by DAS 28 for groups 1, 2 and 3, response was 16.9, 12.5 and 21.5%, respectively. SDAI remission for groups 1, 2 and 3, response was 11.4, 8.8 and 23.1%, respectively. SDAI scores for low disease activity (3.3 to 11) for groups 1, 2 and 3, response was 34.3, 28.8 and 25.6%, respectively. At week 160, 59, 65 and 64% had HAQ improvement ≥0.25 unit in Groups 1, 2 and 3, respectively.
Weinblatt et al.[133] (2013) GO-FURTHER golimumab 2 mg/kg, at weeks 0 and 4 and every 8 weeks plus MTX vs placebo and MTX	DB, MC, PC, RCT Adult patients with RA for ≥3 months and were receiving 15 to 25 mg/week oral MTX for RA for ≥4 weeks before study and active RA (≥6/66 swollen joints and ≥6/68 tender joints at screening/	N=592 24 weeks	Primary: Proportion of patients achieving ACR 20 at week 14 Secondary: DAS28 and HAQ-DI week 14, ACR 50 at week 24, and safety	Primary: There was a significantly higher proportion of patients achieving an ACR 20 in the golimumab group compared to the placebo group (58.5 and 24.9%: P<0.001). Secondary: Significantly more patients in the golimumab treatment groups achieved DAS28 scores for moderate-good response to treatment compared to placebo at 14 weeks (81.3 vs 40.1%; P<0.001). Patients randomized to golimumab treatment groups experienced statistically significant improvements in HAQ-DI scores compared to placebo at 14 weeks (0.5 vs 0.19; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	baseline) and CRP >1.0 mg/dL, anti- cyclic citrullinated peptide antibody-positive and/or rheumatoid factor-positive			Significantly higher proportion of patients randomized to golimumab groups achieved an ACR 50 compared to the placebo group (34.9 vs 13.2%; P≤0.001) at 24 weeks. Significantly higher proportion of patients randomized to golimumab groups achieved an ACR 50 compared to the placebo group (34.9 vs 13.2%; P≤0.001) at 24 weeks. Adverse events reported at rates ≥1.0% higher in the golimumab group vs placebo were observed for infections and infestations (24.3 vs 20.8%); nervous system disorders (6.8% vs 4.1%); gastrointestinal disorders (6.6 vs 5.6%); skin and subcutaneous tissue disorders (6.6% vs 3.6%); respiratory, thoracic and mediastinal disorders (4.8 vs 2.5%); vascular disorders (3.8 vs 2.5%); and metabolism and nutrition disorders (2.3 vs 0.0%).
Ishaq et al.[134] (2011) Leflunomide 20 mg once a day vs methotrexate 20 once a week	AC, DB, DD, RCT Patients 18 years of age or older with diagnosis of RA according to ACR criteria for at least four months and less than ten years, who had active disease and have not used a DMARD for at least 28 days prior to the study	N=240 1 year	Primary: Tender joint count, swollen joint count, physician and patient global assessment score Secondary: Morning stiffness, pain intensity, Health Assessment Questionnaire	Primary: Changes in mean scores ± one standard deviation in the tender joint count, swollen joint count, physician and patient global assessments after one year were, respectively, -8.0±7.9, -7.0±7.3, -1.0±1.0 and -1.0±1.1 in the leflunomide group and -10.0±7.9 and -9.0±7.3, -1.0±1.0, 1.0±1.0 in the methotrexate group. The difference between the baseline and the end-point measurements in all the efficacy end-points was significantly greater in patients taking methotrexate compared to patients taking leflunomide (P=0.001). Secondary: Changes in the mean scores ± one standard deviation in morning stiffness (minutes), pain intensity (mm) and the Health Assessment Questionnaire after one year were -87.3±104.1, -27.3±26.6 and -0.48±0.50 in the leflunomide group and -91.5±94.4, -35.2±24.2 and -0.54±0.47 in the methotrexate group, respectively. Withdrawal from the study due to adverse events occurred in 19 and 15% of patients in the leflunomide and methotrexate groups, respectively.

<table>
<tr><th>Study and Drug Regimen</th><th>Study Design and Demographics</th><th>Study Size and Study Duration</th><th>End Points</th><th>Results</th></tr>
<tr><td></td><td></td><td></td><td></td><td>Withdrawal from the study due to a lack of efficacy occurred in 7 and 3% of patients in each group, respectively.</td></tr>
<tr><td>Osiri et al.[135] (2003)

Leflunomide 20 to 25 mg/day

vs

other DMARDs

vs

placebo

Only results pertaining to the scope of this review are included.</td><td>MA (33 studies)

Patients 18 years and of age older with active RA</td><td>N=not reported

At least 12 weeks</td><td>Primary:
Tender and swollen joint count, pain level, patient’s and physician’s global assessment, functional ability, acute phase reactants, radiographic change of bone and joint damage, ACR criteria, DAS 28

Secondary:
Health Related Quality of Life Questionnaire, SF-36, reported side effects, withdrawals</td><td>Primary:
<table>
<tr><th>Comparison</th><th>Duration (months)</th><th>Risk Ratio, 95% CI</th></tr>
<tr><td colspan="3">ACR 20</td></tr>
<tr><td>vs methotrexate</td><td>3</td><td>0.96 (0.84, 1.10)</td></tr>
<tr><td>vs methotrexate</td><td>6</td><td>0.96 (0.87, 1.06)</td></tr>
<tr><td>vs methotrexate</td><td>12</td><td>1.08 (0.75, 1.55)</td></tr>
<tr><td>vs methotrexate</td><td>24</td><td>1.05 (0.81, 1.37)</td></tr>
<tr><td>vs sulfasalazine</td><td>6</td><td>1.03 (0.83, 1.28)</td></tr>
<tr><td>vs sulfasalazine</td><td>12</td><td>1.03 (0.83, 1.29)</td></tr>
<tr><td>vs sulfasalazine</td><td>24</td><td>0.73 (0.57, 0.93)</td></tr>
<tr><td colspan="3">ACR 50</td></tr>
<tr><td>vs methotrexate</td><td>12</td><td>0.86 (0.52, 1.44)</td></tr>
<tr><td>vs methotrexate</td><td>24</td><td>0.82 (0.60, 1.10)</td></tr>
<tr><td>vs sulfasalazine</td><td>6</td><td>0.92 (0.64, 1.31)</td></tr>
<tr><td>vs sulfasalazine</td><td>12</td><td>0.93 (0.63, 1.36)</td></tr>
<tr><td>vs sulfasalazine</td><td>24</td><td>0.48 (0.28, 0.80)</td></tr>
<tr><td colspan="3">ACR 70</td></tr>
<tr><td>vs methotrexate</td><td>12</td><td>0.44 (0.26, 0.77)</td></tr>
<tr><td>vs methotrexate</td><td>24</td><td>0.72 (0.44, 1.18)</td></tr>
<tr><td>vs sulfasalazine</td><td>6</td><td>0.66 (0.28, 1.55)</td></tr>
<tr><td>vs sulfasalazine</td><td>12</td><td>1.14 (0.57, 2.25)</td></tr>
<tr><td>vs sulfasalazine</td><td>24</td><td>0.70 (0.34, 1.43)</td></tr>
<tr><td colspan="3">DAS 28<3.2</td></tr>
<tr><td>vs methotrexate</td><td>4</td><td>1.24 (0.64, 2.42)</td></tr>
<tr><td colspan="3">DAS 28 remission</td></tr>
<tr><td>vs methotrexate</td><td>6</td><td>1.0 (0.22, 4.56)</td></tr>
<tr><td colspan="3">DAS 28 low disease activity</td></tr>
<tr><td>vs methotrexate</td><td>6</td><td>1.0 (0.28, 3.63)</td></tr>
<tr><td colspan="3">DAS 28 moderate disease activity</td></tr>
<tr><td>vs methotrexate</td><td>6</td><td>1.05 (0.76, 1.44)</td></tr>
<tr><td colspan="3">DAS 28 high disease activity</td></tr>
<tr><td>vs methotrexate</td><td>6</td><td>0.5 (0.05, 5.22)</td></tr>
</table></td></tr>
<tr><td>Scott et al.[136] (2001)

Leflunomide 20</td><td>DB, MC, PC, PG, RCT

Patients ≥18 years</td><td>N=358

Up to 24 months</td><td>Primary:
Tender and swollen joint counts, doctor and patient global</td><td>Primary:
In the six month cohorts, both active groups showed significant improvements in change in tender and swollen joint counts, change in patient and doctor global scores, acute phase reactants, RF, duration of</td></tr>
</table>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs sulfasalazine 2 grams/day vs placebo	of age with active RA functional class I, II, or III with tender joint count ≥6, swollen joint count ≥6; doctor and patient global assessment as fair, poor, or very poor; CRP >20 mg/L or ESR >28 mm/1st hour		assessments, pain intensity assessment, duration of morning stiffness, ESR, CRP, RF, and functional disability Secondary: Safety	morning stiffness, pain intensity, and functional ability compared with placebo and these continued in the 12 and 24 month cohorts. At 24 months, the ACR20 response rate with leflunomide was significantly greater than with sulfasalazine (82 vs 60%; P<0.01). Leflunomide showed significant improvement in functional ability (in both mean health assessment questionnaire scores and functional disability index) compared with placebo and sulfasalazine during the six month placebo controlled phase. Secondary: During the first six months, the most frequent drug related adverse effects in the leflunomide group were diarrhea (leflunomide 17%, sulfasalazine 9%), nausea (leflunomide 10%, sulfasalazine 17%), and alopecia (leflunomide 8%, sulfasalazine 5%). No unexpected adverse events or late toxicity were noted during the two year period. Diarrhea, nausea, and alopecia were less frequent with continued treatment.
Strand et al.[137] (1999) Leflunomide 20 mg per day vs methotrexate 7.5 mg per week vs placebo	DB, MC, RCT Patients ≥18 years of age with active RA for ≥6 months	N=482 12 months	Primary: Comparison of leflunomide therapy with placebo Secondary: Comparisons of leflunomide therapy with methotrexate therapy and methotrexate therapy with placebo	Primary: The ACR20 success rate was significantly higher in the leflunomide treatment group compared with the placebo group (41 vs 19%; P<0.001). Mean changes over time in each component of the ACR response index were significantly better in the leflunomide and methotrexate treatment groups than in the placebo group (P≤0.01). Analyses of function/disability and health-related quality of life demonstrated statistically significant improvement in patients treated with leflunomide compared with patients who received placebo. Secondary: The ACR success rates in the leflunomide and methotrexate treatment groups (41 and 35%, respectively) were statistically equivalent. Responses from patients receiving methotrexate treatment were significantly better than those for patients receiving placebo. The ACR20 response rates over time for patients receiving leflunomide and methotrexate therapy were 52 and 46%, respectively. Onset of effect occurred at a mean of 8.6 weeks for patients in the leflunomide treatment group compared with 9.5 weeks for those in the methotrexate treatment group.
Cohen et al.[138]	DB, MC, RCT	N=235	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ULTRA (2001) Leflunomide 20 mg per day vs methotrexate 7.5 to 20 mg per week vs placebo	Patients 18 to 75 years of age with active RA for ≥6 months	24 months	ACR responses, tender and swollen joint counts, VAS, HAQ, SF-36, safety Secondary: Not reported	At 24 months, leflunomide treatment was associated with higher ACR ≥20% response rates than was MTX treatment (79 vs 67%; P=0.049; 95% CI, 0.1 to 24.4). ACR ≥50% response rates for patients at 24 months were numerically greater following treatment with leflunomide compared with MTX (leflunomide 56 vs MTX 43%; P=0.053). This was also the case for ACR ≥70% response rates (leflunomide 26 vs MTX 20%; P=0.361). Responses were sustained from 12 months to 24 months, reflecting a consistent treatment effect. Maximal improvements evident at 6 months in the HAQ-DI and the physical component score of the SF-36 were sustained over 12 months and 24 months; improvement in the HAQ-DI with leflunomide (−0.60) was superior to that with MTX (−0.37) at 24 months (P=0.005). Over 24 months in the ITT cohort, serious treatment-related adverse events were reported in 1.6% of the leflunomide-treated patients and 3.7% of the MTX-treated patients. Frequently reported adverse events included upper respiratory tract infections, diarrhea, nausea and vomiting, rash, reversible alopecia, and transient liver enzyme elevations. Secondary: Not reported
De Stefano et al.[139] (2010) Leflunomide-anti-TNF-α combination therapy vs MTX-anti-TNFα combination therapy The anti-TNF-alpha drugs used were etanercept, infliximab, or	PRO, RCT Patients 18 to 65 years of age with active RA for >1 year and DAS 28 >5.1 despite MTX or leflunomide treatment	N=120 24 weeks	Primary: Discontinuation rate, DAS 28, clinician's global assessment, VAS score, HAQ, ACR, laboratory parameters Secondary: Not reported	Primary: The discontinuation rates did not differ significantly between the two combination therapies (P=0.63). There were no statistically significant differences in DAS28 variations between the two groups or among the six subgroups (P=0.82). The ACR differences between the two groups and six subgroups were no statistically significant at week four (P=0.69), week 12 (P=0.77), and week 24 (P=0.46). There were no statistically significant differences between the two groups and six subgroups in HAQ score. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
adalimumab				
Genovese et al.[140] (2015) SARIL-RA-MOBILITY Sarilumab 200 mg SQ every two weeks plus MTX vs sarilumab 150 mg SQ every two weeks plus MTX vs placebo plus MTX	DB, MC, PC, RCT Patients 18 to 75 years of age with active RA for ≥3 months despite MTX treatment for at least 12 weeks	N= 1,197 52 weeks	Primary: ACR20 improvement response at week 24, change from baseline in HAQ-DI at week 16, change from baseline in SHS score at week 52 Secondary: ACR70 improvement response, DAS28-CRP <2.6 at week 24	Primary: At 24 weeks, patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving ACR20 at 66% for sarilumab 200 mg, 58% for sarilumab 150 mg and 33% for placebo (P<0.0001 compared to placebo). At 52 weeks, patients treated with sarilumab with MTX demonstrated significantly less radiographic progression of structural damage as measured by SHS at 0.25 for sarilumab 200 mg, 0.90 for sarilumab 150 mg and 2.78 for placebo (P<0.0001 compared to placebo). At 16 weeks, patients treated with sarilumab with MTX demonstrated greater improvement from baseline in physical function as measured by the HAQ-DI at -0.58 for sarilumab 200 mg, -0.54 for sarilumab 150 mg and -0.30 for placebo (P<0.001 compared to placebo). Secondary: Patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving ACR70 at 15% for sarilumab 200 mg, 13% for sarilumab 150 mg and 3% for placebo (P<0.0001 compared to placebo). At 24 weeks, patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving DAS28-CRP <2.6 at 34% for sarilumab 200 mg, 28% for sarilumab 150 mg and 10% for placebo (P<0.0001 compared to placebo).
Genovese et al.[141] (2019) MOBILITY extension study Sarilumab 200 mg (dose reduction to 150 mg permitted) every 2 weeks plus methotrexate	OL, extension study Patients who completed MOBILITY study	N=901 5 years	Primary: Safety Secondary: Efficacy	Primary: The exposure-adjusted incidence rates of adverse events and serious adverse events were 137.7 and 9.1 per 100 patient-years, respectively, for patients receiving either dose of sarilumab. The most common adverse events (with any dose of sarilumab) were injection-site erythema (incidence rate 13.5 per 100 patient-years), neutropenia (12.8 per 100 patient-years) and upper respiratory tract infection (7.6 per 100 patient-years). The most common adverse events of special interest were infections (incidence rate 55.1 per 100 patient-years), injection-site reactions (21.6 per 100 patient-years) and leucopenia (17.7 per 100

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				patient-years). The incidence rate of adverse events was generally stable over >5 years of treatment and there was no signal for an increased rate over time for any of the adverse events (including serious adverse events and serious infections) when analyzed by 6-month interval. Elevations of ALT to >3× ULN occurred in 158 patients (14%) receiving either dose of sarilumab and normalized on treatment in 84 (53%) of these patients. Absolute neutrophil count <1,000 cells/mm^3 was observed but not associated with increased infection rate. Absolute neutrophil count <1,000 cells/mm3 occurred in 143 patients (13%) receiving either dose of sarilumab and normalized on treatment in 104 (73%) of these patients. Platelet counts <100×109 cells/L were observed in 33 patients (3%) receiving either dose of sarilumab and normalized on treatment in 20 (61%) of these patients. Serious infections occurred at a rate of 3.9 events per 100 patient-years in patients treated with either dose of sarilumab. Secondary: Initial treatment with sarilumab 200 mg plus methotrexate was associated with reduced radiographic progression over 5 years versus sarilumab 150 mg + methotrexate or placebo + methotrexate (mean±SE change from baseline in van der Heijde-modified Total Sharp Score: 1.46±0.27, 2.35±0.28 and 3.68±0.27, respectively [P<0.001 for each sarilumab dose vs placebo]). Clinical efficacy was sustained through 5 years according to DAS 28 using CRP, CDAI and HAQ-DI. The number of patients achieving CDAI ≤2.8 at 5 years was similar among initial randomization groups (placebo, 76/398 [19%]; sarilumab 150 mg, 68/400 [17%]; sarilumab 200 mg, 84/399 [21%]).
Fleischmann et al.[142] (2017) SARIL-RA-TARGET Sarilumab 200 mg SQ every two weeks plus DMARD vs	DB, MC, PC, RCT Patients 18 to 75 years of age with active RA for ≥6 months and inadequate response or intolerance to ≥1 anti-TNF therapy	N= 546 24 weeks	Primary: ACR20 improvement response at week 24, change from baseline in HAQ-DI at week 12 Secondary: ACR70	Primary: At 24 weeks, patients treated with sarilumab with DMARD achieved a greater improvement in the proportion of patients achieving ACR20 at 61% for sarilumab 200 mg, 56% for sarilumab 150 mg and 34% for placebo (P<0.0001 compared to placebo). At 16 weeks, patients treated with sarilumab with DMARD demonstrated greater improvement from baseline in physical function as measured by the HAQ-DI at -0.47 for sarilumab 200 mg, -0.46 for sarilumab 150 mg and -0.26 for placebo (P<0.001 compared to placebo).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
sarilumab 150 mg SQ every two weeks plus DMARD vs placebo plus DMARD			improvement response, ACR50 improvement response, DAS28-CRP <2.6 at week 24	Secondary: Patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving ACR70 at 16% for sarilumab 200 mg, 20% for sarilumab 150 mg and 7% for placebo (P<0.001 compared to placebo and P<0.01 compared to placebo, respectively). Patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving ACR50 at 41% for sarilumab 200 mg, 37% for sarilumab 150 mg and 18% for placebo (P<0.0001 compared to placebo). At 24 weeks, patients treated with sarilumab with MTX achieved a greater improvement in the proportion of patients achieving DAS28-CRP <2.6 at 29% for sarilumab 200 mg, 25% for sarilumab 150 mg and 7% for placebo (P<0.0001 compared to placebo).
Burmester et al.[143] (2017) SARIL-RA-MONARCH Sarilumab 200 mg SQ every two weeks plus placebo vs adalimumab 40 mg SQ every two weeks plus placebo	DB, MC, PC, RCT Patients 18 to 75 years of age with active RA for ≥3 months despite MTX treatment for at least 12 weeks	N= 369 24 weeks	Primary: Change from baseline in DAS28-ESR at week 24 Secondary: DAS28-ESR <2.6 at week 24, change from baseline in HAQ-DI at week 12, ACR70 improvement response, ACR50 improvement response, ACR20 improvement response	Primary: At 24 weeks, patients treated with sarilumab achieved a greater improvement from baseline in DAS28-ESR at -3.28 for the sarilumab group and -2.20 for the adalimumab group (P<0.0001). Secondary: At 24 weeks, patients treated with sarilumab achieved a greater improvement in the proportion of patients achieving DAS28-CRP <2.6 at 27% compared to 7% for adalimumab (P<0.0001). At 12 weeks, patients treated with sarilumab demonstrated greater improvement from baseline in physical function as measured by the HAQ-DI at -0.61 for the sarilumab group and -0.43 for the adalimumab group (P=0.0037). Patients treated with sarilumab achieved a greater improvement in the proportion of patients achieving ACR70, ACR50 and ACR20 at 23%, 46% and 72% for the sarilumab group and 12%, 30% and 58% for the adalimumab group, respectively (P=0.0036, P=0.0017 and P=0.0074, respectively).
Jones et al.[144]	DB, DD, PG, RCT	N=673	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2010) AMBITION Tocilizumab 8 mg/kg every 4 weeks vs MTX 7.5 to 20 mg every week or placebo for 8 weeks followed by tocilizumab 8 mg/kg from week nine on	Patients ≥18 years of age, with moderate to severe RA for ≥3 months, oral glucocorticoids (up to 10 mg/day of prednisone or equivalent) and NSAIDs were permitted if the dose was stable for ≥6 weeks	24 weeks	Proportion of patients achieving ACR 20 response at week 24 Secondary: Proportion of patients with ACR 50/70 responses at week 24 and the time to onset of ACR 20/50/70 responses, changes from baseline at week 24 in 28-joint count DAS 28, the proportion of patients in clinical remission (DAS 28 <2.6), with low disease activity (DAS 28 ≤3.2) and with good/ moderate responses at week 24, improvement in physical function was assessed by change from baseline at week 24 in HAQ-DI, and adverse events	At week 24, 70.6% of tocilizumab patients as compared to 52.1% of MTX patients achieved an ACR 20 response (P<0.001). Compared to the placebo arm, a larger proportion of patients treated with tocilizumab also achieved an ACR 20 response at week eight (55.6 vs 13.1%; 95% CI, 0.34 to 0.52). Secondary: The proportion of patients achieving ACR 50 (44.0%) and ACR 70 (28.0%) at week 24 was also statistically significant for tocilizumab as compared to MTX (P<0.001). Improvements in DAS 28 at week 24 were greater in the tocilizumab group than in the MTX group. Additionally, the proportion of patients in remission at week 24 was higher with tocilizumab (P<0.001). By week 24, tocilizumab patients were five times more likely to achieve DAS 28 remission and four times more likely to achieve at least a moderate response (OR vs MTX, 4.24; 95% CI, 2.92 to 6.14). A greater improvement in physical function was seen by a higher mean change in HAQ-DI with tocilizumab when compared to that of MTX. There was no statistically significant difference with regard to the number of adverse events experienced in the tocilizumab group compared to the MTX group (79.9 vs 77.5%; P=0.484). Infection rates/patient year were also found to be similar (1.06 vs 1.09). However, skin and subcutaneous infections were reported more frequently in the tocilizumab group (4.1 vs 1.4%; P value not reported).
Smolen et al.[145] (2008) OPTION Tocilizumab 8	DB, PC, PG, RCT Patients ≥18 years of age, with moderate to severe	N=622 24 weeks	Primary: ACR 20 response at week 24 Secondary:	Primary: At week 24, significantly greater proportion of patients receiving tocilizumab 4 and 8 mg/kg had an ACR 20 response than patients who received placebo (59 and 48 vs 26%, respectively; P<0.0001 for both).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/kg every 4 weeks plus MTX (stable, 10 to 25 mg weekly) vs tocilizumab 4 mg/kg every 4 weeks plus MTX (stable, 10 to 25 mg weekly) vs placebo every 4 weeks plus MTX (stable, 10 to 25 mg weekly)	RA >6 months duration, who had an inadequate response to MTX; all other DMARDs were discontinued before the start of the study, oral glucocorticoids (≤10 mg/day of prednisone or equivalent) and NSAIDs were permitted if doses were stable for six weeks or more		ACR 50/70, DAS 28, and EULAR responses at week 24, difference in HAQ-DI, SF-36, and FACIT-F, scores from baseline, and adverse events	Secondary: Significantly greater proportion of patients in tocilizumab 4 and 8 mg/kg groups achieved ACR 50 (31 and 44 vs 11%, respectively; P<0.0001) and ACR 70 at week 24 (12 and 22 vs 2%, respectively; P<0.0001) compared to patients in the placebo group. Significantly greater proportion of patients in tocilizumab 4 and 8 mg/kg groups had reduced disease activity as measured by a DAS 28 score <2.6 (13.0 and 27.0 vs 0.8%, respectively; P<0.0002 for 4 mg/kg and P<0.0001 for 8 mg/kg groups) compared to the placebo group. EULAR response was also found to be significantly decreased in both tocilizumab 4 and 8 mg/kg groups (21 and 38 vs 3%, respectively; P<0.0001 for both) compared to the placebo group. Greater improvements in physical function were seen in both tocilizumab 4 and 8 mg/kg groups as assessed by the HAQ-DI score (-0.52 and -0.55 vs -0.34, respectively; P<0.0296 for 4 mg/kg and P<0.0082 for 8 mg/kg). Significant differences were seen with regard to changes in the SF-36 physical score in both tocilizumab 4 and 8 mg/kg groups (9.7 and 9.5 vs 5.0, respectively; P<0.0001 for both) and in the SF-36 mental score (5.7 and 7.3 vs 2.7, respectively; P<0.0394 for 4 mg/kg and P<0.0012 for 8 mg/kg). The mean change in FACIT-F score from baseline showed significant improvements in both tocilizumab 4 and 8 mg/kg groups (7.3 and 8.6 vs 4.0, respectively; P<0.0063 for 4 mg/kg and P<0.0001 for 8 mg/kg). Greater proportions of patients in the tocilizumab 4 and 8 mg/kg groups reported experiencing at least one adverse event compared to the placebo group (71 and 69 vs 63%, respectively). The rate of all infections/100 patient years was 98.7 in the tocilizumab 4 mg/kg group, 101.9 in the 8 mg/kg group, and 96.1 in the placebo group.
Genovese et al.[146] (2008) TOWARD	DB, MC, PC, RCT Patients ≥18 years	N=1,220 24 weeks	Primary: ACR 20 responses at week 24	Primary: At week 24, the proportion of patients in the tocilizumab group that were ACR 20 responders was significantly higher than in the control group (61

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Tocilizumab 8 mg/kg plus DMARD every 4 weeks vs placebo plus DMARD every 4 weeks	of age, with moderate to severe RA, who received stable doses of permitted DMARDs (MTX, chloroquine, HCQ, parenteral gold, SSZ, azathioprine, and leflunomide) for ≥8 weeks prior to study entry and oral glucocorticoids (≤10 mg/day of prednisone or equivalent) and NSAIDs or COX2 inhibitors if the doses were stable for ≥6 weeks		Secondary: ACR 50/70 responses at week 24, number of swollen and tender joints, DAS 28, EULAR response, HAQ, FACIT-F score, and SF-36, and adverse events	vs 25%; P<0.0001). No obvious differences were seen in ACR 20 response with regard to patients who received two or more DMARDs. Secondary: At week 24, significantly more patients in the tocilizumab group achieved ACR 50 and ACR 70 responses when compared to the placebo group (ACR 50, 30 vs 9%; ACR 70, 21 vs 3%; P<0.0001 for both). Compared to baseline, a significant decrease was seen in the number of swollen and tender joints in patients receiving tocilizumab when compared to the placebo group (swollen joint count, -10.3 vs -4.9; tender joint count, -15.7 vs -8.5; P<0.0001). Mean DAS 28 improved incrementally over time with greater changes in the tocilizumab group seen by week 24 (-3.17 and -1.16, respectively; P<0.0001). Remission rates at week 24 were also higher in the tocilizumab group when compared to the placebo group (30 vs 3%; P<0.0001). By week 24, 80% of patients in the tocilizumab group and 38% of patients in the placebo group achieved a good or moderate EULAR response (P<0.0001). At week 24, 60% of patients in the tocilizumab group had a clinically meaningful improvement in physical function as compared to 34% with placebo (change from baseline in HAQ ≥0.3). Mean changes from baseline were also significantly higher in the tocilizumab group when compared to the placebo group for the disability index of the HAQ (-0.5 vs -0.2; P<0.0001) and FACIT-F scores (8.0 vs 3.6; P<0.0001). Mean improvements from baseline in SF-36 scores were higher for both physical and mental components at week 24 in the tocilizumab group (8.9 vs 4.1 and 5.3 vs 2.3, respectively; P<0.0001 for both). The occurrence of adverse events was found to be higher with tocilizumab (73 vs 61%). The most frequently occurring adverse events in both groups were infections and infestations (37.4 vs 31.6%), gastrointestinal disorders (20.8 vs 14.7%), and musculoskeletal and connective tissue disorders

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(13.0 vs 17.9%). Infections with a higher incidence in the tocilizumab group were upper respiratory infections (9 vs 7%), other respiratory infections (12 vs 10%), and skin and subcutaneous tissue infections (5 vs 3%).
Kremer et al.[147] (2011) LITHE Tocilizumab 8 mg/kg plus MTX (stable, 10 to 25 mg weekly) for four weeks vs tocilizumab 4 mg/kg plus MTX (stable, 10 to 25 mg weekly) for four weeks vs placebo plus MTX (stable, 10 to 25 mg weekly) for four weeks Oral corticosteroids (≤10 mg/day of prednisone or equivalent) and NSAIDs were permitted if the dosages had been stable for ≥6 weeks before study entry.	DB, MC, PC, PG, RCT Patients with RA, as determined by ACR criteria that was moderate to severe and lasted for ≥6 months; inadequate response to MTX therapy, defined as a swollen joint count of ≥6, a tender joint count of ≥8, and either CRP level ≥1 mg/dl or an ESR ≥28 mm/hour; and had ≥1 radiographically confirmed joint erosion despite having received MTX for ≥12 weeks before baseline	N=1,196 12 months	Primary: Change from baseline in the total Genant-modified Sharp score and change in HAQ-DI Secondary: Change from baseline in erosion and JSN scores (at week 24 and 52), total Genant-modified Sharp score at week 24, proportions of patients with no progression of total, erosion, or JSN scores, ACR 20, ACR 50, and ACR 70, change in DAS 28, and proportions of patients with low levels of disease activity (DAS28 ≤3.2) and DAS remission (DAS28 <2.6).	Primary: The proportion of patients without radiographic progression (change in total Genant-modified Sharp score ≤0 from baseline to week 52) was significantly higher in patients treated with tocilizumab 8 or 4 mg/kg (84 and 81 vs 67%; P<0.0001). The AUC of the change in the HAQ-DI score from baseline to week 52 demonstrated a significantly greater decrease in the 8 and 4 mg/kg tocilizumab groups compared to the placebo group (-144.1 and -128.4 vs -58.1 units; P<0.0001 for both comparisons). Secondary: At week 52, the ACR 20, ACR 50, and ACR 70 response rates were higher in patients treated with tocilizumab compared to placebo; however the difference was only statistically significant for the 8 mg/kg group compared to the placebo group (P<0.0001 for all response rate comparisons). The DAS28 scores were reduced over 52 weeks in all treatment groups, with mean improvements of -3.8, -3.0, and -2.0 in the tocilizumab 8 mg/kg, 4 mg/kg and placebo groups, respectively; however, the difference was only significant with the 8 mg/kg dose compared to placebo (P<0.0001). At 52 weeks, more patients treated with tocilizumab 8 mg/kg achieved remission (47.2 vs 7.9%; P<0.0001) according to the DAS28 score (<2.6) or had low disease activity (DAS28 ≤3.2) compared to placebo (63.6 vs 45.3%; P<0.0001). DAS28 remission rates continued to improve between weeks 24 and 52, with the highest proportion of patients in remission in the tocilizumab 8 mg/kg treatment group. The progression of structural damage from baseline to week 52 was reduced by 74 and 70% with tocilizumab 8 and 4 mg/kg, respectively,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				compared to patients treated with placebo (P<0.0001). The total Genant-modified Sharp score at week 52 showed a decreased frequency and severity of disease progression with tocilizumab therapy.
Yazici et al.[148] (2012) ROSE Tocilizumab 8 mg/kg plus DMARD every four weeks vs placebo plus DMARD every four weeks Permitted DMARD (at stable doses ≥7 weeks before study) included MTX, chloroquine, hydroxychloroquine, parenteral gold, SSZ, azathioprine, and leflunomide. Doses were required to remain stable throughout the study; however, dose reductions were allowed as clinically warranted for safety reasons.	DB, MC, PC, RCT Patients ≥18 years of age with active RA for ≥6 months and an inadequate clinical response to DMARD in addition to ≥6 swollen joints and ≥6 tender joints at screening and baseline, with either a CRP ≥95.24 nmol/l or an ESR ≥28 mm/h or greater at screening	N=619 24 weeks	Primary: ACR 50 response at week 24 Secondary: ACR 20, ACR 50, ACR 70, EULAR response, DAS28, clinically meaningful improvement (change from baseline in DAS28 of ≥1.2), patients achieving low disease activity (DAS28 ≤3.2), clinical remission (DAS28 <2.6), ESR and CRP levels, FACIT-F, and RAPID3 scores	Primary: A significantly higher proportion of patients randomized to receive tocilizumab achieved an ACR 50 response at week 24 compared to placebo (30.1 vs 11.2%; P<0.0001). Secondary: A higher proportion of patients randomized to receive tocilizumab achieved an ACR 20 response at all time points evaluated compared to placebo (P<0.0001). Similarly, an ACR 50 response was achieved in significantly more patients in the tocilizumab group compared to placebo at all treatment weeks except week 16 (P<0.05 at all time-points). A significantly greater proportion of patients in the tocilizumab group compared to the placebo group achieved an ACR 70 response at all time points from week eight onward (P<0.05 for all time points). A higher proportions of patients achieved a EULAR good response in the tocilizumab group compared to placebo at all time points starting at week four (13.2 vs 2.0%; P<0.0001). The mean DAS28 score decreased from baseline to week 24 in both treatment groups starting at week four; however, the improvement was significantly greater in tocilizumab group compared to placebo (P<0.0001). Significantly more patients achieved a clinically meaningful decrease in DAS28 (≥1.2 points from baseline) in the tocilizumab group compared to the placebo group at all time points from week four onward (87.9 vs 53.4%; P<0.0001). Moreover, a greater proportion of patients randomized to receive tocilizumab achieved a low disease activity (P<0.0001) and clinical remission at week 24 (P<0.0001) compared to those in the placebo group. There were significantly greater improvements from baseline in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				RAPID3 scores at 24 weeks in the tocilizumab treatment group compared to placebo (-2.33 vs -1.29; P<0.0001). There was a statistically significant improvement in mean FACIT-F scores over 24 weeks of treatment with tocilizumab compared to placebo (P<0.05). Patients treated with tocilizumab achieved significantly lower mean CRP levels at all time points evaluated compared to the placebo group (P<0.0001). Similarly, the mean ESR was significantly reduced from baseline to a greater degree with tocilizumab compared to the placebo group at week 24 (-34.72 vs -5.70 mm/h; P<0.0001).
Emery et al.[149] (2008) RADIATE Tocilizumab 8 mg/kg plus MTX (stable, 10 to 25 mg weekly) for 4 weeks vs tocilizumab 4 mg/kg plus MTX (stable, 10 to 25 mg weekly) for 4 weeks vs placebo plus MTX (stable, 10 to 25 mg weekly) for 4 weeks	DB, PC, PG Patients ≥18 years of age with moderate to severe active RA with failure to respond to one or more TNF antagonists within the past year; patients must have discontinued TNF agents (Enbrel®, Humira®, Remicade®) or DMARDs (other than MTX) before enrolling	N=499 24 weeks	Primary: ACR 20 responses Secondary: DAS 28, number of patients requiring rescue therapy, and adverse events	Primary: ACR 20 was achieved at week 24 by 50.0, 30.4 and 10.1% of patients in the 8 mg/kg, 4 mg/kg and control group respectively (P<0.001). At week four, more patients achieved ACR 20 in the 8 mg/kg tocilizumab group than those in the control group (P<0.001). Patients responded, as measured by ACR 20 response, regardless of the most recently failed TNF antagonist or the number of failed treatments. Secondary: DAS 28 remission rates at week 24 were dose related, being achieved in 30.1, 7.6, and 1.6% of 8 mg/kg, 4 mg/kg and control groups (P<0.001 for 8 mg/kg; P=0.053 for 4 mg/kg vs control). Rescue therapy with 8 mg/kg of tocilizumab plus MTX was offered at week 16 in all cases of treatment failure (<20% improvement in both tender and swollen joints). More patients in the control group (41%) and in the 4 mg/kg group (19%) received rescue therapy after week 16 compared to 11% of patients in the 8 mg/kg group. Adverse events noted were mild or moderate with overall incidences of 84.0% in the tocilizumab 8 mg/kg group, 87.1% in the tocilizumab 4 mg/kg group, and 80.6% in the placebo plus MTX group. The most common adverse events were infections, gastrointestinal symptoms, rash and headache. The incidence of serious adverse events was higher in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				control group (11.3%) than in the tocilizumab 8 mg/kg (6.3%) and 4 mg/kg (7.4%) groups.
Burmester et al.[150] (2017) FUNCTION Tocilizumab 8 mg/kg IV every four weeks + MTX vs tocilizumab 4 mg/kg IV every four weeks + MTX vs tocilizumab 8 mg/kg IV every four weeks + placebo (TCZ monotherapy) vs placebo + MTX	DB, MC, RCT Patients ≥18 years of age with moderate to severe active, early (≤2 years) RA who were MTX-naïve	N=1,162 104 weeks	Primary: DAS28-ESR remission (<2.6), ACR20/50/70 responses, CDAI remission (<2.8) Secondary: Safety	Primary: DAS28-ESR remission rates were maintained from weeks 52 through 104. More patients achieved DAS28-ESR remission at weeks 24 and 52 with 8 mg/kg TCZ+MTX than with placebo+MTX (45 vs 15% and 49 vs 20%, respectively; P<0.0001). DAS28-ESR remission was achieved by 49.3% of patients in the 8 mg/kg TCZ+MTX group at week 52 and by 47.6% at week 104. Proportions of patients achieving ACR20, ACR50 and ACR70 responses were similar at weeks 52 and 104 in the 8 mg/kg TCZ monotherapy and 8 mg/kg TCZ+MTX groups. After 52 weeks of escape therapy, 30.5% (29/95) and 51.4% (73/142) of patients who originally received 4 mg/kg TCZ+MTX and placebo+MTX, respectively, achieved DAS28-ESR remission. ACR20, ACR50 and ACR70 response rates after 52 weeks of escape therapy were 43.0, 30.3, and 16.2%, respectively, in the placebo+MTX escape group and 29.5, 16.8, and 6.3%, respectively, in the 4 mg/kg TCZ+MTX escape group. Similar proportions of patients in each initial treatment arm achieved remission according to CDAI and ACR/EULAR Boolean and Index criteria at weeks 52 and 104. Secondary: Eighty-three serious adverse events were reported in the 8 mg/kg TCZ+MTX group compared with 67, 58 and 31 for the 8 mg/kg TCZ+placebo, 4 mg/kg TCZ+MTX and placebo+MTX groups, respectively. Rates of serious adverse events per 100 patient-years were 11.6 (95% CI, 9.2 to 14.3), 13.3 (95% CI, 10.3 to 16.9), 14.7 (95% CI, 11.2 to 19.0) and 9.1 (95% CI, 6.2 to 13.0), respectively. Most adverse events were mild or moderate in intensity (96 to 97% across the four treatment groups). Infections were the most frequently reported adverse events/serious adverse events in all treatment arms, with adverse event rates per 100 patient years ranging from 89.4 (95% CI, 82.6 to 96.6) for 8 mg/kg TCZ+MTX to 113.3 (95% CI, 103.0 to 124.3) for 4 mg/kg TCZ+MTX.
Kaneko et al.[151] (2016) SURPRISE	PRO, RCT Patients 20 to 75 years of age with	N=223 52 weeks	Primary: DAS28 remission rate at week 24	Primary: DAS28-ESR remission rates were significantly higher in the add-on group than in the switch group at weeks four and 24 (both P<0.05), but they became comparable at week 52. At week 24, the rate of DAS28 remission

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Tocilizumab added to methotrexate (add-on) vs tocilizumab switched from methotrexate (switch)	moderate or high RA disease activity despite MTX treatment		Secondary: SDAI, CDAI remission rates, safety	was 55.0% in the switch group and 69.6% in the add-on group. At week 52, rates were 70.3 and 72.2%, respectively. Secondary: Remission rates according to the SDAI and the CDAI were not significantly different between the two groups. The number of patients with at least one adverse event was greater in the add-on group than in the switch group (60.0 vs 45.0%, P=0.02), but the percentage of patients with at least one serious adverse event was comparable in the two treatment groups (13.9 vs 8.1%, P=0.20). Adverse events occurring more in the add-on group than in the switch group were infections, gastrointestinal disorders, and liver dysfunction. Eleven patients (9.6%) in the add-on group and 4 (3.6%) in the switch group were withdrawn from the study because of adverse events (P=0.11). There was one death from interstitial pneumonitis in the add-on group in this 1-year observation period.
Dougados et al.[152] (2013) ACT-RAY Tocilizumab 8 mg/kg plus MTX (stable >15 mg weekly) every 4 weeks vs tocilizumab 8 mg/kg plus placebo every 4 weeks	DB, PC, PG Patients ≥18 years of age with active RA with failure to respond to > 12 weeks of MTX treatment (stable dose >15 mg week for 6 weeks prior to study)	N=556 24 weeks	Primary: DAS 28 remission Secondary: DAS 28 low disease activity, ACR 20, ACR 50, ACR 70, ACR 90, and adverse events	Primary: DAS 28 remission rates at week 24 were 40.4% with the tocilizumab/MTX group vs 34.8% with tocilizumab monotherapy (P=0.19). Secondary: DAS 28 scored for low disease activity was significantly lower with combination therapy (tocilizumab/MTX) at week 24 that with the with tocilizumab monotherapy (61.7 vs 51.4%; P=0.029). ACR 20/50/70/90 was 71.5%/45.5%/24.5%/5.8% with tocilizumab/MTX. ACR 20/50/70/90 was 70.3%/40.2%/25.4%/5.1% with tocilizumab monotherapy. The differences between treatment groups were not considered significant. Adverse events noted were comparable in each treatment group with 6.1% of patients on tocilizumab/MTX reporting a serious adverse event while 5.8% reported a serious adverse event with tocilizumab monotherapy. Discontinuations and dose modifications occurred in 3.6% and 27.4% of tocilizumab/MTX patients and 2.5% and 18.5% of tocilizumab monotherapy patients, respectively. Increases in alanine aminotransferase

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				elevations from normal at baseline to greater than upper limit of normal and to more than three times upper limit of normal at one or more time points during 24 weeks occurred in 48.8% and 7.8% on tocilizumab/MTX and in 27.6% and 1.2% of tocilizumab monotherapy patients, respectively.
Bijlsma et al.[153] (2016) U-Act-Early Tocilizumab plus methotrexate vs tocilizumab plus placebo vs methotrexate plus placebo Tocilizumab was given at 8 mg/kg IV every four weeks with a maximum of 800 mg per dose	DB, MC, RCT Patients who had been diagnosed with rheumatoid arthritis within one year before inclusion, were DMARD-naive, ≥18 years of age, met current RA classification criteria, and had a DAS28 score of ≥2.6	N=317 2 years	Primary: Proportion of patients achieving sustained remission (defined as DAS28 <2.6 with a swollen joint count ≤4, persisting for at least 24 weeks) Secondary: EULAR and ACR response rates, HAQ scores	Primary: Sustained remission on the initial treatment regimen was attained by 86% of patients in the tocilizumab plus methotrexate arm, 84% in the tocilizumab arm, and 44% in the methotrexate arm (RR, 2.00; 95% CI, 1.59 to 2.51 for the tocilizumab plus methotrexate arm vs the methotrexate arm and 1.86; 95% CI, 1.48 to 2.32 for the tocilizumab arm vs the methotrexate arm, both P<0.0001). Sustained remission was not different between the tocilizumab plus methotrexate arm versus the tocilizumab arm (P=0.62). Secondary: Proportions of patients with EULAR good response at week 24 were significantly greater in the tocilizumab plus methotrexate arm versus the methotrexate arm and for the tocilizumab arm versus the methotrexate arm (P<0.0001 for both comparisons). At week 52, the proportion of patients with EULAR good response in the tocilizumab arm was significantly greater than that in the methotrexate arm (P=0.0074); at week 104, there were no significant between-group differences. ACR response rates showed a similar pattern over time. The difference between treatment groups for physical function (HAQ scores) was significant only at week 24 (the tocilizumab plus methotrexate arm versus the methotrexate arm; P=0.0275).
Choy et al.[154] (2018) TOZURA Tocilizumab 162 mg weekly SC Concomitant csDMARDs (AZA, chloroquine, HCQ, LEF, MTX or SSZ)	MC, OL, SA Tocilizumab- naïve patients ≥18 years of age with active RA who had an inadequate response to a csDMARD or an anti-TNF agent or who were MTX naïve	N=1,804 24 weeks	Primary: Total tender joint count, total swollen joint count of 28 joints, PGA, HAQ-DI, DAS28-ESR, ACR response scores, EULAR response criteria, CDAI, Simplified Disease Activity	Primary: Of 1,804 patients, 353 (19.6%) received monotherapy and 1451 (80.4%) received combination therapy. The 28-joint DAS-ESR in both groups decreased significantly from baseline to week 24 (mean change: monotherapy, -3.40; combination therapy; -3.46), with no significant difference between groups (P=0.46). The CDAI score decreased comparably from baseline to week 24 in both groups (mean change: monotherapy, 23.54; combination therapy, −23.83; P<0.0001 for both), with no significant difference between groups (P=0.57). EULAR and ACR20/50/70/90 response rates were similar between treatment groups at week 24, with 73.3 and 77.5% of patients achieving a EULAR good

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
were permitted if patients maintained a stable dose for ⩾4 weeks before baseline.			Index and glucocorticoid dose reduction and/or discontinuations Secondary: Safety	response and 57.2 and 57.7% achieving an ACR50 response in the monotherapy and combination therapy groups, respectively. Swollen joint counts and tender joint counts over time were similar between the monotherapy and combination therapy groups. The HAQ-DI score decreased comparably from baseline to week 24 in both groups (mean change: monotherapy, −0.56; combination therapy, −0.57; P<0.0001 for both), with no significant difference between groups (P=0.72). Secondary: Overall, the adverse event rate per 100 patient-years was 622.4, with similar rates between the monotherapy and combination therapy groups (622.1 vs 622.5). The most common adverse events were infections and infestations, occurring in 42.0% of patients (monotherapy 43.1%, combination therapy 41.8%), with nasopharyngitis occurring the most frequently. Overall, 6.2% of patients discontinued the study due to safety reasons (monotherapy 8.8%, combination therapy 5.5%). The most common reasons for withdrawal due to adverse events were skin and subcutaneous disorders in the monotherapy group [5 patients (1.4%)] and laboratory findings [16 patients (1.1%)] in the combination therapy group. There were 29 patients (1.6%) who withdrew due to insufficient therapeutic response, slightly more in the monotherapy than in the combination therapy group.
Van der Heijdge et al.[155] (2019) ORAL Scan Tofacitinib 5 mg BID, vs tofacitinib 10 mg BID vs	DB, PC, PG, RCT Patients ≥18 years of age with a diagnosis of active RA (≥6 tender or painful joints [68 joint count] and ≥6 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L) and evidence of ≥3 joint erosions on posteroanterior	N=539 24 months	Primary: Efficacy including ACR 20, ACR 50, and ACR 70 responses, mean changes from baseline in the DAS28-ESR, remission and low disease activity Secondary: Safety	Primary: ACR 20, ACR 50, and ACR 70, the proportion of patients in whom remission or low disease activity was achieved according to the DAS28-ESR, CDAI, or SDAI, Boolean remission and HAQ-DI scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Responses were similar between treatment sequences once all patients were receiving tofacitinib. Patients receiving tofacitinib 10 mg BID had numerically higher responses than those receiving 5 mg BID; however, since the study was not powered for this comparison, no formal statistical comparison between dosages was conducted. Patients receiving tofacitinib 10 mg BID had low disease activity and disease in remission for a modestly higher number of months, with numerically higher proportions of patients experiencing ≥12 months of uninterrupted low disease activity or remission, compared with the other

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo switched to tofacitinib 5 BID vs placebo switched to tofacitinib 10 BID	hand and wrist radiographs or anteroposterior foot radiographs (if radiographic evidence of joint erosions was unavailable, presence of IgM rheumatoid factor positivity or antibodies to cyclic citrullinated peptide).			treatment groups. Patients who switched from placebo to tofacitinib 5 mg BID showed a modestly lower total number of months in remission and proportion of patients achieving ≥12 months' uninterrupted low disease activity or remission versus other groups. These trends remained similar when only patients who completed the study were analyzed. Furthermore, no patient in any treatment group had more than one flare after month 6. Secondary: Safety events were similar in type and frequency for both tofacitinib dosages and were consistent with those previously reported. The most common treatment emergent adverse events (affecting ≥5% of patients) for months 0 to 24 by treatment sequence were: nasopharyngitis, upper respiratory tract infection, and headache for patients receiving tofacitinib 5 mg BID; nasopharyngitis, upper respiratory tract infection, urinary tract infection, herpes zoster, and bronchitis for patients receiving tofacitinib 10 mg BID; nasopharyngitis, upper respiratory tract infection, and hypertension for patients receiving placebo and then switching to tofacitinib 5 mg BID; and upper respiratory tract infection, nasopharyngitis, herpes zoster, increased ALT level, increased AST level, stomatitis, and diarrhea for patients receiving placebo and then switching to tofacitinib 10 mg BID.
Wollenhaupt et al.[156] (2019) Tofacitinib 5 mg or 10 mb BID Stable background therapy (including conventional synthetic DMARDs) continued	OL, extension study Patients with RA previously completing a phase 1, 2 or 3 qualifying index study of tofacitinib	N=4,481 Up to 9.5 years	Primary: Long-term safety and tolerability profile (including evaluation of adverse event reports and clinical laboratory data) Secondary: Long-term persistence of efficacy (including ACR 20/50/70 response rates, observed mean and	Primary: The majority of all-cause adverse events were mild (59%) or moderate (36%) in severity for all tofacitinib; corresponding data for tofacitinib 5 mg BID were 57% and 36%, respectively, and for tofacitinib 10 mg BID were 59% and 36%, respectively. For all tofacitinib, the most common all-cause adverse event by system organ class leading to discontinuation included infections and infestations (9.4% [n=423/4,481]), investigations (4.6% [n=206/4,481]), and benign, malignant, and unspecified neoplasms (3.7% [n=165/4,481]), and by preferred term included pneumonia (1.8% [n=80/4,481]), blood creatinine increased (1.5% [n=69/4,481]), and herpes zoster (0.7% [n=32/4,481]). The IR (95% CI) for all-cause adverse events leading to discontinuation was 6.78 (6.39, 7.20) for all tofacitinib. For all tofacitinib, the most common (≥ 5% in any treatment group) all-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			improvement in in HAQ-DI, DAS 28, proportions of patients achieving remission)	cause serious adverse events by system organ class included infections and infestations (9.0% [n=405/4,481]) and musculoskeletal and connective tissue disorders (5.5% [n=246/4,481]), and by preferred term included pneumonia (2.1% [n=96/4,481]), osteoarthritis (1.9% [n=86/4,481]), and RA (0.8% [n=34/4,481]). The IR (95% CI) for serious adverse events was 9.03 (8.55, 9.53) for all tofacitinib. A total of 88 deaths occurred in the study. Laboratory variables of interest, including total cholesterol and low-density lipoprotein, ALT, AST and serum creatinine remained generally stable over time, with variability attributable to smaller patient numbers at later time points. Secondary: ACR 20, ACR 50 and ACR 70 response rates were maintained over time between months one and 96 and were generally similar with tofacitinib 5 mg BID (months one to 96) and 10 mg BID (months one to 72). Improvements in mean HAQ-DI scores at month one remained stable over time with tofacitinib 5 mg and 10 mg BID, HAQ-DI ≥ 0.22 improvement from baseline was observed in 64.8% (n=103/159) of patients with all tofacitinib at month 96; in 63.6% (n=91/143) of patients with tofacitinib 5 mg BID at month 96; and in 70.3% (n=201/286) of patients with tofacitinib 10 mg BID at month 72. Mean DAS28 decreased at month one and then remained consistent over time with tofacitinib 5 mg and 10 mg BID. DAS28 defined remission was observed in 24.7% (n=39/158) of patients with all tofacitinib at month 96, in 25.4% (n=36/142) of patients with tofacitinib 5 mg BID at month 96, and in 25.0% (n=71/284) of patients with tofacitinib 10 mg BID at month 72.
Emery et al.[157] (2019) ASCERTAIN Sarilumab 150 mg SC every two weeks vs sarilumab 200 mg	DB, PG, RCT Patients ≥18 years of age with an RA diagnosis for ≥3 months and continuous treatment with one or a combination of conventional	N=202 24 weeks	Primary: Incidences of treatment-emergent adverse events, adverse events of special interest, serious adverse events, and potentially clinically	Primary: The incidence of treatment-emergent adverse events was similar between the sarilumab and tocilizumab groups. A numerically higher incidence of treatment-emergent adverse events leading to treatment discontinuation was observed with sarilumab (150 mg every two weeks, n=6 [12.2%]; 200 mg every two weeks, n=8 [15.7%]) than with tocilizumab (n=4 [3.9%]). The most frequently reported treatment-emergent adverse events were neutropenia, injection-site erythema and nasopharyngitis in the sarilumab groups and accidental overdose, upper respiratory tract infection and nausea in the tocilizumab group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
SC every two weeks vs tocilizumab 4 mg/kg (could be increased to 8 mg) IV every four weeks	synthetic DMARDs for ≥12 consecutive weeks before screening and were on a stable dose for ≥6 weeks		significant laboratory abnormalities Secondary: Not reported	There were two serious infections in the tocilizumab group and one in the sarilumab 200 mg every two weeks group Five patients who received sarilumab discontinued because of laboratory abnormalities (neutropenia, leukopenia and increased transaminases); none of these laboratory changes were associated with clinical manifestations. Three of these five patients had resumed their sarilumab SC injections but were discontinued (placebo for tocilizumab). No discontinuations due to laboratory abnormalities were reported in the tocilizumab group. Two patients in each of the sarilumab groups and one patient in the tocilizumab group discontinued because of infections. Two patients who received sarilumab 200 mg every two weeks discontinued because of injection-site reactions and one patient who received sarilumab 200 mg every two weeks discontinued because of an infusion-related reaction while receiving IV placebo. Secondary: Not reported
Maxwell et al.[158] (2009) Abatacept 2 to 10 mg/kg alone or in combination with DMARDs or biologics vs placebo or DMARDs or biologics	SR RCTs of patients ≥16 years of age with RA meeting the ACR 1987 revised criteria	N=2,908 (7 trials) ≥3 months	Primary: ACR 50 response and safety Secondary: ACR 20, ACR 70, components of ACR radiographic progression, DAS, EULAR response criteria, and changes in HAQ and SF-36	Primary: At three months, the ACR 50 response in the abatacept group was not significantly higher than the control group (RR, 2.50; 95% CI, 0.52 to 11.96). At six and 12 months, the ACR 50 response was significantly higher in the abatacept group compared to the control group (RR, 2.47; 95% CI, 2.00 to 3.07 and RR, 2.21; 95% CI, 1.73 to 2.82, respectively). At one year the NNT in order to achieve ACR 50 was 5 (95% CI, 4 to 7). The RR for adverse events with abatacept compared to controls was 1.05 (95% CI, 1.01 to 1.08). There was a greater number of serious adverse infections with abatacept compared to controls (OR, 1.91; 95% CI, 1.07 to 3.42). However, after removing a study in which patients were treated with combination of etanercept and abatacept, the OR decreased to 1.82 (95% CI, 1.00 to 3.32). Abatacept treated patients had increased number of headaches and infusion reactions (RR, 1.45; 95% CI, 1.20 to 1.74 and RR, 1.30; 95% CI, 1.13 to 1.50). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				ACR 20 response was achieved in significantly more patients treated with abatacept compared to controls at six and 12 months (RR, 1.79; 95% CI, 1.59 to 2.02 and RR, 1.79; 95% CI, 1.55 to 2.07, respectively) but not at three months (RR, 1.70; 95% CI, 0.93 to 3.12). More patients treated with abatacept achieved an ACR 70 at six and 12 months (RR, 3.53; 95% CI, 2.41 to 5.16 and RR, 4.02; 95% CI, 2.62 to 6.18) but not at three months (RR, 5.00; 95% CI, 0.25 to 100.20). There was a statistically significant reduction in the progression of joint damage at 12 months with abatacept (mean difference, -0.27; 95% CI, -0.42 to -0.12). The abatacept treated patients were significantly more likely to reach low DAS (DAS 28 <3.2) compared to controls at 6 and 12 months (RR, 3.36; 95% CI, 2.28 to 4.96 and RR, 4.33; 95% CI, 2.84 to 6.59), and a NNT of 4 (95% CI, 3 to 5). At 12 months, patients in the abatacept group were significantly more likely to achieve DAS remission (DAS 28 <2.6) with RR of 12.74 (95% CI, 4.76 to 34.15). For clinically meaningful improvement on the HAQ; RR, 1.69 (95% CI, 1.51 to 1.90) in favor of abatacept. There was an absolute difference of 24% (95% CI, 16 to 32) and a NNT to achieve HAQ >0.3 of 5 (95% CI, 4 to 7). Improvement in the physical component of the SF-36 was significantly more likely in the abatacept group (RR, 1.90, 95% CI, 1.52 to 2.39). There was no significant difference between the groups in likelihood of scoring worse. The RR of scoring the same was 0.66 in favor of placebo (95% CI, 0.56 to 0.78). There were significantly fewer patients that scored worse on the mental component of the SF-36 (RR, 0.64; 95% CI, 0.44 to 0.94). Scoring the same was not significantly different between the groups. A score of better was significantly higher in the abatacept group (RR, 1.42; 95% CI, 1.14 to 1.76).
Navarro-Sarabia et al.[159] (2005)	SR RCTs of patients	N=2,381 (6 trials)	Primary: ACR, EULAR responses, DAS 28,	Primary: Adalimumab 40 mg every other week was associated with a RR of 1.52 to 4.63 to attain an ACR 20 response at 24 weeks with a NNT of 1.9 to 5.4.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Adalimumab 20, 40, 80 mg every week to every other week, alone or in combination with DMARDs vs placebo or placebo plus DMARDs	with confirmed RA (defined by ACR 1987 criteria), who had active disease and who either failed MTX or other DMARDs therapy, or DMARD naive	12 to 52 weeks	components of ACR responses, and radiographic data Secondary: Safety	The RR to achieve an ACR 50 response was 4.63 (95% CI, 3.04 to 7.05) and NNT was 3.0 (95% CI, 2.0 to 6.0). The RR to achieve an ACR 70 response was reported as 5.14 (95% CI, 3.14 to 8.41) and a NNT of 7 (95% CI, 5 to 13). At 52 weeks, the RRs were reported for ACR 20, ACR 50 and ACR 70 as 2.46 (95% CI, 1.87 to 3.22), 4.37 (95% CI, 2.77 to 6.91) and 5.15 (95% CI, 2.60 to 10.22) and NNTs were 2.9, 3.1 and 5.3, respectively. A significantly slower rate of radiological progression was detected with either adalimumab 40 mg every other week or 20 mg every week in combination with MTX compared to placebo plus MTX, at 52 weeks. Adalimumab monotherapy (40 mg every other week) was associated with a RR of 1.91 (95% CI, 1.17 to 3.10), 2.84 (95% CI, 1.58 to 5.12) and 7.33 (95% CI, 2.25 to 33.90) to achieve an ACR 20, ACR 50 and ACR 70 response, respectively, with NNTs of 5 (95% CI, 3 to 9), 7 (95% CI, 4 to 20) and 9 (95% CI, 3 to 38), respectively at 24 weeks. Secondary: Only one study demonstrated that adalimumab was associated with a significantly higher risk of developing serious infection (RR, 7.64; 95% CI, 1.02 to 57.18; NNH, 30.2).
Smolen et al.[160] (2016) EXXELERATE Certolizumab pegol (400 mg weeks 0, 2, and 4, then 200 mg once every 2 weeks) plus methotrexate vs	PG, SB, RCT Patients >18 years of age with RA who were DMARD-naive and with active disease despite a minimum 12-week course of methotrexate therapy	N=908 104 weeks	Primary: ACR20 at week 12, low disease activity at week 104 Secondary: Percentage of patients with low disease activity at weeks 6, 12, and 52; change from baseline in HAQ-	Primary: The results of the primary analysis showed no significant difference in week 12 ACR20 response (69% and 71%; OR, 0.90; 95% CI, 0.67 to 1.20; P=0.467) or week 104 DAS28-ESR low disease activity (35% and 33%; OR, 1.09; 95% CI, 0.82; 1.45; P=0.532) between certolizumab pegol plus methotrexate and adalimumab plus methotrexate, respectively. At week 12, 65 non-responders to certolizumab pegol were switched to adalimumab and 57 non-responders to adalimumab were switched to certolizumab pegol; 58% of patients switching to certolizumab pegol and 62% of patients switching to adalimumab responded 12 weeks later by achieving low disease activity or a DAS28-ESR reduction 1.2 or greater.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
adalimumab (40 mg once every two weeks) plus methotrexate At week 12, patients were classified as responders (by either achieving low disease activity according to DAS28-ESR ≤3.2 or DAS28-ESR reduction ≥1.2 from baseline) or as non-responders; Non-responders to the first TNF inhibitor to which they were randomized were switched to the other TNF inhibitor with no washout period			DI	Secondary: The secondary efficacy endpoints were similar between certolizumab pegol plus methotrexate and adalimumab plus methotrexate patients. Physical functioning improved for both treatment groups. Change from baseline in HAQ-DI at week 104 was −0.62 for patients assigned to certolizumab pegol plus methotrexate and −0.72 for patients assigned to adalimumab plus methotrexate, and post-hoc analysis shows that normative physical function (HAQ-DI ≤0.25) was achieved by 20% of patients assigned to certolizumab pegol plus methotrexate and 22% of patients assigned to adalimumab plus methotrexate.
Mertens et al.[161] (2009) Anakinra 50 to 150 mg daily vs placebo	SR RCTs of patients >18 years of age with RA	N=2,876 (5 trials) 24 weeks	Primary: Patients achieving ACR 20 Secondary: Patients achieving ACR 50 and ACR 70, and safety	Primary: ACR 20 achievement was noted in significantly more participants taking anakinra (38%) compared to patients taking placebo (23%; RR, 1.61; 95% CI, 1.32 to 1.98). It was concluded that this 15% difference represented a modest yet clinically meaningful difference. Secondary: Both ACR 50 and ACR 70 were obtained at a significantly greater rate with anakinra as opposed to placebo (18 vs 7%; RR, 2.52; 95% CI, 1.56 to 4.03 and 7 vs 2%; RR, 3.71; 95% CI, 1.44 to 9.57, respectively). Anakinra was also associated with significant improvements in HAQ, visual analog score, Larsen radiographic scores and change in ESR compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The number of withdrawals, deaths, adverse events and infections were not significantly different between active treatment and placebo. However, injection site reaction was significantly more prevalent in the anakinra group vs the placebo group (71 vs 28%).
Blumenauer et al.[162] (2003) Etanercept 10 mg or 25 mg twice weekly alone or in combination with MTX vs MTX or placebo	SR RCTs of patients ≥16 years of age meeting the ACR 1987 revised criteria for RA with evidence of active disease as demonstrated by ≥2 of the following: tender joint count, swollen joint count, duration of early morning stiffness >30 minutes, acute phase reactants such as Westergren ESR or CRP	N=949 (3 trials) ≥6 months	Primary: ACR 20, ACR 50, ACR 70 responses, and erosion scores Secondary: Safety	Primary: At six months, 64% of individuals on etanercept 25 mg attained an ACR 20 response vs 15% of patients on control with either MTX alone or placebo (RR, 3.8; 95% CI, 2.5 to 6.0; NNT, 2). ACR 50 was achieved by 39% in the etanercept group compared to 4% in the control group (RR, 8.89; 95% CI, 3.61 to 21.89; NNT, 3). An ACR 70 response was reported in 15 and 1% of etanercept and control patients, respectively (RR, 11.31; 95% CI, 2.19 to 58.30; NNT, 7). Etanercept 10 mg was only associated with significant ACR 20 (51 vs 11% of controls; RR, 4.6; 95% CI, 2.4 to 8.8; NNT, 3) and ACR 50 responses (24 vs 5% of controls; RR, 4.74; 95% CI, 1.68 to 13.36; NNT, 5). Seventy-two percent of patients receiving etanercept had no increase in Sharp erosion score vs 60% of MTX patients. The Sharp erosion scores and JSN were not significantly reduced by either etanercept dose, however etanercept 25 mg was associated with a significantly reduced total Sharp score (WMD, -10.50; 95% CI, -13.33 to -7.67). Secondary: Injection site reactions were reported in 34% of patients on etanercept 10 mg compared to 9% of controls (RR, 3.86; 95% CI, 2.59 to 5.77; NNH, 4) and 41% of patients receiving etanercept 25 mg vs 9% of controls (RR, 4.77; 95% CI, 3.26 to 6.97; NNH, 3.1). The number of withdrawals was reported less frequently in the etanercept 25 mg group (4%) compared to the control group (8%; RR, 0.50; 95% CI, 0.27 to 0.94) and no difference was found between the etanercept 10 mg group and control in the rate of discontinuation.
van Vollenhoven et al.[163]	MC, OL, PG, RCT	N=487	Primary: Proportion of	Primary: At month 18, there was no statistically significant difference in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2012) SWEFOT Infliximab 3 mg/kg at weeks zero, two and six then every eight weeks plus MTX 20 mg weekly (Group B) vs MTX 20 mg weekly plus SSZ 1,000 mg twice-daily plus hydroxychloroquine 400 mg daily (Group A)	Patients ≥18 years of age with RA (ACR) criteria, no previous DMARD treatment, no oral glucocorticoid treatment or stable glucocorticoid treatment for ≥4 weeks of at most 10 mg daily prednisolone (or equivalent), a DAS28 >3.2	24 months	patients achieving a EULAR-define good response (a decrease of DAS28 by ≥1.2 and a resulting DAS28 ≤3.2 or less Secondary: EULAR and ACR responses at months 18 and 24, radiological outcomes at months 24	proportion of patients achieving an EULAR-defined good response for patients treated with infliximab compared to conventional therapy (38 vs 29%, respectively; 95% CI, 0.93 to 1.85). Furthermore, there was no statistically significant difference between the treatment groups at 24 months (38 vs 31%, respectively; P=0.204). Secondary: At 18 months, no statistically significant differences were reported between infliximab and conventional therapy with regard to ACR 20 (45 vs 34%, respectively; 95% CI, 0.99 to 1.82) ACR 70 (17 vs 11%, respectively; 95% CI, 0.86 to 2.98) or EULAR good or moderate response (58 vs 47%, respectively; 95% CI, 0.97 to 1.56). There was, however, a statistically significant difference favoring infliximab with regard to ACR 50 (30 vs 19%, respectively; 95% CI, 1.02 to 2.46). At 24 months there was no statistically significant difference between infliximab and conventional therapy with regard to ACR 20 response (40 vs 33%, respectively; P=0.259), ACR 50 (30 vs 22%; P=0.134), ACR 70 (16 vs 14%; P=0.566) or EULAR good to moderate response (59 vs 50%; P=0.166). Radiological outcomes were not statistically significant between infliximab and conventional therapy at 24 months with regard to total score (P=0.118), erosion score (P=0.0730) or joint-space narrowing score (P=0.054).
Wiens et al.[164] (2009) Infliximab 3 mg/kg at weeks 0, 2 and 6 then every 8 weeks plus MTX vs placebo plus MTX	MA RCTs of adult patients with RA	N=2,129 (7 trials) ≥14 weeks	Primary: ACR 20, ACR 50, and ACR 70 response Secondary: Safety and discontinuation of therapy	Primary: Through 30 weeks, the proportion of patients achieving an ACR 20 was 59% in the infliximab group compared to the control group (RR, 1.87; 95% CI, 1.43 to 2.45). An ACR 50 was achieved in 33% of infliximab treated patients and 12% of controls (RR, 2.68; 95% CI, 1.79 to 3.99). The RR of achieving an ACR 70 was 2.68 (95% CI, 1.78 to 4.03) with 17 and 5% of infliximab and control groups achieving an ACR 70, respectively. After ≥1 year of treatment, 62% of patients in the infliximab group and 26% of controls achieved an ACR 20 (RR, 2.33; 95% CI, 1.90 to 2.87). An ACR 50 was achieved in 43% of the infliximab treated patients and 27% of controls (RR, 1.61; 95% CI, 1.14 to 2.27). The RR for reaching

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				ACR 70 was 1.69 (95% CI, 0.87 to 3.28), and 29% of patients in the infliximab group compared to 17% of patients in the control group achieved an ACR 70. Secondary: There were no statistically significant differences in serious adverse events. There was a higher number of patients that withdrew due to adverse events in the infliximab group compared to the placebo group (7 vs 3%; RR, 2.05, 95% CI, 1.33 to 3.16); however, fewer patients in the infliximab group withdrew due to lack of efficacy compared to the control group (4 vs 12%; RR, 0.41; 95% CI, 0.18 to 0.95).
Nixon et al.[165] (2007) Adalimumab, anakinra, etanercept, or infliximab with or without MTX vs MTX or placebo	MA RCTs of patients with a clinical diagnosis of RA	N=6,694 (13 trials) ≥6 months	Primary: ACR 20 response and ACR 50 response Secondary: Not reported	Primary: The OR for an ACR 20 response was 3.19 (95% CI, 1.97 to 5.48) with adalimumab, 1.70 (95% CI, 0.90 to 3.29) with anakinra, 3.58 (95% CI, 2.09 to 6.91) with etanercept and 3.47 (95% CI, 1.66 to 7.14) with infliximab, all compared to placebo. The OR to achieve an ACR 50 response with adalimumab was 3.97 (95% CI, 2.73 to 6.07), 2.13 (95% CI, 1.27 to 4.22) with anakinra, 4.21 (95% CI, 2.74 to 7.43) with etanercept and 4.14 (95% CI, 2.42 to 7.46) with infliximab, all compared to placebo. The addition of MTX to any of the agents was found to enhance the efficacy of each treatment. The TNF blockers in combination with MTX were associated with higher ACR 20 and ACR 50 responses than anakinra and MTX (OR, 6.35 vs 3.20 and OR, 8.53 vs 4.56, respectively). Further analysis of each agent against another was performed and no significant difference was determined between individual agents in obtaining an ACR 20 and ACR 50 response (adalimumab vs anakinra; OR, 1.88; 95% CI, 0.83 to 4.49 and OR, 1.84; 95% CI, 0.84 to 3.70; adalimumab vs etanercept; OR, 0.89; 95% CI, 0.42 to 1.79 and OR, 0.94; 95% CI, 0.50 to 1.62; adalimumab vs infliximab; OR, 0.92; 95% CI, 0.39 to 2.37 and OR, 0.96; 95% CI, 0.48 to 1.90; etanercept vs anakinra; OR, 2.11; 95% CI, 0.90 to 5.68 and OR, 1.94; 95% CI, 0.87 to 4.36; infliximab vs anakinra; OR, 2.05; 95% CI, 0.74 to 5.50 and OR, 1.93; 95% CI, 0.79 to 4.29; and infliximab vs etanercept; OR, 0.97; 95% CI, 0.34 to 2.33 and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				OR, 0.98; 95% CI, 0.45 to 1.93. However, the TNF blockers as a class showed a greater ACR 20 and ACR 50 response compared to anakinra (OR, 1.96; 95% CI, 1.03 to 4.01 and OR, 1.93; 95% CI, 1.05 to 3.50; P<0.05). Secondary: Not reported
Gabay et al.[166] (2013) ADACTA Tocilizumab 8 mg/kg vs adalimumab 40 mg every 2 weeks	DB, PG, RCT Patients ≥18 years of age with RA > 6 months, intolerant to MTX or were inappropriate for continued MTX treatment	N=326 24 weeks	Primary: DAS 28 improvement Secondary: Percentage of patients with: a remission response (DAS28 <2.6); low disease activity (DAS28 ≤ 3.2); improvements of at least 20%, 50%, or 70% in ACR Score (ACR 20, ACR 50, and ACR 70); and with a EULAR good Response, and a EULAR good or moderate response	Primary: The change from baseline in DAS28 was significantly greater in the tocilizumab group (-3.3) than in the adalimumab group (-1.8) patients (difference -1.5; 95% CI, -1.8 to -1.1; P<0·0001). Secondary: DAS 28 remission rates at week 24 were achieved in 39.9% with tocilizumab and 10.5% in the adalimumab group (difference -1.5, 95% CI, -1.8 to -1.1; P<0·0001). The proportion of patients with low disease activity (DAS 28 ≤3.2) at 24 weeks was 51.5% in tocilizumab group and 19.8% in the adalimumab group (difference -1.5, 95% CI, -1.8 to -1.1; P<0.0001). The proportion of patients on tocilizumab vs adalimumab with improvements of at least 20% in ACR score was 65.0 vs 49.4%, respectively, a 50% improvement was seen in 47.2 vs 27.8% respectively and a 70% improvement was observed in 32.5 vs 17.9%, respectively. The proportion of patients on tocilizumab vs adalimumab with a EULAR good response was 51.5 vs 19.8%, respectively, and percentage with a EULAR good or moderate was response 77.9 vs 54.9%, respectively.
Weinblatt et al.[167] (2013) Abatacept 125 mg subcutaneously once weekly and	MC, RCT Patients 18 years of age with a confirmed diagnosis of RA for ≤5 years, inadequate response to MTX, and who	N=646 12 months	Primary: Noninferiority, assessed based on ACR20 at one year Secondary: ACR 50, ACR 70, DAS 28, remission	Primary: The proportions of patients achieving ACR 20 response were comparable between abatacept and adalimumab treatment groups (59.7 and 60.1%, respectively; difference 1.8%; 95% CI, -5.6 to 9.2%). Secondary: The proportions of patients achieving ACR 50 response were comparable between abatacept and adalimumab treatment groups (46.2 and 46%,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
MTX vs adalimumab 40 mg subcutaneously every other week and MTX Patients were concomitantly treated with a stable dosage of MTX (15 to 25 mg weekly, or ≥7.5 mg weekly in patients with intolerance to higher doses). Concomitant treatment with SSZ, HCQ, NSAIDs and stable low-dose oral corticosteroids (≤10 mg/day prednisone equivalent) were allowed.	had not received previous biologic therapy		response (DAS28 <2.6), low disease activity (DAS28 ≤ 3.2), and HAQ-DI	respectively; 95% CI not reported). The proportions of patients achieving ACR 70 response were comparable between abatacept and adalimumab treatment groups (29.2 and 26%, respectively; 95% CI not reported). Mean improvements in DAS 28 were comparable between abatacept and adalimumab treatment groups (-2.30 and -2.27, respectively; 95% CI not reported). The proportions of patients achieving remission (DAS28 <2.6) were also comparable between abatacept and adalimumab treatment groups (43.3 and 41.9%, respectively; 95% CI not reported). In addition, the proportions of patients achieving low disease activity (DAS28 ≤3.2) were comparable between abatacept and adalimumab treatment groups (59.3 and 61.4%, respectively; 95% CI not reported). Improvements in the HAQ-DI score were comparable between abatacept and adalimumab treatment groups (60.4 and 57.0%, respectively; difference, 3.4%; 95% CI, -4.5 to 11.3%).
Schiff et al.[168] (2013) AMPLE Abatacept 125 mg subcutaneously once weekly	MC, RCT Patients 18 years of age with a confirmed diagnosis of RA for ≤5 years, inadequate response to MTX, and who	N=646 2 years	Primary: ACR20 at two years Secondary: ACR 50, ACR 70, DAS 28, remission response (DAS28	Primary: The proportions of patients achieving ACR 20 response were comparable between abatacept and adalimumab treatment groups (59.7 and 60.1%, respectively; 95% CI not reported). Secondary: The proportions of patients achieving ACR 50 response were comparable between abatacept and adalimumab treatment groups (44.7 and 46.6%,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and MTX vs adalimumab 40 mg subcutaneously every other week and MTX Patients were concomitantly treated with a stable dosage of MTX (15 to 25 mg weekly, or ≥7.5 mg weekly in patients with intolerance to higher doses). Concomitant treatment with SSZ, HCQ, NSAIDs and stable low-dose oral corticosteroids (≤10 mg/day prednisone equivalent) were allowed.	had not received previous biologic therapy		<2.6), low disease activity (DAS28 ≤3.2), HAQ-DI, and mTSS	respectively; 95% CI not reported). The proportions of patients achieving ACR 70 response were comparable between abatacept and adalimumab treatment groups (31.1 and 29.3%, respectively; 95% CI not reported). Mean improvements in DAS 28 were comparable between abatacept and adalimumab treatment groups (-2.35 and -2.33, respectively; 95% CI not reported). The proportions of patients achieving remission (DAS28 <2.6) were also comparable between abatacept and adalimumab treatment groups (50.6 and 53.3%, respectively; 95% CI not reported). In addition, the proportions of patients achieving low disease activity (DAS28 ≤3.2) were comparable between abatacept and adalimumab treatment groups (65.3 and 68.0%, respectively; 95% CI not reported). Improvements in the HAQ-DI score were comparable between abatacept and adalimumab treatment groups (54.1 and 48.8%, respectively; 95% CI not reported). The non-progression rate (change from baseline mTSS ≤smallest detectable change of 2.2) was 84.8% (95% CI, 80.4 to 89.2) vs 83.8% (95% CI, 79.4 to 88.3) in the abatacept and adalimumab groups, respectively.
Fleischmann et al.[169] (2012) ORAL Solo Tofacitinib 5 mg twice daily	DB, PC, PG, RCT Patients ≥18 years of age with a diagnosis of active RA (≥6 tender or painful joints [68	N=611 6 month	Primary: ACR20 response rate at month three, change from baseline in HAQ-DI at month three, and proportion of	Primary: Greater proportions of patients receiving tofacitinib 5 mg and tofacitinib 10 mg twice daily met the criteria for an ACR20 response at month three than those receiving placebo (59.8 and 65.7 vs 26.7%; P<0.001 for both comparisons). Greater reductions from baseline in the HAQ-DI score were observed in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs tofacitinib 10 mg twice daily vs placebo	joint count] and ≥6 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L), and inadequate response or adverse reaction to at least one DMARD; all DMARDs except stable doses of antimalarial agents had to be discontinued; the use of NSAIDs and glucocorticoids (≤10 mg of a prednisone equivalent daily) was permitted		patients with DAS28-4(ESR) <2.6 at month three Secondary: ACR50, and ACR70 response rates, change from baseline in HAQ-DI score, DAS28-4(ESR) and DAS28-4(CRP), proportion of patients with DAS28-4(ESR) and DAS28-4(CRP) <2.6 and ≤3.2 at all visits up to month six, and FACIT-F scores at month three	patients receiving tofacitinib 5 and 10 mg twice daily at month three than those receiving placebo (least-squares mean changes from baseline, -0.50 and -0.57 vs -0.19; P<0.001 for both comparisons). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) <2.6 at month three than those receiving placebo (5.6 and 8.7 vs 4.4%; P=0.62 and P=0.10, respectively); however, improvement was not statistically significant. Secondary: Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR50 response at month three than those receiving placebo (31.1 and 36.8 vs 12.5%; P<0.001 for both comparisons). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR70 response at month three than those receiving placebo (15.4 and 20.3 vs 5.8%; P=0.003 and P<0.001, respectively). Proportions of patients receiving tofacitinib 5 and 10 mg twice daily who achieved DAS28-4(ESR) <2.6 at month six were 9.8 and 14.2%, respectively. Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) ≤3.2 at month three than those receiving placebo (12.5 and 17.0 vs 5.3%; P=0.02 and P<0.001, respectively). Proportions of patients receiving tofacitinib 5 and 10 mg twice daily who achieved DAS28-4(ESR) ≤3.2 at month six were 22.0% and 28.0%, respectively. Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(CRP) <2.6 at month three than those receiving placebo (18.7 and 24.4 vs 5.0%; P<0.001 for both comparisons). Proportions of patients receiving tofacitinib 5 and 10 mg twice daily who

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				achieved DAS28-4(CRP) <2.6 at month six were 26.6 and 34.3%, respectively). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(CRP) ≤3.2 at month three than those receiving placebo (28.2 and 36.8 vs 6.7%; P<0.001 for both comparisons). Proportions of patients receiving tofacitinib 5 and 10 mg twice daily who achieved DAS28-4(CRP) ≤3.2 at month six were 43.6 and 50.8%, respectively. The least-squares mean changes from baseline at month three in FACIT-F scores were 6.7 points with the tofacitinib 5 mg and 8.0 points with the tofacitinib 10 mg doses, as compared to 2.8 points with placebo (P<0.001).
van Vollenhoven et al.[170] (2012) ORAL Standard Tofacitinib 5 mg twice daily vs tofacitinib 10 mg twice daily vs adalimumab 40 mg once every 2 weeks vs placebo	DB, PG, RCT Patients ≥18 years of age with a diagnosis of active RA (≥6 tender or painful joints [68 joint count] and ≥6 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L)	N=717 12 month	Primary: ACR20 response rate at month six, change in HAQ-DI at month three, and proportion of patients with DAS28-4(ESR) <2.6 at month six Secondary: ACR20, ACR50, and ACR70 response rates, change from baseline in HAQ-DI, and DAS28-4(ESR) over time	Primary: Greater proportions of patients receiving tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and adalimumab met the criteria for an ACR20 response at month six than those receiving placebo (51.5, 52.6, and 47.2 vs 28.3%; P<0.001 for all comparisons). Greater reductions from baseline in the HAQ-DI score were observed in patients receiving tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and adalimumab at month three than those receiving placebo (least-squares mean changes from baseline: -0.55, -0.61 and -0.49 vs -0.24; P≤0.001 for all comparisons). Greater proportions of patients receiving tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and adalimumab achieved DAS28-4(ESR) <2.6 at month six than those receiving placebo (6.2, 12.5, and 6.7 vs 1.1%; P≤0.05, P≤0.001, and P≤0.05, respectively). Secondary: Compared to placebo, significantly greater proportions of patient receiving active treatments achieved ACR50 and ACR70 responses and the changes from baseline in DAS28-4(ESR) and HAQ-DI scores over time (P≤0.05 for all comparisons).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients were also receiving MTX 7.5 to 25 mg weekly with an incomplete response.				A significant difference in ACR20 and ACR50 responses with each tofacitinib treatment as compared to placebo was noted after one month (P≤0.001 for all comparisons). Data on comparison between adalimumab and placebo was not reported.
Burmester et al.[171] (2013) ORAL Step Tofacitinib 5 mg twice daily vs tofacitinib 10 mg twice daily vs placebo for 3 months, followed by tofacitinib 5 mg or 10 mg twice daily Patients were also receiving oral or parenteral MTX continuously for ≥4 months at a stable dose of 7.5 to 25 mg weekly for ≥6 weeks. Stable background doses of antimalarial agents (≥8 weeks) were permitted.	DB, MC, PG, RCT Patients ≥18 years of age with a diagnosis of moderate to severe active RA (≥6 tender or painful joints [68 joint count] and ≥6 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L) and inadequate response or intolerance to ≥1 TNF-blocking agents	N=399 6 month	Primary: ACR20 response rate at month three, change from baseline in HAQ-DI score at month three, and proportion of patients with DAS28-4(ESR) <2.6 at month three Secondary: ACR20, ACR50, and ACR70 response rates, change from baseline in HAQ-DI score, changes in DAS28-4(ESR) and DAS28-3(CRP), rates of DAS28-4(ESR) and DAS28-3(CRP) <2.6 and ≤3.2, patient's assessment of arthritis pain, and FACIT-F at all visits	Primary: Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR20 response at month three than those receiving placebo (41.7 and 48.1 vs 24.4%; P=0.0024 and P<0.0001, respectively). Greater reductions from baseline in the HAQ-DI score were observed in patients receiving tofacitinib 5 mg and 10 mg twice daily at month three than those receiving placebo (least-squares mean changes from baseline: -0.43 and -0.46 vs -0.18; P<0.0001 for both comparisons). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) <2.6 at month three than those receiving placebo (6.7 and 8.8 vs 1.7%; P=0.0496 and P=0.0105, respectively). Secondary: Compared to placebo, significantly greater proportions of patients in the tofacitinib 5 mg and 10 mg twice daily met the criteria for an ACR20 response at all visits through month three (P≤0.05 for all visits, except P<0.0001 for 10 mg group vs placebo at month three). Compared to placebo, significantly greater proportion of patients in the tofacitinib 5 mg twice daily group achieved ACR50 at all visits through month three (P≤0.05 at two week and one month visits and P<0.0001 at three month visit). Compared to placebo, significantly greater proportion of patients in the tofacitinib 10 mg twice daily group achieved the ACR50 at three month study visit (P<0.0001); however, responses at two week and at one month visits were not significantly different (P values not reported). Compared to placebo, significantly greater proportions of patients in the tofacitinib 5 mg and 10 mg twice daily groups achieved ACR70 at one

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				month and three months visits (P≤0.05 for all visits, except P<0.001 for 5 mg group vs placebo at month three). The responses between both active treatment groups and placebo at two week visit were not significantly different (P values not reported). Compared to placebo, significantly greater reductions from baseline in the HAQ-DI score were observed in patients receiving tofacitinib 10 mg twice daily at all visits through month three (P≤0.05 for all comparisons, except P<0.0001 at month three). Compared to placebo, significantly greater reductions from baseline in the HAQ-DI score were also observed at three month visit in patients receiving tofacitinib 5 mg twice daily (P<0.0001); however, the changes at two week and one month visits were not significantly different (P values not reported). Compared to placebo, changes from baseline in DAS28-4(ESR) were greater in patients receiving tofacitinib 5 and 10 mg twice daily at all visits through month three (P=0.01 for both comparisons; P values not reported for all other visits). Compared to placebo, significantly greater changes from baseline in DAS28-3(CRP) were observed in patients receiving tofacitinib 5 and 10 mg twice daily at all visits through month three (P<0.0001 for all comparisons). Compared to placebo, significantly greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) <2.6 at month three (P=0.0496 and P=0.0105, respectively; P values not reported for all other visits). Compared to placebo, significantly greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-3(CRP) <2.6 at month three (P<0.0001 for both comparisons; P values not reported for all other visits). Compared to placebo, significantly greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) ≤3.2 at month three (P≤0.05 and P<0.0001, respectively; P values not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				reported for all other visits). Compared to placebo, significantly greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-3(CRP) ≤3.2 at month three (P<0.0001 for both comparisons; P values not reported for all other visits). Changes from baseline in patient's assessment of arthritis pain at month three were greater in tofacitinib 5 and 10 mg twice daily treatment groups than in those receiving placebo (−27.2 and −25.0 vs −8.3; P<0.0001 for both comparisons; P values not reported for all other visits). Improvements in FACIT-F at month three were greater in patients receiving tofacitinib 5 and 10 mg twice daily than in those receiving placebo (6.3 and 4.6 vs 1.1; P<0·0001 and P=0.0043, respectively; P values not reported for all other visits).
Van der Heijde et al.[172] (2013) ORAL Scan Tofacitinib 5 mg twice daily vs tofacitinib 10 mg twice daily vs placebo Patients receiving placebo and not achieving ≥20% improvement in	DB, MC, PG, RCT Patients ≥18 years of age with a diagnosis of active RA (≥6 tender or painful joints [68 joint count] and ≥6 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L) and evidence of ≥3 joint erosions on posteroanterior hand and wrist radiographs or anteroposterior foot radiographs (if radiographic evidence of joint	N=797 12 month	Primary: ACR20 response rate at month six, mean change from baseline in mTSS at month six, change from baseline in HAQ-DI score at month three, and proportion of patients with DAS28-4(ESR) <2.6 at month six Secondary: ACR20, ACR50, and ACR70 response rates, DAS28-4(ESR) at all visits, changes	Primary: Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR20 response at month six than those receiving placebo (51.5 and 61.8% vs 25.3%; P=0.0001 for both comparisons). The least squares mean changes in mTSS at month six were 0.12 and 0.06 for patients receiving tofacitinib 5 and 10 mg twice daily, respectively, vs 0.47 for placebo (P=0.0792 and P≤0.05, respectively). The least squares mean changes in the HAQ-DI score at month three for tofacitinib at 5 and 10 mg twice daily were -0.40 and -0.54, respectively, vs -0.15 for placebo (P value not reported and P<0.0001, respectively). Proportions of patients achieving DAS28-ESR <2.6 at month six were 7.2% and 16.0% for tofacitinib at 5 and 10 mg twice daily, respectively, vs 1.6% for placebo (P value not reported and P<0.0001, respectively). Secondary: Compared to placebo at month six, significantly greater proportions of patients in the tofacitinib 5 mg and 10 mg twice daily groups achieved

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
swollen and tender joint counts after 3 months were switched to a predetermined dose of tofacitinib 5 mg or 10 mg twice daily. All patients continuing to receive placebo were switched in a blinded manner to tofacitinib after 6 months. Patients were also receiving stable doses of MTX (15 to 25 mg weekly or <15 mg if there were safety issues at higher doses) for ≥6 weeks. Stable doses of low-dose corticosteroids (≤10 mg daily prednisone or equivalent) and NSAIDs were permitted. Prior use of biologic or nonbiologic DMARDs was	erosions was unavailable, presence of IgM rheumatoid factor positivity or antibodies to cyclic citrullinated peptide).		from baseline in the ACR code disease activity measures at month six, rates of nonprogressors (≤0.5 unit change from baseline in mTSS or erosion score) at months six, 12, and 24, changes from baseline in mTSS (at months 12 and 24), changes from baseline in erosion score and JSN score (at months six, 12, and 24), change from baseline in HAQ-DI score, the FACIT-F, and the patient's assessment of arthritis pain	ACR50 (32.4 and 43.7 vs 8.4%; P<0.0001 for both comparisons) and ACR70 (14.6 and 22.3 vs 1.3%; P<0.0001 for both comparisons). At month 12, ACR20, ACR50, and ACR70 response rates were 48.5, 32.7, and 18.8%, respectively, for tofacitinib 5 mg and 57.0, 41.1, and 27.5%, respectively, for tofacitinib 10 mg. At month 12, the proportions of patients with DAS28-ESR <2.6 were 10.6 and 15.2% in the groups receiving tofacitinib 5 and 10 mg twice daily, respectively. At month six, the proportions of patients with DAS28-ESR ≤3.2 were 14.3 and 28.4% in the groups receiving tofacitinib 5 and 10 mg twice daily, respectively, compared to 3.1% of patients receiving placebo (P<0.0001 for both comparisons). At month 12, the rates of DAS28-ESR <3.2 for patients receiving tofacitinib at 5 and 10 mg twice daily increased to 23.4 and 30.7%, respectively. At month six, least squares mean changes from baseline in DAS28-ESR were greater for tofacitinib 5 and 10 mg twice daily compared to placebo (-2.1 and -2.5 vs -1.3; P<0.0001 for both comparisons); at month 12, least squares mean changes from baseline in DAS28-ESR were -2.3 and -2.5 for tofacitinib 5 and 10 mg twice daily, respectively. Compared to placebo a month six, statistically significant improvements from baseline were observed in all ACR core components in both tofacitinib 5 and 10 mg twice daily groups, including improvements in tender or painful joint count (P≤0.05 and P<0.01, respectively), swollen joint count (P<0.01 and P<0.0001, respectively), CRP (P<0.0001 for both comparisons), patient's global assessment of disease activity (P<0.0001 for both comparisons), physician's global assessment of disease activity (P<0.0001 for both comparisons), patient's assessment of pain (P<0.01 and P<0.0001, respectively), and HAQ-DI (P<0.0001 for both comparisons). The proportion of patients with no radiographic progression (≤0.5 unit increase from baseline in mTSS) at months six and 12 was similar in both tofacitinib treatment groups and significantly greater than in the placebo treatment group (P≤0.05 for both). At month six, the proportion of patients with no progression in erosion score (≤0.5 unit increase from baseline) was numerically greater, but not statistically significantly different, in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
permitted.				tofacitinib treatment groups compared to the placebo-treated group (P>0.05). The proportion of patients with no progression in erosion score at month 12 was significantly greater in both tofacitinib treatment groups compared to the placebo-treated group (P≤0.05). The plots of changes from baseline in mTSS, JSN score, and erosion score at months six and 12 for both tofacitinib-treated groups were very similar and were different from the plot for the placebo-treated group (P values not reported). Compared to placebo, greater reductions from baseline in the HAQ-DI score were observed in patients receiving tofacitinib 5 and 10 mg twice daily at all visits (P<0.001 for all comparisons, except P<0.01 for tofacitinib 5 mg vs placebo at one month visit). Improvements in FACIT-F from baseline to month six were greater in patients receiving tofacitinib 5 and 10 mg twice daily than in those receiving placebo (5.6 and 6.9 vs 2.1; P<0.001 and P<0.0001, respectively; P values not reported for all other visits). Changes from baseline in patient's assessment of arthritis pain at month six were greater in 5 and 10 mg twice daily treatment groups than in those receiving placebo (-26.4 and -29.7 vs -15.70; P<0.01 and P<0.0001, respectively; P values not reported for all other visits).
Kremer et al.[173] (2013) ORAL Sync Tofacitinib 5 mg twice daily vs tofacitinib 10 mg twice daily vs	DB, MC, PG, RCT Patients ≥18 years of age with a diagnosis of active RA (≥4 tender or painful joints [68 joint count] and ≥4 swollen joints [66 joint count] and either ESR>28 mm/hour or CRP>7 mg/L) and	N=792 12 month	Primary: ACR20 response rate at month six, change from baseline in HAQ-DI score at month three, and proportion of patients with DAS28-4(ESR) <2.6 at month six Secondary:	Primary: Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR20 response at month six than those receiving placebo (52.1 and 56.6 vs 30.8%; P<0.001 for both comparisons). Greater reductions from baseline in the HAQ-DI score were observed in patients receiving tofacitinib 5 and 10 mg twice daily at month three than those receiving placebo (least-squares mean changes from baseline: -0.44 and -0.53 vs -0.16; P<0.001 for both comparisons). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily achieved DAS28-4(ESR) <2.6 at month six than those receiving

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo Patients receiving placebo and not achieving ≥20% improvement in swollen and tender joint counts after 3 months were switched to a predetermined dose of tofacitinib 5 or 10 mg twice daily. All patients continuing to receive placebo were switched in a blinded manner to tofacitinib after 6 months. Patients were also receiving ≥1 nonbiologic DMARDs. Patients receiving MTX ≤25 mg weekly required ≥4 months of therapy at a stable dose for ≥6 weeks. Stable doses of low-dose corticosteroids (≤10 mg daily prednisone or	inadequate response to ≥1 stably dosed nonbiologic or biologic DMARDs		ACR20, ACR50, and ACR70 response rates, change from baseline in HAQ-DI score, changes in DAS28-4(ESR), and FACIT-F score over time	placebo (8.5 and 12.5 vs 2.6%; P=0.005 and P<0.001, respectively). Secondary: Over time, statistically significant response rates were observed for ACR20 and ACR50 by week two in both tofacitinib groups compared to placebo (P≤0.001 for all comparisons) and for ACR70 by week two in the tofacitinib 10 mg group (P≤0.05 at week two and P≤0.001 at all visits thereafter) and one month in the tofacitinib 5 mg group (P≤0.001 for all comparisons). Mean treatment differences in changes from baseline in HAQ-DI, DAS28-4(ESR), and FACIT-F response rates for both tofacitinib groups compared to placebo were statistically significant over time (P≤0.001 for all).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
equivalent) were permitted.				
Fleischmann et al.[174] (2017) ORAL Strategy Tofacitinib 5 mg twice daily by mouth vs tofacitinib 5 mg twice daily by mouth plus methotrexate vs adalimumab 40 mg every other week SC plus methotrexate	DB, MC, NI, RCT patients ≥18 years of age with active RA despite methotrexate therapy	N=1,146 1 year	Primary: ACR50 at 6 months Secondary: ACR 20 and ACR70 at six months, proportion of patients achieving low disease activity	Primary: At six months, ACR50 response was attained in 147 (38%) of 384 patients who received tofacitinib monotherapy, 173 (46%) of 376 patients who received tofacitinib and methotrexate, and 169 (44%) of 386 patients who received adalimumab and methotrexate. Tofacitinib and methotrexate was deemed non-inferior to adalimumab and methotrexate: the difference in the proportion of patients with an ACR50 response for tofacitinib and methotrexate compared with adalimumab and methotrexate was 2% (98.34%; CI, −6 to 11), with the lower bound of the CI above the prespecified non-inferiority boundary (−13%). Non-inferiority of the ACR50 response at six months was not shown for tofacitinib monotherapy versus tofacitinib and methotrexate (difference, −8%; 98.34% CI, −16 to 1) or versus adalimumab and methotrexate (−6%; 98.34% CI, −14 to 3); superiority was not shown for any comparison between the treatment groups. Secondary: ACR20 and ACR70 response rates in each treatment arm showed similar trends to those noted for ACR50, and were maintained over 12 months. In general, secondary efficacy endpoint responses were similar between combination arms, which were higher than in the tofacitinib monotherapy group. The proportions of patients who had low disease activity at six months, as indicated by SDAI (≤11), were similar between combination therapy groups (50% in the tofacitinib and methotrexate group and 47% in the adalimumab and methotrexate group), which were higher than in the tofacitinib monotherapy group (43%); these were maintained at 12 months in each treatment group. The proportions of patients who had low disease activity at six months and at 12 months in all treatment groups, as indicated by CDAI, DAS28-4(ESR), and DAS28-4(CRP), were consistent with those reported when assessing low disease activity as indicated by SDAI.
He et al.[175] (2013) Tofacitinib 1, 3, 5,	MA, SR RCTs including patients ≥18 years of	N=3,791 (8 trials) 12 to 24	Primary: ACR20 and ACR50 response rate at month three	Primary: At month three, the differences in ACR20 response rates between tofacitinib 1 mg twice daily and placebo groups did not reach statistical significance (RR, 1.83; 95% CI, 1.00 to 3.32).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
10, or 15 mg twice daily vs adalimumab 40 mg once every 2 weeks vs placebo	age with a diagnosis of RA	weeks	and six Secondary: Incidence of infections, immunological or hematological adverse events, incidence of withdrawal from the trials, changes in neutrophil count, hemoglobin and serum creatinine levels, incidence of ALT and AST more than one times upper limit of the normal range, and mean percentage changes of LDL and HDL	Greater proportions of patients receiving tofacitinib 3 mg twice daily met the criteria for an ACR20 response at month three than those receiving placebo (RR, 2.20; 95% CI, 1.20 to 4.04). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR20 response at month three than those receiving placebo (RR, 2.20; 95% CI, 1.58 to 3.07) and (RR, 2.38; 95% CI, 1.81 to 3.14), respectively. The effect was maintained at month six for both 5 mg twice daily (RR, 1.94; 95% CI, 1.55 to 2.44) and 10 mg twice daily (RR, 2.20; 95% CI, 1.76 to 2.75) treatment groups. Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR50 response at month three than those receiving placebo (RR, 2.91; 95% CI, 2.03 to 4.16) and (RR, 3.32; 95% CI, 2.33 to 4.72), respectively. Greater proportions of patients receiving tofacitinib 15 mg twice daily met the criteria for an ACR20 response at month three than those receiving placebo (RR, 2.29; 95% CI, 1.19 to 4.41). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR20 response at month three than those receiving adalimumab (RR, 1.65; 95% CI, 1.08 to 2.53) and (RR, 1.97; 95% CI, 1.32 to 2.92), respectively. At month six, there were no significant differences in ACR20 response rates in patients receiving tofacitinib vs adalimumab (P values not reported). Greater proportions of patients receiving tofacitinib 5 and 10 mg twice daily met the criteria for an ACR50 response at month three than those receiving adalimumab (RR, 1.95; 95% CI, 1.00 to 3.80) and (RR, 2.35; 95% CI, 1.26 to 4.38), respectively. Secondary: Compared to placebo, there were no statistically significant differences in the incidences of infections, neutropenia and withdrawal due to adverse events in patients receiving tofacitinib (P values not reported). However,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				significantly fewer patients withdrew from tofacitinib than placebo (RR, 0.60; 95% CI, 0.45 to 0.78). The withdrawal rate due to lack of efficacy was significantly lower in the patients receiving tofacitinib than placebo (RR, 0.18; 95% CI, 0.09 to 0.35). Compared to placebo, the mean neutrophil count significantly declined in patients receiving tofacitinib (P value not reported). The mean hemoglobin level was not significantly different in tofacitinib group compared to placebo group (P value not reported). Compared to placebo, the mean serum creatinine was found to be significantly higher for tofacitinib 10 mg twice daily (P value not reported). The risk ratios of the mean changes of ALT or AST exceeding one times upper limit of the normal range were statistically significant (P values not reported). Compared to placebo, the mean percentage change of HDL and LDL was significant higher in patients receiving tofacitinib (P values not reported).
Berhan et al.[176] (2013) Tofacitinib 3, 5, 10, or 15 mg twice daily (with or without MTX) vs placebo	MA DB, RCT including patients with a diagnosis of active RA for ≥6 months who were on at least one of nonbiologic or biologic DMARD	N=3,260 (8 trials) 12 to 24 weeks	Primary: ACR20 response rate, change from baseline in HAQ-DI score Secondary: Safety	Primary: Compared to placebo, tofacitinib treated patients had higher odds of meeting the criteria for an ACR20 response (OR, 4.15; 95% CI, 3.23 to 5.32). With the exception of one study, ACR20 response rates for patients receiving tofacitinib dosages ≥3 mg twice daily was significantly greater than those who received placebo (P value not reported). The subgroup odds ratios in the subgroups of tofacitinib 10 mg twice daily (OR, 4.3; 95% CI, 3.023 to 6.376) and 15 mg twice daily (OR, 6.06; 95% CI, 2.383 to 15.428) was higher than 3 mg twice daily (OR, 4.06; 95% CI, 1.340 to 12.305) and 5 mg twice daily (OR, 3.55; 95% CI, 2.435 to 5.169) treated groups. A statistically significant improvement in HAQ-DI scores were seen in patients receiving tofacitinib than placebo treated patients (SMD, −0.62; 95% CI, -0.735 to -0.506). Patients treated with tofacitinib dosages ≥5 mg twice daily have shown a statistically significant reduction in HAQ-DI scores (P value not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The proportion of infections was higher in the tofacitinib treated groups than in the placebo groups (SMD, 1.96, 95% CI, 1.428 to 2.676). In contrast to the subgroups of tofacitinib 10 mg (SMD, 3.08; 95% CI, 1.694 to 5.570) and 15 mg (SMD, 1.97; 95% CI, 1.088 to 3.558), the proportion of infections in the subgroups of tofacitinib 3 mg (SMD, 1.64; 95% CI, 0.858 to 3.142) and 5 mg (SMD, 1.52; 95% CI, 0.644 to 3.594) were not significantly different from placebo. There were significant increases from baseline in tofacitinib treated groups in the mean hemoglobin level (SMD, 0.11; 95% CI, 0.130 to 0.210), mean serum creatinine (SMD, 0.24; 95% CI, 0.112 to 0.372), HDL (SMD, 1.01; 95% CI, 0.332 to 1.682), and LDL (SMD, 0.95; 95% CI, 0.337 to 1.555). A significant number of patients with ALT (OR, 1.7; 95% CI, 1.29 to 2.46) and AST (OR, 2.19; 95% CI, 1.50 to 3.19) exceeding one times upper limit of the normal range were reported among tofacitinib treated groups. The rate of tofacitinib discontinuation due to adverse events was not significantly different from placebo (SMD, 1.27; 95% CI, 0.949 to 1.700).
Burmester et al[177] (2018) SELECT-NEXT Upadacitinib 15 mg or 30 mg PO once daily vs placebo	DB, MC, PC, PG, RCT Patients ≥18 years of age with moderate-to-severe active RA and had an inadequate response to at least one csDMARD (methotrexate, sulfasalazine, or leflunomide)	N=661 12 weeks	Primary: Proportion of patients achieving ACR20 at week 12 and proportion of patients who achieved DAS28-CRP of ≤3.2 at week 12 Secondary: Proportion of patients achieving ACR50 at week 12, proportion of patients achieving	Primary: At week 12, an ACR20 response was achieved by 64% of patients receiving upadacitinib 15 mg and 66% of patients receiving upadacitinib 30 mg, compared with 36% of patients receiving placebo (P<0·0001 for both doses). At week 12, DAS28-CRP ≤3.2 was met by 48% of patients receiving upadacitinib 15 mg and 48% of patients receiving upadacitinib 30 mg, compared with 17% receiving placebo (P<0·0001 for both doses). Secondary: At week 12, the proportion of patients who achieved ACR50 was 31% for patients receiving upadacitinib 15 mg, 43% for upadacitinib 30 mg, and 15% for placebo (P≤0.0001). At week 12, the proportion of patients who achieved DAS28-CRP <2.6 was 31% for patients receiving upadacitinib 15 mg, 28% for upadacitinib

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			DAS28-CRP <2.6 at week 12, proportion of patients with CDAI ≤10 and mean changes from baseline in DAS28-CRP	30 mg and 10% for placebo (P≤0.0001). The proportion of patients who achieved CDAI ≤10 was 40% for patients receiving upadacitinib 15 mg, 42% for upadacitinib 30 mg and 9% for placebo (P≤0.0001). The mean change from baseline in DAS28-CRP was -2.125 for patients receiving upadacitinib 15 mg, -2.38 for upadacitinib 30 mg and -1.02 for placebo (P≤0.0001).
Genovese MC et al.[178] (2018) SELECT-BEYOND Upadacitinib 15 mg or upadacitinib 30 mg PO once daily vs placebo	DB, MC, PG, PC RCT Patients ≥18 years of age, with moderate-to-severe active RA and previous inadequate response or intolerance to biologic DMARDs, receiving concomitant background csDMARDs	N=499 24 weeks	Primary: Proportions of patients achieving ACR20 at week 12 and proportion of patients achieving DAS28-CRP of ≤3.2 at week 12 Secondary: Proportion of patients achieving ACR50 at week 12, mean change from baseline in the DAS28-CRP at week 12 and mean change in HAQ-DI score at week 12	Primary: At week 12, ACR20 was achieved by 65% of patients receiving upadacitinib 15 mg and 56% of patients receiving upadacitinib 30 mg compared to 28% of patients receiving placebo (P<0.0001 for both doses). At week 12, DAS28-CRP ≤3.2 was achieved by 43% of patients receiving upadacitinib 15 mg and 42% of patients receiving upadacitinib 30 mg compared to 14% of patients receiving placebo (P<0.0001 for both doses). Secondary: The proportion of patients who achieved ACR50 was 38% for upadacitinib 15 mg, 43% for upadacitinib 30 mg, and 15% for placebo (P<0·001 for both doses). Both doses of upadacitinib had significantly greater DAS28-CRP change than placebo (P<0.0001). Mean change in the HAQ-DI score was -0.41 for upadacitinib 15 mg and -0.44 for upadacitinib 30 mg compared to -0.16 for placebo (P<0·0001).
Van Vollenhoven R et al.[179] (2020) SELECT-EARLY Upadacitinib PO 15 mg or 30 mg once daily	AC, DB, MC, PG, RCT Patients ≥18 years of age with moderate-to-severe active RA who were methotrexate-naïve	N=945 24 weeks	Primary: Proportion of patients achieving ACR50 at week 12 and proportion of patients achieving DAS28-CRP <2.6 at week 24	Primary: At week 12, a significantly higher proportion of patients receiving upadacitinib 15 and 30 mg compared to methotrexate achieved ACR50 responses at 52.1% and 56.4% compared to 28.3% (P<0.001). At week 24, a significantly higher proportion of patients receiving upadacitinib 15 and 30 mg compared to methotrexate achieved DAS28-CRP<2.6 at 48.3% and 50.0% compared to 18.5% (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs methotrexate PO once weekly			Secondary: Mean changes from baseline in mTSS and proportion of patients with no radiographic progression at week 24	Secondary: At week 24, mean changes from baseline in mTSS were significantly lower with upadacitinib 15 and 30 mg compared to methotrexate at 0.14, 0.07 compared to 0.67 (P<0.001). At week 24, a significantly higher proportion of patients upadacitinib 15 and 30 mg compared to methotrexate had no radiographic progression (P<0.001).
Smolen JS et al.[180] (2019) SELECT-MONOTHERAPY Upadacitinib PO 15 mg or 30 mg once daily vs methotrexate PO once weekly	AC, DB, MC, PG, RCT Patients ≥18 years of age with moderate-to-severe active RA and an inadequate response to methotrexate	N= 598 14 weeks	Primary: Proportion of patients achieving ACR20 at week 14 and proportion of patients achieving DAS28-CRP ≤3.2 at week 14 Secondary: Mean changes from baseline in DAS28-CRP at week 14, mean changes from baseline in HAQ-DI at week 14, proportion of patients achieving ACR50 and proportion of patients achieving DAS28-CRP <2.6	Primary: At week 14, an ACR20 response was achieved by 41% in the continued methotrexate group compared to 68% of patients receiving upadacitinib 15 mg and 71% of patients receiving upadacitinib 30 mg (P<0·0001 for both doses). At week 14, 19% in the continued methotrexate group, 45% receiving upadacitinib 15 mg, and 53%receiving upadacitinib 30 mg had achieved DAS28-CRP ≤3.2 (P<0·0001 for both doses). Secondary: At week 14, the mean change from baseline in DAS28-CRP was -2.7 for patients receiving upadacitinib 15 mg, -2.7 for upadacitinib 30 mg and -1.2 for methotrexate (P≤0.0001). At week 14, the mean change from baseline in HAQ-DI was -0.65 for patients receiving upadacitinib 15 mg, -0.73 for upadacitinib 30mg and -0.32 for methotrexate (P≤0.001). At week 14, the proportion of patients who achieved ACR50 was 68% for patients receiving upadacitinib 15 mg, 71% for upadacitinib 30 mg and 41% for methotrexate (P≤0.0001). At week 14, the proportion of patients who achieved DAS28-CRP <2.6 was 28% for patients receiving upadacitinib 15 mg, 41% for upadacitinib 30 mg and 8% for methotrexate (P≤0.0001).
Fleischmann R et	DB, MC, PG, PC	N=1,629	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
al.[181] (2019) SELECT-COMPARE Methotrexate weekly plus upadacitinib 15 mg PO once daily vs methotrexate weekly plus adalimumab SQ 40 mg every other week vs methotrexate PO weekly plus placebo	RCT Patients ≥18 years of age with moderate-to-severe active RA, hsCRP≥5 and evidence of erosive disease and/or seropositivity receiving stable methotrexate background therapy	48 weeks	Proportion of patients achieving ACR20 at week 12 and proportion of patients who DAS28-CRP <2.6 at week 12 Secondary: Mean change from baseline in the DAS28-CRP, proportion of patients achieving a DAS28-CRP of ≤3.2 and mean change in HAQ-DI score at week 12	At week 12, an ACR20 response was achieved by 71% of patients receiving upadacitinib compared to 36% receiving placebo (P≤0.001) and compared to 63% receiving adalimumab (P≤0.05). At week 12, a DAS28-CRP <2.6 was achieved by 29% of patients receiving upadacitinib compared to 6% receiving placebo (P≤0.001) and compared to 18% receiving adalimumab (P≤0.001). Secondary: Significantly greater improvements from baseline in the DAS28-CRP were observed in patients receiving upadacitinib compared to those receiving either placebo or adalimumab at -2.48 in the upadacitinib group versus -1.14 in the placebo and adalimumab groups (P≤0.001). Significantly higher proportions of patients receiving upadacitinib compared to placebo achieved a DAS28-CRP≤3.2 (P≤0.001). Upadacitinib met the noninferiority comparison to adalimumab for achievement of a DAS28-CRP ≤3.2 at 45% versus 29% (P≤0.001). At week 12, the mean change in HAQ-DI score was -0.60 in the upadacitinib group versus -0.49 in the adalimumab group (P≤0.01).
Ulcerative Colitis				
Rutgeerts et al.[182] (2005) ACT 1 and ACT 2 Infliximab 5 to 10 mg/kg at weeks 0, 2, 6 and then every 8 weeks vs placebo	DB, MC, PC, RCT Adult patients with endoscopy confirmed active ulcerative colitis (Mayo score 6 to 12) and moderate to severe active disease on sigmoidoscopy despite concurrent treatment with corticosteroids alone or in combination with azathioprine or	N=364 (ACT 1) N=364 (ACT 2) 30 weeks (ACT 2) 54 weeks (ACT1)	Primary: Clinical response at week eight Secondary: Clinical response or clinical remission with discontinuation of corticosteroids at week 30 (ACT 1 and ACT 2) and week 54 (ACT 1), clinical remission and mucosal	Primary: At week eight in ACT 1, the proportion of patients with clinical response was significantly higher in the infliximab 5 and 10 mg/kg groups (69.4 and 61.5%) compared to the placebo group (37.2%; P<0.001 for both). In ACT 2 at week eight, the proportion of patients with clinical response was significantly higher in the infliximab 5 and 10 mg/kg groups (64.5 and 69.2%) compared to the placebo group (29.3%; P<0.001 for both). Secondary: In ACT 1, the proportion of patients with clinical response at week 30 was significantly higher in the infliximab 5 and 10 mg/kg groups (52.1 and 50.8%) compared to the placebo group (29.8%; P<0.001 and P=0.002, respectively). In ACT 2 at week 30, the proportion of patients with clinical response was significantly higher in the infliximab 5 and 10 mg/kg groups (47.1 and 60.0%) compared to the placebo group (26.0%; P<0.001 for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	mercaptopurine (ACT 1) or despite concurrent treatment with corticosteroids alone or mercaptopurine and medications containing 5-aminosalicylates (ACT 2)		healing at weeks eight and 30 (ACT 1 and ACT 2) and week 54 (ACT 1), and clinical response at week eight in patients with a history of corticosteroid refractory disease	both). In ACT 1 at week 54, the clinical response rate was significantly higher in the infliximab 5 and 10 mg/kg groups compared to the placebo group (45.5 and 44.3 vs 19.8%; P<0.001 for both). In ACT 1, the proportion of patients with clinical remission at week eight was significantly higher in the infliximab 5 and 10 mg/kg groups (38.8 and 32.0%) compared to the placebo group (14.9%; P<0.001 and P=0.002, respectively). In ACT 2 at week eight, the proportion of patients with clinical remission was significantly higher in the infliximab 5 and 10 mg/kg groups (33.9 and 27.5%) compared to the placebo group (5.7%; P<0.001 for both). In ACT 1, the proportion of patients with clinical remission at week 30 was significantly higher in the infliximab 5 and 10 mg/kg groups (33.9 and 36.9%) compared to the placebo group (15.7%; P=0.001 and P<0.001, respectively). In ACT 2 at week 30, the proportion of patients with clinical remission was significantly higher in the infliximab 5 and 10 mg/kg groups (25.6 and 35.8%) compared to the placebo group (10.6%; P=0.003 and P<0.001, respectively). In ACT 1 at week 54, the clinical remission rate was significantly higher in the infliximab 5 and 10 mg/kg groups compared to the placebo group (34.7 and 34.4 vs 16.5%; P=0.001 for both). In ACT 1 at week eight, the proportion of patients refractory to corticosteroids that had a clinical response was significantly higher in the infliximab 5 and 10 mg/kg groups compared to the placebo group (77.4 and 67.7 vs 35.3%; P<0.001 and P=0.010, respectively). In ACT 2 at week eight when compared to the placebo group (37.5%), the proportion of patients refractory to corticosteroids that had a clinical response was significantly higher in the infliximab 10 mg/kg (65.5%; P=0.011), but not 5 mg/kg group (63.3%; P=0.053). In ACT 1, the proportion of patients with mucosal healing at week eight was significantly higher in the infliximab 5 and 10 mg/kg groups (62.0 and 59.0%) compared to the placebo group (33.9%; P<0.001 for both). In ACT 2 at week eight, the proportion of patients with mucosal healing was significantly higher in the infliximab 5 and 10 mg/kg groups (60.3 and 61.7%) compared to the placebo group (30.9%; P<0.001 for both). In ACT 1, the proportion of patients with mucosal healing at week 30 was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				significantly higher in the infliximab 5 and 10 mg/kg groups (50.4 and 49.2%) compared to the placebo group (24.8; P<0.001 for both). In ACT 2 at week 30, the proportion of patients with mucosal healing was significantly higher in the infliximab 5 and 10 mg/kg groups (46.3 and 56.7%) compared to the placebo group (30.1%; P=0.009 and P<0.001, respectively). In ACT 1 at week 54, the mucosal healing rate was significantly higher in the infliximab 5 and 10 mg/kg groups compared to the placebo group (45.5 and 46.7 vs 18.2%; P=0.001 for both).
Hyams et al.[183] (2011) (abstract) Infliximab 5 mg/kg at weeks 0, 2 and 6 then 5 mg/kg every 8 weeks through week 46 vs infliximab 5 mg/kg at weeks 0, 2 and 6 then 5 mg/kg every 12 weeks through week 42	MC, OL, R Patients 6 to 17 years of age with active ulcerative colitis (Mayo score 6 to 12, including endoscopic subscore ≥2) who failed to respond to or tolerate treatment with mercaptopurine, azathioprine, corticosteroids, and/or 5-aminosalicylates	N=60 54 weeks	Primary: Clinical response at week eight (decrease from baseline in Mayo score ≥30% and ≥3 points, with a decrease in rectal bleeding subscore of 0/1) compared to baseline Secondary: Not reported	Primary: At week eight, 73.3% of patients had a clinical response with infliximab (95% CI, 62.1 to 84.5). Clinical remission by Mayo score was achieved in 33.3% of patients. At week 54, there was a greater proportion of patients achieving clinical remission with infliximab 5 mg/kg every eight weeks compared to infliximab 5 mg/kg every 12 weeks; though, this difference was not significant (P=0.146). Secondary: Not reported
Reinisch et al.[184] (2011) Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6 (ADA 160/80 group) vs	DB, MC, PC, RCT Adult patients with moderate to severe active ulcerative colitis, (Mayo score of 6 to 12 with an endoscopy subscore of 2–3) who failed concurrent and stable treatment with oral corticosteroids	N=390 8 weeks	Primary: Proportion of patients in remission (Mayo score ≤2 and no subscore >1) compared to baseline Secondary: Proportion of patients with a	Primary: At week eight, 18.5% of patients in the ADA 160/80 group (P=0.031 vs placebo) and 10.0% in the ADA 80/40 group (P=0.833 vs placebo) were in remission compared to placebo (9.2%). Secondary: At week eight, 54.6% of patients in the ADA 160/80 group (P vs placebo not reported), 51.5% in the ADA 80/40 group (P vs placebo not reported) and 44.6% in the placebo group had a clinical response. At week eight, 46.9% of patients in the ADA 160/80 group (P vs placebo not reported), 37.7% in the ADA 80/40 group (P vs placebo not reported)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Adalimumab 80 mg at week 0, 40 mg at weeks 2, 4 and 6 (ADA 80/40 group) vs placebo	and/or immunomodulators		clinical response (decrease in Mayo Score ≥3 points and ≥30% from baseline plus decrease in rectal bleeding subscore ≥1 or an absolute rectal bleeding subscore of 0 or 1); proportion of patients with mucosal healing (endoscopy subscore of 0 or 1); proportion of patients with rectal bleeding subscore ≤1, PGA subscore ≤1, or stool frequency subscore ≤1	and 41.5% in the placebo group had mucosal healing. At week eight, 77.7% of patients in the ADA 160/80 group (P=0.038 vs placebo), 70.0% in the ADA 80/40 group (P vs placebo not reported) and 66.2% in the placebo group had a rectal bleeding subscore of ≤ 1. At week eight, 60.0% of patients in the ADA 160/80 group (P=0.035 vs placebo), 53.8% in the ADA 80/40 group (P vs placebo not reported) and 46.9% in the placebo group had a PGA subscore of ≤ 1 At week eight, 48.5% of patients in the ADA 160/80 group (P vs placebo not reported), 36.2% in the ADA 80/40 group (P vs placebo not reported) and 37.7% in the placebo group had a stool frequency subscore of ≤ 1
Sandborn et al.[185] (2012) Adalimumab 160 mg at week 0, 80 mg at week 2, then 40 mg every other week vs placebo	DB, MC, PC, RCT Adult patients with moderate to severe active ulcerative colitis >3 months, (Mayo score of 6 to 12 with an endoscopy subscore >2) despite concurrent treatment with oral corticosteroids and/or azathioprine or 6-	N=494 52 weeks	Primary: Proportion of patients in remission (Mayo score ≤2 and no subscore >1) at week 8 and 52 Secondary: Proportion of patients in remission at week 8 and 52; proportion of patients with a	Primary: At week 8, 16.5% of patients in the adalimumab group were in remission compared to placebo (9.3%; P=0.019; 95% CI, 1.2 to 12.9). At week 52, 17.3% of patients in the adalimumab group were in remission compared to placebo (8.5%; P=0.004; 95% CI, 2.8 to 14.5). Secondary: At week 8 and 52, 8.5% of patients in the adalimumab group (P=0.47 vs placebo) and 4.1% in the placebo group were in sustained remission. At week 8, 50.4% of patients in the adalimumab group (P<0.001 vs placebo) and 34.6% in the placebo group had a clinical response. At week 52, 30.2% of patients in the adalimumab group and 18.3% in the placebo group had a clinical response. (P=0.002). At week 8 and 52, 23.8% of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	mercaptopurine.		clinical response (decrease in Mayo Score ≥3 points and ≥30% from baseline plus decrease in rectal bleeding subscore ≥1 or an absolute rectal bleeding subscore of 0 or 1); proportion of patients with mucosal healing (endoscopy subscore of 0 or 1); proportion of patients who discontinued corticosteroid; proportion of patients with rectal bleeding subscore ≤1, PGA subscore ≤1, or stool frequency subscore ≤1	patients in the adalimumab group (P<0.001 vs placebo) and 12.2% in the placebo group were in sustained remission. Mucosal healing was achieved at week 8 in 41.1% of patients in the adalimumab group and 31.7% of patients receiving placebo (P=0.032). At week 52, 25% of patients in the adalimumab group and 15.4% of patients receiving placebo (P=0.009) had mucosal healing. Mucosal healing at week 8 and 52, 18.5% of patients in the adalimumab group (P<0.013 vs placebo) and 10.6% in the placebo group. At week 8, 46.0% of patients in the adalimumab group (P=0.028 vs placebo) and 37.4% in the placebo group had a PGA subscore of ≤ 1. At week 8, 37.9% of patients in the adalimumab group (P=0.058 vs placebo) and 28.5% in the placebo group had a stool frequency subscore of ≤ 1. At week 8, 70.2% of patients in the adalimumab group (P=0.006 vs placebo) and 58.1% in the placebo group had a rectal bleeding subscore of ≤ 1. Proportion of patients that discontinued corticosteroid use before week 52 and achieved remission at week 52 was13.3% of patients in the adalimumab group (P=0.35 vs placebo) and 5.7% in the placebo group. Proportion of patients that for ≥90 days before week 52 and achieved remission at week 52 was 13.3% of patients in the adalimumab group (P=0.35 vs placebo) and 5.7% in the placebo group.
Sandborn et al.[186] (2013) PURSUIT-SC Phase 2 (dose-finding): Golimumab 400 mg subcutaneously at week 0 and 200 mg	2 DB, MC, PC, RCT Patients ≥18 years of age with moderate to severe active ulcerative colitis (Mayo score of 6 to 12 with an endoscopy subscore	Phase 2 N=169 Phase 3 N=774 6 weeks	Primary: Phase 2: Change in Mayo score from baseline to week six Phase 3: Clinical response at week six defined as a	Primary: In phase 2, median changes from baseline in the Mayo score were -3.0, -2.0, and -3.0 in the 100 mg/50 mg, 200 mg/100 mg, and 400 mg/200 mg golimumab treatment groups, respectively, compared to -0.1 in the placebo group (P=0.038, P=0.332 and P=0.038, respectively). In phase 3, the proportion of patients with clinical response at week six was greater for patients treated with golimumab 200 mg/100 mg and 400 mg/200 mg compared to placebo (51.0 and 54.9 vs 30.3%; P≤0.0001 for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
subcutaneously at week 2 (400 mg/200 mg) vs golimumab 200 mg subcutaneously at week 0 and 100 mg subcutaneously at week 2 (200 mg/100 mg) vs golimumab 100 mg subcutaneously at week 0 and 50 mg subcutaneously at week 2 (100 mg/50 mg) vs placebo Phase 3 (dose-confirming): Golimumab 400 mg subcutaneously at week 0 and 200 mg subcutaneously at week 2 (400 mg/200 mg) vs	≥2) despite treatment with ≥1 conventional therapy (oral mesalamine, oral corticosteroids, azathioprine or 6-mercaptopurine) or corticosteroid dependent		decrease from baseline in the Mayo score ≥30% and ≥3 points with either a rectal bleeding subscore of 0 to 1 or a decrease from baseline in the rectal bleeding subscore ≥1 Secondary: Phase 2: Not reported Phase 3: Clinical remission defined as Mayo score ≤2 points, with no individual subscore >1, mucosal healing defined as a Mayo endoscopy subscore of 0 or 1, and IBDQ change from baseline, all at week 6	both comparisons). Secondary: In phase 3, the proportion of patients in clinical remission at week six was greater for patients treated with golimumab 200 mg/100 mg and 400 mg/200 mg compared to placebo (17.8 and 17.9 vs 6.4%; P≤0.0001 for both comparisons). In phase 3, the proportion of patients achieving mucosal healing at week six was greater for patients treated with golimumab 200 mg/100 mg and 400 mg/200 mg compared to placebo (42.3 and 45.1 vs 28.7%; P=0.0014 and P≤0.0001, respectively). In phase 3, the improvements from baseline in IBDQ score at week six were greater in patients treated with golimumab 200 mg/100 mg and 400 mg/200 mg compared to placebo (mean 27.0±33.72 and 26.9±34.28 vs 14.8±31.25%; P<0.0001 for both comparisons).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
golimumab 200 mg subcutaneously at week 0 and 100 mg subcutaneously at week 2 (200 mg/100 mg) vs placebo Patients were required to maintain stable doses of concurrent oral aminosalicylates, oral corticosteroids (<40 mg/day), azathioprine, 6-mercaptopurine, and/or MTX.				
Sandborn et al.[187] (2013) PURSUIT-M Golimumab 50 mg SC every four weeks vs golimumab 100 mg SC every four weeks vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with moderate to severe active ulcerative colitis (Mayo score of 6 to 12 with an endoscopy subscore ≥2) despite treatment with ≥1 conventional therapy (oral mesalamine, oral corticosteroids,	N=464 54 weeks	Primary: Clinical response through week 54 among golimumab-induction responders Secondary: Clinical remission at weeks 30 and 54, mucosal healing at weeks 30 and 54, clinical remission at both weeks 30	Primary: The proportion of patients who maintained a clinical response through week 54 was greater for patients treated with golimumab 100 mg and 50 mg compared to placebo (49.7 and 47.0 vs 31.2%; P<0.001 and P=0.010, respectively). Secondary: The proportion of patients in clinical remission at both weeks 30 and 54 was greater for patients treated with golimumab 100 mg and 50 mg compared to placebo (27.8 and 23.2 vs 15.6%; P=0.004 and P=0.091, respectively); however, the difference was only statistically significant for golimumab 100 mg treatment group. The proportion of patients with mucosal healing at both weeks 30 and 54 was significantly greater for patients receiving golimumab 100 mg

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients were required to maintain stable doses of concurrent oral aminosalicylates, oral corticosteroids (<40 mg/day), azathioprine, 6-mercaptopurine, and/or MTX. After induction, patients in clinical response and receiving concomitant corticosteroids at baseline were required to taper corticosteroids (for dose of >20 mg/day prednisone or equivalent: taper daily dose by 5 mg/week; for dose of ≤20 mg/day prednisone or equivalent: taper daily dose by 2.5 mg/week) beginning at baseline.	azathioprine or 6-mercaptopurine) or corticosteroid dependent who completed PURSUIT-IV or PURSUIT-SC studies		and 54 among patients who had clinical remission at baseline, and corticosteroid-free clinical remission at week 54 among patients receiving concomitant corticosteroids at baseline	compared to placebo (42.4 vs 26.6%; P=0.002). The mucosal healing rate for patients receiving golimumab 50 mg was 41.7% (P value not reported). Greater proportions of patients who received golimumab 100 mg or 50 mg maintained clinical remission compared to placebo (40.4 and 36.5 vs 24.1%; P=0.073 and P=0.365, respectively); however, the differences were not statistically significant. Greater proportions of patients who received golimumab 100 mg or 50 mg were in corticosteroid-free clinical remission at week 54 compared to placebo (22.9 and 27.8 vs 18.4%; P=0.464 and P=0.299, respectively) ; however, the differences were not statistically significant.
Uveitis				
Jaffe et al.[188] (2016) VISUAL I	MC, RCT Patients ≥18 years of age and had a	N=217 80 weeks	Primary: Time to treatment failure at or after week six (treatment	Primary: The median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group. Patients who received adalimumab were significantly less likely than those who received placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Adalimumab 80 mg SC loading dose followed by 40 mg every two weeks vs placebo All patients received a standardized, 60-mg-per-day prednisone burst at trial entry (week 0), after which a mandatory tapering schedule was followed	diagnosis of active noninfectious intermediate uveitis, posterior uveitis, or panuveitis		failure was a multicomponent outcome that was based on assessment of new inflammatory lesions, best corrected visual acuity, anterior chamber cell grade, and vitreous haze grade) Secondary: Nine ranked secondary efficacy end points related to disease state were tested for significance	to have treatment failure (HR, 0.50; 95% CI, 0.36 to 0.70; P<0.001). Secondary: Hierarchical testing of the ranked secondary outcomes showed that worsening of anterior chamber cell grade, worsening of vitreous haze grade, and worsening of best corrected visual acuity were significantly less common among patients who received adalimumab than among those who received placebo (P≤0.01 for all three end points). The difference between the groups in the time to optical coherence tomographic evidence of macular edema was not significant; therefore, no further confirmatory statistical testing of secondary end points was performed.
Nguyen et al.[189] (2016) VISUAL II Adalimumab 80 mg SC loading dose followed by 40 mg every 2 weeks vs placebo All patients received a standardized, 60-mg-per-day prednisone burst at	Double-masked, MC, RCT Patients ≥18 years of age with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10 to 35 mg/day of prednisone	N=229 80 weeks	Primary: Time to treatment failure, a multicomponent endpoint encompassing new active inflammatory chorioretinal or inflammatory retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, and visual acuity	Primary: Treatment failure occurred in 61 (55%) of 111 patients in the placebo group compared with 45 (39%) of 115 patients in the adalimumab group. Time to treatment failure was improved in the adalimumab group compared with the placebo group (43% risk reduction; median not estimated [>18 months; more than half the adalimumab-treated patients did not have treatment failure] vs 8.3 months; HR, 0.57; 95% CI 0.39 to 0.84; P=0.004). Secondary: Hierarchical testing of the nine ranked secondary variables was stopped after the first ranked endpoint because no statistically significant difference was shown between groups. The most common adverse events were arthralgia (11% patients in the placebo group and 23% patients in the adalimumab group), nasopharyngitis (17% and 16% patients, respectively), and headache (15% patients in each group).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
trial entry (week 0), after which a mandatory tapering schedule was followed			Secondary: Nine ranked secondary efficacy end points related to disease state were tested for significance	
Suhler et al.[190] (2018) VISUAL III Adalimumab 40 mg every other week	MC, OL, ongoing ES Patients ≥18 years of age, diagnosed with noninfectious intermediate, posterior, or panuveitis and had either discontinued from VISUAL I or VISUAL II trials for having met predefined treatment failure criteria or successfully completed the parent study without treatment failure	N=371 78 weeks	Primary: Disease quiescence, steroid-free quiescence, active inflammatory chorioretinal/retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity and corticosteroid dose Secondary: Safety	Primary: At study entry, 242/371 (65%) patients had active uveitis; 60% (145/242, nonresponder imputation) achieved quiescence at week 78, and 66% (95/143, as-observed) of those were corticosteroid free. At study entry, 129/371 (35%) patients had inactive uveitis; 74% (96/129, nonresponder imputation) achieved quiescence at week 78, and 93% (89/96, as-observed) of those were corticosteroid free. Inflammatory lesions, anterior chamber grade, and vitreous haze grade showed initial improvement followed by decline in patients with active uveitis and remained stable in patients with inactive uveitis. Best-corrected visual acuity improved in patients with active uveitis from weeks 0 to 78 and remained stable in patients with inactive uveitis. Mean corticosteroid dose decreased from 13.6 mg/day (week 0) to 2.6 mg/day (week 78) in patients with active uveitis and remained stable in those with inactive uveitis (1.5 to 1.2 mg/day). Secondary: The overall exposure-adjusted rate of any adverse event was 424 events/100 patient years. There were 82 adverse events leading to study discontinuation (8.6 events/100 patient years) and 157 serious adverse events (16.5 events/100 patient years).
Ramanan et al.[191] (2019) Adalimumab (20 mg/0.8 mL for patients weighing < 30 kg or 40 mg/0.8 ml for patients weighing	DB, MC, PC, PG RCT Patients 2 to 18 years of age with persistently active JIA-associated uveitis despite optimized MTX	N=90 18 months	Primary: Number of patients failing treatment Secondary: Safety and tolerability	Primary: There were 14 (23%) treatment failures in the adalimumab group and 17 (57%) in the placebo group. The HR of treatment failure was significantly reduced, by 75%, for participants in the adalimumab group (HR, 0.25; 95% CI, 0.12 to 0.51; P<0.0001). Secondary: Adalimumab-treated patients had a much higher incidence of adverse events and serious adverse events. However, this difference was not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
≥ 30 kg) SC every two weeks vs placebo Both given in combination with a stable dose of MTX	treatment for at least 12 weeks			deemed to be clinically significant.
Neonatal-Onset Multisystem Inflammatory Disease				
Sibley et al.[192] (2012) Anakinra 1 to 5 mg/kg/day	OL Patients with NOMID with at least 2 of the following clinical manifestations: urticaria-like rash, CNS involvement (papilledema, cerebrospinal fluid CSF pleocytosis, or sensorineural hearing loss), or epiphyseal and/or patellar overgrowth on radiographs	N=43 60 months	Primary: Sustained improvements in diary scores, parent's/patient's and physician's global scores of disease activity, CHAQ scores, parent's/patient's pain scores, and inflammatory markers (CRP level, ESR, and SAA) Secondary: Reduction or elimination CNS organ inflammation and damage and the absence of leptomeningeal enhancement on MRI, and in the eyes as the absence	Primary: Scores for daily diaries, parent's and physician's global assessment of disease activity, parent's assessment of pain, and C-HAQ decreased significantly from baseline to 36 months (P=0.0016 for C-HAQ and P<0.001 for all other assessments). These parameters did not show significant change from month 36 to month 60. Significant decreases in inflammatory markers (CRP level, ESR, and SAA) were observed from baseline to 12 months and from baseline to 36 months (all P<0.001). These parameters did not show significant change from month 36 to month 60. Secondary: CNS inflammation, including CSF leukocyte count and elevated opening pressure, decreased significantly at the study end points 36 and 60 months compared to baseline (P=0.0026 and P=0.0076, respectively, for CSF WBC count and P=0.0012 and P<0.001, respectively, for opening pressure). These parameters did not show significant change from month 36 to month 60. The number of patients with leptomeningeal enhancement decreased to three of 26 patients at 36 months (P=0.039) and one of 20 patients at 60 months (P=0.016). Improvement in hearing occurred in 30% of ears, and progression of hearing loss was halted in the majority of the patients.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			of eye inflammation on examination. Other endpoints include improvements in hearing, vision, bone lesions and growth, and safety.	Visual acuity and peripheral vision improved or stabilized in most patients over five years. One patient had worsening of visual acuity, and two other patients had worsening of peripheral vision in the absence of clinically detectable intraocular inflammation. (Note-All three of these patients had severely atrophic nerves at baseline). Bony overgrowth was present in 10 of 26 patients, and during the study period the volume of the bony lesions increased significantly; however, no new bone lesions developed in patients while they were receiving anakinra therapy. No dose-limiting toxicity was observed during the study. Upper respiratory infections (58 to 62%), rash (27 to 32%), malaise (17 to 19%) gastroenteritis (11 to 12%), and urinary tract infections (4 to 12%), nausea/vomiting (10 to 11%) injection site reactions (1 to 10%) were frequently observed.
Oral Ulcers Associated with Behcet's Disease				
Hatemi et al.[193] (2019) Apremilast 30 mg BID vs placebo	DB, MC, PC, RCT Patients ≥18 years of age, had received a diagnosis of Behçet's syndrome and had active oral ulcers that had occurred at least three times in the previous 12-month period despite the previous use of at least one nonbiologic medication	N=207 12 weeks	Primary: AUC for the total number of oral ulcers during 12 weeks Secondary: Complete response of oral ulcers, change from baseline in pain associated with oral ulcers and change from baseline in the Behçet's Disease Quality of Life score	Primary: The AUC for the number of oral ulcers was 129.5 for apremilast, as compared with 222.1 for placebo (least-squares mean difference, -92.6; 95% CI, -130.6 to -54.6; P<0.001). Secondary: The percentage of patients who were free from oral ulcers by week 6 and who remained ulcer-free at each visit for at least 6 more weeks was 30% in the apremilast group (31/104 patients) and 5% in the placebo group (5/103 patients) (difference, 25 percentage points; 95% CI, 16 to 35). The median time to oral ulcer resolution was 2.1 weeks in the apremilast group and 8.1 weeks in the placebo group (HR for complete resolution of oral ulcers, 2.4; 95% CI, 1.7 to 3.4). The percentage of patients who were free from oral ulcers at week 12 was 53% in the apremilast group (55 patients) and 22% in the placebo group (23 patients) (adjusted difference, 31 percentage points; 95% CI, 18 to 43). At week 12, the mean reduction from baseline in the pain associated with oral ulcers as assessed on a 100-mm VAS was -42.7 in the apremilast

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				group, as compared with -18.7 in the placebo group (least-squares mean difference, -24.1; 95% CI, -32.4 to -15.7). The change from baseline in the Behçet's Disease Quality of Life score was -4.3 points in the apremilast group, as compared with -1.2 points in the placebo group (least-squares mean difference, -3.1 points; 95% CI, -4.9 to -1.3).

*Not currently available in the United States.
Study abbreviations: CI=confidence interval, DB=double-blind, DD=double dummy, ES=extension study, HR=hazard ratio, IR=incidence rate, MA=meta-analysis, MC=multicenter, NNH=number needed to harm, NNT=number needed to treat, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel group, PRO=prospective, R=randomized, RCT=randomized controlled trial, RD=risk difference, RR=relative risk, SD=standard deviation, SR=systematic review, WMD=weighted mean difference
Miscellaneous abbreviations: ACR=American College of Rheumatology, ACR-N=numeric index of the ACR response, ACR pedi 30=American College of Rheumatology pediatric 30% improvement criteria, ALT=alanine transaminase, AS=ankylosing spondylitis, ASDAS=ankylosing spondylitis disease activity score, ASAS=Assessment of Spondyloarthritis International Society criteria, AST=aspartate aminotransferase, AUC=area under the curve, BASDAI=Bath Ankylosing Spondylitis Disease Activity Index, BASFI=Bath Ankylosing Spondylitis Functional Index, BASMI=Bath Ankylosing Spondylitis Metrology Index, BSA=body surface area, CCP=cyclic citrullinated protein CD=Crohn's disease, CDAI=Crohn's disease activity index, CDAI-100=Crohn's disease activity index decrease of ≥100 points from baseline, CHAQ=Childhood Health Assessment Questionnaire, CNS=central nervous system, COX=cyclooxygenase, CR-70=clinical remission, CR-100=clinical remission 100, CRP=C-reactive protein, CSF=cerebrospinal fluid, CT=computed tomography, DAS 28=Disease Activity Score in 28 joints, DLQI=Dermatology Life Quality Index, DMARD=disease-modifying antirheumatic drug, DOI=definition of improvement, ECL=electrogenerated chemiluminescence, EIM=extra-intestinal manifestations, ELISA=enzyme-linked immunosorbent assay, ESR=erythrocyte sedimentation rate, EULAR=European League Against Rheumatism Response criteria, FACIT-F=Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ=health assessment questionnaire, HAQ-DI=health assessment questionnaire–disability index, HBI=Harvey-Bradshaw index, HCQ=hydroxychloroquine, HDL=high density lipoprotein, IBDQ=inflammatory bowel disease questionnaire, IOIBD=international organization for the study of inflammatory bowel disease, ITT=intent to treat, JIA=juvenile idiopathic arthritis, JRA=juvenile rheumatoid arthritis, JSN=joint space narrowing, LDL=low density lipoprotein, MCR=major clinical response, MRE=magnetic resonance enterography, MRI=magnetic resonance imaging, mTSS=modified Total Sharp Scores, MTX=methotrexate, NOMID=neonatal-onset multisystem inflammatory disease, nr-axSpA= non-radiographic-axial spondyloarthritis, NSAIDs=nonsteroidal anti-inflammatory drugs, PASI=psoriasis area and severity index, PCDAI=pediatric Crohn's disease activity index, PGA=physician global assessment, PsA=psoriatic arthritis, PsARC=psoriatic arthritis response criteria, PSSI=psoriasis scalp severity index, SIAQ=Self-Injection Assessment Questionnaire, RA=rheumatic arthritis, RF=rheumatoid factor, SF-36=short form-36, SF-36 MCS=short form-36-mental component, SF-36 PCS=short form-36-physical component, SAA=serum amyloid A, SHS=Sharp van der Heijde Score, SMD=standardized mean differences, SSZ=sulfasalazine, TB=tuberculosis, TNF=tumor necrosis factor, VAS=visual analog scale

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 17. Relative Cost of the Disease-Modifying Antirheumatic Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Abatacept	injection	Orencia®	$$$$$	N/A
Adalimumab	injection	Humira®	$$$$$	N/A
Anakinra	injection	Kineret®	$$$$$	N/A
Apremilast	tablet	Otezla®	$$$$$	N/A
Baricitinib	tablet	Olumiant®	$$$$$	N/A
Certolizumab pegol	injection	Cimzia®	$$$$$	N/A
Etanercept	injection	Enbrel®	$$$$$	N/A
Golimumab	injection	Simponi®, Simponi Aria®	$$$$$	N/A
Infliximab	injection	Avsola®^, Inflectra®^, Remicade®, Renflexis®^	$$$$$	N/A
Leflunomide	tablet	Arava®*	$$$$$	$$
Sarilumab	injection	Kevzara®	$$$$$	N/A
Tocilizumab	injection	Actemra®	$$$$$	N/A
Tofacitinib	extended-release tablet, tablet	Xeljanz®, Xeljanz XR®	$$$$$	N/A
Upadacitinib	extended-release tablet	Rinvoq®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available
^Biosimilar product.

X. Conclusions

The disease-modifying antirheumatic drugs (DMARDs) are used for a variety of inflammatory and immunologic conditions which include: rheumatoid arthritis, neonatal-onset multisystem inflammatory disease, psoriatic arthritis, plaque psoriasis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, and oral ulcers associated with Behcet's Disease.[1-18] Leflunomide is the only product available in a generic formulation. Infliximab is available in three biosimilar formulations, Avsola®, Inflectra® and Renflexis®.

Since the last review, apremilast has gained the Food and Drug Administration (FDA)-approved indication for the treatment of oral ulcers associated with Behcet's disease and certolizumab pegol for non-radiographic axial spondyloarthritis.[4,5] The expanded indication of Otezla® (apremilast) for the treatment of oral ulcers associated with Behcet's disease was based on a trial that found greater reduction in the total number of oral ulcers with apremilast during 12 weeks of treatment compared to placebo.[193] The expanded indication of Cimzia® (certolizumab pegol) for the treatment of non-radiographic axial spondyloarthritis was based on a trial that found adding certolizumab pegol to background medication being superior to placebo in patients with active nonradiographic axial spondyloarthritis in achievement of major improvement in ASDAS at 52 weeks.[60]

Two new Janus kinase inhibitors, Olumiant® (baricitinib) and Rinvoq® (upadacitinib) have been approved for the treatment of rheumatoid arthritis.[17,18] Two confirmatory phase III trials demonstrated efficacy of baricitinib 2 mg in terms of ACR20 improvement response compared to placebo in conventional DMARD-experienced patients (RA-BUILD) and TNF-blocker-experienced patients (RA-BEACON).[118,119] Five phase III trials demonstrated the efficacy of upadacitinib in terms of proportion of patients achieving at least 20% improvement in the ACR score compared to methotrexate and placebo.[177-181]

The FDA has also approved Humira® (adalimumab) for use in patients with non-infectious intermediate and posterior uveitis and panuveitis. Adalimumab is the first FDA-approved noncorticosteroid therapy for this indication.[2] The approval was based on results from two phase III studies, which showed that adults with noninfectious intermediate and posterior uveitis and panuveitis treated with adalimumab every other week had a significantly lower risk for treatment failure (a combination of uveitic flare and decrease in visual acuity) compared with placebo.[188,189]

Kevzara® (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more DMARDs. It binds soluble and membrane-bound IL-6 receptors and thereby inhibits the release of proinflammatory cytokines and chemokines. IL-6 is produced by synovial and endothelial cells in joints affected by rheumatoid arthritis.[14] Two phase III trials have demonstrated efficacy of sarilumab in terms of ACR20 improvement response, Health Assessment Questionnaire Disability Index and Sharp van der Heijde Score to placebo in TNF-alpha-naïve patients (MOBILITY) and TNF-alpha-experienced patients (TARGET).[140,142]

Current clinical guidelines support the use of the DMARDs with respect to their FDA-approved indications, particularly in conditions where patients were unresponsive or refractory to traditional treatments, which usually include nonsteroidal anti-inflammatory drugs (NSAIDs) and/or methotrexate depending on the disease state.[23-48] As more recent guidelines are published, the recommendations for use tumor necrosis factor (TNF)-α inhibitors earlier in therapy is becoming a more common occurance.[34,36,39] The adverse event profiles are similar across the TNF-α inhibitors; however, routes of administration and dosing frequency may vary. In general, no one TNF-α inhibitor is preferred over another.[23-48] Leflunomide is FDA-approved for use in rheumatoid arthritis. Guidelines for rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis recommend leflunomide as an alternative treatment to methotrexate.[13,31-33,39,43] Clinical trials directly comparing methotrexate and leflunomide have shown mixed results.[134,136,138,139]

Humira® (adalimumab) was granted orphan drug designation for the treatment of moderate to severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a chronic inflammatory skin disease which affects fewer than 200,000 patients in the United States.[2,48] Current literature supports topical or oral antibiotics, intralesional steroids, retinoids, zinc, anti-androgens or laser surgery for mild (stage I) disease. Stage II disease should generally be treated similar to Stage I with the addition of rifampin plus clindamycin, dapsone, and prednisone. Stage III disease is treated with similar measures as Stages I and II; however, the use of anti-

inflammatory agents is recommended, with TNF-α inhibitors, adalimumab and infliximab, having the most positive data.[48]

Most research with these agents is for rheumatoid arthritis. In these trials, the DMARD was compared directly to placebo or methotrexate, either as monotherapy or in combination with methotrexate. Consistently, DMARDs have shown greater improvement in symptoms over the comparator.[112-176] To date, the majority of trials conducted have been placebo-controlled, with very few trials directly comparing two DMARDs head-to-head for any of the FDA-approved indications.[50-193] In those that have been conducted, most have shown comparable results.[166-168] In one trial in rheumatoid arthritis patients who were either intolerant or were not candidates for methotrexate treatment, significantly greater improvements were observed in patients treated with tocilizumab compared to adalimumab.[166] In another trial in rheumatoid arthritis patients with inadequate response to methotrexate, similar responses were observed in patients treated with abatacept and adalimumab.[167,168] The inclusion of adalimumab arm in one phase 3 trial of tofacitinib allowed establishing relative safety and efficacy of tofacitinib; however, formal noninferiority comparison was not performed.[169] The MONARCH trial compared sarilumab and adalimumab in patients with active rheumatoid arthritis. At 24 weeks, patients treated with sarilumab achieved a greater improvement from baseline in DAS28-ESR at -3.28 for the sarilumab group and -2.20 for the adalimumab group ($P<0.0001$).[143] The EXXELERATE trial compared certolizumab and adalimumab in patients with active rheumatoid arthritis. The results of the primary analysis showed no significant difference in week 12 ACR20 response (69 and 71%; $P=0.467$) or week 104 DAS28-ESR low disease activity (35 and 33%; $P=0.532$) between certolizumab pegol plus methotrexate and adalimumab plus methotrexate, respectively.[160] The few direct head-to-head trials available prevent clearly determining superiority of one agent over another. Recently anakinra was FDA-approved for neonatal-onset multisystem inflammatory disease, the only agent FDA-approved for this indication. The approval was based on the results of a single trial demonstrating sustained improvements in affected patients over 60 months.[193]

There is insufficient evidence to support that one brand disease-modifying antirheumatic agent is safer or more efficacious than another within its FDA-approved indication(s). The drugs in this AHFS class are used in a specific patient population. Because these agents have narrow indications with limited usage and serious adverse events, these agents should be managed through the medical justification portion of the prior authorization process.

Therefore, all disease-modifying antirheumatic agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand disease-modifying antirheumatic agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Orencia® [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2020 Jun.
2. Humira® [package insert]. North Chicago (IL): AbbVie Inc; 2020 Mar.
3. Kineret® [package insert]. Stockholm (Sweden): Swedish Orphan Biovitrum AB; 2018 Jun.
4. Otezla® [package insert]. Thousand Oaks (CA): Amgen Inc.; 2020 Jun.
5. Cimzia® [package insert]. Smyrna (GA): UCB, Inc.; 2019 Sep.
6. Enbrel® [package insert]. Thousand Oaks (CA): Immunex Corporation; 2020 Mar.
7. Simponi® [package insert]. Horsham (PA): Janssen Biotech, Inc.; 2019 Sep.
8. Simponi Aria® [package insert]. Horsham (PA): Janssen Biotech, Inc.; 2019 Sep.
9. Inflectra® [package insert]. Lake Forest (IL): Hospira; 2016 Apr.
10. Remicade® [package insert]. Horsham (PA): Janssen Biotech, Inc; 2020 May.
11. Renflexis® [package insert]. Kenilworth (NJ): Merck; 2019 Oct.
12. Avsola® [package insert]. Thousand Oaks (CA): Amgen Inc.; 2019 Dec.
13. Arava® [package insert]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2016 Oct.
14. Kevzara® [package insert]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2018 Apr.
15. Actemra® [package insert]. South San Francisco (CA): Genentech, Inc.; 2020 May.
16. Xeljanz® [package insert]. New York (NY): Pfizer, Inc.; 2019 Dec.
17. Olumiant® [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020 Jul.
18. Rinvoq® [package insert]. North Chicago (IL); AbbVie. 2020 Jul.
19. Drug Facts and Comparisons® eAnswers [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2020 [cited 2020 July]. Available from: http://online.factsandcomparisons.com.
20. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2020 July]. Available from: http://www.thomsonhc.com/.
21. Negm AA and Furst DE. Chapter 36. Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout In: Katzung BG ed. Basic & Clinical Pharmacology, 14e. New York, NY: McGraw-Hill; 2020 [cited 2020 July]. Available from: http://accessmedicine.mhmedical.com/book.aspx?bookid=2249.
22. Biosimilars. U.S. Food and Drug Administration: Silver Spring (MD). Last updated, 2020 Jul. Available at https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm. Accessed 2020 Jul.
23. Van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A et al. 2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-991.
24. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1599-1613.
25. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al. Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Jun;70(6):905-8.
26. National Institute for Health and Clinical Excellence (NICE). TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2016 Feb. (Technology appraisal guidance; no. 383).
27. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-818.
28. Lichtenstein GR, Loftus Jr EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Management of Crohn's Disease in Adults. Am J Gastroenterol 2018; 113:481–517; doi: 10.1038/ajg.2018.27; published online 27 March 2018.
29. National Institute for Health and Clinical Excellence (NICE). Crohn's disease: Management. London (UK): National Institute for Health and Clinical Excellence (NICE); 2019 May. Available at: https://www.nice.org.uk/guidance/ng129
30. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis:

Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-734.
31. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82.
32. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
33. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12.
34. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016 Mar;75(3):499-510.
35. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712.
36. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan;148(1):95-102.
37. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-64.
38. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-59.
39. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-85.
40. Menter A, Stober BE, Kaplan DH, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019 Apr;80 (4):1029-1072.
41. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun;82(6):1445-1486.
42. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26.
43. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Annals of the Rheumatic Diseases. 2020;79:685-699.
44. National Institute for Health and Clinical Excellence (NICE). Rheumatoid arthritis in adults: management. July 2018 Available from https://www.nice.org.uk/guidance/ng100.
45. National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. January 2016 Available from http://www.nice.org.uk/guidance/ta375.
46. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar;105(3):501-23.
47. Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384–413.
48. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44.
49. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54(7):2136-46.

50. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2013 Nov 14.
51. Van der Heijde D, Dougados M, Landewe R et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509.
52. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med. 2002;346(18):1349-56.
53. Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004; 63:1594-600.
54. Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346-52.
55. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept vs sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011 Jun;63(6):1543-51.
56. Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12.
57. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187-93.
58. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb;52(2):582-91.
59. Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013 Sep;33(9):2199-213.
60. Deodhar A, Gensler LS, Kay J et al. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Jul;71(7):1101-1111.
61. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther. 2009;30:977-86.
62. Löfberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, Pollack PF. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis. 2012 Jan;18(1):1-9.
63. Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis. 2017 Mar;23(3):453-460.
64. Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohn’s Colitis. 2012 Mar;6(2):160-73.
65. Shao L-M, Chen M-Y, Chen Q-Y, Cai J-T. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease. Aliment Pharmacol Ther. 2009;29(6):605-14.
66. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029-35.
67. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405.
68. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007 Mar;132(3):863-73;quiz 1165-6.
69. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012 Feb;61(2):229-34.
70. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893.
71. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317-328.

72. Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4;375(5):422-34.
73. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet. 2008 Aug 2;372(9636):383-91.
74. Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015 Oct;67(10):2759-70.
75. Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20.
76. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-9.
77. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein L, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987-94.
78. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004 Dec; 63(12):1638-44.
79. Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, et al. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J. 2017 Feb 6;15(1):11.
80. De Benedetti, Brunner H, Ruperto N, Calvo I, Cuttica R, Schneider R, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial [abstract]. Arthritis Rheum. 2010 Oct; 62(10 Suppl):596S. Abstract no. 1434.
81. Brunner H, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial [abstract]. Arthritis Rheum. 2012 Oct;64(10 Suppl):S682. Abstract no. 1597.
82. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66.
83. Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017 Jul 1;390(10089):40-49.
84. Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et al. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. J Drugs Dermatol. 2017 Aug 1;16(8):801-808.
85. Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517.
86. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012 Jul;67(1):86-92.
87. Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016 Feb;74(2):280-7.e1-3.
88. Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015 Aug 8;386(9993):552-61.
89. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118-28.
90. Schmitt J, Zhang Z, Wozel, G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Derm. 2008;159:513-26.

91. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
92. Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017 Sep;76(9):1550-1558.
93. Genovese MC, Mease PJ, Thomson GTD, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheum. 2007;34:1040-50.
94. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum. 2005; 52(10):3279-89.
95. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020-6.
96. Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83.
97. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct;64(10):3156-67.
98. Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol. 2016 Sep;43(9):1724-34.
99. Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun;75(6):1065-73.
100. Kavanaugh A, Gladman DD, Edwards CJ et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118.
101. Nash P, Ohson K, Walsh J et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018 May;77(5):690-698.
102. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2013 Oct 16.
103. van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2013 Oct 15.
104. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. The Lancet. 2000;356;385-90.
105. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
106. Mease PJ, Gladman DD, Collier DH et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol. 2019 Jul;71(7):1112-1124.
107. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976-86.
108. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150-7.

109. Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8.
110. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16):1537-1550.
111. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-1536.
112. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009 Dec;68(12):1870-7.
113. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept vs intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 Oct;63(10):2854-64.
114. Genovese MC, Pacheco-Tena C, Covarrubias A et al. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol.2018 Aug;45(8):1085-1092.
115. Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012 Jun;71(6):857-61.
116. Haraoui B, Cividino A, Stewart J, Guérette B, Keystone EC. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 2011 Nov 17;12:261.
117. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol. 2013 Sep;40(9):1487-97.
118. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:13.
119. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib, in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2016;0:1-8.
120. Taylor PC, Keystone E, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662.
121. Fleischmann R, Richardson M, Schiff M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017 Mar;69(3):506-517.
122. Keystone E, van der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3319-29.
123. Smolen J, Landewe R, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis. 2009;68:797-804.
124. Fleishmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every four weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009; 68:805-11.
125. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology. 2012 Dec; 51(12):2204-14.
126. Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017 Jan;76(1):96-104.
127. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, GO-FORTH Study Group, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012 Jun;71(6):817-24.
128. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter,

randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 Aug;60(8):2272-83.
129. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumor necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009 Jun;68(6):789-96.
130. Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, et al. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. J Rheumatol. 2016 Feb;43(2):298-306.
131. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18;374(9685):210-21.
132. Smolen JS, Kay J, Landewé RB, Matteson EL, Gaylis N, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomized, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct;71(10):1671-9.
133. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013 Mar; 72(3):381-9.
134. Ishaq M, Muhammad JS, Hameed K, Mirza AI. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Mod Rheumatology. 2011 Aug;21(4):375-80.
135. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(1):CD002047.
136. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001 Oct;60(10):913-23.
137. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50.
138. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 2001 Sep;44(9):1984-92.
139. De Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol. 2010 May;29(5):517-24.
140. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase iii study. Arthritis Rheumatol. 2015;67(6):1424-1437.
141. Genovese MC, van der Heijde D, Lin Y et al. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019 Aug 1;5(2):e000887.
142. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-290.
143. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase 3 trial. Ann Rheum Dis. 2017;76:840-847.
144. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy vs methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88-96.
145. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Aleckck E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008 Mar;371(9617):987-97.
146. Genovese M, McKay J, Nasonov E, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis and Rheumatism. 2008 Oct;58(10):2968-80.

147. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 Mar;63(3):609-21.
148. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205.
149. Emery P, Keystone E, Tony H, Cantagrel A, R van Vollenhoven, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008 July;67:1516-23.
150. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul;76(7):1279-1284.
151. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016 Nov;75(11):1917-1923.
152. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50.
153. Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343-355.
154. Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507.
155. Van der Heijde D, Strand V, Tanaka Y et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019 Jun;71(6):878-891.
156. Wollenhaupt J, Lee EB, Curtis JR et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Apr 5;21(1):89
157. Emery P, Rondon J, Parrino J et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 May 1;58(5):849-858.
158. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277.
159. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005113.
160. Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016 Dec 3;388(10061):2763-2774.
161. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005121.
162. Blumenauer BTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(4):CD004525.
163. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Swefot study group et al. Conventional combination treatment vs biological treatment in methotrexate-refractory early rheumatoid arthritis: two year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012 May 5;379(9827):1712-20.
164. Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol. 2009 Dec;28(12):1365-73.

165. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumor necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology. 2007;46:1140-7.
166. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. ADACTA Study Investigators. Tocilizumab monotherapy vs adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 May 4; 381(9877):1541-50.
167. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept vs adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan; 65(1):28-38.
168. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept vs adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2013 Aug 20.
169. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507.
170. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab vs placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):508-19.
171. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 9;381(9865):451-60.
172. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013 Mar;65(3):559-70.
173. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug 20;159(4):253-61.
174. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29;390(10093):457-468.
175. He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013 Oct 18;14:298.
176. Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskelet Disord. 2013 Nov 26;14:332.
177. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018 Jun 23; 391: 2503–12.
178. Genovese MC, Fleischmann R, Combe B et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018 Jun 13; 391: 2513–24.
179. Van Vollenhoven R, Takeuchi T, Pangan AL et al,. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial. Arthritis Rheumatol. 2020 Jul 8. doi: 10.1002/art.41384. Online ahead of print.
180. Smolen JS, Pangan AL, Emery P et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019 May 23; 393: 2303–11.
181. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & Rheumatology 2019 Nov 11: 71(11); 1788-1800.
182. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.

183. Hyams JS, Damaraju L, Blank M, Johanss J, Guzzo C, Winter H, et al. A randomized multicenter, open-label phase 3 study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate to severe ulcerative colitis [abstract]. Gastroenterology. 2011 May;140(5 Suppl. 1):124S-5S. Abstract no. 747.
184. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780-7.
185. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65.
186. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2013 Jun 2.
187. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-To-Severe Ulcerative Colitis. Gastroenterology. 2013 Jun 14.
188. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43.
189. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92.
190. Suhler EB, Adan A, Brezin AP et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018 Jul;125(7):1075-1087.
191. Ramanan AV, Dick AD, jones AP et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019 Apr;23(15):1-140.
192. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012 Jul;64 (7):2375-86.
193. Hatemi G, Mahr A, Ishigatsubo Y et al. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. N Engl J Med. 2019 Nov 14;381(20):1918-1928.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
New Drug Pharmacotherapy Review: Vumerity®
Immunomodulatory Agents used to treat Multiple Sclerosis: AHFS Class 922000
November 4, 2020

I. Overview

Vumerity® (diroximel fumarate) is Food and Drug Administration (FDA)-approved for the treatment relapsing forms of MS (RMS) in adults, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS). Diroximel fumarate was approved as a new dosage form of dimethyl fumarate (Tecfidera®) via the 505(b)(2) drug approval pathway.[1] Diroximel fumarate, similar to dimethyl fumarate (Tecfidera®), is a fumaric acid ester prodrug that is metabolized to active monomethyl fumarate prior to systemic circulation.[1,2] Monomethyl fumarate is thought to act by modulating cell-signaling pathways, but the exact mechanism of action in MS is unknown. FDA-approval of diroximel fumarate was established based on bioavailability studies in patients with RMS comparing dimethyl fumarate and diroximel fumarate.[1]

Diroximel fumarate was designed to reduce the gastrointestinal (GI) side-effects associated with dimethyl fumarate by reducing the methanol biproduct during prodrug metabolism. The GI side-effects (e.g., diarrhea, nausea, abdominal pain) associated with dimethyl fumarate are considered relatively mild and typically resolve within the first two months of treatment.[3,4] Overall, rates of discontinuation due to side effects were low in clinical studies (4%).[1] Clinical studies for diroximel fumarate focused entirely on safety, particularly gastrointestinal side-effects.[4,5]

MS is a chronic autoimmune disease of the central nervous system (CNS) that leads to progressive disability. It is characterized by CNS demyelination, which leaves neuronal axons susceptible to damage. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The pattern and course of MS is categorized into several subtypes, including CIS, RRMs, SPMS and primary progressive MS (PPMS). CIS represents the first attack that is suggestive of MS. It presents as a monophasic clinical episode with patient-reported symptoms and objective findings that reflect a focal or multifocal inflammatory demyelinating event in the central CNS. The most common form is RRMS, which is characterized by clearly defined attacks, exacerbations or "flare-ups" interspersed with periods of disease remission. SPMS is characterized by an initial RRMS disease course followed by gradual worsening with or without occasional relapses, minor remissions and plateaus. Generally, PPMS is characterized by progressive accumulation of disability with occasional plateaus, temporary minor improvements or acute relapases.[6] At this time, many disease-modifying therapies (DMTs) are approved by the FDA for the management RMS.

The diroximel fumarate products included in this review are listed in Table 1. Diroximel fumarate is not available in a generic formulation.

Table 1. Products Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Diroximel fumarate	delayed-release capsule	Vumerity®	none

PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current clinical guidelines are summarized in Table 2.

Table 2. Treatment Guidelines Using the Immunomodulatory Agents used to treat Multiple Sclerosis

Clinical Guideline	Recommendation(s)
American Academy of Neurology: **Evidence-based**	Starting Disease Modifying Therapy (DMT) • Clinicians should counsel patients just diagnosed with multiple sclerosis (MS) about specific treatment options with DMT at a dedicated treatment visit.

Clinical Guideline	Recommendation(s)
practice guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis (2018)[7]	• Clinicians must ascertain and incorporate/review preferences in terms of safety, route of administration, lifestyle, cost, efficacy, common side effects, and tolerability in the choice of DMT in patients with MS being considered for DMT. • Clinicians must engage in an ongoing dialogue regarding treatment decisions throughout the course of the disease with patients with MS. • Clinicians should counsel that DMTs are prescribed to reduce relapses and new MRI lesion activity. DMTs are not prescribed for symptom improvement in patients with MS. • Clinicians must counsel people with MS on DMTs to notify the clinicians of new or worsening symptoms. • Clinicians should evaluate readiness or reluctance to initiate DMT and counsel on its importance in patients with MS who are candidates to initiate DMT. • Clinicians should counsel about comorbid disease and adverse health behaviors, and potential interactions of the DMT with concomitant medications when patients with MS initiate DMTs. • Clinicians should evaluate barriers to adherence to DMT in patients with MS. • Clinicians should counsel on the importance of adherence to DMT when patients with MS initiate DMTs. • Clinicians should discuss the benefits and risks of DMTs for patients with a single clinical demyelinating event with two or more brain or spinal cord lesions that have imaging characteristics consistent with MS. • After discussing the risks and benefits, clinicians should prescribe DMT to people with a single clinical demyelinating event and two or more brain lesions characteristic of MS who decide they want this therapy. • Clinicians may recommend serial imaging at least annually for the first five years and close follow-up rather than initiating DMT in patients with clinically isolated syndrome (CIS) or relapsing forms of MS not on DMT who have not had relapses in the past two years and who do not have active new MRI lesion activity on recent imaging. • Clinicians should offer DMTs to patients with relapsing forms of MS with recent clinical relapses or MRI activity. • Clinicians should monitor for medication adherence, side effects, tolerability, safety, and effectiveness of the therapy in patients with MS on DMTs. • Clinicians should follow up either annually or according to medication-specific risk evaluation and mitigation strategies in patients with MS on DMT. • Clinicians should monitor patient's reproductive plans and counsel on reproductive risks and on use of birth control while on a DMT in women of childbearing years with MS. • Clinicians should counsel men with MS on their reproductive plans regarding treatment implications before initiating teriflunomide or cyclophosphamide. • Because of the high frequency of severe adverse events, clinicians should not prescribe mitoxantrone to people with MS unless the potential therapeutic benefits greatly outweigh the risks. • Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for patients with highly active MS. • Clinicians may direct patients with MS who are candidates for DMTs to support programs. • Clinicians may recommend azathioprine or cladribine for people with relapsing forms of MS who do not have access to approved DMTs. • Clinicians may initiate natalizumab treatment in people with MS with positive anti-John Cunningham virus (JCV) antibody indexes above 0.9 only when there is a reasonable chance of benefit compared with the low but serious risk of progressive multifocal leukoencephalopathy (PML).

Clinical Guideline	Recommendation(s)
	• Clinicians should offer ocrelizumab to people with primary progressive multiple sclerosis (PPMS) who are likely to benefit from this therapy unless there are risks of treatment that outweigh the benefits. Switching DMT • Clinicians should monitor MRI disease activity from the clinical onset of disease to detect the accumulation of new lesions in order to inform treatment decisions in people with MS using DMTs. • Clinicians should recognize that relapses or new MRI-detected lesions may develop after initiation of a DMT and before the treatment becomes effective in patients with MS on DMTs. • Clinicians should discuss switching from one DMT to another in patients who have been on a DMT long enough to take full effect and are adherent to their therapy when a patient has experienced one or more relapses, two or more unequivocally new MRI lesions, or increased disability on examination, over a one-year period on a DMT. • Clinicians should evaluate the amount of disease activity, adherence, adverse event profiles, and mechanism of action of DMTs when switching DMTs in patients with breakthrough disease activity during DMT use. • Clinicians should discuss a change to a non-injectable or less frequently injectable DMT in patients who report intolerable discomfort with the injections or in those who report "injection fatigue" on injectable DMTs. • Clinicians should inquire about medication adverse effects with patients with MS who are taking a DMT and attempt to manage these adverse effects, as appropriate. • Clinicians should discuss a medication switch with patients for whom these adverse effects negatively influence adherence. • Clinicians should monitor laboratory abnormalities found on requisite laboratory surveillance (as outlined in the medication's package insert) in patients with MS who are on a DMT. • Clinicians should discuss switching DMT or reducing dose or frequency (where there is data on different doses [e.g., interferons, teriflunomide, azathioprine]) when there are persistent laboratory abnormalities. • Clinicians should counsel people with MS considering natalizumab, fingolimod, rituximab, ocrelizumab, and dimethyl fumarate about the PML risk associated with these agents. • Clinicians should discuss switching to a DMT with a lower risk of PML in patients taking natalizumab who are or become JC virus antibody positive, especially with an index of above 0.9 while on therapy. • Clinicians should counsel that new DMTs without long-term safety data have an undefined risk of malignancy and infection in patients starting or using new DMTs. • If a patient with MS develops a malignancy while on a DMT, clinicians should promptly discuss switching to an alternate DMT, especially for patients on azathioprine, methotrexate, mycophenolate, cyclophosphamide, fingolimod, teriflunomide, alemtuzumab, or dimethyl fumarate. • Patients with serious infections potentially linked to their DMT should switch DMTs (note this does not pertain to management of PML in patients on DMT). • Clinicians should check for natalizumab antibodies in patients who have infusion reactions prior to subsequent infusions, or in patients who experience breakthrough disease activity on natalizumab. • Clinicians should switch DMTs in patients who have persistent natalizumab antibodies. • Physicians must counsel patients considering discontinuation of natalizumab

<table>
<tr><th>Clinical Guideline</th><th>Recommendation(s)</th></tr>
<tr><td></td><td>that there is an increased risk of MS relapse or MRI-detected disease activity within six months of discontinuation.
• Physicians and patients choosing to switch from natalizumab to fingolimod should initiate treatment within eight to 12 weeks after discontinuation of natalizumab (for reasons other than pregnancy or pregnancy planning) to diminish the return of disease activity.
• Clinicians should counsel women to stop their DMT before conception for planned pregnancies unless the risk of MS activity during pregnancy outweighs the risk associated with the specific DMT during pregnancy.
• Clinicians should discontinue DMTs during pregnancy if accidental exposure occurs, unless the risk of MS activity during pregnancy outweighs the risk of the specific DMT during pregnancy.
• Clinicians should not initiate DMTs during pregnancy unless the risk of MS activity during pregnancy outweighs the risk associated with the specific DMT during pregnancy.

<u>Stopping DMT</u>
• In patients with relapsing remitting MS who are stable on DMT and wish to discontinue therapy, clinicians should counsel patients regarding the need for ongoing follow-up and periodic reevaluation of the decision to discontinue DMT.
• Clinicians should advocate that people with MS who are stable (that is, no relapses, no disability progression, stable imaging) on DMT should continue on their current DMT unless the patient and physician decide a trial off therapy is warranted.
• Clinicians should assess the likelihood of future relapse in individuals with secondary progressive (SP) MS by assessing patient age, disease duration, relapse history, and MRI-detected activity (e.g., frequency, severity, time since most recent relapse or gadolinium enhancing lesion).
• Clinicians may advise discontinuation of DMT in people with SPMS who do not have ongoing relapses (or gadolinium-enhanced lesions on MRI activity) and have not been ambulatory (expanded disability status scale 7 or greater) for at least two years.
• Clinician should review the risk of continuing DMTs vs the risk of stopping DMTs in patients with CIS using DMTs who have not been diagnosed with MS.</td></tr>
<tr><td>American Academy of Neurology: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis (2018)[8]</td><td><u>In people with relapsing-remitting multiple sclerosis (RRMS), are disease-modifying therapies (DMTs) superior to placebo or other DMTs as measured by annualized relapse rates and the relative risk of relapse at two years?</u>
<table>
<tr><th colspan="3">Reduction of the annualized relapse rate</th></tr>
<tr><th>Confidence strength</th><th>Compared with placebo</th><th>Compared with other DMTs</th></tr>
<tr><td rowspan="8">High</td><td>Cladribine more effective</td><td>Alemtuzumab more effective than IFN-beta-1a SubQ 3x/week</td></tr>
<tr><td>Daclizumab more effective</td><td>Azathioprine more effective than beta-interferons</td></tr>
<tr><td>Dimethyl fumarate more effective</td><td>Fingolimod more effective than IFN-beta-1a once weekly</td></tr>
<tr><td>Glatiramer acetate more effective</td><td>Ocrelizumab more effective than IFN-beta-1a SubQ 3x/week</td></tr>
<tr><td>Natalizumab more effective</td><td></td></tr>
<tr><td>Peg-IFN more effective</td><td></td></tr>
<tr><td>Teriflunomide more effective</td><td></td></tr>
<tr><td rowspan="2">Moderate</td><td>Azathioprine probably more effective</td><td></td></tr>
<tr><td>IFN-beta-1a IM once weekly</td><td></td></tr>
</table></td></tr>
</table>

Clinical Guideline	Recommendation(s)		
		probably more effective	
		IFN-beta-1b SubQ alternate day probably more effective	
		Pulsed corticosteroids added to IFN-beta-1a probably more effective	
			Daclizumab probably more effective than IFN-beta-1a once weekly
	Low	Cyclophosphamide possibly more effective	
	Very low	Azathioprine insufficient to support or refute	
		Immunoglobulins insufficient to support or refute	
		Pulsed corticosteroids insufficient to support or refute	
		Rituximab insufficient to support or refute	

Reduction of risk of relapse at two years		
Confidence strength	Compared with placebo	Compared with other DMTs
High	Daclizumab more effective (outcome measured at one year)	Alemtuzumab more effective than IFN-beta-1a SubQ 3x/week
	Dimethyl fumarate more effective	
	Fingolimod more effective	
	Immunoglobulins more effective	
	IFN-beta-1a IM once weekly more effective	
	IFN-beta-1a SubQ 3x/week more effective	
	Mitoxantrone more effective	
	Natalizumab more effective	
	Peg-IFN more effective (outcome measured at one year)	
Moderate	Cladribine probably more effective	Daclizumab probably more effective than IFN-beta-1a IM once weekly (outcome measured at three years)
	Glatiramer acetate probably more effective	
	IFN-beta-1b SubQ alternate day probably more effective	
	Pulsed corticosteroids added to IFN-beta-1a probably more effective	
	Rituximab probably more effective (outcome measured at one year)	
	Teriflunomide probably more effective	
Low		Mycophenolate mofetil plus IFN-beta-1a IM weekly possibly no more effective than IFN plus placebo (outcome measured at one year)
		Complex nonbiologic generic glatiramer acetate (Glatopa) possibly no more effective than glatiramer acetate (Copaxone)

<table>
<tr><th>Clinical Guideline</th><th>Recommendation(s)</th></tr>
<tr><td></td><td>
<table>
<tr><td></td><td></td><td>IFN-beta-1a IM once weekly possibly no more effective than glatiramer acetate (Copaxone)</td></tr>
<tr><td></td><td></td><td>IFN-beta-1a SubQ 3x/week possibly no more effective than glatiramer acetate (Copaxone)</td></tr>
<tr><td rowspan="5">Very low</td><td></td><td>IFN-beta-1b SubQ alternate day possibly no more effective than glatiramer acetate (Copaxone)</td></tr>
<tr><td>Azathioprine insufficient to support or refute</td><td></td></tr>
<tr><td>Cyclophosphamide insufficient to support or refute (outcome measured at 12 months)</td><td></td></tr>
<tr><td>Methotrexate insufficient to support or refute</td><td></td></tr>
<tr><td>Pulsed corticosteroids insufficient to support or refute</td><td></td></tr>
</table>
</td></tr>
<tr><td>Multiple Sclerosis Coalition:
The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (2019)[9]</td><td>Treatment Considerations
• Initiation of treatment with an FDA-approved disease-modifying therapy (DMT) is recommended:
o As soon as possible following a diagnosis of relapsing MS, regardless of the person’s age.
o For individuals with primary progressive MS, with an agent approved for this phenotype.
o For individuals with a first clinical event and MRI features consistent with MS, in whom other possible causes have been excluded.
o For individuals with relapsing-remitting MS.
o For individuals with active secondary progressive MS with clinical relapses or inflammatory activity on MRI.
• Clinicians should consider prescribing a high efficacy medication such as alemtuzumab, cladribine, fingolimod, ocrelizumab, natalizumab or ocrelizumab for newly-diagnosed individuals with highly active MS.
• Clinicians should also consider prescribing a high efficacy medication for individuals who have breakthrough activity on another DMT, regardless of the number of previously used agents.
• Treatment with a given DMT should be continued indefinitely unless any of the following occur (in which case an alternative DMT should be considered):
o Sub-optimal treatment response as determined by the individual and his or her treating clinician.
o Intolerable side effects, including significant laboratory abnormalities.
o Inadequate adherence to the treatment regimen.
o Availability of a more appropriate treatment option.
o The healthcare provider and patient determine that the benefits no longer outweigh the risks.
• Movement from one DMT to another should occur only for medically appropriate reasons as determined by the treating clinician and patient.
• When evidence of additional clinical or MRI activity while on consistent treatment suggests a sub-optimal response, an alternative regimen (e.g., different mechanism of action) should be considered to optimize therapeutic benefit.
• The factors affecting choice of therapy at any point in the disease course are complex and most appropriately analyzed and addressed through a shared decision-making process between the individual and his or her treating</td></tr>
</table>

Clinical Guideline	Recommendation(s)
	clinician. Neither an arbitrary restriction of choice nor a mandatory escalation therapy approach is supported by data. Access Considerations • MS clinical phenotypes may respond differently to different disease-modifying therapies. • Due to significant variability in the MS population, people with MS and their treating clinicians require access to the full range of treatment options for several reasons: o Different mechanisms of action allow for treatment change in the event of a sub-optimal response. o Potential contraindications limit options for some individuals. o Risk tolerance varies among people with MS and their treating clinicians. o Route of delivery, frequency of dosing, and side effects may affect adherence and quality of life. o Individual differences related to tolerability and adherence may necessitate access to different medications within the same class. o Pregnancy and breastfeeding limit the available options. • Individuals' access to treatment should not be limited by their frequency of relapses, level of disability, or personal characteristics such as age, sex or ethnicity. • Absence of relapses while on treatment is a characteristic of treatment effectiveness and should not be considered a justification for discontinuation of treatment. • Treatment should not be withheld to allow for determination of coverage by payers as this puts the patient at risk for recurrent disease activity.
Association of British Neurologists: **Revised Guidelines for Prescribing in Disease-Modifying Treatments for Multiple Sclerosis (2015)**[10]	General Statements • All of the licensed disease-modifying treatments for multiple sclerosis (MS)- β-interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, natalizumab and alemtuzumab- reduce relapse rate and magnetic resonance imaging (MRI) lesion accumulation in relapsing–remitting MS, to varying extents. • Reducing relapse rate and MRI lesion accumulation data shows only a weak correlation between long-term disability and relapse frequency. • There is a consensus that none of the currently available disease-modifying therapies significantly modifies progressively increasing disability that is unrelated to relapses (progressive non-relapsing MS). • Long-term therapy with disease-modifying agents has not established the following: o Reduces the accumulation of disability by whatever mechanism. o Prevents or slows entry to the secondary progressive stage of the disease. • Immunotherapies appear particularly helpful when given early to people with active relapsing–remitting disease, before there is fixed disability or secondary progression. • Disease-modifying treatment should be started and supervised by an MS specialist neurologist. • When considering potential disease-modifying treatment options, it is important that patients and neurologists fully appreciate the risk and benefit of drugs, and of leaving the disease untreated. • Provide patients accurate information: o Expectations of treatment, including the evidence that disease-modifying treatment efficacy can be only partial, moderate and not curative.

Clinical Guideline	Recommendation(s)
	○ Risk as well as expected benefit of treatment. ○ Monitoring requirements of treatment. • Discuss work, family and other factors that are personally important to them and take their views into account when making the treatment selection. <u>Initial Treatment Recommendations: Relapsing–Remitting MS (RRMS)</u> • Licensed agents are broadly divided into two classes: ○ Drugs of moderate efficacy (Category 1): ▪ β-interferons (including pegylated β-interferon) ▪ glatiramer acetate ▪ teriflunomide ▪ dimethyl fumarate ▪ fingolimod ○ Drugs of high efficacy (Category 2): ▪ alemtuzumab ▪ natalizumab • Consider starting treatment with disease-modifying agents in patients with "active" RRMS • Activity may be established on radiological/clinical grounds: • Active RRMS: ○ Consider treatment in patients: ▪ who have had two or more clinical relapses in the previous two years ▪ who have had a single recent relapse and/or on radiological grounds, including both patients newly diagnosed according to the 2010 'MacDonald criteria' ▪ with established disease who develop new MRI lesions without clinical relapse ○ Usually start with a Category 1 drug. ▪ Dimethyl fumarate and fingolimod appear to be most effective. β-Interferon, teriflunomide and glatiramer acetate appear to be similar (broadly), but are probably a little less effective. ▪ Dimethyl fumarate and fingolimod have the additional benefit of being an oral agent. ▪ β-interferons and glatiramer acetate have been used extensively for decades in MS, and there is a wealth of clinical experience confirming their general safety. • More Active RRMS ○ Patients may be classified as having more active MS by frequent clinical relapses and/or MRI activity either when untreated or while on a Category 1 drug. ○ The formal criteria for high-disease activity despite interferon-β or glatiramer requires one relapse in the previous year on interferon-β and either: ≥1 gadolinium-enhancing MRI lesions or at least nine T2-hyperintensive lesions on cranial MRI ○ It is recommended to begin a Category 2 agent in patients with high disease activity: natalizumab or alemtuzumab. ▪ Indirect comparison suggests that alemtuzumab and natalizumab have similar efficacy. ▪ Appropriate where individuals and their neurologists are most concerned to achieve high efficacy, despite the more complex safety profile compared to Category 1 drugs. ○ It may be appropriate to change from one Category 1 agent to another Category 1 agent:

Clinical Guideline	Recommendation(s)
	▪ Patients with infrequent or occasional minor relapses ▪ Patient may be risk-averse to safety profile of Category 2 agents ▪ Consider the increased potency of fingolimod and dimethyl fumarate People aged under 18 years • Minors aged between 16 and 18 years should be treated according to the above guidelines. • Children with MS aged <16 should be treated in specialist clinics, preferably under a combined team including adult and pediatric neurologists with a particular interest in MS. Primary or secondary progressive MS • None of the current disease-modifying treatments is recommended in non-relapsing secondary progressive MS or in primary progressive MS. • Some people with relapsing secondary progressive MS, whose relapses are their main cause of increasing disability, may benefit from disease-modifying treatment. Recommendations for Stopping Disease-Modifying Treatment • Mandatory stopping criteria that applies to all patients is not appropriate • The difficulty of stopping treatment in people with progressive disease is compounded by the absence of alternative options for disease modification • Clinicians should consider stopping disease-modifying treatment in the following scenarios: o Significant side effects specific to any individual agent o Development of non-relapsing secondary progressive MS o Pregnancy • If significant side effects develop to a specific agent, that agent should be discontinued and an alternative should be considered • Disease-modifying treatments should normally be stopped during pregnancy, as stated in the summary of product characteristics. Known risks and available information vary by agent. o Given the increased risk of relapse in the puerperium, treatment should be restarted early after delivery, depending on discussions concerning breast feeding.

III. Indications

The FDA-approved indications for diroximel fumarate are noted in Table 3.

Table 3. FDA-Approved Indications for Diroximel Fumarate

Indication	Vumerity®
Treatment of adults with CIS in relapsing MS	✔
Treatment of adults with RRMS	✔
Treatment of adults with SPMS	✔

CIS=clinically isolated syndrome, MS=multiple sclerosis, RRMS=relapsing-remitting multiple sclerosis, SPMS=secondary progressive multiple sclerosis

IV. Pharmacokinetics

The pharmacokinetic parameters of diroximel fumarate are listed in Table 4.

Table 4. Pharmacokinetic Parameters of Diroximel Fumarate[1,11]

Generic Name(s)	Bioavailability (%)	Protein Binding† (%)	Metabolism	Excretion† (%)	Half-Life† (hours)
Diroximel fumarate	Not available	27 to 45	Extensively by esterases* to active metabolite, MMF	Respiratory‡ Renal (58 to 63%)§	1

MMF=monomethyl fumarate
*Metabolism via GI, blood and tissue esterases
†Diroximel fumarate is not quantifiable in plasma following oral administration. Data shown for MMF.
‡Active metabolite MMF excreted as carbon dioxide via expired air.
§Primary major inactive metabolites excreted via urine and/or feces (minimal MMF).

V. Drug Interactions

Drug interactions are not expected with diroximel fumarate based on in vitro data of dimethyl fumarate or its active metabolite (monomethyl fumarate). Use of diroximel fumarate in combination with dimethyl fumarate is contraindicated. Diroximel fumarate may be initiated the day following discontinuation of dimethyl fumarate.[1]

VI. Adverse Drug Events

The FDA-approved label of diroximel fumarate provides information on adverse events of dimethyl fumarate, which has the same active metabolite. According to the FDA-approved label, in clinical studies of approximately 700 patients with RRMS treated with diroximel fumarate, the adverse reaction profile of diroximel fumarate was consistent with the experience in the placebo-controlled clinical trials with dimethyl fumarate.[1] The most common adverse drug events reported with dimethyl fumarate are listed in Table 5.

Table 5. Adverse Drug Events (%) Reported with Dimethyl Fumarate[1,11]

Adverse Event	Dimethyl fumarate
Flushing	40
Abdominal pain	18
Diarrhea	14
Nausea	12
Vomiting	9
Pruritus	8
Rash	8
Albumin urine present	6
Erythema	5
Dyspepsia	5
Increased liver enzymes	4
Lymphopenia	2

VII. Dosing and Administration

The usual dosing regimens for diroximel fumarate are listed in Table 6.

Table 6. Usual Dosing Regimens for Diroximel Fumarate[1,11]

Generic Name	Usual Adult Dose*	Usual Pediatric Dose	Availability
Diroximel	Relapsing forms of MS:	Safety and efficacy	Delayed-release

Generic Name	Usual Adult Dose*	Usual Pediatric Dose	Availability
fumarate	Delayed-release capsule: initial, 231 mg BID; maintenance, 462 mg BID; maximum, 462 mg BID Temporary dose reduction to 231 mg BID may be considered in patients who cannot tolerate maintained dosing. Consider discontinuation if unable to return to maintenance dosing after four weeks.	in children have not been established.	capsule: 231 mg

BID=twice daily, MS=multiple sclerosis

VIII. Effectiveness

The efficacy of diroximel fumarate is based upon bioavailability studies in patients with relapsing forms of MS and healthy subjects comparing oral dimethyl fumarate and diroximel fumarate. Clinical studies evaluating the safety and efficacy of dimethyl fumarate are summarized in Table 7.

Table 7. Comparative Clinical Trials with Dimethyl Fumarate

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Gold et al.[12] (2012) DEFINE Dimethyl fumarate 240 mg BID vs dimethyl fumarate 240 mg TID vs placebo	DB, MC, PC, RCT Patients aged 18 to 55 years with a diagnosis of RRMS, an EDSS score of 0 to 5, and at least one clinically documented relapse in the previous 12 months or at least one gadolinium-enhancing lesion 0 to 6 weeks before randomization	N=1,237 96 weeks	Primary: Proportion of patients who had a relapse by two years Secondary: ARR, time to progression of disability, number of gadolinium-enhancing lesions and of new or enlarging hyperintense T2 lesions	Primary: Relapses after two years were observed in 27% and 26% of the patients in the twice daily and three times daily dimethyl fumarate groups, respectively, compared to 46% of patients in the placebo group (HR, 0.51; 95% CI: 0.39 to 0.65 and 0.50; 95% CI: 0.39 to 0.65, respectively). Secondary: Time to first relapse was prolonged by 87 and 91 weeks in patients in the twice and three times daily groups, respectively, compared to placebo. Relative to placebo, the ARR was reduced by 53% and 48% in the twice daily and three times daily groups, respectively (P=0.001). Additionally, the time to progression of disability was reduced by 38% in the twice daily group (HR, 0.62; 95% CI: 0.44 to 0.87) and by 34% in the three times daily group (HR, 0.66; 95% CI: 0.48 to 0.92). Relative to placebo, the number of new or enlarging hyperintense T2 lesions and the number of gadolinium-enhancing lesions was decreased by 85% and 90%, respectively in patients receiving dimethyl fumarate twice daily and by 74% and 73% in patients receiving dimethyl fumarate three times daily (P<0.001 for all) The most common adverse events in patients receiving dimethyl fumarate were flushing, gastrointestinal events, proteinuria and pruritus.
Fox et al.[13] (2012) CONFIRM	DB, MC, PC, RCT Patients aged 18 to 55	N=1,430 96 weeks	Primary: ARR over two years	Primary: The ARR in patients receiving dimethyl fumarate twice daily and three times daily was 0.22 and 0.20, respectively. This

Dimethyl fumarate 240 mg BID vs dimethyl fumarate 240 mg TID vs glatiramer acetate 20 mg QD vs placebo The glatiramer acetate group was not an active comparator, but used as a referenced group. Patients receiving glatiramer were not blinded to treatment regimen.	years with a diagnosis of RRMS, an EDSS score of 0 to 5, and at least one clinically documented relapse in the previous 12 months or at least one gadolinium-enhancing lesion 0 to 6 weeks before randomization		Secondary: Number of new or enlarging hyperintense T2 lesions, number of new hypointense T1 lesions, proportion of patients with a relapse, time to disability progression	corresponded to a reduction relative to placebo of 44% and 51% (P<0.001 for both). Glatiramer acetate was associated with a relative ARR reduction of 29% compared to placebo (P=0.001). Secondary: Dimethyl fumarate twice daily, three times daily and glatiramer acetate reduced the number of T2 lesions by 71%, 73% and 54%, respectively (all P<0.001 compared to placebo). The number of T1 lesions was reduced by 57% (P<0.001), 65% (P<0.001) and 41% (P=0.002) relative to placebo, respectively. Compared to placebo, dimethyl fumarate twice daily, three times daily and glatiramer acetate significantly reduced the risk of relapse by 34% (P=0.002), 45% (P<0.001) and 29% (P<0.01), respectively. However, disability progression was not significantly reduced in any group compared to placebo. Post hoc analysis directly comparing dimethyl fumarate twice daily and three times daily to glatiramer determined that a comparison of ARR resulted in P values of 0.10 and 0.02, respectively favoring dimethyl fumarate. The overall incidence of adverse events, serious adverse events and adverse events leading to discontinuation was similar in all groups. The most common adverse events reported in patients receiving dimethyl fumarate were flushing, gastrointestinal events, upper respiratory tract infections and erythema.

Drug regimen abbreviations: BID=twice daily, QD=once daily, TID=three times daily
Study abbreviations: DB=double blind, CI=confidence interval, HR=hazard ratio, MC=multi-center, PC=placebo-controlled, RCT=randomized controlled trial,
Miscellaneous abbreviations: ARR=annualized relapse rate, EDSS=expanded disability status scale, RRMS=relapsing-remitting multiple sclerosis

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 8. Relative Cost of Diroximel Fumarate

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Diroximel Fumarate	delayed-release capsule	Vumerity®	$$$$$	N/A

N/A=Not available

X. Conclusions

Vumerity® (diroximel fumarate) is Food and Drug Administration (FDA)-approved for the treatment relapsing forms of MS (RMS) in adults, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS). Diroximel fumarate was approved as a new dosage form of dimethyl fumarate (Tecfidera®).[1] Diroximel fumarate is a fumaric acid ester prodrug that is metabolized to active monomethyl fumarate prior to systemic circulation.[1,2] Monomethyl fumarate is thought to act by modulating cell-signaling pathways, but the exact mechanism of action in MS is unknown.[1] FDA-approval of diroximel fumarate was established based on bioavailability studies in patients with RMS comparing dimethyl fumarate and diroximel fumarate. Diroximel fumarate was designed to reduce the gastrointestinal (GI) side-effects associated with dimethyl fumarate by reducing the methanol biproduct during prodrug metabolism. The GI side-effects (e.g., diarrhea, nausea, abdominal pain) associated with dimethyl fumarate are considered relatively mild and typically resolve within the first two months of treatment.[3,4] Overall, rates of discontinuation due to side effects were low in

clinical studies (4%).[1] The efficacy of diroximel fumarate is based upon bioavailability studies in patients with relapsing forms of multiple sclerosis and healthy subjects comparing oral dimethyl fumarate and diroximel fumarate. Efficacy of dimethyl fumarate was established in two well designed clinical trials (CONFRIM and DEFINE).[12,13]

The American Academy of Neurology guidelines provide recommendations for all forms of MS. For patients with CIS, disease-modifying therapies may be recommended if benefits and risks are assessed. For all patients with recent clinical relapses or MRI activity (relapsing MS [RRMS or active SPMS]), disease-modifying therapies are recommended. Except in certain situations, no disease-modifying therapy is recommended over another and selection of DMT should be based on individual factors and preference. Several newer agents, including diroximel fumarate, are not discussed as the guideline has not been updated since 2018.[7]

Therefore, all brand diroximel fumarate agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand diroximel fumarate product is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Vumerity® [package insert]. Cambridge (MA): Biogen Inc.; 2020 Mar.
2. Tecfidera® [package insert]. Cambridge (MA): Biogen Inc.; 2020 Feb.
3. Olek MJ, Mowry E. Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults. In: Dashe JF (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jul 10]. Available from: http://www.utdol.com/utd/index.do.
4. Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, et al. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Adv Ther. 2019 Nov;36(11):3154-3165.
5. A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 (NCT03093324). ClinicalTrials.gov [Internet]. Bethesda (MD): 2000-2020 [cited 2020 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03093324.
6. Olek MJ, Howard J. Clinical presentation, course, and prognosis of multiple sclerosis in adults. In: Dashe JF (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2020 [cited 2020 Jul 10]. Available from: http://www.utdol.com/utd/index.do.
7. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology Apr 2018, 90 (17) 777-788.
8. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24;90(17):789-800.
9. The Multiple Sclerosis Coalition. THE USE OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS (UPDATED). 2019 June. Available from: http://ms-coalition.org/the-use-of-disease-modifying-therapies-in-multiple-sclerosis-updated/.
10. Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015 Aug;15(4):273-9. doi: 10.1136/practneurol-2015-001139. Epub 2015 Jun 22.
11. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Healthcare; Updated periodically [cited 2020 Jul 10]. Available from: http://www.thomsonhc.com/.
12. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098-107.
13. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97.